IMPORTANT SAFETY INFORMATION

Transcription

1 B:.5 in T:0.875 in S:9.875 in program B O O K Pre-meeting Courses: November 9-0, 0 opening lecture and awards, opening event: November 0, 0 Scientific Sessions: November 0-4, 0

2 IMPORTANT LOCATIONS ACR Office...0A; Telephone: (0) Attendee Lounge...Ballroom Pre-Function Business Center...L Street South Lobby (under escalator) Career Connection...Exhibit Hall (Hall A), Booth 945 Child Care...Call for Location; Telephone: (0) CME/Internet Center...Concourse (near entrance to Hall A) Coat/Baggage Check...Registration (Salons G-H-I) Exhibit Hall...Hall A First Aid...Exhibit Hall (Hall A, bottom of escalator) Graffiti Walls...Exhibit Hall (Hall A) & Grand Lobby Hotel Reservations...Registration (Salons G-H-I) Industry-Supported Symposia Information....L Street South Lobby (under escalator) Innovation Theater Hall A, Booth 45 Lost and Found...ACR Office (0A) Membership Booth...Registration (Salons G-H-I) Newsroom....0A-B; Telephone: (0) Nursing Mothers Room... Salon D Poster Hall....Hall B Prayer Room...Salon E (East Building, Street Level) Recharge Areas... exhibit Hall (Hall A, main aisles), Attendee Lounge (Ballroom Pre-Function) and large meeting rooms Registration...Salons G-H-I (Level ) Resource Center...L Street Bridge (Level ) Restaurant Reservations Grand Lobby Rheumatology Research Foundation 5K Run/Walk Registration...Registration (Salons G-H-I) Rheumatology Research Foundation Booth...L Street Bridge (Level ) Rheumatology Research Foundation Donors Lounge...East Overlook (nd Floor) Ribbon Distribution....Registration (Salons G-H-I) SessionSelect Lounge...West Overlook (nd Floor) Shuttle Bus...L Street Speakers Lounge...4 Speaker Ready Room...56 Visitor Information...Grand Lobby Wheelchairs (complimentary-limited availability)...information Desk (Grand Lobby) Wi-Fi Way...Exhibit Hall (Hall A) Special Needs If you require special arrangements, please contact the ACR Office (0A); Telephone: (0) Emergency Contact Information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder.

3 program B O O K ABOUT THE ANNUAL MEETING Participation Statement This annual meeting is sponsored by the American College of Rheumatology for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare professionals at arriving at their own conclusions and consequent application. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the College for reliance on any information presented during these educational activities. The College does not guarantee, warrant or endorse any commercial products or services. The ACR s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians, scientists and other health professionals. The ACR will offer evidence-based educational activities designed to enhance practice performance and improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal diseases. Global Learning Objectives At the conclusion of the 0 ACR/ARHP annual meeting, participants should be able to: identify recent developments in the diagnosis and management of patients with rheumatic diseases outline new technologies for the treatment of rheumatologic problems describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify possible solutions utilize new research data to improve the quality of care of patients with rheumatic diseases summarize recent rheumatology research findings The program is the result of a planning process that identified educational needs to change or enhance the knowledge, competence or performance of rheumatology professionals. The program s content was derived from both needs assessment and practice gap analysis that took professional activities, practice setting, ABIM recertification requirements and physician attributes into account. Printing of this publication is supported by Amgen, Inc. and Pfizer, Inc. This publication was printed by an FSC validated printer on eco-friendly paper.

4 TABLE OF CONTENTS POLICIES Copyright Materials Policy... Media... Embargo Policy... MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices... Children... Child Care... Nursing Mothers Room... Exhibit Hall... Meeting Room Capacity/Important First Safety Information... Photograpy and Videotaping... Name Badges... No Smoking... MEETING NAVIGATION GUIDE Track Icons... Session Formats... Abstract Formats... MEETING SERVICES My Annual Meeting...5 Resource Center...5 Membership Booth...5 Lost and Found...5 Newsroom...6 Attendee Lounge...6 Announcement Boards...6 Career Connection...6 Registration Shuttle Bus...6 Speaker Ready Room...6 Wi-Fi Way and Recharge Access...6 Rheumatology Research Foundation Booth...7 Rheumatology Research Foundation Donors Lounge...7 Rheumatology Research Foundation 5K Run/Walk...7 SPECIAL OFFERS SessionSelect...8 What Would Make the Meeting Better...9 Medical Bag...9 POSTER SESSIONS Poster Session Presenter Instructions...9 ACR Poster Presenter No-show Policy...9 Guided Poster Tours...9 PRE-MEETING PROGRAM Friday, November 9, 0 ACR Musculoskeletal Ultrasound Course for Rheumatologists Day One of Two...0 ACR Certified Rheumatology Coder Course: Unlock the Mystery: A Roadmap for Rheumatology Coding Day One of Two... ACR Basic Research Conference: Mesenchymal Cells in Rheumatic Diseases: Tissue Erosion/Invasion vs. Fibrosis Day One of Two... ACR Clinical Research Conference: Pain Research: New Methods and Challenges Day One of Two... ACR/ABIM Maintenance of Certification Learning Session 0 Update in Rheumatology... Saturday, November 0, 0 ACR Musculoskeletal Ultrasound Course for Rheumatologists Day Two of Two... ACR Review Course...4 ACR Basic Research Conference: Mesenchymal Cells in Rheumatic Diseases: Tissue Erosion/Invasion vs. Fibrosis Day Two of Two...5 ARHP Clinical Focus Course: Treating the Patient with Osteoarthritis: Interventions, Innovations and Clinical Insights...6 CORC Pre-meeting Course for Practice Managers: Helping You Manage A Profitable Practice...7 ACR Clinical Research Conference: Pain Research: New Methods and Challenges Day Two of Two...7 ACR Certified Rheumatology Coder Course Examination: Unlock the Mystery: A Roadmap for Rheumatology Coding Day Two of Two...9 ACR/ARHP ANNUAL MEETING SCIENTIFIC PROGRAM Saturday, November 0, 0 ACR/ARHP Opening Lecture and Awards...9 Sunday, November, 0 ACR Sessions Modifying Causal Risk Factors that Influence the Incidence of Falls by Older Adults...9 Year in Review...0 Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis...0 Tips for Publishing Your Work in a Peer-Reviewed Medical Journal...0 ARHP Sessions ARHP First-time Attendee Orientation...0 ARHP Moderators Orientation...0 Meet the Professor Sessions Behçet s Disease (00)... Controversies in Sjögren s Syndrome (00)... Infections with Biologics (00)... Pediatrics: Dermatomyositis (004)... Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (005)... 0 Program Book

5 TABLE OF CONTENTS Rheumatoid Arthritis: Biological Agents (006)... Spondylarthropathy: An Update (007).... Systemic Arthritis and Still s Disease (008)... Systemic Lupus Erythematosus: Central Nervous System (009)... Vasculitis Mimics (00).... ACR Workshops Basic Statistical Concepts for the Medical Researcher (0)... Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0).... Dermatopathology of Rheumatic Diseases (0).... Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis (04)... ACR Sessions Advances in the Biology of Aging... CORC FORUM: Achieving Economic Goals in an Era of Healthcare Reform.... New Therapies for Modulating Signaling in Rheumatoid Arthritis... The Plasticity of T Regulatory Cells and their Role in Autoimmunity.... Update on Stroke... Extra-articular Involvement in Rheumatoid Arthritis... Medical Education: The Year in Review.... ACR Poster Session A and Poster Tours Abstracts (#-74)... ARHP Session ARHP Keynote Address: It s Not Child s Play: Growing Up With and Mastering Juvenile Idiopathic Arthritis from the Child s Perspective... Rheumatology Research Foundation Special Session Oscar S. Gluck, MD, Memorial Lectureship: Bone Wasn t Built in a Day: New Insights into Destruction and Repair in Rheumatic Disease... Exhibits and Innovation Theater See page 6 of a complete listing of Innovation Theater... ACR Workshops Adult Musculoskeletal Upper Examinations (05)... Musculoskeletal Ultrasound (06)... Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (07)... ACR Plenary Session I: Discovery 0 Abstracts (#75-79)... ARHP Sessions Hands: Non-Surgical Management and Bracing What You Don t Know Can Hurt You New Medication Developments in Rheumatology...7 Rheumatic Disease Update: Vasculitis...7 The 5A Approach to Physical Activity Counseling for Arthritis Patients....7 ACR Session ACR Knowledge Bowl Preliminary Round...7 ARHP Networking Event Networking Forum...7 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (0)...8 Cutaneous Vasculitis (0)...8 Inflammatory Eye Disease/Uveitis (0)...8 Myopathy: Issues in Diagnosis and Treatment (04)...8 Osteoporosis: Novel Treatments (05)...8 Pediatrics: Periodic Fevers in Children (06)...8 Polymyalgia Rheumatica (07)...8 Pregnancy in Rheumatic Diseases (08)...8 Systemic Lupus Erythematosus: Novel Treatments (09)...8 Vitamin D and Bone Health (00)...8 ACR Sessions Endoplasmic Reticulum Stress Unfolded Protein Response in Immunity and Inflammation...8 Mechanisms of Pain in Rheumatic Diseases....8 Preoperative Assessment and Perioperative Management of the Patient with Rheumatic Disease: What Every Rheumatologist Should Know (Clinical Review)...8 ACR Workshops Designing a Website for Your Practice (08)....9 Muscle Involvement in Rheumatic Diseases (09)...9 Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (0)...9 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis ()...9 ACR Sessions Complementary and Alternative Medicine: Evidence-based Options for Arthritis Patients...9 Prospects for Prevention and Cure of Rheumatoid Arthritis...9 The Great Debate: In 0 what are the Roles of Cyclophosphamide versus Rituximab in ANCA-Associated Vasculitis...9 Update on Treatment of Systemic Lupus Erythematosus...9 ACR Concurrent Abstract Sessions Biology and Pathology of Bone and Joint: Osteoarthritis (#70-75)...40 Cytokines, Mediators, and Gene Regulation I (#76-740) Includes 0 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk I...40 Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease (#74-746)...4 Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes (#747-75)...4 Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies (# )...4 Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I (# )...4 Rheumatoid Arthritis Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis (# ) Program Book

6 TABLE OF CONTENTS Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis (#77-776) Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Spondyloarthritis I (#777-78)...45 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (#78-788)...45 ARHP Sessions Non-pharmacological Management of Fibomyalgia: Your Toolbox...46 Practice Managers: Improving Access and Website Marketing (Practice Management Series)...46 Rheumatic Disease Update: Inflammatory Eye Disease...46 ARHP Concurrent Abstract Sessions Foot and Gait Disorders (# )...47 Osteoarthritis (# )...47 ACR Workshops Dermatopathology of Rheumatic Diseases ()...48 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back ()...48 Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (4)...48 Synovial Fluid Analysis and Crystal Identification (5)...48 ACR Sessions Classification and Treatment of Sjögren s Syndrome...48 Metabolic Abnormalities in Autoimmunity...48 Puberty, Adolescence and Rheumatologic Disease...48 Thieves Market: Show Me Your Best Cases...49 Update on Psoriatic Arthritis and the Spondylarthropathies...49X ACR Concurrent Abstract Sessions Fibromyalgia and Soft Tissue Disorders I (#80-806)...49 Imaging of Rheumatic Diseases I: Ultrasound and X-ray (#807-8)...50 Metabolic and Crystal Arthropathies: Clinical (#8-88)...50 Osteoporosis and Metabolic Bone Disease (#89-84)...5 Rheumatoid Arthritis Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies (#85-80)...5 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities (#8-86)...5 Systemic Lupus Erythematosus Clinical Aspects and Treatment I: Renal (#87-84)...5 Systemic Lupus Erythematosus Human Etiology and Pathogenesis I (#84-848)...5 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics I (# )...54 Vasculitis: Pathogenesis (# )...55 ACR Meet the Professor Sessions Ankylosing Spondylitis: 0 Update (0)...56 Antiphospholipid Syndrome (0)...56 Crystal: Diagnosis and Management of Gout (0)...56 Immunodeficiency Syndromes (04)...56 Pain: Evaluation and Treatment of Back Pain (05)...56 Psoriatic Arthritis (06)...56 Pulmonary Hypertension in the Rheumatic Diseases (07)...56 Rheumatoid Arthritis: Challenging Cases (08)...56 Rheumatoid Arthritis: Outcome Measures in Clinical Practice (09)...56 Temporal Arteritis (00)...56 ARHP Sessions Income Inequities Are Perilous to People with Arthritis...56 Practice Management: Patients As Partners in Design and Delivery (Practice Management Series)...56 ARHP Concurrent Abstract Sessions Pediatrics: Disease Flares (#86-865) Psychological Aspects of Rheumatologic Disease (#866-87)...57 Monday, November, 0 ACR Sessions Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis...58 Cross-Sectional Imaging Techniques for Rheumatology...58 Immune Tolerance: From Theory and Clinical Practice...58 Synovial Immunobiology and Response to Therapy in Rheumatoid...58 ARHP Sessions Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care (Arthroplasty/Joint Replacement Series)...58 Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice...59 Infusion Room Information for Medical Professionals (Infusion Series)...59 New and Better Habits! Facilitating Patient Self-management with Proven Behavior Change Strategies...59 ACR Session ILAR The Current Rheumatology Workforce Across the Globe...59 ACR Meet the Professor Sessions Crystal: Diagnosis and Management of Gout (0)...60 Osteoarthritis: Update 0 (0)...60 Pediatric Rheumatology for Adult Rheumatologists (0)...60 Pediatrics: Spondylarthritis in Children (04)...60 Psoriatic Arthritis (05)...60 Rheumatoid Arthritis: Difficult Cases (06)...60 Rheumatoid Arthritis: Difficult Cases (07)...60 Scleroderma: Systemic Sclerosis (08)...60 Scleroderma: Systemic Sclerosis (09)...60 Vasculitis: Update (040)...60 ACR/ARHP Workshops Joint Injections (Knee and Ankle Prosthetics) (6)...60 Musculoskeletal Ultrasound (7)...60 Peripheral Magnetic Resonance Imaging in Rheumatology Practice (8)...60 X-ray Challenges in Rheumatic Diseases (9) Program Book

7 TABLE OF CONTENTS ACR Sessions Epigenetic Factors in Autoimmune Disease...60 New Anticoagulants: What a Hematologist Thinks a Rheumatologist Needs to Know!...6 Rheumatology Research Foundation Special Session Memorial Lectureship: Pathogenesis of Rheumatoid Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint Destruction...6 ARHP Sessions Clinical Trials: Participation and Recruitment...6 Infusion Reactions: Management and Prevention (Infusion Series)...6 Issues in the Management of Rheumatic Disease in Patients Undergoing Joint Replacement (Arthroplasty/Joint Replacement Series)...6 Rheumatic Disease Update: Gout...6 ACR Sessions Creating an Efficient Rheum Practice...6 Legislative Update from Capitol Hill...6 Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond...6 Rheumatology Research Foundation Special Session ACR REF Special Session: Clinician Scholar Educator Presentations...6 ACR/ARHP Poster Session B, Thieves Market Posters and Poster Tours Abstracts (#87-59)...6 Exhibits and Innovation Theater See page 6 of a complete listing of Innovation Theater....6 ARHP Session Distinguished Lecturer: Unraveling the Go-Gene...6 ACR Workshops Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (0)...6 Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm ()...6 ACR Plenary Session II: Discovery 0 (Abstracts #59-598)...64 ACR Sessions ACR Knowledge Bowl Final Round...68 Career Opportunities in Rheumatology: Making a Choice...69 New Developments in Systemic Juvenile Idiopathic Arthritis Management...69 The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization...69 ARHP Networking Event Networking at Noon...69 ACR Meet the Professor Sessions Ankylosing Spondylitis: 0 Update (04)...70 Basic Immunology for Clinical Rheumatologists (04)...70 Challenging Cases in Osteoporosis Management (04)...70 Dermatological Manifestations of Rheumatic Diseases (044)...70 Hereditary Angioedema (045)...70 Pulmonary Manifestations of Rheumatic Disease (046)...70 Raynaud s and Digital Ischemia (047)...70 Scleroderma Mimics (048)...70 Vaccinations for Patients on Biologic Therapies (049)...70 Vasculitis: Update (050)...70 ACR Sessions Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy: Recent Advances, Current Thoughts...70 Innovation in Musculoskeletal Curriculum Development: Lessons from New Medical Schools...70 Pediatric Rheumatology Town Hall Meeting...7 Scleroderma Bowel Disease: From Top to Bottom (Clinical Review)...7 ACR/ARHP Workshops Histopathology of Vasculitis ()...7 Joint Injections (Shoulder and Wrist Prosthetics) ()...7 MRI in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide (4)...7 ACR Sessions Curbside Consults Ask the Professors...7 Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis...7 Mechanotransduction in Bone and Cartilage...7 Neuropsychiatric Lupus in Children and Adolescents...7 Osteoporosis: From Bisphosphonates and Beyond ACR Concurrent Abstract Sessions Cell-cell Adhesion, Cell Trafficking and Angiogenesis (#599-60) Includes 0 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk II...7 Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease (# )...7 Genetics and Genomics of Rheumatic Diseases (#60-65)...7 Imaging of Rheumatic Diseases II: Magnetic Resonance Imaging (#66-6)...74 Infection-related Rheumatic Disease (#6-67)...75 Metabolic and Crystal Arthropathies: Basic Science (#68-6)...76 Rheumatoid Arthritis Animal Models (#64-69)...76 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Safety I (# )...77 Systemic Lupus Erythematosus Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy (#646-65)...78 Vasculitis: Clinical Trials (#65-657)...78 ARHP Sessions Demystifying the Study Section: How Grants Are Reviewed and Scored...79 Depression in Rheumatic Diseases...80 Minimizing Falls in Geriatric Rheumatic Populations...80 Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes Through Examination of Patient Factors, Practice Variation and Best Practice Recommendations (Arthroplasty/ Joint Replacement Series) Program Book 5

8 TABLE OF CONTENTS ACR Workshops Getting Electronic Health Records Right (5)...80 Musculoskeletal Ultrasonography: Basic (6)...80 Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data and Beyond Toward a Standard, Scientific, Quantitative Patient History (7)...8 Systemic Sclerosis: How to Perform Skin Scores (8)...8 ACR Sessions Aging and the Rheumatic Diseases...8 Dermatology Topics for Rheumatologists: What You Need to Know...8 Energetics, Metabolism and Osteoarthritis...8 Gout and Hyperuricemia: Diseases Beyond the Joint...8 Preclinical Autoimmunity Potential for Prevention...8 ACR Concurrent Abstract Sessions Cytokines, Mediators, and Gene Regulation II (#658-66) Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment (# )...8 Muscle Biology, Myositis and Myopathies: Pathogenesis in Idiopathic Inflammatory Myopathies (# )...8 Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II (#676-68)...84 Rheumatoid Arthritis Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease (#68-687)...84 Rheumatoid Arthritis Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis (#688-69)...85 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Safety II (# )...85 Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Spondyloarthritis II (# )...86 Systemic Lupus Erythematosus Clinical Aspects and Treatment III: Cardiovascular (#706-7)...87 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics II (#7-77)...87 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (05)...88 Antiphospholipid Syndrome (05)...88 Controversies in Sjögren s Syndrome (05)...88 Dermatological Manifestations of Rheumatic Diseases (054)...88 Fibromyalgia and Dysautonomia (055)...88 Pain: Evaluation and Treatment of Back Pain (056)...88 Pediatric Systemic Lupus (057)...88 Psoriatic Arthritis (058)...88 Rheumatoid Arthritis: Biological Agents (059)...88 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (060)...88 ARHP Sessions Early Rehabilitation for Hip and Foot Osteoarthritis: Opportunities and Challenges...88 Novel Approaches to Pain Management in Juvenile Idiopathic Arthritis...88 Promoting Participation: Where Is the Field and Where Do We Go Next?...89 ARHP Concurrent Abstract Session Care of Patients With Rheumatoid Arthritis (#78-7)...89 ACR Study Groups...90 Tuesday, November, 0 ACR Sessions Chronic Recurrent Multifocal Osteomyelitis...90 Molecular and Cellular Basis of Tissue Homing...9 Update on Immune Mediated Glomerular Disease...9 Rheumatology Research Foundation Special Session Paul Klemperer, MD Memorial Lectureship: Serum Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, Clinical Subsetting and Predicting Outcomes...9 ARHP Sessions Clinical and Epidemiologic Study Designs in Rheumatic Disease Research...9 Don t Let the Pink Sheets Make You Blue...9 Fungal Infections and Tuberculosis in Patients with Rheumatologic Disease (Infection Series) ACR Meet the Professors Sessions Ankylosing Spondylitis: Disease Modification (06)...9 Crystal: Diagnosis and Management of Gout (06)...9 Infections with Biologics (06)...9 Osteoarthritis: Update 0 (064)...9 Pain: Dealing with Patients with Refractory Pain in Musculoskeletal and Autoimmune Disorders (065)...9 Pediatrics: Juvenile Idiopathic Arthritis for Adult Rheumatologists (066)...9 Pregnancy in Rheumatic Diseases (067)...9 Reactive Arthritis: An Update (068)...9 Scleroderma: Systemic Sclerosis (069)...9 Vasculitis: Update (070)...9 ACR/ARHP Workshops Adult Musculoskeletal Lower Examinations (9)...9 Knee Braces and Foot Orthosis for Knee Osteoarthritis (0)...9 Peripheral Magnetic Resonance Imaging in Rheumatology Practice ()...9 Synovial Fluid Analysis and Crystal Identification ()...9 ACR Sessions Advances in Targeting of B cell Survival Factors...9 Systems Immunology ARHP Sessions Hepatitis in Patients with Rheumatologic Disease (Infection Series)...9 Rheumatic Disease Update: The Approach to Low Back Pain...9 Threats to Validity: Confounding in Rheumatic Disease Research (Research Series)...9 ACR Sessions Contract Negotiations for Physicians...9 Paradigm Shifts in Rheumatoid Arthritis...9 The Guide to Meaningful Use and Beyond Program Book

9 TABLE OF CONTENTS Rheumatology Research Foundation Special Session Disease Targeted Research...94 ARHP Concurrent Abstract Sessions Physical/Occupational Therapy and Exercise in Patients with Rhematologic Disease (#4-46)...94 Programs and Literacy in Patients with Rheumatolgic Diseases (#47-44)...94 ACR/ARHP Poster Session C, Thieves Market Posters and Poster Tours Abstracts (#74-40)...95 Exhibits and Innovation Theater See page 6 of a complete listing of Innovation Theater ACR Session Gouty Inflammation...96 ARHP Sessions Immunizations in Patients with Rheumatologic Disease (Infection Series)...96 Selection Bias in Rheumatic Disease Research Risk Factor Paradox and Other Issues...96 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Rehabilitation Abstract Session (#44-448)...96 ACR Workshops Histopathology of Vasculitis ()...97 Joint Injection Techniques (4)...97 ARHP Sessions A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective...97 Strategies to Enhance Office Efficiencies and Access to Care in Rheumatology Practice...97 ACR Plenary Session III: Discovery 0 Abstracts (# )...97 ACR Sessions Microbiome Influence on Autoimmunity...0 Polymyalgia Rheumatica Recent Advances and Ongoing Questions... 0 Top 0 Compliance Risks Facing Physicians...0 ARHP Networking Event Networking Break...0 ACR Meet the Professor Sessions Basic Immunology for Clinical Rheumatologists (07)...0 Fibromyalgia and Dysautonomia (07)...0 Myopathy: Issues in Diagnosis and Treatment (07)...0 Rheumatoid Arthritis: Challenging Cases (074)...0 Rheumatoid Arthritis: Safety of Novel Therapies (075)...0 Systemic Lupus Erythematosus: Central Nervous System (076)...0 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (077)...0 Systemic Lupus Erythematosus: Lupus Nephritis (078)...0 Temporal Arteritis (079)...0 Vasculitis: Update (080)...0 ACR Sessions Catastrophic Antiphospholipid Syndrome (Clinical Review)...0 Osteoimmunology...0 ACR Study Groups...0 ACR/ARHP Workshops Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (5)...0 MRI in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide(6)...0 Synovial Fluid Analysis and Crystal Identification (7)...0 Web-based Tools for Enhancing and Managing Teaching and Clinical Practice (8)...0 ACR Session ACR Leadership Town Hall Meeting & Business Meeting...0 ACR Sessions Approach and Management of Back Pain in Older Adults...0 Connective Tissue Disease Associated Interstitial Lung Disease...04 New Molecules in Joint Biology...04 Visualizing the Immuno-inflammatory Response...04 ACR Concurrent Abstract Sessions ACR Late-breaking Abstract Session...04 Antiphospholipid Syndrome (# )...04 Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease (#46-466)...05 Osteoarthritis Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments (#467-47)...05 Pediatric Rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus Erythematosus and Other Vasculitides (#47-478)...06 Rheumatoid Arthritis Clinical Aspects IV: Non-biologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events (# )...07 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase (JAK) Inhibitors (# )...08 Spondyloarthritis and Psoriatic Arthritis Pathogenesis, Etiology (#49-496)...08 Systemic Lupus Erythematosus Human Etiology and Pathogenesis II (#497-50)...09 T-cell Biology and Targets in Autoimmune Disease (#50-508)...09 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Epidemiology Abstract Session (#509-54).. 0 ARHP Sessions Myositis: Pathogenesis, Diagnosis and Management...0 Rheumatic Disease Update: Systemic Lupus Erythematosus... Rheumatoid Arthritis Disease Activity Measures and Quality Indicators: Correct Use and Future Directions... Transition Tools for Patients: Pediatric to Adults... ACR Workshop Joint Injection Techniques (9)... 0 Program Book 7

10 TABLE OF CONTENTS 8 ARHP Session Obesity: It is a Chronic Disease... ACR Session Diagnostic Assessments in Myopathy... MicroRNA and the Rheumatic Diseases... Should Ultrasound be Used in Rheumatology Practice?... The Great Masqueraders: Malignancies in Rheumatic Disease... ACR Concurrent Abstract Sessions Biology and Pathology of Bone and Joint: Regulation of Bone Cells (#55-50)... Innate Immunity and Rheumatic Disease (#5-56)... Miscellaneous Rheumatic and Inflammatory I (#57-5)... Osteoarthritis Clinical Aspects I: Weight, Activity, and Metabolic Effects on Osteoarthritis (#5-58)...4 Rheumatoid Arthritis Clinical Aspects V: Comorbidities in Rheumatoid Arthritis (#59-544)...5 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics (# )...5 Sjögren s Syndrome II Clinical (#55-556)...6 Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Psoriatic Arthritis (#557-56)...7 Vasculitis: Clinical Aspects (#56-568)...8 ACR Meet the Professor Sessions Central Nervous System Vasculitis (08)...9 Crystal: Pseudogout (08)...9 Effective Use of Technology (08) Pulmonary Manifestations of Rheumatic Disease (084)...9 Raynaud s and Digital Ischemia (085)...9 Rheumatoid Arthritis: Safety of Novel Therapies (086)...9 Rheumatology Practice 0: Starting Out in Practice for The Graduating Fellow (087)...9 Systemic Lupus Erythematosus: Lupus Nephritis (088)...9 Systemic Lupus Erythematosus: Novel Treatments (089)...9 Vaccinations for Patients on Biologic Therapies (090)...9 Rheumatology Research Foundation Special Session Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloriquine Reduces Thrombosis in Systemic Lupus Erythematosis Particulerly in Antiphospholipid Positive Patients (# )...9 ARHP Sessions Arthritis and the Older Worker...0 Best Practices for Ordering Diagnostic Imaging in Evaluating Rheumatologic Conditions...0 The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together...0 Wednesday, November 4, 0 ACR Sessions Immunology of Pregnancy and Impact on Autoimmune Pathogenesis... Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease... Rheumatology Roundup: Highlights from the 0 Annual Scientific Meeting... 0 Program Book The Unintended Consequences of Health Information Technology... ARHP Sessions An Introduction to Immunology... Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems (Research Series)... ACR Sessions Biosimilars Development: Food and Drug Administration Perspective... IgG4-Related Disease Past Lessons and Future Directions... NIAMS-Sponsored Research in Rheumatology: 0 Highlights... Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?... Predictive Biomarkers: A Journey to Personalized Health Care... ACR Concurrent Abstract Sessions B-cell Biology and Targets in Autoimmune Disease (# )... Imaging of Rheumatic Diseases III: Computed Tomography (#58-586)... Medical Education (#587-59)...4 Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response (#59-598)...4 Quality Measures and Innovations in Practice Management and Care Delivery (# )...5 Rheumatoid Arthritis Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis (#605-60)...6 Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: Psoriatic Arthritis and Spondylarthritis (#6-66)...6 Systemic Lupus Erythematosus Clinical Aspects and Treatment IV: Therapeutics (#67-6)...7 ARHP Sessions Forming An Education and Support Group from the Ground Up...8 Osteoporosis: 0 Update...8 ARHP Concurrent Abstract Sessions Systemic Sclerosis, Vasculitis, Crohn s and Spondylarthropathies (#6-68)...8 Clinical and Rehabilitative Aspects of Osteoarthritis (#69-64)...9 ACR Sessions Amyloidosis Mechanisms of Autoinflammatory Diseases...9 ACR Sessions Making Sense of Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases...9 Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice...0 ACR Concurrent Abstract Sessions Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treat-to-Target Era (#65-640)...0 Fibromyalgia and Soft Tissue Disorders II (#64-646)...0 Orthopedics, Low Back Pain, and Rehabilitation (#647-65)... Pediatric Rheumatology Pathogenesis and Genetics (#65-658)...

11 TABLE OF CONTENTS Rheumatoid Arthritis Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis (# )... Rheumatoid Arthritis Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies (# )... Sjögren s Syndrome I Pathogenesis (#67-676)...4 Systemic Lupus Erythematosus Animal Models (#677-68)...5 Systemic Lupus Erythematosus Clinical Aspects and Treatment V: Clinical Aspects (#68-688)...5 ARHP Sessions Highlights from the 0 ARHP Sessions...6 Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis...6 ARHP Concurrent Abstract Sessions Factors Associated with Rheumatoid Arthritis (# )...6 Systemic Lupus Erythematosus (# )...7 ACR POSTER SESSION A (Abstracts # -74) Biology and Pathology of Bone and Joint (Abstracts # -5)...8 Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I (Abstracts # 5-0)...4 Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging (Abstracts # 0-)...46 Metabolic and Crystal Arthropathies (Abstracts # 4-70)...49 Infection-related Rheumatic Disease (Abstracts # 7-78)...5 Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes (Abstracts #79-04)...5 Muscle Biology, Myositis and Myopathies: Clinical and Therapeutic Aspects of Idiopathic Inflammatory Myopathies (Abstracts # 05-)...54 Osteoarthritis Clinical Aspects (Abstracts # 4-7)...56 Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis (Abstracts # 74-07)...59 Pediatric Rheumatology Pathogenesis and Genetics (Abstracts # 08-5)...6 Rheumatoid Arthritis: Animal Models (Abstracts # 6-47)...6 Rheumatoid Arthritis Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission (Abstracts # )...65 Rheumatoid Arthritis Human Etiology and Pathogenesis (Abstracts # )...70 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy (Abstracts # )...7 Sjögren s Syndrome Pathogenesis (Abstracts # )...79 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (Abstracts # 5-579)...8 Spondylarthritis and Psoriatic Arthritis Pathogenesis, Etiology (Abstracts # )...86 Systemic Lupus Erythematosus: Clinical Aspects (Abstracts # )...87 Systemic Lupus Erythematosus Human Etiology and Pathogenesis (Abstracts # )...9 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics (Abstracts # 69-74)...94 ACR/ARHP POSTER SESSION B (Abstracts # 87-59) Cytokines, Mediators, and Gene Regulation (Abstracts # 87-90)...98 Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II (Abstracts # )...00 Fibromyalgia and Soft Tissue Disorders (Abstracts # )...0 Genetics and Genomics of Rheumatic Diseases (Abstracts # )...04 Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, Computed Tomography and X-ray (Abstracts # )...09 Innate Immunity and Rheumatic Disease (Abstracts # )... Orthopedics, Low Back Pain, and Rehabilitation Poster (Abstracts # )...5 Osteoarthritis Clinical Aspects (Abstracts # 097-8)...6 Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis (Abstracts # 9-74)...9 Rheumatoid Arthritis Human Etiology and Pathogenesis (Abstracts # 75-)... Rheumatoid Arthritis Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease (Abstracts # -70)...5 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy (Abstracts # 7-4)...0 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (Abstracts # 4-85)...8 Systemic Lupus Erythematosus: Clinical Aspects (Abstracts # 86-47)...4 Systemic Lupus Erythematosus Animal Models (Abstracts # )...46 Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics (Abstracts # )...47 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (Abstracts # 490-5) Program Book 9

12 TABLE OF CONTENTS Vasculitis (Abstracts # 5-55)...5 Clinical Practice/Patient Care (Abstracts # )...55 Rehabilitation Sciences (Abstracts # )...57 ACR/ARHP POSTER SESSION C (Abstracts # 74-40) Antiphospholipid Syndrome (Abstracts # )...59 B-cell Biology and Targets in Autoimmune Disease (Abstracts # )...60 Cell-cell Adhesion, Cell Trafficking and Angiogenesis (Abstracts # )...6 Cytokines, Mediators, and Gene Regulation (Abstracts # 78-8)...6 Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology (Abstracts # 8-856)...65 Fibromyalgia and Soft Tissue Disorders (Abstracts # )...69 Medical Education (Abstracts # )...70 Metabolic and Crystal Arthropathies (Abstracts # 90-96)...7 Miscellaneous Rheumatic and Inflammatory Diseases (Abstracts #97-94)...7 Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models (Abstracts # )...74 Osteoporosis and Metabolic Bone Disease (Abstracts # )...76 Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases (Abstracts # )...79 Quality Measures and Innovations in Practice Management and Care Delivery (Abstracts # )...8 Rheumatoid Arthritis: Animal Models (Abstracts # )...85 Rheumatoid Arthritis Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/ Predictors of Rheumatoid Arthritis Activity & Severity (Abstracts # 09-48)...87 Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy (Abstracts # 49-7)...9 Sjögren s Syndrome Clinical (Abstracts # 74-05)...94 Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (Abstracts # 06-5)...97 Systemic Lupus Erythematosus: Clinical Aspects (Abstracts # 6-66)...00 Systemic Lupus Erythematosus Human Etiology and Pathogenesis (Abstracts # 67-85)...0 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (Abstracts # T-cell Biology and Targets in Autoimmune Disease (Abstracts # 0-46)...06 Vasculitis (Abstracts # 47-98)...09 Education/Community Programs (Abstracts # )... Epidemiology and Public Health (Abstracts # )...4 Pediatrics (Abstracts # 40-4)...5 Psychology/Social Sciences (Abstracts # 4-40)...5 INNOVATION THEATER LISTING...6 INDUSTRY-SUPPORTED SYMPOSIA... CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statements...7 Meeting Evaluations, CME Credit/Certificates for Participation... Conflict of Interest /Disclosure Statements... Disclosure Policy... RECOGNITION ACR/ARHP Annual Meeting Leadership...4 Exhibitors... Supporter Acknowledgements...5 INDICIES Invited Speaker Moderator Index...7 ACR/ARHP Abstract Author Index...55 ACR/ARHP Abstract Moderator Index Program Book

13 The most comprehensive online collection of rheumatology-related images. Serving as a centralized resource for clinicians, researchers and health care professionals, the Rheumatology Image Bank provides invaluable assistance in self-study or the education of others. Start your visual exploration of rheumatology today at Stop by the ACR Resource Center, located on the L Street Bridge (Level ), and speak with staff to learn more about the Rheumatology Image Bank and all it can offer you. COPYRIGHT MATERIALS POLICY The annual meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the ACR. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced, or distributed without written permission of the ACR and the presenter. Any use of the program content for commercial purposes, which includes, but is not limited to oral presentations, audiovisual materials used by speakers, and program handouts without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it. The names, insignias, logos and acronyms of the ACR, the ARHP and the RRF are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the express written permission of the ACR. MEDIA Credentialed media attend the annual meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their black press ribbons. Media has access to all general sessions and limited access (at the discretion of speakers) to meet the Professor and Workshop sessions. Media may use hand-held audio recorders and still cameras; moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that no photos or video are allowed in the exhibit hall. Press who would like general photos of the exhibit hall can obtain these after the meeting from the ACR. Attendees who have questions about the ACR s media policies should contact Suzanne Forte at sforte@rheumatology.org. EMBARGO POLICY Accepted abstracts are made available to the public online in advance of the meeting and are published in a special supplement of Arthritis & Rheumatism. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release 0 Program Book

14 to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until 4:0 PM Eastern Time on Saturday, November 0, 0. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices As a courtesy to meeting attendees, electronic devices must be operated in silent/vibrate mode within educational sessions; devices that beep, ring, etc. are prohibited. Cell phone conversations are not permitted in meeting rooms. Children For safety reasons, strollers are not permitted in the exhibit hall and all children must be accompanied by an adult. Only registered attendees will be permitted into meeting rooms. Child Care KiddieCorp is providing child care services for our attendees during meeting hours. If you did not reserve space in advance, you can inquire about space availability by calling (0) Nursing Mothers Room During scientific session hours, a staffed Nursing Mothers room will be available in Salon D. This room will have a private seating area, a refrigerator and a bulletin board for information exchange, advice and suggestions. Exhibit Hall The 0 exhibit hall is located in Hall A. See page for more information. Exhibit Hall hours: Sunday, November... 0:00 AM 5:00 PM Monday, November... 0:00 AM 5:00 PM Tuesday, November... 0:00 AM 5:00 PM Meeting Room Capacity/Important Fire Safety Information Attendance at scientific sessions is on a first-come, first-served basis. Rooms which have reached the maximum capacity may be closed according to local fire and safety regulations. Standing in the aisle or against the walls is not permitted. If overcrowding occurs, staff/security personnel will close the session. If space does not permit you to attend a session, the session may be available on SessionSelect or replayed in the SessionSelect Lounge located in the West Overlook (nd Floor) of the convention center. Photography and Videotaping Photographers will be present at the meeting. Registration and attendance at, or participation in, ACR meetings and other activities constitutes an agreement by the registrant for the ACR s use and distribution (both now and in the future) of the registrant or attendee s image or voice in photographs, videotapes, electronic reproductions, and audio tapes of such events and activities. Visual reproduction of sessions is prohibited without prior written permission of the ACR. The ACR reserves the rights to audio and video reproduction at the 0 ACR/ARHP Annual Meeting. See copyrighted materials policy for more information on page. Name Badges For security reasons, your badge will be required for admittance to all sessions, exhibits, social events and shuttle buses. Please wear your badge so it can be easily seen at all times. Lost badges should be reported to the registration staff immediately. No Smoking All meeting facilities at the convention center, hotel meeting rooms and other venues have been designated as non-smoking areas. 0 Program Book

15 MEETING NAVIGATION GUIDE Use the following track icons to help you identify the most relevant content based on your specialty. PM Basic Science Business/Administration Clinical Practice Clinical Science PAIN MANAGEMENT The ACR designates certain sessions for pain management credit as required by the Medical Board of California (AB487). This designation is identified by the icon shown and will be placed next to the session title. PS PATIENT SAFETY The ACR designates certain sessions that will satisfy patient safety/risk management requirements of the Medical Board of Pennsylvania. This designation is identified by the icon shown and will be placed next to the session title. SESSION FORMATS Basic Science Symposia provide an update of the most recent scientific developments in the field of rheumatology. Clinical Symposia provide instruction to improve patient care. Developments from other specialties and practical patient management skills will be emphasized. Included are Clinical Reviews. Concurrent Sessions offer educational programs of interest to various health professionals. Concurrent sessions include invited speakers; peer-reviewed programs and lectures; research and special interest abstract sessions. Exhibits and Industry-Supported Sessions provide attendees with an opportunity to learn about the latest technological advances in the treatment of rheumatic diseases within the exhibit hall via various exhibitions and non-cme sessions in the Innovation Theater, as well as evening and post-meeting symposia. Meet the Professor Sessions provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. Networking Events provide unique opportunities to socialize and network with peers in smaller group settings. Pre-Meeting Courses offer attendees, with a specific interest, a unique learning opportunity. A separate registration is required. Study Groups bring together attendees with a common interest in one disease, a group of related disorders, or a specialized field of study for discussion and dissemination of information. Workshops foster hands-on learning, and provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. ABSTRACT FORMATS Late-Breaking Session features truly late-breaking research. Oral Presentations are the main forum for didactic presentation of original research related to rheumatic diseases. Plenary Sessions highlight abstracts of significant novelty and importance. There will be three theme-based sessions offered. Poster Presentations feature poster displays of abstracts, while facilitating one-on-one interaction between the presenter and the audience. Poster Tours are small groups guided by experts in a particular field. Each tour will highlight selected posters of novel or recent developments within an abstract category. There is no additional cost to participate, although a separate registration is required. 0 Program Book

16 ACR Resource Center Stop by the acr Resource Center to see what s new with the College! We re located on the L Street Bridge (Level ). Within the Resource Center you can: Demo popular online products and receive daily giveaways Get details about educational activities in 0 Speak with key representatives from the ACR and ARHP journals Learn about the latest advocacy efforts Enroll in the new ACR Rheumatology Musculoskeletal Ultrasound Certification program Get answers to your coding and billing questions Collect complimentary product brochures, publications and patient education materials Speak with ACR staff about health information technology, new initiatives, CME, MOC and much more Come discover all the College offers you, your patients and your practice at the Resource Center where the resources you need are all in one place! Resource Center Hours: Saturday, November 0 Sunday, November Monday, November Tuesday, November Wednesday, November 4 7:00 am - 6:0 pm 7:00 am - 6:0 pm 7:00 am - 6:0 pm 7:00 am - 6:0 pm 7:00 am - :00 pm Located on the L Street Bridge (Level )

17 MEETING SERVICES My Annual Meeting Everything You Need, in One Place Search the program, access syllabi, view abstracts, track your CME and retrieve recorded sessions on SessionSelect. See page 8 for more information on SessionSelect. Resource Center The Spot for All Things ACR! Resource Center Hours: Saturday, November :00 AM 6:0 PM Sunday, November... 7:00 AM 6:0 PM Monday, November... 7:00 AM 6:0 PM Tuesday, November... 7:00 AM 6:0 PM Wednesday, November 4...7:00 AM :00 PM Stop by the Resource Center, located on the L Street Bridge (Level ), to learn more about the exceptional services the College has to offer and the exciting new initiatives under way. Staff will demonstrate popular online resources, provide information and answer any questions you may have. The Resource Center has it all in one place! See page 4 for more information. Look for these specific areas in the Resource Center: Advocacy Get the most up-to-date information on the legislative and regulatory issues affecting your profession. We have talking points on all ACR legislative priorities and tips on how to get more involved with the ACR s advocacy efforts. You can also receive information on RheumPAC the ACR s political action committee. College Showcase Throughout the week, recordings of sessions will be replayed. ACR staff will also present interactive demonstrations of educational resources and practice tools. Quality & Informatics Learn how enrollment in the Rheumatology Clinical Registry can benefit you by providing hands-on measurement tools and reports that enable you to comparatively assess the quality and outcome of rheumatologic care you provide. Plan on attending interactive demonstrations of this tool offered throughout the week. Recertification Need help navigating Maintenance of Certification? We have answers to help steer your route to success with the American Board of Internal Medicine s Maintenance of Certification program. An ABIM representative will be on-site throughout the week to help answer your questions. Musculoskeletal Ultrasound Certification NEW! Interested in certifying in ultrasound? The ACR is providing a voluntary pathway for physicians, physician assistants and nurse practitioners who perform ultrasound as part of their practice in rheumatology to demonstrate competence to patients, peers and payers through its first certification program. Stop by the ACR Rheumatology Musculoskeletal Ultrasound Certification kiosk to enroll in the first exam and learn more about the program. Membership Booth Located in the registration hall (Salons G-H-I ), this is the place to go if you want to become a member, pay dues, reinstate your membership, learn more about member benefits and awards, or volunteer to serve on a committee. Lost and Found Found items should be returned to the ACR Office, room 0A. If you are looking for a lost item, go to the ACR Office or call (0) Lupus Initiative This educational initiative, designed to reduce health disparities in lupus based on gender, race and ethnicity, will offer demonstrations of educational resources for health professionals in training and in practice. Lupus experts are encouraged to drop by to participate in our online discussion. Practice Management & Coding Visit with ACR certified coders and practice management experts for any coding, billing, insurance or practice management questions. We have all the resources you need for an efficient rheumatology practice. You can also pick up the latest copy of the ACR s monthly RheumWATCH. Publications The editorial office staff of the Arthritis & Rheumatism and Arthritis Care & Research journals will be available to answer questions concerning online article submission and article review processes for the journals. 0 Program Book 5

18 Newsroom Located in room 0A-B, use of the Newsroom is limited to media representatives with press passes. Attendee Lounge Across from the Ballroom, attendees are welcome to relax and enjoy seating while networking with colleagues, checking , and recharging their laptops or smartphones. Announcement Boards Located in the Ballroom South Prefunction (attendee lounge), display boards will be available for posting announcements and events of interest. Posted materials are limited to 8.5 x in size. Job postings are not permitted. Career Connection Employers and candidates are encouraged to take advantage of the Career Connection located in the exhibit hall (Hall A, Booth 945) to post position openings, search nationwide rheumatology career opportunities and much more. On Tuesday, November, potential employers and candidates can meet in the exhibit hall and enjoy a complimentary boxed lunch (provided to the first 00 participants) while discussing career opportunities. During this time employers can distribute handouts, flyers or business cards to potential candidates. Career Connection Hours: Sunday, November... 0:00 AM 5:00 PM Monday, November... 0:00 AM 5:00 PM Tuesday, November... 0:00 AM 5:00 PM Registration Registration counters are located in the registration hall (Salons G-H-I). Registration Hours: Friday, November :0 AM 6:00 PM Saturday, November :0 AM 6:0 PM Sunday, November... 6:0 AM 6:00 PM Monday, November... 6:0 AM 6:00 PM Tuesday, November... 6:0 AM 6:00 PM Wednesday, November 4...7:00 AM :00 PM Shuttle Bus Shuttle service will be provided to and from the Walter E. Washington Convention Center and ACR hotels which are designated as non-walking hotels. On Friday, Saturday and Wednesday service operates continuously. On Sunday through Tuesday, service operates from 6:0 0:0 AM and :0 6:0 PM. Special service will be provided on Saturday, November 0 to and from the Opening Event at the Newseum. Full shuttle service information will be posted in ACR hotel lobbies, at the shuttle bus entrance of the convention center and online. This service is complimentary for attendees and registered guests who booked their rooms through ACR Housing. Attendees who have booked their rooms on their own in contracted or noncontracted ACR hotels may purchase an ACR shuttle bus pass at the ACR registration counter for $40. Speaker Ready Room Located in room 56. Check-in is expected of all speakers. Plan to check in hours prior to your presentation time. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual technicians will be available to assist you. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems and make corrections as necessary before your presentation. Speaker Ready Room Hours: Friday, November :0 AM 6:00 PM Saturday, November :0 AM 6:0 PM Sunday, November... 6:0 AM 6:00 PM Monday, November... 6:0 AM 8:00 PM Tuesday, November... 6:0 AM 6:00 PM Wednesday, November 4...7:00 AM :0 PM Wi-Fi Way and Recharge Access Complimentary Wi-Fi access is available in all rooms of the convention center. Recharge areas will be available in the exhibit hall (hall A), poster hall (Hall B), attendee lounge and in large meeting rooms. Park benches, banquet rounds and cocktail tables comprise seating in the new exhibit hall Wi-Fi Way where attendees can enjoy the flurry of activity while surfing the Internet, checking and recharging electronic items. 6 0 Program Book

19 Rheumatology Research Foundation formerly the ACR Research and Education Foundation Visit our Booth Visit the Rheumatology Research Foundation booth located on the L Street Bridge (Level ) to find out more about what we are doing to advance treatment and find cures for rheumatic disease. View and order the latest poster in the Rodnan Commemorative Gout Print poster series, learn more about our programs and initiatives, and even receive a gift just for stopping by! Foundation Booth Hours: Saturday, November :00 AM 6:0 PM Sunday, November... 7:00 AM 6:0 PM Monday, November... 7:00 AM 6:0 PM Tuesday, November... 7:00 AM 6:0 PM Wednesday, November 4...7:00 AM :00 PM Visit the Donors Lounge Plan to spend time in the Foundation Donors Lounge, located in the East Overlook (nd Floor), and take advantage of special perks! Enjoy a hot breakfast each morning and gourmet afternoon coffee service; catch up on work and check at one of the private computer stations; or relax by watching some television and catching up with your colleagues. An official 0 Donors Lounge Access Pass is required for entry and will be distributed to qualified donors at the meeting. A minimum cumulative donation of $500 to the Rheumatology Research Foundation during fiscal year 0 (July, 0 through June 0, 0) qualifies. Donors Lounge Hours: Saturday, November 0... Noon 5:00 PM Sunday, November... 7:00 AM 6:00 PM Monday, November... 7:00 AM 6:00 PM Tuesday, November... 7:00 AM 6:00 PM Wednesday, November 4...7:00 AM :0 PM Participate in the 5K Run/Walk Sunday, November 6:00 7:0 AM The Yards Park We invite you to experience D.C. s newest waterfront destination while supporting rheumatology training and career development. The 5K Run/Walk will take place at the Yards Park, the centerpiece of the Capitol Riverfront neighborhood located just south of Capitol Hill. Participants may register at the 5K Run/Walk Booth until 5:00 PM on Saturday, November 0. Registration is $40 and subject to space availability. Complimentary shuttle service to and from the park is provided. Participants will receive an official Rheumatology Research Foundation 5K Run/Walk T-shirt. All proceeds support activities, grants and awards provided by the Foundation. 0 Program Book 7

20 Maximize Your Learning Opportunities with SessionSelect! VIP ACCESS! Annual meeting registration fee includes automatic access to SessionSelect. SessionSelect is a comprehensive digital library of presentations from the annual meeting. View hundreds of hours of fully-synchronized presentations with speaker slides and audio just as if you were actually in the room. With SessionSelect you can: Access sessions online within 4 hours of the live session Review all or part of key educational sessions at your own pace View content on your mobile device or download MP files for listening to audio on-the-go NEW for 0! SessionSelect Lounges Got some down time between sessions? Kick-back while you replay sessions on YOUR demand in the new SessionSelect lounges, located in the West Overlook (nd Floor) and Exhibit Hall (Hall A). CME Available Ten sessions from this year s annual meeting are available for CME credit. Go to for a list of sessions. To learn more about SessionSelect or to view a demo, stop by the Resource Center located on the L Street Bridge (Level ).

21 SPECIAL OFFERS AT THE ANNUAL MEETING SessionSelect no need to miss a session! Within 4 hours of virtually every live session at the annual meeting, video recordings of the presentations, including oral abstracts, will be available through SessionSelect, your source for ACR education, online. As a scientific attendee, you get FREE online access for one year to hundreds of hours of annual meeting content over $500 of added value. Select sessions will be recorded and available to view as webcasts during and after the meeting. Therefore, if you missed one of the designated sessions, you can watch it the next day through SessionSelect. You can also catch replays of select sessions from SessionSelect in the new SessionSelect lounges located in the West Overlook (nd Floor) and inside the exhibit hall, Hall A. Check these specific areas for a tentative schedule of sessions. Please note, recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in this offer. What Would Make This Meeting Better? You ve got ideas to share, and we ve made it easy for you to share them. Post a suggestion one of the graffiti walls for all to see. Tweet your idea using the #ACR0 hashtag. Drop a comment into one of the idea boxes around the convention center. Medical Bag Don t forget to pick up a Medical Bag prior to visiting the exhibits. Each bag contains special offers and invitations from our exhibitors and will be distributed from the exhibition entrance while supplies last. POSTER SESSIONS Poster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and will remain displayed in the poster hall (Hall B) of the convention center from 9:00 AM 6:00 PM, Sunday, November Tuesday, November. One poster session will be held each day. Presenting authors must be available at their poster from 9:00 :00 AM to answer questions from meeting attendees as well as poster tour participants. There is no poster session on Wednesday. The number on the poster boards refers to the abstract presentation number, and this number will change for each poster session. New this year! Thieves market poster sessions will be held on Sunday, November and Monday, November. Poster Session Presenter Instructions Posters must be mounted by 8:0 AM and dismantled after 6:00 PM during the designated poster session as outlined in the abstract acceptance notification. Posters not picked up after 6:00 PM on Tuesday, November will be recycled. In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00 :00 AM for poster presentations. Poster presenter ribbons will be available in the Speaker Ready Room (room 56). If you elected to have your poster printed by the official ACR/ARHP poster printing service they will hang, take down and store your poster for you. ACR Poster Presenter No-show Policy Please note that the ACR will be monitoring posters during presentation hours in an effort to make certain that the ACR is meeting the educational needs and expectations of attendees. Poster Sessions Sunday, November through Tuesday, November from 9:00 AM 6:00 PM (Posters to remain up until 6:00 pm.) Set Up:... 7:00 8:0 AM Presentation: :00 :00 AM Poster Tours:... 9:00 9:45 AM 0:5 :00 AM Removal:...6:00 6:0 PM Guided Poster Tours Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours. Although there is no fee to participate, pre-registration is required and each tour is limited to 0 registered scientific attendees. If you would like to participate and have not registered you can check tour availability and request a ticket at registration, located in Salons G-H-I. If you registered in advance of the meeting, your ticket was included with your meeting materials. Once you have your ticket, plan to collect your headset and meet your group 0 minutes before your tour departs from the entrance of the poster hall, located in Hall B. 0 Program Book 9

22 FRIDAY November 9, 0 Call for Proposals and Study Group Applications Submission Deadline: Friday, December 4, 0 at noon. This is your opportunity to share your ideas and make a contribution to the 0 Annual Meeting. To view instructions and submit a session proposal, visit Coordinate a study group and create a unique networking opportunity for your colleagues. To view the guidelines and submit an application, visit acr/arhp scientific sessions FRIDAY, NOVEMBER 9, 0 ACR/ARHP REGISTRATION 6:0 am - 6:00 pm Registration Hall (Salons G-H-I) ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS - DAY ONE 7:0 am - 5:0 pm 07 A Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Faculty: Rany Al Haj, MD; David A. Bong, MD; George A.W. Bruyn, MD, PhD; Arnold Ceponis, MD, PhD; Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary Kunkel, MD; Bethany A. Marston, MD; Esperanza Naredo, MD; Anthony M. Reginato, MD, PhD; Johannes Roth, MD; Jonathan Samuels, MD; Wolfgang A. Schmidt, MD; Richard J. Wakefield, BM, MD; Darren Tabechian, MD; Mihaela Taylor, MD; Nikolay Tzaribachev, MD; Alvin F. Wells, MD, PhD Upon completion of this session, participants should be able to: demonstrate proper ultrasound exam technique and procedure guidance applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound 7:00-7:0 AM Continental Breakfast Moderator: Amy M. Evangelisto, MD 7:0 AM Opening Remarks Amy M. Evangelisto, MD Break Out Session: Adult Rheumatology 7:45 AM Principles of Musculoskeletal Ultrasound for Rheumatologists Wolfgang A. Schmidt, MD 8:5 AM Introduction to Typical Sonographic Findings in Rheumatology Esperanza Naredo, MD 0 0 Program Book

23 8:45 AM Image Acquisition and Ultrasound Technique Richard J. Wakefield, BM, MD 9:5 AM Hands-on Scanning: Image Acquisition and Ultrasound Technique Faculty :5 - :0 PM Break Hand and Wrist :0 PM Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology George A. W. Bruyn, MD, PhD November 9, 0 FRIDAY Break Out Session: Pediatric Rheumatology 7:45 AM Principles of Ultrasound in Pediatric Rheumatology Johannes Roth, MD 8:5 AM Ultrasound and MRI in Pediatric Rheumatology Nikolay Tzaribachev, MD 8:45 AM Sonographic Anatomy in Pediatric Rheumatology Johannes Roth, MD 9:0 AM Hands-on Scanning: Image Acquisition and Ultrasound Technique Johannes Roth, MD; Nikolay Tzaribachev, MD; Bethany A. Marston, MD 0:00-0:5 AM Break The Shoulder 0:5 AM Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Gurjit S. Kaeley, MBBS 0:45 AM Demonstration: Scanning of the Shoulder Esperanza Naredo, MD :00 AM Hands-on Scanning: The Shoulder Faculty :0 - :0 PM Boxed Lunch Moderator: Gurjit S. Kaeley, MBBS The Elbow :0 PM Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Amy M. Evangelisto, MD :00 PM Demonstration: Scanning of the Elbow Jonathan Samuels, MD :5 PM Hands-on Scanning: The Elbow 4:00 PM Demonstration: Hand and Wrist Minna J. Kohler, MD 4:5 PM Hands-on Scanning: Hand and Wrist Faculty ACR CERTIFIED RHEUMATOLOGY CODER COURSE: UNLOCK THE MYSTERY: A ROADMAP FOR RHEUMATOLOGY CODING DAY ONE PS 9:00 AM - 5:00 PM 50 B Admission to the ACR Certified Rheumatology Coder Course requires a separate registration. Registration includes a boxed lunch. This course is not eligible for CME credit. Upon completion of this session, participants should be able to: exhibit proficiency in adjudicating claims for accurate medical coding for diagnoses, procedures and services in physicianbased settings display proficiency across a wide range of services, which include evaluation and management, surgical services, radiology, pathology and medicine demonstrate knowledge of medical coding rules and regulations including compliance and reimbursement distinguish how to integrate medical coding and reimbursement rule changes into a practice s reimbursement process Speakers: Antanya Chung, CPC, CPC-I, CRHC, CCP and Melesia Tillman, CPC, CRHC, CHA ACR/ABIM MAINTENANCE OF CERTIFICATION LEARNING SESSION - 0 UPDATE IN RHEUMATOLOGY :00-6:00 PM 46 C Admission to the ACR/ABIM MOC Learning Session requires a separate registration. Learn in an interactive environment as clinical experts lead you through 0 case-based questions from ABIM s 0 Update in Rheumatology Module. After the session, submit your answers online to the ABIM to receive 0 medical knowledge points for the Maintenance of Certification program. Moderator: Carol A. Langford, MD, MHS 0 Program Book

24 FRIDAY November 9, 0 Upon completion of this session, participants should be able to: assess strengths and weaknesses in rheumatology medical base knowledge state major developments in rheumatology over the past ten years satisfy a self-evaluation requirement for the American Board of Internal Medicine Maintenance of Certification program Overview and Session I :00 PM Questions from 0 Update:, 9, 5, 6, 8, 9,, 6, 8, 9 Carol A. Langford, MD, MHS :40 - :00 PM Break Session II :00 PM Questions from 0 Update:, 8,, 4, 0,,, 4, 5, 7 Mary Chester Wasko, MD, MSc Session III 4:0 PM Questions from 0 Update:, 4, 5, 6, 7, 0,,, 7, 0 Seetha U. Monrad, MD 6:00 PM Wrap-up ACR BASIC RESEARCH CONFERENCE: MESENCHYMAL CELLS IN RHEUMATIC DISEASES: TISSUE EROSION/INVASION VS. FIBROSIS DAY ONE :00-5:55 PM Ballroom A Admission to the ACR Basic Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Steffen Gay, MD Upon completion of this session, participants should be able to: describe the role of mesenchymal cells in inflammatory arthritis describe the role of mesenchymal cells in fibrosis identify the factors modulating the function and development of mesenchymal cells Session I: The Biology of Mesenchymal Cells :00 PM Mesenchymal Cells John Varga, MD :0 PM Synovial Cells and the Development of the Synovial Lining Michael B. Brenner, MD :50 PM Interaction of Synovial Fluid with T cells David A. Fox, MD 0 Program Book :5 PM Mesenchymal Cell Plasticity: EMT and Cancer Derek C. Radisky, PhD :45 - :00 PM Break :00 PM Cellular Plasticity and Lung Fibrosis Paul Noble, MD :5 PM Biomechanical Sensing and Signaling Boris Hinz, PhD Session II: Core Signaling Mechanisms in Fibrosis :40 PM Orbital Fibroblasts in Health and Disease Terry J. Smith, MD 4:5 PM Morphogen Pathways or Stem Cell Pathways Joerg H. W. Distler, MD 5:0 PM Novel Lipid Mediators and Eicosanoids Relevant in Synovial Biology Charles Serhan, PhD 5:55-7:00 PM Networking Reception Networking reception combined with ACR Clinical Research Conference participants. ACR CLINICAL RESEARCH CONFERENCE: PAIN RESEARCH: NEW METHODS And CHALLENGES DAY ONE OF TWO PM :00-6:00 PM Ballroom C Admission to the ACR Clinical Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Daniel J. Clauw, MD Upon completion of this session, participants should be able to: discuss the latest clinical research techniques in the pain field, as well as the strengths and weaknesses of each technique stimulate new interdisciplinary relationships, including mentor-mentee relationships in rheumatology community disseminate the knowledge gained from this conference Introduction: State of the Field :00 PM Introductory Remarks Daniel J. Clauw, MD :0 PM Keynote Speaker: Neurophysiology and Preclinical Models Clifford Woolf, MB, BCh, PhD

25 :0 PM Panel Discussion/Question and Answer Clinical Trials :45 PM Academic Prospective Lesley M. Arnold, MD :5 PM Accelerating the Development of Improved Analgesic Treatments: The ACTTION Public-private Partnership and Evidence-based Clinical Trial Design Robert H. Dworkin, PhD :45 PM Panel Discussion/Question and Answer 4:00-4:5 PM Break Special Issues in Pain Research 4:5 PM Past, Present and Future-Regulatory Perspectives on Analgesics Sharon Hertz, MD 4:45 PM Pediatric Pain Research Laura E. Schanberg, MD 5:5 PM Ethics Joseph Ali, JD 5:45 PM Wrap Up 6:00-7:00 PM Networking Reception Networking reception combined with ACR Basic Research Conference participants. Faculty: Rany Al Haj, MD; David A. Bong, MD; George A.W. Bruyn, MD, PhD; Arnold Ceponis, MD, PhD; Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary Kunkel, MD; Bethany A. Marston, MD; Esperanza Naredo, MD; Anthony M. Reginato, MD, PhD; Johannes Roth, MD; Jonathan Samuels, MD; Wolfgang A. Schmidt, MD; Richard J. Wakefield, BM, MD; Darren Tabechian, MD; Mihaela Taylor, MD; Nikolay Tzaribachev, MD; Alvin F. Wells, MD, PhD Upon completion of this session, participants should be able to: demonstrate proper ultrasound exam technique and procedure guidance applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound 6:45-7:5 AM Continental Breakfast Moderator: Alvin F. Wells, MD, PhD 7:5 AM Opening Remarks Amy M. Evangelisto, MD 7:0 AM Lecture: Billing Coding and Report Generation Alvin F. Wells, MD, PhD The Hip 7:50 AM The Hip - Lecture: Standard Scans, Sonongraphic Anatomy, and Basic Sonographic Pathology Wolfgang A. Schmidt, MD 8:0 AM Demonstration: Scanning of the Hip Amy M. Evangelisto, MD SATURDAY November 0, 0 SATURDAY, NOVEMBER 0, 0 8:5 AM Hands-on Scanning: The Hip Faculty ACR/ARHP REGISTRATION 6:0 AM - 6:0 PM Registration Hall (Salons G-H-I) ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY TWO 7:5 AM - 4:0 PM 07 A Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. 9:0-9:40 AM Break The Knee 9:40 AM The Knee - Lecture: Scans, Sonographic Anatomy, and Basic Sonographic Pathology David A. Bong, MD 0:0 AM Demonstration: Scanning of the Knee Jay B. Higgs, MD 0:5 AM Hands-on Scanning: The Knee Faculty 0 Program Book

26 SATURDAY November 0, 0 4 :0 AM - :0 PM Boxed Lunch Moderator: Eugene Y. Kissin, MD Foot and Ankle :0 PM Foot and Ankle - Lecture: Standard Scans, Sonographic Anatomy, and Basic Sonographic Pathology Richard J. Wakefield, BM, MD :00 PM Demonstration: Scanning of Foot and Ankle Paul J. DeMarco, MD :5 PM Hands-on Scanning: Foot and Ankle Faculty :0 - :45 PM Break Ultrasound Guidance :45 PM Lecture: Evidence-base for Ultrasound Guidance of Procedures Eugene Y. Kissin, MD :5 PM Lecture: Technique of Ultrasound Needle Guidance Janak R. Goyal, MD :45 PM Hands-on Scanning: Ultrasound Injection Guidance with Phantoms Faculty ACR REVIEW COURSE 8:00 AM - 4:00 PM Hall D Admission to the ACR Review Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderators: Gregory C. Gardner, MD and Virginia D. Steen, MD 7:00-8:00 AM Continental Breakfast 8:00 AM Review and Update of Ankylosing Spondylitis Speaker: Desiree M. van der Heijde, MD, PhD Upon completion of this session, participants should be able to: describe to a patient or colleague the current understanding of the pathophysiology of ankylosing spondylitis discuss the current criteria for diagnosis and the utility of imaging studies to confirm the diagnosis discuss current recommendations for treating ankylosing spondylitis as well as potential agents that are soon to market that might have an impact on the disease describe important extra-articular manifestations of the disease 0 Program Book 8:45 AM When Thick Skin is Not a Good Thing Speaker: Heidi Jacobe, MD, MSCS Upon completion of this session, participants should be able to: describe what clinically distinguishes scleroderma-like diseases including localized scleroderma (morphea), eosinophilic fasciitis, scleredema, scleromyxedema, and nephrogenic systemic fibrosis from systemic sclerosis discuss how laboratory testing, magnetic resonance imaging and pathology can help make the diagnosis and determine how active the disease is discuss the best therapeutic options and what the role of phototherapy and physical therapy have on the long-term outcomes in these patients 9:0 AM Inflammatory Myositis: 0 Speaker: Ingrid E. Lundberg, MD Upon completion of this session, participants should be able to: discuss the best approach to the diagnosis of inflammatory muscle disease and how to differentiate it from other muscle and other connective tissue diseases describe the important extra muscular problems in myositis, particularly the skin, joint and lung complications recognize which patients are at greatest risk for developing malignancy explain the different treatment approaches and the expected outcomes 0:5-0:45 AM Break 0:45 AM Lupus - More than Nephritis: Treatment of Non-Nephritis Lupus Problems Speaker: Susan Manzi, MD, MPH Upon completion of this session, participants should be able to: describe the use of the laboratory in the management of nonnephritis lupus discuss specific management issues in patients with skin, joint, hematologic, central nervous system, serositis, and lung involvement of lupus describe what the different steroid sparing agents are, and when and who they should be used in, and what to expect from them :0 AM Setting the Stage for Rheumatoid Arthritis Speaker: Hani S. El-Gabalawy, MD Upon completion of this session, participants should be able to: describe the currently understood genetic and environmental factors that impact the development of autoimmunity, the clinical onset of synovitis, and the severity of rheumatoid arthritis describe to a patient with rheumatoid arthritis the sub-clinical immunologic events that may have occurred just prior to disease onset and their relationship to their symptoms discuss the utility of ACPA, RF, and other biomarkers in the diagnosis and prognosis of early rheumatoid arthritis describe the potential utility of very early treatment strategies in changing the trajectory of rheumatoid arthritis, and impacting chronicity and persistence of the disease

27 :5 - :5 PM Boxed Lunch 7:00-8:00 AM Continental Breakfast :5 PM Hypermobility, Diagnosis, Disease Associations, Treatment Speaker: Elizabeth B. Russell, MD Upon completion of this session, participants should be able to: evaluate and clinically diagnose hypermobility in patients and know when to proceed with diagnostic testing define the spectrum of disorders associated with hypermobility describe to a patient with hypermobility the long-term management strategies, including surgical and non-surgical options :00 PM Osteoporosis Update Speaker: Chad L. Deal, MD Upon completion of this session, participants should be able to: describe the pathophysiology of osteoporosis determine when and for how long patients should be treated with the different types of medication discuss how the new biologic medications for osteoporosis will change management Session III: Fibroblasts as Invaders and Aggressors 8:00 AM Overview of Synovial Cell Pathobiology Steffen Gay, MD 8:0 AM Tumor Metastatis: Molecular Insights and Evolving Paradigms Scott J. Valastyan, PhD 8:40 AM Syndecans and Fibroblast Response Thomas Pap, MD Session IV: Immunity and Mesenchymal Cells 9:00 AM Fibroblasts as Tumor Suppressors Douglas T. Fearon, MD 9:0 AM TLR Regulation of Fibroblast Function Cory M. Hogaboam, PhD SATURDAY November 0, 0 :45 - :5 PM Break :5 PM Is It Central Nervous System Vasculitis or Something Else? Speaker: Leonard H. Calabrese, DO Upon completion of this session, participants should be able to: describe to a colleague the evaluation for suspected central nervous system vasculitis and the pearls and pitfalls of imaging studies as well as brain biopsy describe to a colleague why a patient does or does not have central nervous system vasculitis based on the results of the evaluation discuss the conditions that mimic central nervous system vasculitis discuss the current recommendations for treatment of central nervous system vasculitis ACR BASIC RESEARCH CONFERENCE: MESENCHYMAL CELLS IN RHEUMATIC DISEASES: TISSUE EROSION/INVASION VS. FIBROSIS DAY TWO 8:00 AM - 4:0 PM Ballroom A Admission to the ACR Basic Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: John Varga, MD Upon completion of this session, participants should be able to: describe the role of mesenchymal cells in inflammatory arthritis describe the role of mesenchymal cells in fibrosis identify the factors modulating the function and development of mesenchymal cells 9:40 AM Stromal Cell Modulation by Dendritic Cells Theresa T. Lu, MD, PhD 0:00 AM Fibroblasts Maintain Inflammation Christopher D. Buckley, PhD 0:0 AM Microparticles and Inflammation Astrid Jungel, PhD 0:40-0:55 AM Break Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis 0:55 AM Fibrosis Biomarkers Robert Lafyatis, MD :5 AM Macrophages and Matrix Remodeling Jeremy S. Duffield, MD, PhD :5 AM Circulating Fibrocytes in Rheumatoid Arthritis Eleanor Fish, PhD :05 - :45 PM Boxed Lunches :45 PM Abstract Presentations :40 PM Transforming Growth Factors Beta Shelia Violette, PhD 0 Program Book 5

28 :05 PM Methylation and Acetylation in Resetting Fibroblast Function Gary S. Firestein, MD :0 PM Fibroblast Reticular Cells in Inflammation Sanjiv Luther, PhD 8:00 AM Introduction Marie D. Westby, PT, PhD 8:5 AM Osteoarthritis as We Understand It Today Carla R. Scanzello, MD, PhD SATURDAY November 0, 0 :55 PM Adipokines and Mesenchymal Cell Activation Ulf Müller-Ladner, MD :0 - :0 PM Break Session VI: Therapeutic Aspects: Biomarkers and Targeting Fibrosis (continued) :0 PM Chemokines and Synovial Cell Activation Alisa E. Koch, MD 9:00 AM Osteoarthritis Assessment: Thinking Outside of the Joint Charles R. Ratzlaff, BSc(PT), PhD, PT 0:5 AM 0 ACR Guidelines on Osteoarthritis: A Focus on Pharmacologic Management Marc C. Hochberg, MD, MPH :5 AM Addressing Risk Factors for Osteoarthritis through the Lifespan: Let s Start with the Kids! Kristin M. Houghton, MD :50 PM Mesenchymal Stem Cell Therapy Darwin J. Prockop, MD, PhD 4:0 PM Purinergic Receptors Regulating Fibroblasts Bruce N. Cronstein, MD ARHP CLINICAL FOCUS COURSE: TREATING THE PATIENT WITH OSTEOARTHRITIS: INTERVENTIONS, INNOVATIONS And CLINICAL INSIGHTS 8:00 AM - 4:0 PM 4 A Admission to the ARHP Clinical Focus Course requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Moderator: Marie D. Westby, PT, PhD Upon completion of this session, participants should be able to: conduct a comprehensive assessment that identifies impairments, activity limitations, participation restrictions and personal factors in a patient with osteoarthritis in order to inform a clinical treatment plan integrate current evidence-based practice guidelines with patient needs and preferences to formulate pharmacological, non-pharmacological and complementary treatment strategies incorporate the use of valid and clinically feasible osteoarthritis outcome measures in order to inform clinical practice use a variety of professional and public resources and technology to engage patients in arthritis self-management 7:00-8:00 AM Continental Breakfast Noon - :45 PM Boxed Lunch :45 - :0 PM Breakout Session I What s New in Fine Tuning the Care of the Osteoarthritic Hand? Moderator: Kathryn L. Lowenstein, OTR Speaker: Virginia O Brien, OTD, OTR/L, CHT Neuromuscular Training and Joint Mobilizations: Do We Need Both to Optimize Lower Limb Function? Moderator: Marie Westby, PT, PhD Speaker: G. Kelley Fitzgerald, PhD, PT Managing Pain and Promoting Activity: It s Not a Stretch to Suggest Complementary Movement Approaches Moderator: Jessica F. Farrell, PharmD Speaker: Steffany Moonaz, MFA, PhD :45 - :0 PM Breakout Session II What s New in Fine Tuning the Care of the Osteoarthritic Hand? Moderator: Kathryn L. Lowenstein, OTR Speaker: Virginia O Brien, OTD, OTR/L, CHT Neuromuscular Training and Joint Mobilizations: Do We Need Both to Optimize Lower Limb Function? Moderator: Marie Westby, PT, PhD Speaker: G. Kelley Fitzgerald, PhD, PT Managing Pain and Promoting Activity: It s Not a Stretch to Suggest Complementary Movement Approaches Moderator: Jessica F. Farrell, PharmD Speaker: Steffany Moonaz, PhD, RYT-500 :0 - :45 PM Break :45 PM Using Outcome Measures to Inform Clinical Practice Gillian A. Hawker, MD, MSc 6 0 Program Book

29 :5 PM Obesity and Osteoarthritis: Clinicians Can Make a Difference in Promoting Healthier Lifestyles Susan J. Bartlett, PhD :45 PM Osteoarthritis Chronic Disease Management in the Age of the Internet, Apps and Tweets Patricia D. Franklin, MBA, MD, MPH 4:5 PM Concluding Remarks Marie D. Westby, PT, PhD CORC PRE-MEETING COURSE FOR PRACTICE MANAGERS: HELPING YOU MANAGE A PROFITABLE PRACTICE 8:00 AM - 4:0 PM 5 A Admission to the CORC Pre-meeting Course for Practice Managers requires a separate registration fee. Fee includes a continental breakfast and boxed lunch. 8:00 AM Keynote Address: The World s Best Managers Do Manage Differently-Find Your Strengths for Efficiency! Moderator: Laura Wright, MBA, CMPE Speaker: To be announced Upon completion of this session, participants should be able to: identify how to capitalize on the strengths of staff develop techniques to help clarify staff roles, keeping them engaged and assisting with high performance identify ways to understand and communicate effectively with different personality types recognize the seven body language signs to watch for, and what they mean 9:5 AM Improving Revenue Cycle Management Effectiveness and Optimize Cash Flow Moderator: Laura Wright, MBA, CMPE Speaker: Michael Fleischman, FAAHC Upon completion of this session, participants should be able to: identify practical hands-on approach for handling denials to improve the bottom line review standard spreadsheets that will help managing physicians and practice administrators monitor the accounts receivable for the practice establish criteria to assess monthly accounts to streamline process discuss tips and techniques to explore training on handling denial codes to save money 0:00-0:5 AM Break 0:5 AM Effective Marketing for Today s Medical Practice Moderator: Cindy Gutierrez, MBA Speaker: Simon Sikorski, MD Upon completion of this session, participants should be able to: discuss the importance of marketing in 0 and the various marketing styles for physician practices discuss the specifics and do s and dont s of web-based marketing identify easy-to-implement tips and techniques to assist physicians in marketing their practices to prospective patients, including tips to increase the efficiency of marketing campaigns :00 AM Transforming the Practice Front End Moderator: Cindy Gutierrez, MBA Speaker: Sunjanel Avecilla, EMT-P, CPC, CMC, CMOM, CMIS, CMCO Upon completion of this session, participants should be able to: identify the key issues on patient confidentiality and HIPAA compliance discuss the necessity for training on charting and medical record keeping identify areas for cross-training to enhance daily workflow improve patient experience on scheduling appointments, minimize excessive wait time upon arrival Noon - :00 PM Networking Lunch :00 PM Deal Breakers in Payer Contract Negotiations Moderator: Cindy Gutierrez, MBA Speaker: Herbert S. B. Baraf, MD Upon completion of this session, participants should be able to: identify specific contract language that pertains to areas such as recoupment, carve-outs, limitations and clauses evaluate and discuss the best way to negotiate specific requirements that should be included in a contract determine when is the right time to begin new negotiations or sever ties with an insurance company identify the top 0 deal breakers and must have in your contract :00 PM Improving Accounts Receivable for Profitability Moderator: Laura Wright, MBA, CMPE Speaker: Sunjanel Avecilla, EMT-P, CPC, CMC, CMOM, CMIS, CMCO Upon completion of this session, participants should be able to: identify the most common denials and rejection edits discuss how your practice management system tools can directly assist in streamlining outstanding accounts to increase revenue identify a tracking mechanism to secure accurate and timely reimbursement review claim denials and appeals to minimize leaving money on the table SATURDAY November 0, 0 0 Program Book 7

30 SATURDAY November 0, 0 8 :00 - :5 PM Break :5 PM How to Maximize the Use of Your Practice Data Moderator: Cindy Gutierrez, MBA Speakers: Heather McComas, PharmD; Steve Ellwing Upon completion of this session, participants should be able to: discuss the importance of how insurance programs are using provider data to drive their decision-making process regarding new payment methodologies discuss how physician data is used to rate quality and efficiency in physician practices identify how physicians and their staff can access these data from payers review how to use the data strategically to ensure practice efficiency and deliver quality patient care 4:00 PM CORC Pre-meeting Course for Practice Managers - Innovations for the Office Moderator: Cindy Gutierrez, MBA Speakers: Larry Garber, MD and Robert W. Warren, MD, PhD, MPH Upon completion of this session, participants should be able to: describe how online communication can be used to support a more effective and efficient practice employ strategies to encourage patient engagement per the provisions in the CMS EHR Incentive Program, while implementing efficient workflow processes to respond to patient requests for electronic access to health information explain privacy and security requirements and best practices to ensure that electronic patient health information is secure ACR CLINICAL RESEARCH CONFERENCE: PAIN RESEARCH: NEW METHODS And CHALLENGES DAY TWO PS 8:0 AM - 4:5 PM Ballroom C Admission to the Clinical Research Conference requires a separate registration. Registration includes complimentary continental breakfast and a boxed lunch. Pre-conference courses require a separate registration fee. Moderator: Laura E. Schanberg, MD Upon completion of this session, participants should be able to: discuss the latest clinical research techniques in the pain field, as well as the strengths and weaknesses of each technique stimulate new interdisciplinary relationships, including mentor-mentee relationships in rheumatology community disseminate the knowledge gained from this conference 7:0-8:0 AM Continental Breakfast Day Two Introductory Remarks 8:0 AM Importance of Pain Research in NIH/NIAMS Portfolio Stephen I. Katz, MD, PhD 0 Program Book 8:45 AM Importance of Pain Research to ACR David G. Borenstein, MD From Preclinical Models to Clinical Studies Moderator: Gary J. Macfarlane, BSc, MBChB, MD, PhD 9:00 AM Genetic Studies William Maixner, DDS, PhD 9:0 AM Epidemiological Studies John McBeth, PhD Methods for Phenotyping Pain- 0:00 AM Patient Reported Outcome Measures (including PROMIS) David A. Williams, PhD 0:0 AM Quantitative Sensory Testing Roger B. Fillingim, PhD :00 AM Functional, Structural, and Chemical Neuroimaging Irene Tracey, MA, (Oxon), PhD :0 AM Panel Discussion/Question and Answer :45 AM - :00 PM Boxed Lunch Methods for Phenotyping Pain- :00 PM Realtime Assessment and Objective Measures of Function Mark Connelly, PhD :0 PM Using Large Databases Frederick Wolfe, MD :00 PM Panel Discussion/Question and Answer :5 PM Introduction to Breakout Groups Gary J. Macfarlane, BSc, MBChB, MD, PhD :0 - :45 PM Break :45-4:5 PM Break Out Groups Self-Report Outcomes Including PROMIS Measures Esi M. Morgan DeWitt, MD, MSCE, David A. Williams, PhD and James P. Witter, MD, PhD Quantitative Sensory Testing Roger B. Fillingim, PhD and Steven E. Harte, PhD Functional, Structural and Chemical Neuroimaging Dane B. Cook, PhD, Roland Staud, MD and Irene Tracey, Director

31 Real-time Assessment and Objective Measures of Function Mark Connelly, PhD, Susan L. Murphy, ScD and Jennifer N. Stinson, PhD, RN, CPNP Using Large Databases/Epidemiology Gary J. Macfarlane, BSc, MBChB, MD, PhD and John McBeth, PhD Genetics William Maixner, DDS, PhD 4:55 PM Recognition of 0 ACR Masters Recognition of the 0 Awards of Distinction Recipients Recognition of Presidential Gold Medal Award Recipient Recognition of ARHP Merit Awards Lifetime Achievement Award Recognition of Fellows Awards Wrap up/steps Forward Gary J. Macfarlane, BSc, MBChB, MD, PhD ACR CERTIFIED RHEUMATOLOGY CODER COURSE EXAMINATION: UNLOCK THE MYSTERY: A ROADMAP FOR RHEUMATOLOGY CODING DAY TWO OF TWO PS :00 AM - 5:00 PM 50 B Admission to the ACR Certified Rheumatology Coder Course requires a separate registration. Registration includes CRHC review materials and a boxed lunch. This course is not eligible for CME credit. Upon completion of this session, participants should be able to: exhibit proficiency in adjudicating claims for accurate medical coding for diagnoses, procedures and services in physicianbased settings display proficiency across a wide range of services, which include evaluation and management, surgical services, radiology, pathology and medicine demonstrate knowledge of medical coding rules and regulations including compliance and reimbursement distinguish how to integrate medical coding and reimbursement rule changes into a practice s reimbursement process Speaker: Melesia Tillman, CPC, CRHC, CHA ACR/ARHP OPENING LECTURE And AWARDS 4:0-6:5 PM Hall E Moderators: James R. O Dell, MD, ACR President; Audrey B. Uknis, MD, ACR President-elect; Benjamin J. Smith, PA-C, ARHP President 4:0 PM Presidential Address James R. O Dell, MD 4:50 PM Rheumatology Research Foundation Announcement David I. Daikh, MD, PhD 5:0 PM Straight and Swift to My Wounded I Go : The Reality of the American Civil War Medicine Speaker: Robert D. Hicks, PhD Upon completion of this session, participants should be able to: describe the environment of emergency medical care at the outbreak of the American Civil War outline the reforms to emergency medical care led by Surgeon General William Hammond and Medical director Jonathan Letterman identify the chief tenets of medical ideology of the Civil War era, focusing on physiology and medicines describe the nature of and limitations to surgery during the Civil War ACR/ARHP OPENING EVENT 7:00-0:00 PM Newseum Admission to the ACR/ARHP Opening Event at the Newseum is ticketed and requires a separate registration. Purchase your tickets in the ACR/ARHP registration area before 6:0 PM (while supplies last) to ensure you have access to this VIP event. Tickets will not be available for purchase at the Newseum. SUNDAY, NOVEMBER, 0 ACR/ARHP REGISTRATION 6:0 AM - 6:00 PM Registration Hall (Salons G-H-I) RHEUMATOLOGY RESEARCH FOUNDATION 5K RUN/WALK 6:00-7:0 AM The Yards Park See page 7 for more information. ACR SESSIONS 7:0-8:0 AM 46 C Modifying Causal Risk Factors that Influence the Incidence of Falls by Older Adults Moderator: Joel A. Block, MD Speaker: Mark D. Grabiner, PhD SUNDAY November, 0 0 Program Book 9

32 SUNDAY November, 0 0 Upon completion of this session, participants should be able to: summarize current knowledge regarding the prevalence and risk of falling among the elderly and infirm discuss current thoughts regarding the neuromuscular basis of falls in the elderly review potential therapeutic strategies leveraging recent knowledge about pathophysiology Hall D Year in Review Moderator: Chester V. Oddis, MD Upon completion of this session, participants should be able to: discuss selected recent publications on the pathophysiological basis of rheumatic diseases by literature review of important publications describe selected treatment modalities for rheumatic diseases from the recent published literature enumerate how these new advances may impact the practice of rheumatology 7:0 AM Clinical Perspective David A. Isenberg, MD 8:00 AM Basic Science Perspective Daniel L. Kastner, MD, PhD ACR SESSIONS 7:0-9:00 AM 04 A Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis Moderator: Lindsey A. Criswell, MD, MPH Upon completion of this session, participants should be able to: describe genome wide association study designs, including what they can and cannot tell us about genetic susceptibility factors for autoimmune and other complex human diseases review the recently established genetic loci for several autoimmune diseases and which biologic pathways are most strongly implicated by these specific loci describe the types of investigations that will be required to understand more specifically how specific genes operate, within biologic pathways, to influence disease susceptibility and expression review and critique the current evidence that implicates specific genetic variants as predictors of rheumatoid arthritis treatment response 7:0 AM Biologic Pathways Implicated by Recent GWAS of Systemic Autoimmune Disease Peter K. Gregersen, MD 8:00 AM Identification of Genes that Influence Response to Rheumatoid Arthritis Treatment Robert M. Plenge, MD, PhD 0 Program Book 8:0 AM Functional Studies of Autoimmune Disease Genetic Risk Loci Patrick M. Gaffney, MD 07 A Tips for Publishing Your Work in a Peer-Reviewed Medical Journal Moderator: Michael D. Lockshin, MD Upon completion of this session, participants should be able to: assess whether their study findings are of sufficient novelty and significance to warrant submission for publication identify peers and superiors who could provide critical feedback on their manuscripts prior to submission for formal review determine the journal to which they should most appropriately submit their work review how to prepare their manuscripts according to the journals specific requirements 7:0 AM Publishing in Arthritis & Rheumatism Joan M. Bathon, MD 8:5 AM Publishing in Arthritis Care & Research Marian T. Hannan, DSc, MPH ARHP SESSIONS 7:45-9:00 AM 0 ARHP First-time Attendee Orientation First-time ARHP annual meeting attendees are invited to an orientation to learn the ins and outs of the annual meeting. The ARHP Membership and Nominations Committee will assist you in planning how to get the most out of your first annual meeting. This session is not eligible for CME credit. Coffee and tea will be provided. Moderator: Nadine T. James, RN, PhD 06 ARHP Moderators Orientation This session is not eligible for CME credit. Coffee and tea will be provided. Moderators: Linda Ehrlich-Jones, PhD, RN and Afton Hassett, PsyD ACR MEET THE PROFESSOR SESSIONS 7:45-9:5 AM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September 4.

33 48 Behçet s Disease (00) Speaker: Hasan Yazici, MD 5 Controversies in Sjögren s Syndrome (00) Speaker: Alan N. Baer, MD 54 A Infections with Biologics (00) Speaker: John J. Cush, MD 54 B Pediatrics: Dermatomyositis (004) 55 Speaker: Susan Kim, MD, MPH Pediatrics: Difficult to Treat Juvenile Idiopathic Arthiritis (005) Speaker: Murray H. Passo, MD 58 A Rheumatoid Arthritis: Biological Agents (006) Speaker: Edward C. Keystone, MD 58 B Spondylarthropathy: An Update (007) Speaker: Robert D. Inman, MD 59 A Systemic Arthritis and Still s Disease (008) Speaker: Rayfel Schneider, MBBCh 59 B Systemic Lupus Erythematosus: Central Nervous System (009) Speaker: Cynthia Aranow, MD 60 Vasculitis Mimics (00) Speaker: John H. Stone, MD, MPH ACR WORKSHOPS 7:45-9:45 AM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September A Basic Statistical Concepts for the Medical Researcher (0) Speakers: Dorothy D. Dunlop, PhD and JungHwa Lee, MD, PhD 44 C Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD 44 A Dermatopathology of Rheumatic Diseases (0) Speaker: Daniel Miller, MD 44 B Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis (04) Speakers: George V. Lawry, MD and Paul C. Utrie, MD ACR SESSIONS 9:00-0:00 AM 50 B Advances in the Biology of Aging Moderator: Peter A. Nigrovic, MD Speaker: Jan Vijg, PhD Upon completion of this session, participants should be able to: review the role of telomere length in cell senescence, and the importance of this biology for the aging of the immune system discuss the presence of senescent cells in tissues and this role in aging discuss the possible implications of aging biology on rheumatic diseases 47 A CORC FORUM: Achieving Economic Goals in An Era of Healthcare Reform Moderator: Edward L. Morris, MD Speaker: Kevin Lieb Upon completion of this session, participants should be able to: identify effective compensation models to improve financial outcomes develop key integration strategies for success in the practice identify how new payment options will be used in promoting quality, efficiency and improved outcomes SUNDAY November, 0 0 Program Book

34 SUNDAY November, 0 Hall E New Therapies for Modulating Signaling in Rheumatoid Arthritis Moderator: Gregg J. Silverman, MD Speaker: Mark C. Genovese, MD Upon completion of this session, participants should be able to: define the basic factors and cell types involved in these pathways, and the inflammatory responses they control describe the rationale for the development of new agents that target these pathways review recent clinical trial results and appreciate the potential benefits and toxicities that have been reported 5 A The Plasticity of T Regulatory Cells and their Role in Autoimmunity Moderator: Richard M. Pope, MD Speaker: Dario A. A. Vignali, PhD Upon completion of this session, participants should be able to: define mechanisms which promote T regulatory cell plasticity identify the mechanisms by which T regulatory cells promote immune homeostasis identify mechanisms by which alterations of T regulatory cells promote autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus Hall D Update on Stroke Moderator: Fernando E. Figueroa, MD Speaker: Harold Adams, MD Upon completion of this session, participants should be able to: review the main types of acute cerebrovascular disease analyze the current diagnostic tools in the management of stroke review the contemporary therapies and strategies involved in the treatment of ischemic and hemorrhagic stroke ACR SESSIONS 9:00-0:0 AM 0 B Extra-articular Involvement in Rheumatoid Arthritis Moderator: Steven B. Abramson, MD Upon completion of this session, participants should be able to: describe the association between periodontal disease and rheumatoid arthritis examine the role of periodontal disease in the pathogenesis of rheumatoid arthritis determine the role of specific oral flora in the pathogenesis of periodontal disease and rheumatoid arthritis 9:00 AM Periodontal Disease as An Initiation or Propagation Factor for Rheumatoid Arthritis Ted R. Mikuls, MD, MSPH 9:0 AM Does Rheumatoid Arthritis Start in the Lung? Kevin D. Deane, MD, PhD 0:00 AM The Role of ACPA in the Pathogenesis of Rheumatoid Arthritis Patrick Venables, MD 45 A Medical Education: The Year in Review Moderator: Michael J. Battistone, MD Speaker: Karen Szauter, MD Upon completion of this session, participants should be able to: recognize the major research reports and scholarship in the field of medical education over the past year (0) translate results of educational research to their own educational programs formulate ideas for educational research at their own institution ACR POSTER SESSION A And POSTER TOURS 9:00 AM - 6:00 PM Poster presenters will be available from 9:00 - :00 AM (abstracts # - 74). Poster tours will be held 9:00-9:45 AM and 0:5 - :00 AM. Morning snacks will be available from 9:00-0:0 AM. Poster Hall (Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 5 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Salons G-H-I). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 5 minutes of the end of the tour. 9:00-9:45 AM Fellows Only: How to Navigate the Poster Hall (0) Tour Guide: Calvin R. Brown, MD Osteoarthritis: Clinical Aspects (0) Tour Guide: Roy D. Altman, MD Pediatric Rheumatology: Clinical Aspects (0) Tour Guide: Carol A. Wallace, MD 0 Program Book

35 Rheumatoid Arthritis: Clinical Aspects (04) Tour Guide: Inmaculada del Rincon, MD, MSc Rheumatoid Arthritis: Treatment: Small Molecules, Biologics and Gene Therapy (05) Tour Guide: S. Louis Bridges, MD, PhD Systemic Lupus Erythematosus: Clinical Aspects (06) Tour Guide: Barri J. Fessler, MD 0:5 - :00 AM Osteoarthritis - Clinical Aspects (07) Tour Guide: Timothy E. McAlindon, MD, MPH Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy (08) Tour Guide: Martin Aringer, MD Rheumatoid Arthritis: Clinical Aspects (09) Tour Guide: Deborah P. Symmons, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (0) Tour Guide: Désirée van der Heijde, MD Systemic Lupus Erythematosus: Clinical Aspects () Tour Guide: David A. Isenberg, MD ARHP SESSION 9:0-0:0 AM 46 C ARHP Keynote Address: It s Not Child s Play: Growing Up With and Mastering Juvenile Idiopathic Arthritis from the Child s Perspective Moderator: Linda S. Ehrlich-Jones, PhD, RN Speaker: Logan Graham Upon completion of this session, participants should be able to: determine how health professionals can make an impact outside of the normal treatment process discuss ways health professionals can exploit kids abilities for successful treatment describe how health professionals can mobilize their inner child for better results Rheumatology Research Foundation SPECIAL SESSION 0:00 - :00 AM EXHIBITS 0:00 AM - 5:00 PM Exhibit Hall (Hall A) Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 0:00 - :00 AM and :00 - :00 PM. (Booth #45) Innovation Theater Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. These presentations will be held from 0:0 - :5 AM, :0 - :5 PM and :0 - :5 PM. For a complete listing of Innovation Theater presentations, see page 6. ACR WORKSHOPS 0:0 AM - :0 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September C *Adult Musculoskeletal Upper Examinations (05) Speaker: Arthur M. Mandelin II, MD, PhD 44 B *Musculoskeletal Ultrasound (06) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD 49 A * Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (07) Speaker: Megan Troxell, MD SUNDAY November, 0 Ballroom B Oscar S. Gluck, MD, Memorial Lectureship: Bone Wasn t Built in a Day: New Insights into Destruction and Repair in Rheumatic Disease Moderator: Michael Maricic, MD Speaker: Ellen M. Gravallese, MD Upon completion of this session, participants should be able to: describe mechanisms of articular bone loss in different rheumatic diseases discuss the role of osteocytes in regulating key pathways of bone loss and formation identify the potential for repair of articular erosions and the pathways implicated in this process ACR PLENARY SESSION I DISCOVERY 0 :00 AM - :0 PM Hall D Moderators: James R. O Dell, MD and Benjamin J. Smith, PA-C :00 AM Rheumatology Research Foundation Industry Roundtable Awards :0 AM ACR Abstract Presentation and Commentaries 0 Program Book

36 SUNDAY November, 0 :5 AM 75. The Role of Interleukin- in Spondyloarthropathy Jonathan Sherlock, Barbara Joyce-Shaikh, Scott Turner, Cheng- Chi Chao, Manjiri Sathe, Jeff Grein, Dan Gorman, Eddie P. Bowman, Terrill McClanahan, Jennifer Yearley, Gerard Eberl, Christopher D. Buckley 4, Robert Kastelein, Robert Pierce, Drake LaFace and Daniel Cua 5, Merck, Palo Alto, CA, Merck, Palo Alto, Institut Pasteur, Paris, France, 4 School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, 5 Merck Research Laboratory, Palo Alto, CA Background/Purpose: Spondyloarthropathy is characterized by inflammation and bony pathology at the entheseal insertion of tendons to bone. Recent investigations have converged upon interleukin(il)-, demonstrating firstly that genetic variants in its receptor are associated with disease and secondly that HLA-B7, which is present in 90% of patients with ankylosing spondylitis, has a tendency to misfold and form cell surface homodimers resulting, respectively, in production of IL- and stimulation of IL-R+ cells. However why such dysregulation of IL- should result in inflammation primarily at the enthesis has remained deeply enigmatic. We have hypothesized that tissue resident cells fundamentally determine disease localization (Cua and Sherlock, Nature Medicine 7(9):055-6) and herein extend our previous observations (Sherlock et al. in press) to demonstrate the presence of IL-R+ cells in the uvea and to further characterize these cells and their effects. Methods: We used GFP reporter mice to investigate the tissue distribution of IL-R+ cells in the main tissues inflamed in spondyloarthropathy: the enthesis, aortic valve and uvea. Flow cytometric analysis and multiphoton microscopy was employed to characterize the location of such cells and the reactivity of this tissue to IL- was determined in vitro and in vivo. Results: Entheses, the aortic root and the uvea all contain a novel tissue resident IL-R+ T lymphocyte, negative for both CD4 and CD8, which allows the tissue to respond to IL-. Multiphoton microscopy confirms an extremely precise entheseal localization of the IL-R+ cell type. These cells are RAG dependent, but express the PLZF transcription factor which confers an innate like responsiveness on T cells, allowing them to immediately respond to cytokines. Entheses can respond within hours to IL- in vitro in the absence of further cellular recruitment. Moreover, IL- expression in mice is sufficient by itself to induce hallmark features of spondyloarthropathy, with severe inflammation developing very specifically at the enthesis and aortic root. Entheseal bone erosion, new bone formation and periostitis are likewise present. Conclusion: The highly restricted anatomical distribution of IL-R+ cells explains both the exquisitely precise tissue localization of disease in spondyloarthropathy, as well as the known genetic associations with IL-, and gives a very clear mechanism whereby HLA-B7 and its tendency to cause IL- elaboration may predispose to pathology. These IL-R+ tissue resident cells thus form the point of integration between the specific immunological dysregulations known to be associated with disease, and the very precise anatomical sites affected. The importance of these tissue resident cells is emphasized by the ability of IL- to drive enthesitis despite depletion of the conventional IL- responsive Th7 cells. Neutralization of IL- therefore represents an excellent therapeutic strategy in spondyloarthropathy since it will inhibit a potent molecule associated with known genetic factors, and do so directly at the site of pathology. Disclosure: J. Sherlock, Merck, ; B. Joyce-Shaikh, Merck, ; S. Turner, Merck Pharmaceuticals, ; C. C. Chao, Merck Pharmaceuticals, ; M. Sathe, Merck, ; J. Grein, Merck Pharmaceuticals, ; D. Gorman, Merck Pharmaceuticals, ; E. P. Bowman, Merck Pharmaceuticals, ; T. McClanahan, Merck Pharmaceuticals, ; J. Yearley, Merck Pharmaceuticals, ; G. Eberl, None; C. D. Buckley, None; R. Kastelein, Merck Pharmaceuticals, ; R. Pierce, Merck Pharmaceuticals, ; D. LaFace, Merck Pharmaceuticals, ; D. Cua, Merck Research Laboratory, :0 AM 76. Dynamic in vivo Imaging of Th7-Mediated Osteoclastic Bone Resorption in Live Bones by Using Intravital Multiphoton Microscopy Junichi Kikuta and Masaru Ishii, Immunology Frontier Research Center, Osaka University, Osaka, Japan Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint synovial inflammation and progressive cartilage/bone destruction. Although various kinds of cell types, such as T/B lymphocytes, macrophages and synovial fibroblasts, are involved in the pathogenesis of chronic inflammation in RA, bone destruction is considered to be mainly mediated by enhanced activation of osteoclasts. Recently CD4+ T helper 7 (Th7) cells have been reported to express RANKL on the cell surface, which were suggested to be important for osteoclastic bone destruction in arthritic joints. However, the RANKL expressed on the surface of Th7 possesses little ability for inducing differentiation, and the practical function of RANKL and Th7 on bone erosion remained elusive. This study aimed to investigate how the bone-resorptive functions of osteoclasts are regulated in situ and how Th7 cells control the osteoclastic bone resorption in vivo. Methods: To examine in vivo behaviors of mature osteoclasts and Th7 cells, we utilized advanced imaging system for visualizing live bone tissues with intravital multiphoton microscopy that we have originally established. To identify mature osteoclasts in fluorescent microscopy, we utilized the mice in which GFP is expressed under the promoter of a vacuolar type H + -ATPase a subunit, those are preferentially and abundantly expressed in mature osteoclasts (a-gfp mice). Polyclonally differentiated Th7 cells were labeled with fluorescent dye and then adoptively transferred into a-gfp mice. We observed calvaria bone tissues of a-gfp mice by using intravital multiphoton microscopy. Results: We succeeded in visualizing live mature osteoclasts on the bone surface in situ. By using this imaging system, we could identify different populations of live mature osteoclasts in terms of their motility and function, i.e., static bone resorptive (R) and moving non resorptive (N). Treatment with recombinant RANKL or bisphosphonate changed the composition of these populations as well as total number of mature osteoclasts. We also found that rapid RANKL injection converted the moving (N) osteoclasts to static (R) ones without any changes in total number of osteoclasts, suggesting a novel action of RANKL in controlling mature osteoclast function. Furthermore, we could demonstrate that Th7 cells had potency for inducing rapid N to 4 0 Program Book

37 R conversion of mature osteoclasts by RANKL expressed on their cell surface in situ. Conclusion: By visualizing in vivo behaviors of mature osteoclasts, we for the first time identified different functional subsets of live osteoclasts on the bone surface, from static bone resorptive to moving non resorptive. Furthermore, RANKL turned out not only to promote the differentiation of osteoclasts but also to regulate the bone-resorptive function of fully differentiated mature osteoclasts. RANKL-bearing Th7 cells were shown to control bone resorption of mature osteoclasts, demonstrating novel actions of Th7 that may be a novel therapeutic target in RA. Disclosure: J. Kikuta, None; M. Ishii, None. resorption, u-ntx/cr, and significantly increased biomarkers of bone formation, s-pnp and s-bsap, compared to placebo. The increase observed for the bone resorption marker s-ctx with ODN treatment was unexpected. AEs were comparable between the treatment arms. The overall safety profile appeared similar between ODN 50mg OW and placebo. Conclusion: In this study osteoporotic women treated with ODN following ALN treatment show incremental gains in BMD. Biomarker results suggest that ODN decreases bone resorption while preserving bone formation. ODN effects on BMD :45 AM 77. Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate Roland Chapurlat, Sydney Bonnick, Tobias De Villiers, Alberto Odio 4, Santiago Palacios 5, Boyd Scott 6, Celine Le Bailly De Tilleghem 7, Carolyn DaSilva 6, Albert Leung 8 and Deborah Gurner 8, Hôpital Edouard Herriot, Lyon, France, Cooper Clinic, Dallas, TX, Mediclinic Panorama, Cape Town, South Africa, 4 Alta California Medical Group, Simi Valley, CA, 5 Instituto Palacios, Madrid, Spain, 6 Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 7 Merck Sharp & Dohme Corp., Brussels, Belgium, 8 Whitehouse Station, NJ Background/Purpose: Odanacatib (ODN) is a potent, orallyactive cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly (OW) on BMD and biochemical markers of bone turnover in patients previously treated with alendronate (ALN) (dosed daily or weekly) for years, as well as the safety and tolerability of ODN. Methods: This was a randomized, double-blind, placebocontrolled, 4-month study. The primary endpoint was % change in femoral neck (FN) BMD from baseline at Month 4. 4 postmenopausal women 60 years of age with low BMD T-score (T-score range.5 but >-.5) at the total hip, FN or trochanter but no history of hip fracture and who had been treated with ALN for years were randomized in a : ratio to receive ODN 50mg OW or placebo OW for 4 months. All patients received vitamin D 5600 IU/wk and calcium supplementation (to 00 mg/day). BMD was assessed by DXA at baseline, 6, and 4 months. Biochemical markers of bone resorption (s-ctx, u-ntx) and bone formation (s-bsap and s-pnp) were measured at baseline and, 6,, 8 and 4 months. This study was not designed and did not have the power to evaluate the effect of ODN on fractures. Results: In the placebo group, FN and trochanter BMD were not significantly different from baseline levels for the first months, but declined significantly from baseline by Month 4 (-0.94% and -.5%, respectively). BMD at the total hip declined in a linear manner from baseline to month 4 (-.87% at 4 months). BMD at the lumbar spine (LS) was not significantly different from baseline for the entire 4 months of the study. BMD changes from baseline at 4 months in the ODN group were significant vs placebo at all hip sites and the LS. The changes in BMD for the FN, trochanter, total hip and LS from baseline were.7%,.8%, 0.8% and.8%, respectively. ODN 50mg OW significantly decreased the biomarker of bone ODN effects on biomarkers Disclosure: R. Chapurlat, Merck Pharmaceuticals,, Merck Pharmaceuticals, 5; S. Bonnick, Merck Pharmaceuticals, 5; T. De Villiers, None; A. Odio, Merck Pharmaceuticals, ; S. Palacios, None; B. Scott, Merck Pharmaceuticals,, Merck Pharmaceuticals, ; C. Le Bailly De Tilleghem, Merck Pharmaceuticals,, Merck Human Health, ; C. DaSilva, Merck Pharmaceuticals,, Merck Pharmaceuticals, ; A. Leung, Merck Pharmaceuticals,, Merck Pharmaceuticals, ; D. Gurner, Merck Pharmaceuticals,, Merck Pharmaceuticals,. Noon 78. Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis? Results of the International Scleroderma Renal Crisis Survey Marie Hudson, Murray Baron, Solene Tatibouet, De Furst, Dinesh Khanna4 and International Scleroderma Renal Crisis Study Investigaots 5, McGill University, Montreal, QC, Jewish General Hospital, Montreal, QC, University of California at Los Angeles, Los Angeles, CA, 4 University of Michigan, Ann Arbor, MI, 5 Montreal Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent of angiotensin converting enzyme (ACE) inhibitors. The incidence of SRC has also appeared to have decreased, perhaps in part due to the more liberal use of ACE inhibitors in SSc. However, recent retrospective data suggests that patients with SRC exposed to ACE inhibitors prior to the onset of SRC may have worse outcomes. We undertook a prospective study to verify whether SSc patients with incident SRC on ACE inhibitors at the time of onset of SRC had worse outcomes compared to those who were not on these drugs at that time. SUNDAY November, 0 0 Program Book 5

38 SUNDAY November, 0 Methods: We designed a prospective, observational cohort study of incident SRC subjects identified through a webbased survey. Every second week, an was sent to 589 participating physicians from around the world to identify incident cases of SRC. Data on patient demographic and disease characteristics, as well as exposure to ACE inhibitors was collected. A one-year follow-up case report form was sent to all the physicians who identified a case. The primary outcome of interest was death or dialysis at one year after the onset of SRC, comparing patients exposed and unexposed to ACE inhibitors at the time of onset of SRC. Results: We identified 88 incident cases of SRC, of which were lost to follow up (86% follow up rate). Mean age was 5 years, 67% were women, 76% had diffuse SSc and median disease duration since the onset of the first non-raynaud s symptom was.5 years. The majority of cases had a hypertensive SRC (n=7/76) and only 5 had a normotensive SRC. Eighteen patients (4%) were on an ACE inhibitor immediately prior to the onset of the SRC. At one year follow up, 7 (6%) SRC patients had died and an additional (7%) remained on dialysis. The crude one-year cumulative incidence of death in those exposed to ACE inhibitors at the time of onset of SRC compared to the unexposed was.56 (95% confidence interval [CI] ) and the crude one-year cumulative incidence of dialysis was 0.6 (95% CI ). The crude Cox proportional hazard ratio comparing the time to death of SRC patients exposed to ACE inhibitors prior to the onset of SRC to those unexposed was.95 (95% CI ). After controlling for differences in prednisone exposure and history of systemic hypertension in the two groups, the adjusted Cox proportional hazard ratio comparing the time to death of SRC patients exposed to ACE inhibitors prior to the onset of SRC to those unexposed was.5 (95% CI , p=0.094). Conclusion: SRC was associated with poor one-year outcomes. Exposure to an ACE inhibitor prior to the onset of SRC was associated with an increased risk of death during the first year of follow up after SRC. Clinicians caring for patients with early SSc should use ACE inhibitors cautiously. Disclosure: M. Hudson, None; M. Baron, None; S. Tatibouet, None; D. Furst, Amgen, Janssen, Roche, and UCB,, Amgen, Janssen, Roche, and UCB, 5; D. Khanna, Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,, Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics, 5, Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics, 8. :5 PM 79. Apolipoprotein L Risk Variants Underlie Racial Disparities in Lupus Nephritis-Induced End-Stage Renal Disease Robert P. Kimberly, Barry I. Freedman, Carl D. Langfeld, Devin Absher 4, Kelly K. Andringa, Daniel Birmingham 5, Elizabeth E. Brown, Mary E. Comeau 6, Karen H. Costenbader 7, Lindsey A. Criswell 8, Jeffrey C. Edberg 9, John B. Harley 0, Judith A. James, Diane L. Kamen, Joan T. Merrill, Timothy B. Niewold 4, Neha Patel 5, Michelle A. Petri 6, Rosalind Ramsey- Goldman 7, Jane E. Salmon 8, Mark Segal 9, Kathy Moser Sivils, Betty P. Tsao 0, Bruce A. Julian9 and Lupus Nephritis- ESRD Consortium, University of Alabama at Birmingham, Birmingham, AL, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University Health Sciences, Winston-Salem, 4 HudsonAlpha Institute for Biotechnology, Huntsville, 5 Ohio State University Medical Center, Columbus, OH, 6 Wake Forest University Health Sciences, Winston-Salem, NC, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 8 University of California San Francisco, San Francisco, CA, 9 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 0 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 University of Chicago, Chicago, IL, 5 SUNY Downstate Medical Center, Brooklyn, NY, 6 Johns Hopkins University School of Medicine, Baltimore, MD, 7 Northwestern University Feinberg School of Medicine, Chicago, IL, 8 Hospital for Special Surgery, New York, NY, 9 University of Florida, Gainesville, FL, 0 UCLA School of Medicine, Los Angeles, CA, Birmingham, AL Background/Purpose: The G and G coding variants in the apolipoprotein L gene (APOL; G: a compound missense allele (glycine-4/methionine-84) and G: an in-frame deletion (deletion of asparagine-88 and tyrosine-89)), are strongly and reproducibly associated with focal segmental glomerulosclerosis (FSGS), HIV-associated collapsing glomerulopathy, and hypertension-attributed end-stage renal disease (ESRD) in African Americans (AAs) [Genovese G et al. Science 9:84,00; Tzur S et al. Hum Genet 8:45,00]. The role of APOL in lupus nephritis (LN) related ESRD is unexplored. We tested for association between APOLrisk variants and LN-ESRD in a national sample of unrelated AAs with systemic lupus erythematosus (SLE). Methods: The study sample included 668 AA cases with LN-ESRD (456 with kidney biopsy documentation; physician-reported) and 697 AA patients with longstanding SLE lacking LN (mean duration of disease: 0. years). Genotyping was performed on a Sequenom platform. Allele frequency differences between LN-ESRD cases and SLE non-nephropathy cases were analyzed using multivariable logistic regression models, adjusting for non-muscle myosin heavy chain 9 gene single nucleotide polymorphism rs48480 using a recessive genetic model. Results: In cases with LN-ESRD, 87.% were female, 89% received cytotoxic therapy, mean + SD age at SLE onset was years, and duration of SLE to ESRD was years with median at 5 years. In non-nephritis SLE patients, 9.5% were female with age at SLE onset years. Contrasting all cases with and without ESRD, APOL risk variants were significantly associated with LN-ESRD (odds ratio.5 ( % CI); p=4.5e-9); significant differences in association were not observed when comparing cases with or without kidney biopsy documentation to SLE patients without LN. The duration of SLE onset to ESRD for those with the G/G variants was 5.49+/-0.54 (median=4) years, while that for those without the variants was 7.78+/-0.7 (median=6) years, p<0.05. Conclusion: This study demonstrates strong association between both APOL G and G variants and LN-associated ESRD in AAs. It appears likely that APOL G and G coding variants, which are rare in European populations, contribute to nephropathy progression in LN-ESRD, as well as in FSGS and other nondiabetic etiologies of ESRD. These variants, and their higher 6 0 Program Book

39 prevalence in individuals with African ancestry, may explain, in part, disparities in clinical outcomes in LN with there being a higher prevalence of severe LN in AA. Disclosure: R. P. Kimberly, None; B. I. Freedman, None; C. D. Langfeld, None; D. Absher, None; K. K. Andringa, None; D. Birmingham, None; E. E. Brown, None; M. E. Comeau, None; K. H. Costenbader, None; L. A. Criswell, None; J. C. Edberg, None; J. B. Harley, None; J. A. James, None; D. L. Kamen, None; J. T. Merrill, None; T. B. Niewold, None; N. Patel, None; M. A. Petri, None; R. Ramsey-Goldman, None; J. E. Salmon, None; M. Segal, None; K. Moser Sivils, None; B. P. Tsao, None; B. A. Julian, None. ARHP SESSIONS :00 am - Noon 06 Hands: Non-Surgical Management and Bracing - What You Don t Know Can Hurt You Moderator: Donna K. Everix, MPA, BS, PT Speaker: Tracey L. Airth-Edblom, OTR, CHT Upon completion of this session, participants should be able to: describe why early intervention for conservative treatment is indicated for rheumatologic diagnoses define how non-surgical methods can provide pain management techniques identify at least five different strategies of a non-surgical comprehensive program for rheumatologic diagnoses 4 A New Medication Developments in Rheumatology Moderator: Linda J. Pine, PharmD Speaker: Kam Nola, PharmD, MS Upon completion of this session, participants should be able to: identify new molecular entities submitted and approved by the Food and Drug Administration used in rheumatology practice discuss best practices in therapy for new molecular entities report changes in safety of new and existing medications in rheumatology practice explain medication shortage issues facing rheumatology practice 04 A Rheumatic Disease Update: Vasculitis Moderator: James G. Freeman, MD Speaker: Philip Seo, MD, MHS Upon completion of this session, participants should be able to: outline the classification of the major categories of vasculitis explain the diagnostic approach to patients with suspected vasculitis recognize the wide differential diagnosis and potential mimics of vasculitis cite the data supporting the current treatment recommendations for the various forms of vasculitis 0 The 5A Approach to Physical Activity Counseling for Arthritis Patients Moderator: Linda S. Ehrlich-Jones, PhD, RN Speaker: Jennifer M. Hootman, ATC, PhD Upon completion of this session, participants should be able to: describe the history of the 5A model for brief behavior change explain components of the 5A model as applied to physical activity counseling for arthritis patients associate counseling strategies for each stage identify tools to help incorporate the 5A model into clinical practice ACR SESSION :0 - :45 PM 0 B ACR Knowledge Bowl Preliminary Round Moderator: Zsuzsanna H. McMahan, MD, MHS Upon completion of this session, participants should be able to: identify key images that are important to recognize in clinical practice recall factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology Duke University Lisa G. Criscione-Schreiber, MD, Eric Orlowsky, MD and Sara Wasserman, MD Ochsner Medical Center Robert Quinet, MD, Austin Fraser, MD and Sharon Ing, MD University of Colorado Jason R. Kolfenbach, MD, Christina Bright, MD and Kristen Demorouelle, MD University of Michigan David Fox, MD, Nezam Altorok, MD and Shailey Desai, MD University of Minnesota Bryce Binstadt, MD, PhD, Theresa Wampler, MD and Patricia Hobday, MD The University of Pittsburgh Marc Levesque, MD, Christine Peoples, MD and Ximena Ruiz, MD University of Vermont Bonita S. Libman, MD, Narandra Bethina, MD and Tatiana Keck, MD ARHP NETWORKING EVENT :0 - :5 PM Renaissance Washington - Renaissance Ballroom, East & West Networking Forum All ARHP attendees are invited to this kick-off forum for the annual meeting. A box lunch will be provided for the first 50 people. You will have an opportunity to meet and network with other health professionals and the ARHP leadership. This session is not eligible for CME credit. SUNDAY November, 0 0 Program Book 7

40 SUNDAY November, 0 ACR MEET THE PROFESSOR SESSIONS :45 - :5 PM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September Adult Inflammatory Myopathy (0) Speaker: Mary E. Cronin, MD 5 Cutaneous Vasculitis (0) Speaker: Nicole Fett, MD 54 A Inflammatory Eye Disease/Uveitis (0) Speaker: Sergio Schwartzman, MD 54 B Myopathy: Issues in Diagnosis and Treatment (04) Speaker: Lisa Christopher-Stine, MD, MPH 55 Osteoporosis: Novel Treatments (05) Speaker: Michael J. Maricic, MD 58 A Pediatrics: Periodic Fevers in Children (06) Speaker: Daniel L. Kastner, MD, PhD 58 B Polymyalgia Rheumatica (07) Speaker: Bhaskar Dasgupta, MD 59 A Pregnancy in Rheumatic Diseases (08) Speaker: Eliza F. Chakravarty, MD 59 B Systemic Lupus Erythematosus: Novel Treatments (09) Speaker: Mary Anne Dooley, MD, MPH 60 Vitamin D and Bone Health (00) Speaker: Nancy E. Lane, MD ACR SESSIONS :00 - :00 PM 04 A Endoplasmic Reticulum Stress Unfolded Protein Response in Immunity and Inflammation Moderator: Robert Lafyatis, MD Speaker: Randal J. Kaufman, PhD Upon completion of this session, participants should be able to: describe the molecular pathways activated by the unfolded protein response explain the relationship between endoplasmic reticulum stress and apoptosis identify recent advances linking the endoplasmic reticulum stress to inflammation and immunity 46 C Mechanisms of Pain in Rheumatic Diseases Moderator: Anne-Marie Malfait, MD, PhD Speaker: Clifford Woolf, MB, BCh, PhD Upon completion of this session, participants should be able to: classify different types of pain, and how these relate to rheumatological diseases review the neurobiology of pain describe potential for targeting arthritis-related pain Hall E Preoperative Assessment and Perioperative Management of the Patient with Rheumatic Disease: What Every Rheumatologist Should Know (Clinical Review) Moderator: Elana J. Bernstein, MD Speaker: Linda Russell, MD Upon completion of this session, participants should be able to: describe the important components of preoperative assessment of the patient with rheumatic disease undergoing elective surgery discuss preoperative and perioperative management of biologic and non-biologic DMARD therapy discuss preoperative and perioperative management of antiplatelet and anticoagulant therapy identify perioperative complications of common orthopedic procedures ACR WORKSHOPS :5 - :5 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September Program Book

41 49 B Designing a Website for Your Practice (08) Speaker: Peter J. Embi, MD, MS 44 A Muscle Involvement in Rheumatic Diseases (09) Speaker: Sakir Humayun Gultekin, MD 44 C Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (0) :0 PM ACPAs and the Prospects for Immunotherapy for Rheumatoid Arthritis Lars Klareskog, MD, PhD :00 PM Is Rheumatoid Arthritis a Preventable Disease? V. Michael Holers, MD :0 PM Novel Approaches to Rheumatoid Arthritis Michael B. Brenner, MD Speaker: Edward C. Keystone, MD 49 A Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis () Speaker: Megan Troxell, MD ACR SESSIONS :0-4:00 PM Ballroom A Complementary and Alternative Medicine: Evidencebased Options for Arthritis Patients PM Moderator: Sharon L. Kolasinski, MD Upon completion of this session, participants should be able to: contrast traditional physical therapy with alternative exercise options evaluate the literature supporting the use of alternative therapies appreciate the role of tai chi and yoga among exercise options for patients :0 PM Overview of Complementary and Alternative Medicine To be announced :00 PM Tai Chi for Arthritis Chenchen Wang, MD, MSc :0 PM Role of Yoga in the Management of Arthritis Susan J. Bartlett, PhD Salon B Prospects for Prevention and Cure of Rheumatoid Arthritis Moderators: Robert M. Plenge, MD, PhD and Peter A. Nigrovic, MD Upon completion of this session, participants should be able to: define key limitations in our understanding of rheumatoid arthritis consider diverse and novel approaches to the exploration of rheumatoid arthritis review potential new points of intervention in the biology of rheumatoid arthritis Hall D The Great Debate: In 0 What are the Roles of Cyclophosphamide versus Rituximab in ANCA- Associated Vasculitis Moderator: Robert F. Spiera, MD Upon completion of this session, participants should be able to: describe the safety issues with cyclophosphamide versus rituximab in ANCA-associated vasculitis identify what is known about remission induction and relapse with cyclophosphamide versus rituximab in ANCA-associated vasculitis outline the advantages and disadvantages of cyclophosphamide versus rituximab in ANCA-associated vasculitis :0 PM Does Cyclophosphamide Continue to Have a Role in Severe ANCA-Associated Vasculitis Carol A. Langford, MD, MHS :5 PM Should Rituximab be the First Treatment of Choice in Severe ANCA-Associated Vasculitis? Ulrich Specks, MD Hall E Update on Treatment of Systemic Lupus Erythematosus Moderator: Virginia D. Steen, MD Upon completion of this session, participants should be able to: describe the types of cutaneous manifestations of lupus and how to treat them discuss how management of lupus nephritis has changed over the last five years demonstrate the ability to use the newer treatments used in the management of lupus :0 PM Cutaneous Problems in Lupus David Fiorentino, MD, PhD :00 PM Update on Lupus Nephritis James E. Balow, MD :0 PM Other Treatments in Lupus, the Role of New Agents Bevra H. Hahn, MD 0 Program Book 9 SUNDAY November, 0

42 SUNDAY November, 0 ACR CONCURRENT ABSTRACT SESSIONS :0-4:00 PM 50 B Biology and Pathology of Bone and Joint: Osteoarthritis Moderator: Hiroshi Asahara, MD and Mary B. Goldring, PhD :0 PM 70. Disease Modifying Effect of Strontium Ranelate in Experimental Dog Osteoarthritis: Inhibition of Major Catabolic Pathways Jean-Pierre Pelletier, Mohit Kapoor, Daniel Lajeunesse, Hassan Fahmi and Johanne Martel-Pelletier, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC :45 PM 7. A Systems Biology Approach to Elucidating Pathways Active During the Development of Osteoarthritis Richard F. Loeser, Amy L. Olex, Brian Westwood, Margaret A. McNulty, Cathy S. Carlson, Michael Callahan 4, Cristin Ferguson 4 and Jacquelyn S. Fetrow, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University, Winston-Salem, NC, University of Minnesota, St. Paul, MN, 4 Wake Forest School of Medicine, Winston-Salem :00 PM 7. Changes in Subchondral Bone Provide a Sensitive Marker for Osteoarthritis and Its Progression: Results From a Large Osteoarthritis Initiative Cohort Michael A. Bowes, Christopher B. Wolstenholme, Devan Hopkinson, Graham R. Vincent and Philip G. Conaghan, Imorphics Ltd, Manchester, United Kingdom, University of Leeds, Leeds, United Kingdom :5 PM 7. Intra-Articular Injection of Adipose-Derived Stem Cells Inhibits Activation of the Synovium and Protects Against Cartilage Damage and Enthesophyte Formation in Murine Experimental Osteoarthritis Peter L.E.M. van Lent, Menno C. ter Huurne, Arjen B. Blom, Rik Schelbergen, Louis Casteilla, Thomas Vogl, Johannes Roth, Roxane Blattes, Christian Jorgensen 4 and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, INSERM U0, Toulouse, France, University of Muenster, Munster, Germany, 4 Hospital Lapeyronie, Montpellier, France :0 PM 74. Chemokine (C-C Motif) Receptor Signaling Mediates Persistent Pain in Experimental Osteoarthritis Rachel E. Miller, Phuong Tran, Rosalina Das, Nayereh Ghoreishi-Haack, Richard J. Miller and Anne-Marie Malfait, Rush University Medical Center, Chicago, IL, Northwestern University, Evanston, IL :45 PM 75. Mass Spectrometry Assays of Plasma Biomarkers to Predict Radiographic Progression of Knee Osteoarthritis Susan Y. Ritter, William M. Reichmann, Jamie E. Collins, Alejandra Garces, Bryan Krastins, David Sarracino, Mary Lopez, Elena Losina and Antonios O. Aliprantis, Brigham and Women s Hospital, Boston, MA, Thermo Fisher Scientific BRIMS Center, Cambridge, MA 47 A Cytokines, Mediators, and Gene Regulation I Moderators: Erik Lubberts, PhD and Hendrik Schulze-Koops, MD, PhD :0 PM 0 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk I Speaker: Andrew D. Luster, MD, PhD :45 PM 76. Inhibition of Interleukin-7 Signaling Via De-Ubiquitinatio Sarah L. Gaffen and Abhishek Garg, University of Pittsburgh, Pittsburgh, PA :00 PM 77. Citrullination of ENA-78/CXCL5 Results in Conversion From a Non-Monocyte Recruiting to a Monocyte Recruiting Chemokine Ken Yoshida, Olex Korchynskyi, Paul P. Tak, Takeo Isozaki, Jeffrey H. Ruth, Phillip Campbell, Dominique L. Baeten 4, Danielle M. Gerlag 4, M. Asif Amin and Alisa E. Koch 5, University of Michigan, Ann Arbor, MI, Institute of Cell Biology, Lviv, Ukraine, GlaxoSmithKline U.K. and Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, 4 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5 University of Michigan Medical School, Ann Arbor, MI :5 PM 78. A Novel Orally Active Phosphatidylinositol -Phosphate 5-Kinase (PIKfyve) Inhibitor Ameliorates Mouse Psoriasis- Like Model by Inhibition of Interleukin- and Interleukin- Production From Macrophages Ayatoshi Andou, Eviryanti Agung, Yukie Seki, Yoichiro Shima, Sen Takeshita, Takashi Yamamoto and Hiroyuki Eda, Ajinomoto Pharmaceuticals Co., Ltd., Kanagawa, Japan :0 PM 79. The Serine Arginine Protein SF/ASF Is a Novel Regulator of IL- Transcription and Restores IL- Production in T Lymphocytes From SLE Patients Vaishali R. Moulton, Alexandros P. Grammatikos and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA :45 PM 740. Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification Melissa E. Munroe, Jourdan R. Anderson, Julie M. Robertson, Timothy B. Niewold, George C. Tsokos, Michael P. Keith 4, John 40 0 Program Book

43 B. Harley 5 and Judith A. James 6, Oklahoma Medical Research Foundation, Oklahoma City, OK, University of Chicago, Chicago, IL, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4 Walter Reed National Military Medical Center, Bethesda, MD, 5 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 6 Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK 0 B Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease Moderators: Liron Caplan, MD, PhD and Cheryl Barnabe, MD, MSc :0 PM 74. Increased Risk of Recurrent Gout Attacks During Hospitalization Yuqing Zhang, Clara Chen, Hyon K. Choi, Christine E. Chaisson, David J. Hunter 4 and Tuhina Neogi 5, Boston University, Boston, MA, Boston University School of Public Health, Boston, MA, Boston University School of Medicine, University of British Columbia, Arthritis Research Centre of Canada, Boston, MA, 4 University of Sydney, Sydney, Australia, 5 Boston Univ Schl of Med, Boston, MA :45 PM 74. Utility of HLA-B580 Genotyping and Renal Dosing of the Starting Dose of Allopurinol in Preventing Allopurinol Hypersensitivity Syndrome: A Cost-Effectiveness Analysis Yanyan Zhu, Ada Man, Tuhina Neogi and Hyon K. Choi 4, Boston University School of Medicine, Boston, MA, Boston University, Boston, MA, Boston Univ School of Medicine, Boston, MA, 4 Boston University School of Medicine, University of British Columbia, Arthritis Research Centre of Canada, Boston, MA :00 PM 74. Anemia and the Onset of Gout in a Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study Mara McAdams DeMarco, Janet W. Maynard, Josef Coresh and Alan N. Baer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD :5 PM 744. Racial Differences in Reported Knee Pain Severity Persist Even After Adjustment for Knee Examination and Radiographic Findings: Data From the Osteoarthritis Initiative Paige Luneburg, Laura Yerges-Armstrong, Braxton D. Mitchell and Marc C. Hochberg, University of Maryland, Baltimore, MD, University of Maryland School of Medicine, Baltimore, MD :0 PM 745. Soft Drink Intake and Progression of Radiographic Knee Osteoarthritis: Data From the Osteoarthritis Initiative Bing Lu, Jeffrey Driban, Tim McAlindon and Charles Eaton 4, Brigham and Women s Hospital, Boston, MA, Tufts Medical Center, MA, Tufts Medical Center, Boston, MA, 4 Warren Alpert Medical School at Brown University, RI :45 PM 746. Increased Risk of Acute and Chronic Renal Comorbidity in Ankylosing Spondylitis: Results From a Population-Based Study Walter P. Maksymowych, Shelagh Szabo, Sumati Rao, Mary A. Cifaldi and Adrian R. Levy 4, University of Alberta, Edmonton, AB, Oxford Outcomes, Vancouver, BC, Abbott Laboratories, Abbott Park, IL, 4 Oxford Outcomes Ltd, Vancouver, BC 45 A Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes Moderators: Kristine M. Lohr, MD, MS and Katherine K. Temprano, MD :0 PM 747. Familial Mediterranean Fever: Inhibition of IL-6 Signalling As a New Therapeutic Option in a Frequent Autoinflammatory Syndrome. Nicola Stein, Matthias Witt, Michael Baeuerle, Fabian Proft, Hendrik Schulze-Koops and Mathias Gruenke, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, Klinikum Nürnberg, Nuernberg, Germany, University of Munich, Munich, Germany :45 PM 748. Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta- Analysis of 5 Studies Helen J. Lachmann, Jasmin B. Kuemmerle-Deschner, Toshio Heike, Toshiro Hara 4, Shumpei Yokota 5, Phil Mckernan 6, Albert Widmer 6, Nicole Davis 7 and Eric Hachulla 8, University College London Medical School, London, United Kingdom, Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4 Department of Pediatrics, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan, 5 Department of Pediatrics, Yokohama City University, Graduate School of Medicine, Yokohama, Japan, 6 Novartis Pharma AG, Basel, Switzerland, 7 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8 Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France :00 PM 749. Efficacy and Safety of Canakinumab in Patients with TNF Receptor Associated Periodic Syndrome Marco Gattorno, Laura Obici, Antonella Meini, Vincent Tormey 4, Ken Abrams 5, Nicole Davis 6, Christopher Andrews 7 and Helen J. Lachmann 8, Istituto Giannina Gaslini, Genova, Italy, IRCCS Policlinico San Matteo, Pavia, Italy, Pediatric Immunology and Rheumatology, Brescia, Italy, 4 Galway University Hospitals, Galway, Ireland, 5 Novartis Pharmaceutical Corporation, East Hanover, NJ, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7 Novartis Pharmaceuticals UK Limited, Surrey, United Kingdom, 8 University College London Medical School, London, United Kingdom :5 PM 750. Efficacy and Safety of Canakinumab in Adults with Colchicine Resistant Familial Mediterranean Fever A. Gul, H. Ozdogan, B. Erer, S. Ugurlu, Nicole Davis, S. Sevgi 4 0 Program Book 4 SUNDAY November, 0

44 SUNDAY November, 0 and O. Kasapcopur, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, Novartis Pharma Corp, East Hannover, 4 Novartis Pharma, Istanbul, Turkey :0 PM 75. Whole Transcriptome Analysis in Erdheim-Chester Disease: A Multicenter Collaborative Study of 58 Patients Laurent Arnaud, Julien Haroche, Lorenzo Dagna, Augusto Vaglio, Bruno Faivre 4, Karim Dorgham 4, Baptiste Hervier, Fleur Cohen-Aubart, Guy Gorochov 4 and Zahir Amoura, Hopital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, Vita-Salute San Raffaele University School of Medicine and San Raffaele Scientific Institute, Milano, Italy, University of Parma, Parma, Italy, 4 Institut National de la Santé et de la Recherche Médicale, INSERM UMR-S 945, Paris, France :45 PM 75. IFNg Production Is Intimately Associated with Clinical and Laboratory Features of CpG-Induced Secondary Hemophagocytic Lymphohistiocytosis (shlh)/macrophage Activating Syndrome (MAS) in Mice Vanessa Buatois, Laurence Chatel, Laura Cons, Maureen Deehan, Cristina de Min, Marie Kosco-Vilbois and Walter Ferlin, NovImmune S.A., Geneva, Switzerland 5 A Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies Moderators: Ingrid E. Lundberg, MD, PhD and Lisa G. Rider, MD :45 PM 754. The Functional Index- in Adult Dermatomyositis and Polymyositis: Validity and Reliability of an Outcome Measure for Muscle Endurance Christopher Chong, Orla Ni Mhuircheartaigh, Helene Alexanderson, Tanaz A. Kermani, Cynthia S. Crowson 4, Abigail B. Green 4, Ann M. Reed 4 and Floranne C. Ernste 5, Mayo Clinic, Rochester, Karolinska Institutet, Stockholm, Sweden, University of California Los Angeles, Los Angeles, 4 Mayo Clinic, Rochester, MN, 5 Mayo Clinic Rochester, Rochester, MN :00 PM 755. Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody Shows Target Suppression of a Type I IFN Signature in Blood and Muscle of Dermatomyositis and Polymyositis Patients Brandon W. Higgs, Wei Zhu, Chris Morehouse, Wendy White, Philip Brohawn, Charles Le, Anthony A. Amato, David Fiorentino, Steven A. Greenberg, Laura Richman, Warren Greth, Bahija Jallal and Yihong Yao 4, MedImmune, LLC, Gaithersburg, MD, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, Stanford University School of Medicine, Redwood City, CA, 4 MedImmune, Gaithersburg, MD :5 PM 756. Effect of B Cell Depletion Therapy with Rituximab On Myositis Associated Autoantibody Levels in Idiopathic Inflammatory Myopathy Rohit Aggarwal, Chester V. Oddis, Andriy Bandos, Danielle Goudeau, Diane Koontz, Qi Zengbiao, Ann M. Reed, Dana P. Ascherman 4 and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, Mayo Clinic, Rochester, MN, 4 University of Miami, Miami, FL 4 :0 PM 75. Progress Report On Development of Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies Anna Tjärnlund, Matteo Bottai, Lisa G. Rider, Victoria P. Werth 4, Clarissa A. Pilkington 5, Marianne de Visser 6, Lars Alfredsson 7, Anthony A. Amato 8, Richard J. Barohn 9, Matthew H. Liang 0, Jasvinder A. Singh, Frederick W. Miller, Ingrid E. Lundberg and the International Myositis Classification Criteria Project, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, NIEHS, NIH, Bethesda, MD, 4 University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, 5 Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 6 Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, Amsterdam, Netherlands, 7 Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 8 Brigham and Women s Hospital and Harvard Medical School, Boston, MA, 9 Department of Neurology, University of Kansas Medical Center, Kansas City, USA, Kansas City, MO, 0 Brigham & Womens Hospital, Boston, MA, University of Alabama at Birmingham, Birmingham, AL, Karolinska Institutet, Stockholm, Sweden, Stockholm 0 Program Book :0 PM 757. Beneficial Role of Rapamycin in Experimental Autoimmune Myositis Nicolas Prevel, Yves Allenbach, David Klatzman, Benoit Salomon and Olivier Benveniste, UPMC Université Paris 06, UMR 7, Paris, France, Pitie-Salpetriere Hospital, Paris, France :45 PM 758. Cutaneous Ulceration in Dermatomyositis: Association with MDA-5 and Interstitial Lung Disease Neera Narang, Livia Casciola-Rosen, Antony Rosen, David Fiorentino 4 and Lorinda Chung 5, Stanford Univ Medical Center, Stanford, CA, Johns Hopkins University, Baltimore, MD, The Johns Hopkins University, Baltimore, MD, 4 Stanford University School of Medicine, Redwood City, CA, 5 Stanford Univ Medical Center, Palo Alto, CA 07 A Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I Moderators: Rayfel Schneider, MBBCh and Angelo Ravelli, MD :0 PM 759. Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase Trials Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Tamás Constantin, Nico Wulffraat, Gerd Horneff, Riva Brik,

45 Liza McCann, Huri Ozdogan, Lidia Rutkowska-Sak, Rayfel Schneider, Yackov Berkun, Inmaculada Calvo, Muferet Erguven, Laurence Goffin, Michael Hofer, Tilmann Kallinich, Karine Lheritier 4, Ken Abrams 5, Andrea Stancati 4, D. J. Lovell 6 and Alberto Martini, Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Paediatric Rheumatology International Trials Organisation (PRINTO)-Istituto Gaslini, Genova, Italy, Necker-Enfants Malades Hospital, Paris, France, 4 Novartis Pharma AG, Basel, Switzerland, 5 Novartis Pharmaceutical Corporation, East Hanover, NJ, 6 Cincinnati Children s Hospital, Cincinnati, OH :45 PM 760. Catch-up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: -Year Data From a Phase Clinical Trial Fabrizio De Benedetti, Nicolino Ruperto, Graciela Espada, Valeria Gerloni, Berit Flato, Gerd Horneff 4, Barry L. Myones 5, Karen Onel 5, James Frane 6, Andrew Kenwright 7, Terri H. LiPMan 8, Kamal N. Bharucha 6, Alberto Martini and D. J. Lovell 9, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, Paediatric Rheumatology International Trials Organisation IRCCS [PRINTO], Genova, Italy, 4 Centre of Pediatric Rheumatology, Sankt Augustin, Germany, 5 Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 6 Genentech, South San Francisco, CA, 7 Roche, Welwyn Garden City, United Kingdom, 8 University of Pennsylvania School of Nursing, Philadelphia, PA, 9 Cincinnati Children s Hospital, Cincinnati, OH :00 PM 76. Analysis of Biomarkers in Systemic Juvenile Idiopathic Arthritis Patients On Canakinumab Therapy Nico Wulffraat, Hermine I. Brunner, Nicolino Ruperto, Pierre Quartier, Riva Brik, Liza McCann, Huri Ozdogan, Lidia Rutkowska-Sak, Rayfel Schneider, Valeria Gerloni, Liora Harel, Maria Hilário, Kristin Houghton, Rik Joos, Daniel Kingsbury, Arndt Brachat 4, Stephan Bek 4, Martin Schumacher 4, Marie- Anne Valentin 4, N.R Nirmala 5, Hermann Gram 4, Ken Abrams 6, Alberto Martini and D. J. Lovell 7, Paediatric Rheumatology International Trials Organization (PRINTO), Genova, Italy, Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, Necker-Enfants Malades Hospital, Paris, France, 4 Novartis Institutes for Biomedical Research, Basel, Switzerland, 5 Novartis Institutes for Biomedical Research, Cambridge, MA, 6 Novartis Pharmaceuticals Corporation, New Jersey, 7 Cincinnati Children s Hospital, Cincinnati, OH :5 PM 76. Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis Yukiko Kimura, Jennifer E. Weiss, Kathryn L. Haroldson, Tzielan C. Lee, Marilynn G. Punaro, Sheila K. Feitosa de Oliveira 4, Egla C. Rabinovich 5, Meredith P. Riebschleger 6, Jordi Anton 7, Peter R. Blier 8, Valeria Gerloni 9, Melissa M. Hazen 0, Elizabeth Kessler, Karen Onel, Murray H. Passo, Robert M. Rennebohm 4, Carol A. Wallace 5, Patricia Woo 6, Nico M. Wulffraat 7 and CARRAnet Investigators 8, JM Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Stanford Univ School of Med, Stanford, CA, Texas Scottish Rite Hospital, Dallas, TX, 4 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 5 Duke University Medical Center, Durham, NC, 6 University of Michigan Health System, Ann Arbor, MI, 7 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 8 Baystate Children s Hospital, Springfield, MA, 9 Gaetano Pini Chair of Rheum, Milan, Italy, 0 Children s Hospital Boston, Boston, MA, Medical College of Wisconsin, Milwaukee, WI, University of Chicago, Chicago, IL, Medical University of South Carolina, Charleston, SC, 4 Alberta Children s Hospital, University of Calgary, Calgary, AB, 5 Seattle Childrens Hospital, Seattle, WA, 6 University College London, London, United Kingdom, 7 University Medical Center Utrecht, Utrecht, Netherlands, 8 Durham :0 PM 76. Incidence of Selected Opportunistic Infections Among Children with Juvenile Idiopathic Arthritis Timothy Beukelman, Fenglong Xie, John Baddley, Lang Chen, Elizabeth S. Delzell, Carlos Grijalva, Melissa L. Mannion, Nivedita M. Patkar, Kenneth G. Saag, Kevin L. Winthrop and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, Vanderbilt University, Nashville, TN, Oregon Health & Science University, Portland, OR :45 PM 764. The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis D. J. Lovell, Nicolino Ruperto, Katerina Jarosova, Dana Nemcova, Veronika Vargova, Hartmut Michels, Elizabeth Chalom, Norman Ilowite, Carine Wouters, Hermine Brunner, Karolyn Kracht 4, Hartmut Kupper 5, Edward Giannini, Alberto Martini and Neelufar Mozaffarian 4, Cincinnati Children s Hospital, Cincinnati, OH, Paediatric Rheumatology International Trials Organisation IRCCS [PRINTO], Genova, Italy, Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 4 Abbott, Abbott Park, IL, 5 Abbott GmbH and Co. KG, Ludwigshafen, Germany Ballroom C Rheumatoid Arthritis - Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis Moderators: Vivian P. Bykerk, MD and Elizabeth Karlson, MD :0 PM 765. A Prediction Rule for the Development of Rheumatoid Arthritis: A Prospective Cohort Study of Seropositive Arthralgia Patients Lotte van de Stadt, B. I. Witte, W.H. Bos and Dirkjan van Schaardenburg, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands :45 PM 766. Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis Burkhard Moller, Frauke Förger, Peter M. Villiger and Axel Finckh 4, Inselspital University Hospital, Bern, Switzerland, Inselspital University Hospital of Bern, Bern, Switzerland, Inselspital-University Hospital of Bern, Bern, Switzerland, 4 Geneva University Hospitals, Geneva 4, Switzerland 0 Program Book 4 SUNDAY November, 0

46 SUNDAY November, 0 :00 PM 767. Patients with Early Inflammatory Arthritis Who Fulfil the 00 American College Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis Have Increased Mortality Compared to Those Who Do Not: Results From the Norfolk Arthritis Register Jh Humphreys, Suzanne Verstappen, Mark Lunt, Jackie Chipping 4, Kimme Hyrich 5, Tarnya Marshall 6 and Deborah Symmons 7, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4 Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, 5 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 6 Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 7 University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom :5 PM 768. An Easy to Use Referral Model for Arthritis From the Rotterdam Early Arthitis Cohort C. Alves, Jolanda J. Luime, Darian P. Shackleton, P.J. Barendregt 4, A.H. Gerards 5 and Johanna M.W. Hazes 6, Erasmus MC, Rotterdam, Netherlands, Erasmus MC - University Medical Center, Rotterdam, Netherlands, Medisch Centrum Parklaan, Netherlands, 4 Maasstad Hospital, Rotterdam, Netherlands, 5 Vlietland Hospital, Schiedam, Netherlands, 6 Erasmus Medical Center, Rotterdam, Netherlands :0 PM ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes At 8 Months Into Disease in a Canadian Early Arthritis Cohort Ariel Masetto, Arthur J. Fernandes, Patrick Liang, Pierre Cossette and Gilles Boire 4, CHUS, Fleurimont, QC, Universite de Sherbrooke, Sherbrooke N, CHUS, Sherbrooke, QC, 4 CHUS - Sherbrooke University, Sherbrooke, QC :45 PM 770. Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort Ruediger Mueller, Toni Kaegi, Axel Finckh and Johannes von Kempis, MD, St. Gallen, Switzerland, Geneva University Hospitals, Geneva 4, Switzerland Renaissance Washington - Grand Ballroom North Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis Moderators: Joseph A. Markenson, MD and Mark C. Genovese, MD :0 PM 77. Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): -Year Results Yoshiya Tanaka, Shintaro Hirata, Shunsuke Fukuyo, Masao Nawata, Satoshi Kubo, Kunihiro Yamaoka and Kazuyoshi Saito, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan :45 PM 77. Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 4-Week Study Arthur Kavanaugh, Paul Emery, Ronald F. van Vollenhoven, Ara H. Dikranian 4, Rieke Alten 5, Micki Klearman 6, David Musselman 6, Sunil Agarwal 6, Jennifer Green 7 and Cem Gabay 8, UCSD School of Medicine, La Jolla, CA, University of Leeds, Leeds, United Kingdom, Karolinska Institute, Stockholm, Sweden, 4 San Diego Arthritis Medical Clinic, San Diego, CA, 5 Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 6 Genentech Inc, South San Francisco, CA, 7 Welwyn Garden City, United Kingdom, 8 Geneva University Hospitals, Geneva, Switzerland :00 PM 77. Remission Rates with Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria J. S. Smolen, D. Aletaha, D. Gruben, J. D. Bradley, S. H. Zwillich, S. Krishnaswami, B. Benda and C. Mebus, Medical University of Vienna, Vienna, Austria, Pfizer Inc., Groton, CT, Pfizer Inc., Collegeville, PA :5 PM 774. A CD4+ T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis Arthur G. Pratt, Philip M. Brown, Simon J. Cockell, Gillian Wilson and John D. Isaacs 4, Newcastle University, Newcastle Upon Tyne, United Kingdom, Newcastle University, Newcastleupon-Tyne, United Kingdom, Freeman Hospital, Newcastleupon-Tyne, United Kingdom, 4 Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom :0 PM 775. Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach Roy Fleischmann, Ronald F. van Vollenhoven, Josef S. Smolen, Paul Emery 4, Stefan Florentinus 5, Suchitrita S. Rathmann 6, Hartmut Kupper 7 and Arthur Kavanaugh 8, University of Texas Southwestern Medical Center, Dallas, TX, Karolinska Institute, Stockholm, Sweden, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4 Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 5 Abbott, Rungis, France, 6 Abbott, Abbott Park, IL, 7 Abbott GmbH and Co. KG, Ludwigshafen, Germany, 8 UCSD School of Medicine, La Jolla, CA :45 PM 776. A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission Katerina Chatzidionysiou, Carl Turesson, Annika Teleman, Ann Knight 4, Elisabet Lindqvist 5, Per Larsson 6, Lars Cöster 7, Barbro 44 0 Program Book

47 Rydberg 8, Ronald F. van Vollenhoven 9 and Mikael Heimbürger 0, Karolinska Institute, Stockholm, Sweden, Lund University, Malmö, Sweden, Department of Rheumatology, Spenshult Hospital, Oskarstrom, Sweden, 4 Institution for Medical Sciences, Uppsala University, Uppsala, Sweden, 5 Section for Rheumatology Lund University, Lund, Sweden, 6 Karolinska University Hospital, Stockholm, Sweden, 7 University Hospital, Linköping, Sweden, 8 Kärnsjukhuset, Skövde, Sweden, 9 The Karolinska Institute, Stockholm, Sweden, 0 Abbott Scandinavia, Stockholm, Sweden Ballroom B Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I Moderators: Michael M. Ward, MD and Lianne S. Gensler, MD State Medical University, Kazan, Russia, 6 Catholic University of Korea, Seoul, South Korea, 7 Seoul National University, Seoul, South Korea, 8 Merck Sharp and Dohme, Kenilworth, NJ, 9 Merck Sharp and Dohme, Brussels, Belgium :5 PM 780. The Relationship of Inflammation, Fatty Degeneration and the Effect of Long-Term TNF-Blocker Treatment On the Development of New Bone Formation in Patients with Ankylosing Spondylitis Xenofon Baraliakos, Frank Heldmann, Joachim Listing, Johanna Callhoff, Juergen Braun and EASIC 4, Rheumazentrum Ruhrgebiet, Herne, Germany, Rheumazentrum Ruhrgebiet, Herne, Ghana, German Rheumatism Research Center, Berlin, Germany, 4 Herne, Germany :0 PM 777. Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis: 4 Week Results of a Double Blind Randomized Placebo-Controlled Phase Axial Spondyloarthritis Study Robert B. M. Landewé, Martin Rudwaleit, Désirée van der Heijde, Maxime Dougados 4, Walter P. Maksymowych 5, Jurgen Braun 6, Atul A. Deodhar 7, Christian Stach 8, Bengt Hoepken 8, Geoffroy Coteur 9, Danuta Kielar 9, Andreas Fichtner 8, Terri Arledge 0 and Joachim Sieper, Academic Medical Center/ University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, Endokrinologikum Berlin, Berlin, Germany, Leiden University Medical Center, Leiden, Netherlands, 4 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 5 University of Alberta, Edmonton, AB, 6 Rheumazentrum Ruhrgebiet, Herne, Germany, 7 Oregon Health & Science University, Portland, OR, 8 UCB Pharma, Monheim am Rheim, Germany, 9 UCB Pharma, Brussels, Belgium, 0 UCB Pharma, Rtp, NC, Charité Universitätesmedizin Berlin, Berlin, Germany :45 PM 778. Spinal MRI Has Little Incremental Diagnostic Value Compared with MRI of the Sacroiliac Joints Alone in Early Spondyloarthritis Ulrich Weber, Veronika Zubler, Zheng Zhao, Robert GW Lambert, Stanley Chan, Susanne Juhl Pedersen 4, Mikkel Ostergaard 5 and Walter P. Maksymowych, Balgrist University Hospital, Zurich, Switzerland, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, University of Alberta, Edmonton, AB, 4 Glostrup Hospital, Copenhagen, Denmark, 5 Copenhagen University Hospital at Glostrup, Glostrup, Denmark :0 PM 78. Ankylosing Spondylitis Is Associated with an Increased Risk of Osteoporotic Fractures: A Population-Based Cohort Study Juan Muñoz-Ortego, Peter Vestergaard, Josep Blanch, Paul Wordsworth 4, Andrew Judge 5, M. Kassim Javaid 6, Nigel K. Arden 6, Cyrus Cooper 7, Adolfo Díez-Pérez 8 and Daniel Prieto-Alhambra 9, Hospital Sagrat Cor, Barcelona (Spain), Barcelona, Spain, Aarhus University Hospital THG, Aarhus (Denmark), Aarhus, Denmark, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain, 4 Nuffield Orthopaedic Centre, Oxford, United Kingdom, 5 Oxford University, Oxford, United Kingdom, 6 Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, 7 University of Oxford; Southampton General Hospital, Southampton, United Kingdom, 8 Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, 9 URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain :45 PM 78. Anti-TNF Therapy Slows Radiographic Progression of Ankylosing Spondylitis Nigil Haroon, Robert D. Inman, Thomas J. Learch, Michael H. Weisman 4, Michael M. Ward 5, John D. Reveille 6 and Lianne S. Gensler 7, University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Cedars-Sinai, Los Angeles, CA, 4 Cedars- Sinai Medical Center, Los Angeles, CA, 5 NIAMS/NIH, Bethesda, MD, 6 Univ of Texas Health Science Center at Houston, Houston, TX, 7 UCSF, San Francisco, CA SUNDAY November, 0 :00 PM 779. Changes in Active Inflammatory Lesions Assessed by Magnetic Resonance Imaging: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial Joachim Sieper, Jan Lenaerts, Jürgen Wollenhaupt, Vadim Mazurov 4, L. Myasoutova 5, Sung-Hwan Park 6, Yeong W. Song 7, Ruji Yao 8, Denesh Chitkara 8 and Nathan Vastesaeger 9, Charité, University Medicine Berlin, Berlin, Germany, Reuma-instituut, Hasselt, Belgium, Schön-Klinik, Hamburg, Germany, 4 St. Petersburg Medical Academy, St. Petersburg, Russia, 5 Kazan 46 C Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Moderators: John Varga, MD and Maria Trojanowska, PhD :0 PM 78. The Wnt Inhibitors DKK and SFRP Are Downregulated by Promoter Hypermethylation in Systemic Sclerosis Clara Dees, Inga Schlottmann, Robin Funke, Alfiya Distler, Katrin Palumbo-Zerr, Pawel Zerr, Oliver Distler, Georg A. 0 Program Book 45

48 SUNDAY November, 0 Schett and Joerg HW Distler, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University Hospital Zurich, Zurich, Switzerland :45 PM 784. Neutralization of Plasminogen Activator Inhibitor- Resolves Skin Fibrosis and Vascular Injury in a Murine Model of Human Scleroderma Raphael Lemaire, Tim Burwell, Tracy Delaney, Cindy Chen, Julie Bakken, Lily Cheng, Philip Brohawn, Isabelle de Mendez, Dominic Corkill, Anthony Coyle, Ronald Herbst and Jane Connor, MedImmune LLC, Gaithersburg, MD, Medimmune, LLC, Cambridge, England, Pfizer, Inc., Cambridge (formerly at MedImmune LLC, Gaithersburg, MD, USA) :00 PM 785. Resident Lung Fibroblast Gene Expression Signatures Predict Susceptibility or Resistance to Experimental Lung Fibrosis Emma Derrett-Smith, Rachel Hoyles, Korsa Khan, David J. Abraham and Christopher P. Denton, UCL Medical School, London, United Kingdom, UCL, London, United Kingdom :5 PM 786. Crosstalk Between Integrins and TGFβ in the Pathogenesis and Treatment of Multiple Presentations of Scleroderma Elizabeth E. Gerber, Fredrick M. Wigley, Elaine C. Davis, David L. Huso and Harry C. Dietz, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins University, Baltimore, MD, McGill University, Montreal, QC :0 PM 787. Aberrant Adipogenesis in the Pathogenesis of Scleroderma Roberta Goncalves Marangoni, Jun Wei, Monique E. Hinchcliff, Feng Fang, Warren Tourtellotte and John Varga, Northwestern University Medical School, Chicago, IL :45 PM 788. Tenofovir, a Potent Anti-Viral Agent, Is an Ecto- 5 Nucleotidase (CD7) Inhibitor That Prevents Dermal Fibrosis in a Murine Model of Scleroderma Jessica L. Feig, Doreen Tivon, Miguel Perez-Aso, Timothy Cardozo and Bruce N. Cronstein, New York University School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY ARHP SESSIONS :0-4:00 PM 4 A Non-pharmacological Management of Fibromyalgia: Your Toolbox PM Moderator: Dane B. Cook, PhD Upon completion of this session, participants should be able to: discuss the basic components of cognitive-behavioral therapy for chronic pain and the evidence base for associated effectiveness provide the basic knowledge and associated materials needed to integrate multiple aspects of cognitive-behavioral therapy into practice describe various forms of exercise and the evidence base for their use in the treatment of fibromyalgia outline the basic knowledge and associated materials needed to educate patients in regard to exercise and enhance exercise persistence :0 PM Cognitive-behavioral Therapy You Can Use David A. Williams, PhD :5 PM Exercise Options and Motivating Persistence in Fibromyalgia Kim D. Jones, PhD 04 A Practice Managers: Improving Access and Website Marketing (Practice Management Series) Moderator: Laura Wright, MBA, CMPE Upon completion of this session, participants should be able to: recognize the importance of regular patient visits for viability of practice evaluate practice strengths and weaknesses of a growing practice outline ways to minimize barriers and opportunities by improving access and website marketing determine how to effectively reach optimal patient target audiences develop strategies for delivering advertised products (e.g., expertise, specialty, atmosphere, value) outline a viable plan for maintaining and improving quality of services to new patients :0 PM Marketing Chris Alonzo and John O Toole, BA 06 :5 PM Improving Access Michelle Hirschman Rheumatic Disease Update: Inflammatory Eye Disease Moderator: Deborah K. McCurdy, MD Speaker: Gary N. Holland, MD Upon completion of this session, participants should be able to: discuss the associations between rheumatic disorders and inflammatory eye disease recognize anatomical lesions of the eye as they relate to diagnosis identify appropriate therapy options 46 0 Program Book

49 ARHP CONCURRENT ABSTRACT SESSIONS :0-4:00 PM 40 A Foot and Gait Disorders Moderators: Shngpui Betty Chow, PT and Smita Rao, PhD, PT :0 PM 789. Foot Disorders Associated with Over-Pronated and Over- Supinated Foot Types: The Johnston County Osteoarthritis Project Yvonne M. Golightly, Marian T. Hannan, Alyssa B. Dufour, Howard J. Hillstrom 4 and Joanne M. Jordan 5, University of North Carolina, Chapel Hill, NC, Hebrew SeniorLife & Harvard Med Sch, Boston, MA, Hebrew SeniorLife & Boston Univ, Boston, MA, 4 Hospital Special Surgery (HSS), New York, NY, 5 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC :45 PM 790. Biomechanical Function Agrees with Clinical Implications of Foot Disorders in a Population-Based Study Thomas J. Hagedorn, Alyssa B. Dufour, Jody L. Riskowski, Howard J. Hillstrom 4, Virginia A. Casey and Marian T. Hannan 5, Hebrew Senior Life, Boston, MA, Hebrew SeniorLife & Boston Univ, Boston, MA, Hebrew SeniorLife & Harvard Med School, Boston, MA, 4 Hospital Special Surgery (HSS), New York, NY, 5 Hebrew SeniorLife & Harvard Med Sch, Boston, MA :00 PM 79. Leg Muscle Mass Is Not Affected by Foot Pain, Structure or Function: The Framingham Foot Study Alyssa B. Dufour, Marian T. Hannan, Patricia P. Katz, Jody L. Riskowski 4, Thomas J. Hagedorn 5, Virginia A. Casey 5 and Robert R. McLean 6, Hebrew SeniorLife & Boston Univ, Boston, MA, Hebrew SeniorLife & Harvard Med Sch, Boston, MA, Univercity of California San Francisco, San Francisco, CA, 4 Hebrew SeniorLife & Harvard Med School, Boston, MA, 5 Hebrew Senior Life, Boston, MA, 6 Hebrew Senior Life/Harvard Medical School, Boston, MA :45 PM 794. How Many Steps/Day Are Associated with a Community Level Gait Speed Among Older Adults with or At High Risk of Knee OA? Daniel K. White, Roger Fielding, Tuhina Neogi, Michael P. LaValley 4, K. Douglas Gross 5, Michael C. Nevitt 6, C.E. Lewis 7, James Torner 8 and Catrine Tudor-Locke 9, Boston University, Boston, MA, Tufts Medical Center, Boston Univ School of Medicine, Boston, MA, 4 Boston University School of Public Health, Boston, MA, 5 MGH Institute of Health Professions, Boston, MA, 6 University of California-San Francisco, San Francisco, CA, 7 University of Alabama, Birmingham City, AL, 8 University of Iowa, Iowa City, Iowa City, IA, 9 Pennington Biomedical Research Center, Baton Rouge 0 Osteoarthritis Moderators: Charles G. Helmick, MD and Uyen Sa D.T. Nguyen, DSc, MPH :0 PM 795. Racial Differences in Pain Coping Efficacy in Patients with Hip and Knee Osteoarthritis Kelli D. Allen, Hayden B. Bosworth, Cynthia Coffman, Jennifer H. Lindquist, Nina R. Sperber, Morris Weinberger and Eugene Z. Oddone, Duke and Durham VA Medical Center, Durham, NC, University of North Carolina at Chapel Hill & Durham VA Medical Center, Durham, NC :45 PM 796. African American Adults Less Willing to Undergo Joint Replacement Surgery: The Multicenter Osteoarthritis Study Julie J. Keysor, Huan J. Chang, Tianzhong Yang, Cora E. Lewis 4, James Torner 5, Michael C. Nevitt 6 and David T. Felson, Boston Univ Sargent College, Boston, MA, The Journal of the American Medical Association, Chicago, IL, Boston Univ School of Medicine, Boston, MA, 4 University of Alabama, Birmingham City, Birmingham, AL, 5 University of Iowa, Iowa City, Iowa City, IA, 6 University of California-San Francisco, San Francisco, CA SUNDAY November, 0 :5 PM 79. Associations of Foot Structure and Function to Low Back and Lower Extremity Pain Jody L. Riskowski, Alyssa B. Dufour, Thomas J. Hagedorn, Howard J. Hillstrom 4, Virginia A. Casey and Marian T. Hannan, Hebrew SeniorLife & Harvard Medical School, Boston, MA, Hebrew SeniorLife & Boston Univ, Boston, MA, Hebrew SeniorLife, Boston, MA, 4 Hospital Special Surgery (HSS), New York, NY :0 PM 79. Associations of Foot Forces and Pressures to Regional Foot Pain: The Framingham Foot Study Jody L. Riskowski, Thomas J. Hagedorn, Alyssa B. Dufour, Virginia A. Casey 4 and Marian T. Hannan, Hebrew SeniorLife & Harvard Med School, Boston, MA, Hebrew SeniorLife, Boston, MA, Hebrew SeniorLife & Boston Univ, Boston, MA, 4 Hebrew Senior Life, Boston, MA :00 PM 797. Clinical and Biomechanical Characteristics of Total Hip Arthroplasty Responders and Nonresponders Genna Waldman and Kharma C. Foucher, Rush Medical College, Chicago, IL, Rush University Medical Center, Chicago, IL :5 PM 798. A Rich Description of Clinical Exam Features in Patients with Knee Osteoarthritis and Their Correlation with Functional Outcomes Maura D. Iversen, Kelli Sylvester, Abigail Grader, Michelle A. Frits, Marie Boneparth 4, Megan Whitmore 4, Jane Lucas 5, Fatima Shahzad 6, Jeffrey B. Driban 6 and Chenchen Wang 6, Northeastern University, Department of Physical Therapy, and Brigham & Women s Hospital, Harvard Medical School, Boston, MA, Department of Physical Therapy, Northeastern University, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Tufts Medical Center, Boston, 5 Back Bay Physical Therapy, Boston, 6 Tufts Medical Center, Boston, MA 0 Program Book 47

50 SUNDAY November, 0 :0 PM 799. Does Unpredictable Intermittent Knee Pain Limit Functional Ability and Walking Frequency in Knee OA? Daniel K. White, Gillian A. Hawker, David T. Felson, K. Douglas Gross, Jingbo Niu 4, Michael C. Nevitt 5, C.E. Lewis 6, James Torner 7 and Tuhina Neogi 4, Boston University, Boston, MA, Women s College Research Institute, University of Toronto, Toronto, ON, MGH Institute of Health Professions, Boston, MA, 4 Boston Univ School of Medicine, Boston, MA, 5 University of California- San Francisco, San Francisco, CA, 6 University of Alabama, Birmingham City, AL, 7 University of Iowa, Iowa City, Iowa City, IA :45 PM 800. BMI, Occupational Activity, and Leisure-Time Physical Activity: an Exploration of Risk Factors and Modifiers for Knee Osteoarthritis Kathryn Remmes Martin, Diana Kuh, Tamara B. Harris, Jack M. Guralnik, David Coggon 4 and Andrew K. Wills 5, NIA/NIH, Bethesda, MD, Medical Research Council, London, United Kingdom, University of Maryland, Baltimore, 4 University of Southampton, Southampton, United Kingdom, 5 University of Bristol, Bristol, United Kingdom ACR WORKSHOPS 4:00-6:00 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September A Dermatopathology of Rheumatic Diseases () Speaker: Daniel Miller, MD 44 B Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back () Speakers: George V. Lawry, MD and Paul C. Utrie, MD ACR SESSIONS 4:0-6:00 PM Ballroom C Classification and Treatment of Sjögren s Syndrome Moderators: Lindsey A. Criswell, MD, MPH and Frederick B. Vivino, MD Upon completion of this session, participants should be able to: describe how Sjögren s syndrome has been both over diagnosed and under diagnosed summarize the new ACR classification criteria for Sjögren s syndrome discuss the burden of illness in Sjögren s syndrome describe current efforts to develop clinical practice guidelines for Sjögren s syndrome 4:0 PM 0 ACR Classification Criteria for Sjögren s Syndrome Steve Shiboski, PhD 4:55 PM Rationale and Procedures for Guideline Development in Sjögren s Syndrome Ann L. Parke, MD 5:0 PM Preliminary Clinical Practice Guidelines for Sjögren s Syndrome Steven E. Carsons, MD 5:45 PM Questions & Answers 4 A Metabolic Abnormalities in Autoimmunity Moderator: Andras Perl, MD, PhD Upon completion of this session, participants should be able to: describe the close interconnection of metabolic responses with T cell function and autoimmunity explain the scientific basis of therapeutic targets such as mammalian target of rapamycin that are under development summarize how metabolic biomarkers of T cell function may contribute to a scientific understanding of disease exacerbation and remission 4:0 PM Metabolic Control of T cell Differentiation Jonathan Powell, MD, PhD 44 C Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (4) Speaker: Stuart L. Silverman, MD 49 A Synovial Fluid Analysis and Crystal Identification (5) Speakers: Brian F. Mandell, MD, PhD, Lan Chen, MD, PhD, and Gilda M. Clayburne, MLT 5:00 PM The Biology of Reactive Nitrogen Intermediates in Systemic Lupus Erythematosus Jim Oates, MD 5:0 PM Metabolic Control of Systemic Autoimmunity Andras Perl, MD, PhD 48 0 Program Book

51 07 A Puberty, Adolescence and Rheumatologic Disease Moderator: Kenneth N. Schikler, MD Upon completion of this session, participants should be able to: recognize the psychosocial issues expected for early, middle and late adolescents describe the effects of neuro-hormonal maturation on cognitive as well as somatic and pubertal physiologic growth explain the challenges of dealing with the obstacles and challenges chronic diseases present to the adolescent and normative psychosocial development demonstrate clearly and become adept at dealing with reproductive health issues of this population 4:0 PM I m Not a Little Kid Anymore and How and Why I Am Changing Frank M. Biro, MD 5:00 PM Adolescent Sexuality Margaret Blythe, MD 5:0 PM Reproductive Health Issues for Adolescents with Rheumatologic Disorders Susan Paige Hertweck, MD Hall D Thieves Market: Show Me Your Best Cases Moderator: Diane L. Kamen, MD, MS, Zsuzsanna H. McMahan, MD, MHS and Robert F. Spiera, MD Upon completion of this session, participants should be able to: describe unique and challenging diagnostic dilemmas discuss the differential diagnosis review methods used to identify the underlying diagnosis develop a treatment plan specific to the underlying diagnosis 4:0 PM Temporal Arteritis with a Twist Ashima Makol, MD 4:45 PM A Devastating Rash Andreea M. Harsanyi, MD 5:00 PM Gout of Lumbar Spine Sangeetha Pabolu, MD 5:5 PM Steroid-Resistant Systemic Lupus Erythematosus Cristina Arriens, MD Hall E Update on Psoriatic Arthritis and the Spondylarthropathies Moderators: Shelly P. Kafka, MD and Philip Mease, MD Upon completion of this session, participants should be able to: review updated information on the assessment and treatment of psoriatic arthritis describe the rationale and value of the new classification criteria for the spondylarthropathies including the new assessment criteria for axial spondylarthropathies and its utility in treating to target identify the bone and enthesial pathology, including erosion, enthesial calcification, and syndesmophyte formation in spondylarthropathies, treatment implications, and the role imaging modalities 4:0 PM Current State of the Art and Future Directions in the Assessment and Management of Psoriatic Arthritis Philip Mease, MD 5:00 PM New Approaches for the Classification and Assessment of the Spondylarthropathies Desiree Van Der Heijde, MD, PhD 5:0 PM The Paradox of Pathologic Bone Erosions and Bone Formation in the Spondylarthropathies: Clinical Implications Christopher T. Ritchlin, MD, MPH ACR CONCURRENT ABSTRACT SESSIONS 4:0-6:00 PM 0 B Fibromyalgia and Soft Tissue Disorders I Moderators: Daniel J. Clauw, MD and Dane Cook, PhD 4:0 PM 80. Symptom Improvement in Fibromyalgia Patients Is Related to Reduced Network Connectivity As Measured by EEG Coherence Jeffrey B. Hargrove, Robert M. Bennett, Daniel J. Clauw, George Mashour and Lauren Briggs 4, Kettering University, Flint, MI, Oregon Health & Science Univ, Portland, OR, University of Michigan, Ann Arbor, MI, 4 Grand Valley State University, Allendale, MI 4:45 PM 80. Milnacipran Reduces Brain Activity During Pain in Fibromyalgia Anson E. Kairys, Richard E. Harris, Eric Ichesco, Johnson P. Hampson, Steven Harte, Daniel J. Clauw and Tobias Schmidt- Wilcke, University of Michigan, Ann Arbor, MI SUNDAY November, 0 5:0 PM A Boy with Monoarthritis Philip J. Hashkes, MD, MSc 5:45 PM An Old Friend Revisited Shawn Rose, MD, PhD 5:00 PM 80. Frontal Brain Connectivity to the Default Mode Network Is Associated with Subjective Fatigue Irrespective of Pain and Depression Johnson P. Hampson, Daniel J. Clauw, Jieun Kim, Vitaly Napadow and Richard E. Harris, University of Michigan, Ann Arbor, MI, Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, MA, Martinos Center for Biomedical Imaging, Charlestown, MA 0 Program Book 49

52 SUNDAY November, 0 5:5 PM 804. A Comparison of the Nociceptive Flexion Reflex, Pressure Algometry and Summated Widespread Pain in the Diagnosis of Fibromyalgia Robert M. Bennett, Kim D. Jones and Janice Hoffman, Oregon Health & Science Univ, Portland, OR, Oregon Health Sciences University, Portland, OR, Oregon Health & Science University, Portland, OR 5:0 PM 805. Milnacipran Increases Cortical to Brainstem Connectivity During Pain in Fibromyalgia Eric Ichesco, Tobias Schmidt-Wilcke, Anson E. Kairys, Johnson P. Hampson, Steven E. Harte, Daniel J. Clauw and Richard E. Harris, University of Michigan, Ann Arbor, MI 5:45 PM 806. Posterior Insula Combined Glutamate and Glutamine Is Associated with Pain in Fibromyalgia: A Replication Study Eric Ichesco, Daniel J. Clauw, Steven E. Harte, Anson E. Kairys, Johnson P. Hampson, Tobias Schmidt-Wilcke and Richard E. Harris, University of Michigan, Ann Arbor, MI Salon B Imaging of Rheumatic Diseases I: Ultrasound and X-ray Moderators: Ralf G. Thiele, MD and Wolfgang A. Schmidt, MD 4:0 PM 807. Predictors of Rheumatoid Arthritis: Quantitative and Semiquantitative Sonographic Measurements of Peripheral Joints Flavia S. Machado, Rita N.V. Furtado, Rogerio D. Takahashi, Ana Leticia P. de Buosi and Jamil Natour, Universidade Federal de São Paulo, São Paulo, Brazil 4:45 PM 808. Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study Karine R. Luz, Rita N.V. Furtado, Marcelo M. Pinheiro, Giovanna S. Petterle and Jamil Natour, Universidade Federal de São Paulo, São Paulo, Brazil 5:00 PM 809. Ultrasonography Predicts Achievement of Deeper Remission After DAS8-Based Clinical Remission of Rheumatoid Arthritis Ryusuke Yoshimi, Maasa Hama, Daiga Kishimoto, Reikou Watanabe, Takeaki Uehara, Yukiko Asami, Atsushi Ihata, Atsuhisa Ueda, Mitsuhiro Takeno and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 5:5 PM 80. Assessment of Omeract Global Power Doppler Ultrasonography 44-Joint Scoring System and Reduced Joint Scoring Systems in Rheumatoid Arthritis Patients Treated with Abatacept Plus Background Methotrexate MA D Agostino, R. Wakefield, H. Berner Hammer, O. Vittecoq 4, M. Galeazzi 5, P. Balint 6, E. Filippucci 7, I. Moller 8, A. Iagnocco 9, E. Naredo 0, Mikkel Ostergaard, C. Gaillez, K. Van Holder, M. Le Bars and OMERACT-US Task Force 4, AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, University of Leeds, Leeds, United Kingdom, Diakonhjemmet Hospital, Oslo, Norway, 4 University Hospital, Rouen, France, 5 University of Siena, Siena, Italy, 6 National Institute, Budapest, Hungary, 7 University Politecnica delle Marche, Ancona, Italy, 8 Instituto Poal, Barcelona, Spain, 9 Sapienza Università di Roma, Roma, Italy, 0 Hospital Severo Ochoa, Madrid, Spain, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, Bristol- Myers Squibb, Rueil Malmaison, France, Bristol-Myers Squibb, Braine-L Alleud, Belgium, 4 Paris 5:0 PM 8. The Relationship Between Power Doppler Ultrasonography Outcomes and Clinical Efficacy in Abatacept- Treated Patients with Rheumatoid Arthritis and in Inadequate Response to Methotrexate MA D Agostino, R. Wakefield, H. Berner Hammer, O. Vittecoq 4, M. Galeazzi 5, P. Balint 6, E. Filippucci 7, I. Moller 8, A. Iagnocco 9, E. Naredo 0, Mikkel Ostergaard, C. Gaillez, K. Van Holder, M. Le Bars and OMERACT Ultrasound Task Force 4, AP-HP Ambroise Pare Hospital, Boulogne-Billancourt, France, University of Leeds, Leeds, United Kingdom, Diakonhjemmet Hospital, Oslo, Norway, 4 University Hospital, Rouen, France, 5 University of Siena, Siena, Italy, 6 National Institute, Budapest, Hungary, 7 University Politecnica delle Marche, Ancona, Italy, 8 Instituto Poal, Barcelona, Spain, 9 Sapienza Università di Roma, Roma, Italy, 0 Hospital Severo Ochoa, Madrid, Spain, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, Bristol- Myers Squibb, Rueil Malmaison, France, Bristol-Myers Squibb, Braine-L Alleud, Belgium, 4 Paris 5:45 PM 8. Intravenous Golimumab Inhibits Radiographic Progression and Maintains Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: -Year Results of a Phase Trial Michael Weinblatt, Clifton O. Bingham III, Alan Mendelsohn, Lenore Noonan, Shihong Sheng, Lilianne Kim, Kim Hung, Jiandong Lu, Daniel Baker and Rene Westhovens 4, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, Johns Hopkins University, Baltimore, MD, Janssen Research & Development, LLC, Spring House, PA, 4 University Hospital KU Leuven, Leuven, Belgium 5 A Metabolic and Crystal Arthropathies: Clinical Moderators: Michael A. Becker, MD and Fernando Perez-Ruiz, MD, PhD 4:0 PM 8. Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of Clinical Trials Robert Terkeltaub, Robert R. Evans, Steven P. Weinstein, Richard Wu and H. Ralph Schumacher 4, VA Medical Ctr, San Diego, CA, Regeneron Pharmaceuticals Inc, Tarrytown, NY, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 4 University of Pennsylvania and VA Medical Center, Philadelphia, PA 50 0 Program Book

53 4:45 PM 84. Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study Chang-Fu Kuo, Matthew J. Grainge, Lai-Chu See, Kuang- Hui Yu, Shue-Fen Luo, Ana M. Valdes 4, Weiya Zhang and Michael Doherty, University of Nottingham, Nottingham, United Kingdom, Chang Gung University, Taoyuan, Taiwan, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 St. Thomas Hospital, King s College London, London, United Kingdom 5:00 PM 85. Exploratory Analysis of Radiographic Change in Patients Treated with Intensive Urate-Lowering Therapy Nicola Dalbeth, Anthony Doyle, Fiona M. McQueen, John S. Sundy and Herbert S. B. Baraf, University of Auckland, Auckland, New Zealand, Duke University Medical Center, Durham, NC, Arthritis & Rheumatism Associates, Wheaton, MD 5:5 PM 86. Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout Eswar Krishnan, Stanford University, Stanford, CA 5:0 PM 87. Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan Robert D. Goldfien, Michele S. Ng, Goldie M. Yip, Alice Hwe, Alice Pressman and Andy L. Avins, Kaiser Permanente, Richmond, CA, Kaiser Permanente, Oakland, CA 5:45 PM 88. Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout Robert J. Noveck, Zongyao Wang, Ann Forsthoefel, Kristina Sigmon, Pauliana C. Hall, John C. Keogh and John S. Sundy, Duke University Medical Center, Durham, NC, PCH Integrated Regulatory Services, Inc., Laguna Niguel, CA, Keogh Medical Writing, Philadelphia, PA 50 B Osteoporosis and Metabolic Bone Disease Moderators: Willem F. Lems, MD and Chad L. Deal, MD 4:0 PM 89. Trajectories of Change in Physical Function: Effects On Fractures and Mortality Kamil E. Barbour, Li-Yung Lui, Deborah E. Barnes, Kristine E. Ensrud 4, Anne B. Newman 5, Kristine Yaffe, Steven R. Cummings 6 and Jane A. Cauley 5, Centers for Disease Control and Prevention, Atlanta, GA, California Pacific Medical Center, San Francisco, CA, San Francisco, University of California San Francisco, San Francisco, CA, San Francisco, CA, 4 University of Minnesota and Minneapolis VAHS, Minneapolis, MN, Minneapolis, MN, 5 University of Pittsburgh, Pittsburgh, PA, 6 San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA 4:45 PM 80. In Rheumatoid Arthritis Incident Fractures Are Associated with an Increased Risk of Cardiovascular Events Orla Ni Mhuircheartaigh, Cynthia S. Crowson, Sherine E. Gabriel, Veronique L. Roger, L. Joseph Melton III and Shreyasee Amin, Mayo Clinic, Rochester, MN 5:00 PM 8. Association of Serum Uric Acid and Incident Fractures in Elderly Men Nancy E. Lane, Neeta Parimi, Barton Wise, Peggy Cawthon 4, Eric Orwoll 5 and MrOS Investigators Group 6, UC Davis School of Medicine, Sacramento, CA, CPMC Research Institute, SF, CA, UC Davis, School of Medicine, Sacramento, CA, 4 CPMC Research Institute, San Francisco, CA, 5 Portland, OR, 6 Sacramento, CA 5:5 PM 8. Greater Than Expected Increased Mortality Following Fragility Fractures in Women and Men with Rheumatoid Arthritis Shreyasee Amin, Sherine E. Gabriel, Sara J. Achenbach, Elizabeth J. Atkinson and L. Joseph Melton III, Mayo Clinic, Rochester, MN 5:0 PM 8. Positive Effects of Tocilizumab On Bone Remodeling in Patients with Rheumatoid Arthritis Karine Briot, Thierry Schaeverbeke, Fabien Etchepare, Philippe Gaudin 4, Aleth Perdriger 5, Muriel Vray 6, Stephanie Rouanet 7, Ghislaine Steinberg 7 and Christian Roux, Paris Descartes University, Paris, France, Groupe Hospitalier Pellegrin, Bordeaux, France, G.H. Pitié-Salpêtrière, Paris, France, 4 CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 5 Hôpital Sud, Rennes, France, 6 Paris, France, 7 Roche, Neuilly sur Seine, France 5:45 PM 84. Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial Ken Poole, Graham Treece, Andrew Gee, Jacques P. Brown, Michael R. McClung, Andrea Wang 4 and Cesar Libanati 4, University of Cambridge, Cambridge, United Kingdom, CHUQ- CHUL Research Centre, Quebec City, QC, Oregon Osteoporosis Center, Portland, OR, 4 Amgen Inc., Thousand Oaks, CA Renaissance Washington - Grand Ballroom North Rheumatoid Arthritis - Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies Moderators: Eric M. Ruderman, MD and Lin A. Brown, MD 4:0 PM 85. Osteoporosis and Vertebral Fractures Are Important Determinants of Cardiovascular Disease in Rheumatoid Arthritis Ausaf Mohammad, Derek Lohan, Diane Bergin, Sarah Mooney, John Newell, Martin O Donnell, Robert J. Coughlan and John J. Carey, Galway University Hospitals, Galway, Ireland, National University of Ireland, Galway, Ireland SUNDAY November, 0 0 Program Book 5

54 SUNDAY November, 0 4:45 PM 86. Predictors of Return to Work During Years After Start of First Tumor Necrosis Factor Antagonist in a National Cohort of Biologics-Treated Patients with Rheumatoid Arthritis Tor Olofsson, Ingemar F. Petersson, Jonas Eriksson, Martin Englund, Pierre Geborek, Lennart T.H. Jacobsson 4, Johan Askling and Martin Neovius, Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4 Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 5:00 PM 87. Sustained Development of Cardiovascular Disease in Rheumatoid Arthritis Despite Cardioprotective Treatment: The 0-Year Prospective Carre-Study Alper M. van Sijl, Inge A.M. van den Oever, Mike J.L. Peters, Vokko P. van Halm, Alexandre E. Voskuyl, Yvo M. Smulders and Mike T. Nurmohamed, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands, Academic Medical Centre, Amsterdam, Netherlands 5:5 PM 88. Association between Anti-Tumor Necrosis Factor Therapy and the Risk of Ischemic Stroke in Subjects with Rheumatoid Arthritis. Results From the British Society for Rheumatology Biologics Registers-Rheumatoid Arthritis (BSRBR-RA) Audrey S. Low, Mark Lunt, Louise K. Mercer, James B. Galloway, Rebecca Davies, Kath D. Watson 4, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium, Deborah P. Symmons, William G. Dixon, Kimme L. Hyrich and On behalf of the BSRBR 5, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 4 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 5 British Society for Rheumatology, London, United Kingdom 5:0 PM 89. Subcutaneous Nodules Are Significantly Associated with Cardiovascular Events in Patients with Rheumatoid Arthritis: Results From a Very Large US Registry Prashant Kaushik, Susan P. Messing, Jyoti Arora, George Reed, Katherine C. Saunders 4, Jeffrey D. Greenberg 5 and Joel M. Kremer 6, Sratton VAMC, Albany, NY, University of Rochester School of Medicine and Dentistry, Rochester, NY, UMass Medical School, Worcester, MA, 4 CORRONA, Inc., Southborough, MA, 5 New York University School of Medicine, New York, NY, 6 Albany Medical College and The Center for Rheumatology, Albany, NY 5:45 PM 80. Five-Year Favourable Outcome of Patients with Early Rheumatoid Arthritis in the 000s: Data From the Espoir Cohort Bernard G. Combe, Nathalie Rincheval, Joelle Benessiano, Francis Berenbaum 4, Alain G. Cantagrel 5, Jean-Pierre Daurès, Maxime Dougados 6, Patrice Fardellone 7, Bruno Fautrel 8, Rene- Marc Flipo 9, Philippe M. Goupille 0, Francis Guillemin, Xavier X. Le Loet, Isabelle Logeart, Xavier Mariette 4, Olivier Meyer 5, Philippe Ravaud 6, Alain Saraux 7, Thierry Schaeverbeke 8 and Jean Sibilia 9, Hopital Lapeyronie, Montpellier, France, Institut Universitaire de Recherche Clinique, Montpellier, France, Rheumatology, Paris Unervisity Hospital BICHAT, Paris, France, 4 AP-HP, St Antoine Hospital, Paris, France, 5 Hopital Purpan, Toulouse CEDEX 9, France, 6 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 7 C.H.U. D Amiens, Amiens, France, 8 APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 9 Hopital R Salengro CHRU, Lille CEDEX, France, 0 Hopital Trousseau, Tours, France, Faculte de Medecin/BP 84, Vandoeuvre-les- Nancy, France, CHU de ROUEN, Rouen, France, Pfizer, Paris, France, 4 Université Paris-Sud, Le Kremlin Bicetre, France, 5 Hopital Bichat, Paris, France, 6 Hotel Dieu University hospital, Paris, France, 7 CHU de la Cavale Blanche, Brest Cedex, France, 8 Groupe Hospitalier Pellegrin, Bordeaux, France, 9 CHU Hautepierre, Strasbourg, France Ballroom A Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities Moderators: Patrick Hoffstetter, MD and Andrew J. Head, MD 4:0 PM 8. A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 87) in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate Karel Pavelka, Yun Chon, Richard Newmark, Ngozi Erondu and Shao- Lee Lin, Institute and Clinical of Rheumatology, Charles University, Prague, Czech Republic, Amgen Inc, Thousand Oaks, CA 4:45 PM 8. Peroxisome Proliferator-Activated Receptor Gamma Agonist Treatment for Rheumatoid Arthritis: A Proof-of- Concept Randomized Controlled Trial Michelle J. Ormseth, Annette M. Oeser, Andrew Cunningham, Aihua Bian, Ayumi Shintani, S. Bobo Tanner and C. Michael Stein, Vanderbilt Medical Center, Nashville, TN 5:00 PM 8. A Phase, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy Edward Bernton, Eduard Krantz and William Gannon Jr., Protalex Inc., Summit, NJ, Parexel Clinical Pharmacology, Bloemfontein, South Africa, Capital City Technical Consulting, Inc., Washington, DC 5:5 PM 84. Cetrorelix, a Gonadotropin-Releasing Hormone Antagonist, Significantly Reduces Tumour-Necrosis-Factor- Alpha and Demonstrates Efficacy in Patients with Active Rheumatoid Arthritis: A Proof-of-Concept, Double-Blind, Randomised Trial 5 0 Program Book

55 Anita Kåss, Øystein T. Førre, Morten Fagerland, Hans Christian Gulseth, Peter Torjesen 4 and Ivana Hollan 5, University of Oslo, Oslo, Norway, Oslo University Hospital, Oslo, Norway, Betanien Hospital, Skien, Norway, 4 Oslo University Hospital, Norway, 5 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway 5:0 PM 85. Low Doses of Ocaratuzumab, a Fc- and Fab-Engineered Anti-CD0 Antibody, Result in Rapid and Sustained Depletion of Circulating B-Cells in Rheumatoid Arthritis Patients Adrienne O Reilly, Tracy Davis and Vinay Jain, Mentrik Biotech, Dallas, TX 5:45 PM 86. Clinical Responses and Patient Reported Outcomes to NNC (anti-il-0 mab) in Rheumatoid Arthritis (RA) Patients Following -Weeks Dosing and Weeks Follow up: Results From a Phase a Trial Ladislav ŠEnolt, Marie Göthberg, Xavier Valencia and Eva Dokoupilova 4, Institute of Rheumatology, Prague, Czech Republic, Novo Nordisk, A/S, Soeborg, Denmark, Novo Nordisk, Inc., Princeton, NJ, 4 Medical Plus s.r.o, Uherske Hradiste, Czech Republic Ballroom B Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Renal Moderators: Jennifer M. Grossman, MD and Anca Askanase, MD, MPH 4:0 PM 87. Response to MMF Therapy for Lupus Nephritis Is Independent of Genetic Variation of Inosine Monophosphate Dehydrogenase Noa Schwartz, Tejaskumar Patel, Ellen M. Ginzler, Neil Solomons, Jill P. Buyon 4 and Robert M. Clancy, New York University School of Medicine, New York, NY, SUNY-Downstate Medical Center, Brooklyn, NY, Vifor Pharma, 4 NYU School of Medicine, New York, NY 4:45 PM 88. Association of Urinary and Serum Soluble Fn4 Levels and TWEAK Levels with Lupus Nephritis Disease Activity Irene Blanco, Ping Wu, Timothy S. Zheng, Shawn Weng 4, Jennifer S. Michaelson 5, Linda C. Burkly 5 and Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Biogen Idec, Inc, Cambridge, MA, Biogen Idec Inc, Cambridge, MA, 4 Biogen Idec, Inc., Cambridge, MA, 5 Biogen Idec, Cambridge, MA 5:00 PM 89. Urinary Levels of High Mobility Group Box Protein Are Elevated in Patients with Active Lupus Nephritis, and Correlate with Renal Histopathology Irene Blanco, Neelakshi Jog, Chaim Putterman, Iris Lee and Roberto Caricchio, Albert Einstein College of Medicine, Bronx, NY, Temple University, Philadelphia, PA, Temple Univ Med Office Bldg, Philadelphia, PA 5:5 PM 840. Do Serum Hepcidin 5 Levels Predict SLE Renal or Non- Renal Flares? Alexandra Friedman, Nicholas Young, Paul Jensen, Xiaolin Zhang, Wael N. Jarjour, Brad H. Rovin, Daniel Birmingham, Lee Hebert and Stacy P. Ardoin, The Ohio State University Medical Center, Columbus, OH, Ohio State University Medical Center, Columbus, OH, Ohio State University, Columbus, OH 5:0 PM 84. Effect of Partial and Complete Proteinuria Recovery in Lupus Nephritis On Long Term Outcomes Zahi Touma, Murray B. Urowitz, Dominique Ibanez and D. D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 5:45 PM 84. Partial and Complete Recovery From Proteinuria in Lupus Nephritis Patients Receiving Standard of Care Treatment Zahi Touma, D. D. Gladman, Dominique Ibanez and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON 45 A Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Moderators: Alessandra Pernis, MD and Vasileios C. Kyttaris, MD 4:0 PM 84. Interferon Regulatory Factor 5 Associates with Systemic Lupus Erythematosus Through Two Distinct and Independent Effects Erin Zoller, Leah C. Kottyan, Bahram Namjou, Samuel Vaughn, Miranda C. Marion, Carl D. Langefeld, Marta E. Alarcon-Riquelme, Juan-Manuel Anaya 4, Elizabeth E. Brown on behalf of PROFILE 5, Sang-Cheol Bae 6, Jeffrey C. Edberg 7, Patrick M. Gaffney 8, Diane L. Kamen 9, Robert P. Kimberly 5, Chaim O. Jacob 0, Joan T. Merrill, Kathy Moser Sivils, Michelle A. Petri, Rosalind Ramsey-Goldman, John D. Reveille 4, Anne M. Stevens 5, Betty P. Tsao 6, Luis M. Vila 7, Timothy J. Vyse 8 and Kenneth M. Kaufman, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Wake Forest School of Medicine, Winston-Salem, NC, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 4 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 5 University of Alabama at Birmingham, Birmingham, AL, 6 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 7 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 0 Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, Johns Hopkins University School of Medicine, Baltimore, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, 4 Univ of Texas SUNDAY November, 0 0 Program Book 5

56 Health Science Center at Houston, Houston, TX, 5 University of Washington, Seattle, WA, 6 UCLA School of Medicine, Los Angeles, CA, 7 University of PuertoRico Medical Sciences Campus, San Juan, PR, 8 Divisions of Genetics and Molecular Medicine and Immunology, King s College London, London, United Kingdom Carolina, Charleston, SC, 4 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 5 Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 6 National Defense Medical Center, Taipei, 7 Seoul National University Hospital, Seoul, South Korea SUNDAY November, 0 4:45 PM 844. Toll-Like Receptor 9-Independent and Immune Complex- Independent Interferon-α Production by Neutrophils Upon Netosis in Response to Circulating Chromatin Dennis Lindau, Julie Mussard, Armin Rabsteyn, Matthieu Ribon, Ina Kötter, Annette Igney, Gosse Adema 4, Marie- Christophe Boissier 5, Hans-Georg Rammensee and Patrice Decker, University of Tübingen, Institute for Cell Biology, Tübingen, Germany, University of Paris, Sorbonne Paris Cité, Bobigny, France, Department of Internal Medicine II, Rheumatology Division, Tübingen, Germany, 4 Nijmegen Centre for Molecular Life Sciences, Nijmegen, Netherlands, 5 Avicenne Hospital, Rheumatology Department, Bobigny, France 5:00 PM 845. Systemic Lupus Erythematosus Immune Complexes Upregulate the Expression of CD9 and CD9 On Plasmacytoid Dendritic Cells Niklas Hagberg, Jakob Theorell, Gunnar V. Alm, Maija-Leena Eloranta, Yenan Bryceson and Lars Rönnblom, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Center for Infectious Medicine, Karolinska Institutet, Stockholm, Sweden, Swedish University of Agricultural Sciences, Uppsala, Sweden 5:5 PM 846. Preferential Binding to Elk- by SLE-Associated IL0 Risk Allele up-regulates IL0 Expression Daisuke Sakurai, Jian Zhao, Yun Deng, Jennifer A. Kelly, Kathy Moser Sivils, Kenneth M. Kaufman, Elizabeth E. Brown on behalf of PROFILE 4, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network 5, John B. Harley 6, Sang-Cheol Bae 7, Chaim O. Jacob 8, Timothy J. Vyse 9, Timothy B. Niewold 0, Patrick M. Gaffney, Judith A. James, Robert P. Kimberly 4, Gary S. Gilkeson, Diane L. Kamen 4, Carl D. Langefeld 5, Deh- Ming Chang 6, Yeong Wook Song 7, Weiling Chen, Jennifer M. Grossman, Bevra H. Hahn and Betty P. Tsao, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 University of Alabama at Birmingham, Birmingham, AL, 5 Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, 6 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7 Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, 8 Keck School of Medicine, University of Southern California, Los Angeles, CA, 9 King s College London, London, United Kingdom, 0 University of Chicago, Chicago, IL, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, Medical University of South 5:0 PM 847. Enhanced ROCK Activation in Patients with Systemic Lupus Erythematosus Josephine Isgro, Sanjay Gupta, Tanya M. Pavri, Roland Duculan, Kyriakos A. Kirou, Jane E. Salmon and Alessandra B. Pernis, Morgan Stanley Children s Hospital of New-York Presbyterian, Columbia University Medical Center, New York, NY, Hospital for Special Surgery, New York, NY 5:45 PM 848. Targeting Glycosphingolipid Biosynthesis Normalises T Lymphocyte Function in Patients with Systemic Lupus Eyrthematosus Georgia McDonald, Laura Miguel, Cleo Hall, David A. Isenberg, Anthony I. Magee, Terry Butters and Elizabeth C. Jury, University College London, London, United Kingdom, Imperial College London, London, United Kingdom, University of Oxford, Oxford, United Kingdom 46 C Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics I Moderators: Murray Baron, MD and Ami A. Shah, MD, MHS 4:0 PM 849. The Risk of Cardiovascular Disease in Systemic Sclerosis: A Population-Based Cohort Study Ada Man, Yanyan Zhu, Yuqing Zhang, Maureen Dubreuil, Young Hee Rho, Christine Peloquin, Robert W. Simms and Hyon K. Choi, Boston University School of Medicine, Boston, MA, Boston University, Boston, MA, Boston University School of Medicine, University of British Columbia, Arthritis Research Centre of Canada, Boston, MA 4:45 PM 850. Elevation of KL-6 At Early Disease Course Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease Masataka Kuwana, Tsutomu Takeuchi and Junichi Kaburaki, Keio University School of Medicine, Tokyo, Japan, Shinakasaka Clinic, Tokyo, Japan 5:00 PM 85. An Evidence-Based Screening Algorithm for Pulmonary Arterial Hypertension in Systemic Sclerosis James R. Seibold, Christopher D. Denton, Ekkehard Grünig, Diana Bonderman 4, Oliver Distler 5, Dinesh Khanna 6, Ulf Müller-Ladner 7, Janet E. Pope 8, Madelon C. Vonk 9, Martin Doelberg 0, Harbajan Chadha-Boreham 0, Harald Heinzl 4, Daniel M. Rosenberg 0, Vallerie McLaughlin 6 and John G. Coghlan, Scleroderma Research Consultants LLC, Avon, CT, Royal Free Hospital, London, United Kingdom, University Hospital, Heidelberg, Germany, 4 Medical University of Vienna, Vienna, 54 0 Program Book

57 Austria, 5 University Hospital Zurich, Zurich, Switzerland, 6 University of Michigan, Ann Arbor, MI, 7 Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 8 Western University of Canada, St. Joseph s Health Care, London, ON, 9 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 0 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland 5:5 PM 85. C-Reactive Protein Predicts Long-Term Progression of Interstitial Lung Disease and Survival in Patients with Early Systemic Sclerosis Xiaochun Liu, Maureen D. Mayes, John D. Reveille, Emilio B. Gonzalez, Brock E. Harper, Hilda T. Draeger 4 and Shervin Assassi 5, University of Texas Health Science Center at Houston, Houston, TX, Univ of Texas Health Science Center at Houston, Houston, TX, University of Texas Medical Branch, Galveston, TX, 4 Univ of TX Health Sci Ctr, San Antonio, TX, 5 Univ of Texas Health Science Houston, Houston, TX 5:0 PM 85. Systemic Sclerosis Classification Criteria: Developing Methods for Multi-Criteria Decision Analysis Sindhu R. Johnson, Raymond P. Naden, Jaap Fransen, Frank H.J. van den Hoogen 4, Janet E. Pope 5, Murray Baron 6, Alan G. Tyndall 7, Marco Matucci-Cerinic 8 and Dinesh Khanna on behalf of ACR/EULAR Classification Criteria SSc 9, Toronto Western Hospital, Toronto, ON, Auckland City Hospital, Auckland, New Zealand, Austria, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4 Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 5 St. Joseph Health Care London, London, ON, 6 Jewish General Hospital, Montreal, QC, 7 University of Basel, Basel, Switzerland, 8 Univ Florence, Firenze, Italy, 9 University of Michigan, Ann Arbor, MI 5:45 PM 854. Anti-EIFB: A Novel Interstitial Lung Disease Associated Autoantibody in Patients with Systemic Sclerosis Zoe Betteridge, Felix Woodhead, Christopher Bunn, Christopher D. Denton 4, David J. Abraham 5, Sujal Desai 6, Roland du Bois 7, Athol U. Wells 8 and Neil McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, Royal Free Hospital, London, United Kingdom, 4 Royal Free and University College Medical School, London, England, 5 UCL Medical School, London, United Kingdom, 6 Kings College Hosptial, London, United Kingdom, 7 National Jewish Health, Denver, 8 Royal Brompton Hospital, United Kingdom 47 A Vasculitis: Pathogenesis Moderators: Paul A. Monach, MD, PhD and Maria C. Cid, MD 4:0 PM 855. Identification of a Burkholderia-Like Strain From Temporal Arteries of Subjects with Giant Cell Arteritis Curry L. Koening, Bradley J. Katz, Jose Hernandez-Rodriguez, Marc Corbera-Bellalta 4, Maria C. Cid 4, Herbert P. Schweizer 5, Dean Li, Jerry Kaplan, Gary S. Hoffman 6 and Ivana De Domenico, Salt Lake City Veterans Administration, Salt Lake City, UT, University of Utah, Salt Lake City, UT, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 4 Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 5 Colorado State University, Fort Collins, CO, 6 Cleveland Clinic, Cleveland, OH 4:45 PM 856. Am80, a Retinoic Acid Receptor Agonist, Ameliorates Murine Vasculitisthrough the Suppression of Neutrophil Migration and Activation Chie Miyabe, Yoshishige Miyabe, Noriko Miura, Kei Takahashi, Yuya Terashima 4, Etsuko Toda 4, Fumiko Honda, Tomohiro Morio, Naohito Ohno, Jun-ichi Suzuki 4, Mitsuaki Isobe, Kouji Matsushima 4, Ryoji Tsuboi 5, Nobuyuki Miyasaka and Toshihiro Nanki, Tokyo Medical and Dental University, Tokyo, Japan, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan, Toho University Ohashi Medical Center, Tokyo, Japan, 4 The University of Tokyo, Tokyo, Japan, 5 Tokyo Medical University, Tokyo, Japan 5:00 PM 857. Impairment of the Inhibitory PD--PD-L Axis in Giant Cell Arteritis (GCA) Mazen Nasrallah, Augusto Vaglio, Shalini Mohan, Bjorn Hartmann, Joyce Liao, Kenneth J. Warrington 4, Jorg J. Goronzy 5 and Cornelia M. Weyand 6, Stanford University, Stanford, CA, University of Parma, Parma, Italy, Stanford University, Palo Alto, CA, 4 Mayo Clinic, Rochester, MN, 5 Stanford Univ School of Medicine, Stanford, CA, 6 Stanford University School of Medicine, Stanford, CA 5:5 PM 858. Dense Genotyping, Imputation, and Regression Analysis Identifies Multiple Independent Genetic Susceptibility Loci within the HLA Region in Behcet s Disease Travis Hughes, Adam Adler, Patrick S. Coit, Vuslat Yilmaz, Kenan Aksu 4, Nursen Duzgun 5, Gokhan Keser 4, Ayse Cefle 6, Ayten Yazici 6, Andac Ergen 7, Erkan Alpsoy 8, Carlo Salvarani 9, Bruno Casali 0, Ina Koetter, Javier Gutierrez-Achury, Cisca Wijmenga, Haner Direskeneli, Guher Saruhan-Direskeneli 4 and Amr H. Sawalha, University of Michigan, Ann Arbor, MI, Oklahoma Medical Research Foundation, Oklahoma City, OK, Istanbul University, Istanbul Faculty of Medicine, Department of Physiology, Istanbul, Turkey, 4 Ege University, Izmir, Turkey, 5 Ankara University, Ankara, Turkey, 6 Kocaeli University, Kocaeli, Turkey, 7 Okmeydaný Research and Education Hospital, Istanbul, Turkey, 8 Akdeniz University, Antalya, Turkey, 9 Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, 0 Molecular Biology Laboratory, Arcispedale S. Maria Nuova,, Reggio Emilia, Italy, University Hospital, Tuebingen, Germany, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, Marmara University, School of Medicine, Istanbul, Turkey, 4 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 5:0 PM 859. WITHDRAWN 5:45 PM 860. Interleukin-, B Cell Activating Factor and Unmethylated CpG Oligodeoxynucleotides Synergize in Promoting Anti- Proteinase Autoantibody Production in vitro 0 Program Book 55 SUNDAY November, 0

58 Nikola Lepse, Judith Land, Abraham Rutgers, Cees G.M. Kallenberg, Coen A. Stegeman, Peter Heeringa and Wayel H. Abdulahad, University Medical Center Groningen, Groningen, Netherlands, University Medical Center Groningen, Netherlands 60 Temporal Arteritis (00) Speaker: Gene G. Hunder, MD SUNDAY November, 0 ACR MEET THE PROFESSOR SESSIONS 4:0-6:00 PM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September *Ankylosing Spondylitis: 0 Update (0) Speaker: Michael H. Weisman, MD 5 *Antiphospholipid Syndrome (0) Speaker: Munther A. Khamashta, MD ARHP SESSIONS 4:0-6:00 PM 0 Income Inequities Are Perilous to People with Arthritis Moderator: Charles G. Helmick, MD Upon completion of this session, participants should be able to: characterize the social and economic burden of poverty among U.S. adults with arthritis describe the characteristics of U.S. adults with arthritis with income insufficiency explain the association between employment status and income outline policies and interventions that can reduce the susceptibility to job loss and poverty and its adverse effects for U.S. adults with arthritis 4:0 PM Introduction Charles G. Helmick, MD 54 A Crystal: Diagnosis and Management of Gout (0) Speaker: Theodore R. Fields, MD 54 B Immunodeficiency Syndromes (04) Speaker: Alton Melton, MD 4:45 PM Magnitude of Socio-economic Inequities among People with Arthritis Louise Murphy, PhD 5:0 PM Socio-economic Characteristics of People with Arthritis in the U.S. Medical Expenditure Panel Survey Edward H. Yelin, PhD 55 Pain: Evaluation and Treatment of Back Pain (05) PM Speaker: David G. Borenstein, MD 5:5 PM Characteristics of U.S. Adults with Income Insufficiency Kristina A. Theis, BA, MPH A *Psoriatic Arthritis (06) Speaker: Arthur Kavanaugh, MD 58 B Pulmonary Hypertension in the Rheumatic Diseases (07) Speaker: Dinesh Khanna, MD, MSc 59 A *Rheumatoid Arthritis: Challenging Cases(08) Speaker: Jonathan Kay, MD 59 B *Rheumatoid Arthritis: Outcome Measures in Clinical Practice (09) Speaker: J. Timothy Harrington, MD 0 Program Book 04 A Practice Management: Patients as Partners in Design and Delivery (Practice Management Series) Moderator: Laura Wright, MBA, CMPE Upon completion of this session, participants should be able to: outline the steps in establishing a Patient and Family Advisory Council assess the benefits of engaging patients and family members in decision-making describe the Patient and Family Advisory Council s role in designing a safe, healing environment 4:0 PM Practice Management: Patients As Partners in Design and Delivery Janet Porter, PhD 5:5 PM Practice Management: Patients As Partners in Design and Delivery Martie Carnie, AS, PFAC

59 ARHP CONCURRENT ABSTRACT SESSIONS 4:0-6:00 PM 06 Pediatrics: Disease Flares Moderators: Thuy T. Beam, RN and Janalee Taylor, MSN 4:0 PM 86. A Family Based Pedometer Walking Program in an Adolescent Population with Juvenile Idiopathic Arthritis Sara M. Stern, Jill R. Blitz, Amber Richards and Katherine AB Marzan, Children s Hospital Los Angeles, Los Angeles, CA 4:45 PM 86. What Is the Impact of a Transition Program On Adolescents with Juvenile Idiopathic Arthritis and Their Parents? Deborah Hilderson, Rene Westhovens, Rik Joos, Carine H. Wouters and Philip Moons 4, University Hospital Leuven, KU Leuven, Leuven, Belgium, University Hospital KU Leuven, Leuven, Belgium, University Hospital Gent, Ghent, Belgium, 4 KU Leuven, Leuven, Belgium 5:00 PM 86. Employment of a Needs Assessment Survey to Shape a Novel Web-Based Pediatric Rheumatology Curriculum for Primary Care Providers Amy L. Woodward and Z. Leah Harris, Vanderbilt University School of Medicine, Nashville, TN 4:45 PM 867. Events That Trigger the Onset of the Fibromyalgia Syndrome (FMS) Robert S. Katz, Sharon M. Ferbert, Alexandra Small and Susan Shott, Rush University Medical Center, Chicago, IL, Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, University of Illinois Medical School 5:00 PM 868. Illness Perceptions Among Patients with Different Forms of Vasculitis Peter C. Grayson, Naomi Amudala, Carol McAlear, Renée Leduc, Denise Shereff, Rachel Richesson, Liana Fraenkel 4 and Peter A. Merkel 5, Boston University Medical Center, Boston, MA, Vasculitis Clinical Research Consortium, University of Pennsylvania, Philadelphia, University of South Florida, Tampa, FL, 4 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 5 University of Pennsylvania, Philadelphia, PA 5:5 PM 869. Concepts Which Determine Health in a Positive Way Are Important to People with Rheumatoid Arthritis and Are Covered by Some Patient-Reported Outcome Instruments Mona Dür, Michaela Coenen, Josef S. Smolen and Tanja A. Stamm, Medical University of Vienna, Vienna, Austria, Ludwig- Maximilians-University, Munich, Germany, Medical University of Vienna and Hietzing Hospital, Vienna, Austria SUNDAY November, 0 5:5 PM 864. Will I Waste Your Time? Delays in Help-Seeking for RA Flares Caroline A. Flurey, Marianne Morris, Jon Pollock, Rodney A. Hughes, Pamela Richards and Sarah Hewlett, University of the West of England, Bristol, United Kingdom, St. Peters Hospital, Chertsey Surrey, United Kingdom, University of Bristol, Bristol, United Kingdom 5:0 PM 865. A Methodology for Estimating Disease State Transitions: Repeated Measures Markov Models with Covariate Dependence George W. Reed, Andrew S. Koenig, Katherine C. Saunders, David H. Collier 4, Joel M. Kremer 5 and Sameer Kotak 6, University of Massachusetts Medical School, Worcester, MA, Pfizer Inc., Collegeville, PA, CORRONA, Inc., Southborough, MA, 4 Amgen Inc., Thousand Oaks, CA, 5 Albany Medical College and The Center for Rheumatology, Albany, NY, 6 Pfizer Inc., New York, NY 40 A Psychological Aspects of Rheumatologic Disease Moderators: Carol M. Greco, PhD and Karen L. Smarr, PhD 4:0 PM 866. Pain Is Associated with Telomere Shortening in Women with Fibromyalgia Afton L. Hassett, Daniel J. Clauw, Richard E. Harris, Steven E. Harte, Anson E. Kairys, Steven Buyske and David A. Williams, University of Michigan, Ann Arbor, MI, Rutgers University, Piscataway, NJ 5:0 PM 870. To Love and to Hold: Men Describe Parenting in the Presence of Inflammatory Arthritis Catherine L. Backman and Alana Longson, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Vancouver, BC 5:45 PM 87. Depression Predicts Mortality in RA Christina Bode, Chris Tonner, Laura Trupin and Patricia P. Katz 4, University of Twente, Enschede, Netherlands, UCSF, San Francisco, CA, UC San Francisco, San Francisco, CA, 4 Univercity of California San Francisco, San Francisco, CA INDUSTRY-SUPPORTED SYMPOSIA 6:0-9:0 PM These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 7 for more information. 0 Program Book 57

60 MONDAY November, 0 MONDAY, NOVEMBER, 0 ACR/ARHP REGISTRATION 6:0 am - 6:00 PM Registration Hall (Salons G-H-I) ACR SESSIONS 7:0-8:0 AM Hall D Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis Moderator: Victoria K. Shanmugam, MBBS Upon completion of this session, participants should be able to: discuss the evaluation of patients with hepatitis C presenting with polyarticular inflammatory arthritis and review the differential diagnosis of inflammatory diseases seen in patients with hepatitis C interpret synovial fluid findings in the context of the clinical care of complex patients review the evaluation of immunosuppressed patients with inflammatory arthritis and the typical and atypical infections which should be considered 7:0 AM Case Presentation Gail S. Kerr, MD 7:40 AM Hepatitis C Associated Immune Diseases Gail S. Kerr, MD 7:50 AM Gout in the Inpatient Setting Gail S. Kerr, MD 8:00 AM Synovial Fluid Analysis Jack Lichy, MD 8:0 AM Septic Arthritis in the Immunocompromised Host Debra Benator, MD 8:0 AM Discussion Gail S. Kerr, MD Renaissance Washington - Grand Ballroom North Cross-Sectional Imaging Techniques for Rheumatology Moderator: Carol A. Langford, MD, MHS Speaker: John Carrino, MD, MPH Upon completion of this session, participants should be able to: describe the physical basis underlying the cross-sectional imaging modalities appreciate the relative strengths and weaknesses of each imaging modality identify common clinical pathologies on each modality know the current indications and potential future applications of computed tomography, magnetic resonance imaging and ultrasound Ballroom A Immune Tolerance: From Theory and Clinical Practice Moderator: Andrew P. Cope, MD, PhD Speaker: John D. Isaacs, MD, PhD Upon completion of this session, participants should be able to: review the pivotal immunological studies that underpin our current understanding of immune tolerance discuss the key molecular and cellular players responsible for maintaining a state of immunological tolerance, and how these are likely to form the basis for assays of immune tolerance in the clinical laboratory review therapeutic approaches currently under evaluation for inducing a clinical state of operational tolerance in patients with autoimmune disease Salon B 0 Hench Lecture: Synovial Immunobiology and Response to Therapy in Rheumatoid Moderator: Richard M. Pope, MD Speaker: Paul P. Tak, MD, PhD Upon completion of this session, participants should be able to: define mechanisms which promote synovial inflammation in rheumatoid arthritis identify markers of clinical response, examining synovial tissue before and after therapy initiation identify common mechanism(s) responsible for clinical response ARHP SESSIONS 7:0-8:0 AM 0 Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care (Arthroplasty/Joint Replacement Series) PS Moderator: Hazel L. Breland, PhD, OTR/L Upon completion of this session, participants should be able to: describe the utilization of joint replacement across different demographic and sociocultural groups identify conceptual models evaluating mediating factors leading to differential health services utilization examine healthcare disparities in the use of joint arthroplasty: rates, determinants and the role of patients knowledge and preferences compare conceptual models and interventions proposed to decrease disparities and improve equitable access to care for patients with arthritis with an indication for joint arthroplasty 58 0 Program Book

61 06 7:0 AM Differences in the Utilization of Health Services: Disparity, Inequity or Preference? Maria E. Suarez-Almazor, MD, PhD 7:40 AM Ethnic Variation in the Use of Joint Arthroplasty Said Ibrahim, MD, MPH 8:00 AM Gender and Residence As Determinants of Variation in Joint Arthroplasty Gillian A. Hawker, MD, MSc 8:0 AM Panel Discussion Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice PS Moderator: Victoria A. Merrell, MPT, PA-C Upon completion of this session, participants should be able to: discuss the benefits of assimilating physician assistants and nurse practitioners into rheumatology practice describe the scope of practice in various settings review the approaches to training physician assistants and nurse practitioners with limited rheumatology experience discuss the ACR/ARHP online rheumatology training program 7:0 AM A Rheumatologist s Perspective on Incorporating Advanced Practitioners into Rheumatology Practice John R. P. Tesser, MD 7:45 AM Nurse Practitioners in Rheumatology Kori A. Dewing, DNP, ARNP 8:00 AM Physician Assistants in Rheumatology Barbara A. Slusher, PA-C, MSW 8:5 AM Panel Discussion 04 A Infusion Room Information for Medical Professionals (Infusion Series) Moderator: Aimee Wiener, ARNP, MSN Speaker: Sharon Manson, NP Upon completion of this session, participants should be able to: describe processes required to ensure reimbursement of infusion therapies establish skills required for infusion registered nurses and the impact on nursing practice identify issues which impact scheduling and operations of infusion rooms 4 A New and Better Habits! Facilitating Patient Selfmanagement with Proven Behavior Change Strategies PS Moderator: David A. Williams, PhD Upon completion of this session, participants should be able to: compare key elements of behavior change and goal setting theories identify and practice brief strategies that can be incorporated into clinical visits outline components of Self-management and Recovery Training propose strategies for using Self-management and Recovery Training 7:0 AM Introduction Susan J. Bartlett, PhD 7:6 AM Increasing Motivation to Change Susan J. Bartlett, PhD 7:54 AM Guided Discovery Sarah Hewlett, MA, PhD, RN 8: AM Goal Setting Emma Dures, PhD Acr SESSION 7:0-9:00 AM 0 B ILAR The Current Rheumatology Workforce across the Globe Moderator: Peter Brooks, MD Upon completion of this session, participants should be able to: recognize the shortage in the current rheumatology workforce across the globe and the impact it has on the patient population describe programs funded by ILAR to address the need to advance the development of rheumatology by increasing the number of rheumatologists around the world 7:0 AM Review of Current Workforce for Rheumatology in the United States David G. Borenstein, MD 7:45 AM Review of Current Workforce for Rheumatology in the Countries of the Americas John D. Reveille, MD 8:00 AM Review of Current Workforce for Rheumatology in All Countries in Europe Maxime Dougados, MD MONDAY November, 0 0 Program Book 59

62 8:5 AM Review of Current Workforce for Rheumatology in All Countries in the Asia-Pacific Zhan-Guo Li, MD 8:0 AM Review of Current Workforce for Rheumatology in All Countries in Africa Omondi G. Oyoo, MD, MMed 8:45 AM Summary of the Global Rheumatology Workforce Peter Brooks, MD 59 A Scleroderma: Systemic Sclerosis (08) Speaker: Robyn T. Domsic, MD, MPH 59 B Scleroderma: Systemic Sclerosis (09) Speaker: Michael R. York, MD 60 Vasculitis: Update (040) Speaker: Paul A. Monach, MD, PhD MONDAY November, 0 ACR MEET THE PROFESSOR SESSIONS 7:45-9:5 AM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September Crystal: Diagnosis and Management of Gout (0) Speaker: Michael A. Becker, MD 5 *Osteoarthritis: Update 0 (0) Speaker: Joanne M. Jordan, MD, MPH ACR/ARHP WORKSHOPS 7:45-9:45 AM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September C Joint Injections (Knee and Ankle Prosthetics) (6) Speakers: Gregory C. Gardner, MD and Kenneth R. Margules, MD 44 B *Musculoskeletal Ultrasound (7) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD 54 A Pediatric Rheumatology for Adult Rheumatologists (0) Speaker: Peter A. Nigrovic, MD 54 B Pediatrics: Spondylarthritis in Children (04) Speaker: Thomas J. A. Lehman, MD 44 A *Peripheral Magnetic Resonance Imaging in Rheumatology Practice (8) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, MD, PhD, DMSc 49 A *X-ray Challenges in Rheumatic Diseases (9) Speaker: Donald J. Flemming, MD 55 Psoriatic Arthritis (05) Speaker: M. Elaine Husni, MD, MPH ACR SESSIONS 9:00-0:00 AM 58 A Rheumatoid Arthritis: Difficult Cases (06) Speaker: Stanley B. Cohen, MD 58 B Rheumatoid Arthritis: Difficult Cases (07) Speaker: Nancy A. Shadick, MD, MPH 5 A Epigenetic Factors in Autoimmune Disease Moderator: Lindsey A. Criswell, MD, MPH Speaker: Bruce C. Richardson, MD, PhD Upon completion of this session, participants should be able to: describe the different types of epigenetic modifications and how they are currently assessed 60 0 Program Book

63 recognize how epigenetic factors or changes may influence disease through changes in gene expression or other mechanisms evaluate current and emerging evidence that implicates DNA methylation and other epigenetic changes in risk and severity of rheumatoid arthritis, systemic lupus erythematosus and related diseases Hall D New Anticoagulants: What a Hematologist Thinks a Rheumatologist Needs to Know! Moderator: Victoria K. Shanmugam, MBBS Speaker: Craig M. Kessler, MD Upon completion of this session, participants should be able to: discuss the clinical indications for the various currently available anticoagulants discuss the monitoring required for the various anticoagulants describe some of the limitations of the various anticogaulants, and how clinicians should select appropriate therapy for their patients Rheumatology Research Foundation SPECIAL SESSION 9:00-0:00 AM Hall E Memorial Lectureship: Pathogenesis of Rheumatoid Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint Destruction Moderator: Shaun Ruddy, MD Speaker: Gary S. Firestein, MD Upon completion of this session, participants should be able to: appreciate from a historic perspective the evolution of current theories on the causes of rheumatoid arthritis pathogenesis describe how immunogenetic inheritance may lead to the development of inflammatory arthritis explain the relationships between different rheumatoid arthritis associated autoantibodies and their target antigens during pathogenesis describe how improved understanding of pathogenesis has led to progressive advancements in therapeutic interventions 04 A Infusion Reactions: Management and Prevention (Infusion Series) Moderator: Karen Huisinga, MN, ARNP Speaker: Christine Elliott, RN Upon completion of this session, participants should be able to: discuss the types of infusion reactions that may occur with medications used to manage rheumatic diseases review the medications with higher propensity for infusion reactions identify medications that require pre- treatment and discuss measures that may be taken to assist with preventing infusion reactions outline the management of infusion reactions from mild reactions to anaphylaxis 0 Issues in the Management of Rheumatic Disease in Patients Undergoing Joint Replacement (Arthroplasty/Joint Replacement Series) Moderator: James G. Freeman, MD Speaker: Brian F. Mandell, MD, PhD Upon completion of this session, participants should be able to: explain the major medical issues that should be assessed and optimized pre-operatively recognize the rheumatology specific issues that must be addressed pre-operatively discuss the data and current standard of care to help guide clinicians in the use of NSAIDs, DMARDs and biologics, as well as drugs for osteoporosis before and after surgery 06 Rheumatic Disease Update: Gout Moderator: Afton L. Hassett, PsyD Speaker: Naomi Schlesinger, MD Upon completion of this session, participants should be able to: describe current conceptualizations of clinical manifestations, diagnostic procedures and pathophysiology of gout identify common concerns of patients with gout discuss evidence-based treatment strategies to promote optimal outcomes in patients with gout MONDAY November, 0 ARHP SESSIONS 9:00-0:00 AM 4 A Clinical Trials: Participation and Recruitment Moderator: Meenakshi Jolly, MD, MS Speaker: Alan J. Kivitz, MD, CPI Upon completion of this session, participants should be able to: identify challenges facing sponsors in recruiting patients identify challenges facing sites in recruiting patients describe what sponsors are doing in response to these challenges discuss what sites can adopt to recruit patient for clinical trials ACR SESSIONS 9:00-0:0 AM 50 B Creating an Efficient Rheum Practice Moderator: C. Ryan Antolini, MD Speaker: Owen J. Dahl, MBA, FACHE, CHBC, LSSMBB Upon completion of this session, participants should be able to: identify common opportunities to improve practice/ procedure efficiency identify the person or process constraint in your office, and possible ways to leverage or manage that constraint describe the concept of continuous flow recognize strategies to reduce waste and inefficiency 0 Program Book 6

64 47 A Legislative Update from Capitol Hill This session is not eligible for CME credit. Moderator: Timothy Laing, MD Speaker: The Honorable Chris Van Hollen, U.S. Representative (MD 8th District) Upon completion of this session, participants should be able to: describe the latest developments in federal health policy discuss legislative initiatives currently before Congress and how outcomes could affect the rheumatology community recognize the value of engaging in grassroots advocacy with members of Congress discuss new approaches to teaching in the rheumatic and musculoskeletal diseases explain the unique and important roles of the clinician scholar educator in medical education and training 9:00 AM A Web-based, Problem-based Learning: Rheumatology Curriculum for Medical Students, Internal Medicine Residents and Rheumatology Fellows Abby Abelson, MD 9:8 AM Focusing on Basics: Regional Musculoskeletal Modules Jessica Berman, MD MONDAY November, 0 07 A Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond PS Moderators: Arthur Kavanaugh, MD and Michael H. Weisman, MD Upon completion of this session, participants should be able to: identify important safety issues in the drug treatment of rheumatic diseases integrate knowledge of new safety issues into their treatment strategies more fully advise patients about the safety issues related to treatments for rheumatic diseases become aware of evolutions at the Food and Drug Administration that will affect drug safety monitoring and reporting 9:00 AM Introduction Update on Newly Identified Drug Safety Issues and Initiatives from the ACR Drug Safety Subcommittee John J. Cush, MD 9:5 AM Update and Safety Issues of Recently Approved Agents for Rheumatic Diseases Larissa Lapteva, MD, MHS 9:50 AM The Year in Review- Update on Safety Issues at the FDA for the Last Months Sally M. Seymour, MD 0:5 AM Question & Answer Rheumatology Research Foundation SPECIAL SESSION 9:00-0:0 AM 45 A Clinician Scholar Educator Presentations Moderators: Michael J. Battistone, MD and Kenneth S. O Rourke, MD Upon completion of this session, participants should be able to: discuss novel approaches to curriculum development for medical students and residents in the musculoskeletal and rheumatic diseases 9:6 AM Web-based Interactive Rheumatology Experience (WIRE) Christopher E. Collins, MD 9:54 AM Development of a Multimodal Rheumatology Elective: A Controlled Study Deana M. Lazaro, MD 0: AM A Modular Curriculum in Pediatric Rheumatology for Residents, Pediatricians and Adult Specialists Amy L. Woodward, MD, MPH ACR/ARHP POSTER SESSION B, THIEVES MARKET POSTERS, AND POSTER TOURS 9:00 AM - 6:00 PM Poster presenters will be available from 9:00 - :00 AM (abstracts # 87-59). Poster tours will be held 9:00-9:45 AM and 0:5 - :00 AM. Morning snacks will be available from 9:00-0:0 AM. Poster Hall (Hall B) Thieves Market Posters Thieves Market posters feature cases with interesting imaging studies or pictorial displays of physical findings. A Case of Juvenile Arthritis Krati Chauhan, MD, MPH A Case of Perplexing Weakness Andreea Harsanyi, MD Development of Leprosy after Treatment with IL6 Blocker Basma Al Nahlawi, MD; Samina Hayat, MD; Mamatha Katikaneni, MD and Anita S. Mathew, MD Headaches and Heartaches Bansai Gujar, MD Mass Effect Bansai Gujar, MD Stridor Cristina Gale Arriens, MD Voriconazole-induced Periostitis Anna Gramling, MD 6 0 Program Book

65 Poster Hall (Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 5 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Salons G-H-I). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 5 minutes of the end of the tour. 9:00-9:45 AM ARHP Patient Care and Clinically-Focused Research () Tour Guide: Elizabeth G. Salt, PhD Orthopedics, Low Back Pain and Rehabilitation () Tour Guide: Jeffrey N. Katz, MD Rheumatoid Arthritis: Clinical Aspects (4) Tour Guide: Neal S. Birnbaum, MD Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment (5) Tour Guide: Atul A. Deodhar, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s: Clinical Aspects and Therapeutics (6) Tour Guide: Murray Baron, MD Vasculitis (7) Tour Guide: Alexandra Villa-Forte, MD, MPH 0:5 - :00 AM Fibromyalgia and Soft Tissue Disorder (8) Tour Guide: Don L. Goldenberg, MD Osteoarthritis - Clinical Aspects (9) Tour Guide: Joanne M. Jordan, MD, MPH Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy (0) Tour Guide: Eric M. Ruderman, MD EXHIBITS 0:00 AM - 5:00 PM Exhibit Hall (Hall A) Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 0:00 - :00 AM and :00 - :00 PM. (Booth #45) Innovation Theater Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. These presentations will be held from 0:0 - :5 AM, :0 - :5 PM and :0 - :5 PM. For a complete listing of Innovation Theater presentations see page 6. ARHP SESSION 0:0 - :0 AM 06 Distinguished Lecturer: Unraveling the Go-Gene Moderator: Linda S. Ehrlich-Jones, PhD, RN Speaker: Basia Belza, PhD Upon completion of this session, participants should be able to: describe the go-gene identify facilitators and barriers to adopting and maintaining a physically active lifestyle for older adults categorize strategies for adoption and maintenance of regular physical activity based on the socioecological model ACR WORKSHOPS 0:0 AM - :0 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September 4. MONDAY November, 0 Rheumatoid Arthritis: Clinical Aspects () Tour Guide: Iain B. McInnes, PhD Systemic Lupus Erythematosus: Clinical Aspects () Tour Guide: Eliza F. Chakravarty, MD Rheumatology Research Foundation - Health Services/ Outcomes Research () Tour Guide: Michael M. Ward, MD Learn about the excellent work being done by Rheumatology Research Foundation-funded early career investigators. This is also an opportunity for division chiefs looking to recruit junior faculty to meet young productive investigators and vice versa. 44 B Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (0) Speakers: George V. Lawry, MD and Paul C. Utrie, MD 44 A Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm () Speaker: Stuart L. Silverman, MD 0 Program Book 6

66 MONDAY November, 0 ACR PLENARY SESSION II DISCOVERY 0 :00 AM - :0 PM Hall E Moderators: Carol A. Langford, MD, MHS and Richard M. Pope, MD :00 AM 59. The Risk of Lymphoma in Patients Receiving Anti-Tumor Necrosis Factor Therapy for Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register- Rheumatoid Arthritis Louise K. Mercer, Mark Lunt, Audrey S. Low, James B. Galloway, Kath Watson, William G. Dixon, BSRBR Control Centre Consortium, Deborah P. Symmons, Kimme L. Hyrich and On behalf of the BSRBR 4, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 4 British Society for Rheumatology, London, United Kingdom Background/Purpose: The risk of lymphoma is increased in people with RA compared to the general population and is greatest in severe RA. Anti-TNF therapy is now widely used to treat RA, especially severe RA. The aim of this study was to determine whether anti-tnf influences the risk of lymphoma when used in routine UK clinical practice. Methods: The analysis was conducted in the BSRBR-RA, a national cohort study. Patients with RA starting treatment with the TNF inhibitors etanercept (ETA), infliximab (INF) or adalimumab (ADA) and a biologic-naïve comparison cohort exposed to non-biologic therapy (nbdmard) were recruited between Subjects were followed until 09/0/00, first lymphoma or death, whichever came first. Subjects with a history of lymphoproliferative malignancy prior to registration were excluded. Incident cancers were identified in ways; lifelong flagging with national cancer agencies; 6 monthly patient and physician questionnaires for years and annual physician questionnaires thereafter. Only first lymphoma per subject, confirmed by histology or cancer agency, was analysed. The rates of lymphoma and non-hodgkin lymphoma (NHL) in the nbdmard cohort and in patients ever exposed to anti-tnf were compared using Cox proportional hazards models adjusted using deciles of propensity score (DP) which included baseline age, gender, DAS score, HAQ, disease duration, use of steroids, current/previous cyclophosphamide, smoking and registration date. The first 6 months of follow-up were excluded. There were too few Hodgkin lymphoma (HL) to compare rates. Results: 84 incident lymphomas were confirmed: 0 in 465 nbdmard-treated subjects and 64 in 987 anti-tnf (5 versus 96 per person-years (pyrs); Table). After adjusting using DP there was no difference in risk of lymphoma between the cohorts; hazard ratio (HR) for anti-tnf. (95% CI 0.55,.). There were 5 (%) HL in the nbdmard cohort and 9 (%) in anti-tnf. Among 7 NHL, the most frequent subtype was diffuse large B cell lymphoma; 8 (50% of NHL) in nbdmard and 5 (45%) anti-tnf. There was no significant difference in risk of NHL between the cohorts (table). Conclusion: There is no evidence that anti-tnf increases the risk of lymphoma over the background risk associated with RA, but further follow up is needed to establish if the picture changes with time. Table nbdmard N=465 Anti-TNF N=987 Follow-up (pyrs) Median follow-up (pyrs; IQR) 4.5 (.6, 5.9) 6.4 (4.8, 7.4) Age: (years) Mean (SD) 60 () 56 () Gender: N(%) female 545 (7) 945 (76) RA disease duration: (years) Median (IQR) 6 (, 5) (6, 9) DAS8 score: mean (SD) 5. (.) 6.6 (.0) HAQ: mean (SD).5 (0.7).0 (0.6) Lymphoma: N 0 64 Lymphoma: Rate per pyrs (95% CI) Lymphoma: Age and gender adjusted HR (95% CI) Lymphoma: DP adjusted HR (95% CI) 5 (9, 4) 96 (74, ) Referent 0.7 (0.4,.0) Referent. (0.55,.) Hodgkin lymphoma: N 4 9 Hodgkin lymphoma: Rate per pyrs (95% CI) 0 (8, 78) 4 (6, 6) Non-Hodgkin lymphoma: N 6 55 NHL: Rate per pyrs (95% CI) NHL: Age and gender adjusted HR (95% CI) (69, 97) 8 (6, 08) Referent 0.79 (0.44,.40) NHL: DP adjusted HR (95% CI) Referent.6 (0.58,.7) Disclosure: L. K. Mercer, None; M. Lunt, None; A. S. Low, None; J. B. Galloway, None; K. Watson, None; W. G. Dixon, None; D. P. Symmons, None; K. L. Hyrich, None; O. B. O. T. BSRBR, BSR Biologcs Register,. :5 AM 594. Clinical and Radiological Outcomes After One Year of Remission Steered Combination Treatment in Patients with Early Rheumatoid and Undifferentiated Arthritis L. Heimans, K.V.C. Wevers-de Boer, K. Visser, H.K. Ronday, M. van Oosterhout, J. H. L. M. Van Groenendael 4, A.J. Peeters 5, G. Steup-Beekman 6, G. Collee 7, P.B.J Sonnaville 8, B.A. Grillet 9, Tom Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Haga Hospital, The Hague, Netherlands, Groene Hart Hospital, Gouda, Netherlands, 4 Franciscus Hospital, Roosendaal, Netherlands, 5 Reinier de Graaf Gasthuis, Delft, Netherlands, 6 Bronovo Hospital, Netherlands, 7 MCH, The Hague, Netherlands, 8 Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 9 Zorgsaam hospital, Terneuzen, Netherlands Background/Purpose: To evaluate the year clinical and radiological outcomes of remission steered therapy in early arthritis patients treated aiming at remission (DAS<.6). Methods: In the IMPROVED study 60 patients were included with early rheumatoid or undifferentiated arthritis (RA or UA). All patients started with methotrexate (MTX) 5mg/wk and prednisone 60mg/day tapered to 7.5mg/day in 7 weeks. Patients in remission (DAS<.6) after 4 months (early remission) tapered prednisone to zero and, when in remission at 8 months, tapered MTX. Patients not in early remission were randomized either to a combination of MTX 5mg/wk, hydroxychloroquine 64 0 Program Book

67 400mg/day, sulphasalazine 000mg/day and prednisone 7.5mg/ day (arm ) or to adalimumab (ADA) 40mg/weeks with MTX 5mg/wk (arm ). If not in remission after 8 months, patients in arm switched to ADA+MTX and patients in arm increased ADA to 40mg/week. Proportions of remission and radiological progression measured by Sharp-van der Heijde scoring method after one year follow up were compared between the different treatment strategies. Results: After 4 months 75 patients (6%) achieved early remission and (6%) did not, of which 6 patients were randomized, 8 to arm and 78 to arm. In 6 (0%) patients the protocol was not followed, were lost to follow up after 4 months and in total 4 after year. Of those in early remission 6 (96%) tapered prednisone after 4 months and 00 (5%) tapered MTX after 8 months. After year, remission was achieved in 57 (69%) patients and 9 (%, 0% of all patients) were in drug free remission. Patients in arm and achieved remission in similar proportions after 8 months (0 (6%) versus 7 (5%), p=.0), but after year patients in arm more often achieved remission than in arm ( (4%) vs (5%), p=0.0). Patients in arm who at 8 months tapered ADA+MTX combination to MTX monotherapy, more often remained in remission after one year than patients tapering poly-dmards+prednisone to MTX monotherapy in arm (7/6 (65%) vs /0 (7%), p=0.0). After failing to achieve remission on poly-dmards+prednisone, 6/4 patients (8%) who switched to ADA achieved remission after one year, compared to 8/7 (0%) who failed on ADA+MTX and increased ADA (p=0.). Of the total study population 5% were in remission after year. Median (IQR) radiological damage progression after year was 0(0-0) in patients who achieved early remission, and 0(0-0) and 0(0-0) in arms and, respectively (p=0.). Conclusion: After one year of remission steered combination treatment, 5% of the patients with early arthritis achieved remission. Patients in early remission after initial treatment with MTX and prednisone most often achieved remission after one year (69%) and % were in drug free remission. Patients who failed to achieve early remission benefited more from a treatment strategy with adalimumab than with multiple DMARDs+prednisone. In this treat-to-remission cohort, radiological damage progression after year was negligible in all patients. Disclosure: L. Heimans, None; K. V. C. Wevers-de Boer, None; K. Visser, None; H. K. Ronday, None; M. van Oosterhout, None; J. H. L. M. Van Groenendael, None; A. J. Peeters, None; G. Steup- Beekman, None; G. Collee, None; P. B. J. Sonnaville, None; B. A. Grillet, None; T. Huizinga, None; C. F. Allaart, None. :0 AM 595. Genome-Wide Association Study to High-Throughput Cell-Based Phenotypic Screen Identifies Novel Chemical Inhibitors of CD40 Signaling Gang Li, Dorothee Diogo, Di Wu, Jim Spoonamore, Rheumatoid Arthritis Consortium International (RACI), Eli Stahl 4, Nicola Tolliday and Robert M. Plenge, Brigham and Women s Hospital, Boston, MA, Broad Institute, Cambridge, MA, Boston, 4 Brigham and Women s Hospital Background/Purpose: Deriving therapeutic targets from human genetics linked with biological alterations of risk alleles may provide a more successful approach to drug development than traditional efforts that focus on biological insight alone. Here, we successfully translate a SNP association from a genome-wide association study (GWAS) in rheumatoid arthritis (RA) into a high-throughput screen (HTS) based on cellular phenotype in a human B cell line to identify inhibitors of CD40-mediated NF-κB signaling. Methods: We fine-map the CD40 risk locus in 7, seropositive RA patients and 5,870 controls genotyped on the Immunochip, together with deep sequencing of CD40 coding exons in 500 RA cases and 650 controls. We use flow cytometry to measure CD40 protein levels on the surface of primary CD9+ from 90 healthy control individuals. We use gene expression arrays to measure CD40 RNA levels in peripheral blood mononuclear cells from,469 healthy control individuals. We use retroviral shrna infection to perturb the amount of CD40 on the surface of a human B lymphocyte cell line (BL). We develop a highthroughput NF-κB luciferase reporter assay in BL cells activated with trimerized CD40 ligand (tcd40l), and conduct an HTS of,98 chemical compounds and FDA-approved drugs. Counterscreens of the top hit compounds were performed in the BL line activated with both tcd40l and LPS, and in an additional B cell line, Ramos, activated with tcd40l and TNF. Two known and two novel compounds were tested for inhibition of tcd40- NFkB signaling in primary human CD9+ B cells by measuring CD86 expression with flow cytometry. Results: A single common SNP at the CD40 locus explains the entire signal of association (rs480485, P=.4x0-9), without any evidence for independent rare variants contributing to RA risk. Subjects homozygous for the common RA risk allele have ~% more CD40 on the surface of primary human CD9+ B lymphocytes than subjects homozygous for the non-risk allele (P=0-9), a finding corroborated by expression quantitative trait loci (eqtl) analysis in PBMC s (P<0-5). We observe a direct correlation between amount of CD40 protein and phosphorylation of RelA (p65), a subunit of the NF-κB transcription factor. Using our luciferase reporter assay, we identify 8 hit compounds (out of,98) that consistent inhibit luciferase activity following tcd40l activation. After a series of counter-screens and testing in primary human CD9+ B cells, we identify known and novel chemical inhibitors not previously implicated in inflammation or CD40-mediated NFκB signaling. One known inhibitor is tranilast, a drug currently in a phase II clinical trial of RA; the other is a corticosteroid derivative. The two novel compounds represent promising tool compounds to develop new therapies to treat RA. Conclusion: Our study demonstrates proof-of-concept that human genetics can be used to guide the development of phenotype-based, high-throughput small-molecule screens to identify potential novel therapies in complex traits such as RA. Disclosure: G. Li, None; D. Diogo, None; D. Wu, None; J. Spoonamore, None; E. Stahl, None; N. Tolliday, None; R. M. Plenge, None. :45 AM 596. Strontium Ranelate in Knee Osteoarthritis Trial (SEKOIA): A Structural and Symptomatic Efficacy Jean-Yves Reginster, R. Chapurlat, Claus Christiansen, H. Genant 4, N. Bellamy 5, W. Bensen 6, F. Navarro 7, J. Badurski 8, E. Nasonov 9, X. Chevalier 0, PN. Sambrook, T. Spector and Cyrus Cooper, University of Liège, Liège, Belgium, INSERM UMR 0 and Université de Lyon, Hôpital Edouard Herriot, Lyon, MONDAY November, 0 0 Program Book 65

68 MONDAY November, 0 France, CCBR, Ballerup, Denmark, 4 Radiology, Medicine and Orthopaedic Surgery University of California and Synarc, San Francisco, CA, 5 CONROD. The University of Queensland, Royal Brisbane and Women s Hospital, Herston, Queensland, Australia, 6 St. Joseph s Hospital and McMaster University, Hamilton, ON, 7 H. Universitario Virgen de la Macarena, Sevilla, Spain, 8 Center of Osteoporosis and Osteo-articular Diseases, Bialystock, Poland, 9 State Institute of Rheumatology, the Russian Academy of Medical Sciences, Moscow, Russia, 0 Hôpital Henri-Mondor, Creteil, France, Royal North Shore Hospital, St Leonards, Australia, King s College London, St. Thomas Campus, London, United Kingdom, University of Oxford; Southampton General Hospital, Southampton, United Kingdom Background/Purpose: Treatments for osteoarthritis focus on improving symptoms through non-pharmacological and pharmacological approaches. Strontium ranelate (SrRan), a treatment for osteoporosis, was shown to stimulate cartilage matrix formation in vitro, and to reduce radiographic spinal OA progression in osteoporotic women with spinal OA. The objective of SEKOIA phase III study was to compare the efficacy of SrRan with placebo for reducing radiological progression of knee OA. Methods: SEKOIA is a double-blind, placebo-controlled, randomized, -year study involving 68 patients with symptomatic primary knee OA (Kellgren and Lawrence [KL] grade or, joint space width [JSW].5 5 mm) randomly allocated to SrRan or g/day, or placebo. Primary endpoint was radiographic change in JSW of the medial tibiofemoral compartment from baseline to LOCF. Group comparisons were performed in the ITT using a general linear model with Dunnett s multiple comparison procedure with baseline JSW, center and sex as covariates. JSW was measured yearly using a validated computer-assisted centralised reading method. Secondary endpoints included radiological progression (JSN 0.5mm), radio-clinical progression (JSN 0.5mm and WOMAC improvement 0%), WOMAC scores, knee pain, and adverse events. Results: The ITT set included 7 (8%) patients. Age was 6±7 years, BMI was 0±5 kg/m, JSW was.5±0.8 mm. 6% were KL II. 69% were female. SrRan was associated with less progression of cartilage degradation, decrease in JSW was 0.±0.56 mm with g/day; 0.7±0.6 mm with g/day and 0.7±0.59 mm with placebo; estimated differences (SE) were 0.4(0.04),p<0.00 for g/day and 0.0(0.04),p=0.08 for g/ day with no difference between doses. Results were confirmed in the Randomised Set and sensitivity analyses demonstrated minimal impact of missing post-baseline data. There were less radiological and radioclinical progressors with SrRan and g/day: Secondary criteria Strontium ranelate g/day (n=445) Strontium ranelate g/day (n=454) Placebo value (n=47) n % E (SE)* (95% CI) Radiological 99 (%) 0.80 (.9) progression ( 6.54; 5.06) Radioclinical (8%).94 (.98) progression ( 7.8; 0.05) p value n % E (SE)* (95% CI) *Estimated difference versus placebo p value < (6%) 7.50 (.0) (%) (.4;.66) (7%) 5. (.9) ( 8.86;.7) (%) Greater reductions in total WOMAC score (p=0.045), pain (p=0.08) and physical function subscore (p=0.099), and knee pain (p=0.065) were observed with SrRan g/day. SrRan was well tolerated: 86%, 88% and 87% reported an emergent adverse event (EAE) in the SrRan g, g and placebo group respectively, 7% of the patients in each group reported a serious EAE. EAE in each SrRAn group, in the placebo group led to death. Conclusion: SrRan and g/day delayed radiographic progression of knee OA, evidencing a structure-modifying effect. This structural effect is translated clinically into a lower number of patients having a radiological progression over thresholds known to be predictive of OA-related surgery suggesting that SrRan could reduce the number of patients needing knee surgery in the long-term. The structural effect was accompanied by symptom improvement at the dose of g/day. References Bruyere et al, ARD :77-70 Altman et al, Ost Cart 005-,-9 Disclosure: J. Y. Reginster, Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB, 5, Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Teijin, Teva, Ebewee Pharma, Zodiac, Analis, Theramex, Nycomed, Novo-Nordisk,, Bristol Myers Squibb, Merck Sharp and Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier, ; R. Chapurlat, Merck, Amgen, Servier, Lilly, Roche, Novartis, ; C. Christiansen, Nordic, Bioscience A/S, CCBR/Synarc, 9, Roche, Eli Lilly, Novartis, Novo Nordisk, Proctor and Gamble, Groupe Fournier, Besins EscoVesco, Merck Sharp and Dohme, Chiesi, Boehringer Mannheim, Pfizer, GlaxoSmithKline, Amgen., 5; H. Genant, Servier, Novartis, Pfizer, GSK, Roche, Genentech, Lilly, Amgen, Merck, ONO, Bristol Myers Squibb, 5, Synarc, Inc., ; N. Bellamy, Servier, 5; W. Bensen, Abbott, Amgen, Bristol Myers Squibb, Janssen, Merck-Schering, Lilly, Novartis, Pfizer, Wyeth, Proctor and Gamble, Roche, Sanofi, Servier, Aventis, UCB, Warner Chilcott, 5; F. Navarro, Servier, 5; J. Badurski, Servier, Amgen, 5; E. Nasonov, Merck Sharp and Dohme, Rocher, 5; X. Chevalier, Expanscience, Negma, Genevriers, Merck Sharp and Dohme, Rottapharm, Fidia, Servier, Pierre Fabre, Smith Nephews,Ibsa, Genzyme, 5, Roche for the department association, ; P. Sambrook, Servier, 5; T. Spector, Servier, 5, Pfizer Inc,, Expanscience, Ono Pharma, 5; C. Cooper, Amgen, ABBH, Novartis, Pfizer, Merck Sharp and Dohme, Eli Lilly, Servier, 5. Noon 597. Efficacy and Safety of Tocilizumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Data From a Phase Trial Hermine Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane 4, Olivier Harari 4, Andrew Kenwright 4, Rubén J. Cuttica 5, Vladimir Keltsev, Ricardo Xavier, Inmaculada Calvo Penades, Irina Nikishina 6, Nadina Rubio-Perez 7, Ekaterina Alekseeva, Vyacheslav Chasnyk 8, Jose Chavez, Gerd Horneff 9, Violetta Opoka-Winiarska, Pierre Quartier 0, Clovis A. Silva, Earl D. Silverman, Alberto Spindler, D. J. Lovell, Alberto Martini and Fabrizio De Benedetti, Cincinnati Children s Hospital Medical Center and PRSCG, Cincinnati, OH, Paediatric Rheumatology International Trials Organisation [PRINTO], 66 0 Program Book

69 Genova, Italy, Paediatric Rheumatology International Trials Organisation IRCCS [PRINTO], Genoa, Italy, 4 Roche, Welwyn Garden City, United Kingdom, 5 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 6 Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, 7 PRINTO, IRCCS G. Gaslini, Genoa, Italy, 8 International Investigator Consortium for MAS Diagnostic Criteria, Saint-Petersburg, Russia, 9 Centre of Pediatric Rheumatology, Sankt Augustin, Germany, 0 Necker-Enfants Malades Hospital, Paris, France, Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, Cincinnati Children s Hospital, Cincinnati, OH, PRINTO and PRSCG, Genoa, Italy Background/Purpose: Elevated IL-6 levels are associated with disease activity in patients (pts) with juvenile idiopathic arthritis (JIA). Tocilizumab (TCZ), an IL-6 receptor inhibitor, was evaluated for the treatment of polyarticular-course JIA (pcjia; RF+ and RF poly- and extended oligoarticular JIA; systemic JIA was excluded) in the CHERISH study. Methods: CHERISH is a 04-wk study in pts age -7 yrs with active pcjia for 6 mo who failed MTX. In the first 6 wks, all pts received open-label (OL) TCZ every 4 wks (if body weight [BW] 0 kg, 8 mg/kg [n = 9]; if BW <0 kg, pts were randomly assigned to 8 mg/kg [n = 4] or 0 mg/kg [n = 5]). At wk 6, eligible pts (with JIA ACR0 response) entered a 4-wk randomized (pts were assigned [:] to placebo [PBO] or to continue TCZ at the same dose), double-blind (DB) withdrawal period for evaluation of the primary endpoint (JIA ACR0 flare relative to wk 6). Pts who flared or completed the DB period entered an OL extension in which they received the same TCZ dose as in the lead-in period. Efficacy data (until wk 40) are presented for the ITT population; safety data are presented for the safety population to the cut date. Results: 88 pts entered the initial lead-in period (77% girls; 79% and 46% were receiving concurrent MTX and oral corticosteroids [CS], respectively); 66 pts entered the DB period; 5 pts (8%) withdrew due to insufficient response, (%) due to adverse events (AEs), and 4 (%) due to other reasons. The primary endpoint was met, and JIA ACR0/50/70 responses were significantly higher with TCZ compared to PBO at wk 40 (Table). Efficacy responses for the initial lead-in period at wk 6 are shown (Table). The degree of improvement was lower for these endpoints in the TCZ 8 mg/kg <0 kg BW group compared with the other groups (TCZ 0 mg/kg <0 kg BW and TCZ 8 mg/kg 0 kg BW) (Table). At the time of the safety data cut, there were 84 pt-yrs (PY) of follow-up in the 88 pts enrolled. Rates/00PY of AEs and SAEs were 480 and.5; infections were the most common AEs (64/00PY) and SAEs (4.9/00PY). ALT and AST elevations ULN were each reported in.7% and <% of pts. Neutropenia (<000 cells/ mm ) and thrombocytopenia (<50,000 cells/mm ) occurred in.7% and.% of pts. LDL-cholesterol 0 mg/dl occurred in.4% of pts. No grade /4 (> ULN) elevations of serum bilirubin were reported. Conclusion: TCZ treatment in pcjia was efficacious, with a sustained clinically meaningful improvement using a monthly regimen at doses of 8 mg/kg if BW 0 kg and 0 mg/kg if BW <0 kg. The safety profile is consistent with that in other TCZtreated pts (eg, systemic JIA). References. De Benedetti Clin Exp Rheumatol. 99;49.. De Benedetti Ann Rheum Dis 0;70(suppl ):67. Disclosure: H. Brunner, None; N. Ruperto, BMS, Abbott, Novartis, Roche Pharmaceuticals, Centocor, ACRAF, Pfizer, Xoma,, BMS, Roche Pharmaceuticals, 8; Z. Zuber, None; C. Keane, Roche Pharmaceuticals, ; O. Harari, Roche Pharmaceuticals, ; A. Kenwright, Roche Pharmaceuticals, ; R. J. Cuttica, None; V. Keltsev, None; R. Xavier, Roche Pharmaceuticals, BMS, Tousseau, 5, Roche, Janssen, Pfizer, 8; I. Calvo Penades, None; I. Nikishina, None; N. Rubio-Perez, None; E. Alekseeva, None; V. Chasnyk, None; J. Chavez, None; G. Horneff, Abbott Pfizer,, Abbott, Pfizer, Novartis, Roche Pharmaceuticals, Chugai, 8; V. Opoka-Winiarska, None; P. Quartier, Abbott, Novartis, Pfizer,, Abbott, Novartis, Pfizer, Roche Pharmaceuticals, BMS, 5; C. A. Silva, Roche Pharmaceuticals, ; E. D. Silverman, None; A. Spindler, None; D. J. Lovell, National Institutes of Health,, Astra-Zeneca, Centocor, Wyeth, Amgen, BMS, Abbott, Pfizer, Regeneron, Hoffmal-La Roche, Novartis, UCB, Xoma, 5, Arthritis and Rheumatism, 9, Genentech,, 8, Forest Research, 9; A. Martini, BMS, Abbott, Novartis, Roche Pharmaceuticals, Centocor, ACRAF, Pfizer, Xoma,, Novartis, Roche Pharmaceuticals, 5, BMS, 8; F. De Benedetti, Abbott, BMS, Pfizer, SOBI, Novimmune, Roche Pharmaceuticals, Novartis,, BMS, Pfizer, Roche Pharmaceuticals, 5. :5 PM 598. Clinical and Serologic Predictors of Response in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) - the RIM Study Rohit Aggarwal, Ann M. Reed, Dana P. Ascherman, Richard J. Barohn 4, Brian M. Feldman 5, Frederick W. Miller 6, Lisa G. Rider 6, Michael Harris-Love 7, Marc C. Levesque, Chester V. Oddis and the RIM Study Group 8, University of Pittsburgh, Pittsburgh, PA, Mayo Clinic, Rochester, MN, University of Miami, Miami, FL, 4 Department of Neurology, University of Kansas Medical MONDAY November, 0 0 Program Book 67

70 MONDAY November, 0 Center, Kansas City, USA, Kansas City, MO, 5 The Hospital for Sick Children, Toronto, ON, 6 NIEHS, NIH, Bethesda, MD, 7 VA Medical Ctr, Washington, DC, 8 Background/Purpose: The Rituximab in Myositis (RIM) Study evaluated 00 refractory myositis patients treated with rituximab, 8% of whom met the definition of improvement (DOI). The aim of this study was to identify the clinical and laboratory predictors of response in this cohort. Methods: All patients failed corticosteroids and at least other immunosuppressive (IS) agent and received rituximab at weeks 0/ (Early) or 8/9 (Late). The endpoint in this 44-week trial was time to achieve DOI [³0% improvement in of 6 core set measures (CSM) (includes manual muscle testing (MMT), muscle enzymes, HAQ, patient/parent global, physician global disease activity and extramuscular disease activity) with no > CSM worsening by ³5% (excluding MMT)] at consecutive visits. We analyzed the effect of the following baseline variables on the time to DOI: myositis subtype, demographics, laboratory [IgM, IgG, myositis-associated autoantibodies (MAA), CBC, creatinine], damage measures (global, muscle damage and atrophy and organ-related), disease activity and other clinical parameters (skeletal/gi/pulmonary/muscle disease activity, Raynaud, calcinosis, mechanic hands), CSM, medication (early vs. late rituximab, IS agents and corticosteroids) and MAA subset [anti-synthetase (anti-syn), Mi-, SRP, TIF-γ, MJ, other autoantibodies and those without an MAA]. The Wilcoxon test was used to univariately evaluate the association of baseline variables with the time to DOI. A multivariate time-dependent proportional hazard model was built using forward selection (α=0.05) based on univariate variables with p<0.. Results: 00 randomized patients (76 PM/76 DM/48 JDM) were analyzed (96 Early/04 Late).Table lists the baseline variables which predicted time to DOI univariately. The multivariate model included autoantibodies (anti-syn was the best DOI predictor followed by Mi- as compared to the no MAA subset), and global damage (lower damage had a better response). The effects of global damage diminished by week 0. Myositis subtype (JDM had a better response than adult myositis) was not statistically significant univariately, however, final model was stratified by the subtypes due to their clinical relevance and post hoc had statistical significance in multivariate models. Conclusion: Anti-Syn and Mi- autoabs strongly predicted improvement in rituximab-treated refractory myositis patients. JDM and lower disease damage predicted more rapid improvement early in course of treatment. It is unclear whether this effect is due to a delayed beneficial effect of rituximab in patients with higher damage and adult PM/DM. These results suggest that early, more aggressive therapy could be considered in some clinical and serologic myositis subsets to achieve a better therapeutic response and to avoid disease-related damage. Table. Univariate predictive factors and final multivariate model. Univariate variable for predicting future DOI (0. level of significance) Factor Associated with more rapid achievement of DOI (Hazard Ratio) p-value for Wilcoxon test for trend Gender males (.8) p=0.0 Autoantibody Anti-Syn (.8) Mi- (.48), Other MAA (.9) as compared with no MAA p=0.00 White blood count higher counts (.44) p=0.04 Muscle damage lower damage (.6) p=0.0 Muscle atrophy absence of atrophy p=0.0 (.45) Global damage lower damage (.0) p=0.004 Most abnormal muscle enzyme higher result (.0) p=0.09 Extramuscular disease activity higher values (.6) p=0.07 Disability index higher values (.09) p=0.09 Multivariate model based on the variables identified in univariate analysis Autoantibody Hazard ratio of DOI P-value (comments) no MAA - (Baseline) Jo-/other antisyn.0 <0.0 (for adult PM or DM) Mi-.49 <0.0(for JDM or adult DM ) Other MAA (SRP, MJ, TIF-γ, other) Global Damage (dichotomized at median < vs. >) <0.0 for week 8, washes out by week 0 Disclosure: R. Aggarwal, None; A. M. Reed, None; D. P. Ascherman, None; R. J. Barohn, None; B. M. Feldman, baxter and Bayer,, Novartis Pharmaceutical Corporation, 9, Pfizer Inc, 9; F. W. Miller, None; L. G. Rider, None; M. Harris-Love, None; M. C. Levesque, Genentech and Biogen IDEC Inc., ; C. V. Oddis, Genentech and Biogen IDEC Inc., 9. ACR SESSIONS :00 AM - :0 PM Hall D ACR Knowledge Bowl - Final Round Moderator: Zsuzsanna H. McMahan, MD, MHS Upon completion of this session, participants should be able to: identify key images that are important to recognize in clinical practice recall factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology 68 0 Program Book

71 47 A Career Opportunities in Rheumatology: Making a Choice Moderator: Allan C. Gelber, MD Upon completion of this session, participants should be able to: provide examples of different career choices available to young rheumatologists discuss the pros and cons of the various career choices in rheumatology :00 AM Basic Research Anne Davidson, MBBS :0 AM Academic Rheumatology Richard Furie, MD :40 AM Rheumatology Private Practice Joseph Flood, MD Noon Rheumatologists in Government Robert H. Carter, MD :0 PM Discussion Ballroom C New Developments in Systemic Juvenile Idiopathic Arthritis Management Moderators: Alexei A. Grom, MD and Peter A. Nigrovic, MD Upon completion of this session, participants should be able to: review current approaches to management of systemic juvenile idiopathic arthritis in North America discuss the main results of the recent clinical trials in systemic juvenile idiopathic arthritis and their potential impact on systemic juvenile idiopathic arthritis management :00 AM Current Practices in Systemic Juvenile Idiopathic Arthritis Management Based on the Childhood Arthritis & Rheumatology Research Alliance Registry Yukiko Kimura, MD :0 AM Review of the Recent Phase III Clinical Trials of IL-6 and IL- Inhibiting Biologic Agents in Systemic Juvenile Idiopathic Arthritis Ronald M. Laxer, MD Noon Role of New IL- and IL-6 Inhibiting Agents in Systemic Juvenile Idiopathic Arthritis Timothy Beukelman, MD, MSCE 5 A The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization PS Moderator: Deborah S. Collier, MD Upon completion of this session, participants should be able to: identify the key elements in current clinical processes and workflow to help select the features of an electronic health record that will be most useful for a rheumatology clinical practice understand common obstacles in electronic health record implementation and identify strategies to mitigate those barriers employ strategies to work effectively with an electronic health record vendor to incorporate rheumatology-specific templates into the electronic health record system design successful marketing campaigns online and traditional examine the platforms, including Twitter, Facebook and YouTube and when it makes sense to use them to market your practice identify resources for creating and utilizing a web site that patients can find and utilize successfully :00 AM Things I Wish I Had Known about Implementing an Electronic Health Record System William M. McClatchey, MD :0 AM Tips and Tricks to Optimize an Electronic Health Record System for Rheumatology Salahuddin Kazi, MD Noon Using Technology to Engage Patients and Promote Your Practice Simon Sikorski, MD ARHP NETWORKING EVENT Noon - :00 PM Renaissance Washington - Renaissance Ballroom, East & West Networking at Noon Sit down with your colleagues over a complimentary lunch, and participate in open discussion on various research, practice, and clinical topics. Each roundtable discussion will be facilitated by a rheumatology expert. All ARHP attendees are welcome to participate in this event. This session is not eligible for CME credit. Roundtable Topics Form Sharing Adult Form Sharing Pediatric Arthritis and Employment Issues Clinical Research Coordinators Physical Activity Measurement of Disease Activity Meeting the Needs of Underserved Populations ECHO Program MONDAY November, 0 0 Program Book 69

72 MONDAY November, 0 Enhancing Patient Adherence Epidemiology/Public Health Advocacy Patients Access to Medications Issues in Healthcare Education Post-surgical Interventions Infusion and Injectable Therapies Medications for Rheumatic Diseases Physician Assistants Nurse Practitioners Adult Nurse Practitioners Pediatric Office Nurse Qualitative Research Research Mentoring ARHP Grant/Award Opportunities Pain Management Sleep/Fatigue Social Media to Improve Patient Health Care Models Tele Medicine Electronic Health Records Office Managers/Practice Managers International Issues ARHP Volunteering/Mentoring ARHP Past Presidents ACR MEET THE PROFESSOR SESSIONS :45 - :5 PM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September *Ankylosing Spondylitis: 0 Update (04) Speaker: Michael H. Weisman, MD 5 *Basic Immunology for Clinical Rheumatologists (04) Speaker: Antony Rosen, MD 54 A * Challenging Cases in Osteoporosis Management (04) Speaker: Kenneth G. Saag, MD, MSc 54 B * Dermatological Manifestations of Rheumatic Diseases (044) Speaker: Ruth Ann Vleugels, MD 55 Hereditary Angioderma (045) Speaker: Peter Deane, MD 58 A * Pulmonary Manifestations of Rheumatic Disease (046) Speaker: Kristin B. Highland, MD, MSCR 58 B Raynaud s and Digital Ischemia (047) Speaker: Janet E. Pope, MD, MPH 59 A Scleroderma Mimics (048) Speaker: Faye N. Hant, DO, MSCR 59 B Vaccinations for Patients on Biologic Therapies (049) Speaker: Clifton O. Bingham III, MD 60 Vasculitis: Update (050) Speaker: Peter A. Merkel, MD, MPH ACR SESSIONS :00 - :00 PM Ballroom A Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy: Recent Advances, Current Thoughts PM Moderator: Joel A. Block, MD Speaker: Andreas Goebel, MSc, PhD Upon completion of this session, participants should be able to: discuss the current thoughts regarding the etiopathogenesis of complex regional pain syndrome summarize current knowledge regarding the appropriate evaluation of suspected complex regional pain syndrome review potential therapeutic strategies leveraging recent knowledge about pathophysiology 5 A Innovation in Musculoskeletal Curriculum Development: Lessons from New Medical Schools Moderator: Sharon L. Kolasinski, MD Upon completion of this session, participants should be able to: explain the breadth of medical school curricular change identify the goals and objectives of curricular redesign outline expectations for evaluation of medical students enrolled in new schools :00 PM Creating A New Medical School Curriculum at Hofstra North Shore-LIJ Veronica M. Catanese, MD, MBA 70 0 Program Book

73 :0 PM Creating A New Medical School Curriculum at the University of Central Florida Shazia Beg, MD 49 B Histopathology of Vasculitis () Speaker: Allen Burke, MD 0 Pediatric Rheumatology Town Hall Meeting Moderator: Marisa S. Klein-Gitelman, MD, MPH Upon completion of this session, participants should be able to: delineate the changes scheduled for implementation to the American Board of Pediatrics MOC program recognize the current issues affecting the pediatric rheumatology community identify various pediatric rheumatology organizations and their program of work :00 PM Update on the American Board of Pediatrics MOC Program Barbara E. Ostrov, MD :0 PM Update on ACR activities Involving Pediatric Rheumatology Marisa S. Klein-Gitelman, MD, MPH :40 PM Update on Childhood Arthritis & Rheumatology Research Alliance Norman T. Ilowite, MD :50 PM Update on Pediatric Rheumatology Collaborative Study Group Hermine I. Brunner, MD, MSc, MBA Hall E Scleroderma Bowel Disease: From Top to Bottom (Clinical Review) Moderator: Virginia D. Steen, MD Speaker: John Clarke, MD Upon completion of this session, participants should be able to: review the available data involving the pathophysiology and associated complications of gastrointestinal disease in scleroderma summarize the diagnostic and therapeutic strategies in the management of gastrointestinal dysmotility discuss the management of challenging cases of scleroderma bowel disease including the role of parenteral nutrition and the data involving novel therapeutic targets ACR/ARHP WORKSHOPS :5 - :5 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September C Joint Injections (Shoulder and Wrist Prosthetics) () Speakers: Gregory C. Gardner, MD and Kenneth R. Margules, MD 44 B MRI in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide (4) Speaker: Walter P. Maksymowych, MD ACR SESSIONS :0-4:00 PM Hall D Curbside Consults - Ask the Professors Moderators: Diane L. Kamen, MD, MS and Robert F. Spiera, MD Upon completion of this session, participants should be able to: compare their personal management approaches to selected clinical problems with those of the presenters describe therapeutic choices and management options for several common but difficult complications of Sjögren s syndrome develop an approach to evaluating and managing patients presenting with complications attributed to lyme disease appraise the potential impact on fracture risk of various treatments for low bone density and when to consider a drug holiday :0 PM Sjögren s Syndrome: Challenges in Clinical Practice Frederick B. Vivino, MD :00 PM Difficult Complications of Lyme Disease Robert A. Kalish, MD :0 PM To Treat or Not to Treat When Faced with a Bone Density Dilemma Michael R. McClung, MD Renaissance Washington - Grand Ballroom North Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis Moderator: Robert Lafyatis, MD Upon completion of this session, participants should be able to: describe markers in mouse and human for macrophage and dendritic cell activation explain the roles various cytokines play on macrophage activation review macrophages and dendritic cell subpopulations implicated in inflammatory and fibrotic disease 0 Program Book 7 MONDAY NOVEMBER, 0

74 :0 PM Functional Consequences of Monocyte and Macrophage Heterogeneity in Normal and Inflammatory Conditions Frederic Geissmann, MD, PhD :0 PM Epidemiology, Diagnosis and Therapy of Neuropsychiatric Lupus Eyal Muscal, MD, MS MONDAY November, 0 7 :00 PM Dendritic Cell Subsets: Developmental Heterogeneity and Roles in Inflammatory Disease Kenneth M. Murphy, MD, PhD :0 PM Macrophages and Dendritic Cells in Inflammatory Skin Disease Michelle Lowes, MD, PhD 5 A Mechanotransduction in Bone and Cartilage Moderator: Richard F. Loeser, MD Upon completion of this session, participants should be able to: define how mechanical stimulation of bone regulates bone cell function through cell signaling complexes called mechanosomes review key mechanotransduction pathways in articular cartilage that regulate chondrocyte metabolism and survival describe how knowledge of the biomechanics of joint tissues is being used to advance tissue engineering :0 PM Mechanosomes as Mediators of Cell Signaling in Bone Fredrick Pavalko, PhD :00 PM Mechanotransduction Pathways in Articular Cartilage Tonia Vincent, MD, PhD :0 PM Role of Biomechanics in Tissue Engineering Lawrence Bonassar, PhD Ballroom C Neuropsychiatric Lupus in Children and Adolescents Moderator: Karen Onel, MD Upon completion of this session, participants should be able to: describe the mechanisms for the development of neuropsychiatric lupus summarize the utility of new imaging modalities in diagnosing neuropsychiatric review the epidemiology, diagnosis and treatment of neuropsychiatric lupus in childhood :0 PM Mechanisms of Neuropsychiatric Lupus Betty Diamond, MD :00 PM Imaging in Neuropsychiatric Lupus Hermine I. Brunner, MD, MSc, MBA 0 Program Book Ballroom A Osteoporosis: From Bisphosphonates and Beyond Moderators: Jeffrey R. Curtis, MD, MPH, MS and Margaret R. Wilkes, MD Upon completion of this session, participants should be able to: describe current data regarding association of bisphosphonate therapy to osteonecrosis of the jaw and atypical fractures discuss evidence and best data supporting duration of bisphosphonate therapy for osteoporosis evaluate the data regarding increased infection risk in patients receiving denosumab review potential treatment strategies for difficult to manage osteoporosis :0 PM Osteoporosis and Bisphosphonates How Long Should We Treat? Chad L. Deal, MD :00 PM Denosumab: Is Infection a Real Concern? Nelson B. Watts, MD, MACE :0 PM Diagnostic and Therapeutic Dilemmas in Osteoporosis Kenneth G. Saag, MD, MSc ACR CONCURRENT ABSTRACT SESSIONS :0-4:00 PM 40 A Cell-cell Adhesion, Cell Trafficking and Angiogenesis Moderators: Shiva Shahrara, PhD and Douglas J. Veale, MD :0 PM 0 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk II Speaker: Alisa E. Koch, MD :45 PM 599. NF-Kb Inducing Kinase (NIK) Is a Key Regulator of Inflammation-Induced Angiogenesis A.R. Noort, K.P.M. van Zoest, P. Koolwijk, D.V. Novack, M.J. Siemerink, P. P. Tak 4 and S.W. Tas, Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, Institute for Cardiovascular Research (ICaR-VU)/VU University Medical Center, Amsterdam, Netherlands, Washington University School of Medicine, St. Louis, MO, 4 Academic Medical Center/University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands :00 PM 600. Gene Targeting of an Integrin-Mediated Signaling Adaptor Molecule, Crk-Associated Substrate Lymphocyte Type Reduced the Severity of Collagen-Induced Arthritis. Its Possible Involvement in the Pathophysiology of Rheumatoid Arthritis Satoshi Iwata, Tomoki Katayose, Yoshiko Kichikawa, Hiromi Ichihara, Hiroshi Kawasaki, Osamu Hosono, Hirotoshi Tanaka

75 and Chikao Morimoto, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan :5 PM 60. Role of Focal Adhesion Kinase in Synovial Fibroblast Invasion and Arthritis Miriam A. Shelef, David Bennin and Anna Huttenlocher, Univ of Wisconsin Schl of Med, Madison, WI :0 PM 60. Tie Signalling Induces a Pro-Inflammatory and Pro-Angiogenic Phenotype in Differentiated Macrophages, Independently of Macrophage Polarization Conditions, and Contributes to Production of Cytokines Elevated in Early Rheumatoid Arthritis Samuel Garcia, Sarah Krausz, Carmen A. Ambarus, Bea Malvar Fernandez, Dominique L. Baeten, Paul P. Tak and Kris A. Reedquist, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands :00 PM 606. Identifying a Link Between Uranium Exposure and Systemic Lupus Erythematosus in a Community Living near a Uranium Plant Pai-Yue Lu, Leah C. Kottyan, Susan M. Pinney, Judith A. James, Changchun Xie, Jeanette M. Buckholz and John B. Harley 4, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, University of Cincinnati, Cincinnati, OH, Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 4 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH :5 PM 607. The Association Between Thyroxin Substitution and Rheumatoid Arthritis; Results From the Swedish EIRA Study Camilla Bengtsson, Henrik Källberg, Leonid Padyukov and Saedis Saevarsdottir, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden :45 PM 60. Inhibitor of DNA Binding As a Secreted Angiogenic Transcription Factor in Rheumatoid Arthritis Takeo Isozaki, M. Asif Amin, Alisa E. Koch, Ali Arbab, Stephanie A. Shuman, Christine M. Ha, G. Kenneth Haines III 4 and Jeffrey H. Ruth, University of Michigan, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI, Henry Ford Hospital and Medical Centers, Detroit MI 480, Detroit, MI, 4 Yale University, New Haven, CT Salon B Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease Moderators: Evelyne Vinet, MD and Nasim A. Khan, MD :0 PM 604. Parity and the Risk of Developing Rheumatoid Arthritis: Results From the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study Cecilia Orellana, Lars Klareskog, Lars Alfredsson and Camilla Bengtsson, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden :45 PM 605. Anti-Citrullinated Peptide Autoantibodies to Rheumatoid Synovium Epitopes in Women and Risk of Future Rheumatoid Arthritis Elizabeth V. Arkema, Barbara L. Goldstein, William H. Robinson, Catriona Cramb 4, Jeremy Sokolove 5, Jing Cui 6, Susan Malspeis 6, Elizabeth W. Karlson 7 and Karen H. Costenbader 7, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, Stanford University, Palo Alto, CA, 4 VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 5 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6 Brigham and Womens Hospital, Boston, MA, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA :0 PM 608. Overweight and Obesity Increase Risk of Rheumatoid Arthritis in Women in a Large Prospective Study Bing Lu, Chia-Yen Chen, Linda T. Hiraki, Karen H. Costenbader and Elizabeth W. Karlson, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA :45 PM 609. Circulating 5-Hydroxyvitamin D Level and Risk of Developing Rheumatoid Arthritis Linda T. Hiraki, Jing Cui, Susan Malspeis, Karen H. Costenbader 4 and Elizabeth W. Karlson 4, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, Brigham and Womens Hospital, Boston, MA, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 45 A Genetics and Genomics of Rheumatic Diseases Moderators: Soumya Raychaudhuri, MD, PhD and Nan Shen, MD :0 PM 60. The DNA Methylation Signature in Fibroblast-Like Synoviocytes (FLS) Defines Critical Pathogenic Pathways in Rheumatoid Arthritis (RA) David L. Boyle, Robert Shoemaker, David W. Anderson, Wei Wang and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA, NexDx, Inc., San Diego, CA, UCSD, La Jolla, CA :45 PM 6. Targeted Deep Re-Sequencing Implicates Rare and Low Frequency Coding Variants in ILR, MEFV, TLR4, and NOD in Behçet s Disease Yohei Kirino, Qing Zhou, Yoshiaki Ishigatsubo, Nobuhisa Mizuki, Ilknur Tugal-Tutkun, Emire Seyahi 4, Yilmaz Ozyazgan 4, F. Sevgi Sacli 4, Burak Erer 5, Zeliha Emrence 6, Atilla Cakar 7, Duran 0 Program Book 7 MONDAY November, 0

76 MONDAY November, 0 Ustek 7, Akira Meguro, Atsuhisa Ueda, Mitsuhiro Takeno, Michael J. Ombrello, Colleen Satorius, Baishali Maskeri 8, Jim Mullikin 8, Hong-Wei Sun 9, Gustavo Gutierrez-Cruz 9, Yoonhee Kim 0, Ahmet Gül, Daniel L. Kastner and Elaine F. Remmers, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Yokohama City University Graduate School of Medicine, Yokohama, Japan, Istanbul, Turkey, 4 Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, 5 Istanbul Faculty of Medicine, Istanbul University,, Istanbul, Turkey, 6 Institute for Experimental Medicine, Istanbul University, Istanbul, Turkey, 7 Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, 8 National Human Genome Research Institute, National Institutes of Health, Rockville, MD, 9 National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 0 National Human Genome Research Institute, National Institutes of Health, Baltimore, MD, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey :00 PM 6. Ankylosing Spondylitis Is Associated with Single Nucleotide Polymorphisms in Loci Implicating Four Aminopeptidases Philip Robinson, Adrian Cortes, Paul Leo, Australian-Anglo- American Spondylitis Consortium (TASC), Wellcome Trust Case Control Consortium (WTCCC)., International Genetics of Ankylosing Spondylosis Consortium (IGAS) 4, David Evans 5 and Matthew A. Brown, University of Queensland Diamantina Insititute, Brisbane, Australia, Brisbane, Australia, Wellcome Trust Case Control Consortium, Wellcome Trust Case Control Consortium, United Kingdom, 4 IGAS, Igas, Australia, 5 Bristol University, Bristol, United Kingdom :5 PM 6. The SLE-Associated TLR7 Variant Confers Differential Gene Expression Modulated by Microrna-48 Yun Deng, Jian Zhao, Daisuke Sakurai, Kenneth M. Kaufman, Jeffrey C. Edberg, Robert P. Kimberly, Diane L. Kamen 4, Gary S. Gilkeson 5, Chaim O. Jacob 6, Robert H. Scofield 7, Carl D. Langefeld 8, Jennifer A. Kelly 9, Marta E. Alarcün-Riquelme on behalf of BIOLUPUS and GENLES networks 0, John B. Harley, Timothy J. Vyse, Barry I. Freedman, Patrick M. Gaffney, Kathy Moser Sivils 9, Judith A. James, Timothy B. Niewold 4, Rita M. Cantor 5, Weiling Chen, Bevra H. Hahn, Elizabeth E. Brown on behalf of PROFILE and Betty P. Tsao, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 4 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 5 Medical University of South Carolina, Charleston, SC, 6 Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 7 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 8 Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 9 Oklahoma Medical Research Foundation, Oklahoma City, OK, 0 Centro de Genómica e Investigación Oncológica (GENYO) Pfizer-Universidad de Granada-Junta de Andalucia, Granada, Spain, Divisions of Genetics and Molecular Medicine and Immunology, King s College London, London, United Kingdom, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research University of Chicago, Chicago, IL, 5 Department of Human Genetics, University of California Los Angeles, Los Angeles, CA :0 PM 64. Analysis of the Immunochip in a Large Cohort of Juvenile Idiopathic Arthritis Cases Identifies 7 Loci At Genome-Wide Significance Anne Hinks, Joanna Cobb, Miranda C. Marion, Marc Sudman, John Bowes, Kathryn J. A. Steel, Mehdi Keddache 4, John F. Bohnsack 5, Stephen Guthery 5, Lucy R. Wedderburn 6, Johannes Peter Haas 7, David N. Glass 8, Sampath Prahalad 9, Carl D. Langefeld, Wendy Thomson and Susan D. Thompson, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Wake Forest School of Medicine, Winston-Salem, NC, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 University of Utah, Salt Lake City, UT, 6 University College London (UCL), London, United Kingdom, 7 German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 8 Cincinnati Childrens Hospital Medical Center, Cincinnati, OH, 9 Emory Children s Center, Atlanta, GA :45 PM 65. Evidence for Distinct Roles of Environmental and Genetic Factors in the Emergence of Anti Citrullinated-Protein Antibodies Positive Rheumatoid Arthritis-an Epidemiological Investigation in Twins Aase Haj Hensvold, Patrik KE Magnusson, Monika Hansson, Lena Israelsson, Cecilia Carlens, Johan Askling 4, Vivianne Malmström, Lars Klareskog and Anca Irinel Catrina, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Swedish Twin Registry Karolinska Institutet, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden, 4 Rheumatology Unit & Clinical Epidemiology Unit, Stockholm, Sweden 0 B Imaging of Rheumatic Diseases II: Magnetic Resonance Imaging Moderators: John Carrino, MD, MPH and Ali Guermazi, MD, PhD :0 PM 66. Comparison of Conventional and Wholebody Magnetic Resonance Imaging for Assessing Inflammation and Structural Damage in Psoriatic Arthritis and Axial Spondyloarthritis René Panduro Poggenborg, Susanne Juhl Pedersen, Iris Eshed, Inge Juul Sørensen, Ole Rintek Madsen 4, J.M. Møller 5 and Mikkel Østergaard 6, Copenhagen University Hospital in Glostrup, Copenhagen, Denmark, Glostrup 74 0 Program Book

77 Hospital, Copenhagen, Denmark, Sheba Medical Center, Tel Hashomer, Israel, 4 Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 5 Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 6 Copenhagen University Hospital Glostrup, Glostrup, Denmark :45 PM 67. Whole-Body Magnetic Resonance Imaging of Disease Manifestations in Axial and Peripheral Joints and Entheses in Rheumatoid Arthritis Patients Mette Bjørndal Axelsen, Anne Duer, Iris Eshed, Jakob M. Møller 4, Susanne Juhl Pedersen and Mikkel Østergaard, Glostrup Hospital, Copenhagen, Denmark, Copenhagen University Hospital at Hvidovre, Hvidovre, Denmark, Sheba Medical Center, Tel Hashomer, Israel, 4 Copenhagen University Hospital in Herlev, Copenhagen, Denmark :00 PM 68. Prevalence of Inflammatory Sacroiliitis Assessed On MR Imaging of Inflammatory Bowel Disease: A Retrospective Study Performed On 86 Patients Sophie Leclerc-Jacob, Guillaume Lux, Anne-Christine Rat, Valérie Laurent, Alain Blum, Isabelle Chary-Valckenaere, Laurent Peyrin- Biroulet and Damien Loeuille, Nancy Teaching Hospital, Nancy, France :5 PM 69. Quantification of Bone Marrow Edema by Using Magnetic Resonance Imaging for the Assessment of Neck Pain Only Marginally Reflects Clinical Evaluation in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Xenofon Baraliakos, Frank Heldmann, Ravi Suppiah, Fiona M. McQueen 4 and Jurgen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, Rheumazentrum Ruhrgebiet, Herne, Ghana, Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom, 4 University of Auckland, Auckland, New Zealand :0 PM 60. Early Magnetic Resonance Imaging Measures Independently Predict - and - Year X-Ray Progression: Results From a Large Clinical Trial Joshua Baker, Mikkel Østergaard, Paul Emery, Elizabeth C. Hsia 4, J. D. Lu 4, Daniel Baker 5 and Philip G. Conaghan 6, University of Pennsylvania, Philadelphia, PA, Glostrup Hospital, Copenhagen, Denmark, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4 Janssen Research & Development, LLC/U of Penn, Spring House/Phila, PA, 5 Janssen Research and Development, LLC, Spring House, PA, 6 University of Leeds, Leeds, United Kingdom :45 PM 6. In vivo Synovial Oxygen Levels Are Inversely Related to Metabolic Turnover and Disease Activity in Rheumatoid and Psoriatic Arthritis Biologic Responders Leonard C. Harty, John Ryan, Chin Teck Ng, Monika Biniecka, Aisling Kennedy, Eric J. Heffernan 4, Ursula Fearon 5 and Douglas J. Veale, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Ziltron, Unit 4, Castletroy Business Park, Plassey, Limerick, Ireland, Translation Rheumatology Research Group, Dublin, Ireland, 4 St. Vincent s University Hospital, Dublin, Ireland, 5 Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 50 B Infection-related Rheumatic Disease Moderators: Leonard H. Calabrese, DO and James S. Louie, MD :0 PM 6. Characteristics of Patients with Infectious Cryoglobulinemia Vasculitis in the Absence of HCV Infection: Results From the French Nationwide Cryovas Survey Benjamin Terrier Sr., Isabelle Marie, Adeline Lacraz, Pauline Belenotti 4, Fabrice Bonnet 5, Laurent Chiche Sr. 4, Bruno Graffin Sr. 6, Arnaud Hot Sr. 7, Jean-Emmanuel Kahn 8, Thomas Quemeneur 9, Olivier Hermine Sr. 0, Jean-Marc Léger, Patricia Senet, Emmanuelle Plaisier, Xavier Mariette 4 and Patrice Cacoub Sr. 5, Cochin Hospital, Paris, France, Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, Nephrology, CHU Bordeaux, Bordeaux, France, 4 Internal Medicine, CHU Marseille, Marseille, France, 5 Internal Medicine, CHU Bordeaux, Bordeaux, France, 6 Metz hospital, Metz, France, 7 Lyon hospital, Lyon, France, 8 Internal Medicine, Foch Hospital, Suresnes, France, 9 CHR de Valenciennes, Valenciennes, France, 0 Hôpital Necker, Paris, France, Paris, France, Tenon hospital, Paris, France, Nephrology, Tenon Hospital, Paris, France, 4 Université Paris-Sud, Le Kremlin Bicetre, France, 5 CHU Pitié- Salpêtrière, Paris, France :45 PM 6. Serum Biomarkers Signature Identifies Patients with Overt B-Cell Non-Hodgkin Lymphoma Associated with Mixed Cryoglobulinemia in Chronic HCV Infection Benjamin Terrier Sr., Wahiba Chaara, Guillaume Geri, David Saadoun 4, Michelle Rosenzwajg Sr. 5, Damien Sene Sr. 6, Adrien Six, David Klatzmann Sr. 5 and Patrice Cacoub Sr., Cochin Hospital, Paris, France, Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, CHU Pitié-Salpêtrière, Paris, France, 4 Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 5 Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Paris, France, 6 Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France :00 PM 64. Deletion of HLA-B7 T Cells Underlies the Immunodominant Response to Influenza Infection On Class I MHC Transgenic Mice Ali Akram and Robert D. Inman, University of Toronto and University Health Network (UHN), Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON MONDAY November, 0 0 Program Book 75

78 MONDAY November, 0 :5 PM 65. With Chlamydia Infection the Macrophage Serves As Gate-Keeper for Dissemination and Induction of Host Immunity Eric Gracey and R. D. Inman, Toronto Western Hospital, Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON :0 PM 66. Frequent Conversion of Tuberculosis Screening Tests During Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatic Diseases Chrisoula Hatzara, Emilia Hadziyannis, Anna Kandili, Stamatoula Tsikrika, Martha Minopetrou, Georgios Georgiopoulos and Dimitrios Vassilopoulos, Athens University School of Medicine, Athens, Greece :45 PM 67. New Insights Into the Presentation and the Management of Hepatitis B Reactivation in Patients with Autoimmune Diseases and Inflammatory Arthritis Nina Droz, Laurent Gilardin, Patrice Cacoub Sr., Francis Berenbaum 4, Daniel Wendling 5, Bertrand Godeau 6, Anne-Marie Piette 7, Emmanuelle Dernis 8, Mikael Ebbo 9, Bruno Fautrel 0, Arsène Meikinian, Aude Rigolet, Sophie Rivière, Stanislas Pol, Loic Guillevin 4, Luc Mouthon Sr. 5 and Benjamin Terrier Sr., Cochin Hospital, Paris, France, Saint Antoine Hospital, Paris, France, CHU Pitié-Salpêtrière, Paris, France, 4 AP-HP, St Antoine Hospital, Paris, France, 5 Minjoz University Hospital, Besancon, France, 6 Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 7 Foch Hospital, Suresnes, France, 8 Centre Hospitalier, Le Mans, France, 9 Conception Hospital, Marseille, France, 0 APHP- Pitie Salpetriere Hospital / UPMC, Paris, France, Jean Verdier Hospital, Bondy, France, Pitie-Salpetriere Hospital, APHP, UPMC Paris VI, Paris, France, Lapeyronie, Montpellier, France, 4 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, 5 Hopital Cochin, Paris, France 47 A Metabolic and Crystal Arthropathies: Basic Science Moderators: Michael H. Pillinger, MD and John S. Sundy, MD, PhD :0 PM 68. Epistatic Interaction Between Solute Carrier A9 Genotype and Sugar-Sweetened Beverage Consumption in the Determination of Gout Risk Tony R. Merriman, Nicola Dalbeth, Peter J. Gow, Andrew Harrison 4, John Highton 5, Peter B. B. Jones 6, Lisa K. Stamp 7, Murray Cadzow, Marilyn E. Merriman, Ruth Topless, Michael A. Black, Amanda Phipps-Green and Caitlin M. Batt, University of Otago, Dunedin, New Zealand, University of Auckland, Auckland, New Zealand, Middlemore Hospital, Auckland, New Zealand, 4 Hutt Hospital, Lower Hutt, New Zealand, 5 Univ of Otago Med Sch, Dunedin, New Zealand, 6 Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 7 University of Otago, Christchurch, Christchurch, New Zealand :45 PM 69. Microarray Analysis of Acute and Intercritical Gout Alicia Rodriguez-Pla, Lynda Bennett, Kathryn H. Dao, Edwardo Delgado, Typhanie Maurouard, M. Virginia Pascual and John J. Cush, Baylor Institute for Immunology Research, Dallas, TX, Arthritis Care and Research Center, Dallas, TX, Baylor Research Institute, Dallas, TX :00 PM 60. Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 70,000 Individuals Hyon Choi, Robert M. Plenge, Anna Köttgen, Veronique Vitart 4, Murielle Bochud 5, Christian Gieger 6, Mark Caulfield 7, Marina Ciullo 8, Eva Albrecht 6, Alexander Teumer 9, Gary Curhan 0, Jan Krumsiek, Conall O Seaghdha, Caroline Fox and The Global Urate Genetics Consortium (GUGC) 4, Boston University School of Medicine, Boston, MA, Brigham and Women s Hospital, Boston, MA, Renal Division, Freiburg University Hospital, Freiburg, Germany, 4 Western General Hospital, Edinburgh, United Kingdom, 5 Lausanne University Hospital, Switzerland, 6 Neuherberg, Germany, 7 Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 8 A. Buzzati-Traverso, Italy, 9 Ernst- Moritz-Arndt- University Greifswald, Greifswald, Germany, 0 Harvard Medical School, Boston, German Research Center for Environmental Health, Neuherberg, Germany, NHLBI s Framingham Heart Study and Center for Population Studies,, Neuherberg, NHLBI s Framingham Heart Study and Center for Population Studies,, MA, 4 Boston :5 PM 6. Osteoarthritis-Associated Basic Calcium Phosphate Crystals Induce IL-β, IL-8 and S00A8 Production in a Tyrosine Kinase Dependent Manner Geraldine M. McCarthy, Evanna Mills, Kingston Mills and Aisling Dunne, Mater Misericordiae University Hospital, Dublin 7, Ireland, Trinity College Dublin, Dublin, Ireland :0 PM 6. Arhalofenate Is a Novel Dual-Acting Agent with Uricosuric and Anti-Inflammatory Properties Yun-Jung Choi, Vanina Larroca, Annette Lucman, Vic Vicena, Noe Abarca, Tim Rantz, Brian E. Lavan and Charles A. McWherter, Metabolex, Inc., Hayward, CA :45 PM 6. Ulodesine (BCX408) Add-On Therapy to Allopurinol 00mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a -Week Randomized Controlled Trial in Patients with Gout Shanta Bantia, Leigh Harman, Cynthia Parker, Damon Papac, Andreas Maetzel, Brian Taubenheim and Alan S. Hollister, BioCryst Pharmaceuticals, Inc., Durham, NC, Southern Research Institute, Birmingham, AL 07 A Rheumatoid Arthritis - Animal Models Moderators: Charles S. Via, MD and Harris R. Perlman, PhD 76 0 Program Book

79 :0 PM 64. Delivering Mesenchymal Stem Cells to Arthritic Joints with Nano-Fiber Scaffold Resulted in Inhibition of Arthritis and Joint Damage in Arthritis Models Xiangmei Zhang, Kunihiro Yamaoka, Koshiro Sonomoto, Masahiro Kondo, Shunsuke Fukuyo, Makoto Satake, Hiroaki Kaneko, Kazuhisa Nakano, Shingo Nakayamada, Yosuke Okada and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Integrative Technology Research Institute, Teijin Limited, Tokyo, Japan :45 PM 65. Polyarthritis Caused by TIARP (TNFAIP9) Deficiency Critically Dependent On Dysregulated STAT, NF-κB Signaling and Cell Death in Macrophage Asuka Inoue, Isao Matsumoto, Naoto Umeda, Yuki Tanaka, Satoru Takahashi and Takayuki Sumida, University of Tsukuba, Tsukuba city, Ibaraki, Japan, Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba city, Ibaraki, Japan :00 PM 66. Commensal Gut-Derived Bacteria As Therapy for Systemic Autoimmune Disease David Luckey, Eric Marietta, Harvinder S. Luthra, Robin Patel, Joseph A. Murray, Ashutosh Mangalam and Veena Taneja, Mayo Clinic, Rochester, MN, Mayo Clinic, Rochester :5 PM 67. A Novel Peptide Inhibiting the Binding Between Cq and Immunoglobulin Ameliorates Joint Destruction in Rats with Collagen-Induced Arthritis Yu Moriguichi and Tetsuya Tomita, Osaka University Graduate School of Medicine, Suita, Japan :0 PM 68. Synovial Fibroblast Migration Is Modulated by the Focal Contact Protein Lasp- Adelheid Korb-Pap, Jan Hillen, Marianne Heitzmann, Catherine S. Chew, Stefan Butz, Dietmar Vestweber, Hermann Pavenstädt and Thomas Pap, University Hospital Muenster, Muenster, Germany, Medical College of Georgia, Augusta, GA, Max Planck Institute of Molecular Biomedicine, Muenster, Germany :45 PM 69. FLIP in Macrophages Promotes the Progression of Serum Transfer-Induced Arthritis Qi Quan Huang, Robert Birkett, Renee E. Koessler, G. Kenneth Haines III, Harris R. Perlman and Richard M. Pope 4, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Yale University, New Haven, CT, 4 Northwestern Univ Med School, Chicago, IL Hall E Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I Moderators: Josef S. Smolen, MD and Simon M. Helfgott, MD :0 PM 640. Long-Term Safety of Tocilizumab in Patients with Rheumatoid Arthritis and a Mean Treatment Duration of.7 Years Mark C. Genovese, Anthony Sebba, Andrea Rubbert-Roth, Juan José Scali 4, Rieke Alten 5, Joel M. Kremer 6, Laura Pitts 7, Emma Vernon 7 and Ronald F. van Vollenhoven 8, Stanford University Medical Center, Palo Alto, CA, University of South Florida, Tampa, FL, University of Cologne, Cologne, Germany, 4 Durand University Hospital, Buenos Aires, Argentina, 5 Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 6 Albany Medical College, Albany, NY, 7 Roche, Welwyn Garden City, United Kingdom, 8 Karolinska Institute, Stockholm, Sweden :45 PM 64. When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry Maria Victoria Hernández, Miguel A. Descalzo, Juan D. Cañete, Raimon Sanmarti and BIOBADASER Study Group, Hospital Clínic of Barcelona, Barcelona, Spain, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain :00 PM 64. Biologics and Mortality Risk in Rheumatoid Arthritis - Results of a Population Based Study Diane Lacaille, Michal Abrahamowicz, Eric C. Sayre and John Esdaile, Arthritis Research Centre of Canada, University of British Columbia, Vancouver, BC, McGill University, Montreal, QC, Arthritis Research Centre of Canada, Vancouver, BC :5 PM 64. Outcomes of Pregnancy in Subjects Exposed to Certolizumab Pegol Megan Clowse, Douglas C. Wolf, Christian Stach, Gordana Kosutic 4, Susan Williams 4, Ido Terpstra 5 and Uma Mahadevan 6, Duke University Medical Center, Durham, NC, Atlanta Gastroenterology Associates, Atlanta, GA, UCB Pharma, Monheim, Germany, 4 UCB Pharma, Raleigh, NC, 5 UCB Pharma, Brussels, Belgium, 6 University of California, San Francisco, San Francisco, CA :0 PM 644. Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept Michele Hooper, Deborah Wenkert, Bojena Bitman, Virgil C. Dias, Yessinia Bartley, Julie Wang and Julia R. Gage 4, Amgen Inc., Thousand Oaks, CA, Assent Consulting, Solana Beach, CA, One Amgen Center Drive, Thousand Oaks, CA, 4 Gage Medical Writing, LLC, Oak Park, CA :45 PM 645. Combination of Isoniazid for Latent Tuberculosis with Traditional and/or Biologic Disease Modifying Anti-Rheumatic Drugs Is Well Tolerated in Patients with Rheumatic Diseases Dilrukshie Cooray, Saleem A. Waraich, Andrew Phan, Rosalinda C. Moran and George A. Karpouzas, Harbor-UCLA Medical Center, Torrance, CA, Placentia, CA MONDAY November, 0 0 Program Book 77

80 MONDAY November, 0 Ballroom B Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy Moderators: Meenakshi Jolly, MD, MS and Graciela S. Alarcon, MD, MPH :0 PM 646. The Mechanism of Umbilical Cord Mesenchymal Stem Cells in the Upregulation of Regulatory T Cells by TGF-β in Systemic Lupus Erythematosus Lingyun Sun, Dandan Wang, Lin Lu and Xia Li, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China :45 PM 647. Critical Management Decisions in Cardiac Neonatal Lupus: The Role of Fluorinated Steroids Peter M. Izmirly, Sara Sahl, Amit Saxena, Nathalie Costedoat- Chalumeau, Jean-Charles Piette, Munther A. Khamashta 4, Cecilia Pisoni 5, Deborah Friedman 6 and Jill P. Buyon, New York University School of Medicine, New York, NY, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, CHU Pitié-Salpêtrière, Paris, France, 4 Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 5 Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina, 6 New York Medical College, Valhalla, NY :00 PM 648. Lupus Anticoagulant At First Pregnancy Visit Is Predictive of Pregnancy Loss Michelle Petri, Anil Mankee, Ehtisham Akhter, Hong Fang and Laurence S. Magder, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD :5 PM 649. French Cohort Study of 4 Cases of Autoimmune Congenital Heart Block Kateri Levesque, Alice Maltret, Mohamed Hamidou, Moez Jallouli 4, Jean Loup Pennaforte 5, Pauline Orquevaux 5, Jean- Charles Piette 6, Zahir Amoura 4, Francois Barriere 7, Jérome Le Bidois, Laurent Fermont, Laurence Cohen 8, Olivier Meyer 9, Olivier Fain 0, Arnaud Theulin, Hugues Lucron, Francois Sassolas, Holly Bezanahary 4, Gaëlle Guettrot-Imbert 5, Pascal Seve, Elizabeth Diot 6, Nathalie Morel, Christophe Deligny 7, Elisabeth Villain and Nathalie Costedoat-Chalumeau 8, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Groupe Hospitalier Necker - Enfants Malades, Paris, France, Hôtel Dieu, Hôpital Universitaire de Nantes, Nantes, France, 4 CHU Pitié-Salpêtrière, Paris, France, 5 CHU Reims, Reims, France, 6 Paris, 7 CHU Nantes, Nantes, France, 8 Institut Jacques Cartier, 9 Hopital Bichat, Paris, France, 0 Service de médecine interne, Université Paris, AP- HP, Hôpital Jean Verdier, Bondy, France, Strasbourg University Hospital, Strasbourg, France, CHU Fort-de-France, Fort de France, Martinique, CHU Lyon, Lyon, France, 4 University Hospital of Limoges, Limoges, France, 5 Hopital Gabriel Montpied, Clermont-Ferrand, France, 6 Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 7 Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, 8 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France :0 PM 650. Abnormal Serologies in the Absence of Clinical Activity Do Not Predict New or Recurrent Lupus Nephritis During Pregnancy Jill Buyon, Aanam Aslam, Marta M. Guerra, Michael D. Lockshin, Carl A. Laskin, Ware Branch 4, Lisa R. Sammaritano, Michelle Petri 5, Joan T. Merrill 6, Allen D. Sawitzke 7 and Jane E. Salmon, New York University School of Medicine, New York, NY, Hospital for Special Surgery, New York, NY, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, 4 Univ of Utah, Salt Lake City, UT, 5 Johns Hopkins University School of Medicine, Baltimore, MD, 6 Oklahoma Medical Research Foundation, Oklahoma City, OK, 7 University of Utah Medical Ctr, Salt Lake City, UT :45 PM 65. Higher Corticosteroid Doses Early in Disease Have A Long-Term Influence On Metabolic Syndrome in Systemic Lupus Erythematosus: Data from an International Inception Cohort Ben Parker, Murray B. Urowitz, Dafna D. Gladman Gladman, Mark Lunt, Ian N. Bruce 4 and Systemic Lupus International Collaborating Clinic (SLICC) 5, University of Manchester, Manchester, United Kingdom, Toronto Western Hospital and University of Toronto, Toronto, ON, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 4 Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 5 Toronto 46 C Vasculitis: Clinical Trials Moderators: Rula Hajj- Ali, MD and John Stone, MD, MPH :0 PM 65. Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Loic Guillevin, Christian Pagnoux, Alexandre Karras, Chahera Khoutra 4, Olivier Aumaitre 5, Pascal Cohen 6, Francois Maurier 7, Olivier Decaux 8, Hélène Desmurs-Clavel 4, Pierre Gobert 9, Thomas Quemeneur 0, Claire Blanchard-Delaunay, Pascal Godmer, Xavier Puechal, Pierre-Louis Carron 4, Pierre yves Hatron 5, Nicolas Limal 6, Mohamed Hamidou 7, Maize Ducret 8, Florence Vende 9, Elisa Pasqualoni 9, Bernard Bonnotte 0, Philippe Ravaud, Luc Mouthon Sr. and French Vasculitis Study Group (FVSG), Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, Mount Sinai Hospital, Toronto, ON, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4 Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, 5 Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, 6 Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, Paris, France., Paris, France, 7 Division of internal Medicine, CHR Metz, Metz, Metz, France, 8 Hôpital Sud, Rennes, France, 9 Centre Hospitalier d Avignon, Avignon, France, 0 CHR de Valenciennes, Valenciennes, France, Centre 78 0 Program Book

81 Hospitalier, Niort, France, Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, Hôpital Cochin, Paris, France, 4 Centre Hospitalier de Grenoble, Grenoble, France, 5 Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 6 Hôpital Henri Mondor, APHP, Creteil, France, 7 Hôtel Dieu, Hôpital Universitaire de Nantes, Nantes, France, 8 Centre Hospitalier d Annecy, Annecy, France, 9 Hôpital Bicbat, APHP, Paris, France, 0 Centre Hospitalier de Dijon, Dijon, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, Hopital Cochin, Paris, France, Paris, France :45 PM 65. Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener s) Treated with Short- Vs. Long-Term Maintenance Therapy Jason Springer, Benjamin Nutter, Carol A. Langford, Gary S. Hoffman and Alexandra Villa-Forte, Cleveland Clinic Foundation, Cleveland, OH :00 PM 654. Primary Endpoint Failure in the Rituximab in ANCA- Associated Vasculitis Trial Eli Miloslavsky, Ulrich Specks, John H. Stone and RAVE/ITN Research Group 4, Massachusetts General Hopsital, Boston, MA, Mayo Clinic, Rochester, MN, Massachusetts General Hospital, Boston, MA, 4 Bethesda :5 PM 655. An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener s) Carol A. Langford, David Cuthbertson, Gary S. Hoffman, Jeffrey Krischer, Carol McAlear, Paul A. Monach 4, Philip Seo 5, Ulrich Specks 6, Steven R. Ytterberg 6, Peter A. Merkel and for the Vasculitis Clinical Research Consortium, Cleveland Clinic, Cleveland, OH, University of South Florida, Tampa, FL, University of Pennsylvania, Philadelphia, PA, 4 Boston University, Boston, MA, 5 Johns Hopkins Vasculitis Center, Baltimore, MD, 6 Mayo Clinic, Rochester, MN :0 PM 656. Treatment of Systemic Necrotizing Vasculitides in Patients 65 Years Old: Results of the Multicenter Randomized Cortage Trial Christian Pagnoux, Thomas Quemeneur, Jacques Ninet, Elodie Perrodeau 4, Elizabeth Diot 5, Xavier Kyndt 6, Benoit de Wazières 7, jean-luc Reny 8, Xavier Puéchal 9, Pierre-Yves Leberruyer 0, Olivier Lidove, Philippe Vanhille 6, Pascal Godmer, Aimé Albath- Sadiki, Boris Bienvenu 4, Pascal Cohen 5, Luc Mouthon Sr. 6, Philippe Ravaud 4, Loic Guillevin 7 and French Vasculitis Study Group (FVSG), Department of Internal Medicine, National Referral Center for Necrotizing Vasculitides and Systemic Sclerosis, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Université Paris Descartes, Paris, France, Paris, France, CHR de Valenciennes, Valenciennes, France, Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 4 Hopital Hotel Dieu, Paris Descartes University, Paris, France, 5 Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, 6 Valenciennes, France, 7 Department of Internal Medicine and Gerontology, Hôpital Universitaire Carémeau, Nîmes, France, Nimes, France, 8 Geneve, Switzerland, 9 Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 0 Reims, France, Paris, France, Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 7 rue du faubourg Saint Jacques, Paris, 750 4, France, Paris, France, 4 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, Caen, France, 5 Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, Paris, France., Paris, France, 6 Hopital Cochin, Paris, France, 7 Cochin University Hospital, Paris, France :45 PM 657. Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis David Saadoun, Stanislas Pol, Pascal Lebray Sr., François Blanc 4, Gilles Pialoux 5, Alexandre Karras 6, Dorothée Bazin 7, Emmanuelle Plaisier 8 and Patrice Cacoub Sr. 9, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, Hepatology, Cochin Hospital, Paris, France, Hôpital Pitié Salpétrière, Paris, France, 4 hôpital Montpellier, Montpellier, France, 5 hôpital Tenon, Paris, France, 6 Hôpital Européen Georges Pompidou, APHP, Paris, France, 7 Nouvel Hôpital Civil, Strasbourg, France, 8 Nephrology, Tenon Hospital, Paris, France, 9 CHU Pitié- Salpêtrière, Paris, France ARHP SESSIONS :0-4:00 PM 4 A Demystifying the Study Section: How Grants Are Reviewed and Scored Moderator: Jennifer M. Hootman, ATC, PhD Upon completion of this session, participants should be able to: describe the basic process of how peer review sessions for grants are conducted identify elements that lead to a strong early career grant application identify common areas of weakness that can hurt a grant application :0 PM Tips for an Exceptional Grant Review - National Institutes of Health Perspective Susan Marden, MD :45 PM Tips for an Exceptional Grant Review Research and Education Perspective Michael M. Ward, MD :55 PM Overview of Study Section Process Kelli D. Allen, PhD :00 PM Mock Study Section Kelli D. Allen, PhD, Patricia P. Katz, PhD, Susan Marden, MD and Michael M. Ward, MD 0 Program Book 79 MONDAY November, 0

82 MONDAY November, 0 :0 PM Summary of Grant Strengths and Weaknesses Robert R. McLean, DSc, MPH :40 PM Panel Discussion 04 A Depression in Rheumatic Diseases Moderator: Karen L. Smarr, PhD Upon completion of this session, participants should be able to: summarize the incidence of depression in various rheumatic diseases along with associated complications describe the relationship between rheumatic disease and depression in the context pathophysiology utilize diagnostic criteria and screening instruments to identify cases of depression discuss pharmacological and non-pharmacological treatment options in consideration of other common treatments for rheumatic patients 06 :0 PM Depression in Rheumatic Disease: An Overview Lesley M. Arnold, MD :5 PM Pharmacological and Non-Pharmacological Treatment of Depression in Rheumatic Disease Jessica Farrell, PharmD Minimizing Falls in Geriatric Rheumatic Populations Moderator: Lori L. Cyr, BSc, OT Upon completion of this session, participants should be able to: describe the incidence and contributing factors to falls in geriatric rheumatic populations discuss medications associated with increased risk for falls and strategies to ameliorate the risk identify physical and occupational therapies to prevent falls, as well as promote recovery after a fall :0 PM Fractures and Falls in Geriatric Patients with Rheumatic Diseases Marian T. Hannan, DSc, MPH :00 PM The Medication Connection to Falls in Elderly Rheumatic Patients Kam Nola, PharmD, MS 0 Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes through Examination of Patient Factors, Practice Variation and Best Practice Recommendations (Arthroplasty/Joint Replacement Series) Moderator: Donna K. Everix, MPA, BS, PT Upon completion of this session, participants should be able to: describe patient-related factors influencing outcomes after total knee arthroplasty identify screening and assessment tools that can identify patients at risk for poor outcomes explain the variability in current rehabilitation practices after total knee arthroplasty describe best practice recommendations for assessment and rehabilitation after total knee arthroplasty :0 PM Variation in Functional Outcomes for Total Knee Arthroplasty and Tools to Screen for Patients at Risk for Poor Outcomes Patricia D. Franklin, MBA, MD, MPH :50 PM Total Knee Arthroplasty Rehabilitation Practices: Wide Variation and Factors to Consider Carol A. Oatis, PhD, PT :0 PM Best Practice Recommendations for Total Knee Arthroplasty Rehabilitation Marie D. Westby, PT, PhD :0 PM Panel Discussion and Case Study :50 PM Question and Answer ACR WORKSHOPS 4:00-6:00 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September 4. :0 PM After the Fall: The Rehabilitation Process Susan L. Murphy, ScD 49 B Getting Electronic Health Record Right (5) Speaker: Salahuddin Kazi, MD 80 0 Program Book 44 B *Musculoskeletal Ultrasonography: Basic (6) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS

83 44 A Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data and Beyond toward a Standard, Scientific, Quantitative Patient History (7) Speaker: Theodore Pincus, MD 44 C Systemic Sclerosis: How to Perform Skin Scores (8) Speaker: Daniel E. Furst, MD ACR SESSIONS 4:0-6:00 PM 50 B Aging and the Rheumatic Diseases Moderator: Peter A. Nigrovic, MD Upon completion of this session, participants should be able to: discuss updates in the biology of aging review changes in the aging joint which may predispose to inflammation discuss aging in the immune system and its potential relevance to rheumatic disease 4:0 PM Update on the Biology of Aging Toren Finkel, MD, PhD 5:00 PM Age-related Frailty: Age and Susceptibility to Disease Jeremy Walston, MD 5:00 PM Cutaneous Reactions to Biologic Agents Jan P. Dutz, MD 5:0 PM Interpreting the Dermatopathology Report: A Guide for Rheumatologists Soon Bahrami, MD 5 A Energetics, Metabolism and Osteoarthritis Moderator: Richard F. Loeser, MD Upon completion of this session, participants should be able to: describe the effects of a high fat diet and obesity on the development of osteoarthritis define the role of Sirt in the regulation of chondrocyte anabolic and catabolic activity review the changes found in AMPK activity in osteoarthritis and the effects on catabolic activity 4:0 PM The Effects of High Fat Diet and Obesity on Joint Tissue Metabolism in Rodents Timothy M. Griffin, PhD 5:00 PM Actions of the Metabolic Master Switch in Articular Chondrocytes Odile H. Gabay, PhD 5:0 PM Altered AMP-activated kinase Activity in Osteoarthritis Ru Liu-Bryan, PhD MONDAY November, 0 5:0 PM The Aging Immune System and Inflammatory Disease Cornelia M. Weyand, MD, PhD Hall D Dermatology Topics for Rheumatologists: What You Need to Know Moderator: Shelly P. Kafka, MD Upon completion of this session, participants should be able to: describe nail pathology associated with common rheumatic diseases and be familiar with treatment options review cutaneous reactions associated with biological agents, understand the pathology associated in treatment induced skin reactions discuss options in regard to treatment and know when to stop and re-challenge certain agents describe skin biopsies and discuss histopathology associated with autoimmune disorders review procedures and techniques used in obtaining skin biopsies 4:0 PM Nail Signs of Systemic Disease Richard K. Scher, MD, MS Salon B Gout and Hyperuricemia: Diseases Beyond the Joint Moderators: Theodore R. Fields, MD and Jasvinder A. Singh, MD, MPH Upon completion of this session, participants should be able to: describe the cardiovascular risks of hyperuricemia and data linking treatment of hyperuricemia with amelioration of the risk summarize the renal and vascular effects of hyperuricemia and the effects of medications used for treatment of gout and hyperuricemia on kidneys and vascular system discuss the indications and contraindications of new and old therapies for the treatment of gout, especially in patients with refractory disease and in those with renal failure 4:0 PM Hyperuricemia and Atherothrombotic Vascular Disease-What to Do with the Evidence? Eswar Krishnan, MD 5:00 PM Uric Acid as a Kidney Toxin: Revival of a 60-year Old Story Richard J. Johnson, MD 0 Program Book 8

84 5:0 PM Gout Therapy: What to use in my Patient with Refractory Gout and Renal Disease? Ted R. Mikuls, MD, MSPH Ballroom C Preclinical Autoimmunity Potential for Prevention Moderators: Kevin D. Deane, MD, PhD and Diane L. Kamen, MD, MS Upon completion of this session, participants should be able to: identify the patterns of preclinical autoantibody positivity seen prior to the development of certain autoimmune diseases describe potential mechanisms for gene x environment interactions in the development of autoimmunity summarize findings from prospective studies and discuss proposed prevention strategies Seattle, 4 Sanford-Burnham Institute for Medical Research, La Jolla, CA 5:00 PM 660. Development of a Bruton s Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA) Toshio Yoshizawa, Yuko Ariza, Yoshiko Ueda, Shingo Hotta, Masami Narita and Kazuhito Kawabata, Ono Pharmaceutical Co., Ltd., Osaka, Japan 5:5 PM 66. CCR Potentiates Gouty Inflammation Following Initial CXCR-Dependent Neutrophil Recruitment to Sites of Monosodium Urate Crystal Deposition in Mice Robert P. Friday, Terry K. Means, Melissa Tai, Christian D. Sadik and Andrew D. Luster, Massachusetts General Hospital, Boston, MA, Massachusetts General Hospital, Charlestown, MA MONDAY November, 0 4:0 PM The Epidemiology of Autoimmunity Lessons from the Clustering of Cases and Factors Associated with a Rising Incidence Jill M. Norris, MPH, PhD 5:00 PM Studying Genes, Environment and Biomarkers to Identify Targets to Prevent the Onset of Rheumatoid Arthritis Hani S. El-Gabalawy, MD 5:0 PM The Age of Lost Tolerance - the Rise and Fall of Autoantibodies Prior to Onset of Clinical Disease Judith A. James, MD, PhD 5:0 PM 66. Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury Kristine Kuhn, Hiroyuki Miyoshi, Nicholas A. Manieri, Nicole P. Malvin, Vinieth Bijanki, Paul Allen and Thaddeus S. Stappenbeck, Washington University School of Medicine, St. Louis, MO 5:45 PM 66. G Protein Signaling Modulator Is a Key Regulator of Monocyte-Driven Inflammatory Arthritis Matthew J. Billard, Patrick M. Giguére, Brian Buckley, Marcus W. McGinnis, Roman Timoshchenko, Peng Liu, David P. Siderovski and Teresa K. Tarrant, University of North Carolina at Chapel Hill, Chapel Hill, NC 8 ACR CONCURRENT ABSTRACT SESSIONS 4:0-6:00 PM 40 A Cytokines, Mediators, and Gene Regulation II Moderators: Erik Lubberts, PhD and Michael Volin, PhD 4:0 PM 658. Signal Transducer and Activator of Transcription Induced Synovial Invasion and Migration Is Mediated in Part Through the Notch/Hypoxia-Inducible Factor α Pathways Wei Gao, Douglas J. Veale and Ursula Fearon, Translational Rheumatology Research Group, Dublin, Ireland, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Translation Rheumatology Research Group, Dublin, Ireland 4:45 PM 659. Ptpome Profile of Rheumatoid Arthritis Fibroblast-Like Synoviocytes: A Novel Role for the Tyrosine Phosphatase SHP- As a Modulator of Invasion and Survival Stephanie Stanford, Michael Maestre, Beatrix Bartok, David L. Boyle, Heather Arnett, Tomas Mustelin 4, Gary S. Firestein and Nunzio Bottini, La Jolla Institute for Allergy and Immunology, La Jolla, CA, UCSD School of Medicine, La Jolla, CA, Amgen, Inc., 0 Program Book Ballroom B Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment Moderators: Laura L. Tarter, MD and Mariko L. Ishimori, MD 4:0 PM 664. Autoantibodies Are Associated with Subclinical Atherosclerosis and Cardiovascular Endpoints in Caucasian and African American Women in a Prospective Study: the Multi- Ethnic Study of Atherosclerosis (MESA) Darcy S. Majka, Rowland W. Chang, Richard M. Pope, Marius C. Teodorescu, Elizabeth W. Karlson 4, Thanh Huyen T. Vu 5, Joseph Kang 6 and Kiang Liu, Northwestern University, Chicago, IL, Northwestern Univ Med School, Chicago, IL, TheraTest Laboratories Inc, Lombard, IL, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 5 Northwestern University, Feinberg School of Medicine, Chicago, 6 Northwestern University, Feinberg School of Medicine, Chicago, IL 4:45 PM 665. Associations of Race and Ethnicity with Overall Mortality and Cardiovascular Events Among Patients with End-Stage Renal Disease Due to Lupus Nephritis Jose A. Gomez-Puerta, Sushrut Waikar, Graciela S. Alarcon, Jun Liu 4, Daniel H. Solomon, Wolfgang C. Winkelmayer 5 and

85 Karen H. Costenbader, Division of Rheumatology, Immunology, and Allergy, Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, Division of Nephrology, Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, University of Alabama at Birmingham, Birmingham, AL, 4 Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, 5 Stanford University School of Medicine, Stanford, CA 5:00 PM 666. Short Term Use of Glucocorticoids Is Not Associated with Acute Risk of Myocardial Infarction Steven C. Vlad, David T. Felson, Donald R. Miller and Yuqing Zhang, Boston University, Boston, MA, Edith Nourse Rogers Memorial VA Hospital, Bedford, MA 5:5 PM 667. Impact of Rheumatoid Arthritis On Recognition of Hypertension in a Medically Homed Population Christie M. Bartels, Heather Johnson, Katya Voelker, Patrick Mc Bride and Maureen Smith, Univ of Wisconsin School of Medicine and Public Health, Madison, WI, Univ of Wisconsin School of Medicine and Public Health, Madison 5:0 PM 668. Improving the Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis with a New Predictive Model Using the 0-Year Prospective Carre-Study Alper M. van Sijl, Inge A.M. van den Oever, Mike J.L. Peters, Vokko P. van Halm, Alexandre E. Voskuyl, Yvo M. Smulders and Mike T. Nurmohamed, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands, Academic Medical Centre, Amsterdam, Netherlands 5:45 PM 669. Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors Catrina B. Scherrer, Anne AF Mannion, Diego Kyburz, Markus Vogt and Ines A. Kramers-de Quervain, Schulthess Clinic, Zürich, Switzerland, Center of Exp. Rheumatology, Zurich, Switzerland, Cantonal Hospital Zug, Baar, Switzerland 0 B Muscle Biology, Myositis and Myopathies: Pathogenesis in Idiopathic Inflammatory Myopathies Moderators: Lauren M. Pachman, MD and Jiri Vencovsky, MD, DSc 4:0 PM 670. Microarray Analysis for mirna Expression in Juvenile Dermatomyositis (JDM) Dong Xu, Akadia Kachaochana, Gabrielle A. Morgan, Elio F. Vanin, Marcelo Bento Soares and Lauren M. Pachman, Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, Children s Hospital of Chicago Research Center, Cure JM Myositis Center, Chicago, IL, Cancer Biology & Epigenomics Program, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 4:45 PM 67. Characterization of Jo- Autoantibodies in Patients with Inflammatory Myopathy and Interstitial Lung Disease Kyle P. Chiang, Varun Gauba, Darin Lee, Minh-Ha T. Do, Jie J. Zhou, Feng Wang, Ying Buechler, Leslie Nangle, Zhiwen Xu, John Mendlein, Melissa Ashlock and Jeffrey M. Greve, atyr Pharma, San Diego, CA, Hong Kong University of Science and Technology, Kowloon, Hong Kong 5:00 PM 67. Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis Nicholas Young, Rahul Sharma, Alexandra Friedman, Benjamin Kaffenberger and Wael N. Jarjour, The Ohio State University Medical Center, Columbus, OH, University of Virginia Health System, Charlottesville, VA, Ohio State University, Columbus, OH 5:5 PM 67. Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies Zoe Betteridge, Sarah Tansley, Harsha Gunawardena, Lucy R. Wedderburn, Hector Chinoy 4, Robert G. Cooper 5, Jiri Vencovsky 6, Lenka Plestilova 7, Ingrid E. Lundberg 8, Katalin Danko 9, Melinda Vincze 9, Neil McHugh, UK JDRG 0 and EuMyoNet, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, North Bristol NHS Trust, Bristol, United Kingdom, University College London (UCL), London, United Kingdom, 4 The University of Manchester, Manchester, United Kingdom, 5 Hope Hospital, Salford, United Kingdom, 6 Institute of Rheumatology, Prague, Czech Republic, 7 Institute of Rheumatology, Prague, Czech Republic, 8 Karolinska Institutet, Stockholm, Sweden, 9 University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, 0 London, United Kingdom, Stockholm, Sweden 5:0 PM 674. Myeloid Related Proteins Induce Muscle Derived Inflammatory Mediators in Juvenile Dermatomyositis Kiran Nistala, Hemlata Varsani, Helmut Wittkowski, Thomas Vogl, Petra Krol 4, Vanita Shah, Kamel Mamchaoui 5, Paul Brogan, Johannes Roth and Lucy R. Wedderburn, University College London (UCL), London, United Kingdom, Muenster, Germany, University of Muenster, Muenster, Germany, 4 Prague, Czech Republic, 5 Paris, France 5:45 PM 675. Myositis Autoimmunity and Muscle Weakness Are Linked to TNF-Alpha Suppression of Micrornas-,, and 06 in Myoblasts and Myocytes Robert Georgantas III, Katie Streicher, Steven A. Greenberg, Lydia Greenlees V, Wei Zhu 4, Philip Brohawn 4, Brandon W. Higgs 4, Megan Czapiga 5, Chris Morehouse 4, Laura Richman, Bahija Jallal 4, Koustubh Ranade 5 and Yihong Yao, Medimmune, Inc, Gaithersburg, MD, Brigham Women s Hospital, Harvard Medical School, Boston, MA, MedImmune, Gaithersburg, MD, 4 MedImmune, LLC, Gaithersburg, MD, 5 MedImmune, Inc, Gaithersburg, MD MONDAY November, 0 0 Program Book 8

86 MONDAY November, 0 07 A Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II Moderators: Daniel J. Kingsbury, MD and D. J. Lovell, MD, MPH 4:0 PM 676. Abatacept As First Line Biological Treatment for Severe Juvenile Idiopathic Arthritis-Related Uveitis. A Multicenter Study Carolina Birolo, Maria Elisabetta Zannin, Svetlana Arsenyeva, Rolando Cimaz, Elisabetta Miserocchi 4, Margarita Dubko 5, Chantal Deslandre 6, Fernanda Falcini 7, Maria Alessio 8, Francesco La Torre 9, Ekaterina Denisova 0, Irina Nikishina and Francesco Zulian, University of Padua, Padua, Italy, Scientific Research Institute of Rheumatology RAMS, Moskow, Russia, A. Meyer Children s Hospital, Florence, Italy, 4 Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy, 5 Saint-Petersburg Pediatric Medical Academy, Saint-Petersburg, Russia, 6 Cochin Hospital, Paris, France, 7 Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, 8 University of Naples Federico II, Naples, Italy, 9 DIMIMP- University, Rheumatologic Section, Bari, Italy, 0 Helmgoltz Moscow Recearch Institute of Eye Diseases, Moskow, Russia, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, University of Padua, Padova, Italy 4:45 PM 677. Safety and Efficacy of Intra-Articular Infliximab Therapy for Treatment Resistant Temporomandibular Joint Arthritis in Children Matthew L. Stoll, Anthony B. Morlandt, Suwat Teerawattanapong, Daniel Young, Peter D. Waite and Randy Q. Cron, University of Alabama at Birmingham, Birmingham, AL 5:00 PM 678. Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged to <4 Years or 4 Years Weighing <5 Kg Daniel J. Kingsbury, Pierre Quartier, Gina Patel, Vipin Arora, Hartmut Kupper 4 and Neelufar Mozaffarian, Legacy Emanuel Children s Hospital, Portland, OR, Unite d Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, Abbott, Abbott Park, IL, 4 Abbott GmbH and Co. KG, Ludwigshafen, Germany 5:5 PM 679. Cumulative Long-Term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis: Results up to 7 Years of Follow-up D. J. Lovell, N. Ruperto, R. Mouy, E. Paz, N. Rubio-Perez, C. A. Silva, C. Abud-Mendoza, R. Burgos-Vargas, V. Gerloni, J. A. Melo-Gomes, C. Saad-Magalhaes, J. Chavez, C. Huemer, A. Kivitz, F. Blanco, I. Foeldvari, Michael Hofer, H. Huppertz, C. Job Deslandre, K. Minden, A. Flores Nunez 4, A. J. Block 5 and A. Martini, Cincinnati Children s Hospital, Cincinnati, OH, PRINTO, IRCCS G. Gaslini, Genoa, Italy, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, 4 PRINTO, IRCCS Hospital para el Niño Poblano, Puebla, Mexico, 5 Bristol-Myers Squibb, Princeton, NJ 5:0 PM 680. Diagnostic Value of the Assessment of Spondyloarthropathy International Society (ASAS) Criteria for Children with Enthesitis Related Arthritis (ERA): A Single Center Study of 4 Patients Mehul Jariwala, Manjari Agarwal and Sujata Sawhney, Sir Ganga Ram Hospital, New Delhi, India 5:45 PM 68. Increased Arterial Stiffness in Juvenile Idiopathic Arthritis (JIA) Patients Compared with Matched Controls - a Pilot Study Hanne Aulie, Mette-Elise Estensen, Anne Marit Selvaag, Patrick Segers, Oyvind Molberg, Vibke Lilleby, Svend Aakhus and Berit Flatø, Department of Rheumatology, Oslo University hospital, Rikshospitalet, Oslo, Norway, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, IBiTech-bioMMeda, Ghent University, Ghent, Belgium Ballroom A Rheumatoid Arthritis - Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease Moderators: Jon T. Giles, MD and Kimme Hyrich, MD, PhD 4:0 PM 68. Sustained Clinical Remission (Disease Activity Score 8 <.6) Protects for Cardiovascular Disease in Rheumatoid Arthritis Patients Elke.E.A. Arts, Jaap Fransen, Alfons A. den Broeder, Calin Popa and Piet L.C.M. van Riel, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Sint Maartenskliniek, Nijmegen, Netherlands 4:45 PM 68. Associations Between Lipid and Rheumatoid Arthritis Genetic Factors, and Low Density Lipoprotein Levels in RA Patients Katherine P. Liao, Dorothee Diogo, Tianxi Cai, Jing Cui, Raul N. Guzman P. 4, Vivian Gainer 4, Shawn N. Murphy 4, Susanne Churchill 4, Isaac Kohane, Elizabeth W. Karlson 5 and Robert M. Plenge, Brigham and Women s Hospital, Boston, MA, Harvard School of Public Health, Boston, MA, Brigham and Womens Hospital, Boston, MA, 4 Partners Healthcare Systems, Boston, MA, 5 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 5:00 PM 684. Increased Risk of Major Cardiovascular Events in a Nationwide Cohort of Rheumatoid Arthritis Patients Treated with Biological Agents Signe Abitz Winther, Peter Riis Hansen, Søren Lund Kristensen, Lene Dreyer, Ole Ahlehoff, Louise Linde, Christian Torp-Pedersen and Jesper Lindhardsen, Copenhagen University Hospital Gentofte, Hellerup, Denmark 5:5 PM 685. Differential Impact of Cardiac Risk Factors On Coronary Plaque Presence and Features in Asymptomatic Patients with Rheumatoid Arthritis Compared to Controls George A. Karpouzas, Jennifer Malpeso, Tae-Young Choi, Silvia Munoz and Matthew Budoff, Harbor-UCLA, Torrance, CA, Harbor-UCLA Medical Center, Torrance, CA 84 0 Program Book

87 5:0 PM 686. Vertebral Fracture Assessment-Detected Abdominal Aortic Calcification Enhances Cardiovascular Disease Risk Stratification of Rheumatoid Arthritis Patients Ausaf Mohammad, Derek Lohan, Diane Bergin, Sarah Mooney, John Newell, Martin O Donnell, Robert J. Coughlan and John J. Carey, Galway University Hospitals, Galway, Ireland, National University of Ireland, Galway, Ireland 5:45 PM 687. The Risk of Atrial Fibrillation in Patients with Rheumatoid Arthritis Compared to the General Population: A Large Cohort Study Seoyoung C. Kim, Jun Liu and Daniel H. Solomon, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, Brigham & Women s Hospital and Harvard Medical School, Boston, MA 46 C Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis Moderators: Hani S. El-Gabalawy, MD and Alisa E. Koch, MD 4:0 PM 688. Evolution of Preclinical Autoimmunity in Individuals At Risk for Development of Rheumatoid Arthritis Hani S. El-Gabalawy, David B. Robinson, Irene Smolik, Donna M. Hart, Elizabeth D. Ferucci, Marianna M. Newkirk, Marvin J. Fritzler 4, Catriona Cramb 5, Jeremy Sokolove 5 and William H. Robinson 5, University of Manitoba, Winnipeg, MB, Alaska Native Tribal Health Consortium, Anchorage, AK, McGill University Health Centr, Montreal, QC, 4 University of Calgary, Calgary, AB, 5 Stanford University, Palo Alto, CA 4:45 PM 689. Anti-Peptidylarginine Deiminase /4 Cross-Reactive Antibodies: A Novel Biomarker with Clinical and Mechanistic Implications in Rheumatoid Arthritis Erika Darrah, Jon T. Giles, Herbert Bull, Felipe Andrade and Antony Rosen, The Johns Hopkins University School of Medicine, Baltimore, MD, Columbia University Medical Center, New York, NY, Consultant, Westfield, NJ 5:00 PM 690. Citrullination within the Atherosclerotic Plaque: A New Potential Target for Anti-Citrullinated Protein Antibodies Jeremy Sokolove, Orr Share, Matthew Brennan, Lauren J. Lahey, Amy H. Kao, Eswar Krishnan, Mary Chester Wasko 4 and William H. Robinson 5, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, Allegheny Singer Research Institute, Pittsburgh, PA, Stanford University, Stanford, CA, 4 Temple University School of Medicine, Pittsburgh, PA, 5 Stanford University, Palo Alto, CA 5:5 PM 69. Early Signs of Subclinical Inflammation and Local Antibody Production in Early Rheumatoid Lungs Gudrun Reynisdottir, Reza Karimi, Jimmy Ytterberg, Vijay Joshua, Helga Olsen, Aase Haj Hensvold, Anders Harju, Johan Grunewald, Sven Nyren 4, Anders Eklund, Lars Klareskog 5, Roman Zubarev 6, Magnus Skold and Anca Irinel Catrina, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Division of Respiratory Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, 5 Karolinska Institute, Stockholm, Sweden, 6 Karolinska Institutet, Stockholm, Sweden 5:0 PM 69. Lung Microbiome Differs in Subjects with Rheumatoid Arthritis-Related Autoimmunity without Inflammatory Arthritis Compared to Healthy Seronegative Controls M. Kristen Demoruelle, Jill M. Norris, V. Michael Holers, Kevin D. Deane and J. Kirk Harris, University of Colorado School of Medicine, Aurora, CO, Colorado School of Public Health, Aurora, CO, Aurora, CO 5:45 PM 69. Oncogenic Activation of MAPK in Rheumatoid Arthritis Synovial Fibroblasts Niloofar L. Farmani, Keith K. Colburn, Grace Chan, Erica Li, Emil Heinze, Antonia Rubell, Robert Nishimura 4 and Richard H. Weisbart, Olive View-UCLA Medical Center, Sylmar, CA, Loma Linda Univ Medical Center, Loma Linda, CA, VAGLAHS, Sepulveda, CA, 4 The David Geffen School of Medicine at UCLA, Los Angeles, CA Hall E Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety II Moderators: Alan J. Kivitz, MD, and Joseph M. Grisanti, MD 4:0 PM 694. Infection Risk in Patients with Low Immunoglobulins Following Rituximab Treatment in Rheumatoid Arthritis Ronald F. van Vollenhoven, Gregg J. Silverman, Clifton O. Bingham III, Patrick Durez 4, Patrica B. Lehane 5, Nicola Tyson 5 and Elena Fisheleva 5, Karolinska University Hospital, Stockholm, Sweden, NYU School of Medicine, New York, NY, Johns Hopkins University, Baltimore, MD, 4 University Hospital St Luc, UCL, Brussels, Belgium, 5 Roche Products Limited, Welwyn Garden City, United Kingdom 4:45 PM 695. Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data M. C. Genovese, M C. Hochberg, R. B. Cohen, M. E. Weinblatt 4, J. Kaine 5, E. Keystone 6, P. Nash 7, I. Delaet 8 and R. Alten 9, Stanford University, Palo Alto, CA, Department of Medicine, University of Maryland, Baltimore, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 4 Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 5 Sarasota Arthritis Research Center, Sarasota, FL, 6 Mount Sinai Hospital, Toronto, ON, 7 University of Queensland, Brisbane, Australia, 8 Bristol-Myers Squibb, Princeton, NJ and Bristol-Myers Squibb, Hopewell, VA, 9 Schlosspark-Klinik, University Medicine, Berlin, Germany 0 Program Book 85 MONDAY November, 0

88 MONDAY November, :00 PM 696. Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone Tim Pottel, Christoph Schäfer and Gernot Keyßer, 064 Halle (Saale), Germany, 060 Halle (Saale), Germany 5:5 PM 697. Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials Sima Ahadieh, Tina Checchio, Thomas Tensfeldt, Jonathan French, Sriram Krishnaswami, Richard Riese, Sujatha Menon, Mary G. Boy and Jamie L. Geier, Pfizer Inc., Groton, CT, Metrum Research Institute, Tariffville, CT, Pfizer Inc., New York, NY 5:0 PM 698. Predictors of Discontinuation of Biologics in,8 US Patients with Rheumatoid Arthritis Sofia Ramiro, Frederick Wolfe, David J. Harrison, George Joseph, David H. Collier, Désirée van der Heijde 4, Robert Landewé 5 and Kaleb Michaud 6, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, National Data Bank for Rheumatic Diseases, Wichita, KS, Amgen Inc., Thousand Oaks, CA, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, 6 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE 5:45 PM 699. Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events: Date From the Autoimmunity and Rituximab Registry Jean Hugues Salmon, Patrice P. Cacoub Sr., Bernard G. Combe, Jean Sibilia 4, Beatrice Pallot Prades 5, Olivier Fain 6, Alain G. Cantagrel 7, Maxime Dougados 8, Olivier Meyer 9, Philippe Carli 0, Edouard Pertuiset, Isabelle Pane, Philippe Ravaud, Xavier Mariette 4 and Jacques-Eric Gottenberg 5, Rheumatology, Reims, France, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, Hopital Lapeyronie, Montpellier, France, 4 CHU Hautepierre, Strasbourg, France, 5 Saint Etienne university hospital, Saint Etienne, France, 6 Service de médecine interne, Université Paris, AP-HP, Hôpital Jean Verdier, 940, Bondy, France., Bondy, France, 7 Place du Docteur Baylac, Toulouse, France, 8 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 9 Hopital Bichat, Paris, France, 0 Toulon, France, Ch Rene Dubos, Pontoise, France, Hotel Dieu University Hospital Paris, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 4 Université Paris-Sud, Le Kremlin Bicetre, France, 5 Strasbourg University Hospital, Strasbourg, France 45 A Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis II Moderators: Oliver M. FitzGerald, MD and Enrique R. Soriano, MD, MSc 0 Program Book 4:0 PM 700. Prevalence of Spondyloarthritis in Anterior Uveitis Patients: The Sentinel Study Miguel Cordero Coma and Xavier Juanola, Unidad de Uveítis. Hospital Universitario de León, León, Spain, Hospital Universitari de Bellvitge, Barcelona, Spain 4:45 PM 70. Validation of the New ASAS Criteria for Classification of Early Spondyloarthritis in the Esperanza Cohort Eva Tomero, Loreto Carmona, Juan Mulero, Eugenio De Miguel 4, Milena Gobbo 5, Carmen Martínez 6, Miguel A. Descalzo 5, Pedro Zarco 7, Eduardo Collantes-Estevez 8 and Esperanza Group 9, Hospital Universitario La Princesa, Madrid, Spain, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, 4 Hospital Universitario La Paz, Madrid, Spain, 5 Spanish Society of Rheumatology, Madrid, Spain, 6 Sociedad Española de Reumatología, Madrid, Spain, 7 Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 8 IMIBIC-Reina Sofia Hospital, Cordoba 40, Spain, 9 Madrid 5:00 PM 70. Tumor Necrosis Factor Blocking Agents Inhibit the Progression of Preclinical Atherosclerosis in Patients with Ankylosing Spondylitis Alper M. van Sijl, Izhar C. van Eijk, Mike J.L. Peters, Erik H. Serne, Yvo M. Smulders and Mike T. Nurmohamed, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands 5:5 PM 70. Relationship Between Tobacco Smoking and Radiographic Spinal Progression in Axial Spondyloarthritis: The Role of Inflammatory Activity Denis Poddubnyy, Hildrun Haibel, Joachim Listing, Elisabeth Märker-Hermann, Henning Zeidler 4, Jürgen Braun 5, Martin Rudwaleit 6 and Joachim Sieper 7, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, German Rheumatism Research Center, Berlin, Germany, Dr. Horst Schmidt Kliniken, Wiesbaden, Germany, 4 Medizinische Hochschule, Hannover, Germany, 5 Rheumazentrum Ruhrgebiet, Herne, Germany, 6 Endokrinologikum Berlin, Berlin, Germany, 7 Charité Universitätesmedizin Berlin, Berlin, Germany 5:0 PM 704. New Threshold Values for Spinal Mobility Measures Based On a Large Nationally Representative Sample of U.S. Adults Ages 0-69 Years Shervin Assassi, Michael H. Weisman, Zhongxue Chen, Mohammad Rahbar and John D. Reveille, Univ of Texas Health Science Center at Houston, Houston, TX, Cedars-Sinai Medical Center, Los Angeles, CA 5:45 PM 705. Effect of Certolizumab Pegol On Inflammation of Spine and Sacroiliac Joints in Patients with Axial Spondyloarthritis: Week Magnetic Resonance Imaging results of a Phase Double Blind Randomized Placebo-Controlled Study Désirée van der Heijde, Walter P. Maksymowych, Robert B. M. Landewé, Christian Stach 4, Bengt Hoepken 4, Andreas Fichtner 4, Danuta Kielar 5 and Jurgen Braun 6, Leiden University Medical

89 Center, Leiden, Netherlands, University of Alberta, Edmonton, AB, Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 4 UCB Pharma, Monheim am Rheim, Germany, 5 UCB Pharma, Brussels, Belgium, 6 Rheumazentrum Ruhrgebiet, Herne, Germany Renaissance Washington - Grand Ballroom North Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Cardiovascular Moderators: Susan Manzi, MD, MPH and Jose A. Gomez-Puerta, MD, PhD 4:0 PM 706. Predictive Atherosclerotic Risk Factors At Inception in a Multicentre, Multinational Cohort Murray B. Urowitz, Dominique Ibanez, D. D. Gladman and SLICC, Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto, ON University of Pittsburgh, Pittsburgh, PA, Allegheny Singer Research Institute, Pittsburgh, PA, 4 West Penn Allegheny Health System, Pittsburgh, PA 47 A Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics II Moderators: Robyn T. Domsic, MD, MPH and Luc Mouthon Sr., MD 4:0 PM 7. The Submaximal Heart and Pulmonary Evaluation: A Novel Noninvasive Test to Identify Pulmonary Hypertension in Patients with Systemic Sclerosis Elana J. Bernstein, Jessica K. Gordon, Robert F. Spiera, Lisa A. Mandl and Evelyn M. Horn, Hospital for Special Surgery, New York, NY, New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY 4:45 PM 707. The Association of Serum Biomarkers and Metabolic Syndrome with Subclinical Atherosclerosis in Systemic Lupus Erythematosus: A Controlled Analysis in Patients with No Clinical Disease Activity Semra Ertan-Demir, Ahmet Yasar Cizgici, Gaye Erten, Bahar Artim-Esen, Yasemin Sahinkaya, Özlem Pehlivan, Nilüfer Alpay-Kanitez, Kadri Atay, Huseyin Oflaz, Gunnur Deniz and Murat Inanc, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul University, Institute of Experimental Medicine (DETAE), Istanbul, Turkey 5:00 PM 708. Systemic Lupus Erythematosus Cardiovascular Risk Equation Michelle Petri and Laurence S. Magder, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 5:5 PM 709. Biomarkers of Atherosclerosis Are Associated with Progression of Non-Cardiovascular Damage in Patients with SLE Sarah J. Kim, Jennifer M. Grossman, Brian Skaggs, Elaine Lourenco, Lori Sahakian, John D. FitzGerald, Nagesh Ragavendra, Christina Charles-Schoeman, Alan H. Gorn, Bevra H. Hahn and Maureen A. McMahon, UCLA David Geffen School of Medicine, Los Angeles, CA 5:0 PM 70. Increase in Vitamin D Improves Disease Activity and Systolic Blood Pressure in Systemic Lupus Erythematosus Kayode J. Bello, Hong Fang, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 5:45 PM 7. Association of Vascular Calcification and Perivascular Adipose Tissue of the Descending Aorta with Cardiovascular Events in SLE Kelly J. Shields, Emma Barinas-Mitchell, Amy H. Kao, Susan Manzi 4 and Kim Sutton-Tyrrell, Lupus Center of Excellence/ ASRI/West Penn Allegheny Health System, Pittsburgh, PA, 4:45 PM 7. Developing an Index for Disease Activity and Therapeutic Response in Connective Tissue Disease Related Interstitial Lung Disease: Results From A Delphi Exercise: Delivering A Consensus On Domains Lesley Ann Saketkoo, Dörte Huscher, Dinesh Khanna, Paul F. Dellaripa 4, Kevin Flaherty, Chester V. Oddis 5, Kristine Phillips, Athol U. Wells 6, Christopher P. Denton 7, Oliver Distler 8, Otylia M. Kowal-Bielecka 9, Romy Christmann 0, Nora Sandorfi, David Pittrow, Vibeke Strand, James R. Seibold 4, Kevin K. Brown 5 and Eric L. Matteson 6, Louisiana State University Health Science Center, New Orleans, LA, German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, University of Michigan, Ann Arbor, MI, 4 Brigham and Womens Hospital, Boston, MA, 5 University of Pittsburgh, Pittsburgh, PA, 6 Royal Brompton Hospital, United Kingdom, 7 UCL, London, United Kingdom, 8 Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 9 Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, 0 Boston University, Boston, MA, Thomas Jefferson Univ Med Coll, Philadelphia, PA, Dresden, Germany, Stanford University, Portola Valley, CA, 4 Scleroderma Research Consultants LLC, Avon, CT, 5 National Jewish Hospital, Denver, CO, 6 Mayo Clinic, Rochester, MN 5:00 PM 74. Gender Differences in Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations and Estradiol Levels Christine Peoples, Mary Lucas, Zengbiao Qi, Thomas A. Medsger Jr. and Carol A. Feghali-Bostwick, University of Pittsburgh, Pittsburgh, PA 5:5 PM 75. Imatinib Mesylate (Gleevec ) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a 4 Month Open Label, Extension Phase Jessica K. Gordon, Morgana L. Davids, Kamini Doobay, Jamie N. Mersten, Cynthia Magro, Horatio F. Wildman, Stephen L. Lyman, Mary K. Crow and Robert F. Spiera, Hospital for Special Surgery, New York, NY, Weill-Cornell Medical Center, New York 0 Program Book 87 MONDAY November, 0

90 5:0 PM 76. Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis Svetlana I. Nihtyanova, Voon H. Ong and Christopher P. Denton, Royal Free Hospital, Medical School, London, England, UCL Medical School, London, England, UCL, London, United Kingdom 5:45 PM 77. Autologous Lipostructure in the Treatment of Fibrotic Perioral Changes in Systemic Sclerosis: A Pilot Study Nicoletta Del Papa, Fabio Caviggioli, Domenico Sambataro, Eleonora Zaccara, Gabriele Di Luca, Valeriano Vinci and Marco Klinger, G. Pini Hospital, Milano, Italy, UOC Chirurgia Plastica, Multimedica Holding SpA, Università degli Studi di Milano, Milano, Italy, Istituto Clinico Humanitas, Università degli Studi di Milano;, Milano, Italy 58 B Pediatric Systemic Lupus (057) Speaker: Kelly A. Rouster-Stevens, MD, MSc 59 A Psoriatic Arthritis (058) Speaker: M. Elaine Husni, MD, MPH 59 B *Rheumatoid Arthritis: Biological Agents (059) Speaker: Edward C. Keystone, MD 60 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (060) Speaker: Maria Dall Era, MD MONDAY November, 0 ACR MEET THE PROFESSOR SESSIONS 4:0-6:00 PM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September Adult Inflammatory Myopathy (05) Speaker: Mary E. Cronin, MD 5 Antiphospholipid Syndrome (05) Speaker: Munther A. Khamashta, MD ARHP SESSIONS 4:0-6:00 PM 0 Early Rehabilitation for Hip and Foot Osteoarthritis: Opportunities and Challenges Moderator: Donna K. Everix, MPA, BS, PT Upon completion of this session, participants should be able to: describe clinical presentation and assessment of individuals with early osteoarthritis distinguish hip impingement from hip osteoarthritis define how to assess pain, mechanics and physical function in foot osteoarthritis interpret the results of subject specific motion analysis in individuals with hip or foot osteoarthritis identify key components of rehabilitation intervention 4:0 PM Early Hip Osteoarthritis: Clinical Presentation, Intervention Strategies and Implications for Treatment Shingpui Betty Chow, PT, MA, OCS 54 A Controversies in Sjögren s Syndrome (05) Speaker: Alan N. Baer, MD 54 B Dermatological Manifestations of Rheumatic Diseases (054) Speaker: Ruth Ann Vleugels, MD 55 Fibromyalgia and Dysautonomia (055) Speaker: Manuel Martinez-Lavin, MD 58 A Pain: Evaluation and Treatment of Back Pain (056) PM Speaker: David G. Borenstein, MD 4:55 PM Hip Impingement: Clinical Presentation, Evaluation, Principles for Intervention and Implications for Treatment Scott Siverling, PT, OCS 5:0 PM Foot Osteoarthritis: Clinical Presentation, Evaluation of Function and Footwear, Evidence-based Intervention and Implications for Treatment Smita Rao, PT, PhD 5:45 PM Panel Discussion 04 A Novel Approaches to Pain Management in Juvenile Idiopathic Arthritis PM Moderator: Lynn R. Spiegel, MDCM 88 0 Program Book

91 Upon completion of this session, participants should be able to: explain how to design and evaluate interactive health communication applications for youth with musculoskeletal pain using an example from the Teens Taking Charge: Managing Arthritis Online program summarize the use of smartphone health technology as a mode of assessing pain and coping as well as delivering pain management interventions in youth with juvenile idiopathic arthritis, and assess whether this modality may be suitable for their own research appraise information that will help them to consider the inclusion of non-pharmacologic approaches, including complementary and alternative medicine interventions such as yoga, for targeting pain in juvenile idiopathic arthritis 4:0 PM Harnessing the Potential of the Internet: Developing a Web-based Self-management Program for Adolescents with Arthritis Jennifer N. Stinson, PhD, RN, CPNP 5:00 PM DVD-based Yoga Intervention for Adolescent Girls with Juvenile Idiopathic Arthritis Amanda B. Feinstein, MS 5:0 PM Smartphone Delivery of Non-pharmacologic Interventions for Pain in Juvenile Idiopathic Arthritis Laura E. Schanberg, MD 4 A Promoting Participation: Where Is the Field and Where Do We Go Next? Moderator: Jillian A. Rose, LMSW Upon completion of this session, participants should be able to: discuss the importance of examining participation outcomes for persons with rheumatic conditions outline participation outcome measures for assessing work disability identify community and social participant outcome measures for adults with rheumatic conditions apply current evidence to intervening on participation 4:0 PM Participation: Definition and Current Measurement Approaches Julie J. Keysor, PhD, PT 4:45 PM Work Disability and Employment Retention Rawan Alheresh, OT, MSc 5:05 PM Participation and Community Dwelling Adults with Arthritis Julie J. Keysor, PhD, PT ARHP CONCURRENT ABSTRACT SESSION 4:0-6:00 PM 06 Care of Patients with Rheumatoid Arthritis Moderators: Jennifer M. Hootman, PhD and Joan C. McTigue, PA-C 4:0 PM 78. Cost Effectiveness of Nurse-Led Care for People with Rheumatoid Arthritis: A Multicentre RCT Mwidimi Ndosi, Martyn Lewis, Claire Hale, Howard Bird, Sarah Ryan, Helen Quinn, Elizabeth McIvor, Julia Taylor 4, Gail Burbage 5, Deborah Bond 6, Jo White 7, Debbie Chagadama 8, Sandra Green 9, Lesley Kay 0, Adrian V. Pace, Victoria Bejarano, Paul Emery and Jackie Hill, University of Leeds, Leeds, United Kingdom, Keele University, Staffordshire, United Kingdom, Stobhill Hospital, Glasgow, UK, Glasgow, United Kingdom, 4 Poole Hospital NHS Trust, Poole, United Kingdom, 5 King s Mill Hospital, Mansfield, United Kingdom, 6 Queen Elizabeth Hospital King s Lynn, King s Lynn, United Kingdom, 7 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 8 Royal London Hospital, London, United Kingdom, 9 Weston General Hospital, Weston-Super-Mare, United Kingdom, 0 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, Russells Hall Hospital, Dudley, United Kingdom, Barnsley Hospital, Barnsley, United Kingdom, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom 4:45 PM 79. What Do Patients Put up with for the Benefit They Get From Methotrexate? Sandra M. Robinson, Peta S. Heslop and David Walker, North Tyneside General Hospital, North Shields, United Kingdom, Freeman Hospital, Newcastle Upon Tyne, United Kingdom 5:00 PM 70. Cardiovascular Risk Management in Rheumatoid Arthritis Is Nurse Led Intervention Effective? Fiona Niddrie and Gabor AC Major, Bone and Joint Institute; Royal Newcastle Centre, Newcastle, Australia, Bone&Joint Institute; Royal Newcastle Centre, Newcastle, Australia 5:5 PM 7. Development of User-Focused Standards of Care for Rheumatoid Arthritis the Project - Work Package 5 Michaela Stoffer, Josef S. Smolen, Anthony D. Woolf, Tanja A. Stamm 4 and EUMUSC.net working group WP 5 5, Medical University of Vienna, A 090 Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, Royal Cornwall Hospital, Truro Cornwall, United Kingdom, 4 Medical University of Vienna, Vienna, Austria, 5 Truro Cornwall, MONDAY November, 0 5:5 PM Participation and Adults Post Total Knee Joint Replacement Jessica L. Maxwell, DPT, PT United Kingdom 5:45 PM Panel Discussion 0 Program Book 89

92 5:0 PM 7. Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices Linda C. Li, Anne F. Townsend, Paul M. Adam, Catherine L. Backman, Sydney Brooks 4, Gwen A. Ellert 5, Allyson Jones 6, Otto Kamensek, Cheryl Koehn 7, Diane Lacaille, Jenny Leese 8, Colleen Maloney, Elaine Yacyshyn 6, Charlene Yousefi and Dawn Stacey 9, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Vancouver, BC, Mary Pack Arthritis Centre, Vancouver, BC, 4 The Arthritis Society, Ontario Division, Toronto, 5 Trelle Enterprises Inc, Vancouver, BC, 6 University of Alberta, Edmonton, AB, 7 Vancouver, BC, 8 Arthritis Research Centre, Vancouver, BC, 9 University of Ottawa, Ottawa, ON 5:45 PM 7. The Development of the Rheumatoid Arthritis Patient Priorities in Pharmacological Intervention Outcome Measures Tessa Sanderson, John R. Kirwan, Marianne Morris, Jon Pollock, Robert Noddings, Anne Watts and Sarah Hewlett, University of the West of England, Bristol, United Kingdom, Bristol Royal Infirmary, Bristol, United Kingdom ACR STUDY GROUPS 6:0-7:45 PM Study Groups are non-cme activities, open to all attendees. See page 0 for additional Study Group offerings. View Study Group session details online in My Annual Meeting at 45 A ACR-EULAR Study Group - Signal Transduction in the Rheumatic Diseases 06 Gout Classification Criteria 4 A Hypermobility 04 A Interstitial Lung Disease 54 B (JAW) Juvenile Arthritis Workgroup 46 C Macrophage Activation Syndrome 07 A Musculoskeletal Ultrasound 0 B Myositis: New Developments on Myositis Therapies 40 A Neuro Endocrine Immunology 54 A Osteoarthritis - Synovial Inflammation 55 Pediatric Rheumatologists Interested in Medical Education 09 B Pediatric Rheumatology Imaging TUESDAY November, 0 47 A Antiphospholipid Syndrome 50 B Autoantibodies in Diagnosis and Follow-up of Rheumatic Diseases 5 Skin TUESDAY, NOVEMBER, A Childhood Vasculitis 58 A Clinical Research Methodology 5 A or B Degos Disease and Other Atypical Vasculopathies 58 B Geriatric Rheumatology 0 Global Health Initiatives 0 Program Book ACR/ARHP REGISTRATION 6:0 AM - 6:00 PM Registration Hall (Salons G-H-I) ACR SESSIONS 7:0-8:0 AM Ballroom B Chronic Recurrent Multifocal Osteomyelitis Moderator: Peter A. Nigrovic, MD Speaker: Polly J. Ferguson, MD Upon completion of this session, participants should be able to: discuss the clinical presentation and diagnosis of chronic recurrent multifocal osteomyelitis review the potential pathophysiologic mechanisms of chronic recurrent multifocal osteomyelitis and related inflammatory diseases of bone identify and evaluate therapeutic options for chronic recurrent multifocal osteomyelitis

93 5 A Molecular and Cellular Basis of Tissue Homing Moderator: Andrew P. Cope, MD, PhD Speaker: William Agace, PhD Upon completion of this session, participants should be able to: review the main cell surface and soluble factors that regulate migratory behavior of cells discuss the role of external cues in programming dendritic cells to promote tissue specific T cell migration discuss how this knowledge may inform aberrant migratory pathways of cells in the context of chronic immune mediated inflammatory diseases Hall D Update on Immune Mediated Glomerular Disease Moderator: Zsuzsanna H. McMahan, MD, MHS Speaker: Derek M. Fine, MD Upon completion of this session, participants should be able to: develop a differential diagnosis for causes of glomerular disease discuss the most recent literature involving the mechanisms of immune-mediated glomerular injury define the approach to screening, diagnosis, and management of these patients RHEUMATOLOGY RESEARCH FOUNDATION SPECIAL SESSION 7:0-8:0 AM Ballroom C Paul Klemperer, MD Memorial Lectureship: Serum Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, Clinical Subsetting and Predicting Outcomes Moderator: David I. Daikh, MD, PhD Speaker: Thomas A. Medsger Jr., MD Upon completion of this session, participants should be able to: describe and interpret laboratory reports on systemic sclerosis serum autoantibodies use autoantibody test results to classify systemic sclerosis patients into meaningful clinical subsets design clinically relevant and cost-effective followup plans for individual systemic sclerosis patients ARHP SESSIONS 7:0-8:0 AM 0 Clinical and Epidemiologic Study Designs in Rheumatic Disease Research Moderator: Marian T. Hannan, DSc, MPH Speaker: Tuhina Neogi, MD, PhD Upon completion of this session, participants should be able to: discuss measures of disease occurrence (e.g., prevalence, risk, and rate) and measures of effects (e.g., relative risk, rate ratio and odds ratio) explain basic epidemiologic study designs including observational (e.g., cross-sectional, cohort and case-control) and clinical trials, as well as the advantages and disadvantages of each design identify other study designs in rheumatology research such as case-cross over, self-control case series and examples of research using each design 4 A Don t Let the Pink Sheets Make You Blue Moderator: Leigh F. Callahan, PhD Speaker: Nelson Chao, MD Upon completion of this session, participants should be able to: describe the review process using the National Institutes of Health as an example including resubmission success funding rates identify a plan to break down comments and develop a high level strategy to submit a comprehensive response utilize strategies to respond to each reviewer s concerns that will be viewed as thorough and friendly discuss the need to manage expectations and skills to multiply success 45 A Fungal Infections and Tuberculosis in Patients with Rheumatologic Disease (Infection Series) Moderator: Elizabeth G. Salt, PhD Speaker: Neil M. Ampel, MD Upon completion of this session, participants should be able to: identify the risks of fungal infections and tuberculosis in patients with rheumatologic disease review screening for tuberculosis and fungal infections in patients with rheumatic disease outline treatment of rheumatologic disease in areas with high incidence of fungal infections and describe the treatment of rheumatologic disease in the presence of fungal disease discuss treatment of rheumatic disease in the presence of tuberculosis ACR MEET THE PROFESSOR SESSIONS 7:45-9:5 AM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September *Ankylosing Spondylitis: Disease Modification (06) Speaker: Joachim Sieper, MD TUESDAY November, 0 0 Program Book 9

94 5 Crystal: Diagnosis and Management of Gout (06) Speaker: Michael A. Becker, MD 44 C Adult Musculoskeletal Lower Examinations (9) Speaker: Arthur M. Mandelin II, MD, PhD 54 A *Infections with Biologics (06) Speaker: John J. Cush, MD 54 B Osteoarthritis: Update 0 (064) 55 Speaker: Joanne M. Jordan, MD, MPH Pain: Dealing with Patients with Refractory Pain in Musculoskeletal and Autoimmune Disorders (065) PM Speaker: Stephen A. Paget, MD 58 A Pediatrics: Juvenile Idiopathic Arthritis for Adult Rheumatologists (066) Speaker: Mara L. Becker, MD, MSCE 44 A Knee Braces and Foot Orthosis for Knee Osteoarthritis (0) Speakers: Howard J. Hillstrom, PhD and Kelly Krohn, MD 44 B Peripheral Magnetic Resonance Imaging in Rheumatology Practice () Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, MD, PhD, DMSc 49 A Synovial Fluid Analysis and Crystal Identification () Speakers: Brian F. Mandell, MD, PhD, Lan Chen, MD, PhD and Gilda M. Clayburne, MLT ACR SESSIONS 9:00-0:00 AM TUESDAY November, 0 58 *Pregnancy in Rheumatic Diseases (067) Speaker: Eliza F. Chakravarty, MD 59 A Reactive Arthritis: An Update (068) Speaker: John D. Reveille, MD 59 B Scleroderma: Systemic Sclerosis (069) Speaker: Robyn T. Domsic, MD, MPH 60 Vasculitis: Update (070) Speaker: Peter A. Merkel, MD, MPH ACR/ARHP WORKSHOPS 7:45-9:45 AM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September 4. Ballroom A Advances in Targeting of B cell Survival Factors Moderator: William Stohl, MD, PhD Speaker: Eline T. Luning Prak, MD, PhD Upon completion of this session, participants should be able to: identify the ligands and receptors involved in B cell survival pathways explain basic signaling pathways describe emerging approaches and newly developed agents for the targeting of B cells by interruption of survival factor pathways summarize results from recent clinical trials and the new therapeutic opportunities now available for the treatment of autoimmune rheumatic diseases 47 A Systems Immunology Moderator: Richard J. Bucala, MD, PhD Speaker: David A. Hafler, MD Upon completion of this session, participants should be able to: describe how new developments in systems approaches, or the broad-based examination of hundreds to thousands of genetic or phenotypic characteristics, is enhancing our understanding of autoimmune diseases identify how mathematically-based, bioinformatic approaches are enabling a better understanding of RNA expression and genetic data and allowing for the definition of sub-phenotypes of autoimmune disease explain how systems immunology will suggest new approaches to therapy by tailoring drugs for the treatment of particular immune profiles 9 0 Program Book

95 ARHP SESSIONS 9:00-0:00 AM 45 A Hepatitis in Patients with Rheumatologic Disease (Infection Series) Moderator: Elizabeth G. Salt, PhD Speaker: Daniel E. Furst, MD Upon completion of this session, participants should be able to: describe the risks of treatment of rheumatologic conditions in the presence of concomitant hepatitis infection review screening for hepatitis B and C in patients with rheumatic disease discuss treatment of rheumatologic disease in patients with hepatitis B and C infections 4 A Rheumatic Disease Update: The Approach to Low Back Pain PM Moderator: James G. Freeman, MD Speaker: Jeffrey N. Katz, MD Upon completion of this session, participants should be able to: recognize the critical items in the history and exam of a patient with low back pain identify appropriate diagnostic testing in the evaluation of low back pain determine treatment options for patients with low back pain 0 Threats to Validity: Confounding in Rheumatic Disease Research (Research Series) Moderators: Hyon K. Choi, DrPH, MD and Yuqing Zhang, DSc, MPH Speaker: Til Stürmer, MD, MPH Upon completion of this session, participants should be able to: define and describe the concept of confounding identify design methods to reduce confounding (e.g., randomization, restriction, matching) examine analytic methods to adjust for confounding (e.g., stratification, matching, multivariate analyses explain propensity scores and their appropriate uses ACR SESSIONS 9:00-0:0 AM 50 B Contract Negotiations for Physicians Moderator: Seth M. Berney, MD Upon completion of this session, participants should be able to: explain the value of legal advice prior to signing a contract and the legal ramifications of the contract identify a fair private practice or hospital practice contract and how to successfully modify it to correspond with their individual needs negotiate a fair academic or industrial letter of offer/contract 9:00 AM Contract Negotiations for Academics: How to Optimize Your Academic Offer Letter/Contract Marc C. Hochberg, MD, MPH 9:0 AM Contract Negotiations with Industry: How to Optimize Your Industry Offer Letter/Contract Gregory J. Dennis, MD 9:40 AM Contract Negotiations for Private Practice: How to Identify a Fair Private or Hospital Practice Contract and How to Successfully Modify It to Correspond to Your Individual Needs Herbert S. B. Baraf, MD 0:00 AM The Legal Ramifications of the Contract: How to Optimize Your Contract and Protect Yourself Joan M. Roediger, JD, LLM 0:0 AM Panel Discussion Hall D Paradigm Shifts in Rheumatoid Arthritis Moderators: Elana J. Bernstein, MD and Jasvinder A. Singh, MD, MPH Upon completion of this session, participants should be able to: outline the arguments for and against a window of opportunity in rheumatoid arthritis apply comparative safety and efficacy data from metaanalyses of biologic agents to patient care describe the data supporting tapering of therapy in selected patients with rheumatoid arthritis 9:00 AM Window of Opportunity in Rheumatoid Arthritis - Myth or Reality? Vivian P. Bykerk, MD 9:0 AM Biologics in 0: Making Sense of the Data Joel Kremer, PsyD 0:00 AM My Patient Feels Great! Can I Taper Therapy? Stanley B. Cohen, MD Renaissance Washington - Grand Ballroom North The Guide to Meaningful Use and Beyond Moderator: Steven K. Magid, MD Upon completion of this session, participants should be able to: describe the requirements and criteria for receiving the incentive payments under the CMS electronic health record incentive program (meaningful use) identify the electronic health record incentive program s impact on the practice of rheumatology, including best practices from early experiences and how operations must be modified to successfully achieve meaningful use describe the functionality objectives and clinical quality measures most relevant to rheumatology providers understand the implications of future stages of the program, 0 Program Book 9 TUESDAY November, 0

96 specifically how to adopt the second stage of meaningful use 9:00 AM Implementing Stage I of Meaningful Use While Keeping Stage II in Mind Robert W. Warren, MD, PhD, MPH 9:40 AM Attestation Best Practices From Early Adopters Craig W. Carson, MD 0:0 AM Question & Answer Hospital Vienna Speising, 0 Wien, Austria, University of Western Ontario, London, ON, 4 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 5 Royal Cornwall Hospital, Truro Cornwall, United Kingdom, 6 Medical University of Vienna, Vienna, Austria 9:5 AM 4. Arthritis Foundation s Tai Chi Program for People with Arthritis: One Year Follow-up My-Linh Luong, Rebecca J. Cleveland, Betsy Hackney and Leigh F. Callahan, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of North Carolina, Chapel Hill, NC TUESDAY November, 0 Rheumatology Research Foundation SPECIAL SESSION 9:00 AM - 0:0 PM 07 A Disease Targeted Research Moderator: Anne Davidson, MBBS Upon completion of this session, participants should be able to: explain the role of carboxypeptidase B in the pathogenesis of rheumatoid arthritis determine the potential for therapeutic intervention targeting specific WNT inhibitors to prevent bone destruction and/or promote bone repair in rheumatoid arthritis report the genetic basis of measures of rheumatoid arthritis severity 9:00 AM The Role of Carboxypeptidase B and its Substrates in Rheumatoid Arthritis William H. Robinson, MD, PhD 9:0 AM The Role of sfrp and WNT Signaling in Formation and Repair of Erosions in Rheumatoid Arthritis Ellen M. Gravallese, MD 0:00 AM Genome Wide Predictors of Quantitative Phenotypes in Rheumatoid Arthritis Jing Cui, PhD ARHP CONCURRENT ABSTRACT SESSIONS 9:00-0:0 AM 06 Physical/Occupational Therapy and Exercise in Patients with Rhematologic Disease Moderators: Jill R. Blitz, DPT, PT and Maura D. Iverson, DPT, MPH 9:00 AM 4. Are Occupational Therapy Interventions Included in the Most Commonly Used European Clinical-Practice Guidelines for the Management of Osteoarthritis? Michaela Stoffer, Doris Taurok, Birgit Prodinger, Josef S. Smolen 4, Anthony D. Woolf 5 and Tanja A. Stamm 6, Medical University of Vienna, A 090 Vienna, Austria, Orthopaedic 9:0 AM 4. Integration of a Healthy Aging Program Into the Arthritis Foundation Exercise Program: Six-Month Results Elizabeth A. Schlenk, Joni Vander Bilt, Wei-Hsuan Lo-Ciganic, Sarah E. Woody, Janice C. Zgibor, Molly B. Conroy, C. Kent Kwoh and Anne B. Newman, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh, PIttsburgh, PA, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA 9:45 AM 44. Effects of Interventions That Aim to Increase Exercise Adherence in People with Arthritis: A Best Evidence Synthesis Katie, E. MacPherson, Allison M. Ezzat, Jenny Leese and Linda C. Li, New Westminster, BC, University of British Columbia, Vancouver, BC, Arthritis Research Centre, Vancouver, BC 0:00 AM 45. Lumbrical Splinting and Stretching Versus Standard Treatment On Grip, Pinch, and Dexterity in People with Carpal Tunnel Syndrome Nancy A. Baker, Krissy Moehling, Elaine Rubinstein, Norman Gustafson and Mark Baratz 4, University of Pittsburgh, Pittsburgh, PA, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, 4 Alleghancy General Hospital, Pittsburgh, PA 0:5 AM 46. Clinical Effectiveness and Costs of an Integrated Rehabilitation Programme Compared with Outpatient Physiotherapy for Chronic Knee Pain Mike Hurley, Dr Nicola E. Walsh and Sally Jessep, St George s University of London, London, United Kingdom, University of the West of England Bristol, Bristol, United Kingdom, Kent, United Kingdom 04 A Programs and Literacy in Patients with Rheumatologic Diseases Moderators: Susan J. Blalock, PhD and Victoria Gall, PT, MEd 9:00 AM 47. Initiating an Innovative Training Programme to Improve Access to Musculoskeletal Health Care in Kenya Anthony D. Woolf, Jo Erwin, Omondi G. Oyoo, Lillian Mwaniki 4, Ingrid Cederlund 5, Paul Etau 6 and Katie Edwards 7, Royal Cornwall Hospital, Truro Cornwall, United Kingdom, Royal Cornwall Hospital, Teliske, United Kingdom, University of Nairobi, Nairobi, 94 0 Program Book

97 Kenya, 4 Association for Arthritis & Rheumatic Diseases of Kenya, Nairobi, Kenya, 5 Reumatikerforbundet, Stockholm, Sweden, 6 University of Nairobi, Nairobi, Kuwait, 7 Royal Cornwall Hospital, Truro, United Kingdom 9:5 AM 48. The Effect of a Systematic, Personalized Computer Workstation Redesign On Musculoskeletal Symptoms Nancy A. Baker and Krissy Moehling, University of Pittsburgh, Pittsburgh, PA 9:0 AM 49. A Brief Exercise and Self Management Programme Improves Upper Limb Disability in People with Early Rheumatoid Arthritis Lindsay M. Bearne, Victoria L. Manning, David L. Scott, Ernest Choy and Michael V. Hurley 4, Kings College London, London, United Kingdom, King s College London, London, United Kingdom, Cardiff University School of Medicine, Cardiff, United Kingdom, 4 St George s University of London, London, United Kingdom 9:45 AM 440. Decisional Conflict Among Vulnerable Patient Populations with Rheumatoid Arthritis Is Associated with Limited Health Literacy and Non-English Language Laura Trupin, Jennifer Barton, Gina Evans-Young, John B. Imboden, Andrew J. Gross, Dean Schillinger and Edward H. Yelin, UCSF, San Francisco, CA 0:00 AM 44. Readability and Suitability Assessment of Patient Education Materials in Rheumatic Diseases Rennie L. Rhee, Joan Marie Von Feldt, H. Ralph Schumacher and Peter A. Merkel, University of Pennsylvania, Philadelphia, PA, Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA, University of Pennsylvania and VA Medical Center, Philadelphia, PA 0:5 AM 44. Screening of Osteoporosis in Men Age 70 and Older: A Need for Increased Awareness Sian Yik Lim, Kenneth Nugent, Joon Hee Lim, Hoda Mojazi Amiri, Rie Okamura and Dan Nguyen, Texas Tech University Health Sciences Center, Lubbock, TX ACR/ARHP POSTER SESSION C, THIEVES MARKET POSTERS AND POSTER TOURS 9:00 AM - 6:00 PM Poster presenters will be available from 9:00 - :00 AM (abstracts # 74-40). Poster tours will be held 9:00-9:45 AM and 0:5 - :00 AM. Morning snacks will be available from 9:00-0:0 AM. Poster Hall (Hall B) Thieves Market Posters Thieves Market posters feature cases with interesting imaging studies or pictorial displays of physical findings. A Wolf in Sheep s Clothing Reeti Joshi, MBBS Behçet s Disease with Pulmonary Artery Aneurysms Claudia B. Hubbe, MD Medical Re-vascularisation Mark Richard Williams, MD Myalgias: Out of Proportion to Exam Julie Paik, MD Neonate with Sclerodermatous Limbs Murray H. Passo, MD Treatment of Fulminant Myocarditis and Macrophage Activation Syndrome Secondary to Adult Onset Still s Disease Eimear Savage, BAO, BCh, MB Poster Hall (Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 5 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until 5 minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Salons G-H-I). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first served basis 5 minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 5 minutes of the end of the tour. 9:00-9:45 AM ARHP Epidemiology and Public Health (4) Tour Guide: Leigh F. Callahan, PhD Miscellaneous Rheumatic and Inflammatory Diseases (5) Tour Guide: W. Winn Chatham, MD Rheumatoid Arthritis: Clinical Aspects (6) Tour Guide: Merete L. Hetland, MD, PhD, DMSc Systemic Lupus Erythematosus: Human Etiology and Pathogenesis (7) Tour Guide: Mary K. Crow, MD Vasculitis (8) Tour Guide: Philip Seo, MD, MHS 0:5 - :00 AM Antiphospholipid Syndrome (9) Tour Guide: Pier Luigi Meroni, MD Fibromyalgia and Soft Tissue Disorder (0) Tour Guide: Daniel J. Clauw, MD Metabolic and Crystal Arthropathies () Tour Guide: N. Lawrence Edwards, MD 0 Program Book 95 TUESDAY November, 0

98 Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis () Tour Guide: Nancy E. Lane, MD Sjögren s Syndrome () Tour Guide: Jacques-Eric Gottenberg, PhD Rheumatology Research Foundation - Pathogenic Mechanisms in Rheumatic Diseases (4) Tour Guide: Michael H. Pillinger, MD Learn about the excellent work being done by Rheumatology Research Foundation-funded early career investigators. This is also an opportunity for division chiefs looking to recruit junior faculty to meet young productive investigators and vice versa. EXHIBITS 0:00 AM - 5:00 PM Exhibit Hall (Hall A) Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 0:00 - :00 AM and :00 - :00 PM. (Booth #45) Innovation Theater Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. These presentations will be held from 0:0 - :5 AM, :0 - :5 PM and :0 - :5 PM. For a complete listing of Innovation Theater presentations see page 6. 0 Upon completion of this session, participants should be able to: indentify underlying immune dysregulation and immunosuppressive treatments discuss effective methods of infection prevention in patients with autoimmune disease review recommendations for vaccines in adult patients with rheumatic disease Selection Bias in Rheumatic Disease Research Risk Factor Paradox and Other Issues Moderator: Sherine E. Gabriel, MD, MSc Upon completion of this session, participants should be able to: discuss selection bias due to conditioning on an intermediate variable identify major types of selection bias associate design and analytic methods to minimize selection bias 0:0 AM Risk Factor Paradox in Rheumatic Diseases-Selection Bias? Hyon K. Choi, DrPH, MD 0:50 AM Other Major Types of Selection Bias in Rheumatic Disease Research Yuqing Zhang, DSc, MPH :0 AM Minimizing Selection Bias through Study Design and Analytic Methods Panel Discussion Hyon K. Choi, DrPH, MD and Yuqing Zhang, DSc, MPH TUESDAY November, 0 ACR SESSION 0:0 - :0 AM 46 C Gouty Inflammation Moderator: Richard J. Bucala, MD, PhD Speaker: Stephen E. Malawista, MD Upon completion of this session, participants should be able to: describe evolving knowledge of the pathogenetic setting in which urate crystals lead to acute gout review biochemical and cellular determinants that lead to the initiation of gouty inflammation discuss biochemical and cellular determinants that lead to resolution of gouty inflammation ACR/ARHP COMBINED ABSTRACT SESSION 0:0 AM - Noon 40 A ACR/ARHP Combined Rehabilitation Abstract Session Moderators: Nancy A. Baker, MPH, OTR, OTR/L; Julie J. Keysor, PhD, PT 0:0 AM 44. Pain and Function Outcomes in Systemic Lupus Erythematosus Hip and Knee Arthroplasty Ummara Shah, Lisa A. Mandl, Mark P. Figgie, Michael Alexiades and Susan M. Goodman, New York University School of Medicine, NYC, NY, Hospital for Special Surgery, New York, NY ARHP SESSIONS 0:0 - :0 AM 45 A Immunizations in Patients with Rheumatologic Disease (Infection Series) Moderator: Elizabeth G. Salt, PhD Speaker: Gil Y. Melmed, MD 0:45 AM 444. Restricting Back Pain Is Associated with Disability in Community-Living Older Persons Una E. Makris, Liana Fraenkel, Ling Han, Linda Leo-Summers and Thomas M. Gill 4, UT Southwestern Medical Center, Dallas, TX, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Department of Medicine, New Haven, CT, 4 Yale University, New Haven 96 0 Program Book

99 :00 AM 445. Ipsilateral Lower Extremity Joint Involvement Increases the Risk of Poor Pain and Function Outcomes After Hip or Knee Arthroplasty Jasvinder A. Singh and David Lewallen, University of Alabama at Birmingham, Birmingham, AL, Mayo Clinic college of medicine, Rochester :5 AM 446. Activity Limitations Experienced by People with Rheumatoid Arthritis On Biologic Medications and Their Use of Ergonomic Methods Alison Hammond and Sarah Tyson, University of Salford, Salford, United Kingdom, University of Salford, Manchester, United Kingdom :0 AM 447. Accuracy of Sensewear MiniTM and Actigraph GTXTM Accelerometers for Differentiating Sedentary and Light Physical Activities in a Controlled Laboratory Setting April Y. F. Leung, Lynne M. Feehan, Cynthia Macdonald, Jenny Leese, Erin Carruthers and Linda C. Li, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Vancouver, BC :45 AM 448. Sustained Improvement Physical Function Following an Integrated Rehabilitation Programme for Chronic Knee Pain Mike Hurley and Dr Nicola E. Walsh, St George s University of London, London, United Kingdom, University of the West of England Bristol, Bristol, United Kingdom ARHP SESSIONS :00 AM Noon 04 A A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective Moderator: Jillian A. Rose, LMSW Upon completion of this session, participants should be able to: discuss pathophysiologic mechanisms of rheumatoid arthritis and their effect on functional activity review the tools for assessing functional activity and how they can be used in the clinical setting and for research discuss common strategies patients with rheumatoid arthritis use to ensure optimal functioning in the home, at work, and in the community discuss educational strategies to help patients with rheumatoid arthritis improve communication of functional capabilities to health care providers being cognizant of patients level of health literacy :00 AM Integrating Impairment and Functional Activity: Using Patient Self-report Measures to Inform Medial Practice for Patients with Rheumatoid Arthritis Terence W. Starz, MD :0 AM Strategies to Promote Functional Activity in the Home, at Work, and in the Community for Clients with Rheumatoid Arthritis Nancy A. Baker, MPH, OTR, OTR/L ACR WORKSHOPS 0:0 AM - :0 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September B Histopathology of Vasculitis () Speaker: Allen Burke, MD :40 AM The Role of Nursing in the Management of Rheumatoid Arthritis Elizabeth A. Schlenk, PhD, RN 4 A Strategies to Enhance Office Efficiencies and Access to Care in Rheumatology Practice PS Moderator: James G. Freeman, MD Speaker: Eric D. Newman, MD Upon completion of this session, participants should be able to: review some of the problems with traditional practice models that impede efficiency and increase waiting times for new referrals explore alternative models that may improve access to care and triage of new referrals discuss options for improving practice scheduling, workflow and efficiencies TUESDAY November, 0 44 C *Joint Injection Techniques (4) Speakers: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD ACR PLENARY SESSION III DISCOVERY 0 :00 AM - :0 PM Hall E Moderators: Chester V. Oddis, MD and Richard M. Pope, MD 0 Program Book 97

100 TUESDAY November, 0 :00 AM 449. Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial Michael E. Weinblatt, Michael H. Schiff, Roy Fleischmann, Robert Valente 4, Désirée van der Heijde 5, Gustavo Citera 6, Cathy Zhao 7 and Michael A. Maldonado 7, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, University of Colorado, Denver, CO, University of Texas Southwestern Medical Center, Dallas, TX, 4 Arthritis Center of Nebraska, Lincoln, NE, 5 Leiden University Medical Center, Leiden, Netherlands, 6 Instituto de Rehabilitación Psicofísica., Buenos Aires, Argentina, 7 Bristol-Myers Squibb, Princeton, NJ Background/Purpose: The availability of multiple biologic agents to treat rheumatoid arthritis (RA) has created a need for comparative assessment. AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) is the first head-to-head study powered to compare SC abatacept (ABA) and adalimumab (ADA) on a background of methotrexate (MTX). Here, we report key year data from AMPLE including ACR core component data. Methods: AMPLE is an ongoing, phase IIIb, randomized, investigator-blinded study of 4 months duration with a month primary efficacy endpoint. Biologic-naïve RA patients with an inadequate response to MTX were randomized to 5 mg ABA weekly or 40 mg ADA bi-weekly, in combination with MTX. The primary end point was non-inferiority (NI) of ABA to ADA based on ACR 0 at months; key secondary endpoints were rates of radiographic non-progression, safety, injection site reactions and retention. ACR core component data were also analyzed. Results: A total of 646 patients were randomized and treated; 86.% of ABA patients and 8.0% of ADA patients completed months. Baseline characteristics were balanced across both arms (mean DAS8-CRP of 5.5 and disease duration ~.8 yrs). At year, 64.8% of ABA patients and 6.4% of ADA patients achieved an ACR 0 response, with an estimated difference between the two arms (95% CI) of.8 (-5.6, 9.) supporting NI of ABA to ADA. The kinetics of response across ACR scores were comparable overall, with an ACR50 of 46.% and 46% and ACR70 of 9.% and 6.% for ABA and ADA, respectively, at year. Similar responses over time were seen in some ACR core components (Figure). At year, the rates of radiographic non-progression were comparable, as were mean changes in van der Heijde-modified total Sharp scores (0.58 vs. 0.8, for ABA vs. ADA respectively). The rates of AEs, SAEs, serious infections and malignancies were comparable. There were more patients with autoimmune AEs (.% vs. 0.9%) in the ABA arm; however, none were serious. One patient discontinued in each arm due to an autoimmune event. There were fewer discontinuations with ABA due to AEs (.5% vs. 6.%) and due to serious infections (0% vs..5%). Injection site reactions occurred in significantly fewer ABA-treated patients (.8% vs. 9.% [p=0.006]). Conclusion: This first head-to-head study in RA patients comparing biologic agents on background MTX demonstrated that subcutaneous abatacept is comparable to adalimumab by most efficacy measures, including radiographic progression. Safety was generally similar with fewer discontinuations and injection site reactions observed with abatacept. Disclosure: M. E. Weinblatt, Bristol-Myers Squibb, Abbott,, Bristol-Myers Squibb, Abbott, 5; M. H. Schiff, Bristol-Myers Squibb, 5, Abbott Laboratories, 8; R. Fleischmann, Genentech Inc, Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi Aventis, Lexicon, MSD, Novartis, BiogenIdec, Astellas, Astra- Zeneca, Jansen,, Roche, Abbott, Amgen, UCB, Pfizer, BMS, Lilly, Sanofi Aventis, Lexicon, Novartis, Astellas, Astra-Zeneca, Jansen, HGS, 5; R. Valente, UCB,Pfizer,Novartis,Eli Lilly,Takeda, Centocor, ; D. van der Heijde, Abbott, Amgen, AstraZeneca, BMS, Centocor, Chugai, Eli-Lilly, GSK, Merck, Novartis, Otsuka, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, UCB, Wyeth, 5, Owner of Imaging Rheumatology bv, 4; G. Citera, Pfizer Inc,, Pfizer, Bristol-Myers Squib, Astra Zeneca, 5; C. Zhao, Bristol-Myers Squibb,, Bristol-Myers Squibb, ; M. A. Maldonado, Bristol- Myers Squibb,, Bristol-Myers Squibb,. :5 AM 450. Evoked Pain Brain Response Is Associated with Reduced μ-opioid Receptor Binding in Fibromyalgia Heng Wang, Daniel J. Clauw, Jon-Kar Zubieta and Richard E. Harris, University of Michigan, Ann Arbor, University of Michigan, Ann Arbor, MI Background/Purpose: Previous studies indicate that fibromyalgia (FM) patients have augmented clinical and brain responses to painful stimuli (i.e. hyperalgesia/allodynia), as well as increased production of endogenous opioids, and reduced μ-opioid receptor (MOR) binding. However, it is not known if these factors co-occur within the same individual or if these factors act independently. We performed a longitudinal investigation using functional magnetic resonance imaging (fmri) and positron emission tomography (PET) in chronic pain patients diagnosed with FM to address this question. If these factors operate in the same individual, we expected an inverse correlation between changes in fmri evoked pain activity and MOR binding potential (BP). Methods: fmri and PET imaging sessions were performed on 8 female opioid-naïve FM patients (age 45.4+/-.0). Each participant underwent 4 weeks of non-pharmacological treatment. Before and after treatment, each patient underwent 98 0 Program Book

101 an fmri scan with varying levels of pressure pain applied to the thumb as well as a 90-minute [C]carfentanil PET scan under resting conditions. After quantification of the PET data with Logan plots, fmri images and preprocessing of PET data were performed with statistical parametric mapping (SPM5). fmri and PET scans were normalized to the same template. Difference images before and after treatment were calculated for both the fmri contrast and PET images. A whole-brain voxel-by-voxel correlation analysis between the fmri and PET difference images were carried out using the Biological Parametric Mapping toolbox. Activation clusters were defined based on a correlation coefficient, with R >=0.6 uncorrected. Clinical pain was assessed with Short Form McGill Pain Questionnaire (SFMPQ). Results: Negative correlations between the change in the fmri blood oxygenation level dependent (BOLD) signal and MOR BP were observed in multiple regions involved in pain processing and modulation: right posterior insula R=-0.8,P=0.0004; left medial insula R=-0.8, P=0.000; left orbital frontal cortex R=-0.75, P=0.0004; right amygdala R=-0.68, P=0.00; brainstem R=-0.7, P= Positive correlations were observed in right DLPFC R=0.66, P=0.00; posterior cingulate R=0.6, P=0.006; right putamen R=0.7, P= Changes in both functional imaging outcomes were negatively associated with changes in clinical pain: BOLD in right DLPFC and clinical pain SFMPQ; R=- 0.5, P=0.0; MOR BP in left medial insula and SFMPQ present pain R=-0.5, P=0.0. Conclusion: We find strong longitudinal associations between evoked pain activations suggestive of hyperalgesia, and µ-opioid receptor availability (binding potential, BP) within the same brain regions, in individual FM patients. Positive associations were also observed between BOLD responses, and μ-opioid receptor BP (in opposive directions) with respect to clinical pain. These data suggest that the µ-opioid system is somehow involved in the pathogenesis of FM, and may even help explain why these patients are generally not felt to respond to narcotic analgesics, and may even be made worse when these drugs are used therapeutically. Disclosure: H. Wang, None; D. J. Clauw, Pfizer Inc, Forest Laboratories, Merck, Nuvo,, Pfizer, Forest, Lilly, Merck, Nuvo, J and J, 5; J. K. Zubieta, None; R. E. Harris, Pfizer Inc,, Pfizer Inc, 5. :0 AM 45. Laquinimod (LAQ) Is Equivalent to Mycophenolate Mofetil (MMF) in Preventing and Suppressing Murine Lupus Nephritis and Has Greater Effects On Myeloid/Monocyte/ Macrophage Cells Bevra H. Hahn, Maida Wong, Elaine Lourenco and Brian Skaggs, UCLA David Geffen School of Medicine, Los Angeles, CA Background/Purpose: Lupus nephritis (LN) depends on autoab deposition and activation of multiple cell types that infiltrate kidneys and promote inflammation monocytes/macrophages (MM), DCs, T and B cells. Laquinimod (LAQ) administered to humans downregulates Ag presentation, decreases chemokine production, decreases MHC expression on MM, and induces apoptotic pathways in PBMC (Gurevich M et al 00). LAQ reduces progression of relapsing remitting multiple sclerosis (Comi G et al NEJM 0); it is currently in clinical trials in SLE. MMF targets primarily lymphocytes; it is effective in many LN patients Methods: We compared clinical and immune cell changes in groups of 0- BWF female mice treated orally times a week for 4 weeks with a) water; b) LAQ mg/kg; c) LAQ 5 mg/kg; d) MMF 0 mg/kg; e) MMF00 mg/kg. Results: Survival was better in both LAQ groups and the MMF00 group vs controls (p=0.08). LAQ at both doses was equivalent to MMF00 in preventing proteinuria in mice treated before disease appeared. At wks of age 50% of mice on water had proteinuria vs zero in LAQ and MMF00 groups (p<0.000) Renal histology mirrored proteinuria: mean total histologic scores were 7.8 on water,.0 on LAQ and 0.9 on MMF00 (p<0.0 both treatment groups compared to controls). Glomerular deposition of Ig and C were in the normal range in LAQ and MMF, but significantly increased in the water group (p<0.00). Mice treated after clinical nephritis appeared ( + proteinuria) improved on LAQ: after wks of treatment proteinuria was present in 00% on water vs 5% on LAQ (p<0.00). Survival was also better in mice treated with LAQ (p<0.000) Effects on splenic PBMC differed between LAQ and MMF. Neither treatment changed total numbers of B cells. MMF decreased CD4+and CD8+ T cell percents; LAQ did not. LAQ compared to MMF increased numbers of two putative regulatory cells, CD4+CD5+Foxp+ Treg and CDb+Ly6intGR-+ myeloid MM. Most interesting was the observation that LAQ, but not MMF, significantly reduced numbers of MM. Conclusion: LAQ was highly effective in preventing and suppressing proteinuria and glomerular immune disease in BWF mice. Responses to MMF in high dose were similarly good. However, LAQ reduced numbers of MM, and MMF did not. In addition, LAQ induced different types of regulatory cells, distinguishing it from MMF. Since suppression of MM is likely to reduce renal inflammation and damage, future development of LAQ as a therapeutic for lupus nephritis is especially promising. Disclosure: B. H. Hahn, Teva Pharmaceuticals,, Aspreva Pharmaceutical,, Anthera, 5, Abbott, 5, Eli Lilly, 5; M. Wong, None; E. Lourenco, None; B. Skaggs, None. :45 AM 45. Rheumatoid Arthritis-Associated PTPN Modulates Toll- Like Receptor-Mediated, Type Interferon-Dependent Innate Immunoregulation Yaya Wang, Stephanie Stanford, Wenbo Zhou, Jennifer L. Auger, Genhong Cheng, Amanda Campbell, Fernanda M. Shoyama, Henry H. Balfour Jr. 4, Andrew C. Chan 5, Bryce A. Binstadt, Nunzio Bottini and Erik J. Peterson, University of Minnesota, Minneapolis, MN, La Jolla Institute for Allergy and Immunology, La Jolla, CA, University of California, Los Angeles, Los Angeles, CA, 4 University of Minnesota, Minneapolis, 5 Genentech Inc, South San Francisco, CA Background/Purpose: A coding polymorphism (C858T) in PTPN is strongly associated with risk of Rheumatoid Arthritis (RA) and other autoimmune diseases. PTPN encodes Lymphoid Phosphatase (Lyp); the Lyp disease variant bears an R60W substitution ( LypW ). The mechanism by which LypW increases disease susceptibility remains unclear. PTPN- expressing dendritic cells (DC) and macrophages have been implicated in RA pathology. Such myeloid cells produce type interferons (IFN) and proinflammatory cytokines in response to Toll-like receptor (TLR) engagement. We hypothesized that 0 Program Book 99 TUESDAY November, 0

102 TUESDAY November, 0 PTPN might modulate TLR signaling and attendant innate immune responses. Methods: We studied TLR signaling and type IFN-mediated antiviral responses and immunoregulation in Ptpn-deficient myeloid cells and mice, in transgenic mice harboring human LypW or LypR (major allele protein product), and in human LypW carrier peripheral blood mononuclear cells (PBMC). Results: We found markedly decreased induction of type IFN after TLR/4/7/9 activation in Ptpn -/- macrophages, DC, and plasmacytoid DC. Interestingly, Ptpn was dispensable for induction of proinflammatory cytokines, including TNFα, IL- 6, and IL-β, after TLR//4/7/9 stimulation. The selective TLR signalling defect in Ptpn -/- cells was associated with impaired type IFN-dependent immunity, manifested by reduced serum type IFN, impaired dendritic cell activation, and diminished T cell responses after lymphocytic choriomeningitis virus (LCMV) infection of Ptpn -/- mice. In the K/BxN serum transfer model of rheumatoid arthritis, treatment with type IFN-inducing TLR ligands suppresses disease. However, we observed significantly decreased TLR ligand-mediated suppression of inflammatory arthritis in Ptpn -/- mice. RA-associated LypW carrier human PBMC and myeloid cells derived from LypW transgenic mice displayed defective induction of type IFN after TLR stimulation. LypR directly associated with TNF receptor-associated factor (TRAF), a key TLR signaling mediator upstream of type IFN induction. LypR, but not LypW promoted TRAF K6-linked polyubiquitinylation, which is required for TLR-induced type IFN production. Conclusion: PTPN is a key positive regulator of TLR-driven upregulation of type IFN. LypW, product of the RAassociated PTPN allele, exhibits loss of function in type IFN dependent processes, including antiviral host defense and amelioration of inflammatory arthritis. Our findings strongly suggest that PTPN could regulate severity of joint inflammation in RA through modulation of TLR signaling in innate immune cells. Disclosure: Y. Wang, None; S. Stanford, None; W. Zhou, None; J. L. Auger, None; G. Cheng, None; A. Campbell, None; F. M. Shoyama, None; H. H. Balfour Jr., None; A. C. Chan, None; B. A. Binstadt, None; N. Bottini, None; E. J. Peterson, None. Noon 45. The Role of Bob in Rheumatoid Arthritis: Potential Implications for Autoimmunity Nataliya Yeremenko, Tineke Cantaert, Melissa N. van Tok, Ioana Gofita, Juan D. Canete, Paul P. Tak, Hergen Spits and Dominique L. Baeten, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Rheumatology Department, Hospital Clinic, Barcelona, Spain, Tytgat Institute for Liver and Intestinal Research, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such as rheumatoid factor and anticitrullinated protein antibodies in the inflamed synovial tissue. The mechanisms underlying break of B cell tolerance and local autoantibody production remains poorly understood. This study was conducted in order to identify cellular and molecular pathways implicated in RA-specific humoral autoimmunity. Methods: Synovial tissue samples were obtained by arthroscopy from untreated individuals with RA (n=) and inflammation matched SpA controls (n=58). Gene expression profiling was performed on tissue samples of patients with established arthritis using 44K Whole Genome Human microarrays (Agilent). Top differentially expressed genes were validated on three independent cohorts by Taqman based RT-qPCR and immunohistochemistry. Collagen-induced arthritis (CIA) and Experimental autoimmune encephalomyelitis (EAE) experiments were conducted using Bob knockout mice and their littermate controls. Results: Microarray screening for genes differentially expressed in the inflamed synovium, the key target of the disease process in RA, revealed a prominent and disease-specific B cell/plasma cell signature with the B cell-specific transcriptional co-activator Bob and its transcriptional target BCMA among the most upregulated genes. Validation by RT-qPCR on two independent cohorts representing early and established arthritis confirmed microarray data and demonstrated elevated expression of Bob and BCMA not only in established RA, but also at the early phase of the disease. Quantitative evaluation of immunohistochemical stainings of synovial tissue with monoclonal antibody for Bob revealed significant increase in Bob positive cells in RA synovium (p<0.0). Next we determined whether lack of functional Bob modifies disease onset or severity in CIA. Interestingly, the results showed that Bob / mice were fully resistant to CIA induction compared to their wild-type littermates. This remarkable protection from CIA is explained by failure to produce pathogenic anti-collagen autoantibodies in the absence of Bob. In contrast, Bob / mice were susceptible to MOG protein induced EAE and incidence and severity of clinical disease were not altered in these mice comparing to wild-type littermates, suggesting that absence of Bob does not impact on antigen-presentation/costimulatory capacity of B cells. Conclusion: The specific increase in Bob expressing cells in RA synovitis and the resistance of Bob-defecient mice to development of CIA indicate that Bob/BCMA axis may contribute to humoral autoimmunity in RA. The relationship between an aberrant Bob expression and the break of peripheral tolerance in RA is currently under investigation. Disclosure: N. Yeremenko, None; T. Cantaert, None; M. N. van Tok, None; I. Gofita, None; J. D. Canete, None; P. P. Tak, None; H. Spits, None; D. L. Baeten, None. :5 PM 454. Expression of TLR5 Strongly Correlates with Levels of TNF-a and DAS8 in RA Monocytes and Ligation of TLR5 Induces Angiogenesis in RA Nathan D. Chamberlain, Michael Volin, Olga M. Vila, Shiva Arami, Suncica Volkov and Shiva Shahrara, University of Illinois at Chicago, Chicago, IL, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL Background/Purpose: This study was performed to determine whether expression of TLR5 is associated with Rheumatoid Arthritis (RA) disease activity as well as to examine the role of TLR5 ligation in the pathogenesis of RA. Methods: Expression of TLR5 was determined in RA and normal (NL) PB monocytes and in vitro differentiated macrophages by 00 0 Program Book

103 real-time RT-PCR and/or flow cytometry. Next, linear regression analysis was employed to correlate expression of TLR5 with levels of TNF-a and DAS8 score in RA monocytes from 4-48 patients. Finally, the mechanism by which TLR5 ligation mediates RA pathogenesis was determined by endothelial chemotaxis and tube formation. Results: We performed microarray studies to identify differentially regulated genes in RA synovial fluid macrophages from active patients and identified Toll like receptor (TLR)5 as one of the most highly upregulated genes in RA synovial fluid macrophages compared to normal macrophages. Using realtime RT-PCR and FACS analysis we confirmed that expression of TLR5 is significantly elevated in RA synovial fluid macrophages (5 fold) and RA monocytes (7 fold) compared to normal counterpart cells. Interestingly, we found that blockade of TLR5 on RA peripheral blood (PB) monocytes greatly reduces RA synovial fluid mediated TNF-a transcription by 80% suggesting that there are endogenous TLR5 ligands expressed in the RA synovial fluid that are crucial for joint TNF-a modulation. Since TNF-a stimulation is also capable of upregulating TLR5 levels there is a positive feedback modulation in RA monocytes between TNF-a and TLR5 ligation and expression. We found that patients with higher expression of TNF-a expressed elevated levels of TLR5 (R =0.79, p=.6x0-7 ) in RA monocytes and the concentrations of TLR5 and TNF-a strongly correlated with increased disease activity as determined by examination of 8 defined joints (DAS8) (correlation of TLR5 with DAS8; R =0.75) (correlation of TNF-a with DAS8; R =0.58). Since our previous studies demonstrated that TLR5 expression is elevated on RA synovial tissue endothelial cells compared to control tissue we asked whether ligation of this receptor induces angiogenesis and if TLR5 endogenous ligands present in RA synovial fluid play a role in this process. We found that when endothelial cells were exposed to a dose response of flagellin, a TLR5 agonist, migration of endothelial cells was induced at concentrations ranging from 0. to 00 ng/ml (p<0.05). Further, incubation of endothelial cells with neutralizing antibody to TLR5 significantly suppressed RA synovial fluid endothelial migration and tube formation suggesting that the RA synovial fluid contains TLR5 endogenous ligands that are chemotactic for TLR5+ endothelial cells. Conclusion: Our observations highlight that there is a strong correlation between TNF-a and TLR5 expression with disease activity in RA monocytes suggesting that TLR5 may be a TNF-a responsive gene that is linked to RA progression through induction of angiogenesis. Disclosure: N. D. Chamberlain, None; M. Volin, None; O. M. Vila, None; S. Arami, None; S. Volkov, None; S. Shahrara, None. ACR SESSIONS :00 AM - :0 PM explain the potential influence of the commensal microflora and local and systemic immune responses communicate that systemic autoimmunity may be associated with differences in commensal microflora :00 AM Influence of the Microbiome in Immune Responsiveness Charles O. Elson, MD :0 AM The Microbiome in Gut Immunity and Inflammatory Bowel Disease Susan Lynch, PhD Noon The Oral and Intestinal Microbiome in Rheumatoid Arthritis Jose U. Scher, MD Hall D Polymyalgia Rheumatica - Recent Advances and Ongoing Questions Moderators: Curry L. Koening, MD, MS and Carol A. Langford, MD, MHS Upon completion of this session, participants should be able to: recognize the clinical symptoms and diagnostic approach to polymyalgia rheumatica describe the relationship between polymyalgia rheumatica and giant cell arteritis identify treatment strategies in polymyalgia rheumatica, particularly with regards to glucocorticoid dosage and duration :00 AM Classification, Diagnosis, and Imaging of Polymyalgia Rheumatica Eric L. Matteson, MD, MPH :0 AM What is the Relationship between Polymyalgia Rheumatica and Giant Cell Arteritis? Maria C. Cid, MD Noon Treatment of Polymyalgia Rheumatica: Options and Duration of Therapy Carlo Salvarani, MD 0 B Top 0 Compliance Risks Facing Physicians PS Moderator: Alan R. Erickson, MD Speaker: Robert W. Liles, JD TUESDAY November, 0 Renaissance Washington - Grand Ballroom North Microbiome Influence on Autoimmunity Moderator: Steven B. Abramson, MD Upon completion of this session, participants should be able to: describe the close interconnection between commensal microflora and immune system development Upon completion of this session, participants should be able to: identify the greatest risks areas in physician practices and the increase in targeted health care fraud enforcement efforts by the government s Health Care Fraud Prevention and Enforcement Action Team (HEAT) discuss the growing risk of private contractor reviews of Medicare claims to identify outliers and payment fraud 0 Program Book 0

104 identify tracking mechanism to respond timely to auditors for additional documentation requests recognize the new targeted reviews of EMR cloned notes and documentation that are triggering audits ARHP NETWORKING EVENT Noon - :00 PM Renaissance Washington - Congressional Hall B Networking Break All ARHP attendees are invited to an informal networking event. Bring your lunch and enjoy an opportunity to meet with health professionals. Soft drinks will be provided. This session is not eligible for CME credit. 58 B * Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (077) Speaker: Maria Dall Era, MD 59 A * Systemic Lupus Erythematosus: Lupus Nephritis (078) Speaker: Brad H. Rovin, MD 59 B Temporal Arteritis (079) Speaker: Gene G. Hunder, MD TUESDAY November, 0 ACR MEET THE PROFESSOR SESSIONS :45 - :5 PM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September *Basic Immunology for Clinical Rheumatologists (07) Speaker: Antony Rosen, MD 5 Fibromyalgia and Dysautonomia (07) Speaker: Manuel Martinez-Lavin, MD 54 A Myopathy: Issues in Diagnosis and Treatment (07) Speaker: Lisa Christopher-Stine, MD, MPH 54 B Rheumatoid Arthritis: Challenging Cases (074) Speaker: Jonathan Kay, MD 55 * Rheumatoid Arthritis: Safety of Novel Therapies (075) Speaker: Lee S. Simon, MD 58 A Systemic Lupus Erythematosus: Central Nervous System (076) Speaker: Cynthia Aranow, MD 60 Vasculitis: Update (080) Speaker: Paul A. Monach, MD, PhD ACR SESSIONS :00 - :00 PM Hall D Catastrophic Antiphospholipid Syndrome (Clinical Review) Moderator: Fernando E. Figueroa, MD Speaker: Doruk Erkan, MD Upon completion of this session, participants should be able to: review the current classification criteria for catastrophic antiphospholipid syndrome analyze proposed diagnostic algorithms for catastrophic antiphospholipid syndrome describe current treatment guidelines for catastrophic antiphospholipid syndrome Ballroom B Osteoimmunology Moderator: S. Louis Bridges Jr., MD, PhD Speaker: Georg A. Schett, MD, PhD Upon completion of this session, participants should be able to: describe the relationship between osteoclasts and the immune system identify inflammation-associated changes in bone homeostasis appreciate the mechanisms of bone destruction in rheumatoid arthritis and other forms of inflammatory arthritis ACR STUDY GROUPS :00 - :00 PM Study Groups are non-cme activities, open to all attendees. 04 A A Primer on Educational Theory for Medical Educators 06 Capillaroscopy in Rheumatic Diseases 0 0 Program Book

105 07 A Crystal Group 46 C Decision Aids 40 A Latin American 0 B Lupus 49 A Synovial Fluid Analysis and Crystal Identification (7) Speakers: Brian F. Mandell, MD, PhD, Lan Chen, MD, PhD, and Gilda M. Clayburne, MLT 49 B Web-based Tools for Enhancing and Managing Teaching and Clinical Practice (8) Speaker: Laura E. Ray, MA 0 Magnetic Resonance Imaging ACR SESSION :0 - :0 PM 47 A Polymyalgia Rheumatica 45 A Scleroderma Biomarkers 50 B Shaping the Future of Psoriatic Disease Care: Current Controversies and Progress 4 A Sjögren s Syndrome 5 A Veterans Affairs Rheumatology ACR/ARHP WORKSHOPS :5 - :5 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September C Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (5) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD 44 B MRI in the Diagnosis and Management of Spondylarthritis: A Clinician s Guide (6) Speakers: Walter P. Maksymowych, MD Ballroom A ACR Leadership Town Hall Meeting & Business Meeting This session is not eligible for CME Credit. Moderator: James R. O Dell, MD Upon completion of this session, participants should be able to: have interacted with ACR leadership by asking questions and voicing concerns recognize ACR initiatives summarize what the ACR is doing to address various practice and other issues :0 PM Leadership Town Hall Meeting James R. O Dell, MD, Audrey B. Uknis, MD, Joseph Flood, MD, E. William St.Clair, MD, David I. Daikh, MD, PhD, Benjamin J. Smith, PA-C and David G. Borenstein, MD :00 PM Business Meeting James R. O Dell, MD, Audrey B. Uknis, MD, Joseph Flood, MD, E. William St.Clair, MD, David I. Daikh, MD, PhD, Benjamin J. Smith, PA-C and David G. Borenstein, MD ACR SESSIONS :0-4:00 PM Hall E Approach and Management of Back Pain in Older Adults PM Moderator: Una E. Makris, MD Upon completion of this session, participants should be able to: review the painful structures associated with back pain in older persons describe the epidemiological differences, including impact, of back pain in younger vs. older adults discuss the approach to diagnosis of back pain in older adults discuss the pharmacological, non-pharmacological, and surgical management of back pain in older adults :0 PM Where Does the Pain Come From? A Surgeon s Perspective on Back Pain in Older Adults A. Jay Khanna, MD TUESDAY NOVEMBER, 0 0 Program Book 0

106 TUESDAY November, 0 :5 PM Back Pain in Older Adults: Fundamental Differences Between Younger and Older Adults and How Our Approach/ Management Should Differ David G. Borenstein, MD Hall D Connective Tissue Disease Associated Interstitial Lung Disease Moderators: Jessica K. Gordon, MD, MSc and Robert F. Spiera, MD Upon completion of this session, participants should be able to: describe basic pathophysiologic principles underlying interstitial lung disease in association with connective tissue diseases explain diagnostic and therapeutic approaches to these patients and evolving concepts in such approaches :0 PM Connective Tissue Disease Associated Interstitial Lung Disease- Clinical and Pathological Aspects Aryeh Fischer, MD :00 PM Connective Tissue Disease Associated Interstitial Lung Disease: Approach to Therapy Richard M. Silver, MD :0 PM Interstitial Lung Disease Associated Secondary Pulmonary Hypertension: Implications for Diagnosis and Treatment Stephen C. Mathai, MD, MHS 5 A New Molecules in Joint Biology Moderator: Anne-Marie Malfait, MD, PhD Upon completion of this session, participants should be able to: describe form and function of extracellular matrix molecules, with emphasis on novel molecules or roles in joint homeostasis review newly discovered mutations in TRPV4 that cause an inherited arthropathy of hands and feet discuss sclerostin biology in bone and cartilage recognize implications for the pathogenesis of age- and injuryrelated osteoarthritis :0 PM Proteoglycans and More- From Molecules to Biology of Articular Cartilage Dick Heinegard, PhD :00 PM A Role for TRPV4 in Cartilage Homeostasis Shireen Lamande, PhD :0 PM Sclerostin in Bone and Cartilage Di Chen, MD, PhD 50 B Visualizing the Immuno-inflammatory Response Moderator: Andrew P. Cope, MD, PhD :0 PM The Immunological Synapse and its Aberrations in Inflammatory Disease Alexandra Zanin-Zhorov, PhD :00 PM In vivo Imaging of Immunity and Infection Paul Garside, PhD :0 PM The Dynamics of Monocyte Migration in Immune-mediated Inflammatory Disease in Humans Danielle M. Gerlag, MD ACR CONCURRENT ABSTRACT SESSIONS :0-4:00 PM Ballroom A ACR Late-breaking Abstract Session Moderator: Chester V. Oddis, MD 47 A Antiphospholipid Syndrome Moderators: Pier Luigi Meroni, MD and Roger Levy, MD :0 PM 455. Establishment of Standardized International Units for IgG Anti-βglycoprotein Antibody Measurement Rohan Willis, Claudia Grossi, Gabriella Lakos, Pier Luigi Meroni 4, Maria Borghi, Luis R. Lopez 5, Corina Dima 6, Marius C. Teodorescu 7, Nicholas Ozarka 7, Matthias Kast 8, Nina Olschowka 8, Alfredo Villarreal 9, Maria Crisostomo 0, Mike Watkins 9, Wendy Vandam, Tony Prestigiacomo 0, Josep Puig, Kerrie Jaskal, Roger Walker 0, Sarah Paul 9, T. Buckner 4, Fernando S. Cavalcanti and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, INOVA Diagnostics, Inc., San Diego, CA, 4 Division of Rheumatology - Istituto G. Pini, University of Milan, Milano, Italy, 5 Corgenix Inc, Broomfield, CO, 6 Theratest Laboratories Inc, Lombard, IL, 7 TheraTest Laboratories Inc, Lombard, IL, 8 Phadia Thermofisher, Freiburg, Germany, 9 Bio-Rad Laboratories, Benicia, CA, 0 Bio-Rad Laboratories, Hercules, CA, Bio-Rad Laboratories, Hercules, Biokit, Barcelona, Spain, Instrumentation Laboratories, Bedford, MA, 4 Corgenix, Broomfield, CO :45 PM 456. Pro-Inflammatory and Pro-Thrombotic Markers in Persistently Antiphospholipid Antibody-Positive Patients with/ without Systemic Lupus Erythematosus Gurjot Basra, Doruk Erkan, Rohan Willis, JoAnn Vega, Ana Laura Carrera Marin, Patricia Ruiz Limon, Vijaya L. Murthy, Shraddha Jatwani, Neha Dang, Emilio B. Gonzalez and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, Hospital for Special Surgery, New York, NY 04 0 Program Book

107 :00 PM 457. An Open-Label Prospective Pilot Mechanistic Study of Fluvastatin in Persistently Antiphospholipid Antibody-Positive Patients Doruk Erkan, Rohan Willis, JoAnn Vega, Vijaya L. Murthy, Ana Laura Carrera Marin, Gurjot Basra, Patricia Ruiz Limon, Emilio B. Gonzalez and Silvia S. Pierangeli, Hospital for Special Surgery, New York, NY, University of Texas Medical Branch, Galveston, TX :5 PM 458. The Estimated Prevalence of Antiphospholipid Antibodies in General Population Patients with Pregnancy Loss, Stroke, Myocardial Infarction, and Deep Vein Thrombosis Laura Andreoli, Alessandra Banzato, Cecilia B. Chighizola, Guillermo J. Pons-Estel 4, Guilherme Ramires de Jesus 5, Michael D. Lockshin 6, Doruk Erkan 6 and On Behalf of APS Action 7, Rheumatology and Clinical Immunology, University of Brescia, Brescia, Italy, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, Istituto Auxologico Italiano, University of Milan, Milan, Italy, 4 Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 5 Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 6 Hospital for Special Surgery, New York, NY, 7. :0 PM 459. Efficacy of Aspirin for the Prevention of the First Thrombo-Embolic Events in Patients with Antiphospholipid Antibodies: A Metanalysis of Literature Data Laurent Arnaud, Alexis Mathian, Amelia Ruffatti, Maria Tecktonidou, Ricard Cervera 4, Ricardo Forastiero 5, Vittorio Pengo 6, Marc Lambert 7, Stephane Zuily 8, Denis Wahl 8 and Zahir Amoura, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padua, Padua, Italy, First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, 4 Hospital Clínic of Barcelona, Barcelona, Spain, 5 Favaloro University, Argentina, 6 Clinical Cardiology, Department of Cardiac Thoracic and Vascular Sciences, University of Padova, Padova, Italy, 7 Internal Medicine Department, Universitary hospital, Lille, France, 8 Nancy University Hospital, Université de Lorraine & INSERM U96, Vandoeuvre-Les-Nancy, France :45 PM 460. Dual Antiplatelet Therapy As Prophylaxis of Recurrent Arterial Thrombosis in Patients with antiphospholipid Syndrome Yuichiro Fujieda, Olga Amengual, Toshiyuki Watanabe, Michihito Kono, Yusaku Kanetsuka, Takashi Kurita, Toshio Odani, Kotaro Otomo, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Hokkaido University, Sapporo, Japan 0 B Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease Moderators: Kaleb Michaud, PhD and Elena Losina, PhD :0 PM 46. Cost-Effectiveness of Systemic Therapies for Acute Gouty Arthritis Kimberly Reiter, Jeremy Goldhaber-Fiebert and Eswar Krishnan, Stanford University School of Medicine, Palo Alto, CA, Stanford, Stanford, CA, Stanford University, Stanford, CA :45 PM 46. Projecting the Direct Cost Burden of Osteoarthritis in Canada Using a Population-Based Microsimulation Model From [00-0] Behnam Sharif, Jacek A. Kopec, Mushfiqur Rahman, Nick Bansback, Eric C. Sayre, Philippe Finès, Hubert Wong and Aslam H. Anis, Arthritis Research Centre of Canada, Vancouver, BC, St Paul s Hospital, University of British Columbia, Vancouver, V6Z Y6, Canada, Vancouver, BC, Statistics Canada, 50 Tunney s Pasture Driveway, Ottawa, ON, Canada, Ottawa, ON :00 PM 46. Cost-Effectiveness of Tocilizumab Monotherapy Vs. Adalimumab Monotherapy in the Treatment of Severe Active Rheumatoid Arthritis Josh J. Carlson, Sarika Ogale, Fred Dejonckheere and Sean Sullivan, University of Washington, Seattle, WA, Genentech, South San Francisco, CA, F. Hoffmann-La Roche Ltd, Basel, Switzerland :5 PM 464. Cost-Sharing and Utilization of Biologic and Non-Biologic Dmards Among U.S. Medicare Beneficiaries with Rheumatoid Arthritis Chris Tonner, Gabriela Schmajuk and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA :0 PM 465. Seroresponse Rates After Influenza Vaccination in Rheumatoid Arthritis Patients Treated with Biological Agents During the 0 0 Flu Season Masatoshi Hayashi, Toshihisa Kojima, Naoki Ishiguro, Tomonori Kobayakawa and Toshihisa Kanamono, Nagano Red Cross Hospital, Nagano, Japan, Nagoya Univeristy, School of Medicine, Nagoya, Japan, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan :45 PM 466. Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: The OTIS Autoimmune Diseases in Pregnancy Project Christina D. Chambers, Diana L. Johnson, Yunjun Luo, Janina L. Jimenez, Nicole Mirrasoul, Elizabeth Salas, Kenneth Lyons Jones and OTIS Research Group, University of California, San Diego, La Jolla, CA, La Jolla Renaissance Washington - Grand Ballroom North Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments Moderators: Tuhina Neogi, MD, PhD and Martin Englund, MD, PhD TUESDAY November, 0 0 Program Book 05

108 :0 PM 467. Tissue Lesions in Osteoarthritis Initiative Participants with Normal X-Rays and Risk Factors for Incident Cartilage Damage Leena Sharma, Ali Guermazi, Orit Almagor, Michel Crema, Dorothy D. Dunlop, Frank Roemer 4, Marc C. Hochberg 5, Charles Eaton 6, Joan M. Bathon 7, Rebecca D. Jackson 8, W.J. Mysiw 8, C. Kent Kwoh 9, Michael C. Nevitt 0 and Joan S. Chmiel, Northwestern University, Chicago, IL, Boston University School of Medicine, Boston, MA, Boston University, Boston, MA, 4 Klinikum Augsburg, Augsburg, Germany, 5 University of Maryland, Baltimore, MD, 6 Warren Alpert Medical School at Brown University, RI, 7 Columbia University Medical Center, New York, NY, 8 Ohio State University, Columbus, OH, 9 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 0 University of California-San Francisco, San Francisco, CA :45 PM 468. Incident Symptomatic Hip Osteoarthritis Is Associated with Differences in Hip Shape by Active Shape Modeling: The Johnston County Osteoarthritis Project Amanda E. Nelson, Felix Liu, John A. Lynch, Jordan B. Renner, Todd A. Schwartz 4, Nancy E. Lane 5 and Joanne M. Jordan, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, University of California at San Francisco, San Francisco, CA, University of North Carolina at Chapel Hill Dept of Radiology, Chapel Hill, NC, 4 University of North Carolina Gillings School of Global Public Health, Dept of Biostatistics, Chapel Hill, NC, 5 UC Davis School of Medicine, Sacramento, CA :0 PM 47. Oral Glucosamine Sulphate for the Prevention of Knee Osteoarthritis in Overweight Females; The First Ever Preventive Randomized Controlled Trial Jos Runhaar, Marienke van Middelkoop, Max Reijman, Edwin Oei, Dammis Vroegindeweij, Gerjo van Osch, Bart Koes and Sita Bierma-Zeinstra, Erasmus MC, Rotterdam, Netherlands, Maasstad Hospital, Rotterdam, Netherlands :45 PM 47. A Randomized, Multicentre, Double Blind, Placebo- Controlled Trial of Anti TNF Alpha (adalimumab) in Refractory Hand Osteoarthritis: The Dora Study Xavier Chevalier, Philippe Ravaud, Emmanuel Maheu, Gabriel Baron 4, Amandine Rialland 5, Philippe Vergnaud 6, Christian Roux 7, Yves Maugars 8, Denis Mulleman 9, Bernard Combe 0, Daniel Wendling, Pierre Laforgue, Damien Loeuille, Violaine Foltz 4 and Pascal Richette 5, Department of Rheumatology Hopital Henri Mondor, Créteil, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, AP-HP, St Antoine Hospital, Paris, France, 4 Epidemiology, Paris, France, 5 Unité de recherche clinique Henri Mondor, Créteil, France, 6 CCRB Synarc Lyon, Lyon, France, 7 CHU L Archet University Nice, Nice, France, 8 CHU Nantes, Nantes, France, 9 CHU Trousseau Tours, Tours, France, 0 Lapeyronie Hospital, Montpellier, France, Minjoz University Hospital, Besancon, France, CHU la conception Marseille, Marseille, France, CHU Brabois, Vandoeuvre les Nancy, France, 4 Pitié Salpétrière Hospital, Paris, France, 5 Lariboisière Hospital, Paris, France TUESDAY November, 0 06 :00 PM 469. A Virtual Knee Joint Replacement Clinical Endpoint Based On Longitudinal Trends and Thresholds in Koos Knee Pain and Function in Osteoarthritis Initiative Participants Robert M. Boudreau, David J. Hunter, Zhijie Wang, Frank Roemer 4, Felix Eckstein 5, Michael J. Hannon, Ali Guermazi 4 and C. Kent Kwoh 6, University of Pittsburgh, Pittsburgh, PA, University of Sydney, Sydney, Australia, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 Boston University School of Medicine, Boston, MA, 5 Paracelsus Medical University, Salzburg, Austria, 6 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA :5 PM 470. Does Structural Progression of Knee Osteoarthritis Measured with Magnetic Resonance Imaging or Radiography Predict Knee Replacement? - Data From the Osteoarthritis Initiative Felix Eckstein, C. Kent Kwoh, Robert M. Boudreau, Zhijie Wang 4, Michael J. Hannon 4, Wolfgang Wirth, Ali Guermazi 5, Frank Roemer 6, Michael C. Nevitt 7, Markus R. John 8, Leena Sharma 9, Jeffrey W. Duryea 0, David J. Hunter and Osteoarthritis Initiative Investigators, Paracelsus Medical University, Salzburg, Austria, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA, 5 Boston University, Boston, MA, 6 Klinikum Augsburg, Augsburg, Germany, 7 University of California-San Francisco, San Francisco, CA, 8 Novartis Pharma AG, Basel, Switzerland, 9 Northwestern University, Chicago, IL, 0 Brigham & Women, Boston, MA, University of Sydney, Sydney, Australia, San Francisco 0 Program Book 07 A Pediatric Rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus Erythematosus and Other Vasculitides Moderators: Emily von Scheven, MD and Karen Onel, MD :0 PM 47. A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate Nicolino Ruperto, Angela Pistorio, Sheila Oliveira, Rubén J. Cuttica, Angelo Ravelli, Michel Fischbach, Stefan Hagelberg, Tadej Avcin, Emanuel Cheuret, Fabrizia Corona, Gerard Couillault, Frank Dressler, Valeria Gerloni, Gary Sterba, Francesco Zulian, Maria Teresa Apaz, Adriana Cespedes-Cruz, Rolando Cimaz, Fabrizio De Benedetti, Pierre Quartier, Ricardo Russo, Nico Wulffraat, Simona Angioloni and Alberto Martini, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy :45 PM 474. Urine Biomarkers Distinguish Between Proliferative and Membranous Lupus Nephritis in Childhood Onset Systemic Lupus Erythematosus Rina Mina, Michael Bennett, Lining Qi, Shannen Nelson 4, Jessica Hummel 5, Pavel Shiyanov, John Schlager, Prasad Devarajan and Hermine I. Brunner 4, Cincinnati Children s Hospital Medical Center/University of Cincinnati, Cincinnati, OH, Cincinnati Children s Med Ctr, Cincinnati, OH, US Air Force Research Lab, Wright-Patterson Air Force Base, OH, 4 Cincinnati Children s Hospital, Cincinnati, OH, 5 Cincinnati Children s Hospital Medical Center, Cincinnati, OH

109 :00 PM 475. Cancer in Pediatric-Onset Systemic Lupus: What Is the Role of Disease Duration and Other Factors on Risk? Sasha Bernatsky, Ann E. Clarke, Jeremy Labrecque, Emily von Scheven, Laura E. Schanberg 4, Earl D. Silverman 5, Hermine I. Brunner 6, Kathleen A. Haines 7, Randy Q. Cron 8, Kathleen M. O Neil 9, Kiem Oen 0, Alan M. Rosenberg, Ciaran M. Duffy, Jennifer LF Lee, Mruganka Kale, Elizabeth M. Turnbull and Rosalind Ramsey-Goldman 4, McGill University, Montreal, QC, Research Institute of the McGill Univ. Health Ctre, Montreal, QC, UC San Francisco, San Francisco, CA, 4 Duke University Medical Center, Durham, NC, 5 PRSCG, Cincinnati, OH, 6 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 7 Hackensack Univ Med Ctr, Hackensack, NJ, 8 Univ of Alabama-Birmingham, Birmingham, AL, 9 Okla Univ Health Science Ctr, Oklahoma City, OK, 0 University of Manitoba, Winnipeg, MB, Royal University Hospital, Saskatoon, SK, Children s Hospital of Eastern Ontario, Ottawa, ON, RI McGill Univ Health Ctr, Montreal, QC, 4 Northwestern University Feinberg School of Medicine, Chicago, IL :5 PM 476. Role of Whole-Body Magnetic Resonance Imaging in the Assessment of Disease Activity in Juvenile Dermatomyositis. A Pilot Study. Clara Malattia, Annalisa Madeo, Silvia Pederzoli, Anna Providenti, Marta Mazzoni, Agnese Beltramo, Alessandro Consolaro, Stefania Viola, Antonella Buoncompagni and A. Martini, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, Istituto G Gaslini, Genova, UO Fisioterapia, Genova, Italy :0 PM 477. The Comparison of Childhood Polyarteritis Nodosa and Cutaneous Polyarteritis Nodosa and a New Set of Diagnostic Criteria for Cut-Polyarteritis Nodosa Erkan Demirkaya, Seza Ozen, Turker Turker, Rubén J. Cuttica, Paul Brogan, Pierre Quartier, Jordi Anton, Nuray Aktay Ayaz, Stella Maris Garay, Graciela Espada, Raju Khubchandani, Francesco Zulian, Arvind Bagga, Alexandre Belot, Clovis Artur Silva, Sulaiman Al-Mayouf, Amparo Ibanez Estrella, Sheila Oliveira, Cengizhan Acikel, Claudia Saad-Magalhães, Alberto Martini and Nicolino Ruperto, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy :45 PM 478. Identification of Disease-Specific Neuroimaging Phenotypes in Childhood Inflammatory Brain Diseases Tania Cellucci, Pascal N. Tyrrell, Shehla Sheikh, Suzanne Laughlin and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON Ballroom B Rheumatoid Arthritis - Clinical Aspects IV: Nonbiologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events Moderators: Jonathan Kay, MD and Neal S. Birnbaum, MD :0 PM 479. Rheumatoid Arthritis Does Not Increase Risk of Short Term Total Knee Replacement (TKR) Adverse Events (AE) Zachary J. LoVerde, Lisa A. Mandl, Beverly K. Johnson, Mark P. Figgie, Friedrich Boettner and Susan M. Goodman, New York Medical College, Valhalla, NY, Hospital for Special Surgery, New York, NY :45 PM 480. Disease-Modifying Antirheumatic Drug Use and Toxicities Among Elderly Patients with Rheumatoid Arthritis Rebecca L. Manno, Dimitrios A. Pappas, Katherine C. Saunders, George Reed 4, Shannon Grant 5 and Clifton O. Bingham III, Johns Hopkins University, Baltimore, MD, Columbia University, College of Physicians & Surge, New York, NY, CORRONA, Inc., Southborough, MA, 4 UMass Medical School, Worcester, MA, 5 Axio Research LLC, Seattle, WA :00 PM 48. Time Trends in Corticosteroid Use in Rheumatoid Arthritis: Results From a Population Based Inception Cohort Vs Ashima Makol, John M. Davis III, Cynthia S. Crowson, Terry M. Therneau, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, Rochester, MN :5 PM 48. Hydroxychloroquine Has Lipid-Lowering Effects in US Veterans with Rheumatoid Arthritis Nicole A. Kieffer, Gail S. Kerr, J. Steuart Richards, Lisa A. Davis 4, Liron Caplan 5, Jeffrey Huang 6, Grant W. Cannon 7, Harlan Sayles 8 and Kaleb Michaud 9, Georgetown University, Washington, DC, Washington DC VAMC, Georgetown and Howard University, Washington, DC, Washington DC VA and Georgetown University, Washington, DC, 4 Denver VA and Univ of Colorado School of Med, Aurora, CO, 5 Denver VA and Univ of Colorado School of Medicine, Aurora, CO, 6 Washington DC VA and Howard University Hospital, Washington, DC, 7 George E. Wahlen VA Medical Center, Salt Lake City, UT, 8 University of Nebraska Medical School, Omaha, NE, 9 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE :0 PM 48. Folic Acid Pathway Single Neucelotide Polymorphisms Associated with Methotrexate-Related Significant Adverse Events Lisa A. Davis, Brooke Ivan Polk, Alyse D. Mann, Roger K. Wolff 4, Gail S. Kerr 5, Andreas M. Reimold 6, Grant W. Cannon 7, Ted R. Mikuls 8 and Liron Caplan 9, Univ of Colorado School of Med, Aurora, CO, University of Colorado Medical School, Aurora, CO, Denver VA Medical Center, Denver, CO, 4 University of Utah, Salt Lake City, UT, 5 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 6 Dallas VA and University of Texas Southwestern, Dallas, TX, 7 George E. Wahlen VA Medical Center, Salt Lake City, UT, 8 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 9 Denver VA and University of Colorado School of Medicine, Aurora, CO :45 PM 484. Hepatic Steatosis in Rheumatoid Arthritis: Associations with Disease Characteristics, Pharmacotherapies, and Atherosclerosis Jon T. Giles and Joan M. Bathon, Columbia University Medical Center, New York, NY 0 Program Book 07 TUESDAY November, 0

110 TUESDAY November, 0 08 Ballroom C Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase (JAK) Inhibitors Moderators: Daniel Aletaha, MD, MSc and Martin Aringer, MD :0 PM 485. Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 0 versus 5mg Twice Daily in a Pooled Phase and Long-Term Extension Rheumatoid Arthritis Population S. Cohen, S. Krishnaswami, B. Benda, R. Riese, M.G. Boy, D. Gruben, G. Wallenstein, C. A. Mebus, S. H. Zwillich and J. D. Bradley, Metroplex Clinical Research Centre, Dallas, TX, Pfizer Inc., Groton, CT, Pfizer Inc., Collegeville, PA :45 PM 486. Radiographic, Clinical and Functional Comparison of Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis Eun Bong Lee, Roy M. Fleischmann, Stephen Hall, Ronald F. van Vollenhoven 4, John Bradley 5, David Gruben 5, Tamas Koncz 6, Sriram Krishnaswami 5, Gene Wallenstein 5, Samuel H. Zwillich 5, Bethanie E. Wilkinson 5 and the ORAL Start Investigators 7, Seoul National University, Seoul, South Korea, Metroplex Clinical Research Center, Dallas, TX, Cabrini Health and Monash University, Melbourne, Australia, 4 Karolinska Institute, Stockholm, Sweden, 5 Pfizer Inc., Groton, CT, 6 Pfizer Inc., New York, NY, 7 Groton, CT :00 PM Week Results of a Blinded Phase b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase / Januse Kinase Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Mark C. Genovese, Edward Keystone, Peter Taylor, Edit Drescher 4, Pierre-Yves Berclaz 5, Chin H. Lee 5, Douglas E. Schlichting 5, Scott D. Beattie 5, Rosanne K. Fidelus-Gort 6, Monica E. Luchi 6 and William Macias 5, Stanford University Medical Center, Palo Alto, CA, University of Toronto, Toronto, ON, University of Oxford, Oxford, United Kingdom, 4 Veszprém Csolnoky Ferenc County Hospital, Department of Rheumatology and Physical Rehabilitation, Veszprém, Hungary, 5 Eli Lilly and Company, Indianapolis, IN, 6 Incyte Corporation, Wilmington, DE :5 PM 488. Magnetic Resonance Imaging Substudy in a Phase b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase /Janus Kinase Inhibitor, in Combination with Traditional Disease- Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis Charles G. Peterfy, Paul Emery, Mark C. Genovese, Edward Keystone 4, Peter Taylor 5, Pierre-Yves Berclaz 6, Julie C. DiCarlo, Chin H. Lee 6, Douglas E. Schlichting 6, Scott D. Beattie 6, Monica E. Luchi 7 and William Macias 6, Spire Sciences LLC, Kentfield, CA, University of Leeds, Leeds, United Kingdom, Stanford University Medical Center, Palo Alto, CA, 4 University of Toronto, Toronto, ON, 5 University of Oxford, Oxford, United Kingdom, 6 Eli Lilly and Company, Indianapolis, IN, 7 Incyte Corporation, Wilmington, DE 0 Program Book :0 PM 489. Selective JAK Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG064 Frédéric Vanhoutte, Minodora Mazur, Annegret Van der Aa, Piet Wigerinck and Gerben van t Klooster, Galapagos NV, Mechelen, Belgium, State Medical and Pharmaceutical University Nicolae Testemitanu, Chisinau, Moldova :45 PM 490. Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis K. L. Winthrop, H. Valdez, E. Mortensen, R. Chew 4, S. Krishnaswami 4, T. Kawabata 4 and R. Riese 4, Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, Pfizer Inc., New York, NY, Pfizer Inc., Collegeville, PA, 4 Pfizer Inc., Groton, CT Salon B Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, Etiology Moderators: Shervin Assassi, MD, MS and Dominique L. Baeten, MD, PhD :0 PM 49. IL-7 Expression Is Low in Psoriatic Arthritis Synovium Compared to Expression in Matched Skin Lesions Jennifer Belasco, Hiroshi Mitsui, Mayte Suarez-Farinas, James S. Louie, Nathan Wei, Nicholas Gulati and James G. Krueger, The Rockefeller University, New York, NY, UCLA School of Medicine, Los Angeles, CA, Arthritis Treatment Center, Frederick, MD :45 PM 49. Protective and Pathogenic Effects of the IL- Family of Cytokines in Spondyloarthropathy in SKG Mice Helen Benham, Linda Rehaume, Merja Ruutu, Jared Velasco, Kristine Kikly, Geoffrey Strutton, Michael McGuckin 4 and Ranjeny Thomas, Diamantina Institute University of Queensland, Brisbane, Australia, Biotechnology Discovery Research, Eli Lilly and Co., Indianapolis, Department of Pathology, Princess Alexandra Hospital, Brisbane, Australia, 4 Mater Medical Research Institute, Brisbane, Australia :00 PM 49. The Presence of HLA-B7 Shapes Gut Microbiome Composition in Rats Mary H. Bach, Russell N. Van Gelder, Joel D. Taurog and James T. Rosenbaum, University of Washington Medical Center, Seattle, WA, UT Southwestern Medical Center, Dallas, TX, Oregon Health & Science University, Portland, OR :5 PM 494. Incidence and Severity of Spondyloarthritis and Crohn s Ileitis Are Determined by Interaction Between the Microbiota and Genetic Susceptibility in Beta-Glucan-Treated SKG Mice Ranjeny Thomas, Linda Rehaume, Daniel Aguirre de Cárcer, Stan Mondot, Jared Velasco, Helen Benham, Merja Ruutu, Mark Morrison and Michael McGuckin, University of Queensland Diamantina Institute, Brisbane, Australia, CSIRO Livestock Industries, Brisbane, Australia, Mater Medical Research Institute, Brisbane, Australia

111 :0 PM 495. Dense Genotyping of Candidate Genes Identifies 6 New Susceptibility Loci in Ankylosing Spondylitis Adrian Cortes, Philip Robinson, International Spondyloarthritis Genetics Consortium and Matthew A. Brown, The University of Queensland Diamantina Insititute, Brisbane, Australia, Brisbane, Australia Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Division of AnatomoPathology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 4 Division of Nephrology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5 University of Sao Paulo, São Paulo, Brazil :45 PM 496. Elevated Serum Level of the Vascular Endothelial Growth Factor Is Highly Predictive for New Syndesmophytes Formation in Patients with Ankylosing Spondylitis Denis Poddubnyy, Kristina Conrad, Uta Syrbe, Hildrun Haibel, Heiner Appel, Martin Rudwaleit and Joachim Sieper, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, Endokrinologikum Berlin, Berlin, Germany, Charité Universitätesmedizin Berlin, Berlin, Germany 46 C Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II Moderators: Mary K. Crow, MD and Mariana J. Kaplan, MD :0 PM 497. Altered Circulating Follicular Helper T Cell Phenotype and Subset Composition Are Associated with Disease Activity in Patients with Systemic Lupus Erythematosus Hsi-en Ho, Jin Young Choi, Viviane M. Bunin, Sandra G. Pasoto, Solange Carrasco, Eduardo F. Borba, Celio R. Goncalves, Priscila R. Costa 4, Esper G. Kallas 4, Eloisa Bonfa and Joseph E. Craft, Yale University School of Medicine, New Haven, CT, Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, Universidade de São Paulo, Division of Rheumatology, Faculdade de Medicina, Sao Paulo, Brazil, 4 Universidade de São Paulo, Division of Immunology, Faculdade de Medicina, Sao Paulo, Brazil :45 PM 498. Biomarkers of Mitochondrial Dysfunction Correlate with Disease Activity in SLE Zhi-Wei Lai, Tiffany Telarico, Robert Hanczko, Adam Bartos, Lisa Francis, Hajra I. Tily 4, Ricardo Garcia, Maha M. Dawood 5, Jianghong Yu, Ashwini Shadakshari, Paul E. Phillips 6 and Andras Perl 7, SUNY, Syracuse, NY, SUNY Upstate Medical University, Syracuse, NY, SUNY upstate medical university, Syracuse, NY, 4 SUNY, NY, 5 SUNY Upstate, Syracuse, NY, 6 SUNY-Upstate Medical Univ, Syracuse, NY, 7 Upstate Medical University, Syracuse, NY :00 PM 499. The Peroxisome-Proliferator Activated Receptor-γ Agonist Pioglitazone Modulates Aberrant T-Cell Responses in Systemic Lupus Erythematosus Wenpu Zhao, Celine C. Berthier, Matthias Kretzler and Mariana J. Kaplan, University of Michigan, Ann Arbor, MI, University of Michigan, MI :5 PM 500. Podocyte Injury in Membranous and Proliferative Lupus Nephritis: Distinct Underlying Mechanisms? Gabriela M. Rezende, Vilma S. T. Viana, Denise M. Malheiros, Elaine P. Leon, Eduardo F. Borba, Neila AS Silva, Irene L. Noronha 4, Cleonice Silva 4 and Eloisa Bonfá 5, Division of :0 PM 50. Mirorna Mir-50 Contributes to Chronic Kidney Injury in Lupus Nephritis by Increasing the Synthesis of Fibrotic Proteins Via Downregulation of SOCS Hua Zhou, Sarfaraz A. Hasni, Mayank Tandon, Shyh-Ing Jang, Howard A. Austin, James E. Balow, Ilias Alevizos and Gabor G. Illei, NIDCR/NIH, Bethesda, MD, NIAMS/NIH, Bethesda, MD, NIDDK/NIH, Bethesda, MD :45 PM 50. Neutrophil Extracellular Trap-Associated Protein Activation of the Inflammasome Is Enhanced in Lupus M Macrophages J. Michelle Kahlenberg, Carolyne K. Smith, Carmelo Carmona- Rivera and Mariana J. Kaplan, University of Michigan, Ann Arbor, MI 04 A T-cell Biology and Targets in Autoimmune Disease Moderators: Cornelia M. Weyand, MD, PhD and George C. Tsokos, MD :0 PM 50. CD8+Foxp-CD0+ Regulatory T Cells Generated Ex Vivo with TGF-β Suppress Autoimmunity Through IL-0-Dependet Mechanism Ya Liu, An-Ping Xu, David A. Horwitz and Song G. Zheng, USC Keck School of Medicine, Los Angeles, CA, nd Affiliated Hospital of Sun Yat-sen University, Keck School of Medicine of USC, Los Angeles, CA :45 PM 504. SOCS Is One of the Key Molecules to Prevent the Plasticity of Regulatory T Cells and the Development of Autoimmunity Reiko Takahashi, Kenji Itoh, Fumihiko Kimura and Akihiko Yoshimura, National Defense Medical College, Tokorozawa, Japan, Keio University School of Medicine, Tokyo, Japan :00 PM 505. Involvment of CD4+ FoxP+ Regulatory T Cells in Interleukin-6 Receptor Targeted Treatment in Murine Arthritis and Rheumatoid Arthritis Allan Thiolat, Jerome Biton, Luca Semerano, Yves-Marie Pers, Pierre Portales, Delphine Lemeiter, Patrice Decker, Christian Jorgensen, Pascale Louis-Plence, Natacha Bessis and Marie-Christophe Boissier, EA4, LiP, University Paris, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP- HP), Bobigny, 9009, France, Bobigny, France, Inserm U844, CHU saint-eloi, Université Montpellier, CHU Lapeyronie, Montpellier, France 0 Program Book 09 TUESDAY November, 0

112 :5 PM 506. Expression of Helios Facilitates Distinction Between FoxP+ Treg and FoxP+ Activated T Conventional Cells in Patients with Systemic Lupus Erythematosus Amit Golding, Sarfaraz A. Hasni, Gabor G. Illei and Ethan M. Shevach 4, NIAID/National Institutes of Health, Bethesda, MD, National Institutes of Health, Bethesda, MD, NIDCR/ NIH, Bethesda, MD, 4 NIAID/NIH, Bethesda, MD :0 PM 507. Activated Cullin-Ring Ubiquitin Ligases (CRLs) Dampen T Cell Signaling and Inactivation of Crls Arrests the Progression of Inflammatory Arthritis Leonard L. Dragone, Lisa K. Peterson, Allison Berger and Samantha F. Friend, National Jewish Health, Denver, CO, Millennium Pharmaceuticals, Inc, Cambridge, MA :45 PM 508. mir4-p Interfers with T Cell Proliferation by Targeting the Expression of Garp in Patients with Rheumatoid Arthritis Qihui Zhou, Sonja Haupt, Johannes Thomas Kreuzer, Hendrik Schulze-Koops and Alla Skapenko, University of Munich, Munich, Germany ACR/ARHP COMBINED ABSTRACT SESSION :0-4:00 PM 0 ACR/ARHP Combined Epidemiology Abstract Session Moderators: Yuqing Zhang, DSc, MPH and Tuhina Neogi, MD, PhD of the McGill University Health Ctre, Montreal, QC, 4 Southlake Regional Health Centre, Newmarket, ON, 5 William Osler Health Center, Mississauga, ON :5 PM 5. Changes in Bone Marrow Lesion Volume Relate to Changes in Knee Pain. Data From the Osteoarthritis Initiative Jeffrey B. Driban, Lori Lyn Price, Grace H. Lo, Jincheng Pang, Eric Miller, Charles Eaton 4, John A. Lynch 5 and Timothy E. McAlindon, Tufts Medical Center, Boston, MA, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, Tufts University, Medford, MA, 4 Warren Alpert Medical School at Brown University, RI, 5 University of California at San Francisco, San Francisco, CA :0 PM 5. Association of Arthritis and Joint Pain with Accelerometer-Measured Physical Activity in Adults Aged 50 and Older in the United States: Findings From the National Health and Nutrition Examination Survey (00-004) Kathryn Remmes Martin, Dane Van Domelen, Matthew Pantell, Ming-yang Hung, Tamara B. Harris and Kushang Patel, NIA/NIH, Bethesda, MD, University of Washington, Seattle, WA :45 PM 54. Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population Aniket A. Kawatkar, Cecilia Portugal, Li-Hao Chu and Rajan Iyer, Kaiser Permanente Southern California, Pasadena, CA, Kaiser Permanente Southern California, Pasadena TUESDAY November, 0 :0 PM 509. Cost-Effectiveness of Training Rural Providers to Perform Joint Injections Michael J. Battistone, Richard E. Nelson, William D. Ashworth, Andrea Barker, Marissa Grotzke, Timothy A. Huhtala, Robert Z. Tashjian and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT :45 PM 50. Patient and Provider Factors Associated with Compliance with Rheumatoid Arthritis Treatment Recommendations Leslie R. Harrold, George W. Reed, Katherine C. Saunders, Ying Shan, Tanya Spruill 4 and Jeffrey D. Greenberg 5, UMass Medical School, Worcester, MA, University of Massachusetts Medical School, Worcester, MA, CORRONA, Inc., Southborough, MA, 4 NYU School of Medicine, New York, NY, 5 New York University School of Medicine, New York, NY :00 PM 5. Potential Barriers That Limit Access to Rheumatologists Among Patients with Early Rheumatoid Arthritis in a Universal Access Health Care System Jessica Widdifield, J. Michael Paterson, Sasha Bernatsky, Karen Tu, Nadia Gunraj, Noah Ivers, Debra Butt, R. Liisa Jaakkimainen, J. Carter Thorne 4, Vandana Ahluwalia 5 and Claire Bombardier, University of Toronto, Toronto, ON, Institute for Clinical Evaluative Sciences, Toronto, ON, Research Institute ARHP SESSIONS :0-4:00 PM 06 Myositis: Pathogenesis, Diagnosis and Management Moderator: Maura D. Iversen, BSc, DPT, SD, MPH Upon completion of this session, participants should be able to: review the pathogenesis of myositis versus other myopathies discuss the diagnostic approach to myositis including specific objective measures in the clinical setting, laboratory studies, imaging, electromyogram and muscle biopsy identify medications currently being used to treat myositis and emerging therapies summarize the therapeutic approach to myositis and identify specific precautions :0 PM Pathogenesis, Diagnosis and Medication Management of Myositis Dana P. Ascherman, MD :5 PM Exercise in Patients with Idiopathic Inflammatory Myopathies Helene Alexanderson, PhD, RPT 0 0 Program Book

113 45 A Rheumatic Disease Update: Systemic Lupus Erythematosus Moderator: James G. Freeman, MD Speaker: Michelle Petri, MD, MPH Upon completion of this session, participants should be able to: review current knowledge of the pathophysiology and biology of lupus discuss the major manifestations of lupus identify the recently recognized cardiovascular co-morbidities associated with lupus explain the use of laboratory testing in lupus explore the role for newer biological agents in the treatment of lupus 4 A Rheumatoid Arthritis Disease Activity Measures and Quality Indicators: Correct Use and Future Directions Moderator: Barbara A. Slusher, PA-C, MSW Upon completion of this session, participants should be able to: define the term disease activity in patients with rheumatoid arthritis describe the importance of the measuring disease activity in patients with rheumatoid arthritis describe measures of disease activity used in patients with rheumatoid arthritis apply the use of measures of disease activity to clinical scenarios describe quality indicators of rheumatoid arthritis discuss the role of quality inidcators in the health care system :0 PM Disease Activity Measures Arthur M. Mandelin II, MD, PhD :5 PM Quality Indicators Jeffrey R. Curtis, MD, MPH, MS ACR WORKSHOP 4:00-6:00 PM Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September C *Joint Injection Techniques (9) Speaker: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD Upon completion of this session, participants should be able to: discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures perform common joint and soft tissue injections on upper and lower extremities ARHP SESSION 4:0-5:0 PM 40 A Obesity: It IS a Chronic Disease Moderator: Thuy T. Beam, RN, BSN Speaker: Mary R. Ciccarelli, MD Upon completion of this session, participants should be able to: review secondary co-morbidities associated with obesity across the lifespan develop skills to communicate the importance of weight management develop strategies for self- management for the obese patient TUESDAY November, 0 40 A Transition Tools in Youth with Chronic Illness Moderator: Thuy T. Beam, RN, BSN Speaker: Mary R. Ciccarelli, MD Upon completion of this session, participants should be able to: develop an approach to supporting teens and young adults into adult care establish practice skills in motivational interviewing establish practical skills in the management and adherence of the teens and young adults ACR SESSIONS 4:0-6:00 PM Hall D Diagnostic Assessments in Myopathy Moderators: Christina Charles-Schoeman, MD and Chester V. Oddis, MD Upon completion of this session, participants should be able to: recognize the clinical and prognostic factors associated with the more recently identified autoantibodies in patients with myositis identify the nuances of interpreting an electromyogram report in patients presenting with myopathic features interpret accurately the muscle biopsy report received from a neuromuscular pathologist in patients with myopathy 0 Program Book

114 4:0 PM Clinical and Prognostic Correlations of Newly Identified Myositis-Associated Autoantibodies Hector Chinoy, MD, PhD 5:00 PM Electromyography for the Rheumatologist Devon I. Rubin, MD 5:0 PM Interpretation of the Muscle Biopsy Report in Patients with Myopathy David Lacomis, MD 4:40 PM Methods Used to Develop Appropriateness Criteria John Esdaile, MD, MPH 4:50 PM Overview of Literature Review John D. FitzGerald, MD, PhD 5:00 PM Presentation of Recommendations Timothy E. McAlindon, MD, MPH 5:40 PM Panel Discussion TUESDAY November, 0 Ballroom B MicroRNA and the Rheumatic Diseases Moderator: Richard M. Pope, MD Upon completion of this session, participants should be able to: identify the mechanisms regulating the expression and function of MicroRNA define the role of MicroRNA in innate and antigen specific inflammatory responses describe the role of MicroRNA in altered chondrocyte function in osteoarthritis 4:0 PM MicroRNA Control of Cellular Homeostasis: Basic Mechanisms Judy Lieberman, MD, PhD 5:00 PM MicroRNA in the Regulation of Innate and Adaptive Immunity Ryan M. O Connell, PhD 5:0 PM MicroRNA and the Regulation of Chondrocyte Gene Expression in Osteoarthritis Martin K. Lotz, MD Salon B Should Ultrasound be Used in Rheumatology Practice? Moderator: Timothy E. McAlindon, MD, MPH Upon completion of this session, participants should be able to: describe the capability of ultrasound scanning to image pathophysiological changes in and around joints and other anatomical sites pertinent to rheumatology practice identify how musculoskeletal ultrasound might be utilized in typical rheumatology practice assess the use of ultrasound in clinical management of rheumatic diseases with a balanced perspective on its risks and benefits identify when to use musculoskeletal ultrasonography in appropriate clinical scenarios 4:0 PM Possible Uses of Ultrasound in Rheumatology Practice Paul J. DeMarco, MD 46 C The Great Masqueraders: Malignancies in Rheumatic Disease Moderator: Zsuzsanna H. McMahan, MD, MHS Upon completion of this session, participants should be able to: describe the biologic mechanisms associated with neoplastic and paraneoplastic syndromes define the risks of malignancy in patients with rheumatic disease distinguish the features of occult malignancies that distinguish them from rheumatic diseases 4:0 PM Myositis Associated with Neoplastic and Paraneoplastic Syndromes Andrew L. Mammen, MD, PhD 5:00 PM Vasculitis Associated with Neoplastic and Paraneoplastic Syndromes Simon Carette, MD 5:0 PM Malignancies and Scleroderma Ami A. Shah, MD, MHS ACR CONCURRENT ABSTRACT SESSIONS 4:0-6:00 PM 0 Biology and Pathology of Bone and Joint: Regulation of Bone Cells Moderators: Antonios O. Aliprantis, MD and Tariq M. Haqqi, PhD 4:0 PM 55. Low Density Lipoprotein Receptor Deficiency Results in Osteophyte Formation During Experimental Osteoarthritis Which Is Enhanced Under High Cholesterol Conditions Wouter de Munter, Birgitte Walgreen, Monique M. Helsen, Annet W. Sloëtjes, Wim B. van den Berg and Peter L.E.M. van Lent, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 0 Program Book

115 4:45 PM 56. Adenosine Receptors Stimulate Bone Regeneration by Targeting Osteoclasts Aranzazu Mediero, Tuere Wilder and Bruce N. Cronstein, NYU School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 5:00 PM 57. Inhibition of Notch Signaling Increases the Severity of Experimental Osteoarthritis Neng-Yu Lin, Alfiya Distler, Christian Beyer, Clara Dees, Jingang Huang, Francesco Dell Accio 4, Oliver Distler 5, Georg A. Schett and Joerg HW Distler, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Erlangen-Nuremberg, Erlangen, Germany, 4 William Harvey Research Institute, Barts and the London Queen Mary s School of Medicine and Dentistry, Centre for Experimental Medicine and Rheumatology, London, United Kingdom, 5 Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland 5:5 PM 58. The Sphingosine--Phosphate Pathway Is a Key Regulator of Bone Substrate-Mediated Osteoclast Differentiation in Inflammatory Arthritis P. Edward Purdue, Jon Hill, Steven R. Goldring, Nikolaus, B. Binder, Jennifer L. Swantek 4, Zhenxin Shen 5, Tania N. Crotti 5, Gerald H. Nabozny 4 and Kevin P. McHugh 5, Hospital for Special Surgery, Weill Cornell Medical Center, New York, NY, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, Hospital for Special Surgery, New York, NY, 4 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 5 Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, MA 5:0 PM 59. IL-β and TNF-α Regulate the Global and Locus-Specific hydroxymethylation of Genomic DNA by Modulating the Expression and Activity of Tet- in Human OA Chondrocytes Abdul Haseeb and Tariq M. Haqqi, Case Western Reserve University, Cleveland, OH, Metro Health Medical Center, Cleveland, OH 5:45 PM 50. Suppressor of Cytokine Signaling Is Reduced in Obese Patients with Osteoarthritis and Regulates Leptin Responses in Chondrocytes Anna Koskinen, Katriina Vuolteenaho, Riku Korhonen, Teemu Moilanen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, Coxa Hospital for Joint Replacement, Tampere, Finland 4 A Innate Immunity and Rheumatic Disease Moderators: Diego Kyburz, MD and Mariana J. Kaplan, MD 4:0 PM 5. Immunoglobulin G Fc Receptor Activity in vivo Is Under Complement Control Eveline Y. Wu, Haixiang Jiang, C. Garren Hester and Michael M. Frank, Duke Univ Med Ctr, Durham, NC 4:45 PM 5. M-Ficolin, an Activator of the Complement System, Is the Strongest Predictor of Both DAS8 Remission and Low Disease Activity in a Cohort of 80 Early DMARD Naïve Rheumatoid Arthritis Patients Followed in the Opera-Study Christian G. Ammitzbøll, Jens Christian Jensenius, Torkell Ellingsen, Steffen Thiel, Kim Hørslev-Petersen 4, Merete L. Hetland 5, Peter Junker 6, Julia Johansen 7, Mikkel Østergaard 8, Jan Pødenphant 9 and Kristian Stengaard-Pedersen, Arhus University Hospital, Aarhus, Denmark, Aarhus University, Aarhus, Denmark, Silkeborg Regional Hospital, Silkeborg, Denmark, 4 University of Southern Denmark, Graasten, Denmark, 5 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, 6 Odense University Hospital, Odense, Denmark, 7 Glostrup Hospital, Glostrup, Denmark, 8 Copenhagen University Hospital Glostrup, Glostrup, Denmark, 9 Gentofte Hospital 5:00 PM 5. Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a Toll-Like Receptor and Interleukin- Driven Th7 Response Shahla Abdollahi-Roodsaz, Sabrina Garcia de Aquino, Marije I. Koenders, Fons A. van de Loo, Ger J. Pruijn, Mario J. Avila Campos 4, Fernando Q. Cunha 5, Joni A. Cirelli and Wim B. van den Berg, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Department of Diagnosis and Oral Surgery, Periodontic Division, Araraquara Dental School, Sao Paolo, Brazil, Radboud University Nijmegen, Nijmegen, Netherlands, 4 Department of Microbiology, Institute of Biomedical Sciences ICB/USP, Sao Paulo, Brazil, 5 Department of Pharmacology, School of Medicine of Ribeirao Preto, Sao Paolo, Brazil 5:5 PM 54. Snapin Is Critical for the Maturation of Autophagosome and Phagosome in Macrophages Bo Shi, Qiquan Huang, Robert Birkett, Renee E. Koessler, Andrea Dorfleutner, Christian Stehlik and Richard M. Pope, Northwestern University Feinberg School of Medicine, Chicago, IL 5:0 PM 55. Bruton s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants Linda M. Hartkamp, Inge E. van Es, Jay S. Fine, Michael Smith, John Woods, Satwant Narula, Julie DeMartino, Paul P. Tak and Kris A. Reedquist, Academic Medical Center, University TUESDAY November, 0 0 Program Book

116 of Amsterdam, Amsterdam, Netherlands, Hoffmann-La Roche, Nutley, NJ, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 5:45 PM 56. Bruton s Tyrosine Kinase and Calreticulin: A Novel Interaction with Implications for Inflammatory and Autoimmune Disease Jennifer C. Byrne, Joan Ní Gabhann, Kevin Stacey, Barbara M. Coffey, Eoghan M. McCarthy, Warren Thomas, Eamonn S. Molloy 4, Grainne M. Kearns and Caroline Jefferies, Royal College of Surgeons in Ireland, Dublin, Ireland, Beaumont Hospital, Dublin 9, Ireland, Royal College of Surgeons in Ireland, Dublin 9, Ireland, 4 Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland Laurent Arnaud, Hervé Devilliers, Stanford L. Peng, Zahir Amoura 4 and the RPDAI study group 5, Assistance Publique- Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, CHU Dijon, Dijon, France, Virginia Mason Medical Center, Seattle, WA, 4 CHU Pitié-Salpêtrière, Paris, France, 5 Paris 5:45 PM 5. Whole Transcriptome Analysis in Relapsing Polychondritis: A Single-Center Analysis of 5 Patients Laurent Arnaud, Alexis Mathian, Bruno Faivre, Karim Dorgham, Julien Haroche, Nathalie Costedoat-Chalumeau, Jean-Charles Piette, Guy Gorochov and Zahir Amoura, Hôpital Pitié-Salpêtrière, AP-HP & UPMC Univ Paris 06, Paris, France, Institut National de la Santé et de la Recherche Médicale, INSERM UMR-S 945, Paris, France TUESDAY November, 0 45 A Miscellaneous Rheumatic and Inflammatory I Moderators: W. Winn Chatham, MD and Richard M. Keating, MD 4:0 PM 57. Prozone Phenomenon Leads to Low IgG4 Concentrations in IgG4-Related Disease Arezou Khosroshahi, Lynn A. Cheryk, Mollie Carruthers, Judith A. Edwards, Donald B. Bloch and John H. Stone, Massachusetts General Hospital, Boston, MA, Mayo Medical Laboratories, Andover 4:45 PM 58. Hypertrophic Pachymeningitis: IgG4-Related Disease Is A Common Etiology Zachary S. Wallace, Mollie Carruthers, Arezou Khosroshahi, Robert Carruthers, Shweta Shinagare, Anat Stemmer- Rachamimov, Vikram Deshpande and John H. Stone, Massachusetts General Hospital, Boston, MA 5:00 PM 59. Molecular Mechanism of IgG4 Class Switch Recombination in IgG4-Related Disease Hiroto Tsuboi, Mana Iizuka, Hiromitsu Asashima, Sayaka Tsuzuki, Yuya Kondo, Akihiko Tanaka, Masafumi Moriyama, Isao Matsumoto, Seiji Nakamura and Takayuki Sumida, University of Tsukuba, Tsukuba, Japan, Kyushu University, Fukuoka, Japan 5:5 PM 50. Anti-Ribosomal P Antibodies in a Large Cohort of Autoimmune Hepatitis with No Evidence of Lupus: A Common Underlying Mechanism Targeting Liver? Ana Luisa Calich, Vilma S. T. Viana, Eduardo L. Cançado, Débora R. Terrabuio, Francisco Tustumi, Elaine P. Leon, Clovis Artur Silva, Eduardo F. Borba Neto and Eloisa Bonfa, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 5:0 PM 5. The Relapsing Polychondritis Disease Activity Index: International Development and Initial Validation of the First Disease Activity Score for Relapsing Polychondritis 5 A Osteoarthritis - Clinical Aspects I: Weight, Activity, and Metabolic Effects on Osteoarthritis Moderators: Joanne M. Jordan, MD, MPH and Leena Sharma, MD 4:0 PM 5. Weight Loss Is Associated with Structure Modification in Subjects with Radiographic Osteoarthritis of the Knee: Data From the Osteoarthritis Initiative Marc C. Hochberg, Danuta I. Bujak, Jeffrey W. Duryea, Knachelle Favors and John D. Sorkin 4, University of Maryland, Baltimore, MD, Brigham & Women, Boston, MA, VA Maryland Health Care System, Baltimore, 4 VA Maryland Health Care System, Baltimore, MD 4:45 PM 54. The Intensive Diet and Exercise for Arthritis Trial (IDEA): 8-Month Radiographic and MRI Outcomes David J. Hunter, D. Beavers, Felix Eckstein, Ali Guermazi 4, Richard F. Loeser 5, Barbara J. Nicklas 6, Shannon Mihalko 7, Gary D. Miller 7, Mary Lyles 8, Paul DeVita 9, Claudine Legault 8, J. Jeffery Carr 8, Jeff D. Williamson 8 and Stephen P. Messier 7, University of Sydney, Sydney, Australia, Winston Salem, NC, Paracelsus Medical University, Salzburg, Austria, 4 Boston University, Boston, MA, 5 Wake Forest School of Medicine, Winston-Salem, NC, 6 Winston-Salem, NC, 7 Wake Forest University, Winston-Salem, NC, 8 Wake Forest University School of Medicine, Winston-Salem, NC, 9 East Carolina University, Greenville, NC 5:00 PM 55. Childhood Physical Fitness Predicts Adulthood Knee Cartilage Volume and Bone Area: A 5-Year Cohort Study Benny Samuel Eathakkattu Antony, Graeme Jones, Alison Venn, Leigh Blizzard, Flavia Cicuttini, L. March 4, Terry Dwyer 5 and Changhai Ding 6, Menzies Research Institute Tasmania, Hobart, Australia, Hobart, Australia, Monash University, Central and Eastern Clinical School, Melbourne, Australia, 4 University of Sydney, Insitute of Bone and Joint Research, Royal North Shore Hospital, St Leonards - Sydney, Australia, 5 Murdoch Children s Research Institute, Melbourne, Australia, 6 Menzies research institute & Monash University, Hobart, Australia 4 0 Program Book

117 5:5 PM 56. The Effects of Intensive Diet and Exercise On Bone Density in Older Adults with Knee Osteoarthritis: The Intensive Diet and Exercise for Arthritis (IDEA) Trial Nicole R. Walton, Richard F. Loeser, Daniel Beavers, Barbara J. Nicklas 4, Mary Lyles and Stephen P. Messier 5, Wake Forest University School of Medicine, Winston Salem, NC, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University School of Medicine, Winston-Salem, NC, 4 Winston-Salem, NC, 5 Wake Forest University, Winston-Salem, NC 5:0 PM 57. Cross-Sectional and Longitudinal Associations Between Circulating Leptin and Knee Cartilage Thickness in Older Adults Oliver Stannus, Yuelong Cao, Benny Samuel Eathakkattu Antony, Graeme Jones and Changhai Ding 4, Menzies Research Institute Tasmania, Hobart, Australia, Menzies Research Institute Tasmania, Research Institute of Orthopaedics, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Hobart, Australia, Menzies Research institute Tasmania, University of Tasmania, Hobart, 7000, Australia, 4 Menzies research institute & Monash University, Hobart, Australia 5:45 PM 58. The Association of Fat Mass and Skeletal Muscle Mass with Clinical and Structural Knee Osteoarthritis: The Netherlands Epidemiology of Obesity Study A. Willemien Visser, Marieke Loef, Martin den Heijer, Monique Reijnierse, Frits R. Rosendaal and Margreet Kloppenburg, Leiden University Medical Center, Leiden, Netherlands Ballroom A Rheumatoid Arthritis - Clinical Aspects V: Comorbidities in Rheumatoid Arthritis Moderators: Eric L. Matteson, MD and Paul F. Dellaripa, MD 4:0 PM 59. Fine-Specificity of Anti-Citrullinated Peptide Auto- Antibodies: Associations with Cardiac Structure and Function in Rheumatoid Arthritis Laura Geraldino-Pardilla, Jon T. Giles, Jeremy Sokolove, William H. Robinson and Joan M. Bathon, Columbia University Medical Center, New York, NY, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, Stanford University, Palo Alto, CA 5:00 PM 54. High Risk of Intensive Care Unit Admission in Rheumatoid Arthritis Patients: A Population Based Study Christine Peschken, Carol A. Hitchon, Allan Garland, Charles N. Bernstein, Randy Fransoo and Ruth Ann Marrie, University of Manitoba, Winnipeg, MB 5:5 PM 54. The Association Between Inflammatory Markers and Hyperlipidemia and the Risk of Myocardial Infarction in Patients with Rheumatoid Arthritis Jie Zhang, Lang Chen, Elizabeth S. Delzell, Paul M. Muntner, William B. Hillegass, Monika M. Safford, Iris E. Navarro and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, Univ of Alabama- Birmingham, Birmingham, AL 5:0 PM 54. Hospitalized Bacterial Infections Among U.S. Veterans with Rheumatoid Arthritis Initiating TNF Antagonist and Newer Biologic Agents Jeffrey Curtis, Shuo Yang, Nivedita M. Patkar, Lang Chen, Jasvinder A. Singh, Grant W. Cannon, Ted R. Mikuls 4, Elizabeth S. Delzell, Kenneth G. Saag, Monika M. Safford, Scott DuVall 5, Kimberly Alexander 6, Pavel Napalkov 6, Aaron Kamauu 7 and John Baddley, University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama-Birmingham, Birmingham, AL, George E. Wahlen VA Medical Center, Salt Lake City, UT, 4 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 5 VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 6 Genentech, Inc., South San Francisco, CA, 7 Anolinx, Bountiful, UT 5:45 PM 544. Widening Gap Between Cardiovascular Specific Mortality in Patients with Inflammatory Polyarthritis Compared to the General Population? Alexander J. Warner, Jh Humphreys, Mark Lunt, Tarnya Marshall 4, Deborah P. M. Symmons and Suzanne Verstappen 5, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4 Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, 5 University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom TUESDAY November, 0 4:45 PM 540. Prescription of Tumour Necrosis Factor α Antagonists Is Strongly Associated with a Reduction in Hospital Admissions and in Musculoskeletal Surgical Procedures for Rheumatoid Arthritis Based On a 6 Year Analysis of Nationwide Data Leonard C. Harty, Gary O Toole, Kathleen Bennett and Oliver M. FitzGerald 4, Department of Rheumatology, St. Vincent s University Hospital, Dublin, Ireland, Department of Orthopaedic Surgery, St. Vincent s University Hospital, Dublin, Ireland,. Department of Pharmacology & Therapeutics, Trinity centre for Health Sciences, St James s Hospital, Dublin, Ireland, 4 Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland Hall E Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics Moderators: Richard W. Martin, MA, MD and Aaron T. Eggebeen, MD 4:0 PM 545. A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients with Moderate to Severe RA 0 Program Book 5

118 TUESDAY November, 0 G. R. Burmester, Andrea Rubbert-Roth, Alain G. Cantagrel, Stephen Hall 4, Piotr Leszczynski 5, Daniel Feldman 6, Madura J. Rangaraj 7, Georgia Roane 8, Charles L. Ludivico 9, Francesco Ramirez 0 and Min Bao, Charité-Universitätsmedizin Berlin, Berlin, Germany, Klinikum der Universität zu Köln, Köln, Germany, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 4 Cabrini Medical Centre, Malvern, Australia, 5 Hospital J. Strusia, Poznan, Poland, 6 Universidade Federal de de São Paulo, Sao Paulo, Brazil, 7 Arthritis & Diabetes Clinic, Monroe, LA, 8 Rheumatology Associates, P.A., Charleston, SC, 9 East Penn Rheumatology Assoc, Bethlehem, PA, 0 Roche Products Limited, Welwyn, United Kingdom, Genentech, South San Francisco, CA 4:45 PM 546. Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase Trial Désirée van der Heijde, Robert B. M. Landewé and David Gruben, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, Pfizer Inc., Groton, CT 5:00 PM 547. Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose M. Schiff, R. Alten, M. Weinblatt, P. Nash 4, R. Fleischmann 5, P. Durez 6, J. Kaine 7, I. Delaet 8, S. Kelly 8, M. Maldonado 8, S. Patel 8 and M. C. Genovese 9, University of Colorado, Denver, CO, Schlosspark-Klinik, University Medicine, Berlin, Germany, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 4 University of Queensland, Brisbane, Australia, 5 University of Texas Southwestern Medical Center, Dallas, TX, 6 Université Catholique de Louvain, Brussels, Belgium, 7 Sarasota Arthritis Research Center, Sarasota, FL, 8 Bristol-Myers Squibb, Princeton, NJ, 9 Stanford University, Palo Alto, CA 5:5 PM 548. Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients Julie Ducreux, Adrien Nzeusseu Toukap, Frédéric A. Houssiau, Patrick Durez and Bernard Lauwerys, Université catholique de Louvain, Brussels, Belgium 5:0 PM 549. Induction of Remission in Patients with up to Months of Moderate-to-Severe Rheumatoid Arthritis Symptoms Treated with Etanercept Plus Methotrexate Over 5 Weeks Paul Emery, Mohammed Hamoudeh, Oliver M. FitzGerald, Bernard Combe 4, Stefanie Gaylord 5, Theresa Williams 5, Jack Bukowski 5, Ronald Pedersen 5, Andrew S. Koenig 5 and Bonnie Vlahos 5, Leeds General Infirmary, Leeds, United Kingdom, Hamad Medical Corporation, Doha, Qatar, St. Vincent s University Hospital, Dublin, Ireland, 4 Lapeyronie Hospital, Montpellier, France, 5 Pfizer Inc., Collegeville, PA 5:45 PM 550. Clinical, Radiographic, and Immunogenic Effects After Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study Maxime Dougados, Karsten Kissel, Philip G. Conaghan, Emilio Martin-Mola 4, Georg A. Schett 5, Howard Amital 6, Ricardo M. Xavier 7, OM Troum 8, Corrado Bernasconi 9 and T.W.J. Huizinga 0, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, F. Hoffmann-La Roche Ltd, Basel, Switzerland, University of Leeds, Leeds, United Kingdom, 4 Hospital Universitario La Paz, Madrid, Spain, 5 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 6 Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, Tel-hashomer, Israel, 7 Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 8 USC Keck School of Medicine, Santa Monica, CA, 9 Roche, Basel, Switzerland, 0 Leiden University Medical Center, Leiden, Netherlands 07 A Sjögren s Syndrome II - Clinical Moderators: E. William St.Clair, MD and Athanasios G. Tzioufas, MD 4:0 PM 55. Validation of EULAR Primary Sjögren s Syndrome Disease Activity and Patient Indexes Raphaèle Seror, Elke Theander, Johan G. Brun, Manel Ramos- Casals 4, Valeria Valim 5, T. Dorner 6, Xavier Mariette 7, Hendrika Bootsma 8, Athanasios G. Tzioufas 9, Roser Solans-Laqué 0, Jacques-Eric Gottenberg, Eric Hachulla, Wan-Fai NG, Stefano Bombardieri 4, Roberto Gerli 5, Takayuki Sumida 6, Alain Saraux 7, Matija Tomsic 8, Roberto Caporali 9, Roberta Priori 0, Kathy Moser Sivils, A.A. Kruize, Cristina F. Vollenweider, Claudio Vitali 4 and Simon J. Bowman 5, Bicetre university hospital, LE Kremlin-Bicetre, France, Skane University Hospital, Lund University, Malmö, Sweden, Haukeland University Hospital, Bergen, Norway, 4 Hospital Clínic, Barcelona, Spain, 5 Universidade Federal do Espírito Santo, Vitória, Brazil, 6 Charité University Medicine Berlin, Berlin, Germany, 7 Université Paris-Sud, Le Kremlin Bicetre, France, 8 University Medical Center Groningen, Groningen, Netherlands, 9 School of Medicine, National University of Athens, Athens, Greece, 0 Senior Consultant, Barcelona, Spain, Strasbourg University Hospital, Strasbourg, France, Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, Departement of rheumatology, New-Castle University Hospital, UK, Newcastle, England, 4 Rheumatology Unit, University of Pisa, Pisa, Italy, 5 Rheumatology Unit, University of Perugia, Perugia, Italy, 6 University of Tsukuba, Tsukuba City, Japan, 7 Université Brest Occidentale, Brest, France, 8 University Medical Centre Ljubjana, Ljubljana, Slovenia, 9 Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, 0 Rheumatology Unit, Sapienza University of Rome, Rome, Italy, Oklahoma Medical Research Foundation, Oklahoma City, OK, University Medical Center Utrecht, Utrecht, Netherlands, German Hospital, Buenos Aires, Argentina, 4 Casa di Cura di Lecco, Lecco, Italy, 5 Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom 6 0 Program Book

119 4:45 PM 55. Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjögren s Syndrome: Clinical Presentation and Outcome Andreas V. Goules, Ioanna P. Tatouli, Alexandros A. Drosos, Fotini N. Skopouli, Haralampos M. Moutsopoulos 4 and Athanasios G. Tzioufas 5, National University of Athens, Athens, Greece, Professor of Medicine/Rheumatology, Ioannina, Greece, Harokopion University, Athens, Greece, 4 School of Medicine, University of Athens, Athens, Greece, 5 School of Medicine, National University of Athens, Athens, Greece 5:00 PM 55. Histological, Serological and Clinical Changes in Response to Abatacept Treatment of Sjögren s Syndrome Sabine Adler, Meike Koerner, Frauke Foerger, Marco- Domenico Caversaccio and Peter M. Villiger 4, University Hospital Bern, Bern, Switzerland, Inselspital-University Hospital, Bern, Switzerland, University Hospital Bern, Inselspital, Bern, Switzerland, 4 Inselspital-University Hospital of Bern, Bern, Switzerland 5:5 PM 554. Tolerance and Efficacy of Rituximab in Primary Sjogren Syndrome: Final Results of a Randomized Controlled Trial Valerie Devauchelle-Pensec, Xavier Mariette, Sandrine Jousse- Joulin, Jean-Marie Berthelot 4, Aleth Perdriger 5, Eric Hachulla 6, Xavier Puechal 7, Véronique Le Guern 8, Jean Sibilia 9, Jacques- Eric Gottenberg 0, Laurent Chiche Sr., Vincent Goeb, Gilles Hayem, Jacques Morel 4, Charles Zarnitsky 5, JJ Dubost 6, Jacques-Olivier Pers 7, Emmanuel Nowak 8 and Alain Saraux 9, Brest Occidentale university, Brest, France, Université Paris- Sud, Le Kremlin Bicetre, France, Brest university medical school, EA 6, UBO and CHU de la Cavale Blanche,, Brest, France, 4 Nantes University Hospital, Nantes, France, 5 Hôpital Sud, Rennes, France, 6 Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, 7 Hôpital Cochin, Paris, France, 8 Cochin Hospital, Paris, France, 9 EA448 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 0 Strasbourg University Hospital, Strasbourg, France, Internal Medicine, CHU Marseille, Marseille, France, Rouen University Hospital, Rouen, France, Bichat Hospital, Paris, France, 4 Hopital Lapeyronie, Montpellier, France, 5 CH du Havre, Le Havre, France, 6 CHU CLERMONT-FERRAnd, Clermont- Ferrand, France, 7 Brest Occidentale University, Brest, France, 8 CHU Brest, Brest, France, 9 Université Brest Occidentale, Brest, France 5:45 PM 556. Allogenic Mesenchymal Stem Cells Transplantation Alleviates Clinical Sjögren s Syndrome Lingyun Sun, Dandan Wang, Junji Xu and Songlin Wang, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, Salivary Gland Disease Center and Molecular Laboratory for Gene Therapy & Tooth Regeneration, Beijing Key Laboratory of Tooth Regeneration and Function Reconstruction, Capital Medical University School of Stomatology, Beijing, China Ballroom C Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis Moderators: Jeffrey R. Lisse, MD and Andreas M. Reimold, MD 4:0 PM 557. Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase, Multicenter, Double-Blind, Placebo-Controlled Study Christopher T. Ritchlin, Alice B. Gottlieb, Iain B. McInnes, Lluis Puig 4, Proton Rahman 5, Shu Li 6, Yuhua Wang 6, Mittie K. Doyle 7, Alan Mendelsohn 8 and Arthur Kavanaugh 9, University of Rochester Medical Center, Rochester, NY, Tufts Medical Center, Boston, MA, University of Glasgow, Glasgow, United Kingdom, 4 Universitat Autònoma de Barcelona, 5 Memorial University, St. Johns, NF, 6 Janssen Research and Development, LLC, PA, 7 Janssen Research and Development, LLC/U of Penn, Spring House/Phila, PA, 8 Janssen Research & Development, LLC, Spring House, PA, 9 UCSD School of Medicine, La Jolla, CA 4:45 PM 558. Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry Bente Glintborg, Mikkel Østergaard, Niels Steen Krogh, Martin Dehn Andersen 4, Ulrik Tarp 4, Anne Gitte Loft 4, Hanne M. Lindegaard 4, Mette Holland-Fischer 4, Henrik Nordin 4, Dorte Vendelbo Jensen 4 and Merete L. Hetland 5, Copenhagen University Hospital Gentofte, Copenhagen, Denmark, Glostrup Hospital, Copenhagen, Denmark, ZiteLab ApS, Copenhagen, Denmark, 4 DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 5 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark TUESDAY November, 0 5:0 PM 555. Results of the Beliss Study, the First Open Phase Study of Belimumab in Primary Sjogren s Syndrome Xavier Mariette, Luca Quartuccio, Raphaèle Seror, Sara Salvin, Frederic Desmoulins, Martina Fabris 4, Sara Villeneuve 5, Philippe Ravaud 6 and Salvatore De Vita 7, Université Paris-Sud, Le Kremlin Bicetre, France, Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, Bicetre university hospital, LE Kremlin- Bicetre, France, 4 Institute of Clinical Pathology, Udine, Italy, 5 Hospital Hotel dieu, Paris, France, 6 Hopital Hotel Dieu, Paris Descartes University, Paris, France, 7 Rheumatology Clinic, DSMB, University of Udine, Udine, Italy 5:00 PM 559. Mortality in Patients with Psoriatic Arthritis Compared to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the General Population Alexis Ogdie, Kevin Haynes, Andrea Troxel, Thorvardur Love, Hyon K. Choi 4 and Joel Gelfand, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania., Philadelphia, PA, Labspitali University Hospital, Reykjavik, Iceland, 4 Boston University School of Medicine, University of British Columbia, Arthritis Research Centre of Canada, Boston, MA 0 Program Book 7

120 TUESDAY November, 0 8 5:5 PM 560. Response and Drug Survival of st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis - What Is the Role of Co- Medication with Methotrexate? Karen M. Fagerli, Elisabeth Lie, Désirée van der Heijde, Marte S. Heiberg, Erik Rødevand 4, Åse S. Lexberg 5, Synnøve Kalstad 6, Knut Mikkelsen 7 and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet hospital, Oslo, Norway, 4 St. Olavs Hospital, Trondheim, Norway, 5 Drammen Hospital, Drammen, Norway, 6 Tromsø, Norway, 7 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway 5:0 PM 56. Switching Between TNF-Inhibitors in Psoriatic Arthritis: Data From the NOR-DMARD Study Karen M. Fagerli, Elisabeth Lie, Désirée van der Heijde, Marte S. Heiberg, Åse S. Lexberg 4, Knut Mikkelsen 5, Erik Rødevand 6, Synnøve Kalstad 7 and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway, Leiden University Medical Center, Leiden, Netherlands, Diakonhjemmet hospital, Oslo, Norway, 4 Vestre Viken, Drammen, Norway, 5 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 6 St. Olavs Hospital, Trondheim, Norway, 7 Tromsø, Norway 5:45 PM 56. Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase, Multicenter, Double-Blind, Placebo- Controlled Psummit I Study Arthur Kavanaugh, Iain B. McInnes, Alice B. Gottlieb, Lluis Puig 4, Proton Rahman 5, Christopher T. Ritchlin 6, Shu Li 7, Yuhua Wang 7, Alan Mendelsohn 7 and Mittie K. Doyle 7, UCSD School of Medicine, La Jolla, CA, University of Glasgow, Glasgow, United Kingdom, Tufts Medical Center, Boston, MA, 4 Universitat Autònoma de Barcelona, 5 Memorial University, St. Johns, NF, 6 University of Rochester Medical Center, Rochester, NY, 7 Janssen Research & Development, LLC, Spring House, PA 0 B Vasculitis: Clinical Aspects Moderators: Loic Guillevin, MD and David Jayne, MD 4:0 PM 56. Factors Associated with Major Cardiovascular Events in Patients with Primary Systemic Necrotizing Vasculitides: Results of a Longitudinal Long-Term Follow-up Study Benjamin Terrier Sr., Christian Pagnoux, Gilles Chironi, Alain Simon, Luc Mouthon Sr. 4, Loic Guillevin 5 and French Vasculitis Study Group (FVSG) 6, Cochin Hospital, Paris, France, Mount Sinai Hospital, Toronto, ON, HEGP, Paris, France, 4 Hopital Cochin, Paris, France, 5 Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 6 Paris 4:45 PM 564. A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Carla Maldini, Matthieu Resche-Rigon, David Jayne, Kerstin Westman and Alfred Mahr, Hospital Saint-Louis, Paris, France, Addenbrookes Hospital University of Cambridge, Cambridge, 0 Program Book United Kingdom, Skåne University Hospital Malmö, Lund University, Malmö, Sweden 5:00 PM 565. Prevalence of Anti-Neutrophil Cytoplasmic Antibodies in Infective Endocarditis: An Analysis of 09 Cases Alfred Mahr, Frédéric Batteux, Sarah Tubiana, Michel Wolff, Claire Goulvestre, Thomas Papo, François Vrtovsnik, Isabelle Klein, Bernard Iung and Xavier Duval, Hospital Saint-Louis, Paris, France, Hospital Cochin, Paris, France, Hospital Bichat, Paris, France 5:5 PM 566. Aβ-Related Angiitis: Comparison with Patients with Amyloid Cerebral Angiopathy without Inflammation Carlo Salvarani, Caterina Giannini, Robert D. Brown Jr., Teresa J. H. Christianson and Gene G. Hunder, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, Mayo Clinic, Rochester, MN 5:0 PM 567. Predictive Value of Selected Markers of Inflammation and Platelet Activation for Complete Remission in ANCA Associated Vasculitis Gunnar Tomasson, Paul A. Monach, Kahraman Tanriverdi, Ulrich Specks 4, John H. Stone 5, Linna Ding 6, Fernando Fervenza 4, Gary S. Hoffman 7, Cees G.M. Kallenberg 8, Carol A. Langford 7, Deborah J. Phippard 9, Philip Seo 0, Robert F. Spiera, E. William St. Clair, Nadia Tchao 9, Jane E. Freedman and Peter A. Merkel, University of Iceland, Reykjavik, Iceland, Boston University, Boston, MA, University of Massachusetts, Wochester, 4 Mayo Clinic, Rochester, MN, 5 Massachusetts General Hospital, Boston, MA, 6 NIAID, Bethesda, MD, 7 Cleveland Clinic, Cleveland, OH, 8 University Medical Center Groningen, Groningen, Netherlands, 9 Immune Tolerance Network, Bethesda, MD, 0 Johns Hopkins Vasculitis Center, Baltimore, MD, Hospital for Special Surgery, New York, NY, Duke University Medical Center, Durham, NC, University of Pennsylvania, Philadelphia, PA 5:45 PM 568. The Risk of Pulmonary Embolism and Deep Vein Thrombosis in Giant Cell Arteritis: A Population-Based Cohort Study J. Antonio Avina-Zubieta, Diane Lacaille, Eric C. Sayre, Jacek A. Kopec and Hyon K. Choi, Arthritis Research Centre of Canada/ University of British Columbia, Richmond, BC, Boston University School of Medicine, Arthritis Research Centre of Canada/ University of British Columbia, Boston, MA ACR MEET THE PROFESSOR SESSIONS 4:0-6:00 PM Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the -digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in My Annual Meeting at * Sessions denoted with an asterisk were sold out as of September 4.

121 48 Central Nervous System Vasculitis (08) Speaker: Rula Hajj-Ali, MD 5 Crystal: Pseudogout (08) Speaker: Ann K. Rosenthal, MD 54 B Pulmonary Manifestations of Rheumatic Disease (084) Speaker: Kristin B. Highland, MD, MSCR 55 Raynaud s and Digital Ischemia (085) Speaker: Janet E. Pope, MD, MPH 58 A Rheumatoid Arthritis: Safety of Novel Therapies (086) Speaker: Lee S. Simon, MD 58 B Rheumatology Practice 0: Starting Out in Practice for The Graduating Fellow (087) Speaker: Michael J. Maricic, MD 59 A Systemic Lupus Erythematosus: Lupus Nephritis (088) Speaker: Brad H. Rovin, MD 59 B * Systemic Lupus Erythematosus: Novel Treatments (089) Speaker: Robert G. Lahita, MD, PhD 60 Vaccinations for Patients on Biologic Therapies (090) Speaker: Clifton O. Bingham III, MD RHEUMATOLOGY RESEARCH FOUNDATION SPECIAL SESSION 4:0-6:00 PM 47 A Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloriquine Reduces Thrombosis is Systemic Lupus Erythematosis Particularly in Antiphosholipid Positive Patients Moderators: Francisco P. Quismorio Jr., MD and Lindsy J. Forbess, MD 4:0 PM 569. Hydroxychloroquine Reduces Thrombosis in Systemic LUPUS Erythematosus, Particularly in Antiphospholipid Positive Patients Speaker: Genevieve Law, MD Genevieve Law, Laurence S. Magder, Hong Fang and Michelle Petri, University of British Columbia, Vancouver, BC, University of Maryland, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD 4:45 PM 570. Lymphoma Risk in Systemic Lupus: Effects of Disease Activity Versus Treatment Sasha Bernatsky, Ann E. Clarke, Karen H. Costenbader, Murray B. Urowitz 4, Dafna D. Gladman 5, Paul R. Fortin 6, Michelle Petri 7, Susan Manzi 8, D.A. Isenberg 9, Anisur Rahman 0, Daniel Wallace, Caroline Gordon, Christine Peschken, Mary Anne Dooley 4, E.M. Ginzler 5, Cynthia Aranow 6, Steven M. Edworthy 7, Ola Nived 8, Søren Jacobsen 9, Guillermo Ruiz-Irastorza 0, Edward Yelin, Susan G. Barr, Irene Blanco, Candace H. Feldman 4 and R. Ramsey-Goldman 5, Systemic Lupus International Collaborating Clinics, Montreal, QC, Research Institute of the McGill University Health Centre, Montreal, QC, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 Toronto Western Hospital and University of Toronto, Toronto, ON, 5 Toronto Western Hospital and University of Toronto, Toronto, ON, 6 University of Laval, Quebec, 7 Johns Hopkins University School of Medicine, Baltimore, MD, 8 West Penn Allegheny Health System, Pittsburgh, PA, 9 University College of London, London, United Kingdom, 0 University College London, London, United Kingdom, Cedars-Sinai/UCLA, Los Angeles, CA, University of Birmingham, Birmingham, United Kingdom, University of Manitoba, Winnipeg, MB, 4 University of North Carolina at Chapel Hill, Chapel Hill, NC, 5 SUNY-Downstate Medical Center, Brooklyn, NY, 6 Feinstein Institute for Medical Research, Manhasset, NY, 7 The University of Calgary, Calgary, AB, 8 University Hospital - Lund, Lund, Sweden, 9 Copenhagen University Hospital, Copenhagen, Denmark, 0 Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Bizkaia, Spain, University of California San Francisco, San Francisco, CA, University of Calgary, Calgary, AB, Albert Einstein College of Medicine, Bronx, NY, 4 Brigham and Women s Hospital, Boston, MA, 5 Northwestern University Feinberg School of Medicine, Chicago, IL 5:00 PM 57. Lack of Control of Hypertension in Systemic Lupus Erythematosus Hong Fang, Raheel Ahmad, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 5:5 PM 57. Molecular Signatures in SLE: Flare Vs. Infection Meggan Mackay, Michaela Oswald, Jorge Sanchez-Guerrero, Juan J. Lichuaco, Cynthia Aranow, Sean Kotkin, Peter K. Gregersen and Betty Diamond, The Feinstein Institute for Medical Research, Manhasset, NY, Mount Sinai Hospital, University Health Network, Toronto, ON, St. Luke s Medical Center, Quezon City, Philippines TUESDAY November, 0 0 Program Book 9

122 TUESDAY November, 0 5:0 PM 57. Arthoplasty Rates Increased Among US Patients with Systemic Lupus Erythematosus: Christina Mertelsmann-Voss, Ting Jung Pan, Huong Do, Mark P. Figgie and Lisa A. Mandl, Hospital for Special Surgery, Cornell University, New York, NY, Hospital for Special Surgery, New York, NY 5:45 PM 574. Smoking, Autoantibodies and Vascular Events in Systemic Lupus Erythematosus Johanna Gustafsson, Iva Gunnarsson, Susanne Pettersson, Agneta Zickert, Anna Vikerfors 4, Erik Hellbacher 4, Sonia Möller, Kerstin Elvin 4, Henrik Källberg 4, Julia F. Simard 5 and Elisabet Svenungsson, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, Karolinska University Hospital, Stockholm, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5 Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden ARHP SESSIONS 4:0-6:00 PM 04 A Arthritis and the Older Worker Moderator: Kristina A. Theis, BA, MPH Upon completion of this session, participants should be able to: describe the current trends of employment among older adults and specifically those with arthritis identify one CMS policy or service affected by growing numbers of workers aged 65 years and older discuss interventions applicable to helping older workers with arthritis gain or maintain employment describe the public health approach to addressing employment needs for older workers with arthritis 4:0 PM Overview of Demographic Trends of Older Workers Terence McMenamin, MA 5:00 PM Impact of Older Workers on Medicare/Medicaid Shari M. Ling, MD 06 Upon completion of this session, participants should be able to: review common rheumatologic conditions that can be diagnosed with the aid of imaging describe the differences between X-ray, MRI, CT scan and ultrasound for evaluating conditions discuss when and why a specific imaging modality is preferred over another for certain conditions recognize when it is appropriate to order MRI imaging with and without contrast instead of plain X-rays The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together Moderator: Ann Vincent, MD Upon completion of this session, participants should be able to: recognize the impact of the disease process and behavioral factors in the manifestation of fatigue, and the therapeutic implications for patients with rheumatic diseases identify potential psychological and physiological sources of fatigue utilize traditional and novel methods (e.g., computer adaptive testing) of measuring fatigue from the patient perspective cite evidence supporting psychological and physical activity interventions for rheumatoid arthritis fatigue, and some of the questions that remain to be answered 4:0 PM Fatigue in Rheumatic Disease from a Psychophysiological Perspective Rinie Geenen, PhD 4:50 PM Sources of Fatigue: Body, Mind, or Both? Patricia P. Katz, PhD 5:0 PM Novel Methods to Measure Fatigue from the Patient Perspective Christina Bode, PhD 5:0 PM Non-pharmacological Interventions for Rheumatoid Arthritis Fatigue Sarah Hewlett, MA, PhD, RN 5:0 PM The Public Health Perspective on Older Workers with Arthritis Sylvia Furner, PhD 50 B Best Practices for Ordering Diagnostic Imaging in Evaluating Rheumatologic Conditions Moderator: Linda S. Ehrlich-Jones, PhD, RN Speaker: Mark D. Murphey, MD INDUSTRY-SUPPORTED SYMPOSIA 6:0-9:0 PM These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 7 for more information. 0 0 Program Book

123 WEDNESDAY, NOVEMBER 4, 0 ACR/ARHP REGISTRATION 7:00 AM - :00 PM Registration Hall (Salons G-H-I) ACR SESSIONS 7:0-8:0 AM Ballroom A Immunology of Pregnancy and Impact on Autoimmune Pathogenesis Moderator: Gregg Silverman, MD Speaker: J. Lee Nelson, MD Upon completion of this session, participants should be able to: summarize the immunobiology of pregnancy and immune tolerance to the fetus discuss advances in methods to survey the immune status in pregnant women without and with rheumatic diseases discuss the pathogenesis of toxemia of pregnancy in predisposed individuals such as lupus patients consider whether insights into the immunology of pregnancy may offer new therapeutic approaches 45 A Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease Moderator: Cong-Qiu Chu, MD Speaker: Arturo Zychlinsky, PhD Upon completion of this session, participants should be able to: describe neutrophil extracellular traps, their components, and the process of NETosis identify that NETosis is one of the first lines of defense against pathogens review current data implicating NETosis in autoimmune disease, particularly ANCA-associated vasculitis and systemic lupus erythematosus Hall D Rheumatology Roundup: Highlights from the 0 Annual Scientific Meeting Moderator: Chester V. Oddis, MD Speakers: John J. Cush, MD and Arthur Kavanaugh, MD Upon completion of this session, participants should be able to: list research highlights from the scientific presentations discuss the clinical impact of selected research reports presented at the meeting evaluate the therapeutic potential of selected clinical trials presented at the meeting 4 A The Unintended Consequences of Health Information Technology PS Moderator: Christi Joy Inman, MD, MS Speaker: Dean F. Sittig, PhD Upon completion of this session, participants should be able to: discuss the potential unintended consequences of health information technology including workflow errors, changes in communication patterns and practices, overdependence on technology, and paper persistence identify best practices and potential solutions to mitigate unintended consequences of health information technology in the rheumatology practice, including human, organizational, and environmental factors that can significantly improve clinical practice describe potential causative factors of health information technology related errors specific to their practice and then develop appropriate preventative measures ARHP SESSIONS 7:0-8:0 AM 0 An Introduction to Immunology Moderator: Afton L. Hassett, PsyD Speaker: Leonard H. Sigal, MD Upon completion of this session, participants should be able to: distinguish the differences between the innate immune system and the adaptive immune response and how they interact develop insights into the functions of B cells and T cells recognize mechanisms whereby auto-immunity may occur identify the many yins and yangs that cooperate to modulate the immune response 06 Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems (Research Series) Moderator: Sunny Kim, PhD Upon completion of this session, participants should be able to: identify the causes of missing data and how it affects interpretation and analysis of research studies describe statistical principals behind multiple imputation of missing data and why it is preferred over single imputation techniques discuss the analytic techniques (imputation, analysis, pooling) required for multiple imputation apply real-life analyses using multiple imputation in popular statistical packages 7:0 AM How Does Loss to Missing Data Happen and What Are the Implications? Robert R. McLean, DSc, MPH 7:45 AM Overview of Multiple Imputation for Missing Data Alyssa B. Dufour, MA and Robert R. McLean, DSc, MPH 7:55 AM Using SAS and R to Perform Multiple Imputation Alyssa B. Dufour, MA WEDNESDAY November 4, 0 0 Program Book

124 8:0 AM Introduction to the Johnston County Osteoarthritis Project Dataset Yvonne M. Golightly, MS, PhD, PT 8:5 AM Reporting Results in Manuscripts/Take Home Message Robert R. McLean, DSc, MPH ACR SESSIONS 9:00-0:0 AM Ballroom C Biosimilars Development: Food and Drug Administration Perspective Moderator: Nikolay P. Nikolov, MD Upon completion of this session, participants should be able to: summarize the statutory paradigm for the 5(k) biosimilar pathway discuss the Food and Drug Administration s approach to the development of the biosimilar pathway discuss the role analytical similarity assessments and clinical considerations play in biosimilar product development 9:00 AM Regulatory Framework of Biosimilars Development Leah Christl, PhD 0:00 AM Diagnosis and Pathophysiology of IgG4-Related Disease Yoh Zen, MD, PhD 5 A NIAMS-Sponsored Research in Rheumatology: 0 Highlights Moderator: Robert H. Carter, MD Upon completion of this session, participants should be able to: explain funding mechanisms available to rheumatology investigators describe the role of genetics in predicting response to treatment explain the future of juvenile idiopathic arthritis treatment and what the pipeline looks like identify the extent to which the poorer outcomes of those of low socioeconomic status may be due to the quality of care they receive express the importance of patient reported outcomes, and how these outcomes are being evaluated through the PROMIS system 9:00 AM Funding Opportunities Available in Rheumatology Bruce N. Cronstein, MD WEDNESDAY November 4, 0 9:5 AM Biosimilars Development: The Role of Analytics Marjorie Shapiro, PhD 9:45 AM Biosimilars Development: Clinical Considerations Nikolay P. Nikolov, MD 0:0 AM Panel Discussion Badrul Chowdhury, MD, PhD, Leah Christl, PhD, Sarah K. Okada- Yim, MD and Marjorie Shapiro, PhD Hall D IgG4-Related Disease Past Lessons and Future Directions Moderators: Diane L. Kamen, MD, MS and Arezou Khosroshahi, MD Upon completion of this session, participants should be able to: summarize the current nomenclature and diagnostic criteria for retroperitoneal fibrosis and IgG4-related disease identify the patterns of organ involvement and clinical manifestations of retroperitoneal fibrosis and IgG4-related disease describe potential treatment options for retroperitoneal fibrosis and IgG4-related disease 9:00 AM Retroperitoneal Fibrosis Past Lessons and Future Directions Gary S. Gilkeson, MD 9:0 AM Emerging Concepts in IgG4-Related Disease John H. Stone, MD, MPH 9:0 AM Improved Understanding of the Biology and Use of Tumor Necrosis Factor Inhibition in Juvenile Idiopathic Arthritis D. J. Lovell, MD, MPH 9:40 AM Health Systems, Quality of Care, and Outcomes Edward H. Yelin, PhD 0:00 AM Patient Reported Outcomes Measurement Information System (PROMIS) James P. Witter, MD, PhD 0:0 AM Break Ballroom B Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs? Moderators: Tuhina Neogi, MD, PhD and Jasvinder A. Singh, MD, MPH Upon completion of this session, participants should be able to: review the evidence in the literature regarding current therapies for osteoarthritis describe the rationale of new therapies for osteoarthritis, including stem cells and other innovative therapies describe the new approaches to treatment of osteoarthritis and promising new therapies on the horizon recognize how new treatments compliment the current therapies in management of patients with osteoarthritis 0 Program Book

125 9:00 AM What s Effective in Osteoarthritis? Appraisal of Current Therapies Marc C. Hochberg, MD, MPH 9:0 AM Stem cells in Osteoarthritis: They Give Them to My Dog, Are we There Yet for Use in Humans? Rocky S. Tuan, PhD 0:00 AM Future of Osteoarthritis Treatment: Therapeutics in the Pipeline David J. Hunter, MBBS, PhD 50 B Predictive Biomarkers: A Journey to Personalized Health Care Moderator: Wael N. Jarjour, MD Upon completion of this session, participants should be able to: critically review predictive biomarkers in cardiology and hematology/oncology define the status of predictive biomarkers in systemic lupus erythematosus identify models that were used to develop validated predictive biomarkers in cardiology (and other disciplines) and their potential applicability in systemic lupus erythematosus 9:00 AM Predictive Biomarkers in Cardiovascular Disease Alan S. Maisel, MD 9:5 AM 576. Production of Citrullinated Filaggrin-Specific IgG in Rheumatoid Arthritis Patients Is Associated with an Expansion of Citrullinated Filaggrin Tetramer-Binding Switched Memory Blood B Cells Philip Titcombe, Laura O. Barsness, Lauren Giacobbe, Emily Baechler Gillespie, Erik J. Peterson and Daniel L. Mueller, University of Minnesota Medical School, Minneapolis, MN 9:0 AM 577. Characterization of Circulating Human B Cells That Bind Cyclic Citrullinated Peptide Antigens in Clinically Active Rheumatoid Arthritis Gregg J. Silverman, John Jung, Jeffrey D. Greenberg, Adam J. Pelzek, Caroline Gronwall and Jaya Vas, NYU School of Medicine, New York, NY, NYU, New York, NY, New York University School of Medicine, New York, NY 9:45 AM 578. Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients Antigen-Driven Affinity Maturation and Cross Reactivity Khaled Amara, Johanna Steen, Fiona Murray, Henner Morbach, Blanca Fernandez-Rodriguez, Vijay Balasingh, Marianne Engström, Omri Snir, Lena Israelsson, Anca. I. Catrina, Hedda Wardemann 4, Davide Corti, Eric Meffre Sr., Lars Klareskog and Vivianne Malmström, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Yale University School of Medicine, New Haven, CT, Institute for Research in Biomedicine, Bellinzona, Switzerland, 4 Max Planck Institute for Infection Biology, Berlin, Germany 9:0 AM Moving from Prognostic to Predictive Factors in Oncology Neil E. Kay, MD 0:00 AM Predictive Biomarkers in Systemic Lupus Erythematosus: Where are We? Mary K. Crow, MD ACR CONCURRENT ABSTRACT SESSIONS 9:00-0:0 AM 47 A B-cell Biology and Targets in Autoimmune Disease Moderators: Robert A. Eisenberg, MD and William Stohl, MD, PhD 9:00 AM 575. Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of Germinal Center B Cells Via Manipulation of Regulator of G-Protein Signaling John D. Mountz, John H. Wang, James S. New, PingAr Yang, Qi Wu, Bao Luo, Jun Li, Kirk M. Druey 4 and Hui-Chen Hsu, Univ of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, Cedars Sinai Medical Center, Los Angeles, CA, University of Alabama at Birmingham, Birmingham, AL, 4 National Institute of Allergy and Infectious Diseases, Bethesda, MD 0:00 AM 579. Novel Autoantibodies to 4-- Eta Are Highly Specific for Rheumatoid Arthritis Walter P. Maksymowych, Désirée van der Heijde, R. Landewe, Vivian P. Bykerk 4 and Anthony Marotta 5, University of Alberta, Edmonton, AB, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4 Hospital for Special Surgery, New York, NY, 5 Augurex Life Sciences Corp, North Vancouver, BC 0:5 AM 580. Marginal Zone Defects in Wiskott-Aldrich Syndrome Are Dependent On B Cell Intrinsic Toll-Like Receptor Signals Shaun W. Jackson, Nikita Kolhatkar, Marc A. Schwartz, Socheath Khim and David J. Rawlings 4, Seattle Children s Hospital, Seattle, WA, Department of Immunology, University of Washington, Seattle, WA, Seattle Children s Research Institute, Seattle, WA, 4 Washington, Seattle, WA 45 A Imaging of Rheumatic Diseases III: Computed Tomography Moderators: Georg A. Schett, MD, PhD and Fiona M. McQueen, MBChB, MD WEDNESDAY November 4, 0 0 Program Book

126 9:00 AM 58. Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study Carolin Hecht, Stephanie Finzel, Matthias Englbrecht, Sarah Schmidt, Juergen Rech, Elizabeth Araujo and Georg Schett, University of Erlangen-Nuremberg, Erlangen, Germany, Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany 9:5 AM 58. Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors Stephanie Finzel, Sebastian Kraus, Sarah Schmidt, Axel J. Hueber, Juergen Rech, Klaus Engelke, Matthias Englbrecht and Georg Schett, University of Erlangen-Nuremberg, Erlangen, Germany, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 9:0 AM 58. Bone Structure and Perfusion Quantification of Bone Marrow Edema and Pannus Tissue Areas in the Wrist of Patients with RA Jose R. Teruel Antolin, Andrew J. Burghardt, Julien Rivoire, Waraporn Srikhum, Susan M. Noworolski, Thomas M. Link, John B. Imboden and Xiaojuan Li, University of California, San Francisco, San Francisco, CA 9:00 AM 587. Practice Makes Perfect: Assessment of Proficiency of Rheumatology Fellows in Specific Joint Procedural Skills Tara J. Rizvi, Min Xu and Nancy Searle, Baylor College of Medicine, Houston, TX 9:5 AM 588. Standardized Patient Simulation Improves Internal Medicine Resident Musculoskeletal Examination Skills Floranne C. Ernste, Uma Thanarajasingam, Courtney Shourt, Andrew Halvorsen and Furman S. McDonald, Mayo Clinic, Rochester, MN, Mayo Clinic Rochester, Rochester, Mayo Clinic, Rochester 9:0 AM 589. From Novice to Expert: Competency Milestones for Musculoskeletal Ultrasound Karina D. Torralba, Jay B. Higgs, Amy C. Cannella and Gurjit S. Kaeley 4, Keck School of Medicine, University of Southern California, Los Angeles, CA, San Antonio Military Medical Center, Fort Sam Houston, TX, University of Nebraska Med Ctr, Omaha, NE, 4 University of Florida, Ponte Vedra Beach, FL 9:45 AM 590. Consolidating Knowledge, Comprehension, Application and Analysis in Rheumatology Education by Use of an in-house Electronic Module (Web-based Rheumatology Case Scenarios) David A. Kandiah, Diana Jonas-Dwyer and Astrid Davine, University of Western Australia, Crawley, Australia WEDNESDAY November 4, 0 9:45 AM 584. Quantitative and Semi-Quantitative Bone Erosion Assessment On High-Resolution Peripheral Quantitative Computed Tomography in Rheumatoid Arthritis Waraporn Srikhum, Warapat Virayavanich, Andrew J. Burghardt, Andrew Yu, Thomas M. Link, John B. Imboden and Xiaojuan Li, University of California, San Francisco, San Francisco, CA 0:00 AM 585. Magnetic Resonance Imaging Versus Dual Energy Computed Tomography for Detection of Joint Pathology in Gout Fiona M. McQueen, Anthony Doyle, Quentin Reeves, Angela Gao, Amy Tsai, Gregory Gamble, Barbara Curteis, Megan Williams and Nicola Dalbeth, University of Auckland, Auckland, New Zealand, Auckland District Health Board, Auckland, New Zealand 0:5 AM 586. Tendon and Ligament Involvement in Gout: A Dual Energy Computed Tomography Study Nicola Dalbeth, Ramanamma Kalluru, Opetaia Aati, Fiona M. McQueen and Anthony Doyle, University of Auckland, Auckland, New Zealand, Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand 4 A Medical Education Moderators: Michael H. Pillinger, MD and Michael J. Battistone, MD 0:00 AM 59. Assessment of Examination Skills of 4th Year Medical Students Using a Novel Objective Structured Clinical Examination Seetha U. Monrad, Lisa DiPonio, Cliff Craig, John Zeller and R. Brent Stansfield, Univ of Michigan Med Ctr, Ann Arbor, MI 0:5 AM 59. Musculoskeletal Ultrasound Objective Structured Clinical Examination : An Assessment of the Test Eugene Y. Kissin, Peter C. Grayson, Amy C. Cannella, Amy M. Evangelisto 4, Janak R. Goyal 5, Rany Al Haj 6, Jay B. Higgs 7, Daniel G. Malone 8, Midori Jane Nishio 9, Darren Tabechian 0 and Gurjit S. Kaeley, Boston University, Boston, MA, Boston University Medical Center, Boston, MA, University of Nebraska Med Ctr, Omaha, NE, 4 Arthritis, Rheumatic and Back Disease Associates, Voorhees, NJ, 5 Raritan Bay Medical Center, Perth Amboy, NJ, 6 Jersey Shore Arthritis & Rheumatism A, Ocean, NJ, 7 San Antonio Military Medical Center, Fort Sam Houston, TX, 8 Family & Sports Orthopaedic Center, Beaver Dam, WI, 9 Adjunct Assistant Professor of Medicine/ Stanford University, Walnut Creek, CA, 0 Univ of Rochester Schl of Med, Rochester, NY, University of Florida, Ponte Vedra Beach, FL 46 C Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response Moderators: Suzanne C. Li, MD, PhD and Taunton R. Southwood, MD 4 0 Program Book

127 9:00 AM 59. Predictive Markers of Therapeutical Outcome and Their Role in the Ethiopathology of Juvenile Idiopathic Arthritis Maura Rossetti, Roberto Spreafico, Hong Zhang, Maryam Moshref, Nora G. Singer, D. J. Lovell, Carol A. Wallace 4 and Salvatore Albani, Sanford-Burnham Medical Research Institute, La Jolla, CA, MetroHealth Medical Center, Cleveland, OH, Cincinnati Children s Hospital, Cincinnati, OH, 4 Seattle Childrens Hospital, Seattle, WA 9:5 AM 594. Epigenetic Signature of the Response to Anti-TNF in Juvenile Idiopathic Arthritis Roberto Spreafico, Maura Rossetti, Hong Zhang, Maryam Moshref, Carol Wallace, D. J. Lovell and Salvatore Albani, Sanford-Burnham Medical Research Institute, La Jolla, CA, Childrens Hosp & Regional Med, Seattle, WA, Cincinnati Children s Hospital, Cincinnati, OH 9:0 AM 595. S00A At Baseline May Be Useful for Predicting Inactive Disease within Months in Polyarticular Juvenile Idiopathic Arthritis Gali Malul, Joy M. Whitbred, MaryAnn O Riordan, Sarah Ringold, Susan D. Thompson 4, Carol Wallace 5, Salvatore Albani 6 and Nora G. Singer 7, MetroHealth Medical Center, Cleveland, OH, Case Medical Center, Cleveland, OH, Seattle Children s Hospital, Seattle, WA, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Childrens Hosp & Regional Med, Seattle, WA, 6 Sanford-Burnham Medical Research Institute, La Jolla, CA, 7 Director, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH 9:45 AM 596. Rituximab Treatment for Antineutrophil Cytoplasmic Antibody - Associated Vasculitis in Children Katharine F. Moore, Leonard L. Dragone, Jennifer B. Soep and J. Roger Hollister, Seattle Children s Hospital / University of Washington, Seattle, WA, National Jewish Health, Denver, CO, Children s Hospital Colorado, Aurora, CO 0:00 AM 597. Degree of Initial Intracellular Folate Depletion May Predict Methotrexate Response in Juvenile Idiopathic Arthritis Leon van Haandel, Ryan S. Funk, Maria F. Ibarra, Mark F. Hoeltzel, Andrew Lasky, Daisy Dai, Rodger Gaedigk, J. Steven Leeder and Mara L. Becker, Children s Mercy Hospital, Kansas City, MO, Childrens Mercy Hospital, Kansas City, MO 0:5 AM 598. Anti-Drug Antibodies Are Associated with Diminished Drug Levels and Treatment Failure Miha Kosmac, Natasa Toplak, Gabriele Simonini, Ilaria Pagnini, Rolando Cimaz 4, Vladka Curin Serbec and Tadej Avcin 4, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia, University Children s Hospital Ljubljana Slovenia, Ljubljana, Slovenia, Anna Meyer Children s Hospital, Department of Pediatrics, University of Florence, Florence, Italy, 4 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 07 A Quality Measures and Innovations in Practice Management and Care Delivery Moderators: Andreas M. Reimold, MD 9:00 AM 599. Quality of Care for Medicare Recipients with Rheumatoid Arthritis: Vulnerable Populations More Likely to Receive Therapy with Glucocorticoids Alone Chris Tonner, Gabriela Schmajuk, Amal N. Trivedi, Grace Lin and Jinoos Yazdany, UCSF, San Francisco, CA, Brown University, Providence, RI, University of California San Francisco, San Francisco, CA 9:5 AM 600. Assessment of Quality of Care for Incident Lupus Nephritis in the U.S. Medicaid Population Jinoos Yazdany, Candace H. Feldman, Jun Liu, Michael M. Ward 4, Michael A. Fischer and Karen H. Costenbader 5, University of California San Francisco, San Francisco, CA, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, 4 NIAMS/NIH, Bethesda, MD, 5 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 9:0 AM 60. Improving Delivery of Care for JIA Across a Multi- Center Network Using a Shared Data Registry and Quality Improvement Science: The Pediatric Rheumatology Care and Outcomes Improvement Network Catherine A. Bingham, Lynn M. Darbie, Keith Marsolo, Jennifer E. Weiss, Stacy P. Ardoin 4, Ronald M. Laxer 5, D. J. Lovell, Murray H. Passo 6, Sheetal Vora 7, Beth S. Gottlieb 8, Timothy Beukelman 9, Nancy Griffin 0, Jason A. Stock, Michael L. Miller, Karen Onel, Tova Ronis 4, Peter Margolis and Esi M. Morgan DeWitt, Hershey Medical Center, Hershey, PA, Cincinnati Children s Hospital, Cincinnati, OH, Joseph M. Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, 4 Ohio State University, Columbus, OH, 5 The Hospital for Sick Children, Toronto, ON, 6 Medical University of South Carolina, Charleston, SC, 7 Medical College of Wisconsin, Milwaukee, WI, 8 Cohen Children s Medical Center of New York, New Hyde Park, NY, 9 Univ of Alabama-Birmingham, Birmingham, AL, 0 Cincinnati Children s Hospital Medical Center, Cincinnati, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Childrens Memorial Hospital, Chicago, IL, University of Chicago, Chicago, IL, 4 Stanford University Hospital, Palo Alto, CA 9:45 AM 60. The Rheumatology Informatics System for Effectiveness (RISE): Enabling Data Access Across Disparate Sites for Quality Improvement and Research Peter J. Embi, Itara Barnes, Rachel Myslinski, David Ervin, William Stevens, Tara Borlawsky and Philip R.O. Payne, The Ohio State University, Columbus, OH, American College of Rheumatology, Atlanta, GA WEDNESDAY November 4, 0 0 Program Book 5

128 WEDNESDAY November 4, 0 6 0:00 AM 60. Moving Into the Electronic Age: Validation of Rheumatology Self-Assessment Questionnaires On Tablet Computers Jessica M. Sage, Arshia Ali, Jennifer Farrell, Jennifer L. Huggins, Kara Covert, Diane Eskra, Rina Mina, Shweta Srivastava, Janalee Taylor, Tracy V. Ting, Esi M. Morgan DeWitt and Hermine I. Brunner, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, University of Cincinnati, Cincinnati, OH, Cincinnati Children s Hospital Medical Center/University of Cincinnati, Cincinnati, OH 0:5 AM 604. Ask a Doc Rheumatologic Care Delivered Just in Time Eric D. Newman, Chelsea Cedeno, Thomas M. Harrington, Thomas P. Olenginski, Alfred E. Denio, Androniki Bili, Brian DelVecchio, Carolyn Houk and Paul F. Simonelli, Geisinger Medical Center, Danville, PA, Geisinger Health System, Frackville, PA Ballroom A Rheumatoid Arthritis - Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis Moderators: Ernest Choy, MD and Shahin Jamal, MD, MSc 9:00 AM 605. Exploration of Possible Preliminary Descriptions of Remission Based On RAPID, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients Isabel Castrejón, Maxime Dougados, Bernard Combe, Bruno Fautrel 4 and Theodore Pincus, NYU Hospital for Joint Diseases, New York, NY, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, Hopital Lapeyronie, Montpellier, France, 4 APHP- Pitie Salpetriere Hospital / UPMC, Paris, France 9:5 AM 606. Patient Reported Outcomes in Early Arthritis Patients L. Heimans, K.V.C. Wevers-de Boer, K. Visser, R. Goekoop, T.H.E. Molenaar, B.A. Grillet 4, Tom Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Haga Hospital, The Hague, Groene Hart Hospital, Netherlands, 4 Zorgsaam hospital, Terneuzen, Netherlands 9:0 AM 607. Adherence to a Treat-to-Target Strategy in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Remission Induction Cohort Marloes Vermeer, Ina H. Kuper, Hein J. Bernelot Moens, Monique Hoekstra 4, Marcel D. Posthumus 5, Piet L.C.M. van Riel 6 and Mart A.F.J. van de Laar, University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, Medisch Spectrum Twente, Enschede, Netherlands, Ziekenhuisgroep Twente, Hengelo, Netherlands, 4 Isala Klinieken, Zwolle, Netherlands, 5 University Medical Center Groningen, Groningen, Netherlands, 6 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 0 Program Book 9:45 AM 608. Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA) Helga Radner, Farideh Alasti, Josef S. Smolen and Daniel Aletaha, Medical University Vienna, Vienna, Austria, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 0:00 AM 609. Construct and Criterion Validity of Several Proposed DAS8 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study Aatke van der Maas, Elisabeth Lie, Robin Christensen, Ernest Choy 4, Yaël A. de Man 5, Piet L.C.M. van Riel 6, Thasia G. Woodworth 7 and Alfons A. den Broeder, Sint Maartenskliniek, Nijmegen, Netherlands, Diakonhjemmet Hospital, Oslo, Norway, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, 4 Cardiff University School of Medicine, Cardiff, United Kingdom, 5 Erasmus Medical Centre, Rotterdam, Netherlands, 6 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 7 Visiting Clinical Researcher, Geffen School of Medicine, UCLA, Los Angeles, CA 0:5 AM 60. Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis - Results From the Canadian Early Arthritis Cohort Bindee Kuriya, Juan Xiong, Gilles Boire, Boulos Haraoui 4, Carol A. Hitchon 5, Janet E. Pope 6, J. Carter Thorne 7, Diane Tin 7, Edward Keystone, Vivian P. Bykerk 8 and CATCH 9, University of Toronto, Toronto, ON, Mount Sinai Hospital, Toronto, ON, CHUS - Sherbrooke University, Sherbrooke, QC, 4 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 5 University of Manitoba, Winnipeg, MB, 6 St. Joseph s Health Care London, London, ON, 7 Southlake Regional Health Centre, Newmarket, ON, 8 Hospital for Special Surgery, New York, NY, 9 Toronto, ON Salon B Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis and Spondyloarthritis Moderators: Rafael Valle-Oñate, MD and Dirk Elewaut, MD, PhD 9:00 AM 6. Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis? Arane Thavaneswaran, Vinod Chandran and Dafna Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto Western Hospital, University of Toronto, Toronto, ON 9:5 AM 6. Localisation of Bone Marrow Edema in Sacroiliac Joints in Spondyloarthritis Patients: Does the Site of Lesions Change Over a -Month Period? Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Victoria Navarro-Compán, Floris van Gaalen, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands

129 9:0 AM 6. Effect of Certolizumab Pegol On Signs and Symptoms in Patients with Psoriatic Arthritis with and without Prior Anti-TNF Exposure: 4 Week Results of a Phase Double-Blind Randomized Placebo-Controlled Study Philip Mease, Roy M. Fleischmann, Jürgen Wollenhaupt, Atul A. Deodhar 4, Danuta Kielar 5, Franz Woltering 6, Christian Stach 6, Bengt Hoepken 6, Terri Arledge 7 and Désirée van der Heijde 8, Seattle Rheumatology Associates, Seattle, WA, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Schön- Klinik, Hamburg, Germany, 4 Oregon Health & Science University, Portland, OR, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, Monheim am Rheim, Germany, 7 UCB Pharma, Rtp, NC, 8 Leiden University Medical Center, Leiden, Netherlands 9:45 AM 64. The Risk of Diabetes in Psoriatic Arthritis and Rheumatoid Arthritis Maureen Dubreuil, Young Hee Rho, Ada Man, Yanyan Zhu, Yuqing Zhang, Thorvardur Love 4, Alexis Ogdie 5, Joel Gelfand 6 and Hyon Choi, Boston University School of Medicine, Boston, MA, Boston University, Boston, MA, Department of Biostatistics, Boston University School of Public Health, Boston, MA, 4 Labspitali University Hospital, Reykjavik, Iceland, 5 University of Pennsylvania, Philadelphia, PA, 6 University of Pennsylvania., Philadelphia, PA 0:00 AM 65. Circulating Levels of Citrullinated Vimentin Fragments Are Diagnostic and Prognostic in Ankylosing Spondylitis; Evidence for Disease-Related Citrullination Anne C. Bay-Jensen, Morten Asser Karsdal, Efstathios Vassiliadis, Stephanie Wichuk, Zheng Zhao 4, Robert GW Lambert, Rik Lories 5, Claus Christiansen 6 and Walter P. Maksymowych, Nordic Bioscience A/S, Herlev, Denmark, Nordic Bioscience, Herlev, Denmark, University of Alberta, Edmonton, AB, 4 Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, 5 KU Leuven, Leuven, Belgium, 6 CCBR, Ballerup, Denmark Dennis, Alan Oglesby 4, Mark B. McGuire 5, Ramesh Pappu 6, Charles T. Molta 7 and Greg Keenan, Washington Hospital Ctr, Washington, DC, Human Genome Sciences, Inc., Rockville, MD, University of California, San Francisco, San Francisco, CA, 4 GlaxoSmithKline, Research Triangle Park, NC, 5 Medical Data Analytics, Parsippany, NJ, 6 GlaxoSmithKline, USA, Philadelphia, PA, 7 GlaxoSmithKline, Philadelphia, PA 9:5 AM 68. Lupus Disease Activity Severely Impairs Pandemic Influenza A/HN Vaccine Immune Response in Patients without Therapy Eduardo F. Borba, Sandra G. Pasoto, Ana L. Calich, Ricardo Fuller, Vilma S.T. Viana, Margareth Vendramini, Joao Miraglia, Maria A. Ishida and Eloisa Bonfa 4, University of Sao Paulo, Sao Paulo, Brazil, Fundação Butantan, São Paulo, Brazil, Adolfo Lutz Institute, Sao Paulo, Brazil, 4 University of São Paulo, São Paulo, Brazil 9:0 AM 69. A Double-Blind Randomized Placebo-Controlled Trial of the Effect of vitamin D On the Interferon Signature in Patients with Systemic Lupus Erythematosus Cynthia Aranow, Maria Dall Era, Elena M. Massarotti, Meggan C. Mackay 4, Andreea Coca 5, Fotios Koumpouras 6, Marc C. Levesque 7, W. Winn Chatham 8, Megan E. B. Clowse 9, Lisa G. Criscione-Schreiber 9, Sherri Callahan 0, Ellen A. Goldmuntz 0, Lynette Keyes-Elstein, Betty Diamond and Diane L. Kamen, Feinstein Institute for Medical Research, Manhasset, NY, University of California, San Francisco, San Francisco, CA, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 The Feinstein Institute, Manhasset, NY, 5 University of Rochester, Rochester, NY, 6 West Penn Hospital, Pittsburgh, PA, 7 University of Pittsburgh, Pittsburgh, PA, 8 University of Alabama at Birmingham, Birmingham, AL, 9 Duke University Medical Center, Durham, NC, 0 NIAID/NIH Rm 6807, Bethesda, MD, Rho Federal Systems, Inc., Chapel Hill, NC, Feinstein Institute Med Rsch, Manhasset, NY, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC 0:5 AM 66. The Transition From Psoriasis (Ps) to Psoriatic Arthritis (PsA) Is Associated with Elevated Circulating Osteoclast Precursors (OCP) and Increased Expression of DC-STAMP Ya-Hui Chiu, Edward M. Schwarz, Dafna Gladman, Sharon Moorehead, Michelle Smith, Rick Barrett and Christopher T. Ritchlin, University of Rochester, Rochester, NY, Toronto Western Hospital and University of Toronto, Toronto, ON, University of Rochester Medical Center, Rochester, NY Hall E Systemic Lupus Erythematosus - Clinical Aspects and Treatment IV: Therapeutics Moderators: Jose A. Gomez-Puerta, MD, PhD and Daniel Wallace, MD 9:00 AM 67. Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States Christopher E. Collins, Siva Narayanan, Maria Dall Era, Greg 9:45 AM 60. Randomized, Double-Blind, Placebo-Controlled Studies of P40 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE Robert Zimmer, Daniel J. Wallace and Sylviane Muller, ImmuPharma France, Mulhouse, France, Cedars-Sinai Medical Center, Los Angeles, CA, CNRS, Strasbourg, France 0:00 AM 6. Sustained Disease Improvement and Safety Profile Over 745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients Joan T. Merrill, Richard A. Furie, Daniel J. Wallace, William Stohl 4, W. Winn Chatham 5, Arthur Weinstein 6, James D. McKay, Ellen M. Ginzler 8, Z. John Zhong 9, William W. Freimuth 9 and Michelle A. Petri 0, Oklahoma Medical Research Foundation, Oklahoma City, OK, North Shore-LIJ Health System, Lake Success, NY, Cedars-Sinai Medical Center, Los Angeles, CA, 4 University of Southern California Keck School of Medicine, Los Angeles, CA, 5 University of Alabama at Birmingham, Birmingham, AL, 6 Washington Hospital Center, Washington, DC, 7 SUNY-Downstate Medical Center, Brooklyn, NY, 8 Human 0 Program Book 7 WEDNESDAY November 4, 0

130 WEDNESDAY November 4, 0 8 Genome Sciences, Inc., Rockville, MD, 9 Johns Hopkins University School of Medicine, Baltimore, MD 0:5 AM 6. Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo- Controlled Phase Study K. Kalunian, Joan T. Merrill, R. Maciuca, Wenjun Ouyang, J. M. McBride, Michael J. Townsend, E. Park, J. Li, X. Wei, A. Morimoto, R. Boismenu, John C. Davis Jr. and William P. Kennedy, UCSD School of Medicine, La Jolla, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, Genentech, Inc, South San Francisco, CA ARHP SESSIONS 9:00-0:0 AM 06 Forming an Education and Support Group from the Ground up Moderator: Thuy T. Beam, RN, BSN Upon completion of this session, participants should be able to: review the literature of the value of support and education groups for both teens and their parents analyze identified barriers and how to overcome them analyze and evaluate the success of a collaborative effort discuss the development of three programs models, their pro and cons identify options and resources available to develop a strong community program 9:00 AM Getting Started: From Concept to Program Development Sandra J. Watcher, BSN 9:5 AM Building the Community and Engaging Partners to Fulfill the Vision Elyse M. Leon-Reyes, BA, MPA 9:50 AM Bringing It All Together: Patient Impact and Resource Building Jennifer A. Ziegler 0:5 AM Question & Answer 0 Osteoporosis: 0 Update Moderator: Hazel L. Breland, PhD, OTR/L Upon completion of this session, participants should be able to: review osteoporosis treatments and recommendations for duration of therapy describe the importance and effectiveness of medical management post-hip fracture to reduce risk of subsequent fracture cite the evidence for exercise and other non-pharmacologic therapeutic interventions for fracture prevention and hyperkyphosis 0 Program Book 9:00 AM Update on Imaging and Medications: When, Who, and How Long Nancy E. Lane, MD 9:5 AM Post Fracture Management Michael R. McClung, MD 9:50 AM Best Posture, Movement and Exercise for Vertebral Fracture Prevention and Hyperkyphosis Wendy Katzman, DSc, PT 0:5 AM Question & Answer ARHP CONCURRENT ABSTRACT SESSIONS 9:00-0:0 AM 40 A Systemic Sclerosis, Vasculitis, Crohn s and Spondylarthropathies Moderators: Elizabeth G. Salt, PhD and Emily C. Somers, PhD 9:00 AM 6. Taking Charge of Systemic Sclerosis: A Pilot Study of an Internet Self-Management Program Janet L. Poole, Dinesh Khanna, Betty Skipper and Cindy F. Mendelson, University of New Mexico, Albuquerque, NM, University of Michigan, Ann Arbor, MI, University of New Mexico, NM 9:5 AM 64. Changes in Leisure Participation in Persons with Systemic Sclerosis Cindy F. Mendelson, Jessica Greaves and Janet L. Poole, University of New Mexico, Albuquerque, NM 9:0 AM 65. The Impact of Sexual Difficulties in Women with Scleroderma and Interpersonal Relationships Tanaka Ngcozana, Louise Parker, Christopher P. Denton and Voon Ong, UCL Medical School and Royal Free Hosp, London, United Kingdom, UCL, London, United Kingdom, UCL Medical School, London, England 9:45 AM 66. The Utility of the Patient Health Questionnaire-9 to Assess Suicide Risk in Patients with Systemic Sclerosis Ilya Razykov, Marie Hudson, Murray Baron and Brett D. Thombs, McGill University, Montreal, QC, Jewish General Hospital, Montreal, QC 0:00 AM 67. Gender Differences of Concepts Important to People Living with Crohn s Disease and Their Coverage by Commonly Used Patient-Reported Outcome Instruments: Patient s Perspective Elevated by a Qualitative Study Mona Dür, Michaela Coenen, Josef S. Smolen, Clemens Dejaco and Tanja A. Stamm, Medical University of Vienna,

131 Vienna, Austria, Ludwig-Maximilians-University, Munich, Germany, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 0:5 AM 68. The Lumbo-Pelvic Muscles and Axial Spondyloarthritis: A Pilot Observational Study Janet Millner, Julie A. Hides, Patricia Lewis and Jane Zochling, Royal Hobart Hospital, Hobart, Australia, Australian Catholic University, Brisbane, Australia, Menzies Research Institute Tasmania, Hobart, Australia 04 A Clinical and Rehabilitative Aspects of Osteoarthritis Moderators: Leigh F. Callahan, PhD and Dorothy D. Dunlop, PhD 9:00 AM 69. Associations of Current and Early-Life Socioeconomic Positions with Risk of Self-Reported Doctor-Diagnosed Arthritis in a Family-Medicine Cohort of North-Carolinians Antoine A. Baldassari, Rebecca J. Cleveland and Leigh F. Callahan, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of North Carolina, Chapel Hill, NC 9:5 AM 60. Rheumatoid Arthritis and Osteoarthritis in the Population: How Different Is the Impact? Christina H. Chan, Mayilee Canizares and E.M. Badley, Division of Healthcare Outcomes and Research, Toronto Western Research Institute, Toronto, ON, Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON 9:0 AM 6. Radiographic Osteoarthritis Severity Is Associated with an Increased Risk of Developing Knee Pain: Findings From the Osteoarthritis Initiative Jingbo Niu, David T. Felson, Tuhina Neogi and Yuqing Zhang, Boston Univ School of Medicine, Boston, MA 9:45 AM 6. Doing Is Believing: Health Beliefs Before and After an Exercised-Based Rehabilitation Programme for Chronic Knee Pain Mike Hurley and Dr Nicola E. Walsh, St George s University of London, London, United Kingdom, University of the West of England Bristol, Bristol, United Kingdom 0:00 AM 6. Independence At Home: Real or Perceived Hazel L. Breland, Medical University of South Carolina, Charleston, SC 0:5 AM 64. Physical Disability, Perceived Dependence and Depression in Older Women with Osteoarthriti Kisoo Park, Monique A. Gignac and E. M. Badley, Gyeongsang National University, Jinju, South Korea, Arthritis Community Research and Evaluation Unit, Toronto Western Research Institute and University of Toronto, Toronto, ON, Division of Health Care and Outcomes Research,Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON ACR SESSIONS :00 AM - Noon Hall D Amyloidosis 0 Moderator: Gregory C. Gardner, MD Speaker: Jonathan Kay, MD Upon completion of this session, participants should be able to: describe to a colleague the immunology of various forms of amyloidosis compare and contrast the clinical manifestation of amyloidosis order appropriate laboratory/diagnostic testing explain the current therapeutic approaches to amyloidosis 50 B Mechanisms of Autoinflammatory Diseases Moderator: Robert Lafyatis, MD Speaker: Richard M. Siegel, MD, PhD Upon completion of this session, participants should be able to: describe the clinical presentation of patients with TRAPs and other auto-inflammatory diseases explain recent advances in understanding pathogenesis of these diseases ACR SESSIONS :00 AM - :0 PM Ballroom C Making Sense of Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases Moderator: Luis Eduardo C. Andrade, MD, PhD Upon completion of this session, participants should be able to: review the technical basis of the several methodological platforms for autoantibody determination discuss the pros and cons of each methodological platform assess the clinical performance of autoantibodies determined by different methodological platforms recognize the perspectives for optimum autoantibody testing in the globalized world :00 AM Elements for Discriminating a Positive ANA-HEp- Test in Patients with and without Systemic Rheumatic Disease Luis Eduardo C. Andrade, MD, PhD :0 AM Antinuclear Antibody Screening: Indirect Immunofluorescence on HEp- Cells versus ELISA and Related Platforms Donald B. Bloch, MD Noon How May the Choice of the Laboratory Technique Influence Results in the Lab: Critical Analysis of Different Autoantibody Assays and Proposition of Algorithms for Optimal Clinical Value Johan Ronnelid, MD 0 Program Book 9 WEDNESDAY November 4, 0

132 WEDNESDAY November 4, 0 Hall E Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice Moderator: Mark L. Robbins, MD, MPH Upon completion of this session, participants should be able to: explain which measure(s) best fits your practice setting describe the time required to administer and score each measure discuss how to locate the forms/scoring sheets review the strengths and weaknesses of each measure that have practical implications for following patients outline the usefulness of a registry when implementing measures in a practice setting :00 AM Rheumatoid Arthritis Treating to Target: Why the Time has Come For All Rheumatologists to Routinely Measure Rheumatoid Arthritis Disease Activity in their Practices James R. O Dell, MD :0 AM Which Rheumatoid Arthritis Disease Activity Measures to Use in Practice and Why Charles M. King II, MD :40 AM Accessing and Using Rheumatoid Arthritis Disease Activity Measures Kaleb Michaud, PhD Noon Using the ACR Rheumatology Clinical Registry to Document Rheumatoid Arthritis Disease Activity Salahuddin Kazi, MD ACR CONCURRENT ABSTRACT SESSIONS :00 AM - :0 PM 07 A Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treat-to- Target Era Moderators: Lee S. Simon, MD and Jeffrey R. Curtis, MD, MPH :00 AM 65. Exploring the Influence of Patient Perceptions On Medication Escalation in Daily Practice Jos Hendrikx, Wietske Kievit, Jaap Fransen and Piet L.C.M. van Riel, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands :0 AM 67. Cost-Effectiveness and Cost-Utility Analysis of Treat-to- Target Versus Usual Care in Early Rheumatoid Arthritis: Results of the Dutch Rheumatoid Arthritis Monitoring Registry Marloes Vermeer, Wietske Kievit, Ina H. Kuper, Annemarie Braakman-Jansen 4, Hein J. Bernelot Moens 5, Theo R. Zijlstra 6, Alfons A. den Broeder 7, Piet L.C.M. van Riel, Jaap Fransen and Mart A.F.J. van de Laar, University of Twente & Medisch Spectrum Twente, Enschede, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Medisch Spectrum Twente, Enschede, Netherlands, 4 University of Twente, Enschede, Netherlands, 5 Ziekenhuisgroep Twente, Hengelo, Netherlands, 6 Isala Klinieken, Zwolle, Netherlands, 7 Maartenskliniek, Nijmegen, Netherlands :45 AM 68. Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, Ozgur Tunceli, Jeffrey R. Curtis, Tatia C. Woodward, Siting Zhou, Yen-Wen Chen and Ancilla W. Fernandes 4, HealthCore, Inc, Wilmington, DE, Univ of Alabama-Birmingham, Birmingham, AL, MedImmune, LLC, Gaithersburg, MD, 4 MedImmune LLC, Gaithersburg, MD Noon 69. Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort Isabel Castrejón, Maxime Dougados, Bernard Combe, Francis Guillemin 4, Bruno Fautrel 5 and Theodore Pincus, NYU Hospital for Joint Diseases, New York, NY, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, Hopital Lapeyronie, Montpellier, France, 4 Faculte de Medecin/BP 84, Vandoeuvreles-Nancy, France, 5 APHP-Pitie Salpetriere Hospital / UPMC, Paris, France :5 PM 640. Methotrexate Adverse Events in a Cohort of US Veterans with Rheumatoid Arthritis Lisa A. Davis, Brooke Ivan Polk, Alyse D. Mann, Gail S. Kerr 4, Andreas M. Reimold 5, Grant W. Cannon 6, Ted R. Mikuls 7 and Liron Caplan 8, Univ of Colorado School of Med, Aurora, CO, University of Colorado Medical School, Aurora, CO, Denver VA Medical Center, Denver, CO, 4 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 5 Dallas VA and University of Texas Southwestern, Dallas, TX, 6 George E. Wahlen VA Medical Center, Salt Lake City, UT, 7 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 8 Denver VA and University of Colorado School of Medicine, Aurora, CO 0 :5 AM 66. Understanding Why Treat-to-Target Strategies Are Difficult to Follow Liana Fraenkel, Meaghan Cunningham and Paul Falzer, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Yale University School of Medicine, New Haven, CT, VA Connecticut Healthcare System, New Haven, CT 0 Program Book 0 B Fibromyalgia and Soft Tissue Disorders II Moderators: Mary-Ann Fitzcharles, MBChB, MD and Dennis Ang, MD :00 AM 64. Time-to-Improvement of Pain and Sleep in Clinical Trials of Pregabalin Treatment of Fibromyalgia Lesley M. Arnold, Andrew Clair, Birol Emir, Lynne Pauer and

133 E. Malca Resnick, University of Cincinnati College of Medicine, Cincinnati, OH, Pfizer Inc, New York, NY :5 AM 64. Rate and Predictors of Work Disability in Fibromyalgia Frederick Wolfe, Brian T. Walitt, Robert S. Katz and Winfried Häuser 4, National Data Bank for Rheumatic Diseases, Wichita, KS, Washington Hospital Center, Washington, DC, Rush University Medical Center, Chicago, IL, 4 Technische Universität München, Munich, Germany :0 AM 64. Grey Matter Decrease in Fibromyalgia Is Related to Pain Catastrophizing and Pain Sensitivity Marta Ceko, Mary-Ann Fitzcharles, M. Catherine Bushnell and Petra Schweinhardt, McGill University, Montreal, QC :45 AM 644. Functional Magnetic Resonance Imaging of Working Memory in Fibromyalgia: Support for a Competing Demands Theory of Cognitive Function in Chronic Pain Anson E. Kairys, Gabriela Ramirez, Eric Ichesco, Johnson P. Hampson, Richard E. Harris, Daniel J. Clauw, Tobias Schmidt- Wilcke and Jennifer M. Glass, University of Michigan, Ann Arbor, MI Noon 645. The Transcription Factor Mohawk Plays an Important Role for Maintaining Human Anterior Cruciate Ligament Homeostasis Hiroyuki Nakahara, Akihiko Hasegawa, Fumiaki Ayabe, Tetsuya Matsukawa, Koji Otabe, Tomo Yonezawa, Martin K. Lotz and Hiroshi Asahara, The Scripps Research Institute, La Jolla, CA :5 PM 646. Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia John B. Wong and Chenchen Wang, Tufts Medical Center, Boston, MA :0 AM 649. Trends in US Arthroplasty Rates : Patients with Inflammatory Arthritis Continue to Require Joint Replacement Christina Mertelsmann-Voss, Ting Jung Pan, Stephen L. Lyman, Mark P. Figgie and Lisa A. Mandl, Hospital for Special Surgery, Cornell University, New York, NY, Hospital for Special Surgery, New York, NY, Hospital Special Surgery, New York, NY :45 AM 650. The Meteor Trial: Preliminary Results of an RCT of Arthroscopic Partial Meniscectomy Vs. Physical Therapy in Patients greater Than 45 Jeffrey N. Katz, Christine E. Chaisson, Brian Cole, Laurel Donnell-Fink, Morgan Jones 4, Bruce Levy 5, Lisa A. Mandl 6, Scott Martin, Robert Marx 6, Anthony Miniaci 4, Joseph Palmisano 7, Emily Reinke 8, Clare Safran-Norton, Debra J. Skoniecki 9, Daniel Hal Solomon 9, Kurt P. Spindler 8, John Wright, Rick Wright 0 and Elena Losina, Brigham and Women s Hospital, Boston, MA, Boston University School of Public Health, Boston, MA, Rush University, Chicago, IL, 4 Cleveland Clinic, Cleveland, OH, 5 Mayo Clinic, Rochester, MN, 6 Hospital for Special Surgery, New York, NY, 7 Boston University School of Public Health, 8 Vanderbilt University, Nashville, TN, 9 Brigham & Womens Hospital, Boston, MA, 0 Washington University, MO Noon 65. Associations Between Body Mass Index and Physical Activity Following Total Knee Replacement Carol A. Oatis, Wenjun Li, Milagros Rosal, David Ayers and Patricia D. Franklin, Arcadia University, Glenside, PA, University of Massachusetts Medical School, Worcester, MA :5 PM 65. Benefits of Aerobic Training in Patients with Ankylosing Spondylitis Are Not Coupled by Effects On Cytokines: A Randomized Controlled Trial Fabio Jennings, Hilda A. Oliveira, Marcelo C. Sousa, Vaneska G. Cruz, Fabio S. Lira and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil 45 A Orthopedics, Low Back Pain, and Rehabilitation Moderators: Leena Sharma, MD and Agustin Escalante, MD :00 AM 647. Effects of Pain Expectations On Neuromuscular Control of the Spine in Patients with Chronic Low Back Pain and Healthy Participants Yves Henchoz, Charles Tétreau, Jacques Abboud, Mathieu Piché and Martin Descarreaux, Université du Québec à Trois-Rivières, Trois-Rivières, QC :5 AM 648. Randomized Placebo-Controlled Trial of Local Steroid Injection for Moderately Severe Carpal Tunnel Syndrome Isam Atroshi, Magnus Flondell and Manfred Hofer, Lund University, Hässleholm, Sweden, Lund University, Malmö, Sweden, Kristianstad Hospital, Kristianstad, Sweden 4 A Pediatric Rheumatology - Pathogenesis and Genetics Moderators: Anthony R. French, MD and James W. Verbsky, MD, PhD :00 AM 65. A Subset of up-regulated IFN Regulated Genes in Candle Patients Decrease with Treatment with a JAK Inhibitor Adriana Almeida de Jesus, Yin Liu, Gina A. Montealegre, Adam L. Reinhardt, Diane Brown 4, Antonio Torrelo 5, Angel V. Casano 6, Lena Das 7, Yongqing Chen 8, Yan Huang 8, Deborah Stone 9, Dawn C. Chapelle, Nicole Plass 0, Steven H. Zuckerman, William Macias and Raphaela T. Goldbach-Mansky, National Institute of Arthritis Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, NIAMS, Bethesda, MD, Children s Hosp of Omaha/UNMC, Omaha, NE, 4 Children s Hospital Los Angeles, Los Angeles, CA, 5 Departments of Pediatric Dermatology, Hospital Niño Jesús, Madrid, Spain, Madrid, Spain, 6 Meditex Spain, Malaga, Spain, 7 KK Women s and Children s Hospital, Singapore, Singapore, 8 Translational Autoinflammatory WEDNESDAY November 4, 0 0 Program Book

134 Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, 9 National Institutes of Health, Bethesda, MD, 0 National Institutes of Health Clinical Center, Bethesda, MD, Lilly Research Labs, Indianapolis, IN, Eli Lilly and Company, Indianapolis, IN, Translational Autoinflammatory Diseases Section NIAMS NIH, Bethesda, MD :5 AM 654. Genome-Wide Association Study of Methotrexate Response Identifies Novel Genes in a Large Cohort of European Juvenile Idiopathic Arthritis Cases Joanna Cobb, Erika Cule, Halima Moncrieffe, Edward Flynn 4, Anne Hinks, Fiona Patrick, Laura Kassoumeri, Simona Ursu, Maja Bulatovic 5, Marek Bohm 6, Bertrand D. van Zelst 7, Pavla Dolezalova 6, Robert De Jonge 7, Nico M. Wulffraat 5, Stanton Newman 8, Maria de Iorio, Lucy R. Wedderburn and Wendy Thomson, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Imperial College London, United Kingdom, University College London, London, United Kingdom, 4 University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 5 University Medical Centre Utrecht, Utrecht, Netherlands, 6 First Faculty of Medicine and General Faculty Hospital, Prague, Czech Republic, 7 Erasmus Medical Center, Rotterdam, Netherlands, 8 City University London, London, United Kingdom :0 AM 655. Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB7a Leading to Decreased Cytolytic Activity Randy Q. Cron, Mingce Zhang, Christina J. Bemrich-Stolz and Timothy Beukelman, Univ of Alabama-Birmingham, Birmingham, AL Human Genome Research Institute, National Institutes of Health, Bethesda, MD, National Institutes of Health, National Human Genome Research Institute, Bethesda, MD, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 5 University of Genova, Genova, Italy, 6 Istituto Giannina Gaslini, Genova, Italy, 7 Hacettepe University, Ankara, Turkey, 8 Emory Children s Center, Atlanta, GA, 9 University of Utah, Salt Lake City, UT, 0 The Cleveland Clinic, Cleveland, OH, Children s Hospital Montefiore, Bronx, NY, Stanford University Med Ctr, Stanford, CA, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 4 Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, 5 Instituto de Pediatria e Puericultura Martagão Gesteira (IPPMG) da Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 6 Hospital for Sick Children, Toronto, ON, 7 University College London (UCL), London, United Kingdom, 8 University Childrenxs Hospital, Barcelona, Spain, 9 National Human Genome Research Institute, Nationsl Institutes of Health, Bethesda, MD, 0 The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, Wake Forest School of Medicine, Winston-Salem, NC, University College London, London, United Kingdom :5 PM 658. Correlation Between Mefv Genotype and Interleukin (IL)β secretion and Role of the nlr Family Pyrin Domain Containing (Nlrp) Inflammasome in Patients with Familial Mediterranean Fever (FMF) Alessia Omenetti, Sonia Carta, Delfino Laura, Alberto Martini, Anna Rubartelli 4 and Marco Gattorno, Pediatrics II Unit G Gaslini Institute, Genoa, Italy, Cell Biology, lst-san Martino, Genoa, Italy, Pediatrics ll Unit, G Gaslini lnstitute and University of Genoa, Genoa, Italy, 4 lst-san Martino, Genoa, Italy, Genoa, Italy WEDNESDAY November 4, 0 :45 AM 656. Elevated Serum Follistatin-Like Protein Suggests an Interleukin- Independent Pathway for Inflammation in Patients with Cryopyrin Associated Periodic Syndromes Mark Gorelik, Daniel Bushnell, Raphaela T. Goldbach-Mansky, Hal M. Hoffman 4 and Raphael Hirsch 5, Univ of Pittsburgh Med Ctr Children s Hospital, Pittsburgh, PA, Childrens Hospital Pittsburgh, Pittsburgh, PA, Translational Autoinflammatory Diseases Section NIAMS NIH, Bethesda, MD, 4 University of California at San Diego, La Jolla, CA, 5 Childrens Hosp Pittsburgh, Pittsburgh, PA Noon 657. Genome-Wide Association Meta-Analysis of Eight Independent Systemic Juvenile Idiopathic Arthritis Collections Reveals Regional Association Spanning the Major Histocompatibility Complex Class II and III Gene Cluster Michael J. Ombrello, Elaine Remmers, Alexei A. Grom, Wendy Thomson 4, Alberto Martini 5, Marco Gattorno 6, Seza Ozen 7, Sampath Prahalad 8, John F. Bohnsack 9, Andrew Zeft 0, Norman T. Ilowite, Elizabeth D. Mellins, Ricardo A. G. Russo, Claudio Len 4, Sheila K. Oliveira 5, Rae SM Yeung 6, Lucy R. Wedderburn 7, Jordi Anton Lopez 8, Colleen Satorius 9, Ioanna Tachmazidou 0, Carl D. Langefeld, Eleftheria Zeggini 0, Susan D. Thompson, Patricia Woo and Daniel L. Kastner, National Ballroom A Rheumatoid Arthritis - Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis Moderators: Merete L. Hetland, MD, PhD, DMSc and Yvonne C. Lee, MD, MMedSc :00 AM 659. An Expanded Repertoire of Anti-Citrullinated Peptide Antibodies Is Associated with Interstitial Lung Disease in Rheumatoid Arthritis Jon T. Giles, Sonye Danoff, Jeremy Sokolove, Robert Winchester 4, Dimitrios A. Pappas 5, Catriona Cramb 6, Geoffrey Connors 7, Stanley S. Siegelman 8, William H. Robinson 9 and Joan M. Bathon, Columbia University Medical Center, New York, NY, Johns Hopkins School of Medicine, Baltimore, MD, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4 Columbia University, New York, NY, 5 Columbia University, College of Physicians and Surgeons, New York, NY, 6 VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, 7 Division of Pulmonary and Critical Care Medicine, Yale University, New Haven, CT, 8 Department of Radiology, Johns Hopkins University, Baltimore, MD, 9 Stanford University, Palo Alto, CA 0 Program Book

135 :5 AM 660. Progressive Radiographic Joint Damage in Established Rheumatoid Arthritis: Common and Strongly Associated with Seropositivity Siri Lillegraven, Nancy A. Shadick, Zarif Jabbar-Lopez, Anna Potapov, Michelle A. Frits, Christine K. Iannaccone, Espen A. Haavardsholm, Tore K. Kvien, Michael Weinblatt and Daniel H. Solomon, Diakonhjemmet Hospital, Oslo, Norway, Brigham and Women s Hospital, Boston, MA, Harvard School of Public Health, Boston, MA :0 AM 66. Disease Activity Score 8-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable? Roy M. Fleischmann, Désirée van der Heijde, Andrew S. Koenig, Ronald Pedersen, Annette Szumski, Lisa Marshall and Eustratios Bananis, University of Texas, Dallas, TX, Leiden University Medical Center, Leiden, Netherlands, Pfizer Inc., Collegeville, PA :45 AM 66. Tightening up: Musculoskeletal Ultrasound Could Further Individualise Treatment Decisions in Early Rheumatoid Arthritis Patients Treated by a Step-up DMARD Escalation Regimen James Dale, David Purves, Alex McConnachie, Duncan Porter and Iain B. McInnes, University of Glasgow, Glasgow, United Kingdom, Gartnavel General Hosp, Glasgow, United Kingdom Noon 66. A Variant in the Osteoprotegerin Gene Is Associated with Coronary Atherosclerosis in Patients with Rheumatoid Arthritis: Results From a Candidate Gene Study Cecilia P. Chung, Joseph F. Solus, Annette Oeser, Chun Li, Paolo Raggi, Jeffrey R. Smith and C. Michael Stein, Vanderbilt University, Nashville, TN, Emory University, Atlanta, GA :5 PM 664. A Multi-Biomarker Disease Activity (VECTRA DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab Shintaro Hirata, Douglas J. Haney, Guy Cavet, Rebecca Bolce, Wanying Li, Nadine Defranoux, David Chernoff, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Crescendo Bioscience Inc., South San Francisco, CA 46 C Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome- Wide Association Studies Moderators: David S. Pisetsky, MD, PhD and Pierre Miossec, MD, PhD :00 AM 665. Metabolic Reprogramming of Autoimmune T Cells in Rheumatoid Arthritis Zhen Yang, Hiroshi Fujii, Shalini Mohan, Jorg J. Goronzy and Cornelia M. Weyand, Stanford University School of Medicine, Stanford, CA, Tohoku University, Sendai, Japan :5 AM 666. A Link Between B Cells and Bone Erosion in RA: RANKL Production by Memory B Cells Nida Meednu, Teresa Owen, Hengwei Zhang, Christopher A. Cistrone, Lianping Xing and Jennifer H. Anolik, University of Rochester, Rochester, NY :0 AM 667. Activated Memory B Cell Compartment in Rheumatoid Arthritis: Impact of B Cell Depletion Therapy Diana G. Adlowitz, Jennifer Hossler, Jamie Biear, Christopher A. Cistrone, Teresa Owen, Wensheng Wang, Arumugam Palanichamy, Ignacio Sanz and Jennifer H. Anolik, University of Rochester Medical Center, Rochester, NY, Emory University, Atlanta, GA :45 AM 668. Interferon and B-Cell Gene Signatures Contribute to Diagnosis of pre-clinical Rheumatoid Arthritis Joyce Lubbers, Lotte A. van de Stadt, Saskia Vosslamber, John G. Wesseling, Dirkjan van Schaardenburg and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands Noon 669. TLR7 Ligation Contributes to Monocyte Migration in Rheumatoid Arthritis Nathan D. Chamberlain, Seung-jae Kim, Michael Volin, William Swedler, Suncica Volkov and Shiva Shahrara, University of Illinois at Chicago, Chicago, IL, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL, University of Illinios at Chicago, Chicago, IL :5 PM 670. Genome-Wide Association Study On the Severity of Joint Destruction in Autoantibody Positive Rheumatoid Arthritis Identifies a Role for Sperm Associated Antigen 6 Rachel Knevel, Kerstin Klein, Klaartje Somers, Caroline Ospelt 4, Jeanine J. Houwing-Duistermaat 5, Jessica van Nies, Diederik P.C. de Rooy, Laura de Bock, Joris Schonkeren, Gerrie Stoeken-Rijsbergen, Jenna Kiridly 6, Luis Rodriguez-Rodriguez 6, Quinta Helmer 5, Piet Sinissen, Tom W. J. Huizinga, René E.M. Toes 7, Steffen Gay 8, Peter K. Gregersen 9, Veerle Somers and Annette H.M. van der Helm - van Mil, Leiden University Medical Center, Leiden, Netherlands, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Hasselt University, Biomedical Research Institute, Belgium, 4 Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, 5 Department of Medical Statistics and Bioinformatics, Leiden, Netherlands, 6 Feinstein Institute for Medical Research and North Shore Long Island WEDNESDAY November 4, 0 0 Program Book

136 WEDNESDAY November 4, 0 Jewish Health System, Manhasset, New York, 7 Leiden University Medical Centre, Leiden, Netherlands, 8 Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 9 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY 47 A Sjögren s Syndrome I - Pathogenesis Moderators: Xavier Mariette, MD, PhD and Lindsey A. Criswell, MD, MPH :00 AM 67. A Genome-Wide Association Study Establishes Multiple Susceptibility Loci for Sjögren s Syndrome Christopher J. Lessard, He Li, Indra Adrianto, John A. Ice, Roland Jonsson 4, Gabor G. Illei 5, Maureen Rischmueller 6, Gunnel Nordmark 7, Xavier Mariette 8, Corinne Miceli-Richard 9, Marie Wahren-Herlenius 0, Torsten Witte, Michael T. Brennan, Roald Omdal, Patrick M. Gaffney 4, James A. Lessard 5, Wan-Fai Ng 6, Nelson L. Rhodus 7, Barbara M. Segal 8, R. Hal Scofield, Judith A. James 9, Juan-Manuel Anaya 0, John B. Harley, Courtney G. Montgomery and Kathy Moser Sivils, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma CIty, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 University of Bergen, Bergen, Norway, 5 NIDCR/ NIH, Bethesda, MD, 6 Queen Elizabeth Hospital, Adelaide, Australia, 7 Rheumatology, Uppsala, Sweden, 8 Université Paris-Sud, Le Kremlin Bicetre, France, 9 Hopital Bicêtre, Le Kremlin Bicêtre, France, 0 Karolinska Institutet, Stockholm, Sweden, Hannover Medical School, Hanover, Germany, Carolinas Medical Center, Charlotte, NC, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 4 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5 Valley Bone & Joint Clinic, Grand Forks, ND, 6 Newcastle University, Newcastle, England, 7 University of Minnesota, Minneapolis, MN, 8 Hennepin County Medical Center, Minneapolis, MN, 9 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 0 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH :5 AM 67. Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sjögren s Syndrome (SS) According to Specific Subphenotypes and Ancestry Lindsey A. Criswell, Kimberly E. Taylor, Caitlin McHugh, Cathy Laurie, Kimberly Doheny, Mi Y. Lam, Joanne Nititham 4, Laura Bierut 5, Emily L. Harris 6, Alan N. Baer 7, Stephen Challacombe 8, Yi Dong 9, Hector Lanfranchi 0, Morten Schiodt, M. Srinivasan, Susumu Sugai, Hisanori Umehara 4, Frederick B. Vivino 5, Zhao Yan 6, Steve Shiboski, Troy Daniels 7, John S. Greenspan, Caroline Shiboski and SICCA 8, University of California, San Francisco, San Francisco, CA, University of Washington, Seattle, WA, Center for Inherited Disease Research, Baltimore, MD, 4 Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, 5 Washington University, St. Louis, MO, 6 National Institute of Dental and Craniofacial Research, Bethesda, MD, 7 Johns Hopkins University, Baltimore, MD, 8 Kings College London, London, United Kingdom, 9 Peking Univ Med Coll Hospital, East City Beijing, China, 0 University of Buenos Aires, Buenos Aires, Argentina, Righospitalet, Copenhagen, Denmark, Aravind Eye Hospital, Madurai, India, Kanazawa Medical University, Ishikawa, Japan, 4 Kanazawa Medical University, Kanazawa, Japan, 5 Penn Presbyt Med Ctr, Philadelphia, PA, 6 Peking Union Medical College Hospital, Beijing, China, 7 UCSF Schools of Medicine & Dentistry, San Francisco, CA, 8 San Francisco :0 AM 67. Sibling Relative Risk and Heritability of Sjögren s Syndrome: A Nationwide Population Study in Taiwan Chang-Fu Kuo, Matthew J. Grainge, Kuang-Hui Yu, Lai-Chu See, Shue-Fen Luo, Ana M. Valdes 4, I-Jun Chou, Hsiao-Chun Chang, Weiya Zhang and Michael Doherty, University of Nottingham, Nottingham, United Kingdom, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Chang Gung University, Taoyuan, Taiwan, 4 Dept of Twin Research and Genetic Epidemiology, St. Thomas Hospital, King s College London, London, United Kingdom :45 AM 674. Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS As Novel Candidates for Susceptibility to Sjögren s Syndrome He Li, John A. Ice, Jennifer A. Kelly, Indra Adrianto, Stuart B. Glenn, Kimberly S. Hefner, Evan G. Vista 4, Donald U. Stone 5, Raj Gopalakrishnan 6, Glen D. Houston 5, David M. Lewis 5, Michael Rohrer 6, Pamela Hughes 6, John B. Harley 7, Courtney G. Montgomery, James Chodosh 5, James A. Lessard 8, Juan-Manuel Anaya 9, Barbara M. Segal 0, Nelson L. Rhodus 6, Lida Radfar 5, Mark B. Frank, R. Hal Scofield, Christopher J. Lessard and Kathy Moser Sivils, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK, Hefner Eye Care and Optical Center, Oklahoma City, OK, 4 University of Santo Tomas, Taguig City, Philippines, 5 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 6 University of Minnesota, Minneapolis, MN, 7 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 8 Valley Bone & Joint Clinic, Grand Forks, ND, 9 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 0 Hennepin County Medical Center, Minneapolis, MN Noon 675. Oral and Gut Microbiota Influence Immune Responses to Sjogren s Syndrome Associated Antigen Ro60 Agnieszka Szymula, Barbara Szczerba, Harini Bagavant, Shu-Man Fu and Umesh Deshmukh, University of Virginia, Charlottesville, VA :5 PM 676. Long-Term Humoral Autoimmunity to Ro60 in Primary Sjögren s Syndrome Is Driven by Clonal Succession Rhianna Lindop, Isabell Bastian, Georgia Arentz, Lauren 4 0 Program Book

137 Thurgood, Andrew Whyte, Tim, K. Chataway, Michael Jackson and Tom Gordon, Flinders Medical Centre and Flinders University, Adelaide, Australia, Flinders University, Adelaide, Australia 5 A Systemic Lupus Erythematosus - Animal Models Moderators: Keith B. Elkon, MBBCh and Ram P. Singh, PhD :5 PM 68. Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL- Production and Regulatory T Cell Activity in Systemic Lupus Erythematosus Tomohiro Koga, Kunihiro Ichinose, Masayuki Mizui, José C. Crispín and George C. Tsokos, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan :00 AM 677. IL- Controls Autoimmunity by Facilitating Clearance of Apoptotic Bodies in the Marginal Zone in Lupus-Prone BXD Mice Hao Li, Hui-Chen Hsu, Qi Wu, PingAr Yang, Jun Li, Daniel Cua, Mohamed Oukka and John D. Mountz 4, University of Alabama at Birmingham, Birmingham, AL, Merck Research Laboratory, Palo Alto, CA, Seattle, WA, 4 University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL :5 AM 678. Novel Nuclear Export Inhibitors Deplete Autoreactive Plasma Cells and Protect Mice with Lupus-Like Disease From Nephritis Teresa Owen, Wensheng Wang, Dilara McCauley, Laura Strojny, Jennifer Hossler, Javier Rangel-Moreno, Michael Kauffman, Sharon Shacham and Jennifer H. Anolik, University of Rochester Medical Center, Rochester, NY, Karyopharm, Therapeutics Inc., Natick, MA :0 AM 679. Loss of Caspase 8 in Dendritic Cells Induces a Systemic Lupus Erythematosus-Like Disease That Is Independent of the Necroptosome Carla M. Cuda, Alexander V. Misharin, Rana Saber, G. Kenneth Haines III, Jack Hutcheson 4, Chandra Mohan 4 and Harris R. Perlman, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern University, Chicago, IL, Yale University, New Haven, CT, 4 University of Texas Southwestern Medical Center, Dallas, TX :45 AM 680. Soluble Receptor for Advanced Glycation End Products Alleviates Nephritis in NZB/WF Mice Sang-Won Lee, Kyu-Hyoung Park, Sungha Park, Ji-Hye Kim, Sung-You Hong, Soo Kon Lee, Donghoon Choi and Yong-Beom Park, Yonse University College of Medicine, Seoul, South Korea, Yonsei University College of Medicine, Seoul, South Korea Noon 68. Blocking the Serum Protease Inhibitor Activity of Plasminogen Activator Inhibitor- Protects Mice From Development of Glomerulonephritis in a Model of Lupus Nephritis Brian Naiman, Tracy Delaney, Lily Cheng, Philip Brohawn, Chris Morehouse, Christopher Groves, Isabelle de-mendez, Dominic Corkill, Anthony Coyle, Ronald Herbst and Jane Connor, MedImmune, LLC, Gaithersburg, MD, MedImmune, LLC, Cambridge, United Kingdom, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA Ballroom B Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Clinical Aspects Moderators: Kenneth C. Kalunian, MD and Maureen A. McMahon, MD :00 AM 68. Interferon-Associated Cytokine and Chemokine Expression in Patients with Serologically Active Clinically Quiescent (SACQ) Systemic Lupus Erythematosus (SLE) Amanda J. Steiman, Murray B. Urowitz, Dominique Ibanez, Carolina Landolt-Marticorena, Dafna D. Gladman and Joan E. Wither 4, Toronto Western Hospital and University of Toronto, Toronto, ON, University of Toronto, Toronto, ON, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 4 Toronto Western Research Institute, University Health Network, Toronto, ON :5 AM 684. Cerebrospinal Fluid IL-6 and Anti-NMDA Receptor NR Antibodies As Surrogate Markers for CNS Disease Severity in SLE Shunsei Hirohata, Yoshiyuki Arinuma and Eisuke Ogawa, Kitasato University School of Medicine, Sagamihara, Japan :0 AM 685. Overall and Cause Specific Mortality in Patients with Systemic Lupus Erythematosus. A Meta-Analysis of Observational Studies Marko Yurkovich, Kateryna Vostretsova and J. Antonio Avina-Zubieta, University of British Columbia, Vancouver, BC, University of British Columbia, Vancouver, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC :45 AM 686. Difference in Clinical Features and Mortality Between Pediatric-Onset and Adult-Onset Systemic Lupus Erythematosus So-Yeon Park, Jeeseon Shim, Dam Kim, Ji-Young Choi, So- Young Bang, Chan-Bum Choi 4 and Sang-Cheol Bae 4, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Hanyang University Guri Hospital, Guri, South Korea, 4 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea WEDNESDAY November 4, 0 0 Program Book 5

138 WEDNESDAY November 4, 0 Noon 687. Modular Microarray Analysis Fails to Reveal a Significant Biological Effect of Vitamin D Treatment in Patients Participating in a Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D On the Interferon Signature in Patients with Systemic Lupus Erythematosus Michaela Oswald, Cynthia Aranow, Diane L. Kamen, Meggan C. Mackay 4, Ellen A. Goldmuntz 5, Betty Diamond 6, Peter K. Gregersen 7 and ALE0 Study Team 8, The Feinstein Institute for Medical Research, Manhasset, NY, Feinstein Institute for Medical Research, Manhasset, NY, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 4 The Feinstein Institute, Manhasset, NY, 5 NIAID/ NIH Rm 6807, Bethesda, MD, 6 Feinstein Institute Med Rsch, Manhasset, NY, 7 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 8 Bethesda, MD :5 PM 688. The Health Improvement and Prevention Program in Systemic Lupus Erythematosus Demonstrates Improvement in Mental Health and Framingham Risk Score At One Year Paul R. Fortin, Ellie Aghdassi, Anne Cymet, Stacey Morrison 4, Willy Wynant 5, Janet E. Pope 6, Sara Hewitt 7, Christian A. Pineau 8, Carolyn Neville 9, Paula Harvey 0, Jean-Claude Tardif, Michal Abrahamowicz and Deborah DaCosta, Division of Rheumatology, Centre de recherche du centre hospitalier universitaire de Québec, Faculté de médecine de L université Laval, Quebec City, QC, University Health Network Research Institute - Western Division, Toronto, ON, University Health Network - Western Division, Toronto, ON, 4 The Toronto Western Hospital, Toronto, ON, 5 McGill University Health Centre and McGill University, Montreal, QC, 6 Western University of Canada, St. Joseph s Health Care, London, ON, 7 St. Joseph s Health Care, University of Western Ontario, London, ON, 8 McGill University Health Centre, Montreal, QC, 9 Royal Victoria Hospital, Montreal, QC, 0 Women s College Hospital, Toronto, ON, Universite de Montreal endowed research chair in atherosclerosis, Quebec, QC, McGill University, Montreal, QC, Montreal General Hospital, Montreal ARHP SESSIONS :00 AM - :0 PM 0 Highlights from the 0 ARHP Sessions Moderator: To be announced Speakers: Donah Z. Crawford, BS, MA and Robert R. McLean, DSc, MPH Upon completion of this session, participants should be able to: list the highlights from the 0 ARHP abstracts, presentations and sessions gain better awareness of the diversity of ARHP presentations assess the most important trends in ARHP research 06 Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis Moderator: Elizabeth G. Salt, PhD Upon completion of this session, participants should be able to: review a basic overview of the anatomic structure and function of the shoulder describe how rheumatologic conditions result in an abnormal physiologic state summarize the clinical assessment of shoulder pain and the use of diagnostic testing evaluate the management of shoulder pain (with special focus on rotator cuff tears) from the orthopedic surgeon, physical therapy and physiatrist perspective :00 AM Shoulder Pain: Pathophysiology, Assessment, and Medical Management Nitin Jain, MD, MSPH :45 AM Shoulder Pain Management from the Physical Therapy Perspective Robert Gillanders, PT, DPT ARHP CONCURRENT ABSTRACT SESSIONS :00 AM - :0 PM 40 A Factors Associated with Rheumatoid Arthritis Moderators: Beatriz Y. Hanaoka, MD and Afton L. Hassett, PsyD :00 AM 689. Quality of Sleep, Physical Activity and Fatigue in Patients with Rheumatoid Arthritis. A Cross-Sectional Study Katrine Loeppenthin, Bente Appel Esbensen, Poul Jennum, Mikkel Østergaard, Tanja Thomsen and Julie Midtgaard 4, Nursing and Health Science Research Unit, DK-600 Glostrup, Denmark, Danish Centre for Sleep Medicine, Department of Clinical Neurophysiology, DK-600 Glostrup, Denmark, Glostrup Hospital, Copenhagen, Denmark, 4 Health Care Research Centre, Copenhagen, Denmark :5 AM 690. Assessment of Sleep Quality in Patients with Rheumatoid Arthritis Ulku Ucar and Mehmet Tuncay Duruöz, Celal Bayar University Medical School, Manisa, Turkey :0 AM 69. Factors Related to Objectively Measured Physical Activity in the Rheumatoid Arthritis Population Marie Tierney, Alexander D. Fraser and Norelee M. Kennedy, University of Limerick, Limerick, Ireland, Mid Western Regional Hospital, Limerick, Ireland 6 0 Program Book

139 :45 AM 69. Diet and Other Lifestyle Related Factors and the Risk of Developing Rheumatoid Arthritis Björn Sundström, Ingegerd Johansson and Solbritt Rantapää Dahlqvist, Umeå University, Umeå, Sweden, Umeå Universitet, Umeå, Sweden, Umeå University Hospital, Umeå, Sweden Noon 69. Factors Associated with Person-Perceived Disability in Adults Aged 8+ with Rheumatoid Arthritis Yeliz Greenhill, Alison Hammond and Sarah Tyson, University of Salford, Manchester, United Kingdom :5 PM 694. Examination of a Multidimensional Model of Disability and Role Functioning in Patients with Rheumatoid Arthritis Sarah R. Ormseth, Taylor Draper, M. Custodio, M.H. Weisman, M.R. Irwin and Perry M. Nicassio, Loma Linda University, Loma Linda, CA, UCLA, Los Angeles, CA, Cedars- Sinai Medical Center, Los Angeles, CA 04 A Systemic Lupus Erythematosus Moderators: Atul A. Deodhar, MD and Carol M. Greco, PhD Noon 699. Psychosocial Stress and Complement Activation Product C4d On Reticulocytes in Patients with Systemic Lupus Erythematosus Xiaotian Chen, Yu Cheng, Chau Ching Liu, Amy H. Kao, Susan Manzi, Joseph M. Ahearn and Carol M. Greco, University of Pittsburgh, Pittsburgh, PA, Allegheny Singer Research Institute, Pittsburgh, PA, West Penn Allegheny Health System, Pittsburgh, PA :5 PM 700. A Multi-Center Study of the Appropriateness of Anti- Neutrophilic Cytoplasmic Antibody Testing Tarun S. Sharma, Vikash Sinha, Vino Unson, Saurav Acharya, Sahar Mohammadi and Amer Syed, Mount.Sinai School of Medicine-Jersey City Medical Center, Jersey City, NJ INDUSTRY-SUPPORTED POST SYMPOSIA :00-4:00 PM For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 7 for more information. :00 AM 695. Benefits of the Chronic Disease Self-Management Program in Low-Income African American Women with Systemic Lupus Erythematosus: Results of a Pilot Test Cristina Drenkard, Charmayne M. Dunlop-Thomas, Kirk Easley, Gaobin Bao, S. Sam Lim and Teresa J. Brady, Emory University, Atlanta, GA, Centers for Disease Control and Prevention, Atlanta, GA :5 AM 696. The Mary Kirkland Center for Lupus Care General Health Assessment Initiative for Systemic Lupus Erythematosus Patients Monica C. Richey, Doruk Erkan and Kyriakos A. Kirou, Hospital for Special Surgery, New York, NY :0 AM 697. The Short Term Effect of Individualized Nutrition Counseling On Nutrients and Select Cardiovascular Risk Factors in Patients with Systemic Lupus Erythematosus Sotiria Everett, Virginia Haiduc, Monica C. Richey and Doruk Erkan, Hospital for Special Surgery, New York, NY :45 AM 698. FMS and SLE Patients Have Higher Treatment Expectations Than RA Patients Robert S. Katz, Hannah Bond, Jessica L. Polyak, Lauren Kwan and Susan Shott, Rush University Medical Center, Chicago, IL, Rheumatology Associates, Chicago, IL WEDNESDAY November 4, 0 0 Program Book 7

140 ACR POSTER SESSION A 8 Sunday, NOVEMBER, 0 Poster Hall (Hall B) Biology and Pathology of Bone and Joint. Evaluation of Synovial Inflammation Assessed by Macroscopic and Histological Criteria in Patients with Knee Osteoarthritis. Montserrat Romera-Baures Sr., Ramon Valls-Garcia Sr., Antonio Rozadilla Sr., Marta Terricabras Sr.4 and Joan Miquel Nolla Sr. 5, Hospital Universitari Bellvitge, Barcelona, Spain, Hospital de Palamos, Girona, Palamos (Girona), Spain, Hospital Universitari de Bellvitge, Barcelona, Spain, 4 Hospital Universitari de Bellvitge., Barcelona, Spain, 5 Hospital Universitario de Bellvitge, Barcelona, Spain. Microrna-558 Regulates the Expression of Cyclooxygenase- and IL-beta Responses in Human Articular Chondrocytes. Su Jin Park, Eun-Jeong Cheon and Hyun Ah Kim, Hallym University Sacred Heart Hospital, Kyunggi, South Korea. Mesenchymal Stem Cells Differentiate Into Osteoblasts in Response to Inflammation. Koshiro Sonomoto, Kunihiro Yamaoka, Koichi Oshita, Shunsuke Fukuyo, Xiangmei Zhang, Kazuhisa Nakano, Yosuke Okada and Yoshiya Tanaka, University of Occupational and Environmental Health, Kitakyushu, Japan 4. Pro-Inflammatory Effect of Extracellular RNA on Synovial Fibroblasts From Patients with Rheumatoid Arthritis. Birgit Zimmermann, Silvia Fischer, Markus Rickert, Stefan Rehart 4, Angela Lehr 4, Ulf Müller-Ladner, Klaus T. Preissner and Elena Neumann, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, Justus-Liebig- University of Giessen, Medical School, Giessen, Germany, University Hospital Giessen and Marburg, Giessen, Germany, 4 Markus-Hospital, Frankfurt, Germany 5. Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure. Bohdan P. Harvey and Zehra Kaymakcalan, Abbott Laboratories, Worcester, MA, Abbott, Worcester, MA 6. The Effect of Hydrogen Sulfide Donors on Inflammatory Mediators in Human Articular Osteoarthritic Chondrocytes. Elena F. Burguera, Angela Vela Anero, Rosa Meijide Failde and Francisco J. Blanco, Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, Department of Medicine, University of A Coruña, A Coruña, Spain 7. Lamin A Deregulation in Human Mesenchymal STEM CELLS Promotes an Impairment in Their Chondrogenic Potential and Imbalance in Their Response to Oxidative Stress. Jesus Mateos, Alexandre De La Fuente, Ivan A. Lesende- Rodriguez, Maria Carmen Arufe and Francisco J. Blanco, Rheumatology Division, Proteomics Unit-ProteoRed/ISCIII, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, Department of Medicine, Area of Anatomy and Human Embryology, University of A Coruña-INIBIC, A Coruña, Spain 0 Program Book 8. Supercharged Sox9 Protein Induces Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells. Yuan K. Chou, Shili Wu, Camilo Avendano, Tom Caldwell, Brian Maniaci, Kentaro Yomogida, Yong Zhu and Cong-Qiu Chu, Oregon Health & Science University, Portland, OR, VivoScript, Inc, Costa Mesa, CA, Oregon Health & Science Univ and Portland VA Medical Center, Portland, OR 9. Function of the Chondrocyte PI- Kinase-Akt Signaling Pathway Is Stimulus Dependent. Richard F. Loeser and Meredith Greene, Wake Forest School of Medicine, Winston-Salem, NC 0. Fibronectin Fragment Induces Procatabolic Effects Through TLR- Signaling Pathway in Human Articular Chondrocytes. Su Jin Park, Eun-Jeong Cheon and Hyun Ah Kim, Hallym University Sacred Heart Hospital, Kyunggi, South Korea, Hallym university sacred heart hospital, Kyunggi, South Korea. Cartilage Tissue Engineering Using Collagen Scaffolds and Human Mesenchymal Stem Cells. Clara Sanjurjo-Rodriguez, Adela Helvia Martinez-Sanchez, Silvia Diaz-Prado, Emma Muiños-Lopez, Isaac M. Fuentes-Boquete, Francisco J. De Toro and Francisco J. Blanco, Osteoarticular and Aging Res. Lab. CIBER-BBN. Rheumatology Div. INIBIC-Complejo Hosp. Univ. A Coruña, A Coruña, Spain, Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain. Articular Cartilage Expresses the IL-5 Receptor Alpha- Chain and Responds to IL-5 with Increased Matrix Metalloproteinase Release. Anjali Nair, Michael Huvard, Madeline Rollins, Arnavaz Hakimiyan, Lev Rappaport, Arkady Margulis, Susanna Chubinskaya and Carla R. Scanzello, Rush University Medical Center, Chicago, IL, University of Illinois at Chicago, Chicago, IL, Northwestern University, Chicago, IL. Visfatin/Nampt in Osteoarthritis: Sites of Production in Human Joints and Role of Its Enzymatic Activity. Marie- Charlotte Laiguillon, Carole Bougault, Xavier Houard, Marjolaine Gosset, Geoffroy Nourissat, Sabrina Priam, Zvezdana Mladenovic, Claire Jacques, Francis Berenbaum and Jeremie Sellam 4, Pierre et Marie Curie University Paris VI, Paris, France, Paris Descartes University, Montrouge, France, AP-HP, St Antoine Hospital, Paris, France, 4 Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP- HP, 750, France 4. EPAC Activation Is Required for NFkB Nuclear Translocation and Osteoclast Differentiation. Aranzazu Mediero and Bruce N. Cronstein, NYU School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 5. Adenosine A A Receptor Stimulation Inhibits OC Formation by Suppressing NFkB Translocation to the Nucleus by A PKA-ERK/ Mediated Mechanism. Aranzazu Mediero and Bruce N. Cronstein, NYU School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY

141 ACR POSTER SESSION A 6. Adenosine A A Receptor Diminishes Bone Destruction At Inflamed Sites, in Part, Via Downregulating Semaphorin4D- PlexinB Communication Between Osteoclasts and Osteoblasts. Aranzazu Mediero and Bruce N. Cronstein, NYU School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 7. Synovial Overexpression of Wnt and Wnt--Induced Secreted Protein Induces Cartilage Damage by Skewing of TGF-Beta Signaling and Reduction of the Anti-Hypertrophy Factor Sox9. Martijn H. van den Bosch, Arjen B. Blom, Peter L. van Lent, Henk M. van Beuningen, Fons A. van de Loo, Esmeralda N. Blaney Davidson, Peter M. van der Kraan and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 8. Identification of 4--å As a New Subchondral Bone Mediator Involved in Cartilage Degradation During Osteoarthritis. Sabrina Priam Jr., Carole Bougault, Xavier Houard, Marjolaine Gosset, Colette Salvat, Francis Berenbaum 4 and Claire Jacques, Pierre et Marie Curie University Paris VI, Paris, France, Paris Descartes University, Montrouge, France, University Pierre and Marie Curie, Paris, France, 4 AP-HP, St Antoine Hospital, Paris, France 9. Stress-Induced Cartilage Degradation Does Not Depend On NLRP-Inflammasome in Osteoarthritis. Carole Bougault, Marjolaine Gosset, Xavier Houard, Colette Salvat, Lars Godmann 4, Thomas Pap 4, Claire Jacques and Francis Berenbaum 5, Pierre et Marie Curie University Paris VI, Paris, France, Paris Descartes University, Montrouge, France, University Pierre and Marie Curie, Paris, France, 4 University Hospital Münster, Münster, Germany, 5 AP-HP, St Antoine Hospital, Paris, France 0. Osteoclastogenesis Is Inhibited by Immune Complexes Through Activating Fcγ Receptors. Lilyanne C. Grevers, Peter L.E.M. van Lent, Teun J. de Vries, Vincent Everts, J. Sjef Verbeek and Wim B. van den Berg 4, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ACTA, UVA, VU University Amsterdam, Amsterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. IL- and IL-7 Interact and Aggravate Osteoclastogenesis in Rheumatoid Arthritis. Bo Young Yoon, Young-Mee Moon, Yang-Mi Her, Hye Jwa Oh, Jae-Seon Lee, Kyoung- Woon Kim, Seon-Yeong Lee, Yun-Ju Woo, Kyung-Su Park, Sung-Hwan Park, Ho-Youn Kim and Mi-La Cho, Inje University Ilsan Paik Hospital, Goyang, South Korea, Catholic University of Korea, Seoul, South Korea, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea. Protective Properties of Conditioned Media from Adipose Stem Cells On Osteoarthritic Chondrocytes. Maria Isabel Guillén, Julia Platas, Vicente Mirabet, Miguel Angel Castejón, Francisco Gomar 4 and Maria Jose Alcaraz, University of Valencia, Burjasot, Valencia, Spain, Generalitat Valenciana, Valencia, Spain, De la Ribera University Hospital, Alzira, Spain, 4 University of Valencia and University Hospital, Valencia, Spain. Differential Effects of Bone Morphogenetic Protein and 9 On Chondroprotective Transforming Growth Factor β Signaling. Arjan P. van Caam, Esmeralda N. Blaney Davidson, Elly L. Vitters, Laurie de Kroon, Ellen W. van Geffen, Peter ten Dijke, Wim B. van den Berg and Peter M. van der Kraan, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Leiden University Medical Center, Leiden, Netherlands 4. The Negative Effects of Glucocorticoids On Bone Are Primarily Mediated by Genes Involved in Osteoblast Differentiation and Bone Remodelling. Katharina Blankenstein, Tara C. Brennan-Speranza, Karin Lyon, Colin R. Dunstan, Frank Buttgereit, Hong Zhou and Markus J. Seibel, Bone Research Program, Sydney, Australia, Charite University Med-Berlin, Berlin, Germany, ANZAC Research Institute, The University of Sydney, Concord, Australia 5. Activation of the Canonical Wnt Signaling Pathway Is Tissue-Dependent in Osteoarthritic Joints: Distinct Mechanisms of Regulation by Wnt Antagonists. Thomas Funck-Brentano, Wafa Bouaziz, Hilene Lin, Valerie Geoffroy, Eric Hay and Martine Cohen-Solal, INSERM U606 Paris 7 university, Paris, France 6. Quantitative Analysis of Bone Damage/Morphological Changes in the Citrullinated Collagen Induced Arthritis Mouse Model Using Micro-CT. Anand Dusad, Michael J. Duryee, Dong Wang, James R. O Dell, Ted R. Mikuls 4, Geoffrey M. Thiele and Lynell W. Klassen, University of Nebraska Medical Center, Omaha, NE, Univ of Nebraska Medical Ctr, Omaha, NE, Univ of Nebraska Med Ctr, Omaha, NE, 4 Omaha VA and University of Nebraska Medical Center, Omaha, NE 7. Anti-Citrullinated Protein Antibodies As an Indicator of Bone Damage in the Citrullinated Collagen Induced Arthritis Model. Anand Dusad, Michael J. Duryee, Dong Wang, Carlos D. Hunter, Bartlett C. Hamilton III, James R. O Dell 4, Ted R. Mikuls 5, Lynell W. Klassen 4 and Geoffrey M. Thiele 4, University of Nebraska Medical Center, Omaha, NE, Univ of Nebraska Medical Ctr, Omaha, NE, University of Nebraska Medical Centre and Omaha VA Medical Center, Omaha, 4 Univ of Nebraska Med Ctr, Omaha, NE, 5 Omaha VA and University of Nebraska Medical Center, Omaha, NE 0 Program Book 9

142 ACR POSTER SESSION A Role of Microrna-455 Networks in Mesenchymal Cell Differentiation and Osteoarthritis. Fumiaki Ayabe, Shigeru Miyaki, Diana Brinson, Satoshi Yamashita, Hiroyuki Nakahara, Koji Otabe, Stuart Duffy, Shawn Grogan, Shuji Takada, Martin K. Lotz and Hiroshi Asahara, The Scripps Research Institute, La Jolla, CA, Hiroshima University, Hiroshima, Japan, National Research Institute for Child Health and Development, Tokyo, Japan 9. Level of IL-â-Induced Epigenetic Modifications Differ in Chondrocytes From Different Histological Zones of Human Cartilage. Nahid Akhtar and Tariq M. Haqqi, Case Western Reserve University/Metrohealth Medical Center, Cleveland, OH, Metro Health Medical Center, Cleveland, OH 0. A Mouse Myeloid Precursor with Osteoclastogenic Function in Vivo. Julia F. Charles, Erene Niemi, Mary C. Nakamura and Antonios O. Aliprantis 4, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, University of California, San Francisco; VA Medical Center, San Francisco, SFVAMC/UCSF, San Francisco, CA, 4 Brigham and Women s Hospital, Boston, MA. Anti Citrullinated Protein Antibodies from Synovial Fluid of Rheumatoid Arthritis Patients Enhance Osteoclastogenesis. Akilan Krishnamurthy, Nancy Vivar Pomiano, Catia Cerqueira, Elena Ossipova, Karin Lundberg, Ulrike Harre, Vivianne Malmström, Per Johan Jakobsson, Lars Klareskog, Georg Schett and Anca Irinel Catrina, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Karolinska Institute, Stockholm, Sweden. Development of a Quantitative Model of Endotoxin- Induced Calvarial Bone Erosion Utilizing Micro-Computed Tomography and Pax-It Imaging Analysis Software. Diane Thome, Donald Souza, Aruna Behera, Jie Zheng, Jennifer Swantek and Gerald H. Nabozny, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT. Novel Targets for Blocking Osteoclast-Mediated Resorption in Inflammatory Disorders. Kevin P. McHugh, Tania N. Crotti, Jun Li, Jon Hill, Gerald H. Nabozny, Steven R. Goldring 4 and P. Edward Purdue 5, Center for Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center, Boston, MA, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, 4 Hospital for Special Surgery, New York, NY, 5 Hospital for Special Surgery, Weill Cornell Medical Center, New York, NY 4. Rebamipide Attenuates Pain Severity and Cartilage Degeneration in a Rat Model of Osteoarthritis by Downregulating Oxidative Damage and Catabolic Activity in Chondrocytes. Su-Jin Moon, Mi-La Cho, Yeon-Sik Hong, Sung-Hwan Park and Jun-Ki Min, Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea, Catholic University of Korea, Seoul, South Korea, Our Lady of Mercy Hospital, Inchon, South Africa 0 Program Book 5. Changes in Tibial Bone and Cartilage Structure in a Mouse Surgical Model of Osteoarthritis. Brett A. Tonkin, Evange Romas, Natalie A. Sims and Nicole C. Walsh, St Vincent s Institute of Medical Research, Melbourne, Australia, St Vincent s Hospital, Melbourne, Australia 6. Role of FK506 Binding Protein 5 in Osteoclast Differentiation. Miho Kimura, Tatsuo Nagai, Reiko Matsushita, Atsushi Hashimoto, Toshiyuki Miyashita and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Kanagawa, Japan, Kitasato University School of Medicine, Sagamihara 7. Development of a Mouse Model of Natural Osteoarthritis of Knee by Induction of obesity and Bipedal Walking. Hyun Ah Kim, Su Jin Park, Eun-Jeong Cheon, Hyun A. Jung and Kyeong Min Son, Hallym university sacred heart hospital, Kyunggi, South Korea, Hallym University Sacred Heart Hospital, Kyunggi, South Korea, Hallym university Chunchun sacred heart hospital, Chunchun, South Korea 8. Bone Marrow Lesions On Magnetic Resonance Imaging Are Not Associated with Regions of Hypermetabolism in an Animal Model of Osteoarthritis. Arash Panahifar, Jacob Jaremko, Robert GW Lambert, Walter P. Maksymowych and Michael R. Doschak, University of Alberta, Edmonton, AB 9. SDF- Induces Osteoclastogenesis in Rheumatoid Arthritis by Upregulating of RANKL Expression in Synovial Fibroblasts and CD4+ T Cells. Hae-Rim Kim, Kyoung-Woon Kim, Bo-Mi Kim, Mi La Cho and Sang-Heon Lee 4, Konkuk University School of Medicine, Seoul, South Korea, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, Catholic University of Korea, Seoul, South Korea, 4 Konkuk University Hospital, Seoul, South Korea 40. Syndecan-4 Regulates Activation of WNT Signaling in Chondrocytes. Jessica Bertrand, Richard Stange, Giovanna Nalesso, Joanna Sherwood, Lars Godmann, Frank Echtermeyer, Francesco Dell Accio 4 and Thomas Pap, University Hospital Münster, Münster, Germany, Queen Mary University London, London, United Kingdom, University hospital Hanover, Hanover, Germany, 4 William Harvey Research Institute, Barts and the London Queen Mary s School of Medicine and Dentistry, Centre for Experimental Medicine and Rheumatology, London, United Kingdom 4. Long-Distance Physical Connections between Chondrocytes; Cell-to-Cell Communication within Articular Cartilage. Maria Dolores Mayan, Raquel Gago-Fuentes, Paula Carpintero-Fernandez, Patricia Fernandez-Puente, Purificacion Filgueira-Fernandez, Virgin Valiunas, Peter Brink, Gary Goldberg and Francisco J. Blanco Garcia, Osteoarticular and Aging Research Group. Rheumatology Division, Biomedical Research Center (INIBIC). Hospital Universitario A Coruña, As Xubias de Arriba 84, 5006, A Coruña, Spain, Department of Physiology and Biophysics. State University of New York, Stony Brook, New York,

143 ACR POSTER SESSION A SC, Department of Molecular Biology. Medical Center Drive, University of Medicine and Dentistry of New Jersey, Stratford, NJ 4. Role of Stromal Cell-Derived Factor- Alpha through Smad and MAPK Pathway On Endochondral Ossification. Gunwoo Kim, Seungwoo Han, Younkwan Jung, Eunju Lee, Hyeri Park, Shirine E. Usmani, Veronica Ulici and Frank Beier, Daegu Fatima Hospital, Daegu, South Korea, Fatima research institute, Daegu Fatima Hospital, Daegu, South Korea, Schulich School of Medicine and Dentistry, London, ON 4. Serum Amyloid A Level in Knee Osteoarthritis: Systemic and/or Local Production and Pro-Inflammatory Properties On Human Chondrocytes and Fibroblast-Like Synoviocytes. Dominique de Seny, Gaël Cobraiville, Sophie Neuville, Edith Charlier, Biserka Relic, Florence Quesada Calvo, Olivier Malaise, Denis Malaise, Laurence Lutteri, Jean- Paul Chapelle and Michel G. Malaise, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, University of Liège, Liège, Belgium, Medical Chemistry - CHU Liège, Liège, Belgium 44. Inhibition of WNT Signaling Pathway by Sclerostin Maintains Cartilage Homeostasis. Wafa Bouaziz, Thomas Funck-Brentano, Hilene Lin, Eric Hay and Martine Cohen- Solal, INSERM U606 Paris 7 university, Paris, France 45. The Effects of Apremilast On Osteoclasts, Osteoblasts, and Osteocytes. Mary Adams and Peter Schafer, Celgene Corporation, Summit, NJ 46. Synovitis in Secondary Osteoarthritis Due to Rheumatoid Arthritis: A Proof-of-Concept Study. Stefan Vordenbäumen, Tim Lögters, Philipp Sewerin, Thomas Pauly, Ellen Bleck, Paulina Philippski, Matthias Schneider, Michael Schädel-Höpfner and Benedikt Ostendorf, Heinrich- Heine-University, Düsseldorf, Germany, Rheinisches Rheumazentrum St. Elisabeth-Hospital, Meerbusch, Germany 47. Accumulation of CD4+ Hematopoietic Stem Cells in the Initial Inflammatory Human Fracture Hematoma Is Mediated Via Chemokine Receptor Type Ligands. Paula Hoff, Timo Gaber, Martin Hahne, Cindy Strehl, Katharina Schmidt-Bleek, Gerd R. Burmester, Gerhard Schmidmaier, Georg Duda, Carsten Perka and Frank Buttgereit 4, Charité University Medicine, Berlin, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, Heidelberg University Hospital, Heidelberg, Germany, 4 Charite University Med-Berlin, Berlin, Germany 48. Tissue Engineering for Articular Cartilage Repair, Culturing Bone Marrow Mesenchymal STEM CELLS On Collagen and Heparan Sulphate Scaffolds. Adela Helvia Martinez- Sanchez, Clara Sanjurjo-Rodriguez, Silvia Diaz-Prado, Emma Muiños, Isaac M. Fuentes, Francisco J. De Toro, Julia Bujan and Francisco J. Blanco, Osteoarticular and Aging Res. Lab. CIBER-BBN. Rheumatology Div. INIBIC-Complejo Hosp. Univ. A Coruña, A Coruña, Spain, Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain, Department of Medical Specialties. University of Alcala de Henares, Madrid, Spain 49. The Spatial Energy Expenditure Configuration and Possible Applications in an Experimental Model of Arthritis. Susanne Klatt and Rainer H. Straub, Laboratory of Exp. Rheumatology and Neuroendocrine Immunology, University Hospital, Regensburg, Germany, University Hospital Regensburg, Regensburg, Germany 50. Human Chondrocyte Dedifferentiation Is Accompagnied by CD05 Endoglin Expression, ALK-/Smad/5 Phosphorylation and Leptin Production - Stimulation by Prednisolone and Aldosterone Through the Glucocorticoid Receptor. Olivier Malaise, Biserka Relic, Mustapha Zeddou, Edith Charlier, Florence Quesada Calvo, Sophie Neuville, Dominique de Seny and Michel G. Malaise, GIGA Research - University of Liège - CHU Liège, Liège, Belgium 5. Phosphodiesterase 4 Expression in Rheumatoid Arthritis Synovium and Anti-Inflammatory Effects of Apremilast On Synovial Fibroblasts. Lei Wu, Mary Adams, Stacey Parton and Peter Schafer, Celgene Corporation, Summit, NJ Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease I 5. The Validity of the Diagnosis Inflammatory Arthritis in Primary Care. Markus M.J. Nielen, Jennie Ursum, François G. Schellevis and Joke C. Korevaar, NIVEL (Netherlands Institute for Health Services Research), Utrecht, Netherlands, VU University Medical Centre, Amsterdam, Netherlands 5. Comparison of Decision Rules for Identifying Patients with Rheumatoid Arthritis (RA) in Administrative Healthcare Databases. John G. Hanly, Kara Thompson and Chris Skedgel, Dalhousie University and Capital Health, Halifax, NS 54. Use of Health Plan Data to Assess Feasibility of Large Pragmatic Clinical Trials in Rheumatoid Arthritis. Jeffrey Curtis, Lang Chen, Fenglong Xie, Jie Zhang, Kenneth G. Saag, Stacey Cofield, Kevin L. Winthrop 4, Nicole C. Wright and Elizabeth S. Delzell, University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama- Birmingham, Birmingham, AL, Univ of Alabama at Birmingham,, Birmingham, AL, 4 Oregon Health & Science University, Portland, OR 55. Accuracy of Canadian Health Administrative Databases in Identifying Patients with Rheumatoid Arthritis Seen by Rheumatologists. Jessica Widdifield, Sasha Bernatsky, J. Michael Paterson, Karen Tu, Ryan Ng, J. Carter Thorne 4, Janet E. Pope 5 and Claire Bombardier, University of Toronto, Toronto, ON, Research Institute of the McGill University Health Ctre, Montreal, QC, Institute for Clinical Evaluative Sciences, Toronto, ON, 4 Southlake Regional Health Centre, Newmarket, ON, 5 St. Joseph Health Care London, University of Western Ontario, London, ON 0 Program Book 4

144 ACR POSTER SESSION A 56. A Validated Mathematical Model Using Electronic Health Records to Identify Rheumatoid Arthritis Patients for Observational Studies. Aarat M. Patel, Ilinca D. Metes, Larry W. Moreland, Melissa Saul, Stephen R. Wisniewski 4 and Marc C. Levesque, Univ of Pittsburgh Med Ctr / Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, 4 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA 57. A British Survey of Time to Presentation and Treatment of Rheumatoid Arthritis in Subjects of Black and Minority Ethnic Origin. Sonia Panchal, Ash Samanta, Arumugam Moorthy, Sawson Hayat, Ira Pande, Adewale O. Adebajo and Kuntal Chakravarty 4, University Hospitals of Leicester, Leicester, United Kingdom, Nottingham University Hospitals, Nottingham, United Kingdom, Academic Rheumatology Group, D, Sheffield, United Kingdom, 4 University of Bedfordshire Post Graduate Medical School, Romford, United Kingdom Million Patients and Not 0.4% Is Worrisome: Burden of Rheumatoid Arthritis in India Based On a Bone and Joint Decade India Community Oriented Program for Control of Rheumatic Disease. Arvind Chopra, R. Ghorpade, S. Sarmukkadam, VL Joshi, AJ. Mathews, L. Gauri 4, A. Rahim 5, K. Datta 6, S. Chaturvedi 7, B. Thakuria 8, A. Mahajan 9, R. Singh 0, A. Ghosh, R. Handa, M. Saluja, A. Venugopalan, V. Kunjeer, B. Paul 5, S. Pal 6, K. Wangjam 0, T. Kumar and K. Mahendranath, Center for Rheumatic Diseases, Pune, India, BJMC, Pune, India, Government Medical College Hospital, Trivandrum, India, 4 SP Medical College, Bikaner, India, 5 Calicut Medical College, Calicut, India, 6 Advance Rheumatology Clinic, Hyderabad, India, 7 FRCH, Pune, India, 8 Guwahati Medical College & Hospital, Guwahati, India, 9 Government Medical College, Jammu, India, 0 Regional Institute of Medical Sciences, Imphal, Manipur, India, Institute of Post Graduate Medical Education and Research, Kolkata, India, AIIMS, New Delhi, India, Rheumatology Clinic, Bangalore, India 59. A Staggering Burden of Pain and Rheumatic Disorders in India: A National Bone & Joint Decade India Community Oriented Program for Control of Rheumatic Disease Survey Arvind Chopra, R. Ghorpade, S. Sarmukkadam, VL Joshi, AJ. Mathews, L. Gauri 4, A. Rahim 5, K. Datta 6, S. Chaturvedi 7, B. Thakuria 8, A. Mahajan 9, R. Singh 0, A. Ghosh, R. Handa, M. Saluja, A. Venugopalan, V. Kunjeer, B. Paul 5, S. Pal 6, K. Wangjam 0, T. Kumar, CP Rajendran, V. Gajalakshmi 4 and K. Mahendranath 5, Center for Rheumatic Diseases, Pune, India, B J Medical College, Pune, India, Government Medical College Hospital, Trivandrum, India, 4 SP Medical College, Bikaner, India, 5 Calicut Medical College, Calicut, India, 6 Advance Rheumatology Clinic, Hyderabad, India, 7 FRCH, Pune, India, 8 Guwahati Medical College & Hospital, Guwahati, India, 9 Government Medical College, Jammu, India, 0 Regional Institute of Medical Sciences, Imphal, Manipur, India, Institute of Post Graduate Medical Education and Research, Kolkata, India, AIIMS, New Delhi, India, Madras Medical College, Chennai, India, 4 ERC Unit, Chennai, India, 5 Rheumatology clinic, Bangalore, India 60. The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis. Christian A. Waimann, Gustavo Citera, Hernan Maldonado Ficco, Oscar L. Rillo 4, Mariana Benegas 5, Rafael Chaparro del Moral 6, Antonio Catalan Pellet 7, Anastasia Secco 8, Lucila Marino 9, Alberto Berman 0, Horacio Berman 0, Ana Lucía Barbaglia, Juan Carlos Marcos, Josefina Marcos, Francisco Caeiro, Maria Haye Salinas 4, Ana C. Alvarez 5, Enrique Soriano 6, Zaida Bedran 7, Sergio Paira 8, Federico Ceccato 8, Gabriela Salvatierra 9, Ana Quinteros 0, Emilio Buschiazzo and Edson Javier Velozo, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica., Buenos Aires, Argentina, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, 4 Hospital Tornú, Buenos Aires, Argentina, 5 Hospital Tornu, Buenos Aires, Argentina, 6 CONAART, Argentina., Buenos Aires, Argentina, 7 Hospital Rivadavia, Buenos Aires, Argentina, 8 Rivadavia Hospital, Buenos aires, Argentina, 9 Rivadavia Hospital, Buenos Aires, Argentina, 0 Centro Medico Privado de Reumatologia, Tucuman, Argentina, Hospital Padilla, Tucuman, Argentina, Hospital San Martin, La Plata, Argentina, Hospital privado de Cordoba, Cordoba, Argentina, 4 Hospital Privado de Cordoba, Córdoba, Argentina, 5 Hospital Privado, Córdoba, Argentina, 6 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 7 Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8 Hospital Jose Maria Cullen, Santa Fe, Argentina, 9 Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, 0 Centro Integral de Reumatología San Miguel de Tucumán, San Miguel de Tucumán, Argentina, Hospital Señor del Milagro, Salta, Argentina, Sanatorio Adventista del Plata, Entre Rios, Argentina 6. Role of Health Literacy in Population Estimates of Musculoskeletal Disorders. Catherine L. Hill, Sarah L. Appleton, Tiffany K. Gill, Julie Black 4, Rima E. Rudd 5 and Robert J. Adams, The Queen Elizabeth Hospital, Woodville, Australia, University of Adelaide, Woodville South, South Australia, Australia, University of Adelaide, Adelaide, South Australia, Australia, 4 Arthritis SA, Marleston, Australia, 5 Harvard School of Public Health, Boston, MA 6. Clinical Implication of Rheumatoid Factor Formation According to Various Hepatitis B Virus Infection Status and Vaccination. Sang Tae Choi, Hyun Woong Lee, Jung-Soo Song, Soo Kon Lee and Yong-Beom Park, Chung-Ang University School of Medicine, Seoul, South Korea, Chung- Ang University College of Medicine, Seoul, South Korea, Yonse University College of Medicine, Seoul, South Korea 4 0 Program Book

145 ACR POSTER SESSION A 6. The Association between Silica and the Risk of Anti- Citrullinated Protein Antibody Positive RA in the Malaysian and Swedish Epidemiological Investigation of Rheumatoid Arthritis Studies. Abqariyah Yahya, Camilla Bengtsson, Lars Klareskog, Chun Lai Too, Shahnaz Murad 4 and Lars Alfredsson, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, 4 Institute for Medical Research, Kuala Lumpur, Kuala Lumpur, Malaysia 64. Use of Moist Snuff and the Risk of Developing Rheumatoid Arthritis; Results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study. Lars Alfredsson, Lars Klareskog and Camilla Bengtsson, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden 65. Serum Inflammatory Biomarkers Correlated Stronger with a Panel of Serum Steroid and Pituitary Hormones in a Cohort of Pre-Rheumatoid Arthritis (pre-ra) Than in Non- RA Control (CN) Subjects. Alfonse T. Masi, Kevin B. Elmore, Azeem A. Rehman, Jean C. Aldag and Robert T. Chatterton, University of Illinois College of Medicine at Peoria, Peoria, IL, Northwestern University, Chicago, IL 66. Pre-Rheumatoid Arthritis (pre-ra) Subjects Had a Minority Excess with Clearly Low Serum Cortisol Levels and Females Had Lower Mean androstenedione Levels than Control (CN) Cohorts in Analysis of a Large Panel of Serum Steroids and Pituitary Hormones. Alfonse T. Masi, Kevin B. Elmore, Azeem A. Rehman, Jean C. Aldag and Robert T. Chatterton, University of Illinois College of Medicine at Peoria, Peoria, IL, Northwestern University, Chicago, IL 67. Increased Prevalence of Hypothyroidism Preceding Rheumatoid Arthritis an Epidemiological Study. Anne M. Kerola, Tuomo Nieminen, Markku J. Kauppi, Hannu Kautiainen 4, Kari Puolakka 5, Lauri J. Virta 6 and Tuomas Kerola, Medical School, University of Helsinki, Helsinki, Finland, Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, 4 Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 5 Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 6 Research Department, the Social Insurance Institution, Turku, Finland 68. Cardiovascular Comorbidities Antedating the Diagnosis of Rheumatoid Arthritis. Anne M. Kerola, Tuomas Kerola, Markku J. Kauppi, Hannu Kautiainen, Lauri J. Virta 4, Kari Puolakka 5 and Tuomo Nieminen 6, Medical School, University of Helsinki, Helsinki, Finland, Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland, 4 Research Department, the Social Insurance Institution, Turku, Finland, 5 Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, 6 Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland 69. The Presence of Asymptomatic Carotid Plaques in Patients with Inflammatory Joint Disease Results in Inadequate Treatment to Lipid Targets in Cardiovascular Disease Prevention. Anne G. Semb, Silvia Rollefstad, Inge C. Olsen, Desiree van der Heijde and Tore K. Kvien, Diakonhjemmet Hospital, Olso, Norway, Diakonhjemmet Hospital, Oslo, Norway, Leiden University Medical Center, Leiden, Netherlands 70. The Impact of Systemic Autoimmune Rheumatic Disease on One-Year Mortality in Congestive Heart Failure Patients: A Population-Level Analysis. Stephanie O. Keeling, Asvina Bissonauth, Becky Leung and Padmaja Kaul, University of Alberta, Edmonton, AB 7. The Association between Preclinical Markers for Cardiovascular Disease and Rheumatoid Arthritis- Related Autoantibodies in First-Degree Relatives without Rheumatoid Arthritis. Ryan W. Gan, Jan M. Hughes-Austin, Kevin D. Deane, Elaine M. Urbina 4, Peter K. Gregersen 5, Michael H. Weisman 6, V. Michael Holers and Jill M. Norris, Colorado School of Public Health, Aurora, CO, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 6 Cedars-Sinai Medical Center, Los Angeles, CA 7. Relationships between Air Pollution and Presence of Rheumatoid Arthritis-Related Autoantibodies in Individuals without Rheumatoid Arthritis: Studies of the Etiology of Rheumatoid Arthritis. Ryan W. Gan, Kevin D. Deane, Gary O. Zerbe, Michael H. Weisman 4, Jane H. Buckner 5, P. K. Gregersen 6, Ted R. Mikuls 7, James R. O Dell 8, Richard M. Keating 9, V. Michael Holers and Jill M. Norris, Colorado School of Public Health, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 4 Cedars-Sinai Medical Center, Los Angeles, CA, 5 Benaroya Research Institute at Virginia Mason, Seattle, WA, 6 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 7 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 8 Univ of Nebraska Med Ctr, Omaha, NE, 9 The University of Chicago, Chicago, IL 7. Trends in st century Health Care Utilization in a Rheumatoid Arthritis Cohort Compared to the General Population. Sofia Hagel, Ingemar F. Petersson, Ann B. I. Bremander, Elisabet Lindqvist, Charlotte Bergknut 4 and Martin Englund, Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University and Skåne University Hospital, Lund, Lund, Sweden, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, 0 Program Book 4

146 ACR POSTER SESSION A Sweden, Halmstad University School of Business and Engineering,, Halmstad, Sweden, 4 Lund University, Lund, Sweden 74. Length of Stay for Rheumatoid Arthritis Related Orthopedic Surgery Has Improved Over the Past Decades and Is Related to Disease Markers. Results From Two UK Multicentre Inception Cohorts (986-0) Compared with National Data. Elena Nikiphorou, Stephen Morris, David James, Patrick D. Kiely 4, David Walsh 5 and Adam Young 6, ERAS, St Albans City Hospital and University College London (UCL), St Albans, United Kingdom, Research Department of Epidemiology and Public Health, -9 Torrington Place, United Kingdom, Diana Princess of Wales Hospital, Grimsby, United Kingdom, 4 St. Georges Hospital, London, United Kingdom, 5 City Hospital, Nottingham, United Kingdom, 6 St Albans City Hospital, St Albans, United Kingdom 75. Patient-Reported Outcomes Associated with Achieving and Maintaining Low Disease Activity in Rheumatoid Arthritis. Martin J. Bergman, James W. Shaw, Mary Cifaldi, Gourab De, Tony He 4, Rajeev Ayyagari 4 and James Signorovitch 4, Taylor Hospital, Ridley Park, PA, Abbott Laboratories, Abbott Park, IL, Analysis Group, Inc., New York, NY, 4 Analysis Group, Inc., Boston, MA 76. The Difference in Performance of DAS8 and RADAI During Pregnancy Might Explain Discrepancies Between Older and More Recent Studies On the Impact of Pregnancy On Rheumatoid Arthritis. Jan Naterop, Johanna M.W. Hazes and Radboud J.E.M. Dolhain, Erasmus Medical Center, University Medical Center Rotterdam, Rotterdam, The Netherlands, Rotterdam, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands 77. Comorbid Conditions Do Not Explain Divergent Patient Assessments of Disease Activity and Global Health in Patients with Rheumatoid Arthritis. Dörte Huscher, Katja Thiele, Sascha Bischoff, Ulrich von Hinüber, Guido Hoese 4, Kirsten Karberg 5, Wolfgang Ochs 6 and Angela Zink, German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, German Rheumatism Research Centre, Berlin, Germany, Rheumatologist in Private Practice, Hildesheim, Germany, 4 Rheumatologist in Private Practice, Stadthagen, Germany, 5 Rheumatologist in Private Practice, Berlin, Germany, 6 Rheumatologist in Private Practice, Bayreuth, Germany 78. Factors Influencing on the Discordance Between 0 ACR/EULAR Criteria and Physician s Clinical Judgment for Remission in Rheumatoid Arthritis Patients. Yoon-Kyoung Sung, Bo Young Yoon, Soo-Kyung Cho, Chan-Bum Choi, Dae-Hyun Yoo, Jae-Bum Jun, Tae-Hwan Kim, Shin-Seok Lee, Tae-Jong Kim, Jisoo Lee 4, Jung-Yoon Choe 5, Sung-Hoon Park 5, Seung-Jae Hong 6, Yeon-Ah Lee 6, Jinseok Kim 7, Eun-Mi Koh 8, Hoon-Suk Cha 8, Jaejoon Lee 8, Won-Tae Chung 9, Sung Won Lee 9, Choong-Ki Lee 0, Hye-Soon Lee, Wan-Hee Yoo, Young Mo Kang and Sang-Cheol Bae 4, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Inje University Ilsan Paik Hospital, Goyang, South Korea, Chonnam National University Medical School, Gwangju, South Korea, 4 Ewha Womans University Mokdong Hospital, Seoul, South Korea, 5 Catholic University of Daegu School of Medicine, Daegu, South Korea, 6 Kyung Hee University, Seoul, South Korea, 7 Jeju National University, Jeju, Korea, South Korea, 8 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 9 Dong-A University Hospital, Busan, South Korea, 0 Yeungnam University Hospital, Daegu, South Korea, Hanyang University Guri Hospital, Guri, South Korea, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, Kyungpook National University School of Medicine, Daegu, South Korea, 4 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea 79. Physician s Global Assessment Is Affected by Physician s Age and Gender, but Not by Patient Age and Gender in Rheumatoid Arthritis Patients Treated in Routine Care. Data from the Danish Nationwide Danbio Registry. Cecilie Lindstrom Egholm, Theodore Pincus, Lene Dreyer, Torkell Ellingsen 4, Bente Glintborg, Marcin Kowalski 5, Tove Lorenzen 4, Ole Rintek Madsen, Henrik Nordin 6, Claus Rasmussen 7 and Merete L. Hetland 8, Copenhagen University Hospital / DANBIO at Glostrup, Copenhagen, Denmark, NYU Hospital for Joint Diseases, New York, NY, Copenhagen University Hospital at Gentofte, Gentofte, Denmark, 4 Region Hospital Silkeborg, Silkeborg, Denmark, 5 Aalborg Hospital, Aalborg, Denmark, 6 Rigshospitalet, Copenhagen, Denmark, 7 Vendsyssel Hospital, Hjoerring, Denmark, 8 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark 80. Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From Phase III Golimumab Trials. Chenglong Han, E. Keystone, Roy Fleischmann, Josef S. Smolen 4, Paul Emery 5, Mark C. Genovese 6, Mittie K. Doyle 7 and Elizabeth C. Hsia 7, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, University of Toronto, Toronto, ON, University of Texas Southwestern Medical Center, Dallas, TX, 4 Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 5 Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 6 Stanford University Medical Center, Palo Alto, CA, 7 Janssen Research and Development, LLC, Spring House, PA 8. Transitions among Disease Activity States: Estimates and Models of Covariate Associations. George W. Reed, David H. Collier, Andrew S. Koenig, Katherine C. Saunders 4, Joel M. Kremer 5 and Sameer Kotak 6, University of Massachusetts Medical School, Worcester, MA, Amgen Inc., Thousand Oaks, CA, Pfizer Inc., Collegeville, PA, 4 CORRONA, 44 0 Program Book

147 ACR POSTER SESSION A Inc., Southborough, MA, 5 Albany Medical College and The Center for Rheumatology, Albany, NY, 6 Pfizer Inc., New York, NY 8. Variability of the SF-6D Determinants over Time in Early Arthritis: Results From the Espoir Cohort. Cécile Gaujoux- Viala, Bruno Fautrel, Kossar Hosseini, Francis Guillemin, René-Marc Flipo 4 and Anne-Christine Rat 5, Lorraine University, Paris Descartes University, APEMAC, EA 460, F , Nancy; Paris 6 Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, Paris 6 Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, Lorraine University, Paris Descartes University, APEMAC, EA 460, F , Nancy, France, 4 Rheumatology Department, Lille University Hospital, Lille, France, 5 Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy, France 8. Substantial Functional Disability Is the Key Determinant of Discrepancies Between EQ-5D and SF-6D Utility Measures in Early Arthritis: Results From the Espoir Cohort. Cécile Gaujoux-Viala, Bruno Fautrel, Kossar Hosseini, Francis Guillemin 4, René-Marc Flipo 5 and Anne-Christine Rat 4, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy; Paris 6 Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, Paris VI University, Paris, France, Lorraine University, Paris Descartes University, APEMAC, EA 460, F , Nancy, France, 4 Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy, France, 5 Rheumatology Department, Lille University Hospital, Lille, France 84. Benefits of Treat-to-Target Guideline Compliance in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis. Martin J. Bergman, James W. Shaw, Mary A. Cifaldi, Annie Guerin, Pooja Chopra and James Signorovitch 4, Taylor Hospital, Ridley Park, PA, Abbott Laboratories, Abbott Park, IL, Analysis Group, Inc., Montreal, QC, 4 Analysis Group, Inc., Boston, MA 85. WITHDRAWN. 86. Longitudinal Hypertension Diagnosis and Control among a Primary Care Medically Homed Population with Rheumatoid Arthritis. Katya Voelker and Christie M. Bartels, Univ of Wisconsin School of Medicine and Public Health, Madison, Univ of Wisconsin School of Medicine and Public Health, Madison, WI 87. Prediction of Mortality in Rheumatoid Arthritis Using a Serum Cytokine Profile. Agustin Escalante, Roy W. Haas, Daniel F. Battafarano and Inmaculada Del Rincon, University of Texas Health Science Center at San Antonio, San Antonio, TX, Brooke Army Medical Ctr, San Antonio, TX 88. The Effect of Weather on Patient Symptoms in Rheumatoid Arthritis: A Systematic Review of the Literature and Exploration of weather sensitivity. Annika Cutinha, Frederick Wolfe and Kaleb Michaud, University of Nebraska Medical Center, Omaha, NE, National Data Bank for Rheumatic Diseases, Wichita, KS, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE 89. Poor to Moderate Performance of Patient Self-Report in Indentifying Periodontitis in Patients with Rheumatoid Arthritis. Ted R. Mikuls, Jeffrey Payne, Harlan Sayles, Shawneen Gonzalez, Jeffrey Markt 4, Mark Beatty, Grant W. Cannon 5, David McGowan 5, Gail S. Kerr 6, Robert Redman 7, Andreas M. Reimold 8 and Garth Griffiths 8, Omaha VA and University of Nebraska Medical Center, Omaha, NE, University of Nebraska Medical Center, Lincoln, NE, University of Nebraska Medical Center, Omaha, NE, 4 Omaha, NE, 5 George E. Wahlen VA Medical Center, Salt Lake City, UT, 6 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 7 Washington DC VA, Georgetown and Howard University, Washington, DC, 8 Dallas VA and University of Texas Southwestern, Dallas, TX 90. Physical Function, Pain and Fatigue Are Related to Sleep Disturbance in Females with Rheumatoid Arthritis. Cathrine Austad, Tore K. Kvien and Till Uhlig, Diakonhjemmet Hospital, Norway, Oslo, Norway, Diakonhjemmet Hospital, Oslo, Norway 9. Correlations of Single Item Health Literacy Screening Questions with Established Measures of Health Literacy in Subjects with Rheumatoid Arthritis. Itziar Quinzanos, Joel M. Hirsh and Liron Caplan, Denver Health Med Ctr, Denver, CO, Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO 9. Combined Response Index in Diffuse Systemic Sclerosis (CRISS) Which External Anchors to Use When Developing the Index? Baseline Analysis. Dinesh Khanna, Veronica Berrocal, James R. Seibold, Peter A. Merkel, Maureen D. Mayes 4, Kristine Phillips, Robert W. Simms 5, Shervin Assassi 4, Philip J. Clements 6 and Daniel E. Furst 7, University of Michigan, Ann Arbor, MI, Scleroderma Research Consultants LLC, Avon, CT, University of Pennsylvania, Philadelphia, PA, 4 University of Texas Health Science Center at Houston, Houston, TX, 5 Boston University School of Medicine, Boston, MA, 6 UCLA School of Medicine, Los Angeles, CA, 7 UCLA Medical School, Los Angeles, CA 9. Health State Utilities in Systemic Sclerosis: Results From the UCLA Scleroderma Quality of Life Study. Mohsen Sadatsafavi, Dinesh Khanna, Paul Maranian, D. Furst 4, Amir Khakban and Carlo A. Marra, Univ of British Columbia, Vancouver, BC, University of Michigan, Ann Arbor, MI, UCLA Medical School, Los Angeles, CA, 4 University of California at Los Angeles, Los Angeles, CA 0 Program Book 45

148 ACR POSTER SESSION A Medical Costs and Health Care Resource Use in Patients with Systemic Sclerosis in an Insured Population. Daniel E. Furst, Ancilla W. Fernandes, Serban R. Iorga, Warren Greth 4 and Tim Bancroft, UCLA Medical School, Los Angeles, CA, MedImmune LLC, Gaithersburg, MD, OptumInsight, Eden Prairie, MN, 4 MedImmune, LLC, Gaithersburg, MD 95. Smoking Is Associated with Worse and More Widespread Pain, Worse Disease Activity, Function, Fatigue and Health Related Quality of Life in Patients with Axial Spondyloarthritis Results From a Population Based Cohort. Ann B. I. Bremander, Ingemar F. Petersson, Emma Haglund, Stefan Bergman 4 and Lennart TH Jacobsson 5, Halmstad University School of Business and Engineering, Halmstad, Sweden, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden, 4 R&D Center Spenshult, Oskarström, Sweden, 5 Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 96. Quality of Care: Reference and Counter Reference from Family Physicians and Rheumatologists perspectives A Pilot Study. Thiago D. Baumgratz, Raphael Battisti, Mirella Cuziol, Ana Carolina Reiff Janini, R.A. Levy and Mirhelen M. Abreu, Medical Student at Universidade Federal de São Carlos, São Carlos, Brazil, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, Universidade Federal de São Carlos, São Carlos, Brazil 97. Systematic Review of Explanatory and Predictive Models in Rheumatology: Lack of Adhearance to Methodologic Standards. Daniel A. Albert, Dartmouth-Hitchcock Med Ctr, Lebanon, NH 98. How to Assess Risks for Pulmonary Infection in Patients Receiving Immunosuppressive Treatment for Rheumatic Diseases? A Report from a Large-Scale Prospective Cohort Study. Hayato Yamazaki, Ryoko Sakai, Ryuji Koike, Yasunari Miyazaki, Michi Tanaka, Toshihiro Nanki, Kaori Watanabe, Shinsuke Yasuda, Takashi Kurita, Yuko Kaneko, Yoshiya Tanaka 4, Yasuhiko Nishioka 5, Yoshinari Takasaki 6, Kenji Nagasaka 7, Koichi Amano 8, Shigeto Tohma 9, Makoto Dohi 0, Takahiko Sugihara, Haruhito Sugiyama, Yasushi Kawaguchi, Naohiko Inase, Sae Ochi 4, Hiroyuki Hagiyama 5, Nobuyuki Miyasaka and Masayoshi Harigai, Tokyo Medical and Dental University, Tokyo, Japan, Hokkaido University, Sapporo, Japan, Keio Univ School of Medicine, Tokyo, Japan, 4 University of Occupational and Environmental Health, Kitakyushu, Japan, 5 The Univeristy of Tokushima Graduate School, Tokushima, Japan, 6 Juntendo University School of Medicine, Tokyo, Japan, 7 Ome Municipal General Hospital, Ome, Japan, 8 Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 9 Sagamihara National Hospital, Sagamihara, Japan, 0 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Tokyo Metropolitan Geriatric Hospital, Tokyo, 0 Program Book Japan, National Center for Global Health and Medicine, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 4 Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 5 Yokohama-city Bay Red Cross Hospital, Yokohama, Japan 99. Cancer Iincidence and Type of Malignancy in Rrheumatologic Ddiseases in Korea: Head-to-Head Comparison. Sung Hae Chang, Jin Kyun Park and Eun Bong Lee, Seoul National University Hospital, Seoul, South Korea 00. Further Evidence on Biased Cancer Risk Estimation in Studies Comparing A Subpopulation to the General Population. Koray Tascilar and Hasan Yazici, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey 0. Kidney Function and the Risk of Incident Gout in A Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study. Mara McAdams DeMarco, Anna Kottgen, Andrew Law, Janet W. Maynard 4, Josef Coresh and Alan N. Baer 5, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University Hospital Freiburg, Freiburg, Germany, Johns Hopkins, Baltimore, MD, 4 Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 5 Johns Hopkins University, Baltimore, MD Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging 0. Sonographic Assessment of Normal Peripheral Joints: Evaluation According to Demographics Parameters. Flavia S. Machado, Rita N.V. Furtado, Rogerio D. Takahashi, Ana Leticia P. de Buosi and Jamil Natour, Universidade Federal de São Paulo, São Paulo, Brazil 0. A Pragmatic Musculoskeletal Ultrasound Screening Protocol Does Not Add to a Predictive Algorithm for Persistent Inflammatory Arthritis in a UK Early Arthritis Clinic. Arthur G. Pratt, Alice R. Lorenzi, Gillian Wilson, Philip N. Platt and John D. Isaacs, Newcastle University, Newcastle Upon Tyne, United Kingdom, Freeman Hospital, Newcastle upon Tyne, United Kingdom, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom 04. The Usefulness of A NEW Musculoskeletal ULTRASOUND Scoring System of the Hands and Wrist Joints (US0) for Evaluation of EARLY Rheumatoid Arthritis Patients. Karine R. Luz, Rita N.V. Furtado, Marcelo M. Pinheiro, Giovanna S. Petterle and Jamil Natour, Universidade Federal de São Paulo, São Paulo, Brazil 05. Combined Synovial and Structural Ultrasound Score for the Diagnosis of RA. Gary A. Kunkel, Grant W. Cannon and Daniel O. Clegg, George Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, George E. Wahlen VA Medical Center, Salt Lake City, UT

149 ACR POSTER SESSION A 06. Development of a 6 Joint Simplified Ultrasonographic Score to Assess Disease Activity in Patients with Rheumatoid Arthritis. Tomas Cazenave, Christian A. Waimann, Gustavo Citera and Marcos G. Rosemffet, Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica., Buenos Aires, Argentina 07. Sensitivity to Change of the Ultrasound synovitis SONAR Score in RA Patients: Results of the Scqm Cohort. Pascal Zufferey, Almut Scherer, Hans Rudolf Ziswiler, Giorgio Tamborrini 4, Laure Brulhart 5 and Burkhard Moeller 6, Lausanne University Hospital, Lausanne, Switzerland, SCQM Foundation, Zurich, Switzerland, Inselspital, University of Bern, Bern, Switzerland, 4 University Hospital, Zurich, Switzerland, 5 Geneva, Switzerland, 6 Inselspital Bern, Bern, Switzerland 08. Disparity Between Sonographic and Clinical Criteria of Remission in Psoriasis Arthritis. Christian Dejaco, Rusmir Husic, Judith Gretler, Winfried B. Graninger and Josef Hermann, Medical University Graz, Graz, Austria, Auenbruggerplatz 5, Graz, Austria 09. Does Joint Sonography Really Add Clinically Important Information Beyond Clinical Joint Examination? Miriam Gärtner, Helga Radner, Gabriela Supp, Peter Mandl, Daniel Aletaha, Klaus P. Machold and Josef S. Smolen, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 0. Comparing Palmar and Dorsal Ultrasound Assessment of Small Joint Synovitis in Rheumatoid Arthritis: Dorsal Greyscale Mode Yields Significantly Better Concordance with Power Doppler. Matthias Witt, Felix Mueller, Hendrik Schulze-Koops and Mathias Grunke, Division of Rheumatology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, Division of Rheumatology, Medizinische Klinik and Poliklinik IV, University of Munich, Munich, Germany. Ultrasound Measurement of Metacarpal Cartilage Thickness Correlates with Joint Space Narrowing in the Metacarphalangeal Joints of Patients with Rheumatoid Arthritis. Peter Mandl, Helga Radner, Gabriela Supp, Peter V. Balint, Daniel Aletaha and Josef S. Smolen, Medical University of Vienna, Vienna, Austria, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, Medical University of Vienna and Hietzing Hospital, Vienna, Austria. Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists. Kei Ikeda, Daiki Nakagomi, Yoshie Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi Nakajima, Chiba University Hospital, Chiba, Japan. Power Doppler Signal Is Frequently Positive Among Patients with Rheumatoid Arthritis in Clinical Remission and Normal Serum Matrix Metalloproteinase- (MMP- ) Levels. Tadashi Okano, Tatsuya Koike, Masahiro Tada, Kenji Mamoto, Yuko Sugioka, Atsuko Kamiyama and Hiroaki Nakamura, Osaka City University Medical School, Osaka, Japan 4. US Examination of Wrists and Hands: A Comparison between Rheumatoid Arthritis and Psoriatic Arthritis. Andrea Delle Sedie, Elisa Cioffi, Linda Carli, Elena Sardano, Stefano Bombardieri and Lucrezia Riente, Rheumatology Unit, University of Pisa, Pisa, Italy, Immunology Unit, University of Pisa, Italy 5. Composite Ultrasound Score in Spondyloarthropathies. Maria L. Acosta Felquer, Cristian Quiroz, Santiago Ruta, Javier Rosa, Marina Scolnik, Leandro Ferreyra Garrott, Ricardo Garcia-Monaco and Enrique R. Soriano 4, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, 4 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina 6. Correlation between Clinical and Ultrasonographic Examination of the Calcaneal Enthesis in Patients with Ankylosing Spondylitis: A Controlled Study. Suellen Narimatsu, Rita N.V. Furtado, andre Rosenfeld, Germana. B. Q. Estrela, Jorge E. P. Proglhof and Jamil Natour 4, Universidade Federal de São Paulo - UNIFESP, São Paulo, Brazil, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo - UNIFESP, Sao Paulo, Brazil, 4 Universidade Federal de São Paulo, São Paulo, Brazil 7. Ultrasound for Diagnosis of Carpal Tunnel Syndrome Comparison of Different Methods to Determine Median Nerve Volume and Value of Power Doppler Sonography. Christian Dejaco, Martin Stradner, Dorothea Zauner, Werner Seel, Nicole E. Simmet, Alexander Klammer, Kerstin Brickmann, Judith Gretler, Florentine Moazedi-Fürst, Rene Thonhofer, Rusmir Husic, Josef Hermann and Stefan Quasthoff, Medical University Graz, Graz, Austria 8. Colour Doppler Sonography of the Knee Joint: A Useful Tool to Discriminate Arthritis From Osteoarthritis? Wolfgang Hartung, Nelly Beitinger, Boris P. Ehrenstein, Christian Lüring, Joachim Grifka, Benno Schreiner, Martina Müller 4 and Martin Fleck, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, Universitiy Clinic Aachen, Aachen, Germany, University of Regensburg, Bad Abbach, Germany, 4 University Clinic Regensburg, Regensburg 0 Program Book 47

150 ACR POSTER SESSION A 9. Ultrasound (US) Findings in Patients with Knee Pain: Sensitivity and Specificity for the Diagnosis of Knee Osteoarthritis and Development of an US Prediction Score. Erika Catay, Santiago Ruta, Javier Rosa, David A. Navarta, Ricardo Garcia-Monaco and Enrique R. Soriano 4, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, 4 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires and Fundacion PM Catoggio, Buenos Aires, Argentina 0. Evaluation of Joint Involvement in Patients Suffering From Early Polymyalgia Rheumatica Using High Resolution Ultrasound. Sandra Balser, Emmanuelle LeBras, Boris P. Ehrenstein, Martina Müller, Martin Fleck and Wolfgang Hartung, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, University Clinic Regensburg, Regensburg. The Diagnostic Value of Color Doppler Ultrasonography in Giant Cell Arteritis. Merete L. Hetland, Geirmund Myklebust, Glenn Haugeberg and Andreas P. Diamantopoulos, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, Hospital of Southern Norway HF, Kristiansand, Norway. Grey-Scale Ultrasonography with Power Doppler Technique: An Available Tool for the Assessment of Subclinical Joint Inflammatory Activity in Juvenile Idiopathic Arthritis. Paz Collado, Rosa Merino, J. Graña Sr., Sagrario Bustabad-Reyes 4, MariLuz Gamir 5, Mari Luz García 6 and Inmaculada Calvo 7, Severo Ochoa University Hospital, Madrid, Spain, Hospital Universitario La Paz, Madrid, Spain, Hospital Juan Canalejo, Spain, 4 Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 5 Ramon y Cajal University Hospital, Madrid, Spain, 6 Hospital de Basurto, Bilbao, Spain, 7 Hospital de La Fe, Valencia, Spain. Detection of Synovitis in Clinically Inactive Juvenile Idiopathic Arthritis Patients by Ultrasonography with POWER Doppler. Paz Collado, MariLuz Gamir, Rosa Merino, Consuelo Modesto 4, Indalecio Monteagudo 5 and Juan Carlos Lopez-Robledillo 6, Severo Ochoa University Hospital, Madrid, Spain, Ramon y Cajal University Hospital, Madrid, Spain, Hospital Universitario La Paz, Madrid, Spain, 4 Hospital Valle de Hebron, Barcelona, Spain, 5 Gregorio Marañón Hospital, Madrid, Spain, 6 Hospital Niño Jesus, Madrid, Spain 4. Reliability of an Ultrasound Scoring Measure for Juvenile Localized Scleroderma (jls). Suzanne C. Li, Melissa S. Liebling, Andrea S. Doria, Molly Dempsey-Robertson 4, Carsten Hamer 5, Sven Opitz 5, Faridali Ramji 6, Stephanie Edgerton 6, Jose Jarrin, Tanicka Kornyat, Michael Malone 6, Arun Mohanta, Shuzhen Zhang 4 and Knut M. Wittkowski 7, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Hackensack University Medical Center, Hackensack, NJ, Hospital for Sick Children, Toronto, ON, 4 Texas Scottish Rite Hospital, Dallas, TX, 5 Schon Klinik Hamburg Eilbek, Hamburg, Germany, 6 University of OK Health Science Center, Okc, OK, 7 Rockefeller University, New York, NY 5. Borderline Right Ventricular Involvement in Patients with Systemic Sclerosis without Pulmonary Hypertension. Luna Gargani, Piotr Gosciniak, Cosimo Bruni, Serena Guiducci, Silvia Bellando Randone, Lorenza Pratali, Gergely Agoston 4, Alberto Moggi Pignone 5, Albert Varga 4, Rosa Sicari, Eugenio Picano and Marco Matucci Cerinic, Institute of Clinical Physiology, National Research Council, Pisa, Italy, WSZ, Department of Cardiology, Szczecin, Poland, Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, 4 University of Szeged, Faculty of Medicine, nd Dept of Internal Medicine & Cardiology Center, Szeged, Hungary, 5 University of Florence, Department of Medicine, Division of Rheumatology, Florence, Italy 6. Ultrasonography of Salivary Glands: Diagnostic and Prognostic Value in Primary Sjögren s Syndrome. Nicoletta Luciano, Chiara Baldini, Rachele Pascale, Francesco Ferro, Alessandro Paolicchi, Davide Caramella and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy, Diagnostic and Interventional Radiology, University of Pisa, Pisa, Italy 7. Ultrasonographic Evaluation of the Hands of Patients with Primary and Secondary Sjögren s Syndrome. Cristina Hernández-Díaz, Luis M. Amezcua-Guerra, Angélica Vargas, Alberto Lopez-Reyes and Carlos Pineda, Instituto Nacional de Rehabilitación, Mexico City, Mexico, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Instituto Nacional de Rehabilitacion, Mexico City, Mexico 8. Quantitative Assessment of Synovitis in Patients with Rheumatoid Arthritis Using Fluorescence Optical Imaging. Valentin S. Schäfer, Wolfgang Hartung, Patrick Hoffstetter, Jörn Berger, Martina Müller, Martin Fleck and Boris P. Ehrenstein, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, mivenion GmbH, Berlin, Germany, University Clinic Regensburg, Regensburg 9. Comparison of Automated, Computer-Based Assessment and Visually Assessed Disease Activity Scores in ICG- Enhanced Fluorescence Optical Imaging in Patients with Rheumatic Disorders: A Feasibility Study. Stephanie G. Werner, Michael Schirner, Hans-Eckhard Langer, Mathias Cziumplik, Jörn Berger, Marina Backhaus 4 and Malte Bahner, RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, mivenion GmbH, Berlin, Germany, Duesseldorf, Germany, 4 Charite University Hospital, Berlin, Germany 48 0 Program Book

151 ACR POSTER SESSION A 0. Is Bone Scintigraphy Still Useful to Diagnose Rheumatoid Arthritis After the Appearance of 00 ACR/EULAR Classification Criteria? Ji Young Kim, Soo-Kyung Cho, Min-Kyung Han, Yun Young Choi and Yoon-Kyoung Sung, Hanyang University College of Medicine, Seoul, South Korea, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. Subclinical Arthritis Visualised by Positron Emission Tomography and Macrophage Targeting Precedes Clinical Flare in Rheumatoid Arthritis Patients in DAS8 Remission. Y.Y.J. Gent, A.E. Voskuyl, N. Ahmadi, N. Hoetjes and C.J. van der Laken, VU University Medical Center, Amsterdam, Netherlands. FDG-PET Evaluation of Axillary Lymph Nodes and Large Joints of Patients with Rheumatoid Arthritis Treated with Anti-TNF Drugs. Koichi Okamura, Yukio Yonemoto, Tetsuya Kaneko, Kimihiko Takeuchi, Tsutomu Kobayashi and Kenji Takagishi, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, Isesaki Fukushima Hospital, Isesaki, Gunma, Japan. Utility of PET-CT Imaging in IgG4-Related Disease. Arezou Khosroshahi, Leslie Lee, Mollie Carruthers, Rusen Acu, Pietro Bonaffini, Vikram Deshpande, Dushyant Sahani and John H. Stone, Massachusetts General Hospital, Boston, MA Metabolic and Crystal Arthropathies 4. Co-Existence of Gout in Rheumatoid Arthritis: It Does Happen! A Population Based Study. Adlene Jebakumar, Cynthia S. Crowson, P. Deepak Udayakumar and Eric L. Matteson, Mayo Clinic, Rochester, MN 5. A Pilot Study of the Efficacy of IL Blockade by Anakinra in Acute Calcific Periarthritis of the Rotator Cuff. Pascal Zufferey, Melanie Faucherre, Pierre A. Varisco, Berengere Aubry Sr., Isabelle Fabreguet and Alexander K. So Sr., CHUV, Lausanne, Switzerland 6. A Delphi Exercise to Identify Characteristic Features of Gout A Study of Opinions From Patients and Physicians to Inform New Classification Criteria. Rebecca Prowse, Nicola Dalbeth, H. R. Schumacher, Tuhina Neogi 4, Tim L. Jansen 5, Jaap Fransen 6 and William Taylor, University of Otago, Wellington, New Zealand, University of Auckland, Auckland, New Zealand, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4 Boston Univ School of Medicine, Boston, MA, 5 St Radboud University Nijmegen Medical Centre, Netherlands, 6 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 7. Monosodium Urate Crystals Inhibit Tenocyte Viability and Function: Implications for Periarticular Involvement in Chronic Gout. Ashika Chhana, Karen E. Callon, Bregina Pool, Dorit Naot, Gregory Gamble, Brendan Coleman, Fiona M. McQueen, Jillian Cornish and Nicola Dalbeth, University of Auckland, Auckland, New Zealand, Middlemore Hospital, Auckland, New Zealand 8. Evaluating Appropriate Use of Prophylactic Colchicine and Urate Lowering Therapy in Gout. Michael George, Sally W. Pullman-Mooar and H. Ralph Schumacher, Hospital of the University of Pennsylvania, Philadelphia, PA, University of Pennsylvania and Philadelphia Veterans Hospital, Philadelphia, PA, University of Pennsylvania and VA Medical Center, Philadelphia, PA 9. Lack of Effect of Supplemental Vitamin C On Serum Urate in Patients with Gout. Lisa K. Stamp, Christopher Frampton, John L. O Donnell, Jill Drake and Peter T. Chapman, University of Otago, Christchurch, Christchurch, New Zealand, Canterbury Health Laboratories, Christchurch, New Zealand, Christchurch Hospital, Christchurch, New Zealand 40. Patients That Continue to Flare Despite Apparent Optimal Urate Lowering Therapy. Dinesh Khanna, Puja Khanna, David Hagerty, Chris Storgard, Robert Mischler and Robert Morlock, University of Michigan, Ann Arbor, MI, Ardea Bioscience, San Diego, CA 4. Effectiveness of Prophylaxis with Anti-Gout Medications on Risk of Gout Attacks. Tuhina Neogi, Clara Chen, Jingbo Niu, Christine E. Chaisson, David J. Hunter, Hyon K. Choi and Yuqing Zhang 4, Boston University School of Medicine, Boston, MA, Boston University School of Public Health, Boston, MA, Royal North Shore Hospital, Sydney, Australia, 4 Boston University, Boston, MA 4. Efficacy of Canakinumab versus Triamcinolone Acetonide According to Multiple Gouty Arthritis-Related Health Outcomes Measures. Ari Gnanasakthy, Andrew Sarkin, Rachel Lale, Kyle Choi and Jan D. Hirsch, Novartis Pharmaceuticals Corporation, East Hanover, NJ, Health Services Research Center, University of California, San Diego, CA, Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, CA 4. Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals. Jasvinder A. Singh, David Hagerty, Chris Storgard, Robert Mischler and Robert Morlock, University of Alabama at Birmingham, Birmingham, AL, Ardea Bioscience, San Diego, CA 44. Long-Term Safety of Canakinumab in Patients with Gouty Arthritis. Alexander So, Reike Alten, H. Ralph Schumacher, Mark Bloch 4, Thomas Bardin 5, Markus R. John 6, Gerhard Krammer 6, Jan Michael Nebesky 6, Aiyang Tao 7 and Naomi Schlesinger 8, CHUV, Univ of Lausanne, Lausanne, Switzerland, Charité Univ Medicine, Berlin, Germany, Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 4 Holdsworth House Medical Practice, Sydney, Australia, 5 Hôpital Lariboisière, Paris, France, 6 Novartis Pharma AG, Basel, Switzerland, 7 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8 UMDNJ-RWJMS, New Brunswick, NJ 0 Program Book 49

152 ACR POSTER SESSION A Prevalence of Non-Gout Arthritis in Patients with Gout: Not As Sparing As Previously Thought. Fernando Perez- Ruiz and Ana M. Herrero-Beites, Hospital Universitario Cruces, Baracaldo, Spain, Hospital de Gorliz, Gorliz, Spain 46. The Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients with Anakinra. Mary Bach, Jane Park, Pradipta Ghosh, Peter A. Simkin and Gregory C. Gardner, University of Washington, Seattle, WA 47. Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort. Dinesh Khanna, Puja Khanna and Faith D. Ottery, University of Michigan, Ann Arbor, MI, Savient Pharmaceuticals, Inc., East Brunswick, NJ 48. Towards a Preliminary Definition of Remission from Gout. William Taylor, Nicola Dalbeth, Jasvinder A. Singh, Kenneth G. Saag 4 and H. R. Schumacher 5, University of Otago, Wellington, New Zealand, University of Auckland, Auckland, New Zealand, University of Alabama at Birmingham, Birmingham, AL, 4 Univ of Alabama- Birmingham, Birmingham, AL, 5 University of Pennsylvania and VA Medical Center, Philadelphia, PA 49. Natural Language Processing in the Evaluation of Gout Quality Indicators. Gail S. Kerr, J. Steuart Richards, Carl A. Nunziato, Olga V. Patterson, Scott L. DuVall 5, David D. Maron and Richard L. Amdur 6, Washington DC VAMC, Georgetown and Howard University, Washington, DC, Washington DC VA and Georgetown University, Washington, DC, Washington, DC, 4 VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 5 Washington DC VA and Georgetown Unviversity, Washington, DC 50. Ulodesine (BCX408) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 4-Week Blinded Safety Extension and Vaccine Challenge Study. Alan S. Hollister, Andreas Maetzel, Michael A. Becker, Robert Terkeltaub, David Fitz-Patrick 4, Valerie Smith 5 and William P. Sheridan, BioCryst Pharmaceuticals, Inc., Durham, NC, University of Chicago, Chicago, IL, VA Medical Ctr, San Diego, CA, 4 East-West Medical Research Institute, Honolulu, HI, 5 Pharpoint Research, Inc., Durham, NC 5. Management of Gout Attacks in the Community. Tuhina Neogi, Clara Chen, Christine E. Chaisson, David J. Hunter, Hyon Choi and Yuqing Zhang 4, Boston University School of Medicine, Boston, MA, Boston University School of Public Health, Boston, MA, Royal North Shore Hospital, Sydney, Australia, 4 Boston University, Boston, MA 5. Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB). Robert R. Evans, Steven P. Weinstein, George D. Yancopoulos and Yuhwen Soo, Regeneron Pharmaceuticals Inc, Tarrytown, NY, Regeneron Pharmaceuticals, Inc., Tarrytown, NY 0 Program Book 5. Prevention of Recurrent Calcium Stones in Subjects with Hyperuricosuria: A Randomized Controlled Trial of Febuxostat Vs Allopurinol. David S. Goldfarb, Patricia A. MacDonald, Lhanoo Gunawardhana, Solomon Chefo and Lachy McLean 4, New York Universtiy Langone Medical Center, New York, NY, Takeda Pharmaceuticals USA, Inc., Deerfield, IL, Takeda Global Research & Development Center, Inc., Deerfield, IL, 4 Takeda Global Research & Development Center, Inc, Deerfield, IL 54. Dual-Energy Computed Tomography as a Diagnostic Tool for Gout during Intercritical Periods. Gabriel S. Breuer, Naama Bogot and Gideon Nesher, Shaare Zedek Medical Center, Jerusalem, Israel, Shaare Zedek Medical Center p o box 5 Jerusalem, Israel, Israel 55. Accuracy of International Classification of Disease Codes for Calcium Pyrophosphate Disease in the Veterans Adminstration Healthcare System. Karri A. Huber, Lawrence M. Ryan and Ann K. Rosenthal, MCW Froedtert Hospital, Milwaukee, WI, Medical College of Wisconsin, Milwaukee, WI 56. Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study. Eswar Krishnan and Mihoko Bennett, Standford University, Palo Alto, CA, Stanford University, Palo Alto, CA 57. Prevalence of Gout among Adults with Chronic Kidney Disease in the United States, Eswar Krishnan, Standford University, Palo Alto, CA 58. Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study. Puja Khanna, Veronica Berrocal, Tonya Hays, Daniel J. Clauw and David A. Williams, University of Michigan, Ann Arbor, MI, UCLA, Los Angeles, CA, Univ of MI Hlth System-Lobby M, Ann Arbor, MI 59. Clinical Efficacy Outcomes with up to Years of Pegloticase Treatment for Refractory Chronic Gout. Michael A. Becker, Herbert S. B. Baraf, Robert A. Yood, Aileen M. Dillon 4, Janitzia Vazquez-Mellado 5, Faith D. Ottery 6, Dinesh Khanna 7 and John S. Sundy 8, University of Chicago, Chicago, IL, Arthritis & Rheumatism Associates, Wheaton, MD, Reliant Medical Group, Worcester, MA, 4 Kaiser Foundation Hospital, San Francisco, CA, 5 Hospital General de Mexico, Mexico city, Mexico, 6 Savient Pharmaceuticals, Inc., East Brunswick, NJ, 7 University of Michigan, Ann Arbor, MI, 8 Duke University Medical Center, Durham, NC 60. Pegloticase Long-Term Safety: Data from the Open-Label Extension Trial. Michael A. Becker, Herbert S. B. Baraf, Robert A. Yood, Aileen M. Dillon 4, Janitzia Vazquez- Mellado 5, Faith D. Ottery 6, Dinesh Khanna 7 and John S. Sundy 8, University of Chicago, Chicago, IL, Arthritis & Rheumatism Associates, Wheaton, MD, Reliant Medical Group, Worcester, MA, 4 Kaiser Foundation Hospital, San Francisco, CA, 5 Hospital General de Mexico, Mexico city, Mexico, 6 Savient Pharmaceuticals, Inc., East Brunswick, NJ, 7 University of Michigan, Ann Arbor, MI, 8 Duke University Medical Center, Durham, NC

153 ACR POSTER SESSION A 6. Increased Serum Uric Acid: Consequence or Cause of Increased Cardiovascular Risk. Inger L. Meek, Harald E. Vonkeman and Mart A.F.J. van de Laar, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands 6. Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients. Filipi M. Mello, Rafael B. Tomita, Ricardo Fuller, Marco Antonio G. P. Filho, Thiago B. M. Barros, Leandro L. do Prado, Kristopherson L. Augusto and Claudia Goldenstein-Schainberg, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Rheumatology Division - University of São Paulo, São Paulo, Brazil 6. Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout. Melea Ward, Anthony M. Louder, Keith A. Szymanski and Leonardo Tamariz 4, Competitive Health Analytics, Louisville, KY, Competitive Health Analytics, Inc., Louisville, KY, Takeda Pharmaceuticals America, Inc., Deerfield, IL, 4 University of Miami, Miami, FL 64. The Prevalence of Gout in a Large Tertiary Hospital and the Impact of in-hospital Attacks of Acute Gout On Patient Outcomes and Health Resource Utilisation a Nested Case- Control Study. John HY Moi, Mark Tacey, Carol Roberts, Caroline Brand, Alexandra Gorelik and Sharon Van Doornum, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia, The Royal Melbourne Hospital, Melbourne, Australia 65. Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study. Daria B. Crittenden, Cilian J. White, Michael DeBerardine, Grace Kim, Binita Shah, Jessica C. Kimmel, Rima D. Patel, Steven P. Sedlis, Jeffrey D. Greenberg, Craig T. Tenner, Bruce N. Cronstein and Michael H. Pillinger, NYU School of Medicine, Division of Rheumatology, New York, NY, NYU School of Medicine, Division of Cardiology, New York, NY, NYU School of Medicine, Department of Internal Medicine, New York, NY 66. Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Vs Normal Renal Function. Michael DeBerardine, Mark C. Fisher, Robert T. Keenan, Michael H. Pillinger and Daria B. Crittenden, NYU School of Medicine, Division of Rheumatology, New York, NY, Massachusetts General Hospital, Boston, MA, Duke University, Durham, NC 67. Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis from the King Study of the Italian Society for Rheumatology. Maria Manara, Carlo Alberto Scirè, Marco A. Cimmino, Marcello Govoni 4, Fausto Salaffi 5, Greta Carrara, Carlomaurizio Montecucco 6, Marco Matucci-Cerinic 7, Giovanni Minisola 8 and Kick-off of the Italina Network for Gout (KING) Study Group 9, Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, Epidemiology Unit -Italian Society for Rheumatology, Milan, Italy, Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, 4 Section of Rheumatology - Department of Clinical and Experimental Medicine - University of Ferrara, Ferrara, Italy, 5 Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, 6 Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 7 Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, 8 Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, 9 SIR, Italy 68. Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction. Lamiae Grimaldi-Bensouda, Annick Alpérovitch, Elodie Aubrun, Nicolas Danchin, Michel Rossignol 4, Lucien Abenhaim 5, Pascal Richette 6 and PGRx MI Group 7, LA-SER, Paris, France, Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, 4 LA-SER, Centre for Risk Research, Montreal, 5 LA-SER Europe Ltd, London, United Kingdom, 6 Lariboisière Hospital, Paris, France, 7 Paris, France 69. Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout. Kenneth M. Bahrt, Anthony E. Yeo, Tina L. Howson and Faith D. Ottery, Savient Pharmaceuticals, Inc., East Brunswick, NJ 70. Relative Risk of Infusion Reactions with KRYSTEXXA (pegloticase) From Post-Approval Safety Data: Results From Sept 00 to June 0. Raymond L. Malamet, Tina L. Howson, Anthony E. Yeo, Kenneth M. Bahrt and Marsha Wolfson, Savient Pharmaceuticals, Inc., East Brunswick, NJ Infection-related Rheumatic Disease 7. Disease Modifying Agents Combined with Isoniazid for Latent Tuberculosis in Patients with Rheumatic Diseases. Josiane Bourré-Tessier, Mireia Ariño i Torregrosa and Denis Choquette, Institut de Rhumatologie de Montréal, Université de Montréal, Montréal, QC, Universitat de Valencia, Massanassa, Spain, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC 7. A Systematic Review and Meta-Analysis of Antibiotic Treatment for Reactive Arthritis. Claire E. Barber, Joseph Kim, R. D. Inman, John Esdaile 4 and Matthew T. James 5, University of Calgary, Calgary, AB, University of Calgary, Calgary, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 4 University of British Columbia, Vancouver, BC, 5 Univeristy of Calgary, Calgary 7. Latent Tuberculosis Screening and Treatment in Rheumatoid Arthritis Patients Eligible for Anti-TNF Therapy in Endemic Areas: Does It Work? Ieda Laurindo, Ana C. M. Ribeiro, Julio C. B. Moraes, Carla G.S. Saad, Karina Rossi 0 Program Book 5

154 ACR POSTER SESSION A 5 Bonfiglioli, Fernando H.C. Souza, Ana L. G. Calich, Mariana G. Waisberg, Lissiane K. N. Guedes and Eloisa Bonfa, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 74. Prevalence, Risk Factors, and Functional Impact of Arthralgias among Patients with Chronic Hepatitis C Virus Infection. Samir Bhangle, Vincent Lo Re, W. Gina Pang, Kyong-Mi Chang, Valerianna Amorosa, Jay Kostman, H. Ralph Schumacher and Alexis Ogdie, University of Pennsylvania, Philadelphia, PA, Philadelphia VA Medical Center, Philadelphia, PA, University of Pennsylvania and VA Medical Center, Philadelphia, PA 75. The Impact of Hepatitis Screening On Diagnosis and Treatment in Rheumatoid Arthritis. Richard Conway, Michele Doran, Finbar (Barry) D. O Shea and Gaye Cunnane, St James s Hospital, Dublin, Ireland 76. Prevalence and Associations of Hepatitis C Arthritis in Chronic Hepatitis C Virus Infection. Elizabeth D. Ferucci, Holly S. Ryan, Tammy L. Choromanski, Lisa J. Townshend- Bulson, Stephen E. Livingston, Brian J. McMahon and Mark H. Wener, Alaska Native Tribal Health Consortium, Anchorage, AK, University of Washington, Seattle, WA 77. Antibodies to Citrullinated Peptides in Tuberculosis. Isabella Lima, Rodrigo Oliveira, Ajax Atta, Samyra Marchi, Lúcio Barbosa, Eliana Reis, Mitermayer G. Reis and Mittermayer Santiago, Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil, Universidade Federal da Bahia, Salvador, Brazil, Fundação Oswaldo Cruz, Salvador, Brazil 78. Intravenous Immunoglobulin in Parvovirus B9 Mediated Pure Red Cell Aplasia: A Retrospective Study in 0 Patients and a Review of Cases. Yoann Crabol, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes 79. Evaluation of Anakinra Therapy in Seven Adults After Suboptimal Response to Etanercept Therapy for Tumor Necrosis Factor Receptor-Associated Periodic Fever Syndrome. Amanda K. Ombrello, Patrycja M. Hoffmann, Anne Jones, Karyl S. Barron and Daniel L. Kastner, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, NIAID-NIH, Bethesda, MD 80. Safety of Canakinumab in a Large Cohort of Patients with Cryopyrin-Associated Periodic Syndrome: Results From the ß-Confident Registry. H. Hoffman, J. B. Kuemmerle- Deschner, P. Hawkins, T. van der Poll 4, Ulrich A. Walker 5, B. Rauer 6, J. M. Nebesky 6 and H. Tilson 7, University of California at San Diego, San Diego, CA, University Hospital Tuebingen, Tuebingen, Germany, University College London Medical School, London, United Kingdom, 4 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 5 Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, 6 Novartis Pharma AG, Basel, Switzerland, 0 Program Book 7 The University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina 8. Thiopurine S-Methyltransferase Levels in Patients with Behçet s Disease. Hakan Emmungil, Melike Kalfa, Raika Durusoy, Figen Yargucu Zihni, Gokhan Keser and Kenan Aksu, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, Department of Public Health, Ege University, Izmir, Turkey 8. Comprehensive Analysis of Protein Expression in Peripheral Blood Mononuclear Cells From Patients with Behcet s Disease. Takuya Yoshioka, Manae Kurokawa, Yukiko Takakuwa, Hiromasa Nakano, Seido Ooka, Nobuko Iizuka, Toshiyuki Sato, Mitsumi Arito, Kouhei Nagai, Kazuki Okamoto, Naoya Suematsu, Noboru Suzuki, Shoichi Ozaki and Tomohiro Kato, St. Marianna Univ School Med, Kawasaki, Japan, St. Marianna University School of Medicine, Kawasaki, Japan, Kinki Univ., Kinokawa, Japan 8. A Strong Association Between HLA-A*6 and Behçet s Syndrome in Japanese Patients: From Two-Center Cohort Study of Behçet s Syndrome. Tatsuo Kobayashi, Mitsumasa Kishimoto, Kazuki Yoshida, Yuri Ohara, Hiroto Nakano, Masahiro Minoda, Hideto Oshikawa and Kazuo Matsui, Kameda Medical Center, Kamogawa City, Chiba, Japan, St. Luke s International Hospital, Chuo-ku, Tokyo, Japan 84. The Retrospective Review of 9 Intestinal Behcet s Disease Focusing On the Requirement for the Immunosuppresive Drugs Other Than Corticosteroid. Yoshitaka Kimura, Kurumi Asako, Hirotoshi Kikuchi, Akiteru Takeuchi and Hajime Kono 4, Department of Internal Medicine, Teikyo University school of medecine, Tokyo, Japan, Teikyo University, Tokyo, Japan, Arakawa, Tokyo, Japan, 4 Teikyo University School of Medicine, Tokyo, Japan 85. Long-Term Efficacy and Safety of Tumour Necrosis Factor Antagonists for Patients with Behçet s Disease with Uveitis As Main Involvement. M. Victoria Hernández, Marina Mesquida, Gerard Espinosa, Victor Llorens, Laura Pelegrin, Juan D. Cañete, Ricard Cervera, Alfredo M. Adan and Raimon Sanmarti, Hospital Clínic of Barcelona, Barcelona, Spain 86. Long-Term Infliximab Therapy in Patients with Behcet s Disease Is Well Tolerated without Increasing Risk of Serious Infections. Sho Ueda, Hiroshi Tsukamoto, Yasushi Inoue, Masahiro Ayano, Satomi Hisamoto, Naoko Ueki, Atsushi Tanaka, Shun-ichiro Ohta, Naoyasu Ueda, Yojiro Arinobu, Hiroaki Niiro, Takahiko Horiuchi and Koichi Akashi, Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan 87. Effect of Colchicine On Cholesterol Levels in Patients with Familial Mediterranean Fever and Behçet s Syndrome. SerdaL Ugurlu, Emire Seyahi, Idil Hanci, Huri Ozdogan, Seval Masatlioglu-Pehlivan 4 and Hasan Yazici 5, MD, Istanbul, Turkey, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, MD,Division of Rheumatology, Department

155 ACR POSTER SESSION A of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 4 MD,Rheumatology, Istanbul, Turkey, 5 Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey 88. Etiology of Uveitis: A Hospital-Based Study in a Referral Centre. Claudia Ferrari, Rosaria Talarico, Michele Figus, Chiara Stagnaro, Anna d Ascanio and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy, Ophthalmology Unit, University of Pisa, Pisa, Italy 89. Pedal Swelling As a Characteristic Phenotype of the New Category of Autoinflammatory Disease Associated with NOD Gene Mutations. Qingping Yao, Cleveland Clinic, Cleveland, OH 90. NLRP Gene Analysis for Patients with Schnitzler s Syndrome. Cong-Qiu Chu, Carrie R. Austin, Trudy M. Doyle, Kelley A. Goodwin, Noha El Torgomen, Regina Treudler and Tammy M. Martin 4, Oregon Health & Science Univ and Portland VA Medical Center, Portland, OR, Oregon Health & Science University, Portland, OR, Universitätsklinikum Leipzig AöR, Leipzig, Germany, 4 Oregon Health & Science Univ, Portland, OR 9. Analysis of Genes Involved in Autoinflammatory Diseases in Adult Onset Still s Disease. Emma Garcia-Melchor, Dolors Grados, Eva Gonzalez-Roca, Elena Riera, Manel Juan, Jordi Yagüe, Juan Ignacio Aróstegui, Javier Narváez 4 and Alejandro Olivé, Hospital Clinic Barcelona, Barcelona, Spain, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, Hospital Mutua de Terrassa, Terrassa, Spain, 4 Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Spain 9. Clinical and Laboratory Findings in A Cohort of Italian Patients with Adult Onset Still S Disease: The Role of IL-8 As A Disease Biomarker. Roberta Priori, Serena Colafrancesco, Carlo Perricone, Antonina Minniti, Cristiano Alessandri, Giancarlo Iaiani and Guido Valesini, Rheumatology Unit, Sapienza University of Rome, Rome, Italy, Sapienza University of Rome, Rome, Italy, Department of Infectious Diseases and Tropical Medicine, Sapienza University of Rome, Rome, Italy 9. Tocilizumab in Adult Still s Disease: The Israeli Experience. Ori Elkayam, Nizar Jiries, Zvi Dranitzki, Shaye Kivity 4, Merav Lidar 5, Ofer Levy 6, Mahmoud Abu-Shakra 7, Hagit Sarvagil-Maman, Hagit Padova, Dan Caspi 8 and Itzhak Rosner 9, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, Bnai Zion Medical Center, Israel, Hadassah hebrew university, Jerusalem, Israel, 4 Center for Autoimmune Diseases, Sheba Medical Center, Tel-hashomer, Israel, Tel-Hashomer, Israel, 5 Sheba Medical Center, Ramat Gan, Israel, 6 Asaf Harofe Medical Center, 7 Soroka Medical Centre and Ben Gurion University, Beer-Sheva, Israel, 8 Tel Aviv, Israel, 9 Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel 94. LONG-TERM Efficacy of Tocilizumab in A Patient with Amyloidosis and Interstitial Pneumonia Secondary to Multicentric Castleman s Disease (MCD). Michihito Katayama, Soichiro Tsuji, Satoshi Teshigawara, Eriko Kudo-Tanaka, Maiko Yoshimura, Akane Watanabe, Akiko Yura, Yoshinori Harada, Yoshinori Katada, Jun Hashimoto, Masato Matsushita, Yukihiko Saeki and Shiro Ohshima, Osaka-Minami Medical Center, Kawachinagano City, Japan, Kawachinagano City, Japan, Osaka Minami Medical Center, Osaka, Japan 95. Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study. Arsene Mekinian, Olivier Decaux, Geraldine Falgarone, Thorsten Braun Sr. 4, Eric Toussirot 5, Loic Raffray 6, Bruno Gombert 7, Bruno de Wazieres 8, Anne Laure Buchdaul 9, Jean-Marc Ziza 0, David Launay, Guillaume Denis, Serge Madaule, Pierre Fenaux 4 and Olivier Fain 5, Jean Verdier Hospital, Bondy, France, Hôpital Sud, Rennes, France, Hopital avicenne, Paris, France, 4 Avicenne hospital, Bobigny, France, 5 CIC Biotherapy 50 6 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, 6 CHU de Bordeaux, Bordeaux, France, 7 La Rochelle hospital, La Rochelle, France, 8 CHU de Nimes, Nimes, France, 9 Douai hospital, Douai, France, 0 Hopital Croix Saint Simon, Paris, France, Internal Medicine, CHRU Claude Huriez, Lille, France, Rochefoucault hospital, Rochefoucault, France, Albi hospital, Albi, France, 4 Avicenne Hospital, France, 5 Service de médecine interne, Université Paris, AP-HP, Hôpital Jean Verdier, 940, Bondy, France., Bondy, France 96. Sarcoidosis in Northern New England. Clinical Characteristics and Predictive Factors for More Aggressive Therapy. Alireza Meysami, Kevin F. Spratt and Christopher M. Burns, Dartmouth Hitchcock Medical Center, Lebanon, NH, Geisel School of Medicine at Dartmouth, Lebanon, NH, Dartmouth Medical School, Lebanon, NH 97. Collapsing Glomerulopathy in Collagen Vascular-Like Disease. Rawad Nasr, Christine Johns and Elie Gertner, University of Minnesota, Minneapolis, MN, Regions Hospital, St Paul, MN, Regions Hospital and University of Minnesota Medical School, St. Paul, MN 98. Diagnostic Predictors and Clinical Outcomes in Patients Presenting Solely with Lymphadenopathy. Huifang Lu, Xerxes Pundole and Khanh Vu, UT MD anderson Cancer Center, Houston, TX 99. Joint, Hand and Feet Swelling As a Presenting Symptom of Hereditary Angioedema. Maria J. Gutierrez and Timothy J. Craig, Penn State College of Medicine Milton S. Hershey Medical Center, Hershey, PA, Penn State College of Medicine Milton S. Hershey Medical Cente, Hershey, PA 0 Program Book 5

156 ACR POSTER SESSION A 00. Rheumatic Manifestations and Connective Tissue Diseases in Autoimmune Hepatitis of the Child and the Adult. Federico Zazzetti, Nora C. Fernandez, Javier Benavidez, Luis A. Colombato, Graciela R. Rodriguez, Graciela Nardi, Carolina Bru Morón, Oscar L. Rillo 4, Nelo A. Quadrini, Stella M. Garay 5, Mariana Fabi 5, Teresita Gonzalez 5 and Juan C. Barreira, Buenos Aires British Hospital, Buenos Aires, Argentina, Hospital Dr. Ignacio Pirovano, Buenos Aires, Argentina, Hospital Dr. Enrique Tornú, Buenos Aires, Argentina, 4 Hospital Tornú, Buenos Aires, Argentina, 5 Hospital IAEP Sor María Ludovica, La Plata, Argentina 0. High Rate of Autoimmune Manifestations during Idiopathic CD4 Lymphocytopenia. Alexis Régent, Brigitte Autran, Guislaine Carcelain, Benjamin Terrier, Alain Krivitzky 4, Eric Oksenhendler 5, Nathalie Costedoat-Chalumeau 6, Pascale Hubert, Olivier Lortholary 7, Nicolas Dupin 8, Patrice Debré, Loic Guillevin 9 and Luc Mouthon, Hopital Cochin, Paris, France, Laboratoire d Immunologie Cellulaire Et Tissulaire, Paris, France, Cochin Hospital, Paris, France, 4 Département de médecine interne, Hôpital Avicenne, AP-HP, Bobigny, France, 5 Département d Immunologie Clinique, Hôpital Saint-Louis, AP-HP, Paris, France, 6 Assistance Publique- Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 7 Service de maladies infectieuses, Hôpital Necker-Enfants malades, AP-HP, Paris, France, 8 Service de Dermatologie, Hôpital Cochin, AP-HP, Paris, France, 9 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France 0. Diseases Associated with Markedly Elevated Ferritin Levels. Reshma Marri, Payal J. Patel, Amita Thakkar, Rochella A. Ostrowski, Eric McBride and Rodney Tehrani, Loyola Univ Medical Ctr, Maywood, IL 0. Clinical Course Factors Associated with Outcome of Monoarthritis: A Retrospective Study of 7 Cases. Hyemin Jeong, Eun-Jung Park, Jiwon Hwang, Ji Young Chai, Joong Kyong Ahn 4, Eun-Mi Koh 5 and Hoon-Suk Cha 6, Samsung Medical Center, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, 4 Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea, 6 Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea 04. Characterization of Joint Disease in Mucopolysaccharidosis Type I Mice and the Effects of Enzyme Replacement Therapy. Patricia Oliveira, Guilherme Baldo, Fabiana Mayer, Barbara Martinelli, Luise Meurer, Roberto Giugliani, Ursula Matte and Ricardo M. Xavier, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil Muscle Biology, Myositis and Myopathies: Clinical and Therapuetic Aspects of Idiopathic Inflammatory Myopathies 05. Idiopathic Inflammatory Myositis Is Associated with an Increased Incidence of Systemic Sclerosis. Shreyas H. Chaudhary, Susanna Proudman and Vidya S. Limaye, Medical Student University of Adelaide, Adelaide, Australia, Royal Adelaide Hospital, Adelaide, Australia 06. Clinical, Laboratory, and Cellular Responses in the Rituximab in Myositis Trial in Patients Enrolled At the National Institutes of Health. Lisa G. Rider, Adrienne L. Yip, Iren Horkayne-Szakaly, Rita Volochayev, Joseph A. Shrader, Maria L. Turner 4, Heidi H. Kong 4, Minal S. Jain, Anna V. Jansen, Chester V. Oddis 5, Thomas A. Fleisher 6 and Frederick W. Miller, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, Joint Pathology Center, Silver Spring, MD, Rehab Medicine, NIH Clinical Center, Bethesda, MD, 4 NCI, NIH, Bethesda, MD, 5 University of Pittsburgh, Pittsburgh, PA, 6 Laboratory Medicine, NIH Clinical Center, Bethesda, MD 07. Interferon-Driven Chemokines Are Associated with Changes in Disease Activity Among Rituximab-Treated Refractory Myositis Patients with Pulmonary Involvement - the RIM Study. Cynthia S. Crowson, Ann M. Reed, Molly Hein, Abigail B. Green, Consuelo Lopez de Padilla, Rohit Aggarwal, Dana P. Ascherman, Marc C. Levesque 4 and Chester V. Oddis 4, Mayo Clinic, Rochester, MN, University of Pittsburgh Medical Center, Pittsburgh, PA, University of Miami, Miami, FL, 4 University of Pittsburgh, Pittsburgh, PA 08. Outcome of Muscle Function and Disease Activity in Patients Recently Diagnosed with Polymyositis and Dermatomyositis Preliminary Results of a -Year Follow-up Registry Study. Helene Alexanderson, Jenny Bergegård, Christina Ottosson, Maryam Dastmalchi 4 and Ingrid E. Lundberg, Karolinska Institutet, Stockholm, Sweden, Karolinska University Hospital, Solna, Stockholm, Sweden, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, 4 Rheumatology Unit, Karolinska University Hospital in Solna, Karolinska Institutet., Stockholm, Sweden 09. Clinical Study of Determination of Myositis-Associated Autoantibodies in Japanese Patients with Connective Tissue Diseases except Autoimmune Myositis. Toshio Kawamoto, Masakazu Matsushita, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Juntendo University School of Medicine, Tokyo, Japan, Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan 0. An Analysis of Metabolic Syndrome in Adult Dermatomyositis with a Focus On Cardiovascular Disease. Mariana T. Moraes, Fernando H.C. Souza, Thiago B. M. Barros and Samuel K. Shinjo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 54 0 Program Book

157 ACR POSTER SESSION A. Efficacy and Safety of Disease Modifying Drugs, Biologic Therapies and Immunoglobulin in Patients with Polymyositis and Dermatomyositis: A Systematic Literature Review. JA Martinez-Lopez Sr., J. Graña Sr., Santiago Muñoz-Fernandez, I. Rua-Figueroa 4, José M. Pego-Reigosa 5, Estíbaliz Loza Sr. 6 and SER group for the study of systemic autoimmune diseases 7, Fundacion Jimenez Diaz, Madrid, Spain, Hospital Juan Canalejo, Spain, Hospital Infanta Sofía, Madrid, Spain, 4 Hospital de GC Dr Negrin, Las Palmas GC, Spain, 5 Hospital do Meixoeiro, Vigo, Spain, 6 Research Unit. Sociedad Española de Reumatología, Madrid, Spain, 7 Madrid. Distinctive Characteristics of Anti-Mi- and p55/40 Autoantibody Production in Two Cohorts of Mexican Patients with Dermatomyositis. Monica Vazquez-Del Mercado, Marcelo Petri, Luis J. Jara-Quezada, Miguel A. Saavedra-Salinas 4, Claudia Cruz-Reyes 5, Olga-Lidia Vera-Lastra 6, Lilia andrade 7, Mario Salazar-Paramo 8, Laura Gonzalez-Lopez 9, Jorge Gamez-Nava 0, Rosa E. Prieto-Parra 8, Teresita Martin Marquez, Jason Y.F. Chan, Edward K.L. Chan and Minoru Satoh, Universidad de Guadalajara, Guadalajara, Mexico, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, 4 Centro Médico Nacional, México, Mexico, 5 Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico, 6 Inst Mexicano Seguro Social, Mexico City, Mexico, 7 CMN 0 Noviembre ISS STE, Mexico, Mexico, 8 Instituto Mexicano Del SS, Guadalajara, Mexico, 9 Hospital Regional de Zona 0, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, Guadalajara, Jalisco, Mexico, Mexico, 0 Centro Medico de Occidente, Guadalajara Jal, Mexico, University of Florida, Gainesville, FL. Nsaids Suppress the Inflammatory Reaction Related to Muscle Soreness but May Delay Recovery. Matthias Rother, Egbert J. Seidel, Alexander Fischer and Ilka Rother, IMR Partner GmbH, Graefelfing, Germany, Sophien- and Hufeland Clinic, Weimar, Germany 4. Inflammatory Muscle Disease Associated Pulmonary Hypertension - Clinical Features and Survival At a National Referral Centre. Matthew Webber, D. Dobarro, Clive Handler, Christopher P. Denton, Benjamin E. Schreiber and John G. Coghlan, Royal Free Hospital, London, United Kingdom, Royal Free Hospital, London, London, United Kingdom, UCL, London, United Kingdom 5. Abnormal Videofluoroscopy Swallow Study Finding in Inflammatory Myopathy Patient with Dysphagia As Predictor of Prognosis. Hye Won Kim, Hwang Kim, Sung Hae Chang, Hye Jin Oh, Myeong Jae Yoon, Bong Seung Ku, Byeong Mo Oh and Eun Young Lee, Seoul National University College of Medicine, Seoul, South Korea 6. Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis. Yuji Hosono, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Motomu Hashimoto, Koichiro Ohmura, Takao Fujii and Tsuneyo Mimori, Graduate School of Medicine, Kyoto University, Kyoto, Japan 7. Myositis-Associated Usual Interstitial Pneumonia Has Better Survival Than Idiopathic Pulmonary Fibrosis. Christine McBurney, Rohit Aggarwal, Kevin Gibson, Kathleen Lindell 4, Carl Fuhrman, Diane Koontz, Frank Schneider 4, Naftali Kaminski 4 and Chester V. Oddis, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Medical Center, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 Pittsburgh, PA 8. Proteomics Study of a Phase b Trial with an Anti-IFN-α Monoclonal Antibody Indicates Association of Soluble Interleukin Receptor with Type I Interferon Activity in Patients with Dermatomyositis or Polymyositis. Xiang Guo, Brandon W. Higgs, Wei Zhu, Yihong Yao and Wendy White, MedImmune, LLC, Gaithersburg, MD 9. Significant Functional Improvement Using Aggressive Immunomodulatory Therapy in Patients with Inflammatory Myopathy and Interstitial Lung Disease. Ramona Mihu, Roger D. Rossen, Jovan Popovich and Sandra L. Sessoms, Baylor College of Medicine, Houston, TX, The Methodist Hospital, Houston, TX 0. Efficacy of Rituximab for the Treatment of Refractory Inflammatory Myopathies Associated with Anti-HistidyltRNA Synthetase Antibodies (the FORCE Jo Study). Yves Allenbach, Aude Rigolet, Marguerite Guiguet, Isabelle Marie, Eric Hachulla 4, Dominique Farge 5, Kuberaka Mariampillai, Serge Jacquot 6, Fabienne Jouen 7, Olivier Boyer 8, Lucile Musset 9, Serge Herson and Olivier Benveniste, Pitie-Salpetriere Hospital, Paris, France, Paris, France, Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 4 Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, 5 EBMT, Paris, France, 6 INSERM U905, Université de Rouen, Rouen, France, 7 Rouen University Hospital, Rouen Cedex, France, 8 INSERM U905, University of Rouen, Rouen, France, 9 CHU Pitié-Salpêtrière, Paris, France. Expanding the Clinical and Serological Spectrum of MDA5- Associated Dermatomyositis. John C. Hall, Livia Casciola Rosen, Sonye K. Danoff, Lesly-Anne Samedy and Lisa Christopher-Stine, Johns Hopkins University, Baltimore, MD, Johns Hopkins School of Medicine, Baltimore, MD. Lung Nodules in Patients with Idiopathic Inflammatory Myopathies. Laura C. Cappelli, Andrew L. Mammen, Sonye K. Danoff, Grant H. Louie, Thomas E. Lloyd and Lisa Christopher-Stine, Johns Hopkins University, Baltimore, MD, Johns Hopkins, Baltimore, MD, Johns Hopkins School of Medicine, Baltimore, MD 0 Program Book 55

158 ACR POSTER SESSION A. High Prevalence and Clustering Over Time of Anti- PL-7 Autoantibody-Positive Idiopathic Inflammatory Myopathies. Yoshioki Yamasaki, Minoru Satoh, Hidehiro Yamada, Machiko Mizushima, Takahiro Okazaki, Hiroko Nagafuchi, Seido Ooka, Tomohiko Shibata, Hiromasa Nakano, Hitoshi Ogawa, Kohei Azuma, Akihiko Maeda, Hirofumi Mitomi, Tomofumi Kiyokawa, Kosei Tsuchida, Hidenori Mikage, Jason Y.F. Chan and Shoichi Ozaki, St. Marianna University School of Medicine, Kawasaki, Japan, University of Florida, Gainesville, FL 4. Standardized Incidence Ratios and Predictors of Malignancies in 5 Southern Chinese Patients with Inflammatory Myopathies. Chi Chiu Mok, Chi Hung To, ML Yip and King Yee Ying, Tuen Mun Hospital, Hong Kong, Hong Kong, Kwong Wah Hospital, Kowloon, Hong Kong, Princess Margaret Hospital, Hong Kong, Hong Kong 5. Polymyositis in HIV+ Patients Is Associated to Uncontrolled Viral Load. Yves Allenbach, Odile Dubourg, Thierry Maisonobe, Anthony Behin, Charles Duyckaerts, Guillaume Breton, Olivier Fain, Marie-Caroline Meyhoas 4, Catherine Leport 5, Marc-Antoine Valentin 6, Daniel Vittecoq 7, Jean-François Bergmann 8, Thomas Anslik 9, Marie-Paule Chauveheid 0, Zahir Amoura, Thomas de Broucker, Pierre Bourgeois, Bruno Eymard, Serge Herson and Olivier Benveniste, Pitie-Salpetriere Hospital, Paris, France, Institute of Myology, Pitie-Salpetriere Hospital, Paris, France, Service de médecine interne, Université Paris, AP-HP, Hôpital Jean Verdier, 940, Bondy, France., Bondy, France, 4 Department of Infectious Diseases, Saint Antoine Hospital, Paris, France, 5 Paris, France, 6 Department of Infectious Diseases, Pitié-Salpetriere Hospital, Paris, France, 7 Department of Infectious Diseases, K Bicetre Hospital, Kremlin-Bicetre, France, 8 Internal Medicine, Lariboisiere Hospital, Paris, France, 9 Internal Medicine, Ambroise Pare Hospital, Boulogne Billancourt, France, 0 Internal Medicine, Bichat Hospital, Paris, France, CHU Pitié-Salpêtrière, Paris, France, Department of Neurology, Delafontaine Hospital, Saint Denis, France 6. Autoantibodies to Small Ubiquitin-Like Modifier Activating Enzymes in Japanese Patients with Dermatomyositis. Manabu Fujimoto, Takashi Matsushita, Yasuhito Hamaguchi, Kenzo Kaji, Minoru Hasegawa and Kazuhiko Takehara, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan 7. Long Term Outcome of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies and Amyopathic Dermatomyositis. Machiko Mizushima, Hidehiro Yamada, Yoshioki Yamasaki, Masaomi Yamasaki, Minoru Satoh 4 and Shoichi Ozaki 5, St. Marianna University School of Medicine, Kawasaki, Japan, St. Marianna University, Kawasaki, Japan, St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan, 4 University of Florida, Gainesville, FL, 5 St. Marianna University School of Medicine., Kawasaki, Japan 8. Simultaneous Initiating of Glucocorticoids and disease- Modifying Antirheumatic Drug Therapy in Polymyositis and Dermatomyositis Patients Results in the Opportunity to Taper Dosage of Glucocorticoids Early. Kavish J. Bhansing, Piet LCM Van Riel, Sigrid Pillen, Baziel G.M. van Engelen and Madelon C. Vonk, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Catharina Wilhemina Hospital, Nijmegen, Netherlands 9. Clinical Differences between Adult and Juvenile Dermatomyositis Associated with Anti-NXP Autoantibodies. Sarah Tansley, Zoe Betteridge, Harsha Gunawardena, Lucy R. Wedderburn, Hector Chinoy 4, Robert G. Cooper 5, Jiri Vencovsky 6, Lenka Plestilova 7, Ingrid E. Lundberg 8, Katalin Danko 9, Melinda Vincze 9, Neil McHugh, UK JDRG 0 and EuMyoNet, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, North Bristol NHS Trust, Bristol, United Kingdom, University College London (UCL), London, United Kingdom, 4 The University of Manchester, Manchester, United Kingdom, 5 Hope Hospital, Salford, United Kingdom, 6 Institute of Rheumatology, Prague, Czech Republic, 7 Institute of Rheumatology, Prague, Czech Republic, 8 Karolinska Institutet, Stockholm, Sweden, 9 University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, 0 London, United Kingdom, Stockholm, Sweden 0. Hydroxy--Methylglutaryl-Coenzyme A Reductase (HMGCoR) Antibody in Necrotizing Myopathy and the Role of Statins. Ashima Malik, Rohit Aggarwal, Zengbiao Qi, Noreen Fertig, Diane Koontz, Rufus W. Burlingame, David Lacomis and Chester V. Oddis, University of Pittsburgh, Pittsburgh, PA, INOVA Diagnostics, Inc., San Diego, CA, University of Pittsburgh Medical Ctr, Pittsburgh, PA. Pulmonary Hypertension in the Antisynthetase Syndrome. Helena andersson, T. Mogens Aalokken, Torhild Garen, Oyvind Molberg 4 and Jan Tore Gran, Oslo University Hospital, Oslo, Norway, Oslo, Norway, Oslo University Hospital Rikshospitalet, Oslo, Norway, 4 Department of Rhematology, Oslo University hospital, Rikshospitalet, Oslo, Norway. The Natural History of Sporadic Inclusion Body Myositis an Observational Longitudinal Study. Pedro Machado, Andrea Cortese, Jasper Morrow, Liz Dewar, andy Hiscock, Adrian Miller, Stefen Brady, David Hilton- Jones, Matt Parton and Michael G. Hanna, MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, Oxford Muscle and Nerve Centre, John Radcliffe Hospital, Oxford, United Kingdom. IFN Signature Is Associated with Autoantibody Profiles in Patients with Idiopathic Inflammatory Myopathies. Saskia Vosslamber, Louise Ekholm, Anna Tjarnlund, Clio P. Mavragani 4, Lenka Plestilova 5, Martin Klein 5, Mary K. Crow 6, Peter J. Charles 7, Leonid Padyukov 8, Jiri Vencovsky 5, Ingrid E. Lundberg and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands, Rheumatology 56 0 Program Book

159 ACR POSTER SESSION A Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Sweden, Stockholm, Sweden, 4 School of Medicine, University of Athens, Athens, Greece, Athens, Greece, 5 Institute of Rheumatology, Prague, Czech Republic, 6 Hospital for Special Surgery, New York, NY, 7 Oxford University, London, United Kingdom, 8 Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden Osteoarthritis - Clinical Aspects 4. Central Sensitization Is Associated with Spontaneous Pain in Knee Osteoarthritis. Anisha B. Dua, Tuhina Neogi, Rachel A. Mikolaitis, Joel A. Block and Najia Shakoor, Rush Universtiy Medical Center, Chicago, IL, Boston Univ School of Medicine, Boston, MA, Rush University Medical Center, Chicago, IL 5. Peripheral and Central Sensitization in Patients with Different Degree of Knee Osteoarthritis. Lars Arendt- Nielsen, Thomas Navndrup Eskehave, Morten Asser Karsdal, Anne C. Bay-Jensen, Hans Christian Hoeck 4 and Ole Simonsen 5, Aalborg University, Aalborg, Denmark, Ålborg University, Ålborg, Denmark, Nordic Bioscience A/S, Herlev, Denmark, 4 C4Pain, Ålborg, Denmark, 5 Frederikshavn Hospital, Frederikshavn, Denmark 6. The Relationship between Vibratory Sense and Somatosensory Pain Measures in Knee Osteoarthritis. Anisha B. Dua, Rachel A. Mikolaitis, Tuhina Neogi, Joel A. Block and Najia Shakoor, Rush Universtiy Medical Center, Chicago, IL, Rush University Medical Center, Chicago, IL, Boston Univ School of Medicine, Boston, MA 7. Association between Pain Threshold, Symptoms and Radiographic Knee and Hip Osteoarthritis: The Johnston County Osteoarthritis Project. Adam P. Goode, Xiaoyan A. Shi, Jordan Renner, Richard Gracely 4, Mehrnaz Maleki- Fischbach 5 and Joanne M. Jordan 6, Duke University, Durham, NC, SAS Institute, Inc, Cary, NC, University of North Carolina, Chapel Hill, NC, 4 Chapel Hill, NC, 5 National Jewish Health, Denver, CO, 6 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 8. Inevitable Deterioration? Trajectories and Risk Profiles of Pain in Patients with Radiographic, Symptomatic Knee Osteoarthritis. Jamie E. Collins, William M. Reichmann, Jeffrey N. Katz and Elena Losina, Brigham and Women s Hospital, Boston, MA, Brigham and Womens Hospital, Boston, MA 9. Knee Osteoarthritis Symptom Assessments That Combine Pain and Physical Activity Are Superior to Pain Alone. Grace H. Lo, Timothy E. McAlindon, Gillian A. Hawker, Jeffrey B. Driban, Lori Lyn Price, Jing Song 4, Charles Eaton 5, Marc C. Hochberg 6, Rebecca D. Jackson 7, C. Kent Kwoh 8, Michael C. Nevitt 9 and Dorothy D. Dunlop 4, Michael E. DeBakey Veterans Affairs Medical Center / Baylor College of Medicine, Houston, TX, Tufts Medical Center, Boston, MA, Women s College Research Institute, University of Toronto, Toronto, ON, 4 Northwestern University, Chicago, IL, 5 Warren Alpert Medical School at Brown University, RI, 6 University of Maryland, Baltimore, MD, 7 Ohio State University, Columbus, OH, 8 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 9 University of California-San Francisco, San Francisco, CA 40. Degenerative Changes in Patients with Knee Pain: A Comparative Study between Ultrasound and Conventional Radiology. Santiago Ruta, Erika Catay, Javier Rosa, David A. Navarta, Ricardo Garcia-Monaco and Enrique R. Soriano 4, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, 4 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina 4. Excess Body Weight and 4-Year Function Outcomes: Comparison of African-Americans and Caucasians in the Osteoarthritis Initiative. Carmelita J. Colbert, Orit Almagor, Joan S. Chmiel, Jing Song, Dorothy D. Dunlop, Karen W. Hayes and Leena Sharma, Northwestern University, Chicago, IL 4. Relationship of Objective to Self-Reported Physical Activity Measures Among Adults in the Osteoarthritis Initiative. Grace E. Ahn, Jing Song, Jungwha Lee, Pamela A. Semanik, Rowland W. Chang, Leena Sharma, Charles Eaton, Rebecca Jackson, Alex Mysiw 4 and Dorothy D. Dunlop, Northwestern University, Chicago, IL, Warren Alpert Medical School at Brown University, RI, Ohio State University, Columbus, OH, 4 Denison University, Granville 4. Relationship of Physical Activity with Health Utility in the Osteoarthritis Initiative. Dorothy D. Dunlop, Jing Song, Rowland W. Chang, Jungwha Lee, Pamela A. Semanik, Linda S. Ehrlich-Jones, Kai Sun, Leena Sharma, C. Kent Kwoh 4, Charles Eaton 5 and Larry Manheim, Northwestern University, Chicago, IL, Rehabilitation Institute Chicago, Oak Park, IL, Rehabilitation Institute Chicago, Chicago, IL, 4 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 5 Warren Alpert Medical School at Brown University, RI 44. Minimal Clinically Important Difference and Patient Acceptable Symptom State for the Oarsi-Omeract Intermittent and Constant OA Pain (ICOAP) Measure. Z. Anna Liu, Tetyana Kendzerska, Joy Elkayam, Shefali Ram and Gillian A. Hawker, Women s College Research Institute, University of Toronto, Toronto, ON 45. Similarities of Patient Self-Report Scores From a Multidimensional Health Assessment Questionnaire (MDHAQ), Laboratory Tests, Physician Global Assessment, 0 Program Book 57

160 ACR POSTER SESSION A and Polyarticular Involvement in Patients with Osteoarthritis and Rheumatoid Arthritis. Isabel Castrejón, Yusuf Yazici and Theodore Pincus, NYU Hospital for Joint Diseases, New York, NY 46. Routine Assessment of Patient Index Data (RAPID) Is a Valid Index for Routine Care in Patients with Osteoarthritis. Alfredomaria Lurati, Luca Bertani, Daniela Bompane, Mariagrazia Marrazza, Katia Angela Re and Magda Scarpellini, Rheumatology Unit, Magenta, Italy, Ospedale Fornaroli, Magenta, Italy 47. Meager Depression Screening and Mental Health Referral Rates for Patients with Arthritis in a National Sample. Mary Margaretten, Patricia P. Katz, Laura Trupin, Gabriela Schmajuk, Jennifer Barton, Jinoos Yazdany and Edward Yelin, UCSF, San Francisco, CA 48. Synovial Fluid Leptin Level Is Associated with Residual Pain and Functional Disability One Year After Total Joint Arthroplasty. Anne Lübbeke, Gabor J. Puskas, Axel Finckh, Domizio Suva, Sylvette Bas, Cem Gabay, Daniel Fritschy and Pierre Hoffmeyer, Geneva University Hospitals, Geneva, Switzerland, Geneva University Hospitals, Geneva 4, Switzerland, Geneva University Hospitals, Switzerland 49. Medial Subchondral Bone Marrow Lesions Increase the Odds of Knee Joint Replacement Data From the Osteoarthritis Initative. Frank Roemer, C. Kent Kwoh, David Hunter, Michael J. Hannon 4, Robert M. Boudreau 5, Felix Eckstein 6, Zhijie Wang 4, Markus R. John 7 and Ali Guermazi 8, Klinikum Augsburg, Augsburg, Germany, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Sydney, Sydney, Australia, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA, 5 University of Pittsburgh, Pittsburgh, PA, 6 Paracelsus Medical University, Salzburg, Austria, 7 Novartis Pharma AG, Basel, Switzerland, 8 Boston University School of Medicine, Boston, MA 50. Incident and Worsening Cartilage Damage in the Lateral Compartment and Multiple Subregions Worsening in the Medial Compartment Increase the Risk for Knee Replacement - Data From the Osteoarthritis Initiative. Frank Roemer, C. Kent Kwoh, Michael J. Hannon, Robert M. Boudreau 4, Felix Eckstein 5, David J. Hunter 6, Zhijie Wang, Markus R. John 7 and Ali Guermazi 8, Klinikum Augsburg, Augsburg, Germany, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 University of Pittsburgh, Pittsburgh, PA, 5 Paracelsus Medical University, Salzburg, Austria, 6 Royal North Shore Hospital, Sydney, Australia, 7 Novartis Pharma AG, Basel, Switzerland, 8 Boston University School of Medicine, Boston, MA 5. Smaller Baseline and Follow-up Quadriceps Muscle Cross- Sectional Area Increases the Odds of Knee Replacement in Knee Osteoarthritis. Serter Gumus, Michael J. Hannon, Diana Kaya, C. Kent Kwoh and Kyongtae Ty Bae, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA 5. Presence of Severe Medial Mensical Pathology Increases the Odds for Knee Replacement: Data From the Osteoarthritis Initiative. Frank Roemer, C. Kent Kwoh, David J. Hunter, Robert M. Boudreau 4, Michael J. Hannon 5, Markus R. John 6, Felix Eckstein 7, Michel Crema 8, Zhijie Wang 5 and Ali Guermazi 9, Klinikum Augsburg, Augsburg, Germany, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, Royal North Shore Hospital, Sydney, Australia, 4 University of Pittsburgh, Pittsburgh, PA, 5 University of Pittsburgh School of Medicine, Pittsburgh, PA, 6 Novartis Pharma AG, Basel, Switzerland, 7 Paracelsus Medical University, Salzburg, Austria, 8 Boston University, Boston, MA, 9 Boston University School of Medicine, Boston, MA 5. Incidence of Osteoarthritis-Related Knee and Hip Joint Surgery in Southern Sweden. Aleksandra Turkiewicz, Ingemar F. Petersson, Leif E. Dahlberg and Martin Englund, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden 54. Effects of Strontium Ranelate on Knee Osteoarthritis Pain: A Responder Analysis. JY. Reginster, Roland Chapurlat, N. Bellamy, E. Czerwinski 4, JP Devogelaer 5, L. March 6, K. Pavelka 7 and Cyrus Cooper 8, University of Liège, Liège, Belgium, Hôpital Edouard Herriot, Lyon, France, CONROD. The University of Queensland, Royal Brisbane and Women s Hospital, Herston, Queensland, Australia, 4 Krakow Medical Centre, Kraków, Poland, 5 Cliniques Universitaires St. Luc, Brussels, Belgium, 6 University of Sydney, Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards - Sydney, Australia, 7 Institute of Rheumatology, Prague, Czech Republic, 8 University of Oxford; Southampton General Hospital, Southampton, United Kingdom 55. Clinically Meaningful Effect of Strontium Ranelate on Knee Osteoarthritis Symptoms. O. Bruyere, N. Bellamy, J. Brown, P. Richette 4, L. Punzi 5, X. Chevalier 6, Cyrus Cooper 7 and Jean-Yves Reginster, University of Liège, Liège, Belgium, CONROD. The University of Queensland, Royal Brisbane and Women s Hospital, Herston, Queensland, Australia, Rheumatology Centre,, Quebec City, QC, 4 Hôpital Lariboisière, Paris, France, 5 Azienda Ospedaliera di Padova, Padova, Italy, 6 Hôpital Henri-Mondor, Creteil, France, 7 University of Oxford; Southampton General Hospital, Southampton, United Kingdom 56. Strontium Ranelate Decreases the Level of Urinary CTX-II in Patients with Knee Osteoarthritis. Julien Collette, Olivier Bruyere and Jean-Yves Reginster, Labo Ria Chu Sart Tilman, Liege, Belgium, Universite De Liege, Liege, Belgium, University of Liège, Liège, Belgium 57. Meta-Analysis of Four -Week Phase III Clinical Trials Investigating the Effect of TDT 064, a Transdermal Gel, in Osteoarthritis of the Knee. Matthias Rother, Johannes C. Vester, Wolfgang W. Bolten and Philip G. Conaghan 4, IMR 58 0 Program Book

161 ACR POSTER SESSION A Partner GmbH, Graefelfing, Germany, IDV Data Analysis and Study Planning, Krailling, Germany, Klaus-Miehlke-Klink, Wiesbaden, Germany, 4 University of Leeds, Leeds, United Kingdom 58. Efficacy and Safety of the Chinese Herbal Compound Hou-Lou-Xiao-Ling Dan in Patients with Osteoarthritis of the Knee: Results of a Phase II International Study. Marc C. Hochberg, Lixing Lao, Patricia Langenberg, Harry H. S. Fong, David Y-W. Lee and Brian Berman, University of Maryland, Baltimore, MD, University of Illinois at Chicago, Chicago, IL, Harvard Medical School, Boston, MA 59. Long-Term Tanezumab Treatment for Osteoarthritis: Efficacy and Safety Results. Alfonso E. Bello, Evan F. Ekman, David Radin, Isabelle Davignon 4, Michael D. Smith 4, Mark T. Brown 4, Christine R. West 5 and Kenneth M. Verburg 4, Illinois Bone & Joint Institute, Glenview, IL, Southern Orthopaedic Sports Medicine, Columbia, SC, Stamford Therapeutics Consortium, Stamford, CT, 4 Pfizer, Groton, CT, 5 Pfizer, Williamston, MI 60. Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Marc C. Hochberg, Steven B. Abramson, David S. Hungerford, Edward McCarthy 4, Eric P. Vignon 5, Michael D. Smith 6, Leslie Tive 7, Kenneth M. Verburg 6 and Christine R. West 8, University of Maryland, Baltimore, MD, NYU Hospital for Joint Diseases, New York, NY, Johns Hopkins University, Baltimore, MD, 4 The Johns Hopkins University School of Medicine, Baltimore, MD, 5 Centre Hospitalier, Pierre Benite, France, 6 Pfizer, Groton, CT, 7 Pfizer Inc, New York, NY, 8 Pfizer, Williamston, MI 6. Effect of Advancing Age on the Gastrointestinal Safety of Celecoxib versus Nonselective Nonsteroidal Anti- Inflammatory Drugs: A Post Hoc Analysis of GI-Reasons. Lee S. Simon, Byron Cryer, Gurkirpal Singh, Chunming Li 4 and Margaret Noyes Essex 5, SDG LLC Consulting, West Newton, MA, University of Texas Southwestern Medical Center, Dallas, TX, Stanford University School of Medicine, Palo Alto, CA, 4 Pfizer Inc, New York, NY, 5 Pfizer, Inc, New York, NY 6. Flexible Footwear Reduces Dynamic Joint Loads in Knee Osteoarthritis: Results of a 6 Month Randomized Controlled Trial Najia Shakoor, Roy H. Lidtke, Louis F. Fogg, Rachel A. Mikolaitis, Markus A. Wimmer, Kharma C. Foucher, Laura E. Thorp and Joel A. Block, Rush University Medical Center, Chicago, IL, Rush University Medical Center 6. Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac: A Systematic Review of the Literature and Meta-Analysis. Fabiola Atzeni, Pier Carlo Sarzi-Puttini, Luigi Lanata and Michela Bagnasco, University Hospital L Sacco, Milan, Italy, Dompé SpA, Milan, Italy 64. Specialized Footwear Decreases Medial Tibial Bone Mineral Density Over 48 Weeks in Knee Osteoarthritis. Justin B. Gan, Laura E. Thorp, Roy H. Lidtke, Rachel A. Mikolaitis, Louis F. Fogg, Joel A. Block and Najia Shakoor, Rush University Medical Center, Chicago, IL 65. Reducing Loads in the Contralateral Side in Medial Knee Osteoarthritis; A -Year Follow-up Study. Roy H. Lidtke and Joel A. Block, Rush University Medical Center, Chicago, IL 66. Knee Joint Stabilization Therapy in Patients with Osteoarthritis of the Knee: A Randomized, Controlled Trial. Jesper Knoop, Joost Dekker, Marike van der Leeden, Martin van der Esch, Carina A. Thorstensson 4, Martijn Gerritsen, Ramon E. Voorneman, Wilfred FH Peter, Mariette de Rooij, Suzanne Romviel, Willem F. Lems 5, Leo D. Roorda and Martijn P.M. Steultjens 6, Reade, centre for rehabilitation and rheumatology, Amsterdam, Netherlands, VU University Medical Centre, Department of Rehabilitation Medicine, EMGO Institute and Department of Psychiatry, Amsterdam, Netherlands, Reade, Amsterdam, Netherlands, 4 University of Gothenburg, Institute of Neuroscience and Physiology, Gothenburg, Sweden, 5 VU University Medical Center, Amsterdam, Netherlands, 6 Glasgow Caledonian University, Glasgow, Scotland 67. Osteopontin in Patients with Primary Knee Osteoarthritis: Relation to Disease Severity. Ramy Abdelnaby, Ain Shams University, Cairo, Egypt 68. Knee Osteoarthritis and Serum Uric Acid Concentration: The Third National Health and Examination Survey. Tony Ning, Carl Pieper, Virginia B. Kraus, William E. Kraus and Kim M. Huffman, Duke University Medical Center, Durham, NC 69. Differences Between Patients with Hip and Knee Osteoarthritis. Kim F. Le Marshall, Bradley Yee, Paul A. Dieppe, Albert Leung, Carolyn Page, Peter F. Choong, Michelle Dowsey and Keith K. Lim, Western Hospital, Melbourne, Australia, University of Plymouth Campus, Plymouth, United Kingdom, St Vincent s Hospital, Melbourne, Australia 70. Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study. Daniel Prieto-Alhambra and Rosa Morros, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, IDIAP Jordi Gol; Institut Català de la Salut, Spain 7. Bone Marrow Lesions in Knees with Osteoarthritis: Can Parameters From Dynamic Contrast Enhancement Predict Change in Bone Marrow Lesion Volume or Knee Pain Change? Andrew D. Gait, Timothy F. Cootes, Elizabeth J. Marjanovic, Matthew J. Parkes, Charles E. Hutchinson and David T. Felson, University of Manchester, Manchester, United Kingdom, University of Warwick, Coventry, United Kingdom 0 Program Book 59

162 ACR POSTER SESSION A Interim Safety Analysis of a Phase, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Efficacy Study of Apremilast (CC0004) in Subjects with Erosive Hand Osteoarthritis. Juergen Rech, Wolfgang Ochs, Wolfgang Spieler, Herbert Kellner 4, Ulf Müller- Ladner 5, Mathias Grunke 6, Matthias Schneider 7 and Georg Schett 8, University of Erlangen-Nuremberg, Erlangen, Germany, Rheumatology Practice, Bayreuth, Bayreuth, Germany, Rheumatology Specialty Practice, Zerbst, Germany, 4 Centre for Inflammatory Joint Diseases, Munich, Germany, 5 Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 6 Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, 7 Heinrich-Heine-University, Duesseldorf, Germany, 8 Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 7. The Prevalence of Periarticular Lesions On Magnetic Resonance Imaging and Its Relation to Knee Pain in the Community Residents in Korea. In Je Kim, Kyeong Min Son, DH Kim, Yeong Wook Song 4, Ali Guermazi 5 and Hyun Ah Kim 6, Hallym University Kangdong Sacred Heart hospital, Seoul, South Korea, Hallym university Chunchun sacred heart hospital, Chunchun, South Korea, Chunchon, South Korea, 4 Seoul National University Hospital, Seoul, South Korea, 5 Boston University School of Medicine, Boston, MA, 6 Hallym University Sacred Heart Hospital, Kyunggi, South Korea Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis 74. Childhood Onset Angiitis of the Central Nervous System: What Outcomes Can We Expect? Lena Das, Sook Fun Hoh, Terrence Thomas and Thaschawee Arkachaisri, KK Women s and Children s Hospital, Singapore, Singapore 75. Pediatric Rheumatology Practitioners Experience with Biologics in Juvenile Dermatomyositis: Survey Results. Anjali Patwardhan, Kelly Rouster-Stevens, Harry L. Gewanter, Grant D. Syverson 4, Renee F. Modica 5, Kara M. Schmidt 6 and Charles H. Spencer, Nationwide Childrens Hospital, Columbus, OH, Emory-Children s Center, Atlanta,, GA, Pediatric & Adolescent HP, Midlothian, VA, 4 Medical College of Wisconsin, Wauwatosa, WI, 5 University of Florida, Gainesville, FL, 6 Univ of Louisville, Louisville, KY 76. Development of a Longitudinal, Propective Cohort of Young Adults with Childhood-Onset Systemic Lupus Erythematosus. Aimee O. Hersh, Erica F. Lawson, Emily von Scheven, Edward Yelin and John F. Bohnsack, University of Utah, Salt Lake City, UT, UC San Francisco, San Francisco, CA, University of California San Francisco, San Francisco, CA 77. Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity. Katia T. Kozu, Clovis Artur Silva, Eloisa Bonfa, Adriana M. Sallum, Rosa M.R. Pereira 4, Vilma S. Viana, Eduardo F. Borba 5 and Lucia M. A. Campos, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Paediatric Rheumatology International Trials 0 Program Book Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, Faculdade de Medicina da Universidade de São Paulo, São Paulo-SP, Brazil, 4 University of São Paulo, São Paulo, Brazil, 5 University of Sao Paulo, Sao Paulo, Brazil 78. Evaluating Cardiovascular Risk Factors of Impaired Glucose Tolerance, Diabetes Mellitus, and Metabolic Syndrome in a Primarily Latino Population with Pediatric Rheumatic Diseases Associated with Vasculitis. Sara M. Stern, Jamie Wood, Katherine AB Marzan, Andreas Reiff, Bracha Shaham and Diane Brown, Children s Hospital Los Angeles, Los Angeles, CA 79. Distribution of Vasculitides in Childhood Arthritis and Rheumatology Research Alliance-Affiliated Pediatric Rheumatology Centers in the United States. Melissa A. Lerman, Peter A. Merkel and for the CARRA Registry Investigators, Children s Hospital of Philadelphia, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, Stanford 80. Pediatric Automated Neuropsychological Assessment Metrics As a Screening Tool for Neuropsychiatric Childhood-Onset Systemic Lupus Erythematosus. Patricia Vega-Fernandez, Eyal Muscal, Natasha M. Ruth, Frank Zelko 4, Andrea Vincent 5, Erin C. Thomas 6, Marisa S. Klein- Gitelman 7, Debra Canter 8, Alison Tian 9, Lisa Ravindra 0, HaiMei Liu, Jessica Hummel, Deborah M. Levy 9, Hermine Brunner and Tresa Roebuck-Spencer 5, Cincinanti Children s Hospital Medical Center, Cincinnati, OH, Baylor College of Medicine, Houston, TX, Medical University of South Carolina, Charleston, SC, 4 Children s Memorial Hospital, Chicago, IL, 5 University of Oklahoma, Norman, OK, 6 Anne and Robert C Lurie Hospital, Feinstein School of Medicine, Northwestern University, Chicago, IL, 7 Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, 8 Baylor College of Medicine, Texas Children s Hospital, Houston, TX, 9 The Hospital for Sick Children, Toronto, ON, 0 University Hospital, Cincinnati, Cincinnati, OH, Children s Hospital of Fundan University, Shanghai, China, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Cincinnati Children s Hospital Medical Center and PRSCG, Cincinnati, OH 8. The Pediatric Automated Neuropsychological Assessment Metrics - Reproducibility and Responsive to Change in Cognition in Childhood-Onset Lupus. Patricia Vega- Fernandez, Marisa S. Klein-Gitelman, Jessica Hummel, Erin C. Thomas 4, Jennifer L. Huggins, Frank Zelko 5, Tresa Roebuck-Spencer 6, Jun Ying 7 and Hermine Brunner 8, Cincinanti Children s Hospital Medical Center, Cincinnati, OH, Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 Anne and Robert C Lurie Hospital, Feinstein School of Medicine, Northwestern University, Chicago, IL, 5 Children s Memorial Hospital, Chicago, IL, 6 University of Oklahoma, Norman, OK, 7 University of Cincinnati, Cincinnati, OH, 8 Cincinnati Children s Hospital Medical Center and PRSCG, Cincinnati, OH

163 ACR POSTER SESSION A 8. Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children. Gulnara Mamyrova, James D. Katz, Robert V. Jones, Peter A. Lachenbruch, Mona Shah, Olcay Y. Jones, Anupam Chahal, Seema Agrawal, Frederick W. Miller, Lisa G. Rider and the Childhood Myositis Heterogeneity Group, George Washington University, Washington, DC, NIEHS, NIH, Bethesda, MD, Bethesda, MD 8. Hospitalizations for Patients with Chilhood-Onset Systemic Lupus Erythematosus in the Pediatric Health Information System Databse. Aimee O. Hersh, Charlie Casper, Tellen D. Bennett, Susan L. Bratton, John F. Bohnsack and Rajendu Srivastava, University of Utah, Salt Lake City, UT 84. Treatment and Outcome of ANCA-Associated Vasculitis in Children: A Pilot Study. Marinka Twilt, Audrey Bell- Peter, Ronald M. Laxer, Christian Pagnoux, Diane Hebert, Elizabeth Harvey, Shehla Sheikh and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON, Mount Sinai Hospital, Toronto, ON, Hospital for Sick Children, Toronto, ON 85. Rituximab for Severe Disease Flares in Childhood ANCA Vasculitides. Marinka Twilt, Rayfel Schneider, Audrey Bell-Peter, Sharon Dell and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON, the Hospital for Sick Children, Toronto, ON 86. The Association of N-Methyl-D-Aspartate Receptor Antibodies and Neurocognitive Dysfunction in Pediatric Lupus Patients and in the Offspring of Adult Patients with Lupus. Natasha M. Ruth, Mary C. Kral, Stephanie Slan, Tamara K. Nowling, Murray H. Passo and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC, MUSC, Charleston, SC, Medical University of South Carolina, Charlestons, SC 87. Variation in Healthcare Utilization by Region and Number of Rheumatologists Per State Among Pediatric Medicaid Patients with Lupus Nephritis Prior to End-Stage Renal Disease in the United States, Linda T. Hiraki, Candace H. Feldman, Graciela S. Alarcon, Jun Liu 4, Michael A. Fischer, Wolfgang C. Winkelmayer 5 and Karen H. Costenbader 6, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, University of Alabama at Birmingham, Birmingham, AL, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, 5 Stanford University School of Medicine, Stanford, CA, 6 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 88. Validation of Promis Modules for Use in Childhood- Onset Lupus. Alexandria J. Greenler, Laura E. Schanberg, Michael P. Flannery, Shannen Nelson, Janet Wootton, Esi M. Morgan DeWitt and Hermine I. Brunner, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Duke University Medical Center, Durham, NC 89. Mycophenolate Mofetil and Abatacept Combination Therapy in Refractory Pediatric Systemic Lupus Erythematosus Nephritis. Rhina Castillo, Suhas M. Radhakrishna, Andreas O. Reiff and Katherine AB Marzan, Children s Hospital Los Angeles, Los Angeles, CA, Kaiser Permananete Medical Group, Oakland, CA 90. Long-Term Outcomes in Neonatal Lupus. Amit Saxena, Peter M. Izmirly, Deborah Friedman and Jill P. Buyon, New York University School of Medicine, New York, NY, NYU School of Medicine, New York, NY, New York Medical College, Valhalla, NY 9. Illness Features Associated with an Increased Risk of Mortality in Children with Juvenile Idiopathic Inflammatory Myopathies. Adam M. Huber, Gulnara Mamyrova, Julia A. Lee, Peter A. Lachenbruch 4, Ira N. Targoff 5, Frederick W. Miller 4, Lisa G. Rider 4 and Childhood Myositis Heterogeneity Study Group 6, Dalhousie University, Halifax, NS, George Washington University, Washington, DC, NIEHS, Bethesda, MD, 4 NIEHS, NIH, Bethesda, MD, 5 Oklahoma Medical Research Foun, Oklahoma City, OK, 6 Bethesda 9. Clinical Utility of Anti-CADM-40/Melanoma Differentiation-Associated Gene 5 Autoantibody Titers in Patients with Juvenile Dermatomyositis and Rapidly Progressive Interstitial Lung Disease. Shinji Sato, Norimoto Kobayashi, Kazuko Yamazaki and Yasuo Suzuki, Tokai University School of Medicine, Isehara, Japan, Shinshu University School of Medicine, Matsumoto, Japan, Yokohama City University Hospital, Yokohama, Japan 9. Usefulness of Cardiac Magnetic Resonance in the Assessment of Myocardial Inflammation and Fibrosis in Children Born to Mothers with Anti-SSA/Ro Antibodies: A Prospective Study of Cases and 6 Controls. Nathalie Costedoat-Chalumeau, Alice Maltret, Kateri Levesque, Shelby Kutty, Elisabeth Villain, Phalla Ou and Gaëlle Guettrot-Imbert 4, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, Groupe Hospitalier Necker - Enfants Malades, Paris, France, Division of Pediatric Cardiology, university of Nebraska Medical Center and Children s Hospital ans Medical Center, Omaha, NE, USA, Omaha, 4 Hopital Gabriel Montpied, Clermont-Ferrand, France 94. Effects of Obesity On Health-Related Quality of Life in Childhood-Onset Systemic Lupus Erythematosus. Rina Mina, Marisa S. Klein-Gitelman, Shannen Nelson, Lori B. Tucker 4, B. Anne Eberhard 5, Nora G. Singer 6, Deborah M. Levy 7, Kathleen A. Haines 8, Karen Onel 9, Marilynn G. Punaro 0, Kathleen M. O Neil, Michael Henrickson, Jun Ying and Hermine I. Brunner, Cincinnati Children s Hospital Medical Center/ University of Cincinnati, Cincinnati, OH, Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, Cincinnati Children s Hospital, Cincinnati, OH, 4 BC Childrens Hospital, Vancouver, BC, 5 Cohen Children s Hospital Medical Center, New Hyde Park, NY, 6 Director, Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 7 The 0 Program Book 6

164 ACR POSTER SESSION A Hospital for Sick Children, Toronto, ON, 8 Hackensack Univ Med Ctr, Hackensack, NJ, 9 University of Chicago, Chicago, IL, 0 Texas Scottish Rite Hospital, Dallas, TX, Riley Hospital for Children, Indianapolis, IN, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, University of Cincinnati, Cincinnati, OH 95. Brain Biopsy Diagnosis in Magnetic Resonance Imaging Negative Childhood Primary Angiitis of the Central Nervous System. Senq-J Lee, Cynthia Hawkins, Suzanne Laughlin, Shehla Sheikh and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON 96. A Brazilian Multicenter Study of 7 Children and Adolescents with Takayasu s Arteritis. Maria Teresa Terreri, Gleice Clemente, Clovis Silva, Silvana Sacchetti 4, Adriana M. Sallum 5, Lucia M. A. Campos 6, Maria Carolina Santos 4, Flavio Sztajnbok 7, Rozana Gasparello de Almeida 7, Virginia P. Ferriani 8, Blanca E. Bica 9, Teresa Robazzi 0, Marcia Bandeira, andre Cavalcanti, Marise Lessa, Sheila K. Feitosa de Oliveira and Maria Odete Hilario 4, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, Universidade Federal de São Paulo - Unifesp, São Paulo, Brazil, MD; PhD, São Paulo-SP, Brazil, 4 Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, 5 Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo-SP, Brazil, 6 University of São Paulo Medical School, São Paulo, Brazil, 7 Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 8 FMUSP-Ribeirao Preto, Ribeirao Preto, Brazil, 9 International Investigator Consortium for MAS Diagnostic Criteria, Rio de Janeiro, Brazil, 0 Universidade Federal da Bahia, Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, Universidade Federal de Pernambuco, Recife, Brazil, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 4 Universidade Federal de Sao Paulo / UNIFESP, Sao Paulo, Brazil 97. Effectiveness of Intravenous Cyclophosphamide in Severe or Refractory Juvenile Dermatomyositis - A National Cohort Study: UK and Ireland. Elena Moraitis, Katie Arnold, Clarissa Pilkington and Juvenile Dermatomyositis Research Group, Great Ormond Street Hospital, London, United Kingdom, UCL Institute of Child Health, London, United Kingdom, London, United Kingdom 98. Childhood-Onset Predicts Increased Disease Damage and Steroid Toxicity in a Cohort of Adults with Systemic Lupus Erythematosus. Erica F. Lawson, Laura Trupin, Jinoos Yazdany, Aimee O. Hersh, Emily von Scheven and Edward H. Yelin, University of California San Francisco, San Francisco, CA, University of Utah, Salt Lake City, UT 99. Reduction of Cerebral and Corpus Callosum Volumes in Childhood-Onset Systemic Lupus Erythematosus. A Volumetric Magnetic Resonance Imaging Analysis. Aline T. Lapa, Wesley G. Ferreira, Mariana Postal, Nailu A. Sinicato, Roberto Marini, Fernando Cendes and Simone Appenzeller, State University of Campinas, Campinas, Brazil, Universidade Estadual de Campinas, Sao Paulo, Brazil, State University of Campinas, São Paulo, Brazil 00. Prevalence and Clinical Significance of Hippocampal Atrophy in Childhood-Onset Systemic Lupus Erythematosus. Aline T. Lapa, Renata Brabosa, Mariana Postal, Nailu A. Sinicato, Roberto Marini, Fernando Cendes and Simone Appenzeller 4, State University of Campinas, Campinas, Brazil, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Germany, Universidade Estadual de Campinas, Sao Paulo, Brazil, 4 State University of Campinas, São Paulo, Brazil 0. Decreased Frequency of Dystrophic Calcifications in Children with Juvenile Dermatomyositis: A 0-Year Study. Lauren M. Pachman, Gabrielle A. Morgan, Megan L. Curran, Lori J. Ferguson and Chiang-Ching Huang, Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, Children s Hospital of Chicago Research Center, Cure JM Myositis Center, Chicago, IL, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 0. Accuracy of Systemic Lupus International Collaborating Clinics Classiffication Criteria Applied to Juvenile Systemic Lupus Erythematosus Patients. Marìa M. Katsicas, Ezequiel Borgia, Ileana Villarroel and Ricardo Russo, MD, Buenos Aires, Argentina, MD, Caba, Argentina, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 0. Ancestral Group Differences in Pediatric SLE Early Disease Severity: An Analysis of the Carranet Registry. Jennifer M.P. Woo, Alice DC Hoftman, Emily von Scheven, Deborah K. McCurdy, Ornella J. Rullo and CARRA Registry Investigators, Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA, UC San Francisco, San Francisco, CA, Durham 04. Burden of Childhood Central Nervous System Vasculitis: Identifying High Risk Factors for Poor Cognitive Outcome. Peter J. Gowdie, Marinka Twilt, Pascal N. Tyrrell, Robyn Westmacott, Tania Cellucci, Shehla Sheikh, Nick Blancette and Susanne M. Benseler, The Hospital for Sick Children, Toronto, ON 05. Clinicopathologic Correlates for Activity and Damage of Lupus Nephritis in Childhood-Onset Systemic Lupus Erythematosus. Ravi Nunna, Rina Mina, Michael Bennett, Shannen Nelson, Jessica Hummel 4, Prasad Devarajan, David Witte and Hermine I. Brunner, Cincinnati Children s Hospital Medical Center/University of Cincinnati, Cincinnati, OH, Cincinnati Children s Med Ctr, Cincinnati, OH, Cincinnati Children s Hospital, Cincinnati, OH, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 06. Children with Probable SLE by ACR Criteria May Need More Aggressive Lupus Treatment Early in the Disease Course. Anjali Patwardhan, Igor Dvorchik and Charles H. Spencer, Nationwide Childrens Hospital, Columbus, OH, Nationwide Children s Hospital,, Columbus, OH 6 0 Program Book

165 ACR POSTER SESSION A 07. Risk Factors for Poor Outcomes in Hospitalized Patients with Pediatric Systemic Lupus Erythematosus. Mary Beth F. Son, Victor M. Johnson, Mindy S. Lo and Karen H. Costenbader, Children Hospital Boston, Boston, MA, Children s Hospital Boston, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, MA Pediatric Rheumatology - Pathogenesis and Genetics 08. WITHDRAWN. 09. Cell Type Specific Transcriptome Analysis in Patients with Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis (JIA-ERA). Amita Aggarwal, Arpita Myles and Priyanka Gaur, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 0. STAT Plays a Central Role in NLRP Inflammasome- Mediated IL-β Production and Pyronecrosis. Jehad H. Edwan, Tri M. Tran, Mones Abu-Asab, Raphaela T. Goldbach-Mansky and Robert A. Colbert, NIAMS NIH, Bethesda, MD, NEI NIH, Bethesda, Translational Autoinflammatory Diseases Section NIAMS NIH, Bethesda, MD. The DEK Autoantigen Regulates Formation of Neutrophil Extracellular Traps and Zymosan Induced Arthritis in Mice. Nirit Mor-Vaknin, Anjan K. Saha, Maureen Legendre, Marta J. Gonzalez-Hernandez, M. Asif Amin, Bradley J. Rabquer, Julie M. Jorns, Mariana J. Kaplan, Barbara S. Adams 4, David A. Fox 5, Alisa E. Koch and David Markovitz, University of Michigan, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI, Ann Arbor, MI, 4 Univ of Michigan Health System, Ann Arbor, MI, 5 Univ of Michigan Med Ctr, Ann Arbor, MI. Blood-Based Biomarkers of Neurocognitive Dysfunction in Childhood-Onset Systemic Lupus Erythematosus. Hermine I. Brunner, Jessica Hummel, Shannen Nelson, Erin C. Thomas, Jennifer L. Huggins, Megan L. Curran 4, Jun Ying 5 and Marisa S. Klein-Gitelman 6, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Cincinnati Children s Hospital, Cincinnati, OH, Anne and Robert C Lurie Hospital, Feinstein School of Medicine, Northwestern University, Chicago, IL, 4 Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 5 University of Cincinnati, Cincinnati, OH, 6 Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL. Epigenetic Changes in Fibrosis and Myocyte Repair Genes May Contribute to Pathogenesis in Monozygotic Twins Discordant for Cardiac Manifestations of Neonatal Lupus. Paula S. Ramos, Timothy D. Howard, Miranda C. Marion, Satria Sajuthi, Robert M. Clancy, Jill P. Buyon and Carl D. Langefeld, Medical University of South Carolina, Charleston, SC, Wake Forest School of Medicine, Winston- Salem, NC, New York University School of Medicine, New York, NY 4. Transcriptome and Surface Phenotype Analyses Suggest an Alternatively Activated (M) Function for Hemophagocytes. Scott W. Canna, Ana Patrícia Costa Reis, William E. Bernal, Kathleen E. Sullivan, Michele E. Paessler and Edward M. Behrens, Childrens Hospital of Philadelphia, Philadelphia, PA, Childrenxs Hospital of Philadelphia, Philadelphia, PA, Children s Hospital of Philadelphia, Philadelphia, PA 5. Pediatric Lupus Nephritis: Micrornas Macro Inflammation. Patrícia Costa Reis, Pierre Russo and Kathleen E. Sullivan, Children s Hospital of Philadelphia, Philadelphia, PA 6. The Interleukin-0 (IL-0) Producing Regulatory B Cell ( B0 cell ) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (psle). Ioannis Kalampokis, Jeffrey A. Dvergsten and Thomas Tedder, Duke University Medical Center, Durham, NC 7. Fatty Acid Profiling: Potential New Biomarkers in Juvenile Idiopathic Arthritis (pilot study). Weng Tarng Cham, Enzo Ranieri, Janice Fletcher and Christina A. Boros, Women s and Children s Hospital, North Adelaide, SA 5006, Australia, SA Pathology, North Adelaide, SA 5006, Australia, University of Adelaide/Women s and Children s Hospital, Adelaide, Australia 8. Replication Analysis of Non-HLA Gene Variants with Prior Evidence of Association with Juvenile Idiopathic Arthritis. Justine Ellis, Raul Chavez, Anne-Louise Ponsonby, Angela Pezic, Roger Allen, Jonathan Akikusa and Jane Munro, Murdoch Childrens Research Institute, Parkville, Australia, Royal Childrens Hospital, Parkville, Australia 9. Gamma Interferon-Induced Protein-0 (IP-0) As a Potential Biomarker for Disease Activity in Pediatric Localized Scleroderma. Katherine Kurzinski, Carol A. Feghali-Bostwick, Christina Kelsey, Kelsey Magee and Kathryn S. Torok, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA 0. Evaluation of Anti-Citrullinated Type II Collagen and Anti- Citrullinated Vimentin Antibodies in Patients with Juvenile Idiopathic Arthritis. Brooke Gilliam, Anil K. Chauhan and Terry L. Moore, Saint Louis University, St. Louis, MO. Glycosylation of Vitamin D Binding Protein Reduced in Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension. David S. Gibson, Sorcha Finnegan, Gwen Manning, Mark Duncan 4, Stephen R. Pennington 5, Terry L. Moore 6 and Madeleine Rooney 7, Arthritis Research Group, Queens University Belfast, Belfast, United Kingdom, Queen s University, Belfast, Belfast, United Kingdom, Proteome Research Centre, University College Dublin, Dublin, Ireland, 4 Division of Endocrinology, University of Colorado, Denver, 5 UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, 6 Saint Louis University, St. Louis, MO, 7 Queens University Belfast, Belfast, United Kingdom 0 Program Book 6

166 ACR POSTER SESSION A. Immune Response to Porphyromonas Gingivalis Citrullinated α-enolase Cross-Reacts with Human α-enolase in Polyarticular JIA Patients. Peggy Lee, Rebecca Howsmon, Claire Murphy, Sarah Ringold and Anne M. Stevens, University of Washington, Seattle, WA, Seattle Children s Research Institute, Seattle, WA. Immunoprecipitation and Advanced Proteomics for the Discovery of Novel Antigenic Targets in Juvenile Idiopathic Arthritis. Ginger L. Janow, Cristina Clement, Norman T. Ilowite, Laura Santambrogio and Steven A. Porcelli 4, Children s Hospital at Montefiore, Bronx, NY, Albert Einstein College of Medicine, Bronx, NY, Children s Hospital Montefiore, Bronx, NY, 4 Albert Eistein College of Medicine, Bronx, NY 4. Measurement and Evaluation of Isotypes of Anti- Citrullinated Fibrinogen and Anti-Citrullinated Alpha- Enolase Antibodies in Juvenile Idiopathic Arthritis Patients. Brooke Gilliam, Sandra Crespo-Pagnussat, Anil K. Chauhan and Terry L. Moore, Saint Louis University, St. Louis, MO 5. Anti-Cyclic Citrullinated Peptide Antibody Isotyping and Identification of Citrullinated Proteins in the Synovial Fluid of Juvenile Idiopathic Arthritis Patients. Brooke Gilliam, Sandra Crespo-Pagnussat, Anil K. Chauhan, Reema H. Syed and Terry L. Moore, Saint Louis University, St. Louis, MO Rheumatoid Arthritis: Animal Models 6. Silencing Intraarticular Snail Expression Ameliorates Rat Collagen-Induced Arthritis Through Induction of Mesenchymal-Epithelial Transition in Synovial Fibroblasts. Chrong-Reen Wang, Shih-Yao Chen, Ai-Li Shiau, Yuan-Tsung Li, Ming-Fei Liu and Chao-Liang Wu, College of Medicine, National Cheng Kung University, Tainan, Taiwan 7. Tolerogenic Dendritic Cells Ameliorates the Disease Severity of Murine Collagen-Induced Arthritis. Bin Ning, Shang-You Yang, Jianlu Wei, Weiming Gong and Paul H. Wooley, Shandong University Jinan Central Hospital, Jinan, China, Via Christi Wichita Hospitals, Wichita, KS 8. IL-7; An Important Pro-Inflammatory Factor That Affects Myeloid Cell Function in RA and CIA. Nathan D. Chamberlain, Seung-jae Kim, Michael Volin, Anjali Mehta, Nadera J. Sweiss and Shiva Shahrara, University of Illinois at Chicago, Chicago, IL, Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 9. The SYK Inhibitor, Fostamatinib, Administered Alone or in Combination with Methotrexate in Rat Collagen- Induced Arthritis, Reduces Bone Erosions, Biomarkers of Cartilage/Bone Destruction, and Synovial Osteoclastogenic Cytokines. Polly Pine, Ayodele Apatira, Betty Y. Chang, Nathan Schoettler, Elliott B. Grossbard and Ernest Brahn, Rigel Pharmaceuticals, So San Francisco, CA, UCLA School of Medicine, Los Angeles, CA 0. Fut Plays A Unique Role in K/BxN Serum Transfer Arthritis by Regulating Angiogenesis and Adhesion Molecule Expression. M. Asif Amin, Phillip L. Campbell, Takeo Isozaki, Jeffrey H. Ruth, Jonathan Vargo, Steven E. Domino and Alisa E. Koch, University of Michigan Medical School, Ann Arbor, MI. PDL4, a Novel Humanized Monoclonal Antibody, Reveals CD9 As a Therapeutic Target for Rheumatoid Arthritis. Michel P.M. Vierboom, Jacky Woo, Hakju Kwon, Debra Chao, Shiming Ye, Jianmin Li, Karen Lin, Irene Tang, Nicole Belmar, Taymar Hartman, Elia Breedveld, Bert A. t Hart and Gary C. Starling, Biomedical Primate Research Centre, Rijswijk, Netherlands, Abbott Biotherapeutics, Redwood City, CA. Blockade of CTGF Restores Aberrant Ostoclastgenesis in Collagen Induced Arthritis (CIA) Mice Through Inhibition of Th-7 Differentiation. Kazuhisa Nozawa, Maki Fujishiro, Ayako Yamaguchi, Mikiko Kawasaki, Shouzou Ichinose, Mitsuaki Yanagida, Kazuhisa Iwabuchi, Keigo Ikeda 4, Shinji Morimoto 5, Megumi Morioka 6, Yoshinari Takasaki and Iwao Sekigawa 4, Juntendo University School of Medicine, Tokyo, Japan, Juntendo University Graduate School of Medicine, Chiba, Japan, Juntendo University Graduate School of Medicine, Tokyo, Japan, 4 Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 5 Juntendo University Urayasu Hospital, Tokyo kyo, Japan, 6 Nihon Nosan Corporation, Kanagawa, Japan. Pressure and Blood Flow Measurements in Efferent Lymphatics As Biomarkers of Arthritic Flare. Echoe M. Bouta, Ronald Wood, Christopher T. Ritchlin, Lianping Xing and Edward M. Schwarz, University of Rochester, Rochester, NY, University of Rochester School of Medicine and Dentistry, Rochester, NY, University of Rochester Medical Center, Rochester, NY 4. Selective inos Inhibition Increases the Lymphatic Pulse and Drainage from Arthritic Joints in TNF-Tg Mice. Yawen Ju, Ronald Wood, Lianping Xing, Christopher T. Ritchlin and Edward M. Schwarz, University of Rochester Medical Center, Rochester, NY 5. Treatment with Bgp-5, a Novel Insulin Sensitizer Attenuates Collagen-Induced Arthritis in DBA/ Mice. Peter Mandl, Silvia Hayer, Stephan Blüml, Victoria Saferding, Despoina Sykoutri, Kurt Redlich and Josef S. Smolen, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 6. Preclinical Development of ALX-006, an Anti-IL-6R Nanobody For Therapeutic Use in Rheumatoid Arthritis with a High in Vitro Affinity and Potency and a Competitive in Vivo Pharmacological Profile. Maarten Van Roy, Hans Ulrichts, Stefaan Rossenu, Sandy Jacobs, Sofie Poelmans, Gert Verheyden, Michel Vierboom, Bert t Hart, Judith Baumeister and Josefin-Beate Holz, Ablynx N.V., Zwijnaarde, Belgium, Biomedical Primate Research Centre, Rijswijk, Netherlands 64 0 Program Book

167 ACR POSTER SESSION A 7. In Vivo Quantification of Joint Inflammation in a Murine Arthritis Model by Anato-Molecular Imaging. Smriti K. Raychaudhuri, Anupam Mitra, Kuang Gong, Jian Zhou, Jinyi Qi, Siba P. Raychaudhuri and Abhijit J. Chaudhari, UC Davis School of Medicine/VA Sacramento Medical Center, Mather, CA, University of California, Davis, Davis, CA, UC Davis School of Medicine, Sacramento, CA 8. The Potent Phosphoinositide--Kinase-(δ,γ) Inhibitor IPI-45 Is Active in Preclinical Models of Arthritis and Well Tolerated in Healthy Adult Subjects. James R. Porter, Janid Ali, Jonathan P. DiNitto, Joi Dunbar, Kerrie Faia, Jennifer Hoyt, Brianne Leary, Alice R. Lim, Christian Martin, Charlotte McKee, Patrick O Hearn, Melissa Pink, Jennifer Proctor, John Soglia, Bonnie Tillotson, Kerry White, David G. Winkler and Vito J. Palombella, Infinity Pharmaceuticals, Inc., Cambridge, MA 9. Differences between Juvenile and Adult Rodents with Collagen Induced Arthritis. Tracy D. Wilson-Gerwing, Isaac V. Pratt, David M.L. Cooper, Tawni I. Silver and Alan M. Rosenberg, University of Saskatchewan, Saskatoon, SK, Royal University Hospital, Saskatoon, SK 40. Myeloid Deletion of SIRT Aggravates Inflammatory Arthritis Via Nuclear Factor-Kappab Activation in Animal Model of Rheumatoid Arthritis. Sang-il Lee and Yun-Hong Cheon, Gyeongsang National University School of Medicine, Jinju, South Korea 4. Oral Administration of a Novel Small Molecule BET Bromodomain Inhibitor, RVX-97, Reduces Disease Severity in a Rat Collagen-Induced Arthritis Model. R. Jahagirdar, S. Attwell, E.M. Gesner, K.G. McLure, H.C. Hansen, J. Chen, J. Wu, K. Norek, N. Shenoy, G.S. Wagner and P. R. Young, Resverlogix Corporation, Calgary, AB, Aravasc Inc., Sunnyvale, CA 4. Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model. Shireen Vali, Canio Refino, Jay Dela Cruz, Robinson Vidva, Prashant Nair, Saumya Radhakrishnan, Pradeep Fernandes, Taher Abbasi and Gurkirpal Singh, CellWorks Group, Saratoga, CA, InTouch Bio, Alameda, CA, Stanford University School of Medicine, Palo Alto, CA 4. Functional Impairment in an Animal Model for Rheumatoid Arthritis Assessed As Changes in Gait Is Due to Joint Destruction but Not Synovial Inflammation Per Se. Gregor Bauer, Constantin Aschauer, Birgit Niederreiter, Josef S. Smolen, Kurt Redlich and Silvia Hayer, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 44. Non Classical Monocytes Are Required for Initiation Phase While Macrophages Are Necessary for the Resolution Phase in the K/BxN Murine of Inflammatory Arthritis. Alexander V. Misharin, G. Kenneth Haines III and Harris R. Perlman, Northwestern University, Chicago, IL, Yale University, New Haven, CT 45. Predictive Software-Based Mathematical Modeling: A Novel Approach to Development of Oral Therapies for Rheumatoid Arthritis Validation in a Murine Collagen Induced Arthritis Model. Gurkirpal Singh, Robinson Vidva, Prashant Nair, Saumya Radhakrishnan, Pradeep Fernandes, Taher Abbasi, Canio Refino, Jay Dela Cruz and Shireen Vali, Stanford University School of Medicine, Palo Alto, CA, CellWorks Group, Saratoga, CA, InTouch Bio, Alameda, CA 46. Sclerostin Protects against Inflammatory Bone Loss by Regulating Tnfalpha Mediated p8-mapkinase Activation. Corinna Wehmeyer, Christina Wunrau, Athanasios Stratis, Ina Kramer, Michaela Kneissel, Thomas Pap and Berno Dankbar, University Hospital Muenster, Muenster, Germany, CH-4056 Basel, Switzerland 47. The Loss of S00A4 Prevents Induction of Experimental Arthritis in Human Tumour Necrosis Factor Transgenic Mouse Model. Michal Tomcik, Christine Boehm, Carina Scholtysek, Lucie andres Cerezo, Wolfgang Baum, Clara Dees, Christian Beyer, Jerome Avouac 4, Pawel Zerr, Katrin Palumbo-Zerr, Alfiya Akhmetshina, Radim Becvar, Oliver Distler 5, Mariam Grigorian 6, Gerhard Kroenke, Georg A. Schett, Joerg HW Distler and Ladislav Senolt, Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, Medical University of Vienna, Vienna, Austria, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, 4 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 5 Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6 Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission 48. Liver Fibrosis Evaluated by Shearwave Elastograpy Is Associated with Body Mass Index and Serum AST, but Not Methotrexate Cumulative Dose and Duration in Patients with Rheumatoid Arthritis. Tae Yeob Kim, So-Young Bang, Joo Hyun Sohn and Hye-Soon Lee, Hanyang University Guri Hospital, Guri, South Korea 49. Preliminary Results From a Controlled Study Assessing the Humoral Immune Response to Vaccines in Rheumatoid Arthritis Patients Treated with Tocilizumab. CO Bingham III, Warren C. Rizzo, Micki Klearman, Azra Hassanali 4, Ruchi Upmanyu 5 and Alan J. Kivitz 6, Johns Hopkins University, Baltimore, MD, Advanced Arthritis Care & Research, Scottsdale, AZ, Genentech Inc, South San Francisco, CA, 4 Genentech Inc, San Francisco, CA, 5 Roche, Welwyn Garden City, United Kingdom, 6 Altoona Center for Clinical Research, Duncansville, PA 0 Program Book 65

168 ACR POSTER SESSION A Reduction of Inflammation with Abatacept and Tocilizumab Results in Lower N-Terminal Pro Brain Natriuretic Peptide Levels in Patients with Rheumatoid Arthritis: Results from Prospective Cohort Studies. Inge A.M. van den Oever and Mike T. Nurmohamed, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 5. Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry RoAcTEmra). Jacques Morel, Marie-Odile Duzanski, Thomas Bardin, Alain G. Cantagrel 4, Bernard Combe, Maxime Dougados 5, Rene-Marc Flipo 6, Jacques- Eric Gottenberg 7, Xavier Mariette 8, Martin Soubrier 9, Olivier Vittecoq 0, Alain Saraux, Thierry Schaeverbeke and Jean Sibilia, Hopital Lapeyronie, Montpellier, France, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Hôpital Lariboisière, Paris, France, 4 Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 5 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 6 Hopital R Salengro CHRU, Lille CEDEX, France, 7 Strasbourg University Hospital, Strasbourg, France, 8 Université Paris-Sud, Le Kremlin Bicetre, France, 9 CHU CLERMONT-FERRAnd, Clermont-Ferrand, France, 0 Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, CHU de la Cavale Blanche, Brest Cedex, France, Groupe Hospitalier Pellegrin, Bordeaux, France, CHU Hautepierre, Strasbourg, France 5. Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis. Charlotte Hua, Thomas Barnetche, Bernard Combe and Jacques Morel, Hôpital Lapeyronie, Montpellier, France, CHU Bordeaux Pellegrin, Bordeaux, France, Hopital Lapeyronie, Montpellier, France 5. The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis. Inge A.M. van den Oever, Danka J.F. Stuijver, Debby den Uyl, Bregje van Zaane 4, Marieke M. ter Wee 5, Willem F. Lems 5, D. van Schaardenburg, Joost C.M. Meijers 4, Victor E.A. Gerdes 4 and M. T. Nurmohamed 6, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Academic Medical Center, Amsterdam, Netherlands, VU University medical centre, Amsterdam, Netherlands, 4 Slotervaart Hospital, Amsterdam, Netherlands, 5 VU University Medical Center, Amsterdam, Netherlands, 6 VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands 54. Delayed Onset of Hepatitis and/or Neutropenia in Patients with Rheumatoid Arthritis Treated with Combination Therapy of Methotrexate and Leflunomide. Seung Won Choi, Ji Seon Oh, You Jae Kim, Bon San Koo, Min Wook So, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 0 Program Book 55. Metaanalysis of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Transformylase (ATIC) 47C>G Polymorphism Affecting Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis Patients. Fardina Malik and Prabha Ranganathan, Alton Memorial Hospital, Alton, IL, Washington Univ School of Med, St. Louis, MO 56. Safety of Abatacept in Rheumatoid Arthritis with Chronic Hepatitis B VIRUS Infection. Melissa Padovan, Elisabetta Lanciano, Oscar Epis, Alessandro Mathieu 4, Giulia Erba 5, Leopoldo Ciani 6, Sarah Giacuzzo and Marcello Govoni, Section of Rheumatology, Ferrara, Italy, Rheumatology Unit, Bari, Italy, Rheumatology Unit, Milano, Italy, 4 Rheumatology Unit, Cagliari, Italy, 5 Medical Clinics, Monza, Italy, 6 Unit of Internal Medicine, Legnano, Italy 57. Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity? Dietmar MJ Krause, Bernadette Gabriel, Gertraud Herborn and Rolf Rau, Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, Private Practice, Gladbeck, Germany, Evangelisches Fachkrankenhaus, Ratingen, Germany 58. Six Months of an Attenuated Cobra Regimen ( COBRA-light ) Is Clinically Noninferior to the Original Cobra Regimen: An Open-Label Randomized Trial in Early Rheumatoid Arthritis. Debby den Uyl, Marieke M. ter Wee, Maarten Boers, Alexandre Voskuyl, P.J.S.M. Kerstens, Mike T. Nurmohamed, Hennie G. Raterman, D. van Schaardenburg, N. van Dillen, B.A.C Dijkmans and W.F. Lems, VU University Medical Center, Amsterdam, Netherlands, Reade Jan van Breemen Research Institute, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 59. Improved Radiological Outcome of Rheumatoid Arthritis: Early Treatment with methotrexate might be a key Prognostic Factor. Christoph Fiehn, Elisabeth Belke-Voss, Dietmar Krause, Siegfried Wassenberg and Rolf Rau 4, ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, Evangelisches Fachkrankenhaus Ratingen, Rheumazentrum, Ratingen, Germany, 4 Düsseldorf, Germany 60. Initial Introduction of Treat-to-Target Strategy in Patients with Recent Onset Rheumatoid Arthritis Is More Effective Than Delayed Introduction of Strategy with More Clinical and Functional Remission Achieved for -Years: Results of the Treating to Twine Targets (T-4) Study. Yukitomo Urata, Yoshihide Nakamura and Ken-ichi Furukawa, Seihoku Central Hospital, Gosyogawara, Japan, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, Hirosaki, Japan 6. Impact of Tumour Necrosis Factor Inhibitor Treatment On Hand Bone Loss in Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Nationwide Danish Danbio Registry. Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Pernille Bøyesen, Trine David Jensen, Anja Thormann,

169 ACR POSTER SESSION A Ulrik Tarp, Wolfgang Bøhme, Ditte Dencker, Hanne M. Lindegaard, Uta Engling Poulsen, Annette Hansen, Vibeke Stevenius Ringsdal, Annette Schlemmer, Niels Graudal, Anne Rødgaard andersen, Jakob Espesen, Gina Kollerup, Torben Grube Christensen, Randi Pelck, Bente Glintborg, Ole Rintek Madsen, Dorte Vendelbo Jensen, Ole Majgaard and Merete L. Hetland 4, DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, Diakonhjemmet Hospital, Olso, Norway, Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, 4 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark 6. Response to Etanercept, but Not Infliximab or Adalimumab, Is Inversely Associated with Body Mass Index. James R. Maxwell, Darren Plant, Anne Barton, Kimme L. Hyrich, Ann W. Morgan 4, John Isaacs 5 and Anthony G. Wilson 6, University of Sheffield, Sheffield, United Kingdom, University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, 4 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 5 Newcastle University, Newcastle upon Tyne, United Kingdom, 6 Section of Musculoskeletal Sciences, University of Sheffield, Sheffield, United Kingdom 6. Risk Factors for Radiographic Progression During TNF- Inhibitor Treatment in 9 Rheumatoid Arthritis Patients Treated in Clinical Practice: Results from the Nationwide Danish Danbio Registry. Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, Pernille Bøyesen, Anja Thormann, Ulrik Tarp, Wolfgang Bøhme, Ditte Dencker, Hanne M. Lindegaard, Uta Engling Poulsen, Annette Hansen, Vibeke Stevenius Ringsdal, Annette Schlemmer, Niels Graudal, Anne Rødgaard andersen, Jakob Espesen, Gina Kollerup, Torben Grube Christensen, Randi Pelck, Bente Glintborg, Ole Rintek Madsen, Dorte Vendelbo Jensen, Ole Majgaard and Merete L. Hetland, DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, Diakonhjemmet Hospital, Olso, Norway, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark 64. Moderate Rheumatoid Arthritis Despite Methotrexate Treatment: Risk of Radiographic Progression. Bruno Fautrel, Gaia Gallo, Yves Brault and Henk Nab 4, APHP- Pitie Salpetriere Hospital / UPMC, Paris, France, Pfizer, Rome, Italy, Pfizer, Paris, France, 4 Pfizer Europe, Rome, Italy 65. Improvement of Health-Related Quality of Life in RA Patients Treated with Biologics - One-Year Follow-up Data of the German Biologics Register Rabbit. Kerstin Gerhold, Adrian Richter, Matthias Schneider, Hans Joachim Bergerhausen, Winfried Demary 4, Anke Liebhaber 5, Joachim Listing, Angela Zink and Anja Strangfeld, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, Wedau Kliniken - Klinikum Duisburg, Duisburg, Germany, 4 Private Practice, Hildesheim, Germany, 5 Private Practice, Halle, Germany 66. Efficacy of Methotrexate (MTX) According to Anti- Citrullinated Protein Antibody (ACPA) Status in an Early Inflammatory Arthritis Cohort. Sarah C. Horton, David Pickles, Paul Emery, Maya H. Buch and Jane E. Freeston, University of Leeds, Leeds, United Kingdom 67. Improved Fatigue-Related Quality of Life in CAPRA-, a Week Study of 5-Mg Modified (Delayed) Release Prednisone in Rheumatoid Arthritis. Rieke Alten, Amy Grahn, Patricia Rice and Frank Buttgereit 4, Schlosspark- Klinik, University Medicine, Berlin, Germany, Horizon Pharma, Deerfield, IL, CliniRx Research, Naperville, IL, 4 Charite University Med-Berlin, Berlin, Germany 68. Impact of Etanercept-Methotrexate Therapy On Patient- Reported Outcomes in Rheumatoid Arthritis Patients with up to Months of Symptoms. Paul Emery, Piotr Wiland, Wolfgang Spieler, Jean Dudler 4, Stefanie Gaylord 5, Theresa Williams 5, Ronald Pedersen 5, Andrew S. Koenig 5, Bonnie Vlahos 5 and Sameer Kotak 6, Leeds General Infirmary, Leeds, United Kingdom, Wroclaw Medical University, Wroclaw, Poland, Rheumatology Specialty Practice, Zerbst, Germany, 4 University Hospital of Lausanne, Lausanne, Switzerland, 5 Pfizer Inc., Collegeville, PA, 6 Pfizer Inc., New York, NY 69. Differences in Short-Term Radiographic Progression Following Early Response to Adalimumab Plus Methotrexate Vs. Methotrexate Alone. Ronald F. van Vollenhoven, James W. Shaw, Mary A. Cifaldi, James Signorovitch, Eric Q. Wu, Thomas Samuelson, Elizabeth Faust and Paul Emery 4, Karolinska Institute, Stockholm, Sweden, Abbott Laboratories, Abbott Park, IL, Analysis Group, Inc., Boston, MA, 4 University of Leeds, Leeds, United Kingdom 70. Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the st report of Apple Survey). Akitomo Okada, Atsushi Kawakami, Takaaki Fukuda, Toshihiko Hidaka, Tomonori Ishii 4, Yukitaka Ueki 5, Takao Kodera 6, Munetoshi Nakashima 7, Yuichi Takahashi 8, Seiyo Honda 9, Yoshiro Horai, Tomohiro Koga, Ryu Watanabe 0, Hiroshi Okuno 0 and Katsumi Eguchi, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Kurume University Medical Center, Kurume, Japan, Zenjinkai Shimin-No-Mori-Hospital, Miyazaki, Japan, 4 Tohoku University, Sendai, Japan, 5 Sasebo, Japan, 6 Tohoku Kosei Nenkin Hospital, Sendai, Japan, 7 Japanese Red Cross Nagasaki Genbaku Hospital, Nagasahi, Japan, 8 Yu Family Clinic, Sendai, Japan, 9 Kurume University School of Medicene, Kurume, Japan, 0 Tohoku University Hospital, Sendai, Japan, Sasebo City General Hospital, Sasebo, Nagasaki, Japan 0 Program Book 67

170 ACR POSTER SESSION A 7. Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis. Takahiko Sugihara, Tatsuro Ishizaki, Tadashi Hosoya, Shoko Iga, Waka Yokoyama, Fumio Hirano, Nobuyuki Miyasaka and Masayoshi Harigai, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, Tokyo Medical and Dental University, Tokyo, Japan 7. TRAF/C5 Locus Is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Patients with Rheumatoid Arthritis. Helena Canhao, Ana M. Rodrigues, Maria José Santos, Diana Carmona-Fernandes 4, Bruno Bettencourt 5, Jing Cui 6, Fabiana Rocha 5, Jose canas Silva, Joaquim Polido Pereira 4, Jose Alberto Pereira Silva 7, José Antonio Costa 8, Domingos Araujo 9, Candida Silva 0, Helena Santos, Catia Duarte, Fernando Pimentel-Santos, Jaime C. Branco, Robert M. Plenge 6, Daniel H. Solomon 6, Jacome Bruges Armas 5, José A. P. Da Silva 4, João E. Fonseca 5 and Elizabeth W. Karlson 6, Instituto de Medicina Molecular, Lisbon, Portugal, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Lisbon, Portugal, Hospital Garcia de Orta, E.P.E., Almada, Portugal, 4 Instituto Medicina Molecular, Lisbon, Portugal, 5 Hospital de Santo Espirito da Ilha Terceira, Ilha Terceira, Portugal, 6 Brigham and Women s Hospital, Boston, MA, 7 Santa Maria Hospital, Lisbon, Portugal, 8 Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, 9 Unidade Local de Saude, Ponte de Lima, Portugal, 0 Instituto Portugues Reumatologia, Lisbon, Portugal, Instituto Português de Reumatologia, Lisboa, Portugal, Hospitais da Universidade de Coimbra, Coimbra, Portugal, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, 4 Centro Hospitalar e Universitário de Coimbra Hospitais da Universidade de Coimbra, E.P.E., Coimbra, Portugal, 5 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 6 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 7. Patient-Reported Outcomes in Early Rheumatoid Arthritis Patients Failing to Achieve Stable Low Disease Activity: Comparing Addition of Adalimumab to Methotrexate Monotherapy with Maintenance On Adalimumab Plus Methotrexate. Arthur Kavanaugh, Ronald F. van Vollenhoven, Paul Emery, James W. Shaw 4, Mary A. Cifaldi 4, Stefan Florentinus 5 and Josef S. Smolen 6, UCSD School of Medicine, La Jolla, CA, Karolinska Institute, Stockholm, Sweden, University of Leeds, Leeds, United Kingdom, 4 Abbott Laboratories, Abbott Park, IL, 5 Abbott, Rungis, France, 6 Medical University of Vienna and Hietzing Hospital, Vienna, Austria 74. Prevalence of Biologic Utilization over Calendar Time Among Medicare Beneficiaries with Rheumatoid Arthritis. Jie Zhang, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, James Lewis, Kevin Haynes, Kenneth G. Saag 4 and Jeffrey Curtis, University of Alabama at Birmingham, Birmingham, AL, University of Pennsylvania, University of Pennsylvania., Philadelphia, PA, 4 Univ of Alabama-Birmingham, Birmingham, AL 75. Cell Phone Based Automated Monitoring of Patients with Early Rheumatoid Arthritis. Kari Puolakka, Tuulikki Sokka and Hannu Kautiainen, Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, Jyvaskyla Central Hospital, Jyvaskyla, Finland, Orton Rehabilitation, Helsinki, Finland 76. Strategies for Use of Prednisolone in Rheumatoid Arthritis Have Changed Over the Past Decade: Data From the NOR- DMARD Register. Anna-Birgitte Aga, Elisabeth Lie, Till Uhlig, Tore K. Kvien and Espen A. Haavardsholm, Diakonhjemmet Hospital, Oslo, Norway 77. Use and Long Term Use of Complementary and Alternative Medicine in Rheumatoid Arthritis Patients. Peri H. Pepmueller, Ramzy Jandali, Anu Sharma, Shannon Grant and Katherine C. Saunders 4, Saint Louis University, St. Louis, MO, Center for Rheumatic Diseases, Bethesda, MD, Axio Research LLC, Seattle, WA, 4 CORRONA, Inc., Southborough, MA 78. Use of Anti-Tumor Necrosis Factor Monotherapy and Adherence with Non-Biologic Disease-Modifying Anti- Rheumatic Drugs in Combination with Anti-Tumor Necrosis Factor Therapy among Rheumatoid Arthritis Patients in a Real-World Setting. Nicole M. Engel-Nitz, Sarika Ogale and Mahesh Kulakodlu, OptumInsight, Eden Prairie, MN, Genentech, South San Francisco, CA 79. Persistency and Predictors of Persistency of Adalimumab among Rheumatoid Arthritis (RA) Patients in a US Registry. Allan Gibofsky, Katherine C. Saunders, Arijit Ganguli, Mary Cifaldi, Shannon Grant 4, Jerry Clewell, Neelufar Mozaffarian, James Shaw 5, Reva McCaskill, George W. Reed 6 and Jeffrey D. Greenberg 7, Hospital for Special Surgery, New York, NY, CORRONA, Inc., Southborough, MA, Abbott Laboratories, Abbott Park, IL, 4 Axio Research LLC, Seattle, WA, 5 Abbott, Abbott Park, IL, 6 University of Massachusetts Medical School, Worcester, MA, 7 NYU Hospital for Joint Diseases, New York, NY 80. DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry. John J. Cush, George Reed, Katherine C. Saunders, Joel M. Kremer 4, Jeffrey D. Greenberg 5 and Arthur Kavanaugh 6, Baylor Research Institute, Dallas, TX, UMass Medical School, Worcester, MA, CORRONA, Inc., Southborough, MA, 4 Albany Medical College, Albany, NY, 5 NYU Hospital for Joint Diseases, New York, NY, 6 UCSD School of Medicine, La Jolla, CA 68 0 Program Book

171 ACR POSTER SESSION A 8. DAS Does Not Predict Increasing Treatment in Early Rheumatoid Arthritis: Results From the CATCH Study. Lonnie Pyne, Vivian P. Bykerk, Carol A. Hitchon, Edward Keystone 4, J. Carter Thorne 5, Boulos Haraoui 6, Ashley Bonner 7, Janet E. Pope 8 and CATCH Investigators 9, Western University, London, ON, Hospital for Special Surgery, New York, NY, University of Manitoba, Winnipeg, MB, 4 University of Toronto, Toronto, ON, 5 Southlake Regional Health Centre, Newmarket, ON, 6 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 7 McMaster University, Hamilton, ON, 8 St. Joseph Health Care London, University of Western Ontario, London, ON, 9 Toronto, ON 8. Does Biased Risk Perception Explain the Underuse of Disease Modifying Anti-Rheumatic Drugs? Richard W. Martin, Andrew J. Head, James D. Birmingham and Aaron T. Eggebeen, Michigan State University College of Human Medicine, Grand Rapids, MI, College of Human Medicine, Michigan State University, Grand Rapids, MI Vs : Initiation of Combination, and Tapering/Discontinuation (DC) Patterns of TNFi and MTX in a US (RA) Patient Registry: Analysis with CDAI Scores. Deborah Wenkert, Shannon Grant, David H. Collier, Andrew S. Koenig and Joel M. Kremer 4, Amgen Inc., Thousand Oaks, CA, Axio Research LLC, Seattle, WA, Pfizer Inc., Collegeville, PA, 4 Albany Medical College, Albany, NY 84. Treating Rheumatoid Arthritis to Target: A Canadian Patient Survey. Boulos Haraoui, William G. Bensen, J. Carter Thorne, John P. Wade 4, Melissa Deamude 5, Jane M. Prince 6 and Jean Legare 7, Institut de Rhumatologie de Montréal, Montreal, QC, St. Joseph s Hospital and McMaster University, Hamilton, ON, Hamilton, ON, Southlake Regional Health Centre, Newmarket, ON, 4 University of British Columbia, Vancouver, BC, 5 Dr. William G. Bensen Medicine Professional Corporation, Hamilton, ON, 6 Vancouver Coastal Health, Vancouver, BC, 7 Arthritis Alliance of Canada, Montreal, QC 85. The Wide Variation in Corticosteroid Use in Early Rheumatoid Arthritis - There Is Need for Guidelines. A. Bharadwaj and Carol Alves, Basildon & Thurrock University Hospital NHS Trust, Basildon, United Kingdom 86. Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population. Vernon F. Schabert, Crystal Watson, George Joseph, Paige Iversen, Chakkarin Burudpakdee and David J. Harrison, IMS Health, Alexandria, VA, Amgen Inc., Thousand Oaks, CA 87. Medication Choices and Medication Survival in a National Multicentre Community Based Rheumatoid Arthritis Cohort. Lynden Roberts, Kathleen Tymms, Julien P. de Jager, Geoffrey O. Littlejohn 4, Hedley Griffiths 5, Dave Nicholls 6, Paul Bird 7, Julie Hill 8, Philip McCloud 8, James C. Scott 9, Jane Zochling 0 and OPAL Consortium, James Cook University, Townsville, Australia, Canberra Rheumatology, Canberra, Australia, Suite, Osler House, Southport, Australia, 4 Monash Medical Center, Melbourne, Australia, 5 Barwon Rheumatology Service, Geelong, Australia, 6 Coast Joint Care, Maroochydore, Australia, 7 Combined Rheumatology Practice, Sydney, Australia, 8 McCloud Consulting Group, Sydney, Australia, 9 Roche Products Pty Limited, Sydney, Australia, 0 Menzies Research Institute Tasmania, Hobart, Australia, Melbourne, Australia 88. Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data from the Hong Kong Biologics Registry. Chi Chiu Mok, Cherry Kwan, Helen Chan, Ka Lai Lee and Lai-Shan Tam 4, Tuen Mun Hospital, Hong Kong, Hong Kong, Kowloon Hospital, Hong Kong, Hong Kong, Hong Kong, Pamela Youde Eastern Hospital, Hong Kong, Hong Kong, 4 The Chinese University of Hong Kong, Hong Kong, China 89. Oral Glucocorticoid Sparing Effects of Rituximab in Rheumatoid Arthritis Patients Who Have Switched from an Anti-TNF Therapy - an Administrative Claims Database Analysis. Stephen Johnston, Tripthi Kamath, Nianwen Shi, Robert Fowler, Bong-Chul Chu and William Reiss, Truven Health Analytics, Washington, DC, Genentech, Inc., South San Francisco, CA, Genentech Inc., South San Francisco, CA 90. Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis. Bjorn Svensson, Maria LE andersson, Sidona- Valentina Bala, Kristina Forslind and Ingiäld Hafström 4, Lund University, Lund, Sweden, R&D Center, Spenshult Hospital, Oskarström, Sweden, Helsingborgs Lasarett and Lund University Hospital, Helsingborg, Sweden, 4 Karolinska University Hospital, Stockholm, Sweden 9. DAS8 Is Not a Sufficient Disease Activity Measure for Obese Rheumatoid Arthritis Patients - Don t Leave the Feet Behind. Vikram Garg, Paul Maranian, Mihaela B. Taylor, Harold E. Paulus 4, David Elashoff 4 and Veena K. Ranganath 5, UCLA David Geffen School of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, CA, UCLA Medical School, Los Angeles, CA, University of California Los Angeles, Los Angeles, CA, 4 University of California, Los Angeles, Los Angeles, CA, 5 University of California, Los Angeles, Western Consortium of Practicing Rheumatologists, Los Angeles, CA 9. Analysis of Factors Impact on Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis). Yasushi Inoue, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Akiko Kobayashi, Daisuke Hoshi, Naoki Sugimoto, Kumi Shidara, Yohei Seto, Atsuo Taniguchi, Shigeki Momohara and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 9. Defining Criteria for Rheumatoid Arthritis Patient-Derived Disease Activity Score That Corrresponds to Disease Activity Score 8 and Clnical Disease Activity Index Based Statuses and Response Criteria. Alexander MH Leung, 0 Program Book 69

172 ACR POSTER SESSION A Daniel Farewell, Chak S. Lau and Ernest Choy 4, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, Cardiff, ENGLAnd, United Kingdom, Queen Mary Hospital, Hong Kong, Hong Kong, 4 Cardiff University School of Medicine, Cardiff, United Kingdom 94. Remission after One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis. K.V.C. Wevers-de Boer, L. Heimans, K. Visser, A.A. Schouffoer, T.H.E. Molenaar, J.B. Harbers 4, C. Bijkerk 5, I. Speyer 6, M. de Buck 7, P.B. de Sonnaville 8, B.A. Grillet 9, Tom Huizinga and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Haga Hospital, The Hague, Netherlands, Groene Hart Hospital, Netherlands, 4 Franciscus Hospital, Roosendaal, 5 Reinier de Graaf Gasthuis, Delft, Netherlands, 6 Bronovo Hospital, Den Haag, Netherlands, 7 MCH, The Hague, 8 Admiraal de Ruyter hospital, Goes, 9 Zorgsaam hospital, Terneuzen, Netherlands 95. Trends in Disease Activity, Response and Remission Rates in Rheumatoid Arthritis during the Last Decade: Results from the NOR-DMARD Register. Anna-Birgitte Aga, Elisabeth Lie, Karen M. Fagerli, Till Uhlig, Tore K. Kvien and Espen A. Haavardsholm, Diakonhjemmet Hospital, Oslo, Norway 96. Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort. Cédric Lukas, Ihsane Hmamouchi, Xavier Le Loet, Bruno Fautrel 4 and Bernard Combe 5, Montpellier University, Lapeyronie Hospital, Montpellier, France, El Ayachi Hospital, Rabat, Morocco, CHU de ROUEN, Rouen, France, 4 APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 5 Hopital Lapeyronie, Montpellier, France 97. Assessment of Global Disease Activity in Rheumatoid Arthritis Patients Monitored in the Measurement of Efficacy of Treatment in the Era of Rheumatology Database: The patient s versus the rheumatologist s Opinion. E. Gvozdenovic, R. Koevoets, R. Wolterbeek, Désirée van der Heijde, T.W.J. Huizinga, C.F. Allaart and Robert B. M. Landewé, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands 98. Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission. Heather Jones, Annette Szumski and Andrew S. Koenig, Pfizer Inc, Collegeville, PA, Pfizer Inc., Collegeville, PA 99. Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa). Yoichiro Haji, Mitsumasa Kishimoto, Ryo Rokutanda, Sachiko Ohde, Gautam A. Deshpande, Yuri Ohara, Chisun Min, Yasuhiro Suyama, Hisanori Shimizu, Ken-ichi Yamaguchi, Akira Takeda, Yukio Matsui, Masato Okada and Shigeto Tohma, St. Luke s International Hospital, Tokyo, Japan, St.Luke s Life of Science Institute, Tokyo, Japan, Sagamihara National Hospital, Sagamihara City, Japan 400. High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 8-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission. Yasushi Inoue, Eiichi Tanaka, Ayako Nakajima, Eisuke Inoue, Akiko Kobayashi, Daisuke Hoshi, Naoki Sugimoto, Kumi Shidara, Yohei Seto, Atsuo Taniguchi, Shigeki Momohara and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 40. Can We Improve Outcomes in Early Rheumatoid Arthritis by Determining Best Practices? An Analysis of the Canadian Early Rheumatoid Arthritis Cohort (CATCH). Jamie Harris, Vivian P. Bykerk, Carol A. Hitchon, Edward Keystone 4, J. Carter Thorne 5, Gilles Boire 6, Boulos Haraoui 7, Glen S. Hazlewood 4, Ashley Bonner 8, Janet E. Pope 9 and CATCH Investigators 0, Western University, London, ON, Hospital for Special Surgery, New York, NY, University of Manitoba, Winnipeg, MB, 4 University of Toronto, Toronto, ON, 5 Southlake Regional Health Centre, Newmarket, ON, 6 CHUS - Sherbrooke University, Sherbrooke, QC, 7 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 8 McMaster University, Hamilton, ON, 9 St. Joseph Health Care London, University of Western Ontario, London, ON, 0 Toronto, ON 40. Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity. Rebecca Belsom, Archana Jain, Jeffrey Curtis, Shuo Yang, Ted R. Mikuls, Lang Chen and Angelo L. Gaffo 4, University of Alabama, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 4 Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL 40. The Impact of Reaching Low Disease Activity in the First Year on Future Disability and Damage in Patients with Early Rheumatoid Arthritis. Pooneh Akhavan, George A. Tomlinson, Paul R. Fortin and Claire Bombardier, University of Toronto, Toronto, ON, Toronto General Hospital, Toronto, ON, Division of Rheumatology, Centre de recherche du centre hospitalier universitaire de Québec, Faculté de médecine de L université Laval, Quebec City, QC 404. Remission is a Difficult Target in Clinical Practice When RA Disease Is Established. Till Uhlig, Elisabeth Lie, Cecillie Kaufmann, Erik Rødevand, Knut Mikkelsen 4, Synnøve Kalstad 5 and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway, Vestre Viken, Drammen, Norway, St. Olavs Hospital, Trondheim, Norway, 4 Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, 5 Tromsø, Norway 70 0 Program Book

173 ACR POSTER SESSION A 405. Frequencies of Boolean and Index Based ACR-EULAR Remissions Differ Slightly Depending On the Method of Patient Global Assessment. Paul Studenic, Josef S. Smolen and Daniel Aletaha, Medical University Vienna, Vienna, Austria Rheumatoid Arthritis - Human Etiology and Pathogenisis 406. βig-h Regulates the Inflammatory Arthritis by Mediating Selective Recruitment of Effector/Memory T Cells. Keum Hee Sa, Jin Hee Kang, Mahmudul Md Alam, Kyung Hwa Lee, Churl Hyun Im, Eon Jeong Nam, In San Kim and Young Mo Kang, Kyungpook National University School of Medicine, Daegu, South Korea 407. The I50V IL4R SNP Is Associated with Increased Th7 Cell Frequency and Poor Clinical Outcome in Rheumatoid Arthritis. Jan Leipe, Iryna Prots, Markus A. Schramm, Matthias Witt, Axel P. Nigg, Christiane S. Reindl, Claudia Dechant, Mathias Grunke, Hendrik Schulze-Koops and Alla Skapenko, University of Munich, Munich, Germany, Junior Research Group III, Interdisciplinary Center for Clinical Research Nikolaus-Fiebiger Center for Molecular Medicine, Erlangen 408. Alpha-Enolase Facilitates Migration of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis. Kichul Shin, Ji Ah Park, Seyeon Bae, Jae Seung Kang and Yeong Wook Song, College of Medicine, Seoul National University, Seoul, South Korea, Seoul National Hospital, Seoul, South Korea, Seoul National University Hospital, Seoul, South Korea 409. Pathway Analysis of Genome-Wide Association Studies On Rheumatoid Arthritis. Young Ho Lee, Sung Jae Choi, Jong Dae Ji and Gwan Gyu Song, Korea University Medical Center, Seoul, South Korea, Korea Univ College of Med, Seoul 40. Early Growth Response- (EGR-) Controls Synoviocyte Apoptosis, and Its Expression Is Regulated by the Direct Binding of Fibroblast Growth Factor- (FGF) or Insulin-Like Growth Factor- (IGF) to Integrin αvβ. Shino Tanaka, Jun Saegusa, Seiji Kawano, Yoshikazu Takada, Shunichi Kumagai and Akio Morinobu, Kobe University Graduate School of Medicine, Kobe, Japan, University of California, Davis, School of Medicine, Sacramento, CA, Shinko Hospital, Kobe, Japan 4. Early Menopause, Smoking and Circulating Antibodies against Citrullinated Peptides in the Pre-Clinical Phase of Rheumatoid Arthritis. Mitra Pikwer, Johan Rönnelid, Monika Hansson, Ulf Bergström, Lennart T.H. Jacobsson, Linda Mathsson, Per Johan Jakobsson, Guy B. Serre 4, Rikard Holmdahl 5, Lars Klareskog 6 and Carl Turesson, Lund University, Malmö, Sweden, Uppsala University, Uppsala, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Centre National de la Recherche Scientifique - Université de Toulouse, Toulouse, France, 5 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 6 Karolinska Institute, Stockholm, Sweden 4. Single Nucleotide Polymorphisms within the HLA-DRB Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis. Lisbeth Arlestig, Mikael Brink, Monika Hansson, Per Johan Jakobsson, Rikard Holmdahl 4, Linda Mathsson 5, Johan Ronnelid 5, Lars Klareskog 6 and Solbritt M. Rantapaa-Dahlqvist 7, Umeå University, Umea, Sweden, Umea University, Umea, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 5 Uppsala University, Uppsala, Sweden, 6 Karolinska Institute, Stockholm, Sweden, 7 Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umea, Sweden 4. α(,)-linked Fucosylated Cytokines Are Upregulated in Rheumatoid Arthritis. Takeo Isozaki, Jeffrey H. Ruth, M. Asif Amin, Phillip L. Campbell, Christine M. Ha and Alisa E. Koch, University of Michigan, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI 44. First-Degree Relatives without Rheumatoid Arthritis Exhibit Reactivity to Multiple Anti-Citrullinated Protein Antibodies in Association with Rheumatoid Arthritis-Related Clinical Characteristics: Studies of the Etiology of Rheumatoid Arthritis. Kendra A. Young, Kevin D. Deane, Lezlie A. Derber, Jan M. Hughes-Austin 4, Michael H. Weisman 5, Jane H. Buckner 6, Ted R. Mikuls 7, James R. O Dell 8, Richard M. Keating 9, Peter K. Gregersen 0, V. Michael Holers and Jill M. Norris, Colorado School of Public Health, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, University of Colorado Anschutz Medical Campus, Aurora, CO, 4 Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, 5 Cedars- Sinai Medical Center, Los Angeles, CA, 6 Benaroya Research Institute at Virginia Mason, Seattle, WA, 7 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 8 Univ of Nebraska Med Ctr, Omaha, NE, 9 The University of Chicago, Chicago, IL, 0 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY 45. Hypoxia-Induced Endogenous Prostaglandin E Negatively Regulates Hypoxia-Enhanced Aberrant Overgrowth of Rheumatoid Synovial Tissue. Hirofumi Mitomi, Hidehiro Yamada, Toshiko Nozaki Shibata, Hiroshi Ito, Yoshioki Yamasaki, So Nomoto, Atsushi Kusaba, Hiroki Yamashita and Shoichi Ozaki, St. Marianna University, Kawasaki, Japan, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan, Ebina General Hospital, Ebina, Japan 46. Dyslipidaemia in Early Rheumatoid Arthritis Patients Is Common and Not Influenced by Two Years of Effective DMARD Therapy. The Opera Study. Torkell Ellingsen, Kim Horslev-Petersen, Merete L. Hetland, Peter Junker 4, Jan Podenphant 5, Mikkel Ostergaard 5 and Kristian Stengaard- Pedersen 6, Regional Hospital, Silkeborg, Denmark, Southern University, Denmark, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, 4 Odense 0 Program Book 7

174 ACR POSTER SESSION A 7 University Hospital, Denmark, 5 Copenhagen University Hospital at Glostrup, Denmark, 6 Arhus University Hospital, Denmark 47. The Potential Role of PTPRD Gene Copy Number Variation in Susceptibility to Rheumatoid Arthritis. Seung Cheol Shim, Donghyuk Sheen, Mi Kyoung Lim and Hyo Park, Eulji University Hospital, Daejeon, South Korea 48. Immediate Early Response Gene X- Is Over-Expressed and Regulates Apoptosis and Cytokine Production in Rheumatoid Arthritis Synovial Fibroblasts. Akio Morinobu, Masaaki Fujita, Shino Tanaka, Jun Saegusa and Shunichi Kumagai 4, Kobe university graduate school of medicine, Kobe , Japan, Kobe University Graduate School of Medicine, Kobe, Japan, Rheumatology and Clinical Immunology, Kobe, Japan, 4 Shinko hospital, Kobe, Japan 49. Epigenome Analysis of Rheumatoid Arthritis Synovial Fibroblasts Revealed TBX-5 As a Novel Transcription Factor in Chemokine Regulation. Emmanuel Karouzakis, Michelle Trenkmann, Renate E. Gay, Beat A. Michel, Steffen Gay and Michel Neidhart, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland 40. Loss-of-Co-Homozygosity Mapping and Exome Sequencing of a Syrian Pedigree Identified the Candidate Causal Mutation Associated with Rheumatoid Arthritis. Yukinori Okada, Namrata Gupta, Daniel Mirel, Stacey Gabriel, Thurayya Arayssi 4, Faten Mouassess 5, Walid AL Achkar 5, Layla Kazkaz 6 and Robert M. Plenge 7,.Brigham and Women s Hospital, Harvard Medical School,.Program in Medical and Population Genetics, Broad Institute, Boston, MA, The Broad Institute, Cambridge, The Broad Institute, Cambridge, MA, 4 Weill Cornell Medical College-Qatar, Doha, Qatar, 5 Molecular Biology and Biotechnology, Damascus, Syria, 6 Tishreen Hospital and the Syrian Association for Rheumatology, Damascus, Syria, Damascus, Syria, 7 Brigham and Women s Hospital, Boston, MA 4. Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity. Josef S. Smolen, Farideh Alasti and Daniel Aletaha, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, Medical University of Vienna, Vienna, Austria 4. Antibodies to Citrulline from Rheumatoid Arthritis Patients Also Bind Homocitrulline. Mathias Scinocca, Radha Joseph, David A. Bell, Ewa Cairns and Lillian J. Barra, Schulich School of Medicine and Dentistry, Western University, London, ON 4. Sputa Autoantibodies in Patients with Established Rheumatoid Arthritis and Subjects At-Risk for Future Clinically Apparent Disease. Van C. Willis, M. Kristen Demoruelle, Lezlie A. Derber, Catherine J. Chartier-Logan, Mark Parish, Isabel Pedraza, Michael H. Weisman, Jill M. Norris 4, V. Michael Holers and Kevin D. Deane, University of Colorado School of Medicine, Aurora, CO, Cedars Sinai Med Ctr, Los Angeles, Cedars-Sinai Medical Center, Los Angeles, CA, 4 Colorado School of Public Health, Aurora, CO 0 Program Book 44. Influence of Pregnancy on Disease Activity-Associated Genes in Rheumatoid Arthritis. Erik J. Peterson, Shreyasee Amin, Hatice Bilgic, Emily Baechler Gillespie, Jane E. Salmon, Ann M. Reed, Weihua Guan 4 and Daniel L. Mueller, University of Minnesota Medical School, Minneapolis, MN, Mayo Clinic, Rochester, MN, Hospital for Special Surgery, New York, NY, 4 University of Minnesota School of Public Health, Minneapolis, MN 45. Slug Is Induced by Benzo(a)Pyrene and EGF Through PIK/Akt/mTOR Pathway and Is Closely Involved in the Regulation of the Invasive Properties of FLS in Rheumatoid Arthritis. Jaejoon Lee, Jiwon Hwang, Chan Hong Jeon, Joong Kyong Ahn 4, Hoon-Suk Cha and Eun-Mi Koh 5, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Soonchunhyang University College of Medicine, Bucheon, South Korea, 4 Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea 46. Dickkopf- Stimulates Fibroblast-Like Synoviocyte Migration Through Janus Kinase Activation. Yubin Luo, Bryan Dieffenbach, Jung-Soo Song, Jinseok Kim 4, David L. Boyle, Michael Karin, Gary S. Firestein and Maripat Corr 5, UCSD School of Medicine, La Jolla, CA, UCSD School of Medicine, la Jolla, CA, Chung-Ang University College of Medicine, Seoul, South Korea, 4 Jeju National University, Jeju, Korea, South Korea, 5 Univ of California-San Diego, La Jolla, CA 47. Epigenetic Features as Predictive Markers of Responsiveness to Epitope-Specific Therapy in Rheumatoid Arthritis. Roberto Spreafico, Maura Rossetti, Theodorus Van Der Broek, Olivia Morrow and Salvatore Albani, Sanford- Burnham Medical Research Institute, La Jolla, CA 48. TNFα Modulates the Expression of Circadian Clock Gene, Per, Via D-Box Motif in the Promoter Region in Rheumatoid Synovial Cells. Kohsuke Yoshida, Akira Hashiramoto, Takaichi Okano, Nao Shibanuma 4 and Shunichi Shiozawa 5, Hyogo Prefectural Rehabilitation Center at Nishi-harima, Tatsuno, Japan, Department of Internal Medicine, Kobe University Graduate School of Medicine / The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, Kobe University Hospital, Kobe, Japan, 4 The Center for Rheumatic Diseases, Kobe University Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 5 Kyushu University Beppu Hospital, Beppu, Japan 49. The Significance of the Apoptosis Level and the Apoptosis Related Signal Proteins of CD4+t ACD4+Foxp+t Cell in Patients with Rheumatoid Arthritis. Ning Li, Tianrui Ma, Jie Han, Jieru Zhou and Songguo Zheng, Shanghai East Hospital, Shanghai, China, Ningbo Pediatric Hospital, Ningbo, China, Keck School of Medicine of the University of Southern California, Los Angeles, CA

175 ACR POSTER SESSION A 40. Comprehensive Microrna Analysis Identifies Mir- 4, Mir-6a, and Mir-5a-5p As Plasma Biomarkers for Rheumatoid Arthritis. Koichi Murata, Moritoshi Furu, Hiroyuki Yoshitomi, Masahiro Ishikawa, Hideyuki Shibuya, Hiromu Ito and Shuichi Matsuda, Kyoto University Graduate School of Medicine, Kyoto, Japan 4. Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA. Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken- Nakazawa J. Song, Osaka University, Osaka, Japan 4. Identification and Characterization of Fibrinogen-Specific T Cells in Patients with Rheumatoid Arthritis. Laura Su and Mark M. Davis, Stanford University School of Medicine, Stanford, CA 4. Genome Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with Anti-TNF Medication. Results of the DREAM and Danbio Registries. Marieke J.H. Coenen, Masha Umicevic-Mirkov, Hans Scheffer, Sophine B. Krintel, Sita H. Vermeulen, Julia S. Johansen, Wietske Kievit, Mart A.F.J. van de Laar, Piet L.C.M. van Riel, Barbara Franke and Merete L. Hetland 4, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, 4 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark 44. IL- Mediated Pannus Formation in Autoimmune Arthritis Is PIK/Akt/mTOR Dependent. Siba P. Raychaudhuri, Anupam Mitra, Ananya Datta Mitra, Christine Abria and Smriti K. Raychaudhuri, VA Sacramento Medical Center\ UC Davis School of Medicine, Mather, CA, VA Sacramento Medical Center, Mather, CA 45. CIPA Facilitates Apoptotic Resistance of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis Independent of c-myc Expression. Jaejoon Lee, Jiwon Hwang, Jinseok Kim, Joong Kyong Ahn 4, Hoon-Suk Cha and Eun-Mi Koh 5, Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Jeju National University Hospital, Jeju, South Korea, 4 Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea 46. Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis. Youngkyun Kim, Su- Jin Moon, Hyoju Yi and Ji Hyeon Ju, College of Medicine, The Catholic University of Korea, Seoul, South Korea, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA 47. SIRT6 Regulates Cigarette Smoke Induced MMP Expression in Rheumatoid Arthritis Synovial Fibroblasts. Anna Engler, Renate E. Gay, Beat A. Michel, Steffen Gay and Caroline Ospelt, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland 48. Methyl Supplementation of Rheumatoid Arthritis Synovial Fibroblasts Regulates the Expression of Transcription Factors and Matrix Metalloproteinases. Edvardas Bagdonas, Emmanuel Karouzakis, Astrid Jungel, Caroline Ospelt, Renate E. Gay, Steffen Gay, Beat A. Michel and Michel Neidhart, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland 49. Interaction of Antibodies against Citrullinated Peptides with HLA Shared Epitope, PTPN 858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis. Heidi Kokkonen, Mikael Brink, Monika Hansson, Linda Mathsson 4, Ewa Lassen 5, Per Johan Jakobsson, Rikard Holmdahl 6, Johan Rönnelid 4, Lars Klareskog 7 and Solbritt M. Rantapaa-Dahlqvist 8, Umeå University, Umea, Sweden, Umea University, Umea, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Uppsala University, Uppsala, Sweden, 5 Umeå University, Umeå, Sweden, 6 Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 7 Karolinska Institute, Stockholm, Sweden, 8 Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umea, Sweden 440. Effects of Fetal Microchimerisms on Disease Onset and Severity in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Marianne Kekow, Sara Fill Malfertheiner, Maria Barleben, Susanne Drynda, Joern Kekow and Thomas Brune, Univ of Magdeburg, Children s Hospital, Magdeburg, Germany, Univ of Magdeburg, Department of Obstetrics and Gynecology, Magdeburg, Germany, Univ of Magdeburg, Vogelsang-Gommern, Germany 44. Performance of Anti-Cyclic Citrullinated Peptide Assays Differs in Healthy Subjects At Elevated Risk for Future Rheumatoid Arthritis and Subjects with Established Disease. M. Kristen Demoruelle, Mark Parish, Lezlie A. Derber, Michael H. Weisman, William R. Gilliland 4, Jess Edison 4, James R. O Dell 5, Ted R. Mikuls 5, Richard M. Keating 6, Peter K. Gregersen 7, Jane H. Buckner 8, Jill M. Norris 9, V. Michael Holers and Kevin D. Deane, University of Colorado School of Medicine, Aurora, CO, University of Colorado Anschutz Medical Campus, Aurora, CO, Cedars- Sinai Medical Center, Los Angeles, CA, 4 Walter Reed National Military Medical Center, Bethesda, MD, 5 University of Nebraska Medical Center, Omaha, NE, 6 The University of Chicago, Chicago, IL, 7 North Shore University Hospital Research Center, Manhasset, NY, 8 Benaroya Research Institute at Virginia Mason, Seattle, WA, 9 Colorado School of Public Health, Aurora, CO 0 Program Book 7

176 ACR POSTER SESSION A 44. Joint Effects of Known Genetic Markers of Rheumatoid Arthritis Risk and 5-Hydroxyvitamin D On Rheumatoid Arthritis Risk. Linda T. Hiraki, Chia-Yen Chen, Jing Cui, Susan Malspeis 4, Karen H. Costenbader 5 and Elizabeth W. Karlson 5, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Brigham and Womens Hospital, Boston, MA, 5 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 44. Secreted Frizzled-Related Protein 5 Exerts the Anti- Inflammatory Role in Rheumatoid Arthritis Via Down- Regulation of c-jun N-Terminal Kinase. Yong-Jin Kwon, Tae-Yeon Kim, Sang-Won Lee, Yong-Beom Park, Soo Kon Lee and Min-Chan Park, Yonse University College of Medicine, Seoul, South Korea Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy 444. Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. An Open Label Randomized Controlled Trial. Kensuke Kume, Kanzo Amano, Susumu Yamada, Kazuhiko Hatta, Kuniki Amano, Noriko Kuwaba 4 and Hiroyuki Ohta 5, Hiroshima Clinic, Hiroshima, Japan, Hatta Clinic, Kure, Japan, Sky Clinic, Hiroshima, Japan, 4 Sanki Clinical Link, Hiroshima, Japan, 5 Hiroshima, Japan 445. Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study. Kensuke Kume, Kanzo Amano, Susumu Yamada, Kazuhiko Hatta, Kuniki Amano, Hiroyuki Ohta 4 and Noriko Kuwaba 5, Hiroshima Clinic, Hiroshima, Japan, Hatta Clinic, Kure, Japan, Sky Clinic, Hiroshima, Japan, 4 Hiroshima, Japan, 5 Sanki Clinical Link, Hiroshima, Japan 446. Clinical Remission and Rate of Relapse after Tocilizumab Withdrawal in Rheumatoid Arthritis Patients. Cesar Vargas-Serafin, Luis Aguilar-Lozano, Jorge Padilla-Ibarra, Carlos Sandoval-Castro, Jose Dionisio Castillo-Ortiz, Jorge Morales-Torres, Claudia Hernandez and Cesar Ramos- Remus, Unidad de Investigacion en Enfermedades Cronico- Degenerativas, Guadalajara, Mexico, Hospital Aranda de la Parra, Leon, Mexico 447. Long-Term Safety and Efficacy of Tabalumab, an Anti-B- Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 5-Week, Open-Label Extension Study. Maria W. Greenwald, Leszek Szczepanski, Alastair C. Kennedy, Chin H. Lee 4, Emery Polasek 5, Melissa Veenhuizen 5, Rebecca Jones-Taha 6 and Pierre-Yves Berclaz 5, Desert Medical Advances, Palm Desert, CA, Wydz. Fizjoterapii, Wyzsza Skola Spoleczno-Przyrodnicza, Poland, Alastair C. Kennedy, MD, Vero Beach, FL, 4 Eli Lilly and Company, Indianapolis, IN, 5 Eli Lilly & Company, Indianapolis, IN, 6 PharmaNet/i, Blue Bell, PA 448. Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents. Ioan Ancuta, Catalin Codreanu, Ruxandra Ionescu, Magda Parvu 4 and Mihai Bojinca, Dr. I. Cantacuzino Hospital, Bucharest, Romania, Dr. I. Stoia Center for Rheumatic Diseases, Bucharest, Romania, Clinic Hospital Sf. Maria, Bucharest, Romania, 4 N.Gh. Lupu Clinical Hospital, Bucharest, Romania 449. Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission. Ioan Ancuta, Catalin Codreanu, Ruxandra Ionescu, Magda Parvu 4 and Mihai Bojinca, Dr. I. Cantacuzino Hospital, Bucharest, Romania, Dr. I. Stoia Center for Rheumatic Diseases, Bucharest, Romania, Clinic Hospital Sf. Maria, Bucharest, Romania, 4 N.Gh. Lupu Clinical Hospital, Bucharest, Romania 450. Late Onset Neutropenia after Rituximab Treatment for Rheumatological Conditions. Gabriel S. Breuer, Michael Z. Ehrenfeld, Itzhak Rosner, Alexandra Balbir-Gurman 4, Devy Zisman 5 and Daphna Paran 6, Shaare Zedek Medical Center, Jerusalem, Israel, Chaim Sheba Medical Center, Tel HaShomer, Israel, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel, 4 Rambam Health Care Campus, Haifa, Israel, 5 Carmel Medical Center, Haifa, Israel, 6 Tel Aviv Sourasky Medical Ctr, Tel Aviv, Israel 45. Pilot Study of Stimulation of the Cholinergic Anti- Inflammatory Pathway with an Implantable Vagus Nerve Stimulation Device in Patients with Rheumatoid Arthritis. Frieda A. Koopman, Sanda Miljko, Simeon Grazio, Sekib Sokolovic 4, Kevin Tracey 5, Yaakov Levine 6, Ralph Zitnik 6 and Paul-Peter Tak 7, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, University Clinical Hospital, Mostar, Bosnia, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, 4 University Clinical Center, Sarajevo, Bosnia, 5 Feinstein Institute for Medical Research, Manhasset, NY, 6 SetPoint Medical Corporation, Valencia, CA, 7 Academic Medical Center/GlaxoSmithKline, Amsterdam, Netherlands 45. Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose. Daniele F. Pereira, Rita N.V. Furtado, Natalia P. Machado and Jamil Natour, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, Universidade Federal de São Paulo - UNIFESP, São Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 45. Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose. Susanna Proudman, Llew Spargo, Cindy Hall, Leah McWilliams, Anita Lee, Maureen Rischmueller, Robert Gibson, Michael James and Leslie G. Cleland, Royal Adelaide Hospital, Adelaide, Australia, Queen Elizabeth Hospital, Adelaide, Australia, University of Adelaide, Adelaide, Australia 74 0 Program Book

177 ACR POSTER SESSION A 454. Long-Term Efficacy of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Previously Methotrexate Naive or Methotrexate Free for 6 Months. Graeme Jones, Anthony Sebba, Denise Lepley, Jenny Devenport, Corrado Bernasconi 4, Devi Smart 5, Chiedzo Mpofu 4 and Juan J. Gomez-Reino 6, Menzies Research Institute Tasmania, Hobart, Australia, University of South Florida, Tampa, FL, Genentech, South San Francisco, CA, 4 Roche, Basel, Switzerland, 5 Roche Products Ltd, Welwyn Garden City, United Kingdom, 6 Hospital Clinico Universitario, Santiago, Spain 455. Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice. Keisuke Izumi, Yuko Kaneko, Hidekata Yasuoka, Noriyuki Seta, Hideto Kameda, Masataka Kuwana and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Keio Univ School of Medicine, Shinjuku-ku, Japan, Keio university, Tokyo, Japan 456. Factors Influencing Choice of Rituximab Versus an Alternative Tumor Necrosis Factor Inhibitor Following Tumor Necrosis Factor Inhibitor Failure in Patients with Rheumatoid Arthritis: Sub-Analysis of a Global, Observational Comparative Effectiveness Study. Axel Finckh, Jacques-Eric Gottenberg, Chiedzo Mpofu, William G. Bensen 4, Andrea Rubbert-Roth 5, Fedra Irazoque 6, Victor Martínez Taboada 7, Carol Chung 8, Lykke Hinsch-Gylvin, Clodoveo Ferri 9 and Paul Emery 0, University Hospital of Geneva, Geneva, Switzerland, CHU Strasbourg, Strasbourg, France, F Hoffmann-La Roche Ltd, Basel, Switzerland, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON, 5 University of Cologne, Cologne, Germany, 6 Hospital Angeles Mocel, Mexico City, Mexico, 7 Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8 Genentech Inc., South San Francisco, CA, 9 University of Modena and Reggio Emilia, Modena, Italy, 0 University of Leeds, Leeds, United Kingdom 457. Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over. Jean-Pascal Roussy, Louis Bessette, Sasha Bernatsky, Elham Rahme and Jean Lachaine, University of Montreal, Montreal, QC, Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, McGill University, Montreal, QC 458. Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database. Denis Choquette, Diane Sauvageau, Boulos Haraoui and Jean-Pierre Raynauld, Institut de Rhumatologie De Montréal, Montreal, QC, Institut de Rhumatologie de Montréal, Montreal, QC 459. Long-Term Safety of Rituximab: 0-Year Follow-up in the Rheumatoid Arthritis Global Clinical Trial Program. Ronald F. van Vollenhoven, Paul Emery, Clifton O. Bingham III, Edward Keystone 4, Roy M. Fleischmann 5, Daniel E. Furst 6, Nicola Tyson 7, Abdul Mehbob 7 and Patrica B. Lehane 7, Karolinska University Hospital, Stockholm, Sweden, University of Leeds, Leeds, United Kingdom, Johns Hopkins University, Baltimore, MD, 4 Mount Sinai Hospital, Toronto, ON, 5 University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 6 UCLA Medical School, Los Angeles, CA, 7 Roche Products Limited, Welwyn Garden City, United Kingdom 460. Real-World Efficacy and Safety of Abatacept Treatment for Rheumatoid Arthritis: -Month Interim Analysis of the Action Study. H. Nüßlein, R. Alten, M. Galeazzi, H. M. Lorenz 4, Dimitrios Boumpas 5, M. T. Nurmohamed 6, W. Bensen 7, G. R. Burmester 8, H.-H. Peter 9, F. Rainer 0, Karel Pavelka, M. Chartier, C. Poncet, C. Rauch 4 and M. Le Bars 5, University Erlangen, Nürnberg, Germany, Schlosspark-Klinik, University Medicine, Berlin, Germany, University of Siena, Siena, Italy, 4 University Hospital Heidelberg, Heidelberg, Germany, 5 Panepistimio Kritis, Rethymnon, Greece, 6 VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, 7 St. Joseph s Hospital and McMaster University, Hamilton, ON, 8 Charité-Universitätsmedizin, Berlin, Germany, 9 University Medical Center Freiburg, Freiburg, Germany, 0 Hospital Barmherzige Brueder, Graz, Austria, Institute of Rheumatology, Prague, Czech Republic, Chiltern International, Neuilly, France, Docs International, Sévres, France, 4 Bristol-Myers Squibb, Munich, Germany, 5 Bristol- Myers Squibb, Rueil Malmaison, France 46. Patterns of Tocilizumab Use, and Dosing Among Patients with Rheumatoid Arthritis in the Clinical Practice. Preliminary Analyses of ACT-Life Study. J.V. Tovar Beltrán, M.A. Guzmán Úbeda, I. Mateo Bernardo, Rosario García-Vicuña 4, M. Rodríguez-Gómez 5, M. Belmonte- Serrano 6, C. Marras 7, E. Loza Cortina 8, E. Pérez Pampin 9, V. Vila Fayos 0, A.B. Romero Silva and A. Balsa, Hospital General Universitario de Elche, Alicante, Spain, Hospital Universitario Virgen de las Nieves, Granada, Spain, Hospital Universitario de Octubre, Madrid, Spain, 4 Hospital Universitario La Princesa, Madrid, Spain, 5 Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 6 Hospital General de Castellón, Castellón, Spain, 7 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 8 Hospital de Navarra, Navarra, Spain, 9 Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, 0 Hospital Comarcal de Vinaroz, Castellón, Spain, Roche Farma, Madrid, Spain, Hospital La Paz, Madrid, Spain 46. Subcutaneous Abatacept: Long-Term Data From the Acquire Trial. M. C. Genovese, C. Pacheco-Tena, A. Covarrubias, G. Leon 4, E. Mysler 5, M. Keiserman 6, R. Valente 7, P. Nash 8, J. A. Simon-Campos 9, J. Box 0, C. Legerton III, E. Nasonov, P. Durez, I. Delaet 4 and R. Alten 5, Stanford University, Palo Alto, CA, Universidad Autónoma de Chihuahua, Chihuahua, Mexico, Centro Medico De Las Americas, Merida, Mexico, 4 Instituto De Ginecologia Y Reproduccion, Lima, Peru, 5 Organización Médica de Investigación, Buenos Aires, Argentina, 6 Pontificial Catholic 0 Program Book 75

178 ACR POSTER SESSION A 76 University School of Medicine, Porto Alegre, Brazil, 7 Arthritis Center of Nebraska, Lincoln, NE, 8 University of Queensland, Brisbane, Australia, 9 Centro De Especialidades Médicas/ Universidad Marista, Merida, Mexico, 0 Box Arthritis & Rheumatology of the Carolinas, Charlotte, NC, Low Country Rheumatology, Charleston, SC, Institute of Rheumatology, Moscow, Russia, Université Catholique de Louvain, Brussels, Belgium, 4 Bristol-Myers Squibb, Princeton, NJ, 5 Schlosspark-Klinik, University Medicine, Berlin, Germany 46. Drug Survival, Efficacy and Predictors for Survival on Tocilizumab in Real-Life Patients with Rheumatoid Arthritis; Results From the Swedish Biologics Register. Helena Forsblad-d Elia, Karin Bengtsson, Lars-Erik Kristensen and Lennart TH Jacobsson, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, Department of Rheumatology, University Hospital of Skåne, Lund, Sweden 464. Rituximab for Treatment of Rheumatoid Arthritis: Treatment Effectiveness in the Corrona Database. Leslie R. Harrold, George W. Reed, Robert P. Magner, Katherine C. Saunders, Jeffrey D. Greenberg, Joel M. Kremer 4, Ani John 5, William Reiss 5, Steve Zlotnick 5 and Ashwini Shewade 5, University of Massachusetts Medical School, Worcester, MA, CORRONA, Inc., Southborough, MA, New York University School of Medicine, New York, NY, 4 Albany Medical College, Albany, NY, 5 Genentech Inc., South San Francisco, CA 465. The Comparative Effectiveness of Oral Methotrexate versus Subcutaneous Methotrexate for the Treatment of Early Rheumatoid Arthritis. Glen S. Hazlewood, J. Carter Thorne, Janet Pope, Gilles Boire 4, Boulos Haraoui 5, Carol A. Hitchon 6, Edward Keystone, Diane Tin, CATCH Investigators 7 and Vivian P. Bykerk 8, University of Toronto, Toronto, ON, Southlake Regional Health Centre, Newmarket, ON, Schulich School of Medicine and Dentistry, Western University, London, ON, 4 CHUS - Sherbrooke University, Sherbrooke, QC, 5 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 6 University of Manitoba, Winnipeg, MB, 7 Toronto, ON, 8 Hospital for Special Surgery, New York, NY 466. Synovialitis Plus Articular Cartilage Monitoring Via Magnetic Resonance Imaging and Ultrasound Under Tocilizumab Therapy in Patients with Rheumatoid Arthritis. Maria Hoehle and Michael Finkenstaedt, Rheumatology, Hamburg, Germany, Private Practice for Radiology and Neuroradiology, Hamburg, Germany 467. Seropositive Rheumatoid Arthritis Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors Achieve Improved Clinical Effectiveness After Switching to Rituximab Versus Switching to an Alternative Tumor Necrosis Factor Inhibitor. Andrea Rubbert-Roth, Axel Finckh, Piercarlo Sarzi-Puttini, Jacques-Eric Gottenberg 4, Denis Choquette 5, Victor Martínez Taboada 6, Leonor Barile-Fabris 7, Carol Chung 8, Lykke Hinsch-Gylvin 9 and 0 Program Book Paul Emery 0, University of Cologne, Cologne, Germany, University Hospital of Geneva, Geneva 4, Switzerland, L Sacco University Hospital, Milan, Italy, 4 CHU Strasbourg, Strasbourg, France, 5 University of Montreal, Notre-dame Hospital, Montreal, QC, 6 Hospital Universitario Marqués de Valdecilla, Santander, Spain, 7 Hospital de Especialidades Centro Médico Nacional Siglo XXI, Mexico City, Mexico, 8 Genentech Inc., South San Francisco, CA, 9 F Hoffmann-La Roche Ltd, Basel, Switzerland, 0 University of Leeds, Leeds, United Kingdom 468. Adalimumab Treatment Is Associated with Decreased Concomitant Rheumatoid Arthritis Medication Use Over 4 Months. Daniel E. Furst, Neelufar Mozaffarian, Shannon Grant, Mary Cifaldi, Jerry Clewell, Joel M. Kremer 4 and James Shaw, UCLA Medical School, Los Angeles, CA, Abbott Laboratories, Abbott Park, IL, Axio Research LLC, Seattle, WA, 4 Albany Medical College and The Center for Rheumatology, Albany, NY 469. Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses from the Behandelstrategiën Study. E. Gvozdenovic, L. Dirven, M. van den Broek, Kh Han, T.H.E. Molenaar, R. Landewe 4, W.F. Lems 5 and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Maasstad hospital, Rotterdam, Netherlands, Groene Hart Hospital, Netherlands, 4 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5 VU University medical center, Amsterdam, Netherlands 470. Concomitant Assessment of Clinical and Ultrasound Efficacy and Safety of Tocilizumab in Patients with Moderate to Severe Rheumatoid Arthritis: The Torpedo Study. Thierry Schaeverbeke, Philippe Gaudin, Aleth Perdriger, Christian Roux 4, Muriel Vray 5, Stephanie Rouanet 6, Ghislaine Steinberg 6 and Fabien Etchepare 7, Groupe Hospitalier Pellegrin, Bordeaux, France, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, Hôpital Sud, Rennes, France, 4 Paris Descartes University, Paris, France, 5 Paris, France, 6 Roche, Boulogne, France, 7 G.H. Pitié-Salpêtrière, Paris, France 47. Efficacy and Safety of Golimumab as Add-On Therapy to Disease-Modifying Antirheumatic Drugs. Bernard Combe, Bhaskar Dasgupta, Ingrid Louw, Sarvajeet Pal 4, Jürgen Wollenhaupt 5, Cristiano Zerbini 6, andre D. Beaulieu 7, Hendrik Schulze-Koops 8, Patrick Durez 9, Ruji Yao 0, Nathan Vastesaeger and Holly Weng 0, Hôpital Lapeyronie-Service d Immuno-rhumatologie, Montpellier, France, Southend University Hospital, Westcliff-on-Sea, United Kingdom, Panorama Medical Centre, Cape Town, South Africa, 4 Advance Rheumatology Clinic, Hyderabad, India, 5 Schön- Klinik, Hamburg, Germany, 6 Centro Paulista de Investigações, Sao Paulo, Brazil, 7 Centre de Rhumatologie, St. Louis, QC, 8 University of Munich, Munich, Germany, 9 UCL Saint-Luc, Brussels, Belgium, 0 Merck Sharp and Dohme, Kenilworth, NJ, Merck Sharp and Dohme, Brussels, Belgium

179 ACR POSTER SESSION A 47. More Positive Expectations of Treatment with Golimumab for Rheumatoid Arthritis Are Associated with Greater Improvement in Clinical Outcomes. Bhaskar Dasgupta, Bernard Combe, Ingrid Louw, Sarvajeet Pal 4, Jürgen Wollenhaupt 5, Cristiano Zerbini 6, andre D. Beaulieu 7, Hendrik Schulze-Koops 8, Patrick Durez 9, W. Bensen 0, V. Wolff, Ruji Yao, Holly Weng and Nathan Vastesaeger, Southend University Hospital, Westcliff-on-Sea, United Kingdom, Hôpital Lapeyronie-Service d Immuno-rhumatologie, Montpellier, France, Panorama Medical Centre, Cape Town, South Africa, 4 Advance Rheumatology Clinic, Hyderabad, India, 5 Schön-Klinik, Hamburg, Germany, 6 Centro Paulista de Investigações, Sao Paulo, Brazil, 7 Centre de Rhumatologie, St. Louis, QC, 8 University of Munich, Munich, Germany, 9 UCL Saint-Luc, Brussels, Belgium, 0 St. Joseph s Hospital and McMaster University, Hamilton, ON, Hospital del Salvador, Santiago, Chile, Merck Sharp and Dohme, Kenilworth, NJ, Merck Sharp and Dohme, Brussels, Belgium 47. The Addition of Another Disease-Modifying Anti- Rheumatic Drug to Methotrexate in Place of Infliximab Reduces the Flare Rate During Years After Infliximab Discontinuation in Patients with Rheumatoid Arthritis. Hideto Kameda, Takahiko Kurasawa, Hayato Nagasawa, Koichi Amano and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Saitama Medical Ctr, Kawagoe, Japan, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan 474. Dose Reduction in Rituximab Retreatment May Delay Achievement of Optimal Responses. Mohammed I. Sharif, Sudipto Das, Paul Emery, Helen MacIver, Wendy Shingler, Philip S. Helliwell, Katharina Sokoll and Edward M. Vital, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom, NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom 475. Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: Valent Pneumococcal Vaccination. Ankur A. Kamdar, Patricia C. Giclas and Barry L. Myones, University of Texas Medical School at Houston, Houston, TX, National Jewish Health, Denver, CO, Baylor College of Medicine, Houston, TX 476. Effects of Vitamin D Repletion and Maintenance Therapy on Clinical Indicators of Disease Activity in Rheumatoid Arthritis. Uzma J. Haque, Clifton O. Bingham III and Susan J. Bartlett, Johns Hopkins Hospital, Baltimore, MD, Johns Hopkins University, Baltimore, MD, McGill University, Montreal, QC 477. Impact of Etanercept On Incident Cancer in Taiwanese Patients with Rheumatoid Arthritis. Jiunn Horng Chen and Wen-Miin Liang, China Medical University Hospital, Taichung City, Taiwan, China Medical University, Taichung, Taiwan 478. Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis. Sébastien Ottaviani, Anais Gardette, Emilie Quintin, Karen Dawidowicz, Ghislaine Gill, Elisabeth Palazzo, Olivier Meyer and Philippe Dieude, APHP, Paris, France, APHP, Hopital Bichat, Paris, France, Hopital Bichat, Paris, France 479. Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic. Patrick Durez, Pedro Miranda, Antoaneta Toncheva, Alberto Berman Sr. 4, Oscar L. Rillo 5, Yves Boutsen 6, Tatjana Kehler 7, Eugenia Mociran 8, LiAn Soto Saez 9, Bruno Fautrel 0, Xavier Mariette, Panayot Solakov, Eleonora Lucero, Tonko Vlak 4, Simeon Grazio 5, Ksenija Mastrovic 6, Rodica Chiriac 7, Géraldine Grouard-Vogel 8, Olivier Dhellin 8, Stéphane Ouary 8, Pierre Vandepapeliere 8 and Marie-Christophe Boissier 9, Université Catholique de Louvain, Brussels, Belgium, Centro de Estudios Reumatologicos, Santiago de Chile, Chile, National Multiprofile Transport Hospital, Sofia, Bulgaria, 4 Hospital Padilla, Tucuman, Argentina, 5 Hospital Tornú, Buenos Aires, Argentina, 6 UCL Mont-Godinne, Godinne, Belgium, 7 Thalassotherapia Opatija, Opatija, Croatia, 8 Emergency County Hospital Dr Constantin Opis, Maramures, Romania, 9 Sociedad Medica del Aparato Locomotor SA, Santiago de Chile, Chile, 0 APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, Université Paris-Sud, Le Kremlin Bicetre, France, Diagnostic and Consulting Center, Plovdiv, Bulgaria, Centro Investigaciones Reumatológicas, Tucumán, Argentina, 4 University Hospital Split, Split, Croatia, 5 Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, 6 Clinical Hospital Sveti Duh, Zagreb, Croatia, 7 Rehabilitation clinical Hospital Iasi, Iasi, Romania, 8 NEOVACS SA, Paris, France, 9 Hopital Avicenne, Bobigny, France 480. Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis. Claire I. Daien, Anne- Marie Dupuy Gorce, Edith Pinot, Thibault Mura, Jean- Paul Cristol, Bernard Combe and Jacques Morel, Hopital Lapeyronie, Montpellier, France, Hopital Gui De Chauliac, Montpellier, France 48. Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients. Jon T. Einarsson, Pierre Geborek, Tore Saxne and Meliha C. Kapetanovic 4, Dept of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Sweden, Lund, Sweden, Lund University, Lund, Sweden, Dept of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, 4 Dept of Clinical Sciences Lund, Lund, Sweden 48. B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases. Ilias Lazarou, Axel Finckh, Lara Fischer, Camillo Ribi, Joerg Seebach and Pierre A. Guerne, University Hospitals of Geneva, Geneva, Switzerland 0 Program Book 77

180 ACR POSTER SESSION A 48. An Evaluation of Literature on Discontinuation Rates of Biologics in Rheumatoid Arthritis. Setareh A. Williams, Victoria Porter, Victoria Zarotsky, Sujatha Sundaram 4, Elisabeth Nyman 5, Cassie K. Gregson 6 and Paul S. J. Miller 6, AstraZeneca LP, Wilmington, DE, OptumInsight, Mastic Beach, NY, OptumInsight, Calabasas, CA, 4 OptumInsight, Hanover, NH, 5 AstraZeneca, Mölndal, Sweden, 6 AstraZeneca, Macclesfield, United Kingdom 484. Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept. Jipan Xie, Arijit Ganguli, Hongbo Yang, Kejal Parikh, Eric Q. Wu and Mary Cifaldi, Analysis Group Inc., Boston, MA, Abbott Laboratories, Abbott Park, IL 485. Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients. Mathieu Verdet, Clément Guillou, Marie-Laure Potier, Martine Hiron, Fabienne Jouen, Olivier Boyer 4, Thierry Lequerré 5 and Olivier Vittecoq 6, Rouen University Hospital, Bois Guillaume, France, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen University Hospital, Rouen Cedex, France, 4 INSERM U905, University of Rouen, Rouen, France, 5 Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 6 Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France 486. Impact of Adalimumab Therapy on Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis. De Furst, Ana P. Lacerda, Nupun andhivarothai, Jasmina Kalabic 4 and Neelufar Mozaffarian, University of California at Los Angeles, Los Angeles, CA, Abbott Laboratories, São Paulo, Brazil, Abbott Laboratories, Abbott Park, IL, 4 Abbott GmbH & Co. KG, Ludwigshafen, Germany 487. Functional Disability in Early Rheumatoid Arthritis - Contributions of Disease Activity and Structural Damage, and the Impact of Different Treatment Strategies. Josef S. Smolen, Roy Fleischmann, Paul Emery, Ronald F. van Vollenhoven 4, Stefan Florentinus 5, Freddy Faccin 6, Suchitrita S. Rathmann 7, Hartmut Kupper 8 and Arthur Kavanaugh 9, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, University of Texas Southwestern Medical Center, Dallas, TX, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4 The Karolinska Institute, Stockholm, Sweden, 5 Abbott, Rungis, France, 6 Abbott, Abbott Park, IL, 7 Abbott Laboratories, Abbott Park, IL, 8 Abbott GmbH and Co. KG, Ludwigshafen, Germany, 9 UCSD School of Medicine, La Jolla, CA 488. Patient Preferences for Biologic Treatments in Rheumatoid Arthritis. Beenish Nafees, Andrew Lloyd, Carol L. Gaich, Julie Birt and Rodney A. Hughes, Oxford Outcomes, Oxford, United Kingdom, Eli Lilly and Company, Indianapolis, IN, St. Peters Hospital, Chertsey Surrey, United Kingdom 489. The Comparative Effectiveness of Anti-TNF Medications among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population. Huifeng Yun, Fenglong Xie, Elizabeth S. Delzell, Lang Chen, Shuo Yang, Kenneth G. Saag and Jeffrey Curtis, University of Alabama- Birmingham, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama- Birmingham, Birmingham, AL and 4-Week Patient-Reported Outcomes From a Phase b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase / Janus Kinase Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Josef S. Smolen, Douglas E. Schlichting, Kimberly L. Sterling, Edward Keystone, Peter Taylor 4, Mark C. Genovese 5, Louise Johnson 6, Juan C. Rizo Rodriguez 7, Chin H. Lee and Carol L. Gaich, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, Eli Lilly and Company, Indianapolis, IN, University of Toronto, Toronto, ON, 4 Kennedy Institute of Rheumatology, London, United Kingdom, 5 Stanford University Medical Center, Palo Alto, CA, 6 PharmaNet/ i, Eden Prairie, MN, 7 Centro de Alta Especialidad en Reumatología e Investigación del Potosí, San Luis Potosi, San Luis Potosi, Mexico 49. Predictors of Initiating Biologic Monotherapy in Biologic Naïve Patients with Rheumatoid Arthritis (RA) in a US Registry Population. Dimitrios A. Pappas, George W. Reed, Ani John, Ashwini Shewade, Katherine C. Saunders 4, Jenny Devenport 5, Jeffrey D. Greenberg 6 and Joel M. Kremer 7, Columbia University, College of Physicians and Surgeons, New York, NY, University of Massachusetts Medical School, Worcester, MA, Genentech Inc., South San Francisco, CA, 4 CORRONA, Inc., Southborough, MA, 5 Genentech, South San Francisco, CA, 6 NYU Hospital for Joint Diseases, New York, NY, 7 Albany Medical College and The Center for Rheumatology, Albany, NY 49. Divergent Toxicity of TNF Inhibitors on Demyelinating Disorders and Neurological Events. Sergio Schwartzman, John Clark and John J. Cush, Hosp for Special Surgery, New York, NY, RiskBenefits LLC, Flourtown, PA, PA, Baylor Research Institute, Dallas, TX 49. Effect of Infliximab on Employment Status in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis. W. Bensen, J. Carter Thorne, Saeed A. Shaikh, Maqbool K. Sheriff 4, Susan M. Otawa 5, Allen J. Lehman 6 and Hayssam Khalil 7, St. Joseph s Hospital and McMaster University, Hamilton, ON, Southlake Regional Health Centre, Newmarket, ON, McMaster University, St Catharines, ON, 4 Nanaimo Regional General Hospital, Nanaimo, BC, 5 Janssen Canada Inc, Mississauga, ON, 6 Janssen Inc, Toronto, ON, 7 Janssen Canada Inc, Toronto, ON 78 0 Program Book

181 ACR POSTER SESSION A 494. Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis? William Bensen, Denis Choquette, Isabelle Fortin, Alice V. Klinkhoff 4, Susan M. Otawa 5 and Hayssam Khalil 6, St. Joseph s Hospital and McMaster University, Hamilton, ON, University of Montreal, Notredame Hospital, Montreal, QC, Centre de Rhumatologie de l Est du Québec, Rimouski, QC, 4 The Mary Pack Arthritis Ctr, Vancouver, BC, 5 Janssen Canada Inc, Mississauga, ON, 6 Janssen Canada Inc, Toronto, ON 495. Comparison of Discontinuation Rates by Biologic Since 998 in US Patients with Rheumatoid Arthritis. Sofia Ramiro, Frederick Wolfe, David J. Harrison, George Joseph, David H. Collier, Désirée van der Heijde 4, Robert Landewé 5 and Kaleb Michaud 6, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, National Data Bank for Rheumatic Diseases, Wichita, KS, Amgen Inc., Thousand Oaks, CA, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, 6 National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE 496. Real-World Effectiveness of Infliximab in Improving Routine Assessment of Patient Index Data Outcomes: The Canadian Experience. Andrew Chow, Majed M. Khraishi, Jude F. Rodrigues, Susan M. Otawa 4 and Hayssam Khalil 5, Credit Valley Rheumatology, Mississauga, ON, Memorial University of Newfoundland, St Johns, NF, Windsor, ON, 4 Janssen Canada Inc, Mississauga, ON, 5 Janssen Canada Inc, Toronto, ON 497. Golimumab Drug Utilization Patterns in Canada Higher Retention Rate in Golimumab Treated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab. Hayssam Khalil and Amir Tahami, Janssen Canada Inc, Toronto, ON, Janssen Canada Inc., Toronto, ON 498. LIGHT (TNFSF4), Cathepsin-K, DKK- and Sclerostin in Rheumatoid Arthritis Patients: Effect of ANTI TNF-α Treatment in the WNT/β-Catenin Network Signaling. Alberto Cauli, Grazia Dessole, Giovanni Porru, Matteo Piga, Alessandra Vacca, Valentina Ibba, Pietro Garau and Alessandro Mathieu, University of Cagliari, Cagliari, Italy 499. What Is the Right Dose to Start Methotrexate (7.5 or 5mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial). Varun Dhir, Mandeep Singla, Palvi Goyal, Vinay Sagar, Aman Sharma and Shefali K. Sharma, Post Graduate Institute of Medical Education and Research, Chandigarh, India 500. Comparison of Tolerability between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis. Yoshihiro Hishitani, Yoshihito Shima, Toru Hirano, Keisuke Hagihara, Kosuke Ebina, Yasuo Kunugiza, Kenrin Shi, Masashi Narazaki, Atsushi Ogata, Tetsuya Tomita, Toshio Tanaka and Atsushi Kumanogoh, Osaka University Graduate School of Medicine, Suita, Japan 50. TNF Inhibitor Treatment in Rheumatoid Arthritis (RA) Patients with Moderate versus High Disease Activity At Baseline: A Comparison of Utility Gains, Response and Remission Rates. Elisabeth Lie, Siri Lillegraven, Karen M. Fagerli, Till Uhlig and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway 50. Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement. Elena Becerra, Geraldine Cambridge and Maria J. Leandro, University College London, London, United Kingdom 50. Safety Update On Certolizumab Pegol in Patients with Active Rheumatoid Arthritis with Long Term Exposure. Xavier Mariette, RF. van Vollenhoven, Vivian P. Bykerk, Marc de Longueville 4, Catherine Arendt 4, Kristel Luijtens 5 and John J. Cush 6, Université Paris-Sud, Le Kremlin Bicetre, France, The Karolinska Institute, Stockholm, Sweden, Hospital for Special Surgery, New York, NY, 4 UCB Pharma, Brussels, Belgium, 5 UCB, Brussels, Belgium, 6 Baylor Research Institute, Dallas, TX Sjögren s Syndrome - Pathogenesis 504. Pathogenic Autoantibodies to the Anti-Muscarinic Type Receptor Act by Competitive Inhibition of Acetylcholine- Mediated Receptor Signalling in Sjögren s Syndrome. Michael W. Jackson, Isabell Bastian and Thomas P. Gordon, Flinders University, Adelaide, Australia, Flinders University and Flinders Medical Centre, Adelaide, Australia, Flinders Medical Centre, Bedford Park, Australia 505. Characterization of an in Vitro Model of Human Salivary Gland for Studying Sjögren Syndrome (SS). M. Jesus Dominguez-Luis, M.Teresa Arce-Franco, Estefania Armas-Gonzalez, Ada Herrera-Garcia, Teresa Giraldez, Pablo Miranda, Diego Alvarez de la Rosa, Jose Garcia- Verdugo 4, Carlos Martinez-Jimeno 5 and Federico Diaz- Gonzalez, Rheumatology Service. Hospital Universitario de Canarias., La Laguna, Spain, Unidad de Investigación of Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain, Department of Physiology. Universidad de La Laguna,, La Laguna, Spain, 4 Cellular Morphology Laboratory, Centro de Investigación Príncipe Felipe., Valencia, Spain, 5 Maxilofacial Department, Hospital Universitario de Canarias,, La Laguna, Spain 506. Ebv-Mir-Bart Affects the Expression of AQP5 in Human Salivary Gland Cell Lines Contributing to the Pathogenesis of Sjögren s Syndrome. Alessia Gallo, Mayank Tandon, Shyh-Ing Jang, Hwei Ling Ong, Indu Ambudkar, Gabor G. Illei and Ilias Alevizos, NIDCR, Bethesda, MD, NIDCR/ NIH, Bethesda, MD, NIDCR/ NIH #0 N0, Bethesda, MD 507. Expression of Micrornas (mirnas) Predicted to Target Ro/ SSA and La/SSB Autoantigens in Sjögren s Syndrome (SS). Vasiliki C. Gourzi, Efstathia K. Kapsogeorgou, Nikolaos C. Kyriakidis, Menelaos N. Manoussakis, Haralampos M. Moutsopoulos and Athanasios G. Tzioufas, School of Medicine, National University of Athens, Greece, Athens, 0 Program Book 79

182 ACR POSTER SESSION A 80 Greece, School of Medicine, University of Athens, Athens, Greece, School of Medicine, National University of Athens, Athens, Greece 508. TLR-Signaling Induces the Expression of Ro/SSA and La/ SSB Autoantigens in Salivary Gland Epithelial Cells (SGECs). Nikolaos C. Kyriakidis, Efstathia K. Kapsogeorgou, Vasiliki C. Gourzi, Haralampos M. Moutsopoulos and Athanasios G. Tzioufas, School of Medicine, National University of Athens, Greece, Athens, Greece, School of Medicine, University of Athens, Athens, Greece, School of Medicine, National University of Athens, Athens, Greece 509. IL- 7 and Toll-Like Receptor 7 Synergistically Increase Th/ Th7/Th Cytokine Secretion and Activity of B Cells. A. Bikker, A.A. Kruize, F. Redegeld, W. de Jager, F.P.J.G. Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands, Dept Pharmacology UU, Utrecht, Netherlands, Dept Immunology, UMC Utrecht, Utrecht, Netherlands 50. IL- 7 and IL-7 Receptor Blockade to Selectively Inhibit TLR7- Induced B Cell Activation in Primary Sjögren s Syndrome. A. Bikker, C.R. Willis, A.A. Kruize, J.W.J. Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands, Amgen Inc., Seattle, WA 5. A New Pathogenic Role of Salivary Gland Epithelial Cells in the Costimulation of T Lymphocytes in Primary Sjögren s Syndrome: 0X40 Ligand Expression, T-Cell Induction of OX40 and Promotion of T-Cell Survival, Proliferation and Activation. Yazhuo Gong, Ghada Alsaleh, Jean Sibilia and Jacques-Eric Gottenberg, EA448 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France 5. Memory B Cell Phenotypic and Gene Expression Profiling in Primary Sjogren s Syndrome: Implications for Disease Diagnosis. Mustimbo E. P. Roberts, Craig Maguire, Alex Rosenberg, andreea Coca, Jennifer H. Anolik and Inaki Sanz 4, University of Rochester School of Medicine and Dentistry, Rochester, NY, University of Rochester, Rochester, NY, Univ of Rochester, Rochester, NY, 4 Rochester, Rochester, NY 5. Regulatory B Cells in Primary Sjögren s Syndrome. Gabriela Hernandez-Molina, Janette Furusawa-Carballeda, Guadalupe Lima, Yahaira Rivera and Luis Llorente, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 54. Frequencies and Numbers of Circulating IL-0 Producing Regulatory B Cells Are Not Disturbed in Pss-Patients but Correlate Negatively with the EULAR Sjögren Syndrome Disease Activity Score (ESSDAI). Wayel H. Abdulahad, Gwenny Verstappen, Arjan Vissink, Minke G. Huitema, Petra M. Meiners, Hendrika Bootsma and Frans Kroese, University Medical Center Groningen, Groningen, Netherlands 55. Stages of Sjögren s Syndrome Defined by Immune Mediators. Lakshmanan Suresh, Julian Ambrus Jr. and Long Shen, IMMCO Diagnostics Inc., Amherst, NY, State 0 Program Book University of New York at Buffalo, Buffalo, NY, SUNY at Buffalo, Buffalo, NY 56. Characterization of Dominant B- and Plasma Cell Clones in Patients with Primary Sjögren s Syndrome and Patients with Sicca Syndrome. Marieke E. Doorenspleet, Erlin Haecke, Paul L. Klarenbeek, Annie Visser, Rebecca E. Esveldt, Fred Spijkervet, Paul-Peter Tak, Hendrika Bootsma, Niek de Vries and Frans Kroese, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, University Medical Center Groningen, Groningen, Netherlands 57. Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren s Syndrome Patients and Mice. Hongen Yin, Javier Cabrera-Perez, Zhennan Lai, Drew Michael, Melodie Weller, Bill Swaim, Noreen Rana, Xibao Liu, Ilias Alevizos, Indu Ambudkar and John A. Chiorini, NIH/NIDCR, Bethesda, MD, NIDCR/ NIH #0 N0, Bethesda, MD, NIDCR, Bethesda, MD 58. Spontaneous Sialadenitis like Sjögren s Syndrome in Orphan Nuclear Receptor γt (RORγt) Transgenic Mice. Mana Iizuka, Hiroto Tsuboi, Hiromitsu Asashima, Yuya Kondo, Satoru Takahashi, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan 59. Sex-Specific Regulatory T Cell Dysfunction in a Mouse Model of Sjögren Syndrome. Scott M. Lieberman, Portia A. Kreiger and Gary A. Koretzky, The Children s Hospital of Philadelphia, Philadelphia, PA, Nemours/A.I. DuPont Hospital for Children, Wilmington, DE, University Pennsylvania, Philadelphia, PA 50. Genetic Associations to Germinal Centre Formation in Primary Sjögren s Syndrome. Tove Ragna Reksten, Malin V. Jonsson, Roland Jonsson, Gunnel Nordmark and The Swedish-Norwegian Sjögren s syndrome Network 4, Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway, University of Bergen, Bergen, Norway, Rheumatology, Uppsala, Sweden, 4 Bergen 5. Differences in Genome-Wide DNA Methylation Profiles across Multiple Cell and Tissue Types in Sjögren s Syndrome (SS). Lindsey A. Criswell, Diana Quach, Hong L. Quach, Emon Elboudwarej and Lisa F. Barcellos, University of California San Francisco, San Francisco, CA, University of California, Berkeley, Berkeley, CA 5. Genetic Variation in the NCR Locus Is Associated with Anti-SSA SSB Positive Primary Sjögren s Syndrome in Scandinavian Samples. Gunnel Nordmark, Maija-Leena Eloranta, Per Eriksson, Elke Theander, Helena Forsbladd Elia 4, Roald Omdal 5, Marie Wahren-Herlenius 6, Roland Jonsson 7 and Lars Rönnblom, Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala,

183 ACR POSTER SESSION A Sweden, Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, Skane University Hospital, Lund University, Malmö, Sweden, 4 Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 5 Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 6 Karolinska Institutet, Stockholm, Sweden, 7 Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway 5. Use of Global Gene Expression Profiling to Characterize Sjögren s Patients Who Underexpress Interferon- Inducible Genes. John A. Ice, He Li, Jennifer A. Kelly, Indra Adrianto, Stuart B. Glenn, Kimberly S. Hefner, Evan G. Vista 4, Donald U. Stone, Raj Gopalakrishnan 5, Glen D. Houston, David M. Lewis, Michael Rohrer 5, Pamela Hughes 5, John B. Harley 6, Courtney G. Montgomery, James Chodosh 7, James A. Lessard 8, Juan-Manuel Anaya 9, Barbara M. Segal 0, Nelson L. Rhodus 5, Lida Radfar, Mark B. Frank, R. Hal Scofield, Christopher J. Lessard and Kathy Moser Sivils, Oklahoma Medical Research Foundation, Oklahoma City, OK, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Hefner Eye Care and Optical Center, Oklahoma City, OK, 4 University of Santo Tomas, Taguig City, Philippines, 5 University of Minnesota, Minneapolis, MN, 6 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7 Harvard Clinical and Translational Science Center, Boston, MA, 8 Valley Bone & Joint Clinic, Grand Forks, ND, 9 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 0 Hennepin County Medical Center, Minneapolis, MN, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK 54. RNA-Sequencing Identifies Novel Differentially Expressed Coding and Non-Coding Transcripts in Sjögren s Syndrome. Indra Adrianto, Graham B. Wiley, John A. Ice, He Li, Jennifer A. Kelly, Astrid Rasmussen, Stuart B. Glenn, Kimberly Hefner, Donald U. Stone, Raj Gopalakrishnan 4, Glen D. Houston, David M. Lewis, Michael Rohrer 4, James A. Lessard 5, Juan-Manuel Anaya 6, Barbara M. Segal 7, Nelson L. Rhodus 4, Lida Radfar, John B. Harley 8, Judith A. James 9, Courtney G. Montgomery, R. Hal Scofield, Patrick M. Gaffney 0, Kathy Moser Sivils and Christopher J. Lessard, Oklahoma Medical Research Foundation, Oklahoma City, OK, Hefner Eye Care and Optical Center, Oklahoma City, OK, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4 University of Minnesota, Minneapolis, MN, 5 Valley Bone & Joint Clinic, Grand Forks, ND, 6 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 7 Hennepin County Medical Center, Minneapolis, MN, 8 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 9 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 0 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK 55. Gene Expression Profiling in a Large Cohort of Europeans with Sjögren s Syndrome Reveals Candidate Genes in Viral, Immune, and Interferon-Related Pathways. He Li, John A. Ice, Jennifer A. Kelly, Indra Adrianto, Stuart B. Glenn, Kimberly S. Hefner, Evan G. Vista 4, Donald U. Stone 5, Raj Gopalakrishnan 6, Glen D. Houston 5, David M. Lewis 5, Michael Rohrer 6, Pamela Hughes 6, John B. Harley 7, Courtney G. Montgomery, James Chodosh 5, James A. Lessard 8, Juan-Manuel Anaya 9, Barbara M. Segal 0, Nelson L. Rhodus 6, Lida Radfar 5, Mark B. Frank, R. Hal Scofield, Christopher J. Lessard and Kathy Moser Sivils, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma City, OK, Hefner Eye Care and Optical Center, Oklahoma City, OK, 4 University of Santo Tomas, Taguig City, Philippines, 5 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 6 University of Minnesota, Minneapolis, MN, 7 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 8 Valley Bone & Joint Clinic, Grand Forks, ND, 9 Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 0 Hennepin County Medical Center, Minneapolis, MN 56. Use of a Novel Probe to Demonstrate Granzyme B Activity in Sjögren s Syndrome Salivary Glands. Kimberly Doering Maurer, Laura Gutierrez-Alamillo, Efstathia K. Kapsogeorgou, Athanasios G. Tzioufas, Livia Casciola- Rosen 4 and Antony Rosen 5, Johns Hopkins University School of Medicine, Baltimore, MD, School of Medicine, National University of Athens, Greece, Athens, Greece, School of Medicine, National University of Athens, Athens, Greece, 4 Johns Hopkins University, Baltimore, MD, 5 The Johns Hopkins University, Baltimore, MD 57. Multiplexed Nanostring Screening for Salivary Gland Viral Elements in Sjögren s Syndrome. Kristin Haffizulla, Glen Barber, Juan Chen and Eric L. Greidinger, University of Miami Miller School of Medicine, Miami, FL, The First Afflicted Hospital of Xiamen University, China, Miami, FL, University of Miami, Miami, FL 58. Mxa As a Biomarker for Systemic Interferon Type I Activation in Primary Sjögren s Syndrome. Naomi I. Maria, Zana Brkic, Matti Waris, Cornelia G. van Helden- Meeuwsen, Kim Heezen, Joop P. van de Merwe, Paul L. van Daele, Virgil A. Dalm, Hemmo A. Drexhage and Marjan A. Versnel, Erasmus Medical Center, Rotterdam, Netherlands, University of Turku, Turku, Finland 59. The Axis PX7 Receptor-Inflammasome: A Role in Modulating Inflammatory Response in Primary Sjögren s Syndrome? Chiara Baldini, Chiara Rossi, Eleonora Santini, Francesco Ferro, Alessia Gallo, Daniela Martini, Francesca Sernissi, Valentina Donati, Camillo Giacomelli, 0 Program Book 8

184 ACR POSTER SESSION A Nicoletta Luciano, Anna Solini and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy, NIDCR, Bethesda, MD 50. S00A8/A9 Is Upregulated and Triggers the Secretion of Pro-Inflammatory Cytokines in Primary Sjögren s Syndrome. Laura Weichselbaum and Muhammad S. Soyfoo, Department of rheumatology,hôpital Erasme, Brussels, Belgium, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment 5. Developmen and Validation of a New Instrument to Asess Health Related Quality of Life in Psoriasis Arthritis: The Vitacora Questionnaire. Juan Carlos Torre-Alonso, J. Santos-Rey, JM Ruiz-Martin, P. Valdazo-De Diego 4, Mireia Moreno 5 and Juan-Antonio Fernández 6, Hospital Monte Naranco, Oviedo, Spain, Rheumatology, Toledo, Spain, Rheumatology, Viladecans, Spain, 4 Rheumatology, Zamora, Spain, 5 Corporació Sanitària Parc Taulí, Sabadell, Spain, 6 MP, Oviedo, Spain 5. The Prevalance of Autoimmune Thyroid Disfunction in Ankylosing Spondylitis. Hakan Emmungil, Mehmet Erdogan, Melike Kalfa, Gonca Karabulut, Hayriye Kocanaogullari, Vedat Inal, Yasemin Kabasakal, Fahrettin Oksel, Kenan Aksu 4 and Gokhan Keser, Dept. of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey, Dept. of Internal Medicine, Division of Endocrinolgy, Ege University, Izmir, Turkey, Ege University, Izmir, Turkey, 4 Dept. Of Internal Medicine, Division of Rheumatology, Ege University, Izmir, Turkey 5. NT-Probnp and Inflammation in Active Ankylosing Spondylitis Receiving TNF Blockers: Is There a Link? Julio C. B. Moraes, Ana C. M. Ribeiro, Carla G.S. Saad, Alessandro C. Lianza 4, Nadia E. Aikawa, Clovis Artur Silva 5 and Eloisa Bonfa, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, University of Sao Paulo, São Paulo, Brazil, 4 Radiology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 54. WITHDRAWN 55. Reduced Joint Counts Misclassify Psoriatic Arthritis Patients with Oligoarthritis and Miss Significant Active Disease. Laura C. Coates, Oliver M. FitzGerald, Dafna D. Gladman Gladman, Neil J. McHugh 4, Philip Mease 5, Vibeke Strand 6, Philip S. Helliwell 7 and GRAPPA Composite Exercise (GRACE) collaboration 8, Division of Rheumatic and Musculoskeletal Disease, Leeds, United Kingdom, St. Vincent s Univ Hospital, Dublin, Ireland, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 5 Swedish Medical Center, Seattle, WA, 6 Stanford University, Portola Valley, CA, 7 NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 8 Leeds 56. Psoriasis and Psoriatic Arthritis in a Diverse Ethnic Cohort. Gail S. Kerr, Seema Qaiyumi, John S. Richards, Chesahna Kindred, Sean A. Whelton 4 and Florina M. Constantinescu 5, Washington DC VAMC, Georgetown and Howard University, Washington, DC, Washington DC VA and Georgetown University, Washington, DC, Howard University Hospital, Washington, DC, 4 Georgetown University, Washington, DC, 5 Washington Hospital Center, Washington, DC 57. The Association of alpha7 Nicotinic Acetylcholine Receptor Polymorphisms with Psoriatic Arthritis and Its Interaction with Smoking. Lihi Eder, Vinod Chandran, Fawnda Pellett, Remy Pollock, Fatima Abji, Adele Carty, Sutharshini Shanmugarajah, Cheryl Rosen and D. D. Gladman, Carmel Medical Center, Haifa, Israel, Toronto Western Hospital and University of Toronto, Toronto, ON 58. Association between Biomarkers (Metalloproteinase-, Dikkopf- and Sclerostin) with Disease Activity and Prediction of Anti-TNFá Therapy Response in Patients with Ankylosing Spondylitis. Victoria Navarro-Compán, Rafael Ariza, Rufino Mondéjar-García, Virginia Moreira-Navarrete, Enrique Melguizo-Madrid, Blanca Hernández-Cruz, Concepción González-Rodríguez and Federico Navarro- Sarabia, University Hospital Virgen Macarena, Sevilla, Spain 59. Efficacy and Safety of Adalimumab for the Treatment of Peripheral Arthritis in Spondyloarthritis Patients without Ankylosing Spondylitis or Psoriatic Arthritis. Jacqueline E. Paramarta, Leen De Rycke, Tanja F. Heijda, Carmen A. Ambarus, Koen Vos, Huib J. Dinant, Paul P. Tak and Dominique L. Baeten, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 540. The Predictors of Reduced Work Productivity in Patients with Psoriatic Arthritis. Anjali Papneja, Matthew Kennedy, Arane Thavaneswaran, Daniel Pereira, Vinod Chandran and Dafna D. Gladman, University of Toronto, Toronto, ON, University of Toronto, TOronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON 54. Prevalence of Sacroiliitis in the General Population: Comparative Analysis with Cutaneous Psoriasis and Psoriatic Arthritis. Jose Luis Fernandez-Sueiro, Carlos Fernandez-Lopez, S. Pertega-Diaz, JA Pinto, E. Gonzalez, Francisco J. de Toro-Santos and Francisco J. Blanco, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain 8 0 Program Book

185 ACR POSTER SESSION A 54. Validation of a Reference Imaging Module for Calibration of Readers Scoring with the Modified Stoke Ankylosing Spondylitis Spine Score. Walter P. Maksymowych, Thomas J. Learch, Robert GW Lambert, Michael M. Ward, Nigil Haroon 4, David Salonen 5, Robert D. Inman 6 and Michael H. Weisman 7, University of Alberta, Edmonton, AB, Cedars-Sinai, Los Angeles, CA, NIAMS/NIH, Bethesda, MD, 4 University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, 5 University Health Network, Toronto, ON, 6 Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 7 Cedars-Sinai Medical Center, Los Angeles, CA 54. Wnt Pathway Inhibitors in Patients with Psoriatic and Rheumatoid Arthritis Treated with Anti-TNF Therapy. Agnes Szentpetery, Harjit P. Bhattoa, Peter Antal-Szalmas, Zoltan Szekanecz and Oliver M. FitzGerald 4, Department of Rheumatology, St. Vincent s University Hospital, Dublin, Ireland, Department of Laboratory Medicine, University of Debrecen, Medical and Health Science Center, Debrecen, Hungary, Department of Rheumatology, University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary, 4 Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 544. Anterior Chest Wall Pain in Recent Inflammatory Back Pain. Data From the DESIR Cohort. Daniel Wendling, Clément Prati, Christophe Demattei, Damien Loeuille 4, P. Richette 5 and Maxime Dougados 6, Minjoz University Hospital, Besancon, France, CHU J Minjoz, Besancon, France, CHU, Nimes, France, 4 CHU Brabois, Vandoeuvre les Nancy, France, 5 Hôpital Lariboisière, Paris, France, 6 Paris-Descartes University, APHP, Cochin Hospital, Paris, France 545. Correlates of Inflammatory Back Pain in a Nationally Representative Sample of the US Population. Shervin Assassi, Michael H. Weisman, Zhongxue Chen, Mohammad Rahbar, Daniel O. Clegg, Robert A. Colbert 4, Atul A. Deodhar 5, Laurie M. Savage 6, Tiffany Graham, James P. Witter 7 and John D. Reveille, Univ of Texas Health Science Center at Houston, Houston, TX, Cedars-Sinai Medical Center, Los Angeles, CA, George E. Wahlen VA Medical Center, Salt Lake City, UT, 4 NIAMS NIH, Bethesda, MD, 5 Oregon Health & Science University, Portland, OR, 6 Spondylitis Association of America, Van Nuys, CA, 7 NIH, Bethesda, MD 546. The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti- TNF in Spondyloarthritis Patients. Chamaida Plasencia, Dora Pascual-Salcedo, Sara Garcia-Carazo, Gema Bonilla, Leticia Lojo, Laura Nuño, Alejandro Villalba, Diana Peiteado, Concepcion Castillo-Gallego Jr. 4, Florencia Arribas, Daniel Nagore 5, E. Martin-Mola 4 and Alejandro Balsa 6, Rheumatology Unit, Spain, Spain, Hospital La Paz. IdiPaz, Madrid, Spain, Hospital La Paz-IdiPaz, Madrid, Spain, 4 Hospital Universitario La Paz, Madrid, Spain, 5 Proteomika S.L., 6 Hospital La Paz, Madrid, Spain 547. Comparison and Validation of Screening Questionnaires for Psoriatic Arthritis in Patients with Psoriasis. Devy Zisman, Lihi Eder, Bosmat Zamir, Arie Laor and Joy Feld, Carmel Medical Center, Haifa, Israel, Clalit Health Services, Haifa and Western Galilee District, Haifa, Israel 548. Assessment of the T-Weighted Sequence Is Essential in Defining a Positive MRI Scan of the Sacroiliac Joints in Spondyloarthritis. Ulrich Weber, Veronika Zubler, Susanne Juhl Pedersen, Kaspar Rufibach, Robert GW Lambert 4, Stanley Chan 4, Mikkel Ostergaard 5 and Walter P. Maksymowych 4, Balgrist University Hospital, Zurich, Switzerland, Glostrup Hospital, Copenhagen, Denmark, University of Zurich, Zurich, Switzerland, 4 University of Alberta, Edmonton, AB, 5 Copenhagen University Hospital at Glostrup, Glostrup, Denmark 549. A Randomized, Open-Label Study of Maintenance of Partial Remission with Naproxen Vs No Treatment: Results of the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial, Part II. Joachim Sieper, Jan Lenaerts, Jürgen Wollenhaupt, Vadim Mazurov 4, L. Myasoutova 5, Sung-Hwan Park 6, Yeong W. Song 7, Ruji Yao 8, Denesh Chitkara 8 and Nathan Vastesaeger 9, Charité, University Medicine Berlin, Berlin, Germany, Reuma-instituut, Hasselt, Belgium, Schön-Klinik, Hamburg, Germany, 4 St. Petersburg Medical Academy, St. Petersburg, Russia, 5 Kazan State Medical University, Kazan, Russia, 6 Catholic University of Korea, Seoul, South Korea, 7 Seoul National University, Seoul, South Korea, 8 Merck Sharp and Dohme, Kenilworth, NJ, 9 Merck Sharp and Dohme, Brussels, Belgium 550. Differences in the Prevalence of Inflammatory Articular Disease in Psoriatic Patients, Applying Clinical, Ultrasound and/or Radiological Data. Implications in the Classification of Psoriatic Arthritis according to Caspar Criteria. Jose Luis Fernandez-Sueiro, S. Pertega-Diaz, JA Pinto and E. Gonzalez, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain 55. Prevalence of Enthesitis in Psoriatic Patients: Agreement between Clinical and Power Doppler Ultrasonography Exploration and Its Implications for the Classification of Psoriatic Arthritis. Jose Luis Fernandez-Sueiro, JA Pinto, S. Pertega-Diaz and Carlos Fernandez-Lopez, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, INIBIC- Complejo Hospitalario Universitario La Coruña(CHUAC). Rheumatology Division., La Coruña, Spain 55. Simple Questions in the Dermatology Office May Reasonably Exclude, but Do Not Reliably Identify Psoriatic Arthritis Patients: Results From the Center of Excellence for Psoriasis and Psoriatic Arthritis. Neha Garg, Atul A. Deodhar, Benjamin Ehst, Andrew Blauvelt, Jennifer Ku and Brian Truong, Oregon Health and Sciences University, Portland, OR, Oregon Health & Science University, Portland, OR 0 Program Book 8

186 ACR POSTER SESSION A Identification of Axial Spondyloarthritis Among Patients with Chronic Back Pain in Primary Care How Does Determination of HLA B7 Influence the Performance of Clinical Assessments of Inflammatory Back Pain? Annalina Braun, Holger Gnann, Ertan Saracbasi, Joachim Grifka, Uta Kiltz, J. Schnittker 4, Katrin Letschert 5 and Juergen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbh, München, Germany, University of Regensburg, Bad Abbach, Germany, 4 Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, Bielefeld, Germany, 5 Abbott Inc., Wiesbaden, Germany 554. A Reduction in Ultrasound Synovitis Score Discriminates Between Clinical Responders and Non-Responders and Is Predictive for a Favourable Clinical Outcome in Early Psoriartic Arthritis. Axel P. Nigg, Anna M. Malchus, Joerg C. Prinz, Mathias Gruenke and Hendrik Schulze-Koops, Medizinische Klinik IV, University of Munich, Munich, Germany, Department of Dermatology, University of Munich, Munich, Germany 555. Performances of the ASAS Axial Spondyloarthritis Criteria for Diagnosis and Classification Purposes in Patients Visiting a Rheumatologist Because of Chronic Back Pain: The Declic Study. Anna Moltó, Simon Paternotte, Denis Comet, Cécile Hacquard-Bouder, Martin Rudwaleit 4, Pascal Claudepierre 5, Désirée van der Heijde 6 and Maxime Dougados, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, Axonal, Nanterre, France, Abbott France, Rungis, France, 4 Endokrinologikum Berlin, Berlin, Germany, 5 Université Paris Est, Laboratoire d Investigation Clinique (LIC) EA 49, AP-HP, Hôpital Henri-Mondor, Rheumatology department, Creteil, France, 6 Leiden University Medical Center, Leiden, Netherlands 556. Eos Imaging Could Replace Conventional Computed Radiography for Ankylosis Assessment in Axial Spondyloarthritis. Anna Moltó, Veronique Freire, Antoine Feydy, Simon Paternotte, Walter P. Maksymowych, Mathilde Benhamou 4, François Rannou 4, Maxime Dougados and Laure Gossec, Rheumatology B Department, Paris- Descartes University, Cochin Hospital, Paris, France, Radiology B Department, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, University of Alberta, Edmonton, AB, 4 Physical Medicine and Rehabilitation Service, Paris-Descartes University, Cochin Hospital, Paris, France 557. Effect of Certolizumab Pegol On the Multiple Facets of Psoriatic Arthritis As Reported by Patients: 4 Week Patient Reported Outcome Results of a Phase Double Blind Randomized Placebo-Controlled Study. Dafna D. Gladman, Roy M. Fleischmann, Geoffroy Coteur, Franz Woltering 4 and Philip Mease 5, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, UCB Pharma, Brussels, Belgium, 4 UCB Pharma, Monheim, Germany, 5 Seattle Rheumatology Associates, Seattle, WA 0 Program Book 558. Rapid Improvements in Patient Reported Outcomes with Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 4 Week Results of a Phase Double Blind Randomized Placebo- Controlled Study. Joachim Sieper, Alan J. Kivitz, A.M. Van Tubergen, Atul A. Deodhar 4, Geoffroy Coteur 5, Franz Woltering 6 and Robert B. M. Landewé 7, Charité University Medicine, Berlin, Germany, Altoona Center for Clinical Research, Duncansville, PA, Maastricht University Medical Center, Maastricht, Netherlands, 4 Oregon Health & Science University, Portland, OR, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, Monheim, Germany, 7 Academic Medical Center/University of Amsterdam & Atrium Medical Center, Heerlen, Netherlands 559. Utility of Dual-Energy X-Ray absorptiometry Scanning and Risk of Osteoporosis in Ankylosing Spondylitis; A Prospective Study. Marina N. Magrey and Muhammad Asim Khan, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, CASE at MetroHealth Med Center, Cleveland, OH 560. Proteomic Profiling of Synovial Fluid Reveals Candidate Psoriatic Arthritis Biomarkers. Daniela Cretu, Ihor Batruch, Punit Saraon, Dafna Gladman, Fawnda Pellett, Eleftherios Diamandis and Vinod Chandran 4, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Mount Sinai Hospital, Toronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 Toronto Western Hospital, University of Toronto, Toronto, ON 56. Performance of Magnetic Resonance Imaging in Detection of Chronic Structural Changes in Sacroiliac Joints As Compared to Conventional X-Rays in Axial Spondyloarthritis. Denis Poddubnyy, Inna Gaydukova, Hildrun Haibel, In-Ho Song and Joachim Sieper, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, Saratov State Medical University, Saratov, Russia 56. Prevalence and Predictors of Significant Liver Fibrosis in Methotrexate Treated Rheumatoid and Psoriatic Arthritis Patients Using Transient Elastography (fibroscan). WC Chan, ML Yip and CK Loo, Kwong Wah Hospital, Kowloon, Hong Kong 56. In Ankylosing Spondylitis, a Decrease in MRI Spinal Inflammation Predicts Improvement in Spinal Mobility Independently of Patient Reported Symptomatic Improvement. Pedro Machado, Robert Landewé, Jürgen Braun, Xenofon Baraliakos, Kay-Geert A. Hermann 4, Benjamin Hsu 5, Daniel Baker 5 and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany, 4 Charité Medical School, Berlin, Germany, 5 Centocor Inc., Malvern/ Philadelphia, PA

187 ACR POSTER SESSION A 564. Almost 40% of Patients with Chronic Back Pain Starting Before the Age of 45 Fulfill the ASAS Axial Spondyloarthritis Criteria. Manouk de Hooge, Rosaline van den Berg, Floris van Gaalen, Monique Reijnierse, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands 565. Fetuin A: A New Biomarker Related with Syndesmophytes in Patients with Ankylosing Spondylitis. Tugba Tuylu, Dilek Solmaz, Ismail Sari, Didem L. Kozaci, Servet Akar, Necati Gunay and Nurullah Akkoc 4, Dokuz Eylul University School of Medicine, Izmir, Turkey, Adnan Menderes University School of Medicine, Aydin, Turkey, Dokuz Eylul University School of Medicine Department of Internal Medicine Division of Rheumatology, Izmir, Turkey, 4 Dokuz Eylul University School Of Medicine, Department Of Internal Medicine, Division Of Rheumatology, Izmir, Turkey 566. Effect of TNF Antagonists On Radiographic Progression in Psoriatic Arthritis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Radjiv Goulabchand, Gael Mouterde, Cédric Lukas, Thomas Barnetche, Jacques Morel and Bernard Combe, Montpellier University, Lapeyronie Hospital, Montpellier, France, CHU Bordeaux Pellegrin, Bordeaux, France 567. Prevalence of Psoriasis and Psoriatic Arthritis in a Northern Population of Spain. Jose Luis Fernandez-Sueiro, JA Pinto, S. Pertega-Diaz, Manuel Acasuso and Ignacio Herrero de Padura, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, Centro de Salud, San José, La Coruña, Spain Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis. Anthony Marotta, A. W van Kuijk, Walter P. Maksymowych and Paul Peter Tak 4, Augurex Life Sciences Corp, North Vancouver, BC, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, University of Alberta, Edmonton, AB, 4 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 569. Ustekinumab Improves Arthritis-Related and Skin-Related Quality of Life in Patients with Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized and Double Blinded Phase III Psummit I Trial. Arthur Kavanaugh, Iain B. McInnes, Alice B. Gottlieb, Lluis Puig 4, Proton Rahman 5, Christopher T. Ritchlin 6, Shu Li 7, Yuhua Wang 7, Chenglong Han 8, Alan Mendelsohn 7 and Mittie K. Doyle 7, UCSD School of Medicine, La Jolla, CA, University of Glasgow, Glasgow, United Kingdom, Tufts Medical Center, Boston, MA, 4 Universitat Autònoma de Barcelona, 5 Memorial University, St. Johns, NF, 6 University of Rochester Medical Center, Rochester, NY, 7 Janssen Research & Development, LLC, Spring House, PA, 8 Johnson & Johnson Pharmaceutical Services, LLC., Malvern, PA 570. Randomized Controlled Trial of Adalimumab in Patients with Peripheral Spondyloarthritis. Philip Mease, Joachim Sieper, Filip Van den Bosch, Proton Rahman 4, Katie Obermeyer 5 and Aileen L. Pangan 5, Swedish Medical Center, Seattle, WA, Charité Universitätesmedizin Berlin, Berlin, Germany, Ghent University Hospital, Ghent, Belgium, 4 Memorial University, St. Johns, NF, 5 Abbott Laboratories, Abbott Park, IL 57. Description of Distribution of Active Inflammatory Lesions On Magnetic Resonance Imaging of the Sacroiliac Joints and the Spine in Patients with Early Axial Spondyloarthritis Analysis of the Esther Trial Baseline Data. In-Ho Song, Christian Althoff, Hildrun Haibel, Joachim Listing, Anja Weiß 4, Bruce Freundlich 5, Martin Rudwaleit 6 and Joachim Sieper 7, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, Charite Medical School, Berlin, Germany, German Rheumatism Research Center, Berlin, Germany, 4 German Rheumatism Research Centre, Berlin, Germany, 5 Villanova, PA, 6 Endokrinologikum Berlin, Berlin, Germany, 7 Charité Universitätesmedizin Berlin, Berlin, Germany 57. Radiographic Damage in Ankylosing Spondylitis Over Years of Follow-up: A Longitudinal Analysis. Sofia Ramiro, Carmen Stolwijk, A.M. Van Tubergen, Désirée van der Heijde and Robert Landewé 4, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Maastricht University Medical Center, Maastricht, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands 57. Differential Association between Human Leukocyte Antigen (HLA) Alleles and Joint Subluxation and Ankylosis in Patients with Psoriatic Arthritis. Vinod Chandran, Arane Thavaneswaran, Amir Haddad, Fawnda Pellett and Dafna Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 574. Long Term Inhibition of Interleukin (IL)-7A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis. Xenofon Baraliakos, Jurgen Braun, D. D. Laurent, D. Baeten, D. van der Heijde 4, J. Sieper 5, Paul Emery 6, Iain B. McInnes 7, J. van Laar 8, R. Landewe 9, Paul Wordsworth 0, Jurgen Wollenhaupt, Herbert Kellner, Andrew Wright, Francois Vandenhende, Kath Radford 4, Babul Borah 4 and Hueber Wolfgang 4, Rheumazentrum Ruhrgebiet, Herne, Germany, Novartis Pharma AG, Basel, Switzerland, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Charitè Berlin, Campus Benjamin Franklin, Berlin, Germany, 6 University of Leeds, Leeds, United Kingdom, 7 University of Glasgow, Glasgow, United Kingdom, 8 Newcastle University, Newcastle upon Tyne, United Kingdom, 9 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 0 Nuffield Orthopaedic Centre, Oxford, United Kingdom, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, Centre for Inflammatory Joint Diseases, Munich, Germany, Munich, Germany, Clinbay, Genappe, Belgium, Genappe, Belgium, 4 Novartis Institutes for BioMedical Research, Basel, Switzerland 0 Program Book 85

188 ACR POSTER SESSION A 575. Profiling of Response to Anti-TNFα Therapy by Serum Markers of Tissue Degradation End Products in Ankylosing Spondylitis Patients. Anne Sofie Siebuhr, Anne C. Bay- Jensen, Morten Asser Karsdal, Efstathios Vassiliadis, Stephanie Wichuk, Claus Christiansen 4 and Walter P. Maksymowych, Nordic Bioscience, Herlev, Denmark, Nordic Bioscience A/S, Herlev, Denmark, University of Alberta, Edmonton, AB, 4 CCBR, Ballerup, Denmark 576. Reference Intervals of Spinal Mobility Measures in Normal Individuals the Mobility Study. Sofia Ramiro, Carmen Stolwijk, A.M. Van Tubergen, Patrick Royston, Désirée van der Heijde 4 and Robert Landewé 5, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Maastricht University Medical Center, Maastricht, Netherlands, MRC Clinical Trials Unit, University College of London, London, United Kingdom, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands 577. MRI of the Spine for Detection of Bone Spurs and Ankylosis in Patients with Ankylosing Spondylitis: Does MRI Offer Any Advantages Over Radiography? Susanne Juhl Pedersen, Mikkel Østergaard, Robert GW Lambert and Walter P. Maksymowych, Glostrup Hospital, Copenhagen, Denmark, University of Alberta, Edmonton, AB 578. Assessment of the Link between Inflammation and Fat Metaplasia in Patients with Spondyloarthritis On Non- Biological Therapy: A Long Term Magnetic Resonance Imaging Study. Zheng Zhao, Susanne Juhl Pedersen, Robert GW Lambert, Stephanie Wichuk, Mikkel Ostergaard 4 and Walter P. Maksymowych, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, Glostrup Hospital, Copenhagen, Denmark, University of Alberta, Edmonton, AB, 4 Copenhagen University Hospital at Glostrup, Glostrup, Denmark 579. Prevalence of Psoriatic Arthritis in Psoriasis Patients According to Newer Classification Criteria. Hernan Maldonado-Ficco, Gustavo Citera, Ana Alba Porrini and Jose A. Maldonado-Cocco, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, Hospital Argerich, Buenos Aires, Argentina Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology 580. Changes in Sclerostin, Dickkopf- and Serum Markers of Inflammation, Cartilage and Bone Turnover in Patients with Axial Spondyloarthritis Treated with Adalimumab. Susanne Juhl Pedersen, Inge Juul Sørensen, Julia S. Johansen, Patrick Garnero 4, Anne Gitte Loft 5, Jens Skoedt 6, Gorm Thamsborg, Karsten Asmussen 7, Elka Kluger 8, Jesper Nørregaard 9, Torben Grube Christensen 0 and Mikkel Østergaard, Glostrup Hospital, Copenhagen, Denmark, Hvidovre Hospital, Copenhagen, Denmark, Herlev Hospital, Herlev, Denmark, 4 INSERM, Lyon, France, 5 Sygehus Lillebaelt, Vejle, Copenhagen, Denmark, 6 Gentofte Hospital, Copenhagen, Denmark, 7 Bispebjerg Hospital, Copenhagen, Denmark, 8 King Christian 0th Rheumatism Hospital at Gråsten, Denmark, 9 Hørsholm Hospital, Denmark, 0 Slagelse Hospital, Slagelse, Denmark 58. Examining a Role for Th7 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis. Fatima Abji, Remy Pollock, Fawnda Pellett, Vinod Chandran and Dafna D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 58. Proteomic Analysis of Synovial Tissue: A Unique Tool to Predict Response to Anti-TNF Alpha Therapy in Patients with Inflammatory Arthritis. Opeyemi S. Ademowo, Emily S. Collins, Cathy Rooney, A. W van Kuijk, Danielle M. Gerlag, Paul P. Tak, Oliver M. FitzGerald 4 and Stephen R. Pennington, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4 St. Vincent s University Hospital, Dublin, Ireland 58. Familial Aggregation and Heritability of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study. Chang-Fu Kuo, Matthew J. Grainge, Lai-Chu See, Kuang- Hui Yu, Shue-Fen Luo, Ana M. Valdes 4, I-Jun Chou, Weiya Zhang and Michael Doherty, University of Nottingham, Nottingham, United Kingdom, Chang Gung University, Taoyuan, Taiwan, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 St. Thomas Hospital, King s College London, London, United Kingdom 584. Association of Platelet Endothelial Cell Adhesion Molecule- and â Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis. Seung Cheol Shim, Donghyuk Sheen, Mi Kyoung Lim and Hyo Park, Eulji University Hospital, Daejeon, South Korea 585. Relative Overexpression of Membrane-Bound versus Soluble TNF in Human and Experimental Spondyloarthritis. Carmen Ambarus, Leonie M. van Duivenvoorde, Huriatul Masdar, Melissa N. van Tok, Paul P. Tak, Nataliya Yeremenko and Dominique L. Baeten, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 586. High Prevalence of Anti-CD-74 Antibodies with Specificity for the Class II-Associated Invariant Chain Peptide in Patients with Axial Spondyloarthritis but Not in Controls. Xenofon Baraliakos, Niklas T. Baerlecken, Frank Heldmann, Torsten Witte 4 and Jügen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, MD, Hannover, Germany, Rheumazentrum Ruhrgebiet, Herne, Ghana, 4 Hannover Medical School, Hanover, Germany 86 0 Program Book

189 ACR POSTER SESSION A 587. Brain MRI and Psychophysics Analysis Demonstrate Neuropathic Pain to Be a Component of Back Pain in Ankylosing Spondylitis. Q. Wu, R. D. Inman and Karen Davis, Toronto Western Research Institute, Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 588. Discovery of Two Public T Cell Receptor Clonotypes in B7+ Ankylosing Spondylitis by Deep Repertoire Sequence Analysis. Malek Faham, Victoria Carlton and R. D. Inman, Sequenta, Inc., South San Francisco, CA, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 589. NGF and Trka: A Novel Therapeutic Target in Chronic Inflammation. Siba P. Raychaudhuri, Ananya Datta Mitra and Smriti K. Raychaudhuri, VA Sacramento Medical Center/UC Davis School of Medicine, Mather, CA, VA Sacramento Medical Center, Mather, CA 590. The Association between KIRDL Alleles and Psoriatic Arthritis. Remy Pollock, Jeffrey Berinstein, Arane Thavaneswaran, Fawnda Pellett, Dafna Gladman and Vinod Chandran, Toronto Western Hospital and University of Toronto, Toronto, ON 59. Structural Progression of Ankylosing Spondylitis Associated with Elevation in Two NOVEL, Inflammatory Biomarkers; Matrix Metalloproteinase and Cathepsin-Derived. Anne C. Bay-Jensen, Morten Asser Karsdal, Stephanie Wichuk, Zheng Zhao, Robert GW Lambert, Per Qvist 4 and Walter P. Maksymowych, Nordic Bioscience A/S, Herlev, Denmark, University of Alberta, Edmonton, AB, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, 4 Nordic Bioscience, Herlev, Denmark 59. Two Novel Diagnostic Biomarkers of Cartilage Degradation and Connective Tissue Inflammation Are Predictive of Disease Progression in Ankylosing Spondylitis. Anne C. Bay- Jensen, Stephanie Wichuk, Inger Byrjalsen, Zheng Zhao 4, Robert GW Lambert, Morten Asser Karsdal and Walter P. Maksymowych, Nordic Bioscience A/S, Herlev, Denmark, University of Alberta, Edmonton, AB, Nordic Bioscience, Herlev, Denmark, 4 Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China 59. DKK Serum Level Is Increased in Recent Spondyloarthritis and Is Associated with Higher Prevalence of Syndesmophytes. Sclerostin Is Highly Correlated with Age. Data From the DESIR Cohort. Gaetane Nocturne, Stephan Pavy, Désirée van der Heijde, Philipe M. Goupille 4, Maxime Dougados 5, Christian Roux 6, Xavier Mariette 7 and Corinne Miceli-Richard, Université Paris Descartes, Paris, France, Université Paris Sud, Le Kremlin Bicêtre, France, Leiden University Medical Center, Leiden, Netherlands, 4 Hopital Trousseau, Tours, France, 5 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 6 Paris Descartes University, Paris, France, 7 Université Paris-Sud, Le Kremlin Bicetre, France 594. Evidence of Human Leucozyte Antigen-B7 in Healthy Individuals and Patients with Uveitis Is a Risk Factor for Alterations in Bone Metabolism. Sarah Schmidt, Stephanie Finzel, Jürgen Rech, Matthias Englbrecht, Silke Winkler, Isabel Schmidt, Roula Said-Nahal, Maxime A. Breban and Georg A. Schett, University of Erlangen-Nuremberg, Erlangen, Germany, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne- Billancourt, France, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany 595. A Genomewide Association Study of Anterior Uveiti. Dorith Claushuis, Adrian Cortes, Linda A. Bradbury, Tammy M. Martin, James T. Rosenbaum 4, John D. Reveille 5, Paul Wordsworth 6, Jennifer Pointon 6, Australo-Anglo-American Spondyloarthritis Consortium 7, David Evans 8, Paul Leo, Pamela Mukhopadhyay and Matthew A. Brown, The University of Queensland Diamantina Institute, Brisbane, Australia, The University of Queensland Diamantina Insititute, Brisbane, Australia, Oregon Health & Science Univ, Portland, OR, 4 Oregon Health & Science University, Portland, OR, 5 Univ of Texas Health Science Center at Houston, Houston, TX, 6 Nuffield Orthopaedic Centre, Oxford, United Kingdom, 7 Houston, TX, 8 Bristol University, Bristol, United Kingdom 596. Evolution of Atherosclerosis in Psoriatic Arthritis: Is the Former an Independent Inflammatory Process?Roberta Ramonda, Massimo Puato, Valentina Modesti, Mariagrazia Lorenzin, Paola Frallonardo, Augusta Ortolan, Carla Campana, Alessandro Lo Nigro and Leonardo Punzi, Unit of Rheumatology, University of Padova, Padova, Italy, Department of Internal Medicine, University of Padova, Padova, Italy, Rheumatology Unit - University of Padova, Padova, Italy 597. Investigating the Genetic Association between ERAP and Spondyloarthritis. Amir Kadi, Brigitte Izac, Roula Said- Nahal, Ariane Leboime, Kurt L. de Vlam, Dirk Elewaut 4, Gilles Chiocchia and Maxime A. Breban, Institut Cochin - INSERM U06 - CNRS (UMR 804), Paris, France, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France, University Hospitals Leuven, Leuven, Belgium, 4 Ghent University Hospital, Ghent, Belgium 598. The Non-Synonymous Polymorphism ILR Arg8Gln Is Associated with Ankylosis in Spondyloarthritis. Amir Kadi, Félicie Costantino, Brigitte Izac, Ariane Leboime, Roula Said-Nahal, Gilles Chiocchia and Maxime A. Breban, Institut Cochin - INSERM U06 - CNRS (UMR 804), Paris, France, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France 599. LIGHT (TNFSF4), Cathepsin K, DKK- and Sclerostin in Ankylosing Spondylitis: Osteoclast/OSTEOBLAST Imbalance Unrelated to Disease Activity and Effect of ANTI-TNFα Treatment On the WNT/β Catenin Pathway. Alberto Cauli, Grazia Dessole, Giovanni Porru, Matteo 0 Program Book 87

190 ACR POSTER SESSION A Piga, Alessandra Vacca, Valentina Ibba, Pietro Garau and Alessandro Mathieu, University of Cagliari, Cagliari, Italy 600. Regulatory T Cells in Spondyloarthritis (SpA) Animal Model and Modulatory Role of Inducible Costimulator (ICOS). Luiza Krause, Ingrid Fert, Karine Labroquère, Muriel andrieu, Gilles Chiocchia and Maxime A. Breban, Institut Cochin - INSERM U06 - CNRS (UMR 804)-Université Paris Descartes (UMR-S 06), Paris, France, Cochin Immunobiology Facility, Paris, France, Ambroise Paré Hospital (AP-HP), and Versailles Saint Quentin en Yvelines University, Boulogne-Billancourt, France 60. Bath Ankylosing Spondylitis Functional Index (BASFI) Is a Better Indicator of Poor Quality of Life Than Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in Ankylosing Spondylitis: Results From SIRAS the Scotland and Ireland Registry for Ankylosing Spondylitis. Gareth T. Jones, Linda E. Morton, Gary J. Macfarlane and Scotland and Ireland Registry for Ankylosing Spondylitis, University of Aberdeen, Aberdeen, United Kingdom, Aberdeen Systemic Lupus Erythematosus: Clinical Aspects 60. Sexual and Reproductive Health Counseling Among Adolescents with Systemic Lupus Erythematosus. Xue Tian, Murray H. Passo, Janice D. Key, Thomas C. Hulsey and Natasha M. Ruth, The Medical University of South Carolina, Charleston, SC 60. Cell Bound Complement Activation Products Are Associated with Disease Activity in Systemic Lupus Erythematosus. Kenneth C. Kalunian, W. Winn Chatham, Elena M. Massarotti, Joyce Reyes-Thomas 4, Richard Furie 5, Jill P. Buyon 6, Emily C. Somers 7, Chaim Putterman 8, Rachel L. Gross 9, Kyriakos A. Kirou 0, Rosalind Ramsey-Goldman, Christine Hsieh, Thierry Dervieux and A. Weinstein 4, UCSD School of Medicine, La Jolla, CA, University of Alabama at Birmingham, Birmingham, AL, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 Albert Einstein College of Med, Bronx, NY, 5 North Shore- LIJ Health System, Lake Success, NY, 6 New York University School of Medicine, New York, NY, 7 University of Michigan, Ann Arbor, MI, 8 Albert Einstein College of Medicine, Bronx, NY, 9 Albert Einstein College of Medicine, New York, NY, 0 Hospital for Special Surgery, New York, NY, Northwestern University Feinberg School of Medicine, Chicago, IL, University of Chicago, Chicago, IL, Exagen Diagnostics, Albuquerque, NM, 4 Washington Hospital Center, Washington, DC 604. Comparing the ACR and the SLICC Criteria for the Classification of SLE Patients Using Data from an Existing Multi-Ethnic Cohort. Graciela S. Alarcon, Gerald McGwin Jr., Larry Madger and Michelle Petri, University of Alabama at Birmingham, Birmingham, AL, University of Maryland, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD 605. Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus. Eliza F. Chakravarty, Kaleb Michaud, Robert S. Katz and Frederick Wolfe 4, Oklahoma Medical Research Foundation, Oklahoma City, CA, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, Rush University Medical Center, Chicago, IL, 4 National Data Bank for Rheumatic Diseases, Wichita, KS 606. Risk Factors Associated with Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: The Role of Rituximab. Mario Garcia- Carrasco, Claudia Mendoza Pinto, Alejandro Taboada- Cole, Verónica Vallejo-Ruiz, Julio Reyes-Leyva and Aurelio Lopez-Colombo, HGR 6 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Hospital General de Zona No. 5, Puebla, Mexico, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico 607. Activity Index after Renal Failure in a Cohort of Patients with Lupus Nephritis. Cristina Gonzalez-Pulido, Sara Croca and D.A. Isenberg, University Hospital Virgen del Rocio, Seville, Spain, University College London, London, United Kingdom, University College of London, London, United Kingdom 608. Association of Discoid Lupus with Other Clinical Manifestations Among Patients with Systemic Lupus Erythematosus. Joseph F. Merola, Christina Iversen, Jose A. Gomez-Puerta, Tabatha Norton, Hsun Tsao, Peter H. Schur, Elena M. Massarotti, Bonnie L. Bermas and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 609. Peripheral Neuropathy in Systemic Lupus Erythematosus. Amin Oomatia, Hong Fang, Michelle Petri and Julius Birnbaum, University of Cambridge, Cambridge, United Kingdom, Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins University, Baltimore, MD 60. B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation. Eoghan M. McCarthy, Ruth Lee, Joan Ni Gabhann, Siobhan Smith, Michele Doran, Gaye Cunnane, Donough G. Howard, Paul G. O Connell, Grainne M. Kearns and Caroline Jefferies, Beaumont Hospital, Dublin 9, Ireland, Royal College of Surgeons in Ireland, Dublin, Ireland, St. James Hospital, Dublin, Ireland 6. Impaired Diffusion Tensor Imaging Findings in the Corpus Callosum and Cingulum May Underlie Impaired Learning and Memory Abilities in Systemic Lupus Erythematosus. Daphna Paran, Elissa Ash, Ira Litinsky, Valerie Aloush, Marina Anouk, Dan Caspi, Talma Hendler and Irit Shapira- Lichter, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, Tel Aviv, Israel, Tel-Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel 88 0 Program Book

191 ACR POSTER SESSION A 6. Thrombosis Recurrence in Systemic Lupus Erythematosus Patients with and without Antiphospholipid Antibodies. Ibrahim AlHomood, D. D. Gladman, Dominique Ibanez and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON 6. Serum Level of Syndecan- Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus. In- Woon Baek, Ki-Jo Kim, Ji-Young Kim, Su-Jung Park, Chong- Hyeun Yoon 4, Wan-Uk Kim 5 and Chul Soo Cho 6, Internal medicine, Catholic University of Korea, Callege of Medicine, Seoul, South Korea, College of Medicine, Catholic University of Korea, Seoul, South Korea, Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, 4 College of Medicine, The Catholic University of Korea, Seoul, South Korea, 5 College of Medicine, The Catholic University of Korea, Suwon, South Korea, 6 St Marys Hospital, Seoul, South Korea 64. Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics from the Combined Placebo Groups in the Phase Belimumab Trials. Ronald F. van Vollenhoven, Michelle A. Petri, Roger A. Levy, Sandra V. Navarra 4, Jill P. Buyon 5, Z. John Zhong 6, William W. Freimuth 6 and Ricard Cervera 7, Karolinska University Hospital, Stockholm, Sweden, Johns Hopkins University School of Medicine, Baltimore, MD, Univ Estado Do Rio De Janeiro, Rio de Janeiro, Brazil, 4 University of Santo Tomas Hospital, Manila, Philippines, 5 New York University School of Medicine, New York, NY, 6 Human Genome Sciences, Inc., Rockville, MD, 7 Hospital Clínic of Barcelona, Barcelona, Spain 65. Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase Belimumab Trials Are Predictive of Severe Flare At 5 Weeks. Michelle A. Petri, Ronald F. van Vollenhoven, Roger A. Levy Sr., Sandra V. Navarra 4, Ricard Cervera 5, Z. John Zhong 6, William W. Freimuth 6 and Jill P. Buyon 7, Johns Hopkins University School of Medicine, Baltimore, MD, Karolinska University Hospital, Stockholm, Sweden, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, 4 University of Santo Tomas Hospital, Manila, Philippines, 5 Hospital Clinic, Barcelona, Spain, 6 Human Genome Sciences, Inc., Rockville, MD, 7 New York University School of Medicine, New York, NY 66. Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects. Wendy Cai, Cecil Chen, Z. John Zhong, William W. Freimuth, William Lewis and David Subich, Human Genome Sciences, Inc., Rockville, MD, Covance Clinical Research Unit, Inc., Dallas, TX, Covance Clinical Research Unit, Inc., Daytona Beach, FL 67. Soluble Urokinase Plasminogen Activator Receptor (supar) Levels Reflect Organ Damage in Systemic Lupus Erythematosus. Helena Enocsson, Jonas Wetterö, Thomas Skogh and Christopher Sjöwall, Linkoping University, Linkoping, Sweden, Linköping University, Linköping, Sweden 68. BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year. Eric Zollars, Hong Fang, Jadwiga Bienkowska, Norm Allaire, Susan Kalled and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Biogen Idec Inc., Cambridge, MA 69. Elevated Plasma Levels of CXCL and CXCL0 Have Distinct Predictive Value in Systemic Lupus Erythematosus. Felipe andrade, Ehtisham Akhter, Hong Fang and Michelle Petri, The Johns Hopkins University School of Medicine, Baltimore, MD, Johns Hopkins University School of Medicine, Baltimore, MD 60. Development of A Quantitative PCR Method to Determine Interferon Signature Metric Status in SLE Patients: Distribution and Clinical & Serological Associations in Two Lupus Clinical Trials. Bruce C. Richardson, William P. Kennedy, John C. Davis Jr., R. Maciuca, A. Morimoto, J. M. McBride, Alexander R. Abbas, Timothy W. Behrens and Michael J. Townsend, University of Michigan, Ann Arbor, MI, Genentech, Inc, South San Francisco, CA 6. Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide. Thomas J. A. Lehman, Emily Baird, Anusha Ramanathan, Risa Alperin, Emma J. MacDermott, Alexa B. Adams, Laura V. Barinstein 4 and Lakshmi N. Moorthy 5, Hosp for Special Surgery, New York, NY, Hospital for Special Surgery, NY, Hospital for Special Surgery, New York, NY, 4 Maimonides Medical Center, Brooklyn, NY, 5 Robert Wood Johnson-UMDNJ, New Brunswick, NJ 6. Headache in Systemic Lupus Erythematosus (SLE): Results from a Prospective, International, Inception Cohort Study. John G. Hanly and Systemic Lupus International Collaborating Clincs, Dalhousie University and Capital Health, Halifax, NS, (SLICC) 6. Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus. Ben Parker, Awal Zaki, M. Yvonne Alexander and Ian N. Bruce 4, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, The University of Manchester, Manchester, United Kingdom, 4 Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom 64. Excess Health Care Utilization Prior to Diagnosis of Systemic Lupus Erythematosus in England. Amy Steffey, Trung N. Tran, Jie Li and Herve Caspard, MedImmune, Gaithersburg, MD, MedImmune LLC, Gaithersburg, MD 65. Control of Hypertension and Hypercholesterolemia Is Not Associated with a Decreased Rate of Atherosclerotic Vascular Events in Patients with Systemic Lupus Erythematosus. Joanna Ueng, D. D. Gladman, Dominique 0 Program Book 89

192 ACR POSTER SESSION A Ibanez and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON 66. The Interferon Alpha Gene Signature Is Not Associated with nor Does It Predict Progression of Coronary Artery Calcium (CAC) or Carotid Intima-Media Thickness (IMT) in Systemic Lupus Erythematosus (SLE). Adnan Kiani, Hong Fang, Jie Xu, Ehtisham Akhter and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 67. Zostavax Vaccine Is Safe in Lupus Patients with Low Disease Activity. Eliza F. Chakravarty, Joel M. Guthridge, Joan T. Merrill, Abigail Cogman, Tiny Powe, Virginia C. Roberts and Judith A. James 4, Oklahoma Medical Research Foundation, Oklahoma City, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, OMRF, Oklahoma City, OK, 4 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK 68. Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion. Ki-Jo Kim, In-Woon Baek, Chong-Hyeun Yoon, Wan-Uk Kim and Chul-Soo Cho, College of Medicine, The Catholic University of Korea, Seoul, South Korea, Callege of Medicine, The Catholic University of Korea, Seoul, South Korea, College of Medicine, The Catholic University of Korea, Suwon, South Korea 69. Inflammatory Biomarkers of Atherosclerosis and Oxidative Stress Are Associated with Disease Flare in SLE. Maureen A. McMahon, Jennifer M. Grossman, Brian Skaggs, Elaine Lourenco, Cheryl Lee, Lori Sahakian, John D. FitzGerald, Christina Charles-Schoeman, Alan H. Gorn, George A. Karpouzas, Michael H. Weisman 4, Daniel J. Wallace 4, Weiling Chen and Bevra H. Hahn, UCLA David Geffen School of Medicine, Los Angeles, CA, University of California, Los Angeles, CA, Harbor-UCLA Medical Center, Torrance, CA, 4 Cedars-Sinai Medical Center, Los Angeles, CA 60. Risk Factors Associated with Early Central Nervous System Damage Detected Through Diffusion Tensor Imaging (DTI) in Patients with Systemic Lupus Erythematosus. Paola Tomietto, Federica Casagrande, Maja Ukmar, Luca Weis, Pia Morassi 4, Rita Moretti, Gianni Biolo, Carlo Giansante and Maria Assunta Cova, AOU Ospedali Riuniti, Trieste, Italy, University of Trieste, Trieste, Italy, University of Trieste, Trieste, 4 AOU Ospedali Riuniti di Trieste, Trieste, Italy 6. Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome. Simone Fargetti, Samuel K. Shinjo, Sandra G. Pasoto, Ana L. Calich, Eloisa Bonfa and Eduardo F. Borba, University of Sao Paulo, Sao Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, University of São Paulo, São Paulo, Brazil 6. The Effects of Co-Existing Proliferative Histopathology on Membranous Lupus Nephritis. Jennifer L. Graybill, Catarina Vila-Inda, Chaim Putterman and Irene Blanco, Albert Einstein College of Medicine, Bronx, NY 6. Missed Work Days in Systemic Lupus Erythematosus. Jie Xu, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 64. Adherence to Adult Treatment Panel III Guidelines for Systemic Lupus Patients. Matthew Basiaga and Lisabeth Scalzi, Penn State Univ/ Hershey, Hershey, PA 65. Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients. Leslie Harris, Ratnesh Chopra, Ann K. Rosenthal and Mary E. Cronin, Medical College of Wisconsin, Milwaukee, WI 66. Retrospective Study of Allogenic Mesenchymal Stem Cells Transplantation in Active and Refractory Lupus Nephritis for Induction Therapy. Lingyun Sun, Dandan Wang, Xia Li and Huayong Zhang, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 67. Anti-Mullerian Hormone and Ovarian Reserve in Systemic Lupus Erythematosus. Chi Chiu Mok, Pak To Chan and Chi Hung To, Tuen Mun Hospital, Hong Kong, Hong Kong, Hong Kong, Hong Kong 68. The Progression of Brain MRI Biomarker of Cognitive Impairment (White Matter Hyperintensity) in Systemic Lupus: A Clinical and Imaging Longitudinal Study. Jamal Mikdashi and Umran Ashruf, University of Maryland School of Medicine, Baltimore, MD 69. Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006). K. Hobbs, D.J. Wallace, V. Strand, K. Kalunian 4, B. Kilgallen 5, S. Bongardt 6, W.A. Wegener 7 and D.M. Goldenberg 7, Denver Arthritis Clinic, Denver, CO, Cedars-Sinai Medical Center, Los Angeles, CA, Stanford University, Palo Alto, CA, 4 UCSD School of Medicine, La Jolla, CA, 5 UCB Pharma, Smyrna, GA, 6 UCB Pharma, Brussels, Belgium, 7 Immunomedics Inc, Morris Plains, NJ 640. Association of Body Weight with Cardiovascular Events in Systemic Lupus Erythematosus. George Stojan, Homa Timlin, Hong Fang, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, West Drayton, United Kingdom, University of Maryland, Baltimore, MD 64. Study of Anti-Müllerian Hormone and Probability of Pregnancy in Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide. Nathalie Morel, Anne Bachelot, Zeina Chakhtoura, Zahir Amoura, Olivier Aumaitre, Jean-Emmanuel Kahn, Du Boutin, Pierre Duhaut 4, Dominique Farge 5, Camille Francès, Lionel Galicier 6, Gaëlle Guettrot-Imbert, Jean-Robert Harlé 7, Olivier Lambotte 8, Véronique Le Guern 9, Jean-Charles Piette, Jacques Pourrat 7, Karim Sacre 0, Damien Sene, Salim Trad, Elisabeth Vidal, Lamiae Grimaldi 4, Christiane Coussieu, Nathalie Costedoat-Chalumeau and PLUS 5, Groupe Hospitalier Pitié-Salpétrière, Paris, France, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, 90 0 Program Book

193 ACR POSTER SESSION A Internal Medicine, Foch Hospital, Suresnes, France, 4 CHU Nord, Amiens, France, 5 EBMT, Paris, France, 6 Hopital Saint Louis, Paris, France, 7 CHU Toulouse, Toulouse, France, 8 Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, 9 Cochin Hospital, Paris, France, 0 Bichat Hospital, University Paris- 7, APHP, Paris, France, Hopital Lariboisière, Paris, France, Hopital Ambroise Paré, Paris, France, Hopital de Limoges, Limoges, France, 4 Société Laser, Paris, France, 5 Paris, France 64. Effects of Treatment on the Expression of CCL and CXCL0 in Systemic Lupus Erythematosus Patients. Paul R. Dominguez-Gutierrez, Angela Ceribelli, Minoru Satoh, Eric S. Sobel, Westley H. Reeves and Edward K.L. Chan, University of Florida, Gainesville, FL 64. Clinical Characteristics for Future Development of Systemic Lupus Erythematosus in Korean Patients with Idiopathic Thrombocytopenic Purpura. Yeon-Ah Lee, Somi Kim, Ran Song and Sang-Hoon Lee, Kyung Hee University, Seoul, South Korea, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea 644. Pulmonary Hypertension in Systemic Lupus Erythematosus: A 6-Year Follow-up Study Cohort. Claudia Hübbe-Tena, Selma Gallegos-Nava, Rafael Bojalil and Luis M. Amezcua-Guerra, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico 645. Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European- American Lupus Patients Who Receive Influenza Vaccination. Melissa E. Munroe, Jourdan R. anderson, Joan T. Merrill, Joel M. Guthridge, Virginia C. Roberts, Gillian M. Air, Linda F. Thompson and Judith A. James, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK 646. Comparison of the Lupusqol and SF-6 Scores As Valid Measures of Change in Health Related Quality of Life. Zahi Touma, Murray B. Urowitz, Dominique Ibanez, Shahrzad Taghavi-Zadeh and D. D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 647. Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years. Murray B. Urowitz, Dominique Ibanez, D. D. Gladman, SLICC and Systemic Lupus International Collaborating Clinics (SLICC), Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto, ON 648. Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus: Incidence over a Ten Year Period. D. D. Gladman, Dominique Ibanez, Murray B. Urowitz and SLICC, Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto, ON 649. Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus. Evelyne Vinet, Sasha Bernatsky, Mohammed Kaouache, Emil P. Nashi, Christian A. Pineau, Ann E. Clarke, Robert W. Platt 4, Meggan C. Mackay 5 and Cynthia Aranow 6, McGill University Health Centre, Montreal, QC, Research Institute of the McGill University Health Ctre, Montreal, QC, MUHC, Montreal, QC, 4 McGill University, Montreal, QC, 5 The Feinstein Institute, Manhasset, NY, 6 Feinstein Institute for Medical Research, Manhasset, NY 650. Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences between Patients with Positive/Negative Lupus Anticoagulant. Andrea Hinojosa-Azaola, Alba Cicero-Casarrubias, Mario César Ocampo-Torres, Juanita Romero-Díaz and Jorge Sánchez-Guerrero, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mount Sinai Hospital and University Health Network, Toronto Canada 65. Suicidal Ideation in Patients with Systemic Lupus Erythematosus: Incidence and Relationship with Anxiety/ Depression Score, Disease Activity and Organ Damage. Chi Chiu Mok, Kelly Chan and Paul Yip, Tuen Mun Hospital, Hong Kong, Hong Kong, University of Hong Kong, Hong Kong, Hong Kong 65. Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis. Venkat Reddy, Sara Croca, Delia Gerona, Inmaculada De La Torre Ortega, David A. Isenberg, Maria Leandro and Geraldine Cambridge, University College London, London, United Kingdom, Gregorio Marañón Hospital, Madrid, Spain 65. Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of LUPUS FLARE. Mikhail Olferiev, Kyriakos A. Kirou, Elena Gkrouzman, Dorthe Lundsgaard 4, Klaus S. Frederiksen 5, Jan Fleckner 5 and Mary K. Crow, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, Hospital for Special Surgery, New York, NY, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, New York, NY, 4 Novo Nordisk A/S, Måløv, Denmark, 5 NovoNordisk, Copenhagen, Denmark 654. Incidence Studies of Systemic Lupus Erythematosus in Southern Sweden. Have the Tides Turned? Ragnar Ingvarsson, Andreas Jönsen, Ola Nived, Gunnar Sturfelt and anders Bengtsson 4, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, Section of Rheumatology, Lund, Sweden, University Hospital - Lund, Lund, Sweden, 4 University Hospital Lund, Lund, Sweden 655. Non-White Race, Younger Age, and Use of Primary and Gynecologic Care Are Associated with Higher Rates of Cervical Cancer Screening in Systemic Lupus Erythematosus Patients At a Public Hospital. Jennifer Stichman, Angela Keniston, Joann Zell, Jinoos Yazdany, Itziar Quinzanos 0 Program Book 9

194 ACR POSTER SESSION A and Joel M. Hirsh, Denver Health Med Ctr, Denver, CO, National Jewish Health, Denver, CO, University of California San Francisco, San Francisco, CA 656. Effects of Nelfinavir on Anti-dsDNA Antibody Binding and Pro-Inflammatory Cytokine Gene Expression. Maria Espinosa, Julisa Patel, Meggan Mackay, Cynthia Aranow 4 and Betty Diamond 5, Cohen Children s Hospital-North Shore LIJ, New Hyde Park, NY, Cohen Children s Hospital, New Hyde Park, NY, The Feinstein Institute for Medical Research, Manhasset, NY, 4 Feinstein Institute for Medical Research, Manhasset, NY, 5 Feinstein Institute Med Rsch, Manhasset, NY 657. Serial Screening Shows That 8% of Systemic Lupus Erythematosus Adult Patients Carry an Underlying Primary Immunodeficiency. Sandro F. Perazzio, Reinaldo Salomao, Neusa P. Silva, Magda Carneiro-Sampaio and Luis Eduardo C. andrade 4, Federal University of Sao Paulo, Sao Paulo, Brazil, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 4 Universidade Federal de São Paulo, Sao Paulo, Brazil Systemic Lupus Erythematosus - Human Etiology and Pathogenesis 658. Up-Regulation of A Disintegrin and Metalloprotease with Thrombospondin Type I Repeats- Correlates with Ischemic Cerebrovascular Disease in Systemic Lupus Erythematosus Patients. Consuelo Lopez de Padilla, Molly Hein, Cynthia S. Crowson, Christopher Choo, Abigail B. Green, Michelle Petri, Hatice Bilgic 4, Emily Baechler Gillespie 4 and Ann M. Reed, Mayo Clinic, Rochester, MN, Rochester, MN, Johns Hopkins University School of Medicine, Baltimore, MD, 4 University of Minnesota Medical School, Minneapolis, MN 659. The Small Molecule Activator to ACE Prevents the Inhibition of ACE Activity by Autoantibodies. Shiori Haga, Yuko Takahashi, Yukihito Ishizaka and Akio Mimori, National Center for Global Health and Medicine, Research Institute, Tokyo, Japan, National Center for Global Health and Medicine, Tokyo, Japan 660. Abnormal Neutrophil Development in Human Systemic Lupus Erythematosus. Namrata Singh, Mariana J. Kaplan, Philip L. Cohen and Michael F. Denny, Temple University, Philadelphia, PA, University of Michigan, Ann Arbor, MI 66. Co-Localization of C - reactive protein, Immunoglobulin G and Complement in Renal Subendothelial Immune Deposits of Proliferative Lupus Nephritis Detected Using Immunogold Electron Microscopy. Christopher Sjöwall, anders I. Olin, Thomas Skogh, Jonas Wetterö, Mattias Mörgelin, Ola Nived 4, Gunnar Sturfelt 5 and anders A. Bengtsson 5, Linkoping University, Linkoping, Sweden, Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, Linköping University, Linköping, Sweden, 4 University Hospital Lund, Lund, Sweden, 5 Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden 66. Increased Cq, C 4 and C Deposition on Platelets in Patients with Systemic Lupus Erythematosus A Possible Link to Venous Thrombosis? Christian Lood, Sam Eriksson, Birgitta Gullstrand, Andreas Jönsen, Gunnar Sturfelt, Lennart Truedsson and anders A. Bengtsson, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund, Sweden 66. The Clinical Significance and Expression of PX7 Purinergic Receptor in Peripheral Blood from Patients with New- Oneset Systemic Lupus Erythematosus. Xiangpei Li, Meiyun Wang, Jinhui Tao, Xiaomei Li and Ning Yu, Anhui Medical University Affiliated Provincial Hospital, Hefei, Anhui, China 664. Estrogen Upregulates Interleukin- Production of Clusters of Differentiation 4 Positive T Lymphocytes in Patients with Systemic Lupus Erythematosus. Jennifer Lee, Daejun Kim, Jae Ho Lee, Seung Min Jung, Mi-La Cho, Seung-Ki Kwok, Ji Hyeon Ju, Kyung-Su Park, Sung-Hwan Park and Ho-Youn Kim, Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea, Rheumatic research center, Catholic University of Korea, Seoul, South Korea 665. Cytokines and Their Relation to Autoantibodies before Disease Onset in Systemic Lupus Erythematosus. Catharina Eriksson and Solbritt Rantapää Dahlqvist, Department of Clinical Immunology/clinical microbiology, Umeå, Sweden, Umeå University Hospital, Umeå, Sweden 666. Leukadherin, a CR Mimetic, Negatively Regulates Toll Like Receptor (TLR) Dependent Inflammatory Responses via Degradation of an Adaptor Protein. Kristen Lee, Joanne H. Reed, Vineet Gupta, Tejaskumar Patel, Jill P. Buyon and Robert M. Clancy, New York University School of Medicine, New York, NY, Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miami, FL 6, U.S.A., Miami, FL, NYU School of Medicine, New York, NY 667. Interferon-Alpha Impairs the Survival and Function of Circulating Angiogenic Cells in Vitro: A Model of Failed Endothelial Repair in SLE. John A. Reynolds, David W. Ray, Terence O Neill, M. Yvonne Alexander and Ian N. Bruce, The University of Manchester, Manchester, United Kingdom, University of Manchester, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom 668. Markers of Nitric Oxide and Hydroxyl Radical Formation Are Increased in Proliferative Lupus Nephritis and May Emanate From Increased Nitric Oxide Synthase and NADPH Oxidase Production and Reduced Endothelial Nitric Oxide 9 0 Program Book

195 ACR POSTER SESSION A Synthase-Derived NO Scavenging. Jim Oates, Ahmad Mashmoushi, Thomas Fleury, Ann Hofbauer and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC 669. Serum Anti N-Methyl-D-Aspartate Receptor Subunit Antibodies Are Elevated in SLE. Ogawa Eisuke, Nagai Tatsuo, Arinuma Yoshiyuki and Hirohata Shunsei, Kitasato University School of Medicine, Kanagawa, Japan 70. Prolidase Deficiency Induces Antibodies to Sm, Ro60 and Double Stranded DNA. Biji T. Kurien, Anil D souza, Skyler P. Dillon, Benjamin F. Bruner, Timothy Gross 4, Judith A. James 5, Ira N. Targoff 6, Jacen S. Maier-Moore, Isaac T.W. Harley 7, Heng Wang 8 and Robert H. Scofield, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Harding University, Searcy, AR, 4 Oklahoma Medical Research Foundation, Oklahoma City, OK, 5 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 6 Oklahoma Medical Research Foun, Oklahoma City, OK, 7 Cincinnati Children s Hospital Research Foundation, Cincinnati, OH, 8 Das Deutsch Center Clinic for Special Needs Children, Middlefield, OH 67. Differences in the SLE Clinical Phenotype by Age of Diagnosis. T. Clark Powell, Elizabeth E. Brown on behalf of PROFILE, Gerald McGwin Jr., Luis M. Vila, Yesenia C. Santiago-Casas, Michelle Petri 4, Rosalind Ramsey- Goldman 5, John D. Reveille 6, Sergio Duran 7, Sergio M.A. Toloza 8, Robin L. Brey 9, Agustin Escalante 0, Randy Q. Cron, Robert P. Kimberly on behalf of PROFILE investigators and Graciela S. Alarcon, University of Alabama at Birmingham, Birmingham, AL, University of PuertoRico Medical Sciences Campus, San Juan, PR, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 4 Johns Hopkins University School of Medicine, Baltimore, MD, 5 Northwestern University Feinberg School of Medicine, Chicago, IL, 6 Univ of Texas Health Science Center at Houston, Houston, TX, 7 UIECD, Guadalajara, Mexico, Guadalajara, Mexico, 8 Hospital San Juan Bautista, Catamarca, Argentina, 9 UTHSCSA, San Antonio, TX, 0 University of Texas Health Science Center at San Antonio, San Antonio, TX, Univ of Alabama- Birmingham, Birmingham, AL, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 67. Immune Complexes and Autoantibodies to Oxidized Lipids in Systemic Lupus Erythematosus. Yujin Ye, Tianfu Wu and Chandra Mohan, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX 67. Altered Soluble Mediators in Individuals with Incomplete Lupus (ILE) in the Lupus Autoimmunity in Relatives (LAUREL) Study. Melissa E. Munroe, Jill M. Norris, Joel M. Guthridge, Diane L. Kamen, Kathy Moser Sivils, Timothy B. Niewold 4, Gary S. Gilkeson 5, Michael H. Weisman 6, Mariko L. Ishimori 6, Daniel J. Wallace 6, David R. Karp 7, John B. Harley 8 and Judith A. James 9, Oklahoma Medical Research Foundation, Oklahoma City, OK, Colorado School of Public Health, Aurora, CO, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 4 University of Chicago, Chicago, IL, 5 Medical University of South Carolina, Charleston, SC, 6 Cedars-Sinai Medical Center, Los Angeles, CA, 7 UT Southwestern Medical Center, Dallas, TX, 8 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 9 Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK 674. Altered Response to B Cell Receptor (BCR) Crosslinking in SLE: Correlation with Genetic Risk Variants Predicted to Impact BCR Signaling. Nan-Hua Chang, Timothy Li, Paul R. Fortin, Dafna D. Gladman, Carolina Landolt-Marticorena 4, Jorge Sanchez-Guerrero 5, Murray B. Urowitz 4 and Joan E. Wither, Toronto Western Research Institute, University Health Network, Toronto, ON, University of Laval, Quebec, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 4 University Health Network, University of Toronto, Toronto, ON, 5 Mount Sinai Hospital, University Health Network, Toronto, ON 675. Differential Impairment of Serum Cholesterol Efflux Capacity in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Pier Luigi Meroni, Nicoletta Ronda, Elda Favari, Orietta Borghi 4, Francesca Zimetti, Mariapia Adorni 5, Francesca Ingegnoli 6, Maria Gerosa 7, Claudia Grossi 8 and Franco Bernini 5, Istituto G. Pini, University of Milan, Milano, Italy, Parma, Italy, University of Parma, Parma, Italy, 4 University of Milan, Milan, Italy, , Parma, Italy, 6 Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, 7 Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, 8 Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy 676. A Novel Biomarker: Nucleotide-Binding Oligomerization Domain 7 in Systemic Lupus Erythematosus. Annika Cutinha, Yangsheng Yu, Kaihong Su, James R. O Dell, Lynell W. Klassen, Amy C. Cannella, Ted R. Mikuls, Alan R. Erickson, Gerald F. Moore and Michelene Hearth-Holmes, University of Nebraska Medical Center, Omaha, NE, Department of Pathology and Microbiology, Omaha, NE, UNMC Physicians - Brentwood, LaVista, NE 677. Antibodies to Oxidized Low Density Lipoprotein or Anti- Lipoprotein Lipase May Lead to More Atherosclerotic Plaque in a Sub-Set of SLE Patients. Biji T. Kurien, James Fesmire, Skyler P. Dillon, Marianne Reichlin 4, Morris Reichlin 5 and Robert H. Scofield 6, University of Oklahoma Health Sciences Center, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma 0 Program Book 9

196 ACR POSTER SESSION A 94 City, OK, 4 Oklahoma Medical Res Fndn, Oklahoma City, OK, 5 Oklahoma Medical Research Foun, Oklahoma City, OK, 6 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK 678. Estrogen Modulation of ZAS Is Mediated Through Estrogen Receptor α: An Underlying Mechanism of Gender- Bias in Systemic Lupus Erythematosus? Nicholas Young, Alexandra Friedman, Lai-Chu Wu and Wael N. Jarjour, The Ohio State University Medical Center, Columbus, OH, Ohio State University, Columbus, OH 679. ZAP70+ B Cells and Plasmablasts as Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis. Elisa Gremese, Barbara Tolusso, Laura Messuti, Marcin Nowik, Silvia Canestri, Luca Petricca, Maria Rita Gigante and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy 680. Plasma Level of Galectin- Binding Protein Reflects Type I Interferon Activity and Is Highly Increased in Patients with Systemic Lupus Erythematosus. Christoffer T. Nielsen, Ole Østergaard, Line V. Iversen, Christian Lood, anders A. Bengtsson 4, Anne Voss 5, Søren Jacobsen 6 and Niels H. H. Heegaard, Statens Serum Institut, Copenhagen S, Denmark, Statens Serum Institute, Copenhagen S, Denmark, Department of Clinical Sciences Lund, Lund, Sweden, 4 Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, 5 Odense University Hospital, Odense C, Denmark, 6 Copenhagen University Hospital, Copenhagen, Denmark 68. Interferon Alpha Decreases Endothelial Nitric Oxide Synthase Function and Expression in Human Umbilical Vein Endothelial Cells. Joy Buie and Jim Oates, Medical University of South Carolina, Charleston, SC 68. IL-p70 Levels Play a Role in Damage Accrual in SLE Patients. Eoghan M. McCarthy, Ruth Lee, Joan Ni Gabhann, Siobhan Smith, Michele Doran, Gaye Cunnane, Donough G. Howard, Paul G. O Connell, Caroline Jefferies and Grainne M. Kearns, Beaumont Hospital, Dublin 9, Ireland, Royal College of Surgeons in Ireland, Dublin, Ireland, St. James s Hospital, Dublin, Ireland 68. Prevalence of Inhibitory or Non-Inhibitory Autoantibodies to Angiotensin Converting Enzyme (ACE) in Patients with Systemic Lupus Erythematosus. Yuko Takahashi, Shiori Haga, Yukihito Ishizaka and Akio Mimori, National Center for Global Health and Medicine, Tokyo, Japan, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan 684. Correlation of Signal Transducers and Activators of Transcription- and Microrna-46a with Anaemia and Other Clinical Features in Systemic Lupus Erythematosus 0 Program Book Patients. Paul R. Dominguez-Gutierrez, Angela Ceribelli, Minoru Satoh, Eric S. Sobel, Yi Li, Westley H. Reeves and Edward K.L. Chan, University of Florida, Gainesville, FL 685. Using a Library of Synthetic Autoantigen Mimics to Discover Biomarkers of Systemic Lupus Erythematosus. Akshai Lakhanpal, Jiexia Quan, Sayed Zaman, Nancy J. Olsen and David R. Karp, UT Southwestern Medical Center, Dallas, TX, Penn State MS Hershey Medical Center, Hershey, PA 686. Cell-Type Specific Type I Interferon Signatures in Autologous Stem Cell Transplanted Lupus Patients: Different Molecular Behavior between CD4+ T Cells and Monocytes. Chieko Kyogoku, Joachim R. Grün, Tobias Alexander, Robert Biesen, Falk Hiepe, Thomas Häupl, Andreas Radbruch and Andreas Grützkau, German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, Charité University Hospital Berlin, Berlin, Germany 687. Gammadelta T Cells and Their Intracellular Cytokine Profile in Peripheral Blood of Patients with Systemic Lupus Erythematosus. Lingyun Sun, Xia Li and Zhimin Lu, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 688. Expression of the Mer Receptor Tyrosine Kinase on Peripheral Blood Mononuclear Cells from Systemic Lupus Erythematosus Patients. Brendan A. Hilliard, Gaetano Zizzo, Margaret K. Linan and Philip L. Cohen, Temple University School of Medicine, Philadelphia, PA, Temple University, Philadelphia, PA 689. Activation of the Interferon Pathway Is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients. Kichul Ko, Yelena Koldobskaya, Elizabeth Rosenzweig and Timothy B. Niewold, University of Chicago, Chicago, IL 690. Molecular Analysis of 9G4+ Antibodies in Systemic Lupus Erythematosus. Christopher Richardson, Asiya Seema Chida, Erin Fox, Lin Silver, Diana G. Adlowitz, Scott Jenks, Elise Palmer, Christopher Tipton and Ignacio Sanz, University of Rochester, Rochester, NY, Emory University, Atlanta, GA 69. Characterization of Pro-Inflammatory Cytokines and Vitamin D Levels in a Lupus Cohort and Correlation with Disease Activity. Rohan Willis, Praveen Jajoria, Brock E. Harper, Emilio B. Gonzalez, Michelle Petri, Ehtisham Akhter, Hong Fang and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, Johns Hopkins University School of Medicine, Baltimore, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics 69. A Phase Multicenter, Open-Label Study of MEDI-546, a Human Anti-Type I Interferon Receptor Monoclonal Antibody, in Adults with Scleroderma. Avram Z. Goldberg,

197 ACR POSTER SESSION A Thomas D. Geppert, Elena Schiopu, Tracy M. Frech 4, Vivien M. Hsu 5, Robert W. Simms 6, Stanford L. Peng 7, Yihong Yao 8, Nairouz Elgeioushi 8, Bing Wang 9, Linda Chang 9 and Stephen Yoo 8, North Shore-LIJ Health System, Lake Success, NY, Metroplex Clinical Research Center, LLC, Dallas, TX, University of Michigan, Ann Arbor, MI, 4 University of Utah School of Medicine, SLC, UT, 5 RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 6 Boston University School of Medicine, Boston, MA, 7 Benaroya Research Institute at Virginia Mason Medical Center, Seattle, WA, 8 MedImmune, Gaithersburg, MD, 9 MedImmune, Hayward, CA 69. A Placebo-Controlled Phase II Study of Hyperimmune Caprine Serum in Diffuse Cutaneous Systemic Sclerosis: Safety and Potential Efficacy. Niamh P. Quillinan, Deirdre McIntosh, Syed Haq and Christopher P. Denton, UCL Medical School, London, United Kingdom, Daval International Ltd, Eastbourne, East Sussex, United Kingdom, UCL, London, United Kingdom 694. Nilotinib (Tasigna ) in the Treatment of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial. Jessica K. Gordon, Morgana L. Davids, Kamini Doobay, Cynthia Magro, Horatio F. Wildman, Stephen L. Lyman, Mary K. Crow and Robert F. Spiera, Hospital for Special Surgery, New York, NY, Weill-Cornell Medical Center, New York, NY, Weill-Cornell Medical Center, New York 695. Comparison of Intense Pulsed Light and Laser Treatment of Telangiectases in Systemic Sclerosis. Graham Dinsdale, Andrea Murray, Tonia Moore, Janice E. Ferguson, Holly Ennis, Christopher E.M Griffiths and Ariane Herrick 4, School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, 4 University of Manchester, Salford, United Kingdom 696. Risk Factors for EARLY Mortality in Scleroderma Patients: A Report From the EULAR Scleroderma Trials and Research Group (EUSTAR) Database. Patricia E. Carreira, Loreto Carmona, Beatriz E. Joven, Christopher P. Denton 4, Yannick Allanore 5, Ulrich A. Walker 6, Marco Matucci-Cerinic 7, Ulf Müller-Ladner 8 and Eustar 9, Hospital Universitario de Octubre, Madrid, Spain, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, HOSPITAL UNIVERSITARIO DE OCTUBRE, Madrid, Spain, 4 UCL, London, United Kingdom, 5 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 6 Universitäts- Poliklinik, Felix-Platter Spital, Basel, Switzerland, 7 University of Florence, Florence, Italy, 8 Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, 9 Florence 697. Demographic, Clinical, Serologic and Socioeconomic Measures Each Predict Mortality in Scleroderma. Allan C. Gelber, Rebecca L. Manno, Adrianne Woods, Ami A. Shah, Francesco Boin, Laura K. Hummers and Fredrick M. Wigley, Johns Hopkins University, Baltimore, MD 698. External Validation of a Two-Year Mortality Risk Prediction Rule in Early Diffuse Systemic Sclerosis Patients. Robyn T. Domsic, Svetlana Nihtyanova, Stephen R. Wisniewski, Michael J. Fine 4, C. Kent Kwoh 5, Christopher P. Denton 6 and Thomas A. Medsger Jr. 7, University of Pittsburgh, Pittsburgh, PA, Royal Free Hospital, Medical School, London, England, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4 University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, 5 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 6 UCL, London, United Kingdom, 7 Univ of Pittsburgh, Pittsburgh, PA 699. Endothelial Dysfunction and Vascular Stiffness in Early Diffuse Systemic Sclerosis. Robyn T. Domsic, Dana Ivanco, Hunter C. Champion, Ali Shoushtari and Thomas A. Medsger Jr., University of Pittsburgh, Pittsburgh, PA, Univ of Pittsburgh, Pittsburgh, PA 700. Clinical Correlation of Flow-Mediated Endothelium- Dependent Vasodilatation in Systemic Sclerosis. Takehiro Takahashi, Yoshihide Asano, Eisuke Amiya, Masaru Hatano, Atsuko Ozeki, Aya Watanabe, Shuichi Kawarasaki, Tomoko Nakao, Zenshiro Tamaki, Takashi Taniguchi, Yohei Ichimura, Tetsuo Toyama, Masafumi Watanabe, Yasunobu Hirata, Ryozo Nagai and Shinichi Sato, Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan 70. Vascular Differences Associated to Genetic Polymorphisms of Endothelial Nitric Oxide Synthase in Mexican Patients with Systemic Sclerosis. A Preliminary Report. Maria Pilar Cruz-Dominguez, Maria Angeles Martinez-Godinez, Angel Miliar-Garcia, Daniel Hector Montes-Cortes, Olga Vera- Lastra 4, Luis J. Jara-Quezada 5 and Anabel Reyes-Salazar 6, Hospital de Especialidades Centro Medico Nacional La Raza., Mexico, DF, Mexico, Escuela Superior de Medicina. IPN,, Mexico, D.F., Mexico, Hospital General CMN La Raza, IMSS, Mexico DF, Mexico, 4 MD, Mexico City, Mexico, 5 Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, 6 Hospital de especialidades Centro Medico National La Raza, IMSS, Mexico, D.F., Mexico 70. Arterial Stiffness Is Increased in Systemic Sclerosis: A Cross-Sectional Comparison with Matched Controls. Gene-Siew Ngian, Joanne Sahhar, Ian Wicks and Sharon Van Doornum 4, The University of Melbourne, Parkville, Australia, Monash Medical Centre, Clayton, Australia, Royal Melbourne Hospital, Parkville, Australia, 4 The University of Melbourne, The Royal Melbourne Hospital, Melbourne, Australia 0 Program Book 95

198 ACR POSTER SESSION A 70. Vascular Ischemic Events in Systemic Sclerosis - A Cross- Sectional Comparision with Population-based Controls. Annica Nordin, Kerstin Jensen-Urstad, Lena Björnådal and Elisabet Svenungsson, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, Department of Clinical Physiology, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden 704. Decreased Number of Endothelial Progenitor Cells in Systemic Sclerosis Patients with Early Disease. Fernando V. andrigueti, Maria I. Arismendi, Pâmela C.C. Ebbing and Cristiane Kayser, Universidade Federal de São Paulo, São Paulo, Brazil 705. Adipose Derived Stem Cells As an Alternative Source of Cellular Repair for Vascular Dysfunction in Systemic Sclerosis. Nevin Hammam and Hazem Orabi, Assiut University, Assiut, Egypt, Knuppe Molecular Laboratory, San Francisco, CA 706. Excess Mortality From Atherosclerotic Cardiovascular Disease in Systemic Sclerosis Compared to Lupus and Rheumatoid Arthritis. Amish J. Dave, Bharathi Lingala, David Fiorentino, Eswar Krishnan 4 and Lorinda Chung 5, Stanford University, Stanford, CA, Stanford University, Redwood City, CA, Stanford University School of Medicine, Redwood City, CA, 4 Standford University, Palo Alto, CA, 5 Stanford Univ Medical Center, Palo Alto, CA 707. Risk of Cancer in Systemic Sclerosis: Meta-Analysis of Population-Based Cohort Studies. Akira Onishi, Daisuke Sugiyama, Akio Morinobu and Shunichi Kumagai, Kobe University Graduate School of Medicine, Kobe, Japan, School of Medicine, Keio University, Tokyo, Japan, Shinko Hospital, Kobe, Japan 708. Histological Features of Localized Scleroderma en Coup De Sabre : A Study of 6 Cases. Takashi Taniguchi, Yoshihide Asano, Zenshiro Tamaki, Kaname Akamata, Naohiko Aozasa, Shinji Noda, Takehiro Takahashi, Yohei Ichimura, Tetsuo Toyama, Miki Sugita, Hayakazu Sumida, Yoshihiro Kuwano, Miki Miyazaki, Koichi Yanaba and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan 709. Fingertip Skin Hardness in Limited Scleroderma: Durometry versus Manual Assessment. Thomas Osborn, Eric Matteson, Floranne Ernste, Cynthia S. Crowson, Deana D. Hoganson and Irene Z. Whitt 4, Mayo Clinic, Rochester, MN, Mayo Clinic Rochester, Rochester, MN, Mercy Arthritis and Osteoporosis Center, Urbandale, IA, 4 NIH/NIEHS/ Environmental Autoimmunity Group, Bethesda, MD 70. Optical Density Measure of the Papillary Dermis Discriminates As Abnormal Clinically Uninvolved Skin in Systemic Sclerosis and Correlates with Severity of Skin Thickness. Giuseppina Abignano, Sibel Z. Aydin, Concepcion Castillo-Gallego Jr., Daniel Woods 4, Adam Meekings 4, Dennis McGonagle, Paul Emery and Francesco Del Galdo, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, Hospital Universitario La Paz, Madrid, Spain, 4 Michelson Diagnostics Ltd, Kent, United Kingdom, Kent, United Kingdom 7. Myopathy Is a Poor Prognostic Feature in Systemic Sclerosis: Results From the Canadian Scleroderma Research Group. MIchelle Jung, Murray Baron, Marie Hudson, Ashley Bonner 4, Janet E. Pope 5 and Canadian Scleroderma Research Group 6, Western University, London, ON, Jewish General Hospital, Montreal, QC, McGill University, Montreal, QC, 4 McMaster University, Hamilton, ON, 5 St. Joseph Health Care London, University of Western Ontario, London, ON, 6 Montreal, QC 7. Autoantibodies to Survival of Motor Neuron (SMN) Complex Are Common in Patients with Anti-URNP/Sm and Are Associated with Features of Scleroderma and Myopathy. Jason YF Chan, Yi Li, Angela Ceribelli, Eric S. Sobel, Westley H. Reeves, Edward K.L. Chan and Minoru Satoh, University of Florida, Gainesville, FL 7. Rpp5 Is a Major Target of Autoantibodies to the Th/to Complex As Measured by ELISA and a New Chemilumiscence Assay. Michael Mahler, Cristina Gascon, Sima Patel, Angela Ceribelli, Edward K.L. Chan and Minoru Satoh, INOVA Diagnostics, Inc., San Diego, CA, University of Florida, Gainesville, FL 74. Line Blot Assay, a Screening Test for Autoantibodies in Systemic Sclerosis (SSc). Kae Takagi, Yasushi Kawaguchi, Sayuri Kataoka, Yuko Ota, Yuko Okamoto, Masanori Hanaoka, Hisae Ichida, Takahisa Gono, Yasuhiro Katsumata and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Tokyo Women s Medical University, Tokyo, Japan, Institute of Rheumatology,Tokyo Women s Medical University, Tokyo, Japan 75. WITHDRAWN. 76. Utility of Novel Patient-Reported Outcome Instruments in Predicting Cardiac Involvement and Pulmonary Hypertension in Patients with Systemic Sclerosis. Monique E. Hinchcliff, Mary A. Carns, Sofia Podlusky, John Varga and Sanjiv J. Shah, Northwestern University Feinberg School of Medicine, Chicago, IL 77. Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative. Lesley Ann Saketkoo, Reuben Escorpizo, Kevin J. Keen, Kim Fligelstone 4 and Oliver Distler 5, Louisiana State University Health Science Center, New Orleans, LA, ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications Department of Health Sciences; and Health Policy, University of Lucerne, Switzerland, University of Northern British Columbia, Prince George, BC, 4 Royal Free Hospital, Scleroderma Unit and Scleroderma 96 0 Program Book

199 ACR POSTER SESSION A Society, London, United Kingdom, 5 Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland 78. Worsening Carbon Monoxide Diffusing Capacity Predicts Mortality in Patient with Systemic Sclerosis and Pulmonary Arterial Hypertension Enrolled in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Elena Schiopu, Dinesh Khanna, Virginia D. Steen and PHAROS Investigators, University of Michigan, Ann Arbor, MI, Georgetown Univ Medical Center, Washington, DC, Washington DC 79. Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study. Zsuzsanna H. McMahan, Florian Schoenhoff, Jennifer van Eyk, Fredrick M. Wigley and Laura K. Hummers, Johns Hopkins University, Baltimore, MD, Berne, Switzerland 70. Left-Heart Disease Is a Frequent Cause of Pulmonary Hypertension in Systemic Sclerosis, Is Associated with Increased Levels of MR-ProANP and MR-ProADM but Is Unrelated to Elevated NT-ProBNP Levels: A Retrospective Cohort Analysis. Lada Miller, Sandra Chartrand, Martial Koenig, Jean-Richard Goulet, Eric Rich, Michal Abrahamowicz, Jean-Luc Senécal and Tamara Grodzicky, Hôpital Notre-Dame du CHUM, Montreal, QC, Hôpital Notre-Dame du CHUM, Montréal, QC, Centre Universitaire de Santé McGill (CUSM), Montreal, QC 7. Measurement of Pulmonary Arteries by Cardiac Magnetic Resonance Imaging: A Simple and Useful Tool for the Detection of Pulmonary Hypertension in Systemic Sclerosis Patients without Overt Cardiac Microvascular Perfusion Defects or Fibrosis. Sandra Chartrand, Lada Miller, Martial Koenig, Jean-Richard Goulet, Eric Rich, Anne S. Chin, Yves Provost, Carl Chartrand-Lefebvre, Pauline Gou, Jean-Luc Senécal and Tamara Grodzicky, Hôpital Notre-Dame du CHUM, Montréal, QC, Hôtel-Dieu de Montréal du CHUM, Montréal, QC 7. Systemic Sclerosis Associated Pulmonary Hypertension - Is Pulmonary Veno-Occlusive Disease As Common As They Say? Benjamin E. Schreiber, Greg Keir, D. Dobarro, Clive Handler, Svetlana Nihtyanova 4, Jay Suntharaligam 5, Nicola Sverzelatti 6, Graham Robinson 5, David Hansell 7, Athol U. Wells, Christopher P. Denton 8 and John G. Coghlan, Royal Free Hospital, London, London, United Kingdom, Royal Brompton Hospital, United Kingdom, Royal Free Hospital, London, United Kingdom, 4 Royal Free Hospital, Medical School, London, England, 5 Royal United Hospital, Bath, United Kingdom, 6 University of Parma, Parma, Italy, 7 Royal Brompton Hospital, London, United Kingdom, 8 UCL, London, United Kingdom 7. Renal Dysfunction and Disease Severity in Scleroderma- Associated Pulmonary Arterial Hypertension. Stephen C. Mathai, Laura K. Hummers and Virginia D. Steen, Johns Hopkins University, Baltimore, MD, Georgetown Univ Medical Center, Washington, DC 74. Survival, Hospitalization or Need for Combination Therapy at One Year in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension. Robyn T. Domsic, Lorinda Chung, Jessica K. Gordon, Yona Cloonan, Virginia D. Steen 4 and PHAROS Investigators 5, University of Pittsburgh, Pittsburgh, PA, Stanford Univ Medical Center, Palo Alto, CA, Hospital for Special Surgery, New York, NY, 4 Georgetown Univ Medical Center, Washington, DC, 5 Washington, DC 0 Program Book 97

200 ACR POSTER SESSION B Monday, NOVEMBER, 0 Poster Hall (Hall B) Cytokines, Mediators, and Gene Regulation 87. Monocyte Chemoattractant Protein- and Eotaxin Are Associated with Parameters of Cardiac Dysfunction in Juvenile Dermatomyositis. Thomas Schwartz, Ivar Sjaastad, Berit Flatø, Maria Vistnes, Geir Christensen and Helga Sanner, Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway 87. Imbalance between Histone Acetyl Transferase and Histone Deacteylase Activities and Modulation of HDAC Activity and Tnfa Production by HDAC Inhibitors in Patients with Ankylosing Spondylitis or Rheumatoid Arthritis. Eric Toussirot, Wasim Abbas, Kashif Aziz Khan, Marion Tissot, Alicia Jeudy, Lucile Baud, Ewa Bertolini 4, Daniel Wendling 5, Georges Herbein 6 and CIC Biotherapy 7, CIC Biotherapy 50 6 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, EA 466 Pathogens and Inflammation, Besançon, France, EA Pathogens and Inflammation, Besançon, France, 4 Rheumatology, Besançon, France, 5 Minjoz University Hospital, Besancon, France, 6 Virology and EA 466 Pathogens and Inflamamtion, Besançon, France, 7 University Hospital, Besançon, France 874. TNFα Induces Sustained Signaling and a Prolonged and Unremitting Inflammatory Response in Synovial Fibroblasts. Angela Lee, Galina Grigoriev, Janice Chen, Lionel B. Ivashkiv and George D. Kalliolias, Hospital for Special Surgery, New York, NY 875. Discovery of Pharmacologic MIF Antagonists by Structure- Based Molecular Design. William L. Jorgensen, Alissa A. Hare, Zoe Cournia, Sunilkumar Gandavadi, Xin Du, Lin Leng and Richard J. Bucala, Yale University, New Haven, CT, Yale University School of Med, New Haven, CT 876. Xanthine Oxidase-Derived ROS Direct Context-Dependent Action of NFAT5 Toward Inflammatory Response in Macrophages. Nam Hoon Kim, Catholic university of Korea, Seoul of Korea, Seoul, South Korea 877. Aberrant Expression of BAFF Receptor (BR) in Peripheral Monocytes of Patients with Primary Sjögren s Syndrome Impacts Abnormal Activation of BAFF Signaling Through IKK-Alphaand IKK-Beta. Keiko Yoshimoto, Maiko Tanaka, Masako Kojima, Hideko Ogata, Hideto Kameda, Katsuya Suzuki, Tohru Abe and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Saitama Medical School, Kawagoe-shi Saitama, Japan 878. Differential Regulation of Cytokines by Extracellular- Signal Regulated Kinase and c-jun N-Terminal Kinase in Map Kinase Kinase- and -6 Deficiency. Deepa Hammaker, Katharyn Topolewski, Monica Guma, David L. Boyle and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA 879. Fucosyltransferase (fut) is Overexpressed in Rheumatoid Arthritis Synovial Tissue and Modifies Cytokine Production. Takeo Isozaki, Jeffrey H. Ruth, M. Asif Amin, Phillip L. Campbell, Steven E. Domino, G. Kenneth Haines III and Alisa E. Koch, University of Michigan, Ann Arbor, MI, Yale University, New Haven, CT, University of Michigan Medical School, Ann Arbor, MI 880. Interferon Regulatory Factor 8 Regulates BAFF Production in Murine Macrophages and Is a Nexus for Cross Talk Between IFN-γ and TGF-β. Weijia Yuan, Sanjay Gupta, Jane E. Salmon and Alessandra B. Pernis, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 88. Microrna-55 Regulates Chemokines and Chemokine Receptors in Rheumatoid Arthritis Monocyte. Aziza Elmesmari, Derek S. Gilchrist, Alasdair R. Fraser, Diane Vaughan, Ross McQueenie, Gerard J. Graham, James Brewer, Iain B. McInnes and Mariola Kurowska-Stolarska, Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom 88. Anti-Inflammatory Effects of Phosphodiesterase 4 Inhibition Are Mediated by Mitogen-Activated Protein Kinase Phosphatase-. Riku Korhonen, Tuija Hömmö, Mirka Laavola, Tiina Keränen, Mari Hämäläinen and Eeva Moilanen, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland 88. Role of Phospholipase D (PLD) in the Expression of Proinflammatory Genes in Rheumatoid Arthritis Synovial Fibroblasts (RASF). Sean C. Friday and David A. Fox, The University of Michigan, Ann Arbor, MI, Univ of Michigan Med Ctr, Ann Arbor, MI 884. Receptor Activator of Nuclear Factor ÊB Ligand-Mediated Osteoclastogenesis Is Augmented by Interleukin-â via up-regulation of Endoplasmic Reticulum Stress Signals. Myong-Joo Hong, Myung-Soon Sung, Eun-Gyeong Lee, Yoon Kyung Hong, Chang-Hoon Lee, Myeung Su Lee and Wan-Hee Yoo, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, Reumatology, Iksan, Chonbuk, South Korea 885. Interferon α and Self-Organized Criticality Theory. Shunichi Shiozawa, Yumi Miyazaki and Ken Tsumiyama, Kyushu University Beppu Hospital, Beppu, Japan, Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan 886. Association between Neutrophil Gene Signature and Disease Characteristics in Systemic Lupus Erythematosus Patients. Michelle Petri, Hong Fang, Jadwiga Bienkowska, Norm Allaire, Jeff Browning and Susan Kalled, Johns Hopkins University School of Medicine, Baltimore, MD, Biogen Idec Inc., Cambridge, MA 98 0 Program Book

201 ACR POSTER SESSION B 887. WITHDRAWN Plasma Cells Express the Novel Cytokine Interleukin-6α in Psoriatic and Rheumatoid Arthritis Synovium. Anja Derer, Silke Frey, Maria-Elena Messbacher, Serena Bugatti, D. Baeten, Carlomaurizio Montecucco 4, Georg A. Schett 5 and Axel J. Hueber, University of Erlangen, Erlangen, Germany, Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4 University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, 5 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 889. Modeling Environmental and Genetic Determinants to Identify the Association of Risk Genes in Anti-Ro60- Mediated Injury: Relaxin Receptor I and Tumor Necrosis Factor. Joanne H. Reed, Paula S. Ramos, Jiri Zavadil, Jill P. Buyon and Robert M. Clancy, New York University School of Medicine, New York, NY, Medical University of South Carolina, Charleston, SC 890. The Role of Adipocytokines in Osteophyte Formation in Osteoarthritis. Susann Junker, Grit Krumbholz, Klaus Frommer, Angela Lehr, Stefan Rehart, Jürgen Steinmeyer, Markus Rickert 4, Georg A. Schett 5, Ulf Müller-Ladner and Elena Neumann 6, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, Markus-Hospital, Frankfurt, Germany, University Hospital Gießen and Marburg, Gießen, Germany, 4 University Hospital Giessen and Marburg, Giessen, Germany, 5 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 6 Justus- Liebig-University of Gießen, Kerckhoff-Klinik, Bad Nauheim, Germany 89. Fatty Acids Promote Secretion of Proinflammatory and Prodestructive Factors by Synovial Fibroblasts. Klaus W. Frommer, Andreas Schäffler, Stefan Rehart, Angela Lehr, Ulf Müller-Ladner and Elena Neumann, Justus-Liebig- University of Gießen, Bad Nauheim, Germany, University of Regensburg, Regensburg, Germany, Markus-Hospital, Frankfurt, Germany 89. The Epigenetically Repressed Long Noncoding RNA Hotair Influences the Expression of Matrix Metalloproteases in Synovial Fibroblasts. Michelle Trenkmann, Matthias Brock, Renate E. Gay, Beat A. Michel, Lars C. Huber and Steffen Gay, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 89. Nuclear Factor-κB Activation by Type II Collagen Peptide in Osteoarthritic Chondrocytes: Its Inhibition by Hyaluronan Via CD44. Tadashi Yasuda, Tenri University, Tenri, Japan 894. Genetic Variants in the IL- 4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts. A. Krabben, A. G. Wilson, R. Knevel, A. Zhernakova, E. Brouwer, E. Lindqvist 4, T. Saxne 4, G. Stoeken-Rijsbergen, J. A. B. van Nies, D. P. C. de Rooy, T.W.J. Huizinga, B. P. C. Koeleman 5, R. E. M. Toes, P. K. Gregersen 6 and A. H. M. van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands, University of Sheffield, Sheffield, United Kingdom, University of Groningen, University Medical Center, Groningen, Netherlands, 4 Lund University, Lund, Sweden, 5 University Medical Center Utrecht, Utrecht, Netherlands, 6 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY 895. Transcriptomics of Synovial Tissue of Early Human (CHECK) and Experimental OA Identify Pathways Associated with Cartilage Damage. Arjen B. Blom, Peter L.E.M. van Lent, Martijn H. van den Bosch, Hans Cats, Peter M. van der Kraan and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Sint Maartenskliniek, Nijmegen, Netherlands, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 896. Tyro, Axl, MerTK-Receptor Activation by Gas6 or Pros Gene Delivery, ameliorates Collagen-induced arthritis. Fons A.J. van de Loo, Ben T. van Den Brand, Shahla Abdollahi- Roodsaz, Eline A. Vermeij, Miranda B. Bennink, Onno J. Arntz and Wim B. van den Berg, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Nijmegen, Netherlands 897. IL- Promotes Mast Cell Survivial Via Inhibition of Apoptosis Associated with Enhanced Expression of Bcl-XL. Shinjiro Kaieda, Jun-Xia Wang and Peter A. Nigrovic, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Brigham and Women s Hospital, Boston, MA 898. Nuclear Receptor Related Induces Synovial Hyperplasia via Transcriptional Regulation of Novel Target Genes. Kimberlee S. Mix, Loyola University New Orleans, New Orleans, LA 899. A Role for Soluble Interleukin-6 Receptor as an Antagonist of Interleukin-7 Signaling. Misato Hashizume, Keiko Esaki and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan 900. Deletion of RBP-J in a Murine Model of Inflammatory Arthritis Reveals Differential Pro-Inflammatory Cytokine and FoxP Gene Expression. Soumya D. Chakravarty, Karmen Au, Xiaoyu Hu and Lionel B. Ivashkiv, Hospital for Special Surgery, New York, NY 90. Colony-Stimulating Factor (CSF) Receptor Blockade Overcomes Overlapping Effects of M-CSF and Interleukin-4 On Myeloid Differentiation and Gene 0 Program Book 99

202 ACR POSTER SESSION B 00 Expression to Reduce Inflammation in Human and Murine Models of Rheumatoid Arthritis. Samuel Garcia, Linda M. Hartkamp, Inge E. van Es, Haishan Lin, Li Long, Emma L. Masteller, Brian R. Wong, Paul P. Tak and Kris A. Reedquist, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Five Prime Therapeutics, Inc., South San Francisco, CA, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 90. Activation of NF-Kb Via Poly(I:C)-Induced Monocyte- Derived Microparticles Decreases TRAIL-Induced Apoptosis of Rheumatoid Arthritis Synovial Fibroblasts. Mojca Frank Bertoncelj, Blaz Rozman, Beat A. Michel, Renate E. Gay, David S. Pisetsky 4, Oliver Distler 5, Steffen Gay 6 and Astrid Juengel, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4 Duke University Medical Center, Durham, NC, 5 Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6 Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, CH-809, Switzerland 90. NR4A Mediates Anti-Inflammatory Effects of Apoptotic Cells. Natacha Ipseiz, Stefan Uderhardt, Georg A. Schett and Gerhard Kronke, University of Erlangen, Erlangen, Germany, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II 904. Perinatal Characteristics, Maternal Reproductive History and Juvenile Idiopathic Arthritis: A Case-Control Study. Samantha W. Bell, Beth A. Mueller, J. Lee Nelson, Parveen Bhatti and Susan Shenoi, University of Washington, Seattle, WA, Fred Hutchinson Cancer Rsch, Seattle, WA, Seattle Children s Hospital, University of Washington, Seattle, WA 905. The Association between Lower Body Mass Index and Increased Risk of Giant Cell Arteritis Is Not Explained by Differences in Physical Activity. Karin Jakobsson, Lennart T.H. Jacobsson, Kenneth J. Warrington, Eric L. Matteson, Kimberly P. Liang, Olle Melander and Carl Turesson, Lund University, Malmö, Sweden, Mayo Clinic, Rochester, MN, University of Pittsburgh, Pittsburgh, PA 906. Patient-Rheumatologist Communication Concerning Medication and Disease Risks. Susan J. Blalock, University of North Carolina at Chapel Hill, Chapel Hill, NC 0 Program Book 907. Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis. Liana Fraenkel, Charles Cunningham, Gillian A. Hawker and Lisa G. Suter 4, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, McMaster University, Hamilton, ON, Women s College Research Institute, University of Toronto, Toronto, ON, 4 Yale University, New Haven, CT 908. Race, Gender and Total Knee Replacement Consideration: The Role of Social Support. Ernest R. Vina, Yona Cloonan, Said Ibrahim, Michael J. Hannon 4, Robert M. Boudreau and C. Kent Kwoh, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA 909. Determinants of Patient Preferences for Total Knee Replacement: A Comparison of Whites and African- Americans. C. Kent Kwoh, Robert M. Boudreau, Yona Cloonan, Michael J. Hannon, Ernest R. Vina and Said Ibrahim 4, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 90. The Cost-Effectiveness of Total Joint Arthroplasty: A Systematic Review of Published Literature. Meghan E. Daigle, Alexander M. Weinstein, Jeffrey N. Katz and Elena Losina, Brigham and Women s Hospital, Boston, MA 9. Race- and Sex-Specific Estimates of 0-, 0 -, 0-Year, and Lifetime Risk of Diagnosed Symptomatic Knee Osteoarthritis and the Need for TKR in the US. Elena Losina, Meghan E. Daigle, Sara A. Burbine and Jeffrey N. Katz, Brigham and Women s Hospital, Boston, MA 9. Clinical Features Associated with Progression of Knee Radiographic Osteoarthritis: Data From the Osteoarthritis Initiative. Michelle S. Yau, Laura Yerges-Armstrong, Braxton D. Mitchell and Marc C. Hochberg, University of Maryland School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 9. Consultation Prevalence of Osteoarthritis in Southern Sweden. Aleksandra Turkiewicz, Ingemar F. Petersson, Jonas Björk, Leif E. Dahlberg and Martin Englund, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden, Lund, Sweden 94. Prognosis for the Year 00: The Consultation Prevalence of Osteoarthritis in Sweden May Increase by 50%. Aleksandra Turkiewicz, Ingemar F. Petersson, Jonas Björk, Leif E. Dahlberg and Martin Englund, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden, Lund, Sweden

203 ACR POSTER SESSION B 95. Incidence of Knee, Hip, and Hand Clinical Osteoarthritis: A Population-Based Cohort Study. Daniel Prieto-Alhambra, Aina Pagès-Castellà, M. Kassim Javaid, Andrew Judge 4, Cyrus Cooper 5, Nigel K. Arden and Adolfo Díez-Pérez 6, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, IDIAP Jordi Gol; Institut Català de la Salut, Barcelona, Spain, Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, 4 Oxford University, Oxford, United Kingdom, 5 University of Oxford; Southampton General Hospital, Southampton, United Kingdom, 6 Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain 96. Population Incidence of Soft Tissue Knee Injury: Estimates From a Swedish Health Care Register. Charlotte Bergknut, George Peat, Richard Frobell and Martin Englund, Lund University, Lund, Sweden, Arthritis Research UK Primary Care Centre, Keele University, United Kingdom, Department of Orthopedics, Clinical Sciences Lund, Lund University, Sweden, Sweden 97. Feasibility of Remote Activity and Functional Status Monitoring of Patients with Hip or Knee Pain. Pim Jetanalin, Hyeon Eui Kim, Zia Agha, Nathaniel Heintzman, Lucila Ohno-Macado and Susan J. Lee, University of California, San Diego, La Jolla, CA, San Diego Veterans Affairs Medical Center, San Diego, CA 98. Impact of Comorbidities On Measuring Indirect Utility by the Medical Outcomes Study Short Form 6D in Lower-Limb Osteoarthritis. Kossar Hosseini, Cécile Gaujoux-Viala, Joel Coste, Jacques Pouchot, Bruno Fautrel, Anne-Christine Rat and Francis Guillemin, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , France, Nancy, France, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy; Paris 6 Pierre et Marie Curie University; Rheumatology, Pitié- Salpêtrière Hospital, Paris, France, Paris VI University, Paris, France 99. Sedentary Time, Physical Activity, and Concurrent Blood Pressure in Osteoarthritis Initiative Participants. Min- Woong Sohn, Rowland W. Chang, Grace Ahn, Linda S. Ehrlich-Jones, Marc C. Hochberg, Jungwha Lee, Michael C. Nevitt 4, Pamela A. Semanik 5, Jing Song, Kai Sun 6 and Dorothy D. Dunlop, Northwestern University, Chicago, IL, Rehabilitation Institute Chicago, Chicago, IL, University of Maryland, Baltimore, MD, 4 University of California-San Francisco, San Francisco, CA, 5 Northwestern University, IL, 6 Northwestern University, Feinberg School of Medicine, Chicago, IL 90. A Multimodal Intervention to Improve Osteoporosis Care in Home Health Settings: Results from a Cluster Randomized Trial. Meredith Kilgore, Kenneth G. Saag, Jeroan Allison, Elizabeth Kitchin 4, Julie L. Locher, Amy Mudano 4, Ryan C. Outman and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama-Birmingham, Birmingham, AL, University of Massachusetts Medical School, 4 Birmingham, AL 9. Association between Metabolic Syndrome and Bone Mineral Density in a Community-Dwelling Older Women: The São Paulo Ageing & Health Study (SPAH). Luana G. Machado, Diogo S. Domiciano, Jaqueline B. Lopes, Camille P. Figueiredo, Valéria Caparbo, Liliam Takayama and Rosa M.R. Pereira, University of São Paulo, São Paulo, Brazil 9. Risk of Fracture among Treated and Untreated Men with Osteoporosis. Karen Tomic, Joanne Lafleur, Liisa Palmer, David M. Smith, Carly J. Paoli, Irene Agodoa and Nicole Yurgin, Truven Health Analytics, Washington, DC, University of Utah College of Pharmacy, Salt Lake City, UT, Amgen Inc, Thousand Oaks, CA 9. Low Bone Mineral Density and Higher Parathyroid Hormone Levels As Independent Factors to All-Cause Mortality in Community-Dwelling Older Adults: the São Paulo Ageing & Health Study (SPAH). Diogo S. Domiciano, Luana G. Machado, Jaqueline B. Lopes, Camille P. Figueiredo, Valéria Caparbo, Liliam Takayama, Eloisa Bonfa and Rosa M.R. Pereira, University of São Paulo, São Paulo, Brazil 94. Methods to Link a U.S. Arthritis Cohort with Medicare Administrative Claims Data. Jeffrey R. Curtis, Lang Chen, Timothy Beukelman, Aseem Bharat, Fenglong Xie, Kenneth G. Saag and Elizabeth S. Delzell, Univ of Alabama- Birmingham, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL 95. Use of Rheumatology Services for Arthritis: The Role of SES and Geographic Availability of Rheumatologists and Primary Care Physicians. E. M. Badley, Mayilee Canizares and Aileen M. Davis, Division of Health Care and Outcomes Research,Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Division of Health Care and Outcomes Research,Toronto Western Research Institute, Toronto, ON, Toronto, ON, Division of Health Care and Outcomes Research, Toronto Western Research Institute, Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON 96. Accuracy of Canadian Health Administrative Databases in Identifying Patients with Rheumatoid Arthritis Using a Random Sample of 7500 Patients Seen in Primary Care. Jessica Widdifield, Claire Bombardier, Sasha Bernatsky, J. Michael Paterson, Jacqueline Young, Diane Green, J. Carter Thorne 4, Noah Ivers, Debra Butt, R. Liisa Jaakkimainen, Myra Wang, Vandana Ahluwalia 5, George A. Tomlinson 6 and Karen Tu, University of Toronto, Toronto, ON, Research Institute of the McGill University Health Ctre, Montreal, QC, Institute for Clinical Evaluative Sciences, Toronto, ON, 4 Southlake Regional Health Centre, Newmarket, ON, 5 William Osler Health Center, Mississauga, ON, 6 Toronto General Hospital, Toronto, ON 0 Program Book 0

204 ACR POSTER SESSION B 97. Shared Decision Making in Secondary Care: Rheumatologic Patient s Perspective. Raphael Battisti, Thiago D. Baumgratz, Mirella Cuziol, Ana Carolina Reiff Janini, Roger A. Levy Sr. and Mirhelen M. Abreu 4, Medical Student, São Carlos, Brazil, Medical Student at Universidade Federal de São Carlos, São Carlos, Brazil, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, 4 Universidade Federal de São Carlos, São Carlos, Brazil 98. Is There an Optimal Treatment Strategy for Disease- Modifying-Antirheumatic-Drug Naïve Patients with Rheumatoid Arthritis? Roopa Akkineni and Daniel A. Albert, Dartmouth Hitchcock Medical Center, Lebanon, NH, Dartmouth-Hitchcock Med Ctr, Lebanon, NH 99. Epidemiology of the US National Burden of Pediatric Lupus Hospitalization From Andrea Knight, Pamela Weiss, Knashawn Morales and Ron Keren, Children s Hospital of Philadelphia, Philadelphia, PA, The Children s Hospital of Philadelphia, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA 90. Disease Burden and Cost of Illness in SLE During 8 Years Follow up. Andreas Jönsen, anders A. Bengtsson, Frida Hjalte, Minna Willim, Ragnar Ingvarsson, Ulf Persson, Ingemar F. Petersson 4 and Ola Nived 5, Section of Rheumatology, Lund, Sweden, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, Lund, Sweden, 4 Musculoskeletal Scienes, Department of Orthopedics, Clinical Sciences, Lund, Sweden, 5 University Hospital - Lund, Lund, Sweden 9. Health Care Utilization among Medicaid Enrollees with Systemic Lupus Erythematosus Preceding the Development of End-Stage Renal Disease: Sociodemographic Variation. Candace H. Feldman, Linda T. Hiraki, Graciela S. Alarcon, Jinoos Yazdany 4, Jun Liu 5, Michael A. Fischer, Wolfgang C. Winkelmayer 6 and Karen H. Costenbader 7, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital/ Harvard School of Public Health, Boston, MA, University of Alabama at Birmingham, Birmingham, AL, 4 University of California San Francisco, San Francisco, CA, 5 Brigham and Women s Hospital, Harvard Medical School, Boston, Boston, MA, 6 Stanford University School of Medicine, Stanford, CA, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 9. Medical Costs and Health Care Resource Use in Patients with Systemic Lupus Erythematosus in an Insured Population. Daniel E. Furst, Ann E. Clarke, Ancilla W. Fernandes, Tim Bancroft 4, Kavita Gajria, Warren Greth 5 and Serban R. Iorga 4, UCLA Medical School, Los Angeles, CA, McGill University, Montreal, QC, MedImmune LLC, Gaithersburg, MD, 4 OptumInsight, Eden Prairie, MN, 5 MedImmune, LLC, Gaithersburg, MD 9. Economic Burden of Systemic Lupus Erythematosus by Flare Severity in a Commercially Insured Population in the United States. Siva Narayanan, Emily Durden, Alan Oglesby, Paul Juneau 4 and Kathleen L. Wilson 5, Human Genome Sciences, Inc., Rockville, MD, Thomson Reuters, Austin, TX, GlaxoSmithKline, Research Triangle Park, NC, 4 Truven Health Analytics, Washington, DC, 5 Thomson Reuters Healthcare, Cambridge, MA 94. Direct Medical Cost Associated with Organ System Involvement in a Commercially Insured Population with Systemic Lupus Erythematosus in the United States. Alan Oglesby, Emily Durden, Siva Narayanan, Paul Juneau 4 and Kathleen L. Wilson 5, GlaxoSmithKline, Research Triangle Park, NC, Thomson Reuters, Austin, TX, Human Genome Sciences, Inc., Rockville, MD, 4 Truven Health Analytics, Washington, DC, 5 Thomson Reuters Healthcare, Cambridge, MA 95. Primary Care Preventive Services in Patients with Systemic Lupus Erythematosus Compared to Others in Their Community. Cristina Drenkard, Kimberley Rask, Gaobin Bao, Gnanesh Patel, Suparna Bagchi and S. Sam Lim, Emory University, Atlanta, GA, Georgia Department of Public Health, Atlanta, GA 96. Autoimmune Diseases: Declining Mortality Between 99 9 and 008 However Continuing to be a Leading Cause of Death in Children-A 0-Year Retrospective Review. Eric Y. Yen and Deborah K. McCurdy, Mattel Children s Hospital, University of California at Los Angeles, Los Angeles, CA, Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA 97. Changes in Ten Year Survival among SLE Patients at an Academic Center in North America (970-0). Joseph F. Merola, Bonnie L. Bermas, Bing Lu, Peter Hsun Tsao, Tabatha Norton, Christina Iversen, Elizabeth W. Karlson, Peter H. Schur and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 98. Hospitalizations in Systemic Lupus Erythematosus: A Longitudinal Study. Hong Fang, Jie Xu and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 99. Shared High Risk of Intensive Care Unit Admission in Three Autoimmune Inflammatory Diseases. Christine Peschken, Carol A. Hitchon, Allan Garland, Charles N. Bernstein, Randy Fransoo and Ruth Ann Marrie, University of Manitoba, Winnipeg, MB 940. Incidence of Systemic Lupus Erythematosus in England, Herve Caspard, Amy Steffey, Jie Li and Trung N. Tran, MedImmune LLC, Gaithersburg, MD, MedImmune, Gaithersburg, MD 94. Validity and Reliability of the Systemic Lupus Activity Questionnaire (SLAQ): A Prospective Study. Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan 94. Validity and Reliability of the Lupus Damage Index Questionnaire (LDIQ): A Prospective Study. Yuko Okamoto, Yasuhiro Katsumata, Yasushi Kawaguchi, Sayumi Baba, Kae 0 0 Program Book

205 ACR POSTER SESSION B Takagi, Hisae Ichida, Takahisa Gono, Masanori Hanaoka, Yuko Ota and Hisashi Yamanaka, Tokyo Women s Medical University, Tokyo, Japan 94. Impact of Systemic Lupus Erythematosus on Work Productivity and Income in the United States. Alan Oglesby, Ellen Sulcs, Siva Narayanan, Mechele Lee and Cindy Garris, GlaxoSmithKline, Research Triangle Park, NC, Harris Interactive Inc., Rochester, NY, Human Genome Sciences, Inc., Rockville, MD 944. Job-Related Burden and Effort-Reward Imbalance in Patients with Systemic Lupus Erythematosus. Jutta G. Richter, Thomas Muth, Ralph Brinks, Tobias Koch, Johannes Siegrist, Nicole Hoffmann, Peter Angerer and Matthias Schneider, Heinrich-Heine-University, Duesseldorf, Germany 945. Work Loss in Systemic Lupus Erythematosus, the General Public, and Other Chronic Conditions. S. Sam Lim, Greg Dennis, Hong Kan, Priti M. Jhingran 4, Charles T. Molta 5, Gaobin Bao and Cristina Drenkard, Emory University, Atlanta, GA, Human Genome Sciences, Inc., Rockville, MD, GlaxoSmithKline, Research Triangle Park, NC, 4 GlaxoSmithKline R&D, Research Triangle Park, NC, 5 GlaxoSmithKline, Philadelphia, PA 946. Self-Reported Disease Activity and Health-Related Quality of Life in a Longitudinal Cohort of Patients with Systemic Lupus Erythematosus. Siva Narayanan, Ellen Sulcs, Alan Oglesby, Cindy Garris 4 and Mechele Lee, Human Genome Sciences, Inc., Rockville, MD, Harris Interactive Inc., Rochester, NY, GlaxoSmithKline, Research Triangle Park, NC, 4 GlaxoSmithKline R&D, Research Triangle Park, NC 947. The Impact of Dyspigmentation and Scarring in Cutaneous Lupus On Quality of Life. Saroj M. Verma, Joyce Okawa, Kathleen Propert and Victoria P. Werth, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA 948. Antibody-Based Prediction Rules for Connective Tissue Disease: Analysis of,555 Patients with Antinuclear Antibody Testing. Ryo Rokutanda, Mitsumasa Kishimoto, Yasuharu Tokuda, Ken-ichi Yamaguchi, Hisanori Shimizu, Yasuhiro Suyama, Yuri Ohara, Yoichiro Haji, Chisun Min, Akira Takeda, Yukio Matsui and Masato Okada, St. Luke s International Hospital, Tokyo, Japan, University of Tsukuba, Ibaraki, Japan 949. The Inverse Association between Obesity and Anti-Nuclear Antibodies Is Modified by Systemic Inflammation and Maybe Associated with Body Composition. Irene Blanco, Monalyn Labitigan and Matthew Abramowitz, Albert Einstein College of Medicine, Bronx, NY 950. Performance of Various Anti-Nuclear Antibody Methodologies in the Assessment of Autoimmune Connective Tissue Diseases. Xiaoli Deng, Cynthia S. Crowson, Helen Khun, Melissa R. Snyder and Kevin G. Moder, Mayo Clinic, Rochester, MN 95. A Systematic Review of Quality of Prognosis Studies in Systemic Lupus Erythematosus. Lily Siok Hoon Lim, Senq-J Lee, Brian M. Feldman, D. D. Gladman, Eleanor Pullenayegum 4 and Earl D. Silverman 5, Hospital for Sick Children, Toronto, ON, The Hospital for Sick Children, Toronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 McMaster University, Hamilton, ON, 5 Pediatric Rheumatology Collaborative Study Group (PRSCG), Toronto, ON Fibromyalgia and Soft Tissue Disorders 95. Cognitive Behavioral Therapy and Milnacipran in Combination Appears to Be More Efficacious Than Either Therapy Alone. Dennis C. Ang, Mark P. Jensen, Jennifer L. Steiner, Janna Hilligoss, Richard Gracely 4 and Chandan Saha 5, Indiana University, Indianapolis, IN, Seattle, WA, Indianapolis, IN, 4 Chapel Hill, NC, 5 Indiana University 95. Comparative Symptom Severity of Patients Satisfying Chronic Widespread Pain and Fibromyalgia Criteria. Frederick Wolfe, Brian Wallitt, Robert S. Katz and Winfried Häuser 4, National Data Bank for Rheumatic Diseases, Wichita, KS, Washington Hospital Center, Baltimore, MD, Rush University Medical Center, Chicago, IL, 4 Klinikum Saarbrücken, Saarbrücken, Germany 954. Diagnosis of Secondary Fibromyalgia in an Established Rheumatoid Arthritis Cohort. Yvonne C. Lee, Christine K. Iannaccone, Michelle A. Frits, M. Weinblatt and Nancy A. Shadick, Brigham and Women s Hospital, Boston, MA, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA 955. Post Surgical Outcome Is Correlated with Pre Surgical Symptoms of Fibromyalgia in Patients Undergoing Spinal Surgery. Jacob N. Ablin, Mark Berman, Eyal Behrbalk, Dan Buskila, Gilad Regev and Zvi Lidar, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Department of Neurosurgery and Orthopedic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, Beer-Sheva, Israel 956. Learning Disability in Fibromyalgia Patients: FMS Patients Report More Language and Spatial Difficulties. Robert S. Katz, Alexandra Small, Carlen Katz and Susan Shott, Rush University Medical Center, Chicago, IL, University of Illinois Medical School, Rheumatology Associates, Chicago, IL 957. Key Psychological Processes Associated with the Fibromyalgia Phenotype Exist On a Continuous Spectrum with Asymptomatic People. Katrina Malin and Geoffrey O. Littlejohn, Monash University, Clayton, Australia, Monash Medical Centre and Monash University, Clayton, Victoria, Australia 0 Program Book 0

206 ACR POSTER SESSION B 958. Prevelance of Spondyloarthropathy in Fibromyalgia Patients. A.Eftal Yucel, Derya Kaskari and Muhtesem Agýldere, Baskent University, Ankara, Turkey 959. Treatment of Lateral Epicondylitis with Injection of Platelet-Rich Plasma or Corticosteroid Versus Saline: A Randomized, Double-Blind, Placebo-Controlled Trial. Thoger Krogh, Ulrich Fredberg, Kristian Stengaard- Pedersen, Pia Jensen, Robin Christensen and Torkell Ellingsen, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, Arhus University Hospital, Aarhus, Denmark, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark 960. Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (ncbp) Are Potent Antagonists of Human Serotonin Receptor a (5HTa), Histamine Receptor H- and á-adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality. Bruce Daugherty, Leland Gershell and Seth Lederman, Tonix Pharmaceuticals, Inc., New York, NY 96. Cerebral Grey and White Matter Changes in Fibromyalgia Depend On Patients Age. Marta Ceko, Mary-Ann Fitzcharles, M. Catherine Bushnell and Petra Schweinhardt, McGill University, Montreal, QC 96. Pain, Sleep Disturbance, and Depression Mediate the Association Between Body Mass Index and Fatigue in Fibromyalgia. Mary O. Whipple, Loren L. Toussaint, Daniel J. Clauw, David A. Williams 4, Terry H. Oh, Jeffrey M. Thompson, Connie A. Luedtke and Ann Vincent, Mayo Clinic, Rochester, MN, Luther College, Decorah, IA, University of Michigan, Ann Arbor, MI, 4 Univ of MI Hlth System-Lobby M, Ann Arbor, MI 96. Efficacy of Long-Term Milnacipran Treatment in Patients Meeting Different Thresholds of Clinically Relevant Pain Relief: Subgroup Analysis of a Double-Blind, Placebo- Controlled Discontinuation Study. Daniel J. Clauw, Philip Mease, Robert H. Palmer, Joel M. Trugman and Yimin Ma, University of Michigan, Ann Arbor, MI, Swedish Medical Center and University of Washington, Seattle, WA, Forest Research Institute, Jersey City, NJ 964. High-Energy Extracorporeal Shock Wave Therapy Is Effective for Treating Chronic Calcific Tendonitis of the Shoulder: A Meta-Analysis. Nina E. Flavin, Raveendhara R. Bannuru, William F. Harvey and Timothy E. McAlindon, Tufts Medical Center, Boston, MA 965. Increased Number of Painful Body Sites Is Associated with Worse Pain and Disability-Associated Outcomes Among Returning Operations Enduring Freedom/Operation Iraqi Freedom Service Members. Dennis C. Ang, Jingwei Wu, Samantha Outcalt, Zhangsheng Yu and Matthew Bair, Indiana University, Indianapolis, IN, Indiana University School of Medicine 966. A Systematic Review of Evidence for the Effectiveness of Practitioner-Based Complementary and Alternative Therapies in the Management of Fibromyalgia. Gareth T. Jones, Priya Paudyal, Gary J. Macfarlane and the Arthritis Research UK Working Group on Complementary and, University of Aberdeen, Aberdeen, United Kingdom, University of Plymouth, Plymouth, United Kingdom, Aberdeen 967. Haplotypes of GTP Cyclophydrolase Gene Polymorphisms Are Protective in the Susceptibility of Fibromyalgia Syndrome. Hwajeong Lee, Shin-Seok Lee, Seong-Kyu Kim, Jung-Yoon Choe, Seong-Ho Kim KIM 4, Seong-Su Nah 5, Ji Hyun Lee 6, Seung-Jae Hong 7, Hyun-Sook Kim 8, Hye- Soon Lee 9, Hyun Ah Kim 0 and Chung-Il Joung, Catholic University of Daegu School of Medicine, Daegu, South Korea, Chonnam National University Medical School, Gwangju, South Korea, and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 4 Inje University Haeundae Paik Hospital, Busan, South Korea, 5 Soonchunhyang University, College of Medicine, Cheonan, South Korea, 6 Maryknoll Medical Center, Busan, South Korea, 7 Kyung Hee University, Seoul, South Korea, 8 Internal Medicine, Chosun University Hospital, Gwangju, South Korea, 9 Hanyang University Guri Hospital, Guri, South Korea, 0 Hallym university sacred heart hospital, Kyunggi, South Korea, Konyang University Medical School, Daejeon, South Korea 968. Sympathetic Nervous System Dysfunction in Fibromyalgia and in Overlapping Central Sensitivity Syndromes. A Systematic Review of Controlled Studies. Laura Aline Martinez, Tania Mora, Angelica Vargas, Mario Fuentes and Manuel Martinez-Lavin, National Institute of Cardiology, Mexico City, Mexico 969. Presence of Small Fiber Neuropathy in a Cohort of Patients with Fibromyalgia. Todd Levine, Victoria Lawson, Aidan Levine, Kevin V. Hackshaw and David Saperstein, Phoenix Neurological Associates, Phoenix, AZ, Ohio State University, Columbus, OH, Ohio State Univ/Wm Davis Res, Columbus, OH Genetics and Genomics of Rheumatic Diseases 970. Genetic Interactions between SNP Variants in C Receptor Subunits in Patients with SLE. Jeffrey C. Edberg, Christine W. Duarte, Amit Patki, Elizabeth E. Brown MPH, Kenneth M. Kaufman, Jennifer A. Kelly 4, Mary E. Comeau 5, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS and GENLES 6, Sang-Cheol Bae 7, Lindsey A. Criswell 8, Barry I. Freedman 9, Patrick M. Gaffney 0, Gary S. Gilkeson, Chaim O. Jacob, Judith A. James, Diane L. Kamen 4, Kathy Moser Sivils 4, Timothy B. Niewold 5, Robert H. Scofield 6, Betty P. Tsao 7, Timothy J. Vyse 8, John B. Harley 9, Carl D. Langefeld 0, Hemant Tiwari and Robert P. Kimberly, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, Cincinnati Children s Hospital Medical 04 0 Program Book

207 ACR POSTER SESSION B Center, Cincinnati, OH, 4 Oklahoma Medical Research Foundation, Oklahoma City, OK, 5 Wake Forest University Health Sciences, Winston-Salem, NC, 6 Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de andalucia, Oklahoma City, OK, 7 Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, 8 University of California San Francisco, San Francisco, CA, 9 Department of Internal Medicine, Wake Forest School of Medicine, Winston- Salem, NC, 0 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, Medical University of South Carolina, Charleston, SC, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 4 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 5 University of Chicago, Chicago, IL, 6 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 7 UCLA School of Medicine, Los Angeles, CA, 8 Divisions of Genetics and Molecular Medicine and Immunology, King s College London, London, United Kingdom, 9 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 0 Wake Forest School of Medicine, Winston-Salem, NC 97. Association of adam Polymorphisms with Systemic Lupus Erythematosus. Seung Cheol Shim, Mi Kyoung Lim, Donghyuk Sheen and Hyo Park, Eulji University Hospital, Daejeon, South Korea 97. Associations of Genetic Polymorphisms of Microrna-46a and Its Target Interleukin--Receptor-Associated Kinase with Ankylosing Spondylitis. Chun-Huang Huang, Jia-Yan Zhan, Kai-Jieh Yeo, James C. Wei, Chih-Shien Chuang and Ruey-Hong Wong, Chung Shan Medical University, Taichung, Taiwan, Chung Shan Medical University Hospital, Taichung, Taiwan, Chung Shan Med Univ Hospital, Taichung, Taiwan 97. New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis. Diederik P.C. de Rooy, Sacha Zhernakova, Roula Tsonaka, Fina Kurreeman, René E.M. Toes, Tom W. J. Huizinga, Jeanine Houwing-Duistermaat, Peter K. Gregersen and Annette H.M. van der Helm-van Mil, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Statistics, Leiden University Medical Center, Leiden, Netherlands, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY 974. Identification of Susceptibility Loci for Inflammatory Arthritis. K. J. A. Steel, Anne Hinks, John Bowes, Joanna Cobb, Edward Flynn, Carl D. Langefeld, Sampath Prahalad 4, Johannes Peter Haas 5, John F. Bohnsack 6, Stephen Guthery 6, Anne Barton, Susan D. Thompson 7 and Wendy Thomson, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom, Wake Forest School of Medicine, Winston-Salem, NC, 4 Emory Children s Center, Atlanta, GA, 5 Childrens Hospital, Erlangen, Germany, 6 University of Utah, Salt Lake City, 7 Cincinnati Children s Hospital Medical Center, Cincinnati, OH 975. Dense Genotyping of Risk Loci in Black South Africans with Rheumatoid Arthritis: An Association Study. Nimmisha Govind, Ananyo Choudhury, Bridget Hodkinson, Claudia Ickinger, Jacqueline Frost, Annette T. Lee 4, Peter K. Gregersen 4, Richard J. Reynolds 5, S. Louis Bridges Jr. 5, Scott Hazelhurst, Michèle Ramsay and Mohammed Tikly, Division of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Wits Bioinformatics Department, University of the Witwatersrand, Johannesburg, South Africa, Division of Human Genetics, National Health Laboratory Service, University of the Witwatersrand, Johannesburg, South Africa, 4 Feinstein Institute for Medical Research, Manhasset, NY, 5 Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 976. Effect of Interactions between Validated Rheumatoid Arthritis Genetic Factors and Environmental Factors On Rheumatoid Arthritis Risk. Chia-Yen Chen, Linda T. Hiraki, Susan Malspeis, Jing Cui 4, Bing Lu 4, Robert M. Plenge, Karen H. Costenbader 4 and Elizabeth W. Karlson 4, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Brigham and Women s Hospital, Boston, MA, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, MA Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients. Walter P. Maksymowych, Vivian P. Bykerk, Désirée van der Heijde, R. Landewe 4 and Anthony Marotta 5, University of Alberta, Edmonton, AB, Hospital for Special Surgery, New York, NY, Leiden University Medical Center, Leiden, Netherlands, 4 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5 Augurex Life Sciences Corp, North Vancouver, BC 978. A Genome-Wide Interaction Study with Smoking Suggests New Risk Loci for Two Different Subsets of Rheumatoid Arthritis; Results From Swedish Epidemiological Investigation of Rheumatoid Arthritis Study. Xia Jiang, Henrik Källberg, Leonid Padyukov, Lars Klareskog and Lars Alfredsson, Karolinska Institutet, Stockholm, Sweden, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden 979. Cell-Type Specific Type I Interferon Signatures in Systemic Lupus Erythematosus and Viral Infection: What Makes the Difference? Chieko Kyogoku, Joachim R. Grün, Tobias Alexander, Robert Biesen, Falk Hiepe, Thomas Häupl, 0 Program Book 05

208 ACR POSTER SESSION B Andreas Radbruch and Andreas Grützkau, German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, Charité University Hospital Berlin, Berlin, Germany 980. Genomewide Association Study in Systemic Lupus Erythematosus: Known Loci. Antonio Fernandez-Nebro, Patricia E. Carreira, Ricardo Blanco, Victor M. Martinez- Taboada 4, Luis Carreño 5, Alejandro Olive 6, José Luis andreu 7, Mª Angeles Aguirre 8, Paloma Vela 9, Jose Javier Pérez Venegas 0, Jose Luís Marenco 7, Joan Miquel Nolla, Antonio Zea, José M. Pego-Reigosa, Mercedes Freire González 4, Gabriela Ávila 5, María América López-Lasanta 5, Raül Tortosa 5, Antonio Julià 5 and Sara Marsal 5, Hospital Regional Universitario Carlos Haya, Málaga, Spain, Instituto de Investigación Hospital de Octubre, Madrid, Spain, Hospital Universitario Marques De Valdecilla, Santander, Spain, 4 Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 5 Gregorio Marañón Hospital, Madrid, Spain, 6 Germans Trias Pujol Hospital, Barcelona, Spain, 7 HU Puerta de Hierro Majadahonda, Madrid, Spain, 8 IMIBIC- Reina Sofia Hospital, Cordoba, Spain, 9 Hospital General Universitario de Alicante, Alicante, Spain, 0 Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, Hospital Universitari de Bellvitge, Barcelona, Spain, Hospital Universitario Ramon y Cajal, Madrid, Spain, Hospital do Meixoeiro, Vigo, Spain, 4 Complejo Hospitalario Universitario de La Coruña,, La Coruña, Spain, 5 Vall d Hebron Hospital Research Institute, Barcelona, Spain 98. Aggregated Genetic Information Explains Variations On Hand Radiographic Scores in Rheumatoid Arthritis Patient. Jing Cui, Nancy A. Shadick, Katherine P. Liao, Michael Weinblatt, Robert M. Plenge and Elizabeth W. Karlson 4, Brigham and Women s Hospital, Boston, MA, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 4 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 98. Genetic Variants near Insulin-Like Growth Factor Binding Protein (IGFBP) Are Associated with Hip Osteoarthritis. Daniel S. Evans, Neeta Parimi, Ana M. Valdes, Hanneke J.M Kerkhof, Frederic Cailotto 4, Michael C. Nevitt 5, Steven R. Cummings, Rik J. Lories 4, Timothy D. Spector, Nigel K. Arden 6, Joyce B. van Meurs and Nancy E. Lane 7, California Pacific Medical Center Research Institute, San Francisco, CA, Dept of Twin Research and Genetic Epidemiology, St. Thomas Hospital, King s College London, London, United Kingdom, Department of Internal Medicine, Erasmus Medical Center and The Netherlands Genomics Initiative-Sponsored Netherlands Consortium for Healthy Aging, Rotterdam, Netherlands, 4 Laboratory for Skeletal Development and Joint Disorders, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, 5 University of California-San Francisco, San Francisco, CA, 6 Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK, Oxford, United Kingdom, 7 UC Davis School of Medicine, Sacramento, CA 98. Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 As a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. Jing Cui and International RA Consortium on Therapy (InteRACT), Brigham and Women s Hospital, Boston, MA, Boston, MA 984. Association of Elevated C5a Levels, but Not the Presence of Anti-Cfh IgG Autoantibodies, with the Deletion of CFHR and CFHR in SLE. Jian Zhao, Seema Kamble, Yun Deng, Magdangal Erika, Daisuke Sakurai, Rongqun Li, Weiling Chen, Jennifer M. Grossman, Bevra H. Hahn and Betty P. Tsao, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, UCLA David Geffen School of Medicine, Los Angeles, CA 985. Inverse Relation Between the tumor Necrosis Factor Promoter Methylation and Trascript Leveles in Leukocytes from Patients with Rheumatoid Arthritis. James R. Maxwell, Lyndsey H. Taylor, Richardo A. Pachecho, Neil Lawrence, Gordon W. Duff, M. Dawn. Teare and Anthony G. Wilson 4, University of Sheffield, Sheffield, United Kingdom, University of Sheffield, United Kingdom, Royal Hallamshire Hospital, Sheffield, United Kingdom, 4 Section of Musculoskeletal Sciences, University of Sheffield, Sheffield, United Kingdom 986. Genome Wide Association Studies of Knee Osteoarthritis in Large North American Cohorts: A Meta-Analysis with 667 Cases. Marc C. Hochberg, Laura Yerges-Armstrong, Changwan (Larry) Lu, Michelle S. Yau, Braxton D. Mitchell, Joanne M. Jordan, Youfang Liu 4, Jordan B. Renner 5, T. McSherry 6, D.M. Taverna 6, David Duggan 6, W.J. Mysiw 7 and Rebecca D. Jackson 8, University of Maryland, Baltimore, MD, University of Maryland School of Medicine, Baltimore, MD, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, 4 University of North Carolina, Chapel Hill, NC, 5 University of North Carolina at Chapel Hill Dept of Radiology, Chapel Hill, NC, 6 TGen, Pheonix, AZ, 7 Ohio State University, Columbus, 8 Ohio State University, Columbus, OH 987. Autoimmune Susceptibility Genes Are Regulators of Gene Expression Response to ER Stress. William E. Bernal, Michael P. Morley and Vivian G. Cheung, The Children s Hospital of Philadelphia, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, Howard Hughes Medical Institute, Chevy Chase, MD; University of Pennsylvania, Philadelphia, PA 988. Zone-Specific Protein Profiles in Human Cartilage Unraveled by a Quantitative Proteomic Approach. Patricia Fernandez-Puente, Lucia Lourido, Valentina Calamia, Jesus Mateos, Cristina Ruiz-Romero, Martin K. Lotz and Francisco J. Blanco, Osteoarticular and Aging Research Group. Rheumatology Division, Biomedical Research Center (INIBIC). Hospital Universitario A Coruña, As Xubias de 06 0 Program Book

209 ACR POSTER SESSION B Arriba 84, 5006, A Coruña, Spain, Rheumatology Division, Proteomics Group/ProteoRed-ISCIII, INIBIC-C. Hospitalario, A Coruña, Spain, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 989. Genome-Wide Analysis Reveals a Recessive Association of ERAP Variants with Behçet s Disease and Epistasis between ERAP and HLA-B*5. Elaine F. Remmers, Yohei Kirino, George Bertsias, Yoshiaki Ishigatsubo, Yoonhee Kim, Michael J. Ombrello, Ilknur Tugal-Tutkun 4, Emire Seyahi 5, Yilmaz Ozyazgan 5, F. Sevgi Sacli 5, Burak Erer 4, Zeliha Emrence 6, Atilla Cakar 6, Neslihan Abaci 6, Duran Ustek 6, Colleen Satorius, Mitsuhiro Takeno, Ahmet Gül 4 and Daniel L. Kastner, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Yokohama City University Graduate School of Medicine, Yokohama, Japan, National Human Genome Research Institute, National Institutes of Health, Baltimore, MD, 4 Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 5 Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey, 6 Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey 990. Proteomic Shotgun Analysis of Mesenchymal Stem Cells Reveals an Alterated Regulation of Proteosomal Proteins in Osteoarthritis Patients. Jose Ramon Lamas, Hospital clinico San Carlos, Madrid, Spain 99. MTHFR Polymorphisms in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Associations with Intima Media Thickness Scores. Clio P. Mavragani, Maira Giannelou, Ioanna Papadaki, Eleni Antypa 4, Dimitrios Ioakeimidis 5, Haralampos M. Moutsopoulos and Michael Koutsilieris, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, School of Medicine, University of Athens, Athens, Greece, General Hospital of Athens G.Gennimatas, Athens, Greece, 4 General Hospital of Athens, Greece, 5 General Hospital, Greece 99. Functional Genomics of the Human ITGAM Locus. Yebin Zhou, Dan C. Bullard, Alexander Szalai, Jianming Wu and Jeffrey C. Edberg 4, University of Alabama at Birmingham, Birmingham, AL, University of alabama at birmingham, Birmingham, AL, University of minnesota, St. Paul, MN, 4 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 99. A Genome-Wide DNA Methylation Analysis Reveals Different Methylation Patterns in the OA Disease. Ignacio Rego-Pérez, Juan Fernandez-Tajes, Mercedes Fernandez- Moreno, Maria Tamayo Novas, Alejandro Mosquera Rey, Natividad Oreiro, Carlos Fernandez-Lopez, Jose Luis Fernandez Garcia and Francisco J. Blanco, INIBIC-Hospital Universitario A Coruña. Rheumatology Division. Genomic Group, A Coruña, Spain, INIBIC-Hospital Universitario A Coruña. Genetic Deparment., A Coruña, Spain 994. The Genome-Wide Expression of Human Osteoarthritic Cartilage Shows A Differential Pattern Between Two Subgroups of OA Patients. Ignacio Rego-Perez, Juan Fernandez-Tajes, Angel Soto-Hermida, Mercedes Fernandez Moreno, Maria Eugenia Vazquez Mosquera, Natividad Oreiro, Carlos Fernandez-Lopez, Estefania Cortes Pereira, Sara Relaño-Fernandez and Francisco J. Blanco, INIBIC-Hospital Universitario A Coruña. Genomic Group. Rheumatology Division., A Coruña, Spain 995. Genetic Effects of HLA-DRB, IL4R, and FcγRIIb On Long-Term Treatment Responses in Patients with Early Rheumatoid Arthritis: 78-Week Results of a Phase 4 Study. Alla Skapenko, Josef S. Smolen, Arthur Kavanaugh, Vipin Arora 4, Hartmut Kupper 5 and Hendrik Schulze- Koops, University of Munich, Munich, Germany, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, UCSD School of Medicine, La Jolla, CA, 4 Abbott, Abbott Park, IL, 5 Abbott GmbH and Co. KG, Ludwigshafen, Germany 996. Genetic Predictors of Methotrexate Efficacy and Toxicity in Early Rheumatoid Arthritis: Results From the Treatment of Early Aggressive Rheumatoid Arthritis Trial. Stella Aslibekyan, Elizabeth Brown, Richard J. Reynolds, David T. Redden, Sarah L. Morgan, Joseph Baggott, Jin Sha, Larry W. Moreland 4, James R. O Dell 5, Jeffrey R. Curtis 6, S. Louis Bridges Jr. 7 and Donna K. Arnett, University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, University of Alabama Birmingham, Birmingham, AL, 4 University of Pittsburgh, Pittsburgh, PA, 5 Univ of Nebraska Med Ctr, Omaha, NE, 6 Univ of Alabama-Birmingham, Birmingham, AL, 7 Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 997. Evidence of Novel Genetic Predictors of Methotrexate Efficacy in Rheumatoid Arthritis. Stella Aslibekyan, Maria I. Danila, Jin Sha, David T. Redden, Richard J. Reynolds, Elizabeth Brown, Laura B. Hughes, Molly S. Bray, Sarah L. Morgan 4, Larry W. Moreland 5, James R. O Dell 6, Jeffrey R. Curtis, Robert P. Kimberly, Lindsey A. Criswell 7, Robert M. Plenge 8, S. Louis Bridges Jr. 9 and Donna K. Arnett, University of Alabama at Birmingham, Birmingham, AL, Univ of Alabama-Birmingham, Birmingham, AL, Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 4 University of Alabama Birmingham, Birmingham, AL, 5 University of Pittsburgh, Pittsburgh, PA, 6 Univ of Nebraska Med Ctr, Omaha, NE, 7 University of California San Francisco, San Francisco, CA, 8 Brigham and Women s Hospital, Boston, MA, 9 Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 998. Association Study of Genetic Risk Variants for Psoriasis in a Large Cohort of Psoriatic Arthritis, Psoriasis and Controls of the Spanish Population and Association with Relevant Clinical Subphenotypes. J. D. Cañete, Jose Luis Fernandez-Sueiro, Raimon Sanmarti, Jesus Rodriguez 4, Jordi Gratacós 5, Rubén Queiro 6, Juan Carlos Torre-Alonso 7, 0 Program Book 07

210 ACR POSTER SESSION B 08 Jose Perez Venegas 8, Santiago Muñoz-Fernandez 9, Carlos Gonzalez 0, Carlos Montilla, Daniel Roig, Alba Erra, Isabel Acosta 4, Antonio Fernández-Nebro 5, Pedro Zarco 6, Arnald Alonso 7, María América López-Lasanta 7, Antonio Julià 7, Raül Tortosa 7 and Sara Marsal 8, Hospital Clínic de Barcelona,, Barcelona, Spain, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, Hospital Clínic of Barcelona, Barcelona, Spain, 4 Hospital Universitari de Bellvitge, Barcelona, Spain, 5 Hospital Parc Taulí, Sabadell (Barcelona), 6 Hospital Universitario Central de Asturias, Oviedo, Spain, 7 Hospital Monte Naranco, Oviedo, Spain, 8 Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, 9 Hospital Infanta Sofía, Madrid, Spain, 0 Hospital Gregorio Marañon, Madrid, Spain, Hospital Universitario de Salamanca, Salamanca, Spain, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, Hospital San Rafael, Barcelona, Spain, 4 Hospital Universitari Vall d Hebron, Barcelona, Spain, 5 Hospital Regional Universitario Carlos Haya, Málaga, Spain, 6 Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 7 Vall d Hebron Hospital Research Institute, Barcelona, Spain, 8 University Hospital Vall d Hebron, Barcelona, Spain 999. Identification of New Epistatic Interactions with the HLA Region in the Genetic Etiology of Psoriasis and Psoriatic Arthritis. Sara Marsal, Juan D. Cañete, Jose Luis Fernandez- Sueiro, Raimon Sanmarti, Jesus Rodriguez Moreno 4, Jordi Gratacós 5, Rubén Queiro 6, Carlos Montilla 7, Juan Carlos Torre-Alonso 8, Jose Perez Venegas 9, Santiago Muñoz- Fernández 0, Carlos M. Gonzalez, Daniel Roig, Alba Erra, Isabel Acosta, Antonio Fernández-Nebro 4, Pedro Zarco 5, Arnald Alonso 6, María América López-Lasanta 6, Raül Tortosa 6 and Antonio Julià 6, Hospital Universitari Vall d Hebron, Barcelona, Spain, Hospital Clínic of Barcelona, Barcelona, Spain, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, 4 Hospital Universitario de Bellvitge., Barcelona, Spain, 5 Hospital Parc Taulí, Sabadell (Barcelona), 6 Hospital Universitario Central de Asturias, Oviedo, Spain, 7 Hospital Universitario de Salamanca, Salamanca, Spain, 8 Hospital Monte Naranco, Oviedo, Spain, 9 Hospital del SAS de Jerez de la Frontera, Jerez De La Frontera, Spain, 0 Hospital Universitario Infanta Sofía, San Sebastián de los Reyes (Madrid), Spain, Hospital Gregorio Maranon, Madrid, Spain, Hospital Universitari de Bellvitge, Hospitalet de Llobregat- Barcelona, Spain, Hospital San Rafael, Barcelona, Spain, 4 Hospital Regional Universitario Carlos Haya, Málaga, Spain, 5 Fundación Hospital Alcorcon, Alcorcon, Madrid, Spain, 6 Vall d Hebron Hospital Research Institute, Barcelona, Spain 000. Epistatic Interaction between BANK and BLK in Rheumatoid Arthritis: Results From a Large Trans-Ethnic Meta-Analysis. Emmanuelle Genin, Baptiste Coustet, Yannick Allanore, Maria Teruel 4, Arnaud L. Constantin 5, Shigeto Tohma 6, O. Vittecoq 7, Hiroshi Furukawa 8, Alejandro Balsa 9, Thierry Schaeverbeke 0, Miguel Angel González- Gay, Gilles Chiocchia, Naoyuki Tsuchiya, Javier Martin 4 and Philippe Dieude 5, INSERM UMR-S946, Paris, France, 0 Program Book Université Paris Descartes, Hopital Cochin, Paris, France, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 4 Instituto de Parasitologia y Biomedicina Lopez-Neyra, CSIC, Granada, Spain, 5 Purpan University Hospital, Toulouse Cedex 9, France, 6 Sagamihara National Hospital, Sagamihara City, Japan, 7 University Hospital, Rouen, France, 8 Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan, 9 La Paz Hospital. IdiPaz, Madrid, Spain, 0 Groupe Hospitalier Pellegrin, Bordeaux, France, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Institut Cochin - INSERM U06 - CNRS (UMR 804), Paris, France, Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Tsukuba, Japan, 4 Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 5 APHP, Hopital Bichat, Paris, France 00. CNstream: Improved SNP and CNV Genotyping Reveals New Loci Associated with Rheumatic Diseases. Arnald Alonso, Antonio Julià, Raül Tortosa and Sara Marsal, Vall d Hebron Hospital Research Institute, Barcelona, Spain 00. Microrna Expression Profiles in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis. G. Ciancio, Manuela Ferracin, Barbara Zagatti, Elena Saccenti, Valentina Bagnari, Ilaria Farina, Matteo Colina, Marco Seri 4, Francesco Trotta, Massimo Negrini and Marcello Govoni, Rheumatology Unit-Azienda Ospedaliera-Universitaria Sant Anna, Ferrara, Italy, Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy, Section of Internal Medicine A.Ospedale Maggiore, Bologna, Italy, 4 Medical Genetics Unit, Bologna, Italy 00. Role of Particular Class I MHC Haplotypes in Determining Different Traits within the Psoriatic Arthritis Phenotypes. Muhammad Haroon, Jon T. Giles, Robert Winchester and Oliver M. FitzGerald, Dublin Academic Medical Center, St. Vincent s University Hospital, Dublin, Ireland, Columbia University Medical Center, New York, NY, Columbia University, New York, NY 004. A Unique Single Nucleotide Polymorphism in the UTR of the MED9 Gene On Chromosome 9 Is Associated with the Clinical Outcome of Different Biologic Response Modifiers. Susanne Drynda, David Leesch, Marietta Gloetzner and Joern Kekow, Univ of Magdeburg, Vogelsang- Gommern, Germany 005. The Identification of Pathway Markers in Behcet s Disease Using Genomewide Association Data from Two Different Populations. Burcu Bakir-Gungor, Elaine Remmers, Daniel L. Kastner, Akira Meguro 4, Nobuhisa Mizuki 4, Ahmet Gul 5 and Osman Ugur Sezerman 6, Bahcesehir University, Istanbul, Turkey, National Institutes of Health, National Human Genome Research Institute, Bethesda, MD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 4 Yokohama City University Graduate

211 ACR POSTER SESSION B School of Medicine, Yokohama, Japan, 5 Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 6 Sabancı University, Istanbul, Turkey 006. Dynamic Gene Expression of Wnt Signaling Pathway during Osteogenic Stimulation in Vitro of Osteoarthritis Mesenchymal Stem Cells. A. Peralta-Sastre, M. Hernandez- Molinero, P. Tornero-Esteban, E. Villafuertes, B. Fernandez-Gutierrez and Jose Ramon Lamas 4, UGC de Reumatología, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain., Hospital Clinico San Carlos, Madrid, Spain, Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 4 Hospital clinico San Carlos, Madrid, Spain Imaging of Rheumatic Diseases: Magnetic Resonance Imaging, Computed Tomography and X-ray 007. High Resolution Peripheral Quantitative CT Detects Marked Differences in Metacarpal Head and Shaft and Ultra-Ultra- Distal Radius Bone Volumetric Density and Microstructure in Early Rheumatoid Arthritis. Lynne M. Feehan, Helen R. Buie, Linda C. Li, Kamran Shojania, Cheryl Barnabe and Heather A. McKay, Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, University of Calgary, Calgary, AB, University of British Columbia, Vancouver, BC 008. Segmentation and Quantification of Bone Erosions in the Hands of Patients with Rheumatoid Arthritis Using High Resolution Computed Tomography. Dominique Toepfer, Stephanie Finzel, Oleg Museyko, Klaus Engelke and Georg A. Schett, University of Erlangen-Nuremberg, Erlangen, Germany, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 009. A New Approach for Detecting Progressive Joint Damage Using D Imaging From High-Resolution Peripheral Quantitative Computed Tomography: Measuring Reproducibility. Cheryl Barnabe, Helen R. Buie, Michelle Kan, Susan G. Barr, Liam Martin and Steven K. Boyd, University of Calgary, Calgary, AB 00. Bone Loss before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies. Stephanie Finzel, Veronika Lang, Arnd Kleyer, Juergen Rech, Bernhard Manger, Elizabeth Araujo, Axel J. Hueber, Ulrike Harre and Georg Schett, University of Erlangen- Nuremberg, Erlangen, Germany, University of Erlangen- Nuremberg, Germany, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 0. Structural Damage Is Reduced by Early Achievement of Clinical Remission. Paul Emery, Vibeke Strand, Andrew S. Koenig, Ronald Pedersen and Eustratios Bananis, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Stanford University, Portola Valley, CA, Pfizer Inc., Collegeville, PA 0. Radiographic Deformity of the Foot Is Starting From the Early Stage of Rheumatoid Arthritis. Kenji Mamoto, Tatsuya Koike, Tadashi Okano, Atsuko Kamiyama, Yuko Sugioka, Masahiro Tada and Hiroaki Nakamura, Osaka City University Graduate School of Medicine, Osaka, Japan 0. The Influence of Vertebral Fractures On the Functional Disability of Patients with Rheumatoid Arthritis. Soo-Kyung Cho, Joo-Hyun Lee, Min-Kyung Han, Seunghun Lee 4, Ji Young Kim 4, Jeong Ah Ryu 4, Yun Young Choi 4, Sang-Cheol Bae 5 and Yoon-Kyoung Sung 5, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Ilsan Paik Hospital, Inje University, Goyang, South Korea, Hanyang University Hospital for Rheumatic Disease, Seoul, South Korea, 4 Hanyang University College of Medicine, Seoul, South Korea, 5 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea 04. Trimmed Analyses, a New Approach to the Analysis of Sharp Score Data in the Assessment of Progression in Patients with Rheumatoid Arthritis. Robert B. M. Landewé, Désirée van der Heijde, Carol Connell, John Bradley, David Gruben and Michael Brown, Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands, Pfizer Inc., Groton, CT 05. Analysis of Integrated Radiographic Data for Two Long- Term, Open-Label Extension Studies of Adalimumab. Désirée van der Heijde, Robert Landewé, Edward C. Keystone, Ferdinand C. Breedveld, Shufang Liu 4 and Neelufar Mozaffarian 4, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center, Amsterdam, Netherlands, Professor of Medicine, Toronto, ON, 4 Abbott, Abbott Park, IL 06. The Effect of Evaluation Variability At the Unit of Measurement On the Reliability of Omeract Ramris and Van Der Heijde-Modified Sharp Score. Ruben Tavares, Naveen Parasu, Karen Finlay, Erik Jurriaans, Hao Wu, Karen A. Beattie, Maggie Larche, Lawrence E. Hart, William G. Bensen 4, Raja S. Bobba, Alfred A. Cividino, Colin E. Webber 5, Jean-Eric Tarride 6 and Jonathan D. Adachi 7, McMaster University, Hamilton, ON, Hamilton Health Sciences, Hamilton, St. Joseph s Health Care, Hamilton, ON, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON, Hamilton, ON, 5 Hamilton Health Sciences, Hamilton, ON, 6 Programs for Assessment of Technology in Health (PATH) Research Institute, Hamilton, ON, 7 Charlton Medical Centre, Hamilton, ON 07. Bye Bye Biopsy: Diffusion Tensor and Dynamic Contrast Enhance Magnetic Resonance Imaging Parameters Reflect Molecular Events of Inflammation in the Synovium. Vikas Agarwal, Rishi Awasthi, Deepak Tripathi, Vinita Agrawal, Ram Kishore Singh Rathore 4, Kusum Sharma 5, CM Pandey and Rakesh K. Gupta, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, 0 Program Book 09

212 ACR POSTER SESSION B India, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India,, Lucknow, India, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, 4 Indian Institute of Technology, Kanpur, India, 5 Postgraduate Institute of Medical Education and Research, Chandigarh, India 08. Reliability of the Early Erosions in Rheumatoid Arthritis Software When Quantifying Bone Loss. Melissa XP. Koh, Joshua WJ. Barbosa, Ruben Tavares, Stephen Tytus, Patrick Emond, Chris Gordon, George Ioannidis, Karen A. Beattie, William G. Bensen, Raja S. Bobba, Alfred A. Cividino, Lawrence E. Hart, Maggie Larche, Arthur N. Lau and Jonathan D. Adachi 4, McMaster University, Hamilton, ON, St. Joseph s Hospital and McMaster University, Hamilton, ON, St. Joseph s Health Care, Hamilton, ON, 4 St. Joseph s Health Care and McMaster University, Hamilton, ON 09. Visualization of Cartilage in High-Resolution Magnetic Resonance Imaging Is a New Imaging Biomarker for the Quantification of Joint Damage in Rheumatoid Arthritis. Barbara Herz, Stephanie Finzel, Andreas Albrecht, Juergen Rech, Matthias Englbrecht, Goetz Welsch and Georg Schett, University of Erlangen-Nuremberg, Erlangen, Germany, Department of Traumatic Surgery, University Clinic of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 00. Location of Erosions At the Metatarsophalangeal Joints in Patients with Rheumatoid Arthritis. Heidi J. Siddle, Richard J. Hodgson, Andrew J. Grainger, Anthony C. Redmond 4, Richard J. Wakefield 4 and Philip S. Helliwell 5, University of Leeds, Leeds, United Kingdom, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, Leeds Teaching Hospitals NHS Trust and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 4 University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 5 NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 0. Magnetic Resonance Imaging in Follow-up of Clinical Remission in Juvenile Idiopathic Arthritis. Mira van Veenendaal, Robert Hemke, Marjolein I. Bos, Mario Maas, Marion A. J. Van Rossum and Taco W. Kuijpers, Emma Children s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, Academic Medical Center (AMC), Amsterdam, Netherlands 0. Imaging of Ankle Joints by MRI in Murine Models of Inflammatory Arthritis. Shawn M. Rose, Harris R. Perlman, Emily Alex Waters and Thomas Meade, Northwestern University, Chicago, IL, Northwestern University, Evanston, IL 0. Scoring Radiographic Progression in Axial Spa: Should We Use the Modified Stoke in Ankylosing Spondylitis Spine Score or the Radiographic Ankylosing Spondylitis Spinal Score? Sofia Ramiro, A.M. Van Tubergen, Carmen Stolwijk, Robert Landewé and Désirée van der Heijde 4, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Maastricht University Medical Center, Maastricht, Netherlands, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, 4 Leiden University Medical Center, Leiden, Netherlands 04. What Constitutes the Characteristic Fat Lesion On MRI of the Sacroiliac Joints in Early Spondyloarthritis? Ulrich Weber, Susanne Juhl Pedersen, Veronika Zubler, Kaspar Rufibach, Stanley Chan 4, Robert GW Lambert 4, Mikkel Ostergaard 5 and Walter P. Maksymowych 4, Balgrist University Hospital, Zurich, Switzerland, Copenhagen University Hospital Glostrup, Copenhagen, Denmark, University of Zurich, Zurich, Switzerland, 4 University of Alberta, Edmonton, AB, 5 Copenhagen University Hospital at Glostrup, Glostrup, Denmark 05. Spinal Inflammation in the Absence of SI Joint Inflammation on MRI in Patients with Active Non- Radiographic Axial Spondyloarthritis. Désirée van der Heijde, Joachim Sieper, Walter P. Maksymowych, Matthew A. Brown 4, Suchitrita S. Rathmann 5 and Aileen L. Pangan 5, Leiden University Medical Center, Leiden, Netherlands, Charité Universitätesmedizin Berlin, Berlin, Germany, University of Alberta, Edmonton, AB, 4 University of Queensland Diamantina Insititute, Brisbane, Australia, 5 Abbott Laboratories, Abbott Park, IL 06. Psoriatic Arthritis and Spondyloarthritis: Inflammation Assessed by Head to Toe Wholebody Magnetic Resonance Imaging - A Comparison with Clinical Joint Examination. René Panduro Poggenborg, Susanne Juhl Pedersen, Iris Eshed, Inge Juul Sørensen, Ole Rintek Madsen 4, J.M. Møller 5 and Mikkel Østergaard 6, Copenhagen University Hospital in Glostrup, Copenhagen, Denmark, Glostrup Hospital, Copenhagen, Denmark, Sheba Medical Center, Tel Hashomer, Israel, 4 Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 5 Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 6 Copenhagen University Hospital Glostrup, Glostrup, Denmark 07. Frequency of MRI-Detected Hip Osteoarthritis Features in Persons with Chronic Hip Pain and the Diagnostic Performance of Radiography Using MRI as the Reference. Li Xu, Daichi Hayashi, Ali Guermazi, David J. Hunter, Anton Winterstein, Ling Li 4, Klaus Bohndorf and Frank Roemer, Boston University School of Medicine, Boston, MA, Royal North Shore Hospital, Sydney, Australia, Klinikum Augsburg, Augsburg, Germany, 4 New England Baptist Hospital, Boston, MA 0 0 Program Book

213 ACR POSTER SESSION B 08. Semi-Quantitative Assessment of Bone Marrow Edema and Synovitis-Effusion in Osteoarthritis with the Knee Inflammation MRI Scoring System: A Target Lesion Based Methodology. Walter P. Maksymowych, Ulrich Weber, Marcus Pianta and Robert GW Lambert, University of Alberta, Edmonton, AB, Balgrist University Hospital, Zurich, Switzerland, University of Alberta, AB 09. Frequency of Mediopatellar Plica in Persons with Chronic Knee Pain and Its Cross-Sectional Association with Patellofemoral Cartilage Damage and Bone Marrow Lesions: Data From the Joints On Glucosamine Study. Li Xu, Daichi Hayashi, Ali Guermazi, C. Kent Kwoh, Michael J. Hannon, Mohamed Jarraya, Carolyn E. Moore 4, John M. Jakicic 5, Stephanie M. Green 6 and Frank Roemer 7, Boston University School of Medicine, Boston, MA, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 Texas Women s University, Houston, TX, 5 University of Pittsburgh, PA, 6 University of Pittsburgh, Pittsburgh, PA, 7 Klinikum Augsburg, Augsburg, Germany 00. Frequency and Fluctuation of Susceptibility Artifacts in the Tibio-Femoral Joint Space in Painful Knees On T MRI and Association with Meniscal Tears, Radiographic Joint Space Narrowing and Calcifications. Daichi Hayashi, Mohamed Jarraya, Ali Guermazi, C. Kent Kwoh, Michael J. Hannon, Carolyn E. Moore 4, John M. Jakicic 5, Stephanie M. Green 6 and Frank Roemer 7, Boston University School of Medicine, Boston, MA, Univ of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 Texas Women s University, Houston, TX, 5 University of Pittsburgh, PA, 6 University of Pittsburgh, Pittsburgh, PA, 7 Klinikum Augsburg, Augsburg, Germany 0. High Degree of Symmetricity of MRI-Detected Articular Tissue Damage in Subjects with Knee Pain: A within- Person Analysis From the JOG Study. Frank Roemer, C. Kent Kwoh, Michael J. Hannon, Robert M. Boudreau 4, Stephanie M. Green 4, John M. Jakicic 5, Carolyn E. Moore 6 and Ali Guermazi 7, Klinikum Augsburg, Augsburg, Germany, University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4 University of Pittsburgh, Pittsburgh, PA, 5 University of Pittsburgh, PA, 6 Texas Women s University, Houston, TX, 7 Boston University School of Medicine, Boston, MA 0. Medial Meniscal Root Tears and the Association with Meniscal Extrusion, Prevalent Cartilage Damage and Longitudinal Cartilage Loss: The MOST Study. Mohamed Jarraya, David T. Feslon, Daichi Hayashi, Frank Roemer, Yuqing Zhang, Jingbo Niu, Michel Crema, Martin Englund, John A. Lynch 4, Michael C. Nevitt 5, James Torner 6, C.E. Lewis 7 and Ali Guermazi, Boston University, Boston, MA, Klinikum Augsburg, Augsburg, Germany, Lund University, Lund, Sweden, 4 University of California at San Francisco, San Francisco, CA, 5 University of California-San Francisco, San Francisco, CA, 6 University of Iowa, Iowa City, IA, 7 University of Alabama at Birmingham, Birmingham City, AL 0. Reliability and Responsiveness of Two Methods for Assessment of Magnetic Resonance Imaging Abnormalities in Hip Osteoarthritis in a Placebo-Controlled Trial of Intra-Articular Steroid Injection. Walter P. Maksymowych, Jolanda Cibere, Ulrich Weber, Jacob Jaremko, Damien Loeuille 4, Veronika Zubler, Frank Roemer 5, Eric C. Sayre 6 and Robert GW Lambert, University of Alberta, Edmonton, AB, Arthritis Research Ctr of CA, Vancouver, BC, Balgrist University Hospital, Zurich, Switzerland, 4 CHU Brabois, Vandoeuvre les Nancy, France, 5 Klinikum Augsburg, Augsburg, Germany, 6 Arthritis Research Centre of Canada, Vancouver, BC 04. Changing Osteoarthritis Treatment Assessment Paradigms: Subchondral Bone Is a More Responsive Measure of Progression Than the Current Radiographic Standard. Michael A. Bowes, Christopher B. Wolstenholme, Devan Hopkinson, Graham R. Vincent and Philip G. Conaghan, Imorphics Ltd, Manchester, United Kingdom, University of Leeds, Leeds, United Kingdom 05. Characterisation of New Bone Formation in Gout: A Quantitative Site-by-Site Analysis Using Plain Radiography and Computed Tomography. Nicola Dalbeth, Aaron Milligan, Barnaby Clark, Fiona M. McQueen and Anthony Doyle, University of Auckland, Auckland, New Zealand, Department of Radiology, Auckland District Health Board, Auckland, New Zealand 06. The Prevalence of Chondrocalcinosis of the Acromioclavicular Joint On Chest Radiographs and correlation with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease. Konstantinos M. Parperis, Guillermo F. Carrera, Keith E. Baynes, Alan P. Mautz, Melissa S. DuBois, Ross M. Cerniglia and Lawrence M. Ryan, Medical College of Wisconsin, Milwaukee, WI 07. Magnetic Resonance Imaging (MRI) Assessment of Inflammatory Myopathy: Quantitative Fat-Corrected Muscle T and Conventional T Measurement Versus Standard MRI and Clinical Metrics. Lawrence Yao, Adrienne L. Yip, Sepehr Mesdaghinia, Ashkan Shademan, Joseph A. Shrader, Anna V. Jansen, Frederick W. Miller and Lisa G. Rider, Clinical Center, NIH, Bethesda, MD, NIEHS, NIH, Bethesda, MD, NIEHS, NIH, Bethesda 08. Assessment of Aortic Stiffness by Cardiac Magnetic Resonance Imaging in Systemic Autoimmune Rheumatic Diseases. Galia Karp, Arik Wolak, Nina Baram, Victor Novack 4, Philip Rosen, Yael Perl 5, Talia Wolak 6, Ilan Shelef and Mahmoud Abu-Shakra 7, Department of Medicine, Soroka Medical Centre and Ben Gurion University, Beer- Sheva, Israel, Dept. of Cardiology, Cardiac MRI unit, Soroka University Medical Center, and Ben Gurion University, Beer-Sheva, Israel, Radiology division, Soroka University Medical Center and Ben Gurion University, 4 Department of Medicine, Clinical Research center, Soroka University Medical Center and Ben Gurion University, 5 Clinical Research center, Soroka University Medical Center and Ben Gurion University, 6 Department of Medicine and Hypertension 0 Program Book

214 ACR POSTER SESSION B unit, Soroka University Medical Center and Ben-Gurion University, 7 Department of Medicine and Rheumatology, Soroka Medical Centre and Ben Gurion University, Beer- Sheva, Israel 09. Cardiac Involvement in Systemic Sclerosis: The Added Value of Magnetic Resonance Imaging. Luna Gargani, Alessandro Pingitore, Daniele De Marchi, Serena Guiducci, Giancarlo Todiere, Silvia Bellando Randone, Cosimo Bruni, Marica Doveri 4, Laura Bazzichi 4, Stefano Bombardieri 4, Massimo Lombardi, Eugenio Picano and Marco Matucci Cerinic, Institute of Clinical Physiology, National Research Council, Pisa, Italy, Gabriele Monasterio Foundation, CNR- Regione Toscana, Pisa, Italy, Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, 4 Rheumatology Unit, University of Pisa, Pisa, Italy 040. Combined High-Resolution Single Photon Emission Computed Tomography and Magnetic Resonance Imaging for Therapy Monitoring in Rheumatoid Arthritis. Philipp Sewerin, Christian Buchbender, Katalin Mattes-György, Falk Miese, Hans-Jörg Wittsack, Christof Specker, Gerald Antoch, Matthias Schneider, Axel Scherer and Ben Ostendorf, Heinrich-Heine-University, Düsseldorf, Germany, Hospital Essen Sued, Essem, Germany, Heinrich- Heine-University, Duesseldorf, Germany 04. Whole-Body Magnetic Resonance Imaging - A New Diagnostic Tool in the Assessment of Activity in Juvenile Dermatomyositis Patients? Tania Monteiro de Castro, Henrique Lederman, Maria Teresa Terreri, Wanda I. Caldana, Edmar Zanoteli and Maria Odete Hilario, Federal University of São Paulo, São Paulo, Brazil, University of São Paulo, São Paulo, Brazil 04. Psoriatic Arthritis Patients Assessed by Dynamic Contrast- Enhanced MRI in High Disease Versus Minimal Disease Activity State - a Cross-Sectional Study Correlating Conventional MRI and Clinical Composite Measures. René Panduro Poggenborg, Pernille Bøyesen, Charlotte Wiell, Susanne Juhl Pedersen 4, Inge Juul Sørensen 5, Ole Rintek Madsen 6, Ole Slot, Jakob M. Møller 7, Mikael Boesen 8, Henning Bliddal 9, Olga Kubassova 0 and Mikkel Østergaard, Copenhagen University Hospital in Glostrup, Copenhagen, Denmark, Diakonhjemmet Hospital, Olso, Norway, Copenhagen University Hospital in Gentofte, Copenhagen, Denmark, 4 Copenhagen University Hospital Glostrup, Copenhagen, Denmark, 5 Glostrup Hospital, Copenhagen, Denmark, 6 DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 7 Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 8 Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, 9 Copenhagen University Hospital at Frederiksberg, Frederiksberg, Denmark, 0 Image Analysis Ltd., Leeds, United Kingdom, Glostrup Hospital, Glostrup, Denmark 04. Assessment of Rheumatoid Arthritis Disease Activity by Power Doppler Ultrasonography: Association with Routine Clinical Indices and Its Usefulness in Detecting Remission. Hiroaki Taguchi, Kazuo Nishi, Takeo Kudo and Yutaka Okano, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan 044. Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis. Rusmir Husic, Josef Hermann, Judith Gretler, Winfried B. Graninger and Christian Dejaco, Medical University Graz, Graz, Austria, Auenbruggerplatz 5, Graz, Austria 045. Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Wrist in Rheumatoid Arthritis Patients Treated with Methotrexate, Intra-Articular Glucocorticoid and Adalimumab/Placebo. Mette Bjørndal Axelsen, Merete L. Hetland, Kim Hørslev-Petersen, Kristian Stengaard- Pedersen 4, Peter Junker 5, Jan Pødenphant 6, Jakob M. Møller 7, Henning Bliddal 8, Olga Kubassova 9, Mikael Boesen 0 and Mikkel Østergaard, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, University of Southern Denmark, Graasten, Denmark, 4 Arhus University Hospital, Aarhus, Denmark, 5 Odense University Hospital, Odense C, Denmark, 6 Copenhagen University at Gentofte, Hellerup, Denmark, 7 Copenhagen University Hospital in Herlev, Copenhagen, Denmark, 8 The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, 9 Image Analysis Ltd., Leeds, United Kingdom, 0 Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark 046. Automated Breast Volume Scanner (ABVS), a New Automated Ultrasonic Device, Is Useful to Examine Joint Injury in Patients with Rheumatoid Arthritis. Shin-ya Kawashiri, Takahisa Suzuki, Yoshikazu Nakashima, Akitomo Okada, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Kazuhiko Arima, Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Kiyoshi Aoyagi and Atsushi Kawakami, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki University, Nagasaki, Japan 047. Evaluation of Ankle Swelling Due to Löfgren s Syndrome: A Pilot Study Using B mode and Power Doppler Ultrasonography. Emmanuelle LeBras, Sandra Balser, Valentin S. Schäfer, Boris P. Ehrenstein, Patrick Hoffstetter, Martina Müller, Martin Fleck and Wolfgang Hartung, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, University Clinic Regensburg, Regensburg 048. Tenosynovitis in Carpal Tunnel Syndrome Prevalence and Comparison between Ultrasonography, Surgery and Histology. David F. Ten Cate, Nick Glaser, Jolanda J. Luime, K.H. Lam, Johannes W.G. Jacobs 4, Ruud W. Selles, Johanna Hazes 5 and M. Bertleff 6, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus MC - University Medical Center, Rotterdam, Netherlands, Erasmus 0 Program Book

215 ACR POSTER SESSION B University Medical Center, Netherlands, 4 University Medical Center Utrecht, Utrecht, Netherlands, 5 Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 6 Xpert Clinic, Rotterdam, Netherlands 049. The Prevalence of the Ultrasonographic Positive Power Doppler Synovitis Is High and Predicts the Risk of Relapse and Structural Progression in Rheumatoid Arthritis in Clinical Remission: A Systematic Literature Review and Meta Analysis. Huong Nguyen, Adeline Ruyssen- Witrand, Arnaud L. Constantin, Violaine Foltz, Frédérique Gandjbakhch and Alain G. Cantagrel, Purpan University Hospital, Toulouse, France, Pitié Salpétrière Hospital, Paris, France 050. Assessment of Validity of Magnetic Resonance Imaging Measures of Joint Inflammation and Damage in Rheumatoid Arthritis Wrist/Hand a Systematic Literature Review. TG Woodworth, O. Morgacheva, OM Troum, OL Pimienta, P. Maranian, V.K. Ranganath and D.E. Furst, Visiting Clinical Researcher, David Geffen School of Medicine, UCLA, Los Angeles, CA, David Geffen School of Medicine, UCLA, Los Angeles, CA, USC Keck School of Medicine, Santa Monica, CA 05. Magnetic Resonance Imaging in Inflammatory Bowel Disease Patients with Arthralgia. W. Stomp, L.K.P.M. Brakenhoff, F.A. van Gaalen, D. van der Heijde, H.H. Fidder, D.W. Hommes, M. Reijnierse and J.L Bloem, Leiden University Medical Center, Leiden, Netherlands, University Medical Center Utrecht, Utrecht, Netherlands, University of California Los Angeles, Los Angeles, CA 05. Systematic Review of the Association between Magnetic Resonance Imaging and Radiographic Detection of Erosions in Rheumatoid Arthritis. Ruben Tavares, Stephen R. Tytus, Karen A. Beattie, Maggie Larche, Naveen Parasu, Colin E. Webber 4, Lawrence E. Hart 5 and Jonathan D. Adachi 6, McMaster University, Hamilton, ON, Northern Ontario School of Medicine, Sudbury, Qatar, Hamilton Health Sciences, Hamilton, 4 Hamilton Health Sciences, Hamilton, ON, 5 St. Joseph s Health Care, Hamilton, ON, 6 Charlton Medical Centre, Hamilton, ON 05. Severe Joint Injury Assessed by Musculoskeletal Ultrasonography (MSKUS) Predicts the Presence of MRI- Proven Osteitis in Patients with Rheumatoid Arthritis. Shin-ya Kawashiri, Takahisa Suzuki, Yoshikazu Nakashima, Yoshiro Horai, Naoki Iwamoto, Kunihiro Ichinose, Kazuhiko Arima, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Kiyoshi Aoyagi and Atsushi Kawakami, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Nagasaki University, Nagasaki, Japan 054. Diffusion Tensor and Dynamic Contrast Enhanced Perfusion Imaging Metrics Discriminate Chronic Tubercular Synovitis From Chronic Inflammatory Synovitis of the Knee. Vikas Agarwal, Rakesh K. Gupta, Rishi Awasthi, Deepak Tripathi, Prativa Sahoo, Vinita Agrawal, Kusum Sharma 4, Rungmei Marak 5, Ram Kishore Singh Rathore and CM Pandey, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, Indian Institute of Technology, Kanpur, India, 4 Postgraduate Institute of Medical Education and Research, Chandigarh, India, 5 Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India Innate Immunity and Rheumatic Disease 055. Sec6 Is Indispensable for Antigen Cross-Presentation and the Development of Lupus Nephritis: A Novel Self- Organized Criticality Theory Explaining the Cause of Systemic Lupus Erythematosus (SLE). Ken Tsumiyama and Shunichi Shiozawa, Kyushu University Beppu Hospital, Beppu, Japan 056. Fc Receptor Gamma-Dependent Autoimmune Endocarditis in K/BxN Mice. Patricia M. Hobday, Jennifer L. Auger, J. Sjef Verbeek, Jeffrey V. Ravetch and Bryce A. Binstadt, University of Minnesota, Minneapolis, MN, Leiden University Medical Center, Leiden, Netherlands, The Rockefeller University, New York, NY 057. A Specific Inhibitor of Spleen Tyrosine Kinase, PRT0660 7, Is a Potent Modulator of Innate Immune Cell Function. Lynn A. Kamen, Gillian Stephens, Anjali Pandey and Uma Sinha, Portola Pharmaceuticals, South San Francisco, CA 058. Fulminant Toll-Like Receptor 9-Induced Macrophage Activation Syndrome and Hemophagocytosis Occur Independently of Interferon Gamma. Scott W. Canna, Julia Wrobel, Portia A. Kreiger, Michele E. Paessler and Edward M. Behrens 4, Childrens Hospital of Philadelphia, Philadelphia, PA, The Children s Hospital of Philadelphia, Philadelphia, PA, Nemours/A.I. DuPont Hospital for Children, Wilmington, DE, 4 Children s Hospital of Philadelphia, Philadelphia, PA 059. Endogenous Complement Factor H Plays an Important Role in Controlling Immune Complex-Induced Inflammatory Arthritis. Nirmal K. Banda, Gaurav Mehta, Viviana P. Ferreira, Claudio Cortes, Michael K. Pangburn, William P. Arend and V. Michael Holers, University of Colorado School of Medicine, Aurora, CO, University of Toledo Health Science Campus, Toledo, OH, University of Texas Health Sciences Center, Tyler, TX 060. Protein Kinase C Inhibitor Generates Human Tolerogenic Dendritic Cells That Induce Tr and Foxp+ Regulatory T Cells. Takuya Matsumoto, Hitoshi Hasegawa, Jun Ishizaki, Koichiro Suemori, Sachiko Onishi and Masaki Yasukawa, Ehime University Graduate School of Medicine, Toon, Japan 06. Generation of Myeloid-Derived Suppressor Cells in Vitro from Murine Bone Marrow Precursors. Julia Kurko, Beata Tryniszewska, Tibor A. Rauch, Colt Egelston, Tibor T. Glant and Katalin Mikecz, Rush University Medical Center, Chicago, IL 0 Program Book

216 ACR POSTER SESSION B 06. Identification of Highly Potent and Selective Interleukin- Receptor-Associated Kinase 4 Inhibitors for the Treatment of Rheumatic Diseases. Divya Chaudhary, Shaughnessy Robinson, Craig E. Masse, Matthew D. Wessel, Shawn Watts, Jeremy Greenwood, Mee Shelley, Mark Brewer, Geraldine Harriman, Leah L. Frye, Ronald T. Wester, Rosana Kapeller and Donna Romero, Nimbus Discovery, Inc., Cambridge, MA, Schrödinger, Inc., New York, NY 06. Dysfunction of Natural Killer and Natural Killer T Cells in Patients with Adult Onset Still s Disease. Young-Nan Cho, Sung-Ji Lee, Tae-Jong Kim, Hye-Mi Jin, Dong-Jin Park, Seung-Jung Kee and Yong-Wook Park, Chonnam National University Medical School and Hospital, Gwangju, South Korea, Chonnam National University Medical School, Gwangju, South Korea 064. CDc-Expressing Myeloid Dendritic Cells From Joints of Rheumatoid Arthritis Patients Produce Increased Levels of T Cell-Attracting Chemokines and Strongly Activate Autologous T Cells. F.M. Moret, C.E. Hack, F.P.J.G. Lafeber, T.R.D.J. Radstake and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 065. Hypoxia-Inducible Factor-α: Trigger of Toll-Like Receptor Signalling-Engaged Inflammation in Rheumatoid Arthritis. Fanlei Hu, Rong Mu, Jiaxin Zhu, Wenwei Shao, Lianjie Shi, Philip L. Cohen, Xiaoyan Qiu and Zhanguo Li, Peking University People s Hospital, Beijing, China, School of Basic Medical Science, Peking University, Beijing, China, Temple University, Philadelphia, PA 066. Extrathymic Autoimmune Regulator (AIRE) Expression in Rheumatoid Arthritis. A.R. Noort, K.P.M. van Zoest, M.C. Lebre, P. P. Tak and S.W. Tas, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 067. Spontaneous Aggregation of the Anti-Viral Mavs Protein in Certain Systemic Lupus Erythematosus Patients May Explain Excessive Type I Interferon Production. Philip L. Cohen and Wen-Hai Shao, Temple University, Philadelphia, PA, Temple University School of Medicine, Philadelphia, PA 068. A Selective Inhibitor of Endosomal Toll-Like Receptors, IMO-8400, Suppresses Activation of Multiple Cytokines, Th7 Response and Inflammasome Activation. Weiven Jiang, Fugang Zhu, Dong Yu, Ekambar R. Kandimalla, Nicola La Monica and Sudhir Agrawal, Idera Pharmaceuticals, Cambridge, MA 069. The Effects of TNF Stimulation on Control of Apoptosis in Neutrophils. Direkrit Chiewchengchol, Connie Lam, Kate Roberts, Helen Wright, Huw Thomas, Robert Moots and Steven Edwards, University of Liverpool, Liverpool, United Kingdom 070. CDc+ Dendritic Cells Play an Important Proinflammatory Role in Inflammatory Arthritis. Antonia Puchner, Stephan Blüml, Harald Leiss, Victoria Saferding and Kurt Redlich, Medical University Vienna, Vienna, Austria, Medical University of Vienna, Vienna, Austria 07. WITHDRAWN. 07. Enzymatic Lipid Oxidation Contributes to the Maintenance of Self-Tolerance by Regulating Antigen Clearance and Dendritic Cell Function. Stefan Uderhardt, Tobias Rothe, Elisabeth Zinser, Olga Oskolkova, Martin Herrmann, Alexander Steinkasserer 4, Valery Bochkov, Georg Schett 5 and Gerhard Kronke, University of Erlangen, Erlangen, Germany, Department of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, PhD, Erlangen, Germany, 4 Department of Immune Modulation at the Department of Dermatology, University Hospital Erlangen, Erlangen, Germany, 5 Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 07. Increased Oxidative Burst in Neutrophils but Not Monocytes in Systemic Lupus Erythematosus. Sandro F. Perazzio, Reinaldo Salomao, Neusa P. Silva and Luis Eduardo C. andrade, Federal University of Sao Paulo, Sao Paulo, Brazil, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil 074. TLR Deletion Promotes Arthritis and Joint Destruction Through Reduction of IL-0. Qi Quan Huang, Renee E. Koessler, Robert Birkett, Harris R. Perlman, Lianping Xing and Richard M. Pope 4, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, University of Rochester, Rochester, NY, 4 Northwestern Univ Med School, Chicago, IL 075. Effects of sirna Depletion of Interferon Regulatory Factor 5 on Pro-Inflammatory Cytokine Production and IgG Secretion by Primary Human Immune Cells in Response to TLR7/8 Stimulation. Dinesh Srinivasan, Sandip Panicker, Gang Lu, Yajuan Gu, Rothschild Soto, Seng-Lai Tan and Julie Demartino, Hoffmann-La Roche, Nutley, NJ, Hoffmann La Roche, Nutley, NJ 076. FLIP in Dendritic Cells May Regulate Hematopoietic Homeostasis and Modulating Inflammation and Immunity. Qi Quan Huang, Robert Birkett, Harris R. Perlman and Richard M. Pope, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern Univ Med School, Chicago, IL 077. p Promotes Inflammatory Arthritis Resolution by Facilitating Alternative Activation of Macrophages. Angelica K. Gierut, Carla M. Cuda, Alexander V. Misharin, Rana Saber and Harris R. Perlman, Northwestern Med Faculty Found, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Northwestern University, Chicago, IL 4 0 Program Book

217 ACR POSTER SESSION B 078. Prolactin Is Increased in Responders to Anti-TNFá Treatment and the Role of the Prolactin Receptor in Rheumatoid Arthritis. Man Wai Tang, Danielle Marie Gerlag, Veronica Codullo, Elsa Vieira-Sousa 4, Anne Q. Reuwer 5, Marcel T. Twickler 5, Robert B. M. Landewé 6 and Paul Peter Tak 7, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center, Amsterdam, Netherlands, Academic Medical Center/Univeristy of Amsterdam / University of Pavia, IRCCS Policlinico San Matteo Foundation, Amsterdam / Pavia, Netherlands, 4 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, 5 Academic Medical Center/University of Amsterdam, Amsterddam, Netherlands, 6 Academic Medical Center/ University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 7 Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands 079. Polyclonal CD4+Foxp+ treg Cells Induce TGFb-Dependent Tolerogenic Dendritic Cells That Suppress Murine Lupus- Like Syndrome. Qin Lan and Song G. Zheng, University of Southern California, Los Angeles, CA, Keck School of Medicine of USC, Los Angeles, CA 080. Effect of Anti-NKGA Antibody Treatment on NK Cell Receptor Expression in Rheumatoid Arthritis Patients. Joseph Wahle, John Bui and Kristen Bontadelli, Novo Nordisk, Seattle, WA 08. Toll-Like Receptor 7, 8 and 9 Activation of Primary Human Cells by Lupus Immune Complexes Is Dependent On Interleukin Receptor Associated Kinase 4 Activity. Aaron Winkler, Weiyong Sun, Ken Dower, Elizabeth A. Murphy, Julia Shin, Michael Luong, Michael J. Primiano, Varenka A. Rodriguez, Tatyana Souza, Lih-Ling Lin, J. Perry Hall, Katherine Lee, Vikram R. Rao and Margaret Fleming, Pfizer, Cambridge, MA Orthopedics, Low Back Pain, and Rehabilitation Poster 08. Predictors of Persistence in People with Subacute Low Back Pain. Souraya Torbey, Ali Mansour, Kristina Herrmann, Marwan Baliki, Thomas J. Schnitzer and A. Vania Apkarian, Northwestern University, Chicago, IL 08. Physicians Recommendations for Total Knee Arthroplasty in Younger Persons with Moderate Osteoarthritis. Liana Fraenkel, Lawrence Weis and Lisa G. Suter, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, Yale University, New Haven, CT 084. In Vivo Kinematics of Three-Component Mobile-Bearing Total Ankle Replacement for Rheumatoid Arthritis. Keiji Iwamoto, Tetsuya Tomita, Takaharu Yamazaki, Kenrin Shi, Norimasa Shimizu, Masahiro Kurita, Kazuma Futai, Yasuo Kunugiza, Hideki Yoshikawa and Kazuomi Sugamoto, Osaka University Graduate School of Medicine, Osaka, Japan, Osaka University, Osaka, Japan 085. Differences in Baseline Characteristics between TKR and THR Patients: Results from a National Research Consortium. Patricia D. Franklin, Benjamin Snyder, Jeroan Allison, Wenjun Li, Milagros Rosal, Leslie R. Harrold, Bruce Barton and David Ayers, University of Massachusetts Medical School, Worcester, MA, University of Massachusetts Medical School, UMass Medical School, Worcester, MA 086. Has the Level of Disability At Time of TKR Changed Over the Past 0 Years?: Results From Two National Cohorts. Patricia D. Franklin, Wenjun Li, Benjamin Snyder, Courtland Lewis, Philip Noble and David Ayers, University of Massachusetts Medical School, Worcester, MA, CT Joint Replacement Institute, St. Francis Hospital, Hartford, CT, Baylor College of Medicine, Houston, TX 087. Do Younger TKR Patients Have Similar Disability At Time of Surgery As Older Adults? Patricia D. Franklin, Wenjun Li, Leslie R. Harrold, Benjamin Snyder, Courtland Lewis, Philip Noble 4 and David Ayers, University of Massachusetts Medical School, Worcester, MA, UMass Medical School, Worcester, MA, CT Joint Replacement Institute, St. Francis Hospital, Hartford, CT, 4 Baylor College of Medicine, Houston, TX 088. Factors Influencing Long-Term Recovery of Total Knee Arthroplasty. C. Allyson Jones, Gian S. Jhangri and Maria E. Suarez-Almazor, Departments of Physical Therapy and School of Public Health, University of Alberta, Edmonton, AB, School of Public Health, University of Alberta, Edmonton, AB, University of Texas MD anderson Cancer Center, Houston, TX 089. The Number of Ruptured Tendons as a Prognostic Factor for Reconstructing Extensor Tendon Rupture in Patients with Rheumatoid Arthritis. Yu Sakuma, Kensuke Ochi, Takuji Iwamoto, Shinji Yoshida, Asami Saitou, Katsunori Ikari and Shigeki Momohara, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 090. A Comparison of Patient-Reported and Measured Range of Motion in a Cohort of Total Knee Replacement Patients. Jamie E. Collins, Benjamin N. Rome, Vladislav Lerner, Jeffrey N. Katz and Elena Losina, Brigham and Women s Hospital, Boston, MA 09. Trends in Patient Physical Activity before and After Primary Total Hip Arthroplasty. Anne Lübbeke, Dorith Zimmermann, Constantinos Roussos, Alexis Bonvin, Robin Peter and Pierre Hoffmeyer, Geneva University Hospitals, Geneva, Switzerland 09. Effect of FULL Contact FOOT Orthosis On Plantar Fasciitis. Hilda A. Oliveira, Anamaria Jones, Emilia Moreira, Fabio Jennings and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 0 Program Book 5

218 ACR POSTER SESSION B 09. Obesity Is Not a Risk Factor for Poor Pain and Function Two Years after Total Knee Replacement. Lisa A. Mandl, Mark P. Figgie, Alejandro Gonzalez Della Valle, Michael Alexiades and Susan M. Goodman, Hospital for Special Surgery, New York, NY 094. The Relationship between Lumbar Spine Individual Radiographic Features and Low Back Symptoms with and without Associated Leg Symptoms: The Johnston County Osteoarthritis Project. Adam P. Goode, Janet K. Freburger, Timothy S. Carey, Chad E. Cook 4, Jordan Renner 5, Sean D. Rundell 6 and Joanne M. Jordan 7, Duke University, Durham, NC, University of NC CB 7590, Chapel Hill, NC, Cecil G. Sheps Center for Health Services Research University of North Carolina, Chapel Hill, NC, 4 Walsh University, OH, 5 University of North Carolina, Chapel Hill, NC, 6 University of Washington, Seatle, WA, 7 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC 095. Metal Concentrations in Patients with Failed Metal- On-Metal Hip Prostheses Determine the Inflammatory Phenotype in Peri-Implant Tissue. Erja-Leena Paukkeri, Riku Korhonen, Antti Eskelinen, Marko Pesu, Kaija Vasama 4, Teemu Moilanen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, Coxa Hospital for Joint Replacement, Tampere, Finland, Immunoregulation, Institute of Biomedical Technology, University of Tampere, Tampere, Finland, 4 Fimlab Laboratories, Tampere, Finland 096. Lower Income Paradoxically Associated with Better Patient-Reported Outcomes After Knee Arthroplasty in the U.S. Jasvinder A. Singh and David Lewallen, University of Alabama at Birmingham, Birmingham, AL, Mayo Clinic college of medicine, Rochester Osteoarthritis - Clinical Aspects 097. The Association of Fat Distribution and Clinically Defined Hand Osteoarthritis: The Netherlands Epidemiology of Obesity Study. A. Willemien Visser, Marieke Loef, andreea Ioan-Fascinay, Martin den Heijer, Frits R. Rosendaal and Margreet Kloppenburg, Leiden University Medical Center, Leiden, Netherlands 098. Knee Osteoarthritis and Frailty in Older Adults: Findings from the Multicenter Osteoarthritis Study and Osteoarthritis Initiative. Devyani Misra, Michael C. Nevitt, Cora E. Lewis, James Torner 4, David T. Felson and Tuhina Neogi, Boston University School of Medicine, Boston, MA, University of California-San Francisco, San Francisco, CA, University of Alabama, Birmingham City, Birmingham, AL, 4 University of Iowa, Iowa City, Iowa City, IA 099. Whole Blood Lead Is Associated with Symptoms, but Not Radiographic Osteoarthritis, in Multiple Joint Sites: The Johnston County Osteoarthritis Project. Amanda E. Nelson, Xiaoyan A. Shi, Todd A. Schwartz, Jordan B. Renner 4, Kathleen L. Caldwell 5, Charles G. Helmick 5 and Joanne M. Jordan, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, SAS Institute, Inc, Cary, NC, University of North Carolina Gillings School of Global Public Health, Dept of Biostatistics, Chapel Hill, NC, 4 University of North Carolina School of Medicine, Dept of Radiology, Chapel Hill, NC, 5 Centers for Disease Control and Prevention, Atlanta, GA 00. A Functional Growth Hormone Receptor Polymorphism, Exon Deleted Ghr, Is Associated with Radiographic Knee Osteoarthritis in Females with Familial Osteoarthritis At Multiple Sites: The Garp Study. Kim M.J.A. Claessen, Margreet Kloppenburg, H.M. Kroon, Jessica Bijsterbosch, Alberto M. Pereira, Hans A. Romijn, Tahar Straaten van der, Marian Beekman, P.E. Slagboom, Nienke R. Biermasz and Ingrid Meulenbelt, Leiden University Medical Center, Leiden, Netherlands, Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Leiden, Netherlands, The Netherlands Genomics Initiative- Sponsored Netherlands Consortium for Healthy Aging, Rotterdam, Netherlands 0. Condroitin Sulfate Decreases Chemokine Levels and Synovitis in knee osteoarthritis Patients. Jordi Monfort, Paula Escudero, Cristobal Orellana, Laura Piqueras 4, Laura Tio 5, Francisco Montañés, Natalia García 5, Chantal Company, Pere Benito and Maria Jesús Sanz, Hospital del Mar, Barcelona, Spain, Universitary Clinic Hospital Research Foundation-INCLIVA, University of Valencia, Valencia, Spain, Corporació Sanitaria Parc Taulí, Sabadell, Spain, 4 University Clinic Hospital Research Foundation-INCLIVA, University of Valencia, Valencia, Spain, 5 GRICIC. FIMIM, Barcelona, Spain 0. Immunoreactive Collagen Type II Cleavage Products and Their Nitrated Forms in Rheumatoid Arthritis and Osteoarthritis: An Outpatient Cross-Sectional Study. Ruediger Mueller, Axel Finckh, Guy Heynen and Johannes von Kempis 4, Cantonal Hospital, St. Gallen, Switzerland, Geneva University Hospitals, Geneva 4, Switzerland, Consulting, CH-600 Zug, Switzerland, 4 MD, St. Gallen, Switzerland 0. Cumulative Occupational Physical Load as Risk Factor for Knee Osteoarthritis. Allison M. Ezzat, Jolanda Cibere, Mieke Koehoorn, Eric C. Sayre and Linda C. Li, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Vancouver, BC 04. The Association of Demographic, Modifiable, Structural and Biomechanical Risk Factors with Medial and Lateral Patellofemoral Joint Structural Damage on MRI: The Multicenter Osteoarthritis Study. Joshua J. Stefanik, Ke Wang, K. Douglas Gross, Frank Roemer, John A. Lynch 4, Neil Segal 5, Cora E. Lewis 6, Michael C. Nevitt 4, Ali Guermazi and David T. Felson, Boston University, Boston, MA, MGH Institute of Health Professions, Boston, MA, Klinikum Augsburg, Augsburg, Germany, 4 University of California-San Francisco, San Francisco, CA, 5 University of Iowa, Iowa City, 6 University of Alabama, Birmingham City, Birmingham, AL 6 0 Program Book

219 ACR POSTER SESSION B 05. Lateral Tibio-Femoral Shift Related to Medial Knee Osteoarthritis. Roy H. Lidtke, Berna Goker, Abdurrahman Tufan, Laura E. Thorp and Joel A. Block, Rush University Medical Center, Chicago, IL, Gazi University Medical School, Ankara, Turkey 06. Evaluation of Foot Posture and Plantar Pressure Changes in Knee Osteoarthritis: Preliminary Report. Necati Balci and Lale Cerrahoglu, Celal Bayar University Medical School, Manisa, Turkey 07. Baseline Knee Flexion Pain, Age and Joint Line Tenderness Predict the Progression of Asymptomatic, Radiographic Knee Osteoarthritis to Symptomatic Knee Osteoarthritis Over 5 Years. Abhiram Gande and James J. Irrgang, University of Pittsburgh School of Medicine, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA 08. A Randomized Controlled Trial of Hylan G-F 0 for the Treatment of Carpometacarpal Osteoarthritis. Lisa A. Mandl, Scott Wolfe, Aaron Daluiski, Robert N. Hotchkiss, Stephen L. Lyman and Jeffrey N. Katz 4, Hospital for Special Surgery, New York, NY, Hospital For Special Surgery, New York, NY, Hospital Special Surgery, New York, NY, 4 Brigham and Women s Hospital, Boston, MA 09. Effects of Strontium Ranelate On Hand Osteoarthritis Analysis of Data From the Sekoia Trial. E. Maheu, C. Cadet and F. Berenbaum, AP-HP St Antoine Hospital, Paris, France, Paris, France 0. Radiologic Progression in Hand Osteoarthritis (OA) Over.6 Years - Data from the Sekoia Trial. Emmanuel Maheu, Christian Cadet and Francis Berenbaum, AP-HP, St Antoine Hospital, Paris, France, Rheumatology, Paris, France. Erosive Evolution in Hand Osteoarthritis Is Associated with Incident Joint Tenderness Independent of MRI-Defined Bone Marrow Lesions and Synovitis. Ida K. Haugen, Barbara Slatkowsky-Christensen, Pernille Boyesen, Sølve Sesseng, Désirée van der Heijde and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway, Leiden University Medical Center, Leiden, Netherlands. Patients with Erosive Osteoarthritis Have Less Extensive Synovitis Than Patients with Rheumatoid Arthritis On Histopathology. Allen P. Anandarajah, Stephen Kates, Kate Burns and Ellen Giampoli 4, Univ of Rochester Medical Ctr, Rochester, NY, University of Rochester Medical Center, Rochester, University of Rochester, Rochester, NY, 4 University of Rochester Medical Ctr, Rochester, NY. Characterization of Lumbar Spine Individual Radiographic Features in African American and White Women and Men: The Johnston County Osteoarthritis Project. Adam P. Goode, Amanda E. Nelson, Kelli D. Allen, Jordan Renner 4, Timothy S. Carey 5 and Joanne M. Jordan, Duke University, Durham, NC, University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC, Duke and Durham VA Medical Center, Durham, NC, 4 University of North Carolina, Chapel Hill, NC, 5 Cecil G. Sheps Center for Health Services Research University of North Carolina, Chapel Hill, NC 4. Prevalence of Radiographic and Symptomatic Hip Osteoarthritis in an Urban US Population: The Framingham Osteoarthritis Study. Katherine D. Linsenmeyer, Ali Guermazi, Kyu-Chan Kim, David T. Felson, Mary M. Clancy and Steven C. Vlad, Boston Medical Center, Boston, MA, Boston University, Boston, MA 5. Relation between Hip Dysplasia, Pain, and Osteoarthritis in a Cohort of Patients with Hip Symptoms. Johanne Morvan, Ronan Bouttier, Bernard Mazieres, Evelyne Verrouil, Jacques Pouchot 4, Anne-Christine Rat 5, Joel Coste 6 and Alain Saraux 7, CH Quimper, Quimper, France, CHU Brest, Brest, Hopital de Rangueil, Toulouse, FRANCE, France, 4 Hopital Louis Mourier, Colombes, FRANCE, France, 5 Nancy Teaching Hospital, Nancy, France, 6 Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , France, Nancy, France, 7 Université Brest Occidentale, Brest, France 6. Diagnostic Value of Internal Rotation Measurement in Patients with Cam- and Pincer-Type Deformities of the Hip. Stephan Reichenbach, Michael Leunig, Stefan Werlen, Andreas Limacher, Christian W. Pfirrmann 4, Reinhold Ganz and Peter Jüni, University of Bern, Bern, Switzerland, Schulthess Clinic, Zurich, Switzerland, Hospital Sonnenhof, Bern, Switzerland, 4 Balgrist University Hospital, Zurich, Switzerland 7. Association between Hip Bone Marrow Lesions (BMLs) and Bone Mineral Density: A Cross-Sectional and Longitudinal Population-Based Study. Harbeer Ahedi, Dawn Dore, Leigh Blizzard, Flavia Cicuttini and Graeme Jones, Menzies Research institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 8. Association Between Hip and Knee Cartilage Measured Using Radiographs and Magnetic Resonance Imaging: The Tasmanian Older Adult Cohort Study. Hussain Ijaz Khan, Dawn Dore, Guangju Zhai, Changhai Ding, Jean Pierre Pelletier 4, Johanne Martel-Pelletier 4, Flavia Cicuttini 5 and Graeme Jones, Menzies Research institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, St John s, NL, Menzies research institute & Monash University, Hobart, Australia, 4 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 5 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, 004, Australia 9. Prediction of MRI-Detected Cartilage Loss Over 0 Months Using Simplified Radiographic and Clinical Stratification: The MOST Study. Frank Roemer, David T. Felson, Jingbo Niu, Yuqing Zhang, Michael C. Nevitt 4, Michel Crema, Cora E. Lewis 5, James Torner 6 and Ali Guermazi 7, Klinikum Augsburg, Augsburg, Germany, Boston Univ School of Medicine, Boston, MA, Boston University, Boston, MA, 4 University of California-San Francisco, San Francisco, CA, 5 University of Alabama, Birmingham City, Birmingham, 0 Program Book 7

220 ACR POSTER SESSION B 8 AL, 6 University of Iowa, Iowa City, Iowa City, IA, 7 Boston University School of Medicine, Boston, MA 0. Cartilage Volume Loss Occurs in Most Older Adults and the Rate of Loss Increases with Age. andreea M. Harsanyi, Dawn Dore, Changhai Ding, Jean-Pierre Pelletier, Johanne Martel-Pelletier, Flavia Cicutinni 4 and Graeme Jones, Menzies Research Institute Tasmania, Hobart, Australia, Menzies Research institute Tasmania, University of Tasmania, Hobart, 7000, Australia, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 4 Monash University, Melbourne, Australia, Melbourne, Australia. Degenerative Medial Meniscal Pathology May Initiate in the Posterior Horn: Data From the Osteoarthritis Initiative. Robert J. Ward, Jeffrey B. Driban, Eric E. Wong, Jonathan W. Pack, Kunal K. Kothari, Grace H. Lo and Timothy E. McAlindon, Tufts Medical Center, Boston, MA, Tufts University School of Medicine, Boston, MA, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX. Identifying Radiographic Phenotypes of Early Knee Osteoarthritis Using Separate Quantitative Features Might Improve Patient Selection for More Targeted Treatment. Margot B. Kinds, Anne C. A. Marijnissen, Max A. Viergever, P.J. Emans, J.W.J. Bijlsma, F.P.J.G. Lafeber and P.M.J. Welsing, University Medical Center Utrecht, Utrecht, Netherlands, Maastricht University Medical Center, Maastricht, Netherlands. Comparison of Anatomic Knee Alignment On Physical Examination and Radiographs. Iman Hemmati, Eric C. Sayre, Ali Guermazi, Savvakis Nicolaou, Anona Thorne 4, Joel Singer and Jolanda Cibere, University of British Columbia, Vancouver, BC, Arthritis Research Centre of Canada, Vancouver, BC, Boston University, Boston, MA, 4 Canadian Institutes of Health Research HIV Trials Network, Vancouver, BC 4. Total Knee Replacement As an Osteoarthritis Study Outcome: Predictors Derived From Long-Term Observation Following a Randomized Clinical Trial. Jean-Pierre Raynauld, Johanne Martel-Pelletier, Marc Dorais, Boulos Haraoui, Denis Choquette, François Abram, andré Beaulieu 4, Louis Bessette 5, Frédéric Morin 6, Lukas M. Wildi and Jean Pierre Pelletier 7, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, StatSciences Inc., Notre-Dame de l Île Perrot, QC, Imaging Research & Development, ArthroLab Inc., Montreal, QC, 4 Faculty of Medicine, Laval University, Quebec, QC, 5 Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, 6 Centre de Recherche Musculo-squelettique, Trois-Rivières, QC, 7 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC 5. Three Trajectories of Activity Limitations in Early Symptomatic Knee Osteoarthritis: A 5-Year Follow-up Study. Jasmijn F. M. Holla, Marike van der Leeden, Leo D. 0 Program Book Roorda, Martijn W. Heymans, Sita M.A. Bierma-Zeinstra, Maarten Boers, Willem F. Lems, Martijn P.M. Steultjens 4 and Joost Dekker, Reade, Amsterdam, Netherlands, VU University Medical Center, Amsterdam, Netherlands, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 4 Glasgow Caledonian University, Glasgow, Scotland 6. Comparison between Osteoartritis Initiative and CHECK study (Cohort Hip & Cohort Knee); Development of pain and function during 4 years follow-up. Janet Wesseling, Sita M.A. Bierma-Zeinstra, Margreet Kloppenburg, Johannes WJ Bijlsma and CHECK steering group 4, University Medical Center Utrecht, Utrecht, Netherlands, Erasmus MC - University Medical Center, Rotterdam, Netherlands, Department Rheumatology and Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, The Netherlands, Leiden, Netherlands, 4 Utrecht 7. Dynamic Stereo X-Ray Evaluation of Knee Joint Mechanics during Downhill Walking in Subject with Knee Osteoarthritis. Shawn Farrokhi, Carrie A. Rainis, G. Kelley Fitzgerald and Scott Tashman, University of Pittsburgh, Pittsburgh, PA, Univ of Pittsburgh, Pittsburgh, PA 8. Different of Patterns Knee Pain Trajectories: Longitudinal Data from the Osteoarthritis Initiative (OAI). Joseph Devich Jr., Michael J. Hannon, Zhijie Wang, Robert M. Boudreau and C. Kent Kwoh 4, UPMC Shadyside, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, 4 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA 9. Prevalence of Symptomatic Basilar Thumb Joint Osteoarthritis in the General Population. Jennifer Moriatis Wolf, Aleksandra Turkiewicz, Isam Atroshi and Martin Englund, University of Connecticut Health Center, Farmington, CT, Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden, Lund University, Hässleholm, Sweden 0. The Effect of Age On the Number of Osteoarthritis Flares with Continuous Versus Intermittent Celecoxib Treatment. George H. Sands, Pritha Bhadra and Margaret Noyes Essex, Pfizer, Inc, New York, NY. Intraarticular Infliximab for Knee Osteoarthritis: High Baseline Levels of Synovial Cellularity and High MRI Cartilage Injury At the Lateral Tibial Plateau Predict Improvement in Total WOMAC Score. Jeremy R. Schue, Ossama Tawfik, Rebecca Bolce, Donald D. Smith, Gary Hinson, Jo A. Wick and Herbert B. Lindsley, Kansas University Med Ctr, Kansas City, KS, Crescendo Bioscience Inc., South San Francisco, CA. Prevalence of Knee Pain in Ultramarathon Runners. Victoria M. Kelly, Martin Hoffman, Bharathi Lingala, Mihoko Bennett and Eswar Krishnan, Stanford University, Palo Alto, CA, Department of Veteran s Affairs, Northern California Health Care System and University of California Davis Medical Center, Sacramento, CA

221 ACR POSTER SESSION B. Gait Differences Are Present in Subjects with Symptomatic Vs. Asymptomatic Mild Radiographic Hip Osteoarthritis. Samir S. Chabra, Najia Shakoor and Kharma C. Foucher, University of Illinois at Chicago, Chicago, IL, Rush University Medical Center, Chicago, IL 4. What Are the Levels of Physical Activities and Their Associations with Quality of Life in Patients with Symptomatic Hip and/or Knee Osteoarthritis? Irawati Lemonnier, Anne Vuillemin and Anne-Christine Rat, Lorraine Université Paris Descartes University, EA 460 Apemac, Nancy, France, Nancy, France, Universite de Lorraine, Paris Descartes University, EA 460 Apemac, Nancy, France, Nancy, France, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy, France 5. Combined Glucosamine and Chondroitin Sulfate, Once of Three Times Daily, Provide Clinically Relevant Analgesia in Knee Osteoarthritis. Jose R. Provenza, Samuel K. Shinjo, Joyce M. Silva, Carla RGS. Peron 4 and Francisco AC Rocha 5, Pontifícia Universidade Católica de Campinas, Campinas, Brazil, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, Sao Paulo, Brazil, 4 Laboratórios Aché Ltda, Sao Paulo, Brazil, 5 Federal University of Ceara, Fortaleza, Brazil 6. Aesthetic Dissatisfaction in Hand Osteoarthritis Patients, Its Impact and Risk Factors. R. Liu, L.J.J. Beaart-van de Voorde, T.W.J. Huizinga and M. Kloppenburg, Leiden University Medical Center, Leiden, Netherlands 7. Clinimetric Properties of a New Outcome Measure: The Hand-Osteoarthritis Aesthetic Damage Index. N. Bellamy and Joan Hendrikz, The University of Queensland, Herston, Queensland, Australia 8. Nonpharmacologic and Pharmacologic Therapy Utilization by Primary Care Providers for Hand Osteoarthritis- Comparative Review by Electronic Health Record Data Mining and in-home Visit Verification. Gale A. McCarty, President, Rheum.Ed Consulting, Harborside, ME Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis 9. Inhaled Nitrous Oxide Facilitates Access to Intra-Articular Corticosteroid Injections in Children with Juvenile Idiopathic Arthritis. Mercedes O. Chan, Ruth Wyllie and H. E. Foster, University of British Columbia and British Columbia s Children s Hospital, Vancouver, BC, Newcastle Hospitals, NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom, Newcastle Hospitals NHS Foundation Trust, Great North Children s Hospital and Newcastle University, Newcastle Upon Tyne, United Kingdom 40. Response to Adalimumab in 40 Patients with refractory juvenile Idiopathic Arthritis-Associated Uveitis. A Multicenter Study. Vanesa Calvo-Río, Ricardo Blanco, Manuel Díaz-Llopis, David Salom, Carmen García-Vicuña 4, Miguel Cordero-Coma 5, Norberto Ortego 6, Marta Suarez-de- Figueroa 7, J. Carlos Fernandez-Cid 8, A. Fonollosa Calduch 9, Ángel M. García-Aparicio 0, Jose M. Benítez-del-Castillo, Jose L. Olea, Javier Loricera and Miguel Angel González- Gay, Hospital Universitario Marqués de Valdecilla-IFIMAV, Santander, Spain, Hospital Universitario La Fe de Valencia, Valencia, Hospital Universitario La Fe de Valencia, Valencia, Spain, 4 Hospital Sant Joan de Déu, Barcelona, Barcelona, 5 Hospital de León, León, Spain, 6 Hospital Santa Cecilio, Granada, Spain, 7 Hospital Ramon y Cajal, Madrid, Spain, 8 Hospital de Pontevedra, Pontevedra, Spain, 9 Hospital de Cruces, Barakaldo, Spain, 0 Hospital Virgen Salud, Toledo, Toledo, Hospital Clínico San Carlos, Madrid, Hospital Son Dureta, Palma de Mallorca, Spain, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain 4. Safety of Celecoxib and Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Juvenile Idiopathic Arthritis. Rachel E. Sobel, D. J. Lovell, Hermine I. Brunner, Jennifer E. Weiss 4, Paula W. Morris 5, Beth S. Gottlieb 6, Elizabeth C. Chalom 7, Lawrence K. Jung 8, Karen Onel 9, Lisa Petinoit 0, Donald P. Goldsmith, Staci Abramsky-Risman, James P., Young and Edward H. Giannini 4, Pfizer, Inc., New York, NY, Cincinnati Children s Hospital, Cincinnati, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 4 Hackensack Univ Med Ctr, Hackensack, NJ, 5 Univ of Arkansas for Med Sci, Little Rock, AR, 6 Cohen Children s Medical Center of New York, New Hyde Park, NY, 7 St. Barnabas Medical Center, Livingston, NJ, 8 Children s National Medical Center, Washington, DC, 9 University of Chicago, Chicago, IL, 0 Specially for Children, Dell Children s Medical Center, Austin, TX, St Christopher s Hospital for Children/ Drexel College of Medicine, Philadelphia, PA, Pfizer Inc, New York, NY, United BioSource Corporation, Ann Arbor, MI, 4 PRCSG-Cincinnati Children s Hospital Medical Center, Cincinnati, OH 4. Efficacy of Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review Using Indirect Comparisons. Janneke Anink, Marieke H. Otten, Sandra Spronk and Lisette W.A. Van Suijlekom-Smit, Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands, Erasmus MC, Rotterdam, Netherlands 4. Tocilizumab Therapy in Children with Systemic Onset Juvenile Idiopathic Arthritis. Russian Experience. Ekaterina Alekseeva, Rina Denisova, Saniya Valieva, Tatyana Bzarova, Kseniya Isayeva, Alexandra Chomakhidze, Evgeniya Chistyakova, Tatyana Sleptsova and Elena Mitenko, Scientific Center of Children s Health, Moscow, Russia 44. Phenotypic Characterization of Childhood Onset Rheumatoid Arthritis. Emily G. Ferrell, Lori Ponder, Lauren Minor, Sheila T. Angeles-Han, Christine W. Kennedy, Kelly A. Rouster-Stevens 4, Mina Pichavant, Larry B. Vogler 4 and Sampath Prahalad, Emory University School of Medicine, Atlanta, GA, Emory Children s Center, Atlanta, GA, Emory University, Atlanta, GA, 4 Emory Univ School of Medicine, Atlanta, GA 0 Program Book 9

222 ACR POSTER SESSION B 45. Use of Non-Etanercept Biologics in Children with Juvenile Idiopathic Arthritis: Results from the Biologics for Children with Rheumatic Diseases Study. Lianne Kearsley-Fleet, Eileen Baildam, Michael Beresford, Rebecca Davies, Helen E. Foster 4, Katy Mowbray, Taunton R. Southwood 5, Wendy Thomson and Kimme L. Hyrich 6, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, Alder Hey Children s Foundation NHS Trust, Liverpool, United Kingdom, Institute of Translational Medicine (Child Health), Alder Hey Children s Foundation NHS Trust, Liverpool, United Kingdom, 4 Musculoskeletal Research Group, Newcastle upon Tyne, United Kingdom, 5 University of Birmingham and Birmingham Children s Hospital, Birmingham, United Kingdom, 6 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom 46. Choice of Systemic JIA Treatment among Childhood Arthritis and Rheumatology Research Alliance (CARRA) Rheumatologists. Jennifer E. Weiss, Esi M. Morgan DeWitt, Timothy Beukelman, Laura E. Schanberg 4, Rayfel Schneider 5 and Yukiko Kimura, Joseph M. Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Univ of Alabama-Birmingham, Birmingham, AL, 4 Duke University Medical Center, Durham, NC, 5 The Hospital for Sick Children, Toronto, ON 47. Definition of Improvement Thresholds in Juvenile Idiopathic Arthritis Using the JADAS. Gerd Horneff and Ingrid Kaul, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany 48. Adalimumab - Effective Control under Refractory JIA Associated Uveitis. Ekaterina Alekseeva, Elena Mitenko, Tatyana Bzarova, Saniya Valieva, Kseniya Isayeva, Alexandra Chomakhidze, Evgeniya Chistyakova, Tatyana Sleptsova and Rina Denisova, Scientific Center of Children s Health, Moscow, Russia 49. Long-Term Safety of Etanercept in Patients with Juvenile Idiopathic Arthritis (JIA). Kirsten Minden, Martina Niewerth, Jens Klotsche, Michael Hammer 4, Johannes Peter Haas 5, Gerd Ganser 6 and Gerd Horneff 7, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany, German Rheumatism Research Centre, Berlin, Germany, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, 4 St. Josef-Stift, Sendenhorst, Germany, 5 German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 6 Sankt Josef Stift, Sendenhorst, Germany, 7 Centre of Pediatric Rheumatology, Sankt Augustin, Germany 50. Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project. Sarah Ringold, Audrey F. Hendrickson, Carol A. Wallace and Rachel E. Sobel, Seattle Children s Hospital, Seattle, WA, Seattle Childrens Hospital, Seattle, WA, Pfizer, Inc., New York, NY 5. Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide. Ryan S. Funk, Leon van Haandel, Mara L. Becker and J.S. Leeder, Children s Mercy Hospital, Kansas City, MO 5. Improvement in Health-Related Quality of Life for Children with Juvenile Ideopathic Arthritis after Start of Treatment with Etanercept. Jens Klotsche, Kirsten Minden and Gerd Horneff, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany, Centre of Pediatric Rheumatology, Sankt Augustin, Germany 5. Perceived Health-Related Quality of Life and Its Determining Factors in Children with Recent-Onset JIA. Jens Klotsche, Ina Liedmann, Martina Niewerth, Gerd Horneff, Johannes Peter Haas 4 and Kirsten Minden 5, German Rheumatism Research Center, a Leibniz institute, Berlin, Germany, German Rheumatism Research Centre, Berlin, Germany, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, 4 German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 5 German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany 54. Impact of FokI VDR and TNFalpha 08 Polymorphism on Disease Severity and Long Term Outcome in JIA Patients On Anti-TNF Treatment. Jelena Vojinovic, Jelena Basic, Gordana Susic, Dragana Lazarevic and Nemanja Damjanov 4, Prof, Nis, Serbia, Dr, Nis, Serbia, Dr, Belgrade, Serbia, 4 Prof, Belgrade, Serbia 55. A New Measure of Visual Function for Children with Juvenile Idiopathic Arthritis-Associated Uveitis. Sheila T. Angeles-Han, Steven Yeh, Courtney McCracken, Larry B. Vogler, Kelly A. Rouster-Stevens, Christine W. Kennedy, Kirsten Jenkins, Matthew Kent, Scott Lambert, Carolyn Drews-Botsch 4 and Sampath Prahalad, Emory Univ School of Medicine, Atlanta, GA, Emory Children s Center, Atlanta, GA, Children s Healthcare of Atlanta, Atlanta, GA, 4 Emory University School of Public Health, Atlanta, GA 56. Effectivity of Methotrexate in Therapy of Juvenile Idiopathic Enthesitis-Related Arthritis. Katharina Geitz and Ivan Foeldvari, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany 57. The Phenotypic Characterization of Juvenile Idiopathic Arthritis in African American Children. Lauren Minor, Lori Ponder, Emily G. Ferrell, Sheila Angeles-Han, Christine W. Kennedy, Kelly Rouster-Stevens, Mina Pichavant, Larry B. Vogler and Sampath Prahalad, Emory University School of Medicine, Atlanta, GA, Emory Children s Center, Atlanta, GA 58. Development of Cut-off Values for High Disease Activity in Juvenile Idiopathic Arthritis Based On the Juvenile Arthritis Disease Activity Score. Alessandro Consolaro, Stefano 0 0 Program Book

223 ACR POSTER SESSION B Lanni, Sara Verazza, Maria C. Gallo, Marta Bertamino, Giulia C. Varnier, Serena Calandra, Nicolino Ruperto, Alberto Martini 4 and Angelo Ravelli 5, Istituto Giannina Gaslini, Genova, Italy, University of Genova, Genova, Italy, Paediatric Rheumatology International Trials Organisation [PRINTO], Genova, Italy, 4 Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 5 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 59. Reasons and Predictors of Methotrexate Discontinuation in Children with JIA: Results From the Childhood Arthritis Prospective Study (CAPS). Suzanne Verstappen, Lucy R. Wedderburn, H. E. Foster, Eileen Baildam 4, Janet Gardner-Medwin 5, Joyce Davidson 5, Alice Chieng 6, Wendy Thomson 7 and Kimme L. Hyrich 8, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, University College London (UCL), London, United Kingdom, Newcastle Hospitals NHS Foundation Trust and Great North Children s Hospital, Newcastle Upon Tyne, United Kingdom, 4 Alder Hey Children s Foundation NHS Trust, Liverpool, United Kingdom, 5 Royal Hospital for Sick Children, Glasgow, United Kingdom, 6 Manchester Children s Hospital, Manchester, United Kingdom, 7 Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 8 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom 60. Assessment of Subclinical Synovitis by Power Doppler Ultrasonography in Patients with Juvenile Idiopathic Arthritis. Maria Teresa Terreri, Vanessa M. Bugni, Claudio A. Len, Sônia de A.V. Mitraud, Rita NV. Furtado 4 and Jamil Natour 5, Universidade Federal de São Paulo / UNIFESP, Sao Paulo, Brazil, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, Universidade Federal de São Paulo / UNIFESP, São Paulo, 4 Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 5 Universidade Federal de São Paulo, São Paulo, Brazil 6. Current Evidence of Anti-TNFα Treatment Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis Approach Comparing the Different Drugs. Gabriele Simonini, Kate Druce, Rolando Cimaz, Gary J. Macfarlane and Gareth T. Jones, Anna Meyer Children s Hospital-University of Florence, Firenze, Italy, University of Aberdeen, Aberdeen, United Kingdom 6. Patients with Juvenile Idiopathic Arthritis From a Low Socio-Economic Background Perceive Their Disease Activity and Physical Limitations Higher Than Patients from a High Socio-Economic Background. Suzanne Verstappen, Joanna Cobb, H. E. Foster, Eileen Baildam 4, Lucy R. Wedderburn 5, Janet Gardner-Medwin 6, Alice Chieng 7, Joyce Davidson 6, Wendy Thomson 8 and Kimme L. Hyrich 9, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Newcastle Hospitals NHS Foundation Trust and Great North Children s Hospital, Newcastle Upon Tyne, United Kingdom, 4 Alder Hey Children s Foundation NHS Trust, Liverpool, United Kingdom, 5 University College London (UCL), London, United Kingdom, 6 Royal Hospital for Sick Children, Glasgow, United Kingdom, 7 Manchester Children s Hospital, Manchester, United Kingdom, 8 Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, 9 Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom 6. Risk Factors for Radiologic Progression in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents. Tomohiro Kubota, Tsuyoshi Yamatou, Yukiko Nonaka, Harumi Akaike, Tomokazu Nagakura, Yuichi Yamasaki, Tomoko Takezaki, Yasuhito Nerome, Hiroyuki Imanaka and Syuji Takei, Kagoshima University, Kagoshima City, Japan, Kagoshima University, Kagoshima, Japan, House of Meguminoseibo, Usuki, Japan 64. Orofacial Anomalies in Children with Confirmed Juvenile Idiopathic Arthritis. Bernd Koos, Franka Stahl de Castrillon, Robert Ciesielski and Nikolay Tzaribachev, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, Department of Orthodontics, University of Rostock, Germany, Rostock, Germany, Center for Rheumatic Diseases, Bad Bramstedt, Germany 65. Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. Nicoletta Solari, Elena Palmisani, Alessandro Consolaro, Sara Dalprà, Benedetta Schiappapietra, Giulia Bracciolini, Silvia Rosina, Giorgia Negro, Alberto Martini and Angelo Ravelli, Istituto Giannina Gaslini, Genova, Italy, Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 66. Clinical and Therapeutic Features of Patients with Macrophage Activation Syndrome Enrolled in a Multinational Survey. Sergio Davì, Francesca Minoia, Erkan Demirkaya, Chiara Suffia, Mario Abinun, Amita Aggarwal 4, Nuray Aktay Ayaz 5, Maria Alessio 6, Jordi Anton 5, Maria Apaz 5, Tadej Avcin 7, Patrizia Barone 8, Blanca E. Bica 9, Isabel Bolt 0, Luciana Breda, Vyacheslav Chasnyk, Rolando Cimaz 5, Fabrizia Corona 5, Ruben Cuttica, Gianfranco D Angelo 4, AnnaCarin Horne 5, Nicola Ruperto, Alberto Martini 6, Randy Q. Cron 7 and Angelo Ravelli 5, Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy, International Investigator Consortium for MAS Diagnostic Criteria, Ankara, Turkey, International Investigator Consortium for MAS Diagnostic Criteria, Newcastle upon Tyne, United Kingdom, 4 Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 5 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, 6 University of Naples Federico II, Naples, Italy, 7 International Investigator Consortium for MAS Diagnostic 0 Program Book

224 ACR POSTER SESSION B Criteria, Ljubljana, Slovenia, 8 International Investigator Consortium for MAS Diagnostic Criteria, Catania, Italy, 9 International Investigator Consortium for MAS Diagnostic Criteria, Rio de Janeiro, Brazil, 0 International Investigator Consortium for MAS Diagnostic Criteria, Zurich, Switzerland, International Investigator Consortium for MAS Diagnostic Criteria, Chieti, Italy, International Investigator Consortium for MAS Diagnostic Criteria, Saint-Petersburg, Russia, International Investigator Consortium for MAS Diagnostic Criteria, Buenos Aires, Argentina, 4 International Investigator Consortium for MAS Diagnostic Criteria, Ancona, Italy, 5 Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, 6 Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 7 Univ of Alabama- Birmingham, Birmingham, AL 67. Golimumab in 5 Young Adults Affected by Juvenile Idiopathic ARTHRITIS NON Responders to OTHER Biological Agents: Preliminary DATA. Irene Pontikaki, Orazio De Lucia, Maurizio Gattinara, Alessandra Salmaso, Pier Luigi Meroni and Valeria Gerloni, Orthopedic Institute Gaetano Pini, Milano, Italy, Istituto G. Pini, University of Milan, Milano, Italy 68. Cost-Effectiveness Analysis of Early Biologic Treatment in Polyarticular Juvenile Idiopathic Arthritis. Nadia Luca, Heather Burnett, Wendy Ungar, Timothy Beukelman, Brian M. Feldman, Gwen Schwartz 4 and Ahmed Bayoumi 5, Hospital for Sick Children, Toronto, ON, The Hospital for Sick Children, Toronto, ON, Univ of Alabama-Birmingham, Birmingham, AL, 4 St. Michael s Hospital, Toronto, ON, 5 Keenan Research Centre of the Li Ka Shing Knowledge Institute of St. Michael s Hospital, Toronto, ON 69. Obstetrical Complications in Women with Juvenile Idiopathic Arthritis. Evelyne Vinet, Sasha Bernatsky, Mohammed Kaouache, Christian A. Pineau, Ann E. Clarke, Elizabeth Hazel, Ciaran M. Duffy 4, Anick Bérard 5 and Debbie Ehrmann Feldman 6, McGill University Health Centre, Montreal, QC, Research Institute of the McGill University Health Ctre, Montreal, QC, MUHC, Montreal, QC, 4 Children s Hospital of Eastern Ontario, Ottawa, ON, 5 Université de Montréal, 6 Université de Montréal, Hampstead, QC 70. Folate Usage in Methotrexate -Treated Juvenile Idiopathic Arthritis Patients Is Inconsistent and Highly Variable. Gil Amarilyo, Ornella J. Rullo, Deborah K. McCurdy, Jennifer M.P. Woo and De Furst, Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA, University of California at Los Angeles, Los Angeles, CA 7. Validation of BASDAI and BASFI in Children with Spondyloarthritis. Alisa C. Rachlis, Bertha Wong, Kristi J. Whitney-Mahoney, Michelle Batthish, Michelle anderson, JoAnne Marcuz, Margaret Reaume, Ashley DeLaurier, Ronald M. Laxer, Brian M. Feldman and Shirley M. Tse, Hospital for Sick Children, Toronto, ON, The Hospital for Sick Children, Toronto, ON 7. Delineating the Role of Multiple Corticosteroid Joint Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era. Charalampia Papadopoulou, Maria I. Gonzalez, Juan C. Nieto, Mikhail Kostik, Marek Bohm, Stefano Lanni, Valentina Muratore, Alessandro Consolaro, Alberto Martini and Angelo Ravelli 4, Istituto Giannina Gaslini, Genova, Italy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 4 University of Genova, Genova, Italy 7. Targeting Remission in Juvenile Idiopathic Arthritis in Routine Clinical Care: Experience in 75 Newly-Diagnosed Patients. Alessandro Consolaro, Giorgia Negro, Nicoletta Solari, Cristina Ferrari, Sergio Davì, Silvia Pederzoli, Giulia Bracciolini, Maria C. Gallo, Alberto Martini and Angelo Ravelli, Istituto Giannina Gaslini, Genova, Italy, Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 74. Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study. Ricardo A. G. Russo and Marìa M. Katsicas, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina Rheumamtoid Arthritis - Human Etiology and Pathogenesis 75. Decreased Frequency of Th7 Cells in Early Rheumatoid Arthritis. Irene Arroyo-Villa, M. Belén Bautista-Caro, Alejandro Balsa, Pilar Aguado, Laura Nuño, Gema Bonilla, Amaya Puig-Kröger, Emilio Martín-Mola and M. Eugenia Miranda-Carús, Hospital La Paz-IdiPaz, Madrid, Spain, Hospital Gregorio Marañon, Madrid, Spain 76. Galactosylation, and Not Sialylation, of Immunoglobulin G Is Associated with Improvement of Rheumatoid Arthritis During Pregnancy. Albert Bondt, Maurice H.J. Selman, andré M. Deelder, Johanna M.W. Hazes, Manfred Wuhrer and Radboud J.E.M. Dolhain, Erasmus University Medical Center, Rotterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands 77. Talin Is Cleaved and Expressed As a Short Form in Patients with Rheumatoid Arthritis. Kensei Tsuzaka, Masako Takao, Naoshi Shinozaki and Jiro Nishida, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan, Ichikawa, Japan 78. IL-6 and IL- in Rheumatoid Arthritis. Gustavo Carbone, Augusta Wilson, Sean Diehl, Janice Bunn, Sheldon Cooper 4 and Mercedes Rincon, University of Vermont College of Medicine, Burlington, VT, University of Vermont College of Medicine, University of Vermont, Burlington, 4 Univ Vermont College of Med, Burlington, VT 79. Vitamin D Receptor Polymorphisms Are Associated with Clinical Outcomes and IgM Responses to Common Pathogens but Not Baseline Disease Activity in Early Inflammatory Arthritis. Carol A. Hitchon, Linda Larcombe, 0 Program Book

225 ACR POSTER SESSION B Neeloffer Mookherjee, Christine A. Peschken, Marianna M. Newkirk and Hani S. El-Gabalawy, University of Manitoba, Winnipeg, MB, McGill University Health Centre, Montreal, QC 80. The Sex-Determining Region Y Box 6 Locus: Shared Genetic Susceptibility Between Rheumatoid Arthritis and Psychotic Disorder. Tony R. Merriman, Nicola Dalbeth, Andrew Harrison, John Highton 4, Lisa K. Stamp 5, Malcolm D. Smith 6, Benedicte A. Lie 7, Tore K. Kvien 8, Timothy Radstake 9, Marieke J.H. Coenen 0, Barbara Franke 0, Jasper Broen, Piet Van Riel 0, Pilar Barrera 0, Sophia Steer, Marilyn E. Merriman, Amanda Phipps-Green, Ruth Topless, Mansour Zamanpoor and Wan Rohani Wan Tain, University of Otago, Dunedin, New Zealand, University of Auckland, Auckland, New Zealand, Hutt Hospital, Lower Hutt, New Zealand, 4 Univ of Otago Med Sch, Dunedin, New Zealand, 5 University of Otago, Christchurch, Christchurch, New Zealand, 6 Rheumatologist, Adelaide, Australia, 7 Oslo University Hospital, Oslo, Norway, 8 Diakonhjemmet Hospital, Oslo, Norway, 9 Radboud University Nijmegen Medical Centre, University Medical Center Utrecht, Nijmegen, Utrecht, Netherlands, 0 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Department of Rheumatology & Clinical Immunology, University Medical Center, Utrecht, Netherlands, Sloane Ct East Flat 7, London, United Kingdom, Universiti Sains Malaysia, Malaysia 8. The Role of á-defensin- and Its Signal Transduction Mechanisms in the Production of IL-6, IL-8 and MMPs in Rheumatoid Fibroblast-Like Synoviocytes. Joong Kyong Ahn, Bo Huang, Eun-Jung Park, Jiwon Hwang, Jaejoon Lee, Chan Hong Jeon, Eunmi Koh and Hoon-Suk Cha, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Soonchunhyang University College of Medicine, Bucheon, South Korea 8. Familial Aggregation and Heritability of Rheumatoid Arthritis in Taiwan: A Nationwide Population Study. Chang- Fu Kuo, Matthew J. Grainge, Kuang-Hui Yu, Lai-Chu See, Shue-Fen Luo, Ana M. Valdes 4, I-Jun Chou, Hsiao-Chun Chang, Weiya Zhang and Michael Doherty, University of Nottingham, Nottingham, United Kingdom, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Chang Gung University, Taoyuan, Taiwan, 4 St. Thomas Hospital, King s College London, London, United Kingdom 8. Podoplanin-Mediated Interaction of Rheumatoid Arthritis Synovial Fibroblasts with Platelets Modulates IL-8 Expression. Manuel J. Del Rey, Elena Izquierdo, Regina Faré, Alicia Usategui, Vanessa Miranda, Gabriel Criado, J. D. Cañete and Jose L. Pablos, Instituto de Investigación Hospital de Octubre (I+), Madrid, Spain, Hospital Clínic de Barcelona,, Barcelona, Spain 84. Negative Association Between Testosterone Levels and Risk of Future Rheumatoid Factor Negative Rheumatoid Arthritis in Men. Mitra Pikwer, Aleksander Giwercman, Ulf Bergström, Jan-Åke Nilsson, Lennart T.H. Jacobsson and Carl Turesson, Lund University, Malmö, Sweden, Skåne University Hospital, Malmö, Sweden 85. Regulatory Role of, 5 Dihydroxyvitamin D in the Pathogenesis of Autoimmune Arthritis. Siba P. Raychaudhuri, Ananya Datta Mitra, Anupam Mitra, Christine Abria and Smriti K. Raychaudhuri, VA Sacramento Medical Center/UC Davis School of Medicine, Mather, CA, VA Sacramento Medical Center, Mather, CA 86. A Single Nucleotide Polymorphism of Tumor Necrosis Factor Receptor-Associated Factor Predicts Clinical Response to Anti-Tumor Necrosis Factor Treatments in Japanese Patients with Rheumatoid Arthritis. Tetsuya Nishimoto, Noriyuki Seta, Ryusuke Anan, Tatsuya Yamamoto, Yuko Kaneko, Masataka Kuwana and Tsutomu Takeuchi, Keio university, Tokyo, Japan, Keio Univ School of Medicine, Shinjuku-ku, Japan, Keio University School of Medicine, Tokyo, Japan 87. Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity in Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis: Decreased Inflammation and Disease Improvement with Smoking Cessation? Catriona Cramb, Jeremy Sokolove, Geoffrey M. Thiele, Gail S. Kerr 4, Grant W. Cannon 5, Andreas M. Reimold 6, Ted R. Mikuls 7 and William H. Robinson 8, VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, Univ of Nebraska Med Ctr, Omaha, NE, 4 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 5 Salt Lake City VA and Univeristy of Utah, Salt Lake City, UT, 6 Dallas VA and University of Texas Southwestern, Dallas, TX, 7 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 8 Stanford University, Palo Alto, CA 88. Fibrinogen Induced Inhibition of Osteoclastogenesis Is Reversed by Citrullination of Fibrinogen by Peptidylarginine Deiminase. Eun Young Lee, Ji Soo Kim, Hye Won Kim, Sung Hae Chang, Jin-Su Song, Hie-Joon Kim, Kyung-Hyun Park-Min, Lionel B. Ivashkiv, Eun Bong Lee and Yeong Wook Song, Seoul National University College of Medicine, Seoul, South Korea, Seoul National University, Seoul, South Korea, Hospital for Special Surgery, New York, NY 89. Stromal Cell Markers in the Synovial Tissue of Patients with Early Arthritis and Preclinical Rheumatoid Arthritis. Yuen Kei Choi, Olga N. Karpus, Paul Peter Tak, Jörg Hamann, Christopher D. Buckley, Andrew Filer 4 and Danielle M. Gerlag 5, Academic Medical Center, Amsterdam, Netherlands, Division of Clinical Immunology and Rheumatology, Department of Experimental Immunology, Academic Medical Center / University of Amsterdam 0 Program Book

226 ACR POSTER SESSION B 4 and GlaxoSmithKline, Amsterdam, Netherlands, School of Immunity and Infection, MRC Center for Immune Regulation, Birmingham, United Kingdom, 4 Rheumatology Department, Birmingham, United Kingdom, 5 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 90. Fine Specificity of Anti-Citrullinated Peptide Antibodies Discloses a Heterogeneous Antibody Population in Rheumatoid Arthritis (RA). John D. Goules, Andreas V. Goules and Athanasios G. Tzioufas, School of Medicine, National University of Athens, Athens, Greece 9. Nicotinamide Adenine Dinucleotide Phosphate Oxidase Mediated Angiogenesis and Inflammation in the Arthritic Joint. Monika Biniecka, Wei Gao, Chin Teck Ng, Emese Balogh, Douglas J. Veale and Ursula Fearon, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Translation Rheumatology Research Group, Dublin, Ireland 9. IL- Regulates B Cell Proliferation and Differentiation in Rheumatoid Arthritis. Lingyun Sun, Rui Liu and Xia Li, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 9. Podoplanin Expression in Rheumatoid Stroma Correlates with Lymphoid Neogenesis and Is Downregulated by Anti- TNF-α Therapy. Regina Faré, Elena Izquierdo, Manuel J. Del Rey, Raquel Celis, Alicia Usategui, Juan D. Cañete and Jose L. Pablos, Instituto de Investigación Hospital de Octubre (I+), Madrid, Spain, Hospital Clínic of Barcelona, Barcelona, Spain 94. Prevalence of Anti-Peptidylarginine Deiminase Type 4 Antibodies in Rheumatoid Arthritis and Unaffected First-Degree Relatives in Indigenous North American Populations. Elizabeth D. Ferucci, Irene Smolik, Tammy L. Choromanski, David B. Robinson, Marianna M. Newkirk, Marvin J. Fritzler 4, Antony Rosen 5, Erika Darrah 5 and Hani S. El-Gabalawy, Alaska Native Tribal Health Consortium, Anchorage, AK, University of Manitoba, Winnipeg, MB, McGill University Health Centr, Montreal, QC, 4 University of Calgary, Calgary, AB, 5 The Johns Hopkins University, Baltimore, MD 95. Identification of Follicular Helper T Cells As a Novel Cell Population Potentially Involved in the Pathogenesis of Rheumatoid Arthritis. Sharon Ing, Anika Alarakhia, Elvira Lindwall, Austin Fraser, Jerald M. Zakem, William E. Davis, Tamika A. Webb-Detiege, Robert Quinet 4 and Xin Zhang 5, Ochsner Medical Center, New Orleans, LA, Ochsner Clinic, New Orleans, LA, Ochsner Medical Ctr, New Orleans, LA, 4 Ochsner Medical Center - New Orleans, New Orleans, LA, 5 Ochsner Clinic Foundation, New Orleans, LA 96. Analysis of Gene Expression Patterns in Rheumatoid Arthritis (RA) Synovial Macrophages from Patients Undergoing Disease Flare. Karen L. Berg, Adedayo Hanidu, Jon Hill, Xiaoyu Jiang, Tom Freeman, Jennifer Swantek, 0 Program Book Anna Yarlina, George D. Kalliolias, Lionel B. Ivashkiv and Gerald H. Nabozny, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, Hospital for Special Surgery, New York, NY 97. Porphyromonas Gingivalis and the Pathogenesis of Rheumatoid Arthritis: Analysis of the Synovial Tissue and of Other Compartments. Michele C. Totaro, Sara D Onghia, Elisa Gremese, Luca Petricca, Simona Marchetti, Silvia Canestri, Barbara Tolusso, Stefano Alivernini, Paola Cattani and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, Laboratory of Clinical Analyses CIC, Catholic University of the Sacred Heart, Rome, Italy 98. Cardiovascular Risk Factors and Events Are More Frequent Prior to the Onset of Rheumatoid Arthritis Than in the General Population. Helen Pahau, Vibeke Videm, Sanjoy Paul and Ranjeny Thomas, University of Queensland Diamantina Institute, Brisbane, Australia, Department of Laboratory Medicine, Children s and Women s Health, Norwegian University of Science and Technology, and Department of Immunology and Transfusion Medicine, Trondheim University Hospital,, Trondheim, Norway, University of Queensland School of Population Health, Brisbane, Australia 99. Proteases Produced by Porphyromonas Gingivalis Can Cleave and Citrullinate Substrates Found in the Joint and Oral Mucosa: Implications for Autoimmunity in Rheumatoid Arthritis. Nidhi Sofat, Saralili Robertson and Robin Wait, St. George s University of London, London, United Kingdom, University of Oxford, Oxford, United Kingdom 00. Anti-Cyclic Citrullinated Peptide Antibodies in Idiopathic Pulmonary Fibrosis Are Not Citrulline-Specific: Implications for the Pathogenesis of Rheumatoid Arthritis. Elena B. Lugli, Muslima Chowdhury, Peter J. Charles, Michael G. Crooks, Simon P. Hart, Patrick J. Venables and Benjamin A. Fisher, Oxford University, London, United Kingdom, Hull York Medical School, Cottingham, United Kingdom, University of Birmingham, Birmingham, United Kingdom 0. Anti-Citrullinated Protein Antibody Specific Fc Glycosylation Patterns in Arthralgia Patients. Hans Ulrich Scherer, Yoann Rombouts, Ewoud Ewing, Lotte van de Stadt, Maurice H.J. Selman, andré M. Deelder, Tom W.J. Huizinga, Manfred Wuhrer, D. van Schaardenburg and René E.M. Toes, Leiden University Medical Centre, Leiden, Netherlands, Leiden University Medical Center, Leiden, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 0. Antibodies against Porphyromonas Gingivalis Correlate with Rheumatoid Arthritis-Specific Auto-Immunity in Arthralgia Patients. M. J. de Smit, L. A. van de Stadt, J. Westra, B. Doornbos-van der Meer, K.M.J. Janssen,

227 ACR POSTER SESSION B A. Vissink, A. J. van Winkelhoff, E. Brouwer and D. van Schaardenburg, University of Groningen, University Medical Center, Groningen, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 0. High Expression of Genes in the Toll-Like Receptor and Interferon Pathways Are Associated with Radiographic Damage in African-Americans with ACPA-Positive RA. Maria I. Danila, A. D. Steg, Xiangqin Cui, David Redden, M. R. Johnson, Richard J. Reynolds, D. van der Heijde 4, Doyt L. Conn 5, Beth L. Jonas 6, Leigh F. Callahan 7, Larry W. Moreland 8, P. K. Gregersen 9 and S. Louis Bridges Jr. 0, Univ of Alabama-Birmingham, Birmingham, AL, University of Alabama at Birmingham, University of Alabama at Birmingham, Birmingham, AL, 4 Leiden University Medical Center, Leiden, Netherlands, 5 Emory Univ School of Medicine, Atlanta, GA, 6 University of North Carolina at Chapel Hill, Chapel Hill, NC, 7 University of North Carolina, Chapel Hill, NC, 8 University of Pittsburgh, Pittsburgh, PA, 9 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 0 Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 04. Porphyromonas Gingivalis Antibody Responses and Clinical Associations in Patients with Early Rheumatoid Arthritis. Sheila L. Arvikar, Klemen Strle, Deborah S. Collier, Mark C. Fisher, Gail McHugh, Toshihisa Kawai, Alpdogan Kantarci and Allen C. Steere, Massachusetts General Hospital, Boston, MA, Forsyth Institute, Cambridge, MA 05. Study of Association of CD40-CD54 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients. Mercedes García- Bermúdez, Carlos González-Juanatey, Alfonso Corrales, Raquel López-Mejías 4, Maria Teruel 5, Jose A. Miranda-Filloy 6, Santos Castañeda-Sanz 7, Alejandro Balsa 8, B. Fernández- Gutierrez 9, Isidoro González-Álvaro 0, Carmen Gómez- Vaquero, R. Blanco Alonso, Javier Llorca, Javier Martin and Miguel Angel González-Gay 4, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, Hospital Xeral-Calde, Lugo, Spain, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 4 Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5 Instituto de Parasitologia y Biomedicina Lopez- Neyra, CSIC, Granada, Spain, 6 Hospital Universitario Lucus Augusti, Lugo, Spain, 7 Hospital de La Princesa, Madrid, Spain, 8 La Paz Hospital. IdiPaz, Madrid, Spain, 9 Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, 0 Reumatología (Hospital Universitario de La Princesa), Madrid, Spain, Hospital Universitario de Bellvitge, IDIBELL, Barcelona, Spain, Hospital Universitario Marques de Valdecilla, Santander, Spain, Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain 06. Gp96 Exacerbate the Inflammation of Rheumatoid Arthritis. Qi Quan Huang, Robert Birkett, J.-P. Jin and Richard M. Pope 4, Northwestern University, Chicago, IL, Northwestern University Feinberg School of Medicine, Chicago, IL, Wayne State University, Detroit, MI, 4 Northwestern Univ Med School, Chicago, IL 07. Impact of Anti Tumor Necrosis Factor-Alpha Therapy in Rheumatoid Arthritis On Osteoclast Activation and B Cells. Ezinma Ezealah, Jennifer Hossler, Jamie Biear, Christopher A. Cistrone, Teresa Owen, Nida Meednu, Kelly Callahan, Arumugam Palanichamy, Ignacio Sanz, Allen P. Anandarajah, Ralf G. Thiele, Darren Tabechian, R. John Looney and Jennifer H. Anolik, University of Rochester Medical Center, Rochester, NY, Emory University, Atlanta, GA, Univ of Rochester Schl of Med, Rochester, NY 08. Stable Synovial Fluid Phenotype for Anti Citrullinated- Protein Antibodies in Established Rheumatoid Arthritis. Vijay Joshua, Lena Israelsson, Lars Klareskog, Anca Irinel Catrina and Vivianne Malmström, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden 09. Functional Role of Chondrogenic Progenitor Cells in Rheumatoid Arthritis. Sabine Blaschke, Sandra Trautmann, Alexander W. Beham, Burkhard Mai, Sebastian Koelling, Caroline Breysach 4, Gabriele Wolf, Gerhard A. Mueller and Nicolai Miosge 5, University Medical Center Goettingen, Goettingen, Germany, Department of Surgery, Germany, Vitos Orthopaedic Clinic Kassel, Kassel, Germany, 4 Department of Surgery, Goettingen, Germany, 5 Dept. of Prosthodontics, Goettingen, Germany 0. Effect of HLA-DRB*090 Suggest Distinctive Mechanisms of Rheumatoid Arthritis Susceptibility. So-Young Bang, Hye-Soon Lee, Kyung Wha Lee and Sang-Cheol Bae 4, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Hanyang University Guri Hospital, Guri, South Korea, Hallym Institute for Genome Application,Hallym University Sacred Heart Hospital, Anyang, South Korea, 4 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea. ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients. Chary Lopez-Pedrera, Carlos Perez-Sanchez, Patricia Ruiz-Limon, Mª Angeles Aguirre, Rosario M. Carretero-Prieto, Antonio Rodriguez- Ariza, Nuria Barbarroja, Pilar Font, Francisco Martinez, Inmaculada Gomez-Gracia, Mª Jose Cuadrado 4 and Eduardo Collantes-Estevez, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, IMABIS and Virgen de la Victoria Hospital, Malaga, Spain, 4 The Rayne Institute, London, United Kingdom 0 Program Book 5

228 ACR POSTER SESSION B. Elevated Fecal Secretory Immunoglobulin A, Anti-Cyclic Citrullinated Peptide Antibodies, and Cytokine Levels in Rheumatoid Arthritis Patients. Sam Dalvi, Jose U. Scher*, Mukundan Attur, Jyoti Patel and Steven B. Abramson, NYU Hospital for Joint Diseases, New York, NY Rheumatoid Arthritis - Clinical Aspects II: Clinical Features and Comorbidity/Cardiovascular Disease. The Serum Cytokine Profile of Interstitial Lung Disease in Rheumatoid Arthritis. Jose Felix Restrepo, Inmaculada del Rincon, Roy Haas, Daniel F. Battafarano 4 and Agustin Escalante 5, University of Texas Health Science Center, San Antonio, TX, University Of Texas, Health Science Center, San Antonio, TX, TX, 4 Brooke Army Medical Ctr, San Antonio, TX, 5 University of Texas Health Science Center at San Antonio, San Antonio, TX 4. The Impact of Periodontal Disease On Early Inflammatory Arthritis Persists Even After All Teeth Are Lost. Gisela Westhoff, Paola de Pablo, Thomas Dietrich, Georg Schett 4 and Angela Zink 5, German Rheumatism Research Center Berlin, Berlin, Germany, University of Birmingham, Birmingham, United Kingdom, The School of Dentistry, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, 4 Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 5 German Rheumatism Research Center and Charité University Medicine, Berlin, Germany 5. Rates of Orthopaedic Interventions for Rheumatoid Arthritis Have Changed Over the Last 5 Years. A Report From Two UK Inception Cohorts Reflecting Treatment Changes From Sequential DMARD Monotherapy to Anti-TNF Agents (986-0). Elena Nikiphorou, Lewis Carpenter, Sam Norton, David James 4, Patrick D. Kiely 5, David Walsh 6, Richard Williams 7 and Adam Young, ERAS, St Albans City Hospital and University College London (UCL), London, United Kingdom, University of Hertfordshire, Hatfield, United Kingdom, ERAS, St Albans City Hospital, St Albans, United Kingdom, 4 Diana Princess of Wales Hospital, Grimsby, United Kingdom, 5 St. Georges Hospital, London, United Kingdom, 6 City Hospital, Nottingham, United Kingdom, 7 County Hospital, Hereford, United Kingdom 6. Flare Self Management Strategies Used by Patients with Rheumatoid Arthritis. Susan J. Bartlett, Clifton O. Bingham III, Juan Xiong, Ernest Choy 4, Gilles Boire 5, Carol A. Hitchon 6, Janet E. Pope 7, J. Carter Thorne 8, Diane Tin 8, Boulos Haraoui 9, E. Keystone 0, Vivian P. Bykerk, OMERACT Flare Working Group and CATCH, McGill University, Montreal, QC, Johns Hopkins University, Baltimore, MD, Mount Sinai Hospital, Toronto, ON, 4 Cardiff University School of Medicine, Cardiff, United Kingdom, 5 CHUS - Sherbrooke University, Sherbrooke, QC, 6 University of Manitoba, Winnipeg, MB, 7 St. Joseph Health Care London, University of Western Ontario, London, ON, 8 Southlake Regional Health Centre, Newmarket, ON, 9 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 0 University of Toronto, Toronto, ON, Hospital for Special Surgery, New York, NY, Ottawa, Toronto, ON 7. Decreased Survival in Rheumatoid Arthritis Complicated with Bronchiectasis: A Family-Based Cohort Study. Xavier Puéchal, Emmanuelle Génin, Thierry Bienvenu and Daniel J. Dusser, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, INSERM UMR-S946, Université Paris Diderot, Paris, France 8. Genetic Markers of Functional Stress Response in Patients with Rheumatoid Arthritis. Olga Malysheva and Christoph G. Baerwald, University Hospital, Leipzig, Germany 9. Periodontal Disease Is Associated with Rheumatoid Arthritis but Its Severity Is Not Correlated with Rheumatoid Arthritis Disease Activity. In Ah Choi, Jin-Hee Kim, Kyung Hwa Kim, Hye Won Kim, Myeong Jae Yoon, Bon Seung Ku, Hyejin Oh, Joo Youn Lee, Eun Young Lee, Eun Bong Lee, Yong-Moo Lee and Young Wook Song, Department of Internal Medicine, School of Medicine, Seoul National University, Seoul, South Korea, Department of Periodontology, School of Dentistry, Seoul National University, Seoul, South Korea 0. Occurrence and Morbidity of Lower Extremity Ulcer in Rheumatoid Arthritis - A Population Based Study. Adlene Jebakumar, Cynthia S. Crowson, Prabhu D. Udayakumar, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, Rochester, MN. Low Muscle Density in Rheumatoid Arthritis and Modified Association with Total Fat Mass, Results of a Pilot Study. Joshua Baker, Joan Marie Von Feldt and Mary Beth Leonard, University of Pennsylvania, Philadelphia, PA, Univ of Pennsylvania/Philadelphia VAMC, Philadelphia, PA, The Children s Hospital of Philadelphia, Philadelphia, PA. Incidence and Time Trends of Malignancy in Rheumatoid Arthritis: A Population Based Study Kerry Wright, Cynthia S. Crowson, Sherine E. Gabriel and Eric L. Matteson, Mayo Clinic, Rochester, MN. Frequency of Deep Vein Thromboses and Pulmonary Emboli in Rheumatoid Arthritis. Christian A. Pineau, Evelyne Vinet and Sasha Bernatsky, McGill University Health Centre, Montreal, QC, Research Institute of the McGill University Health Ctre, Montreal, QC 4. Rheumatoid Arthritis Disease Activity During Pregnancy Affects the Postnatal Catch-up Growth of the Child. Florentien D.O. de Steenwinkel, Anita C.S. Hokken-Koelega, Maria A.J. de Ridder, Johanna M.W. Hazes and Radboud J.E.M. Dolhain, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus Medical Center- Sophia Children s Hospital, Rotterdam, Netherlands 5. Self Reported Comorbidity Is Common in Early Inflammatory Arthritis and Associated with Poorer Function and Quality of Life and Greater Disease Activity: Results From the Canadian Early Arthritis Cohort. Carol A. 6 0 Program Book

229 ACR POSTER SESSION B Hitchon, Gilles Boire, Boulos Haraoui, Edward Keystone 4, Janet E. Pope 5, Vivian P. Bykerk 6 and Canadian Early Arthritis Cohort (CATCH) Investigators 7, University of Manitoba, Winnipeg, MB, CHUS - Sherbrooke University, Sherbrooke, QC, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 4 University of Toronto, Toronto, ON, 5 St. Joseph Health Care London, University of Western Ontario, London, ON, 6 Hospital for Special Surgery, New York, NY, 7 Toronto 6. Transition Time to Osteoporosis in Patients with Rheumatoid Arthritis. Jiwon Hwang, Joong Kyong Ahn, Ji Young Chai, Hoon-Suk Cha, Jaejoon Lee and Eunmi Koh, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea 7. Rheumatoid Arthritis-Associated Interstitial LUNG Disease: Clinical Spectrum of A Large Cohort From A Respiratory Referral Center. Joshua J. Solomon, Gloria M. Russell, Jill B. Ketzer, Amy L. Olson 4, Evans R. Fernandez-Perez 4, Tristan J. Huie 4, Jeffrey J. Swigris 4, Kevin K. Brown 5 and Aryeh Fischer 4, Denver, Pontificia Universidad Católica Madre y Maestra, Santiago, Dominican Republic, National Jewish Health, Denver, 4 National Jewish Health, Denver, CO, 5 National Jewish Hospital, Denver, CO 8. Contributions of Inflammation, Inactivity, and Low Dose Prednisone Use to Skeletal Muscle Insulin Resistance in Well-Controlled Rheumatoid Arthritis. Hiba Abouassi, Lori Bateman, Gary E. McDaniel, Lorraine Elliott-Penry, Michael Muehlbauer, E. William St. Clair, William E. Kraus and Kim M. Huffman, Duke University Medical Center, Durham, NC 9. Rheumatoid Arthritis and Risks of Malignant Lymphoma - Are Risks Still Increased? Karin Hellgren, Eva Baecklund, Karin E Smedby, Carin Backlin 4, Christer Sundstrom 5 and Johan Askling 6, Unit of Rheumatology, Stockholm, Sweden, Unit of Rheumatology,, Uppsala, Sweden, Clinical Epidemiology Unit, Stockholm, Sweden, 4 Department of Medical Sciences,, Uppsala, Sweden, 5 Department of Genetics and Pathology, Uppsala, Sweden, 6 Rheumatology Unit & Clinical Epidemiology Unit, Stockholm, Sweden 0. The Role of Sleep Problems in Conditioned Pain Modulation in Rheumatoid Arthritis. Yvonne C. Lee, Bing Lu, Robert R. Edwards, Ajay Wasan 4, Nicholas Nassikas, Daniel J. Clauw 5, Daniel H. Solomon and Elizabeth W. Karlson, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Brigham & Womens Hospital, Chestnut Hill, MA, 4 Brigham and Women s Hospital, Chestnut Hill, MA, 5 University of Michigan, Ann Arbor, MI. Rheumatoid Arthritis Is Associated with Likelihood of Being Overweight in Women. Irum-Mona Idrees, H. Lester Kirchner and androniki Bili, Geisinger Medical Center, Danville, PA, Geisinger Health System, Danville, PA. Association of Actometer Assessed Physical Activity and Fatigue in Patients with Rheumatoid Arthritis: Patients with a Lower Daily Activity Have More Fatigue. Sanne van Dartel, Han Repping-Wuts, Dewy van Hoogmoed, Hans Knoop, Gijs Bleijenberg, Piet L.C. van Riel and J. Fransen, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands. Effect of Insoles on the Rheumatoid Foot. Emilia Moreira, Anamaria Jones, Hilda A. Oliveira, Fabio Jennings, Artur R.C. Fernandes and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 4. Barriers, Benefits and Preferences for Exercise in RA Patients: A Cross Sectional Study. Yves Henchoz, Pascal Zufferey and Alexander So, Université du Québec à Trois- Rivières, Trois-Rivières, QC, Lausanne University Hospital, Lausanne, Switzerland, CHUV, Univ of Lausanne, Lausanne, Switzerland 5. Orthopedic Surgery Among Patients with Rheumatoid Arthritis : A Population-Based Study to Identify Predictors of Large Joint Vs Small Joint Surgeries. Ashima Makol, Cynthia S. Crowson and Eric L. Matteson, Mayo Clinic, Rochester, MN 6. Important Prognostic Factor in Rheumatoid Arthritis Patients with Interstitial Lung Disease Is Not Usual Interstitial Pneumonia Pattern but Interstitial Lung Disease Extent On Chest High-Resolution Computed Tomography. Hwajeong Lee, Jung-Yoon Choe, Seong-Kyu Kim, Sung Hoon Park, Ji Hun Kim, Dae Sung Hyun, Kyung Jae Jung and Jisuk Bae 4, Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, Division of Pulmonology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, South Korea, Radiology, Catholic University of Daegu School of Medicine, South Korea, 4 Department of Preventive Medicine, Catholic University of Daegu School of Medicine, South Korea 7. Baseline Evaluation of Insulin Resistance in Patients with early Non-Treated Rheumatoid Arthritis. Sara Manrique- Arija, María América López-Lasanta, Pilar Espiño- Lorenzo, Pedro Valdivielso, José Rioja, Inmaculada Ureña, Francisco Gabriel Jimenez- Núñez, Carmen M. Romero- Barco, Veronica Rodríguez-García, Laura Nieves, Mari Carmen Ordoñez-Cañizares, Laura Cano, Maria Victoria Irigoyen and Antonio Fernández-Nebro, Hospital Carlos Haya. University of Malaga, Malaga, Spain, Department of Medicine. University of Malaga, Malaga, Spain 8. Effects of Stress on Clinical Presentation of Patients with Early Rheumatoid Arthritis. Yun A. Kim, Jane E. Salmon, Juan Xiong, Boulos Haraoui 4, Carol A. Hitchon 5, Edward Keystone 6, Janet Pope 7, Diane Tin 8, J. Carter Thorne 8, Gilles Boire 9, Vivian P. Bykerk and CATCH 0, Hospital for Special Surgery (and Kwangju Christian Hospital, Gwangju, Korea), 0 Program Book 7

230 ACR POSTER SESSION B New York, NY, Hospital for Special Surgery, New York, NY, Mount Sinai Hospital, Toronto, ON, 4 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 5 University of Manitoba, Winnipeg, MB, 6 University of Toronto, Toronto, ON, 7 Schulich School of Medicine and Dentistry, Western University, London, ON, 8 Southlake Regional Health Centre, Newmarket, ON, 9 CHUS - Sherbrooke University, Sherbrooke, QC, 0 Toronto 9. Soluble Glycoprotein VI: A Novel Risk Marker for Thrombosis in Patients with Inflammatory Arthritis. Leann Bell, Anne M. Madigan, Paul A. MacMullan, Eimear Dunne, Dermot Kenny and Geraldine M. McCarthy, Mater Misericordiae University Hospital, Dublin 7, Ireland, RCSI, Dublin, Ireland 40. Serum Anti-Müllerian Hormone Can Be Used to Determine Ovarian Reserve in Women with Rheumatoid Arthritis. Jenny Brouwer, Johanna M.W. Hazes, Joop S.E. Laven, Izaäk Schipper and Radboud J.E.M. Dolhain, Erasmus Medical Center, Rotterdam, Netherlands 4. Glucocorticoid Use is associated with increase in HDL in Rheumatoid Arthritis Patients. Lisa L. Schroeder, Xiaoqin Tang, Mary Chester M. Wasko and androniki Bili 4, Geisinger Health System, Danville, PA, Geisinger Center for Health Research, Danville, PA, Temple University School of Medicine, Pittsburgh, PA, 4 Geisinger Medical Center, Danville, PA 4. Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis. Mike Nurmohamed, Yanjun Bao, James Signorovitch, Parvez M. Mulani and Daniel E. Furst 4, VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, Abbott Laboratories, Abbott Park, IL, Analysis Group, Inc., Boston, MA, 4 UCLA Medical School, Los Angeles, CA 4. Effect of Tocilizumab Treatment On Regional Left Ventricular Function, As Assessed by Cardiac Magnetic Resonance Imaging, in Rheumatoid Arthritis Patients without Cardiac Symptoms. Hitomi Kobayashi, Isamu Yokoe, Hiroshi Sato and Yasuyuki Kobayashi, Itabashi Chuo Medical Center, Tokyo, Japan, St Marianna Univ Sch of Med, Kawasaki, Japan 44. Group Cycling in Rheumatoid Arthritis: Positive Effects On Aerobic Capacity and Blood Pressure. Lars Ångström, Kristina Hörnberg and Solveig Wållberg Jonsson, Dept of Rheumatology, Umeå, Sweden 45. Age-Specific Association between Disease-Related Measures and Incident Cardiovascular Events and All-Cause Mortality in Early Rheumatoid Arthritis. Sofia Ajeganova, Maria LE andersson, Johan Frostegård and Ingiäld Hafström, Karolinska Institutet, Unit of Rheumatology, Department of Medicine Huddinge, Stockholm, Sweden, R&D Center, Spenshult Hospital, Oskarström, Sweden, Karolinska Institutet, Section of Immunology and chronic disease, Institute of Environmental Medicine, Stockholm, Sweden 46. Cardiovascular Risk Assessment in Rheumatoid Arthritis (RA) Patients Treated by Biologic Response Modifiers. Majed M. Khraishi, Rana Aslanov and Katie Doyle, Memorial University of Newfoundland, St Johns, NF, Memorial University of Newfoundland, St.John s, NF 47. Delay in Diagnosis of Rheumatoid Arthritis Increases the Cardiovascular Risk. Chan-Bum Choi, Yoon-Kyoung Sung, Soo-Kyung Cho, Dae-Hyun Yoo, Shin-Seok Lee, Jisoo Lee 4, Jinseok Kim 5, Hye-Soon Lee 6, Tae-Hwan Kim, Bo Young Yoon 7, Wan-Hee Yoo 8, Jung-Yoon Choe 9, Sang-Heon Lee 0, Seung-Cheol Shim, Won-Tae Chung, Seung-Jae Hong, Choong Ki Lee 4, Eunmi Koh 5, Jae-Bum Jun 6, So- Young Bang 6, Seong-Kyu Kim 7, Hoon-Suk Cha 8, Jeeseon Shim 9, Sang-Cheol Bae 0 and Korean Observational Study Network for Arthritis (KORONA), Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, Chonnam National University Medical School, Gwangju, South Korea, 4 Ewha Womans University Mokdong Hospital, Seoul, South Korea, 5 Jeju National University Hospital, Jeju, South Korea, 6 Hanyang University Guri Hospital, Guri, South Korea, 7 Inje University Ilsan Paik Hospital, Goyang, South Korea, 8 Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 9 Catholic university of Daegu School of mediine, Arthritis and autoimmunty research center, Daegu, 0 Konkuk University School of Medicine, Seoul, South Korea, Eulji University Hospital, Daejeon, South Korea, Dong-A University Hospital, Busan, South Korea, Kyung Hee University, Seoul, South Korea, 4 Yeungnam University, Daegu, South Korea, 5 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 6 Hanyang University Hospital for Rheumatic Disease, Seoul, South Korea, 7 and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 8 Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, 9 Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 0 Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, Seoul 48. Accelerated Aging Influences Cardiovascular Disease Risk in Rheumatoid Arthritis. Cynthia S. Crowson, Terry M. Therneau, John M. Davis III, Veronique L. Roger, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 49. The Impact of Statin Use On Lipid Levels in Statin-Naive Patients with Rheumatoid Arthritis (RA) Vs. Non-RA Subjects: Results From a Population-Based Study. Elena Myasoedova, Cynthia S. Crowson, Abigail B. Green, Eric L. Matteson and Sherine E. Gabriel, Mayo Clinic, Rochester, MN 8 0 Program Book

231 ACR POSTER SESSION B 50. Heightened Aortic Wall Inflammation in Patients with Rheumatoid Arthritis Versus Patients with Established Coronary Artery Disease without Autoimmune Disease. Jeffrey D. Greenberg, Zahi Fayad, Victoria Furer, Michael Farkouh, Michael J. Colin, Pamela B. Rosenthal, Jonathan Samuels, Svetlana Krasnokutsky Samuels 4, Soumya M. Reddy, Peter M. Izmirly, Cheongeun Oh, Manish Jain and Venkatesh Mani, New York University School of Medicine, New York, NY, Mount Sinai School of Medicine, New York, NY, NYU School of Medicine, New York, NY, 4 NYU School of Medicine, New York 5. Vulnerability Features Are Common in Coronary Plaques of Asymptomatic Patients with Rheumatoid Arthritis Compared to Controls: Associations with Lipid and Oxidative Stress Biomarkers. George A. Karpouzas, Jennifer Malpeso, Tae-Young Choi, Silvia Munoz and Matthew Budoff, Harbor-UCLA, Torrance, CA, Harbor-UCLA Medical Center, Torrance, CA 5. Association of Paraoxonase Gene Polymorphisms and Enzyme Activity with Carotid Plaque in Rheumatoid Arthritis. Christina Charles-Schoeman, Yuen Yin Lee, Veena K. Ranganath, John D. FitzGerald, Mihaela B. Taylor, Maureen A. McMahon, David Elashoff and Srinivasa T. Reddy, University of California, Los Angeles, CA 5. Identifying Vulnerable Plaque in Rheumatoid Arthritis: A Pilot Study Using Novel Microbubble-Contrast Enhanced Carotid Ultrasonography. Kimberly P. Liang, Douglas P. Landsittel, Suresh R. Mulukutla, Steven E. Reis, Marc C. Levesque, Flordeliza S. Villanueva, Hunter C. Champion and Larry W. Moreland, University of Pittsburgh, Pittsburgh, PA 54. In Treatment-Naive Early RA the Left Ventricular Function Is Correlated to CRP, Doctors Global and Anti-CCP Status. BB Løgstrup, LD Kristensen, A. Hedemann-Andersen and Torkell Ellingsen, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, Diagnostic Centre Regional Hospital Silkeborg, Silkeborg, Denmark 55. Vascular Calcification on Hand and Feet X-Rays, VFA Imaging of the Spine, and Cardiovascular Disease in Rheumatoid Arthritis. Ausaf Mohammad, Collette English, Derek Lohan, Diane Bergin, Sarah Mooney, John Newell, Martin O Donnell, Robert J. Coughlan and John J. Carey, Galway University Hospitals, Galway, Ireland, National University of Ireland, Galway, Ireland 56. High Inflammation May Condition the Antiatherogenic Function of Small, Dense HDL in Patients with Active Rheumatoid Arthritis. Carla Saucedo, Leonardo gomez Rosso, Tomas Meroño, Fernando Brites, Anatol Kontush, Luis J. Catoggio, Enrique Soriano 4, Laurent Camont 5, Marie Lhomme 5, Veronica Malah 6, Patricia Sorroche 7, Sandrine Chantepie 5, Paul Robillard 8 and John Chapman 5, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Laboratory of Lipids and Lipoproteins, School of Pharmacy and Biochemistry, Buenos Aires, Argentina, Université Pierre et Marie Curie-Paris, Paris, France, 4 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5 Université Pierre et Marie Curie, Paris, France, 6 Rheumatology section, Hospital de Clínicas José de San Martín, Buenos Aires, Argentina, 7 Central Laboratory, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8 Université Pierre et Marie Curie, Paris, Argentina 57. Subclinical Atherosclerosis in Hispanic Patients with Rheumatoid Arthritis. Correlation with the Presence of Anti-Oxidized LDL Antibodies and Serum Levels of CD40L. Yurilis Fuentes-Silva, Soham Al Snih, Natali Serra-Bonett, Juan De Sanctis and Martin A. Rodriguez 4, Centro Nacional de Enfermedades Reumáticas, Caracas, Venezuela, University of Texas Medical Branch, Galveston, TX, Instituto de Inmunología, Caracas, Venezuela, 4 Hospital Universitario de Caracas, Caracas, Venezuela 58. Association between Low Vitamin D Levels and Indicators of Osteoporosis and Atherosclerosis. Barry J. Sheane, Ruth Dunne, Ken Scott, Mary Hall, Michelle O Connor, Martin Healy, John Feely, J.B. Walsh and Gaye Cunnane, St. James s Hospital, Dublin, Ireland, St James s Hospital, Dublin, Ireland, Trinity College Dublin, Dublin 8, Ireland 59. Association between Subclinical Atherosclerosis and Bone Mineral Density in Rheumatoid Arthritis. Barry J. Sheane, Ruth Dunne, Ken Scott, Mary Hall, Michelle O Connor, Martin Healy 4, John Feely, J.B. Walsh 5 and Gaye Cunnane 6, St. James Hospital, Dublin, Ireland, St James s Hospital, Dublin 8, Ireland, Trinity College Dublin, Dublin 8, Ireland, 4 Central Pathology Laboratory, Dublin 8, Ireland, 5 Medicine for the Elderly, Dublin 8, Ireland, 6 St James s Hospital, Dublin, Ireland 60. Hydroxychloroquine Reduces the Risk of Coronary Artery Disease in Patients with Rheumatoid Arthritis. Li Chun, Mu Rong, Su Yin, Li Xiaofeng, Wang Yongfu, Wang Guochun 4, Zhu Ping 5, Liu Xiangyuan 4, Chen Haiying 6, Cui Liufu 7, Zhang Zhuoli 4, Li Zhenbin 6, Li Junfang 8, Zhang Fengxiao 9, Han Shuling 4, Lin Jinying 0, Liu Xiaomin 4, Hu Shaoxian, Yang Xiuyan, Huang Cibo Sr., Li Xingfu 4, Wang Yi 5 and Li Zhanguo, Peking University People s Hospital, Beijing, China, Taiyuan, China, Baotou, China, 4 Beijing, China, 5 Xian, China, 6 Shijiazhuang, China, 7 Tangshan, China, 8 Handan, China, 9 China, 0 Nanning, China, Wuhan, China, Guangzhou, China, Beijing Hospital, Ministry of Health, Beijing, China, 4 Jinan, China, 5 Lanzhou, China 6. Epicardial Adipose Tissue Is Associated with Cardiometabolic Risk and the Metabolic Syndrome in Patients with Rheumatoid Arthritis. Michelle J. Ormseth, Aliza Lipson, Nikolaos Alexopoulos, Gregory R. Hartlage, Annette M. Oeser, Aihua Bian, Tebeb Gebretsadik, Ayumi Shintani, Paolo Raggi and C. Michael Stein, Vanderbilt Medical Center, Nashville, TN, Emory University, Atlanta, GA 6. Rheumatoid Arthritis Patients with Higher Disease Severity and Subclinical Carotid Plaque Experience More Cardiovascular Events Despite a Favorable Conventional Cadiovascular Risk Profiles. Yeon-Ah Lee, Somi Kim, Sang- 0 Program Book 9

232 ACR POSTER SESSION B Hoon Lee, Ran Song, Hyung In Yang and Seung-Jae Hong, Kyung Hee University, Seoul, South Korea, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea 6. Carotid Arterial Wall Inflammation Is Associated with a Specific Profile of Inflammatory Biomarkers and Anti- Citrullinated Protein Antibodies in Rheumatoid Arthritis Patients. Caroline Grönwall, Gregg Silverman, Zahi Fayad, Venkatesh Mani, Victoria Furer, Michael Farkouh, Manish Jain, Cheongeun Oh, John Todd, Mukundan Attur 4, Steven B. Abramson 4 and Jeffrey D. Greenberg 5, NYU School of Medicine, New York, NY, Mount Sinai Hospital, New York, NY, Singulex, Alameda, California, Alameda, CA, 4 NYU Hospital for Joint Diseases, New York, NY, 5 New York University School of Medicine, New York, NY 64. Vascular Age in Rheumatoid Arthritis Patients. Jl Rosales- Alexander, César Magro Checa, Juan Salvatierra, Silvia Montes García, Jesús Cantero Hinojosa and Enrique Raya Álvarez, University Hospital San Cecilio, Granada, Spain 65. Lipoprotein Subclass Particles and Small Vessel Elasticity As a Potential Marker for Early Atherosclerosis in Rheumatoid Arthritis: a Prospective, Controlled Study. Marty T. Mertens and Elie Gertner, University of Minnesota, Minneapolis, MN, Regions Hospital and University of Minnesota Medical School, St. Paul, MN 66. Evaluation of Metabolic Syndrome in 97 Patients with Rheumatoid Arthritis. Fernanda G. G Chaer, Juliana Lucena, Rogerio Castro Reis, Fabiola Brasil, Murilo Melo, Amanda Callegari and Branca Souza, Irmandade da Santa Casa de Misericordia de Sao Paulo, São Paulo, Brazil, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil 67. Inflammatory Burden Predicts Progression of Carotid Plaque in Rheumatoid Arthritis: A 4-Month Longitudinal Analysis. Churl Hyun Im, Na Ri Kim, Jong Wan Kang, Young Ji Kim, Kyung Hye Kim, Eon Jeong Nam and Young Mo Kang, Kyungpook National University School of Medicine, Daegu, South Korea 68. Lipid Alterations and Measurement of Arterial Stiffness in Rheumatoid Arthritis. Marina Scolnik, Carla Saucedo, David A. Navarta, Leandro Ferreyra Garrott, Erika Catay, Maria L. Acosta Felquer, Eliana Lancioni, Cristian Quiroz, Federica Varela Guidetti, Zaida Bedran, Mirtha Sabelli, Javier Rosa, Maria Victoria Garcia, Patricia M. Imamura, Patricia Sorroche, Jose Alfie, Margarita Morales, Gabriel Waisman, Luis J. Catoggio and Enrique Soriano 4, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Central Laboratory, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Hypertension Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina 69. Serum Cytokines Associated with Carotid Atherosclerosis in Rheumatoid Arthritis. Inmaculada del Rincon, Roy W. Haas, Daniel H. O Leary, Joseph F. Polak, Daniel F. Battafarano and Agustin Escalante, University of Texas Health Science Center at San Antonio, San Antonio, TX, Tufts University-Boston Campus, Boston, MA, Brooke Army Medical Ctr, San Antonio, TX 70. Role of Inflammation, Serologic Status and Low Density Lipoprotein in Coronary Heart Disease Among Patients with Rheumatoid Arthritis: Data From the National Veterans Health Administration. Iris Navarro-Millan, Shuo Yang, Scott L. DuVall, Lang Chen, John Baddley, Grant W. Cannon 4, Elizabeth S. Delzell, Jie Zhang, Monika M. Safford, Nivedita M. Patkar 5, Ted R. Mikuls 6, Jasvinder A. Singh and Jeffrey Curtis, University of Alabama Birmingham, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 4 Salt Lake City VA and Univeristy of Utah, Salt Lake City, UT, 5 Univ of Alabama-Birmingham, Birmingham, AL, 6 Omaha VA and University of Nebraska Medical Center, Omaha, NE Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy 7. Two-Year Drug Survival and Treatment Effect of Abatacept and Tocilizumab in the Treatment of Rheumatoid Arthritis in Routine Care. Results from the Nationwide Danish Danbio Registry. HC Leffers, Mikkel Østergaard, Bente Glintborg, Niels Steen Krogh, Ulrik Tarp 4, Tove Lorenzen 5, Annette Hansen, Michael Sejer Hansen, Lene Dreyer, Martin S. Jakobsen and Merete L. Hetland 6, DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Glostrup, Denmark, DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ZiteLab ApS, Copenhagen, Denmark, 4 DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Aarhus, Denmark, 5 DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Silkeborg, Denmark, 6 Copenhagen University and Glostrup Hospital, Copenhagen, Denmark 7. Rheumatoid Arthritis (RA) Incomplete Secondary Responders to TNF-Alpha Safely Achieve Efficacy by Switching to Certolizumab Pegol in a 4-Week Study: A Phase IV, Randomized Multicenter, Double-Blind, Twelve- Week Study Followed by a -Week Open-Label Phase. M. Schiff, Ronald Goldblum and John RP Tesser, University of Colorado, Denver, CO, CPC, Inc, Carlsbad, CA, AZ Arthritis Rheum Assoc, Paradise Valley, AZ 7. Can Response Duration After the First Rituximab Treatment Be Used in Timing of Rituximab Retreatment? Noortje van Herwaarden, Aatke van der Maas, Tim L. Jansen, Ellen Dutmer, andre Hartkamp 4, Piet L.C.M. van Riel, Wietske Kievit, Bart J.F. van den Bemt and Alfons A. 0 0 Program Book

233 ACR POSTER SESSION B den Broeder, Sint Maartenskliniek, Nijmegen, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, Gelderse Vallei Hospital, Ede, Netherlands, 4 Jeroen Bosch Hospital, s-hertogenbosch, Netherlands 74. Relationship between Morning Stiffness Duration and Severity, Pain Intensity, and Measures of Disease Activity in a Week Efficacy Study of a Modified (Delayed- Release) Prednisone Plus Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Frank Buttgereit, John R. Kirwan, Kenneth G. Saag, Reike Alten 4, Amy Grahn 5, Patricia Rice 6 and Maarten Boers 7, Charite University Med-Berlin, Berlin, Germany, Bristol Royal Infirmary, Bristol, United Kingdom, Univ of Alabama-Birmingham, Birmingham, AL, 4 Charité Univ Medicine, Berlin, Germany, 5 Horizon Pharma, Deerfield, IL, 6 CliniRx Research, Naperville, IL, 7 VU University Medical Center, Amsterdam, Netherlands 75. Fast Remission Response to Etanercept At Week 4 Predicts Better Long-Term Outcomes in Early and Established Rheumatoid Arthritis Compared to Slower Response At Week. Bernd Raffeiner, Costantino Botsios, Francesca Ometto, Mariagrazia Canova, Livio Bernardi, Cristiana Vezzari, Silvano Todesco, Paolo Sfriso and Leonardo Punzi, Rheumatology Unit - University of Padova, Padova, Italy 76. Changes in B Cell Populations and Serum Immunoglobulins and Their Relationship to Infections in a One Year, Uncontrolled Open Label Study of Tabalumab. Maria W. Greenwald, Melissa Veenhuizen, Wendy Komocsar, Rebecca Jones-Taha, Chin H. Lee and Pierre-Yves Berclaz, Desert Medical Advances, Palm Desert, CA, Eli Lilly & Company, Indianapolis, IN, PharmaNet/i, Blue Bell, PA 77. Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year Efficacy and Safety Results From a 4-Month Phase Study. D. van der Heijde, Y. Tanaka, R. M. Fleischmann, E. Keystone 4, J. M. Kremer 5, C. Zerbini 6, M. H. Cardiel 7, S. B. Cohen 8, P. T. Nash 9, Y. Song 0, D. Tegzova, B. Wyman, D. Gruben, B. Benda, G. Wallenstein, S. Krishnaswami, S. H. Zwillich, J. Bradley, C. A. Connell and ORAL Scan Investigators 4, Leiden University Medical Center, Leiden, Netherlands, University of Occupational and Environmental Health, Kitakyushu, Japan, Metroplex Clinical Research Center, Dallas, TX, 4 Mount Sinai Hospital, Toronto, ON, 5 Albany Medical College, Albany, NY, 6 CEPIC Centro Paulista de Investigação Clínica, São Paulo-SP, Sao Paulo, Brazil, 7 Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 8 Metroplex Clinical Research Centre, Dallas, TX, 9 Nambour Hospital, Sunshine Coast, Australia, 0 Seoul National University Hospital, Seoul, South Korea, Institute of Rheumatology, Prague, Czech Republic, Pfizer Inc., Groton, CT, Pfizer Inc., Collegeville, PA, 4 Groton 78. Tuberculosis and Tofacitinib Therapy in Patients with Rheumatoid Arthritis. Kevin L. Winthrop, S.-H. Park, A. Gul, M. Cardiel 4, JJ Gomez-Reino 5, D. Ponce de Leon 6, R. Riese 7, R. Chew 7, T. Kawabata 7, E. Mortensen 6 and H. Valdez 8, Oregon Health & Science University, Portland, OR, The Catholic University of Korea, Seoul, South Korea, Istanbul University, Istanbul, Turkey, 4 Centro de Investigación Clínica de Morelia SC, Morelia, Mexico, 5 Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, 6 Pfizer Inc., Collegeville, PA, 7 Pfizer Inc., Groton, CT, 8 Pfizer Inc., New York, NY 79. First in Human Study with Recombinant Anti-IL- Monoclonal Antibody in Healthy Subjects and Patients with Rheumatoid Arthritis. Stanislav Ignatenko, Birte K. Skrumsager, Adam Steensberg and Ulrik Mouritzen, Charité Research Organization GmbH, Berlin, Germany, Novo Nordisk A/S, Copenhagen, Denmark 80. Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment Over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumour Necrosis Factor Inhibitors. Edward Keystone, Stanley B. Cohen, Paul Emery, Joel M. Kremer 4, Maxime R. Dougados 5, James E. Loveless 6, Carol Chung 7, Pamela Wong 7, Patrica B. Lehane 8 and Helen Tyrrell 8, Mount Sinai Hospital, Toronto, ON, Metroplex Clinical Research Center, Dallas, TX, University of Leeds, Leeds, United Kingdom, 4 Albany Medical College, Albany, NY, 5 René Descartes University, Paris, France, 6 St Luke s Rheumatology, Boise, ID, 7 Genentech, Inc., South San Francisco, CA, 8 Roche Products Limited, Welwyn Garden City, United Kingdom 8. IL-6 Signaling Inhibition Improves Abnormal Bone Homeostasis in Active Rheumatoid Arthritis. Masayasu Kitano, Sachie Kitano, Chieri Sato, Kazuyuki Fujita, Takahiro Yoshikawa, Yuki Katashima, Masahiro Sekiguchi, Naoto Azuma, Naoaki Hashimoto, Shinichiro Tsunoda, Kiyoshi Matsui and Hajime Sano, Hyogo College of Medicine, Nishinomiya-city, Japan 8. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months. Jurgen Wollenhaupt, Joel C. Silverfield, Eun Bong Lee, Susan P. Wood 4, Koshika Soma 4, Lisy Wang 4, Hiroyuki Nakamura 5, Yoshihiro Komuro 5, Chudi I. Nduaka 4, David Gruben 4, Birgitta Benda 6, Samuel H. Zwillich 4, Richard Riese 4 and John D. Bradley 4, Schoen- Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, Tampa Medical Group, Tampa, FL, Seoul National University, Seoul, South Korea, 4 Pfizer Inc., Groton, CT, 5 Pfizer Japan Inc., Tokyo, Japan, 6 Pfizer Inc., Collegeville, PA 8. Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable- Dose Methotrexate: Results of Two Phase Studies. Gerd R. Burmester, Désirée van der Heijde, Vibeke Strand, Cristiano A. F. Zerbini 4, Carol A. Connell 5, Charles A. Mebus 5, Samuel H. Zwillich 5, John D. Bradley 5, David Gruben 5 and Gene Wallenstein 5, Charité University Medicine Berlin, Berlin, Germany, Leiden University Medical Center, Leiden, 0 Program Book

234 ACR POSTER SESSION B Netherlands, Stanford University, Palo Alto, CA, 4 Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 5 Pfizer Inc., Groton, CT 84. Evaluation of Influenza and Pneumococcal Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Tofacitinib. K. L. Winthrop, A. Racewicz, E. B. Lee, B. Wilkinson 4, S. H. Zwillich 4, K. Soma 4, S. Rottinghaus 4, T. Kawabata 4, R. Riese 4, S. Wood 4, J. Bradley 4 and C. O. Bingham III 5, Oregon Health and Science University, Portland, OR, Department of Internal Medicine and Osteoarthrology, Bialystok Regional Hospital, Bialystok, Poland, Seoul National University, Seoul, South Korea, 4 Pfizer Inc., Groton, CT, 5 Johns Hopkins University, Baltimore, MD 85. Short-Term Efficacy of Etanercept Plus Methotrexate Vs.Various Disease-Modifying Anti-Rheumatic Combinations with Methotrexate in Established Rheumatoid Arthritis. Roy Fleischmann, Andrew S. Koenig, Annette Szumski, Henk Nab, Lisa Marshall and Eustratios Bananis, University of Texas Southwestern Medical Center, Dallas, TX, Pfizer Inc., Collegeville, PA, Pfizer Europe, Rome, Italy 86. Antibodies to Etanercept and Adalimumab in Rheumatoid Arthritis Inadequate Responders and Clinical Outcomes After an Active Switch to Infliximab. Chad Pool, Gopi Shankar, Allen Schantz, George Gunn, Rebecca Bolce, Marjatta Leirisalo-Repo 4, Jim Wang 5, John A. Goldman 6, Raphael J. DeHoratius, Roy M. Fleischmann 7 and Dennis Decktor, Janssen Services, LLC, Horsham, PA, Janssen R&D, LLC, PA, Crescendo Bioscience Inc., South San Francisco, CA, 4 Helsinki University Central Hospital, Helsinki, Finland, 5 Janssen Services, LLC, Horsham, 6 Medical Quarters #9, Atlanta, GA, 7 University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX 87. Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti- Rheumatic Drugs Before Biologicals. James R. O Dell, Ted R. Mikuls, Thomas Taylor, Vandana Ahluwalia, Mary Brophy 4, Stuart Warren 5, Robert Lew 6, Ciaran Phibbs 7, Aslam H. Anis 8, Amy C. Cannella, Gary A. Kunkel 9, Alan R. Erickson 0, Edward Keystone and the CSP55 RACAT Research Group, Omaha VA and University of Nebraska Medical Center, Omaha, NE, VA Medical Center, White River Junction, VT, William Osler Health Center, Mississauga, ON, 4 VA Boston Healthcare System, Boston, MA, 5 VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, 6 VA Boston HealthCare System, Boston, MA, 7 Palo Alto VA Health Care System, Menlo Park, CA, 8 Univ of British Columbia, Vancouver, BC, 9 George Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, 0 UNMC Physicians - Brentwood, LaVista, NE, University of Toronto, Toronto, ON, Boston 0 Program Book 88. A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice. Jose Inciarte- Mundo, Maria Victoria Hernández, Violeta Rosario, Sonia Cabrera, Virginia Ruiz-Esquide, Maria Eugenia Gomez- Caballero, Jose A. Gómez-Puerta, Julio Ramirez, Juan D. Cañete and Raimon Sanmarti, Hospital Clínic of Barcelona, Barcelona, Spain, Hospital Clínic of Barcelona., Barcelona, Spain 89. Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study. Tsutomu Takeuchi, Tsukasa Matsubara, Shuji Ohta, Masaya Mukai 4, Koichi Amano 5, Shigeto Tohma 6, Yoshiya Tanaka 7, Hisashi Yamanaka 8 and Nobuyuki Miyasaka 9, Keio University School of Medicine, Tokyo, Japan, Matsubara Mayflower Hospital, Hyogo, Japan, Taga General Hospital, Ibaraki, Japan, 4 Sapporo City General Hospital, Sapporo, Japan, 5 Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 6 Sagamihara National Hospital, Sagamihara City, Japan, 7 University of Occupational and Environmental Health, Kitakyushu, Japan, 8 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 9 Tokyo Medical and Dental University, Tokyo, Japan 90. Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis. Christina Charles-Schoeman, Roy M. Fleischmann, Jean Davignon, Howard Schwartz 4, Scott Turner 5, Carine Beysen 5, Mark Milad 6, Zheng Luo 7, John Bradley 7, Irina Kaplan 7, Richard Riese 7, Andrea Zuckerman 7 and Iain B. McInnes 8, University of California, Los Angeles, CA, Metroplex Clinical Research Center, Dallas, TX, University of Montreal, Montreal, 4 Miami Research Associates, Miami, FL, 5 KineMed Inc., Emeryville, CA, 6 Milad Pharmaceutical Consulting LLC, Plymouth, MI, 7 Pfizer Inc., Groton, CT, 8 University of Glasgow, Glasgow, United Kingdom 9. A Phase Ib Clinical Trial with F8-IL0, an Anti-Inflammatory Immunocytokine for the Treatment of Rheumatoid Arthritis (RA), Used in Combination with Methotrexate (MTX). Mauro Galeazzi, Caterina Baldi, Elena Prisco, Marco Bardelli, Dario Neri, Leonardo Giovannoni 4, Enrico Selvi and Roberto Caporali, University of Siena, Siena, Italy, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland, 4 Philogen S.p.A., Siena, Italy 9. Fatigue Is an Independent Variable Predicting Physical Function and Disease Activity Score-8 Remission for Patients with Rheumatoid Arthritis Treated with Intravenously Administered Golimumab: Results From Phase, Placebo Controlled Clinical Trial. Rene Westhovens, Michael Weinblatt, Chenglong Han, Tim Gathany, Lilianne Kim 4, Michael Mack 5, Jiandong Lu 5, Daniel Baker 5, Alan Mendelsohn 5 and Clifton O. Bingham III 6, University Hospital KU Leuven, Leuven, Belgium,

235 ACR POSTER SESSION B Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, 4 Janssen Research & Development, LLC, Malvern, PA, 5 Janssen Research & Development, LLC, Spring House, PA, 6 Johns Hopkins University, Baltimore, MD 9. Importance of Steady-State Trough Concentrations after Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis. J. H. Leu, Z. Xu, C. Hu, Alan Mendelsohn, J. Ford, Hugh M. Davis and H. Zhou, Janssen Research and Development, LLC, Spring House, PA 94. A Phase Ib Multiple Ascending Dose Study Evaluating Safety, Pharmacokinetics, and Early Clinical Response of Brodalumab (AMG 87), a Human Anti-Interleukin 7 Receptor (IL-7R) Antibody, in Rheumatoid Arthritis. Melvin A. Churchill, Luis F. Flores-Suarez, Daniel J. Wallace, Kristine Phillips 4, Richard W. Martin 5, Mario H. Cardiel 6, Jeffrey Kaine 7, Edgar Bautista 8, David H. Salinger 9, Erin Stevens 9, Christopher B. Russell 9 and David A. Martin 9, Arthritis Center of Nebraska, Lincoln, NE, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico, Cedars-Sinai Medical Center, Los Angeles, CA, 4 University of Michigan Medical School, Ann Arbor, MI, 5 Michigan State University College of Human Medicine, Grand Rapids, MI, 6 Hospital, Morelia, Mexico, 7 Sarasota Arthritis Research Center, Sarasota, FL, 8 Amgen, Thousand Oaks, CA, 9 Amgen, Seattle, WA 95. Effectiveness and Tolerability of Subcutaneous Tocilizumab in Rheumatoid Arthritis Patients Switched From Intravenous Tocilizumab: Results From the Extension Period of the Musashi Study. Atsushi Ogata and the MUSASHI study group, Osaka University Graduate School of Medicine, Suita, Japan, Japan 96. An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP- Level after Treatment with Abatacept Versus Anti- TNF Agents. Masahiro Sekiguchi, Kiyoshi Matsui, Masayasu Kitano, Mitsuo Namiki, Koichiro Ohmura, Takao Fujii, Hideko Nakahara, Keiji Maeda, Hideo Hashimoto 4, Takanori Kuroiwa 5, Kenji Miki 6, Masanori Funauchi 7, Kazuhiro Hatta 8, Kenshi Higami 9, Shunzo Namiuchi 0, Ichiro Yoshii, Teruyuki Nakatani, Takashi Ikawa, Takaji Matsutani 4, Kosaku Murakami 5, Satoshi Morita 6, Yutaka Kawahito 7, Norihiro Nishimoto 4, Tsuneyo Mimori and Hajime Sano, Hyogo College of Medicine, Nishinomiya, Japan, Kyoto University, Kyoto, Japan, NTT West Osaka Hospital, Osaka, Japan, 4 Rinku Hashimoto Rheumatology, Osaka, Japan, 5 Yukioka Hospital, Osaka, Japan, 6 Amagasaki Central Hospital, Amagasaki, Japan, 7 Kinki University Faculty of Medicine, Osaka, Japan, 8 Tenri Yorozu Sodansyo Hospital, Nara, 9 Higami Hospital, Nara, Japan, 0 Saiseikai Nakatsu Hospital, Osaka, Japan, Yoshii Hospital, Shimanto, Japan, Kishiwada City Hospital, Osaka, Japan, Kobe-Konan Yamate Clinic, Kobe, Japan, 4 Wakayama Medical University, Ibaraki, Japan, 5 Osaka Red Cross Hospital, Osaka, Japan, 6 Yokohama City University, Kanagawa, Japan, 7 Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan 97. Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis Lack of Improvement in Disease Activity Score by Months Predicts Low Likelihood of Low Disease Activity At Year. Ronald F. van Vollenhoven, Sriram Krishnaswami, Birgitta Benda, David Gruben, Bethanie Wilkinson, Charles A. Mebus, Samuel H. Zwillich and John Bradley, Karolinska Institute, Stockholm, Sweden, Pfizer Inc., Groton, CT, Pfizer Inc., Collegeville, PA 98. Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach. Shunichi Kumagai, Yoshiaki Hagiwara, Yoshihide Ichise, Sho Sendo, Nobuhiko Okada, Jun Saegusa and Goh Tsuji, Shinko hospital, Kobe, Japan, Kobe University Graduate School of Medicine, Kobe, Japan, Shinko Hospital, Kobe, Japan 99. Rituximab versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study. Edward Keystone, Juan Xiong, Deborah Weber and Ye Sun, Mount Sinai Hospital, Toronto, ON 00. Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population. Dimitrios A. Pappas, George W. Reed, Katherine C. Saunders, Ani John 4, Ashwini Shewede 5, Jenny Devenport 6, Jeffrey D. Greenberg 7 and Joel M. Kremer 8, Columbia University, College of Physicians and Surgeons, New York, NY, University of Massachusetts Medical School, Worcester, MA, CORRONA, Inc., Southborough, MA, 4 Genentech Inc., South San Francisco, CA, 5 Genentech Inc., South San Francisco, 6 Genentech, South San Francisco, CA, 7 NYU Hospital for Joint Diseases, New York, NY, 8 Albany Medical College and The Center for Rheumatology, Albany, NY 0. Predictors of Significant Disease Activity Score-8 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase, Multicenter, Double-Blind, Placebo-Controlled Trial. Clifton O. Bingham III, Michael Weinblatt, Alan Mendelsohn, Lilianne Kim, Michael Mack, Jiandong Lu, Daniel Baker and Rene Westhovens 4, Johns Hopkins University, Baltimore, MD, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, Janssen Research & Development, LLC, Spring House, PA, 4 University Hospital KU Leuven, Leuven, Belgium 0. Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis. Marie Kostine, Thomas Barnetche, Elodie 0 Program Book

236 ACR POSTER SESSION B 4 Ardouin, Marlene Joly 4, Emilie Rabois 5, Baptiste Glace Sr. 6, Delphine Nigon 7, Thierry Schaeverbeke 8 and Christophe Richez 9, Rheumatology, CHU Pellegrin, Bordeaux, France, CHU Bordeaux Pellegrin, Bordeaux, France, Rheumatology, Limoges University Hospital, Limoges, France, 4 Rheumatology, Montpellier University Hospital, Montpellier, France, 5 CHU Gabriel Montpied, Clermont- Ferrand, France, 6 Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, 7 CHU Purpan, Toulouse, France, 8 Groupe Hospitalier Pellegrin, Bordeaux, France, 9 Hôpital Pellegrin and Université Victor Segalen Bordeaux, France 0. Achieving Comprehensive Disease Control in Long- Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone. Edward C. Keystone, Ferdinand C. Breedveld, Désirée van der Heijde, Ronald F. van Vollenhoven, Stefan Florentinus 4, Freddy Faccin 5, Shufang Liu 5, Hartmut Kupper 6 and Arthur Kavanaugh 7, Professor of Medicine, Toronto, ON, Leiden University Medical Center, Leiden, Netherlands, Karolinska Institute, Stockholm, Sweden, 4 Abbott, Rungis, France, 5 Abbott, Abbott Park, IL, 6 Abbott GmbH and Co. KG, Ludwigshafen, Germany, 7 UCSD School of Medicine, La Jolla, CA 04. Long-Term Use of Adalimumab as Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate. Edward C. Keystone, Ferdinand C. Breedveld, Hartmut Kupper, Shufang Liu 4 and Stefan Florentinus 5, Professor of Medicine, Toronto, ON, Leiden University Medical Center, Leiden, Netherlands, Abbott GmbH and Co. KG, Ludwigshafen, Germany, 4 Abbott, Abbott Park, IL, 5 Abbott, Rungis, France 05. Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry. Filip De Keyser, Patrick Durez, Rene Westhovens, marie-joelle Kaiser 4 and Ilse Hoffman 5, Universitair Ziekenhuis Gent, Gent, Belgium, Université Catholique de Louvain, Brussels, Belgium, University Hospital KU Leuven, Leuven, Belgium, 4 Dept Rheumatology, University Hospital Liege, Belgium, Belgium, 5 Dept Rheumatology, GZA St-Augustinus Hospital Antwerp, Belgium 06. How Well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data from a Large UK Cohort. Calum T. Goudie, John D. Fitzpatrick, Anshuman P. Malaviya and Andrew J. Ostor, University of Cambridge Medical School, Cambridge, United Kingdom, Addenbrooke s Hospital, Cambridge, United Kingdom 07. Anti-IL-6 Receptor Nanobody (ALX-006) Seamless First-in-Human Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment. Steven De Bruyn, Béla Gachályi, Bernadette Rojkovich, Slavomir Bruk 4, Petr Sramek 5, Mariusz Korkosz 6, Krzysztof Krause 7, Pieter Schoen, Laura Sargentini-Maier, Joke D Artois, Katrien 0 Program Book Verschueren, Katelijne De Swert, Gerhard Arold 8 and Josefin-Beate Holz, Ablynx N.V., Zwijnaarde, Belgium, Péterfy Sándor Utcai Kórház, Budapest, Hungary, Budai Irgalmasrendi Kórház Kht., Budapest, Hungary, 4 Nemocnice Trinec, Trinec, Czech Republic, 5 Pharmaceutical Research Associates CZ, Praha, Czech Republic, 6 Szpital Uniwersytecki w Krakowie, Krakow, Poland, 7 Wojewodzki Szpital, Wroclaw, Poland, 8 PRA International GmbH, Berlin, Germany 08. Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: Data From the Autoimmunity and Rituximab Registry. Jacques-Eric Gottenberg, Philippe Ravaud, Thomas Bardin, Patrice P. Cacoub Sr. 4, Alain G. Cantagrel 5, Bernard Combe 6, Maxime Dougados 7, Rene-Marc Flipo 8, Bertrand Godeau 9, Loic Guillevin 0, Xavier X. Le Loet, Eric Hachulla, Thierry Schaeverbeke, Jean Sibilia 4, Isabelle Pane 5, Gabriel Baron 6 and Xavier Mariette 7, Strasbourg University Hospital, Strasbourg, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, Hôpital Lariboisière, Paris, France, 4 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 5 Place du Docteur Baylac, Toulouse, France, 6 Hopital Lapeyronie, Montpellier, France, 7 Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, 8 Hopital R Salengro CHRU, Lille CEDEX, France, 9 Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 0 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, CHU de ROUEN, Rouen, France, Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, Groupe Hospitalier Pellegrin, Bordeaux, France, 4 CHU Hautepierre, Strasbourg, France, 5 Hotel Dieu University Hospital Paris, France, 6 Strasbourg, France, 7 Université Paris-Sud, Le Kremlin Bicetre, France 09. Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry. Jacques-Eric Gottenberg, Philippe Ravaud, Alain G. Cantagrel, Bernard Combe 4, René-Marc Flipo 5, Thierry Schaeverbeke 6, Eric Houvenagel 7, Philippe Gaudin 8, Damien Loeuille 9, Stephanie Rist 0, Maxime Dougados, Jean Sibilia, Xavier Le Loet, Christian Marcelli 4, Thomas Bardin 5, Isabelle Pane 6, Elodie Perrodeau 7, Gabriel Baron 8 and Xavier Mariette 9, Strasbourg University Hospital, Strasbourg, France, Hopital Hotel Dieu, Paris Descartes University, Paris, France, Place du Docteur Baylac, Toulouse, France, 4 Hopital Lapeyronie, Montpellier, France, 5 Rheumatology Department, Lille University Hospital, Lille, France, 6 Groupe Hospitalier Pellegrin, Bordeaux, France, 7 St Philibert Hospital, Lomme 5946, France, 8 CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, 9 CHU Brabois, Vandoeuvre les Nancy, France, 0 Hospital University Orléans, France, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, CHU Hautepierre, Strasbourg, France, CHU de

237 ACR POSTER SESSION B ROUEN, Rouen, France, 4 Rheumatology Department, Caen University Hospital, 5 Hôpital Lariboisière, Paris, France, 6 Hotel Dieu University Hospital Paris, France, 7 Epidemiologist, Paris, France, 8 Epidemiology, Paris, France, 9 Université Paris-Sud, Le Kremlin Bicetre, France 0. Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF. Raphaèle Seror, Houria Chavez, anne-aurélie Mazet, Jeremie Sellam, Bruno Fautrel 4, Maxime Dougados 5, Yassine Taoufik and Xavier Mariette 6, Bicetre university hospital, LE Kremlin- Bicetre, France, Hopital Bicetre, Université Paris Sud, AP-HP, France, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 750, France, 4 APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, 5 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 6 Université Paris-Sud, Le Kremlin Bicetre, France. A Novel Individualized Treatment Approach in Open- Label Extension Study of Ozoralizumab (ATN-0) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate. Roy M. Fleischmann, Steven De Bruyn, Christian Duby, Katrien Verschueren, Judith Baumeister, Laura Sargentini-Maier, Cedric Ververken and Josefin- Beate Holz, University of Texas, Dallas, TX, Ablynx N.V., Zwijnaarde, Belgium. Clinical Response At Weeks Predicts Long-Term Remission and the Extent of Radiographic Progression in Japanese Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol with and without Methotrexate Coadministration. Tsutomu Takeuchi, Kazuhiko Yamamoto, Hisashi Yamanaka, Naoki Ishiguro 4, Yoshiya Tanaka 5, Katsumi Eguchi 6, Akira Watanabe 7, Hideki Origasa 8, Toshiharu Shoji 9, Nobuyuki Miyasaka 0 and Takao Koike, Keio University School of Medicine, Tokyo, Japan, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 4 Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 5 University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 6 Sasebo City General Hospital, Sasebo, Nagasaki, Japan, 7 Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan, 8 University of Toyama School of Medicine, Toyama, Toyama, Japan, 9 Otsuka Pharmaceutical Co., Ltd, Shinagawa-ku, Tokyo, Japan, 0 Tokyo Medical and Dental University, Tokyo, Japan, Sapporo medical center NTT EC, Sapporo, Japan. Tolerance of Rituximab in Patients with a History of Cancer: Data from the Registry Air. Jacques-Eric Gottenberg, Marie- Odile Duzanski, Thomas Bardin, Patrice P. Cacoub Sr. 4, Alain G. Cantagrel 5, Bernard Combe 6, Maxime Dougados 7, Rene-Marc Flipo 8, Bertrand Godeau 9, Loic Guillevin 0, Eric Hachulla, Xavier Le Loet, Thierry Schaeverbeke, Jean Sibilia 4, Isabelle Pane 5, Philippe Ravaud 6, Gabriel Baron 7 and Xavier Mariette 8, Strasbourg University Hospital, Strasbourg, France, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Hôpital Lariboisière, Paris, France, 4 Assistance Publique-Hôpitaux de Paris, Hopital Pitié- Salpétrière, Paris, France, 5 Hopital Purpan, Toulouse CEDEX 9, France, 6 Hopital Lapeyronie, Montpellier, France, 7 Paris- Descartes University, APHP, Cochin Hospital, Paris, France, 8 Hopital R Salengro CHRU, Lille CEDEX, France, 9 Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 0 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, CHU de ROUEN, Rouen, France, Groupe Hospitalier Pellegrin, Bordeaux, France, 4 CHU Hautepierre, Strasbourg, France, 5 Hotel Dieu University Hospital Paris, France, 6 Hopital Hotel Dieu, Paris Descartes University, Paris, France, 7 Epidemiology, Paris, France, 8 Université Paris-Sud, Le Kremlin Bicetre, France 4. Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients. Tsukasa Matsubara, Satoru Koyano, Keiko Funahashi, James E. Middleton, Takako Miura, Kosuke Okuda, Takeshi Nakamura, Akira Sagawa, Takeo Sakurai 4, Hiroaki Matsuno 5, Tomomaro Izumihara 6, Eisuke Shono 7, Kou Katayama 8, Toyomitsu Tsuchida 9, Mitsuyoshi Iwahashi 0, Tomomi Tsuru and Motohiro Oribe, Matsubara Mayflower Hospital, Kato, Japan, Research Institute of Joint Diseases, Kobe, Japan, Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 4 Inoue Hospital, Takasaki, Japan, 5 Toyama, Japan, 6 Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 7 Shono Rheumatology Clinic, Fukuoka, Japan, 8 Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, 9 Tsuchida Clinic, Chiba, Japan, 0 Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, PS Clinic, Fukuoka, Japan, Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan 5. Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis. Wendy J. Komocsar, Mark C. Genovese, Ernst R. Dow, Poulabi Banerjee, Michelle A. Penny, Eric P. Nantz, Sergey Stepaniants, Anne Ho, Pierre-Yves Berclaz and Robert W. Hoffman, Eli Lilly and Company, Indianapolis, IN, Stanford University Medical Center, Palo Alto, CA, Covance Genomics Laboratory LLC, Seattle, WA 6. Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study. Roy M. Fleischmann, Ronald F. van Vollenhoven, Jiri Vencovsky, Rieke Alten 4, Owen Davies 5, Christian Stach 6, Marc de Longueville 5, Brenda Van Lunen 7 and Ernest Choy 8, University of Texas Southwestern Medical Center at 0 Program Book 5

238 ACR POSTER SESSION B 6 Dallas, Dallas, TX, Karolinska Institute, Stockholm, Sweden, Institute of Rheumatology, Prague, Czech Republic, 4 Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, Monheim, Germany, 7 UCB Pharma, Raleigh, NC, 8 Cardiff University School of Medicine, Cardiff, United Kingdom 7. One-Year Results From the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate Versus Etanercept Alone in Rheumatoid Arthritis. Janet E. Pope, Boulos Haraoui, J. Carter Thorne, Melanie Poulin-Costello 4, Andrew Vieira 4 and Edward Keystone 5, St. Joseph Health Care London, University of Western Ontario, London, ON, Institut de Rhumatologie de Montréal, Montreal, QC, Southlake Regional Health Centre, Newmarket, ON, 4 Amgen Canada Inc., Mississauga, ON, 5 University of Toronto, Toronto, ON 8. Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study. Vibeke Strand, Oana Purcaru, Ronald F. van Vollenhoven, Ernest Choy 4 and Roy Fleischmann 5, Stanford University, Portola Valley, CA, UCB Pharma, Brussels, Belgium, Karolinska Institute, Stockholm, Sweden, 4 Cardiff University School of Medicine, Cardiff, United Kingdom, 5 University of Texas Southwestern Medical Center, Dallas, TX 9. Certolizumab Pegol Plus Methotrexate Is Similarly Effective in Active Rheumatoid Arthritis Secondary Non-Responders to Anti-TNF Inhibitors: Post-Hoc Analysis of a Phase Iiib Trial. Daniel Furst, Saeed A. Shaikh, Maria W. Greenwald, Michael H. Schiff 4, Barbara Bennett 5, Owen Davies 6, Fabienne Staelens 6, Will Koetse 7 and Philippe Bertin 8, University of California at Los Angeles, Los Angeles, CA, McMaster University, St Catharines, ON, Desert Medical Advances, Palm Desert, CA, 4 University of Colorado, Denver, CO, 5 BABennett Consulting, LLC, Marietta, GA, 6 UCB Pharma, Brussels, Belgium, 7 UCB Pharma, Rtp, NC, 8 Dupuytren Hospital, Limoges, France 0. Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Effects On Hemoglobin Levels in a Clinical Trial for the Treatment of Moderate-to-Severe Rheumatoid Arthritis. Mark C. Genovese, Roy M. Fleischmann, Martine Jasson, Allen R. Radin 4, Jennifer Hamilton 5 and Tom W.J. Huizinga 6, Stanford University Medical Center, Palo Alto, CA, University of Texas, Dallas, TX, Sanofi, Paris, France, 4 Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 6 Leiden University Medical Center, Leiden, Netherlands. C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of B Cell Activating Factor in Rheumatoid Arthritis. Ernst R. Dow, Poulabi Banerjee, Michelle A. Penny, Eric P. Nantz, Sergey Stepaniants, Anne Ho, Wendy 0 Program Book J. Komocsar, Pierre-Yves Berclaz and Robert W. Hoffman, Eli Lilly and Company, Indianapolis, IN, Covance Genomics Laboratory LLC, Seattle, WA. Coadministration of ASP05K, a Novel Janus Kinase Inhibitor with Methotrexate Demonstrates Tolerability and Lack of Pharmacokinetic Interactions in Patients with Rheumatoid Arthritis. Tong Zhu, Kazuo Oda, Udaya Valluri, Bogie Moore, Ying Cao, Vishala Chindalore and Bola Akinlade, Astellas Pharma Global Development, Inc., Northbrook, IL, Astellas Pharma Inc., Osaka, Japan, Pinnacle Research Group/Anniston Medical Clinic, Anniston, AL. Effects of Dose Escalation of Tocilizumab in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: Sub-Analysis of a 4-Week Study in a United States Population. M. E. Weinblatt, Herbert S. B. Baraf, Ara H. Dikranian, Andrew M. Anisfeld 4, Jenny Devenport 4 and Sheldon Cooper 5, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, Arthritis & Rheumatism Associates, Wheaton, MD, San Diego Arthritis Medical Clinic, San Diego, CA, 4 Genentech, South San Francisco, CA, 5 Univ Vermont College of Med, Burlington, VT 4. Golimumab, A Human Anti-TNF Monoclonal Antibody, Administered Subcutaneously Every Four Weeks As Monotherapy in Patients with Active Rheumatoid Arthritis Despite Disease Modifying Antirheumatic Drug Therapy: Week 04 Results of Clinical, Radiographic and Safety Assessments. Tsutomu Takeuchi, Masayoshi Harigai, Yoshiya Tanaka, Hisashi Yamanaka 4, Naoki Ishiguro 5, Kazuhiko Yamamoto 6, Minoru Kanazawa 7, Yoshinori Murakami 8, Toru Yoshinari 9, Daniel Baker 0, Nobuyuki Miyasaka and Takao Koike, Keio University School of Medicine, Tokyo, Japan, Tokyo Medical and Dental University, Tokyo, Japan, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 4 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 5 Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 6 Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 7 Director of Respiratory Center Professor of Respiratory, Medicine Saitama Medical University, Moroyama, Iruma- Gun, Saimata, Japan, 8 Janssen Pharmaceutical KK, Tokyo, Japan, 9 Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, 0 Janssen Research and Development, LLC, Spring House, PA, Sapporo medical center NTT EC, Sapporo, Japan 5. Prevention of Joint Destruction in Patients with High Disease Activity or High C - reactive protein. Yoshiya Tanaka, Masayoshi Harigai, Tsutomu Takeuchi, Hisashi Yamanaka 4, Naoki Ishiguro 5, Kazuhiko Yamamoto 6, Yutaka Ishii 7, Daniel Baker 8, Nobuyuki Miyasaka and Takao Koike 9, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Tokyo Medical and Dental University, Tokyo, Japan, Keio University School of Medicine, Tokyo, Japan, 4 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 5 Nagoya

239 ACR POSTER SESSION B University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan, 6 Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 7 Janssen Pharmaceutical K.K, Tokyo, Japan, 8 Janssen Research and Development, LLC, Spring House, PA, 9 Sapporo medical center NTT EC, Sapporo, Japan 6. Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons. Lillian J. Barra, Andrew Ha, Louise Sun, Catarina Fonseca 4 and Janet Pope, Schulich School of Medicine and Dentistry, Western University, London, ON, The University of Toronto, Toronto, ON, University of Ottawa, Ottawa, ON, 4 Universidade de Lisboa, Lisbon, Portugal 7. Comparison of Four Different Intensive Treatment Strategies in Patients with Early Rheumatoid Arthritis in Korea. Mi-Il Kang, Yoon Kang, Hee-Jin Park, Hyang-Sun Lee, Sang-Won Lee, Yong-Beom Park and Soo-Kon Lee, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea 8. The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment. Yoshinobu Koyama, Kazunori Hase, Daisuke Hidaka, Shuji Nagano, Toshiyuki Ota and Ayumi Uchino, Okayama Red Cross General Hospital, Okayama, Japan, Iizuka Hospital, Iizuka, Japan 9. Differential Effect of 4 and 8 Mg/Kg Tocilizumab in Combination with Methotrexate On Serum Biomarkers of Cartilage, Connective Tissue and Bone Turnover. Anne C. Bay-Jensen, Inger Byrjalsen, Andrew Kenwright, Thierry Sornasse 4, Claus Christiansen 5 and Morten Asser Karsdal, Nordic Bioscience A/S, Herlev, Denmark, Nordic Bioscience, Herlev, Denmark, Roche, Welwyn Garden City, United Kingdom, 4 Genentech, South San Francisco, 5 CCBR, Ballerup, Denmark 0. High Body Mass Index Is Associated with Decreased Response to Initial Combination Therapy in Recent Onset RA Patients. Marianne van den Broek, L. Heimans, S. le Cessie, B. Siegerink, H.K Ronday, K.H. Han, P.J.S.M. Kerstens 4, T.W.J. Huizinga, W.F. Lems 5 and C.F. Allaart, Leiden University Medical Center, Leiden, Netherlands, Haga Hospital, The Hague, Netherlands, MCRZ hospital, Rotterdam, Netherlands, 4 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 5 VU University medical center, Amsterdam, Netherlands. Once Daily High Dose Regimens of GLPG064 in Healthy Volunteers Are Safe and Provide Continuous Inhibition of JAK but Not JAK. Florence Namour, René Galien, Lien Gheyle, Frédéric Vanhoutte, Béatrice Vayssière, Annegret Van der Aa, Bart Smets and Gerben van t Klooster, Galapagos SASU, Romainville, France, SGS Clinical Pharmacology Unit, Antwerp, Belgium, Galapagos NV, Mechelen, Belgium. The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non- TNF Blockers in RA. Tamao Nakashita, Shinji Motojima, Natsuki Fujio and Akira Jibatake, Kameda Medical Center, Kamogawa City, Japan, Kameda Medical Center, Kamogawa city, Japan. The Predictive Value of CD64 Counts for Infectious Disease in Patients Treated with Tocilizumab On the Infectious Disease Risk Management Cohort (ACT4Ustudy). Atsushi Ihata, Hiroyuki Hagiyama, Shouhei Nagaoka, Junichi Obata 4, Kiyomitsu Miyachi 5, Hidehiro Yamada 6, Shunsei Hirohata 7, Norihiko Koido 8, Masaomi Yamasaki 9, Kenichi Miyagi 0, Shigeru Ohno, Daiga Kishimoto, Reikou Watanabe, Takeaki Uehara, Kaoru Takase, Maasa Hama, Ryusuke Yoshimi, Atsuhisa Ueda, Mitsuhiro Takeno and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan, Yokohama-city Bay Red Cross Hospital, Yokohama, Japan, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 4 Hikarichuo Clinic, Kawasaki, Japan, 5 Keigu Clinic, Kawasaki, Japan, 6 St. Marianna University, Kawasaki, Japan, 7 Kitasato University School of Medicine, Sagamihara, Japan, 8 Kawasaki Rheumatism & Internal Medecine Clinic, Kawasaki, 9 St Marianna University, Yokohama City Seibu Hospital, Yokohama, Japan, 0 Miyagi Naika Clinic, Yokohama, Yokohama City University Medical Center, Yokohama, Japan 4. Intra-Articular Etanercept Treatment in Inflammatory Arthritis: A Randomized Double-Blind Placebo-Controlled Trial. Caroline J. Aalbers, Danielle M. Gerlag, Koen Vos, Gertjan Wolbink, R. Landewe and Paul P. Tak, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 5. Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy. Patrick Durez, Geneviève Depresseux, Marie Avaux, Adrien Nzeusseu Toukap, Bernard Lauwerys, Laurent Meric de Bellefon, Maria S. Stoenoiu and Frédéric A. Houssiau, Université catholique de Louvain, Brussels, Belgium 6. Changes in the Levels of Anti-Cyclic Citrullinated Protein Antibody and Immunoglobulins in Rheumatoid Arthritis Patients After Administration of Tocilizumab. Masao Sato, Masao Takemura, Ryuki Shinohe, Tsuneo Watanabe and Katsuji Shimizu, Gifu University, Gifu, Japan 7. Sarilumab, a Subcutaneously-Administered, Fully- Human Monoclonal Antibody Inhibitor of the IL-6 Receptor: Pharmacokinetic Profile and Its Relationship to Changes in Pharmacodynamic Markers in Patients with Rheumatoid Arthritis. Pavel Belomestnov, Jennifer Hamilton, A. Thomas DiCioccio, Martine Jasson and Allen R. Radin, Regeneron Pharmaceuticals, Inc., Tarrytown, 0 Program Book 7

240 ACR POSTER SESSION B NY, Sanofi, Paris, France, Regeneron Pharmaceuticals Inc, Tarrytown, NY 8. Anti-Tumor Necrosis Factor Therapy Reduces Serum Levels of Chemerin in Rheumatoid Arthritis: A New Mechanism by which Anti-Tumor Necrosis Factor Might Reduce Inflammation. M.M. Herenius, A.S.F. Oliveira, C.A. Wijbrandts, D. Gerlag, Paul P. Tak and Maria C. Lebre, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 9. A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/ Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis. Roy Fleischmann, Alan J. Kivitz, Frank Wagner, Jeffrey A. Feinstein 4, Uwe Fuhr 5, Jürgen Rech 6, Jagdev Sidhu 7, Philip L. Hill 8, Ruth Oliver 8 and Kosmas Kretsos 9, University of Texas Southwestern Medical Center, Dallas, TX, Altoona Center for Clinical Research, Duncansville, PA, Charité Research Org GmbH, Berlin, Germany, 4 San Antonio, TX, 5 Hospital of the University of Cologne (AöR), Köln, Germany, 6 University of Erlangen-Nuremberg, Erlangen, Germany, 7 CSL Limited, Parkville, Australia, 8 UCB Celltech, Slough, United Kingdom, 9 UCB, Slough, United Kingdom 40. Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial. Roy Fleischmann, Michael H. Schiff, Michael E. Weinblatt, Michael A. Maldonado 4, Elena M. Massarotti 5 and Yusuf Yazici 6, University of Texas Southwestern Medical Center, Dallas, TX, University of Colorado, Denver, CO, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 4 Bristol-Myers Squibb, Princeton, NJ, 5 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 6 New York University, New York, NY 4. Beneficial Effect of Anti-TNF Therapy in the Lipoprotein Atherogenic Risk Profile in Comparison with DMARD Standard Therapy in RA Patients. Jaime Calvo-Alen, Ignacio Villa, Victor M. Martinez-Taboada, Jose Luis Peña-Sagredo 4, Mario Agudo 4, Ana Carmen García 5 and Juan Gomez- Gerique 6, Hospital Universitario Sierrallana, Torrelavega, Spain, Hospital Sierrallana, Torrelavega, Spain, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, 4 Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 5 Fundación de Octubre, Madrid, Spain, 6 Hospital Universitario Marqués de Valdecilla, Santander, Spain 4. Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial. Roy Fleischmann, Michael E. Weinblatt, Michael H. Schiff, Dinesh Khanna 4, Daniel Furst 5 and Michael A. Maldonado 6, University of Texas Southwestern Medical Center, Dallas, TX, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, University of Colorado, Denver, CO, 4 University of Michigan, Ann Arbor, MI, 5 University of California at Los Angeles, Los Angeles, CA, 6 Bristol-Myers Squibb, Princeton, NJ Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment 4. EARLY Improvements in the Lower Limbs Enthesis by Ultrasound Predicting Later Favorable Responses in TNF Inhibotors-Treated Patients with Spondyloarthritis. Kensuke Kume, Kanzo Amano, Kuniki Amano, Hiroyuki Ohta and Noriko Kuwaba 4, Hiroshima Clinic, Hiroshima, Japan, Sky Clinic, Hiroshima, Japan, Hiroshima, Japan, 4 Sanki Clinical Link, Hiroshima, Japan 44. Diagnostic Value of High Sensitivity C Reactive Protein for Early Axial Spondyloarthritis: Results From the Devenir Des Spondylarthopathies Indifferenciees Recentes Cohort. Victoria Navarro-Compán, Désirée van der Heijde, Bernard Combe, Claudine Cosson and Floris van Gaalen, Leiden University Medical Center, Leiden, Netherlands, Hopital Lapeyronie, Montpellier, France, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Paris, France 45. Validation of the Health Assessment Questionnaire for Spondyloarthritis in Patients with Non-Radiographic Axial Spondyloarthritis. Dennis Revicki, Wen-Hung Chen, Ying Jin, Sumati Rao, Philip Mease and Mary Cifaldi, United Biosource Corporation, Bethesda, MD, Abbott Laboratories, Abbott Park, IL, Swedish Rheumatology Research Group, Seattle, WA 46. Comparison of Three Screening Tools in Psoriatic Arthritis: The Contest Study. Laura C. Coates, Tariq Aslam, A. D. Burden, Esther Burden-Teh, Anna R. Caperon 4, Rino Cerio 5, Chandra Chattopadhyay 6, Hector Chinoy 7, Mark J. D. Goodfield 8, Lesley Kay 9, Bruce W. Kirkham 0, Christopher R. Lovell, Helena Marzo-Ortega, Neil McHugh, Ruth Murphy, Costantino Pitzalis 4, NJ Reynolds 9, Catherine H. Smith 5, Elizabeth Stewart 6, Richard B. Warren 7, Hilary E. Wilson 6 and Philip S. Helliwell 7, Division of Rheumatic and Musculoskeletal Disease, LIMM, University of Leeds, Leeds, United Kingdom, Western Infirmary, Dumbarton Road, United Kingdom, Nottingham Independent Treatment Centre, Nottingham, United Kingdom, 4 University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 5 Bart s and The London NHS Tust, United Kingdom, 6 Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, 7 The University of Manchester, Manchester, United Kingdom, 8 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 9 Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 0 4th Fl Thomas Guy 8 0 Program Book

241 ACR POSTER SESSION B House, London, United Kingdom, Royal United Hospital, Bath, United Kingdom, University of Leeds, Leeds, United Kingdom, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4 Barts and The London School of Medicine and Dentistry, London, United Kingdom, 5 London, 6 NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, 7 NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 47. Anti-TNFá Discontinuation in Psoriatic Arthritis: Is It Possible After Achieving Minimal Disease Activity? Amir Haddad, Arane Thavaneswaran, Vinod Chandran and Dafna D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 48. Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis. Amir Haddad, Arane Thavaneswaran, Sergio M.A. Toloza, Vinod Chandran and Dafna D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON, Hospital San Juan Bautista, Catamarca, Argentina 49. Trends in Incidence and Clinical Features of Ankylosing Spondylitis in Olmsted County ( ): A Population Based Study. Kerry Wright, Cynthia S. Crowson, Clement J. Michet and Eric L. Matteson, Mayo Clinic, Rochester, MN 50. Inflammatory Biomarkers in Psoriatic Arthritis. Ibrahim AlHomood, Arane Thavaneswaran, D. D. Gladman and Vinod Chandran, Toronto Western Hospital and University of Toronto, Toronto, ON 5. Ultrasonographic Entheseal Abnormalities among Patients with Psoriatic Arthritis, Psoriasis Alone and Healthy Individuals and Their Correlation with Disease-Related Variables. Lihi Eder, Jai Jayakar, Arane Thavaneswaran, Amir Haddad, Daniel Pereira, Sutharshini Shanmugarajah, David Salonen 4, Cheryl Rosen, Vinod Chandran and Dafna D. Gladman, Carmel Medical Center, Haifa, Israel, University of Western Ontario, London, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 University Health Network, Toronto, ON 5. Adalimumab Significantly Reduces Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis. J. Christiaan van Denderen, Ingrid M. Visman, M. T. Nurmohamed, Maria S.A. Suttorp-Schulten and Irene E. van der Horst-Bruinsma 4, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, 4 VU University Medical Centre, Department of Rheumatology, Amsterdam, Netherlands 5. Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Nonradiographic Axial Spa: Wk-5 Results From Ability-. Désirée van der Heijde, Philip Mease, Aileen L. Pangan, Sumati Rao 4, Naijun Chen 4 and Mary A. Cifaldi 4, Leiden University Medical Center, Leiden, Netherlands, Swedish Rheumatology Research Group, Seattle, WA, Abbott, Abbott Park, IL, 4 Abbott Laboratories, Abbott Park, IL 54. The Prevalence of Psoriatic Arthritis Based On Rheumatologists Clinical Assessment Before and After Laboratory and Radiographic Tests in Psoriasis Patients in European/North American Dermatology Clinics. Dafna D. Gladman, Philip J. Mease, Rafat Y. Faraawi, Eustratios Bananis 4, Andrew S. Koenig 4, Robert Northington 4, Joanne Fuiman 4 and Daniel Alvarez 4, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Swedish Medical Center, Seattle, WA, McMaster University, Kitchener, ON, 4 Pfizer Inc., Collegeville, PA 55. Hand Bone Loss Is Arrested in Early Psoriatic Arthritis but Not in Rheumatoid Arthritis Following Anti-Rheumatic Treatment Assessed by Digital X-Ray Radiogrammetry. Agnes Szentpetery, Muhammad Haroon, Phil Gallagher, Martina Cooney, Eric J. Heffernan 4 and Oliver M. FitzGerald 5, Department of Rheumatology, St. Vincent s University Hospital, Dublin, Ireland, Dublin Academic Medical Center, St. Vincent s University Hospital, Dublin, Ireland, Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, 4 Department of Radiology, St. Vincent s University Hospital, Dublin, Ireland, 5 Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 56. Gender Differences Among Spondylitis Associated with Psoriasis, Inflammatory Bowel Disease and Primary Ankylosing Spondylitis. Margarita Landi, Hernan Maldonado-Ficco, Jose A. Maldonado-Cocco, Gustavo Citera, Pablo Arturi, Percival Sampaio-Barros, Diana Flores 4, Ruben Burgos-Vargas 5, Helena Santos 6, Jose Chavez- Corrales 7, Daniel Palleiro 8, Miguel A. Gutierrez 9, Elsa Vieira- Sousa 0, Fernando Pimentel-Santos, Sergio O. Paira, Alberto Berman Sr., Janitzia Vazquez-Mellado 4, Eduardo Collantes-Estevez 5 and On behalf of RESPONDIA Group 6, Instituto de Rehabilitacion Psicofisica and Fundacion Reumatologica Argentina, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica., Buenos Aires, Argentina, University of Sao Paulo School of Medicine, Sao Paulo, Brazil, 4 Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico, 5 Hospital General de Mexico, Mexico DF, Mexico, 6 Instituto Português de Reumatologia, Lisboa, Portugal, 7 Hospital Nacional E. Rebagliti-ESSALUD, Lima, Peru, 8 Instituto Nacional de Reumatologia, Montevideo, Uruguay, 9 Pontificia Universidad Catolica de Chile, Santiago, Chile, 0 Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, Hospital Jose Maria Cullen, Santa Fe SFE S000BFP, Argentina, Hospital Padilla, Tucuman, Argentina, 4 Hospital General de Mexico, Mexico city, Mexico, 5 IMIBIC-Reina Sofia Hospital, Cordoba 40, Spain, 6 Buenos Aires 0 Program Book 9

242 ACR POSTER SESSION B 57. Psoriatic Arthritis and Biologic Therapy: Treatment Response, Drug Survival and Outcome After Switching. Dinny Wallis, Deepak Jadon, William Tillett, Nicola Waldron, Charlotte Cavill, Neil McHugh and Eleanor Korendowych, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath, United Kingdom, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, Bath Institute for Rheumatic Disease, Bath, United Kingdom 58. Performance of Remission Criteria and Activity Indices in Psoriatic Arthritis. Maria L. Acosta Felquer, Leandro Ferreyra Garrott, Erika Catay, Josefina Marin, Marina Scolnik, Maria Victoria Garcia, Santiago Ruta, Mirtha Sabelli, Zaida Bedran, Javier Rosa, Luis J. Catoggio 4 and Enrique R. Soriano 4, Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM. Catoggio, Buenos Aires, Argentina 59. Comparison of Sacroiliac MRI Evaluation Versus Sacroiliac x-rays in Peripheral Psoriatic Arthritis: Evidence of Silent Disease and Lack of Association to HLA-B7. Jose Luis Fernandez-Sueiro, JA Pinto, S. Pertega-Diaz, E. Gonzalez and Francisco J. Blanco, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain 60. Spinal Involvement in Axial Psoriatic Artritis Is Not Determined by the Presence of HLA-B7. Is the HLA-B7 Arm of the Axial Spa Criteria Reliable for Classifying Axial Psoriatic Arthritis? Jose Luis Fernandez-Sueiro, JA Pinto, S. Pertega-Diaz, E. Gonzalez, Ignacio Rego-Perez, Francisco J. de Toro-Santos and Francisco J. Blanco 4, Complejo Hospitalario Universitario La Coruña, La Coruña, Spain, INIBIC-Hospital Universitario A Coruña. Genomic Group. Rheumatology Division., A Coruña, Spain, Complejo Hospitalario Universitario Juan Canalejo, Universidad de la Coruña, La Coruña, Spain, 4 INIBIC-Hospital Universitario A Coruña, A Coruña, Spain 6. Disease Burden Is Comparable in Patients with Non- Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis. Joachim Sieper, Désirée van der Heijde, Dirk Elewaut, Aileen L. Pangan 4 and Jaclyn K. anderson 4, Charité Universitätesmedizin Berlin, Berlin, Germany, Leiden University Medical Center, Leiden, Netherlands, Ghent University Hospital, Ghent, Belgium, 4 Abbott Laboratories, Abbott Park, IL 6. Evaluation of Spondyloarthritis activity by the Patients and the Physicians: ASDAS, Basdai, PASS and Flare. Marie Godfrin-Valnet, Clément Prati, Marc Puyraveau, Eric Toussirot, Helene Letho-Gyselinck 4 and Daniel Wendling 4, CHU, Besançon, France, CHU J Minjoz, Besancon, France, CIC Biotherapy 50 6 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, 4 Minjoz University Hospital, Besancon, France 6. Validation of the Self-Administered Comorbidity Questionnaire in Patients with Ankylosing Spondylitis. Carmen Stolwijk, A.M. Van Tubergen, Sofia Ramiro, Ivette Essers, Marc Blaauw, Désirée van der Heijde, Robert B. M. Landewé 4, Filip Van den Bosch 5, Maxime Dougados 6 and Annelies Boonen, Maastricht University Medical Center, Maastricht, Netherlands, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Leiden University Medical Center, Leiden, Netherlands, 4 Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 5 Ghent University Hospital, Ghent, Belgium, 6 Paris-Descartes University, APHP, Cochin Hospital, Paris, France 64. Development, Sensibility and Reliability of a New Case- Finding Questionnaire, the Toronto Axial Spondyloarthritis Questionnaire in Inflammatory Bowel Disease. Khalid A. Alnaqbi, Zahi Touma, Laura A. Passalent, Sindhu R. Johnson, George A. Tomlinson, Adele Carty and R. D. Inman, Toronto Western Hospital, Toronto, ON, Toronto General Hospital, Toronto, ON 65. Double-Blind, Placebo-Controlled, 8-Week Trial of Efficacy and Safety of Infliximab Plus Naproxen Vs Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early, Active Axial Spondyloarthritis Trial, Part I. Joachim Sieper, Jan Lenaerts, Jürgen Wollenhaupt, Vadim Mazurov 4, L. Myasoutova 5, Sung-Hwan Park 6, Yeong W. Song 7, Ruji Yao 8, Denesh Chitkara 8 and Nathan Vastesaeger 9, Charité, University Medicine Berlin, Berlin, Germany, Reuma-instituut, Hasselt, Belgium, Schön-Klinik, Hamburg, Germany, 4 St. Petersburg Medical Academy, St. Petersburg, Russia, 5 Kazan State Medical University, Kazan, Russia, 6 Catholic University of Korea, Seoul, South Korea, 7 Seoul National University, Seoul, South Korea, 8 Merck Sharp and Dohme, Kenilworth, NJ, 9 Merck Sharp and Dohme, Brussels, Belgium 66. Golimumab Administered Subcutaneously Every 4 Weeks in Chinese Patients with Active Ankylosing Spondylitis: Week 4 Safety and Efficacy Results From a Randomized, Placebo - Controlled Study. Chunde Bao, Feng Huang, Muhammad Asim Khan, Kaiyin Fei 4, Zhong Wu 4 and Elizabeth C. Hsia 5, Shanghai Renji Hospital, Shanghai, China, Chinese PLA General Hospital, Beijing, China, Case Western Reserve University Hospital, Cleveland, OH, 4 Janssen Research & Development, LLC, Spring House, PA, 5 Janssen Research & Development, LLC/U of Penn, Spring House/ Phila, PA 67. Clinical Features and Treatment Results of Japanese Patients with SAPHO (Synovitis-Acne-Pustulosis- Hyperostosis-Osteitis) Syndrome. Hiroki Yabe, Takashi 40 0 Program Book

243 ACR POSTER SESSION B Kuroiwa, Aya Nonaka, Tomomi Tsutsumi, Tadashi Sakurai, Masato Moriguchi, Hisaji Oshima, Kensuke Ochi and Chihiro Terai, Jichi Medical University Saitama Medeical Center, Saitama City, Japan, Tokyo Medical Ctr, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 68. Psoriatic Arthritis in South Asians- Comparison with Caucasians of European Descent. Vinod Chandran, Arane Thavaneswaran and Dafna D. Gladman Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 69. Severe Joint Damage in Psoriatic Arthritis: Mutilans and Ankylosis. Amir Haddad, Arane Thavaneswaran, Dafna D. Gladman Gladman and Vinod Chandran, Toronto Western Hospital and University of Toronto, Toronto, ON 70. Clinical and Ultrasonographic Features of Nail Disease in Psoriasis and Psoriatic Arthritis. Amir Haddad, Arane Thavaneswaran, Vinod Chandran and Dafna D. Gladman Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 7. Predictors of Erosion-Free Psoriatic Arthritis. Zahi Touma, Arane Thavaneswaran, Vinod Chandran and D. D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 7. Increased Participation in Daily Activities After 4 Weeks of Certolizumab Pegol Treatment of Axial Spondyloarthritis Patients, Including Patients with Ankylosing Spondylitis: Results of a Phase Double-Blind Randomized Placebo- Controlled Study. Désirée van der Heijde, Jurgen Braun, Martin Rudwaleit, Oana Purcaru 4 and Arthur Kavanaugh 5, Leiden University Medical Center, Leiden, Netherlands, Rheumazentrum Ruhrgebiet, Herne, Germany, Endokrinologikum Berlin, Berlin, Germany, 4 UCB Pharma, Braine, Belgium, 5 UCSD School of Medicine, La Jolla, CA 7. Influence of Early Onset on the Clinical Characteristics and Prognosis of Ankylosing Spondylitis. Maria Aparicio, Jesús Rodríguez-Moreno, Paula Estrada, Irene Martín-Esteve, Laura López-Vives, Vicenç Torrente, Jordi Anton, Joan Miquel Nolla and Xavier Juanola, Hospital Universitari de Bellvitge, Barcelona, Spain, Hospital Sant Joan de Déu, Barcelona, Spain, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 74. Value of C - reactive protein Level at Diagnosis of Psoriatic Arthritis in Predicting the Future Need for Treatment with Tumor Necrosis Factor-á Inhibitors. Yair Molad and Shachaf Ofer-Shiber, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah-Tikva, Israel, Beilinson Hospital, Rabin Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel 75. Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors. Emily McDonough, Arane Thavaneswaran, Adele Carty, Sutharshini Shanmugarajah, Renise Ayearst, Lihi Eder 4, Vinod Chandran 5, Cheryl Rosen and Dafna Gladman, University of Toronto, Ontario, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto Western Hospital, Toronto, ON, 4 Carmel Medical Center, Haifa, Israel, 5 Toronto Western Hospital, University of Toronto, Toronto, ON 76. Development of A Health Index for Patients with Ankylosing Spondylitis - First Steps of A Global Initiative Based On the ICF Guided by ASAS. Uta Kiltz, Désirée van der Heijde, Annelies Boonen, Alarcos Cieza 4, Gerold Stucki 5, Muhammad Asim Khan 6, Walter P. Maksymowych 7, Helena Marzo-Ortega 8, John D. Reveille 9, William Taylor 0, Cristina Bostan and Jügen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, Leiden University Medical Center, Leiden, Netherlands, University Hospital Maastricht, Maastricht, Netherlands, 4 Munich, Germany, 5 University of Lucerne, Lucerne, Switzerland, 6 CASE at MetroHealth Med Center, Cleveland, OH, 7 University of Alberta, Edmonton, AB, 8 University of Leeds, Leeds, United Kingdom, 9 Univ of Texas Health Science Center at Houston, Houston, TX, 0 University of Otago, Wellington, New Zealand, Paraplegic Research Unit, Nottwil, Switzerland 77. Prevalence of Spondyloarthritis-Related Comorbidities, Osteoporosis and Fractures in Ankylosing Spondylitis: a Systematic Literature Review. Carmen Stolwijk, A.M. Van Tubergen, Jose Dionisio Castillo-Ortiz and Annelies Boonen, Maastricht University Medical Center, Maastricht, Netherlands, Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico 78. Validity of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Early Spondyloarthritis. Cruz Fernández-Espartero, Eugenio De Miguel, Milena Gobbo, Carmen Martínez 4, Miguel A. Descalzo, Estíbaliz Loza Sr. 5 and Esperanza Group 6, Hospital Universitario de Móstoles, Madrid, Spain, Hospital Universitario La Paz, Madrid, Spain, Spanish Society of Rheumatology, Madrid, Spain, 4 Sociedad Española de Reumatología, Madrid, Spain, 5 Research Unit. Sociedad Española de Reumatología, Madrid, Spain, 6 Madrid 79. Ultrasonographic Is More Sensitive Than Traditional Clinical Evaluation in the Detection of Hands and Wrists Synovitis and Digital Soft Tissue Involvement in Early Psoriatic Arthritis. Francesca Bandinelli, Valentina Denaro, Francesca Prignano, Diletta Bonciani, Ledio Collaku and Marco Matucci-Cerinic, University of Florence, Florence, Italy, Florence, Italy, University of Tirana, Tirana, Albania 80. A Spondyloarthritis Research Consortium of Canada Score Cut-off As Best Match for the Assessment of Spondyloarthritis International Society Definition of a Positive MRI of the Sacroiliac Joints. Rosaline van den Berg, Manouk de Hooge, Victoria Navarro-Compán, Monique Reijnierse, Floris van Gaalen, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands 8. Non-Radiographic Spondyloarthritis Has Greater Work Instability Than Other Spondyloarthritis Subtypes in a 0 Program Book 4

244 ACR POSTER SESSION B National Database. Sherry Rohekar, Robert D. Inman, Renise Ayearst, Proton Rahman 4, Walter P. Maksymowych 5 and Dafna D. Gladman 6, St. Joseph s Hospital, London, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 Memorial University, St. Johns, NF, 5 University of Alberta, Edmonton, AB, 6 Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON 8. A Comparison of Three Methods of Measuring Intermalleolar Distance in Patients with Ankylosing Spondylitis. Buse Ozata, Burak Uyar, Dilek Solmaz, Ismail Sari, Servet Akar and Nurullah Akkoc 4, Dokuz Eylul University School of Medicine, Izmir, Dokuz Eylul University School of Medicine, Izmir, Turkey, Dokuz Eylul University School of Medicine Department of Internal Medicine Division of Rheumatology, Izmir, Turkey, 4 Dokuz Eylul University School Of Medicine, Department Of Internal Medicine, Division Of Rheumatology, Izmir, Turkey 8. The Burden of Ankylosing Spondylitis and the Cost- Effectiveness of Anti-Tumor Necrosis Factor α Agents in Romania. Ioan Ancuta, Catalin Codreanu, Ruxandra Ionescu, Magda Parvu 4 and Mihai Bojinca, Dr. I. Cantacuzino Hospital, Bucharest, Romania, Dr. I. Stoia Center for Rheumatic Diseases, Bucharest, Romania, Clinic Hospital Sf. Maria, Bucharest, Romania, 4 N.Gh. Lupu Clinical Hospital, Bucharest, Romania 84. The Frequency of Non-Radiographic Axial Spondyloarthritis in Relation to Symptom Duration in Patients Referred Because of Chronic Back Pain: Results From the Berlin Early Spondyloarthritis Clinic. Denis Poddubnyy, Henning Brandt, Janis Vahldiek, Inge Spiller, In-Ho Song, Martin Rudwaleit and Joachim Sieper, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, Endokrinologikum Berlin, Berlin, Germany, Charité Universitätesmedizin Berlin, Berlin, Germany 85. Increased Body Mass Index in Ankylosing Spondylitis Is Associated with a Greater Burden of Symptoms and Poor Perceptions of the Benefits of Exercise. Laura J. Durcan, Fiona Wilson, Richard Conway, Gaye Cunnane and Finbar (Barry) D. O Shea, St James s Hospital, Dublin, Ireland, Trinity College, Dublin, Ireland Systemic Lupus Erythematosus: Clinical Aspects 86. Genetic Variation and Coronary Atherosclerosis in Patients with Systemic Lupus Erythematosus. Cecilia P. Chung, Joseph F. Solus, Annette Oeser, Chun Li, Paolo Raggi, Jeffrey R. Smith and C. Michael Stein, Vanderbilt University, Nashville, TN, Emory University, Atlanta, GA 87. Hospitalizations and Reasons for Admission in a Clinical SLE Cohort. Alaa Dekis, Kenjey Chan, Christian A. Pineau, Evelyne Vinet, Emil P. Nashi, Sasha Bernatsky and Ann E. Clarke, McGill University, Montreal, QC, McGill University Health Centre, Montreal, QC, Research Institute of the McGill University Health Centre, Montreal, QC 88. Diagnostic Accuracy of Anti-dsDNA Antibodies in Unselected Patients with Recent Onset of Rheumatic Symptoms. Michele Compagno, Søren Jacobsen, Ole Petter Rekvig, Lennart Truedsson 4, Niels H. H. Heegaard 5, Johannes C. Nossent 6, Andreas Jönsen, Rasmus Sleimann Jacobsen, Gro Østli Eilertsen 6, Gunnar K. Sturfelt and anders Bengtsson, Lund University, Lund, Sweden, Copenhagen University Hospital, Copenhagen, Denmark, University Hospital, Tromsø, Norway, 4 Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund, Sweden, 5 Statens Serum Institut, Copenhagen S, Denmark, 6 University of Tromsø, Tromso, Norway 89. Erythrocyte Sedimentation Rate Is a Predictor of Renal and Overall Systemic Lupus Erythematosus Disease Activity. George Stojan, Hong Fang, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 90. Vitamin D Deficiency Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium or Carotid Intima-Media Thickness in Systemic Lupus Erythematosus. Adnan Kiani, Hong Fang, Ehtisham Akhter, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 9. Anti-Ku Autoantibodies in Systemic Lupus Erythematosus versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay. Michael Mahler, Jason Wu, Magdalena Szmyrka-Kaczmarek, Andreas Swart 4, Marvin J. Fritzler 5, Jean-Luc Senécal 6 and John G. Hanly 7, INOVA Diagnostics, Inc., San Diego, CA, INOVA Diagnostics, San Diego, Wroclaw Medical University, Wroclaw, Poland, 4 Rheumatology clinic Neuss, Neuss, Germany, 5 University of Calgary, Calgary, AB, 6 Hôpital Notre-Dame du CHUM, Montréal, QC, 7 Dalhousie University and Capital Health, Halifax, NS 9. Clinical Correlation with Anti Double Stranded Deoxyribonucleic Acid via Enzyme Linked Immunoassay Versus Multiplex Immunoassay. Megan L. Krause, Melissa R. Snyder, Cynthia S. Crowson, Abigail B. Green and Kevin G. Moder, Mayo Clinic, Rochester, MN 9. Predictors of Panniculitis in Systemic Lupus Erythematosus. Ashika Odhav, Michelle Petri and Hong Fang, University of Missouri Kansas City School of Medicine, Kansas, MO, Johns Hopkins University School of Medicine, Baltimore, MD 94. Health Status Burden and Impact of Fatigue on Patient Functioning in SLE Patients from a Phase b Study. Michelle Petri, Ariane K. Kawata, Ancilla W. Fernandes, Kavita Gajria, Warren Greth 4 and Asha Hareendran 5, Johns Hopkins University School of Medicine, Baltimore, 4 0 Program Book

245 ACR POSTER SESSION B MD, United Biosource Corporation, Bethesda, MD, MedImmune LLC, Gaithersburg, MD, 4 MedImmune, LLC, Gaithersburg, MD, 5 United Biosource Corporation, London, United Kingdom 95. The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification. Majed M. Khraishi, Rana Aslanov and Krista Fudge, Memorial University of Newfoundland, St Johns, NF, Memorial University of Newfoundland, St.John s, NF, Corner Brook, NF 96. Associates of a History of Thrombosis in Systemic Lupus Erythematosus. Melissa Nastacio, Hong Fang, Thomas Kickler, Jayesh Jani, Laurence S. Magder and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD 97. Risk Factors Associated with Early Central Nervous System Damage Detected Through Perfusion MRI in Patients with Systemic Lupus Erythematosus. Paola Tomietto, Federica Casagrande, Maja Ukmar, Luca Weis, Pia Morassi, Rita Moretti, Gianni Biolo, Carlo Giansante and Maria Assunta Cova, AOU Ospedali Riuniti di Trieste, Trieste, Italy, Radiology Department, University of Trieste, Trieste, Italy, Internal Medicine Department, University of Trieste, Trieste, Italy 98. Inflammatory Back Pain Is Increased in SLE and Associated with Anti-Sm Antibodies. Neslihan Yilmaz, Ayten Yazici, Sibel Z. Aydin and Sule Yavuz 4, Marmara University, Faculty of Medicine, Istanbul, Turkey, Sakarya Research and Training Hospital, Sakarya, Turkey, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, 4 Marmara University, Istanbul, Turkey 99. Regional Fat Distribution Is Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Female Patients. Manuel F. Ugarte-Gil, Rocio V. Gamboa-Cardenas, Karim E. Diaz-Deza, Mariela Medina-Chinchon, J. Mariano Cucho-Venegas, Risto A. Perich-Campos, Jose L. Alfaro- Lozano, Alfredo A. Sanchez-Torres, Zoila Rodriguez-Bellido, Sheyla Rodriguez-Ulloa and Cesar A. Pastor-Asurza, Hospital Almenara, Lima, Peru 400. Predictors of Obesity in Systemic Lupus Erythematosus. Michelle Petri, Sesha Adusumilli and Hong Fang, Johns Hopkins University School of Medicine, Baltimore, MD 40. Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus. Kristen Foering, Aileen Y. Chang, Evan W. Piette, Joyce Okawa and Victoria P. Werth 4, University of Pennsylvania, Philadelphia VAMC, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, Perelman School of Medicine at the University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA, 4 University of Pennsylvania and Philadelphia V.A. Medical Center, Philadelphia, PA 40. Anti-ApoA Antibodies Associate with Disease Activity in Lupus and Are Lower in Patients Taking Hydroxychloroquine: A Longitudinal Analysis of 98 Samples. Sara Croca, Ian Giles, David A. Isenberg, Yiannis Ioannou and Anisur Rahman, University College London, London, United Kingdom 40. Anti-Nucleosome Antibodies Are Associated with Disease Activity and Hydroxychloroquine Use in Patients with Lupus: A Longitudinal, Multivariate Analysis of 98 Samples. Sara Croca, Ian Giles, David A. Isenberg, Yiannis Ioannou and Anisur Rahman, University College London, London, United Kingdom 404. There Is an Association Between Disease Activity and Risk of Thromboembolism in SLE. Reem Jan, Emily E. Lewis, Ting Ting Lu, Emily Siegwald and W. Joseph McCune, University of Michigan, Ann Arbor, MI 405. Real World Experience Comparing Multiplex Immunobead Assay versus Immunoflorescence Assay for Anti-Nuclear Antibody Detection At a University Hospital. Neha Dang, Brock E. Harper, Emilio B. Gonzalez, Silvia S. Pierangeli, Trisha M. Parekh, Michael J. Loeffelholz and Kimberly K. Bufton, University of Texas Medical Branch, Galveston, TX 406. The Cost of Management of Adult Active Systemic Lupus Erythematosus in the UK. Munther A. Khamashta, Christina Donatti, Ian N. Bruce, Caroline Gordon 4, David A. Isenberg 5 and Ateka-Barrutia Oier, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, IMS Health, United Kingdom, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 4 University of Birmingham, Birmingham, United Kingdom, 5 University College London, London, United Kingdom 407. The Effect of the Antiphospholipid Syndrome (APS) On Survival in Chinese Patients with SLE: A Prospective Study of 679 Patients. Chi Chiu Mok, Ling Yin Ho, Ka Lung Yu and Chi Hung To, Tuen Mun Hospital, Hong Kong, Hong Kong 408. Monitoring Patients with Systemic Lupus Erythematosus in Clinical Practice: Have You Already Checked the Vaccination Status in Your Patients? Olga Malysheva, Jean-Philipp Ivanov, Sybille Arnold and Christoph G. Baerwald, University Hospital, Leipzig, Germany 409. A Multicentre Clinical Study of Umbilical Cord Mesenchymal Stem Cells Transplantation in Active Systemic Lupus Erythematosus. Lingyun Sun, Dandan Wang, Jing Li, Miao Zhang, Yu Zhang 4 and Xia Li, Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China, Department of Rheumatology, Jiangsu Provincial People s Hospital, Nanjing, China, 4 Department of Rheumatology, Subei People s Hospital of Jiangsu Province, Yangzhou, China 0 Program Book 4

246 ACR POSTER SESSION B 40. Relationship between Individual Organ Damage and Mortality of Systemic Lupus Erythematosus (SLE): A Prospective Cohort Study of 679 Patients. Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Tuen Mun Hospital, Hong Kong, Hong Kong 4. Equivalence of Various Language Versions of Lupus Specific Patient Reported Outcomes Measure (LupusPRO). Meenakshi Jolly, Mark Kosinski, Sergio M.A. Toloza, Joel A. Block, Rachel A. Mikolaitis, Sergio Durán-Barragan 4, Ana M. Bertoli 5, Ivana Blazevic 6, Luis M. Vila 7, Dilrukshie Cooray 8, Emmanuel P. Katsaros 9, Karina Marianne D. Torralba 0, Ioana Moldovan, Arif Kaya, Berna Goker, Seminur Haznedaroglu, Mehmet E. Tezcan, Josiane Bourré-Tessier, Sasha Bernatsky 4, Ann E. Clarke 5, Michael H. Weisman 6, Sandra V. Navarra 7, Daniel J. Wallace 6 and Graciela S. Alarcon 8, Rush University Medical Center, Chicago, IL, QualityMetric Inc, Lincoln, RI, Hospital San Juan Bautista, Catamarca, Argentina, 4 Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, 5 Instituto Reumatológico Strusberg, Cordoba, Cordoba, Argentina, 6 University of Buenos Aires, Buenos Aries, Argentina, 7 University of PuertoRico Medical Sciences Campus, San Juan, PR, 8 Harbor UCLA Medical Center, Torrance, CA, 9 Loma Linda Univ, Loma Linda, CA, 0 USC Keck Schl of Medicine, Los Angeles, CA, Loma Linda Univ Medical Center, Loma Linda, CA, Gazi University Medical School, Ankara, Turkey, McGill University, Montréal, QC, 4 Research Institute of the McGill University Health Ctre, Montreal, QC, 5 MUHC, Montreal, QC, 6 Cedars- Sinai Medical Center, Los Angeles, CA, 7 University of Santo Tomas Hospital, Manila, Philippines, 8 University of Alabama at Birmingham, Birmingham, AL 4. Vascular Cell Adhesion Molecule (VCAM-) and Angiostatin in Systemic Lupus Erythematosus. Adnan Kiani, Hong Fang, Tianfu Wu, Chandra Mohan and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, University of Texas Southwestern Medical Center, Dallas, TX 4. Clinical Presentation, Treatment and Outcome of Membranous Nephropathy in SLE: A Comparison with Proliferative Lupus Glomerulonephritis in 4 Patients. Chi Chiu Mok, Ling Yin Ho and Ka Lung Yu, Tuen Mun Hospital, Hong Kong, Hong Kong 44. Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: A -Month Open-Labeled Trial. Chi Chiu Mok, Pak To Chan, Ling Yin Ho and Ka Lung Yu, Tuen Mun Hospital, Hong Kong, Hong Kong 45. Effect of Renal Disease On Survival of Patients with Systemic Lupus Erythematosus: A Prospective Cohort Study of 694 Patients. Chi Chiu Mok, Raymond Kwok and Paul Yip, Tuen Mun Hospital, Hong Kong, Hong Kong, University of Hong Kong, Hong Kong, Hong Kong 46. Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus. Mariana Postal, Aline T. Lapa, Nailu A. Sinicato, Karina Peliçari, Lilian Costallat and Simone Appenzeller, State University of Campinas, Campinas, Brazil, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil, State University of Campinas, São Paulo, Brazil 47. Favorable Response to Belimumab At Three Months. Katrina M. Shum, Jill P. Buyon, H. Michael Belmont, Andrew G. Franks, Richard Furie, Diane L. Kamen 4, Susan Manzi 5, Michelle Petri 6, Rosalind Ramsey-Goldman 7, Chung-E Tseng, Ronald F. van Vollenhoven 8, Daniel Wallace 9 and Anca Askanase, NYU School of Medicine, New York, NY, New York University, New York, NY, North Shore-LIJ Health System, Lake Success, NY, 4 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 5 West Penn Allegheny Health System, Pittsburgh, PA, 6 Johns Hopkins University School of Medicine, Baltimore, MD, 7 Northwestern University Feinberg School of Medicine, Chicago, IL, 8 The Karolinska Institute, Stockholm, Sweden, 9 Cedars-Sinai/UCLA, Los Angeles, CA 48. Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI. Anca D. Askanase, Katrina M. Shum, Stan Kamp, Fredonna C. Carthen, Teresa J. Aberle and J.T. Merrill, NYU School of Medicine, New York, NY, Oklahoma Medical Research Foundation, Oklahoma City, OK 49. Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 495 Patient Years of Follow-up. Renata Baronaite Hansen and Søren Jacobsen, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, Copenhagen University Hospital, Copenhagen, Denmark 40. Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus. A. Lois-Iglesias, J. Ishorari and D.A. Isenberg, University Hospital Ramón y Cajal, Madrid, Spain. University College London, London, United Kingdom, University College London, London, United Kingdom 4. Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease. Ioana Ruiz-Arruza, D. D. Gladman, Dominique Ibanez and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON 4. Clinical Associations of Anti-Smith Antibodies in Profile: A Multiethnic Lupus Cohort. Yesenia C. Santiago-Casas, Luis M. Vila, Gerald McGwin Jr., Ryan S. Cantor, Michelle Petri, Rosalind Ramsey-Goldman 4, John D. Reveille 5, Robert P. Kimberly, Graciela S. Alarcon and Elizabeth E. Brown, University of Puerto Rico Medical Sciences Campus, San Juan, PR, University of Alabama at Birmingham, Birmingham, AL, Johns Hopkins University School of Medicine, Baltimore, MD, 4 Northwestern University 44 0 Program Book

247 ACR POSTER SESSION B Feinberg School of Medicine, Chicago, IL, 5 Univ of Texas Health Science Center at Houston, Houston, TX 4. Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia. Amir Haddad, Murray B. Urowitz, Dominique Ibanez and D. D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 44. Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology). José M. Pego-Reigosa, Íñigo Rúa-Figueroa, Francisco J. López-Longo, María Galindo 4, Jaime Calvo-Alén 5, Alejandro Olivé 6, Loreto Horcada 7, Esther Uriarte 8, Eva Tomero 9, Ana Sánchez-Atrio 0, Carlos Montilla, José Rosas, Antonio Fernández-Nebro, Paloma Vela 4, Mercedes Freire 5, Lucía Silva 6, Elvira Díez-Álvarez 7, Carlos Marras 8, Antonio Zea 9, Javier Narváez 0, Jose Luis Marenco, Monica Fernández de Castro, Olaia Fernánde-Berrizbeitia, Marian Gantes 4 and Celia Erausquin 5, Hospital do Meixoeiro, Vigo, Spain, Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, Hospital Gregorio Marañón, Madrid, Spain, 4 Instituto de Investigación Hospital de Octubre, Madrid, Spain, 5 Hospital Sierrallana, Torrelavega, Spain, 6 Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 7 Hospital de Navarra, Spain, 8 Hospital de Donosti, Donosti, Spain, 9 Hospital Universitario La Princesa, Madrid, Spain, 0 Hospital Príncipe de Asturias, Madrid, Spain, Hospital Universitario de Salamanca, Salamanca, Spain, Hospital de Marina Baixa, Alicante, Spain, Hospital Carlos Haya, Malaga, Spain, 4 Hospital General de Alicante, Alicante, Spain, 5 Hospital Universitario Juan Canalejo, La Coruña, Spain, 6 Hospital de Guadalajara, Guadalajara, Spain, 7 Hospital de León, León, Spain, 8 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 9 Hospital Universitario Ramon y Cajal, Madrid, Spain, 0 Hospital de Bellvitge, Barcelona, Spain, Hospital de Valme, Seville, Spain, Hospital Puerta del Hierro-Majadahonda, Madrid, Spain, Hospital de Basurto, Basurto, Spain, 4 Hospital Clinico de Tenerife, Spain, 5 Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain 45. Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE. Gregg J. Silverman, John Jung, Ehtisham Akhter, Michelle Petri and Caroline Grönwall, NYU School of Medicine, New York, NY, Johns Hopkins University School of Medicine, Baltimore, MD 46. The Clinical Relevance of a False Negative Enzyme Linked Immunoassay: Which Antinuclear Antibody Screening Test Is Preferred by Rheumatologists in an Integrated Health System? Rachita Bansal, David Bulbin, Alfred E. Denio, Sandi Kelsey and Harold Harrison, Geisinger Medical Center, Danville, PA 47. Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant? Juan G. Ovalles-Bonilla, Julia Martínez- Barrio, Javier Lopez-Longo, Inmaculada de la Torre, Carlos Gonzalez Fernandez, María Montoro Álvarez, Francisco Aramburu, Carolina Marin, Lina Martinez-Estupiñan, Juan C. Nieto, Michelle Hinojosa, Natalia Bello, Indalecio Monteagudo and Luis Carreño, Gregorio Marañón Hospital, Madrid, Spain, Istituto Giannina Gaslini, Genova, Italy 48. Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus. Evelyne Vinet, Mohammed Kaouache, Christian A. Pineau, Ann E. Clarke, Caroline P. Gordon 4, Robert W. Platt 5 and Sasha Bernatsky, McGill University Health Centre, Montreal, QC, Research Institute of the McGill University Health Ctre, Montreal, QC, MUHC, Montreal, QC, 4 Medical School, Birmingham, United Kingdom, 5 McGill University, Montreal, QC 49. Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Aorta Calcium (AS) Than Women without SLE. Apinya Lertratanakul, Peggy W. Wu, Alan Dyer, William Pearce, George Kondos, Daniel Edmundowicz, James Carr 4 and Rosalind Ramsey-Goldman 4, Northwestern University, Chicago, IL, University of Illinois at Chicago, Chicago, IL, Temple University School of Medicine, Philadelphia, 4 Northwestern University Feinberg School of Medicine, Chicago, IL 40. Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Coronary Artery Calcium (CAC) Than Women without SLE. Apinya Lertratanakul, Peggy W. Wu, Alan Dyer, William Pearce, George Kondos, Daniel Edmundowicz, James Carr 4 and Rosalind Ramsey-Goldman 4, Northwestern University, Chicago, IL, University of Illinois at Chicago, Chicago, IL, Temple University School of Medicine, Philadelphia, 4 Northwestern University Feinberg School of Medicine, Chicago, IL 4. Single Photon Emission Computed Tomography Contributes to Clinical Assessments in Neuropsychiatric Systemic Lupus Erythematosus Patients. Maasa Hama, Mitsuhiro Takeno, Atsushi Ihata, Daiga Kishimoto, Reikou Watanabe, Takeaki Uehara, Ryusuke Yoshimi, Yukiko Asami, Atsuhisa Ueda and Yoshiaki Ishigatsubo, Yokohama City University Graduate School of Medicine, Yokohama, Japan 4. Safety and Efficacy of Etanercept in Systemic LUPUS Erythematosus. Josefina Cortes-Hernandez, Natalia Egri, Miquel Vilardell-Tarres and Josep Ordi-Ros, Hospital Universitari Vall dxhebron, Institut de Recerca (VHIR),, Barcelona, Spain, Vall De Hebron General Hospt, Barcelona, Spain 4. Persistent Dyslipidemia Is a Risk Factor of Progression to Chronic Kidney Disease in Patients with Lupus Nephritis. Dong-Jin Park, Kyung-Eun Lee, Tae-Jong Kim, Yong-Wook Park and Shin-Seok Lee, Chonnam National University Medical School, Gwangju, South Korea 0 Program Book 45

248 ACR POSTER SESSION B Cardiovascular Morbidity in a Long-Term Follow-up Cohort of Systemic Lupus Erythematosus Patients in Southern Sweden. Ragnar Ingvarsson, Ola Nived, Gunnar Sturfelt, anders Bengtsson and Andreas Jönsen 4, Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden, University Hospital - Lund, Lund, Sweden, University Hospital Lund, Lund, Sweden, 4 Section of Rheumatology, Lund, Sweden 45. Identifying Systemic Lupus Erythematosus Patients At Higher Risk of Coronary Artery Disease. Dominique Ibanez, D. D. Gladman and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON 46. Application of European League Against Rheumatism Recommendations for the Management of Systemic Lupus Erythematosus Patients with Neuropsychiatric Involvement May Limit Unnecessary Diagnostic Testing and Curve Intensification of Immunosuppressive Therapy of Unclear Benefit. Cristina Pamfil, Antonios Fanouriakis, Argyro Repa, Maria Melissourgaki, Prodromos Sidiropoulos, Ileana Filipescu, Mirela Rinzis, Simona Rednic, George Bertsias and Dimitrios Boumpas 4, University of Medicine and Pharmacy, Cluj, Romania, University of Crete, Iraklion, Greece, Emergency County Clinical Hospital Cluj Napoca, Cluj-Napoca, Romania, 4 Panepistimio Kritis, Rethymnon, Greece 47. Majority of Lupusqol Domains Are Negatively Correlated with Systemic Lupus Activity Questionnaire (SLAQ) Score. Wendy Marder, Martha Ganser, Margaret Hyzy and Emily C. Somers, University of Michigan, Ann Arbor, MI, Universitiy of Michigan, Ann Arbor, MI Systemic Lupus Erythematosus - Animal Models 48. Development of Systemic Lupus Erythematosus (SLE) in NZM 8 Mice in the Absence of Any Single BAFF Receptor. Chaim O. Jacob, Ning Yu, Shunhua Guo, Noam Jacob, William J. Quinn III, Michael P. Cancro, Beatrice Goilav 4, Chaim Putterman 5, Thi-Sau Migone 6 and William Stohl, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, University of Southern California Keck School of Medicine, Los Angeles, CA, University of Pennsylvania School of Medicine, Philadelphia, PA, 4 Children s Hospital at Montefiore, Bronx, NY, 5 Albert Einstein College of Medicine, Bronx, NY, 6 Human Genome Sciences, Rockville, MD 49. CTL-Promoting Effects of IL- Results in B Cell Elimination and Disease Improvement in a Murine Model of Lupus. Vinh Nguyen, Daniel Veizaga-Udaeta, Horea Rus and Violeta Rus, University of Maryland School of Medicine, Baltimore, MD, University of Maryland at Baltimore County, MD, University of Maryland School of Medicine and Veteran Affairs Medical Center, Baltimore, MD 440. Lupus-Prone Mice Demonstrate Enhanced Neutrophil Extracellular Trap Formation: Implications for Autoantibody Formation and Organ Damage. Jason 0 Program Book S. Knight, Alexander A. O Dell, Wenpu Zhao, Ritika Khandpur, Srilakshmi Yalavarthi and Mariana J. Kaplan, University of Michigan Rheumatology, Ann Arbor, MI, University of Michigan, Ann Arbor, MI 44. Epstein Barr Virus CD40 Functional Mimic Latent Membrane Protein- Drives Cellular Molecular Mimicry in the Presence of Epstein Barr Virus Nuclear Antigen- in a Novel Murine Model of Lupus-Like Disease. Melissa E. Munroe, Jourdan R. anderson, Timothy F. Gross, Laura L. Stunz, Gail A. Bishop and Judith A. James, Oklahoma Medical Research Foundation, Oklahoma City, OK, The University of Iowa, Iowa City, IA, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK 44. IRF- Deficient Lupus-Prone MRL/Lpr Mice Show Reduced Glomerulonephritis but Develop Severe Interstitial Nephritis, Renal Vasculitis and Pulmonary Granulomas with Propensity for Th Polarity. Hidemaru Sekine, Takeshi Machida, Natsumi Sakamoto, Eiji Suzuki, Xian Zhang, Christopher Reilly 4 and Gary S. Gilkeson, Fukushima Medical University, Fukushima, Japan, Medical University of South Carolina, Charleston, SC, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC, 4 Virginia Tech, Blacksburg, VA 44. Caspase- Modulates Endothelial Dysfunction and Vascular Repair in Murine Lupus. J. Michelle Kahlenberg, Wenpu Zhao, Srilakshmi Yalavarthi and Mariana J. Kaplan, University of Michigan, Ann Arbor, MI 444. HLA-DR Controls Autoantibody Response to Sm in NZM8.DR+.AE0 Transgenic Mice. Vaidehi R. Chowdhary, Chao Dai, Shu Man Fu and Chella S. David, Mayo Clinic, Rochester, MN, University of Virginia Health System, Charlottesville, VA 445. Shared and Unique Molecular Features of Nephritis in Models of Murine SLE. Ramalingam Bethunaickan, Celine C. Berthier, Matthias Kretzler and Anne Davidson 4, Feinstein Institute for Medical research, Manhasset, NY, University of Michigan, Ann Arbor, MI, University of Michigan, MI, 4 Feinstein Institute for Medical Research, Manhasset, NY 446. The Granulocyte Signature and Organ Inflammation in TLR7 Responsive Mice Is RNA and Type Interferon Dependent. Xizhang Sun, Alice Wiedeman, Thomas H. Teal, Nalini Agrawal, Jeffrey Duggan, Matt B. Buechler, Jeffrey A. Ledbetter, Denny Liggitt, Jessica A. Hamerman 4 and Keith B. Elkon, Division of Rheumatology, Department of Medicine, University of Washington, Seattle, WA, University of Washington, Seattle, WA, Benaroya Research Institute at Virginia Mason, Seattle, WA, Seattle, 4 Benaroya Research Institute at Virginia Mason, Seattle, WA 447. A Synthetic Triterpenoid CDDO-Me Prevents and Reverses Murine Lupus Nephritis. Tianfu Wu, Yujin Ye, Mei Yan, Xin J. Zhou, Michael andreef and Chandra Mohan, University of Texas, Southwestern Medical Center at Dallas, Dallas, TX,

249 ACR POSTER SESSION B University of Texas Southwestern Medical Center at Dallas, Dallas, TX, The University of Texas M. D. anderson Cancer Center, Houston, TX 448. Inhibition of Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses the Autoimmunity in Lupus-Prone Mice. Kunihiro Ichinose, Atsushi Kawakami and George C. Tsokos, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 449. Numbers of Splenic Long-Lived Plasma Cells in Autoimmune and Pre-Autoimmune Lupus Mice Are Linked to a Hyper-Responsive Variant of the Thrombopoietin Receptor and Enhanced Megakaryopoiesis. Oliver Winter, Katrin Moser, Rudolf A. Manz and Falk Hiepe 4, Charité - University Medicine Berlin, Berlin, Germany, German Arthritis Research Center (DRFZ Berlin), Berlin, Germany, University of Lübeck, Lübeck, Germany, 4 Charité University Hospital Berlin, Berlin, Germany 450. MEDI-55 Depletes a Majority of Murine B Cells and Reduces Serum Titers of Autoantibodies in the SLE- hucd9 TG Mice. Sandra Gallagher, Yue Wang, Isharat Yusuf, Thomas McCaughtry, Ronald Herbst and Laura Carter, MedImmune, Gaithersburg, MD 45. Estrogen Receptor Alpha Deficiency Protects Against Cognitive Defects in Murine Lupus. Melissa A. Cunningham, Osama S. Naga, Heather A. Boger, Ann- Charlotte E. Granholm-Bentley and Gary S. Gilkeson, MUSC, Charleston, SC, Medical University of SC, Charleston, SC, Medical University of South Carolina, Charleston, SC 45. Inherent Strain-Based Differences in Qualitative CD4 T Cell Responses Determine Lupus Severity. Kateryna Soloviova, Maksym Puliaiev and Charles S. Via, Uniformed Services University of Health Sciences, Bethesda, MD 45. Estrogen Receptor Alpha Impacts Th7 Expansion in Murine Lupus. Melissa A. Cunningham, Osama S. Naga, Jackie G. Eudaly and Gary S. Gilkeson, MUSC, Charleston, SC, Medical University of SC, Charleston, SC, Medical University of South Carolina, Charleston, SC 454. Characterization of Renal Mononuclear Phagocyte Populations in Murine SLE Nephritis. Ranjit Sahu, Ramalingam Bethunaickan and Anne Davidson, Feinstein Institute for Medical Research, Manhasset, NY, Feinstein Institute for Medical research, Manhasset, NY 455. Mitochondrial Dysfunction in the Liver of Lupus-Prone MRL/Lpr Mice Prior to Disease Onset. Zachary A. Oaks, Tiffany Telarico and andras Perl, SUNY, Syracuse, NY, SUNY Upstate Medical University, Syracuse, NY, Upstate Medical University, Syracuse, NY 456. A Tolerogenic Peptide Down-Regulates the Expression of Interferon-a in Murine and Human Systemic Lupus Erythematosus. Zev M. Sthoeger, Heidy Zinger, Amir Sharabi, Ilan Asher and Edna Mozes, Kaplan Hospital, Rehovot, Israel, The Weizmann institute of Science, Rehovot, Israel 457. A Novel Small Molecular Anti-Rheumatic Drug, T-6 4, Ameliorates Lupus-Like Disease in MRL/Lpr Mice by Suppressing B Cell Functions. Qingran Yan, Fang Du and Chunde Bao, Renji Hospital, Shanghai, China Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics 458. Left Ventricular Diastolic Dysfunction May Play a Role in Pathophysiology and Poor Prognosis of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis. Sumiaki Tanaka, Eisuke Ogawa, Tatsuhiko Wada, Tatsuo Nagai, Jun Okada and Shunsei Hirohata, Kitasato University School of Medicine, Sagamihara, Japan, Kitasato University, Sagamihara, Japan 459. Limited Utility of Pulmonary Function Tests and B-Type Natriuretic Peptide As Screening Tools for Pre-Capillary Pulmonary Hypertension in Patients with Systemic Sclerosis. Yuichiro Shirai, Yuichi Tamura, Hidekata Yasuoka, Tsutomu Takeuchi, Toru Satoh and Masataka Kuwana, Keio University School of Medicine, Tokyo, Japan, Kyorin University School of Medicine, Tokyo, Japan 460. Unmasking Latent Pulmonary Arterial Hypertension by Fluid Challenge in Patients with Systemic Sclerosis. Amee Sonigra, Melanie Hurford, Patricia Lewis, David Kilpatrick, Nathan Dwyer and Jane Zochling, Royal Hobart Hospital, Hobart, Australia, Menzies Research Institute, Hobart, Australia, Menzies Research Institute Tasmania, Hobart, Australia 46. Clinical Outcomes of Scleroderma Patients At High Risk for Pulmonary Hypertension. Analysis of the Pulmonary Hyparternsion Assessment and Recognition of Outcomes in Scleroderma Registry. Avram Z. Goldberg, Vivien M. Hsu and Virginia D. Steen, North Shore-LIJ Health System, Lake Success, NY, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, Georgetown Univ Medical Center, Washington, DC 46. Expert Consensus for Performing Right Heart Catheterization in Suspicion of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis: A Delphi Consensus Study with Cluster Analysis From the Eposs Group. Jerome Avouac, Dörte Huscher, Daniel E. Furst, Oliver Distler 4 and Yannick Allanore, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, UCLA Medical School, Los Angeles, CA, 4 University Hospital Zurich, Zurich, Switzerland 46. Pulmonary Hypertension and Interstitial Lung Disease within Pharos: Impact of Extent of Fibrosis and Pulmonary Physiology On Cardiac Hemodynamic Parameters. Aryeh Fischer, Stephen C. Mathai, Marcy B. Bolster, Lorinda Chung 4, Mary Ellen Csuka 5, Robyn T. Domsic 6, Tracy M. 0 Program Book 47

250 ACR POSTER SESSION B Frech 7, Monique E. Hinchcliff 8, Vivien M. Hsu 9, Laura K. Hummers, Jason R. Kolfenbach 0, Mardi Gomberg- Maitland, Aida Manu, Robert W. Simms and Virginia D. Steen 4, National Jewish Health, Denver, CO, Johns Hopkins University, Baltimore, MD, Medical Univ of South Carolina, Charleston, SC, 4 Stanford Univ Medical Center, Palo Alto, CA, 5 Medical College of Wisconsin, Milwaukee, WI, 6 University of Pittsburgh, Pittsburgh, PA, 7 University of Utah School of Medicine, SLC, UT, 8 Northwestern Univ Med School, Chicago, IL, 9 RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, 0 Univ of Colorado School of Med, Aurora, CO, University of Chicago, Chicago, Rheumatology, Georgetown University Medical Center, Disrict of Columbia, Boston University School of Medicine, Boston, MA, 4 Georgetown Univ Medical Center, Washington, DC 464. Comparison of Baseline Characteristics of the Combined Response Index for Systemic Sclerosis (CRISS) Cohort to Patients Enrolled in Clinical Trials of Diffuse Systemic Sclerosis. Heather Gladue, De Furst, Veronica Berrocal, James R. Seibold, Peter A. Merkel 4, Maureen D. Mayes 5, Kristine Phillips 6, Robert W. Simms 7, Shervin Assassi 8, Philip J. Clements 9, Paul Maranian 0 and Dinesh Khanna, University of Michigan, Ann Arbor, MI, University of California at Los Angeles, Los Angeles, CA, Scleroderma Research Consultants LLC, Avon, CT, 4 University of Pennsylvania, Philadelphia, PA, 5 University of Texas Health Science Center at Houston, Houston, TX, 6 University of Michigan Medical School, Ann Arbor, MI, 7 Boston University School of Medicine, Boston, MA, 8 Univ of Texas Health Science Houston, Houston, TX, 9 UCLA School of Medicine, Los Angeles, CA, 0 UCLA Medical School, Los Angeles, CA 465. World Health Organization Classification of Pulmonary Hypertension and Survival in Systemic Sclerosis Patients in the Pharos Cohort. Jessica K. Gordon, Lorinda Chung, Robyn T. Domsic, Wei-Ti Huang 4, Stephen L. Lyman, Evelyn M. Horn 5, Virginia D. Steen 6 and PHAROS Investigators 7, Hospital for Special Surgery, New York, NY, Stanford Univ Medical Center, Palo Alto, CA, University of Pittsburgh, Pittsburgh, PA, 4 Hospital for Special Surgery, New York, 5 New York Presbyterian Hospital/Weill Cornell Medical College, New York, NY, 6 Georgetown Univ Medical Center, Washington, DC, 7 Washington, DC 466. Patients with Systemic Sclerosis Are Dying of Non-Systemic Sclerosis Related Causes, However Interstitial Lung Disease Remains the Predominant Systemic Sclerosis Related Cause of Death. Rebecca L. Batten and Bridget Griffiths, Freeman Hospital, Newcastle Upon Tyne, United Kingdom 467. Association of Gastroesophageal Factors and Progression of Interstitial Lung Disease in the Canadian Scleroderma Research Group, a Large, Multicenter Database. Xuli Jerry Zhang, Ashley Bonner, Murray Baron, Marie Hudson 4, Janet E. Pope 5 and Canadian Scleroderma Research Group 6, Western University, London, ON, McMaster University, Hamilton, ON, Jewish General Hospital, Montreal, QC, 4 McGill University, Montreal, QC, 5 St. Joseph Health Care London, University of Western Ontario, London, ON, 6 Montreal 468. Patient Perspective Informs Core Sets, Constructs of Metrics and Communication Tools for Patients with Connective Tissue Disease Related Interstitial Lung Disease. Shikha Mittoo, Sid Frankel, Daphne LeSage, Flavia V. Castelino 4, Lisa Christopher-Stine 5, Sonye Danoff 6, Aryeh Fischer 7, Laura K. Hummers 5, Ami A. Shah 5, Jeffery J. Swigris 7, Spohia Cena 8, Sancia Ferguson 9, Ignacio Garcia- Valladares 8, Maithy Tran, Harmanjot K. Grewal 0 and Lesley Ann Saketkoo 8, University of Toronto, Toronto, ON, University of Manitoba, Winnipeg, Center for CCH at State of Louisiana, New Orleans, LA, 4 Massachusetts General Hospital, Boston, MA, 5 Johns Hopkins University, Baltimore, MD, 6 Johns Hopkins School of Medicine, Baltimore, MD, 7 National Jewish Health, Denver, CO, 8 Louisiana State University Health Science Center, New Orleans, LA, 9 Tulane University School of Medicine, 0 Lousiana State University Health Sciences Center, New Orleans, LA 469. WITHDRAWN Clinical Features Associated with Anti-Th/to in Non- Scleroderma Patients - Sine Scleroderma? Ann D. Chauffe, Minoru Satoh, Angela Ceribelli, Edward K.L. Chan, Yi Li, Eric S. Sobel, Westley H. Reeves and Michael R. Bubb, University of Florida, Gainesville, FL 47. Differential Expression of Hepatocyte Growth Factor (HGF) in Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Lorinda Chung, Catriona Cramb, William H. Robinson, Virginia D. Steen 4 and Roham T. Zamanian, Stanford Univ Medical Center, Palo Alto, CA, VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, Stanford University, Palo Alto, CA, 4 Georgetown Univ Medical Center, Washington, DC 47. Enhanced Liver Fibrosis Test: A Further Step Toward Depiction of Fibrotic Process in Very Early Diagnosis of Systemic Sclerosis. Francesca Ingegnoli, Roberta Gualtierotti, Tommaso Schioppo, Annalisa Orenti, Patrizia Boracchi, Chiara Lubatti, Sara Lodi Rizzini, Antonella Murgo, Silvana Zeni, Claudio Mastaglio, Valentina Galbiati, Claudia Grossi 4, Maria Borghi 4, William M. Rosenberg 5 and Pier Luigi Meroni 6, Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy, Medical Statistics and Biometry, University of Milan, Milano, Italy, Rheumatology Unit, Ospedale Moriggia-Pelascini, Italia Hospital, Gravedona, Italy, 4 Lab of immunology, IRCCS Istituto Auxologico Italiano, Milano, Italy, 5 Centre for Hepatology - UCL, London, United Kingdom, 6 Istituto G. Pini, University of Milan, Milano, Italy 47. Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis. Giuseppina Abignano, Giovanna Cuomo, Maya H. Buch, William M. Rosenberg, Gabriele Valentini, Paul Emery and Francesco Del Galdo, University of Leeds, Leeds Institute of Molecular Medicine 48 0 Program Book

251 ACR POSTER SESSION B and LMBRU, Leeds, United Kingdom, Second University of Naples, Rheumatology Unit, Naples, Italy, Centre for Hepatology - UCL, London, United Kingdom 474. Interferon-Inducible Chemokines Correlate with Disease Severity in Systemic Sclerosis. Xiaochun Liu, Maureen D. Mayes, Filemon K. Tan, Minghua Wu, John D. Reveille, Brock E. Harper, Hilda T. Draeger 4, Emilio B. Gonzalez and Shervin Assassi 5, University of Texas Health Science Center at Houston, Houston, TX, Univ of Texas Health Science Center at Houston, Houston, TX, University of Texas Medical Branch, Galveston, TX, 4 Univ of TX Health Sci Ctr, San Antonio, TX, 5 Univ of Texas Health Science Houston, Houston, TX 475. Does Skin Gene Expression Profile Predict Response to Imatinib? Shervin Assassi, Jeffrey T. Chang, Dinesh Khanna, Xiaochun Liu, Daniel Furst and Maureen D. Mayes, Univ of Texas Health Science Center at Houston, Houston, TX, University of Michigan, Ann Arbor, MI, University of California at Los Angeles, Los Angeles, CA 476. Caveolin- Deficiency May Play a Role in the Predisposition of African Americans to SSc ILD. Elena Tourkina, Charles Reese, Beth Perry, Shanice Dyer, Michael Bonner, Richard P. Visconti, Jing Zhang, Richard M. Silver and Stanley Hoffman, Medical University of South Carolina, Charleston, SC, Medical University of SC, Charleston, SC, Medical University of SC, Charleston 477. Skin Autofluorescence As a Measure of Oxidative Stress in Systemic Sclerosis Is Not Affected by Skin Thickness, Erythema or Melanin. Andrea Murray, T. Moore, J. Manning, Christopher E.M Griffiths and Ariane Herrick 4, School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, Department of Clinical Rheumatology, Salford Royal NHS Foundation Trust, Salford, United Kingdom, Dermatology Centre, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, 4 University of Manchester, Salford, United Kingdom 478. Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis. Svetlana I. Nihtyanova, Voon H. Ong and Christopher P. Denton, Royal Free Hospital, Medical School, London, England, UCL Medical School, London, England, UCL, London, United Kingdom 479. Early Versus Late Onset Systemic Sclerosis: Analysis of 07 Patients From Rescle Registry. Marco A. Alba, Juan Carlos Mejia, Gerard Espinosa, María-Victoria Egurbide 4, Carles Tolosa 5, Luis Trapiella 6, Carmen Pilar Simeon 7, Vicent Fonollosa 8 and and RESCLE investigators 9, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, Hospital Clinic University Barcelona, Barcelona, Spain, Hospital Clínic of Barcelona, Barcelona, Spain, 4 Hospital de Cruces, UPV/EHU, Barakaldo, Spain, Barakaldo, Spain, 5 Corporación Sanitaria Universitaria Parc Taulí, Barcelona, Spain, 6 Hospital Universitario Central de Asturias, Asturias, Spain, 7 Hospital Valle de Hebron, Barcelona, Spain, 8 Hospital Vall dxhebron, Barcelona, Spain, 9 RESCLE, Barcelona, Spain 480. The 5% Rule in Scleroderma: A Systematic Review of the Frequency of Organ Complications in Systemic Sclerosis. Chayawee Muangchan, Murray Baron, Janet E. Pope and Canadian Scleroderma Research Group 4, Mahidol University, Siriraj Hospital, Bangkok, Thailand, Jewish General Hospital, Montreal, QC, St. Joseph Health Care London, University of Western Ontario, London, ON, 4 Montreal, QC 48. A Double-Blind Placebo-Controlled Crossover Trial of the Alpha-C Adrenoceptor Antagonist Orm-74 for Prevention of Cold-Induced Vasospasm in Patients with Systemic Sclerosis. Ariane Herrick, Andrea Murray, Angela Ruck, Juha Rouru 4, Tonia Moore, John Whiteside, Pasi Hakulinen 4, Fredrick M. Wigley 5 and Amir Snapir 4, University of Manchester, Salford, United Kingdom, School of Translational Medicine, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, United Kingdom, Orion Pharma UK, Research & Development, Nottingham, United Kingdom, 4 Orion Corporation Orion Pharma, Turku, Finland, 5 Johns Hopkins University, Baltimore, MD 48. Laser Speckle Contrast Imaging May Help in the Differential Diagnosis of Raynaud s Phenomenon. Alessandra Della Rossa, Massimiliano Cazzato, Walter Bencivelli, Anna d Ascanio, Marta Mosca and Stefano Bombardieri, Rheumatology Unit, Pisa, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy 48. Predictors of Digital Ulcers in Systemic Sclerosis: Correlation between Clinical and Hemodynamic Features, Capillaroscopy, Endothelium Dysfunction and Angiogenesis Biomarkers. Ivone Silva, Isabel Almeida, António Marinho and Carlos Vasconcelos, Raynaud Clinics, Porto, Portugal, Unidade de Imunologia Clínica, Porto, Portugal, Hospital Geral Santo Antonio, Porto, Portugal 484. Investigating Determinants of Subjective and Objective Assessments of Peripheral Vascular Function in Primary Raynaud s Phenomenon and Systemic Sclerosis. John D. Pauling, Jacqueline A. Shipley, Nigel Harris and Neil McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom 485. Patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) Present Esophageal and Anorectal Involvement: Data from a Single Centre. Gemma Lepri, Silvia Bellando- Randone, Serena Guiducci, Iacopo Giani, Cosimo Bruni, Giulia Carnesecchi 4, Jelena Blagojevic, Alessandra Radicati, Filippo Pucciani 5 and Marco Matucci Cerinic, Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, University of Florence, Florence, Italy, General Surgery, ASL 8, Arezzo, Italy, Arezzo, Italy, 4 Department of Internal Medicine, Rheumatology 0 Program Book 49

252 ACR POSTER SESSION B Section, University of Florence, Florence, Italy, 5 General and Urgency Surgery, University of Florence, Florence, Italy, Florence, Italy 486. Poor Outcome in Patients with Systemic Sclerosis and Myocardial Involvement: A Combined Approach Based On Clinical and Laboratory Findings, EKG-Holter and Cardiac Magnetic Resonance. Silvia Laura Bosello, Giacomo De Luca, Antonella Laria, Giorgia Berardi and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy 487. Incidence of Fibromyalgia Syndrome in Systemic Sclerosis and Rheumatoid Arthritis. Comparative Results According to Clinical Diagnosis, Screening Test with Fibromyalgia Rapid Screening Tool, Diagnosis with ACR990 and ACR 00 Criteria. Serge Perrot, Mariana Peixoto, Philippe Dieude, Eric Hachulla 4, Sébastien Ottaviani 5 and Yannick Allanore 6, Hopital Hotel Dieu, Paris, France, Cochin Hospital, Paris, France, APHP, Hopital Bichat, Paris, France, 4 Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, 5 APHP, Paris, France, 6 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France 488. Prevalence and Risk Factors of Low Bone Mineral Density in Chinese Patients with Systemic Sclerosis: A Case-Control Study. Chi Chiu Mok, Pak To Chan, Kar Li Chan, Ling Yin Ho and Chi Hung To, Tuen Mun Hospital, Hong Kong, Hong Kong 489. Peripheral Neuropathy: A Complication of Systemic Sclerosis. Melissa Reily, Tracy M. Frech, Maureen Murtaugh, Jason Penrod and Barry M. Stults 4, University of Utah, Salt Lake City, UT, University of Utah School of Medicine, SLC, UT, University of Utah, Salt Lake City, 4 Salt Lake City Veterans Affairs Medical Center and University of Utah, Salt Lake City, UT Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics 490. Dysregulation of Angiogenic Homeostasis in Systemic Sclerosis. Naglaa Y. Assaf, Hanan M. Farouk and Iman M. Aly, Faculty of Medicine, Ain-Shams University, Cairo, Egypt, Ain-Shams University, Cairo, Egypt 49. Systemic Sclerosis Effects of Agonistic Autoantibodies Directed Against the Angiotensin Receptor Type and the Endothelin Receptor Type A On Effector Cells. Jeannine Guenther, Angela Kill, Mike O. Becker and Gabriela Riemekasten 4, Charite University Hosptial, Berlin, Germany, Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, Charité University Hospital, Berlin, Germany, 4 Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany 49. IL- Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis. Yuko Ota, Yasushi Kawaguchi, Atsushi Kitani, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Takahisa Gono, Masanori Hanaoka, Yuko Okamoto and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Mucosal Immunity Section, NIAID/NIH, Bethesda, MD 49. Transforming Growth Factor-β and Endothelin- Induce Endothelial-to-Mesenchymal Transition in Cultured Human Endothelial Cells. Stefano Soldano, Paola Montagna, Renata Brizzolara, Barbara Villaggio, Alberto Sulli and Maurizio Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, Genova, Italy, Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy 494. CD40 Signaling Results in Microvascular Endothelial Dysfunction: A Possible Clue to the Pathogenesis of Scleroderma Vasculopathy. Bashar Kahaleh and Yongqing Wang, University of Toledo, Toledo, OH 495. Platelet Aggregability, Eicosanoid Biosynthesis and Oxidative Stress in Primary Raynaud s Phenomenon and Systemic Sclerosis. John D. Pauling and Neil McHugh, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom 496. Downregulated Expression of Metallothionein Genes in Response to the Gadolinium Contrast Agent Omniscan in Normal Human Differentiated Macrophages and Dermal Fibroblasts. Peter J. Wermuth, Francesco Del Galdo, Sankar Addya, Paolo Fortina and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 497. Activation of Sirt Attenuates Bleomycin Induced Scleroderma Through Inhibiting Mammalian Target of Rapamycin Activation. Xiaoxia Zhu, Jianhua Qiu, Qiong Liu, Minrui Liang 4 and Hejian Zou 5, Huashan Hospital, Fudan University, Shanghai, China, Neuroscience Center, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA, Boston, MA, Institute of Rheumatology, Immunology and Allergy,Shanghai Medical College, Fudan University, Shanghai, China, 4 Huashan Hospital,Fudan University,Shanghai, Shanghai, China, 5 Huashan Hospital, Shanghai, China 498. Wisp- Neutralization Reduces Gvhd-Induced Skin Fibrosis by Altering TSLP-OX40L Axis-Dependent Th Responses. Raphael Lemaire, Tim Burwell, Rachel Griffin, Julie Bakken, Joseph Madary, Lynne Murray, Ronald Herbst and Jane Connor, MedImmune LLC, Gaithersburg, MD 50 0 Program Book

253 ACR POSTER SESSION B 499. The Soluble Guanylate Cyclase Mediates Its Anti-Fibrotic Effects by Inhibiting TGF-β Signaling. Christian Beyer, Sonia C. Schindler, Alfiya Distler, Clara Dees, Helena Reichert, Hümeyra Akan, Peter Sandner, Oliver Distler 4, Georg Schett 5 and Joerg HW Distler 6, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Erlangen-Nuremberg, Erlangen, Germany, Bayer Health Care, Global Drug Discovery Common Mechanism Research, Wuppertal, Germany, 4 University Hospital Zurich, Zurich, Switzerland, 5 Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 6 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 500. Activation of Pregnane X Receptor Induces Regression of Experimental Dermal Fibrosis. Christian Beyer, Alla Skapenko, Alfiya Distler, Clara Dees, Helena Reichert, Louis E. Munoz, Jan Leipe 4, Hendrik Schulze-Koops, Oliver Distler 5, Georg Schett 6 and Joerg HW Distler 7, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, University of Munich, Munich, Germany, University of Erlangen-Nuremberg, Erlangen, Germany, 4 Division of Rheumatology and Clinical Immunology, Munich, Germany, 5 University Hospital Zurich, Zurich, Switzerland, 6 Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 7 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 50. Increased Periostin Levels in Patients with Systemic Sclerosis. Yukie Yamaguchi, Junya Ono, Miho Masuoka, Shoichiro Ohta 4, Kenji Izuhara, Zenro Ikezawa 5, Michiko Aihara and Kazuo Takahashi, Yokohama City University Graduate School of Medicine, Yokohama, Japan, Shino-Test Corporation, Sagamihara, Japan, Saga Medical School, Saga, Japan, 4 Saga medical School, Saga, Japan, 5 International University of Health and Welfare Atami Hospital, Atami, Japan 50. Hedgehog Signaling in Murine Chronic Sclerodermatous Graft-Versus-Host Disease. Pawel Zerr, Katrin Palumbo- Zerr, Alfiya Distler, Michal Tomcik, Stefan Vollath, Louis E. Munoz, Christian Beyer, Clara Dees, Friederike Egberts, Ilaria Tinazzi 4, Francesco Del Galdo 4, Oliver Distler 5, Georg Schett, Bernd M. Spriewald 6 and Joerg HW Distler 7, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, Department of Dermatology, Schleswig-Holstein University Hospital, Campus Kiel, Kiel, Germany, 4 Scleroderma Research Program, Leeds Institute of Molecular Medicine, Division of Musculoskeletal Diseases, University of Leeds, Leeds, United Kingdom, 5 Center of Experimental Rheumatology and Zurich Center of Integrative Human Physiology, University Hospital Zurich, Zurich, Switzerland, 6 Department of Internal Medicine V, University of Erlangen-Nuremberg, Erlangen, Germany, 7 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 50. Effect of Thiol Antioxidants On the Profibrotic Phenotype of Scleroderma Dermal Fibroblasts. Pei-Suen Tsou, Beatrix Balogh, Adam J. Pinney, Elena Schiopu, Dinesh Khanna and Alisa E. Koch, University of Michigan Medical School, Ann Arbor, MI, University of Michigan, Ann Arbor, MI 504. A Possible Contribution of Visfatin to the Resolution of Skin Sclerosis in Patients with Diffuse Cutaneous Systemic Sclerosis Via a Direct Anti-Fibrotic Effect On Dermal Fibroblasts and Th Polarization of the Immune Response. Tetsuo Toyama, Yoshihide Asano, Yuri Masui, Sayaka Shibata, Kaname Akamata, Shinji Noda, Naohiko Aozasa, Takashi Taniguchi, Takehiro Takahashi, Yohei Ichimura, Hayakazu Sumida, Koichi Yanaba, Takafumi Kadono and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan 505. Inactivation of Tankyrases Ameliorates Canonical Wnt Signaling and Prevents Experimental Fibrosis. Alfiya Distler, Lisa Deloch, Jingang Huang, Clara Dees, Neng Yu Lin, Christian Beyer, Oliver Distler, Georg A. Schett 4 and Joerg HW Distler 4, Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, University of Erlangen- Nuremberg, Erlangen, Germany, University Hospital Zurich, Zurich, Switzerland, 4 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 506. Primary Human Scleroderma Dermal Endothelial Cells Exhibit Defective Angiogenesis. Pei-Suen Tsou, Bradley J. Rabquer, Beatrix Balogh, Ann Kendzicky, Bashar Kahaleh, Elena Schiopu, Dinesh Khanna and Alisa E. Koch, University of Michigan Medical School, Ann Arbor, MI, University of Toledo, Toledo, OH, University of Michigan, Ann Arbor, MI 507. Propylthiouracil Reduces Fibrosis in Chronic Oxidant Stress Mouse Model of Scleroderma. Gianluca Bagnato, Alessandra Bitto, Natasha Irrera, Gabriele Pizzino, Neal Roberts, Maurizio Cinquegrani, Donatella Sangari, Francesco Squadrito, Gianfilippo Bagnato and Antonino Saitta, University of Messina, Messina, Italy, Medical College of Virginia, Richmond, VA 508. Simvastatin Attenuates Pulmonary Fibrosis in a Murine Model of Systemic Sclerosis. Gianluca Bagnato, Alessandra Bitto, Natasha Irrera, Gabriele Pizzino, Donatella Sangari, Maurizio Cinquegrani, Neal Roberts, Gianfilippo Bagnato, Francesco Squadrito and Antonino Saitta, University of Messina, Messina, Italy, Medical College of Virginia, Richmond, VA 0 Program Book 5

254 ACR POSTER SESSION B Correlates of Skin Gene Expression Profile in Systemic Sclerosis. Shervin Assassi, Jeffrey T. Chang, Filemon K. Tan, Minghua Wu, Gloria A. Salazar Cintora, Irum Zaheer, Dinesh Khanna, Daniel E. Furst 4 and Maureen D. Mayes, Univ of Texas Health Science at Houston, Houston, TX, Methodist Hospital, Houston, TX, University of Michigan, Ann Arbor, MI, 4 UCLA Medical School, Los Angeles, CA 50. Critical Role of the Adhesion Receptor Dnax Accessory Molecule- (DNAM-) in the Development of Inflammation-Driven Dermal Fibrosis in Mouse Model of Systemic Sclerosis. Jerome Avouac, Muriel Elhai, Michal Tomcik, Manuel Friese 4, Marco Colonna 5, Günter Bernhardt 6, andre Kahan, Gilles Chiocchia 7, Joerg HW Distler 8 and Yannick Allanore, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, Paris Descartes University, INSERM U0 6, Institut Cochin, Sorbonne Paris Cité, Paris, France, Institute of Rheumatology, Department of Rheumatology, st Faculty of Medicine, Charles University, Prague, Czech Republic, 4 Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, 5 Department of Immunology, St. Louis, MO, 6 Institute of Immunology, Hannover Medical School, Hannover, Germany, 7 Institut Cochin - INSERM U06 - CNRS (UMR 804), Paris, France, 8 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 5. Low Circulating Endothelial Progenitor Cell Levels and High VEGF Serum Levels Are Associated with the Late Nailfold Capillaroscopic Pattern in Systemic Sclerosis. Jerome Avouac, Maeva Vallucci, Vanessa Smith, Barbara Ruiz, Alberto Sulli 4, Carmen Pizzorni 4, Gilles Chiocchia 5, Maurizio Cutolo 4 and Yannick Allanore, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, Paris Descartes University, INSERM U06, Institut Cochin, Sorbonne Paris Cité, Paris, France, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 4 Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, 5 Institut Cochin - INSERM U06 - CNRS (UMR 804), Paris, France 5. Bleomycin Delivery by Osmotic Pump: A Superior Model for Human ILD. Rebecca Lee, Michael Bonner, Charles Reese, Elena Tourkina, Zoltan Hajdu, Jing Zhang, Richard Visconti and Stanley Hoffman, Medical University of South Carolina, Charleston, SC 5. TSLP Receptor Deficiency Reduces IL- Expression and Prevents Fibrosis in Experimental Scleroderma. Alicia Usategui, Vanessa Miranda, Gabriel Criado, Manuel J. Del Rey, Elena Izquierdo, Warren J. Leonard and Jose L. Pablos, Instituto de Investigación Hospital de Octubre (I+), Madrid, Spain, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 0 Program Book 54. Differences in the Activation Levels and Expression Patterns of the Molecular Targets of Tyrosine Kinase Inhibitors May Account for the Heterogeneous Treatment Responses. Britta Maurer, Alfiya Akhmetshina, Renate E. Gay, Beat A. Michel, Steffen Gay, Joerg H. W. Distler and Oliver Distler, Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland 55. Pharmacological Blockade of Adenosine AA Receptors (AAR) Prevents Radiation-Induced Dermal Injury. Miguel Perez Aso, Yee C. Low, Obinna Ezeamuzie, Jamie Levine and Bruce N. Cronstein, NYU School of Medicine, New York, NY, New York Univ Medical Center, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 56. TSLP Upregulation in Human SSc Skin and Induction of Overlapping Profibrotic Genes and Intracellular Signaling with IL- and TGFb. Romy Christmann, Allison Mathes, Giuseppina Stifano, Alsya J. Affandi, andreea Bujor, Cristina Padilla and Robert Lafyatis, Boston University, Boston, MA 57. TLR9 Signaling in Fibroblasts Promotes Pro-Fibrotic Responses Via TGF-Beta. Yang Yang, Feng Fang, Lei Liu, Junjie Shangguan, Boping Ye and John Varga, China Pharmaceutical University, Nanjing, China, Northwestern University, Chicago, IL 58. Damage-Associated Endogenous TLR4 Ligand Fibronectin- EDA Is Overexpressed in Scleroderma and Drives Persistent Fibrosis Via TLR 4 and Inhibition of TLR4 Prevents and Reverses Experimental Dermal Fibrosis: Novel Target for Scleroderma Therapy. Swati Bhattacharyya, Zenshiro Tamaki, Wenxia Wang, Paul Hoover, Adam Booth 4, Alyssa Dreffs 5, Monique E. Hinchcliff 6, Feng Fang, Spiro Getsios, Hang Yin 7, Eric S. White 5 and John Varga 8, Northwestern University, Feinberg School of Medicine, Chicago, IL, Northwestern Univ Med School, Chicago, IL, Chicago, IL, Northwestern University, Chicago, IL, 4 Ann Arbor, MI, 5 University of Michigan Medical School, Ann Arbor, MI, 6 Northwestern Univ Med School, Chicago, IL, 7 University of Colorado at Boulder, Boulder, CO, 8 Northwestern University Medical School, Chicago, IL 59. Heterogeneous Nuclear RNP-K Is a Novel Cold-Related Autoantigen in Patients with Raynaud s Phenomenon. Satoshi Serada, Minoru Fujimoto and Tetsuji Naka, National Institute of Biomedical Innovation, Ibaraki, Japan 50. Role of /5-Lipoxygenase (LOX) in Patients with Systemic Sclerosis. Hirahito Endo, Makoto Kabraki, Koutarou Shikano, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kanako Kitahara, Kaichi Kaneko, Yoshie Kusunoki, Natsuko Kusunoki, Kenji Takagi, Tomoko Hasunuma and Shinichi Kawai, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

255 ACR POSTER SESSION B 5. A Possible Contribution of Decreased Cathepsin V Expression to the Development of Dermal Fibrosis, Proliferative Vasculopathy, and Altered Keratinocyte Phenotype in Systemic Sclerosis. Yoshihide Asano, Shinji Noda, Takehiro Takahashi, Sayaka Shibata, Kaname Akamata, Naohiko Aozasa, Takashi Taniguchi, Yohei Ichimura, Tetsuo Toyama, Hayakazu Sumida, Yoshihiro Kuwano, Koichi Yanaba and Shinichi Sato, University of Tokyo Graduate School of Medicine, Tokyo, Japan 5. Differential Response to Endoplasmic Reticulum Stress between Alveolar Epithelial Cells and Lung Fibroblasts in Systemic Sclerosis. Jun Liang, Tanjina Akter, Ilia Atanelishvili, Richard M. Silver and Galina S. Bogatkevich, Medical University of SC, Charleston, SC, Medical University of SC, Charleston Vasculitis 5. Systemic Vasculitis and Pregnancy: a Multicenter Study on Maternal and Neonatal Outcome of 4 Prospectively Followed Pregnancies. Micaela Fredi, Maria Grazia Lazzaroni, Chiari Tani, Véronique Ramoni, Maria Gerosa 4, Flora Inverardi 5, Laura andreoli, Laura Trespidi 6, Mario Motta 7, Andrea Lojacono 8, Renato Sinico 9, Antonio Brucato 0, Roberto Caporali 5, Pier Luigi Meroni 4, Carlomaurizio Montecucco 5, Marta Mosca and Angela Tincani, Rheumatology Unit, University of Brescia, Brescia, Italy, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, IRCCS Policlinico San Matteo Foundation and University of Pavia and USC Internal Medicine, Bergamo, Italy, 4 Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 5 Division of Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, 6 Milan, 7 Neonathology and NICU, Spedali Civili, Brescia, Italy, 8 Obstetric and Gynecology of Brescia, Brescia, Italy, 9 Ospedale San Carlo Borromeo, Milano, Italy, 0 USC Internal Medicine, Ospedali Riuniti, Bergamo, Italy 54. The Use of the International Classification of Function, Disability and Health As a Conceptual Framework for Comparison of the Content of Core Outcome Instruments with the Patient Perspective in Vasculitis. Nataliya Milman, Peter A. Merkel, Annelies Boonen, Lee Strunin 4, Ryan Borg 4 and Peter Tugwell 5, Ottawa Hospital, Riverside Campus, Ottawa, ON, University of Pennsylvania, Philadelphia, PA, University Hospital Maastricht, Maastricht, Netherlands, 4 Boston University School of Public Health, Boston, MA, 5 University of Ottawa, Ottawa General Hospital, Ottawa, ON 55. Determinants of Poor Quality of Life in ANCA Associated Vasculitis (AAV). Neil Basu, Andrew McClean, Raashid Luqmani, Lorraine Harper, Oliver Flossmann 4, David Jayne 5, Mark Little 6, Esther N. Amft 7, Neeraj Dhaun 8, John McLaren 9, Vinod Kumar 0, Lars Erwig, Gareth T. Jones, David M. Reid and Gary J. Macfarlane, University of Aberdeen, Aberdeen, United Kingdom, University of Birmingham, Birmingham, United Kingdom, University of Oxford, Oxford, United Kingdom, 4 Royal Berkshire Hospital, Reading, United Kingdom, 5 Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 6 Trinity College Dublin, Dublin, Ireland, 7 Western General Hospital, Edinburgh, United Kingdom, 8 Edinburgh Royal Infirmary, Edinburgh, United Kingdom, 9 NHS Fife, Whyteman s Brae Hospital, Kirkcaldy, United Kingdom, 0 Ninewells Hospital, Dundee, United Kingdom 56. Patient Reported Outcomes in ANCA-Associated Vasculitis. A Prospective Comparison Between Birmingham Vasculitis Activity Score and Routine Assessment of Patient Index Data. Osama ElSallabi, Joel A. Block and Antoine Sreih, Rush University Medical Center, Chicago, IL 57. Patient Global Assessments for Disease Activity Are Predictive of Future Flare in Granulomatosis with Polyangiitis (Wegener s). Gunnar Tomasson, John C. Davis Jr., Gary S. Hoffman, W. Joseph McCune 4, Ulrich Specks 5, Robert F. Spiera 6, E. William St. Clair 7, John H. Stone 8 and Peter A. Merkel 9, University of Iceland, Reykjavik, Iceland, Genentech, Inc, South San Francisco, CA, Cleveland Clinic, Cleveland, OH, 4 University of Michigan, Ann Arbor, MI, 5 Mayo Clinic, Rochester, MN, 6 Hospital for Special Surgery, New York, NY, 7 Duke University Medical Center, Durham, NC, 8 Massachusetts General Hospital, Boston, MA, 9 University of Pennsylvania, Philadelphia, PA 58. Assessing Fatigue in Systemic Vasculitis from the Patient s Perspective. Peter C. Grayson, Naomi Amudala, Carol McAlear, Renée Leduc, Denise Shereff, Rachel Richesson, Liana Fraenkel 4 and Peter A. Merkel 5, Boston University Medical Center, Boston, MA, Vasculitis Clinical Research Consortium, University of Pennsylvania, Philadelphia, University of South Florida, Tampa, FL, 4 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 5 University of Pennsylvania, Philadelphia, PA 59. Upper Airway Gene Expression Profiling in Granulomatosis with Polyangiitis. Peter C. Grayson, Katrina Steiling, Paul A. Monach, Ji Xiao, Xiaohui Zhang, Yuriy Alekseyev, Stephano Monti, Avrum Spira and Peter A. Merkel 4, Boston University Medical Center, Boston, MA, Boston University, Boston, MA, Boston University Medial Center, Boston, MA, 4 University of Pennsylvania, Philadelphia, PA 50. Plasma Cell Analysis As a Biomarker for Disease Activity in Patients with Granulomatosis with Polyangiitis. Bimba F. Hoyer, Adriano Taddeo, Maika Rothkegel, Gerd R. Burmester, Andreas H. Radbruch and Falk Hiepe 4, Charite University Hospital, Berlin, Germany, Deutsches Rheumaforschungszentrum, Berlin, Germany, Charité University Medicine Berlin, Berlin, Germany, 4 Charité University Hospital Berlin, Berlin, Germany 5. Comparative Proteomic Analysis of Neutrophils between Microscopic Polyangiitis and Granulomatosis with Polyangiitis. Teisuke Uchida, Kouhei Nagai, Toshiyuki Sato, 0 Program Book 5

256 ACR POSTER SESSION B Mitsumi Arito, Nobuko Iizuka, Manae Kurokawa, Naoya Suematsu, Kazuki Okamoto, Shoichi Ozaki 4 and Tomohiro Kato, Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine,, Kawasaki, Japan, St. Mariannna University Graduate School of Medicine., Kawasaki, Japan, St. Marianna University School of Medicine., Kawasaki, Japan 5. Serum Angiopoietin- Level Reflects the Disease Activity and Renal Function in Antineutrophilic Cytoplasmic Antibody-Associated Vasculitis. Yoko Wada, Hiroe Sato, Takeshi Nakatsue, Shuichi Murakami, Takeshi Kuroda, Masaaki Nakano and Ichiei Narita, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, Niigata University, Niigata, Japan, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan 5. Increased Circulating FoxP+ T-Cells in Patients with Granulomatosis with Polyangiitis Are Attributed to an Increase in the Non-Suppressor FoxPLow CD45RO+ TReg Cell Subpopulation. Wayel H. Abdulahad, Coen A. Stegeman, Minke G. Huitema, Abraham Rutgers, Peter Heeringa, Pieter C. Limburg and Cees G.M. Kallenberg, University Medical Center Groningen, Groningen, Netherlands, University Medical Center Groningen, Netherlands 54. IgG4 Plasma Cell Infiltration in Granulomatosis with Polyangiitis (formerly Wegener s) Lung Biopsies. Mollie Carruthers, Shweta Shinagare, Arezou Khosroshahi, Vikram Deshpande and John H. Stone, Massachusetts General Hospital, Boston, MA 55. Genetic Background of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Japanese Population: Association of STAT4 with Myeloperoxidase Antineutrophil Cytoplasmic Antibody-Positive Vasculitis. Aya Kawasaki, Naoya Inoue, Chihiro Ajimi, Ikue Ito, Ken-ei Sada, Shigeto Kobayashi, Hidehiro Yamada 4, Hiroshi Furukawa 5, Makoto Tomita 6, Takayuki Sumida, Shigeto Tohma 5, Nobuyuki Miyasaka 6, Shoichi Ozaki 4, Hiroshi Hashimoto 7, Hiroshi Makino, Masayoshi Harigai 6 and Naoyuki Tsuchiya, University of Tsukuba, Tsukuba, Japan, Okayama University, Okayama, Japan, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4 St. Marianna University, Kawasaki, Japan, 5 Sagamihara National Hospital, National Hospital Organization, Sagamihara, Japan, 6 Tokyo Medical and Dental University, Tokyo, Japan, 7 Juntendo University School of Medicine, Tokyo, Japan 56. Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen. Yuji Yamanishi, Toshiko Ito-Ihara, Shigeto Kobayashi, Peter Y. Shane 4, Gary S. Firestein 5, Hiroshi Hashimoto 6 and Kazuo Suzuki 7, Hiroshima Rheumatology Clinic, Hiroshima, Japan, Kyoto University Hospital, Kyoto, Japan, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4 Tokyo Medical and Dental University, Tokyo, Japan, 5 UCSD School of Medicine, La Jolla, CA, 6 Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, 7 National Institute of Infectious Diseases, Tokyo, Japan 57. Pathogenesis of Atherosclerosis in Granulomatosis Polyangiitis. Rula Hajj-Ali, Roy L. Silverstein, Gary S. Hoffman and Carol A. Langford 4, Cleveland Clinic Foundation, Cleveland, OH, Medical College of Wisconsin, Milwaukee, WI, Cleveland Clinic Found A50, Cleveland, OH, 4 Cleveland Clinic, Cleveland, OH 58. ANCA-Associated Vasculitis in Hispanic Americans: An Unrecognized Severity. Ranadeep Mandhadi, Fadi Aldaghlawi, Asad Khan, Vajiha Irshad, Joel A. Block and Antoine Sreih, Mount Sinai Hospital, Chicago, IL, Rush University Medical Center, Chicago, IL, Stroger Hospital of Cook County, Chicago, IL 59. Microscopic Polyangiitis: A Large Single Center Series. Leslie D. Wilke, Guy P. Fiocco and Marilyn Prince-Fiocco, Scott & White Memorial Center, Temple, TX, Scott & White Clinic, Temple, TX, Temple, TX 540. Practice Patterns in the Treatment of ANCA-Associated Vasculitis: Exploring Differences among Subspecialties at a Single Academic Medical Center. Lindsy J. Forbess, Kenneth W. Griffin and Robert F. Spiera, Cedars-Sinai Medical Center, Los Angeles, CA, Weill Cornell Medical College, New York, NY, Hospital for Special Surgery, New York, NY 54. Does Leflunomide Have a Place As Remission Maintenance Therapy in ANCA-Associated Vasculitis? A Bayesian Network Meta-Analysis with Hypothesis Driven Sensitivity Analyses to Adjust for Potential Biases. Glen S. Hazlewood, Claudia Metzler, George A. Tomlinson, Wolfgang L. Gross, Brian M. Feldman 4, Loic Guillevin 5 and Christian Pagnoux 6, University of Toronto, Toronto, ON, University of Lubeck, Bad Branstedy, Germany, Medical University at Lubeck, Lubeck, Germany, 4 The Hospital for Sick Children, Toronto, ON, 5 Cochin University Hospital, Paris, France, 6 Mount Sinai Hospital, Toronto, ON 54. The Efficacy of Rituximab Vs Cyclophosphamide for Treatment of Renal Disease in ANCA-Associated Vasculitis: The RAVE Trial Geetha D, Fervenza FC for the RAVE-Itn Research Group. Duvuru Geetha and Fernando Fervenza, Johns Hopkins University, Baltimore, MD, Mayo Clinic, Rochester, MN 54. Rituximab for ANCA-Associated Vasculitis: A Meta-Analysis of Randomized Trials. Carolina Mejia and Carlos J. Lozada, Mount Sinai Medical Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL 544. Long-Term Outcome of Patients with Granulomatosis with Polyangiitis (Wegener s) Treated with Rituximab. Lama Azar, Jason Springer, Meng Xu, Tiffany M. Clark, Carol A. Langford and Gary S. Hoffman, Cleveland Clinic Foundation, Cleveland, OH, Cleveland Clinic, Cleveland, OH 545. Long-Term Follow-up of 8 Polyarteritis Nodosa and Microscopic Polyangiitis without Poor-Prognosis Factors Program Book

257 ACR POSTER SESSION B Maxime Samson, Xavier Puechal, Hervé Devilliers, Camillo Ribi 4, Pascal Cohen 5, Boris Bienvenu 6, Christian Pagnoux 7, Luc Mouthon 8, Loic Guillevin 9 and French Vasculitis Study Group FVSG 5, Hôpital Cochin, University Paris Descartes, Paris, France, Hôpital Cochin, Paris, France, CHU Dijon, Dijon, France, 4 Hôpital Universitaire Cantonal de Genève, Geneve, Switzerland, 5 Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, Paris, France., Paris, France, 6 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, 7 Mount Sinai Hospital, Toronto, ON, 8 Hopital Cochim, Paris, France, 9 Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France 546. Rhinosinusits and Nasal Polyps in the Diagnosis and Follow up of Patients with Eosinophilic Granulomatosis with Polyangitis (ex-churg Strauss Syndrome). Chiara Baldini, Veronica Seccia, Manuela Latorre, Paolo Iannicelli, Daniela Martini, Francesco Ferro, Nicoletta Luciano, Antonio Tavoni, Stefano Sellari Franceschini and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy, Unit of Otorhinolaryngology, Department of Neuroscience, University of Pisa, Pisa, Italy, Pisa, Italy, Pneumology Unit, Italy 547. A 4 Plus Infusion Protocol of Rituximab Provides Long- Term Beneficial Effects in Patients with HCV-Associated Mixed Cryoglobulinemia with Membranoproliferative Nephritis and Severe Polyneuropathy. Dario Roccatello, Savino Sciascia, Simone Baldovino and Daniela Rossi, Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom 548. Cutaneous Vasculitis as a Paraneoplastic Syndrome. Javier Loricera, Vanesa Calvo-Rio, Francisco Ortiz Sanjuan, Marcos Antonio Gonzalez-Lopez, Hector Fernandez-Llaca, Javier Rueda-Gotor, Carmen Gonzalez-Vela, Cristina Mata-Arnaiz, Miguel A. Gonzalez-Gay and Ricardo Blanco, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain 549. Sibling Relative Risk and Heritability of Kawasaki Disease: A Nationwide Population Study in Taiwan. I-Jun Chou, Chang-Fu Kuo, Jing-Long Huang, Chang-Teng Wu, Shao- Hsuan Hsia and Hsiao-Chun Chang, Chang Gung Memorial Hospital, Taoyuan, Taiwan, University of Nottingham, Nottingham, United Kingdom 550. Long-Term Outcomes of Patients with Reversible Cerebral Vasoconstriction Syndromes (RCVS). Seby John, Leonard H. Calabrese, Stewart Tepper, Mark Stillman, Ken Uchino and Rula Hajj-Ali, Cleveland Clinic Foundation, Cleveland, OH 55. Primary Angiitis of the Central Nervous System: Description of the First 5 Adult Patients Enrolled in the French COVAC Cohort. Hubert de Boysson, Mathieu Zuber, Olivier Naggara, Jean-Philippe Neau 4, Françoise Gray 5, Marie-Germaine Bousser 6, Isabelle Crassard 6, Emmanuel Touze 7, Pierre-Olivier Couraud 8, Philippe Kerschen 9, Catherine Oppenheim, Olivier Detante 0, Anthony Faivre, Nicolas Gaillard, Caroline Arquizan, Boris Bienvenu 4, Antoine Neel 5, Loic Guillevin, Christian Pagnoux 6 and French Vasculitis Study Group and NeuroVascular Society 7, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, Department of Neurology, Groupe Hospitalier Saint-Joseph, Université Paris Descartes, Paris, France, Department of Neuroradiology, Hôpital Sainte-Anne, Paris, France, 4 Department of Neurology, Centre Hospitalier Universitaire La Milétrie, Poitiers, France, 5 Department of Pathology, APHP Hôpital Lariboisière, Université Paris Diderot, Paris, France, 6 Department of Neurology, APHP Hôpital Lariboisière, Université Paris Diderot, Paris, France, 7 Department of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, Paris, France, 8 Department of Cellular Biology, Institut Cochin, Paris, France, 9 Department of Neurology, Centre Hospitalier Universitaire Henri Mondor, Créteil, France, 0 Department of Neurology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France, Department of Neurology, Hôpital d Instruction des Armées Saint-Anne, Toulon, France, Department of Neurology, Centre Hospitalier de Perpignan, Perpignan, France, Department of Neurology, Hôpital Gui de Chauliac, Université Montpellier, Montpellier, France, 4 Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, 5 Department of Internal Medicine, Centre Hospitalier Universitaire de Nantes, Nantes, France, 6 Mount Sinai Hospital, Toronto, ON, 7 Paris, France 55. Clinical Correlates, Treatment Outcomes and Predictors of Vasculitis Associated with Rheumatoid Arthritis in the Biologic Era : A Case-Control Study. Ashima Makol, Cynthia S. Crowson, Eric L. Matteson and Kenneth J. Warrington, Mayo Clinic, Rochester, MN Clinical Practice/Patient Care 55. The Effect of Knee Replacement on Participation Outcomes: The Multicenter Osteoarthritis Study and Osteoarthritis Initiative. Jessica L. Maxwell, Jingbo Niu, Julie J. Keysor, Tuhina Neogi, Tianzhong Yang, Michael C. Nevitt, Jasvinder A. Singh 4, Laura Frey-Law 5 and David T. Felson, Boston Univ Sargent College, Boston, MA, Boston Univ School of Medicine, Boston, MA, University of California-San Francisco, San Francisco, CA, 4 University of Alabama at Birmingham, Birmingham, AL, 5 University of Iowa, Iowa City, IA 554. Clusters of Fatigue- a Comparison between Persons with Systemic Lupus Erythematosus and Age and Gender Matched Controls. Susanne Pettersson, Karin Eriksson, Carina Boström, Elisabet Svenungsson, Iva Gunnarsson and Elisabet MB Welin Henriksson 4, Karolinska University 0 Program Book 55

258 ACR POSTER SESSION B Hospital, Stockholm, Sweden, Division of Physiotherapy, Karolinska Institutet Huddinge, Stockholm, Sweden, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska Institutet Rheum, Stockholm, Sweden 555. Minimal Clinically Important Difference for Seven Measures of Fatigue in Patients with Systemic Lupus Erythematosus Results From a Swedish Setting. Susanne Pettersson, Ingrid E. Lundberg and Elisabet MB Welin Henriksson, Karolinska University Hospital, Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, Karolinska Institutet Rheum, Stockholm, Sweden 556. The Effect of Ginger Therapy on Symptoms of Osteoarthritis: An Open Pilot Study. Tessa Therkleson, Edith Cowan University, Perth, Australia 557. What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center? Marvin Vaishnani and Feyrouz T. Al- Ashkar, Cleveland Clinic,Lorain Institute, Lorain, OH 558. It Gets Me Down Every Single Day : Are Men with Rheumatoid Arthritis Getting the Support They Need? Caroline A. Flurey, Marianne Morris, Jon Pollock, Rodney A. Hughes, Pamela Richards and Sarah Hewlett, University of the West of England, Bristol, United Kingdom, St. Peters Hospital, Chertsey Surrey, United Kingdom, University of Bristol, Bristol, United Kingdom 559. Treatment Outcomes from a Nurse-Led Rheumatology Clinic in Monitoring of anti-tnf Therapy a Randomised Controlled Trial. Ingrid Larsson, Bengt Fridlund, Barbro Arvidsson, Annika Teleman and Stefan Bergman 4, School of Health Sciences, Jönköping University, Jönköping, Sweden, School of Social and Health Sciences, Halmstad University, Halmstad, Sweden, Spenshults Hosp of Rheum Dis, Oskarstrom, Sweden, 4 R&D Center, Spenshult Hospital, Oskarström, Sweden 560. What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review. Annelieke Pasma, Adriaan van t Spijker, Jan van Busschbach, Johanna M.W. Hazes and Jolanda J. Luime, Erasmus MC University Medical Centre, Rotterdam, Netherlands, Erasmus MC - University Medical Center, Rotterdam, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands 56. Factors Influencing Implementation of Intensive Treatment Strategies for Early Rheumatoid Arthritis. Sabrina Meyfroidt, Diederik De Cock, Kristien Van der Elst, Laura van Hulst, Marlies Hulscher, Johan Joly, Rene Westhovens and Patrick Verschueren, University Hospitals KULeuven, Leuven, Belgium, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 56. Benign Joint Hypermobility Syndrome More Common Than Expected, Both in Controls and in SLE Patients. Pia Malcus-Johnsson, Lotta Köhlin, Gunnar K. Sturfelt and Ola Nived, Department of Rheumatology, University Hospital, Lund, Sweden, Lund University, Lund, Sweden, University Hospital - Lund, Lund, Sweden 56. Is Automated DATA Capture As Reliable As Manual DATA Entry in Survey Based Research? Rachel A. Mikolaitis, Jessica Cornejo, Chris Alonzo, Joel A. Block and Meenakshi Jolly, Rush University Medical Center, Chicago, IL 564. Misperceptions of FMS Patients about Their Disease. Robert S. Katz, Hannah Bond, Jessica L. Polyak, Lauren Kwan and Susan Shott, Rush University Medical Center, Chicago, IL, Rheumatology Associates, Chicago, IL 565. How FMS Patients Become Workaholics. Robert S. Katz, Hannah Bond, Jessica L. Polyak, Lauren Kwan and Susan Shott, Rush University Medical Center, Chicago, IL, Rheumatology Associates, Chicago, IL 566. Fibromyalgia s Impact on Relationships. Robert S. Katz, Alexandra Small, Sharon M. Ferbert and Susan Shott, Rush University Medical Center, Chicago, IL, University of Illinois Medical School, Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL 567. Sleep Study with Armband Device in Fibromyalgia Patients: Fibromyalgia Patients Don t Rest Their Weary Muscles. Robert S. Katz, Alexandra Small, Ben J. Small and Jessica L. Polyak 4, Rush University Medical Center, Chicago, IL, University of Illinois Medical School, Rush University Medical School, Chicago, IL, 4 Rheumatology Associates, Chicago, IL 568. A Survey Study of Methotrexate Use by Rheumatologists and Their Patients with Rheumatoid Arthritis. Peter Nash and Dave Nicholls, University of Queensland, Brisbane, Australia, Coast Joint Care, Maroochydore, Australia 569. Optimizing Care for Patients with Rheumatoid Arthritis Newly Treated with Biologics by Evaluating Health Status with AIMS-. Mie Fusama, Hideko Nakahara, Keisuke Kawamoto, Satoko Nozato, Midori Taguchi, Kohji Nishioka, Shinji Higa, Eiji Takeuchi, Kayoko Higashi, Masao Yukioka, Tsuyoshi Igarashi, Taro Kuritani, Keiji Maeda and Yasushi Miura, Kobe University, Kobe, Japan, NTT West Osaka Hospital, Osaka, Japan, Yukioka Hospital, Osaka, Japan 570. Discrepancies between Disease Activity and Disease Burden. Margot J.M. Walter, Adriaan van t Spijker, Annelieke Pasma, Johanna M.W. Hazes and Jolanda J. Luime, Erasmus MC - University Medical Center, Rotterdam, Netherlands, Erasmus MC University Medical Centre, Rotterdam, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands 57. Pain and Fatigue in Adult Patients with Rheumatoid Arthritis - Associations with Demographic Factors, Disease Related Factors, Body Awareness, Emotional and Psychosocial Factors. Helena Lööf, Fredrik Saboonchi, Elisabet Welin Henriksson, Staffan Lindblad 4 and Unn- Britt Johansson, Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden, 56 0 Program Book

259 ACR POSTER SESSION B Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Medicine, Stockholm, Sweden, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society., Stockholm, Sweden, 4 Karolinska University Hospital, Stockholm, Sweden 57. Developing a Health Literacy Universal Precautions Toolkit for Rheumatology. Leigh F. Callahan, Victoria Hawk, Kimberly A. Broucksou, Betsy Hackney, Deb MacDonald, Lindsay Penny Prizer, Beth L. Jonas, Thomas K. Bauer 4, Rima E. Rudd 5, Cindy Brach 6 and Darren Dewalt, University of North Carolina, Chapel Hill, NC, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of North Carolina Chapel Hill, Chapel Hill, NC, 4 Winston Salem, NC, 5 Harvard School of Public Health, Boston, MA, 6 Agency for Health Care Research and Quality, Rockville, MD 57. Baseline Screening Recommendations for Rheumatoid Arthritis Patients Treated with Disease Modifying Anti- Rheumatic Drugs: Does an Educational Intervention Change Practice in an Outpatient Clinic? Debra C. Lloyd, John N. Mecchella and Daniel Albert, Dartmouth- Hitchcock Med Ctr, Lebanon, NH, Dartmouth Hitchcock Medical Center, Lebanon, NH, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH 574. The Correlation of Disease Activity, Functional Status and Quality of Life with Sleep Disturbance and Balance Status in Ankylosing Spondylitis (AS). Mehmet Tuncay Duruoz, Zuhre Sari Surmeli and Esra Topcu, Celal Bayar University Medical School, Manisa, Turkey 575. The Impact of Targeted Exercise Intervention on Health Outcomes in Rheumatoid Arthritis. Laura J. Durcan, Fiona Wilson, Finbar (Barry) D. O Shea and Gaye Cunnane, St James s Hospital, Dublin, Ireland, Trinity College, Dublin, Ireland 576. Identifying Subgroups of Rheumatoid Arthritis Patients Based On Levels of Pain, Disability, and Depression. Taylor Draper, Sarah R. Ormseth, M. Custodio, M.H. Weisman, M.R. Irwin and Perry M. Nicassio, Loma Linda University, Loma Linda, CA, UCLA, Los Angeles, CA, Cedars-Sinai Medical Center, Los Angeles, CA 577. Barriers to Recruit Unaffected Family Members of Patients with Rheumatoid Arthritis. Axel Finckh, A. Debost-Legrand, Martin Soubrier, I. von Muehlenen 4, I. Creveaux, JJ Dubost, MH Papon, H. Ayadi 5, P. Migliorini 6, E. Petit-Teixeira 7, F. Cornélis and Eprac 8, Geneva University Hospitals, Geneva 4, Switzerland, GenHotel-Auvergne, Clermon-Ferrand, France, CHU CLERMONT-FERRAnd, Clermont-Ferrand, France, 4 Universitäts-Poliklinik, Felix- Platter Spital, Basel, Switzerland, 5 Sfax university, Sfax, Tunisia, 6 Pisa university hospital, Pisa, Italy, 7 GenHotel-Evry- EA88 6, Evry, France, 8 Clermont-Ferrand, France 578. How Disease Activity Trajectories Affect the Willingness to Change Treatment. Paul Falzer and Liana Fraenkel, VA Connecticut Healthcare System, New Haven, CT, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT Rehabilitation Sciences 579. Why Do We Need to Pilot Interventions? Essential Refinements Identified During Pilots of a Fatigue Intervention. Emma Dures, Nicholas Ambler, Debbie Fletcher, Denise Pope, Frances Robinson 4, Royston Rooke 4 and Sarah Hewlett, University of the West of England, Bristol, United Kingdom, Frenchay Hospital, Bristol, United Kingdom, University Hospitals Bristol, United Kingdom, 4 University of Bristol, Bristol, United Kingdom 580. The Relationship between Perceived Cognitive Dysfunction and Objective Neuropsychological Performance in Persons with Rheumatoid Arthritis. So Young Shin, Patricia P. Katz and Laura J. Julian, University of California San Francisco, San Francisco, CA 58. The Association between Symptoms, Pain Coping Strategies, and Physical Activity among People with Symptomatic Knee and Hip Osteoarthritis. Susan L. Murphy, Anna Kratz, David A. Williams and Michael E. Geisser, University of Michigan, Ann Arbor, MI, Univ of MI Hlth System-Lobby M, Ann Arbor, MI 58. Long Term Costs and Cost-Effectiveness of an Integrated Rehabilitation Programme for Chronic Knee Pain. Mike Hurley and Dr Nicola E. Walsh, St George s University of London, London, United Kingdom, University of the West of England Bristol, Bristol, United Kingdom 58. Therapist and Patient Perspectives On Exercise Adherence: Are We On the Same Page? Jill R. Blitz, Talitha Cox and Amber Richards, Children s Hospital Los Angeles, Los Angeles, CA, Children s Hospital of Los Angeles, Los Angeles, CA, Children s Hospital, Los Angeles California, Los Angeles, CA 584. Validity of the Nurses Health Study II Physical Activity Questionnaire (NHSPAQ) in Estimating Physical Activity in Adults with Rheumatoid Arthritis (RA). Maura D. Iversen, Thomas Quinn and Michelle A. Frits, Northeastern University, Department of Physical Therapy, and Brigham & Women s Hospital, Harvard Medical School, Boston, MA, Northeastern University, Boston, MA, Brigham and Women s Hospital, Boston, MA 585. Physical Activity and Timing of Discharge from Physical Therapy Following Total Knee Replacement. Carol A. Oatis, Wenjun Li, Milagros Rosal, David Ayers and Patricia D. Franklin, Arcadia University, Glenside, PA, University of Massachusetts Medical School, Worcester, MA 586. Resistance Exercise Training for Fibromyalgia: A Systematic Review. Angela J. Busch, Sandra Webber, Rachel Richards, Julia Bidonde, Candice Schachter, Laurel Schafer, Adrienne Danyliw 4, Anuradha Sawant 5, Vanina Dal Bello Haas 6 and Tamara Rader 7, University of Saskatchewan, Saskatoon, SK, North Vancouver, BC, Central Avenue 0 Program Book 57

260 ACR POSTER SESSION B Physiotherapy, Swift Current, SK, 4 Health Quality Council, SK, 5 London Health Sciences Center, ON, 6 McMaster University, Hamilton, ON, 7 University of Ottawa, Ottawa, ON 587. Despite Low Disease Activity Patients with Poly- and Dermatomyositis Perceive Activity Limitation, Reduced Grip Force and Quality of Life Longitudinally. Malin Regardt, Marie-Louise Schult, Ingrid E. Lundberg and Elisabet MB Welin Henriksson 4, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet., Stockholm, Sweden, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska Institutet Rheum, Stockholm, Sweden 588. Relationship Over Time between Beliefs, Motivation, and Worries about Physical Activity and Physical Activity Participation in Persons with Knee Osteoarthritis. Linda S. Ehrlich-Jones, Jungwha Lee, Dorothy D. Dunlop, Pamela A. Semanik, Min-Woong Sohn, Jing Song and Rowland W. Chang, Rehabilitation Institute Chicago, Chicago, IL, Northwestern University, Chicago, IL 589. Obesity and Rehabilitation Outcomes after Lower Extremity Arthroplasty. Soham Al Snih, Amol Karmarkar, Timothy A. Reistetter, Jinhyung Lee, Amit Kumar, James E. Graham and Kenneth J. Ottenbacher, University of Texas Medical Branch, Galveston, TX 590. Post-Operative Rehabilitation Provides Unmet Need for Better Patient Support and Advice Following Lumbar Spinal Fusion. Michael V. Hurley, James Greenwood and Dr Nicola E. Walsh, St George s University of London, London, United Kingdom, University College Hospital London, London, United Kingdom, University of the West of England Bristol, Bristol, United Kingdom 59. Efficacy of Neoprene Wrist Supports for Patients with Rheumatoid Arthritis. Kinue Matsuo, Koji Tateishi, Natsuko Nakagawa and Yasushi Miura, Kobe University Graduate School of Health Sciences, Kobe, Japan, Konan Kakogawa Hospital, Kakogawa, Japan 59. A Novel Approach to the Early Detection of Axial Spondyloarthritis in Patients with Inflammatory Bowel Disease: The Implementation of an Advanced Practice Physiotherapist Led Screening Program. Laura A. Passalent, Rebecca Morton, Khalid A. Alnaqbi, Nigil Haroon, Stephen Wolman 4, Mark Silverberg 5, A. Hillary Steinhart 5 and Robert D. Inman, Allied Health, Toronto Western Hospital, Toronto, ON, Toronto Western Hospital, Toronto, ON, Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON, 4 Toronto General Hospital, Toronto, ON, 5 Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, Toronto, ON 58 0 Program Book

261 ACR POSTER SESSION C Tuesday, NOVEMBER, 0 Poster Hall (Hall B) Antiphospholipid Syndrome 74. Pandemic Influenza Immunization in Primary Antiphospholipid Syndrome (PAPS): A Trigger to Autoantibody Production? Danielle M. Medeiros, Cleonice Bueno, Ana Cristina M. Ribeiro, Ana L. G. Calich, Karina Rossi Bonfiglioli, Vilma S. Viana, Jozelio F. Carvalho, Clovis Artur Silva and Eloisa Bonfá, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 75. ANTI-Factor Xa Antibodies ARE Significantly Increased in Patients with Systemic LUPUS Erythematosus and Antiphospholipid Syndrome. Bahar Artim-Esen, Charis Pericleous, Ian Mackie, Yiannis Ioannou, Anisur Rahman, David A. Isenberg and Ian Giles, University College London, London, United Kingdom 76. Lack of Correlation between Mannose-Binding Lectin Gene Polymorphisms and the Thickness of the Carotid Artery Intima-Media (IMT) in Primary Antiphspholipid Syndrome. Antonio Barrera-Cruz, Luis J. Jara-Quezada, Gabriela Medina and Miguel A. Saavedra Salinas 4, Instituto Mexicano del Seguro Social, México, Mexico, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico, Hospital de Especialidades Centro Medico Nacional La Raza, Mexico City, Mexico, 4 Hospital de Especialidades, Mexico City, Mexico 77. Affinity Purified Antibodies Directed to Domain I of βgpi Are Pathogenic in a Mouse Model of Thrombosis. Charis Pericleous, Patricia Ruiz-Limon, Zurina Romay- Penabad, Ana Laura Carrera Marin, Acely Garza-Garcia, Lucy Murfitt, Paul C. Driscoll 4, Ian Giles, Yiannis Ioannou, Anisur Rahman and Silvia S. Pierangeli, University College London, London, United Kingdom, University of Texas Medical Branch, Galveston, TX, MRC National Institute of Medical Research, London, London, United Kingdom, 4 MRC National Institute of Medical Research, London, United Kingdom 78. Purified IgG From Antiphospholipid Syndrome Patients with Pregnancy Morbidity Alone Inhibit Trophoblast Migration and Activate a TLR4 MyD88 Independent Pathway. Katie Poulton, Vera Ripoll, Charis Pericleous, Yiannis Ioannou, Anisur Rahman and Ian Giles, University College London, London, United Kingdom 79. Ribophorin II Is Involved in the Tissue Factor Expression Mediated by Phosphatidylserine-Dependent Antiprothrombin Antibody On Monocytes. Yuichiro Fujieda, Olga Amengual, Yusaku Kanetsuka, Toshio Odani, Kotaro Otomo, Kenji Oku, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda, Kimiko Kuroki, Katsumi Maenaka, Masaki Matsumoto, Shigetsugu Hatakeyama 4 and Tatsuya Atsumi, Hokkaido University,Medicine II, Sapporo, Japan, Hokkaido University,Laboratory of Biomolecular Science, Sapporo, Japan, Kyusyu University,Divison of proteomics, Multi-scale Reserch Center for Prevention of Medical Science, Fukuoka, Japan, 4 Hokkaido University,Biochemistry, Sapporo, Japan 70. Antiphosphatidylethanolamine Is Not Associated with Thrombosis or Pregnancy Loss in Systemic Lupus Erythematosus. Ehtisham Akhter, Hong Fang, Nathalie Bardin, Marielle San Marco and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Hopital de la Conception, Marseille, France 7. IgA Anti-βglycoprotein I Antibodies Are Pathogenic in a Mouse Model of APS. Patricia Ruiz Limon, Zurina Romay- Penabad, Ana Laura Carrera Marin, Elizabeth Papalardo and Silvia S. Pierangeli, University of Texas Medical Branch, Galveston, TX, Univ of TX Medical Branch, Galveston, TX 7. Annexin A5 Resistance Identifies a Subset of Thrombosis Patients in Systemic Lupus Erythematosus. Ehtisham Akhter, Hong Fang, Xiao Xuan Wu, Jacob Rand and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Montefiore Medical Center, Bronx, NY 7. Effect of Hydroxychloroquine (HCQ) On the Annexin A5 Resistance Assay (AnxA5-RA) in Antiphospholipid Antibody (apl)-positive Patients: Preliminary Results of an Ongoing Prospective Study. Alana B. Levine, Jacob H. Rand, Xiao Xuan Wu, JoAnn Vega, Glendalee Ramon, Stephen L. Lyman, Doruk Erkan and Michael D. Lockshin, Hospital for Special Surgery, New York, NY, Montefiore Medical Center, Bronx, NY 74. Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of Possible Combinations of Antiphospholipid Antibody Specificities. Savino Sciascia, Veronica Murru, Giovanni Sanna, Dario Roccatello, Munther A. Khamashta and Maria Laura Bertolaccini, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, Louise Coote Lupus Unit, St. Thomas Hospital, London, United Kingdom, Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy 75. Independent Validation of the Antiphospholipid Score (apl-s) for the Diagnosis of Antiphospholipid Syndrome (APS). Savino Sciascia, Maria Laura Bertolaccini, Dario Roccatello and Munther A. Khamashta, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, Centro di Ricerche di Immunologia Clinica ed Immunopatologia e Documentazione su Malattie Rare (CMID), Università di Torino, Torino, Italy 76. The Estimated Prevalence of Antiphospholipid Antibodies in the General Population with Pregnancy Morbidity. Cecilia B. Chighizola, Guilherme Ramires de Jesus, Laura 0 Program Book 59

262 ACR POSTER SESSION C 60 andreoli, Alessandra Banzato 4, Guillermo J. Pons-Estel 5, Michael D. Lockshin 6, Doruk Erkan 6 and On Behalf of APS Action 7, Istituto Auxologico Italiano, University of Milan, Milan, Italy, Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rheumatology Unit, University of Brescia, Brescia, Italy, 4 () Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua Italy, Padua, Italy, 5 (4) Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 6 Hospital for Special Surgery, New York, NY, Diffuse Alveolar Hemorrhage Caused by Primary Antiphospholipid Syndrome. Rodrigo Cartin-Ceba, Tobias Peikert, Karina Keogh, Steven R. Ytterberg, Aneel Ashrani and Ulrich Specks, Mayo Clinic, Rochester, MN 78. Myocardial Dysfunction and Valvulopathy Worsens with Time in Patients with Antiphospholipid Syndrome: A 0-Year Follow-up Study. MG Tektonidou, CF Kampolis, I. Moyssakis, GE Tzelepis, Haralampos M. Moutsopoulos and P. Vlachoyiannopoulos, University of Athens Medical School, Laiko Hospital, Athens, Greece, Laiko Hospital, Athens, Greece 79. Primary and Secondary Antiphospholipid Syndrome in Childhood. Senq-J Lee, Leonardo Brandao, Earl D. Silverman, Mahendranath Moharir, Julie Barsalou and Deborah M. Levy, The Hospital for Sick Children, Toronto, ON 740. Impairment of Quality of Life in Patients with Antiphospholipid Syndrome. Stephane Zuily, Francis Guillemin, Veronique Regnault, Pierre Kaminsky 4, Patrick Mismetti 5, Jacques Ninet 6, Nicolas Baillet 7, Nadine Magy-Bertrand 8, Bernard Lorcerie 9, Jean-Louis Pasquali 0, Thomas Lecompte, Anne-Christine Rat and Denis Wahl, Vascular Medicine Unit and Regional Competence Center For Rare Vascular and Systemic Autoimmune Diseases, Vandoeuvre-Les-Nancy, France, INSERM, Centre d Investigation Clinique - Epidémiologie Clinique (CIC-EC) CIE 6, Nancy, France, INSERM U96, Université de Lorraine, Nancy, France, 4 Orphan disease Unit, Nancy, France, 5 CHU Saint-Etienne, Unité de Pharmacologie Clinique, Groupe de Recherche sur la Thrombose (EA 065), Saint Etienne, France, 6 Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 7 Hôpitaux civils de Colmar, Service de Médecine interne, Colmar, France, 8 CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, 9 Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, 0 Hôpitaux Universitaires de Strasbourg, Hôpital civil, Service de médecine interne et immunologie clinique, Strasbourg, France, Hôpitaux Universitaires de Genève, Département d hématologie, Genève, France, Université de Lorraine, INSERM, CIC-EC CIE 6, Rheumatology, Epidemiology, Nancy, France, Nancy University Hospital and INSERM U96, Vascular medicine division and Regional Competence Center For Rare Vascular and Systemic Autoimmune Diseases, Nancy, France 0 Program Book B-cell Biology and Targets in Autoimmune Disease 74. Suppression of Glomerulonephritis in NZB/W F Mice by a Selective Inhibitor of Bruton s Tyrosine Kinase (RN486). Paola Mina-Osorio, Jacob LaStant, Natalie Keirstead, Toni Whittard, Stella Stefanova, Alka Patel, Jennifer Postelnek, John Woods, Soo Min, Yong Kim, Julie Demartino, Satwant Narula and Daigen Xu, Hoffmann-La Roche, Nutley, NJ 74. A Novel Murine Model of B Cell-Mediated Proteinuria Suggests Cytokines Mediate Podocyte Injury. Alfred H. Kim and andrey S. Shaw, Washington Univ School of Med, St. Louis, MO, Washington University School of Medicine, Saint Louis, MO 74. IL-5-Induced FasL+ Regulatory B Cells Are Inhibited by IL- 4 and Cyclosporine. Matthew W. Klinker, Brian R. Alzua, Tamra J. Reed, David A. Fox and Steven K. Lundy, University of Michigan, Ann Arbor, MI, Univ of Michigan Med Ctr, Ann Arbor, MI 744. Regulatory B Cells Supress the Progression of Fatal Autoimmunity in Lupus-Prone Mice. Yuriy Baglaenko, Nan-Hua Chang, Evelyn Pau and Joan E. Wither, Toronto Western Research Institute, University Health Network, Toronto, ON, Toronto Western Hospital, University Health Network, Toronto, ON 745. Amelioration of Experimental Autoimmune Arthritis by Adoptive Transfer of Foxp-Expressing Regulatory B Cells Is Associated with the Regulatory T Cell/T helper 7 cell Balance. Young Ok Jung, Yu Jung Heo, Mi Kyung Park, Mi- La Cho 4, Seung Ki Kwok 5, Ji Hyeon Ju, Kyung Su PARK, Sung Hwan PARK, Ho Youn Kim and Jun-Ki Min 6, Seoul, South Korea, Catholic University, Seoul, South Korea, The Catholic University of Korea, Seoul, South Korea, 4 Catholic University of Korea, Seoul, South Korea, 5 The Catholic University, Seoul, South Korea, 6 Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul, South Korea 746. Semaphorin A Increases the Regulatory Characteristics of B-Regulatory Cells. Zahava Vadasz, Aharon Kessel and Elias Toubi, Bnai-Zion Medical Center, Haifa, Israel, Bnai-Zion Medical Center, Israel 747. Gemin5 Is a New Target of Autoantibodies That Are Produced in Tight Connection with Antibodies to Snrnps and Survival of Motor Neuron (SMN) Complex. Jason YF Chan, Yi Li, Angela Ceribelli, Eric S. Sobel, Westley H. Reeves, Edward K.L. Chan and Minoru Satoh, University of Florida, Gainesville, FL 748. Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies. Kenneth Smith, Jennifer Muther, Angie Duke, Emily McKee, Alina Lorant, Patrick C. Wilson and Judith A. James, Oklahoma Medical Research Foundation, Oklahoma City, OK, University of Chicago, Chicago, IL, Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK

263 ACR POSTER SESSION C 749. Targeting of CD by Epratuzumab Potentially Raises the Threshold of B Cell Receptor Activation. N. Sieger, S.J. Fleischer, K. Reiter, H.E. Mei, A. Shock, G. Burmester, C. Daridon and T. Dorner, Charité University Medicine Berlin, Berlin, Germany, UCB Pharma, Slough, United Kingdom 750. Phosphoprotein Changes Induced with Epratuzumab, an Antibody Targeting CD On B Cells. S. Lumb, N. Torbett, I. Vandrell, H. Turner, M. Page, P. Hales, A. Maloney, B. Vanhaesebroeck, P. Cutillas and A. Shock, UCB Pharma, Slough, United Kingdom, Activiomics Ltd., London, United Kingdom 75. Effect of Repeated Infusions of Rituximab in Patients with Primary Sjögren s Syndrome. Maria Perez-Ferro, Sheila Recuero, Fredeswinda I. Romero, Cristina Serrano, Maria J. Rodriguez-Nieto, Julio Gomez-Seco, Teresa Presa, Javier R. Godo, Gabriel Herrero-Beaumont and Olga Sanchez- Pernaute, Jimenez Díaz Foundation University Hospital, Madrid, Spain 75. Depletion of CD4-Effector Memory T Cells and Clonally Expanded IgG4 Memory B Cells May Explain the Therapeutic Efficacy of Rituximab in IgG4-Related Disease: Studies Using Flow Cytometry and Single-Cell Sequencing. Hamid Mattoo, Arezou Khosroshahi, Vinay Mahajan, Mollie Carruthers, John Stone and Shiv Pillai, Massachusetts General Hospital, Harvard Medical School, Boston, MA, Massachusetts General Hospital, Boston, MA 75. A Rheumatoid Factor Paradox: Inhibition of Rituximab- Induced Complement Dependent Cytotoxicity of B Cells. Jonathan D. Jones, Irene Shyu, Marianna M. Newkirk and William F. C. Rigby, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, McGill University Health Centr, Montreal, QC 754. Disruption of Dominant B-Cell and Plasma Cell Clones in Rheumatoid Arthritis Synovium by Rituximab Correlates with Treatment Response. Marieke E. Doorenspleet, Paul L. Klarenbeek, Maartje J. Boumans, Rogier M. Thurlings, Rebecca E. Esveldt, Barbera D. van Schaik, Antoine H. van Kampen, Danielle M. Gerlag, Frank Baas, Paul-Peter Tak, Robert M. Plenge and Niek de Vries, Academic Medical Center of the University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Brigham and Women s Hospital, Boston, MA 755. The Alternative ΔCD0 Transcript Variant Is Not Expressed in B Cells and Synovial Tissue from Patients with Rheumatoid Arthritis. Clémentine Gamonet, Marina Deschamps, Béatrice Gaugler, Philippe Saas 4, Isabelle Auger 5, Christophe Ferrand 6, Eric Toussirot 7 and CIC BT506 8, INSERM UMR098/ Etablissement Français du Sang / Université de Franche Comté, France, INSERM UMR098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, INSERM UMR098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 4 INSERM UMR098 / Plateforme de Biomonitoring, Besançon, France, 5 INSERM UMR09 7, Marseille, France, 6 INSERM UMR098 Etablissement Français du Sang / Université de Franche Comté, Besançon, France, 7 CIC Biotherapy 50 6 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, 8 Clinical Investigation Center Biotherapy 50 6, Besançon, France 756. Peripheral Blood B Cell Subsets and BAFF/APRIL Receptor Expression, Together with Circulating BAFF and APRIL Levels, Are Disturbed in Rheumatoid Arthritis but Not in Ankylosing Spondylitis. Béatrice Gaugler, Caroline Laheurte, Ewa Bertolini, Daniel Wendling 4, Philippe Saas 5, Eric Toussirot 6 and CIC BT506 7, INSERM UMR098 / Etablissement Français du Sang / Université de Franche Comté, Besançon, France, INSERM UMR098 / Plateforme Biomonitoring, Besançon, France, Rheumatology, Besançon, France, 4 Minjoz University Hospital, Besancon, France, 5 INSERM UMR098 / Plateforme de Biomonitoring, Besançon, France, 6 CIC Biotherapy 506 and Rheumatology and EA 466 Pathogens and Inflammation, Besançon, France, 7 Clinical Investigation Center Biotherapy, Besançon, France 757. B Cell Activating Factor Receptor Expression After Rituximab: Comparison of Patients with Rheumatoid Arthritis and Thrombotic Thrombocytopenic Purpura. Elena Becerra, Maria J. Leandro, Edward O. Heelas, John P. Westwood, Inmaculada de la Torre, Marie A. Scully and Geraldine Cambridge, Rheumatology, University College London, London, United Kingdom, Hematology, University College London, London, United Kingdom, Rheumatology, Gregorio Marañón Hospital, Madrid, Spain 758. Serum BAFF Levels and Relationship with BAFF Binding Receptors in Patients with Rheumatoid Arthritis Relapsing after B Cell Depletion Therapy. Elena Becerra, Inmaculada de la Torre, Maria J. Leandro and Geraldine Cambridge, University College London, London, United Kingdom, Gregorio Marañón Hospital, Madrid, Spain 759. Expression of Surface APRIL and Its Receptor, TACI, Is Upregulated On B Cells From Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients. Abby Jones Weldon, Sheri Hsu, Seyed K. Nazeri, Saru Sachdeva, Jennifer Gonzalez, Andrea D. Parra, Abigail Benitez, Keith K. Colburn 4, Ioana Moldovan 4 and Kimberly J. Payne, Loma Linda University, Loma Linda, CA, Loma Linda University Medical Center, Loma Linda, CA, Loma Lida University Medical Center, Loma Lida, CA, 4 Loma Linda Univ Medical Center, Loma Linda, CA 760. A Gene Expression Signature to Monitor Depletion of Plasma Cells Following MEDI-55 (anti-cd9) Administration. Katie Streicher, Chris Morehouse, Christopher Groves, Bhargavi Rajan, Fernanda Pilataxi, Kim Lehmann, Philip Brohawn, Kathleen McKeever, Volker Knappertz, Ronald Herbst, Yihong Yao and Koustubh Ranade, MedImmune, LLC, Gaithersburg, MD 0 Program Book 6

264 ACR POSTER SESSION C 76. Suppression of Rheumatoid Arthritis B Cells by XmAb587, an Anti-CD9 Monoclonal Antibody That Co-Engages the B Cell Antigen Receptor and the FcγRIIb Inhibitory Receptor. Seung Y. Chu, Karen Yeter, Roshan Kotha, Erik Pong, Yvonne Miranda, Hsing Chen, Sung-Hyung Lee, Irene Leung, John R. Desjarlais, William Stohl and David E. Szymkowski, Xencor, Inc., Monrovia, CA, University of Southern California Keck School of Medicine, Los Angeles, CA 76. IL-6 Receptor Inhibition by Tocilizumab Modulates Double Negative (CD9+IgD-CD7-) B Cells in RA. Zafar Mahmood, Khalid Muhammad, Petra Roll, Stefan Kleinert, Thomas Dörner and Hans Peter Tony, University of Würzburg, Würzburg, Germany, Charite Universitätsmedizin Berlin and DRFZ,, Berlin,, Germany 76. The Role of SYK in Human B CELL Activation and Its Relevance to Autoimmune Diseases. Shigeru Iwata, Kunihiro Yamaoka, Hiroaki Niiro, Kazuhisa Nakano, Sheau- Pey Wang, Koichi Akashi and Yoshiya Tanaka, University of Occupational and Environmental Health, Kitakyushu, Japan, Kitakyushu, Japan, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Fukuoka, Japan 764. B Cells in Early Rheumatoid Arthritis: ZAP-70 More Than SYK Characterize Seropositive Disease. Anna Laura Fedele, Barbara Tolusso, Elisa Gremese, Silvia Laura Bosello, Angela Carbonella, Silvia Canestri and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy 765. Rheumatoid Arthritis Is Associated with Signaling Alterations in Naturally Occurring Autoreactive B-Lymphocytes. Taras Lyubchenko, Ganna Liubchenko, Holly C. Appleberry, Christopher C. Striebich, Karen E. Franklin, Lezlie A. Derber and V. Michael Holers, University of Colorado Denver, Aurora, CO 766. Synovial Gene Expression and Response to Rituximab: Preliminary Data. Yasser El-Sherbiny, Sarah Churchman, Frederique Ponchel, Paul Emery and Edward M. Vital, NIHR Leeds Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, University of Leeds, Leeds, United Kingdom 767. Circulating Plasmablasts as a Source of Anti-Citrullinated Protein Antibodies in Patients with Rheumatoid Arthritis. Priscilla Kerkman, Ellen I.H. van der Voort, Leendert A. Trouw, Tom W.J. Huizinga, René E.M. Toes and Hans Ulrich Scherer, Leiden University Medical Center, Leiden, Netherlands 768. The Absolute Concentration of Anti Citrullinated Protein Antibodies in Serum and Synovial Fluid in Relation to Total Immunoglobulin-Concentrations. Annemiek Willemze, Jing Shi, Marlies Mulder, Gerrie Stoeken-Rijsbergen, Tom W. J. Huizinga, René E. M. Toes and Leendert A. Trouw, Leiden University Medical Center, Leiden, Netherlands 769. Affinity Purification and Characterisation of Anti- CCP Antibodies from Plasma and Synovial Fluids of Patients with Rheumatoid Arthritis. Elena Ossipova, Catia Cerqueira, Evan Reed, Nastya Kharlamova, Lena Israelsson, Rikard Holmdahl, Anca Irinel Catrina, Vivianne Malmström, Yngve Sommarin 4, Lars Klareskog, Per Johan Jakobsson and Karin Lundberg, Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, 4 Euro-Diagnostica AB, Malmö, Sweden 770. Recognition of Citrullinated and Carbamylated Proteins by Human Antibodies: Specificity, Cross-Reactivity and the AMC-Senshu Method. Jing Shi, George Janssen, Peter van Veelen, Janwouter Drijfhout, Antony Cerami, Tom Huizinga, Leendert A. Trouw and René E.M. Toes, LUMC, Leiden, Netherlands, Leiden University Medical Center, Leiden, Netherlands, Leiden University Medical Centre, Leiden, Netherlands 77. Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Jing Shi, Lotte van de Stadt, Nivine Levarht, T.W.J. Huizinga, R. E. M. Toes, Leendert A. Trouw 4 and Dirkjan van Schaardenburg, LUMC, Leiden, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Leiden University Medical Centre, Leiden, Netherlands 77. Expansion of Autoreactive Unresponsive CD-/Low B Cells in Sjögren s Syndrome Associated Lymphoproliferation. David Saadoun, Benjamin Terrier Sr., J. Bannock Sr., T. Vazquez Sr. 4, C. Massad Sr., Florence Joly Sr. 5, Michelle Rosenzwajg Sr. 6, Damien Sene Sr. 7, Philippe Benech Sr. 5, David Klatzmann Sr. 6, Eric Meffre Sr. and Patrice Cacoub Sr. 8, Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U95 9, Groupe Hospitalier Pitié- Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, Cochin Hospital, Paris, France, Yale University School of Medicine, New Haven, CT, 4 CNRS UMR 7 and INSERM U95 9, Paris, France, 5 Prediguard, Marseille, France, 6 Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U95 9, Paris, France, 7 Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, 8 CHU Pitié-Salpêtrière, Paris, France 77. Hyperammaglobulinemia in Primary Sjögren s Syndrome Is Induced by Triggering of TLR 7 and 9. Susanna Brauner, Marika Kvarnstrom, Gunnel Nordmark and Marie Wahren- Herlenius, Karolinska Institutet, Stockholm, Sweden, Rheumatology, Uppsala, Sweden 6 0 Program Book

265 ACR POSTER SESSION C 774. Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach. Alexis Régent, Hanadi Dib, Guillaume Bussone, Mathieu C. Tamby, Nicolas Tamas, Christian Federici, Cédric Broussard, Loic Guillevin 4 and Luc Mouthon Sr., Hopital Cochin, Paris, France, Université Paris Descartes, Paris, France, INSERM U06, Institut Cochin, CNRS UMR 80 4, Paris, France, 4 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France Cell-cell Adhesion, Cell Trafficking and Angiogenesis 775. The Phosphoinositide -Kinase Pathway Regulates Fibroblast-Like Synoviocyte Invasion. Beatrix Bartok, Deepa Hammaker and Gary S. Firestein, UCSD, La Jolla, CA, Univ of California San Diego, La Jolla, CA, UCSD School of Medicine, La Jolla, CA 776. Anti-SSA/Ro Mediated Injury to the Endothelium via Urokinase Plasminogen Activator Receptor/Tgfbeta Activation: Implications in the Pathogenesis of Congenital Heart Block. Paraskevi Briasouli, Mark Halushka, Jill P. Buyon and Robert M. Clancy 4, New York University Medical Center, New York, NY, John Hopkins PAthology, Baltmore, MD, NYU School of Medicine, New York, NY, 4 New York University School of Medicine, New York, NY 777. The Bioenergetic Role of HIF- and HIF- during Angiogenesis of Human Microvascular Endothelial Cells. Martin Hahne, Cindy Strehl, Manuela Jakstadt, Paula Hoff, Timo Gaber, Gerd R. Burmester and Frank Buttgereit, Charité University Medicine, Berlin, Germany, Charite University Med-Berlin, Berlin, Germany 778. Adenosine AA Receptor (AAR) Activation Stimulates Increased Expression of Collagen- and Collagen- by Different Signaling Pathways in Normal Human Dermal Fibroblasts. Miguel Perez Aso and Bruce N. Cronstein, NYU Univ Medical Center, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 779. The Loss of Syndecan-4 Aggravates Inflammatory Colitis in Mice. Athanasios Stratis, Dominik Bettenworth, Mareike Fröhling, Peter Paruzel, Adelheid Korb-Pap, Corinna Wehmeyer, Berno Dankbar, Frank Echtermeyer, Andreas Lügering and Thomas Pap, University Hospital Muenster, Muenster, Germany, University Hospital Hannover, Hanover, Germany 780. Association between Chondrocyte Hypertrophy and Angiogenesis of Cartilage in Osteoarthritis. Laurence Pesesse, Christelle Sanchez, Jean-Pierre Delcour, Caroline Baudouin 4, Philippe Msika 4 and Yves Henrotin 5, University of Liège, Liège, Belgium, Bone and Cartilage Research Unit, Liege, Belgium, Centre hospitalier du Bois de l Abbaye, Seraing, Belgium, 4 Laboratoires Expanscience, Epernon, France, 5 Univ of Liege/Pathology Inst, Liege, Belgium 78. Functional Analysis of the Primary Cilium in Rheumatoid Arthritis Synovial Fibroblasts. Kerstin Klein, Beat A. Michel, Alexander Vogetseder, Renate Gay, Steffen Gay and Caroline Ospelt, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, Department of Pathology, University Hospital Zurich, Zurich, Switzerland Cytokines, Mediators, and Gene Regulation 78. Dual Effects of Soluble FasL and Membrane Bound FasL On Fibroblast-Like Synoviocytes Cells (FLS) From Rheumatoid Arthritis (RA) Patients. Rachel Audo, Flavia Calmon- Hamaty, Bernard Combe, Michael Hahne and Jacques Morel, IGMM, CNRS UMR555, Montpellier, Montpellier, France, Hopital Lapeyronie, Montpellier, France 78. TNFα Influences RasGRP and RasGRP Expression Levels in PBMC, B and T Cells. Marie-Laure Potier, Martine Hiron, Clément Guillou, Céline Derambure, Olivier Boyer, Xavier Le Loët, Olivier Vittecoq and Thierry Lequerré, Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Inserm 905, Institute for Biomedical research, University of Rouen, Rouen, France, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France 784. Dual Function of Interleukin- in Fibroblast-Like Synoviocytes in Patients with Rheumatoid Arthritis. Min W. So, Bon S. Koo, You J. Kim, You-G Kim, Wook J. Seo, Chang-K Lee and Bin Yoo, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul Veterans Hospital, Seoul, South Korea 785. MiR-0* Family Negatively Regulates B-Cell Activating Factor (BAFF) Synthesis in Rheumatoid Synoviocytes. Ghada Alsaleh, Antoine Francois, Lucas Philippe, Jean Sibilia, Jacques-Eric Gottenberg, Philippe Georgel and Dominique Wachsmann, EA448 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, Laboratoire d ImmunoGénétique Moléculaire Humaine, Strasbourg, France 786. Targeting CDc-Expressing mdcs to Inhibit Increased Thymus and Activation Regulated Chemokine Levels in RA. M.R. Hillen, F.M. Moret, F.P.J.G. Lafeber, C.E. Hack, T.R.D.J. Radstake and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 787. Evolution of the Cytokine and Chemokine Profile in Patients Receiving Oral Daily Vitamin D: Results from a Randomized Controlled Trial. Benjamin Terrier Sr., Marlène Garrido and Patrice Cacoub Sr., Cochin Hospital, Paris, France, Pitié-Salpétrière, Paris, France, CHU Pitié- Salpêtrière, Paris, France 788. TSLP Induces TNFα Production by CDc Myeloid Dendritic Cells and Myeloid DC-Activated T Cells From Rheumatoid Arthritis Patients. F.M. Moret, T.R.D.J. Radstake, J.W.J. 0 Program Book 6

266 ACR POSTER SESSION C 64 Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 789. Evidence for an Additive Effect of Tumor Necrosis Factor Alpha and Hypoxia to Promote Bone Destruction in Arthritis. Shankar Revu, Akilan Krishnamurthy, Vivekananda Sunkari, Ileana R. Botusan, Xiaowei Zheng, Sergiu-Bogdan Catrina and Anca Irinel Catrina, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden 790. Notch Promotes Matrix Metalloproteinase Expression by Inducing Interleukin-6 in Primary Murine Chondrocytes. Stefano Zanotti and Ernesto Canalis, Saint Francis Hospital and Medical Center, Hartford, CT 79. Different Mechanisms Responsible for IVIG Inhibition of Immune Complex versus TLR Stimulated Interferon-Alpha. Alice Wiedeman, Fabian Käsermann, Sylvia Miescher and Keith B. Elkon, University of Washington, Seattle, WA, CSL Behring, Bern, Switzerland 79. Identification of the Antimicrobial Peptide LL-7 As a Potential Mediator of Synovial Inflammation in Rheumatoid Arthritis. Petra Neregård, Marianne Engström, Erik Af Klint, Birgitta Agerberth and Anca Irinel Catrina, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden 79. The Cyclooxygenase/Prostaglandin-E Pathway Is Critical for Autocrine IL-7A Production by Th7 Cells Upon Synovial Fibroblast Interaction. Sandra M.J. Paulissen, Jan Piet van Hamburg, Nadine Davelaar, Patrick S. Asmawidjaja, Johanna M.W. Hazes 4 and Erik Lubberts, Erasmus MC, University Medical Center, Rotterdam, Rotterdam, Netherlands, Erasmus MC, Rotterdam, Netherlands, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4 Erasmus Medical Center, Rotterdam, Netherlands 794. Matrix Metalloproteinase and Acute Phase Proteins as Markers of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis. Mahmood MTM Ally, Bridget Hodkinson, Pieter W.A Meyer, Eustasius Musenge, Mohammed Tikly 4 and Ronald anderson, University of Pretoria, Pretoria, South Africa, University of the Witwatersrand, Johannesburg, South Africa, University of Witwatersrand, Johannesburg, South Africa, 4 Division of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa 795. Correction for Basophil and Monocyte Frequencies Identifies Specific Gene Expression Differences Associated with SLE Disease Flare: Interim Report From the Bold (Biomarkers of Lupus Disease) Study. Mikhail G. Dozmorov, Nicolas Dominguez, Stan Kamp, Cory Giles, Jonathan D. Wren, Sudhakar T. Sridharan, Joan T. Merrill, Judith A. James 4 and Joel M. Guthridge, Oklahoma Medical Research 0 Program Book Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, Pfizer Inc, Collegeville, PA, 4 Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK 796. Anti-IL-0 Targets Local Tissue Inflammation As Opposed to Systemic Inflammation. Amanda L. Blasius, Joshua N. Beilke, Hal Blumberg, John Bui, Jennifer H. Cox, Tom Cox, Heidi J. Jessup, Phillip L. Kong, Steven D. Levin, Valerie H. Odegard, Jason A. Stucky, Evan P. Thomas, Joseph A. Wahle and John Rømer, Novo Nordisk Inflammation Research Center, Seattle, WA, Novo Nordisk, Måløv, Denmark 797. Wnt Signaling Pathway Status, Determined by Serum Dkk- and R-Spondin Levels, in Rheumatoid Arthritis and Ankylosing Spondylitis. Byoong Yong Choi, Hyon Joung Cho, Eun Ha Kang, Yeong Wook Song and Yun Jong Lee, Seoul National University Bundang Hospital, Seongnam-si, South Korea, Seoul National University Hospital, Seoul, South Korea 798. Macrophage Migration Inhibitory Factor Regulates Dual- Specificity Phosphatases Via Glucocorticoid Induced Leucine Zipper. Huapeng Fan, Devi Ngo, Ran Gu and Eric Morand, Monash University, Melbourne, Australia 799. ONO A Novel Small Molecule Bruton s Tyrosine Kinase (Btk) Inhibitor, Suppresses Osteoclast Differentiation and Activation. Yuko Ariza, Toshio Yoshizawa, Yoshiko Ueda, Shingo Hotta, Masami Narita and Kazuhito Kawabata, Ono Pharmaceutical Co., Ltd., Osaka, Japan 800. Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-. Sarah Aynsley, Ursula Fearon, Anthony G. Wilson and Munitta Muthana 4, University of Sheffield, Sheffield, United Kingdom, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Section of Musculoskeletal Sciences, University of Sheffield, Sheffield, United Kingdom, 4 University of sheffield, Sheffield, United Kingdom 80. Biological Roles of C5orf0 in Rheumatoid Arthritis. Munitta Muthana, Sachin Khetan, Gbadebo Adeleke Adeleke, Simon Tazzyman, Sarah Aynsley, Fiona Morrow, Sarah Hawtree, Barbara Ciani and Anthony G. Wilson, University of Sheffield, Sheffield, United Kingdom, Dr, Sheffield, United Kingdom, Section of Musculoskeletal Sciences, University of Sheffield, Sheffield, United Kingdom 80. Interleukin-9 Modulates Proinflammatory Cytokine Production in Synovial Inflammation of Rheumatoid Arthritis. Miaojia Zhang, Fang Wang, Lingxiao Xu and Wenfeng Tan, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China 80. Chemokine-Like Receptor (CMKLR), a G Protein Coupled Receptor Expressed On Proinflammatory Monocytes in

267 ACR POSTER SESSION C Arthritis, Is Negatively Regulated by GRK. D. Stephen Serafin, Roman Timoshchenko, Marcus W. McGinnis and Teresa K. Tarrant 4, Thurston Arthritis Research Center, Chapel Hill, NC, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of North Carolina Sch of Med, Chapel Hill, NC, 4 UNC School of Medicine, Chapel Hill, NC 804. TNF-Like Protein A/Death Receptor Pathway Regulates Osteoclastogenesis and Is Associated with Erosive Disease in Rheumatoid Arthritis. Fraser L. Collins, Michael D. Stone, Rhian Goodfellow, Ernest Choy 4, Edward C. Wang and Anwen S. Williams, Cardiff University, Institute of Infection and Immunity, Cardiff, United Kingdom, University Hospital Llandough, Cardiff & Vale University Health Board, Cardiff, United Kingdom, Cardiff University, Cardiff, ENGLAnd, United Kingdom, 4 Cardiff University School of Medicine, Cardiff, United Kingdom 805. The Pro-Fibrotic Cytokines IL- and IL- Modulates Dermal Fibrosis Via the AA Adenosine Receptor. Ross C. Radusky, Jessica L. Feig, Bruce N. Cronstein, Andrew G. Franks 4 and Edwin SL Chan, New York University School of Medicine, New York, NY, New York Univ School of Medicine, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY, 4 New York University, New York, NY 806. A Novel Angiopoetin/TEK Tyrosine Kinase Receptor Mediated Effect on Leukocyte Cell Influx and Oxidative Damage in Inflammatory Arthritis. Emese Balogh, Chin T. Ng, Douglas J. Veale, Ursula Fearon and Monika Biniecka, Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 807. WITHDRAWN Immune Activating Effects of Co-Stimulation of TLR Agonists and Cytokines on Primary and Immortalized Keratinocytes From a Patient with a CARD4 Mediated Pustular Psoriasis (CAMPS) and Healthy Controls. Yongqing Chen, Yin Liu, Yan Huang, Carole Yee, Alison MacBride 4, Anne Bowcock 5, Michelle Lowes 6 and Raphaela T. Goldbach- Mansky 7, Translational Autoinflammatory Disease Section, Office of the Clinical Director NIAMS, Bethesda, MD, NIAMS, Bethesda, MD, NCI, NIH, Bethesda, MD, 4 NIAID, NIH, Bethesda, MD, 5 Washington University, St. Louis, MO, 6 Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, 7 Translational Autoinflammatory Diseases Section NIAMS NIH, Bethesda, MD 809. Serum IFNα Activity in Systemic Lupus Erythematosus Drops in Response to Immunosuppressive Therapy Only When There Is Concurrent Clinical Response. Elzbieta E. Jacek, Elena Gkrouzman, Mikhail Olferiev, Nancy Pan, Roland Duculan, Kyriakos A. Kirou and Mary K. Crow, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, New York, NY, Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, Hospital for Special Surgery, New York, NY 80. Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL7A. David Livingston, Sethu Alexander, Julian Bond, Timothy Briggs, Andrew Fraley, Stephen Hale, Tanya Landsman, Richard Martinelli, Kelley Shortsleeves, Nick Terrett and Nathan Walsh, Ensemble Therapeutics, Cambridge, MA 8. On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis. T.D. de Jong, Saskia Vosslamber, Maija-Leena Eloranta, Lars Rönnblom, Kyra Gelderman, Mary von Blomberg, Irene Bultink, Alexandre Voskuyl and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands, Section of Rheumatology, Uppsala University, Uppsala, Sweden Epidemiology and Health Services Research: Rheumatic Disease Pharmacoepidemiology 8. A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol. Joy Higa, Gregory Reardon and Gregory Tong, Long Term Care Research Center, Kaneohe, HI, Informagenics, LLC, Worthington, OH, Deerfield, IL 8. Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization. Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL 84. Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat. Michael A. Becker, Xiangyang Ye, Kasem S. Akhras, Rima H. Tawk 4, Sudhir Unni, Jason Young and Carl V. Asche 5, University of Chicago, Chicago, IL, University of Utah College of Pharmacy, Salt Lake City, UT, Takeda Pharmaceuticals International, Inc., Deerfield, IL, 4 University of Illinois at Chicago, Chicago, IL, 5 University of Illinois College of Medicine at Peoria, Peoria, IL 85. Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout. Rebecca Sharim, Meghan Musselman and Marissa Blum, Temple University Hospital, Philadelphia, PA, Temple University School of Medicine, Philadelphia, PA 86. Relationship Between Race, Uric Acid Levels, Urate- Lowering Therapy and Resource Use in Patients with Gout. Kim Coley, Melissa Saul and Karen Pater, University of Pittsburgh, Pittsburgh, PA 87. The Role of Repeating Tuberculin Skin Tests During Biologic Therapy. Joseph R. Lutt and Kevin L. Winthrop, Colorado Center for Arthritis & Osteoporosis, Boulder, CO, Oregon Health & Science University, Portland, OR 88. Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey. Fabrizio Cantini, Ennio Lubrano, Alessandro Mathieu, Antonio Marchesoni 4, Carlo Salvarani 5, Raffaele Scarpa 6 and Antonio Spadaro 7, Ospedale Misericordia e Dolce di Prato, Prato, Italy, Università del 0 Program Book 65

268 ACR POSTER SESSION C 66 Molise, Campobasso, Italy, University of Cagliari, Cagliari, Italy, 4 Istituto Ortopedico Gaetano Pini, Milano, Italy, 5 Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, 6 Via Pansini 5, Naples, Italy, 7 Univeristà La Sapienza di Roma, Roma, Italy 89. Predictors of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Anna Gramling, Kaleb Michaud, Harlan Sayles, Frederick Wolfe 4 and Michelene Hearth-Holmes 5, University of Nebraska Medical Center, Omaha, NE, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, University of Nebraska Medical School, Omaha, NE, 4 National Data Bank for Rheumatic Diseases, Wichita, KS, 5 Univ. of Nebraska Medical Center, Omaha, NE 80. Human Papillomavirus Vaccine [Types 6,, 6, 8] (Gardasil ) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System. Lamiae Grimaldi-Bensouda, Michel Rossignol, Elodie Aubrun, Pamela Leighton, Didier Guillemot 4, Alfred Mahr 5, Jacques Benichou 6, Paul-Henri Lambert 7, Bertrand Godeau 8 and Lucien Abenhaim 9, LA-SER, Paris, France, LA-SER, Centre for Risk Research, Montreal, LA-SER Europe Ltd., London, United Kingdom, 4 Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris- Ile de France Ouest, Paris, France, 5 Hospital Saint-Louis, Paris, France, 6 INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, 7 Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, 8 Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 9 LA-SER Europe Ltd, London, United Kingdom 8. Clinical Predictors of Methotrexate-Induced Liver Enzyme Elevation in Patients with Rheumatoid Arthritis in an Electronic Medical Record. Monica Ramirez, Bing Lu, Michelle A. Frits, Anne H. Fossel, Katherine P. Liao, Robert M. Plenge, Jonathan S. Coblyn, Nancy A. Shadick 4 and Elizabeth W. Karlson 5, Brigham and Women s Hospital, Boston, MA, Brigham & Womens Hospital, Boston, MA, Brigham & Womens Hosp, Boston, MA, 4 Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA, 5 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 8. Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans. Gabriela Schmajuk, Yinghui Miao, Jinoos Yazdany, Mary Margaretten and Michael Steinman, UCSF, San Francisco, CA, San Francisco Veterans Affairs Medical Center, San Francisco, CA, University of California San Francisco, San Francisco, CA 0 Program Book 8. Short Periods of Glucocorticoid Use Increase the Risk of Gastrointestinal Bleeding. Steven C. Vlad, David T. Felson, Donald R. Miller and Yuqing Zhang, Boston University, Boston, MA, Edith Nourse Rogers Memorial VA Hospital, Bedford, MA 84. Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study. Thomas W. Schmidt, Daniel F. Battafarano, Christopher R. Frei, Eric M. Mortensen and Ishak Mansi 4, San Antonio Military Medical Center, San Antonio, TX, University of Texas Health Science Center at San Antonio, San Antonio, TX, University of Texas Southwestern Medical Center, Dallas, TX, 4 San Antonio Military Medical Center, San Antonio 85. Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities. Chanseok Rhee, Janet E. Pope, Andrew E. Thompson, Nicole G. H. Le Riche 4, Gina Rohekar 4 and Sherry Rohekar 4, Schulich School of Medicine and Dentisty, Western University, London, ON, St. Joseph Health Care London, University of Western Ontario, London, ON, St. Josephs Health Ctr, London, ON, 4 St. Joseph s Hospital, London, ON 86. Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo Controlled Trial. Rene Westhovens, Michael Weinblatt, Chenglong Han, Tim Gathany, Lilianne Kim 4, Michael Mack 4, Jiandong Lu 4, Daniel Baker 4, Alan Mendelsohn 4 and Clifton O. Bingham III 5, University Hospital KU Leuven, Leuven, Belgium, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, 4 Janssen Research & Development, LLC, Spring House, PA, 5 Johns Hopkins University, Baltimore, MD 87. Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis. Vibeke Strand, Thomas V. Jones, Wenzhi Li, Andrew S. Koenig and Sameer Kotak 4, Stanford University, Portola Valley, CA, Pfizer, Inc, Collegeville, PA, Pfizer Inc., Collegeville, PA, 4 Pfizer Inc., New York, NY 88. Smoking Is Associated with Worse and More Widespread Pain, Worse Fatigue, General Health and Quality of Life in a Swedish Population Based Cohort of Patients with Psoriatic Arthritis. Ann B. I. Bremander, Lennart TH Jacobsson, Stefan Bergman, Emma Haglund 4 and Ingemar F. Petersson 5, Halmstad University School of Business and Engineering, Halmstad, Sweden, Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, R&D Center Spenshult, Oskarström, Sweden, 4 Spenshult Hospital for Rheumatic Diseases, Halmstad, Sweden, 5 Department of Orthopedics, Clinical Sciences Lund, Lund University, Lund, Sweden

269 ACR POSTER SESSION C 89. Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance. Machaon Bonafede, Crystal Watson, George Joseph, Nicole Princic and David J. Harrison, Thomson Reuters Healthcare, Cambridge, MA, Amgen Inc., Thousand Oaks, CA 80. Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data. Bruno Fautrel, Sandy Lucier, Georges Haour, Hassani Maoulida, Stephanie Harvard, Alain Saraux, Xavier Mariette 4, Francis Guillemin 5, Isabelle Durand-Zaleski and Karine Chevreul, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, APHP - URC Eco, Paris, France, Université Brest Occidentale, Brest, France, 4 Université Paris-Sud, Le Kremlin Bicetre, France, 5 Faculte de Medecin/BP 8 4, Vandoeuvre-les-Nancy, France 8. Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database. Eiichi Tanaka, Eisuke Inoue, Daisuke Hoshi, Akiko Kobayashi, Naoki Sugimoto, Kumi Shidara, Eri Sato, Yasushi Inoue, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 8. Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients. Charlotte L. M. Krieckaert, Sandhya C. Nair, M. T. Nurmohamed, Carlo J.J. van Dongen, Willem F. Lems 4, Floris P.J.G. Lafeber, J.W.J. Bijlsma, Gertjan Wolbink and Paco M.J. Welsing, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, University Medical Center Utrecht, Utrecht, Netherlands, VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, 4 VU University Medical Center, Amsterdam, Netherlands 8. Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate. Frank Zhang, Robert Hiscock and Jeffrey Curtis, Celgene Corporation, Warren, NJ, Analysis Group, Inc., Montreal, QC, University of Alabama at Birmingham, Birmingham, AL 84. Utilization and Expected Cost of Rheumatoid Arthritis Patients Treated with Golimumab: A Specialty Pharmacy Perspective. Lorie Ellis, Susan Bolge, Heidi Hanna, Christina White and Patricia Rice, Janssen Scientific Affairs, LLC, Horsham, PA, Diplomat Specialty Pharmacy, Flint, MI, CliniRx Research, Naperville, IL 85. Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 00-0: A Study of Prescription Rates and Baseline Disease Activity. Elisabeth Lie, Karen M. Fagerli, Knut Mikkelsen, Åse S. Lexberg, Erik Rødevand 4, Till Uhlig and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, Drammen Hospital, Drammen, Norway, 4 St. Olavs Hospital, Trondheim, Norway 86. Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Sharon Van Doornum, Lynden Roberts, Mark D. Reed and Danny Liew, The University of Melbourne, Melbourne, Australia, James Cook University, Townsville, Australia, Sir Charles Gairdiner Hospital, Nedlands, Australia 87. Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti- TNFá Therapy? Alain Saraux, Jacques Benichou, Chantal Deslandre, Loic Guillevin 4, Latifa Idbrik 5, Jean Sibilia 6, Marc Soudan 5, Daniel Wendling 7 and Francis Guillemin 5, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, EA448 Laboratoire Physiopathologie des Arthrites, Rouen, France, Cochin Hospital, Paris, France, 4 Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 5 Faculte de Medecin/BP 84, Vandoeuvre-les-Nancy, France, 6 EA448 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 7 Minjoz University Hospital, Besancon, France Year Trends in the Use of Disease Modifying Anti- Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study. Bernard Ng, Nancy Petersen, Hong-Jen Yu, Myrna Khan and Maria E. Suarez-Almazor, Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, University of Texas MD anderson Cancer Center, Houston, TX 89. The Progression of the Rate of Biologic Initiation in Early Rheumatoid Arthritis Is Constant Over the First 5 Years in the Espoir Cohort. Stéphanie Emilie, Cécile Gaujoux- Viala, Benjamin Granger, Anne-Christine Rat 4, Bernard Combe 5 and Bruno Fautrel 6, Paris 6,Pierre and Marie Curie University, AP-HP, Pitié-Salpêtrière Hospital, Department of Rheumatology, Paris, France, Paris 6 Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, 4 Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy, France, 5 Hopital Lapeyronie, Montpellier, France, 6 APHP-Pitie Salpetriere Hospital / UPMC, Paris, France 840. Treatment Patterns in Psoriatic Arthritis Patients Newly Initiated On Non-Biologic Disease-Modifying Anti- Rheumatic Drugs. Jeffrey Curtis, Genevieve Gauthier, Robert Hiscock and Frank Zhang, University of Alabama at Birmingham, Birmingham, AL, Analysis Group, Inc., Montreal, QC, Celgene Corporation, Warren, NJ 84. Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients. Denis Choquette, Oliver Thomas and Mark Arundine, University of Montreal, Notre-dame Hospital, Montreal, QC, Roche, Toronto, ON 0 Program Book 67

270 ACR POSTER SESSION C 84. Disease Activity and Treatment Strategies in Moderate Rheumatoid Arthritis Patient Population: Data from the Consortium of Rheumatology Researchers of North America. Sameer Kotak, Andrew S. Koenig, David H. Collier, Katherine C. Saunders 4, Ping He 5, Joel M. Kremer 6 and George W. Reed 7, Pfizer Inc., New York, NY, Pfizer Inc., Collegeville, PA, Amgen Inc., Thousand Oaks, CA, 4 CORRONA, Inc., Southborough, MA, 5 UMASS Medical School, Worcester, MA, 6 Albany Medical College and The Center for Rheumatology, Albany, NY, 7 University of Massachusetts Medical School, Worcester, MA 84. Predictors of Starting and Stopping Disease Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: A Year Longitudinal Cohort. Daniel H. Solomon, Edward Yelin, Jeffrey N. Katz, Chris Tonner 4, M. Alan Brookhart 5, Seoyoung C. Kim, Bing Lu and John Z. Ayanian 6, Brigham and Women s Hospital, Boston, MA, University of California San Francisco, San Francisco, CA, Brigham & Women s Hospital, Boston, MA, 4 UCSF, San Francisco, CA, 5 University of North Carolina, 6 Brigham and Women s Hospital 844. Inequities in Access to Biologic Disease-Modifying Anti- Rheumatic Drugs for Patients with Rheumatoid Arthritis Across 46 European Countries. Polina Putrik, Sofia Ramiro, Milena Pavlova, Tore K. Kvien, Tuulikki Sokka 4, Till Uhlig, Annelies Boonen 5 and Equity In Access To Treatment of RA Across Europe 6, Maastricht University, Maastricht, Netherlands, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Diakonhjemmet Hospital, Oslo, Norway, 4 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 5 University Hospital Maastricht, Maastricht, Netherlands, 6 European Region 845. Inequalities Across 46 European Countries in Clinical Eligibility Criteria for the Start of A First (Reimbursed) Biologic in Patients with Rheumatoid Arthritis. Polina Putrik, Sofia Ramiro, Tore K. Kvien, Tuulikki Sokka 4, Till Uhlig, Annelies Boonen 5 and Equity in Clinical Eligibility Criteria for RA treatment 6, Maastricht University, Maastricht, Netherlands, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Diakonhjemmet Hospital, Oslo, Norway, 4 Jyvaskyla Central Hospital, Jyvaskyla, Finland, 5 University Hospital Maastricht, Maastricht, Netherlands, 6 European Region 846. Observation of Persistence Rates and Potential Costs Savings Associated with Certolizumab Pegol Treatment for Rheumatoid Arthritis in England, Wales and Northen Ireland Clinical Practice. Mike Russell, Jen Timoshanko, Graeme Duncan, Angela Spandley and Samantha Roskell, UCB Pharma, Slough, United Kingdom, Healthcare at Home Ltd, Burton on Trent, United Kingdom, Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom 847. Status of the Rheumatology Clinical Trials Portfolio: Data from Clinicaltrials.Gov. Ankoor Shah, Samuel Broderick, Karen Chiswell, Asba Tasneem and John S. Sundy, Duke University Medical Center, Durham, NC, Duke University Medical Center, Durham 848. Impact of Biologics On Total Knee Replacement and Total Hip Replacement Rates in Rheumatoid Arthritis Patients: Results From US Marketscan Database. Andrew S. Koenig, Jack Mardekian and Sameer Kotak, Pfizer Inc., Collegeville, PA, Pfizer Inc, New York, NY, Pfizer Inc., New York, NY 849. Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort. Bruno Fautrel, Benjamin Granger, Bernard Combe, Francis Guillemin 4, Alain Saraux 5 and Xavier Le Loët 6, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, Lapeyronie Hospital, Montpellier, France, 4 Faculte de Medecin/BP 84, Vandoeuvre-les-Nancy, France, 5 Université Brest Occidentale, Brest, France, 6 Rouen University Hospital and Inserm U 90 5, Rouen, France 850. Association of Clinical Trial Characteristics with Positive Study Outcome Reporting in Randomized Controlled Trials of Rheumatoid Arthritis Therapy. Fatima M. Khan, Juan I. Lombeida, Horace Spencer, Karina D. Torralba, Winnie K. Pang and Nasim A. Khan 4, University of Arkansas for Medical Sciences, Little Rock, AR, Mercy Medical Center, Rogers, AR, University of Southern California Keck School of Medicine, Los Angeles, CA, 4 University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR 85. Exploring the Relationship of Anti-Tumor Necrosis Factor Drugs and Methicillin Resistant Staphylococcus Aureus Nasal Colonization in Patients with Rheumatologic Conditions and Psoriasis. Daniel E. Kreutz, Santosh P. Reddy, Guy P. Fiocco, Colleen Colbert and Juhee Song, Scott & White Healthcare/Texas A&M University, Temple, TX, Scott & White Clinic, Temple, TX 85. Tumour Necrosis Factor-Alpha Antagonists and Alopecia: A Case/Non-Case Study in a Nationwide Pharmacovigilance Database. Johana Béné, Guillaume Moulis, Marine Auffret, Claire Fessier, Guillaume Lefevre and Sophie Gautier, Lille University Hospital, Lille Pharmacovigilance Regional Centre, Lille, France, Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, UMR INSERM-UPS 0 7, Toulouse, France, Lille University Hospital, Internal Medicine Department, Lille, France 85. Rheumatoid Arthritis Patients Experiences of Medication Side Effects and Subsequent Decision Making about Medications. Yomei Shaw, Ilinca D. Metes, Susan L. Zickmund, Dawn McBride, Kelly A. Reckley, Stephen R. Wisniewski, Larry W. Moreland, Mark S. Roberts and Marc C. Levesque, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, University of Pittsburgh School of Medicine, Pittsburgh, PA 68 0 Program Book

271 ACR POSTER SESSION C 854. The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis - A Meta-Analysis of 5 RCTs. Tzuyu Lin, Tatyana Shamliyan, Hyon Choi, Young Hee Rho and Karen Kuntz, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, Boston University School of Medicine, Boston, MA 855. Prevalence of Potential Drug-Drug and Drug-Condition Interactions in Fibromyalgia Patients Newly-Initiating Pregabalin or Duloxetine. Stephen Johnston, Margarita Udall, Joseph C. Cappelleri, Barbara H. Johnson, George Shrady and Stuart L. Silverman 4, Truven Health Analytics, Washington, DC, Pfizer Inc., New York, NY, Pfizer Inc., Groton, CT, 4 Cedars-Sinai Medical Center, UCLA Center of Excellence, Beverly Hills, CA 856. Burden of Adverse Events Associated with Immunosuppressant Therapy for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review. Alan Oglesby, Arthur Weinstein, Greg Dennis, Alissa Shaul 4, Tiffany Pokora 4, Clark Paramore 5, Lael Cragin 6 and Siva Narayanan, GlaxoSmithKline, Research Triangle Park, NC, Washington Hospital Center, Washington, DC, Human Genome Sciences, Inc., Rockville, MD, 4 United BioSource Corporation, Bethesda, MD, 5 United BioSource Corporation, Lexington, MA, 6 United BioSource, Bethesda, MD Fibromyalgia and Soft Tissue Disorders 857. Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data from Milnacipran Clinical Studies. Philip Mease, Robert M. Bennett, Robert H. Palmer and Yong Wang, Swedish Medical Center and University of Washington, Seattle, WA, Oregon Health & Science Univ, Portland, OR, Forest Research Institute, Jersey City, NJ 858. Hypervigiliance in Fibromyalgia. Robert S. Katz, Ben J. Small, Susan Shott and Sharon M. Ferbert, Rush University Medical Center, Chicago, IL, Rush University Medical School, Chicago, IL, Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL 859. The Polysymptomatic Distress Scale and the Effect of Age On Polysymptomatic Distress and Fibromyalgia: A Survey in a Representative Population Sample. Winfried Häuser, Frederick Wolfe, Johannes Rasker, Elmar Brähler 4 and Heide Glaesmer 4, Technische Universität München, Munich, Germany, National Data Bank for Rheumatic Diseases, Wichita, KS, University Twente, Enschede, Netherlands, 4 University of Leipzig, Leipzig, Germany 860. Fibromyalgia and the Disease and Statistical Manual Classification As a Somatic Symptom Disorder. Frederick Wolfe, Brian T. Walitt and Winfried Häuser, National Data Bank for Rheumatic Diseases, Wichita, KS, Washington Hospital Center, Washington, DC, Technische Universität München, Munich, Germany 86. Efficacy and Safety of Pregabalin in Japanese Patients with Fibromyalgia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase III Trial and Open-Label Extension Study. Hiroyoshi Ohta, Masayuki Ohkura, Makoto Suzuki, Hiroshi Oka, Chie Usui and Kusuki Nishioka 4, Pfizer Japan Inc, Tokyo, Japan, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, Juntendo University Nerima Hospital, Tokyo, Japan, 4 Tokyo Medical University, Tokyo, Japan 86. The 0 Canadian Fibromyalgia Guidelines: Clinically Applicable Recommendations for the Management of Fibromyalgia. Mary-Ann Fitzcharles, Peter A. Ste- Marie, Don L. Goldenberg, John X. Pereira 4, Susan Abbey 5, Manon Choinière, Gordon Ko 5, Dwight Moulin 6, Pantelis Panopalis 7, Johanne Proulx 8 and Yoram Shir, McGill University, Montreal, QC, University of Montreal, Montreal, QC, Newton-Wellesley Hosp, Newton, MA, 4 University of Calgary, Calgary, AB, 5 University of Toronto, Toronto, ON, 6 University of Western Ontario, London, ON, 7 McGill University Health Center, Montreal, QC, 8 Patient Representative, Montreal, QC 86. Resetting the Naming Speed Clock with Methylphenidate (Ritalin). Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL 864. Swimming Is As Effective As Walking for Treating Fibromyalgia: A Randomized Controlled Trial. Giovana Fernandes, Fabio Jennings, Michele V. Nery, Ana Leticia P. de Buosi and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil 865. Emotional Pain and Catastrophizing Influence Quality of Life in Fibromyalgia. Neda Faregh, Peter A. Ste-Marie and Mary-Ann Fitzcharles, McGill University, Montreal, QC, University of Montreal, Montreal, QC 866. Association of Opioid Use with Symptom Severity and Quality of Life in Patients with Fibromyalgia. Terry H. Oh, Chul H. Kim, Connie A. Luedtke, Jeffrey Thompson, W. Michael Hooten and Ann Vincent, Mayo Clinic, Rochester, MN, Kyungpook National University, Daegu, South Korea 867. Assessment of ART Therapy Program for Women with Fibromyalgia: Randomized, Controlled, Blinded Study. andreia S. Baptista, Anamaria Jones, Fernanda P. Cardoso, Betina C. Schaffir, Elisa R. W. Coelho, Aline Orlandi and Jamil Natour, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil 868. Clinical Outcome in Fibromyalgia Patients Treated with Milnacipran Is Largely Independent of Symptom Duration. Philip Mease, Robert M. Bennett, Robert H. Palmer and Yong Wang, Swedish Medical Center and University of Washington, Seattle, WA, Oregon Health & Science University, Portland, OR, Forest Research Institute, Jersey City, NJ 0 Program Book 69

272 ACR POSTER SESSION C Predictors of Fatigue in Fibromyalgia. Ann Vincent, Mary O. Whipple, Debra L. Barton, Daniel J. Clauw, David A. Williams, Terry H. Oh and Loren L. Toussaint 4, Mayo Clinic, Rochester, MN, University of Michigan, Ann Arbor, MI, Univ of MI Hlth System-Lobby M, Ann Arbor, MI, 4 Luther College, Decorah, IA 870. Financial Conflicts of Interest and Industry Sponsorship Are Associated with Positive Outcomes in Fibromyalgia Randomized Controlled Trials. Winnie K. Pang, Karen Yeter, Nasim A. Khan and Karina D. Torralba, University of Southern California Keck School of Medicine, Los Angeles, CA, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR 87. Tender Point Count and Pressure Pain Threshold As Predictors of Chronic Widespread Pain and Health Status in a Seven Year Prospective Study. Emma Jacobsen and Stefan Bergman, R&D center Spenshult, Oskarström, Sweden, R&D Center Spenshult, Oskarström, Sweden 87. Quality of Reporting in Pharmacological Randomized Controlled Trials for Fibromyalgia. Karen Yeter, Winnie Pang, Nasim A. Khan and Karina D. Torralba, University of Southern California Keck School of Medicine, Los Angeles, CA, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR 87. Clinical Characteristics and Health Care Utilization Patterns Among Patients with Fibromyalgia Newly Prescribed Amitriptyline, Duloxetine, Gabapentin or Pregabalin: A Large Cohort Study. Seoyoung C. Kim, Joan E. Landon and Daniel H. Solomon, Brigham and Women s Hospital, Boston, MA 874. Genomic Categories of Fatigue in Women with Fibromyalgia. Nada Lukkahatai, Brian T. Walitt, Majors Benjamin, Gelio Alves and Leorey Saligan, National Institute of Nursing Research, National Institutes of Health, Bethesda, MD, Washington Hospital Center, Washington, DC, National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD 875. A Patient and Physician Survey of Impact and Management of Fibromyalgia Across Latin America and Europe. Patricia Clark, Hospital Infantil de México Federico Gómez, Mexico City, Mexico 876. The Assessment and Treatment of Nonsurgical Periarticular Post-Traumatic Soft Tissue Injuries of the Knee. Dan Nemes, Elena Amaricai, Liliana Catan, Daniel Popa, Simona Cerbu and Paula Bicov, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania, Telescan Imaging Centre, Timisoara, Romania 877. Is the Amount of T and B Lymphocytes, Natural Killer Cells and Macrophages in Biopsies From Non-Ruptured Chronic Tendinopathic Achilles Tendons Predictive for Long Term Outcome? A > Years Prospective Study of 7 Patients. Maja S. Kragsnæs, Ulrich Fredberg, Katrine Stribolt, Søren G. Kjær, Knud Bendix and Torkell Ellingsen, Region Hospital Silkeborg, Silkeborg, Denmark, Diagnostic 0 Program Book Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, Aarhus University Hospital, Aarhus, Denmark 878. Cognitive Manifestations of Fibromyalgia and Lupus. Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL 879. Work Related Injuries Causing or Aggravating Fibromyalgia in the Medicolegal Arena: A Jurisprudential Analysis. Mary-Ann Fitzcharles, Peter A. Ste-Marie and Yoram Shir, McGill University, Montreal, QC, University of Montreal, Montreal, QC 880. A Brazilian Portuguese Validation of the Revised Fibromyalgia Impact Questionnaire (FIQR). Eduardo S. Paiva, Roberto E. Heymann, Marcelo C. Rezende, Milton Helfenstein Jr. 4, José E. Martinez 5, José R. Provenza 6, Aline Ranzolin 7, Marcos Renato Assis 8, Vivian D. Pasqualin 9 and Robert M. Bennett 0, Universidade Federal do Paraná, Curitiba, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil, Santa Casa de Campo Grande, Campo Grande, Brazil, 4 Universidade Federal de de São Paulo, São Paulo, Brazil, 5 Pontifícia Universidade Católica de São Paulo, Sorocaba, Brazil, 6 Pontifícia Universidade Católica de Campinas, Campinas, Brazil, 7 Universidade Federal de Pernambuco, Recife, Brazil, 8 Faculdade de Medicina de Marilia, Marilia, Brazil, 9 Pontifícia Universidade Católica do Paraná, Curitiba, Brazil, 0 Oregon Health & Science Univ, Portland, OR 88. Increased Psychosocial Stress Is a Major Component of Fibromyalgia Triggers. Emma K. Guymer, Kathleen Elford and Geoffrey O. Littlejohn, Monash Medical Centre and Monash University, Clayton, Victoria, Australia, Monash Medical Centre, Clayton, Victoria, Australia 88. Predictors of a Favorable Outcome in Patients with Fibromyalgia: Results from the -Year Follow-up. Dong- Jin Park, Shin-Seok Lee, Seong-Ho Kim, Seong-Su Nah, Ji Hyun Lee 4, Seong-Kyu Kim 5, Yeon-Ah Lee 6, Seung-Jae Hong 6, Hyun-Sook Kim 7, Hye-Soon Lee 8, Hyoun Ah Kim 9, Chung-Il Joung 0 and Sang-Hyon Kim, Chonnam National University Medical School, Gwangju, South Korea, Inje University Haeundae Paik Hospital, Busan, South Korea, Soonchunhyang University, South Korea, 4 Maryknoll Medical Center, Busan, South Korea, 5 and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 6 Kyung Hee University, Seoul, South Korea, 7 Internal Medicine, Chosun University Hospital, Gwangju, South Korea, 8 Hanyang University Guri Hospital, Guri, South Korea, 9 Ajou University School of Med, Suwon, South Korea, 0 Konyang University Medical School, Daejeon, South Korea, Dongsan Medical Center, Keimyung University, Daegu, South Korea 88. Efficacy and Safety of Joint and Soft Tissue Injections; A Retrospective Study. Jenny Cabas-Vargas, Leah Alon, Nina Ramessar, Dimitre Stefanov, Jose B. Toro and Deana M. Lazaro 4, SUNY Downstate, Brooklyn, NY, SUNY Downstate Medical Center, Brooklyn, NY, Brooklyn VA, Brooklyn, NY

273 ACR POSTER SESSION C 884. Fibromyalgia Patients Who Meet the ACR 990 Criteria Have More Severe Disease. Carmen E. Gota, Benjamin Nutter and William Wilke, The Cleveland Clinic Desk A50, Cleveland, OH, Cleveland Clinic, Cleveland, OH, Cleveland Clinic Foundation, Cleveland, OH Medical Education 885. Rheumatologists Ultrasound Confidence and Interpretation of Normal Anatomy Are Improved by a Cadaver Based Sonoanatomy Course. Iain Goff, David Wright and Debra Patten, Newcastle University, Newcastle upon Tyne, United Kingdom, Sunderland Royal Hospital, Sunderland, United Kingdom, School of Medical Sciences Education and Development, Newcastle upon Tyne, United Kingdom 886. Evaluation of a New Educational Tool: A Resident s Guide to Pediatric Rheumatology. Tania Cellucci and Ronald M. Laxer, The Hospital for Sick Children, Toronto, ON 887. Facebook Support Groups in Systemic Lupus Erythematosus: Content Analysis. Evelyne Vinet, William Shihao Lao, Christian A. Pineau, Ann E. Clarke and Sasha Bernatsky 4, McGill University Health Centre, Montreal, QC, McGill University, Montreal, QC, MUHC, Montreal, QC, 4 Research Institute of the McGill University Health Ctre, Montreal, QC 888. Immunology for Rheumatology Residents: Working towards a National Curriculum Consensus. Shirley L. Chow, Dharini Mahendira, Sari Herman-Kideckel and Heather McDonald-Blumer 4, University of Toronto, Toronto, ON, St Michael s Hospital, Toronto, ON, University of Toronto, North York, ON, 4 Mt. Sinai Hospital, Toronto, ON 889. The Effects of Physical & Mental Health Rehabilitation Program (PMHRP) for Hemophilic Arthritis Patients. Won Sook BAK, Myung Chul Yoo, Nam Su Cho, Sang Hack Lee, Yoon Hee Kim and Ki Young Yoo, Kyung Hee University Hospital at Gangdong, Seoul, South Korea, Seoul, South Korea 890. The Current State of Mentoring Among Pediatric Rheumatology Fellows and Junior Faculty in the United States and Canada. Meredith P. Riebschleger, Eyal Muscal, Matthew M. Davis, Hermine Brunner 4, B. Anne Eberhard 5, C.J. Inman 6, Marisa S. Klein-Gitelman 7, Lakshmi N. Moorthy 8, Marc D. Natter 9, Sampath Prahalad 0, Rayfel Schneider and Peter A. Nigrovic, University of Michigan Health System, Ann Arbor, MI, Baylor College of Medicine, Houston, TX, University of Michigan, Ann Arbor, MI, 4 Cincinnati Children s Hospital Medical Center and PRSCG, Cincinnati, OH, 5 Cohen Children s Hospital Medical Center, New Hyde Park, NY, 6 University of Utah, Salt Lake City, UT, 7 Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, 8 Robert Wood Johnson-UMDNJ, New Brunswick, NJ, 9 Children s Hospital Boston, Boston, MA, 0 Emory Children s Center, Atlanta, GA, The Hospital for Sick Children, Toronto, ON, Brigham and Women s Hospital, Boston, MA 89. Teaching Medical Students Principles of Chronic Disease: Medicine of the 4th and 5th Dimension at Weill-Cornell. Michael D. Lockshin, Greg McDermott, Lester Zambrana and Alana B. Levine, Hospital for Special Surgery, New York, NY, Weill-Cornell Medical College, New York 89. Impact of a Lupus Patient Education Event on Knowledge about Systemic Lupus Erythematosus. Mithu Maheswaranathan, Melissa A. Cunningham, Sharon Wolf and Diane L. Kamen, Medical University of South Carolina, Charleston, SC, MUSC, Charleston, SC, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC 89. Eliciting Prescribing Choices of Anti-Tumour Necrosis Factor Therapy from Rheumatology Trainees. Rodney A. Hughes and Alison J. Carr, St. Peters Hospital, Chertsey Surrey, United Kingdom, Hamell Communications, London, United Kingdom 894. Factors Associated with Confidence Level of Rheumatology Fellows in Joint Procedural Skills. Tara J. Rizvi, Min Xu and Nancy Searle, Baylor College of Medicine, Houston, TX 895. Safety Competences Knowledge and Behavioural Skills of Patients Treated by Biologics in Rheumatology. Anne- Christine Rat, Bruno Fautrel, Elisabeth Flipon, Laure Gossec 4, Benoit-Damien Caritey 5, Laurent Marguerie 6, Henri Nataf 7, Beatrice Pallot Prades 8, Rose Marie Poilvert 9, Valerie Royant 0, Fathia Sadji, Christelle Sordet, Corinne Thevenot and Catherine Beauvais 4, Université de Lorraine, Paris Descartes University, APEMAC, EA 460, F , Nancy, France, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, Cochin hospital, Paris, France, 4 Paris-Descartes University, Cochin Hospital, Paris, France, 5 Université de lorraine, Nancy, France, 6 Institut Calot, Berck, France, 7 Mantes-la-Jolie, Mantes-la-Jolie, France, 8 Saint Etienne university hospital, Saint Etienne, France, 9 Saint Antoine Hospital, Paris, France, 0 Chartres, Chartres, Victor Jousselin Hospital, Dreux, France, Strasbourg University Hospital, Strasbourg, France, Laon hospital, Laon, France, 4 Saint Antoine, Paris, France 896. Variation in US Pediatric Rheumatology Fellowship Training. Anjali Patwardhan, Michael Henrickson, Sandy D. Hong, Laura Laskosz and Charles H. Spencer, Nationwide Childrens Hospital, Columbus, OH, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, U of Iowa Children s Hosp, Iowa City, IA 897. Pregnancy and Contraception in Adolescents and Teens with SLE: Are pediatric rheumatologists adequately screening and Educating Their Patients? Deirdre I. De Ranieri, Karen Onel, Linda Wagner-Weiner and Melissa S. Tesher, University of Chicago, Chicago, IL, University of Chicago Hospital, Chicago, IL 898. A Competence-Based Model for Teaching Rheumatology in Undergraduate Medical Students in Pontificia Universidad Católica De Chile: A Five Years Experience. Pamela Díaz, 0 Program Book 7

274 ACR POSTER SESSION C 7 Carolina Cuellar, Miguel Gutiérrez and Marcela Cisternas, Pontificia Universidad Católica de Chile, Santiago, Chile 899. Factors Contributing to Non-Publication of Abstracts Presented At the American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting. Jennifer M.P. Woo, De Furst, Deborah K. McCurdy, Olivia I. Lund, Rotem Eyal, Cijin Piao and Gil Amarilyo, Mattel Children s Hospital, University of California, Los Angeles, Los Angeles, CA, University of California at Los Angeles, Los Angeles, CA, David Geffen School of Medicine at UCLA, Los Angeles, CA 900. Mormed Project: A New st Century Web Platform for Multilingual Communication in systemic Lupus Erythematosus and Antiphospholipid Syndrome. Oier Ateka-Barrutia, Adriane Rinsche, Maria Laura Bertolaccini, Munther A. Khamashta and MORMED consortium, Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, Language Technology Center Ltd., Kingston, United Kingdom, EU Metabolic and Crystal Arthropathies 90. Chronic Gout. Improvement According to Outcome Meaures in Rheumatology Domains in Daily Clinical Practice. Janitzia Vazquez-Mellado, Betsabé Serrano, Jaime Mendoza, Sergio Garcia-Mendez, V.Chantal Hernández, Virginia Pascual Ramos, Ruben Burgos-Vargas and Marina Rull-Gabayet, Hospital General de Mexico, Mexico city, Mexico, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico 90. What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout? Nicola Dalbeth, Meaghan House, Anne Horne, Keith J. Petrie, Fiona M. McQueen and William Taylor, University of Auckland, Auckland, New Zealand, University of Otago, Wellington, New Zealand 90. Oxidation of Urate to Allantoin by Myeloperoxidase in Gout. Lisa K. Stamp, Irada Khalilova, Mei Zhang, Rufus Turner and Anthony Kettle, University of Otago, Christchurch, Christchurch, New Zealand 904. Patterns of Gout Treatment and Related Outcomes in US Community Rheumatology Practices: the Relation between Gout Flares, Time in Treatment, Serum Uric Acid Level and Urate Lowering Therapy. Max I. Hamburger, John RP Tesser, John L. Skosey, Allan H. Morton 4 and Karl M. Kilgore 5, Rheumatology Associates, Melville, NY, AZ Arthritis Rheum Assoc, Paradise Valley, AZ, Illinois Bone & Joint Institut, Chicago, IL, 4 Warren, MI, 5 Cetus Group, LLC, Hunt Valley, MD 905. Increase of Thyroid Stimulating Hormone in Patients On Febuxostat Treatment. Fernando Perez-Ruiz and Ana M. Herrero-Beites, Hospital Universitario Cruces, Baracaldo, Spain, Hospital de Gorliz, Gorliz, Spain 0 Program Book 906. Changes in Gout patient s Clinical Profile in the Last Two Decades. Fernando Perez-Ruiz and Ana M. Herrero-Beites, Hospital Universitario Cruces, Baracaldo, Spain, Hospital de Gorliz, Gorliz, Spain 907. Pharmacological Management of Gout in Italy in the Years : A Nationwide, Population-Based Study. Lorenzo Cavagna, Gianluca Trifirò, Roberto Caporali, P. Morabito, C. Ferrajolo 4, S. Pecchioli 5, M. Simonetti 5, G. Medea 6, C. Cricelli 7, A. Caputi, G. Mazzaglia 5 and Carlomaurizio Montecucco 8, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, University of Messina, Italy, Division of Rheumatology, IRCCSPoliclinico S. Matteo Foundation, Pavia, Italy, 4 Second University of Naples, Naples, Italy, 5 Italian College of General Practitioners, Italy, 6 Italian college of General Practitioner, Italy, 7 Italian college of General Practitioner, Pavia (italy), Italy, 8 University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy 908. Multinational Evidence-Based Recommendations for Diagnosis and Management of Gout: Integrating Systematic Literature Research and Expert Opinion of a Broad Panel of Rheumatologists in the E Initiative. Mariano andres, Francisca Sivera, Alison Kydd, John Moi 4, Rakhi Seth 5, Melonie K. Sriranganathan 6, Caroline van Durme 7, Irene AAM van Echteld 8, Ophir Vinik 9, Mihir D. Wechalekar 0, Daniel Aletaha, Claire Bombardier 9, Rachelle Buchbinder, Loreto Carmona, Christopher J. Edwards 4, R. Landewe 5 and Désirée van der Heijde 6, Hospital General Universitario de Alicante, Alicante, Spain, Hospital General de Elda, Alicante, Spain, University of British Columbia, Vancouver, BC, 4 Royal Melbourne Hospital, Melbourne, Australia, 5 University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, 6 St. Mary s Hospital, Isle of Wight, United Kingdom, 7 Maastricht University Medical Centre, Maastricht, Netherlands, 8 Atrium Medical Center, Heerlen, Netherlands, 9 University of Toronto, Toronto, ON, 0 Flinders University School of Medicine, Adelaide, Australia, Medical University of Vienna, Vienna, Austria, Monash Department of Clinical Epidemiology at Cabrini Hospital, Department of Epidemiology and Preventive Medicine, Monash University, Malvern, Australia, Malvern, Victoria, Australia, Universidad Camilo José Cela, Villanueva de la Cañada, Spain, 4 University Hospital Southampton, Southampton, United Kingdom, 5 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 6 Leiden University Medical Center, Leiden, Netherlands 909. Use of Uric Lowering Therapies within a Large Health Care System. Robert A. Overman, Brian F. Mandell and Chad L. Deal, Cleveland Clinic Foundation, Cleveland, OH, The Cleveland Clinic, Cleveland, OH, Cleveland Clinic, Cleveland, OH 90. Regulation of Microrna Expression in a Gouty Arthritis. Gianina Statache, Ashleigh-Ann Rainey, Seth Masters, andra Balanescu, Iain B. McInnes and Mariola Kurowska-

275 ACR POSTER SESSION C Stolarska 4, University of Glasgow, Glasgow, United Kingdom, Trinity College Dublin, Dublin, United Kingdom, University of Medicine and Pharmacy, Bucharest, Romania, 4 Institute of Infection,Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow,, Glasgow, United Kingdom 9. Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT. T. Bardin, A. So, R. Alten, M. Bloch 4, M. R. John 5, G. Krammer 5, J. M. Nebesky 5, A. Tao 6 and N. Schlesinger 7, Service de Rhumatologie, Hôpital Lariboisière, Paris, France, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, Charité Univ Medicine, Berlin, Germany, 4 Holdsworth House Medical Practice, Sydney, Australia, 5 Novartis Pharma AG, Basel, Switzerland, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7 UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 9. Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 6 Hours in Patients with Acute Gout Flares. Suman Wason, Thomas Lauterio, Steve Crockett and Matthew W. Davis, URL Pharma, Philadelphia, PA 9. Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment. Michael A. Becker, Neil J. Gonter, Janet E. Pope, Raymond L. Malamet 4 and Herbert S. B. Baraf 5, University of Chicago, Chicago, IL, Rheumatology Associates of North Jersey, Teaneck, NJ, St. Joseph Health Care London, University of Western Ontario, London, ON, 4 Savient Pharmaceuticals, Inc., East Brunswick, NJ, 5 Arthritis & Rheumatism Associates, Wheaton, MD 94. The Diagnosis and Management of Gout in 0: Survey of US and Canadian Rheumatologists. John J. Cush and Robert T. Keenan, Baylor Research Institute, Dallas, TX, Duke University, Durham, NC 95. Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients. Sang Tae Choi, Jung- Soo Song, Jin Su Kim, Eun-Jin Kang, Kwang-Hoon Lee 4 and You-Jung Ha 5, Chung-Ang University School of Medicine, Seoul, South Korea, Chung-Ang University College of Medicine, Seoul, South Korea, Busan Medical Center, Busan, South Korea, 4 Dongguk University Ilsan Hospital, Goyang, South Korea, 5 Kwandong University college of Medicine, Goyang, South Korea 96. Serum Uric Acid As a Biomarker for Mitigation of Infusion Reactions in Patients Treated with Pegloticase for Refractory Chronic Gout. Herbert S. B. Baraf, Robert A. Yood, John S. Sundy, Faith D. Ottery 4 and Michael A. Becker 5, Arthritis & Rheumatism Associates, Wheaton, MD, Reliant Medical Group, Worcester, MA, Duke University Medical Center, Durham, NC, 4 Savient Pharmaceuticals, Inc., East Brunswick, NJ, 5 University of Chicago, Chicago, IL Miscellaneous Rheumatic and Inflammatory Diseases 97. Long-Term Follow-up of IgG4-Related Diseases Presenting with Lacrimal and Salivary Gland Involvement. Hiroki Takahashi, Motohisa Yamamoto, Tetsuya Tabeya, Chisako Suzuki, Yasuyoshi Naishiro, Yasuhisa Shinomura and Kohzoh Imai, Sapporo Medical University School of Medicine, Sapporo, Japan, The University of Tokyo, Tokyo, Japan 98. Cluster Analysis of Organ Involvements Patients with Serum IgG4 Elevation; IgG4 related Disease Is a Distinct Subtype of Patients with Hyper-IgG4. Masamitsu Tatewaki, Kazuhiro Kurasawa, Ayae Tanaka, Junya Nagasawa, Satoko Arai, Reika Maezawa, Takayoshi Owada and Takeshi Fukuda, Dokkyo Medical University, Mibu, Tochigi, Japan 99. Regulatory T Cells in IgG4-Related Disease Patients Presenting with Sclerosing Sialadenitis and Dacryoadenitis. Winnie K. Pang, Ya Liu, Julie Wang, Song Guo Zheng, Kiran Qidwai, Russell K. Brynes and Francisco P. Quismorio Jr., University of Southern California Keck School of Medicine, Los Angeles, CA 90. Spectrum of IgG4-Related Disease and Diagnostic Value of Serum IgG4 Determinations. Emma Kotisalmi, Tom Pettersson, Aaro Miettinen, Johanna Arola 4 and Martti Färkkilä, University of Helsinki, Helsinki, Finland, Helsinki University Central Hospital, Helsinki, Finland, Huslab, Helsinki, Finland, 4 University of Helsinki and Huslab, Helsinki, Finland 9. Diagnostic Utility of Serum IgG4 in IgG4-Related Disease. Mollie Carruthers, Tamara Augustin, John H. Stone and Arezou Khosroshahi, Massachusetts General Hospital, Boston, MA, Internal Medicine, Northshore Medical Center, Salem, MA 9. Articular Involvement in Relapsing Polychondritis: A Case Series. Laura O. Damian, Linda Ghib, Ioana Felea, Alma Maniu, Nadia Radics, Simona Falaus, Ileana Filipescu 4, Siao-pin Simon and Simona Rednic 4, Emergency County Clinical Hospital Cluj Napoca, Cluj Napoca, Romania, Emergency County Clinical Hospital Cluj Napoca, Cluj- Napoca, Romania, University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca, Cluj Napoca, Romania, 4 University of Medicine and Pharmacy Iuliu Hatieganu Cluj Napoca, Cluj-Napoca, Romania 9. Biologics in Relapsing Polychondritis: A Single Center Case- Series. Guillaume Moulis, Laurent Sailler, Grégory Pugnet, Leonardo Astudillo and Philippe Arlet, Toulouse University Hospital, University of Toulouse, Toulouse, France, Toulouse University Hospital, University of Toulouse, INSERM UR 07, Toulouse, France, Toulouse University Hospital, University of Toulouse, INSERM UMR 07, Toulouse, France 94. What Do Patients with Polmyalgia Rheumatica Mean When They Describe Stiffness? A Qualitative Study. Rodney A. Hughes, Sarah Mackie, John R. Kirwan, Colin T. Pease 4, Margaret Walsh and Marianne Morris 5, St. Peters 0 Program Book 7

276 ACR POSTER SESSION C 74 Hospital, Chertsey Surrey, United Kingdom, University of Leeds, Leeds, United Kingdom, Bristol Royal Infirmary, Bristol, United Kingdom, 4 Leeds Teaching Hospitals NHS Trust, Harrogate, United Kingdom, 5 University of the West of England, Bristol, United Kingdom 95. Patient Satisfaction and Experience with Golimumab, Adalimumab, and Etanercept for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Susan Bolge, Helen Eldridge, Dilesh Doshi, Lorie Ellis, Barbara Roland and John Woelfel, Janssen Scientific Affairs, LLC, Horsham, PA, Janssen Pharmaceuticals, Inc, Titusville, NJ, The Dominion Group, Reston, VA 96. Evaluation of Strategies to Taper Anti-TNF Drugs in Patients with Inflammatory Rheumatic Disease (Rheumatoid Arthritis, Ankyloing Spondylitis, Psoriatic Arthritis, Adultage Juvenile Idiopatic Arthritis) in Long-Term Remission. Jakub Zavada, Katarina Hviscova, Katerina Jarosova, Sarka Forejtova, Jiri Stolfa, Liliana Sedova, Dana Tegzova, Jiri Vencovsky and Karel Pavelka, Institute of Rheumatology, Prague, Czech Republic 97. Inflammatory Meningeal Involvement in Patients with Rheumatic Diseases Responsive to Rituximab. Jane Park, Eyal Kedar, Ingeborg Sacksen, John Henson and Gregory C. Gardner, University of Washington, Seattle, WA, Swedish Neuroscience Institute, Seattle, WA 98. Evaluating the Therapeutic Effects of B Cell Depletion Therapy with Rituximab in a Longitudinal Cohort of Mixed Connective Tissue Disease Patients. Ragnar Gunnarsson, Inge-Margrethe Gilboe, Torhild Garen and Øyvind Molberg, Oslo University Hospital Rikshospitalet, Oslo, Norway 99. Pernicious Anemia and Vitamin B- Deficiency in Autoimmune Disease: Neglecting the Feet Will Lead You Astray. Michael R. Lovy, Desert Oasis Healthcare, Palm Springs, CA 90. Progranulin Plays a Protective Role in the Pathogenesis of Inflammatory Bowel Disease. Fanhua Wei, Jinlong Jian, Yuying Zhang, Jiqiang Lin, Juan Lafaille, Michael Dustin, Lloyd Mayer 4 and Chuanju Liu 5, NYU Hospital for Joint Diseases, New York, NY, New York, NY, NYU School of Medicine, New York, NY, 4 Mount Sinai Medical Center, New York, NY, 5 New York University, New York, NY 9. Influence of Trough Serum Drug Level and Immunogenicity on the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients. Shui Long Wang, Scott Hauenstein, Linda Ohrmund, Reshma Shringarpure, Douglas C. Wolf, Isam A. Diab, Jared Salbato, Rukmini Reddy, Kevin McCowen, Shawn Shah, Steven Lockton, Emil Chuang and Sharat Singh, Prometheus Laboratories, San Diego, CA, Atlanta Gastroenterology Associates, Atlanta, GA, Paramount Medical Research & Consulting, Middleburg Heights, OH 0 Program Book 9. Clinical Features of an Aromatase Inhibitor Associated Syndrome Presenting as Rheumatoid Arthritis Ronald J. anderson, MD, Brigham &Women s Hospital. Ronald J. anderson, Brigham & Womens Hospital, Boston, MA 9. Incidence and Early Detection of Retinal Toxicity in Patients Treated with Chloroquine and Hydroxichloroquine in Rheumatology Practice. Sandra Soro Marin, Ana del Carmen Haro Martínez, Deseada Palma Sanchez, María del Rocío Gonzalez Molina, Marta Mayor Gonzalez and Elena Rubio Velazquez, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, Rafael Mendez Hospital, Lorca (Murcia), Spain, Rafael Mendez Hospital, Lorca (Murcia) 94. Improvement in Cryoglobulin Detection Employing a Temperature Controlled Sample Transporter. W. Winn Chatham, Moon Nahm and William H. Benjamin Jr., University of Alabama at Birmingham, Birmingham, AL Muscle Biology, Myositis and Myopathies: Genetics, Autoantibodies and other Molecular Aspects of Idiopathic Inflammatory Myopathies and Models 95. Longitudinal Peripheral Blood Lymphocyte Subsets Correlate with Decreased Disease Activity in Juvenile Dermatomyositis. Floranne C. Ernste, Cynthia S. Crowson, Consuelo Lopez de Padilla, Molly Hein, Abigail B. Green and Ann M. Reed, Mayo Clinic Rochester, Rochester, MN, Mayo Clinic, Rochester, MN 96. The human leukocyte antigen DRB*:0-DQB*06:04 - DPB*04:0 haplotype isclosely associated with dermatomyositis patients with Anti-CADM-40 (melanoma differentiation-associated protein 5: MDA5) Antibody. Yuji Hosono, Chikashi Terao, Ran Nakashima, Yoshitaka Imura, Naoichiro Yukawa, Hajime Yoshifuji, Motomu Hashimoto, Koichiro Ohmura, Takao Fujii and Tsuneyo Mimori, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto University, Kyoto, Japan 97. HLA-DRB*00/*0405 Is Associated with Susceptibility to Anti-MDA5 Antibody-Positive Dermatomyositis in the Japanese Population. Takahisa Gono, Yasushi Kawaguchi, Masataka Kuwana, Tomoko Sugiura, Takefumi Furuya, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Masanori Hanaoka, Yuko Okamoto, Yuko Ota, Sayuri Kataoka and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Keio University School of Medicine, Tokyo, Japan 98. A New Enzyme-Linked Immunosorbent Assay System for Detecting Autoantibodies to Aminoacyl-tRNA Synthetases: Clinical Usefulness in Myositis and Interstitial Pneumonia. Ran Nakashima, Yoshitaka Imura, Minae Seto, Akihiro Murakami, Yuji Hosono, Kizuku Watanabe 4, Tomohiro Handa 4, Michiaki Mishima 4, Michito Hirakata 5, Tsutomu Takeuchi 6, Keishi Fujio 7, Kazuhiko Yamamoto 8, Hitoshi Kohsaka 9, Yoshinari Takasaki 0, Noriyuki Enomoto, Kingo Chida, Toshihiro Nukiwa and Tsuneyo Mimori, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto University Graduate School of Medicine, Kyoto, Japan,

277 ACR POSTER SESSION C Medical & Biological Laboratories Co., Ltd., Ina, Japan, 4 Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, 5 Keio University, Tokyo, Japan, 6 Keio University School of Medicine, Tokyo, Japan, 7 Graduate school of Medicine, The University of Tokyo, Tokyo, Japan, 8 Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 9 Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 0 Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan, Hamamatsu University School of Medicine, Hamamatsu, Japan, Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan 99. Overexpression of Ankyrin Repeat Domain Containing Protein Gene (ANKRD) in Dermatomyositis Muscle Biopsies Is Correlated to Hypoxia and Perifascicular Atrophy. Samuel K. Shinjo, Sueli M. Oba-Shinjo, Miyuki Uno and Suely K. N. Marie, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 940. A Comprehensive Study of Novel Serum Markers of ILD Associated with Inflammatory Myopathies. Fang Chen, Xiaoming Shu, Xin Lu and Guochun Wang, China-Japan Friendship Hospital, Beijing, China 94. Clinical Evaluation of Anti-Aminoacyl trna Synthetase Antibodies in Japanese Patients with Connective Tissue Diseases. Masakazu Matsushita, Toshio Kawamoto, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Juntendo University School of Medicine, Tokyo, Japan 94. Increased Levels of Eotaxin and MCP- in Juvenile Dermatomyositis Median 7 Years after Diagnosis; Associations with Disease Activity, Duration and Organ Damage. Helga Sanner, Thomas Schwartz, Berit Flatø, Maria Vistnes, Geir Christensen and Ivar Sjaastad, Oslo University Hospital, Oslo, Norway, University of Oslo, Oslo, Norway 94. Autophagy Expressions Were Decreased in Circulating T Cells in Inflammatory Myopathies Patients. Fang Chen, Xiaoming Shu, Xin Lu and Guochun Wang, China-Japan Friendship Hospital, Beijing, China 944. Expression of Human Leukocyte Antigen-G in Polymyositis or Dermatomyositis. Xiaolan Tian, Xiaoming Shu, Xin Lu, Qinglin Peng and Guochun Wang, China-Japan Friendship Hospital, Beijing, China 945. Anti-Transcription Intermediary Factor -Gamma (TIF-Υ) Autoantibody Detection by ELISA and Immunoprecipitation in a Prospective Myositis Cohort: Predictive Value for Cancer Associated Myositis. Rohit Aggarwal, Noreen Fertig, Danielle Goudeau, Chad Stephans, Qi Zengbiao, Diane Koontz, Mary Lucas, Marc C. Levesque and Chester V. Oddis, University of Pittsburgh, Pittsburgh, PA 946. Effect of Immunosuppressive Treatment On Gene Expression in Patients with Polymyositis and Dermatomyositis. Ingela M. Loell, Yi-Wen Chen, Marina Korotkova, Kanneboyina Nagaraju and Ingrid E. Lundberg, Karolinska Institutet, Stockholm, Sweden, Children s National Medical Center, Washington, Children s National Medical Center, Washington, DC 947. Muscle Wasting in HTNFtg Mice, an Animal Model for Rheumatoid Arthritis, Due to Increased Cathepsin L and LCB Expression. Martin Willburger, Birgit Niederreiter, Ewald Unger, Josef S. Smolen, Kurt Redlich and Silvia Hayer, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 948. Decreased C4A Gene Copy Numbers in Children with Juvenile Dermatomyositis: Association with Decreased C4 Protein and Lower Absolute Number of CD Negative CD6/56+ Natural Killer Cells. Lauren M. Pachman, Katherine E. Lintner, Yee Ling Wu, Lori J. Ferguson, Gabrielle A. Morgan, Chiang-Ching Huang 4 and C. Yung Yu, Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, The Research Institute at Nationwide Children s Hospital and The Ohio State University, Columbus, OH, Children s Hospital of Chicago Research Center, Cure JM Myositis Center, Chicago, IL, 4 Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 949. Anti-Transcription Intermediary Factor -Gamma (TIF-Υ) Autoantibody ELISA Development and Validation. Rohit Aggarwal, Chester V. Oddis, Noreen Fertig, Danielle Goudeau, Diane Koontz, Chad Stephans, Zengbiao Qi and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA 950. Anti-Signal Recognition Particle Autoantibody ELISA Development and Validation: Utility in Patients with Necrotizing Myopathy. Rohit Aggarwal, Chester V. Oddis, Danielle Goudeau, Chad Stephans, Noreen Fertig, Qi Zengbiao, Diane Koontz and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA 95. Elevated Level of Tumor Necrosis Factor-Like Weak Inducer of Apoptosis in Patients with Polymyositis or Dermatomyositis. Qinglin Peng, Xin Lu, Ning Zu, Lu Zhang and Guochun Wang, China-Japan Friendship Hospital, Beijing, China 95. The Effect of CXCL0 Blockade in C Protein-Induced Myositis. Jinhyun Kim, Jiyong Choi, Sung Hae Chang, Ki Chul Shin, Sung-Hye Park, Hye Won Kim 4, Hye Jin Oh, Myeong Jae Yoon 4, Bong Seung Ku 5, Eun Young Lee, Eun Bong Lee, Hiroshi Kawachi 6, Hitoshi Kohsaka 7 and Yeong Wook Song, Chungnam National University School of Medicine, Daejeon, South Korea, Seoul National University College of Medicine, Seoul, South Korea, Seoul National University Hospital, Seoul, South Korea, 4 Department of Internal Medicine, School of Medicine, Seoul National University, Seoul, South Korea, 5 Department of Internal 0 Program Book 75

278 ACR POSTER SESSION C 76 Medicine, School of Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, South Korea, 6 Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 7 Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan 95. Antibodies to NXP- and Transcriptional Intermediary Factor-Gamma Identify Patients with Cancer-Associated Dermatomyositis. David Fiorentino, Lisa Christopher-Stine, Lorinda Chung, Bharathi Lingala 4, Andrew L. Mammen 5, Antony Rosen 6 and Livia Casciola-Rosen, Stanford University School of Medicine, Redwood City, CA, Johns Hopkins University, Baltimore, MD, Stanford Univ Medical Center, Palo Alto, CA, 4 Stanford University, Redwood City, CA, 5 Johns Hopkins, Baltimore, MD, 6 The Johns Hopkins University, Baltimore, MD 954. Immune Responses to NXP- and TIF-g Are Associated with Distinct Clinical Phenotypes and Prognosis for Skin Disease in Dermatomyositis Patients. David Fiorentino, Lorinda Chung, Lisa Zaba, Bharathi Lingala, Antony Rosen 4 and Livia Casciola-Rosen 5, Stanford University School of Medicine, Redwood City, CA, Stanford Univ Medical Center, Palo Alto, CA, Stanford University, Redwood City, CA, 4 The Johns Hopkins University, Baltimore, MD, 5 Johns Hopkins University, Baltimore, MD 955. Is the Pattern of Capillary Deposition of Complement Membrane Attack COPMLEX Useful in the Differential Diagnosis of Inflammatory? Patrick Gordon, Nuria Villagra, Istvan Bodi, Andrew King, Stefan Buk, Tibor Hortobagyi and Safa Al-Sarraj, Department of Rheumatology, King s College London, London, United Kingdom, Department of Clinical Neuropathology, King s College Hospital, London, United Kingdom 956. A New Linked Set of Autoantibodies in Dermatomyositis: Anti-Mi- and Anti-Transcription Intermediary Factor (TIF) alpha. Minoru Satoh, Jason YF Chan, Yi Li, Monica Vázquez-Del Mercado, Marcelo Petri, Luis J. Jara 4, Miguel A. Saavedra 5, Claudia Cruz-Reyes 6, Eric S. Sobel, Westley H. Reeves, Angela Ceribelli and Edward K.L. Chan, University of Florida, Gainesville, FL, Universidad de Guadalajara, Guadalajara, Jalisco, México, Mexico, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, Mexico, 4 Hospital de Especialidades Centro Medico La Raza, México City, Mexico, 5 Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., México D.F., Mexico, 6 Centro Medico La Raza Instituto Mexicano del Seguro Social Mexico D.F., Mexico D. F., Mexico Osteoporosis and Metabolic Bone Disease 957. Prevalence and Associated Factors of Vitamin D Insufficiency and Deficiency in 4,79 Japanese Patients with Rheumatoid Arthritis. Takefumi Furuya, Takayuki Hosoi, Eiichi Tanaka, Ayako Nakajima, Atsuo Taniguchi, Shigeki Momohara and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, National Center for Geriatrics and Gerontology, Aichi, Japan 0 Program Book 958. Bone Mineral Density in Lupus Erythematosus Women One Year after Rituximab Therapy. Claudia Mendoza- Pinto, Mario Garcia-Carrasco, Mario Jiménez-Hernández, Alma Rodríguez-Gallegos, Socorro Méndez-Martínez and Aurelio Lopez-Colombo, HGR 6 CMN Manuel Ávila Camacho, Instituto Mexicano del Seguro Social, Puebla, Mexico, Laboratorios Clínicos de Puebla, Puebla, Mexico, Delegación Estatal, Instituto Mexicano del Seguro Social, Puebla, Mexico 959. Low Fracture Incidence Is Maintained in Postmenopausal Women 75 Years with Osteoporosis with Long-Term Denosumab Treatment. Socrates Papapoulos, Michael R. McClung, Nathalie Franchimont, Jonathan D. Adachi 4, Henry G. Bone 5, Claude-Laurent Benhamou 6, Jordi Farrerons 7, JC Gallagher 8, Johan Halse 9, Kurt Lippuner 0, Salvatore Minisola, Ove Törring, Nadia Daizadeh, Andrea Wang, Rachel B. Wagman and Steven Boonen, Leiden University Medical Center, Leiden, Netherlands, Oregon Osteoporosis Center, Portland, OR, Amgen Inc., Thousand Oaks, CA, 4 Charlton Medical Centre, Hamilton, ON, 5 Michigan Bone and Mineral Clinic, Detroit, MI, 6 EA 4708 University Orleans, Orleans, France, 7 Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, 8 Creighton University Medical Center, Omaha, NE, 9 Osteoporoseklinikken, Oslo, Norway, 0 University Hospital, Bern, Switzerland, Sapienza, Università di Roma, Rome, Italy, Karolinska Institutet Sodersjukhuset, Stockholm, Sweden, Leuven University, Leuven, Belgium 960. Initiation of Tumor Necrosis Factor Alpha (TNFα) Antagonists and Risk of Fractures in Patients with Selected Rheumatic and Autoimmune Diseases. Vivian K. Kawai, Carlos Grijalva, Patrick Arbogast, Jeffrey R. Curtis, Daniel H. Solomon, Elizabeth S. Delzell, Lang Chen, Lisa Herrinton 4, Liyan Liu 4, Edward F. Mitchell Jr., C. Michael Stein 5 and Marie Griffin, Vanderbilt University, Nashville, TN, University of Alabama at Birmingham, Birmingham, AL, Brigham and Women s Hospital, Boston, MA, 4 Kaiser Permanente, Oakland, CA, 5 Vanderbilt Medical Center, Nashville, TN 96. In Postmenopausal Women with Osteoporosis, Denosumab Significantly Improved Trabecular Bone Score (TBS), an Index of Trabecular Microarchitecture. Michael R. McClung, Kurt Lippuner, Maria Luisa Brandi, Jean-Marc Kaufman 4, Jose R. Zanchetta 5, Marc-Antoine Krieg 6, Henry G. Bone 7, Roland Chapurlat 8, Didier Hans 6, Andrea Wang 9, Jang Yun 9, Carol Zapalowski 9 and Cesar Libanati 9, Oregon Osteoporosis Center, Portland, OR, University of Berne, Berne, Switzerland, University of Florence, Florence, Italy, 4 University Hospital of Ghent, Ghent, Belgium, 5 Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, 6 Lausanne University Hospital, Lausanne, Switzerland, 7 Michigan Bone and Mineral Clinic, Detroit, MI, 8 Hôpital Edouard Herriot, Lyon, France, 9 Amgen Inc., Thousand Oaks, CA

279 ACR POSTER SESSION C 96. The Specific Role of Glutaredoxin Isoform b (Glrxb) in RANKL-Induced Osteoclastogenesis through Activation of the p8-mapk Signaling Pathway. Chang-Hoon Lee, Wan- Hee Yoo, Jin-Jung Choi, Myong-Joo Hong, Ji-Min Kim 4 and Jeong-Tae Yeon 5, Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, CHA University Hospital, Seongnam, South Korea, 4 Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea, 5 Department of anatomy, school of medicine, Wonkwang university, Iksan, Chonbuk, South Korea 96. Fracture Sites, Frequencies and Causes in 9,70 Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Cohort Study. Kensuke Ochi, Takefumi Furuya, Eisuke Inoue, Katsunori Ikari, Atsuo Taniguchi, Shigeki Momohara and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 964. Rolofylline, an Adenosine AR Antagonist, Acts As an Inverse Agonist to Inhibit Osteoclast Differentiation. Wenjie He and Bruce N. Cronstein, NYU, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 965. Adenosine Regulates Bone Metabolism Via A, AA and AB Receptors in Bone Marrow Cells From Normal and Patients with Multiple Myeloma. Wenjie He, Amitabha Mazumder and Bruce N. Cronstein, NYU, New York, NY, NYU Cancer Center, New York, NY, NYU School of Medicine, Division of Rheumatology, New York, NY 966. Cost-Effectiveness of Bazedoxifene Compared with Raloxifene in the Treatment of Postmenopausal Osteoporotic Women. Mickaël Hiligsmann, Wafa Ben Sedrine and J.-Y. Reginster, University of Liege, Liege, Belgium 967. Hypophosphatemic Osteomalacia Induced by Tenofovir in Patients with Human Immunodeficiency Virus Infection. Beatriz Tejera, Lourdes Mateo-Soria, Susana Holgado, Luisa Mariñoso, Ricard Pérez, Anna Bonjoch, Melania Martínez-Morillo, Dolors Grados and Alejandro Olivé, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, Hospital del Mar, Barcelona, Spain 968. The Specific Role of Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) As a Regulator of Osteoclastogenesis Via Modulation of Phospholipase Cã(PLCã-Ca+-NFAT Signaling. Chang-Hoon Lee, Wan- Hee Yoo, Jin-Jung Choi, Myong-Joo Hong, Ji-Min Kim 4 and Sik-Won Choi 5, Department of Internal Medicine, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, CHA University Hospital, Seongnam, South Korea, 4 Division of Rheumatology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, South Korea, 5 School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea 969. Correction of Vitamin D Insufficiency with the Fixed Daily Combination Strontium Ranelate g/vitamin D 000 IU Over Months. René Rizzoli, Bess Dawson-Hughes, Jean- Marc Kaufman, Patrice Fardellone 4, Maria Luisa Brandi 5, Bruno Vellas 6, Julien Collette 7 and Jean-Yves Reginster 8, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, Bone Metabolism Laboratory, Tufts University, Boston, MA, University Hospital of Ghent, Ghent, Belgium, 4 Hôpital Nord, C.H.U. d Amiens, Amiens, France, 5 University of Florence, Firenze, Italy, 6 CHU La Grave, Toulouse, France, 7 Labo RIA, CHU Sart Tilman, Liege, Belgium, 8 University of Liege, Liege, Belgium 970. Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX). Tristan Blackburn, Diantha Howard and Edward S. Leib, Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, Vermont Center for Clinical and Translational Science, Burlington, VT 97. Resolution of Effects On Bone Turnover Markers and Bone Mineral Density After Discontinuation of Long-Term Bisphosphonate Use. Kenneth G. Saag, Claude-Laurent Benhamou, Tobias De Villiers, C. Conrad Johnston Jr. 4, Bente Langdahl 5, Andrew Denker 6, Annpey Pong 6, John P. McGinnis 6, Elizabeth Rosenberg 6 and Arthur Santora 6, Univ of Alabama-Birmingham, Birmingham, AL, EA 4708 University Orleans, Orleans, France, Mediclinic Panorama, Cape Town, South Africa, 4 Indiana University School of Medicine, Indianapolis, IN, 5 Aarhus University Hospital, Aarhus, Denmark, 6 Merck Sharp & Dohme Corp., Whitehouse Station, NJ 97. Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis. Sina Esmaeilzadeh, Nurten Eskiyurt, Ekin Sen and Merih Akpinar, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey 97. Effect of Adalimumab On the Serum Level of Undercarboxylated Osteocalcin (ucoc), Bone Biochemical Markers and Bone Mineral Density. Yoshitada Sakai, Akira Hashiramoto, Takaichi Okano, Yoshiko Kawasaki, Nao Shibanuma and Masahiro Kurosaka, Kobe University Hospital, Kobe, Japan, The Center for Rheumatic Diseases, Kobe University Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, Kobe University Graduate School of Medicine, Kobe, Japan 974. Incidence of Atypical Femur Fractures Associated with Bisphosphonate Use for Osteoporosis: A Systematic Review of the Literature. John N. Mecchella, John A. 0 Program Book 77

280 ACR POSTER SESSION C 78 Batsis, Robin J. Larson and Gautham Suresh, Dartmouth Hitchcock Medical Center, Lebanon, NH, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH 975. Mortality After Fragility Hip Fracture in Middle Aged and Elderly Men and Women in Southern Norway. Andreas P. Diamantopoulos, Mari Hoff, Marc C. Hochberg and Glenn Haugeberg, Hospital of Southern Norway HF, Kristiansand, Norway, and St Olavs Hospital, Trondheim, Norway, University of Maryland, Baltimore, MD 976. Treatment Satisfaction in Postmenopausal Women Previously Treated with Bisphosphonates Who Transitioned to Denosumab Vs Ibandronate Therapy in an Open-Label Study. Santiago Palacios, Giovanni Iolascon, Irene Agodoa, Hema Viswanathan, Prayashi Ghelani 4, Irene Ferreira 5, Cynthia O Malley, Rachel B. Wagman 6 and Sydney Bonnick 7, Instituto Palacios, Madrid, Spain, Seconda Universita di Napoli, Naples, Italy, Amgen Inc, Thousand Oaks, CA, 4 Ovatech Solutions, London, United Kingdom, 5 Amgen Inc., Cambridge, United Kingdom, 6 Amgen Inc., Thousand Oaks, CA, 7 Clinical Research Center of North Texas, Denton, TX 977. Relationship Between Baseline Bone Turnover Marker Levels and Bone Mineral Density Changes in Men with Low Bone Mineral Density Receiving Denosumab or Placebo. Eric Orwoll, Ugis Gruntmanis, Steven Boonen, Yu-Ching Yang 4, Rachel B. Wagman 4, Jesse W. Hall 4 and Paul D. Miller 5, Oregon Health and Science University, Portland, OR, Dallas Veterans Affairs Medical Center and University of Texas Southwestern Medical Center, Dallas, TX, Leuven University, Leuven, Belgium, 4 Amgen Inc., Thousand Oaks, CA, 5 Colorado Center for Bone Research, Lakewood, CO 978. A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids. Amy H. Warriner, Ryan C. Outman, Nathan Markward, Ronald Aubert, Jeffrey R. Curtis, Robert Epstein, Felix Freuh, Julia McEachern, David T. Redden, Monika M. Safford, Eric Stanek, Amy Steinkellner and Kenneth G. Saag, University of Alabama at Birmingham, Birmingham, AL, Medco, Bethesda, MD, Univ of Alabama-Birmingham, Birmingham, AL 979. Care Gap in the Treatment of Patients with High Risk for Fractures in a Single Canadian Academic Center. Arthur N. Lau, Michael Branch, Robert Bensen, Jonathan D. Adachi 4, Alexandra Papaioannou, William Wong-Pack 5 and William G. Bensen 6, McMaster University, Hamilton, ON, CEO, Inovex, Oakville, ON, Rheumatology Health Team, Dr. Bensen s Rheumatology Clinic, Hamilton, ON, 4 Charlton Medical Centre, Hamilton, ON, 5 Hamilton, ON, 6 St. Joseph s Hospital and McMaster University, Hamilton, ON, Hamilton, ON 980. Intermittent Nitrate Use and Risk of Hip Fracture. Devyani Misra, Christine Peloquin, Hyon Choi, Tuhina Neogi and Yuqing Zhang, Boston University School of Medicine, Boston, MA, Boston Univ School of Medicine, Boston, MA 0 Program Book 98. Low Body Mass Index, Medication Use and Social Factors Such As Smoking but Not Secondary Medical Disorders or Older Age May Be More Prevalent in Males with Low Bone Mineral Density. Vandana J. Vedanarayanan, Allison V. Jones and Vikas Majithia, University of Mississippi Medical Center, Jackson, MS 98. Five Years of Treatment to Target in Early Active Rheumatoid Arthritis: Prevalence and Predictors of Vertebral Fractures. L. Dirven, M. van den Broek, A.J. Peeters, N. Riyazi, P.J.S.M. Kerstens 4, T.W.J. Huizinga, C.F. Allaart and W. F. Lems 5, Leiden University Medical Center, Leiden, Netherlands, Reinier de Graaf Gasthuis, Delft, Netherlands, Haga Hospital, The Hague, Netherlands, 4 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 5 VU University medical center, Amsterdam, Netherlands 98. Comparative Risk of Fracture in Men and Women with Human Immunodeficiency Virus. Lydia Gedmintas, Elizabeth Wright, Jeffrey N. Katz, Elena Losina and Daniel H. Solomon, Brigham s Women s Hospital, Boston, MA, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women s Hospital, Boston, MA, Brigham and Women s Hospital, Boston, MA 984. Orally Administered Parathyroid Hormone Analog Tablets in a Randomized Phase Study Demonstrated Consistent Exposure and Increased Bone Mineral Density. Morten Asser Karsdal, Nozer M. Mehta, William Stern, Amy M. Sturmer, Sheela J. Mitta, Roxanne Tavakkol, Ali Bolat, Jenna Giacchi, Kim Henriksen, Lorraine A. Fitzpatrick, Claus Christiansen 4, Jeffrey A. Wald, Antonio J. Nino, Peter Alexandersen 4, Bente J. Riis 5, Jeppe andersen, Ivo Valter 6, Bettina Nedergaard 4, Christence Teglbjaerg 4, Felicia Cosman 7 and John M. Trang 8, Nordic Bioscience A/S, Herlev, Denmark, Unigene Laboratories, Inc., Boonton, NJ, GSK, King of Prussia, PA, 4 CCBR, Ballerup, Denmark, 5 Nordic Bioscience, Herlev, Denmark, 6 Ctr for Clinical & Basic Rsrch, Tallinn, Estonia, 7 Helen Hayes Hospital, West Haverstraw, NY, 8 PK/PD International Inc., Tucson, AZ 985. The Effect of Calcium and Vitamin D on Bone Loss in an Epileptic Population. Philip Dussault, Samuel Davis Jr. and Antonio A. Lazzari, Boston VA HCS, Boston, MA, Boston VA Medical Center, Boston, MA 986. Impaired Endothelial Function in Post-Menopausal Women with Osteoporosis. Auleen M. Millar, Aaron McCann, Vivian McClenaghan, Paul Hamilton, Caroline Bleakley, Kristopher Lyons and Gary McVeigh, Musgrave Park Hospital, Belfast, United Kingdom, Belfast, United Kingdom 987. A Comparison of Unilateral and Bilateral Hip BMD. Steven C. Schaub, Edward S. Leib and Diantha Howard, U of Vermont College of Med, Burlington, VT, Vermont Center for Clinical and Translational Science, Burlington, VT 988. Zoledronate Efficacy and Safety in Active Paget s Disease Long-Term Follow-up and Retreatment in Clinical Practice. Elsa Vieira-Sousa, Ana M. Rodrigues, Joana

281 ACR POSTER SESSION C Caetano-Lopes, Susana Capela, Filipa Ramos, Ricardo Figueira, Joaquim Polido-Pereira, Cristina Ponte, Raquel Campanilho-Marques, Rita Barros, JC Romeu and José A. Pereira da Silva, Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHLN and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal, Rheumatology and Metabolic Bone Diseases Department, Santa Maria Hospital,CHLN, Lisbon, Portugal 989. Risk Factors for Vertebral Fractures in Patients with Rheumatoid Arthritis - the Tomorrow Study -. Tadashi Okano, Tatsuya Koike, Masahiro Tada, Kenji Mamoto, Yuko Sugioka, Atsuko Kamiyama and Hiroaki Nakamura, Osaka City University Medical School, Osaka, Japan 990. Risk of Falling Is Equivalent between Patients with Rheumatoid Arthritis and Healthy Individuals the Tomorrow Study-. Kenji Mamoto, Tatsuya Koike, Tadashi Okano, Atsuko Kamiyama, Yuko Sugioka, Masahiro Tada and Hiroaki Nakamura, Osaka City University Graduate School of Medicine, Osaka, Japan 99. Effects of Odanacatib on the Distal Radius and Tibia in Postmenopausal Women: Improvements in Cortical Geometry and Estimated Bone Strength. Roland Chapurlat, K. Brixen, A.M. Cheung, Sharmila Majumdar 4, B. Dardzinski 5, A. Cabal 6, N. Verbruggen 7, S. Ather 6, Elizabeth Rosenberg 5 and A. de Papp 5, Hôpital Edouard Herriot, Lyon, France, University of Southern Denmark, Odense, Denmark, University of Toronto, Ontario, 4 University of California San Francisco, San Francisco, CA, 5 Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 6 Merck Sharp & Dohme Corp., Whitehouse Station, 7 MSD Belgium, Brussels, Belgium 99. Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels. Allen P. Anandarajah, Jennifer Hossler, Kate Burns, Kelly Callahan, Yahui Grace Chiu and Jennifer H. Anolik, Univ of Rochester Medical Ctr, Rochester, NY, University of Rochester, Rochester, NY 99. Contribution of Lifestyle Factors to Healthy-Adherer Bias in Prevalent Users of Osteoporotic Drugs. Mitsuyo Kinjo and Daniel H. Solomon, Okinawa Chubu Hospital, Uruma City Okinawa, Japan, Brigham and Women s Hospital, Boston, MA 994. The Influence of Percentage Body Fat On Bone Mineral Density in Thin Patients. Andrew Blanshard and Marwan Bukhari, Lancaster University, Lancaster, United Kingdom, Royal Lancaster Infirmary, Lancaster, United Kingdom 995. What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs? Nicole C. Wright, Ana Oliveira, Amy H. Warriner, Jeffrey Curtis, Neil Binkley, Steven R. Cummings, Marc C. Hochberg 4, Andrea LaCroix 5, E. Michael Lewiecki 6, John T. Schousboe 7, Daniel H. Solomon 8, Robert B. Wallace 9 and Kenneth G. Saag, University of Alabama at Birmingham, Birmingham, AL, University of Wisconsin, Madison, WI, San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, 4 University of Maryland, Baltimore, MD, 5 Fred Hutchinson Cancer Research Center, Seattle, WA, 6 New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 7 Park Nicollet Health Services, Minneapolis, MN, 8 Brigham and Women s Hospital, Boston, MA, 9 University of Iowa, Iowa City, IA 996. Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied? Marlies C. van der Goes, Johannes W.G. Jacobs, Maud S. Jurgens, Marije F. Bakker, Maaike J. van der Veen, Jacobine H. van der Werf, Paco M.J. Welsing and Johannes W.J. Bijlsma, University Medical Center Utrecht, Utrecht, Netherlands, St. Jansdal hospital, Harderwijk, Netherlands, Diakonessenhuis, Utrecht, Netherlands 997. Safety and Efficacy of Denosumab Vs Ibandronate in Postmenopausal Women Sub-Optimally Treated with Daily or Weekly Bisphosphonates: A Randomized, Open-Label Study. Michael A. Bolognese, Edward Czerwinski, Henry G. Bone, Sydney Bonnick 4, Neil Binkley 5, Alfred Moffett Jr. 6, Suresh Siddhanti 7, Irene Ferreira 8, Prayashi Ghelani 9, Rachel Wagman 7, Jesse W. Hall 7 and Chris Recknor 0, Bethesda Health Research Center, Bethesda, MD, Krakow Medical Center, Krakow, Poland, Michigan Bone and Mineral Clinic, Detroit, MI, 4 Clinical Research Center of North Texas, Denton, TX, 5 University of Wisconsin, Madison, WI, 6 OB- GYN Associates of Mid Florida, PA, Leesburg, FL, 7 Amgen Inc., Thousand Oaks, CA, 8 Amgen Inc., Cambridge, United Kingdom, 9 Ovatech Solutions, London, United Kingdom, 0 United Osteoporosis Centers, Gainesville, GA 998. Relationship between Changes in Bone Mineral Density and Incidence of Fracture with 6 Years of Denosumab Treatment. Michael A. Bolognese, Paul D. Miller, Jean- Yves Reginster, Nathalie Franchimont 4, Gerolamo Bianchi 5, Roland Chapurlat 6, Federico G. Hawkins 7, David L. Kendler 8, Beatriz Oliveri 9, Jose R. Zanchetta 0, Nadia Daizadeh 4, Andrea Wang 4, Rachel B. Wagman 4 and Socrates Papapoulos, Bethesda Health Research Center, Bethesda, MD, University of Colorado Health Sciences Center and Colorado Center for Bone Research, Lakewood, CO, University of Liège, Liège, Belgium, 4 Amgen Inc., Thousand Oaks, CA, 5 Azienda Sanitaria Genovese, Genoa, Italy, 6 Hôpital Edouard Herriot, Lyon, France, 7 Hospital Universitario, Madrid, Spain, 8 University of British Columbia, Vancouver, BC, 9 Laboratorio Enfermedades Metabólicas Oseas, Hospital de Clínicas, INIGEM UBA-CONICET, Buenos Aires, Argentina, 0 Instituto de Investigaciones Metabólicas and University of Salvador, Buenos Aires, Argentina, Leiden University Medical Center, Leiden, Netherlands 0 Program Book 79

282 ACR POSTER SESSION C Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases 999. Immunogenicity and Safety of Two Doses of Influenza A HN 009 Vaccine in Young Autoimmune Rheumatic Diseases Patients Under 9 Years Old. Guilherme Trudes, Nadia E. Aikawa, Lucia M. Campos, Rosa M.R. Pereira, Julio C. B. Moraes, Ana Cristina Ribeiro, Joao Miraglia, Maria do Carmo S. Timenetsky 4, Eloisa Bonfa and Clovis Artur Silva 5, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, University of São Paulo Medical School, São Paulo, Brazil, Fundação Butantan, São Paulo, Brazil, 4 Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5 Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 000. Whole Body Magnetic Resonance Imaging in Evaluation of Enthesitis in Spondyloarthropathy. Hemalatha Srinivasalu, Suvimol C. Hill, Gina A. Montealegre Sanchez, April D. Brundidge, Michael M. Ward and Robert A. Colbert, NIAMS NIH, Bethesda, MD, NIH Clinical Center, Bethesda, MD 00. Methotrexate and Injectable Tumor Necrosis Factor Alpha Inhibitor Adherence and Persistence in Children with Rheumatic Diseases. Sarah Ringold, Shannon Grant, Charmaine Girdish, Carol A. Wallace 4 and Sean Sullivan 5, Seattle Children s Hospital, Seattle, WA, Axio Research LLC, Seattle, WA, CVS Caremark, Scottsdale, AZ, 4 Seattle Childrens Hospital, Seattle, WA, 5 University of Washington, Seattle, WA 00. Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise? Petra C.E. Hissink Muller, Bahar Yildiz, Cornelia F. Allaart, Danielle M.C. Brinkman, Marion A. J. Van Rossum, J. Merlijn Van den Berg 4, Lisette W.A. Van Suijlekom-Smit 5, Rebecca Ten Cate and Martine C. de Vries, Leiden University Medical Center, Leiden, Netherlands, Rijnland Hospital, Leiderdorp, Netherlands, Emma Children s Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, 4 Emma Children s Hospital / Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, 5 Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands 00. Colchicine As a Therapeutic Option in Periodic Fever Aphtous Stomatitis, Pharingitis Syndrome and Cervical Adenitis (PFAPA). Yonatan butbul Aviel, Sameh Tatour, Ruth Gershoni and Riva Brik 4, Rambam Medical center, Haifa, Israel, Rambam Medical Center, Israel, Rambam, Israel, 4 Rambam Medical center 004. Do We Need Minimum Standards in Care for Children with Localized Scleroderma- Result of the Consensus Meeting in Hamburg Germany On the th of December 0. Part I. Diagnosis and Assessment of the Disease. Ivan Foeldvari, Tamás Constantin, Peter Hoeger, Monika Moll 4, Clare Pain 5, Dana Nemcova 6, Kathryn S. Torok 7, Lisa Weibel 8 and Philip J. Clements 9, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, Semmelweis Egyetem, AOK, II.sz. Gyermekgyogyaszati Klinika, Budapest, Hungary, Kinderkrankenhaus Wilhelmstift, Hamburg, Germany, 4 University Childrenxsxhospital, Tübingen, Germany, 5 University Childrenxsxhospital, Liverpool, United Kingdom, 6 University Childrenxsxhospital, Prague, Czech Republic, 7 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 8 University Childrenxs Hospital, Zurich, Switzerland, 9 UCLA School of Medicine, Los Angeles, CA 005. Clinical Course and Outcomes of Children with Juvenile Idiopathic Arthritis-Associated Uveitis and Idiopathic Uveitis. Sheila T. Angeles-Han, Steven Yeh, Courtney McCracken, Larry B. Vogler, Kelly Rouster-Stevens, Christine W. Kennedy, Matthew Kent, Kirsten Jenkins, Scott Lambert, Carolyn Drews-Botsch 4 and Sampath Prahalad, Emory Univ School of Medicine, Atlanta, GA, Emory Children s Center, Atlanta, GA, Children s Healthcare of Atlanta, Atlanta, GA, 4 Emory University School of Public Health, Atlanta, GA 006. Sexual Health and Substance Abuse in Adolescents with Rheumatic Conditions. Sara M. Stern, Rhina Castillo, Katherine AB Marzan, Jennifer Jackson, Mona Desai, Ellen Iverson, Leslie F. Clark and Diane Tanaka, Children s Hospital Los Angeles, Los Angeles, CA 007. Radiological Peripheral Involvement At Hands, Feet and Hips in Young Adults with Polyarticular Idiopathic Juvenile Arthritis. Muriel Elhai, Ramin Bazeli, Veronique Freire, Antoine Feydy, andre Kahan, Chantal Job-Deslandre and Julien Wipff, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Radiology B, Paris Descartes University, Cochin Hospital, APHP, Paris, France 008. Initial Evaluation of a Localized Scleroderma (LS) Clinical Activity Measure. Suzanne C. Li, Kathryn S. Torok, Christina Kelsey, Mara L. Becker, Fatma Dedeoglu 4, Robert C. Fuhlbrigge 5, Gloria C. Higgins 6, Sandy D. Hong 7, Maria F. Ibarra, Ronald M. Laxer 8, Thomas G. Mason II 9, Marilynn G. Punaro 0, Elena Pope, Egla C. Rabinovich and Katie G. Stewart 0, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, Children s Mercy Hospital, Kansas City, MO, 4 Boston Childrens Hosp, Boston, MA, 5 Childrens Hospital, Boston, MA, 6 Nationwide Childrens Hosp, Columbus, OH, 7 U of Iowa Children s Hosp, Iowa City, IA, 8 The Hospital for Sick Children, Toronto, ON, 9 Mayo Clinic Rochester, Rochester, MN, 0 Texas Scottish Rite Hospital, Dallas, TX, Hospital for Sick Children, Toronto, ON, Duke University Medical Center, Durham, NC 009. Does Breastfeeding Influence the Presentation of Juvenile Idiopathic Arthritis? Results from the Childhood Arthritis Prospective Study. Hannah Pickford, Eileen Baildam, Alice Chieng, Joyce Davidson 4, Helen E. Foster 5, Janet Gardner- Medwin 4, Lucy R. Wedderburn 6, Wendy Thomson and Kimme L. Hyrich, Arthritis Research UK Epidemiology 80 0 Program Book

283 ACR POSTER SESSION C Unit, Manchester, United Kingdom, Alder Hey Children s Foundation NHS Trust, Liverpool, United Kingdom, Manchester Children s Hospital, Manchester, United Kingdom, 4 Royal Hospital for Sick Children, Glasgow, United Kingdom, 5 Musculoskeletal Research Group, Newcastle upon Tyne, United Kingdom, 6 University College London (UCL), London, United Kingdom 00. Administration of Routine Preventative Vaccinations in Children with Juvenile Idiopathic Arthritis Receiving Adalimumab. Neelufar Mozaffarian and Vipin Arora, Abbott, Abbott Park, IL 0. ACR Criteria, Providers Global Rating of Change and Role of Patient Self-Report in Evaluating Change in Disease Over Time: A Patient Reported Outcomes Measurement Information System Study. Bin Huang, Jennifer Farrell, Adam Carle, Stacey Niehaus, Hermine Brunner, Alexei A. Grom, Michael Henrickson, Jennifer L. Huggins, D. J. Lovell, Tracy V. Ting and Esi M. Morgan DeWitt, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, Cincinnati Children s Hospital Medical Center and PRSCG, Cincinnati, OH, Cincinnati Children s Hospital, Cincinnati, OH 0. Pediatric Rheumatology Productivity: Results of the American Academy of Pediatrics 00 Workforce Survey. Michael Henrickson and Laura Laskosz, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, The American Academy of Pediatrics, Elk Grove Village, IL 0. Cross-Sectional and Longitudinal comparison of Bone Mass Status, Using pqct, in a Large Cohort of Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus Patients. Fernanda Falcini, Stefano Stagi, Loredana Cavalli, Giulia Carnesecchi 4, Federico Bertini, Laura Masi, Marco Matucci-Cerinic 5 and Maria Luisa Brandi, Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, Mugello s Hospital, Borgo San Lorenzo, Firenze, Italy, University of Florence, Firenze, Italy, 4 University of Florence, Florence, Italy, 5 Univ Florence, Firenze, Italy 04. Serum 5(OH)D Levels in Adolescents and Young Adults with Juvenile Idiopathic Arthritis and Juvenile Onset Systemic Lupus Erythematosus: Prevalence and Association with Disease Activity. Fernanda Falcini, Stefano Stagi, Loredana Cavalli, Giulia Carnesecchi, Federico Bertini, Laura Masi, Marco Matucci-Cerinic and Maria Luisa Brandi, Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Florence, Italy, Pediatric Unit, Mugello s Hospital, Borgo San Lorenzo, Firenze, Italy, Department of Internal Medicine, Endocrinology Unit, University of Florence, Firenze, Italy 05. Recognizing Two Distinct Clinical Phenotypes in Muckle- Wells Syndrome. J B. Kuemmerle-Deschner, Samuel Dembi Samba, Isabelle Kone-Paut, Isabelle Marie, Pascal N. Tyrrell and Susanne M. Benseler, University Hospital Tuebingen, Tuebingen, Germany, CHU Bicêtre, Paris, France, The Hospital for Sick Children, Toronto, ON 06. Primary Raynaud s Phenomenon in a Multicenter Cohort of Italian Children and Adolescents: Which Prognostic Relevance for Serological Tests? Fernanda Falcini, Valentina Denaro, Federica Cuoco, Giorgia Martini, Susanna Cappelli, Antonella Petaccia, Fabrizia Corona, Giulia Carnesecchi, Francesco La Torre 4, Marco Matucci-Cerinic 5 and Donato Rigante 6, Department of Internal Medicine, Rheumatology Section, University of Florence, Firenze, Italy, Department of Pediatrics, University of Milan, Milan, Italy, University of Padua, Padua, Italy, 4 DIMIMP-University, Rheumatologic Section, Bari, Italy, 5 University of Florence, Florence, Italy, 6 Università Cattolica Sacro Cuore, Rome, Italy 07. Orthopaedic Treatment of Temporomandibular Joint (TMJ) Damage in Adolescents with Juvenile Idiopathic Arthritis (JIA): Longitudinal Evaluation. Fernanda Falcini, Daniela Melchiorre, Giulia Carnesecchi, Federico Bertini, Katia Biondi, Mario Bosco and Marco Matucci-Cerinic 4, Department of Internal Medicine, Rheumatology Section, University of Florence, Florence, Italy, Department of Odontostomatologic Sciences, University of Pavia, Pavia, Italy, Pavia, Italy, 4 University of Florence, Florence, Italy 08. Juvenile Idiopathic Arthritis in Adulthood: Evaluation of Disease Activity, Damage and Quality of Life. Alessandra Salmaso, Lorenzo Ceri, Serena Capannini, Francesco La Torre, Maurizio Gattinara, Irene Pontikaki, Pier Luigi Meroni 4, Fernanda Falcini and Valeria Gerloni, Pediatric Rheumatology, G. Pini Institute, Department and Chair of Rheumatology, Milan, Italy, Department of Internal Medicine, Rheumatology Section, Transition Clinic, University of Florence, Firenze, Italy, DIMIMP- University, Rheumatologic Section, Bari, Italy, 4 Division of Rheumatology, Istituto G. Pini, University of Milan, Milano, Italy 09. A Novel MRI Scoring System for the Evaluation of Early- Stage Disease Activity of the Wrist in Juvenile Idiopathic Arthritis. Charlotte M. Nusman, Robert Hemke, Taco W. Kuijpers, Eline E. Deurloo, Dieneke Schonenberg, J. Merlijn Van den Berg, Koert M. Dolman 4, Marion A.J. Van Rossum and Mario Maas, Academic Medical Center, Amsterdam, Netherlands, Emma Children s Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, Emma Children s Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, 4 St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands 00. Assessment of Procedure Safety and Cannula Position in Temporomandibular Joint Puncture Evaluated by Cone Beam Computerized Tomography. Thomas K. Pedersen, Kasper D. Kristensen, Per Alstergren, Peter Stoustrup, Annelise Küseler and Troels Herlin, University of Aarhus, Aarhus C, Denmark, Karolinska Institutet, Huddinge, Sweden, Aarhus University Hospital Skejby, Aarhus N, Denmark 0 Program Book 8

284 ACR POSTER SESSION C 8 0. The Schedule of Administration of Canakinumab in Cryopyrin Associated Periodic Syndrome Is Driven by the Phenotype Severity Rather Than the Age. Roberta Caorsi, Loredana Lepore, Francesco Zulian, Maria Alessio 4, Achille Stabile 5, Antonella Insalaco 6, Martina Finetti, Antonella Battagliese 4, Giorgia Martini, Chiara Bibalo, Alberto Martini 7 and Marco Gattorno, G. Gaslini Institute, Genova, Italy, Ospedale-Infantile Trieste, Trieste, Italy, University of Padua, Padova, Italy, 4 Federico II Hospital, Napoli, Italy, 5 DipartimentoPediatria, Policlinico Gemelli, Roma, Italy, 6 Ospedale Pediatrico Bambino Gesù, Roma, Italy, 7 Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH 0. Individual Disease Burden in Children and Adolescents with Chronic Musculoskeletal Pain Multilevel-Analysis of a Nationwide Prospective Longitudinal Observation Study. Kerstin Gerhold, Rebecca Muckelbauer, Jacqueline Müller-Nordhorn, Angelika Thon, Thomas Müller 4, Gerd Ganser 5, Martina Niewerth and Kirsten Minden 6, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, 4 Universitätsklinikum Halle (Saale), Halle (Saale), Germany, 5 Sankt Josef Stift, Sendenhorst, Germany, 6 German Rheumatism Research Center, a Leibniz Institute, Berlin, Germany 0. Should Joint Ultrasound Contribute to Therapeutic Decisions in Juvenile Idiopathic Arthritis? Marie Halbwachs, Geraldine Durand, Caroline Robin, Catherine Gambert Abdel Rahman, Pierre Ingrand and Elisabeth Solau-Gervais, University Hospital, Poitiers, France 04. Articular Symptoms in Cryopyrin-Associated Periodic Syndrome: Retrospective French Study. Laetitia Houx, Pierre Quartier, Isabelle Kone-Paut, Xavier Guennoc 4, Pascal Pillet 5, Thierry Lequerre 6, Irene Lemelle 7, Mohamed Hamidou 8, Gilles Grateau 9, Eric Hachulla 0, Jean-Marie Berthelot, Benedicte Neven, Christophe Richez, Anne Pagnier 4, Veronique Hentgen 5 and Valerie Devauchelle- Pensec 6, Brest, France, Necker-Enfants Malades Hospital,, Paris, France, Hospital Kremlin Bicêre, Kremlin-Bicêtre, France, 4 Hopital de Saint Brieuc, France, 5 Paediatry, CHU, Bordeaux, France, 6 Rouen, France, 7 Paediatry, CHU, Nancy, France, 8 Hôtel Dieu, Hôpital Universitaire de Nantes, Nantes, France, 9 Hopital Tenon, Paris, France, 0 Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, Nantes University Hospital, Nantes, France, Inserm U76 8, Paris, France, Hôpital Pellegrin and Université Victor Segalen Bordeaux, Bordeaux, France, 4 Service de pediatrie, Grenoble, France, 5 Paediatric Unit, Le Chesnay, France, 6 Brest Occidentale university, Brest, France 05. Clinical Characteristics and Therapy Response in a Large Single-Centre Cohort of Patients with Periodic Fever with Aphtous Stomatitis, Pharyngitis and Cervical Adenitis Syndrome. Francesca Ricci, Antonella Meini, Lucio 0 Program Book Verdoni, Laura Dotta, Marta Bolis, Marco Berlucchi, Gianfranco Savoldi and Marco Cattalini, Pediatric Immunology and Rheumatology Unit, Brescia, Italy, Department of Pediatric Otorhinolaryngology, Brescia, Italy, Angelo Nocivelli Institute of Molecular Medicine, Brescia, Italy 06. High Prevalence of Cervical Spine and Temporomandibular Joint Involvement in Patients with Juvenile Idiopathic Arthritis. Nikolay Tzaribachev, Catrin Tzaribachev and Bernd Koos, Center for Rheumatic Diseases, Bad Bramstedt, Germany, University Medical Center Schleswig- Holstein, Campus Kiel, Kiel, Germany 07. Chronic Nonbacterial Osteomyelitis of the Mandible in Children: a Tertiary Center Experience. Daniela S. Ardelean and Ronald M. Laxer, Hospital for Sick Children, Toronto, ON, The Hospital for Sick Children, Toronto, ON 08. Medication Adherence and Quality of Life in Children with Rheumatic Disease. Stacey E. Tarvin, Lisa M. Macharoni, Christine M. Raches and Nicole M. Taylor, Riley Hospital for Children, Indianapolis, IN, University of Indianapolis, Indianapolis, IN 09. Reliability of Scoring a Disease Damage Measure for Juvenile Localized Scleroderma. Kathryn S. Torok, Suzanne C. Li, Christina Kelsey, Mara L. Becker, Fatma Dedeoglu 4, Robert C. Fuhlbrigge 5, Gloria Higgins 6, Sandy D. Hong 7, Maria F. Ibarra, Ronald M. Laxer 8, Thomas G. Mason II 9, Marilynn G. Punaro 0, Elena Pope, Egla C. Rabinovich and Katie G. Stewart 0, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, Joseph M Sanzari Children s Hospital, Hackensack University Medical Center, Hackensack, NJ, Children s Mercy Hospital, Kansas City, MO, 4 Boston Childrens Hosp, Boston, MA, 5 Childrens Hospital, Boston, MA, 6 PRCSG-Cincinnati Children s Hospital Medical Center, Columbus, OH, 7 U of Iowa Children s Hosp, Iowa City, IA, 8 The Hospital for Sick Children, Toronto, ON, 9 Mayo Clinic Rochester, Rochester, MN, 0 Texas Scottish Rite Hospital, Dallas, TX, Hospital for Sick Children, Toronto, ON, Duke University Medical Center, Durham, NC 00. A Multi-Modal Amplified Musculoskeletal Pain Treatment Program: Associations of Previous Pharmacotherapy with Subsequent Outcomes. Cara M. Hoffart, Pamela Weiss, David D. Sherry, Chris Feudtner and Margaret Stineman 4, The Children s Hospital of Philadelphia, Philadelphia, PA, Children s Hospital of Philadelphia, Philadelphia, PA, Division of General Pediatrics, Children s Hospital of Philadelphia; University of Pennsylvania Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 4 The University of Pennsylvania, Philadelphia, PA 0. Safety and Efficacy of Anakinra in Patients with Deficiency of Interleukin- Receptor Antagonist. Gina A. Montealegre, Adriana Almeida de Jesus, Dawn C. Chapelle, Paul Dancey, Joost Frenkel 4, Annet van Royen-Kerkhoff 4, Ronit Herzog 5, Giovanna Ciocca 6, Rafael F. Rivas-Chacon 6, Ann M. Reed 7, Nicole Plass 8, Ivona Aksentijevich 9, Polly J.

285 ACR POSTER SESSION C Ferguson 0, Suvimol C. Hill, Edward Cowen and Raphaela T. Goldbach-Mansky, NIAMS, Bethesda, MD, National Institute of Arthritis Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, Memorial University of Newfoundland, St Johns, 4 University of Utrecht, Utrecht, Netherlands, 5 Cornell University, New York, NY, 6 Miami Children s Hospital, Miami, FL, 7 Mayo Clinic, Rochester, MN, 8 National Institutes of Health Clinical Center, Bethesda, MD, 9 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 0 University of Iowa Carver College of Medicine, Iowa City, IA, NIH Clinical Center, Bethesda, MD, NCI/NIH, Bethesda, MD, Translational Autoinflammatory Diseases Section NIAMS NIH, Bethesda, MD 0. Results from a Multicentre International Registry of Familial Mediterranean Fever: Impact of Genetic and Environment Factors On the Expression of a Monogenic Disease in Children. Seza Ozen, Erkan Demirkaya, Gayane Amaryan, Isabelle Koné-Paut, Adem Polat, Turker Turker, Patricia Woo, Yosef Uziel, Consuelo Modesto, Martina Finetti, Pierre Quartier, Efimia Papadopoulou-Alataki, Sulaiman Al-Mayouf, Giovanna Fabio, Romina Gallizzi, Luca Cantarini, Joost Frenkel, Susan Nielsen, Michael Hofer, Antonella Insalaco, Huri Ozdogan, Nicolino Ruperto and Marco Gattorno, Hacettepe University, Ankara, Turkey, Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy 0. Infliximab Is an Effective Therapy in Pediatric Renal Sarcoidosis. Elisa Wershba, Laura Lewandowski, Heather Van Mater and Egla C. Rabinovich, Duke University Medical Center, Durham, NC 04. Magnetic Resonance Imaging Is a Reliable Tool to Monitor Chronic Non-Bacterial Osteomyelitis in Children. Grazia Minardo, Giulia Zanon, Simone Corradin, Pietro Zucchetta, Giorgia Martini, Fabio Vittadello and Francesco Zulian, University of Padua, Padua, Italy, University of Padua, Padova, Italy 05. Performance of Icbd (International Criteria for Behcet s Disease) in Iranian Children with Behcet s Disease. Nahid Shafaie, Bahar Sadeghi Abdollahi and Fereydoun Davatchi, Shariati Hospital-Tehran Univ, Tehran, Iran 06. Children s Hospital of Pittsburgh Pediatric Onset En Coup De Sabre and Parry-Romberg Syndrome Cohort. Kristin M. Brown, Darren Smith, Christina Kelsey, Katherine Kurzinski 4 and Kathryn S. Torok, University of Pittsburgh, Pittsburgh, PA, university of Pittsburgh Division of Plastic and Reconstructive Surgery, Children s Hospital of Pittsburgh, Pittsburgh, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 4 Children s Hospital of Pittsburgh of UPMC, Pittsburgh, PA Quality Measures and Innovations in Practice Management and Care Delivery 07. Poor Quality of Gout Care Is Strongly Associated with Higher Gout-Related Health Care Utilization. Jasvinder A. Singh and Joshua Richman, University of Alabama at Birmingham, Birmingham, AL, UAB School of Medicine, Birmingham, AL 08. Expanding Access in Rheumatology Specialty Care in New Mexico Via an Innovative Community Outreach Program. Arthur Bankhurst, Sanjeev Arora, Summers Kalishman, Jeannie F. Boyle, Cynthia Olivas, Rebecca Monette, Dara Som and Yolanda Hubbard, University of New Mexico School of Medicine, Albuquerque, NM, University of New Mexico School of Medicine, Albuquerque 09. Uveitis Surveillance through Lean-Six Sigma for Quality Assurance in Juvenile Idiopathic Arthritis. Anjali Patwardhan, Kelly Kelleher, Jeffery Hoffman, Karla B. Jones, Stacy P. Ardoin and Charles H. Spencer, Nationwide Childrens Hospital, Columbus, OH, Nationwide Children s Hospital, Columbus, OH, Ohio State University, Columbus, OH 040. Provisions of Quality Driven Care in Childhood-Onset Systemic Lupus Erythematosus. Matthew C. Hollander, Jessica M. Sage, Alexandria J. Greenler, Tadej Avcin, Michael W. Beresford 4, Graciela Espada 5, Marisa S. Klein- Gitelman 6, Michael Henrickson, Tsz-Leung Lee 7, Joshua D. Pendl, Marilynn G. Punaro 8, Jennifer L. Huggins, Anne M. Stevens 9 and Hermine I. Brunner, Seattle Children s Hospital, Seattle, WA, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, International Investigator Consortium for MAS Diagnostic Criteria, Ljubljana, Slovenia, 4 Alder Hey Children s NHS Foundation Trust, Liverpool, United Kingdom, 5 Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, 6 Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, 7 Queen Mary Hospital, Hong Kong, Hong Kong, 8 Texas Scottish Rite Hospital, Dallas, TX, 9 University of Washington, Seattle, WA 04. Improving Access and Patient Education in Rheumatology: the Gout Shared Medical Appointment; a Quality Improvement Initiative. Alicia J. Zbehlik and Nicole M. Orzechowski, Dartmouth-Hitchcock Medical Center, Lebanon, NH, Dartmouth-Hitchcock Med Ctr, Lebanon, NH 04. Enhancing Shared Decision-Making in Juvenile Idiopathic Arthritis. Jessica M. Sage, Ellen A. Lipstein, William B. Brinkman, Carole M. Lannon and Esi M. Morgan DeWitt, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 04. Documentation of Improvement Over Months in Osteoarthritis, Systemic Lupus Erythematosus, Spondyloarthropathy and Gout Similarly to Rheumatoid Arthritis According to Function, Pain, Patient Global Estimate and RAPID On a Multidimensional Health Assessment Questionnaire (MDHAQ). Isabel Castrejón, Martin J. Bergman and Theodore Pincus, NYU Hospital for Joint Diseases, New York, NY, Taylor Hospital, Ridley Park, PA 0 Program Book 8

286 ACR POSTER SESSION C Trying to Improve Care: A Review of the Morbidity and Mortality Conference in the Division of Rheumotology. Michelle Batthish, Shirley Tse, Brian M. Feldman, G. Ross Baker and Ronald M. Laxer, The Hospital for Sick Children, Toronto, ON, The University of Toronto, Toronto, ON 045. Treatment Patterns and Monitoring of Serum Uric Acid Levels in a Large Cohort of Gout Patients in the United States: Is There Room for Improvement? Yong Chen, Kasem S. Akhras, Michael Grabner, Rima H. Tawk and Ralph Quimbo, HealthCore, Inc., Wilmington, DE, Takeda Pharmaceuticals International, Inc., Deerfield, IL, University of Illinois at Chicago, Chicago, IL 046. Matching of Patients Actual and Desired Roles in Treatment Decision Making and Trust in Physicians. Akiko Aoki, Akiko Suda, Shouhei Nagaoka, Mitsuhiro Takeno 4, Yoshiaki Ishigatsubo 4, Tatsuto Ashizawa 5, Osamu Takahashi 6, Sachiko Ohde 7 and Sadayoshi Ohbu 8, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan, Yokohama Minami Kyousai Hospital, Yokohama, Japan, Yokohama Minami Kyosai Hospital, Yokohama, Japan, 4 Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5 Tokyo Medical University Hachioji Medical Center, Chuo-ku,Tokyo, Japan, 6 St Luke s life science instutute, Chuoku,Tokyo, Japan, 7 St.Luke s Life of Science Institute, Tokyo, Japan, 8 Rikkyo University, Tokyo, Japan 047. Impact of a Rheumatology Consultation Service in Hospitalized Patients. Shirley L. Chow, Dafna D. Gladman Gladman and Heather McDonald-Blumer, University of Toronto, Toronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, Mt. Sinai Hospital, Toronto, ON 048. Four Physician Global Assessments for Overall Status, Inflammation, Damage, and Unexplained Symptoms Are Useful in Usual Care of Patients with Osteoarthritis, Fibromyalgia, Systemic Lupus Erythematosus, and Spondyloarthropathy, As Well As Rheumatoid Arthritis. Isabel Castrejón, Martin J. Bergman and Theodore Pincus, NYU Hospital for Joint Diseases, New York, NY, Taylor Hospital, Ridley Park, PA 049. Improving Pneumococcal Vaccination and Documentation for Immunosuppressed Patients At a University-Based Rheumatology Clinic. Christine Peoples, Rohit Aggarwal, Heena Sheth, Aarat Patel, Daniel Lupash, Christine McBurney, Ashima Malik, Swati Modi, Ximena D. Ruiz and Douglas W. Lienesch, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh Medical Center, Pittsburgh, PA 050. Are Patients Meeting the Updated Physical Activity Guidelines? Physical Activity Participation, Recommendation, and Preferences among Adults with Rheumatic Diseases. Victoria L. Manning, Michael V. Hurley, David L. Scott and Lindsay M. Bearne, King s College London, London, United Kingdom, St George s University of London, London, United Kingdom 0 Program Book 05. Standardized Data Collection Supports Reliable Reporting of Rheumatoid Arthritis (RA) Measures for the Medicare Physicians Quality Reporting System. J. Timothy Harrington, George Reed, Katherine C. Saunders, Lisa Lemire, Aimee Whitworth, Jeffrey D. Greenberg 4 and Joel M. Kremer 5, University of Wisconsin (retired), Madison, WI, UMass Medical School, Worcester, MA, CORRONA, Inc., Southborough, MA, 4 New York University School of Medicine, New York, NY, 5 Albany Medical College and The Center for Rheumatology, Albany, NY 05. Effect of Community Characteristics on Quality of Care in Systemic Lupus Erythematosus. Edward Yelin, Laura Trupin, Chris Tonner and Jinoos Yazdany, University of California San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA, UCSF, San Francisco, CA 05. Tele-Rheumatology: The Future Is Now. Daniel Albert, Krista Merrihew and Sarah Pletcher, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH, Dartmouth-Hitchcock Medical Center, Lebanon, NH 054. Safety of Joint and Soft Tissue Injections in Patients on Warfarin Anti-Coagulation. Richard Conway, Finbar (Barry) D. O Shea, Gaye Cunnane and Michele Doran, St James s Hospital, Dublin, Ireland 055. TEAM-Managed Care of Biological Patients at A Canadian Centre. Melissa Deamude, Dawn Heap, Melanie Kanellos, Debbie Kislinsky, Kathy Kislinsky, Cynthia Mech 4, Helena Ross, Peggy Saldanha, Lauri Vanstone, Kathleen Brown and William G. Bensen 5, Dr. William G. Bensen Medicine Professional Corporation, Hamilton, ON, Dr. Bensen s Rheumatology Clinic, Hamilton, ON, Dr. William Bensen Rheumatology Clinic, Hamilton, ON, 4 Rheumatology Health Team, Dr. Bensen s Rheumatology Clinic, Hamilton, ON, 5 St. Joseph s Hospital and McMaster University, Hamilton, ON, Hamilton, ON 056. Effectiveness of a Focused Educational Intervention in Improving the Supplementation of Vitamin D Deficiency and Insufficiency. Candice Low, Richard Conway, Gaye Cunnane, Michele Doran and Finbar (Barry) D. O Shea, St James s Hospital, Dublin, Ireland 057. Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus. Linda Carli, Chiari Tani, Francesca Querci, Alessandra Della Rossa, Sabrina Vagnani, Anna d Ascanio, Rossella Neri, Antonio Tavoni, Stefano Bombardieri and Marta Mosca, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, Immunoallergology Unit, Department of Internal Meicine, University of Pisa, PISA, Italy 058. Differences in Psychological Characteristics between Patients with Rheumatoid and Psoriatic Arthritis. Panagiota Tsitsi, Athina Theodoridou, Foteini Lada, Konstantinos Papanikolaou, Despina Dimopoulou, Georgios Garyfallos, Alexios Benos 4 and Alexandros Garyfallos,

287 ACR POSTER SESSION C 4 th Department of Internal Medicine,Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, Psychiatric Hospital of Petra Olympus, Katerini, Greece, Katerini, Greece, nd Department of Psychiatry, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, 4 Department of Hygiene, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece 059. The Efficacy of Clinical Guidelines in Promoting Co- Prescription of Bone Protection with Glucocorticoids Among Hospital Doctors Treating Inpatients. Leonard C. Harty, James Clare, Dylan Finnerty, Susan Van Der Kamp, Fionnuala Kennedy, Malachi McKenna 4 and Oliver M. FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Department of Rheumatology, St. Vincent s University Hospital, Dublin, Ireland, Pharmacy Department, St. Vincent s University Hospital, Dublin, Ireland, 4 Department of Endocrinology & Metabolic Bone Disease, St. Vincent s University Hospital, Dublin, Ireland 060. Using the Electronic Medical Record to Increase Rates of Physician Assessment of Lipids in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Quality Improvement Initiative. Astrud Lorraine Leyva, Laura L. Tarter, Elizabeth Blair Solow and David R. Karp, UT Southwestern Medical Center, Dallas, TX 06. Physician Variation in Documentation of Rheumatoid Arthritis Quality Measures and Evaluation of Relationship with Radiographic Progression. Sonali Desai, Jinoos Yazdany, Nancy A. Shadick, Siri Lillegraven 4, Chih-Chin Liu 5, Michelle A. Frits 6, Tabatha Norton 7, Jonathan S. Coblyn 8, Michael Weinblatt 5 and Daniel H. Solomon 6, Boston, MA, University of California San Francisco, San Francisco, CA, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA, 4 Diakonhjemmet Hospital, Oslo, Norway, 5 Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 6 Brigham and Women s Hospital, Boston, MA, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 8 Brigham & Womens Hosp, Boston, MA 06. Increasing Pneumococcal Vaccination for Immunosuppressed Patients: A Cluster Quality Improvement Trial. Sonali Desai, Lara Szent-gyorgyi, Alexander Turchin, Bing Lu, Anna A. Bogdanova, Michael Weinblatt, Jonathan S. Coblyn 4, Jeffrey O. Greenberg, Allen Kachalia and Daniel H. Solomon 5, Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 4 Brigham & Womens Hosp, Boston, MA, 5 Brigham and Women s Hospital, Boston, MA 06. Detection of Inflammatory Arthritis and Musculoskeletal Conditions in a First Nations Community: Results of an Onsite Screening Program. Cheryl Barnabe, Carrissa Low Horn, Margaret Kargard, Stephen Mintsioulis, Sharon Leclercq, Dianne P. Mosher, Hani S. El-Gabalawy, Tyler White and Marvin J. Fritzler, University of Calgary, Calgary, AB, Siksika Health Services, Siksika, AB, University of Manitoba, Winnipeg, MB 064. Regular Measure of Disease Activity during the Routine Care of Rheumatoid Arthritis Patients Involves Some Extra Work but Positive Results. Lissiane K. N. Guedes, Ana Cristina Medeiros Ribeiro, Karina Rossi Bonfiglioli, Diogo Domiciano, Carolina Reither Vizioli, Gilmara Franco da Cunha, andressa Silva Abreu, Filipi M. Mello, Ana Luiza de Aguiar Foelkel, Celio R. Gonçalves and Ieda Laurindo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 065. Uptake of the American College of Rheumatology s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data. Salahuddin Kazi, Itara Barnes, Jinoos Yazdany and Rachel Myslinski, UT Southwestern Medical Center, Dallas, TX, American College of Rheumatology, Atlanta, GA, University of California San Francisco, San Francisco, CA 066. Improving Outpatient Follow-up for Osteoporosis Management After a Hip Fracture. Anika Alarakhia and Robert Quinet, Ochsner Medical Center, New Orleans, LA, Ochsner Medical Center - New Orleans, New Orleans, LA 067. Access to Technology and Interest in Mobile app for Disease Management Among Patients with Systemic Lupus Erythematosus Seeking Care At a Large Referral Center. Wendy Marder, Holly Witteman, Margaret Hyzy, Martha Ganser, Emily C. Somers and Lawrence An, University of Michigan, Ann Arbor, MI, University of Michigan Medical School, Ann Arbor, MI, Universitiy of Michigan, Ann Arbor, MI 068. Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting? C.J. Inman, Frederick Wolfe and Kaleb Michaud, University of Utah, Salt Lake City, UT, National Data Bank for Rheumatic Diseases, Wichita, KS, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE Rheumatoid Arthritis: Animal Models 069. Proteinase Activated Receptor-4 Stimulation Promotes Leukocyte Adhesion in the Rat Knee Joint. Jason J. McDougall, Dalhousie University, Halifax, NS 070. Myeloid-Derived Suppressor Cells Accumulated in Spleens of Mice with Collagen-Induced Arthritis and Inhibited Immune Response of CD4+ T Cells. Wataru Fujii, Eishi Ashihara, Hideyo Hirai, Hidetake Nagahara, Kazuki Fujioka, Ken Murakami, Kaoru Nakamura, Takahiro Seno, Aihiro Yamamoto, Hidetaka Ishino, Masataka Kohno, Taira Maekawa and Yutaka Kawahito, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto Pharmaceutical University, Kyoto, Japan, Kyoto University Hospital, Kyoto, Japan 0 Program Book 85

288 ACR POSTER SESSION C The Potent, Highly Selective and Orally Bioavailable Spleen Tyrosine Kinase Inhibitor GSK4 Demonstrates Efficacy in B Cell Receptor and Fc Receptor Signalling in Models of Inflammatory and Autoimmune Disease. Marion C. Dickson, Nicholas Smithers, Huw Lewis, Cesar Ramirez- Molina, Scott McCleary, Mike Barker and John Liddle, GSK, Stevenage, United Kingdom 07. Bone Formation and Resorption Are Both Increased in Autoimmune Arthritis. Kresten K. Keller, Jesper Skovhus Thomsen, Kristian Stengaard-Pedersen, Frederik Dagnæs- Hansen, Jens R. Nyengaard 4 and Ellen-Margrethe Hauge, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Institute of Anatomy, Aarhus University, Institute of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark, 4 Stereology and Electron Microscopy Laboratory, Centre for Stochastic Geometry and Advanced Bioimaging. Aarhus University hospital, Aarhus, Denmark 07. Green Tea Epigallocatechin--Gallate Ameliorates Murine Arthritis by Inducing IDO Producing Dendritic Cells Via Nrf Antioxidant Pathway. Soyoun Min, Mei Yan, Kamala Vanarsa, Anna Bashmakov and Chandra Mohan, University of Texas Southwestern Medical Center, Dallas, TX 074. Combined Effects of a c-fos/ap- Inhibitor T-54 and Methotrexate On Collagen-Induced Arthritis in Mice. Tomomi Date, Yukihiko Aikawa, Tetsuya Yamamoto, Hirokazu Narita, Shuichi Hirono and Shunichi Shiozawa, Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan, Department of Medicine & Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan 075. CCR6+ Foxp+ Regulatory T Cells Regulate the Development of Collagen Induced Arthritis in T Cell Specific RORγt Transgenic Mice. Yuya Kondo, Masahiro Tahara, Mana Iizuka, Hiroto Tsuboi, Satoru Takahashi, Isao Matsumoto and Takayuki Sumida, University of Tsukuba, Tsukuba, Japan 076. Efficacy of the Potent PIK-δ,γ Inhibitor IPI-45 in Rat Adjuvant Arthritis. David L. Boyle, Katharyn Topoleweski and Gary S. Firestein, UCSD School of Medicine, La Jolla, CA 077. IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen- Induced Arthritis. Miho Suzuki, Hiroto Yoshida, Misato Hashizume, Masashi Shiina, Keisuke Tanaka and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan 078. Low-Density Lipoprotein Receptor Deficiency Ameliorates the Development of Inflammatory Arthritis. Shawn Rose and Harris R. Perlman, Northwestern University, Chicago, IL 079. Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate 0 Program Book Isomerase-Induced Arthritis. Hiroto Yoshida, Miho Suzuki, Misato Hashizume, Keisuke Tanaka, Masashi Shiina, Isao Matsumoto, Takayuki Sumida and Yoshihiro Matsumoto, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, University of Tsukuba, Tsukuba City, Japan 080. IL-0 Is Not Involved in Mouse Collagen Induced Arthritis. Christina andersson, Kyle Serikawa, Hermann Pelzer, Peter Thygesen, Patricia Smith, Kim Kruse, Shameek Biswas, Brian Fox, anders Milner, Peter Kvist, Josephine Hebsgaard, Jesper Pass and John Rømer, Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark, Biopharmaceutical Research Unit, Novo Nordisk A/S, Seattle, WA 08. Avβ Integrin Inhibition with Cilengitide Both Prevents and Treats Collagen Induced Arthritis. Despoina Sykoutri, Nisha Geetha, Silvia Hayer, Peter Mandl, Josef S. Smolen, Gerald Prager and Kurt Redlich, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 08. Peripheral and Local Effects of Anti-C5aR Treatment in the Collagen Induced Arthritis Model. Christina andersson, Carola Wenander, Pernille Usher, Josephine Hebsgaard and Lars Hornum, Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark 08. New Treatment Approach of Rheumatoid Arthritis Based On Inhibition of Cyclin Dependent Kinase-9. Annelie Hellvard, Lutz Zeitlmann, Ulrich Heiser, andré Niestroj, Hans-Ulrich Demuth, Jan Potempa 4 and Piotr Mydel, Broegelmann Research Laboratory, The Gade Institute, University of Bergen, Bergen, Norway, Ingenium Pharmaceuticals GmbH, Martinsried, Germany, Probiodrug AG, Halle/Saale, Germany, 4 Jagiellonian University, Krakow, Poland 084. ASP05K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats. Shunji Yamazaki, Masamichi Inami, Misato Ito, Yasutomo Fujii, Kaori Hanaoka, Kaoru Yamagami, Kenji Okuma, Yoshiaki Morita, Shohei Shirakami, Takayuki Inoue, Susumu Miyata and Yasuyuki Higashi, Astellas Pharma Inc., Tsukuba, Japan 085. T Cell-Mediated Murine Antigen-Induced Arthritis Is Resistant to Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts and Osteocytes in Vivo. Cornelia M. Spies, Edgar Wiebe, Jinwen W. Tu, Aiqing Li, Timo Gaber, Dörte Huscher, Markus J. Seibel, Hong Zhou and Frank Buttgereit, Charité University Medicine, Berlin, Germany, ANZAC Research Institute, The University of Sydney, Concord, Australia, Charite University Med-Berlin, Berlin, Germany 086. PI-Kinase Controls Inflammatory Bone Destruction by Regulating the Osteoclastogenic Potential of Myeloid Cells. Stephan Blueml, Gernot Schabbauer, Antonia Puchner, Emine Sahin, Victoria Saferding, Birgit Niederreiter, Josef S. Smolen and Kurt Redlich, Medical University of Vienna, Vienna, Austria, Medical University Vienna, Vienna, Austria,

289 ACR POSTER SESSION C Medical University of Vienna and Hietzing Hospital, Vienna, Austria 087. Regulatory Effect of the Combination of Methotrexate and,5-dihydroxyvitamin D On the Balance of Treg and Th7 in Collagen-Induced Arthritis. Jing Luo, the Second Hospital of Shanxi Medical University, Taiyuan, China 088. Annexin A Receptor Agonist Suppresses Development of Inflammatory Arthritis. Yuan Hang Yang, Yuan Jia, Wenping Kao, Wuqi Song, Zhan-guo Li and Eric F. Morand, Monash University, Melbourne, Australia, Peking University People s Hospital, Beijing, China, Harbin Medical University, Harbin, China 089. High Local Cathepsin Activity in a Murine Rheumatoid Arthritis Model, but Not in an Osteoarthritis Model, Explains the Difference in Cartilage Vdipen Neoepitope Formation. Eline A. Vermeij, Marije I. Koenders, Onno J. Arntz, Miranda B. Bennink, Arjen B. Blom, Peter L.E.M. van Lent, Wim B. van den Berg and Fons A.J. van de Loo, Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands 090. Orchestrating the Orchestrators: Blockade of FltL Signaling-Dependent Dendritic Cells Protects Against Collagen Induced Arthritis. Maria I. Martins Ramos, Karpus O.N. Karpus, Pleun Broekstra, Saïda Aarrass, Paul P. Tak and Maria C. Lebre, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 09. The Effect of Pretreatment with Capsaicin On Measurement of Arthritis Pain by Dynamic Weight Bearing and Evoked Pain Responses in an Acute Murine Arthritis Model. Hollis E. Krug, Christopher W. Dorman, Sandra Frizelle and Maren L. Mahowald, VA Health Care System, Minneapolis, MN, Minneapolis VA Health Care System, Minneapolis, MN, University of Minnesota Medical School and Minneapolis VA Health Care System, Minneapolis, MN Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/ Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity 09. No Significant Effect of Hepatitis B Virus Infection On Disease Activity, Synovitis or Joint Destruction in Rheumatoid Arthritis. Chan Juan Zou, Yan Hua Li, Ying Qian Mo, Lang Jing Zhu, Dong Hui Zheng, Jian Da Ma, Xia Ouyang and Lie Dai, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China 09. Rates of Opportunistic Infections among Rheumatoid Arthritis Patients Switching Biologic Therapy. John Baddley, Shuo Yang, Klye Brizendine, Scott DuVall, Kevin L. Winthrop 4, Mary J. Burton 5, Nivedita M. Patkar 6, Elizabeth S. Delzell, Monika M. Safford, Jasvinder A. Singh, Iris E. Navarro, Grant W. Cannon 7, Ted R. Mikuls 8, Lang Chen, Kenneth G. Saag 6, Kimberly Alexander 9, Pavel Napalkov 9, Aaron Kamauu 0 and Jeffrey R. Curtis 6, University of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, 4 Oregon Health & Science University, Portland, OR, 5 VA Hospital, Jackson, 6 Univ of Alabama-Birmingham, Birmingham, AL, 7 George E. Wahlen VA Medical Center, Salt Lake City, UT, 8 Omaha VA and University of Nebraska Medical Center, Omaha, NE, 9 Genentech, Inc., South San Francisco, CA, 0 Anolinx, Bountiful, UT 094. Reactivation of Hepatitis B Virus in Autoimmune Disease Patients Receiving Immunosuppressive Agents. Daisuke Kobayashi, Satoshi Ito, Megumi Unno, Ichiei Narita and Akira Murasawa, Niigata Rheumatic Center, Niigata, Japan, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan 095. Identifying Arthralgia Patients At Risk for Rheumatoid Arthritis in the Rotterdam Early Arthritis Cohort. M. van der Veer, D. van Zeben, A.E.A.M. Weel, P.J. Barendregt, A.H. Gerards 4, Johanna M.W. Hazes 5 and Jolanda J. Luime 6, ErasmusMC, Rotterdam, Netherlands, Sint Franciscus Gasthuis, Rotterdam, Netherlands, Maasstad Hospital, Rotterdam, Netherlands, 4 Vlietland Hospital, Schiedam, Netherlands, 5 Erasmus Medical Center, Rotterdam, Netherlands, 6 Erasmus MC - University Medical Center, Rotterdam, Netherlands 096. A Prediction Rule for the Progression to Rheumatoid Arthritis Applied in a Mexican Mestizo Cohort with Undifferentiated Arthritis. Ana Arana Guajardo, Lorena Pérez Barbosa, David Vega Morales, Janett Riega Torres, Roberto Negrete López, Jacqueline Rodríguez Amado, Jorge Esquivel Valerio, Cassandra Skinner Taylor, Diana Flores Alvarado, Dionicio Galarza Delgado, Miguel Villarreal Alarcon and Mario Garza Elizondo, Hospital Universitario, UANL, Monterrey, Mexico 097. Adiponectin Is Associated with Pro-Inflammatory Cytokines in Autoantibody Positive First-Degree Relatives (FDRs) of Patients with Rheumatoid Arthritis. Jan M. Hughes-Austin, Kevin D. Deane, Lezlie A. Derber, Gary O. Zerbe, Dana M. Dabelea, Jeremy Sokolove 4, William H. Robinson 5, V. Michael Holers and Jill M. Norris 6, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, University of Colorado School of Medicine, Aurora, CO, University of Colorado Anschutz Medical Campus, Aurora, CO, 4 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 5 Stanford University, Palo Alto, CA, 6 Colorado School of Public Health, Aurora, CO 098. Patient Report Outcomes Variance Between Centers Is Much Lower Than Physician and Laboratory Assessed Measures of Rheumatoid Arthritis Activity: Results From a Multinational Study. Nasim A. Khan, Horace Spencer, Tuulikki Sokka and QUEST-RA 4, University of Arkansas for 0 Program Book 87

290 ACR POSTER SESSION C 88 Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, University of Arkansas for Medical Sciences, Little Rock, AR, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 4 Jyväskylä 099. Patient Self-Assessments and Selected Patient Reported Outcomes May Reliably Identify Rheumatoid Disease Flare in Early Rheumatoid Arthritis Patients. Vivian P. Bykerk, CO Bingham III, Ernest Choy, Juan Xiong 4, Gilles Boire 5, Carol A. Hitchon 6, Janet E. Pope 7, J. Carter Thorne 8, Boulos Haraoui 9, Edward Keystone 0 and Susan J. Bartlett, Hospital for Special Surgery, New York, NY, Johns Hopkins University, Baltimore, MD, Cardiff University School of Medicine, Cardiff, United Kingdom, 4 Mount Sinai Hospital, Toronto, ON, 5 CHUS - Sherbrooke University, Sherbrooke, QC, 6 University of Manitoba, Winnipeg, MB, 7 St. Joseph Health Care London, University of Western Ontario, London, ON, 8 Southlake Regional Health Centre, Newmarket, ON, 9 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 0 University of Toronto, Toronto, ON, McGill University, Montreal, QC 00. Relative, Reliability-Adjusted Diagnostic Test Accuracy of Erosion Detection between Magnetic Resonance Imaging and Radiography in Rheumatoid Arthritis. Ruben Tavares, Naveen Parasu, Karen Finlay, Erik Jurriaans, Hao Wu, Karen A. Beattie, Maggie Larche, Lawrence E. Hart, William G. Bensen 4, Raja S. Bobba, Alfred A. Cividino, Colin E. Webber 5, Jean-Eric Tarride 6 and Jonathan D. Adachi 7, McMaster University, Hamilton, ON, Hamilton Health Sciences, Hamilton, St. Joseph s Health Care, Hamilton, ON, 4 St. Joseph s Hospital and McMaster University, Hamilton, ON, Hamilton, ON, 5 Hamilton Health Sciences, Hamilton, ON, 6 Programs for Assessment of Technology in Health (PATH) Research Institute, Hamilton, ON, 7 Charlton Medical Centre, Hamilton, ON 0. How Much Patient Can Reported Outcomes Improve Among Rheumatoid Arthritis Patients Who Have a Clinical Response to Biologic Therapy but Have Not Attained Low Disease Activity? Jeffrey Curtis, Ying Shan, Jie Zhang, Jeffrey D. Greenberg and George W. Reed 4, University of Alabama at Birmingham, Birmingham, AL, New York University School of Medicine, New York, NY, University of Massachusetts Medical School, Worcester, MA 0. Patient versus Physician Global Assessments in Ethnic Patients Wtih Rheumatoid Arthritis. Gail S. Kerr, Yusuf Yazici, Christopher J. Swearingen, Luis R. Espinoza 4, Edward L. Treadwell 5, Yvonne R. S. Sherrer 6, Angelia D. Mosley- Williams 7, Akgun Ince 8, Raj G. Nair 9, Theresa Lawrence Ford 0, Jeffrey Huang and Carl A. Nunziato, Washington DC VAMC, Georgetown and Howard University, Washington, DC, New York University, New York, NY, University of Arkansas, Little Rock, AR, 4 Louisiana State University, New Orleans, LA, 5 East Carolina University, Greenville, NC, 6 Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, 7 John Dingell VAMC, Detroit, MI, 8 Saint Louis University, St. Louis, 0 Program Book MO, 9 Washington Hospital Center, Washington DC, DC, 0 North Georgia Rheumatology, Lawrenceville, GA, Howard University Hospital, Washington, DC 0. Reliability of DAS8 in Rheumatoid Arthritis When Based On Patient Self-Assessment of Tender and Swollen Joints. Ole Rintek Madsen and Cecilie Heegaard, Copenhagen University Hospital Gentofte, Hellerup, Denmark 04. Quantitation in Patients with Rheumatoid Arthritis of Inflammation, Joint Damage and Unexplained Symptoms (e.g., Fibromyalgia) in Addition to Overall Status, According to 4 Physician Global Estimates Scored 0-0. Isabel Castrejón, Martin J. Bergman and Theodore Pincus, NYU Hospital for Joint Diseases, New York, NY, Taylor Hospital, Ridley Park, PA 05. Significant Correlation between ACR/EULAR Remission Criteria and a Simplified Measure Using RAPID and Careful Joint Examination without a Formal Joint Count. Martin J. Bergman, Isabel Castrejón and Theodore Pincus, Taylor Hospital, Ridley Park, PA, NYU Hospital for Joint Diseases, New York, NY 06. Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in U.S. Veterans with Rheumatoid Arthritis. Archana Jain, Rebecca Belsom, Jeffrey Curtis, Shuo Yang, Ted R. Mikuls, Lang Chen and Angelo L. Gaffo 4, University of Alabama, Birmingham, AL, University of Alabama at Birmingham, Birmingham, AL, Omaha VA and University of Nebraska Medical Center, Omaha, NE, 4 Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL 07. Assessing Subclinical Synovitis in Rheumatoid Arthritis: Arthrosonographic Findings in Patients with Good Response to Therapy. Matthias Witt, Felix Mueller, Axel Nigg, Christiane Reindl, Hendrik Schulze-Koops and Mathias Grunke, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany 08. Identification of Four Parameters That Drive the Discordance between the Patient and Physician Global Assessment in Rheumatoid Arthritis. William Bensen, Denis Choquette, Milton F. Baker, Susan M. Otawa 4 and Hayssam Khalil 4, St. Joseph s Hospital and McMaster University, Hamilton, ON, University of Montreal, Notredame Hospital, Montreal, QC, University of Victoria, Victoria, BC, 4 Janssen Canada Inc, Toronto, ON 09. Discrepancy Between Patient and Physician Global Assessments Over Time in Early Rheumatoid Arthritis. Pooneh Akhavan, Vivian P. Bykerk, Juan Xiong, Janet Pope 4, Boulos Haraoui 5, J. Carter Thorne 6, Gilles Boire 7, Carol A. Hitchon 8, Diane Tin 6, E. Keystone and CATCH 9, University of Toronto, Toronto, ON, Hospital for Special Surgery, New York, NY, Mount Sinai Hospital, Toronto, ON, 4 Schulich School of Medicine and Dentistry, Western University, London, ON, 5 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal,

291 ACR POSTER SESSION C QC, 6 Southlake Regional Health Centre, Newmarket, ON, 7 CHUS - Sherbrooke University, Sherbrooke, QC, 8 University of Manitoba, Winnipeg, MB, 9 Toronto 0. Prospective Assessement of Bone Texture Parameters At the Hand in Rheumatoid Arthritis. Laetitia Sparsa, Sami Kolta, Karine Briot, Simon Paternotte, Rashra Masri, Damien Loeuille, Piet P. Geusens and Christian Roux, Paris Descartes University, Cochin hospital, Paris, France, CHU Brabois, Vandoeuvre les Nancy, France, Maastricht University, Maastricht, Netherlands. Diagnostic Performance of the 00 American College of Rheumatology/European League against Rheumatism Classification Criteria for Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. Garifallia Sakellariou, Carlo Alberto Scirè, Roberto Caporali and Carlomaurizio Montecucco, Division of Rheumatology, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Epidemiology Unit, Italian Society for Rheumatology (SIR), Milano, Italy, University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. Combination of Magnetic Resonance Imaging (MRI)-Proven Osteitis with 00 RA Classification Criteria Improves the Diagnostic Probability of Rheumatoid Arthritis (RA). Mami Tamai, Yoshikazu Nakashima, Takahisa Suzuki, Yoshiro Horai, Akitomo Okada, Junko Kita, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Kazuhiko Arima, Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Kiyoshi Aoyagi, Katsumi Eguchi and Atsushi Kawakami, Nagasaki University, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Sasebo City General Hospital, Sasebo, Nagasaki, Japan. Performance of the New ACR/EULAR Classification Criteria for Rheumatoid arthritis a Systematic Literature Review. Helga Radner, Josef Smolen and Daniel Aletaha, Medical University Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, Medical University of Vienna, Vienna, Austria 4. Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB Shared Epitope and Anti-CCP. Jose Felix Restrepo, Inmaculada del Rincon, Roy W. Haas, Daniel F. Battafarano and Agustin Escalante, University of Texas Health Science Center at San Antonio, San Antonio, TX, Brooke Army Medical Ctr, San Antonio, TX 5. Altered Serum Levels of Bone Metabolism Markers in Rheumatoid Arthritis. Lang Jing Zhu, Xia Ouyang, Lie Dai, Dong Hui Zheng, Ying Qian Mo, Xiu Ning Wei, Chan Juan Zou and Bai Yu Zhang, Sun Yat-Sen Memorial Hospital, Sun Yat- Sen University, Guangzhou, China 6. The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis. Mehret Birru Talabi, Rachel Mackey, Larry W. Moreland, Jan Dorman, Kevin D. Deane 4, Jeremy Sokolove 5, V. Michael Holers 4, William H. Robinson 6, Brian Wallitt 7 and Lewis Kuller, University of Pittsburgh Medical Center, Pittsburgh, PA, University of Pittsburgh, Pittsburgh, PA, University of Pittsburgh School of Nursing, Pittsburgh, PA, 4 University of Colorado School of Medicine, Aurora, CO, 5 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6 Stanford University, Palo Alto, CA, 7 Washington Hospital Center, Baltimore, MD 7. Algorithm Using Genome-Wide SNP Analysis for Prediction of Radiographic Progression per Year in RA Patients From Multiple Medical Cohorts. Tsukasa Matsubara, Satoru Koyano, Yoshitada Sakai, Keiko Funahashi, James E. Middleton, Takako Miura, Kosuke Okuda, Takeshi Nakamura, Akira Sagawa 4, Takeo Sakurai 5, Hiroaki Matsuno 6, Tomomaro Izumihara 7 and Eisuke Shono 8, Matsubara Mayflower Hospital, Kato, Japan, Research Institute of Joint Diseases, Kobe, Japan, Kobe University Hospital, Kobe, Japan, 4 Sagawa Akira Rheumatology Clinic, Sapporo, Japan, 5 Inoue Hospital, Takasaki, Japan, 6 Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, 7 Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, 8 Shono Rheumatology Clinic, Fukuoka, Japan 8. Validation of Prognostic Biomarkers for RA: Testing of 4-- Eta According to the Omeract Soluble Biomarker Criteria. Walter P. Maksymowych, Désirée van der Heijde, R. Landewe, George A. Wells 4, Joan M. Bathon 5, CO Bingham III 6, Vivian P. Bykerk 7, Mikkel Ostergaard 8, Hilde B. Hammer 9, Maarten Boers 0, Paul Peter Tak, Oliver M. FitzGerald, Christopher T. Ritchlin, Dafna Gladman 4, Philip Mease 5, Dirkjan van Schaardenburg 6, Marina Backhaus 7, Bernard Combe 8, Gianfranco Ferraccioli 9 and Anthony Marotta 0, University of Alberta, Edmonton, AB, Leiden University Medical Center, Leiden, Netherlands, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 4 Univ of Ottawa Faculty of Med, Ottawa, ON, 5 Columbia University Medical Center, New York, NY, 6 Johns Hopkins University, Baltimore, MD, 7 Hospital for Special Surgery, New York, NY, 8 Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 9 Diakonhjemmet Hospital, Oslo, Norway, 0 VU University Medical Center, Amsterdam, Netherlands, Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, University of Rochester Medical Center, Rochester, NY, 4 Toronto Western Hospital and University of Toronto, Toronto, ON, 5 Swedish Rheumatology Research Group, Seattle, WA, 6 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 7 Charite University Hospital, Berlin, Germany, 8 Hopital Lapeyronie, Montpellier, France, 9 Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, 0 Augurex Life Sciences Corp, North Vancouver, BC 0 Program Book 89

292 ACR POSTER SESSION C 9. Interleukin-6 as a Biomarker for the Clinical and Radiological Effectiveness of Methotrexate in Rheumatoid Arthritis. Naoshi Nishina, Hideto Kameda, Yuko Kaneko, Masataka Kuwana and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan 0. Predictive Value of Anti-CCP Positivity on Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results from the Swedish EIRA Study. Saedis Saevarsdottir, Marie Holmqvist, Johan Askling, Lars Alfredsson and Lars Klareskog, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Karolinska Institute, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. A Multi-Biomarker Disease Activity (VECTRA DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab. Yoshiya Tanaka, Kentaro Hanami, Hisashi Tasaka, Shunsuke Fukuyo, Douglas J. Haney, Nadine Defranoux, Rebecca Bolce, Guy Cavet, David Chernoff, Kunihiro Yamaoka, Kazuyoshi Saito and Shintaro Hirata, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Crescendo Bioscience Inc., South San Francisco, CA. Plasma chemerin as a Useful Marker for Disease Activity in Patients with Rheumatoid Arthritis. Sang Tae Choi, You-Jung HA, Eun-Jin Kang, Kwang-Hoon Lee 4 and Jung-Soo Song, Chung-Ang University College of Medicine, Seoul, South Korea, Kwanding University College of Medicine, Myongji Hospital, Goyang, South Korea, Busan Medical Center, Busan, South Korea, 4 Dongguk University Ilsan Hospital, Goyang, South Korea. Circulating Mir- Is Associated with Disease Activity and May Predict the Response to Therapy in Treatment naïve Patients with Early Rheumatoid Arthritis. Maria Filkova, Caroline Ospelt, Serena Vettori, Ladislav ŠEnolt, Herman F. Mann, Beat A. Michel, Jiri Vencovsky, Karel Pavelka, Renate E. Gay, Steffen Gay and Astrid Jüngel, Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, Institute of Rheumatology, Department of Clinical and Experimental Rheumatology of the st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland 4. Serum Concentrations of Soluble Interferon Receptor in Patients with Rheumatoid Arthritis. Masao Sato, Masao Takemura, Ryuki Shinohe, Tsuneo Watanabe and Katsuji Shimizu, Gifu University, Gifu, Japan 5. Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (VectraTM DA) Test and DAS8-ESR. J.W.J. Bijlsma, M. Verhoef-Jurgens, M.F. Bakker, J.W.G. Jacobs, F.P.J.G. Lafeber, P.M.J. Welsing, G. Cavet, D. Chernoff and D.J. Haney, University Medical Center Utrecht, Utrecht, Netherlands, Crescendo Bioscience, Inc., South San Francisco, CA 6. Changes of Serological Markers in the Course of Traditional and Biological Disease Modifying Therapy of Rheumatoid Arthritis. Christoph Böhler, Helga Radner, Josef S. Smolen and Daniel Aletaha, Medical University of Vienna, Vienna, Austria, Medical University of Vienna and Hietzing Hospital, Vienna, Austria 7. Rheumatoid Arthritis (RA) Patients Discordant for Rheumatoid Factor and Anti-CCP Positivity Have Different Clinical and Laboratory Features Than RA Patients Seropositive or Seronegative for Both Markers. Swati Modi, Yona Cloonan, Danielle Goudeau, Donald M. Jones, Christine L. Amity, Lynne M. Frydrych, Kelly A. Reckley 4, Heather Eng, Stephen R. Wisniewski 5, Larry W. Moreland and Marc C. Levesque, University of Pittsburgh, Pittsburgh, PA, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, Univ of Pittsburgh, Pittsburgh, PA, 4 University of Pittsburgh School of Medicine, Pittsburgh, PA, 5 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA 8. Matrix Metalloproteinase : A Biomarker of Disease Activity in Rheumatoid Arthritis. Sandra Reuter, Torsten Matthias and Bruno Larida, AIRA e.v., AESKU.KIPP Institute, Wendelsheim, Germany, AESKU.Diagnostics GmbH & Co. KG, Wendelsheim, Germany, AESKU. DIAGNOSTICS INC, Oakland, CA 9. Dickkopf- Is Increased in Rheumatoid Arthritis of Recent Onset and Might Be a New Biomarker of Structural Progression. Data from the Espoir Cohort. Raphaèle Seror, Stephan Pavy, Thierry Schaeverbeke, Alain Saraux 4, Xavier Mariette 5 and Corinne Miceli-Richard, Université Paris Sud, Le Kremlin Bicêtre, France, Hopital Bicetre, Paris, France, Groupe Hospitalier Pellegrin, Bordeaux, France, 4 CHU de la Cavale Blanche, Brest Cedex, France, 5 Université Paris-Sud, Le Kremlin Bicetre, France 0. Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate. Aase Haj Hensvold, Saedis Saevarsdottir*, Wanyiang Li*, Vivianne Malmström, Guy Cavet, Lars Klareskog 4 and Anca Irinel Catrina, Rheumatology Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, Crescendo Bioscience Inc. 4 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, Crescendo Bioscience Inc., South San Francisco, CA, 4 Karolinska Institute, Stockholm, Sweden. An Evaluation of Prognostic Factors for Orthopaedic Joint Surgery in Rheumatoid Arthritis. Results From Two Multicentre UK Inception Cohorts (986-0). Elena Nikiphorou, Lewis Carpenter, Sam Norton, David James 4, Patrick D. Kiely 5, David Walsh 6, Richard Williams 7 and Adam Young 8, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, University of Hertfordshire, Hatfield, United Kingdom, ERAS, St Albans City Hospital, St Albans, United Kingdom, 4 Diana 90 0 Program Book

293 ACR POSTER SESSION C Princess of Wales Hospital, Grimsby, United Kingdom, 5 St. Georges Hospital, London, United Kingdom, 6 City Hospital, Nottingham, United Kingdom, 7 County Hospital, Hereford, United Kingdom, 8 St Albans City Hospital, St Albans, United Kingdom. Disease Activity and Anti-CCP Status, but Not Sociodemographic Factors or Patient Comorbidities, Affect Time to Diagnosis in Early Rheumatoid Arthritis. Cheryl Barnabe, Juan Xiong, Gilles Boire, Carol A. Hitchon 4, Boulos Haraoui 5, Janet E. Pope 6, J. Carter Thorne 7, Edward Keystone 8, Diane Tin 7, Vivian P. Bykerk 9 and Canadian ArThritis CoHort 0, University of Calgary, Calgary, AB, University of Toronto, Toronto, CHUS - Sherbrooke University, Sherbrooke, QC, 4 University of Manitoba, Winnipeg, MB, 5 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, 6 St. Joseph Health Care London, University of Western Ontario, London, ON, 7 Southlake Regional Health Centre, Newmarket, ON, 8 University of Toronto, Toronto, ON, 9 Hospital for Special Surgery, New York, NY, 0 Toronto. Relationship between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis. Josef S. Smolen, Ronald F. van Vollenhoven, Andrew S. Koenig, Ronald Pedersen, Annette Szumski and Eustratios Bananis, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, The Karolinska Institute, Stockholm, Sweden, Pfizer Inc., Collegeville, PA 4. The Changed Prognosis of Patients with Early Rheumatoid Arthritis. Karin Britsemmer and D. van Schaardenburg, Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, Jan van Breemen Research Institute Reade, Amsterdam, Netherlands 5. Trabecular Bone Texture parameters are Correlated with Magnetic Resonance Imaging (MRI) bone Edema At Hand and Wrist in Active Rheumatoid Arthritis (RA). Thao Pham, Sophie Trijau, Roland Chapurlat, Damien Loeuille, Thierry Schaeverbeke 4, Christian Roux 5, Claude-Laurent Benhamou 6, Olivier Vittecoq 7, Jean Sibilia 8, Frederic Mistretta 9 and Cécile Hacquard-Bouder 0, Sainte Marguerite Hospital, Marseille, France, Hôpital Edouard Herriot, Lyon, France, CHU Brabois, Vandoeuvre les Nancy, France, 4 Groupe Hospitalier Pellegrin, Bordeaux, France, 5 Paris Descartes University, Paris, France, 6 EA 4708 University Orleans, Orleans, France, 7 Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, 8 CHU Hautepierre, Strasbourg, France, 9 Lyon, France, 0 Abbott France, Rungis, France 6. Alcohol Use and Radiographic Disease Progression in African Americans with Recent Onset Rheumatoid Arthritis. Marshall Davis, Kaleb Michaud, Harlan Sayles, Doyt L. Conn, Larry W. Moreland, S. Louis Bridges Jr. 4 and Ted R. Mikuls, University of Nebraska Medical Center, Omaha, NE, Emory Univ School of Medicine, Atlanta, GA, University of Pittsburgh, Pittsburgh, PA, 4 Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 7. Contribution of Disease Activity, Joint Damage and Comorbidity to Impairment (SOFI) and Disability (HAQ) in Rheumatoid Arthritis Patients Over 0 Years. Meliha C. Kapetanovic, Elisabet Lindqvist, Jan-Åke Nilsson, Pierre Geborek 4, Tore Saxne 5 and Kerstin Eberhardt, Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, Department of Clinical Sciences Lund, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden, Lund University, Malmö, Sweden, 4 Sweden, 5 Dept of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden 8. Racial and Ethnic Disparities in Rheumatoid Arthritis Outcomes in Community-Based U.S. Rheumatology Practices: Results From the Consortium of Rheumatology Researchers of North America Registry. Jeffrey D. Greenberg, Tanya Spruill, Gbenga Ogedebe, Joel M. Kremer 4, Ying Shan 5, Katherine C. Saunders 6, Yusuf Yazici 7 and Leslie R. Harrold 5, NYU Hospital for Joint Diseases, New York, NY, NYU School of Medicine, New York, NY, New York University School of Medicine, New York, NY, 4 Albany Medical College and The Center for Rheumatology, Albany, NY, 5 UMass Medical School, Worcester, MA, 6 CORRONA, Inc., Southborough, MA, 7 New York University, New York, NY 9. Smoking Is Associated with Worsening Functional Status Over Time in a Diverse Cohort of Patients with Rheumatoid Arthritis. Matthew Reimert, Laura Trupin, Patricia P. Katz, Edward Yelin, Jennifer Barton 4 and John B. Imboden 5, University of CA San Francisco, San Francisco, CA, UC San Francisco, San Francisco, CA, University of California San Francisco, San Francisco, CA, 4 UCSF, San Francisco, CA, 5 University of California, San Francisco, San Francisco, CA 40. A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study. Paul Bird, David Nicholls, Julien P. de Jager, Hedley Griffiths 4, Lynden Roberts 5, Kathleen Tymms 6, Jane Zochling 7, Mark H. Arnold 8, Geoffrey O. Littlejohn 9 and OPAL Consortium 0, Combined Rheumatology Practice, Sydney, Australia, Coast Joint Care, Maroochydore, Australia, Suite, Osler House, Southport, Australia, 4 Barwon Rheumatology Service, Geelong, Australia, 5 James Cook University, Townsville, Australia, 6 Canberra Rheumatology, Canberra, Australia, 7 Menzies Research Institute Tasmania, Hobart, Australia, 8 Level The Gallery, Chatswood, Australia, 9 Monash Medical Center, Melbourne, Australia, 0 Melbourne, Australia 4. Effects of Cigarette Smoking On EARLY Arthritis (CONAART). Maria Haye Salinas, Ana C. Alvarez, Rafael Chaparro del Moral, Mariana Benegas, Christian A. Waimann, Rodolfo Perez Alamino, Rodrigo Garcia Salinas 4, Ana Lucía Barbaglia 5, Veronica Bellomio 5, Josefina Marcos 6, Adrian Salas 6, Cristian Quiroz 7, Federico Ceccato 8, Sergio Paira 8, Dora Lia Vazquez 9, Gabriela Salvatierra 0, M. Crespo, 0 Program Book 9

294 ACR POSTER SESSION C 9 Edson Javier Velozo, Oscar L. Rillo, Enrique Soriano 4, Antonio Catalan Pellet 4, Alberto Berman Sr. 5, Juan Carlos Marcos 6, Gustavo Citera 5 and Francisco Caeiro 6, Hospital Privado, Córdoba, Argentina, Hospital Tornu, Buenos Aires, Argentina, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 4 Hospital Rivadavia, Buenos Aires, Argentina, 5 Hospital Padilla, Tucuman, Argentina, 6 Hospital San Martin, La Plata, Argentina, 7 Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 8 Hospital Jose Maria Cullen, Santa Fe, Argentina, 9 Centro Integral de Reumatologia, Santiago del Estero, Argentina, 0 Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, Hospital Señor del Milagro, Salta, Argentina, Sanatorio Adventista del Plata, Entre Rios, Argentina, Hospital Tornú, Buenos Aires, Argentina, 4 Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5 Instituto de Rehabilitación Psicofísica., Buenos Aires, Argentina, 6 Hospital privado de Cordoba, Cordoba, Argentina 4. Magnetic Resonance Imaging-Proven Osteitis At Baseline Predicts the Early Rheumatoid Arthritis Patients Who Will Develop Rapid Radiographic Progression: MRI Is Beneficial to Find the Window of Opportunity in Early RA. Mami Tamai, Yoshikazu Nakashima, Takahisa Suzuki, Yoshiro Horai, Akitomo Okada, Junko Kita, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Kazuhiko Arima, Hideki Nakamura, Tomoki Origuchi, Masataka Uetani, Kiyoshi Aoyagi, Katsumi Eguchi and Atsushi Kawakami, Nagasaki University, Nagasaki, Japan, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, Sasebo City General Hospital, Sasebo, Nagasaki, Japan 4. Analysis of Factors Associated with the Health Assessment Questionnaire Score Change in Five Years. Shinji Yoshida, Katsunori Ikari, Kensuke Ochi, Yoshiaki Toyama, Atsuo Taniguchi, Hisashi Yamanaka and Shigeki Momohara, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Institute of Rheumatology, Tokyo Women s Medical University, Shinjuku-ku, Japan, Keio University, Shinjuku, Japan 44. Early RA Patients Fulfilling the New 00 ACR/EULAR Criteria, Display Better Clinical Responses to DMARD Therapy but Have Higher Radiographic Damage Progression Than Patients with Early RA Not Fulfilling the 00 ACR/EULAR Criteria. Ruediger Mueller, Toni Kaegi, Axel Finckh and Johannes von Kempis, MD, St. Gallen, Switzerland, Geneva University Hospitals, Geneva 4, Switzerland 45. Age at Onset Determines Severity and choice of Treatment in Early Rheumatoid Arthritis. Lena Innala, Bozena Möller, Lotta Ljung, Torgny Smedby, Anna Södergren, Staffan Magnusson 4, Ewa H. Berglin, Solbritt M. Rantapää- Dahlqvist and Solveig Wållberg-Jonsson, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Department of Rheumatology, Sunderby Hospital, Luleå, Sweden, Department of Rheumatology, Östersund hospital, 0 Program Book Östersund, Sweden, 4 Department of Internal Medicine, Sundsvall Hospital, Sundsvall, Sweden 46. Impact of Severity Index for Rheumatoid Arthritis on Healthcare Costs and Utilizations in Patients with Rheumatoid Arthritis. Onur Baser, Li Wang, Juan Du, Hai Wang and Lin Xie, STATinMED Research/The University of Michigan, Ann Arbor, MI, STATinMED Research, Dallas, TX, STATinMED Research, Ann Arbor, MI 47. Risks to Visit Emergency Room in Patients with Rheumatoid Arthritis: A Two-Year Retrospective Study. Yoshiki Nagai, Naoto Yokogawa, Kota Shimada and Shoji Sugii, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan 48. Peer to Peer Mentoring for Individuals with Early Inflammatory Arthritis: Feasibility Pilot. Mary J. Bell, Paula Veinot, Gayathri Embuldeniya, Joyce Nyhof-Young, Joanna Sale 4, Joan Sargeant 5, Peter Tugwell 6, Sydney Brooks 7, Susan Ross 7, Ruth Tonon 7, Sharron Sandhu, Dawn Richards 8, Jennifer Boyle 7, Kerry Knickle 9, Nicky Britten 0, Emma Bell, Fiona Webster 9 and Mary Cox-Dublanski, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON, Sunnybrook Health Sciences Centre, Toronto, ON, University Health Network, University of Toronto, Toronto, ON, 4 University of Toronto, St. Michael s Hospital, Toronto, ON, 5 Dalhousie University, Halifax, NS, 6 University of Ottawa, Ottawa General Hospital, Ottawa, ON, 7 The Arthritis Society, Ontario Division, Toronto, ON, 8 Canadian Arthritis Network Consumer Advisory Council, Toronto, ON, 9 University of Toronto, Toronto, ON, 0 University of Exeter, Exeter, United Kingdom, St. Mary s General Hospital, Kitchener, ON Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy 49. Atsttrin-â, an Engineered Protein Derived From Progranulin Growth Factor, Binds to TNF Receptors and Exhibits Potent Anti-Inflammatory Activity in Mice. Yunpeng Zhao, Qingyun Tian, Haicheng Song, Fanhua Wei and Chuanju Liu, NYU Hospital for Joint Diseases, New York, NY, New York University, New York, NY 50. Action of Tofacitinib via Human Dendritic Cells. Satoshi Kubo, Kunihiro Yamaoka, Shigeru Iwata and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 5. WITHDRAWN. 5. Inhibition of Fucose Incorporation Abrogates the Development of Arthritis by Suppressing the Inflammatory Macrophage Development and TNF-α Production. Jun Li, Hui-Chen Hsu, PingAr Yang, Qi Wu, David M. Spalding, W. Winn Chatham, Robert P. Kimberly, S. Louis Bridges Jr. and John D. Mountz, University of Alabama at Birmingham, Birmingham, AL, University of Alabama at Birmingham and Birmingham VA Medical center, Birmingham, AL 5. Target-Directed Development of a Proposed Biosimilar Rituximab (GP0): Comparability of Antibody-

295 ACR POSTER SESSION C Dependent Cellular Cytotoxicity Activity and Pre-Clinical Pharmacokinetics and Pharmacodynamics with Originator Rituximab. Antonio da Silva, Ulrich Kronthaler, Ines Meyer, Anastassia Papandrikopoulou, Thomas Stangler and Jan Marinus Visser, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany 54. Regulation of Folate Pathway Related Genes in Methotrexate naïve and Methotrexate Treated Patients with Rheumatoid Arthritis. Marjolein Blits, Gerrit Jansen, Saskia Vosslamber, Yehuda G. Assaraf and Cornelis L. Verweij, VU University Medical Center, Amsterdam, Netherlands, Haifa, Israel 55. The Annualized Progression of Radiologic Damage in Placebo Arms of Rheumatoid Arthritis Trials Is Much Lower Than the Mean Annual Progression Since Disease Onset. Jean-Marie Berthelot and Celine Cozic, Nantes University Hospital, Nantes, France 56. Anti-Cyclic Citrullinated Protein Antibodies as a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study. Kensuke Kume, Kanzo Amano, Susumu Yamada, Kuniki Amano, Kazuhiko Hatta, Hiroyuki Ohta 4 and Noriko Kuwaba 5, Hiroshima Clinic, Hiroshima, Japan, Sky Clinic, Hiroshima, Japan, Hatta Clinic, Kure, Japan, 4 Hiroshima, Japan, 5 Sanki Clinical Link, Hiroshima, Japan 57. Resveratrol Counters Pro-Atherogenic Effects of Systemic Lupus Erythematosus and Rheumatoid Arthritis Plasma On Cholesterol Efflux in Human Macrophages. Allison B. Reiss, Iryna Voloshyna, Ofek Hai, Michael J. Littlefield, Elise Belilos, Kristina B. Belostocki, Lois A. Bonetti, Gary C. Rosenblum and Steven E. Carsons, Winthrop University Hospital, Mineola, NY 58. Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis. Maurits C.F.J. De Rotte, Saskia M.F. Pluijm, Maja Bulatovic, Johanna M.W. Hazes and Robert De Jonge, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus Medical center, Rotterdam, Netherlands, University Medical Centre Utrecht, Netherlands 59. Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 8 (C - reactive protein) Response Assessment and Omeract Ramris Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET). DJ Haney, G. Cavet, P. Durez, R. Alten 4, G. R. Burmester 5, P. P. Tak 6, Anka. I. Catrina 7, C. Gaillez 8, M. Le Bars 8, S. Connolly 9 and R. Townsend 9, Crescendo Bioscience Inc., South San Francisco, CA, Crescendo Bioscience, Inc., South San Francisco, CA, Université Catholique de Louvain, Brussels, Belgium, 4 Schlosspark-Klinik, University Medicine, Berlin, Germany, 5 Charité-Universitätsmedizin, Berlin, Germany, 6 Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, United Kingdom, 7 Karolinska Institute, Stockholm, Sweden, 8 Bristol-Myers Squibb, Rueil Malmaison, France, 9 Bristol-Myers Squibb, Princeton, NJ 60. Fcγ Receptor IIIb Polymorphism Is Associated with Injection Reaction to Adalimumab in Patients with Rheumatoid Arthritis. Masako Tsukamoto, Yosuke Hashimoto, Tatsuhiro Ohshige, Keiko Yoshimoto, Yuko Kaneko, Hideto Kameda and Tsutomu Takeuchi, Keio University School of Medicine, Tokyo, Japan, Keio Univ School of Medicine, Shinjuku-ku, Japan 6. Methotrexate Polyglutamate Concentrations in Erythrocytes Are a Potential Tool for Therapeutic Drug Monitoring of Methotrexate Response in Rheumatoid Arthritis. Maurits C.F.J. De Rotte, Ethan den Boer, Maja Bulatovic, Saskia M.F. Pluijm 4, Johanna M.W. Hazes and Robert De Jonge, Erasmus Medical Center, Rotterdam, Netherlands, Erasmus University Hospital, Rotterdam, Netherlands, University Medical Centre Utrecht, Netherlands, 4 Erasmus Medical center, Rotterdam, Netherlands 6. Correlation of A Multi-Biomarker Disease Activity (VECTRA DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib. Kunihiro Yamaoka, Satoshi Kubo, Koshiro Sonomoto, Shintaro Hirata, Guy Cavet, Rebecca Bolce, Michael W. Rowe, David Chernoff, Nadine Defranoux, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, Crescendo Bioscience Inc., South San Francisco, CA 6. Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation into Osteoclasts. Sandra Mueller- Schmucker, Roland Axmann, Sonja Herman, Mario Zaiss, Manuela Le Bars, Thomas Harrer and Georg A. Schett 4, University of Erlangen-Nuremberg, Erlangen, Germany, Medical University of Vienna, Vienna, Austria, Bristol- Myers Squibb, Rueil Malmaison, France, 4 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany 64. Evidence for NF-Kb Intracellular Signaling Involvement Following CTLA4-Ig (Abatacept) Treatment of Human Macrophages. Renata Brizzolara, Paola Montagna, Stefano Soldano, Alberto Sulli, Bruno Seriolo, Barbara Villaggio, Pierfranco Triolo, Lamberto Felli 4 and Maurizio Cutolo, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy, Rheumatoid Arthritis Unit, Orthopedic Surgery Department, CTO Hospital, Turin, taly, Turin, Italy, 4 Orthopedic Department, University of Genova, Genova, Italy 0 Program Book 9

296 ACR POSTER SESSION C Utility of Vectra-DA On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study from a Phase Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Sarah Lamberth, Yauheniya Cherkas, Carrie Brodmerkel and Mark Curran, Janssen Research and Development, LLC, Spring House, PA 66. Identification of Serological Biomarker Profiles Associated with Response to IL-6 Intervention in Rheumatoid Arthritis. Morten Asser Karsdal, Anne C. Bay-Jensen, Inger Byrjalsen, Andrew Kenwright, Adam Platt, Thierry Sornasse 4 and Claus Christiansen 5, Nordic Bioscience A/S, Herlev, Denmark, Nordic Bioscience, Herlev, Denmark, Roche, Welwyn Garden City, United Kingdom, 4 Genentech, Inc., South San Francisco, USA, San Fransisco, CA, 5 CCBR, Ballerup, Denmark 67. Serum Based Biomarkers of Joint Destruction Can Identify Responders and Non-Responder to Tocilizumab. Anne C. Bay-Jensen, Inger Byrjalsen, Claus Christiansen and Morten Asser Karsdal, Nordic Bioscience A/S, Herlev, Denmark, Nordic Bioscience, Herlev, Denmark, CCBR, Ballerup, Denmark 68. Tolerance and Efficacy of Rituximab in Elderly Patients with Rheumatoid Arthritis Enrolled in the French Society of Rheumatology Air Registry. Sarah Payet, Jacques-Eric Gottenberg, Xavier Mariette, Philippe Ravaud 4, Elodie Perrodeau 5, Thomas Bardin 6, Patrice P. Cacoub Sr. 7, Alain G. Cantagrel 8, Bernard Combe 9, Maxime Dougados 0, Rene- Marc Flipo, Bertrand Godeau, Loic Guillevin, Xavier X. Le Loet 4, Eric Hachulla 5, Thierry Schaeverbeke 6, Jean Sibilia 7, Isabelle Pane 8, Gabriel Baron 9 and Martin Soubrier 0, CHU G.-Montpied, Clermont-Ferrand, France, Strasbourg University Hospital, Strasbourg, France, Université Paris- Sud, Le Kremlin Bicetre, France, 4 Hopital Hotel Dieu, Paris Descartes University, Paris, France, 5 Epidemiologist, Paris, France, 6 Hôpital Lariboisière, Paris, France, 7 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 8 Centre Hospitalier Universitaire de Toulouse, Toulouse, France, 9 Hopital Lapeyronie, Montpellier, France, 0 Paris-Descartes University, APHP, Cochin Hospital, Paris, France, Hopital R Salengro CHRU, Lille CEDEX, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 4 CHU de ROUEN, Rouen, France, 5 Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, 6 Groupe Hospitalier Pellegrin, Bordeaux, France, 7 EA448 Laboratoire Physiopathologie des Arthrites, Illkirch- Strasbourg, France, 8 Hotel Dieu University Hospital Paris, France, 9 Epidemiology, Paris, France, 0 CHU CLERMONT- FERRAnd, Clermont-Ferrand, France 69. Short to Medium Term Safety of Glucocorticoid Therapy in Rheumatoid Arthritis: A Systematic Review and Dose- Response Analysis of Randomized Controlled Trials. Simon 0 Program Book Tarp, Daniel E. Furst, John R. Kirwan, Maarten Boers 4, Henning Bliddal, Thasia Woodworth 5, Else Marie Bartels, Bente Danneskiold-Samsoe, Lars Erik Kristensen 6, Steffen Thirstrup 7, Mette Rasmussen 7, Marian Kaldas 8 and Robin Christensen, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen F, Denmark, UCLA Medical School, Los Angeles, CA, Bristol Royal Infirmary, Bristol, United Kingdom, 4 VU University Medical Center, Amsterdam, Netherlands, 5 Leading Edge Clinical Research LLC, Florida, FL, 6 Lund University, Lund, Sweden, 7 University of Copenhagen, Copenhagen, Denmark, 8 University of California in Los Angeles, Los Angeles, CA 70. Methotrexate and Interstitial Lung Disease in Rheumatoid Arthritis A Systematic Literature Review and Meta- Analysis. Richard Conway, Candice Low, Robert J. Coughlan, Martin O Donnell and John J. Carey, St James s Hospital, Dublin, Ireland, St. James Hospital, Dublin, Ireland, Galway University Hospitals, Galway, Ireland 7. Comparative Efficacy of Biologics as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis. Felicity Buckley, Axel Finckh, Tom W. J. Huizinga, Fred Dejonckheere 4 and Jeroen P. Jansen, MAPI Consultancy, Boston, MA, University Hospital of Geneva, Geneva, Switzerland, Leiden University Medical Center, Leiden, Netherlands, 4 F. Hoffmann-La Roche Ltd, Basel, Switzerland 7. An Update of Management of Coccidioidomycosis in Patients on Biologic Response Modifiers and Disease- Modifying Antirheumatic Drugs. Susan Knowles, Dominick Sudano, Sara Taroumian, Neil M. Ampel, John Galgiani, Jeffrey R. Lisse and Susan E. Hoover, University of Arizona, Tucson, AZ, University of California, Los Angeles, Los Angeles, CA, Valley Fever Center for Excellence, Tucson, AZ 7. Pharmacoeconomic Evaluation of Tocilizumab Monotherapy vs. Adalimumab Monotherapy in Reducing Disease Activity in Patients with Rheumatoid Arthritis. Navarro Sarabia F, Francisco J. Blanco, Álvaro Gracia JM, JA García Meijide 4 and Jl Poveda 5, Hospital. Virgen Macarena, Sevilla, Spain, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, H. Universitario La Princesa, Madrid, Spain, 4 Hospital Ntra. Sra. La Esperanza, Santiago de Compostela, Spain, 5 Hospital Universitario La Fe, Valencia, Spain Sjögren s Syndrome - Clinical 74. Natural History of Sjögren s Syndrome Phenotypic Features in the Sjögren s International Collaborative Clinical Alliance Registry. Caroline Shiboski, Alan N. Baer, Mi Y. Lam, Stephen Challacombe, Hector Lanfranchi 4, Morten Schiødt 5, Hisanori Umehara 6, Frederick B. Vivino 7, Yan Zhao 8, Yi Dong 8, Bruce W. Kirkham 9, Kenneth E. Sack 0, Susumu Sugai 6, Cristina F. Vollenweider, Wen Zhang 8, John S. Greenspan, Troy Daniels, Lindsey A. Criswell and Sjögren s International Collaborative Clinical Alliance, University of

297 ACR POSTER SESSION C California San Francisco, San Francisco, CA, Johns Hopkins University, Baltimore, MD, Kings College London, London, United Kingdom, 4 University of Buenos Aires, Buenos Aires, Argentina, 5 Rigshospitalet, Copenhagen, Denmark, 6 Kanazawa Medical University, Ishikawa, Japan, 7 Penn Presbyt Med Ctr, Philadelphia, PA, 8 PUMCH, Bejing, China, 9 Guys Hospital, London, United Kingdom, 0 Univ of Calif-San Francisco, San Francisco, CA, German Hospital, Buenos Aires, Argentina, University of California San Francisco, CA 75. Interstitial Lung Disease in Sjogren Syndrome: A Population-Based Study. Carlotta Nannini, Adlene Jebakumar, Jay H. Ryu, Cynthia S. Crowson and Eric Matteson, Prato Hospital, Prato, Italy, Mayo Clinic, Rochester, MN 76. Pulmonary Manifestations and Treatment of Primary Sjogren s Syndrome-Associated Lung Involvement Patients: A Prospective Study. Hui Gao, Xuewu Zhang, Jing He, Min Feng, Wei Zhao, Yan Ding and Zhan-guo Li, Peking University People s Hospital, Beijing, China 77. The Forced Oscillation Technique Is a Sensitive Method for Detection of Obstructive Airway Disease in Patients with Primary Sjögren s Syndrome. Anna M. Nilsson, Elke Theander, Roger Hesselstrand, Per Wollmer and Thomas Mandl, Skane University Hospital Malmo, Lund University, Malmo, Sweden, Skane University Hospital Malmo, Lund University, Malmö, Sweden, Skane University Hospital Lund, Lund University, Lund, Sweden Fludeoxyglucose Positron Emission Tomography Is a Valuable Marker of Activity of Interstitial Lung Disease in Primary Sjögren s Syndrome. Camille Cohen, Arsene Mekinian, Michael Soussan, Yurdagul Uzunhan, Veronique Eder, Robin Dhote, Dominique Valeyre 4 and Olivier Fain 5, Jean Verdier Hospital, Bondy, France, Bobigny, France, Avicenne Hospital, Bobigny, France, 4 Avicenne Hospital (AP-HP), Bobigny, France, 5 Service de médecine interne, Université Paris, AP-HP, Hôpital Jean Verdier, 940, Bondy, France., Bondy, France 79. High Resolution CT Findings and Concomitant Nontuberculosis Mycobacterial Infection (NTM) in Patients with the Diagnosis of Primary Sjögren s Syndrome Evaluated At a Respiratory Referral Center. Mehrnaz Maleki-Fischbach and Gloria M. Russell, National Jewish Health, Denver, CO, Pontificia Universidad Católica Madre y Maestra, Santiago, Dominican Republic 80. Coronary Flow Reserve and Asymmetric Dimethylarginine Levels: New Measurements for Identifying Subclinical Atherosclerosis in Patients with Primary Sjögren s Syndrome. F. Atzeni, L. Boccassini, M.C. Signorello, MA Carrideo, L. Gianturco, V. De Gennaro Colonna, L. Drago 4, M. Turiel and P. Sarzi-Puttini, Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, IRCCS Galeazzi Orthopedic Institute, University of Milan, Department of Health Technologies, Cardiology Unit,, Milan, Italy, Pharmacology Department, University of Milan, Milan, Italy, 4 Laboratory Unit, IRCCS Galeazzi Orthopedic Institute, Department of Health Technologies, University of Milan, Milan, Italy 8. Concomitant Atheosclerosis and Impaired Bone Health in Patients with Primary Sjogren s Syndrome. Clio P. Mavragani, Fotini Gravani, andrianos Nezos, Eleni Antypa, Kiki Maselou, Dimitrios Ioakeimidis 4, Michael Koutsilieris and Haralampos M. Moutsopoulos 5, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, School of Medicine, University of Athens, Athens, Greece, M Asias st, Athens, Greece, Athens, Greece, General Hospital of Athens, Greece, 4 General Hospital of Athens G.Gennimatas, Greece, Greece, 5 School of Medicine, University of Athens, Athens, Greece 8. Prevalence of Fibromyalgia Is Increased in Primary Sjögren s Syndrome Compared with SLE and Associated with Depression and Severe Vitamin D Deficiency. Byoong Yong Choi, Hye Jin Oh, Jun Won Park, Bon Seung Ku, Sung Hae Chang, Eun Young Lee, Eun Bong Lee and Yeong Wook Song, Seoul National University Hospital, Seoul, South Korea 8. Common Features in Lymphoproliferative Complications in the Course of Primary Sjögren s Syndrome: Results From a Multicenter Cohort of 70 Patients. Luca Quartuccio, Chiara Baldini, Roberta Priori, Elena Bartoloni Bocci 4, Francesco Carubbi 5, Miriam Isola 6, Marta Maset, Sara Salvin, Nicoletta Luciano, Giovanna Picarelli, Alessia Alunno 4, Roberto Giacomelli 7, Roberto Gerli 8, Guido Valesini 9, Stefano Bombardieri and Salvatore De Vita 0, Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, Rheumatology Unit, University of Pisa, Pisa, Italy, Rheumatology Unit, Sapienza University of Rome, Rome, Italy, 4 Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, 5 Rheumatology Clinic, University of L Aquila, L Aquila, Italy, 6 Institute of Statistics, University of Udine, Udine, Italy, 7 Rheumatology Unit, University of Aquila, L Aquila, Italy, 8 Rheumatology Unit, University of Perugia, Perugia, Italy, 9 Sapienza, Universita di Roma, Rome, Italy, 0 Rheumatology Clinic, DSMB, University of Udine, Udine, Italy 84. Pregnancy and Fetal Outcome in Patients with an Established Diagnosis of Primary Sjögren s Syndrome. Roberta Priori, Angelica Gattamelata, Mariagrazia Modesti, Serena Colafrancesco, Marta Maset, Luca Quartuccio, Salvatore De Vita, Elena Bartoloni Bocci, Alessia Alunno, Roberto Gerli, Francesca Strigini 4, Chiara Baldini 4, Chiari Tani 4, Marta Mosca 4, Stefano Bombardieri 4 and Guido Valesini, Rheumatology Unit, Sapienza University of Rome, Rome, Italy, Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, 4 Rheumatology Unit, University of Pisa, Pisa, Italy 0 Program Book 95

298 ACR POSTER SESSION C Prevalence of Severe Extra-Glandular Manifestations in a Large Cohort of Patients with Primary Sjögren s Syndrome. Chiara Baldini, Pasquale Pepe, Luca Quartuccio, Roberta Priori, Elena Bartoloni Bocci 4, Alessia Alunno 4, Serena Colafrancesco, Angelica Gattamelata, Marta Maset, Mariagrazia Modesti, Antonio Tavoni, Salvatore De Vita, Roberto Gerli 4, Guido Valesini and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy, Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, Rheumatology Unit, Sapienza University of Rome, Rome, Italy, 4 Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy 86. Ultrasonography of Major Salivary Glands in Primary Sjögren s syndrome. Malin V. Jonsson, Daniel Hammenfors, Johan G. Brun and Roland Jonsson, University of Bergen, Bergen, Norway, Haukeland University Hospital, Bergen, Norway 87. Safety of Minor Labial Salivary Gland Biopsy. ŽIga Rotar, Alojzija Hočevar, NatašA. Gašperšič, Branka Hostnik, Anita Antolić and Matija Tomšič, University Medical Centre Ljubljana, 0 00 Ljubljana, Slovenia 88. How to Better Define Inclusion Criteria in a Large Controlled Trial in Primary Sjögren Syndrome? Valerie Devauchelle-Pensec, Xavier Mariette, Jacques-Eric Gottenberg, Raphaèle Seror 4, Anne-Laure Fauchais 5, Olivier Vittecoq 6, Véronique Le Guern 7, Jacques Morel 8, JJ Dubost 9, Philippe Dieude 0, Eric Hachulla, Pierre yves Hatron, C. Larroche, Aleth Perdriger 4, Xavier Puechal 5, Damien Sene Sr. 6, Stephanie Rist 7 and Alain Saraux 8, Brest Occidentale university, Brest, France, Université Paris-Sud, Le Kremlin Bicetre, France, Strasbourg University Hospital, Strasbourg, France, 4 Bicetre university hospital, LE Kremlin-Bicetre, France, 5 Hospital, Limoges, France, 6 Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, 7 Cochin Hospital, Paris, France, 8 Hopital Lapeyronie, Montpellier, France, 9 CHU CLERMONT-FERRAnd, Clermont- Ferrand, France, 0 APHP, Hopital Bichat, Paris, France, Department of Internal Medicine, Claude Huriez Hospital, University of Lille, Lille CEDEX, France, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, Hospital University Bobigny, France, 4 Hôpital Sud, Rennes, France, 5 Hôpital Cochin, Paris, France, 6 Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, Paris, France, 7 Orleans Hospital, Orleans, France, 8 Université Brest Occidentale, Brest, France 89. Efficacy of Belimumab on Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren s Syndrome: Results of the Beliss Study. Salvatore De Vita, Raphaèle Seror, Luca Quartuccio, Frederic Desmoulins 4, Sara Salvin, Gabriel Baron 5, Martina Fabris 6, Philippe Ravaud 5, Miriam Isola 7 and Xavier Mariette 8, Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, 4 Université 0 Program Book Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, 5 Université Paris-Descartes, Paris,, Paris, France, 6 Institute of Clinical Pathology, Udine, Italy, 7 Institute of Statistics, University of Udine, Udine, Italy, 8 Université Paris-Sud, Le Kremlin Bicetre, France 90. Antimalarials for Sjögren s Syndrome Treatment in Adults, Meta-Analysis. Vibian A. Coy, Carlos E. Granados, Diana Gil, Alejandro Junca, Daniel Jaramillo, Antonio A. Iglesias- Gamarra, Jose Felix Restrepo 4 and Federico Rondon- Herrera 4, Fellow of Rheumatology Universidad Nacional de Colombia, Bogotá, Colombia, Professor -Universidad Nacional de Colombia, Bogotá, Colombia, Professor- Universidad Nacional de Colombia, Bogota, Colombia, 4 Professor -Universidad Nacional de Colombia, Bogota, Colombia 9. Secretagogue Use in Patients with Primary Sjögren s Syndrome. Ghaith Noaiseh, Joshua Baker and Frederick B. Vivino, University of Pennsylvania, Philadelphia, PA, Penn Presbyt Med Ctr, Philadelphia, PA 9. Phenotypic Features of Sjögren s Syndrome Among Patients with Low-Titer SSA/B Antibodies. Mara McAdams DeMarco, Mi Y. Lam, Stephen Shiboski, Lindsey A. Criswell, Caroline Shiboski and Alan N. Baer 4, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University of California, San Francisco, San Francisco, CA, University of California San Francisco, San Francisco, CA, 4 Johns Hopkins University, Baltimore, MD 9. Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren s Syndrome. Mara McAdams DeMarco, Mi Y. Lam, Stephen Shiboski, Lindsey A. Criswell, Caroline Shiboski and Alan N. Baer 4, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University of California, San Francisco, San Francisco, CA, University of California San Francisco, San Francisco, CA, 4 Johns Hopkins University, Baltimore, MD 94. Cathepsin S Activity in Tears as a Marker of Sjögren s Syndrome. S.E. Whitt, K. Renduchintala, S. Janga, M. Shah, J. Zhu, K. Silka, S. Bricel, D. Bach, M. Heur 4, S. Christianakis, J. Irvine 4, D. Arkfeld, W.J. Mack, William Stohl and S.F. Hamm-Alvarez, University of Southern California Keck School of Medicine -These authors contributed equally to this work, Los Angeles, CA, University of Southern California School of Pharmacy, Los Angeles, CA, University of Southern California Keck School of Medicine, Los Angeles, CA, 4 Doheny Eye Institute, Los Angeles, CA 95. Long-Term Changes in Autoantibody Profile after Pandemic Unadjuvanted Influenza A/HN Vaccine in Sjögren s Syndrome. Sandra G. Pasoto, Ana C. Ribeiro, Vilma S.T. Viana, Elaine P. Leon, Cleonice Bueno, Mauricio Levy Neto, Alexander R. Precioso, Maria do Carmo S. Timenetsky 4 and Eloisa Bonfa, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina da Universidade

299 ACR POSTER SESSION C de São Paulo, São Paulo, Brazil, Fundação Butantan - Instituto Butantan, São Paulo, Brazil, 4 Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 96. Decreased Expression of TSLP in Labial Salivary Glands of Patients with pss Is Associated with Local and Systemic Disease Parameters. M.R. Hillen, A. Bikker, A.A. Kruize, M. Wenting-van Wijk, F.P.J.G. Lafeber, C.E. Hack and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 97. Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren s Syndrome Patients. Divi Cornec, Alain Saraux, Jacques- Olivier Pers, Sandrine Jousse-Joulin, Yves Renaudineau, Thierry Marhadour and Valerie Devauchelle-Pensec, Brest Occidentale University, Brest, France, Brest Occidentale university, Brest, France, CHU de la Cavale Blanche, Brest, France 98. Interstitial Lung Disease in Primary Sjögren s syndrome: Any Association with IgG4 Related Sclerosing Disease? Adlene Jebakumar, Carlotta Nannini, Eunhee S. Yi, Hiroshi Sekiguchi, Jay H. Ryu, Cynthia S. Crowson and Eric L. Matteson, Mayo Clinic, Rochester, MN, Prato Hospital, Prato, Italy 99. Elevated IgG4 Serum Levels among Primary Sjögren s Syndrome Patients: Do They Unmask Underlying IgG4- Related Disease? Clio P. Mavragani, George Fragoulis, Dimitra Rontogianni, Maria Kanariou 4 and Haralampos M. Moutsopoulos, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, School of Medicine, University of Athens, Athens, Greece, Evangelismos General Hospital, Athens, Greece, 4 Aghia Sophia Children s Hospital, Athens, Greece 00. IgE Autoantibodies against SSA and SSB in Patients with Sjögren s Syndrome and Healthy Controls. Stamatina Danielides, Barbara Dema, Juan Rivera and Gabor G. Illei, NIH, Bethesda, MD, Laboratory of Molecular Immunogenetics, NIAMS, NIH, Bethesda, MD, NIDCR/ NIH, Bethesda, MD 0. Involvement of Interleukin- in the Pathogenesis of Sjögren s Syndrome. Ahmad Awada, Valérie Gangji and Muhammad S. Soyfoo, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium 0. Classification Criteria for Sjögren s Syndrome: Comparison of the Performance of the 00 American-European Consensus Group Criteria (AECG) and the 0 ACR Criteria. Elke Theander, Peter Olsson and Thomas Mandl, Skane University Hospital, Lund University, Malmö, Sweden, Department of Rheumatology, Skåne University Hospital, Lund University, Malmö, Sweden, Skane University Hospital Malmo, Lund University, Malmö, Sweden 0. Effects of Reclassification Using the American College of Rheumatology Criteria On a Large cohort Sjögren s Syndrome Patients. Astrid Rasmussen, John A. Ice, He Li, Kiely Grundahl, Jennifer A. Kelly, Lida Radfar 4, Kimberly S. Hefner 5, Donald U. Stone 4, Juan-Manuel Anaya 6, Michael Rohrer 7, Glen D. Houston 4, David M. Lewis 4, James Chodosh 8, John B. Harley 9, Pamela Hughes 7, Jacen S. Maier-Moore 4, Courtney G. Montgomery, Nelson L. Rhodus 7, A. Darise Farris 0, Barbara M. Segal, Christopher J. Lessard, R. Hal Scofield 0 and Kathy Moser Sivils, Oklahoma Medical Research Foundation, Oklahoma City, OK, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, Oklahoma Medical Research Foundation, oklahoma CIty, OK, 4 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5 Hefner Eye Care and Optical Center, Oklahoma City, OK, 6 Universidad del Rosario- Corporacion para Investigaciones Biologicas, Bogota, Colombia, 7 University of Minnesota, Minneapolis, MN, 8 Harvard Clinical and Translational Science Center, Boston, MA, 9 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 0 Oklahoma Medical Research Foun, Oklahoma City, OK, Hennepin County Medical Center, Minneapolis, MN, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK 04. Overall Agreement between Sjögrens s Minor Salivary Gland Biopsy and 00 and 0 Classification Criteria. Laura Aline Martinez, Candido Flores, Alberto Arana Fraustro and Luis H. Silveira, Instituto Nacional de Cardiologia Ignacion Chavez, Mexico City, Mexico, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, Instituto Nacional Cardiología Ignacio Chávez, Mexico City, Mexico 05. Longitudinal Evaluation of the Performance of Different Classification Criteria in Patients with Primary Sjögren s Syndrome. Martina Plešivčnik Novljan, ŽIga Rotar, Aleš Ambrožič, Gaj Vidmar and Matija Tomšič, University Medical Centre Ljubljana, 000 Ljubljana, Slovenia, University Rehabilitation Institute, 000 Ljubljana, Slovenia Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment 06. Patients Fulfilling the Imaging-Arm and Patients Fulfilling the HLA-B7+ Arm of the Assessment of Spondyloarthritis International Society Axial Spondyloarthritis Classification Criteria: Are They Similar? Rosaline van den Berg, Manouk de Hooge, Floris van Gaalen, Monique Reijnierse, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands 07. How Useful is imaging of the Sacroiliac Joints (MRI and/ or X-ray) in Patients with Possible Spondyloarthritis in the Diagnostic Work-up? Rosaline van den Berg, Manouk de Hooge, Victoria Navarro-Compán, Floris van Gaalen, Monique Reijnierse, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands 0 Program Book 97

300 ACR POSTER SESSION C 08. Referral Patterns and Diagnosis of Patients with Axial Spondyloarthritis: Results of an International Survey. Désirée van der Heijde, Joachim Sieper, Dirk Elewaut, Aileen L. Pangan 4 and Dianne Nguyen 5, Leiden University Medical Center, Leiden, Netherlands, Charité Universitätesmedizin Berlin, Berlin, Germany, Ghent University Hospital, Ghent, Belgium, 4 Abbott Laboratories, Abbott Park, IL, 5 Abbott Laboratories, Singapore, Singapore 09. Assessing Active Inflammation in Sacroiliac Joints in Spondyloarthritis Patients: No Added Value of Gadolinium Compared to Short Tau Inversion Recovery Sequence. Manouk de Hooge, Rosaline van den Berg, Victoria Navarro- Compán, Floris van Gaalen, Désirée van der Heijde, Tom Huizinga and Monique Reijnierse, Leiden University Medical Center, Leiden, Netherlands 0. The Canada-Denmark Fat Spondyloarthritis Spine Score: Validation of a New Scoring Method for the Evaluation of Fat Lesions in the Spine of Patients with Axial Spondyloarthritis. Susanne Juhl Pedersen, Zheng Zhao, Robert GW Lambert, Mikkel Østergaard, Ulrich Weber 4 and Walter P. Maksymowych, Glostrup Hospital, Copenhagen, Denmark, Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, China, University of Alberta, Edmonton, AB, 4 Balgrist University Hospital, Zurich, Switzerland. Is It Useful to Repeat an MRI of the Sacroiliac Joints in the Diagnostic Work-up for Spondyloarthritis? Rosaline van den Berg, Manouk de Hooge, Victoria Navarro-Compán, Floris van Gaalen, Monique Reijnierse, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands. How Much Does the Spondyloarthritis Research Consortium of Canada Score of the Sacroiliac Joints Change Over a -Month Period in Patients On Non-Biological Treatment? Rosaline van den Berg, Manouk de Hooge, Victoria Navarro-Compán, Floris van Gaalen, Monique Reijnierse, Tom Huizinga and Désirée van der Heijde, Leiden University Medical Center, Leiden, Netherlands. Ankylosing Spondylitis Is Strongly Related to Clinical Spine Fractures Independently of Drugs Use: A Register- Based Case-Control Study. Daniel Prieto-Alhambra, Juan Muñoz-Ortego, Cyrus Cooper, Adolfo Díez-Pérez 4 and Peter Vestergaard 5, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, Hospital Sagrat Cor, Barcelona (Spain), Spain, University of Oxford; Southampton General Hospital, Southampton, United Kingdom, 4 Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, 5 Aarhus University Hospital THG, Aarhus (Denmark), Aarhus, Denmark 4. Similar Levels of Disease Activity in Patients with Oligoarticular vs. Polyarticular Peripheral Spondyloarthritis. Filip Van den Bosch, Philip Mease, Désirée van der Heijde, Martin Rudwaleit 4, Katie Obermeyer 5 and Aileen L. Pangan 5, Ghent University Hospital, Ghent, Belgium, Swedish Medical Center, Seattle, WA, Leiden University Medical Center, Leiden, Netherlands, 4 Endokrinologikum Berlin, Berlin, Germany, 5 Abbott Laboratories, Abbott Park, IL 5. Assessment of Vascular Age in Psoriatic Arthritis Patients. Jl Rosales-Alexander, César Magro Checa, Juan Salvatierra, Jesús Cantero Hinojosa and Enrique Raya Álvarez, University Hospital San Cecilio, Granada, Spain 6. Cardiovascular Risk Assessment in Spondyloarthritis Using the Score Chart and Reclassification by Presence of Plaques on Ultrasonography. Jl Rosales-Alexander, Juan Salvatierra, César Magro Checa, Jesús Cantero Hinojosa and Enrique Raya Álvarez, University Hospital San Cecilio, Granada, Spain 7. Even after Pretreatment with up to Three Biologics, Anti-TNFs Shows Effectiveness in Active Psoriatic Arthritis Patients. Frank Behrens, Michaela Koehm, Diamant Thaci, Brigitte Krummel-Lorenz, Gerd Greger 4, Bianca Wittig 4 and Harald Burkhardt 5, CIRI/Div. Rheumatology, J.W. Goethe-University, Frankfurt/Main, Germany, Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, CIRI/ Endokrinologikum, Frankfurt/Main, Germany, 4 Abbott GmbH & Co KG, Wiesbaden, Germany, 5 CIRI/Div. Rheumatology, J.W. Goethe University, Frankfurt/Main, Germany 8. 5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study. Arthur Kavanaugh, Desiree M. van der Heijde, Iain B. McInnes, Philip Mease 4, Gerald G. Krueger 5, Dafna Gladman 6, Yiying Zhou 7, J. D. Lu 7, Zhenhua Xu 7, Lenore Noonan 7 and Anna Beutler 7, UCSD School of Medicine, La Jolla, CA, Leiden University Medical Ctr, Leiden, Netherlands, University of Glasgow, Glasgow, United Kingdom, 4 Swedish Medical Center, Seattle, WA, 5 University of Utah, Salt Lake City, UT, 6 Toronto Western Hospital and University of Toronto, Toronto, ON, 7 Janssen Research & Development, LLC, Spring House, PA 9. Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Show Similar Response Rates after One Year of Treatment with Etanercept - results of the Esther Trial. In-Ho Song, Kay-Geert A. Hermann, Hildrun Haibel, Christian Althoff, Denis Poddubnyy, Joachim Listing 4, Anja Weiß 5, Ekkehard Lange 6, Bruce Freundlich 7, Martin Rudwaleit 8 and Joachim Sieper 9, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, Charité Medical School, Berlin, Germany, Charite Medical School, Berlin, Germany, 4 German Rheumatism Research Center, Berlin, Germany, 5 German Rheumatism Research Centre, Berlin, Germany, 6 Berlin, Germany, 7 Villanova, PA, 8 Endokrinologikum Berlin, Berlin, Germany, 9 Charité Universitätesmedizin Berlin, Berlin, Germany 98 0 Program Book

301 ACR POSTER SESSION C 0. Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry. Andreas M. Reimold, Liron Caplan, Daniel O. Clegg, Gail S. Kerr 4, Elizabeth Chang 5, Lisa A. Davis 6, Prashant Kaushik 7, Vikas Majithia 8, J. Steuart Richards 9, Joel D. Taurog 0 and Jessica Walsh, Dallas VA and University of Texas Southwestern, Dallas, TX, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, George E. Wahlen VA Medical Center, Salt Lake City, UT, 4 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 5 Phoenix, AZ, 6 Denver VA and Univ of Colorado School of Med, Aurora, CO, 7 Sratton VAMC, Albany, NY, 8 University of Mississippi Medical Center, Jackson, MS, 9 Washington DC VA and Georgetown University, Washington, DC, 0 UT Southwestern Medical Center, Dallas, TX, University of Utah Hospital, Salt Lake City, UT. Major Adverse Cardiovascular Events Are More Common in Rheumatoid Arthritis Than in Psoriatic Arthritis and Are Associated with Different Risk Factors. Allen P. Anandarajah, Katherine C. Saunders, George W. Reed, Alina U. Onofrei 4, Jeffrey D. Greenberg 5 and Christopher T. Ritchlin 6, Univ of Rochester Medical Ctr, Rochester, NY, CORRONA, Inc., Southborough, MA, University of Massachusetts Medical School, Worcester, MA, 4 UMass Medical School, Worcester, MA, 5 NYU Hospital for Joint Diseases, New York, NY, 6 University of Rochester Medical Center, Rochester, NY. Spinal Mobility Measures in Normal Individuals the Mobility Study. Sofia Ramiro, Carmen Stolwijk, A.M. Van Tubergen, Désirée van der Heijde and Robert Landewé 4, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, Maastricht University Medical Center, Maastricht, Netherlands, Leiden University Medical Center, Leiden, Netherlands, 4 Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands. Dysregulation of Chromatin Modification Enzymes in Psoriatic Arthritis. Remy Pollock, Fawnda Pellett, Vinod Chandran and Dafna Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON 4. Oral Contraceptive Pill Use in Women with Ankylosing Spondylitis Is Associated with a Younger Age at Diagnosis. Dharini Mahendira, Arane Thavaneswaran, Adele Carty, Nigil Haroon 4, Ammepa Anton, Laura A. Passalent, Khalid A. Alnaqbi, Laurie M. Savage 5, Elin Aslanyan 6 and Robert D. Inman 7, St Michael s Hospital, Toronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto Western Hospital, Toronto, ON, 4 University Health Network, Toronto Western Research Institute, University of Toronto, Toronto, ON, 5 Spondylitis Association of America, Van Nuys, CA, 6 Spondylitis Association of America, Van Nuys, 7 Toronto Western Research Institute, University Health Network and University of Toronto, Toronto, ON 5. Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-7A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S00A 8 and A9 (Calgranulin A and B). Dominique L. Baeten, Stephan Bek, Jiawei Wei, Arndt Brachat 4, Joachim Sieper 5, Paul Emery 6, Jurgen Braun 7, Desiree M. van der Heijde 8, Iain B. McInnes 9, Jacob M. van Laar 0, R. Landewe, Paul Wordsworth, Jurgen Wollenhaupt, Herbert Kellner 4, Jacqueline E. Paramarta 5, Arthur Bertolino, Andrew Wright 4 and Hueber Wolfgang, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Novartis Institutes for BioMedical Research, Basel, Switzerland, Beijing Novartis Pharma Co. Ltd., Shanghai,, China, 4 Novartis Pharma AG, Basel, Switzerland, 5 Charité Universitätesmedizin Berlin, Berlin, Germany, 6 Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 7 Rheumazentrum Ruhrgebiet, Herne, Germany, 8 Leiden University Medical Ctr, Leiden, Netherlands, 9 University of Glasgow, Glasgow, United Kingdom, 0 Musculoskeletal Research Group, Newcastle, United Kingdom, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Nuffield Orthopaedic Centre, Oxford, United Kingdom, Schoen- Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 4 Centre for Inflammatory Joint Diseases, Munich, Germany, 5 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands 6. Application of Classification Criteria for Psoriatic Arthritis to Patients of the Rotterdam Early Arthritis Cohort. Jos Van der Kaap, Johanna M.W. Hazes, M. Vis, Ilya Tchetverikov and Jolanda J. Luime 5, Rotterdam, Netherlands, Erasmus Medical Center, Rotterdam, Netherlands, VU University medical center, Amsterdam, Netherlands, 4 Erasmus MC - University Medical Center, Rotterdam, Netherlands 7. Low Dosage with Escalating Dosage of Infliximab in Psoriatic Arthritis Gives the Same Treatment Results as Standard Dosage of Adalimumab or Etanercept: Results From the Nationwide Registry ICEBIO. Bjorn Gudbjornsson and Niels Steen Krogh, Center for Rheumatology Research, Reykjavik, Iceland, ZiteLab ApS, Copenhagen, Denmark 8. The Caspar Classification Criteria and Response to TNF Blockade in Rheumatologists Practice: A Large Observational Cohort Study. Burkhard Moller, Almut Scherer, J. Dudler, Bettina Weiss 4, Nikhil Yawalkar 5 and Peter M. Villiger 6, Inselspital University Hospital, Bern, Switzerland, SCQM Foundation, Zurich, Switzerland, Cantonal Hospital Fribourg, Fribourg, Switzerland, 4 Balgrist University Hospital, Zurich, Switzerland, 5 MD, Bern, Switzerland, 6 Inselspital-University Hospital of Bern, Bern, Switzerland 9. Analysis of Clinical, CRP- and MRI- Responses to TNF- Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration. Anja Weiss, In-Ho Song, Hildrun Haibel, Joachim Listing and Joachim Sieper 4, German 0 Program Book 99

302 ACR POSTER SESSION C 00 Rheumatism Research Centre, Berlin, Germany, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, German Rheumatism Research Center, Berlin, Germany, 4 Charité Universitätesmedizin Berlin, Berlin, Germany 0. The Early Clinical Response of TNF-Alpha Blockers Is a Predictor of Metrology Outcome in Ankylosing Spondylitis. Eon Jeong Nam, Jung Soo Eun, Na Ri Kim, Jong Wan Kang, Churl Hyun Im and Young Mo Kang, Kyungpook National University School of Medicine, Daegu, South Korea. Treatment of Psoriatic Arthritis with Tumour Necrosis Factor á Antagonists Successfully Maintains Work Capacity: Year Results of a Prospective Cohort Study. Leonard C. Harty, Alex Franciosi, Naomi Pettysan, Paul Rushe and Oliver M. FitzGerald, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, Department of Rheumatology, St. Vincent s University Hospital, Dublin, Ireland. Performance of Berlin Criteria in Patients with EARLY Spondyloarthritis. Beatriz E. Joven, Milena Gobbo, Miguel A. Descalzo, Eugenio De Miguel and Esperanza Group 4, HOSPITAL UNIVERSITARIO DE OCTUBRE, Madrid, Spain, Spanish Society of Rheumatology, Madrid, Spain, Hospital Universitario La Paz, Madrid, Spain, 4 Madrid. Assessing the Clinical and Economic Burden of U.S. Veteran Ankylosing Spondylitis Patients. Lin Xie, Onur Baser, Ahong Huang, Lu Li, Elyse K. Fritschel and Li Wang, STATinMED Research, Ann Arbor, MI, STATinMED Research/ The University of Michigan, Ann Arbor, MI, STATinMED Research, Dallas, TX 4. US Treatment Patterns of Psoriatic Arthritis Patients Newly Initiated On Etanercept or Adalimumab. Frank Zhang, Stan Li and Jeffrey R. Curtis, Celgene Corporation, Warren, NJ, Univ of Alabama-Birmingham, Birmingham, AL 5. How Important Is the Assessment of ASDAS in the Long-Term Evaluation of Disease Activity in Ankylosing Spondylitis? A Comparison with Currently Used Clinical Parameters. Xenofon Baraliakos, Claudia Fritz, Joachim Listing, Hildrun Haibel 4, Joachim Sieper 5 and Jürgen Braun, Rheumazentrum Ruhrgebiet, Herne, Germany, German Rheumatism Research Centre, Berlin, Germany, German Rheumatism Research Center, Berlin, Germany, 4 Charité Medical University, Campus Benjamin Franklin, Berlin, Germany, 5 Charité Universitätesmedizin Berlin, Berlin, Germany Systemic Lupus Erythematosus: Clinical Aspects 6. Cross Cultural Validation of English and French Versions of a Disease Specific Patient Reported Outcome Measure for Lupus in Canada. Josiane Bourré-Tessier, Ann E. Clarke, Rachel A. Mikolaitis, Mark Kosinski 4, Sasha Bernatsky 5, Joel A. Block and Meenakshi Jolly, McGill University, Montréal, QC, McGill University, Montreal, QC, Rush University Medical Center, Chicago, IL, 4 QualityMetric Inc, Lincoln, RI, 5 McGill, Montreal, QC 0 Program Book 7. Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic. Itziar Quinzanos, Angela Keniston, Joann Zell, Jinoos Yazdany, Alyssa Nash, Rebecca Fransen, Jennifer Stichman and Joel M. Hirsh, Denver Health Med Ctr, Denver, CO, National Jewish Health, Denver, CO, University of California San Francisco, San Francisco, CA 8. Alpha-Chlorofatty Acid Does Not Correlate with Baseline Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus. Mary A. Mahieu, Camelia Guild, Carolyn J. Albert, George Kondos, James Carr, Daniel Edmundowicz 4, David A. Ford and Rosalind Ramsey- Goldman, Northwestern University Feinberg School of Medicine, Chicago, IL, Saint Louis University, Saint Louis, MO, University of Illinois at Chicago, Chicago, IL, 4 Temple University School of Medicine, Philadelphia 9. Characterization of Pure Membranous Lupus Nephritis: A Cohort of 50 Patients. Lucía Silva, Teresa Oton, Anca Askanase, Patricia Carreira, Francisco Javier López-Longo 4, Anne Riveros 5, Íñigo Rúa-Figueroa 6, Javier Narvaez 7, Esther Ruiz-Lucea 8, Mariano andres 9, Enrique Calvo 0, Francisco Toyos, Juan J. Alegre, Eva Tomero, Carlos Montilla 4, Antonio Zea 5, Esther Uriarte-Isacelaya 6, Jaime Calvo-Alen 7, Carlos Marras 8, Víctor M. Martínez-Taboada 9, María Ángeles Belmonte 0, Jose Rosas, Enrique Raya, Gema Bonilla and Mercedes Freire 4, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain, NYU School of Medicine, New York, NY, Hospital Universitario de Octubre, Madrid, Spain, 4 Hospital General Universitario Gregorio Marañón, Madrid, Spain, 5 Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 6 Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, 7 Hospital Universitario de Bellvitge, Barcelona, Spain, 8 Hospital de Basurto, Bilbao, Spain, 9 Hospital General Universitario de Alicante, Alicante, Spain, 0 Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Spain, Hospital Universitario Virgen Macarena, Sevilla, Spain, Hospital Universitario Dr Peset, Valencia, Spain, Hospital Universitario La Princesa, Madrid, Spain, 4 Hospital Universitario de Salamanca, Salamanca, Spain, 5 Hospital Universitario Ramon y Cajal, Madrid, Spain, 6 Hospital Universitario de Donostia, Donosti, Spain, 7 Hospital Sierrallana, Torrelavega, Spain, 8 Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 9 Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 0 Hospital Universitario Carlos Haya, Málaga, Spain, Hospital Marina Baixa, Villajoyosa, Spain, University Hospital San Cecilio, Granada, Spain, Hospital La Paz- IdiPaz, Madrid, Spain, 4 Hospital Universitario Juan Canalejo, La Coruña, Spain 40. Systematic Review of Skin Nontuberculous Mycobacteria Infection in Systemic Lupus Erythematosus: An Unusual Skin Infection Mimicking Lupus Vasculitis. Zahi Touma, Amir Haddad, Dafna D. Gladman, Elizabeth Uleryk and Murray B. Urowitz, Toronto Western Hospital and

303 ACR POSTER SESSION C University of Toronto, Toronto, ON, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, The Hospital for Sick Children, Toronto, ON 4. Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Baseline Disease Activity. Ann E. Clarke, Susan Manzi, Michelle A. Petri, Richard Furie 4, Ronald F. van Vollenhoven 5, Simon Cooper 6, Z. John Zhong 6, William W. Freimuth 6 and Arthur Weinstein 7, MUHC, Montreal, QC, West Penn Allegheny Health System, Pittsburgh, PA, Johns Hopkins University School of Medicine, Baltimore, MD, 4 North Shore-LIJ Health System, Lake Success, NY, 5 Karolinska University Hospital, Stockholm, Sweden, 6 Human Genome Sciences, Inc., Rockville, MD, 7 Washington Hospital Center, Washington, DC 4. Clinical Manifestations and Predictive Factors for Response to Induction Therapy and Maintenance of Remission in ISN/RPS Class V Lupus Nephritis. Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hirotaka Kaneko, Kae Takagi, Hisae Ichida, Yasuhiro Katsumata, Yuko Okamoto, Yuko Ota, Sayuri Kataoka and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, Tokyo Women s Medical University, Tokyo, Japan 4. A Comparison of Systemic Lupus Erythematosus (SLE) Patients Achieving Prolonged Clinical Quiescence (PCQ) on and off Corticosteroids and/or Immunosuppressive Medications. Amanda J. Steiman, Dafna D. Gladman, Dominique Ibanez, Anjali Papneja and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, University of Toronto, Toronto, ON 44. Predicting Sjögren s Syndrome at Diagnosis of Systemic Lupus Erythematosus. Gabriela Hernandez-Molina, Tatiana Zamora-Legoff, Juanita Romero-Diaz, Carlos Alberto Nuñez-Alvarez, Francisco Cárdenas-Velázquez, Carlos Hernández-Hernández, Maria Luisa Calderillo, Martha Marroquín, Claudia Recillas-Gispert, Carmen Ávila-Casado and Jorge Sánchez-Guerrero, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, University Health Network, Toronto Canada., Mount Sinai Hospital, Toronto Canada. 45. Vitamin D Deficiency is associated with, but Does Not Predict, Change in hscrp in Systemic Lupus Erythematosus (SLE). Adnan Kiani, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD 46. Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study. Susan S. Kim, Tanya Pavri, Kyriakos A. Kirou, Jane Salmon and Doruk Erkan, Hospital for Special Surgery, New York, NY 47. The First Report of Desensitization to Trimethoprim/ Sulfamethoxazole in Patients with Systemic Lupus Eryhtematosus. Yasuhiro Suyama, Mitsumasa Kishimoto, Hiroto Nakano, Ken-ichi Yamaguchi, Hisanori Shimizu, Ryo Rokutanda, Chisun Min, Yuri Ohara, Yoichiro Haji, Kazuo Matsui, Akira Takeda, Yukio Matsui and Masato Okada, St. Luke s International Hospital, Tokyo, Japan, Kameda Medical Center, Kamogawa City, Japan 48. Serum Phosphatidylserine-Specific Phospholipase A (PS-PLA) Identified As a Novel Biomarker for Systemic Lupus Erythematosus (SLE). Tetsuji Sawada, Kazuhiro Nakamura, Ryunosuke Ohkawa, Aki Shoji, Koichiro Tahara, Haeru Hayashi, Eri Kimura, Koji Igarashi, Junken Aoki 4 and Yutaka Yatomi 5, Tokyo Medical University, Tokyo, Japan, The University of Tokyo Hospital, Tokyo, Japan, TOSOH Corporation, Kanagawa, Japan, 4 Graduate School of Pharmaceutical Sciences, Tohoku University, Miyagi, Japan, 5 Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 49. Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis. Dong-Jin Park, Kyung-Eun Lee, Tae-Jong Kim, Yong-Wook Park and Shin-Seok Lee, Chonnam National University Medical School, Gwangju, South Korea 50. A Clinical Analysis of Adult Patients with Autoimmune- and Infection-Associated Hemophagocytic Lymphohistiocytosis. Min W. So, Bon S. Koo, You J. Kim, Yong-G Kim, Wook J. Seo, Chang-K Lee and Bin Yoo, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, Seoul Veterans Hospital, Seoul, South Korea 5. High Sensitivity C - reactive protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus. Chi Chiu Mok, Daniel Birmingham, Ling Yin Ho and Brad H. Rovin, Tuen Mun Hospital, Hong Kong, Hong Kong, Ohio State University Medical Center, Columbus, OH 5. Epratuzumab-Treated Systemic Lupus Erythematosus Patients Report Improvements in Health-Related Quality of Life: Final Results from an Open-Label Extension Study (SL0006). V. Strand, K. Hobbs, D.J. Wallace, K. Kalunian 4, B. Kilgallen 5, E. Nikaï 6, W.A. Wegener 7 and D.M. Goldenberg 8, Stanford University, Palo Alto, CA, Denver Arthritis Clinic, Denver, CO, Cedars-Sinai Medical Center, Los Angeles, CA, 4 UCSD School of Medicine, La Jolla, CA, 5 UCB Pharma, Smyrna, GA, 6 UCB Pharma, Brussels, Belgium, 7 Immunomedics Inc, Morris Plains, NJ, 8 Centre for Molecular Medicine and Immunology, Morris Plains, NJ 5. Metabolic Syndrome Is Not Only a Risk Factor for Cardiovascular Events in Systemic Lupus Erythematosus but Also Associated with Cumulative Organ Damage: A Cross-Sectional Analysis of Patients. Semra Ertan- Demir, Bahar Artim-Esen, Yasemin Sahinkaya, Özlem Pehlivan, Nilüfer Alpay-Kanitez, Ahmet Omma, Burak Erer, Sevil Kamali, Ahmet Gul, Orhan Aral, Lale Ocal and Murat Inanc, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul Faculty of Medicine, 0 Program Book 0

304 ACR POSTER SESSION C 0 Istanbul University, Istanbul, Turkey 54. Discoid Lupus in Patients with Systemic Lupus Erythematosus. Ghassan AlJohani, Dominique Ibanez, D. D. Gladman and Murray B. Urowitz, Toronto Western Hospital and University of Toronto, Toronto, ON 55. Apolipoprotein B Containing Lipoprotein Subclasses and Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus (SLE). Adnan Kiani, Hong Fang, Ehtisham Akhter, Carmen Quiroga, Nancy Simpson, Petar Alaupovic and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD, Oklahoma Medical Research Foundation, Oklahoma, OK 56. A Population of IL- Producing CD4+ T Cells Correlates with Disease Damage in Systemic Lupus Erythematosus (SLE) Patients. Babak Noamani, Stacey Morrison, Dafna Gladman, Jorge Sanchez-Guerrero 4, Murray B. Urowitz, Joan E. Wither 5 and Carolina Landolt-Marticorena 6, Toronto Western Research Institute, Toronto, ON, The Toronto Western Hospital, Toronto, ON, Toronto Western Hospital and University of Toronto, Toronto, ON, 4 Mount Sinai Hospital, University Health Network, Toronto, ON, 5 Toronto Western Research Institute, University Health Network, Toronto, ON, 6 University of Toronto, Toronto, ON 57. Association of Low Vitamin D with High Disease Activity in an Australian Systemic Lupus Erythematosus Cohort. Kristy S. Yap, Alberta Y. Hoi and Eric F. Morand, Monash Medical Centre, Clayton, Australia, Monash University, Melbourne, Australia 58. Risk Factors for Total Joint Replacement in Systemic Lupus Erythematosus Patients with Avascular Necrosis. Jennifer Lee, Dae-Jun Kim, Jae Ho Lee, Seung Min Jung, Seung-Ki Kwok, Ji Hyeon Ju, Kyung-Su Park, Sung-Hwan Park and Ho-Youn Kim, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary s Hospital, The Catholic University of Korea College of Medicine, Seoul, South Korea, College of Medicine, The Catholic University of Korea, Stanford University, Seoul, Palo Alto, CA 59. Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey. V. Strand, C. Galateanu, S. Lobosco, D.S. Pushparajah, J. Sayers 4 and R.F. van Vollenhoven 5, Stanford University, Portola Valley, CA, UCB Pharma, Brussels, Belgium, Adelphi Real World Ltd., Macclesfield, United Kingdom, 4 Adelph Real World Ltd., Macclesfield, United Kingdom, 5 The Karolinska Institute, Stockholm, Sweden 60. Serum DNAse I Anti DNAse I Antibodies, CRP and Antibodies to CRP Relation to Disease Activity in Systemic Lupus Eryhtematous: Longitudinal Studies. Ramnath Misra, Avadesh Pratap, Amit Singh and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Technician, Lucknow, India 6. Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus. Olívio B. Malheiro, Carolina 0 Program Book P. Rezende, Gilda A. Ferreira and Fernando M. Reis, Federal University of Minas Gerais, Belo Horizonte, Brazil 6. Hypogammaglobulinemia in Pediatric Systemic Lupus Erythematosus. Emilina Lim and Megan A. Cooper, Washington University in Saint Louis- St. Louis Children s Hospital, St. Louis, MO, Washington University, Saint Louis, MO 6. The Association between Prior Pregnancy Morbidity and Cardiovascular Events in Women with Systemic Lupus Erythematosus. Megan Clowse, Eliza F. Chakravarty, Jill P. Buyon and Gerald McGwin Jr. 4, Duke University Medical Center, Durham, NC, Oklahoma Medical Research Foundation, Oklahoma City, CA, New York University School of Medicine, New York, NY, 4 University of Alabama at Birmingham, Birmingham, AL 64. Improving Outcomes for Pregnant Lupus Patients: Is There a Geographic Link? Darneesh Thornton-Johnson and Daniel Albert, Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Lebanon, NH 65. Clinical Manifestations of Systemic Lupus Erythematosus Vary Based On Age of Disease Onset. Flora Simmons, Natasha M. Ruth, Gary S. Gilkeson and Diane L. Kamen, Medical University of South Carolina, Charleston, SC, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC 66. Outcome of Renal Transplantation in Lupus Patients with Positive and Negative Serology: Survival of the Graft and Patients after Transplant. Zahi Touma, Murray B. Urowitz, Dominique Ibanez and D. D. Gladman, Toronto Western Hospital and University of Toronto, Toronto, ON Systemic Lupus Erythematosus - Human Etiology and Pathogenesis 67. Genome-Wide Pathway Analysis of Genome-Wide Association Studies On Systemic Lupus Erythematosus. Young Ho Lee, Sung Jae Choi, Jong Dae Ji and Gwan Gyu Song, Korea University Medical Center, Seoul, South Korea, Korea Univ College of Med, Seoul 68. Hyperacetylation of Histone H4 in Systemic Lupus Erythematosus. Yiu Tak Leung, Lihua Shi, Kelly Maurer, Li Song, Zhe Zhang, Michelle Petri 4 and Kathleen E. Sullivan, University of Pennsylvania, Philadelphia, PA, Children s Hospital of Philadelphia, Philadelphia, PA, Bioinformatics, Children s Hospital of Philadelphia, Philadelphia, PA, 4 Johns Hopkins University School of Medicine, Baltimore, MD 69. The Differences of DNA Methylome and Transcriptome among Diverse Clinical Manifestations of Systemic Lupus Erythematosus. Ming Zhao, Shuangyan Luo, Honglong Wu, Siyang Liu, Meini Tang, Wenjing Cheng, Qing Zhang, Xinhai Yu, Tak Mao Chan, Yudong Xia, Na Yi, Fei Gao, Li Wang, Ning Li and Qianjin Lu, Second Xiangya Hospital, Central South University; Hunan Key Laboratory of Medical Epigenomics, Changsha, China, Beijing Genomics Institute

305 ACR POSTER SESSION C at Shenzhen, Shenzhen, China, Shenzhen, China, Division of Nephrology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China 70. The DNA Methylome of Systemic Lupus Erythematosus (SLE) From Whole Peripheral Blood Mononuclear Cells (PBMCs). Robert Shoemaker, Lou H. Bookbinder, David L. Boyle, Gary S. Firestein, Jonathan E. Lim and David W. anderson, NexDx, Inc., San Diego, CA, NexDx, Inc., San Diego, UCSD School of Medicine, La Jolla, CA 7. Variation of Interferon-Alpha Production in Healthy Individuals and Association with Autoimmune Susceptibility Genes. Olof Berggren, andrei Alexsson, Gunnar V. Alm, Ann-Christine Syvänen, Lars Rönnblom and Maija-Leena Eloranta, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Swedish University of Agricultural Sciences, Uppsala, Sweden, Molecular Medicine, Uppsala University, Uppsala, Sweden 7. Gene Expression Signatures in Monocytes From Primary Antiphospholipd Syndrome, Systemic Lupus Erythematosus and Lupus with Antiphospholipid Syndrome Identify Specific Pathways Involved in the Pathogenesis of Atherosclerosis and Cardiovascular Disease. Chary Lopez- Pedrera, Sebastiano Messineo, Carlos Perez-Sanchez, Patricia Ruiz-Limon, Mª Angeles Aguirre, Rosario M. Carretero-Prieto, Antonio Rodriguez-Ariza, Nuria Barbarroja, Francisco Velasco, Munther A. Khamashta 4, Eduardo Collantes-Estevez and Mª Jose Cuadrado 4, IMIBIC- Reina Sofia Hospital, Cordoba, Spain, Dipartimento di Scienze della Salute, Universitá Magna Graecia di Catanzaro, Italy., Catanzaro, Italy, IMABIS and Virgen de la Victoria Hospital, Malaga, Spain, 4 Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom 7. Functional Genetic Polymorphisms in Immunoglobulin- Like Transcript Are Associated with Decreased Surface Expression On Dendritic Cells and Increased Serum Cytokines in Lupus Patients. Mark A. Jensen, Karen C. Patterson, Akaash A. Kumar, Marissa Kumabe, Beverly S. Franek and Timothy B. Niewold, University of Chicago, Chicago, IL 74. Genes Associated with Systemic Lupus Erythematosus Show Evidence of Selection in the Gullah African American Population. Paula S. Ramos, Satria Sajuthi, Yiqi Huang, Diane L. Kamen 4, Jasmin Divers, Kenneth M. Kaufman 5, John B. Harley 5, Robert P. Kimberly 6, Carl D. Langefeld, Michèle M. Sale, W. Timothy Garvey 6 and Gary S. Gilkeson, Medical University of South Carolina, Charleston, SC, Wake Forest School of Medicine, Winston-Salem, NC, University of Virginia, Charlottesville, VA, 4 Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 5 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 6 University of Alabama at Birmingham, Birmingham, AL 75. NRH (LXR alpha) Gene Polymorphisms Are Associated with Systemic Lupus Erythematosus in Koreans. Ja-Young Jeon, Hyoun-Ah Kim and Chang-Hee Suh, Ajou University School of Medicine, Suwon, South Korea 76. Signature of Circulating Micro-RNA in Systemic Lupus Erythematosus. Anting L. Carlsen, Aaron J. Schetter, Christoffer T. Nielsen, Christian Lood, Steen Knudsen 4, Anne Voss 5, Curtis C. Harris 6, Thomas Hellmark 7, Mårten Segelmark 8, Søren Jacobsen 9, anders A. Bengtsson 0 and Niels H. H. Heegaard, Statens Serum Institut, Copenhagen S, Denmark, National Institutes of Health, Bethesda, MD, Department of Clinical Sciences Lund, Lund, Sweden, 4 Medical Prognosis Institute, Horsholm, Denmark, 5 Odense University Hospital, Odense C, Denmark, 6 National Cancer Institute NIH, Bethesda, MD, 7 Lund, Sweden, 8 Sweden, 9 Copenhagen University Hospital, Copenhagen, Denmark, 0 Department of Clinical Sciences Lund, Section of Rheumatology, Lund, Sweden 77. Familial Aggregation and Heritability of Systemic Lupus Erythematosus in Taiwan: A Nationwide Population Study. Chang-Fu Kuo, Matthew J. Grainge, Lai-Chu See, Kuang- Hui Yu, Shue-Fen Luo, Ana M. Valdes 4, Hsiao-Chun Chang, I-Jun Chou, Weiya Zhang and Michael Doherty, University of Nottingham, Nottingham, United Kingdom, Chang Gung University, Taoyuan, Taiwan, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 St. Thomas Hospital, King s College London, London, United Kingdom 78. Single Nucleotide Polymorphisms (SNPs) of Integrin-á-M (ITGAM) Are Associated with Susceptibility to Systemic Lupus Erythematosus (SLE) in an Asian Lupus Cohort. Weng-Giap Law, Kok Ooi Kong, Bernard Pui Lam Leung, Chack-Yung Yu, Yeong W. Song, Yun Deng 4, Hiok-Hee Chng, Betty P. Tsao 5 and Hwee-Siew Howe, Tan Tock Seng Hospital, Singapore, Singapore, 7Center for Molecular and Human Genetics, The Research Institute at Nationwide Children s Hospital and The Ohio State University, Columbus, OH, Seoul National University, Seoul, South Korea, 4 David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 5 UCLA School of Medicine, Los Angeles, CA 79. Genetic Markers for Circulating Vitamin D and the Associations with Risk of Systemic Lupus Erythematosus. Linda T. Hiraki, Adrienne H. Williams, Arun-Prasad Manoharan, Peter Kraft 4, Carl D. Langefeld 5, Robert R. Graham 6 and Elizabeth W. Karlson 7, Brigham and Women s Hospital, Harvard School of Public Health, Boston, MA, Wake Forest School of Medicine, Winston-Salem, NC, Genentech, Inc., 4 Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, 5 Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 6 Genentech, Inc., South San Francisco, CA, 7 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 0 Program Book 0

306 ACR POSTER SESSION C 80. Serum Metabolomics As a Novel Diagnostic Approach for Systemic Lupus Erythematosus. Jun Saegusa, Yasuhiro Irino, Masaru Yoshida, Shino Tanaka, Yoshinori Kogata, Goichi Kageyama, Seiji Kawano, Goh Tsuji, Shunichi Kumagai and Akio Morinobu, Kobe University Graduate School of Medicine, Kobe, Japan, Shinko Hospital, Kobe, Japan 8. Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Jie An, Tracy A. Briggs, Nalini Agrawal, Alice Wiedeman, Laurence Chaperot, Joel Plumas, Yanick J. Crow and Keith B. Elkon, University of Washington, Seattle, WA, University of Manchester, Manchester, United Kingdom, Immunobiology & Immunotherapy of Cancers, La Tronche, France 8. Low Gene Copy Number for C4, C4A and C4B Is a Strong Risk Factor for Developing Systemic Lupus Erythematosus in Childhood. Luis Eduardo C. andrade, Kaline M.C. Pereira, Atila G. A. Faria, Bernadete Liphaus 4, Adriana A. Jesus 5, Clovis Silva 6 and Magda Carneiro-Sampaio 5, Universidade Federal de São Paulo, Sao Paulo, Brazil, Universidade Federal de São Paulo and Fleury Health and Medicine Laboratories, Sao Paulo, Brazil, Sao Paulo, Brazil, 4 Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 5 Instituto da Criança da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil, 6 MD; PhD, São Paulo-SP, Brazil 8. Preferential Association of Complement Receptor Variants with Anti-dsDNA Autoantibodies in Systemic Lupus Erythematosus. Brendan M. Giles, Jian Zhao, Kara M. Lough, Patrick M. Gaffney on behalf of LLAS, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS 4, Elizabeth E. Brown on behalf of PROFILE 5, Lindsey A. Criswell 6, Gary S. Gilkeson 7, Chaim O. Jacob 8, Judith A. James 9, Joan T. Merrill, Kathy L. Moser, Timothy B. Niewold 0, R. Hal Scofield, Timothy J. Vyse, John B. Harley, Kenneth M. Kaufman, Jennifer A. Kelly, Carl D. Langefeld, Jeffrey C. Edberg 4, Robert P. Kimberly 5, Daniela Ulgiati 5, Betty P. Tsao 6 and Susan A. Boackle, University of Colorado School of Medicine, Aurora, CO, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4 Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de andalucia, Oklahoma City, OK, 5 University of Alabama at Birmingham, Birmingham, AL, 6 University of California San Francisco, San Francisco, CA, 7 Medical University of South Carolina, Charleston, SC, 8 Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 9 Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK, 0 University of Chicago, Chicago, IL, King s College London, Guy s Hospital, London, United Kingdom, Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, Wake Forest School of Medicine, Winston-Salem, NC, 4 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5 University of Western Australia, Perth, Western Australia, Australia, 6 UCLA School of Medicine, Los Angeles, CA 84. Epigenetic Profiling in Monozygotic Twins Discordant for Systemic Lupus Erythematosus Reveals Prominent Hypomethylation of Interferon-Inducible Genes. Paula S. Ramos, Timothy D. Howard, Miranda C. Marion, Satria Sajuthi, Jennifer A. Kelly, Kathy L. Moser and Carl D. Langefeld, Medical University of South Carolina, Charleston, SC, Wake Forest School of Medicine, Winston- Salem, NC, Oklahoma Medical Research Foundation, Oklahoma City, OK 85. Systemic Lupus Erythematosus RNA-Seq: Endogenous Retroviral Group K Overexpression in Monocytes. Lihua Shi, Zhe Zhang, Michelle Petri and Kate Sullivan 4, Children s Hospital of Philadelphia, Philadelphia, PA, Bioinformatics, Children s Hospital of Philadelphia, Philadelphia, PA, Johns Hopkins University School of Medicine, Baltimore, MD, 4 THe Children s Hospital of Philadelphia, Philadelphia, PA Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics 86. Dysregulated Discoidin Domain Receptor -Microrna 96a-Mediated Negative Feedback Against Excess Type I Collagen Expression in Scleroderma Dermal Fibroblasts. Katsunari Makino, Masatoshi Jinnin, Jun Aoi, Ikko Kajihara, Takamitsu Makino, Keisuke Sakai, Satoshi Fukushima, Yuji Inoue and Hironobu Ihn, Kumamoto University, Kumamoto, Japan 87. Altered Regulation of Metabolic Pathways in Systemic Sclerosis Evidenced by Metabolomics. Emmanuel Chatelus, Jacques-Eric Gottenberg, François-Marie Moussallieh, Christelle Sordet, Arnaud Theulin, Alain Meyer, Jean- Francois Kleimann, Jean Sibilia and Izzie Jacques Namer, Strasbourg University Hospital, Strasbourg, France 88. The Role of TCR Vä+ NKT Cells in Systemic Sclerosis Patients with Interstitial Pneumonitis. Seiji Segawa, Daisuke Goto, Masanobu Horikoshi, Shinya Hagiwara, Naoto Umeda, Hiroshi Ogishima, Yuya Kondo, Hiroto Tsuboi, Makoto Sugihara, Taichi Hayashi, Yusuke Chino, Isao Matsumoto and Takayuki Sumida, University of Tsukuba, Tsukuba City, Japan 89. Adiponectin Has Potent Anti-Fibrotic Effects Mediated Via AMP Kinase: Novel Target for Fibrosis Therap. Feng Fang, Lei Liu, Yang Yang, Jun Wei, Swati Bhattacharyya, Ross Summer, Boping Ye and John Varga, Northwestern University, Chicago, IL, China Pharmaceutical University, Nanjing, China, Boston University, Boston, MA 90. Type I Interferon Associated Gene IRF7 in the Pathogenesis of Fibrosis in Systemic Sclerosis (SSc). Minghua Wu, Michael R. Blackburn, Shervin Assassi, Xiaochun Liu, John D. Reveille, Filemon K. Tan, Sandeep K. Agarwal and 04 0 Program Book

307 ACR POSTER SESSION C Maureen D. Mayes, University of Texas Health Science Center at Houston, Houston, TX, The University of Texas Medical School at Houston, Houston, TX, Baylor College of Medicine, Houston, TX 9. Enhanced Release of S00A9 and Hepatocyte Growth Factor by the Epidermis in Systemic Sclerosis. Joanna Nikitorowicz Buniak, Christopher P. Denton, David J. Abraham and Richard J. Stratton, UCL Medical School, London, United Kingdom, UCL, London, United Kingdom 9. Increased Synthesis of Leukotrienes by Peripheral Blood Mononuclear Cells Is Associated with More Severe Disease and Worse Prognosis in Patients with Systemic Sclerosis. Otylia M. Kowal-Bielecka, Anna Lapinska, Marek Bielecki, Oliver Distler 4, Izabela Domyslawska, Lech Chyczewski, Stanislaw Sierakowski, Steffen Gay 5 and Krzysztof Kowal 6, Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, Department of Medical Pathomorphology, Medical University in Bialystok, Bialystok, Poland, Department of Orthopedics and Traumatology, Medical University in Bialystok, Bialystok, Poland, 4 Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 5 Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, 6 Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland 9. Interleukin-7A Positive Cells Are Increased in Systemic Sclerosis Skin and Their Number Is Inversely Correlated to Skin Thickness. Marie-Elise Truchetet, Nicolò Costantino Brembilla, Elisa Montanari, Paola Lonati, Pier Luigi Meroni and Carlo Chizzolini, University hospital of Geneva, Geneva, Switzerland, Istituto G. Pini, University of Milan, Milan, Italy, Istituto G. Pini, University of Milan, Milano, Italy 94. The Histone Deacetylase SIRT Is Anti-Fibrotic and Mediates Resveratrol Effects. Roberta G. Marangoni, Archit Ghosh, Jun Wei and John Varga, Northwestern University, Feinberg School of Medicine, Chicago, IL, Northwestern University, Chicago, IL, Northwestern University Medical School, Chicago, IL 95. Caveolin- Deficiency Induces Spontaneous Endothelialto-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells in Vitro. Zhaodong Li, Peter J. Wermuth, Bryan Benn, Michael P. Lisanti and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, Jefferson Stem Cell Biology and Regenerative Medicine Center, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 96. Platelet Release Products Mediate Endothelial Apoptosis: A Possible Role for Thrombospondin - CD6 Pathway in SSc-Endothelial Apoptosis. Bashar Kahaleh and Yongqing Wang, University of Toledo, Toledo, OH 97. Decrease Activity of DNA Demethylase in SSc Fibroblast and Microvascular Endothelial Cells: A Possible Mechanism for Persistence of SSc Phenotype. Bashar Kahaleh and Yongqing Wang, University of Toledo, Toledo, OH 98. The Arachidonate 5-Lipoxygenase Activating Protein (ALOX5AP) Polymorphism Is Associated with Risk of Scleroderma-Related Interstitial Lung Disease: A Multicenter Study From the EULAR Scleroderma Trial and Research Group. Otylia M. Kowal-Bielecka, Sylwia Chwiesko-Minarowska, Pawel Bernatowicz, Yannick Allanore, Timothy RD Radstake 4, Jasper Broen 5, Marco Matucci-Cerinic 6, Roger Hesselstrand 7, Dorota Krasowska 8, Gabriela Riemekasten 9, Madelon C. Vonk 4, Oksana Kowalczuk, Marek Bielecki 0, Robert Milewski, Lech Chyczewski, Jacek Niklinski and Krzysztof Kowal, Department of Rheumatology and Internal Medicine, Medical University in Bialystok, Bialystok, Poland, Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 4 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5 Department of Rheumatology & Clinical Immunology, University Medical Center, Utrecht, Netherlands, 6 University of Florence, Florence, Italy, 7 Skane University Hospital Lund, Lund University, Lund, Sweden, 8 Department of Dermatology, Venereology and Pediatric Dermatology, Medical University of Lublin, Lublin, Poland, 9 Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 0 Department of Orthopedics and Traumatology, Medical University of Bialystok, Bialystok, Poland, Department of Statistics and Medical Informatics, Medical University of Bialystok, Bialystok, Poland, Department of Medical Pathomorphology, Medical University in Bialystok, Bialystok, Poland, Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland 99. Acroosteolysis Is Associated with Increased Propensity for Osteoclast Formation and Higher VEGF Levels in the Peripheral Blood of Systemic Sclerosis Patients. Jin Kyun Park, Andrea Fava, Antony Rosen and Francesco Boin, Seoul National University Hospital, Seoul, South Korea, Johns Hopkins University, Baltimore, MD, The Johns Hopkins University, Baltimore, MD 00. The Effects of Salvianolic Acid B in Fibrotic Models in Vivo and in Vitro. Qingmei Liu, Wenyu Wu, Wenzheng Tu, Haiyan Chu, Yanyun Ma, Hejian Zou, Xiaodong Zhou 4 and Jiu-Cun Wang, Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China, Huashan Hospital, Shanghai, China, Shanghai Traditional Chinese Medicine-Integrated Hospital, Shanghai, China, 4 University of Texas-Houston Medical School, Houston, TX 0. The Interferon Type I Signature Is Increased in Monocytes from Systemic Sclerosis Patients. Zana Brkic, Lenny van 0 Program Book 05

308 ACR POSTER SESSION C Bon, Cornelia G. van Helden-Meeuwsen, Madelon C. Vonk, Hanneke Knaapen, Wim van den Berg, Paul L. Van Daele, Virgil A. Dalm, Timothy Radstake and Marjan A. Versnel, Erasmus Medical Center, Rotterdam, Netherlands, University Medical Center Utrecht/Radboud University Nijmegen Medical Center, Utrecht/Nijmegen, Netherlands, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 0. Secreted Frizzled-Related Protein 4 Induces a Profibrotic Phenotype in Systemic Sclerosis Fibroblasts by Activating a Non-Canonical WNT Signaling Pathway. Justin Gillespie, Paul Emery and Francesco Del Galdo, University of Leeds, Leeds, United Kingdom, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom 0. Confirmation of TNIP as a Susceptibility Locus for Systemic Sclerosis in a Large Multicentre Study. Lara Bossini-Castillo, Jose Ezequiel Martin, Carmen Pilar Simeon, Lorenzo Beretta, Olga Y. Gorlova 4, Madelon C. Vonk 5, Patricia Carreira 6, the Spanish Scleroderma Group 7, Annemie Schuerwegh 8, Alexandre Voskuyl 9, Anna- Maria Hoffmann-Vold 0, Roger Hesselstrand, Annika Nordin, Claudio Lunardi, Jaap Van Laar 4, Paul Shiels 5, Ariane Herrick 6, Jane Worthington 7, Carmen Fonseca 8, Christopher P. Denton 8, Shervin Assassi 9, Bobby P.C. Koeleman 0, Maureen D. Mayes 9, T.R.D.J. Radstake 0 and Javier Martin, Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN-CSIC), Granada, Spain, Hospital Valle de Hebron, Barcelona, Spain, IRCCS Fondazione Policlinico- Mangiagalli-Regina Elena & University of Milan, Milan, Italy, 4 UT M. D. anderson Cancer Center, Houston, TX, 5 Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6 Hospital Universitario de Octubre, Madrid, Spain, 7 Granada, Spain, 8 Leids Univ Medisch Centrum, Leiden, Netherlands, 9 VU University Medical Center, Amsterdam, Netherlands, 0 Oslo University Hospital, Oslo, Norway, Skane University Hospital Lund, Lund University, Lund, Sweden, Karolinska Institute, Stockholm, Sweden, Policlinico G B Rossi, Verona, Italy, 4 Leiden University Hospital, Leiden, Netherlands, 5 University of Glasgow, Glasgow, United Kingdom, 6 University of Manchester, Salford, United Kingdom, 7 University of Manchester, Manchester, United Kingdom, 8 Royal Free and University College Medical School, London, United Kingdom, 9 University of Texas Health Science Center at Houston, Houston, TX, 0 University Medical Center Utrecht, Utrecht, Netherlands 04. Differential Association of IRAK and MECP with Specific Systemic Sclerosis Phenotypes. F. David Carmona, M.C. Cénit, L.M. Díaz-Gallo, Carmen P. Simeón, Patricia Carreira, the Spanish Scleroderma Group 4, Nicolas Hunzelmann 5, Gabriela Riemekasten 6, Torsten Witte 7, Alexander Kreuter 8, Jörg HW Distler 9, Paul Shiels 0, Jacob M. van Laar, Annemie Schuerwegh, Madelon C. Vonk, Alexandre Voskuyl 4, Carmen Fonseca 5, Christopher Denton 6, Ariane Herrick 7, Frank C. Arnett 8, Filemon K. Tan 8, Shervin Assassi 8, T.R.D.J. Radstake 9, Maureen D. Mayes 8 and Javier Martin, Consejo Superior de Investigaciones Científicas, Armilla (Granada), Spain, Hospital Valle de Hebron, Barcelona, Spain, Hospital Universitario de Octubre, Madrid, Spain, 4 Granada, Spain, 5 University of Cologne, Cologne, Germany, 6 Charité University Hospital, German Rheumatology Research Center, a Leibniz Institute, Berlin, Germany, 7 Hannover Medical School, Hanover, Germany, 8 Ruhr University Bochum, Bochum, Germany, 9 Department of Internal Medicine and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, 0 University of Glasgow, Glasgow, United Kingdom, Musculoskeletal Research Group, Newcastle, United Kingdom, Leids Univ Medisch Centrum, Leiden, Netherlands, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4 VU University Medical Center, Amsterdam, Netherlands, 5 Royal Free Hospital, London, United Kingdom, 6 Royal Free Hospital, London, England, 7 University of Manchester, Salford, United Kingdom, 8 University of Texas Health Science Center at Houston, Houston, TX, 9 University Medical Center Utrecht, Utrecht, Netherlands 05. A Putative Role for the TGFβ Accessory Receptors Betaglycan and Endoglin in pulmonary Complications of Scleroderma. Sarah L. Trinder, Adrian Gilbane, Markella Ponticos, Johanna Donovan, Christopher P. Denton, David J. Abraham and Alan M. Holmes, UCL, London, United Kingdom 06. Intratracheal Instillation of Omniscan in an Adenine- Induced Model of Chronic Renal Failure: A New Model of Nephrogenic Systemic Fibrosis. Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA 07. Role of Endosomal and Cell Membrane Toll-Like Receptors in Keratinocyte Activation by Systemic Sclerosis Autoantibodies. James M. Watson, Joanna Nikitorowicz Buniak, Xu Shiwen, David J. Abraham, Christopher P. Denton and Richard J. Stratton, UCL Medical School, London, United Kingdom, Royal Free Hospital, London, United Kingdom, Royal Free and University College Medical School, London, United Kingdom 08. CDc+ Cells Are Necessary for Myofibroblast Maintenance in Bleomycin-Induced Cutaneous Fibrosis. Jennifer J. Chia, Sha Tian and Theresa T. Lu, Weill Cornell/Rockefeller/ Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY, Hospital for Special Surgery, New York, NY 09. Increased Levels of Ser 8 Phosphorylated SOX9 in SSc Dermal Fibroblasts: A Novel Participant in the Pathogenesis of SSc Fibrotic Process. Sonsoles Piera- Velazquez, Jolanta Fertala and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective 06 0 Program Book

309 ACR POSTER SESSION C Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA T-cell Biology and Targets in Autoimmune Disease 0. Enhancement of CRACM Expression in Functionally Aberrant Naïve CD4+ T Cells in Active Rheumatoid Arthritis. Shuang Liu, Shohei Watanabe, Miyuki Kuno, Hiromasa Miura and Kazutaka Maeyama, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, Ehime University Graduate School of Medicine, Toon, Japan, Osaka City University Graduate School of Medicine, Osaka, Japan. Total Glucosides of Paeony Th and Th7 Cell Differentiation by Blocking STAT and STAT Activation in Vivo. Ningli Li and JP Lin, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China. Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis. Johannes Fessler, Rusmir Husic, Elisabeth Lerchbaum, Verena Schwetz, Claudia Stiegler, Barbara Obermayer-Pietsch, Winfried B. Graninger and Christian Dejaco, Medical University Graz, Graz, Austria. The Autoantibody-Inducing CD4 T Cell (aicd4 T cell) Belongs to CCR4+CD45RBlolo CD4 Subpopulation: A Novel Self-Organized Criticality Theory Explains the Cause of Systemic Lupus Erythematosus (SLE). Yumi Miyazaki, Ken Tsumiyama and Shunichi Shiozawa, Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan, Kyushu University Beppu Hospital, Beppu, Japan 4. Correlation Between Abatacept and Rheumatoid Factor Can Rheumatoid Factor Be a Predictive Factor for Abatacept? Tomonori Kobayakawa, Masatoshi Hayashi, Toshihisa Kanamono, Atsushi Kaneko, Toshihisa Kojima and Naoki Ishiguro 4, Nagano Red Cross Hospital, Nagano, Japan, Nagoya Medical Center, Nagoya, Japan, Nagoya Univeristy, School of Medicine, Nagoya, Japan, 4 Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan 5. Foxp+ Treg Cells Decreased in Overexpression of T-Bet in PD- Deficient Mice. Masahiro Tahara, Yuya Kondo, Hiroto Tsuboi, Satoru Takahashi, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan, Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba city, Ibaraki, Japan 6. Generation of CD4+ Follicular Helper T cells by Complement and Immune Complexes. Anil K. Chauhan, Richard DiPaolo and Terry L. Moore, Saint Louis University, St. Louis, MO, Saint Louis, MO 7. Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression in CD4+ T Cells. Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, University of Michigan, Ann Arbor, MI 8. Reduced Thymus Function and Accelerated T-Cell Aging in Patients with Axial Spondylarthritis. Christian Dejaco, Wolfgang Schwinger, Andrea Raicht, Rusmir Husic, Johannes Fessler, Christoph G. Ammann, Christina Duftner, Winfried B. Graninger and Michael Schirmer 4, Medical University Graz, Graz, Austria, Medical Uiversity Innsbruck, Innsbruck, Austria, Hopital Elisabethinen, Klagenfurt, Austria, 4 Innsbruck Medical University, Innsbruck, Austria 9. T Follicular Helper Cell and Regulatory T cell Frequencies Are Affected by B Cell Depletion in Patients with Granulomatosis with Polyangiitis. Yuan Zhao, Jessica Thomas, Shirish Sangle, Pamela M.K Lutalo, Lee Meng Choong 4, Jennifer R. Tyler, Jo Spencer, Timothy Tree and David P. D Cruz, School of Medicine, King s College London, London, United Kingdom, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom, Louise Coote Lupus Unit, St Thomas Hospital, London, United Kingdom, 4 St Thomas Hospital, London, United Kingdom 0. Superantigen Induces IL-7 Production From Extremely Polarized Th Clones. Kentaro Yomogida, Yuan K. Chou and Cong-Qiu Chu, Oregon Health & Science University, Portland, OR, Oregon Health & Science Univ and Portland VA Medical Center, Portland, OR. Interleukin Is Involved in an Interferon Type I Signature through Crosstalk of CD4+ T Cells and Plasmacytoid Dendritic Cells. Corinne Miceli-Richard, Nicolas Gestermann, Federico Simoneta, Saida Boudaoud, Gaetane Nocturne, Yann Lecluze 4, Christine Bourgeois and Xavier Mariette, Université Paris-Sud, Le Kremlin Bicêtre, France, INSERM U0, Le Kremlin Bicêtre, France, Université Paris-Sud, Le Kremlin Bicetre, France, 4 Villejuif, France. Dynamic Regulation of T Follicular Helper Cell Differentiation through STAT Signaling. Shingo Nakayamada, Yuka Kanno, Golnaz Vahedi, John J. O Shea and Yoshiya Tanaka, First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD. A Genetic Polymorphism on New Zealand Black Chromosome Is Associated with Abnormal Dendritic Cell Function Leading to Expansion of TH, TH 7 and T Follicular Helper (TFH) Cells. Nafiseh Talaei, Carolina Landolt-Marticorena, Babak Noamani, Evelyn Pau, Nan-Hua Chang and Joan E. Wither, Toronto Western Research Institute, University Health Network, Toronto, ON, University Health Network, Toronto, ON 4. An Essential Role for TNF and PD-L in the Generation of Human CD8+CD5+Foxp+ Regulatory T Cells That Are More Protective in Vivo Than CD4regs. David A. Horwitz, Stephanie Pan, Julie Wang and Song G. Zheng, Keck School of Medicine of USC, Los Angeles, CA 0 Program Book 07

310 ACR POSTER SESSION C PD- Signaling Promotes Suppressive Function of CD4+ Regulatory T Cells in (New Zealand Black x New Zealand White) F Lupus-Prone Mice in a Dose-Dependent Manner. Maida Wong, Antonio La Cava and Bevra H. Hahn, University of California, Los Angeles, Los Angeles, CA, UCLA David Geffen School of Medicine, Los Angeles, CA 6. Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK Kinase. Ronald J. Hill, Angelina Bisconte, J. Michael Bradshaw, Ken Brameld, Eun Ok Kim, Xiaoyan Li, Tim Owens, Erik Verner and David M. Goldstein, Principia Biopharma, South San Francisco, CA, Principia Biopharma 7. CGEN-500, a Novel Negative Costimulatory Fusion Protein Is Effective in the Collagen-Induced Arthritis Mouse Model of Rheumatoid Arthritis. Iris Hecht, Kay McNamee, Ilan Vaknin, Anat Oren, Joseph R. Podojil, Galit Rotman, Eyal Neria, Stephen D. Miller and Richard O. Williams, Compugen Ltd., Tel Aviv, Israel, Oxford University, London, United Kingdom, Northwestern University, Chicago, IL 8. A Novel Method for Quantitative and Functional Analysis of Autophagy Using Flow Cytometry in Activated Human Primary T Cells. Ryu Watanabe, Hiroshi Fujii, Yukiko Kamogawa, Kyohei Nakamura, Tsuyoshi Shirai, Yumi Tajima, Shinichiro Saito, Tomonori Ishii and Hideo Harigae, Tohoku University, Sendai, Japan 9. Increase of CD4+CD5+FoxP+ T cell in Patients with Systemic Sclerosis Could Secret IL-7 with Dysfunction of Immunosuppression. Xinjuan Liu, Na Gao, Mengtao Li, Dong Xu, Yong Hou, Qian Wang, Guohua Zhang, Qiuning Sun, Henghui Zhang and Xiaofeng Zeng, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Peking University, People s Hospital, Beijing, China 0. Mucosal-Associated Invariant T Cells Are Inactivated by IFNα and Reduced in Systemic Lupus Erythematosus. Asako Chiba, Naoto Tamura, Ran Matsudaira, Takashi Yamamura, Yoshinari Takasaki and Sachiko Miyake, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan, Juntendo University School of Medicine, Tokyo, Japan. The Effects of Anti Tumor Necrosis Factor Agents on the Expansion of T Helper-Type 7 Cells Driven by Lipopolysaccharide-Stimulated Monocytes. Gianluca Fossati, Louise Healy and Andrew Nesbitt, UCB Pharma, Slough, United Kingdom, UCB Pharma, SLough, United Kingdom. Suppression of PPAc Causes DNA Hypermethylation through Enhanced Pmek/Perk Activity in T Cells. Katsue S. Watanabe, Kamalpreet Nagpal and George C. Tsokos, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 0 Program Book. A Novel Subset of CD4 T Cells That Provides Help for Human Memory B cell Responses. Sang T. Kim, Jin Young Choi, Begona Lainez and Joseph E. Craft, Yale University School of Medicine, New Haven, CT 4. T-Cell Cross Reactivity with Citrullinated Antigen and P. Gingivalis Membrane Antigen Following Infection with P. Gingavalis and/or Injection of Citrullinated Mouse Type II Collagen in DBA/J Mice. Michael J. Duryee, Anand Dusad, Carlos D. Hunter, Ke Ren, Dong Wang, James R. O Dell, Lynell W. Klassen, Ted R. Mikuls 4 and Geoffrey M. Thiele, University of Nebraska Medical Center, Omaha, NE, Univ of Nebraska Medical Ctr, Omaha, NE, Univ of Nebraska Med Ctr, Omaha, NE, 4 Omaha VA and University of Nebraska Medical Center, Omaha, NE 5. Increased TSLP Expression in Joints of Rheumatoid Arthritis Patients Causes Increased Activation of Intra-Articular Myeloid Dendritic Cells with Enhanced Th and Th7 Cell Activity. F.M. Moret, C.E. Hack, T.R.D.J. Radstake, J.W.J. Bijlsma, F.P.J.G. Lafeber and J.A.G. van Roon, University Medical Center Utrecht, Utrecht, Netherlands 6. Elevated Frequency of Synovial Interleukin-+ CD4+ T Cells Co-Expressing Tumor Necrosis Factor-a in Rheumatoid Arthritis. Maria C. Lebre, Pedro L. Vieira, Saïda Aarrass, Thomas Newsom-Davis, Paul P. Tak and Gavin R. Screaton, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands, Imperial College London, London, United Kingdom, Academic Medical Center, University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 7. Therapeutic Promotion of CD8 CTL by CpG Oligodeoxynucleotides (ODN) in an Induced Model of Lupus. Maksym Puliaiev, Kateryna Soloviova and Charles S. Via, Uniformed Services University of Health Sciences, Bethesda, MD 8.,5(OH)D Modulates the Migration Pattern of Th7 Cells From Patients with Rheumatoid Arthritis. Wendy Dankers, Jan Piet van Hamburg, Patrick S. Asmawidjaja, Nadine Davelaar, Hoyan Wen, Anne-Marie Mus, Edgar Colin, Johannes van Leeuwen, Johanna M.W. Hazes 4 and Erik Lubberts, Erasmus MC, University Medical Center, Rotterdam, Netherlands, Erasmus MC, Rotterdam, Netherlands, Erasmus MC, University Medical Center, Rotterdam, Rotterdam, Netherlands, 4 Erasmus Medical Center, Rotterdam, Netherlands 9. Lowering Fli Levels Decreases the Levels of Lipid Mediators in the Kidneys and T Cells of MRL/Lpr Lupus Prone Mice. Marlene Bunni, Zainab Amani, Andrew Mather, Jennifer Berglind Schepp, Leah Siskind and Tamara K. Nowling, Medical University of South Carolina, Charleston, SC, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC 40. A Numeric Expansion of Invariant Natural Killer T Cells Protects Against the Progression of Fatal Autoimmunity

311 ACR POSTER SESSION C in Lupus-Prone Mice. Yuriy Baglaenko, Nan-Hua Chang, Evelyn Pau, Christina Loh and Joan E. Wither, Toronto Western Research Institute, University Health Network, Toronto, ON, Toronto Western Hospital, University Health Network, Toronto, ON 4. Exacerbation of Collagen-Induced Arthritis by an Anti-CD Antibody Targeting Aminoterminal-Deficient CDε. María J. Pérez-Lorenzo, Elena Gonzalo, José M. Rojo, María Galindo, Jose L. Pablos and Gabriel Criado, Instituto de Investigación Hospital de Octubre (I+), Madrid, Spain, Centro de Investigaciones Biológicas-CSIC, Madrid, Spain 4. Synovial Tissue Analysis in the Pre-Clinical Phase of Arthritis: T-Cell Infiltration Preceding the Development of Arthritis. Maria J. H. de Hair, Marleen G. H. van de Sande, Tamara H. Ramwadhdoebe, Robert B. M. Landewé, Christiaan van der Leij 4, Mario Maas 4, D. van Schaardenburg 5, Danielle Marie Gerlag, Lisa G.M. van Baarsen and Paul P. Tak 6, Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 4 Department of Radiology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 5 Jan van Breemen Research Institute Reade, Amsterdam, Netherlands, 6 Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands 4. The Therapeutic Antibody Tregalizumab (BT-06) Induces Activation of Regulatory T Cells by Engaging a Unique CD4 Mediated Signaling That Strongly Differs From Signaling Events Induced by Standard Anti-CD4 Antibodies. Bianca Helling, Benjamin Daelken, Holger Wallmeier, Silke Aigner, Chantal Zuber, Martin Koenig, andre Engling, Frank Osterroth, Niklas Czeloth and Christoph Uherek, Biotest AG, Dreieich, Germany, Condor Scientific Computing & Consulting, Sulzbach, Germany 44. Transcriptional Regulation of Garp Expression. Sonja Haupt, Qihui Zhou, Johannes Thomas Kreuzer, Simon Herrmann, Hendrik Schulze-Koops and Alla Skapenko, University of Munich, Munich, Germany 45. HRES-/RAB4-Mediated Loss of DRP Inhibits Mitophagy, Promotes Accumulation of Mitochondria and Serves As Target for Treatment in SLE. Tiffany Telarico, David Fernandez, Zachary A. Oaks, Gergely Talaber, Mark Haas, Michael P. Madaio 4 and andras Perl 5, SUNY Upstate Medical University, Syracuse, NY, SUNY, Syracuse, NY, Cedars- Sinai Medical Center, Los Angeles, CA, 4 Medical College of Georgia, Augusta, GA, 5 Upstate Medical University, Syracuse, NY 46. MHC II-Independent Regulation of Intestinal Tregs. Lisa L. Korn and Terri M. Laufer, University of Pennsylvania, Philadelphia, PA Vasculitis 47. Specificity of the New American College of Rheumatology/ European League Against Rheumatism Classification Criteria for Polymyalgia Rheumatica in Comparison with the Former Ones : A Single Centre Study. Pierluigi Macchioni, Luigi Boiardi, Mariagrazia Catanoso, Giulia Pazzola and Carlo Salvarani, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Arcispedale S Maria Nuova, Reggio Emilia, Italy, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy 48. Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP. EM McCarthy, Paul A. MacMullan, S. Al-Mudhaffer, Anne M. Madigan, S. Donnelly, C. J. McCarthy, Dermot Kenny, Eamonn S. Molloy and G M. McCarthy, Mater Misericordiae University Hospital, Dublin 7, Ireland, RCSI, Dublin, Ireland, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 49. Corticosterois Therapy Restaured Treg/Th7 Balance in Patients with Polimyalgia Rheumatica. Lorena Alvarez- Rodriguez, Marcos Lopez-Hoyos, Jaime Calvo-Alen, Elena Aurrecoechea, Teresa Ruiz Jimeno, Ignacio Villa, Carmen Gonzalez-Vela and Victor M. Martinez-Taboada, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, Hospital Universitario Sierrallana, Torrelavega, Spain, Hospital de Sierrallana, Torrelavega, Spain 50. Similarities Exceeds Differences in the Pattern of Joint and Vascular Positron Emission/Computed Tomography Uptake in Polymyalgia Rheumatica and Giant Cell Arteritis. Dario Camellino, Silvia Morbelli, Francesco Paparo, Michela Massollo, Gianmario Sambuceti and Marco A. Cimmino, Clinica Reumatologica, Genova, Italy, Medicina Nucleare, Genova, Italy, E.O. Ospedali Galliera, Genoa, Italy 5. Correlation between Hypoechoic Halo of the Temporal Arteries and Clinical, Laboratory, and Temporal Artery Biopsy Findings in Patients with Giant Cell Arteritis. Luigi Boiardi, Giulia Pazzola, Alberto Cavazza, Francesco Muratore, Giovanna Restuccia, Alberto Nicolini, Giuseppe Germanò, Nicolo Pipitone, Pierluigi Macchioni, Niccolò Possemato, Gianluigi Bajocchi, Ilaria Padovano, Olga Addimanda, Alberto Lo Gullo, Maria Grazia Catanoso and Carlo Salvarani, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Arcispedale S Maria Nuova, Reggio Emilia, Italy, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy 5. Temporal Artery Biopsy Culture in Tridimensional Matrix. An in Vitro Model for Functional Studies in Giant-Cell Arteritis. Marc Corbera Bellalta, Ester Planas Rigol, Ester Lozano, Marco A. Alba, Itziar Tavera-Bahillo, Sergio Prieto- González, Georgina Espígol Frigolé, Montserrat Butjosa, José Hernández-Rodríguez, Ana García-Martínez and Maria 0 Program Book 09

312 ACR POSTER SESSION C 0 C. Cid, Hospital Clinic University Barcelona, Barcelona, Spain, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, Vasculitis Research Unit. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain 5. TLR Activation by Acute Serum Amyloid A Induces Pro- Inflammatory Mechanisms in a Novel Ex Vivo Temporal Artery Explant Culture/Model of Giant Cell Arteritis. Peadar Rooney, Danielle Molloy, Jennifer McCormick, Mary Connolly, Sinead M. Miggin, Ashwini Maratha, Douglas J. Veale, Conor Murphy 4, Eamonn S. Molloy and Ursula Fearon 5, Dublin Academic Medical Centre, Dublin, Ireland, Immune Signalling Laboratory, Maynooth, Ireland, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland, 4 Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 5 Translation Research Group, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 54. The Prevalence of Low Bone Mineral Density in Patients with New Onset Giant Cell Arteritis. Do They Get Appropriate Bone Protective Treatment? Andreas P. Diamantopoulos and Glenn Haugeberg, Hospital of Southern Norway HF, Kristiansand, Norway 55. Increase in Duration and Cumulative Dose of Glucocorticoid Therapy in Recent Decades: Observations From a Population-Based Cohort of Patients with Giant Cell Arteritis. P. Deepak Udayakumar, Tanaz A. Kermani, Kenneth J. Warrington, Cynthia S. Crowson and Eric L. Matteson, Mayo Clinic, Rochester, MN 56. Visual Manifestations in Giant Cell Arteritis: Trend Over Five Decades. Abha G. Singh, Cynthia S. Crowson, Tanaz A. Kermani, Cornelia M. Weyand, Eric L. Matteson and Kenneth J. Warrington, Mayo Clinic, Rochester, MN, University of California Los Angeles, Los Angeles, Stanford University School of Medicine, Stanford, CA 57. Relapses in Patients with Giant-Cell Arteritis: Prevalence, Characteristics and Associated Clinical Findings in a Prospectively Followed Cohort of 06 Patients. Marco A. Alba, Ana García-Martínez, Itziar Tavera-Bahillo, Sergio Prieto-González, Montserrat Butjosa, Georgina Espígol, Marc Corbera, Ester Planas, Jose Hernandez-Rodriguez 4 and Maria C. Cid 5, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, Hospital Clinic University Barcelona, Barcelona, Spain, Vasculitis research unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 4 Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 5 Vasculitis Research Unit. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain 58. Large Vessel Giant Cell Arteritis: A Cohort Study. Francesco Muratore, Tanaz A. Kermani, Cynthia S. Crowson, Abigail B. Green, Eric L. Matteson and Kenneth J. Warrington, Arcispedale S Maria Nuova, Reggio Emilia, Italy, University of California Los Angeles, Los Angeles, Mayo Clinic, Rochester, MN 0 Program Book 59. Outcome of Aortic Involvement in GIANT CELL Arteritis (GCA) After -Year Follow-up: Prospective Study in 5 Patients Using Computed Tompography Angiography (CTA). Sergio Prieto-González, Pedro Arguis, Ana García- Martínez, Itziar Tavera-Bahillo, Marc Corbera-Bellalta, Marco A. Alba, Georgina Espígol-Frigolé, Ester Planas- Rigol, José Hernández-Rodríguez and Maria C. Cid, Vasculitis Research Unit. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, Vasculitis Research Unit. Department of Autoimmune Diseases. Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain 60. Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients. Pravin Patil, Shaifali Jain, Katerina Achilleos, Tochukwu Adizie, Mark Williams, Matthew Tam and Bhaskar Dasgupta, Southend University Hospital, Westcliff on sea, United Kingdom, Southend University Hospital, Westcliff-on-Sea, United Kingdom 6. Misdiagnosis of Giant Cell Arteritis Presenting As Fever of Unknown Origin. Chiara Stagnaro, Rosaria Talarico, Claudia Ferrari, Anna d Ascanio and Stefano Bombardieri, Rheumatology Unit, University of Pisa, Pisa, Italy 6. Evaluation of Disease Activity Using FDG PET-CT in Patients with Large Vessel Vasculitis. Giulia Pazzola, Luca Magnani, Luigi Boiardi, Nicolo Pipitone, Annibale Versari, Debora Formisano, Olga Addimanda, Riccardo Meliconi, Lia Pulsatelli, Gianluigi Bajocchi, Pierluigi Macchioni, Maria Grazia Catanoso, Niccolò Possemato, Ilaria Padovano, Alberto Lo Gullo and Carlo Salvarani 4, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, Istituto Ortopedico Rizzoli, University of Bologna, Bologna, Italy, Istituto Ortopedico Rizzoli, Bologna, Italy, 4 Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy 6. Assessment of Disease Activity in Large Vessel Vasculitis: Initial Results of an International Delphi Exercise. Sibel Z. Aydin, Haner Direskeneli, Eric L. Matteson and Peter A. Merkel 4, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, Marmara University, School of Medicine, Istanbul, Turkey, Mayo Clinic, Rochester, MN, 4 University of Pennsylvania, Philadelphia, PA 64. CROSS-Sectional Assessment of Damage in Takayasu Arteritis with A Validated Tool. Ahmet Omma, Burak Erer, Omer Karadag, Neslihan Yilmaz, Fatma Alibaz-Oner, Fatih Yildiz 4, Melike Kalfa 5, Gezmis Kimyon 6, Sedat Kiraz, Haner Direskeneli, Eren Erken 4, Kenan Aksu 5, Ahmet Mesut Onat 6, Ahmet Gul, Lale Ocal, Murat Inanc and Sevil Kamali, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Hacettepe University, Faculty of Medicine, Ankara, Turkey, Marmara University, Faculty of Medicine, Istanbul, Turkey, 4 Cukurova University, Faculty of Medicine, Adana, Turkey, 5 Ege University, Faculty of Medicine, Izmir, Turkey, 6 Gaziantep University, Faculty of Medicine, Gaziantep, Turkey 65. Asymptomatic Myocardial Ischemic Disease in Takayasu s Arteritis. Chloe Comarmond, Odile Dessault, jean-yves

313 ACR POSTER SESSION C Devaux, Nathalie Costedoat-Chalumeau, Mathieu Resche Rigon 4, Richard Isnard 5, Fabien Koskas 6, Patrice Cacoub Sr. 7 and David Saadoun, Hôpital Pitié Salpétrière, Paris, France, Groupe Hospitalier Saint-Antoine, Paris, France, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 4 Department of Internal Medicine and Laboratory I Immunology, Immunopathology, Immunotherapy, UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 5 Department of Cardiology, CHU Pitié-Salpêtrière, 47-8 Boulevard de l hôpital, 7565 Paris Cedex, Paris, France, Paris, France, 6 Department of Internal Medicine and Laboratory I «Immunology, Immunopathology, Immunotherapy», UMR CNRS 7, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 7 CHU Pitié-Salpêtrière, Paris, France 66. Aortic and Coronary Calcifications in Takayasu Arteritis. Emire Seyahi, Ayca Ucgul, Serdal Ugurlu, Canan Akman, Deniz Cebi Olgun, Sebahattin Yurdakul and Hasan Yazici, Istanbul University, Cerrahpasa Medical Faculty, Istanbul, Turkey, University of Istanbul, Cerrahpasa Medical Faculty, Istanbul, Turkey, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey 67. Presence of Fibromyalgia and Fatigue Is Not Increased in Patients with Takayasu s Arteritis. Fatma Alibaz- Oner, Meryem Can, Birkan Ilhan, Ozge Polat and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey 68. Tocilizumab in Refractory Takayasu s Arteritis: 7 Patients Followed At a Single Italian Centre. Enrico Tombetti, Elena Baldissera, Stefano Franchini, Patrizia Aiello, Francesca Motta, Barbara Gulgielmi and Maria Grazia Sabbadini, Vita- Salute San Raffaele University, Milan, Italy 69. Aspects of Innate Immunity in Behçet s Disease: A Model of Autoinflammatory Disease? Sandro F. Perazzio, Paulo Vitor Soeiro Pereira, Alexandre Wagner S. de Souza, Antonio Condino-Neto and Luis Eduardo C. andrade 4, Federal University of Sao Paulo, Sao Paulo, Brazil, USP, São Paulo, Brazil, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 4 Universidade Federal de São Paulo, Sao Paulo, Brazil 70. A Genome-Wide DNA Methylation Study Identifies Significant Epigenetic Changes Across the Genome and in Multiple HLA Loci in Behcet s Disease. Haner Direskeneli, Patrick S. Coit, Filiz Ture-Ozdemir, Fatma Alibaz-Oner, Guher Saruhan-Direskeneli, Matlock A. Jeffries 4 and Amr H. Sawalha, Marmara University, School of Medicine, Istanbul, Turkey, University of Michigan, Ann Arbor, MI, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4 University of Oklahoma and Oklahoma Medical Research Foundation, Oklahoma City, OK 7. The Unmet Need in Behcet s Disease: Most Patients Are Not in Complete Remission in the Long-Term Follow-up. Fatma Alibaz-Oner, Gonca Mumcu, Gülsen Ozen, Zeynep Kubilay, Meryem Can, Sibel Yýlmaz Oner, Tülin Ergun 4 and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey, Marmara University,Faculty of Health Sciences, Department of Health Informatics and Technologies, Istanbul, Turkey, Marmara University, School of Medicine., Istanbul, Turkey, 4 Marmara University School of Medicine, Istanbul, Turkey 7. Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet s Disease. Hirotoshi Kikuchi, Maki Takayama, Yoshitaka Kimura, Kurumi Asako, Hajime Kono, Yasuo Ono and Shunsei Hirohata, Teikyo University Shool of Medicine, Tokyo, Japan, Teikyo University School of Medicine, Tokyo, Japan, Kitasato University School of Medicine, Sagamihara, Japan 7. The Clinical Course of the Acute Deep Vein Thrombosis of the Legs in Behçet s Syndrome. Yesim Ozguler, Melike Melikoglu, Firat Cetinkaya, Serdal Ugurlu 4, Emire Seyahi 5, Koray Tascilar 4 and Hasan Yazici, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey, Rheumatology, Istanbul, Turkey, Istanbul, Turkey, 4 Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, 5 Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey 74. Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet s Syndrome: Experience in A Dedicated Center. Ibrahim Hatemi, Gulen Hatemi, Yusuf Erzin, Aykut Ferhat Celik and Hasan Yazici, Istanbul University, Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey, Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, Istanbul University, Cerrahpasa Medical School, Rheumatology, Istanbul, Turkey 75. WHAT Affects the Quality of Life in Patients with BEHCET S Disease? Mehmet Melikoglu and Meltem Alkan Melikoglu, Health Ministry Erzurum Regional Training and Research Hospital, Erzurum, Turkey, Ataturk University School of Medicine, Erzurum, Turkey 76. Behcet s Disease: Combination of Pulse Cyclophosphamide, Azathioprine, and Prednisolone for the Treatment of Retinal Vasculitis; Longitudinal Study On 0 Years. Fereydoun Davatchi, Farhad Shahram, Bahar Sadeghi Abdollahi, Hormoz Shams, Abdolhadi Nadji, Massoomeh Akhlaghi, Tahereh Faezi and Farimah Ashofteh, Shariati Hospital-Tehran Univ, Tehran, Iran 77. Impaired Endothelial Function in Patients with Takayasu s Arteritis. Fatma Alibaz-Oner, Selen Yurdakul, Yelda Tayyareci, Saide Aytekin and Haner Direskeneli, Marmara University, School of Medicine, Istanbul, Turkey, ISTANBUL FLORENCE NIGHTINGALE HOSPITAL, Istanbul, Turkey 78. Evaluation of the EULAR/ACR 0 Classification Criteria for Polymyalgia Rheumatica: Comparison of the New Algorithms with and without Ultrasound to the Formerly Used Criteria. Sandra Balser, Wolfgang Hartung, 0 Program Book

314 ACR POSTER SESSION C Emmanuelle LeBras, Boris P. Ehrenstein, Martina Müller and Martin Fleck, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, University Clinic Regensburg, Regensburg 79. Successful Treatment of Churg-Strauss Syndrome with Rituximab. Christin Dubrau, Fabian Arndt, Wolfgang L. Gross and Frank Moosig, University Hospital Schleswig- Holstein, Campus Luebeck and Klinikum Bad Bramstedt, Bad Bramstedt, Germany, University Hospital Schleswig Holstein and Klinikum Bad Bramstedt, Bad Bramstedt, Germany 80. High Frequency of Ferritin Autoantibodies in Takayasu Arteritis. Niklas T. Baerlecken, Katherina Große, Frank Moosig, Wolfgang L. Gross 4, Reinhold E. Schmidt 5 and Torsten Witte 6, MD, Hannover, Germany, Student, Hannover, Germany, Stormarnzing 5 6, Bad Bramstedt, Germany, 4 Medical University at Lubeck, Lubeck, Germany, 5 Hannover Medical School, Hannover, Germany, 6 Hannover Medical School, Hanover, Germany 8. Serum Level of IL- and Soluble ST and Their Association with Disease Activity in Patients with Behcet s Disease. Dae-Jun Kim, Jae-Ho Lee, Ji Hyeon Ju, Sung-Hwan Park, Ho-Youn Kim and Seung-Ki Kwok, The Catholic University of Korea, Seoul St. Mary s Hospital, Seoul, South Korea, Catholic University of Korea, Seoul, South Korea 8. Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica. E.M. McCarthy, Paul A. MacMullan, S. Al-Mudhaffer, Anne M. Madigan, S. Donnelly, C. J. McCarthy, Dermot Kenny, Eamonn S. Molloy and G M. McCarthy, Mater Misericordiae University Hospital, Dublin 7, Ireland, RCSI, Dublin, Ireland, Dublin Academic Medical Centre, St. Vincent s University Hospital, Dublin, Ireland 8. Rituximab as Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients. Pierre Charles, Antoine Néel, Nathalie Tieulié, Arnaud Hot Sr. 4, Grégory Pugnet 5, Olivier Decaux 6, Isabelle Marie 7, Mehdi Khellaf 8, Jean- Emmanuel Kahn 9, Alexandre Karras 0, Jean-Marc Ziza, Christophe Deligny, Colas Tchérakian and Loic Guillevin, Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, Paris, France, Internal Medicine, Nantes University Hospital, Nantes, France, Service de Médecine onterne, CHU Nice, Nice, France, 4 Lyon hospital, Lyon, France, 5 Toulouse University Hospital, University of Toulouse, INSERM UMR 07, Toulouse, France, 6 Hôpital Sud, Rennes, France, 7 Service de médecine interne, CHU de Rouen, Rouen, France., Rouen, France, 8 Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, 9 Internal Medicine, Foch Hospital, Suresnes, France, 0 Hôpital Européen Georges Pompidou, APHP, Paris, France, Hopital Croix Saint Simon, Paris, France, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, Service de pneumologie, hôpital Foch, Suresnes, France 84. Giant Cell Arteritis and Cardiovascular Events in the French Apogee Cohort. A Population-Based Study Using the French Health Insurance System Database. Grégory Pugnet, Laurent Sailler, Robert Bourrel, Jean-Louis Montastruc 4 and Maryse Lapeyre-Mestre 4, Toulouse University Hospital, University of Toulouse, INSERM UMR 07, Toulouse, France, Toulouse University Hospital, University of Toulouse, INSERM UR 07, Toulouse, France, Caisse Nationale de l Assurance Maladie échelon régional, Midi- Pyrénées, Toulouse, France, 4 Toulouse University Hospital, INSERM U07, University of Toulouse, France, Toulouse, France 85. Prognostic Impact of HLA-B*5 and HLA-A*6:0 On Ocular Behcet s Disease. Jun Won Park, Eun Ha Kang, Hye Won Kim, Chaerin Park, Hyeong Gon Yu, Eun Young Lee, Yun Jong Lee, Eun Bong Lee and Yeong Wook Song, Seoul National University Hospital, Seoul, South Korea, Seoul National University Bundang Hospital, Seongnam-si, South Korea 86. Disability and Mortality Related to Cerebrovascular Disease in Systemic Vasculitis. Jamal Mikdashi and Marcia Wozniak, University of Maryland School of Medicine, Baltimore, MD 87. Takayasu s Arteritis: Features and Management of 6 Patients in China. Xia Liu, Tao Zhang, Xiaofeng Zhuang, Kai Yuan, Xiaoming Shu and Guochun Wang, China-Japan Friendship Hospital, Beijing, China, Chinese PLA General Hospital, Beijing, China, FuWai Hospital and Cardiovascular Institute, Beijing, China 88. Urticarial Vasculitis: Clinical Study. Javier Loricera, Vanesa Calvo-Rio, Francisco Ortiz Sanjuan, Marcos Antonio Gonzalez-Lopez, Hector Fernandez-Llaca, Javier Rueda- Gotor, Carmen Gonzalez-Vela, Cristina Mata-Arnaiz, Jose Luis Peña-Sagredo, Miguel A. Gonzalez-Gay and Ricardo Blanco, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, Hospital Laredo, Santander, Spain 89. Cutaneous Leukocytoclastic Angiitis: Study of 7 Patients. Javier Loricera, Vanesa Calvo-Rio, Francisco Ortiz-Sanjuan, Marcos Antonio Gonzalez-Lopez, Hector Fernandez-Llaca, Javier Rueda-Gotor, Carmen Gonzalez-Vela, Miguel A. Gonzalez-Gay and Ricardo Blanco, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain 90. Color Doppler Ultrasonography an Alternative to CT/MR Angiography for Identifying Large Vessel Involvement in Giant Cell Arteritis? Andreas P. Diamantopoulos, Glenn Haugeberg and Geirmund Myklebust, Hospital of Southern Norway HF, Kristiansand, Norway, Hospital of Southern Norway, Kristiansand, Norway 9. New Disease Manifestations after Diagnosis in Six Types of Vasculitis. Peter C. Grayson, David Cuthbertson, Simon Carette, Gary S. Hoffman 4, Nader A. Khalidi 5, Curry 0 Program Book

315 ACR POSTER SESSION C L. Koening 6, Carol A. Langford 4, Kathleen Maksimowicz- McKinnon 7, Paul A. Monach 8, Philip Seo 9, Ulrich Specks 0, Steven R. Ytterberg 0 and Peter A. Merkel, Boston University Medical Center, Boston, MA, University of South Florida, Tampa, FL, UHN/MSH, Toronto, ON, 4 Cleveland Clinic, Cleveland, OH, 5 McMaster University, Hamilton, ON, 6 Salt Lake City Veterans Administration, Salt Lake City, UT, 7 University of Pittsburgh, Pittsburgh, PA, 8 Boston University, Boston, MA, 9 Johns Hopkins Vasculitis Center, Baltimore, MD, 0 Mayo Clinic, Rochester, MN, University of Pennsylvania, Philadelphia, PA 9. Blood Vessel Instability and Oxidative Damage in Giant Cell Arteritis. Danielle Molloy, Jennifer McCormick, Mary Connolly, Muhammad Haroon, Douglas J. Veale, Conor Murphy, Ursula Fearon and Eamonn S. Molloy, Dublin Academic Medical Center, St. Vincent s University Hospital, Dublin, Ireland, Royal Victoria Eye and Ear Hospital, Dublin, Ireland 9. High Mobility Group Box Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins. Alexandre Wagner S. de Souza, Karina de Leeuw, Johanna Westra, andries J. Smit, Anne Marijn van der Graaf, Hans L. A. Nienhuis, Johan Bijzet, Pieter C. Limburg, Coen A. Stegeman, Marc Bijl and Cees G.M. Kallenberg, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, University Medical Center Groningen, Groningen, Netherlands, Martini Hospital, Groningen, Netherlands 94. Fibromyalgia in Behçet s Disease Is Associated with Disease Activity. Meryem Can, Fatma Alibaz-Öner, Sibel Yılmaz- Öner, Birkan İlhan, Tülin Ergun, Gonca Mumcu and Haner Direskeneli, Marmara University School of Medicine, Istanbul, Turkey, Marmara University School of Medicine, Turkey, Marmara University,Faculty of Health Sciences, Department of Health Informatics and Technologies, Istanbul, Turkey 95. Body Composition, Strength, and Function in Elderly Patients with Giant Cell Arteritis. Rebecca L. Manno, Allan C. Gelber, Philip Seo, Stuart M. Levine, Sharon R. Ghazarian, Po-Han Chen, Kerry J. Stewart, Jeffrey Metter 4, Luigi Ferrucci 4 and Kevin R. Fontaine 5, Johns Hopkins University, Baltimore, MD, Johns Hopkins Vasculitis Center, Baltimore, MD, Baltimore, MD, 4 National Institute on Aging, Baltimore, MD, 5 The University of Alabama at Birmingham, Birmingham, AL 96. Higher Homocysteine Levels Are Associated with Ischemic Arterial Events Rather Than Disease Activity and the Extension of Arterial Involvement in Takayasu Arteritis. Alexandre W.S. Souza, Carla S. Lima, Ana Cecilia D. Oliveira, Luiz Samuel G. Machado, Frederico A. G. Pinheiro, Sonia Hix 4 and Vânia D Almeida 5, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, Escola Paulista de Medicina - Universidade Federal de São Paulo, São Paulo, Brazil, Universidade Federal de São Paulo, São Paulo, Brazil, 4 Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil, 5 Universidade Federal de São Paulo- Escola Paulista de Medicina, São Paulo, Brazil 97. Urinary Biomarkers in Vasculitis Associated with Anti- Neutrophil Cytoplasmic Antibodies. Jason G. Lieberthal, David Cuthbertson, Simon Carette, Gary S. Hoffman 4, Nader A. Khalidi 5, Curry L. Koening 6, Carol A. Langford 4, Kathleen Maksimowicz-McKinnon 7, Philip Seo 8, Ulrich Specks 9, Steven R. Ytterberg 9, Peter A. Merkel 0 and Paul A. Monach, Boston University School of Medicine, Boston, MA, University of South Florida, Tampa, FL, UHN/MSH, Toronto, ON, 4 Cleveland Clinic, Cleveland, OH, 5 McMaster University, Hamilton, ON, 6 Salt Lake City Veterans Administration, Salt Lake City, UT, 7 University of Pittsburgh, Pittsburgh, PA, 8 Johns Hopkins Vasculitis Center, Baltimore, MD, 9 Mayo Clinic, Rochester, MN, 0 University of Pennsylvania, Philadelphia, PA, Boston University, Boston, MA 98. Pauci-Immune Glomerulonephritis in the Elderly: Disease Severity and Outcomes. Rebecca L. Manno, Duvuru Geetha, Stuart M. Levine, Philip Seo and Allan C. Gelber, Johns Hopkins University, Baltimore, MD, Johns Hopkins Vasculitis Center, Baltimore, MD Education/Community Programs 99. Exercise on Prescription: Barriers to Participation in Community Based Exercise Programmes. Dr Nicola E. Walsh and Professor Mike Hurley, University of the West of England, Bristol, United Kingdom, St George s University of London, London, United Kingdom 400. Hospital for Special Surgery Osteoarthritis Wellness Initiative: the Impact of a Hospital-Based Exercise Program On Osteoarthritis. Sandra Goldsmith, Dana Friedman, Linda Roberts, Dana Sperber and Laura Robbins, Hospital for Special Surgery, New York, NY 40. An International Framework for Chronic Condition Self Management Support: Results from an International Electronic Consultation Process. Teresa J. Brady, Sue Mills, Peter Sargious and Shabnam Ziabakhsh 4, Centers for Disease Control and Prevention, Atlanta, GA, University of British Columbia, Vancouver, BC, Alberta Health Services, Calgary, AB, 4 BC Women s Hospital & Health Centre, Vancouver, BC 40. Clinical Utility of the Hospital Anxiety and Depression Scale for an Outpatient Fibromyalgia Education Program. Diane Tin, Lorna J. Bain, J. Carter Thorne, Seungree Nam and Liane Ginsburg, Southlake Regional Health Centre, Newmarket, ON, York University, Toronto, ON 40. The Effect of a Rheumatoid Arthritis Peer Support Program On Clinical Outcomes. Rebecca Thrower, Christine K. Iannaccone, Hsun Tsao, Michael Weinblatt, Jing Cui 4 and Nancy A. Shadick 5, Brigham and Women s Hospital, 0 Program Book

316 ACR POSTER SESSION C Boston, MA, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, Rheumatology & Immunology, Brigham & Women s Hospital, Boston, MA, 4 Brigham and Womens Hospital, Boston, MA, 5 Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women s Hospital, Boston, MA 404. Cardiovascular Disease Prevention Counseling Program for Systemic Lupus Erythematosus and/or Antiphospholipid Antibody Positive Patients: Two-Year Preliminary Analysis of Diet and Exercise Habits. Virginia Haiduc, Monica C. Richey, Sotiria Everett, Aeshita Dwivedi, Lisa Konstantellis, Hassan Ghomrawi and Doruk Erkan, Hospital for Special Surgery, New York, NY 405. A Proof-of-Concept Study of an Animated, Web-Based Methotrexate Decision Aid for Patients with Rheumatoid Arthritis. Linda C. Li, Paul M. Adam, Catherine L. Backman, Sydney Brooks, Gwen A. Ellert 4, Allyson Jones 5, Otto Kamensek 6, Cheryl Koehn 7, Diane Lacaille 6, Colleen Maloney 6, Anne F. Townsend 6, Elaine Yacyshyn 5, Charlene Yousefi 6 and Dawn Stacey 8, University of British Columbia, Vancouver, BC, Mary Pack Arthritis Centre, Vancouver, BC, The Arthritis Society, Ontario Division, Toronto, 4 Trelle Enterprises Inc, Vancouver, BC, 5 University of Alberta, Edmonton, AB, 6 Arthritis Research Centre of Canada, Vancouver, BC, 7 Vancouver, BC, 8 University of Ottawa, Ottawa, ON 406. Implementation of a Pilot Nutrition Education Intervention for Culturally Diverse Teens with Lupus and Their Families in Hospital for Special Surgery s Charla De Lupus /Lupus Chat Teen and Parent Support Group. Jillian A. Rose, Roberta Horton, Dariana M. Pichardo, Dana Friedman, Robyn Wiesel, Sandra Goldsmith, Sotiria Everett and Lisa F. Imundo, Hospital for Special Surgery, New York, NY, Hospital For Special Surgery, New York, NY, Morgan Stanely Children s Hospital of New York-Presbyterian, Columbia University Medical Center, New York, NY 407. Perceptions of the Chronic Disease Self-Management Program Among Low Income African American Women with Lupus. Charmayne M. Dunlop-Thomas, Terrika Barham, Natasha DeVeauuse Brown and Cristina Drenkard, Emory University, Atlanta, GA Epidemiology and Public Health 408. Effects of Ground and Joint Reaction Force Exercise On Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Randomized Controlled Trials. George A. Kelley, Kristi S. Kelley and Wendy M. Kohrt, West Virginia University, Morgantown, WV, University of Denver, Aurora, CO 409. Work Productivity in a Population Based Cohort of Patients with Spondyloarthritis. Emma Haglund, Ann B. I. Bremander, Stefan Bergman, Lennart TH Jacobsson, Britta Strömbeck 4 and Ingemar F. Petersson 4, R&D Center Spenshult, Oskarstrom, Sweden, Halmstad University School of Business and Engineering, Halmstad, Sweden, Department of Rheumatology, Clinical sciences, Skane University Hospital, Malmö, Sweden, 4 Musculoskeletal Sciences, Department of Orthopedics, Clinical Sciences, Lund, Sweden 40. WITHDRAWN. 4. Obesity Is Associated with Higher Levels of Fatigue in RA. Patricia P. Katz, Vladimir Chernitskiy and Mary Margaretten, University of California San Francisco, San Francisco, CA, UCSF, San Francisco, CA 4. Valdiation of a Diagnosis of Gout in the Epiccare Electronic Medical Records. Neera Narang and Eswar Krishnan, Stanford Univ Medical Center, Stanford, CA, Standford University, Palo Alto, CA 4. The Impact of Asymptomatic Vertebral Fractures On Quality of Life in Community-Dwelling Older Women: The Sao Paulo Ageing & Health Study (SPAH). Jaqueline B. Lopes, Leandro Fung, Carolina C. Cha, Camille P. Figueiredo, Liliam Takayama, Valéria Caparbo and Rosa M.R. Pereira, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 44. Multisite Joint Pain and Fatigue: the Role of Pain Severity and Sleep Problems in Adults with Arthritis. Mayilee Canizares and E.M. Badley, Division of Health Care and Outcomes Research. Toronto Western Research Institute, Toronto, ON, Division of Health Care and Outcomes Research, Toronto Western Research Institute;Dalla Lana School of Public Health,University of Toronto, Toronto, ON 45. Does Interleukin-6 Mediate the Relation Between Estrogen and Bone? an Epidemiologic Approach in the Framingham Osteoporosis Study. Robert R. McLean, Xiaochun Zhang, Andrea D. Coviello, Joao D.T. Fontes 4, L. Adrienne Cupples 5, Douglas P. Kiel and Marian T. Hannan, Hebrew SeniorLife & Harvard Medical School, Boston, MA, Hebrew Senior Life, Boston, MA, Boston University School of Medicine, Boston, MA, 4 Framingham Heart Study and Boston University, Framingham, MA, 5 Boston University School of Public Health, Boston, MA 46. Arthritis-Attributable Interference in Routine Life Activities. Kristina A. Theis, Teresa J. Brady, Charles G. Helmick, Louise Murphy and Kamil E. Barbour, Centers for Disease Control and Prevention, Atlanta, GA, CDC, Atlanta, GA 47. Transitioning to Adulthood: Employment Experiences of Young Adults with Lupus and Juvenile Arthritis. Arif Jetha, E. M. Badley, Dorcas Beaton, Paul R. Fortin 4, Natalie J. Shiff 5, Alan M. Rosenberg 6, Lori B. Tucker 7, Dianne P. Mosher 8 and M. A. Gignac 9, Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Division of Health Care and Outcomes Research,Toronto Western Research Institute; Dalla Lana School of Public 4 0 Program Book

317 ACR POSTER SESSION C Health, University of Toronto, Toronto, ON, Institute for Work & Health; Mobility Program, Clinical Research Unit, St. Michaels Hospital, Toronto, ON, 4 Division of Rheumatology, Centre de recherche du centre hospitalier universitaire de Québec, Faculté de médecine de L université Laval, Quebec City, QC, 5 University of Saskatchewan, Saskatoon, SK, 6 Royal University Hospital, Saskatoon, SK, 7 BC Childrens Hospital, Vancouver, BC, 8 University of Calgary, Calgary, AB, 9 Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto; Institute for Work & Health, Toronto, ON 48. The Everyday Challenge of Living with Lupus. Brenda L. Frie, St. Catherine University, St. Paul, MN 49. Novel Candidate Genes for Structural Foot Disorders: A Genome-Wide Association Study in an Older Caucasian Population. Marian T. Hannan, Yi-Hsiang Hsu, Chia Ho Cheng, Youfang Liu and Joanne M. Jordan 4, Hebrew SeniorLife & Harvard Medical School, Boston, MA, Hebrew SeniorLife & Harvard Med Sch, Boston, MA, University of North Carolina, Chapel Hill, NC, 4 University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC Pediatrics 40. Frequent Self-Reported Pain and Disease Symptoms in Juvenile Idiopathic Arthritis Persist Despite Advances in Medication Therapies: An Electronic Diary Study. Maggie H. Bromberg, Mark Connelly, Kelly K. Anthony, Karen M. Gil and Laura E. Schanberg, University of North Carolina at Chapel Hill, Chapel Hill, NC, Children s Mercy Hospitals and Clinics, Kansas City, MO, Duke University Medical Center, Durham, NC 4. The Pediatric Rheumatology Nursing Network: An International MANAGED COMMUNICATION System. Norma L. Liburd, All Children s Hospital, St. Petersburg, FL Psychology/Social Sciences 4. Sexual Activity and Sexual Functioning Among Women with Systemic Sclerosis Compared to Women From a Population Sample. Brooke Levis, Andrea Burri, Marie Hudson, Murray Baron and Brett D. Thombs, McGill University, Montreal, QC, King s College, London, United Kingdom, Jewish General Hospital, Montreal, QC 4. Perceptions Regarding Cardiovascular Risk Factors and Barriers to Risk Reduction Among African American Women with Lupus. Barron Mia, Lynne Nemeth, Diane L. Kamen and Youlanda C. Gibbs, Medical University of South Carolina, Charleston, SC, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC 44. Sleep Disturbances in Systemic Sclerosis: Evidence for the Role of Gastrointestinal Symptoms, Pain, and Pruritus. Katherine Milette, Marie Hudson, Annett Koerner, Murray Baron and Brett D. Thombs, McGill University, Montreal, QC, Jewish General Hospital, Montreal, QC 45. A Qualitative Study of Self-Image and Body Image in Individuals with Systemic Lupus Erythematosus. Afton L. Hassett, Diane C. Radvanski and Elizabeth Hale, University of Michigan, Ann Arbor, MI, Robert Wood Johnson Medical School, NJ, Dudley Group NHS Foundation Trust, Dudley, United Kingdom 46. Prevalence and Characteristics of Sleep Problems in Rheumatoid Arthritis: A Systematic Review of the Literature. Cassandra Coleman and Yvonne C. Lee, Brigham and Women s Hospital, Boston, MA 47. Health-Related Quality of Life in Adolescents with Rheumatic Disease. Sandra J. Watcher, Maggie Sepkowitz, Suhas M. Radhakrishna, Anusha Ramanathan, Elizabeth Morasso, Jennifer Chang and Jeffrey I. Gold 4, Children s Hospital of LA, Los Angeles, CA, Kaiser Permananete Medical Group, Oakland, CA, Childrens Hospital Los Angeles, Los Angeles, CA, 4 Keck School of Medicine, University of Southern California - Children s Hospital Los Angeles, Los Angeles, CA 48. Causal Beliefs of Disease among Patients with Systemic Vasculitis. Peter C. Grayson, Naomi Amudala, Carol McAlear, Renée Leduc, Denise Shereff, Rachel Richesson, Liana Fraenkel 4 and Peter A. Merkel 5, Boston University Medical Center, Boston, MA, Vasculitis Clinical Research Consortium, University of Pennsylvania, Philadelphia, University of South Florida, Tampa, FL, 4 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, 5 University of Pennsylvania, Philadelphia, PA 49. Balancing Work and Health: Do Younger Workers Experience More Work-Health Conflict Than Middle- and Older-Aged Workers with Rheumatic Diseases? Arif Jetha, Xingshan Cao and Monique A. Gignac, Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Arthritis Community Research and Evaluation Unit, Toronto Western Research Institute, Toronto, ON, Arthritis Community Research and Evaluation Unit, Toronto Western Research Institute, University of Toronto and Institute for Work and Health, Toronto, ON 40. Using the Internet in Help-Seeking As Illness Develops in Early Rheumatoid Arthritis. Anne F. Townsend, Jenny Leese, Catherine L. Backman, Paul M. Adam 4 and Linda C. Li 5, Arthritis Research Centre of Canada, Vancouver, BC, Arthritis Research Centre, Vancouver, BC, University of British Columbia, Vancouver, BC, 4 Mary Pack Arthritis Centre, Vancouver, BC, 5 Arthritis Centre of Canada and Department of Physical Therapy, University of British Columbia, Vancouver, BC 0 Program Book 5

318 INNOVATION THEATER These non-cme accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. All Innovation Theater presentations will be held in Hall A (Booth #45) at their designated time. Sunday, NOVEMBER, 0 0:0 - :5 am ACTEMRA Monotherapy: From Clinical Trial Experience to Clinical Practice Presented by Genentech, a member of the Roche Group :0 - :5 pm Role of Multi-Biomarker Test in RA Patient Management Presented by Crescendo Bioscience Monday, NOVEMBER, 0 0:0 - :5 am Rituxan RA - Pivotal and Long-term Efficacy and Safety Data Presented by Genentech, a member of the Roche Group Tuesday, NOVEMBER, 0 0:0 - :5 am Evaluation of Clinical Endpoints for SLE Disease Activity in Worldwide Clinical Trials: Optimization of Treatment Effects through Targeted Training and Centralized Data Review Presented by ReSearch Pharmaceutical Services, Inc. :0 - :5 pm Are You Using Your Father s Prednisone to Treat Your Mother s RA?: New Understanding of a Familiar Therapy Presented by Horizon Pharma :0 - :5 pm Pathophysiology of Pain: Processes, Plasticity, and Perception Presented by Lilly USA, LLC :0 - :5 pm Introducing an Innovative New Patient Educational and Support Program Presented by Janssen Biotech, Inc. :0 - :5 pm Case Studies: Practical Management of Gout Presented by Takeda Pharmaceuticals 6 0 Program Book

319 INDUSTRY-SUPPORTED SYMPOSIA Sunday, NOVEMBER, 0 6:0 PM Non-CME Symposium The event listed below is a non-cme Programs wholly sponsored and supported by the commercial entities listed. By holding the Program, the commercial entity has represented that the Program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the Program. The content and views expressed during the Program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the Program nor the products discussed and reviewed during the Program. Innovative pathways in science and patient care: From genetic and therapeutic discovery to 5 years of clinical experience Developed and offered by Abbott Third-Party Organization: MedEd Link Grand Hyatt, Independence Ballroom Learning Objectives Upon completion of this activity, participants should be able to: review the discovery of TNF-alpha, the role it has on the inflammatory process and the impact it has had on developing treatments for inflammatory diseases review the development of HUMIRA to specifically target TNF-alpha and the role inhibiting TNF-alpha plays in the chronic inflammatory diseases have a deeper understanding of the impact of 5 years of clinical trial experience 6:0-7:00 PM Registration and Dinner 7:00-7:05 PM Introductions and Program Overview Dr. Arthur Kavanaugh, Professor of Clinical Medicine, Director of Center for Innovative Therapy, UC San Diego, School of Medicine 7:05-7:5 PM Discovery of TNF-α Nobel Prize Winner, Dr. Bruce Beutler, UT Southwestern Medical Center, Center for the Genetics of Host Defense 7:5-8:00 PM Targeting TNF-α: Discovery and Development of HUMIRA Dr. Jochen Salfeld, Divisional Vice President, Abbott Bioresearch Center 8:00 8:0 PM Patient Case Study & Clinical Review 4 years of clinical experience Dr. Arthur Kavanaugh, Professor of Clinical Medicine, Director of Center for Innovative Therapy, UC San Diego, School of Medicine 8:0 8:40 PM Question and Answer session with the faculty Led by Dr. Kavanaugh, with participation by Dr. Jochen Salfed and Dr. Bruce Beutler 8:40 pm 9:00 PM Dessert and Refreshments 6:0 PM CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Treatment of SLE: Bridging the Gap from Clinical Trials to Practice Supported by an educational grant from Human Genome Sciences, INC. Sponsored by Cleveland Clinic Grand Hyatt, Constitution Ballroom Physician (ACCME) Accreditation Statement The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of.0 AMA PRA Category Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement As research into the biologic basis of SLE pathogenesis and the therapeutic management of the disease rapidly moves forward, achieving optimal patient outcomes depends on increasing rheumatologists medical understanding of the molecular and cellular basis of SLE pathogenesis is crucial to improving outcomes in these patient populations. Many clinicians have knowledge gaps regarding the latest SLE clinical research, biologic agents, and targeted therapies, creating a need for an educational activity in which experts compile and critically appraise new evidence and interpret its implications for clinical practice. Learning Objectives Upon completion of this activity, participants should be able to: recognize the common clinical features of SLE that are most likely to require therapy and describe how they affect morbidity and mortality summarize the algorithms of care for generalized SLE and organ-specific disease associated with SLE compare and contrast the efficacy and utility of instruments and techniques for monitoring disease activity summarize leading pathogenic theories and describe the role of B cells in the integrated immune response as they relate to SLE pathogenesis assess data from recent clinical trials of novel therapeutics targeting related pathways describe biologic agents (including preclinical development, early to late stage trials, etc.) for SLE treatment, their mechanism of action, side effects, and clinical indications highlight important long-term extension data from phase trials and assess the potential impact on clinical practice 6:0-7:0 PM Registration and Dinner 7:0-7:40 PM Introduction Historical Overview of SLE Therapy Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 7:40-8:00 PM SLE Unmet Medical Needs and Therapeutic Standards of Care Bevra Hahn, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA 0 Program Book 7

320 INDUSTRY-SUPPORTED SYMPOSIA 8:00 8:0 PM Measuring Disease Activity & Severity in Clinical Trials and the Clinic- Same or Different? Michelle Petri, MD, MPH, Johns Hopkins University School of Medicine, Baltimore, MD 8:0-8:40 PM B Cell Dysregulation and the Pathogenesis of SLE Peter Lipsky, MD, Arthritis Research and Therapy, Bethesda, MD 8:40-9:00 PM Clinical Impact of Biologic Therapies in the Treatment of SLE Daniel Wallace, MD, Cedars-Sinai Medical Center, Los Angeles, CA 9:00-9:0 PM Panel Discussion All Faculty 6:0 PM Non-CME Symposium The event listed below is a non-cme Programs wholly sponsored and supported by the commercial entities listed. By holding the Program, the commercial entity has represented that the Program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the Program. The content and views expressed during the Program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the Program nor the products discussed and reviewed during the Program. Women s Health Issues in Rheumatology: Challenges, Concerns and Considerations Developed and offered by UCB, Inc. Third-Party Organization: ETHOS Health Communications Renaissance Hotel, Renaissance Ballroom Learning Objectives Upon completion of this activity, participants should be able to: identify and discuss clinical challenges in women s health across a spectrum of rheumatic diseases relate the physical and emotional impact of family planning for women living with chronic inflammatory diseases delineate future areas of research, clinical strategies and guidelines development in this area 6:0-7:00 PM Registration and Dinner 7:00-7:05 PM Welcome and Introductions Megan Clowse, MD, MPH, Duke Medical Center, Durham, NC 7:05-7:0 PM Overview of Issues in Women s Health in Rheumatic Disease Eliza Chakravarty, MD, Oklahoma Medical Research Foundation, Oklahoma City, OK 7:0-7:0 PM Women and Rheumatoid Arthritis: The Patient Perspective Patient of Dr. Clowse and Dr. James 7:0-7:50 PM Effects of Infertility, Pregnancy Loss and Patient Concerns on Family Size of Women with Rheumatoid Arthritis Megan Clowse, MD, MPH, Duke Medical Center, Durham, NC 7:50-8:0 PM Obstetric Care & Complications in Rheumatic Diseases Andra James, MD, University of Virginia, Charlottesville, VA 8:0-8:0 PM Preconceptional Counseling in Women with Rheumatic Disease Monika Østensen MD, PhD, University of Bern, Bern, Switzerland 8:0-8:55 PM Question and Answer Session/ Panel Discussion 9:00 PM Conclusion and Closing Remarks Megan Clowse, MD, MPH, Duke Medical Center, Durham, NC Tuesday, NOVEMBER, 0 6:0 PM Non-CME Symposium The event listed below is a non-cme Programs wholly sponsored and supported by the commercial entities listed. By holding the Program, the commercial entity has represented that the Program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the Program. The content and views expressed during the Program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the Program nor the products discussed and reviewed during the Program. Navigating the Course of Psoriatic Disease Look Inside for a New Perspective Developed and offered by Celgene Third-Party Organization: Veraxis Health Communications Grand Hyatt, Constitution Ballroom Learning Objectives Upon completion of this activity, participants should be able to: understand the burden of psoriatic disease and the design and methodology of the Global Psoriasis Survey explain the inflammatory basis of psoriatic disease discuss the diagnosis and management of psoriatic arthritis 6:0-7:00 PM Registration/ Beverages & Hors d oeuvres 7:00-7:05 PM Welcome, Introductions, and Opening Remarks Arthur Kavanaugh, MD, University of California, San Diego School of Medicine, San Diego, CA 7:05-7:5 PM Understanding the Burden of Psoriatic Disease: Design and Methodology of the Global Psoriasis Survey Arthur Kavanaugh, MD, University of California, San Diego School of Medicine, San Diego, CA 8 0 Program Book

321 INDUSTRY-SUPPORTED SYMPOSIA 7:5-7:45 PM Psoriatic Arthritis: Mechanism of Disease Iain B. McInnes, MBCHB FRCP FMedSci, University of Glasgow, Glasgow, Scotland 7:45-8:05 PM Challenges in Diagnosis and Management of Psoriatic Arthritis Philip Mease, MD, University of Washington, Seattle, WA 8:05-8:0 PM Question and Answer Panel 6:0 PM CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Osteoarthritis Update: Bridging the Gap between NSAIDs and Surgery Supported by an educational grant from Eli Lilly Sponsored by Creative Educational Concepts Renaissance Hotel, Congressional Ballroom Physician (ACCME) Accreditation Statement Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement CEC designates this educational activity for a maximum of.0 AMA PRA Category Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the activity. Needs Assessment Statement Osteoarthritis (OA) is one of the leading causes of disability in the United States (US), and it represents a significant burden on the US healthcare system. Approximately half of persons over the age of 65 report having OA, making arthropathies the fifth most common office visit diagnosis. Projections regarding the rate of hip and knee revisions, which are typically last-line therapies, have provided that they are expected to expand dramatically over the coming decades. Because of this, there is a need for more effective methods to treat the pain associated with OA and this activity will provide clinicians with the tools necessary to bridge the chasm that exists between first-line therapies and total joint replacement. Learning Objectives Upon completion of this activity, participants should be able to: identify the different pathophysiologic processes responsible for the generation of pain in osteoarthritis differentiate how the mechanisms responsible for producing pain affect the appropriate selection of therapeutic agents evaluate the risks and benefits of new treatment options in OA, and identify how they fit within the existing treatment paradigm 6:0-7:00 PM Registration and Dinner 7:00-7:0 PM Welcome and Introductions Marc Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD 7:0-7:5 PM Advances in Understanding the Mechanisms of Pain in Osteoarthritis C. Kent Kwoh, MD, University of Pittsburgh, Pittsburgh, PA 7:5-8:00 PM Bridging the Gap I: Pharmaceutical Options in Patients with an Inadequate Response to NSAIDs Marc Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD 8:00-8:5 PM Bridging the Gap II: Intra-articular Therapies in Osteoarthritis Roy D. Altman, MD, University of California, Los Angeles, Los Angeles, CA 8:5-9:00 PM Conversations with the Experts: Audience Q&A Moderated by Marc Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD Wednesday, November 4, 0 :00 PM CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Treatment Success in Osteoarthritis: Advances in Pharmacologic Therapy Supported by an educational grant from Bioiberica S.A. Sponsored by Medical Education Resources Renaissance Hotel, Grand Ballroom North Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications (CMC). MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement MER designates this live activity for a maximum of.5 AMA PRA Category Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement Effective treatment of OA must focus on addressing all aspects of pathophysiology, including preventing cartilage loss and damage to the joint. Current data support the use of chondroitin sulfate, alone or in combination with glucosamine, as an effective treatment for patients with OA. These substances may result in an improvement of quality of life for patients with OA as well as significantly reduce the costs this disease generates in society. This program will investigate the pathophysiology of osteoarthritis, review the pharmacologic actions and clinical efficacy of chondroitin sulfate and glucosamine, and discuss strategies to effectively manage patients with OA. Learning Objectives Upon completion of this activity, participants should be able to: discuss the pathophysiology of osteoarthritis and identify diseasemodifying strategies to reduce disability describe the synergistic effects of concomitant glucosamine and chondroitin sulfate therapy in the prevention of osteoarthritis joint damage discuss currently available clinical data on the use of chondroitin sulfate, with or without glucosamine, in the treatment of osteoarthritis :00 - :0 PM Registration and Lunch 0 Program Book 9

322 INDUSTRY-SUPPORTED SYMPOSIA :0 - :5 PM Welcome and Introduction Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD :5 - :40 PM The Pathophysiology of Osteoarthritis Virginia Byers Kraus, MD, PhD, Duke University Medical Center, Durham, NC :40 - :55 PM Synovitis in Osteoarthritis: How Important Is It? Timothy E. McAlindon, MD, MPH, Tufts University School of Medicine, Boston, MA :55 - :0 PM Synovium Angiogenesis: A New Therapy Target for Osteoarthritis Treatment Yves Henrotin, PhD, University of Liege, Liege, Belgium :0 - :5 PM Chondroitin Sulfate May Reduce Total Knee Replacement in a -month Multicentre Clinical Trial in Knee Osteoarthritis: Results from a 4- Year Observation Jean-Pierre Pelletier, MD, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Quebec, Canada :5 - :40 PM Can Chondroitin Sulfate and Glucosamine Combination Reduce Total Knee Replacement? Patrick du Souich, MD, PhD, University of Montreal, Montreal, Quebec, Canada :40 - :55 PM Question and Answer Session :55 :00 PM Concluding Remarks Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD :00 PM CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Selecting Appropriate Biologic Therapy for RA: A Practical Evaluation of Comparative Effectiveness Data Supported by an educational grant from Bristol-Myers Squibb Jointly sponsored by PeerView Institute for Medical Education, Inc. and University of Florida College of Medicine Renaissance Hotel, Congressional Ballroom Physician (ACCME) Accreditation Statement The University Of Florida College Of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement The University of Florida College of Medicine designates this live activity for a maximum of.0 AMA PRA Category Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement Rheumatologists and other professionals managing RA have an expanding range of management options available; however, it is imperative that these therapies are used appropriately. Although the body of evidence shows that biologic DMARDs are effective in treating RA, there has been a scarcity of head-to-head comparison studies, a barrier that has confounded the establishment of clear guidelines on how biologic DMARDs should be used and sequenced in the clinic. As an increasing amount of comparative effectiveness research begins to yield evidence which can potentially inform clinical decisions, it is essential to keep rheumatologists and other professionals abreast of these emerging studies to begin to clarify the appropriate selection of biologic therapy for RA with the ultimate goal of improving long term patient outcomes. It is imperative that rheumatologists and other clinicians managing RA remain updated on recent advances in the management of this disease, and are aware of practical strategies for implementing treatment to a main goal of remission. Appropriate use of biologic therapy is particularly important, as these drugs have the potential to change the natural history of RA. Learning Objectives Upon completion of this activity, participants should be able to: recognize the impact of early treatment and tight control on long-term patient outcomes in RA discuss the current safety and efficacy data from direct head-to-head comparison studies of biologic therapies for RA compare and contrast the mechanisms of action and optimal use of biologic therapies for RA individualize biologic therapy for patients with RA based on patient factors and treat-to-target goals :00 - :0 PM Registration and Lunch :0 - :40 PM Welcome and Introduction :40 - :55 PM Comparative Effectiveness Data in Rheumatoid Arthritis: Is There A Need? Professor Paul Emery, University of Leeds, Leeds, United Kingdom :55 - :0 PM Head-to-Head Trials Comparing Biologic Therapies in Rheumatoid Arthritis: Clinical Implications of the Data Cem Gabay, MD, University Hospitals of Geneva, Geneva, Switzerland :0 - :5 PM Mid-Session Panel Discussion & Ask the Faculty :5 - :50 PM Clinical Trial Design in Rheumatoid Arthritis: Past, Present, and Future Josef S. Smolen, MD, Center for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria :50 - :0 PM Case-Based Expert Roundtable Discussion: Contemporary Implementation of Biologic Therapies in Rheumatoid Arthritis All Speakers :0 - :0 PM Ask the Faculty and Conclusions 0 0 Program Book

323 INDUSTRY-SUPPORTED SYMPOSIA :00 PM CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Debating the Future of RA Management: Focus on the Mechanisms of Action and Roles of Novel Agents, A Core Symposium Supported by an educational grant from MedImmune, LLC Sponsored by North American Center for Continuing Medical Education, LLC (NACCME) Renaissance Hotel, Grand Ballroom South Physician (ACCME) Accreditation Statement North American Center for Continuing Medical Education, LLC (NACCME), is accredited by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nurses Credentialing Center to provide continuing education for the healthcare team. Credit Designation Statement NACCME designates this live activity for a maximum of.0 AMA PRA Category Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This continuing nursing education activity awards.00 contact hours. Provider approved by the California Board of Registered Nursing, Provider #55 for.00 contact hours. Needs Assessment Statement Rheumatologists understand that RA is a chronic disease that requires aggressive treatment and monitoring; the challenge is to improve clinical inertia with clinical measurement tools and timing of treatment decisions. Education on the value of measurement tools, what constitutes an inadequate response, how to switch between biologic agents, and emerging treatment options will provide rheumatologists with the knowledge and confidence to adopt the necessary practice changes to improve patient health. Learning Objectives Upon completion of this activity, participants should be able to: align RA treatment strategies with updated diseases classification and remission criteria outline and overcome controllable factors and available therapy shortfalls that impact patient adherence to therapy describe the safety and efficacy of newer and emerging treatment options for RA management correlate the mechanisms-of-action of novel therapies to their potential role in patient-centric treatment :00 - :0 PM Registration and Lunch :0 - :00 PM Crossfire Presidential Debate Pursuing updated remission criteria through aggressively treating RA with available agents Overcoming controllable factors that impact patient adherence to therapy Safety and efficacy of newer and emerging biologics for RA management Matching the mechanisms-of-action of novel therapies to their potential role in patient-centric treatment Moderator: Leonard H. Calabrese, DO, Case Western Reserve University, Cleveland, OH Co-Presenters: Bernard Combe, MD, PhD, Université Montpellier, Montpellier, France Jeffrey Curtis, MD, MS, MPH, University of Alabama at Birmingham, Birmingham, AL Daniel E. Furst, MD David Geffen School of Medicine at UCLA, Los Angeles, CA :00 - :0 PM Closing Arguments and Audience Voting :00 PM CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Challenging Gout: Newest Recommendations and Emerging Treatments Jointly sponsored by Interstate Postgraduate Medical Association and MedEdRules, LLC. Supported by an educational grant from Savient Pharmaceuticals, Inc. Renaissance Hotel, Renaissance Ballroom Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Interstate Postgraduate Medical Association (IPMA) and MedEdRules, LLC. (MEDEDR). IPMA is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement IPMA designates this live activity for a maximum of.0 AMA PRA Category Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Continuing Education Units IPMA is approved by the California Board of Registered Nursing, provider number 697, for.4 contact hours. Each person should retain this certificate for 4 years after the course has been completed. RNs outside of California must verify with their licensing agency for approval of this course. 0 Program Book

324 INDUSTRY-SUPPORTED SYMPOSIA Needs Assessment Statement IPMA and MEDEDR have completed a detailed needs assessment of the educational needs of clinicians who are interested in improving patient outcomes in gout. This needs assessment is based upon feedback from previously successful CME interventions, interviews with experts in the field, and a thorough literature search. This needs assessment shows awareness and knowledge transfer is needed to help the rheumatologist and related health care provider (including primary care, podiatrists and nephrologists) better manage patients with gout, including those with comorbid conditions as well as those who are difficult to manage or become refractory to therapy. Rheumatologists and other clinicians must be able to tailor an individualized management strategy utilizing the most advanced treatment options available. Educational gaps include the following: clinicians do not provide consistent treatment; clinicians may not appreciate the seriousness of the disease; clinicians may not recognize the debilitating effects of advanced crystal deposition in gout; clinicians need to identify common comorbidities in patients associated with advanced gout and effectively manage these patient types; clinicians need to keep updated on the safety, efficacy, and use of all available gout treatment options, including new and emerging therapies. Learning Objectives Upon completion of this activity, participants should be able to: assess the ascending level of disease in patient case studies, including evaluation of serum urate, pain and inflammation, joint destruction, and quality of life, and understand the evidence supporting options to lower urate levels, treat inflammation, and prevent joint destruction in refractory disease devise a long-term management plan, within each case study, to treat the patient effectively according to their level of disease select the appropriate individualized medical regimen based on the most recent recommendations, taking into consideration the efficacy and safety profiles and risk-benefit ratios of available therapies discuss how emerging agents for gout might address the therapeutic needs of treatment-refractory patients :00 - :0 PM Registration and Refreshments :0 - :5 PM Welcome, Introduction, Overview Jonathan Kay, MD, UMass Memorial Medical Center, Worchester, MA :5 - :05 PM Case Study : Approaching the Gout Patient with Frequent Flares Jonathan Kay, MD, UMass Memorial Medical Center, Worchester, MA :05 - :5 PM Case Study : Current Modalities and Latest Recommendations for Treatment of Monoarticular Flares Robert Keenan, MD, MPH, Duke University Medical Center, Durham, NC :5 - :0 PM Case Study : Challenging Gout - How to Treat the Refractory Patient Robert Terkeltaub, MD, Veterans Affairs Medical Center; San Diego, CA :0 - :0 PM Summary and Question and Answer Session 0 Program Book

325 CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: The ACR designates this live educational activity for a maximum of AMA PRA Category credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. International Physicians: International physicians who register as part of a group and require AMA PRA Category Credit(s), must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers, and address. The information will be used to verify your meeting attendance. The American Medical Association has an agreement of mutual recognition of continuing medical education credit with the European Union of Medical Specialties. International physicians interested in converting AMA PRA Category Credit to EACCME credit should contact the UEMS. Health Professionals: Participants may claim hours to receive a Certificate of Participation for an activity designated for AMA PRA Category Credit(s). For non-cme sessions, attendees may also request a certificate of participation. MEETING EVALUATIONS, CME CREDIT/ CERTIFICATES OF PARTICIPATION New this year! Use My Annual Meeting and the My Annual Meeting APP to complete your meeting and session evaluations online while tracking your participation as you go. Access My Annual Meeting at to or print your CME certificate or certificate of participation. Computers are also available for you to complete your CME/ Certificate of Participation and session evaluations online during the meeting at the CME/Internet Center located in the Concourse, near the entrance to the exhibit hall (Hall A). International physicians, requiring a Certificate of Attendance, can find one enclosed in your meeting bag. If your country recognizes AMA PRA Category Credit(s) in accordance with AMA PRA requirements, please complete the session evaluations and CME application online using My Annual Meeting or the My Annual Meeting APP. Your evaluation of the meeting is very important. The ACR/ ARHP annual meeting planning committees use feedback from attendees to assist in the development of future educational activities; therefore, we encourage you to complete your session evaluations and CME/Certificate application. Conflict of Interest/Disclosure Statements As an educational provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American College of Rheumatology must ensure balance, independence, objectivity and scientific rigor in all its educational activities. Therefore, all speakers and moderators participating in an ACR-sponsored activity are required to disclose to the planning committee and audience any financial or other relationships including, but not limited to: None: Nothing to disclose. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan. Research grants. Employment (full or part-time) 4. Ownership or partnership 5. Consulting fees or other remuneration (payment) 6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson 7. Receipt of royalties 8. Speakers bureau 9. Other Speakers, moderators and abstract authors submitted their disclosure online prior to publication. Disclosures for invited speakers are listed in the indices by presenters last name. Abstract author disclosures are published online and in a supplement to the October issue of Arthritis & Rheumatism. Disclosures for the late-breaking abstracts are published online and in the December issue of Arthritis & Rheumatism. Any individual who refuses to disclose relevant financial relationships will be disqualified from being a planning committee member, a presenter, an author of a CME activity, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. Disclosure Policy It is the policy of the American College of Rheumatology to ensure that its CME activities are independent and free of commercial bias. To ensure content objectivity and balance, and guarantee that the content presented is in the best interest of its learners and the public, the ACR requires that everyone in a position to control content disclose all relevant financial relationships with any commercial interest if the relationship is financial and occurred within the past months. If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content. This annual meeting is sponsored by the American College of Rheumatology for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare professionals at arriving at their own conclusions and consequent application. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the College for reliance on any information presented during these educational activities. The College does not guarantee, warrant or endorse any commercial products or services. 0 Program Book

326 0 ACR/ARHP ANNUAL MEETING LEADERSHIP Thank You! The ACR/ARHP board of directors extends its gratitude to the ACR/ARHP Annual Meeting Planning Subcommittee, ACR Abstract Oversight Committee, ACR Abstract Selection Committee, ARHP Abstract Review Panels, and ARHP Clinical Focus Task Force members for their leadership and volunteering their services to plan the 0 annual meeting. Their significant contributions and expertise make the annual meeting the premier event for specialists in the field of rheumatology. ACR/ARHP Annual Meeting Planning Subcommittee Chester V. Oddis, MD, ACR Chair Mary Cronin, MD, ACR Clinical Sub-chair Linda S. Ehrlich-Jones, PhD, RN, ARHP Chair Afton Hassett, PsyD, ARHP Chair Elect Carol A. Langford, MD, MHS, Abstract Selection Chair (Clinical) Richard F. Loeser, MD, ACR Basic Science Sub-chair Richard M. Pope, MD, Abstract Selection Chair (Basic) Mary-Chester Wasko, MD, MSc, ACR MTP/ Workshop/Study Group Sub-chair Joel A. Block, MD, ACR Immediate Past Chair Joan M. Bathon, MD, A&R Editor Thuy T. Beam, BSN Elana Bernstein, MD, Fellow Representative Hazel L. Breland, PhD, OTR/L S. Louis Bridges, Jr., MD, PhD Richard Bucala, MD, PhD Andrew P. Cope, MD, PhD Lindsey A. Criswell, MD, MPH Donna K. Everix, MPA, PT Fernando E. Figueroa, MD James G. Freeman, MD Gregory C. Gardner, MD Alexei A. Grom, MD Raymond Hong, MD, MBA, CORC Representative Shelly P. Kafka, MD Diane Kamen, MD Salahuddin Kazi, MD, RHIT Representative Sharon L. Kolasinski, MD Robert A. Lafyatis, MD Anne-Marie Malfait, MD, PhD Richard W. Martin, MD, MA Zsuzsanna McMahan, MD Victoria A. Merrell, PA-C, MPT Tuhina Neogi, MD, PhD, Quality Measures Committee Uyen Sa D. Nguyen, DSc, MPH Peter A. Nigrovic, MD Karen Onel, MD Elizabeth G. Salt, PhD, ARNP Kenneth N. Schikler, MD Victoria K. Shanmugam, MBBS Gregg J. Silverman, MD Jasvinder Singh, MD, MPH Robert F. Spiera, MD Virginia D. Steen, MD Margaret R. Wilkes, MD Laura C. Wright, MBA Ex Officio Members Richard A. Furie, MD, COE Chair James R. O Dell, MD, ACR President ACR/ARHP Abstract Oversight Committee Robert Fuhlbrigge, MD, PhD, Chair Shreyasee Amin, MD Emily Somers, PhD, ScM Steven Ytterberg, MD ARHP Clinical Focus Task Force Marie D. Westby, PT, PhD, Chair Jessica F. Farrell, PharmD Kathryn L. Lowenstein, OTR Taraneh Mehrani, MD ACR and ARHP Abstract Selection Committees (including category chairs and reviewers) Carol A. Langford, MD, MHS, ACR Clinical Science Chair, Abstract Selection Richard M. Pope, MD, ACR Basic Science Chair, Abstract Selection Elizabeth Salt, PhD, ARHP Abstract Selection Chair. Cytokines, Mediators, and Gene Regulation Erik Lubberts, PhD, Co-Chair Michael Volin, PhD, Co-Chair Sarah L. Gaffen, PhD Katalin Mikecz, MD, PhD Hendrik Schutze-Koops, MD, PhD Zoltan Szekanecz, MD, PhD. Cell-cell Adhesion, Cell Trafficking and Angiogenesis Shiva Shahrara, PhD, Co-Chair Douglas J. Veale, MD, Co-Chair Alexander D. Fraser, MD Charles J. Malemud, PhD David Walsh, MD Song G. Zheng, MD, PhD. Innate Immunity and Rheumatic Disease Susan A. Boackle, MD, Co-Chair Diego Kyburz, MD, Co-Chair Maripat Corr, MD Mariana J. Kaplan, MD Timothy Radstake, MD, PhD Ranjeny Thomas, MBBS, MD 4. B cell Biology and Targets in Autoimmune Disease Robert A. Eisenberg, MD, Co-Chair William Stohl, MD, PhD, Co-Chair Philip L. Cohen, MD Bevra H. Hahn, MD David A. Isenberg, MD Gregg J. Silverman, MD 5. T cell Biology and Targets in Autoimmune Disease Jorg J. Goronzy, MD, PhD, Co-Chair Joseph Holoshitz, MD, Co-Chair Alison Finnegan, PhD Shu-Man Fu, MD, PhD Terri M. Laufer, MD Linda K. Myers, MD 6. Biology and Pathology of Bone and Joint Hiroshi Asahara, MD, Co-Chair Mary C. Nakamura, MD, Co-Chair Antonios O. Aliprantis, MD Di Chen, MD, PhD Mary B. Goldring, PhD Mary Beth Humphrey, MD, PhD 7. Osteoarthritis Clinical Aspects Joanne M. Jordan, MD, MPH, Co-Chair Tuhina Neogi, MD, PhD, FRCPC, Co-Chair Martin Englund, MD, PhD William F. Harvey, MD, MSc Najia Shakoor, MD Leena Sharma, MD 4 0 Program Book

327 0 ACR/ARHP ANNUAL MEETING LEADERSHIP 8. Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis Robin K. Dore, MD, Co-Chair Anthony D. Woolf, MBBS, Co-Chair Chad L. Deal, MD Andrew J. Laster, MD Willem F. Lems, MD, PhD S. Bobo Tanner, MD 9. Fibromyalgia and Soft Tissue Disorders Daniel J. Clauw, MD, Co-Chair Mary-Ann Fitzcharles, MBChB, MD, Co-Chair Jacob N. Ablin, MD Dennis C. Ang, MD Chad S. Boomershine, MD, PhD Pier Carlo Sarzi-Puttini, MD 0. Orthopedics, Low Back Pain, and Rehabilitation John D. FitzGerald, MD, PhD, Chair Jeffrey N. Katz, MD, Chair Erin L. Arnold, MD Aileen M. Davis, PhD M. Elaine Husni, MD, MPH Ernest R. Vina, MD, MSc. Pediatric Rheumatology Clinical and Therapeutic Aspects Daniel J. Lovell, MD, MPH, Co-Chair Rayfel Schneider, MBBCh, Co-Chair Emily von Scheven, MD, Co-Chair Carol A. Wallace, MD, Co-Chair Kristin M. Houghton, MD Daniel J. Kingsbury, MD Suzanne C. Li, MD, PhD Lakshmi N. Moorthy, MD, MS Karen Onel, MD Angelo Ravelli, MD Taunton R. Southwood, FRCP Richard K. Vehe, MD. Pediatric Rheumatology Pathogenesis and Genetics Alexei A. Grom, MD, Co-Chair Raphael Hirsch, MD, Co-Chair Abbe N. de Vallejo, PhD Anthony R. French, MD, PhD Kathryn S. Torok, MD James W. Verbsky, MD, PhD. Infection-related Rheumatic Disease John D. Carter, MD, Co-Chair Dimitrios Vassilopoulos, MD, Co-Chair Leonard H. Calabrese, DO Prashant Kaushik, MD James S. Louie, MD Frank B. Vasey, MD 4. Metabolic and Crystal Arthropathies Naomi Schlesinger, MD, Co-Chair John S. Sundy, MD, PhD, Co-Chair Michael A. Becker, MD Nicola Dalbeth, MBChB, MD Puja Khanna, MD H. Ralph Schumacher, MD 5. Muscle Biology, Myositis and Myopathies Ingrid E. Lundberg, MD, PhD, Chair Lauren M. Pachman, MD, Chair Dana P. Ascherman, MD Carol B. Lindsley, MD Lisa G. Rider, MD Jiri Vencovsky, MD, PhD 6. Imaging of Rheumatic Diseases John Carrino, MD, MPH, Co-Chair Wolfgang A. Schmidt, MD, Co-Chair Harry K. Genant, MD Ali Guermazi, MD Fiona M. McQueen, MBChB, MD Ralf G. Thiele, MD 7. Rheumatoid Arthritis Clinical Aspects Vivian P. Bykerk, MD, Chair Ernest Choy, MD, Chair Jon T. Giles, MD, Chair Merete L. Hetland, MD, PhD, DMSc, Chair Jonathan Kay, MD, Chair Eric L. Matteson, MD, MPH, Chair Rieke Alten, MD Neal S. Birnbaum, MD Lin A. Brown, MD Loreto Carmona, MD, PhD Paul F. Dellaripa, MD Kimme Hyrich, MD, PhD Shahin Jamal, MD, MSc Elizabeth W. Karlson, MD Yvonne C. Lee, MD, MMedSc Grant H. Louie, MD, MHS Eric M. Ruderman, MD Sergio Schwartzman, MD 8. Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy John J. Cush, MD, Co-Chair Daniel E. Furst, MD, Co-Chair Joseph A. Markenson, MD, Co-Chair Richard W. Martin, MD, MA, Co-Chair Josef S. Smolen, MD, Co-Chair Daniel H. Solomon, MD, MPH, Co-Chair Martin Aringer, MD CO Bingham, MD Maya H. Buch, MBChB, MRCP, PhD Marc D. Cohen, MD Aaron T. Eggebeen, MD Roy Fleischmann, MD Andrew J. Head, MD Kathryn Hobbs, MD Arthur Kavanaugh, MD Marc C. Levesque, MD, PhD Alan K. Matsumoto, MD Mark H. Wener, MD 9. Rheumatoid Arthritis Human Etiology and Pathogenesis Alisa E. Koch, MD, Co-Chair David S. Pisetsky, MD, PhD, Co-Chair Andrew P. Cope, MD, PhD Gary S. Firestein, MD Pierre Miossec, MD, PhD William H. Robinson, MD, PhD 0. Rheumatoid Arthritis Animal Models Harris R. Perlman, PhD, Co-Chair Charles S. Via, MD, Co-Chair Ewa Cairns, PhD Tibor T. Glant, MD Thomas Pap, MD Wim van den Berg, PhD. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics Murray Baron, MD, Co-Chair Robyn T. Domsic, MD, MPH, Co-Chair Tracy M. Frech, MD Jerry A. Molitor, MD, PhD Luc Mouthon, MD Ami A. Shah, MD, MHS 0 Program Book 5

328 0 ACR/ARHP ANNUAL MEETING LEADERSHIP. Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Arnold E. Postlethwaite, MD, Co-Chair Richard M. Silver, MD, Co-Chair Francesco Boin, MD Oliver Distler, MD Robert Lafyatis, MD Marco Matucci-Cerinic, MD, PhD. Sjögren s Syndrome Gabor G. Illei, MD, Co-Chair Xavier Mariette, MD, PhD, Co-Chair Simon J. Bowman, PhD Lindsey A. Criswell, MD, MPH E. William St. Clair, MD Athanasios G. Tzioufas, MD 4. Antiphospholipid Syndrome Doruk Erkan, MD, Co-Chair Pierluigi Meroni, MD, Co-Chair Laura Andreoli, MD Maria Laura Bertolaccini, MD, PhD Pojen P. Chen, PhD Roger A. Levy, MD, PhD 5. Systemic Lupus Erythematosus Clinical Aspects and Treatment Maria Dall Era, MD, Co-Chair Kenneth C. Kalunian, MD, Co-Chair Elena M. Massarotti, MD, Co-Chair Michelle Petri, MD, MPH, Co-Chair Rosalind Ramsey-Goldman, MD, Co-Chair Daniel J. Wallace, MD, Co-Chair Graciela S. Alarcon, MD, MPH Anca Askanase, MD, MPH Jose A. Gomez-Puerta, MD, PhD Jennifer M. Grossman, MD Meenakshi Jolly, MD, MS Diane L. Kamen, MD, MS S. Sam Lim, MD, MPH Meggan C. Mackay, MD Maureen A. McMahon, MD Juanita Romero-Diaz, MD Emily C. Somers, PhD, ScM David Wofsy, MD 6. Systemic Lupus Erythematosus Human Etiology and Pathogenesis Mary K. Crow, MD, Co-Chair Vasileios C. Kyttaris, MD, Co-Chair Jill P. Buyon, MD Judith A. James, MD, PhD Insoo Kang, MD Andras Perl, MD, PhD 7. Systemic Lupus Erythematosus Animal Models Keith B. Elkon, MBBCh, Co-Chair Ram P. Singh, PhD, Co-Chair Anne Davidson, MBBS Dwight H. Kono, MD Ann Marshak-Rothstein, PhD John D. Mountz, MD, PhD 8. Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment Daniel O. Clegg, MD, Co-Chair Luis R. Espinoza, MD, Co-Chair Robert D. Inman, MD, Co-Chair Neil J. McHugh, MB, ChB, Co-Chair Desiree van der Heijde, MD, PhD, Co-Chair Michael H. Weisman, MD, Co-Chair Maxime Dougados, MD Dirk Elewaut, MD, PhD Oliver M. FitzGerald, MD Lianne S. Gensler, MD Jeffrey R. Lisse, MD Walter P. Maksymowych, MD Andreas M. Reimold, MD John D. Reveille, MD Enrique R. Soriano, MD, MSc Rafael R. Valle, MD Filip Van den Bosch, MD, PhD Michael M. Ward, MD 9. Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Robert A. Colbert, MD, PhD, Co-Chair Joachim Sieper, MD, Co-Chair Shervin Assassi, MD, MS Dominique L. Baeten, MD, PhD Maxime A. Breban, MD, PhD Siba P. Raychaudhuri, MD 0. Vasculitis Rula Hajj-Ali, MD, Co-Chair Paul A. Monach, MD, PhD, Co-Chair Maria C. Cid, MD Loic Guillevin, MD Curry L. Koening, MD, MS Stuart M. Levine, MD. Epidemiology and Health Services Research Karen H. Costenbader, MD, MPH, Co-Chair Jeffrey R. Curtis, MD, MPH, MS, Co-Chair Lisa A. Mandl, MD, MPH, Co-Chair Ted R. Mikuls, MD, MSPH, Co-Chair Gabriela Schmajuk, MD, MS, Co-Chair Jasvinder A. Singh, MBBS, Co-Chair Cheryl Barnabe, MD, MSc Liron Caplan, MD, PhD Mariko L. Ishimori, MD Nasim A. Khan, MD Eswar Krishnan, MD Elena Losina, PhD Kaleb Michaud, PhD Vk Ranganath, MD Lee S. Simon, MD Laura Tarter, MD Evelyne Vinet, MD Jie Zhang, PhD. Quality Measures and Innovations in Practice Management and Care Delivery Gary L. Bryant, MD, Co-Chair Salahuddin Kazi, MD, Co-Chair C. J. Inman, MD, MS Eric D. Newman, MD Catalina Orozco, MD Kara H. Prescott, MD. Genetics, Genomics and Proteomics John B. Harley, MD, PhD, Co-Chair Betty P. Tsao, PhD, Co-Chair Gary S. Gilkeson, MD Robert M. Plenge, MD, PhD Soumya Raychaudhuri, MD, PhD Nan Shen, MD 4. Education Robert A. Kalish, MD, Co-Chair Joan Marie Von Feldt, MD, MSEd, Co-Chair Michael J. Battistone, MD Richard D. Brasington, MD John A. Flynn, MD Paulette C. Hahn, MD 6 0 Program Book

329 0 ACR/ARHP ANNUAL MEETING LEADERSHIP 5. Miscellaneous Rheumatic and Inflammatory Diseases W. Winn Chatham, MD, Chair Kristine M. Lohr, MD, MS, Chair Corey M. Hatfield, DO Richard M. Keating, MD Cummins Lue, MD Katherine K. Temprano, MD 6. Clinical Practice/Patient Care James G. Freeman, MD, Chair Marcia G. Chwalek, MS, RN, ANP Atul A. Deodhar, MD Beatriz Y. Hanaoka, MD Bernadette McNally, MS, PAC Leonard H. Sigal, MD 7. Education/Community Programs Linda S. Ehrlich-Jones, PhD, RN, Chair Paul M. Adam, MSW Janet S. Austin, PhD Susan J. Blalock, PhD Victoria Gall, PT, MEd Deanna S. Yamamoto, NP 8. Epidemiology and Public Health Uyen Sa D.T. Nguyen, DSc, MPH, Chair Alison H. Chang, PT, DPT, MS Yvonne M. Golightly, MS, PhD, PT Charles G. Helmick, MD Sunny Kim, PhD Robert R. McLean, DSc, MPH 9. Health Services Research Mary E. Christenson, PhD, PT, Chair Catherine L. Backman, OT, PhD Laura D. Bilek, PhD, PT Donna K. Everix, MPA, BS, PT Linda J. Pine, PharmD Elizabeth A. Schlenk, hd, RN 4. Psychology/Social Sciences Afton L. Hassett, PsyD, Chair E. M. Badley, PhD Carol M. Greco, PhD Vanessa L. Malcarne, PhD Perry M. Nicassio, PhD Karen L. Smarr, PhD 4. Rehabilitation Sciences Hazel L. Breland, PhD, OTR/L, Chair Nadine M. Fisher, EdD Julie J. Keysor, PhD, PT Andrea S. Martin, MSN, FNP-C Janet L. Poole, OTR, PhD Mary Wright, BS, OT 4. Research Methodology Elizabeth G. Salt, PhD, Chair Susan J. Bartlett, PhD Leigh F. Callahan, PhD Mary-Beth Coty, PhD, RN Kori A. Dewing, DNP, ARNP Una E. Makris, MD Basic Research Conference Abstract Reviewers Bruce N. Cronstein, MD Steffen Gay, MD Lionel B. Ivashkiv, MD John Varga, MD Clinical Research Conference Abstract Reviewers Laura E. Schanberg, MD Danie J. Clauw, MD Bruce N. Cronstein, MD 40. Pediatrics Thuy T. Beam, BSN, RN, Chair Susan Johnson, MSN Norma L. Liburd, MN Janalee Taylor, CNS, CPNP, MSN Akaluck Thatayatikom, MD Susan Tupper, PhD 0 Program Book 7

330 Corporate Roundtable The American College of Rheumatology Research Foundation has launched Journey to Cure a $60 million multi-year campaign to directly invest in two mission priorities rheumatology training and development, and diseasetargeted research. Journey to Cure serves as a rallying point to accelerate these mission priorities on a scale never before achieved. The Foundation thanks the Corporate Roundtable, including current Industry Roundtable members, for their exemplary support: Within Our Reach Pinnacle Donor Within Our Reach Partner Donor * Industry Roundtable members

331 Educate Network Discover You can do all this and more in the Exhibit Hall Educate Attend a session in the Innovation Theater L isten to a missed session in the SessionSelect Lounge L earn about the latest rheumatology products and services Network Meet for lunch in the food court Catch up in the networking lounges Connect with employers at Career Connection Discover New exhibitors Search the web on WiFi Way Sunday, November : :00 am 5:00 pm Monday, November : :00 am 5:00 pm Tuesday, November : :00 am 5:00 pm

332 0 Fellows Education Fund Through the Fellows Education Fund, the ACR is accelerating the education and training of the next generation of rheumatologists. The ACR Fellows Education Fund has a proven track record of successfully providing rheumatology fellows-in-training with outstanding educational opportunities to advance their knowledge and skills to treat an ever-changing patient population. The ACR thanks the following organizations for their support of the 0 Fellows Education Fund: Genentech, A Member of the Roche Group UCB, Inc. Janssen Biotech, Inc.

333 EXHIBITORS Abbott Pharmaceuticals Booth #: 005, Suite F ACP/Annals of Internal Medicine Nonprofit Organization, Publisher Booth #: 4 ACR Simple Tasks Nonprofit Organization Booth #: 94 Actelion Pharmaceuticals Pharmaceuticals Booth #: AESKU.DIAGNOSTICS Diagnostic Equipment/Products, Laboratory Equipment/Products Booth #: 40 American Regent, Inc. Pharmaceuticals Booth #: Amgen, Inc. Biotech, Pharmaceuticals Booth #: Amgen, Inc. and Pfizer Inc. Pharmaceuticals Booth #: Arthritis Foundation Nonprofit Organization Booth #: 04 Arthritis Health Monitor TV Publisher, TV Network Booth #: 4 Autoimmune Diseases Association Nonprofit Organization Booth #: Auxilium Pharmaceuticals Pharmaceuticals Booth #: 55, Besse Medical Distributor, Pharmaceuticals Booth #: 5 BioMed Central Publisher Booth #: 48 Bioventus, LLC Biotech, Therapeutic/Patient Aid Products Booth #: 4 Bristol-Myers Squibb Pharmaceuticals Booth #: 5 British Society for Rheumatology Nonprofit Organization Booth #: 06 Buzzy4Shots.com Laboratory Equipment/Products Booth#: 5 Cardinal Health Pharmacy Services Booth #: 59 Celgene Corporation Biotech, Pharmaceuticals Booth #: 89 Cellestis, a QIAGEN Company Biotech, Diagnostic Products Booth #: 84 Celltrion Healthcare Co., LTD Biotech, Pharmaceuticals Booth #: 6 Chugai Pharmaceutical Co., Ltd. Pharmaceuticals Booth #: 76 en.jsp Cleveland Clinic Nonprofit Organization Booth #: Clinical and Experimental Rheumatology Publisher Booth #: Compulink Business Systems, Inc. Office Software/Equipment Booth #: ContextMedia:Health s Rheumatoid Health Network Educational Materials for Patients Booth #: 4 CORRONA, Inc. Other: Registry Booth #: 509, Suite G Crescendo Bioscience, Inc. Diagnostic Equipment/Products Booth #: 47, Suite B CuraScript SD Pharmacy Services Booth #: 49 CVS/Caremark Specialty Pharmacy Pharmacy Services Booth #: 69 DePuy Mitek Medical Device Booth #: 5 eclinicalworks EHR Booth #: 57 Elsevier Publisher Booth #: 90 Esaote North America Diagnostic Equipment/Products Booth #: 4 Euroimmun US Biotech, Diagnostic Equipment/Products Booth #: Program Book

334 EXHIBITORS European League Against Rheumatism (EULAR) Nonprofit Organization Booth #: 5 Exhibitchek Market Research Booth #: 4 Ferring Pharmaceuticals Inc. Medical Device Booth #: 54 Fidia Pharma USA Medical Device Booth #: 64 Forest Pharmaceuticals, Inc. Pharmaceuticals Booth #: GE Healthcare Diagnostic Equipment/Products Booth #: 74 Genentech and Roche Biotech, Pharmaceuticals Booth #: Genzyme Biotech Booth #: 46 Gilead Sciences, Inc. Pharmaceuticals Booth #: 57 GlaxoSmithKline, LLC Pharmaceuticals Booth #: 08 Gout & Uric Acid Education Society (GUAES) Nonprofit Organization, Educational Materials for Patients Booth #: 05 Hologic Diagnostic Equipment/Products, Medical Device Booth #: Horizon Pharma, Inc. Pharmaceuticals Booth #: 545 www. horizonpharma.com Hospira Pharmaceuticals Booth #: Hospital for Special Surgery Nonprofit Organization Booth #: 9 Inova Diagnostics, Inc. Biotech, Diagnostic Equipment/Products Booth #: Intellogics Biotech, Distributor Booth #: 56 Janssen Biotech, Inc. Pharmaceuticals Booth #: 0, 6 Johns Hopkins Rheumatology Nonprofit Organization Booth #: 80 Journal of Rheumatology, The Publisher Booth #: 8 La Lettre Du Rhumatologue - Edimark Santé Publisher Booth #: 60 Letter to Editor Rheumatology Nonprofit Organization, Publisher Booth #: Lilly USA, LLC. Pharmaceuticals Booth #: 7A, 7B, 7C Lone Oak Medical Technology Diagnostic Equipment/Products, Medical Device Booth #: 45 Lupus Initiative, The Nonprofit Organization Booth #: 04 Mayo Clinic Nonprofit Organization Booth #: McKesson Specialty Health Distributor Booth #: 55 medac pharma, Inc. Pharmaceuticals Booth #: 847 MedImmune, LLC Biotech Booth #: 7 Merck Pharmaceuticals Booth #: 57 METEOR Nonprofit Organization, Office Software/ Equipment Booth #: 08 Metro Medical Supply Pharmacy Services Booth #: 849 metromedical.com Metroplex Clinical Research Center Research Booth #: 48 National Data Bank for Rheumatic Diseases Nonprofit Organization Booth #: 5 National Fibromyalgia Partnership Nonprofit Organization Booth #: 05 National Institute of Arthritis and Musculoskeletal and Skin Diseases Government Booth #: 0 Program Book

335 EXHIBITORS National Scleroderma Core Centers Contract Research Booth #: 09 Novartis Pharmaceuticals Corporation Pharmaceuticals Booth #: 8 Nutramax Laboratories, Inc. Nutritional Products Booth #: 68 NYU Langone Medical Center - NYU Hospital for Joint Diseases Nonprofit Organization Booth #: OMERACT Nonprofit Organization Booth #: 07 Optasia Medical, Inc Diagnostic Equipment/Products Booth #: 05 Organization of Teratology Information Specialists Contract Research, Registry Booth #: Ossur Americas Medical Device Booth #: 67 Oxford Immunotec Inc Diagnostic Products Booth #: 95 Oxford University Press Publisher Booth #: PANLAR Nonprofit Organization Booth #: PatientPoint Educational Materials for Patients, Publisher Booth #: Pfizer, Inc. Pharmaceuticals Booth #: 4, 74 Pulmonary Hypertension Association Nonprofit Organization Booth #: 0 Questcor Pharmaceuticals, Inc. Biotech, Pharmaceuticals Booth #: 44 Quidel Corporation Diagnostic Equipment/Products Booth #: R. J. Fasenmyer Center for Clinical Immunology Nonprofit Organization, Medical Conference Booth #: 9 RDL Reference Laboratory Diagnostic Products Booth #: 69 Regeneron Pharmaceuticals, Inc. Biotech, Pharmaceuticals Booth #: 47 ReSearch Pharmaceutical Services Contract Research Booth #: 44 Rheumatoid Patient Foundation Nonprofit Organization Booth #: 50 Rheumatology News Publisher Booth #: 49 Rheumatology Nurses Society Nonprofit Organization Booth #: 09 Rheumatology Practice News Publisher Booth #: 47 Roche Biotech, Pharmaceuticals Booth #: Suite J (40) Rottapharm Ltd Pharmaceuticals Booth #: 85 Sanofi Biosurgery Biotech Booth #: Savient Pharmaceuticals Biotech Booth #: 4, Suite C Scandinavian Journal of Rheumatology Nonprofit Organization Booth #: 0 Scleroderma Foundation Nonprofit Organization, Educational Materials for Patients Booth #: 0 Siemens Medical Solutions USA Inc. Diagnostic Equipment/Products, Imaging Core Lab Booth #: Silver Ring Splint Company Medical Device, Therapeutic/Patient Aid Products Booth #: 76 Sjogren s Syndrome Foundation Nonprofit Organization Booth #: 04 SNBL Contract Research Booth #: SOBI Biotech, Pharmaceuticals Booth #: Program Book

336 EXHIBITORS SonoSite Diagnostic Equipment/Products, Medical Device Booth #: 50 Spondylitis Association of America Educational Materials for Patients, Therapeutic/Patient Aid Products Booth #: 4 Springer Publisher Booth #: 46 Takeda Pharmaceuticals Pharmaceuticals Booth #: 6 The JAMA Network Publisher Booth #: 9 The Myositis Association Nonprofit Organization Booth #: 0 TheraTest Laboratories, Inc. Diagnostic Equipment/Products Booth #: 7 Trimer Biotech, LLC Biotech Booth #: TSI Healthcare Rheumatology PM & EHR Booth #: 44 UCB, Inc. Biotech Booth #: 7 United Regional Health Care System Recruitment Booth #: 45 UpToDate Wolters Kluwer Health Office Software/Equipment, Publisher Booth #: 59 US Pain Foundation Inc. Nonprofit Organization Booth #: 07 Value-Based Care in Rheumatology Publisher Booth #: Vasculitis Foundation Nonprofit Organization Booth #: Vindico Medical Education Publisher Booth #: 5 VQ OrthoCare Medical Device Booth #: 65 Wiley Blackwell Publisher Booth #: Program Book

337 ACKNOWLEDGEMENTS The ACR, the ARHP and the Foundation wish to thank the following organizations for providing support for the 0 ACR/ARHP Annual Meeting. Abbott Convention Center Banner Exhibit Hall Internet Centers Exhibit Hall Networking Lounges Amgen, Inc. Session Tracker Amgen, Inc. and Pfizer Inc Scientific Program Book Bristol-Myers Squibb Company Exhibit Hall Wi-Fi Way Exhibit Hall Aisle Signs Genentech, A Member of the Roche Group Convention Center Banner Hotel Key Cards Pfizer, Inc. Poster Hall Services Convention Center Digital Signs Savient Pharmaceuticals, Inc. Convention Center Banner Conference Notepad Exhibit Hall Floor Decals Takeda Pharmaceuticals U.S.A., Inc. Clinical Scenario Challenge Convention Center Digital Signs UCB, Inc. Convention Center Banner Conference Shuttle Buses Attendee Lounge 0 Program Book 5

338 ACKNOWLEDGEMENTS In addition to the support provided for the 0 ACR/ARHP Annual Meeting, the ACR, the ARHP and the Foundation wish to thank the following organizations for providing support for activities and programs held throughout the year. Abbott Corporate Roundtable, Leadership level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and November) Musculoskeletal Ultrasound Course for Rheumatologists Intermediate Musculoskeletal Ultrasound Course for Rheumatologists Train-the-Trainer Hands-on Workshop Student Achievement Award Medical and Pediatric Resident Research Award Health Professional Graduate Student Research Preceptorship Medical Student Clinical Preceptorship Medical Student Research Preceptorship Annual Meeting Industry-Supported Symposium Amgen, Inc. Corporate Roundtable, Leadership level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and November) Musculoskeletal Ultrasound Course for Rheumatologists Intermediate Musculoskeletal Ultrasound Course for Rheumatologists Train-the-Trainer Hands-on Workshop Amgen Pediatric Visiting Professorship Program Amgen Pediatric Research Award Amgen Fellowship Training Award ARHP Networking Forum Bioiberica Annual Meeting Industry-Supported Post-Conference Symposium Bristol-Myers Squibb Company Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Annual Meeting Industry-Supported Post-Conference Symposium Celgene Corporation Corporate Roundtable, Principal level Annual Meeting Industry-Supported Symposia Eli Lilly and Company Roundtable Member, Partner level* Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course 6 0 Program Book Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and November) Musculoskeletal Ultrasound Course for Rheumatologists Intermediate Musculoskeletal Ultrasound Course for Rheumatologists Train-the-Trainer Hands-on Workshop Annual Meeting Industry-Supported Symposium Genentech, A Member of the Roche Group Corporate Roundtable, Principal level Fellows Education Fund 0 ACR/ARHP Membership Directory Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Human Genome Sciences, Inc. Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Human Genome Sciences, Inc. Corporate Roundtable, Partner level* Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Annual Meeting Industry-Supported Symposium Janssen Biotech, Inc. Corporate Roundtable, Partner level* Fellows Education Fund ACR REF Rheumatology Scientist Development Award MedImmune, LLC Annual Meeting Industry-Supported Post-Conference Symposium Pfizer, Inc. Corporate Roundtable, Partner level* Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals (April and November) Musculoskeletal Ultrasound Course for Rheumatologists Intermediate Musculoskeletal Ultrasound Course for Rheumatologists Train-the-Trainer Hands-on Workshop Savient Pharmaceuticals, Inc. Annual Meeting Industry-Supported Post-Conference Symposium UCB, Inc. Corporate Roundtable, Partner level* Fellows Education Fund Winter Rheumatology Symposium Rheumatology Maintenance of Certification Course Rheumatology Training Directors Conference State-of-the-Art Clinical Symposium Clinical Focus Course: Targeted Approaches to Complex Pain Management CARE 0 ARHP Advanced Rheumatology Course ARHP Fundamentals of Rheumatology Course Annual Meeting Industry-Supported Symposium *Industry Roundtable Member

339 A Abelson, Abby, MD Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Abramson, Steven B., MD Extra-articular Involvement in Rheumatoid Arthritis... Disclosure: Pfizer Inc., 5 Microbiome Influence on Autoimmunity.. 0 Disclosure: Pfizer Inc., 5 Adams, Harold, MD Update on Stroke... Disclosure: Medical Review Ltd Japan, 8; Medtronic, 5; Merck Pharmaceuticals, 5; Pierre Fabre, 8 Agace, William, PhD Molecular and Cellular Basis of Tissue Homing...9 Aggarwal, Rohit, MD, MS Plenary Session II: Discovery Airth-Edblom, Tracey L., OTR, CHT Hands: Non-Surgical Management and Bracing - What You Don t Know Can Hurt You...7 Al Haj, Rany, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists...0, Al Nahlawi, Basma, MD Thieves Market Poster Presentation - Development of Leprosy After Treatment With IL6 Blocker...6 Alexanderson, Helene, PhD, RPT Myositis: Pathogenesis, Diagnosis and Management...0 Alheresh, Rawan, OT, MSc Promoting Participation: Where Is the Field and Where Do We Go Next?...89 Ali, Joseph, JD Clinical Research Conference - Special Issues in Pain Research... Allen, Kelli D., PhD Demystifying the Study Section: How Grants Are Reviewed and Scored...79 Alonzo, Chris Practice Managers: Improving Access and Website Marketing...46 Ampel, Neil M., MD Fungal Infections and Tuberculosis in Patients with Rheumatologic Disease...9 Andrade, Luis Eduardo C., MD, PhD Making Sense of Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases.. 9 Disclosure: Fleury Medicine and Health Laboratories, 5 Antolini, C. Ryan, MD Creating an Efficient Rheum Practice...6 Aranow, Cynthia, MD Systemic Lupus Erythematosus: Central Nervous System (009)... Systemic Lupus Erythematosus: Central Nervous System (076)...0 Arnold, Lesley M., MD Clinical Research Conference - Clinical Trials Disclosure: Daiichi Sankyo, 5; Dainippo Sumtomo Pharma, 5; Eli Lilly and Company, ; Forest Laboratories,, 5; Grunenthal, 5; Pfizer Inc,, 5, 8; Takeda, ; Theravance, 5 Depression in Rheumatic Diseases...80 Disclosure: Daiichi Sankyo, 5; Dainippo Sumtomo Pharma, 5; Eli Lilly and Company, ; Forest Laboratories,, 5; Grunenthal, 5; Pfizer Inc,, 5, 8; Takeda, ; Theravance, 5 Arriens, Cristina, MD Thieves Market Poster Presentation - Stridor Thieves Market: Show Me Your Best Cases Ascherman, Dana P., MD Myositis: Pathogenesis, Diagnosis and Management...0 Avecilla, Sunjanel, EMT-P, CPC, CMC, CMOM, CMIS, CMCO CORC Pre-meeting Course for Practice Managers - Improving Accounts Receivable for Profitability...7 CORC Pre-meeting Course for Practice Managers - Transforming the Practice Front End...7 B Baer, Alan N., MD Controversies in Sjögren s Syndrome (05).. 88 Disclosure: Cellgene, 5; Merck Serono, 5 Controversies in Sjögren s Syndrome (00).. Disclosure: Cellgene, 5; Merck Serono, 5 Bahrami, Soon, MD Dermatology Topics for Rheumatologists: What You Need to Know...8 Baker, Nancy A., MPH, OTR, OTR/L A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective...97 Balow, James E., MD Update on Treatment of Systemic Lupus Erythematosus...9 Baraf, Herbert S. B., MD Contract Negotiations for Physicians...9 CORC Pre-meeting Course for Practice Managers - Deal Breakers in Payer Contract Negotiations...7 Bartlett, Susan J., PhD Clinical Focus Course - Obesity and Osteoarthritis: Clinicians Can Make a Difference in Promoting Healthier Lifestyles...7 Complementary and Alternative Medicine: Evidence Based Options for Arthritis Patients...9 New and Better Habits! Facilitating Patient Self-management with Proven Behavior Change Strategies...59 Bathon, Joan M., MD Tips for Publishing Your Work in a Peer- Reviewed Medical Journal...0 Battistone, Michael J., MD Medical Education: The Year in Review... Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Beam, Thuy T., BSN, RN Forming an Education and Support Group from the Ground Up...8 Obesity in Rheumatic Diseases of Children and Adults... Transition Tools for Patients: Pediatric to Adults... Becker, Mara L., MD, MSCE Pediatrics: Juvenile Idiopathic Arthritis for Adult Rheumatologists (066)...9 Crystal: Diagnosis and Management of Gout (0)...60 Disclosure: Ardea Biociences INC, 5; BioCryst Pharmaceuticals Inc, 5; Metabolex Pharmaceuticals Inc, 5; Regeneron Pharmaceuticals Inc, 5; Savient Pharmaceuticals Inc, 5; Takeda Pharmaceuticals Inc, 5; UpToDate Inc, 7; URL Pharmaceuticals Inc, 5 Crystal: Diagnosis and Management of Gout (06)...9 Disclosure: Ardea Biociences INC, 5; BioCryst Pharmaceuticals Inc, 5; Metabolex Pharmaceuticals Inc, 5; Regeneron Pharmaceuticals Inc, 5; Savient Pharmaceuticals Inc, 5; Takeda Pharmaceuticals Inc, 5; UpToDate Inc, 7; URL Pharmaceuticals Inc, 5 Invited Speaker /Moderator Index 0 Program Book 7

340 Invited Speaker /Moderator Index 8 Bég, Shazia, MD Innovation in Musculoskeletal Curriculum Development: Lessons from New Medical Schools...7 Belza, Basia, PhD Distinguished Lecturer: Unraveling the Go- Gene...6 Benator, Debra, MD Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis...58 Berman, Jessica, MD Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Berney, Seth M., MD Contract Negotiations for Physicians...9 Disclosure: Biogen/Idec, Genentech, Medimmune, Roche, UCB, ; MedStudy, 8; Pfizer Inc, Bernstein, Elana J., MD Paradigm Shifts in Rheumatoid Arthritis...9 Preoperative Assessment and Perioperative Management of the Patient with Rheumatic Disease: What Every Rheumatologist Should Know (Clinical Review)...8 Bethina, Narandra, MD ACR Knowledge Bowl - Preliminary Round.. 7 Beukelman, Timothy, MD, MSCE New Developments in Systemic Juvenile Idiopathic Arthritis Management...69 Disclosure: Genentech and Biogen IDEC Inc., 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, Bingham III, Clifton O., MD Vaccinations for Patients on Biologic Therapies (049)...70 Vaccinations for Patients on Biologic Therapies (090)...9 Binstadt, Bryce, MD, PhD ACR Knowledge Bowl - Preliminary Round.. 7 Biro, Frank M., MD Puberty, Adolescence and Rheumatologic Disease...49 Bloch, Donald B., MD Making Sense of Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases Program Book Block, Joel A., MD Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy: Recent Advances, Current Thoughts...70 Disclosure: Allergan USA, Inc., 5; Pfizer, Inc., 5 Modifying Causal Risk Factors that Influence the Incidence of Falls by Older Adults...9 Disclosure: Allergan USA, Inc., 5; Pfizer, Inc., 5 Blythe, Margaret J., MD Puberty, Adolescence and Rheumatologic Disease...49 Disclosure: Merck Pharmaceuticals, 8 Bode, Christina, PhD The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together...0 Bonassar, Lawrence, PhD Mechanotransduction in Bone and Cartilage Disclosure: Fidia Farmaceutici, SpA, Bong, David A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two... Borenstein, David G., MD Pain: Evaluation and Treatment of Back Pain (056)...88 Disclosure: Abbott Laboratories, 5; Pfizer Inc, 5 Clinical Research Conference - Day Two Introductory Remarks...8 Disclosure: Abbott Laboratories, 5; Pfizer Inc, 5 ILAR The Current Rheumatology Workforce Across the Globe...59 Disclosure: Abbott Laboratories, 5; Pfizer Inc, 5 Pain: Evaluation and Treatment of Back Pain (05)...56 Disclosure: Abbott Laboratories, 5; Pfizer Inc, 5 Approach and Management of Back Pain in Older Adults...04 Disclosure: Abbott Laboratories, 5; Pfizer Inc, 5 ACR Town Hall Meeting & Business Meeting Disclusure: Abbott Laboratories, 5; Pfizer Inc, 5 Breland, Hazel L., PhD, OTR/L Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care...58 Osteoporosis: 0 Update...8 Brenner, Michael B., MD Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Disclosure: Calcimedica Inc, 5; Synovex Corp,, 5 Prospects for Prevention and Cure of Rheumatoid Arthritis...9 Disclosure: Calcimedica Inc, 5; Synovex Corp,, 5 Bridges Jr., S. Louis, MD, PhD Osteoimmunology...0 Bright, Christina, MD ACR Knowledge Bowl - Preliminary Round.. 7 Brooks, Peter, MD ILAR The Current Rheumatology Workforce across the Globe...59 Brunner, Hermine, MBA, MD, MSc Plenary Session II: Discovery Neuropsychiatric Lupus in Children and Adolescents...7 Pediatric Rheumatology Town Hall Meeting Bruyn, George A. W., MD, PhD Musculoskeletal Ultrasound Course for Rheumatologists - Hand and Wrist... Bucala, Richard J., MD, PhD Gouty Inflammation...96 Systems Immunology...9 Buckley, Christopher D., PhD Basic Research Conference - Session IV: Immunity and Mesenchymal Cells...5 Burke, Allen, MD Histopathology of Vasculitis ()...7 Histopathology of Vasculitis ()...97 Bykerk, Vivian P., MD Paradigm Shifts in Rheumatoid Arthritis...9 Disclosure: Amgen, Pfizer, Abbott, BMS, Janssen Biotech, Roche, UCB, ; Pfizer, Astellis Pharmaceuticals, Boehringer Ingelheim, BMS, Roche, UCB, Abbott, 5 C Calabrese, Leonard H., DO Review Course - Is It Central Nervous System Vasculitis or Something Else?...5 Disclosure: Amgen, 8; Bristol-Myers Squibb, 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 5; Sanofi-Aventis Pharmaceutical, 5; ucb, 5 Callahan, Leigh F., PhD Don t Let the Pink Sheets Make You Blue...9 Carette, Simon, MD The Great Masqueraders: Malignancies in Rheumatic Disease Carnie, Martie, AS, PFAC Practice Management: Patients As Partners in Design and Delivery...56 Carrino, John, MD, MPH Cross-Sectional Imaging Techniques for Rheumatology...58 Disclosure: Carestream, Siemens, General Electric, 6; Medtronic, General Electric, Quality Medical Metrics, Vital Images, 5; Merge Healthcare, ; Siemens, Toshiba, Carestream,

341 Carson, Craig W., MD The Guide to Meaningful Use and Beyond Carsons, Steven E., MD Classification and Treatment of Sjögren s Syndrome...48 Carter, Robert H., MD Career Opportunities in Rheumatology: Making a Choice...69 NIAMS-Sponsored Research in Rheumatology: 0 Highlights... Catanese, Veronica M., MD, MBA Innovation in Musculoskeletal Curriculum Development: Lessons from New Medical Schools...70 Chakravarty, Eliza F., MD Pregnancy in Rheumatic Diseases (08)...8 Pregnancy in Rheumatic Diseases (067)...9 Chao, Nelson, MD Don t Let the Pink Sheets Make You Blue...9 Chapurlat, Roland, MD Plenary Session I: Discovery Disclosure: Merck Pharmaceuticals,, 5 Charles-Schoeman, Christina, MD Diagnostic Assessments in Myopathy... Chauhan, Krati, MD, MPH Thieves Market Poster Presentation - A Case of Juvenile Arthritis...6 Chen, Di, MD, PhD New Molecules in Joint Biology Chen, Lan, MD, PhD Synovial Fluid Analysis and Crystal Identification (5)...48 Synovial Fluid Analysis and Crystal Identification ()...9 Synovial Fluid Analysis and Crystal Identification (7)...0 Chinoy, Hector, MD, PhD Diagnostic Assessments in Myopathy...0 Choi, Hyon K., DrPH, MD Selection Bias in Rheumatic Disease Research Risk Factor Paradox and Other Issues...96 Threats to Validity: Confounding in Rheumatic Disease Research...9 Chow, Shingpui Betty, PT, MA, OCS Osteoarthritis: Opportunities and Challenges Chowdhury, Badrul, MD, PhD Biosimilars Development: Food and Drug Administration Perspective... Christl, Leah, PhD Biosimilars Development: Food and Drug Administration Perspective... Christopher-Stine, Lisa, MD, MPH Myopathy: Issues in Diagnosis and Treatment (04)...8 Disclosure: Inova Diagnostics, Inc., 7; Medimmune, 5; Novartis Pharmaceutical Corporation, 5; Questcor, 5 Myopathy: Issues in Diagnosis and Treatment (07)...0 Disclosure: Inova Diagnostics, Inc., 7; Medimmune, 5; Novartis Pharmaceutical Corporation, 5; Questcor, 5 Chu, Cong-Qiu, MD Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease Chung, Antanya, CPC, CPC-I, CRHC, CCP Certified Rheumatology Coder Course: Unlock the Mystery: A Roadmap for Rheumatology Coding - Day One... Ciccarelli, Mary R., MD Obesity in Rheumatic Diseases of Children and Adults... Transition Tools for Patients: Pediatric to Adults... Cid, Maria C., MD Polymyalgia Rheumatica - Recent Advances and Ongoing Questions...0 Clarke, John, MD Scleroderma Bowel Disease: From Top to Bottom (Clinical Review)...7 Disclosure: ProStrakan, 9; Wyeth Pharmaceuticals, 9 Clauw, Daniel J., MD Clinical Research Conference - Introduction: State of the Field... Disclosure: Pfizer Inc, Forest Laboratories, Merck, Nuvo, ; Pfizer, Forest, Lilly, Merck, Nuvo, J and J, 5 Clayburne, Gilda M., MLT Synovial Fluid Analysis and Crystal Identification (5)...48 Synovial Fluid Analysis and Crystal Identification ()...9 Synovial Fluid Analysis and Crystal Identification (7)...0 Cohen, Stanley B., MD Paradigm Shifts in Rheumatoid Arthritis...9 Disclosure: Abbott Laboratories, ; Amgen, 5; Astellas, 8; BMS, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc;, 5; Roche Pharmaceuticals, 5; UCB, Rheumatoid Arthritis: Difficult Cases (06).. 60 Disclosure: Abbott Laboratories, ; Amgen, 5; Astellas, 8; BMS, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc;, 5; Roche Pharmaceuticals, 5; UCB, Collier, Deborah S., MD The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization...69 Collins, Christopher E., MD Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Conaghan, Philip G., MD, PhD Peripheral Magnetic Resonance Imaging in Rheumatology Practice (8)...60 Peripheral Magnetic Resonance Imaging in Rheumatology Practice ()...9 Connelly, Mark, PhD Clinical Research Conference - Day Two - Break Out Groups...9 Disclosure: Arthritis Foundation, ; NIAMS, Clinical Research Conference - Day Two - Methods for Phenotyping Pain-...8 Disclosure: Arthritis Foundation, ; NIAMS, Cook, Dane B., PhD Clinical Research Conference - Day Two - Break Out Groups...8 Non-pharmacological Management of Fibomyalgia: Your Toolbox Cope, Andrew P., MD, PhD Immune Tolerance: From Theory and Clinical Practice...58 Molecular and Cellular Basis of Tissue Homing...9 Visualizing the Immuno-inflammatory Response...04 Crawford, Donah Z., BS, MA Highlights from the 0 ARHP Sessions...04 Criscione-Schreiber, Lisa G., MD ACR Knowledge Bowl - Preliminary Round.. 7 Invited Speaker /Moderator Index 0 Program Book 9

342 Invited Speaker /Moderator Index 40 Criswell, Lindsey A., MD, MPH Classification and Treatment of Sjögren s Syndrome...48 Epigenetic Factors in Autoimmune Disease.. 60 Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis...0 Cronin, Mary E., MD Adult Inflammatory Myopathy (05)...88 Adult Inflammatory Myopathy (0)...8 Cronstein, Bruce N., MD Basic Research Conference - Session VI: Therapeutic Aspects: Biomarkers and Targeting Fibrosis (continued)...6 Disclosure: Arthritis Foundation, SLE Foundation, 6; Bristol-Myers Squibb, Novartis, URL, Regeneron, Gismo Therapeutics, 5; Canfite BioPharma, ; NIH, URL Pharma, OSI, ; Patents on use of adenosine receptor antagonists to treat or prevent fibrosis. Multiple other patents., 9 NIAMS-Sponsored Research in Rheumatology: 0 Highlights... Disclosure: Arthritis Foundation, SLE Foundation, 6; Bristol-Myers Squibb, Novartis, URL, Regeneron, Gismo Therapeutics, 5; Canfite BioPharma, ; NIH, URL Pharma, OSI, ; Patents on use of adenosine receptor antagonists to treat or prevent fibrosis. Multiple other patents., 9 Crow, Mary K., MD Predictive Biomarkers: A Journey to Personalized Health Care... Disclosure: Baxter, 5; Celgene, 5; EMD Merck Serono, 5; Genentech and Biogen IDEC Inc., 5; Idera, 5; Johnson & Johnson, ; Johnson and Johnson, 5; MedImmune, 5; Novo Nordisk, ; Pfizer Inc, ; Takeda, 5 Cui, Jing, PhD Rheumatology Research Foundation Special Session: Disease Targeted Research...94 Curtis, Jeffrey R., MD, MPH, MS Osteoporosis: From Bisphosphonates and Beyond...7 Disclosure: Roche/Genetech, UCB, Centocor, CORRONA, Amgen Pfizer, BMS, Crescendo, Abbott,, 5 Rheumatoid Arthritis Disease Activity Measures and Quality Indicators: Correct Use and Future Directions... Disclosure: Roche/Genetech, UCB, Centocor, CORRONA, Amgen Pfizer, BMS, Crescendo, Abbott,, 5 Cush, John J., MD Infections with Biologics (00)... Disclosure: Genentch, Pfzer, UCB, Celgene, Amgen, Novartis, CORRONA, NIH, ; Jensen, Savient,Pfizer, BMS,Amgen, Genetech Abbott, UCB, 5 Infections with Biologics (06)...9 Disclosure: Genentch, Pfzer, UCB, Celgene, Amgen, Novartis, CORRONA, NIH, ; Jensen, Savient,Pfizer, BMS,Amgen, Genetech Abbott, UCB, 5 0 Program Book Rheumatology Roundup: Highlights from the 0 Annual Scientific Meeting... Disclosure: Genentch, Pfzer, UCB, Celgene, Amgen, Novartis, CORRONA, NIH, ; Jensen, Savient,Pfizer, BMS,Amgen, Genetech Abbott, UCB, 5 Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond...6 Disclosure: Genentch, Pfzer, UCB, Celgene, Amgen, Novartis, CORRONA, NIH, ; Jensen, Savient,Pfizer, BMS,Amgen, Genetech Abbott, UCB, 5 Cyr, Lori L., BSc, OT Clinical and Epidemiologic Study Designs in Rheumatic Disease Research...9 Minimizing Falls in Geriatric Rheumatic Populations...80 D Daikh, David I., MD, PhD ACR Leadership Town Hall Meeting & Business Meeting...0 Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Serum Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, Clinical Subsetting and Predicting Outcomes...9 Dall Era, Maria, MD Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (060)...88 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (077)...0 Dasgupta, Bhaskar, MD Polymyalgia Rheumatica (07)...8 Disclosure: Merck Pharmaceuticals, 5 Davidson, Anne, MBBS Rheumatology Research Foundation Special Session: Disease Targeted Research...94 Career Opportunities in Rheumatology: Making a Choice...69 Deal, Chad L., MD Osteoporosis: From Bisphosphonates and Beyond...7 Disclosure: Amgen, Lilly, 5, 8 Review Course - Osteoporosis Update...5 Disclosure: Amgen, Lilly, 5, 8 Deane, Kevin D., MD, PhD Extra-articular Involvement in Rheumatoid Arthritis... Preclinical Autoimmunity Potential for Prevention...8 Deane, Peter, MD Hereditary Angioedema (045)...70 DeMarco, Paul J., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists...0,, 4 Disclosure: Abbott Immunology Pharmaceuticals, 8; Auxilium Pharmaceuticals, 5; Sonosite Inc, 5 Should Ultrasound be Used in Rheumatology Practice?... Disclosure: Abbott Immunology Pharmaceuticals, 8; Auxilium Pharmaceuticals, 5; Sonosite Inc, 5 Dennis, Gregory J., MD Contract Negotiations for Physicians...9 Disclosure: Awarded stock options at Human Genome Sciences, ; Was a full time employee of HGS, Deodhar, Atul A., MD Joint Injection Techniques (4)...97 Joint Injection Techniques (9)... Desai, Shailey S., MD ACR Knowledge Bowl - Final Round...7 Dewing, Kori A., DNP, ARNP Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice...59 Diamond, Betty, MD Neuropsychiatric Lupus in Children and Adolescents...7 Distler, Joerg HW, MD Basic Research Conference - Session II: Core Signaling Mechanisms in Fibrosis... Disclosure: 4D Science Gmbh, ; Bayer Pharma, Celgene, Boehringer Ingelheim, JB Therapeutics, Anaphore, Actelion, Pfizer, Roche, 5; Bayer Pharma, Celgene, JB Therapeutics, Anaphore, Actelion, Pfizer, Roche, 8; Celgene, Bayer Pharma, Novartis, Array Biopharma, Pfizer, BMS, Domsic, Robyn T., MD, MPH Scleroderma: Systemic Sclerosis (08)...60 Scleroderma: Systemic Sclerosis (069)...9 Dooley, Mary Anne, MD, MPH Systemic Lupus Erythematosus: Novel Treatments (09)...8 Disclosure: Cephalon, 9; GSK/HGS, 8; HGS GSK, 9; UCB, 9 Dougados, Maxime, MD ILAR The Current Rheumatology Workforce Across the Globe...59 Duffield, Jeremy S., MD, PhD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...5 Disclosure: Biogen Idec, Boehringer Ingelheim, BMS, GSK, Takeda, Gilead, 5; Muregen LLC, ; Promedior Inc., ; Regulus Therapeutics, Dufour, Alyssa B., MA Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems...

343 Dunlop, Dorothy D., PhD Basic Statistical Concepts for the Medical Researcher (0)... Disclosure: Pearson Publishing Company, 5 Dures, Emma, PhD New and Better Habits! Facilitating Patient Selfmanagement with Proven Behavior Change Strategies...59 Dutz, Jan P., MD Dermatology Topics for Rheumatologists: What You Need to Know...8 Disclosure: Centocor, ONO Pharmaceuticals, 9; Janssen-Ortho, Abbott, Amgen, Leo Pharma, 5, 8 Dworkin, Robert H., PhD Clinical Research Conference - Clinical Trials... Disclosure: Adynxx, Analgesic Solutions, Astellas, Avanir, Biogen, Bioness, Bristol-Myers Squibb, Depomed, Depuy, Epicept, Flexion, Johnson & Johnson, Lilly, Merck, MMS Holdings, NeurogesX, Pfizer, Sanofi-Aventis, Smith & Nephew, and Spinifex, 5; NIH and FDA, E Ehrlich-Jones, Linda S., PhD, RN ARHP Keynote Address: It s Not Child s Play: Growing Up With and Mastering Juvenile Idiopathic Arthritis from the Child s Perspective... Best Practices for Ordering Diagnostic Imaging in Evaluating Rheumatologic Conditions...0 Distinguished Lecturer: Unraveling the Go- Gene...6 The 5A Approach to Physical Activity Counseling for Arthritis Patients...7 El-Gabalawy, Hani S., MD Preclinical Autoimmunity Potential for Prevention...8 Review Course - Setting the Stage for Rheumatoid Arthritis...4 Elliott, Christine, RN Infusion Reactions: Management and Prevention...6 Elson, Charles O., MD Microbiome Influence on Autoimmunity.. 0 Embi, Peter J., MD, MS Designing a Website for Your Practice (08) Erickson, Alan R., MD Top 0 Compliance Risks Facing Physicians.. 0 Erkan, Doruk, MD Catastrophic Antiphospholipid Syndrome (Clinical Review)...0 Disclosure: Genentech and Biogen IDEC Inc.,, 5; Human Genome Sciences, Inc., 8; Lupus Clinical Trials Consortium, Esdaile, John, MD, MPH Should Ultrasound be Used in Rheumatology Practice?... Evangelisto, Amy M., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two... Disclosure: Abbott Immunology Pharmaceuticals,, 8 Musculoskeletal Ultrasound (06)... Disclosure: Abbott Immunology Pharmaceuticals,, 8 Musculoskeletal Ultrasound (7)...60 Disclosure: Abbott Immunology Pharmaceuticals,, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Break Out Session: Adult Rheumatology...0 Disclosure: Abbott Immunology Pharmaceuticals,, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Opening Remarks...0 Disclosure: Abbott Immunology Pharmaceuticals,, 8 Musculoskeletal Ultrasound Course for Rheumatologists - The Elbow... Disclosure: Abbott Immunology Pharmaceuticals,, 8 Musculoskeletal Ultrasound Course for Rheumatologists - The Shoulder... Disclosure: Abbott Immunology Pharmaceuticals,, 8 Everix, DOnna K., MPA, BS, PT Early Rehabilitation for Hip and Foot Osteoarthritis: Opportunities and Challenges Hands: Non-Surgical Management and Bracing - What You Don t Know Can Hurt You...7 Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes Through Examination of Patient Factors, Practice Variation and Best Practice Recommendations F Farrell, Jessica, PharmD Clinical Focus Course - Breakout Session I...6 Clinical Focus Course - Breakout Session II.. 6 Depression in Rheumatic Diseases...80 Fearon, Douglas T., MD Basic Research Conference - Session IV: Immunity and Mesenchymal Cells...5 Feinstein, Amanda B., MS Novel Approaches to Pain Management in Juvenile Idiopathis Arthritis...89 Ferguson, Polly J., MD Chronic Recurrent Multifocal Osteomyelitis Fett, Nicole, MD Cutaneous Vasculitis (0)...8 Fields, Theodore R., MD Crystal: Diagnosis and Management of Gout (0)...56 Disclosure: Savient Pharmaceuticals, 5, 8; Takeda Pharmaceuticals, 5, 8; URL Pharmaceuticals, 5, 8 Gout and Hyperuricemia: Diseases Beyond the Joint...8 Disclosure: Savient Pharmaceuticals, 5, 8; Takeda Pharmaceuticals, 5, 8; URL Pharmaceuticals, 5, 8 Figueroa, Fernando E., MD Catastrophic Antiphospholipid Syndrome (Clinical Review)...0 Update on Stroke... Fillingim, Roger B., PhD Clinical Research Conference - Break Out Groups...8 Disclosure: Algynomics, ; American Pain Society, 6; MedScape, 5 Clinical Research Conference - Methods for Phenotyping Pain-...8 Disclosure: Algynomics, ; American Pain Society, 6; MedScape, 5 Fine, Derek M., MD Update on Immune Mediated Glomerular Disease...9 Finkel, Toren, MD, PhD Aging and the Rheumatic Diseases...8 Fiorentino, David, MD, PhD Update on Treatment of Systemic Lupus Erythematosus...9 Firestein, Gary S., MD Rheumatology Research Foundation Memorial Lectureship: Pathogenesis of Rheumatoid Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint Destruction...6 Disclosure: NexDx, Inc, 9 Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...6 Disclosure: NexDx, Inc, 9 Fischer, Aryeh, MD Connective Tissue Disease Associated Interstitial Lung Disease Disclosure: Actelion Pharmaceuticals US, 5, 8; Gilead Pharmaceuticals, 8; NIH, Fish, Eleanor, PhD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...5 Invited Speaker /Moderator Index 0 Program Book 4

344 Invited Speaker /Moderator Index Fitzgerald, G. Kelley, PhD, PT Clinical Focus Course - Breakout Session I...6 Clinical Focus Course - Breakout Session II.. 6 FitzGerald, John D., MD, PhD Should Ultrasound be Used in Rheumatology Practice?... Disclosure: American College of Rheumatology, Fleischman, Michael, FAAHC CORC Pre-meeting Course for Practice Managers - Improve Revenue Cycle Management Effectiveness and Optimize Cash Flow...7 Flemming, Donald J., MD X-ray Challenges in Rheumatic Diseases (9)...60 Disclosure: Elsevier, 7 Flood, Joseph, MD Career Opportunities in Rheumatology: Making a Choice...69 Fox, David A., MD ACR Knowledge Bowl - Preliminary Round.. 7 Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Disclosure: Genentech and Biogen IDEC Inc., ; Karyopharm, Franklin, Patricia D., MD, MBA, MPH Clinical Focus Course - Osteoarthritis Chronic Disease Management in the Age of the Internet, Apps and Tweets...7 Disclosure: Zimmer, Inc., Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes Through Examination of Patient Factors, Practice Variation and Best Practice Recommendations...80 Disclosure: Zimmer, Inc., Freeman, James G., MD Issues in the Management of Rheumatic Disease in Patients Undergoing Joint Replacement.. 6 Rheumatic Disease Update: Systemic Lupus Erythematosus... Rheumatic Disease Update: The Approach to Low Back Pain...9 Rheumatic Disease Update: Vasculitis...7 Strategies to Enhance Office Efficiencies and Access to Care in Rheumatology Practice...97 Furie, Richard A., MD Career Opportunities in Rheumatology: Making a Choice...69 Plenary Session III: Discovery Furner, Sylvia, PhD, MPH Arthritis and the Older Worker...0 Furst, Daniel E., MD Hepatitis in Patients with Rheumatologic Disease...9 Disclosure: Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 5; Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, ; Abbott, Actelion, UCB, 8 Systemic Sclerosis: How to Perform Skin Scores (8)...8 Disclosure: Abbott, Actelion, Amgen, BMS, BiogenIdec, Centocor, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, 5; Abbott, Actelion, Amgen, BMS, Gilead, GSK, NIH, Novartis, Pfizer, Roche/Genentech, UCB, ; Abbott, Actelion, UCB, 8 G Gabay, Odile H., PhD Energetics, Metabolism and Osteoarthritis.. 8 Gabriel, Sherine E., MD, MSc Selection Bias in Rheumatic Disease Research Risk Factor Paradox and Other Issues...96 Gaffney, Patrick M., MD Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis...0 Garber, Larry, MD CORC Pre-meeting Course for Practice Managers - Innovations for the Office...8 Gardner, Gregory C., MD Review Course...4 Amyloidosis Joint Injections (Knee and Ankle Prosthetics) (6)...60 Joint Injections (Shoulder and Wrist Prosthetics) ()...70 Garside, Paul, PhD Visualizing the Immuno-inflammatory Response...04 Gay, Steffen, MD Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Disclosure: IAR, Basic Research Conference - Session II: Core Signaling Mechanisms in Fibrosis... Disclosure: IAR, Basic Research Conference - Session III: Fibroblasts as Invaders and Aggressors...5 Geenen, Rinie, PhD The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together...0 Geissmann, Frederic, MD, PhD Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis...7 Gelber, Allan C., MD Career Opportunities in Rheumatology: Making a Choice...69 Genovese, Mark C., MD New Therapies for Modulating Signaling in Rheumatoid Arthritis... Disclosure: Eli Lilly and Company,, 5 Gerlag, Danielle M., MD Visualizing the Immuno-inflammatory Response...04 Gilkeson, Gary S., MD IgG4-Related Disease Past Lessons and Future Directions... Gillanders, Robert, PT, DPT Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis...6 Goebel, Andreas, MSc, PhD Complex Regional Pain Syndrome/Reflex Sympathetic Dystrophy: Recent Advances, Current Thoughts...70 Disclosure: Baxter, UK, CSL-Behring, Biotest, ; CSL-Behring, 9 Golightly, Yvonne M., MS, PhD, PT Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems... Goncalves Marangoni, Roberta, MD, PhD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...46 Gordon, Jessica K., MD, MSc Connective Tissue Disease Associated Interstitial Lung Disease Goyal, Janak R., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two...0,, 4 Musculoskeletal Ultrasonography: Basic (6)...80 Grabiner, Mark D., PhD Modifying Causal Risk Factors that Influence the Incidence of Falls by Older Adults...9 Disclosure: University of IIllinois, 7 Graham, Logan ARHP Keynote Address: It s Not Child s Play: Growing Up With and Mastering Juvenile Idiopathic Arthritis from the Child s Perspective Program Book

345 Gramling, Anna, MD Thieves Market Poster Presentation - Voriconazole-Induced Periostitis...6 Gravallese, Ellen M., MD Rheumatology Research Foundation Special Session: Disease Targeted Research...94 Disclosure: Abbott Laboratories, 5; Lilly, Rheumatology Research Foundation Oscar S. Gluck, MD, Memorial Lectureship: Bone Wasn t Built in a Day: New Insights into Destruction and Repair in Rheumatic Disease... Disclosure: Abbott Laboratories, 5; Lilly, Gregersen, Peter K., MD Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis...0 Disclosure: Illumina and Amgen,, 9 Griffin, Timothy M., PhD Energetics, Metabolism and Osteoarthritis.. 8 Grom, Alexei A., MD New Developments in Systemic Juvenile Idiopathic Arthritis Management...69 Disclosure: Novartis Pharmaceutical Corporation, 5 Gujar, Bansari, MD Thieves Market Poster Presentation - Headaches and Heartaches Thieves Market Poster Presentation - Mass Effect...6 Gultekin, Sakir Humayun, MD Muscle Involvement in Rheumatic Diseases (09)...9 Gutierrez, Cindy, MBA CORC Pre-meeting Course for Practice Managers - Deal Breakers in Payer Contract Negotiations...7 CORC Pre-meeting Course for Practice Managers - Effective Marketing for Today s Medical Practice...7 CORC Pre-meeting Course for Practice Managers - How to Maximize the Use of Your Practice Data...8 CORC Pre-meeting Course for Practice Managers - Innovations for the Office...8 CORC Pre-meeting Course for Practice Managers - Transforming the Practice Front End...7 H Hafler, David A., MD Systems Immunology...9 Disclosure: Pfizer Inc, 5; Teva Neuroscience, 5 Hahn, Bevra H., MD Plenary Session III: Discovery Disclosure: Abbott, 5; Anthera, 5; Aspreva Pharmaceutical, ; Eli Lilly, 5; Teva Pharmaceuticals, Update on Treatment of Systemic Lupus Erythematosus...9 Disclosure: Abbott, 5; Anthera, 5; Aspreva Pharmaceutical, ; Eli Lilly, 5; Teva Pharmaceuticals, Hajj-Ali, Rula, MD Central Nervous System Vasculitis (08)...9 Hannan, Marian T., DSc, MPH Minimizing Falls in Geriatric Rheumatic Populations...80 Tips for Publishing Your Work in a Peer- Reviewed Medical Journal...0 Hant, Faye N., DO, MSCR Scleroderma Mimics (048)...70 Harrington, J. Timothy, MD Rheumatoid Arthritis: Outcome Measures in Clinical Practice (09)...56 Disclosure: Abbott Laboratories, 5, 8; American Orthopedic Association, 5; Consortium of Rheumatology Researchers of North America CORRONA), 5; Joiner Associates LLC, 4; Springer Publishers, 7; US Treat to Target Committee, 8 Harris, Richard E., PhD Plenary Session III: Discovery Disclosure: Pfizer Inc,, 5 Harsanyi, Andreea M., MD Thieves Market: Show Me Your Best Cases , 6 Harte, Steven E., PhD Clinical Research Conference - Day Two...8 Disclosure: Analgesic Solutions, Natick, MA, 9 Hashkes, Philip J., MD, MSc Thieves Market: Show Me Your Best Cases...49 Hassett, Afton L., PsyD Rheumatic Disease Update: Gout...6 Disclosure: Bristol-Myers Squibb,, 5; Pfizer Inc,, 5 An Introduction to Immunology... Disclosure: Bristol-Myers Squibb,, 5; Pfizer Inc,, 5 Hawker, Gillian A., MD, MSc Clinical Focus Course - Using Outcome Measures to Inform Clinical Practice...6 Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care...59 Hayat, Samina Q., MD Thieves Market Poster Presentation - Development of Leprosy After Treatment With IL6 Blocker...6 Heimans, L., MD Plenary Session II: Discovery Heinegard, Dick, PhD New Molecules in Joint Biology Disclosure: Anamar Medical, ; IDS Ltd, Helmick, Charles G., MD Income Inequities Are Perilous to People with Arthritis...56 Hertweck, Susan Paige, MD, OB/GYN Puberty, Adolescence and Rheumatologic Disease...49 Hewlett, Sarah, MA, PhD, RN New and Better Habits! Facilitating Patient Selfmanagement with Proven Behavior Change Strategies...59 The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together...0 Hicks, Robert D., PhD Opening Lecture and Awards...9 Higgs, Jay B., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two...0, Highland, Kristin B., MD, MSCR Pulmonary Manifestations of Rheumatic Disease (046)...70 Disclosure: Actelion Pharmaceuticals US, 9; Genentech and Biogen IDEC Inc., 8; Gilead Sciences, 9; United Therapeutics, 9 Pulmonary Manifestations of Rheumatic Disease (084)...9 Disclosure: Genentech and Biogen IDEC Inc., 8 Hillstrom, Howard J., PhD Knee Braces and Foot Orthosis for Knee Osteoarthritis (0)...9 Hinz, Boris, PhD Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Hirschman, Michelle Practice Managers: Improving Access and Website Marketing...46 Hochberg, Marc C., MD, MPH Clinical Focus Course - 0 ACR Guidelines on Osteoarthritis: A Focus on Pharmacologic Management...6 Disclosure: Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma., 5 Contract Negotiations for Physicians...9 Disclosure: Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma., 5 Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?... Disclosure: Abbott Laboratories, Astra-Zeneca, Bioiberica S.A., Eli Lilly Inc., Genentech/Roche, Merck Inc., Novartis Pharma A.G., Pfizer Inc., Stryker LLC, Xoma., 5 Invited Speaker /Moderator Index 0 Program Book 4

346 Invited Speaker /Moderator Index 44 Hogaboam, Cory M., PhD Basic Research Conference - Session IV: Immunity and Mesenchymal Cells...5 Disclosure: Medimmune Inc, ; Novartis Pharmaceutical Corporation, Holers, V. Michael, MD Prospects for Prevention and Cure of Rheumatoid Arthritis...9 Disclosure: Diagnostic Companies, 7 Holland, Gary N., MD Rheumatic Disease Update: Inflammatory Eye Disease...46 Hootman, Jennifer M., ATC, PhD Demystifying the Study Section: How Grants Are Reviewed and Scored...79 The 5A Approach to Physical Activity Counseling for Arthritis Patients...7 Houghton, Kristin M., MD Clinical Focus Course - Addressing Risk Factors for Osteoarthritis through the Lifespan: Let s Start with the Kids!...6 Hudson, Marie, MD, MPH Plenary Session I: Discovery Huisinga, Karen, MN, ARNP, FNP Infusion Reactions: Management and Prevention...6 Disclosure: Pfizer Inc, 8 Hunder, Gene G., MD Temporal Arteritis (00)...56 Temporal Arteritis (079)...0 Hunter, David J., MBBS, PhD Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?... Disclosure: DonJoy, 7; NHMRC, ARC, NIH, FNIH, Husni, M. Elaine, MD, MPH Psoriatic Arthritis (05)...60 Psoriatic Arthritis (058)...88 Hübbe, Claudia, MD Thieves Market Poster Presentation - Behçet s Disease with Pulmonary Artery Aneurysms Ibrahim, Said, MD, MPH Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care...59 Ilowite, Norman T., MD Pediatric Rheumatology Town Hall Meeting Program Book I Inman, Christi Joy, MD, MS The Unintended Consequences of Health Information Technology... Inman, Robert D., MD Spondylarthropathy: An Update (007)... Disclosure: Abbott, Amgen, Merck, Pfizer, Sanofi- Aventis, 5 Isaacs, John D., MD, PhD Immune Tolerance: From Theory and Clinical Practice...58 Disclosure: GSK, ; No company, Treatment of chronic joint inflammation using an antibody against the CD antigen complex, 9 Isenberg, David A., MD Year in Review... Iversen, Maura D., BSc, DPT, SD, MPH Myositis: Pathogenesis, Diagnosis and Management...0 Jacobe, Heidi, MD, MSCS Review Course - When Thick Skin is Not a Good Thing...4 Jain, Nitin, MD, MSPH Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis...6 Disclosure: AAPMU Faculty, 9; NIAMS-NIH, James, Judith A., MD, PhD Preclinical Autoimmunity Potential for Prevention...8 Jarjour, Wael N., MD Predictive Biomarkers: A Journey to Personalized Health Care... Disclosure: Human Genome Sciences, Inc., 9 J Johnson, Richard J., MD Gout and Hyperuricemia: Diseases Beyond the Joint...8 Disclosure: Ardea, Novartis, Biocryst, 5; NHLBI- NIH, ; Univ of Florida, 9; Univ of WA,, 9 Jolly, Meenakshi, MD, MS Clinical Trials: Participation and Recruitment...6 Disclosure: GlaxoSmithKline, 5; Lupus Foundation of America, ; MedImmune, 7; The Binding Site, Jones, Kim D., PhD Non-pharmacological Management of Fibomyalgia: Your Toolbox Jordan, Joanne M., MD, MPH Osteoarthritis: Update 0 (0)...60 Disclosure: Algynomics, Inc., ; Eli Lilly and Company, 5; Interleukin Genetics, Inc., 5; Johnson & Johnson, ; Johnson and Johnson, 5; Mutual Pharmaceutical Company, 5 Osteoarthritis: Update 0 (064)...9 Disclosure: Algynomics, Inc., ; Eli Lilly and Company, 5; Interleukin Genetics, Inc., 5; Johnson & Johnson, ; Johnson and Johnson, 5; Mutual Pharmaceutical Company, 5 Joshi, Reeti K., MBBS Thieves Market Poster Presentation - A Wolf in Sheep s Clothing...95 Jungel, Astrid, PhD Basic Research Conference - Session IV: Immunity and Mesenchymal Cells...5 Disclosure: IAR,Masterswitch-FP7,IMI-BTCure, K Kaeley, Gurjit S., MBBS, MRCP Musculoskeletal Ultrasonography: Basic (6)...80 Disclosure: Esaote, Sonosite, Musculoskeletal Ultrasound Course for Rheumatologists...0,, Disclosure: Esaote, Sonosite, Kafka, Shelly P., MD Dermatology Topics for Rheumatologists: What You Need to Know...8 Disclosure: Janssen Pharmaceutica Product, L.P., Abbott, Amgen, Takeda, HGSI, UCB, Forest, 8; Pfizer Inc, Lilly, Amgen, Jannsen,Vertex, Abbott, Takeda, Savient, UCB, GSK/HGSI, Update on Psoriatic Arthritis and the Spondylarthropathies...49 Disclosure: Janssen Pharmaceutica Product, L.P., Abbott, Amgen, Takeda, HGSI, UCB, Forest, 8; Pfizer Inc, Lilly, Amgen, Jannsen,Vertex, Abbott, Takeda, Savient, UCB, GSK/HGSI, Kalish, Robert A., MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0)...0 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (5)... Curbside Consults - Ask the Professors...7 Kamen, Diane L., MD, MS Curbside Consults - Ask the Professors...7 IgG4-Related Disease Past Lessons and Future Directions... Preclinical Autoimmunity Potential for Prevention...8 Thieves Market: Show Me Your Best Cases Kastner, Daniel L., MD, PhD Pediatrics: Periodic Fevers in Children (06) Disclosure: National Institutes of Health, 7 Year in Review... Katikaneni, Mamatha, MD Thieves Market Poster Presentation - Development of Leprosy After Treatment With IL6 Blocker...6

347 Katz, Jeffrey N., MD Rheumatic Disease Update: The Approach to Low Back Pain...9 Katz, Patricia P., PhD Demystifying the Study Section: How Grants are Reviewed and Scored...79 The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together...79 Katz, Stephen I, MD, PhD Clinical Research Conference - Day Two Introductory Remarks...8 Katzman, Wendy, DSc, PT Osteoporosis: 0 Update...8 Kaufman, Randal J., PhD Endoplasmic Reticulum Stress Unfolded Protein Response in Immunity and Inflammation...8 Disclosure: Proteostasis Therapeutics, Inc., Cambridge, MA, 6; Syndexa Pharm, Cambridge, MA, 6 Kavanaugh, Arthur, MD Psoriatic Arthritis (06)...56 Disclosure: Amgen, Abbott, BMS, Celgene, Roche, UCB, Janssen, Pfizer, Rheumatology Roundup: Highlights from the 0 Annual Scientific Meeting... Disclosure: Amgen, Abbott, BMS, Celgene, Roche, UCB, Janssen, Pfizer, Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond...6 Disclosure: Amgen, Abbott, BMS, Celgene, Roche, UCB, Janssen, Pfizer, Kay, Jonathan, MD Rheumatoid Arthritis: Challenging Cases (08)...56 Disclosure: Abbott Immunology Pharmaceuticals, ; Amgen, 5; Ardea Biosciences, ; Bristol-Myers Squibb, 5; Celgene, 5; Crescendo BioScience, 5; Eli Lilly and Company, ; Fidia Farmaceutici SpA, ; fourteen, 5; Genentech and Biogen IDEC Inc., 5; Horizon Pharma, 5; Janssen Biotech, 5; Molecular Partners AG, 5; Pfizer Inc, 5; Roche Pharmaceuticals, ; Sanofi-Aventis Pharmaceutical, ; Savient, 5; UCB, 5 Amyloidosis Rheumatoid Arthritis: Challenging Cases (074)...0 Disclosure: Abbott Immunology Pharmaceuticals, ; Amgen, 5; Ardea Biosciences, ; Bristol-Myers Squibb, 5; Celgene, 5; Crescendo BioScience, 5; Eli Lilly and Company, ; Fidia Farmaceutici SpA, ; fourteen, 5; Genentech and Biogen IDEC Inc., 5; Horizon Pharma, 5; Janssen Biotech, 5; Molecular Partners AG, 5; Pfizer Inc, 5; Roche Pharmaceuticals, ; Sanofi-Aventis Pharmaceutical, ; Savient, 5; UCB, 5 Kay, Neil E, MD Predictive Biomarkers: A Journey to Personalized Health Care... Kazi, Salahuddin, MD Getting Electronic Health Records Right (5)...80 Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice...0 The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization...69 Keck, Tatiana, MD ACR Knowledge Bowl - Final Round...7 Kerr, Gail S., MD Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis...58 Kessler, Craig M., MD New Anticoagulants: What a Hematologist Thinks a Rheumatologist Needs to Know!...6 Keysor, Julie J., PhD, PT Promoting Participation: Where Is the Field and Where Do We Go Next?...89 Keystone, Edward C., MD Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (0)...9 Rheumatoid Arthritis: Biological Agents (006)... Disclosure: Abbott Laboratories, 5; Abbott Pharmaceutical, 8; Abbottt Laboratories, ; Amgen, 8; Amgen Inc., ; Astrazeneca Pharmaceuticals, 5; Astrazeneca Pharmaceuticals LP, ; Biotest, 5; Bristol-Myers Squibb,, 8; Centocor, Inc., ; F. Hoffman La-Roche Inc, ; F. Hoffman La-Roche Ltd, 5, 8; Genentech and Biogen IDEC Inc., 5; Genzyme Corporation, ; Janssen Pharmaceuticals, 8; Merck Pharmaceuticals,, 5, 8; Novartis Pharmaceuticals, ; Nycomed, 5; Pfizer Pharmaceuticals,, 5; UCB,, 5, 8 Rheumatoid Arthritis: Biological Agents (059)...88 Khamashta, Munther A., MD Antiphospholipid Syndrome (0)...56 Antiphospholipid Syndrome (05)... Khanna, Dinesh, MD, MSc Pulmonary Hypertension in the Rheumatic Diseases (07)...4 Disclosure: Actelion, BMS, Gilead, Genentech, ISDIN, and United Therapeutics,, 5, 8 Khosroshahi, Arezou, MD IgG4-Related Disease Past Lessons and Future Directions... Kikuta, Junichi, MD Plenary Session I: Discovery Kim, Sunny, PhD Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems... Kim, Susan, MD, MPH Pediatrics: Dermatomyositis (004)... Kimberly, Robert P., MD Plenary Session I: Discovery Kimura, Yukiko, MD New Developments in Systemic Juvenile Idiopathic Arthritis Management...69 Disclosure: Genentech and Biogen IDEC Inc., 5; Novartis Pharmaceutical Corporation, 5 King II, Charles M., MD Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice...0 Kissin, Eugene Y., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two... Disclosure: SonoSite Inc., 9 Musculoskeletal Ultrasound (06)... Disclosure: SonoSite Inc., 9 Musculoskeletal Ultrasound (7)...60 Disclosure: SonoSite Inc., 9 Kivitz, Alan J., MD, CPI Clinical Trials: Participation and Recruitment...6 Disclosure: Bristol-Myers Squibb, 8; Forest Laboratories, 8; Genentech and Biogen IDEC Inc., 5; Pfizer Inc, 8; Takeda, 8 Klareskog, Lars, MD, PhD Prospects for Prevention and Cure of Rheumatoid Arthritis...9 Klein-Gitelman, Marisa S., MD, MPH Pediatric Rheumatology Town Hall Meeting...7 Koch, Alisa E., MD Basic Research Conference - Session VI: Therapeutic Aspects: Biomarkers and Targeting Fibrosis (continued)...6 Koening, Curry L., MD, MS Polymyalgia Rheumatica - Recent Advances and Ongoing Questions...0 Kohler, Minna J., MD Musculoskeletal Ultrasound Course for Rheumatologists - Hand and Wrist... Kolasinski, Sharon L., MD Complementary and Alternative Medicine: Evidence Based Options for Arthritis Patients...9 Invited Speaker /Moderator Index 0 Program Book 45

348 Invited Speaker /Moderator Index Innovation in Musculoskeletal Curriculum Development: Lessons from New Medical Schools...70 Kolfenbach, Jason R., MD ACR Knowledge Bowl - Final Round...68 ACR Knowledge Bowl - Preliminary Round.. 7 Kremer, Joel M, MD Paradigm Shifts in Rheumatoid Arthritis...9 Disclosure: Abbott, BMS, Genentech, Pfizer, HGS, Lilly, Novartis, ; Amgen, BMS, Genentech, Pfizer, Lilly, 5 Krishnan, Eswar, MD Gout and Hyperuricemia: Diseases Beyond the Joint...8 Disclosure: takeda, Metabolex, URL, ; takeda, URL Metabolex, 5 Krohn, Kelly, MD Knee Braces and Foot Orthosis for Knee Osteoarthritis (0)...9 Disclosure: LIlly USA, LLC,, L Lacomis, David, MD Diagnostic Assessments in Myopathy... Lafyatis, Robert, MD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...5 Disclosure: Shire, Sanofi/Genzyme, Regeneron, Actelion, ; Shire, Sanofi/Genzyme, Regeneron, Roche/Genentech, Biogen, 5 Endoplasmic Reticulum Stress Unfolded Protein Response in Immunity and Inflammation...8 Disclosure: Shire, Sanofi/Genzyme, Regeneron, Actelion, ; Shire, Sanofi/Genzyme, Regeneron, Roche/Genentech, Biogen, 5 Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis...7 Disclosure: Shire, Sanofi/Genzyme, Regeneron, Actelion, ; Shire, Sanofi/Genzyme, Regeneron, Roche/Genentech, Biogen, 5 Mechanisms of Autoinflammatory Diseases...9 Disclosure: Shire, Sanofi/Genzyme, Regeneron, Actelion, ; Shire, Sanofi/Genzyme, Regeneron, Roche/Genentech, Biogen, 5 Lahita, Robert G., MD, PhD Systemic Lupus Erythematosus: Novel Treatments (089)...9 Disclosure: Human Genome Sciences, Inc. Glaxo Smith Kline, 8 Laing, Timothy, MD Legislative Update from Capitol Hill...6 Lamande, Shireen, PhD New Molecules in Joint Biology Lane, Nancy E., MD Osteoporosis: 0 Update...8 Vitamin D and Bone Health (00)...8 Langford, Carol A., MD, MHS ACR/ABIM Maintenance of Certification Learning Session - 0 Update in Rheumatology... Cross-Sectional Imaging Techniques for Rheumatology...58 Plenary Session II: Discovery Disclosure: Bristol-Myers Squibb, 9; Genentech and Biogen IDEC Inc., 9 Polymyalgia Rheumatica - Recent Advances and Ongoing Questions...0 Disclosure: Bristol-Myers Squibb, 9; Genentech and Biogen IDEC Inc., 9 The Great Debate: In 0 What are the Roles of Cyclophosphamide versus Rituximab in ANCA-Associated Vasculitis...9 Lapteva, Larissa, MD, MHS Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond...6 Lawry, George V., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis (04)... Disclosure: McGraw-Hill Co., 7 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back ()...48 Disclosure: McGraw-Hill Co., 7 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (0)...6 Disclosure: McGraw-Hill Co., 7 Laxer, Ronald M., MD New Developments in Systemic Juvenile Idiopathic Arthritis Management...69 Disclosure: Novartis Pharmaceutical Corporation,, 5 Lazaro, Deana M., MD Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Lee, Jungwha, PhD, MPH Basic Statistical Concepts for the Medical Researcher (0)... Lehman, Thomas J. A., MD Pediatrics: Spondylarthritis in Children (04)...60 Disclosure: Abbott Immunology Pharmaceuticals, 8 Leon-Reyes, Elyse M., BA, MPA Forming An Education and Support Group from the Ground Up...8 Levesque, Marc C., MD, PhD ACR Knowledge Bowl - Final Round...68 ACR Knowledge Bowl - Preliminary Round.. 7 Li, Zhan-Guo, MD ILAR The Current Rheumatology Workforce Across the Globe...60 Libman, Bonita S., MD ACR Knowledge Bowl - Final Round...68 ACR Knowledge Bowl - Preliminary Round.. 7 Lichy, Jack H., MD, PhD Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis...58 Lieb, Kevin CORC FORUM: Achieving Economic Goals in an Era of Healthcare Reform... Lieberman, Judy, MD, PhD MicroRNA and the Rheumatic Diseases... Liles, Robert W., JD Top 0 Compliance Risks Facing Physicians Disclosure: Liles Parker, 9 Ling, Shari M., MD Arthritis and the Older Worker...0 Liu-Bryan, Ru, PhD Energetics, Metabolism and Osteoarthritis.. 8 Lockshin, Michael D., MD Tips for Publishing Your Work in a Peer- Reviewed Medical Journal...0 Loeser, Richard F., MD Energetics, Metabolism and Osteoarthritis.. 8 Mechanotransduction in Bone and Cartilage...7 Lotz, Martin K., MD MicroRNA and the Rheumatic Diseases... Lovell, D. J., MD, MPH NIAMS-Sponsored Research in Rheumatology: 0 Highlights... Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 9; AstraZeneca, 5; Bristol-Myers Squibb, 5; Centocor, Inc., 5; Forest Laboratories, 9; Hoffmann-La Roche, Inc., 5; horizon pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Regeneron, 5; Wyeth Pharmaceuticals, 8 Lowenstein, Kathryn L., OTR Clinical Focus Course - Breakout Session I...6 Clinical Focus Course - Breakout Session II Program Book

349 Lowes, Michelle, MD, PhD Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis...7X Lu, Theresa T., MD, PhD Basic Research Conference - Session IV: Immunity and Mesenchymal Cells...5 Lundberg, Ingrid E., MD, PhD Review Course - Inflammatory Myositis: Disclosure: Bristol-Myers Squibb, ; MedImmune, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, Luning Prak, ElineT., MD, PhD Advances in Targeting of B cell Survival Factors...9 Disclosure: Genentech and Biogen IDEC Inc., 5 Luther, Sanjiv, PhD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...6 Lynch, Susan, PhD Microbiome Influence on Autoimmunity.. 0 Disclosure: Second Genome, 6 M Macfarlane, Gary J., BSc, MBChB, MD, PhD Clinical Research Conference - Break Out Groups...8 Clinical Research Conference - From Preclinical Models to Clinical Studies...8 Magid, Steven K., MD The Guide to Meaningful Use and Beyond.. 9 Maisel, Alan S., MD Predictive Biomarkers: A Journey to Personalized Health Care... Disclosure: Alere, Abbott, Brahms-Thermofisher, ; Alere, Critical Diagnostics, 5 Maixner, William, DDS, PhD Clinical Research Conference - Break Out Groups...9 Disclosure: Algynomics,, 4, 5; NIH, Clinical Research Conference - From Preclinical Models to Clinical Studies...8 Disclosure: Algynomics,, 4, 5; NIH, Makol, Ashima, MD Thieves Market: Show Me Your Best Cases...49 Makris, Una E., MD Approach and Management of Back Pain in Older Adults...0 Maksymowych, Walter P., MD MRI in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide(4).. 7 Disclosure: Abbott Laboratories,, 5; Amgen, ; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P.,, 5; Merck Pharmaceuticals, 5; Pfizer Inc,, 5; UCB, 5 MRI in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide(6) Disclosure: Abbott Laboratories,, 5; Amgen, ; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P.,, 5; Merck Pharmaceuticals, 5; Pfizer Inc,, 5; UCB, 5 Malawista, Stephen E., MD Gouty Inflammation...9 Malfait, Anne-Marie, MD, PhD Mechanisms of Pain in Rheumatic Diseases...8 Disclosure: NIAMS-NIH, New Molecules in Joint Biology...04 Disclosure: NIAMS-NIH, Mammen, Andrew L., MD, PhD The Great Masqueraders: Malignancies in Rheumatic Disease Disclosure: anti-hmgcr antibody test, 9 Mandelin II, Arthur M., MD, PhD Adult Musculoskeletal Lower Examinations (9)...9 Adult Musculoskeletal Upper Examinations (05)... Rheumatoid Arthritis Disease Activity Measures and Quality Indicators: Correct Use and Future Directions... Mandell, Brian F., MD, PhD Issues in the Management of Rheumatic Disease in Patients Undergoing Joint Replacement...6 Synovial Fluid Analysis and Crystal Identification (5)...48 Synovial Fluid Analysis and Crystal Identification ()...9 Synovial Fluid Analysis and Crystal Identification (7)...0 Manson, Sharon, RN, MS, NP Infusion Room Information for Medical Professionals...59 Manzi, Susan, MD, MPH Review Course - Lupus - More than Nephritis: Treatment of Non-Nephritis Lupus Problems...4 Disclosure: Anthera, Bristol-Myers Squibb Company, Cephalon, HGS- Exagen, Human Genome Sciences,, 5; Patent Patents Examined and Allowed for Issuance as a Patent, 7 Marden, Susan, MD Demystifying the Study Section: How Grants Are Reviewed and Scored...79 Disclosure: Anthera, Bristol-Myers Squibb Company, Cephalon, HGS- Exagen, Human Genome Sciences,, 5; Patent Patents Examined and Allowed for Issuance as a Patent, 7 Margules, Kenneth R., MD Joint Injections (Knee and Ankle Prosthetics) (6)...60 Joint Injections (Shoulder and Wrist Prosthetics) ()...7 Maricic, Michael J., MD Osteoporosis: Novel Treatments (05)...8 Disclosure: Amgen, 5; Eli Lilly and Company, 8; Novartis Pharmaceutical Corporation, 8 Rheumatology Practice 0: Starting Out in Practice for The Graduating Fellow (087).. 9 Martinez-Lavin, Manuel, MD Fibromyalgia and Dysautonomia (055)...88 Fibromyalgia and Dysautonomia (07)...0 Mathai, Stephen C., MD, MHS Connective Tissue Disease Associated Interstitial Lung Disease Disclosure: Actelion Pharmaceuticals US, 5; Bayer HealthCare, 5; Gilead Sciences, 5; United Therapeutics, 5 Mathew, Anita S., MD Thieves Market Poster Presentation - Development of Leprosy After Treatment With IL6 Blocker...6 Matteson, Eric L., MD, MPH Polymyalgia Rheumatica - Recent Advances and Ongoing Questions...0 Disclosure: American College of Rheumatology and EULAR grant to develop classification criteria for rheumatoid arthritis., ; Horizon, 5; Novartis Pharmaceutical Corporation, Maxwell, Jessica L., DPT, PT Promoting Participation: Where Is the Field and Where Do We Go Next?...89 McAlindon, Timothy E., MD, MPH Should Ultrasound be Used in Rheumatology Practice?... Disclosure: Arthritis and Rheumatism, 9; BioIberica, 9; Croma, ; Flexion; Sanofi; Wintherix, 5; NIH; ACR, ; OARSI, 6 McBeth, John, PhD Clinical Research Conference - Break Out Groups...9 Clinical Research Conference - From Preclinical Models to Clinical Studies...8 Invited Speaker /Moderator Index 0 Program Book 47

350 Invited Speaker /Moderator Index McClatchey, William M., MD The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization...69 McClung, Michael R., MD Curbside Consults - Ask the Professors...7 Disclosure: Amgen, Lilly, Merck, Novartis, 5; Amgen, Lilly, Novartis, Warner-Chilcott, 8; Amgen, Merck, Osteoporosis: 0 Update...8 Disclosure: Amgen, Lilly, Merck, Novartis, 5; Amgen, Lilly, Novartis, Warner-Chilcott, 8; Amgen, Merck, McComas, Heather, PharmD CORC Pre-meeting Course for Practice Managers - How to Maximize the Use of Your Practice Data...8 McCurdy, Deborah K., MD Rheumatic Disease Update: Inflammatory Eye Disease...46 McLean, Robert R., DSc, MPH Beyond the Basics: A Real Life Example of Multiple Imputation for Missing Data Problems... Demystifying the Study Section: How Grants Are Reviewed and Scored...79 Highlights from the 0 ARHP Sessions...6 McMahan, Zsuzsanna H., MD, MHS ACR Knowledge Bowl - Final Round...68 ACR Knowledge Bowl - Preliminary Round.. 7 The Great Masqueraders: Malignancies in Rheumatic Disease Thieves Market: Show Me Your Best Cases...49 Update on Immune Mediated Glomerular Disease...9 McMenamin, Terence, MA Arthritis and the Older Worker...0 Mease, Philip, MD Update on Psoriatic Arthritis and the Spondylarthropathies...49 Disclosure: Abbott Immunology Pharmaceuticals, 5, 8; Abbott Laboratories, ; Amgen,, 5, 8; Bristol Myers Squibb,, 5, 8; Celgene,, 5; Crescendo,, 5; Cresendo, 8; Forest Laboratories,, 5, 8; Genentech and Biogen IDEC Inc.,, 5, 8; Janssen Pharmaceutica Product, L.P.,, 5, 8; Lilly,, 5, 8; Merck Pharmaceuticals,, 5; Novartis Pharmaceutical Corporation,, 5; Pfizer Inc,, 5, 8; UCB,, 5, 8 Medsger Jr., Thomas A., MD Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Serum Autoantibodies in Systemic Sclerosis: Usefulness in Diagnosis, Clinical Subsetting and Predicting Outcomes...9 Melmed, Gil Y., MD Immunizations in Patients with Rheumatologic Disease...96 Disclosure: Abbott Laboratories, 8; Jannsen, 5; Pfizer, Melton, Alton, MD Immunodeficiency Syndromes (04)...56 Mercer, Louise K., MBChB, MRCP Plenary Session II: Discovery Merkel, Peter A., MD, MPH Vasculitis: Update (050)...70 Disclosure: Actelion Pharmaceuticals US, 5; Bristol-Myers Squibb, ; Celgene, ; Genentech and Biogen IDEC Inc., ; Genzyme Corporation, 5; Human Genome Sciences, Inc., ; Proteon Therapeutics, Vasculitis: Update (070)...9 Disclosure: Actelion Pharmaceuticals US, 5; Bristol-Myers Squibb, ; Celgene, ; Genentech and Biogen IDEC Inc., ; Genzyme Corporation, 5; Human Genome Sciences, Inc., ; Proteon Therapeutics, Merrell, Victoria A., MPT, PA-C Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice...59 Michaud, Kaleb, PhD Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice...0 Mikuls, Ted R., MD, MSPH Extra-articular Involvement in Rheumatoid Arthritis... Gout and Hyperuricemia: Diseases Beyond the Joint...8 Miller, Daniel, MD Dermatopathology of Rheumatic Diseases (0)... Dermatopathology of Rheumatic Diseases ()...48 Monach, Paul A., MD, PhD Vasculitis: Update (040)...60 Vasculitis: Update (080)...0 Monrad, Seetha U., MD ACR/ABIM Maintenance of Certification Learning Session - 0 Update in Rheumatology... Moonaz, Steffany, PhD, RYT-500 Clinical Focus Course - Breakout Session I...6 Disclosure: Arthritis Foundation, 5; NIH, 5; Yoga for Arthritis, 4 Clinical Focus Course - Breakout Session II...6 Disclosure: Arthritis Foundation, 5; NIH, 5; Yoga for Arthritis, 4 Morgan DeWitt, Esi M., MD, MSCE Clinical Research Conference - Break Out Groups...8 Morris, Edward L., MD CORC FORUM: Achieving Economic Goals in an Era of Healthcare Reform... Murphey, Mark D., MD Best Practices for Ordering Diagnostic Imaging in Evaluating Rheumatologic Conditions...0 Murphy, Kenneth M., MD, PhD Macrophage and Dendritic cell Heterogeneity in Tissue Inflammation and Fibrosis...7 Income Inequities Are Perilous to People with Arthritis...56 Clinical Research Conference - Break Out Groups...9 Minimizing Falls in Geriatric Rheumatic Populations...80 Muscal, Eyal, MD, MS Neuropsychiatric Lupus in Children and Adolescents...7 Müller-Ladner, Ulf, MD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis...6 Disclosure: German Research Foundation, N Naredo, Esperanza, MD Musculoskeletal Ultrasound Course for Rheumatologists - Break Out Session: Adult Rheumatology...0 Musculoskeletal Ultrasound Course for Rheumatologists - The Shoulder... Nelson, J. Lee, MD Immunology of Pregnancy and Impact on Autoimmune Pathogenesis... Neogi, Tuhina, MD, PhD Clinical and Epidemiologic Study Designs in Rheumatic Disease Research...9 Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs? Program Book

351 Newman, Eric D., MD Strategies to Enhance Office Efficiencies and Access to Care in Rheumatology Practice...97 Nigrovic, Peter A., MD Advances in the Biology of Aging... Aging and the Rheumatic Diseases...8 Chronic Recurrent Multifocal Osteomyelitis New Developments in Systemic Juvenile Idiopathic Arthritis Management...69 Pediatric Rheumatology for Adult Rheumatologists (0)...60 Prospects for Prevention and Cure of Rheumatoid Arthritis...9 Nikolov, Nikolay P., MD Biosimilars Development: Food and Drug Administration Perspective... Noble, Paul, MD Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Nola, Kam, PharmD, MS Minimizing Falls in Geriatric Rheumatic Populations...80 New Medication Developments in Rheumatology...7 Norris, Jill M., MPH, PhD Preclinical Autoimmunity Potential for Prevention...8 O O Brien, Virginia, OTD, OTR/L, CHT Clinical Focus Course - Breakout Session I...6 Disclosure: Books on Hand, Caring for the Painful Thumb, nd ed.,editor s royalty per book, 5 Clinical Focus Course - Breakout Session II...6 Disclosure: Books on Hand, Caring for the Painful Thumb, nd ed.,editor s royalty per book, 5 O Connell, Ryan M., PhD MicroRNA and the Rheumatic Diseases... O Dell, James R., MD ACR Leadership Town Hall Meeting & Business Meeting...0 Plenary Session I: Discovery 0... Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice...0 O Rourke, Kenneth S., MD Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Joint Injection Techniques (4)...97 Joint Injection Techniques (9)... O Toole, John, BA Practice Managers: Improving Access and Website Marketing...46 Oates, Jim, MD Metabolic Abnormalities in Autoimmunity.. 48 Oatis, Carol A., PhD, PT Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes through Examination of Patient Factors, Practice Variation and Best Practice Recommendations Oddis, Chester V., MD Diagnostic Assessments in Myopathy... Plenary Session III: Discovery Rheumatology Roundup: Highlights from the 0 Annual Scientific Meeting... Year in Review...0 Okada-Yim, Sarah K., MD Biosimilars Development: Food and Drug Administration Perspective... Onel, Karen, MD Neuropsychiatric Lupus in Children and Adolescents...7 Ostergaard, Mikkel, MD, PhD, DMSc Peripheral Magnetic Resonance Imaging in Rheumatology Practice (8)...60 Peripheral Magnetic Resonance Imaging in Rheumatology Practice ()...9 Ostrov, Barbara E., MD Pediatric Rheumatology Town Hall Meeting...7 Oyoo, Omondi G., MD, MMed ILAR The Current Rheumatology Workforce Across the Globe...60 P Pabolu, Sangeetha, MD Thieves Market: Show Me Your Best Cases...49 Paget, Stephen A., MD Pain: Dealing with Patients with Refractory Pain in Musculoskeletal and Autoimmune Disorders (065)...9 Paik, Julie J., MD Thieves Market Poster Presentation - Myalgias: Out of Proportion to Exam...95 Pap, Thomas, MD Basic Research Conferance - Session III: Fibroblasts as Invaders and Aggressors...5 Disclosure: Abbott Laboratories, 5; Artialis S.A., 5; Bioiberica S.A., 5; Chugai, 5; Eli Lilly and Company, 5; Mundipharma, 8 Parke, Ann L., MD Classification and Treatment of Sjögren s Syndrome...48 Passo, Murray H., MD Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (005)... Disclosure: Pfizer Inc,, 5 Thieves Market Poster Presentation - Neonate with Sclerodermatous Limbs Disclosure: Pfizer Inc,, 5 Pavalko, Fredrick, PhD Mechanotransduction in Bone and Cartilage...7 Perl, Andras, MD, PhD Metabolic Abnormalities in Autoimmunity.. 76 Petri, Michelle, MD, MPH Rheumatic Disease Update: Systemic Lupus Erythematosus... Disclosure: Anthera, 5; Genentech and Biogen IDEC Inc., 5; GlaxoSmithKline, 5; HGS, 5; Medimmune, 5; Pfizer Inc, 5; UCB, 5 Pincus, Theodore, MD Patient Questionnaires: Multi-Dimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data and Beyond toward a Standard, Scientific, Quantitative Patient History (7)...8 Pine, Linda J., PharmD New Medication Developments in Rheumatology...7 Disclosure: Amgen, 5 Plenge, Robert M., MD, PhD Genetics as a Tool for Elucidating Autoimmune Disease Pathogenesis...0 Plenary Session II: Discovery Prospects for Prevention and Cure of Rheumatoid Arthritis...9 Pope, Janet E., MD, MPH Raynaud s and Digital Ischemia (047)...70 Disclosure: Actelion and Pfizer,, 5 Raynaud s and Digital Ischemia (085)...9 Disclosure: Actelion and Pfizer,, 5 Pope, Richard, MD MicroRNA and the Rheumatic Diseases... Plenary Session II: Discovery Invited Speaker /Moderator Index 0 Program Book 49

352 Invited Speaker /Moderator Index 50 Synovial Immunobiology and Response to Therapy in Rheumatoid...58 The Plasticity of T Regulatory Cells and their Role in Autoimmunity... Porter, Janet, PhD Practice Management: Patients as Partners in Design and Delivery...56 Powell, Jonathan, MD, PhD Metabolic Abnormalities in Autoimmunity.. 48 Prockop, Darwin J., MD, PhD Basic Research Conference - Session VI: Therapeutic Aspects: Biomarkers and Targeting Fibrosis (continued)...6 Disclosure: <5% Temple Theraeutics, LLC, 6 R Radisky, Derek C., PhD Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Rao, Smita, PT, PhD Early Rehabiliation for Hip and Foot Osteoarthritis: Opportunities and Challenges Ratzlaff, Charles, PhD, PT, FCAMT Clinical Focus Course - Osteoarthritis Assessment: Thinking Outside of the Joint.. 6 Ray, Laura E., MA, MLS Web-based Tools for Enhancing and Managing Teaching and Clinical Practice (8)...0 Reginster, Jean-Yves, MD, PhD Plenary Session II: Discovery Disclosure: Bristol Myers Squibb, Merck Sharp and Dohme, Rottapharm, Teva, Lilly, Novartis, Roche, GlaxoSmithKline, Amgen, Servier, ; Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed, NPS, Theramex, UCB, 5 Reveille, John D., MD ILAR The Current Rheumatology Workforce across the Globe...59 Reactive Arthritis: An Update (068)...9 Richardson, Bruce C., MD, PhD Epigenetic Factors in Autoimmune Disease.. 60 Disclosure: Sequenom, Ritchlin, Christopher T., MD, MPH Update on Psoriatic Arthritis and the Spondylarthropathies...49 Disclosure: Abbott Laboratories, 5; Amgen, 5; Janssen., 5 Robbins, Mark L., MD, MPH Rheumatoid Arthritis Treating to Target: How to Incorporate Rheumatoid Arthritis Disease Activity Measures into Routine Practice Program Book Robinson, William H., MD, PhD Rheumatology Research Foundation Special Session: Disease Targeted Research...94 Roediger, Joan M., JD, LLM Contract Negotiations for Physicians...9 Rose, Jillian A., LMSW A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective...97 Promoting Participation: Where Is the Field and Where Do We Go Next?...89 Rose, Shawn, MD, PhD Thieves Market: Show Me Your Best Cases Rosen, Antony, MD Basic Immunology for Clinical Rheumatologists (04)...70 Basic Immunology for Clinical Rheumatologists (07)...0 Rosenthal, Ann K., MD Crystal: Pseudogout (08)...9 Roth, Johannes, MD Musculoskeletal Ultrasound Course for Rheumatologists - Break Out Session: Pediatric Rheumatology... Rouster-Stevens, Kelly A., MD, MSc Pediatric Systemic Lupus (057)...88 Rovin, Brad H., MD Systemic Lupus Erythematosus: Lupus Nephritis (078)...0 Disclosure: Genentech and Biogen IDEC Inc., 5; Lilly, 5; Teva Pharmaceuticals, Systemic Lupus Erythematosus: Lupus Nephritis (088)...9 Disclosure: Genentech and Biogen IDEC Inc., 5; Lilly, 5; Teva Pharmaceuticals, Rubin, Devon I., MD Diagnostic Assessments in Myopathy... Ruddy, Shaun, MD Rheumatology Research Foundation Memorial Lectureship: Pathogenesis of Rheumatoid Arthritis: The Voyage from Pre-Rheumatoid Arthritis to Joint Destruction...6 Ruiz, Ximena D., MD ACR Knowledge Bowl - Preliminary Round.. 7 Russell, Elizabeth B., MD Review Course - Hypermobility, Diagnosis, Disease Associations, Treatment...5 Preoperative Assessment and Perioperative Management of the Patient with Rheumatic Disease: What Every Rheumatologist Should Know (Clinical Review)...8 Rönnelid, Johan, MD, PhD Making Sense of Autoantibodies in the Diagnosis of Systemic Rheumatic Diseases.. 9 Disclosure: Phadia/Thermifischer, BMD/ Theradiag, Euroimmun, 9; Phadia/Thermofischer, 9; Phadia/Thermofisher, Abbott and Pfizer, 5 S Saag, Kenneth G., MD, MSc Challenging Cases in Osteoporosis Management (04)...70 Disclosure: Amgen,, 5; Eli Lilly and Company,, 5; Merck Pharmaceuticals,, 5 Osteoporosis: From Bisphosphonates and Beyond...7 Disclosure: Amgen,, 5; Eli Lilly and Company,, 5; Merck Pharmaceuticals,, 5 Salt, Elizabeth G., PhD Fungal Infections and Tuberculosis in Patients with Rheumatologic Disease...9 Hepatitis in Patients with Rheumatologic Disease...9 Immunizations in Patients with Rheumatologic Disease...96 Shoulder Pain and Rotator Cuff Tear in Rheumatoid Arthritis...6 Salvarani, Carlo, MD Polymyalgia Rheumatica - Recent Advances and Ongoing Questions...0 Samuels, Jonathan, MD Musculoskeletal Ultrasound Course for Rheumatologists...0,, Savage, Eimear, MB, BAO, BCh Thieves Market Poster Presentation - Treatment of Fulminant Myocarditis and Macrophage Activation Syndrome Secondary to Adult Onset Still s Disease...95 Scanzello, Carla R., MD, PhD Clinical Focus Course - Osteoarthritis as We Understand It Today...6 Schanberg, Laura E., MD Clinical Research Conference - Day Two Introductory Remarks...8 Disclosure: AstraZeneca, 5; GlaxoSmithKline, 5; Pfizer Inc, ; UCB, 5 Clinical Research Conference - Special Issues in Pain Research... Disclosure: AstraZeneca, 5; GlaxoSmithKline, 5; Pfizer Inc, ; UCB, 5 Novel Approaches to Pain Management in Juvenile Idiopathis Arthritis...89 Disclosure: AstraZeneca, 5; GlaxoSmithKline, 5; Pfizer Inc, ; UCB, 5

353 Scher, Jose U., MD Microbiome Influence on Autoimmunity.. 0 Scher, Richard K., MD, MS Dermatology Topics for Rheumatologists: What You Need to Know...8 Schett, Georg A., MD, PhD Osteoimmunology...0 Schikler, Kenneth N., MD Puberty, Adolescence and Rheumatologic Disease...48 Schlenk, Elizabeth A., PhD, RN A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective...97 Disclosure: UCB, Schlesinger, Naomi, MD Rheumatic Disease Update: Gout...6 Disclosure: Novartis Pharmaceutical Corporation, ; Novartis Pharmaceutical Corporation; Takeda, Savient, 8; Novartis Pharmaceutical CorporationTakeda, Savient, Enzyme Rx, URL Pharma ;, 5; Sobi, 5; Takeda, 8 Schmidt, Wolfgang A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two...0 Disclosure: Abbott Immunology Pharmaceuticals,, 5, 8; Actelion Pharmaceuticals US, ; Berlin- Chemie / Menarini, 5, 8; Esaote, ; General Electric, ; Medac, 8; Merck Sharp Dohme,, 8; Novartis Pharmaceutical Corporation, ; Pfizer Inc, 8; Roche Pharmaceuticals,, 5, 8; UCB, 8 Musculoskeletal Ultrasound Course for Rheumatologists - Break Out Session: Adult Rheumatology...0 Disclosure: Abbott Immunology Pharmaceuticals,, 5, 8; Actelion Pharmaceuticals US, ; Berlin- Chemie / Menarini, 5, 8; Esaote, ; General Electric, ; Medac, 8; Merck Sharp Dohme,, 8; Novartis Pharmaceutical Corporation, ; Pfizer Inc, 8; Roche Pharmaceuticals,, 5, 8; UCB, 8 Schneider, Rayfel, MBBCh Systemic Arthritis and Still s Disease (008)... Disclosure: Hoffmann-La Roche, Inc., 5, 8; Innomar Strategies, 5 Schwartzman, Sergio, MD Inflammatory Eye Disease/Uveitis (0)...8 Disclosure: Janssen, Abbott, UCB, Amgen, Pfizer, Genentech, Human Genome Science, 8 Seo, Philip, MD, MHS Rheumatic Disease Update: Vasculitis...7 Serhan, Charles, PhD Basic Research Conference - Session II: Core Signaling Mechanisms in Fibrosis... Disclosure: BayerHealth Care, 7; NIH grants, ; Resolvyx Pharmaceutical, ; Schiff, 9; Solutex Corporation, 5 Seymour, Sally M., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond...6 Shadick, Nancy A., MD, MPH Rheumatoid Arthritis: Difficult Cases (07).. 60 Disclosure: Abbott Immunology Pharmaceuticals, ; Amgen, ; Crescendo Bioscience, ; Genentech and Biogen IDEC Inc., ; Medimmune, Shah, Ami A., MD, MHS The Great Masqueraders: Malignancies in Rheumatic Disease Shahrara, Shiva, PhD Plenary Session III: Discovery Shanmugam, Victoria K., MBBS Clinicopathologic Conference: A Patient with Hepatitis C and Inflammatory Polyarticular Arthritis...58 Disclosure: Spouse is a partner at the law firm of Williams and Connolly LLP which represents various pharmaceutical and medical device companies. The partners in the firm share in the profits related to representing these companies., 9 New Anticoagulants: What a Hematologist Thinks a Rheumatologist Needs to Know!...6 Disclosure: Spouse is a partner at the law firm of Williams and Connolly LLP which represents various pharmaceutical and medical device companies. The partners in the firm share in the profits related to representing these companies., 9 Shapiro, Marjorie, PhD Biosimilars Development: Food and Drug Administration Perspective... Sherlock, Jonathan, DM, MBBCh Plenary Session I: Discovery Disclosure: Merck, Shiboski, Stephen, PhD Classification and Treatment of Sjögren s Syndrome...48 Siegel, Richard M., MD, PhD Mechanisms of Autoinflammatory Diseases...9 Sieper, Joachim, MD Ankylosing Spondylitis: Disease Modification (06)...9 Disclosure: Abbott, Merck, Pfizer, Janssen, ; Abbott, Merck, Pfizer, Lilly, UCB, 5; Abbott, Merck, Pfizer, UCB, 8 Sigal, Leonard H., MD An Introduction to Immunology... Sikorski, Simon, MD CORC Pre-meeting Course for Practice Managers - Effective Marketing for Today s Medical Practice...7 Disclosure: Healthcare Marketing Center of Excellence, 4 The Connected Rheumatology Practice: Electronic Health Record and Social Media Implementation and Customization...69 Disclosure: Healthcare Marketing Center of Excellence, 4 Silver, Richard M., MD Connective Tissue Disease Associated Interstitial Lung Disease Disclosure: Genentech and Biogen IDEC Inc., 8; Sanofi-Aventis Pharmaceutical, 5; Takeda, 8 Silverman, Gregg J., MD Immunology of Pregnancy and Impact on Autoimmune Pathogenesis... New Therapies for Modulating Signaling in Rheumatoid Arthritis... Silverman, Stuart L., MD Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (4)...48 Disclosure: Amgen, Genentech, Lilly, Novartis and Pfizer/Wyeth, 5; Amgen, Lilly, Novartis and Pfizer/ Wyeth, 8; Cedars-Sinai Medical Center, ; Lilly, Pfizer/Wyeth, Osteoporosis: Interpreting Dual Energy X-ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm ()...6 Disclosure: Amgen, Genentech, Lilly, Novartis and Pfizer/Wyeth, 5; Amgen, Lilly, Novartis and Pfizer/ Wyeth, 8; Cedars-Sinai Medical Center, ; Lilly, Pfizer/Wyeth, Simon, Lee S., MD Rheumatoid Arthritis: Safety of Novel Therapies (075)...0 Disclosure: Affinergy, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Nitec, Bayer, Rigel, Chelsea, 5; Alder, Cephalon, Purdue, EMDSerono, Altea, Talagen, Tigenix, Antigenics, Forest, Genzyme, CaloSyn, King, Horizon, Pozen, ILPharma, Analgesic Solutions, Creabilis, Kowa, Array, Astra Zeneca, 5; Regeneron, Cypress, Savient, Nicox, Fidelity, Extera, Wyeth, Asahi, Winterex, Metabolix, Solace, Puretechventures, White Mountain Pharma, Abbott, Omeros, Jazz, Takeda, Teva, Zydus, Proprius, Savient, 5 Rheumatoid Arthritis: Safety of Novel Therapies (086)...9 Disclosure: Affinergy, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Nitec, Bayer, Rigel, Chelsea, 5; Alder, Cephalon, Purdue, EMDSerono, Altea, Talagen, Tigenix, Antigenics, Forest, Genzyme, CaloSyn, King, Horizon, Pozen, ILPharma, Analgesic Solutions, Creabilis, Kowa, Array, Astra Zeneca, 5; Regeneron, Cypress, Savient, Nicox, Fidelity, Extera, Wyeth, Asahi, Winterex, Metabolix, Solace, Puretechventures, White Mountain Pharma, Abbott, Omeros, Jazz, Takeda, Teva, Zydus, Proprius, Savient, 5 Singh, Jasvinder A., MBBS Gout and Hyperuricemia: Diseases Beyond the Joint...8 Disclosure: Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis, 5; Takeda and Savient, Invited Speaker /Moderator Index 0 Program Book 5

354 Invited Speaker /Moderator Index Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?... Disclosure: Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis, 5; Takeda and Savient, Paradigm Shifts in Rheumatoid Arthritis...9 Disclosure: Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis, 5; Takeda and Savient, Sittig, Dean F., PhD The Unintended Consequences of Health Information Technology... Disclosure: Office of the National Coordinator for Health Information Technology; AHRQ, Siverling, Scott, PT, OCS Early Rehabiliation for Hip and Foot Osteoarthritis: Opportunities and Challenges Slusher, BArbara A., PA-C, MSW Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice...59 Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; cardinal health specialty services, 5; Pfizer Inc, 8; UCB, 8 Rheumatoid Arthritis Disease Activity Measures and Quality Indicators: Correct Use and Future Directions... Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; cardinal health specialty services, 5; Pfizer Inc, 8; UCB, 8 Smarr, Karen L., PhD Depression in Rheumatic Diseases...80 Smith, Benjamin J., PA-C ACR Leadership Town Hall Meeting & Business Meeting...0 Plenary Session I: Discovery 0... Smith, Terry J., MD Basic Research Conference - Session II: Core Signaling Mechanisms in Fibrosis... Specks, Ulrich, MD The Great Debate: In 0 What are the Roles of Cyclophosphamide versus Rituximab in ANCA-Associated Vasculitis...9 Disclosure: Genentech and Biogen IDEC Inc.,, 5 Spiegel, Lynn R., MDCM Novel Approaches to Pain Management in Juvenile Idiopathis Arthritis...88 Spiera, Robert F., MD Connective Tissue Disease Associated Interstitial Lung Disease Curbside Consults - Ask the Professors...7 The Great Debate: In 0 What are the Roles of Cyclophosphamide versus Rituximab in ANCA-Associated Vasculitis...9 Thieves Market: Show Me Your Best Cases. 49 Starz, Terence W., MD A Practical Understanding of Function in Rheumatoid Arthritis: A Multidisciplinary Perspective...97 Staud, Roland, MD Clinical Research Conference - Break Out Groups...8 Disclosure: Forest Laboratories, ; Pfizer Inc, Steen, Virginia D., MD Review Course - Hypermobility, Diagnosis, Disease Associations, Treatment...5 Disclosure: Actelion Pharmaceuticals US, ; Gilead Science, ; Roche Pharmaceuticals, ; United Therapeutics, Review Course - Inflammatory Myositis: Disclosure: Actelion Pharmaceuticals US, ; Gilead Science, ; Roche Pharmaceuticals, ; United Therapeutics, Review Course - Lupus - More than Nephritis: Treatment of Non-Nephritis Lupus Problems Disclosure: Actelion Pharmaceuticals US, ; Gilead Science, ; Roche Pharmaceuticals, ; United Therapeutics, Review Course - When Thick Skin is Not a Good Thing...4 Disclosure: Actelion Pharmaceuticals US, ; Gilead Science, ; Roche Pharmaceuticals, ; United Therapeutics, Scleroderma Bowel Disease: From Top to Bottom (Clinical Review)...7 Disclosure: Actelion Pharmaceuticals US, ; Gilead Science, ; Roche Pharmaceuticals, ; United Therapeutics, Update on Treatment of Systemic Lupus Erythematosus...9 Disclosure: Actelion Pharmaceuticals US, ; Gilead Science, ; Roche Pharmaceuticals, ; United Therapeutics, Stinson, Jennifer N., PhD, RN, CPNP Clinical Research Conference - Break Out Groups...9 Novel Approaches to Pain Management in Juvenile Idiopathis Arthritis...89 Disclosure: CIHR, NIH, CAN, Stohl, William, MD, PhD Advances in Targeting of B cell Survival Factors...9 Disclosure: Eli Lilly and Company, 9; Human Genome Sciences, Inc., 9; Pfizer Inc, 9; Xencor, Inc., Stone, John H., MD, MPH IgG4-Related Disease Past Lessons and Future Directions... Disclosure: Genentech, 5 Vasculitis Mimics (00)... Disclosure: Genentech, 5 Stürmer, Til, MD, MPH, PhD Threats to Validity: Confounding in Rheumatic Disease Research...9 Disclosure: AHRQ, ; GlaxoSmithKline, ; Merck Pharmaceuticals, ; NIH, ; Sanofi-Aventis Pharmaceutical, Suarez-Almazor, Maria E., MD, PhD Disparities in the Use of Joint Arthroplasty: A Pervasive Matter Leading to Inequitable Care...59 Disclosure: Zimmer, 5 Szauter, Karen, MD Medical Education: The Year in Review... T Tak, Paul P., MD, PhD Synovial Immunobiology and Response to Therapy in Rheumatoid...58 Disclosure: GlaxoSmithKline, Tesser, John RP, MD Incorporating Physician Assistants and Nurse Practitioners into Rheumatology Practice...59 Theis, Kristina A., BA, MPH Arthritis and the Older Worker...0 Income Inequities Are Perilous to People with Arthritis...56 Tillman, Melesia, CPC, CRHC, CHA Certified Rheumatology Coder Course: Unlock the Mystery: A Roadmap for Rheumatology Coding - Day One... Certified Rheumatology Coding Course Examination: Unlock the Mystery: A Roadmap for Rheumatology Coding - Day Two...9 Tracey, Irene, MA, (Oxon), PhD Clinical Research Conference - Break Out Groups...8 Clinical Research Conference - Methods for Phenotyping Pain-...8 Troxell, Megan, MD Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (07)... Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis ()...9 Tuan, Rocky S., PhD Osteoarthritis Therapeutics: Will This be the Decade for Breakthroughs?... Tzaribachev, Nikolay, MD Musculoskeletal Ultrasound Course for Rheumatologists - Break Out Session: Pediatric Rheumatology... U Utrie, Paul C., MD Musculoskeletal Exam Skills I: General Musculoskeletal Examination for Arthritis (04) Program Book

355 Musculoskeletal Exam Skills II: Regional Musculoskeletal Examination of the Neck and Low Back ()...48 Musculoskeletal Exam Skills III: Regional Musculoskeletal Examination of the Shoulder and Knee (0)...6 V Valastyan, Scott J., PhD Basic Research Conference - Session III: Fibroblasts as Invaders and Aggressors...5 van der Heijde, Desiree M., MD, PhD Review Course - Review and Update of Ankylosing Spondylitis...4 Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; AstraZeneca, 5; Bristol-Myers Squibb, 5; Centocor, Inc., 5; Chugai, 5; Eli Lilly and Company, 5; GlaxoSmithKline, 5; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; otsuka, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; Sanofi-Aventis Pharmaceutical, 5; Schering-Plough, 5; UCB, 5; Wyeth Pharmaceuticals, 5 Update on Psoriatic Arthritis and the Spondylarthropathies Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; AstraZeneca, 5; Bristol-Myers Squibb, 5; Centocor, Inc., 5; Chugai, 5; Eli Lilly and Company, 5; GlaxoSmithKline, 5; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 5; otsuka, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; Sanofi-Aventis Pharmaceutical, 5; Schering- Plough, 5; UCB, 5; Wyeth Pharmaceuticals, 5 Varga, John, MD Basic Research Conferance - Session III: Fibroblasts as Invaders and Aggressors... 5 Disclosure: JBT, Basic Research Conference - Session I: The Biology of Mesenchymal Cells... Disclosure: JBT, Basic Research Conference - Session IV: Immunity and Mesenchymal Cells Disclosure: JBT, Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis... 5 Disclosure: JBT, Basic Research Conference - Session VI: Therapeutic Aspects: Biomarkers and Targeting Fibrosis (continued)... 6 Disclosure: JBT, Venables, Patrick, MD Extra-articular Involvement in Rheumatoid Arthritis... Vignali, Dario AA, PhD The Plasticity of T Regulatory Cells and their Role in Autoimmunity... Disclosure: BMS, 7 Vijg, Jan, PhD Advances in the Biology of Aging... Villasenor Ovies, Pablo, MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (0)... Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (5)... 0 Vincent, Ann, MD The Puzzle of Fatigue in Rheumatoid Arthritis: Putting the Pieces Together... 0 Mechanotransduction in Bone and Cartilage Violette, Shelia, PhD Basic Research Conference - Session V: Therapeutic Aspects: Biomarkers and Targeting Fibrosis... 5 Disclosure: Bioge Idec, ; Biogen Idec, Vivino, Frederick B., MD Classification and Treatment of Sjögren s Syndrome Curbside Consults - Ask the Professors... 7 Vleugels, Ruth Ann, MD, MPH Dermatological Manifestations of Rheumatic Diseases (054)...88 W Wakefield, Richard J., BM, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two... Musculoskeletal Ultrasound Course for Rheumatologists - Break Out Session: Adult Rheumatology... Walston, Jeremy, MD Aging and the Rheumatic Diseases...8 Wang, Chenchen, MD, MSc Complementary and Alternative Medicine: Evidence Based Options for Arthritis Patients. 9 Wang, Heng, MS Plenary Session III: Discovery Ward, Michael M., MD Demystifying the Study Section: How Grants Are Reviewed and Scored...79 Warren, Robert W., MD, PhD, MPH CORC Pre-meeting Course for Practice Managers - Innovations for the Office...8 The Guide to Meaningful Use and Beyond.. 94 Wasko, Mary Chester M., MD, MSc ACR/ABIM Maintenance of Certification Learning Session - 0 Update in Rheumatology... Wasserman, Sara, MD ACR Knowledge Bowl - Preliminary Round.. 68 Watcher, Sandra J., BSN Forming An Education and Support Group from the Ground Up...8 Watts, Nelson B., MD Osteoporosis: From Bisphosphonates and Beyond...7 Disclosure: OsteoDynamics, Weinblatt, Michael E., MD Plenary Session III: Discovery Disclosure: Bristol-Myers Squibb, Abbott,, 5 Weisman, Michael H., MD Ankylosing Spondylitis: 0 Update (0).. 56 Ankylosing Spondylitis: 0 Update (04).. 70 Update on Safety Issues in the Treatment of Rheumatic Diseases From the Food and Drug Administration and Beyond...6 Wells, Alvin F., MD, PhD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Day Two... Disclosure: Terason, 5 Westby, Marie D., PT, PhD Clinical Focus Course - 0 ACR Guidelines on Osteoarthritis: A Focus on Pharmacologic Management...6 Clinical Focus Course - Addressing Risk Factors for Osteoarthritis through the Lifespan: Let s Start with the Kids!...6 Clinical Focus Course - Breakout Session I...6 Clinical Focus Course - Breakout Session II.. 6 Clinical Focus Course - Concluding Remarks Clinical Focus Course - Introduction...6 Clinical Focus Course - Obesity and Osteoarthritis: Clinicians Can Make a Difference in Promoting Healthier Lifestyles...7 Clinical Focus Course - Osteoarthritis as We Understand It Today...6 Clinical Focus Course - Osteoarthritis Assessment: Thinking Outside of the Joint.. 6 Clinical Focus Course - Osteoarthritis Chronic Disease Management in the Age of the Internet, Apps and Tweets...7 Clinical Focus Course - Using Outcome Measures to Inform Clinical Practice...6 Total Knee Arthroplasty Rehabilitation: Optimizing Functional Outcomes Through Examination of Patient Factors, Practice Variation and Best Practice Recommendations Invited Speaker /Moderator Index 0 Program Book 5

356 Invited Speaker /Moderator Index Weyand, Cornelia M., MD, PhD Aging and the Rheumatic Diseases...8 Wiener, Aimee, ARNP, MSN Infusion Room Information for Medical Professionals...59 Wilkes, Margaret R., MD Osteoporosis: From Bisphosphonates and Beyond...7 Williams, David A., PhD Clinical Research Conference - Break Out Groups...8 Disclosure: Eli Lilly and Company, 5; Forest Laboratories, 5; Pfizer Inc, 5 Clinical Research Conference - Methods for Phenotyping Pain-...8 Disclosure: Eli Lilly and Company, 5; Forest Laboratories, 5; Pfizer Inc, 5 New and Better Habits! Facilitating Patient Selfmanagement with Proven Behavior Change Strategies...59 Disclosure: Eli Lilly and Company, 5; Forest Laboratories, 5; Pfizer Inc, 5 Non-pharmacological Management of Fibomyalgia: Your Toolbox Disclosure: Eli Lilly and Company, 5; Forest Laboratories, 5; Pfizer Inc, 5 Williams, Mark, MBBS, BSc, (Hons) Thieves Market Poster Presentation - Medical Re-vascularisation...95 Witter, James P., MD, PhD Clinical Research Conference - Break Out Groups...8 NIAMS-Sponsored Research in Rheumatology: 0 Highlights... Wolfe, Frederick, MD Clinical Research Conference - Methods for Phenotyping Pain-...8 Woodward, Amy L., MD, MPH Rheumatology Research Foundation Special Session: Clinician Scholar Educator Presentations...6 Woolf, Clifford, MB, BCh, PhD Clinical Research Conference - Introduction: State of the Field... Disclosure: Abbott Laboratories, 5; Bristol-Myers Squibb, 5; GlaxoSmithKline, ; Lupin Laboratories, 5; Pfizer Inc, 5 Mechanisms of Pain in Rheumatic Diseases...8 Disclosure: Abbott Laboratories, 5; Bristol-Myers Squibb, 5; GlaxoSmithKline, ; Lupin Laboratories, 5; Pfizer Inc, 5 Wright, Laura, MBA, CMPE CORC Pre-meeting Course for Practice Managers - Improve Revenue Cycle Management Effectiveness and Optimize Cash Flow...7 CORC Pre-meeting Course for Practice Managers - Improving Accounts Receivable for Profitability CORC Pre-meeting Course for Practice Managers - Keynote Address: The World s Best Managers Do Manage Differently-Find Your Strengths for Efficiency!... 7 Practice Management: Patients As Partners in Design and Delivery...46 Practice Managers: Improving Access and Website Marketing...46 Y Yazici, Hasan, MD Behçet s Disease (00)... Yelin, Edward H., PhD Income Inequities Are Perilous to People with Arthritis...56 NIAMS-Sponsored Research in Rheumatology: 0 Highlights... Yeremenko, Nataliya, PhD Plenary Session III: Discovery York, Michael R., MD Scleroderma: Systemic Sclerosis (09)...60 Z Zanin-Zhorov, Alexandra, PhD Visualizing the Immuno-inflammatory Response...04 Zen, Yoh, MD, PhD IgG4-Related Disease Past Lessons and Future Directions... Zhang, Yuqing, DSc, MPH Selection Bias in Rheumatic Disease Research Risk Factor Paradox and Other Issues...96 Threats to Validity: Confounding in Rheumatic Disease Research...9 Ziegler, Jennifer A Forming An Education and Support Group from the Ground Up...8 Zychlinsky, Arturo, PhD Neutrophil Extracellular Traps (NETosis) in Rheumatic Disease Program Book

357 A Aakhus, S 68 Aalbers, CJ 4 Aalokken, TM Aarrass, S 090, 6 Aati, O 586 Abaci, N 989 Abarca, N 6 Abbas, AR 60 Abbas, W 87 Abbasi, T 4, 45 Abbey, S 86 Abboud, J 647 Abdelnaby, R 67 Abdollahi-Roodsaz, S 896, 5 Abdulahad, WH 54, 860, 5 Abe, T 877 Abenhaim, L 68, 80 Aberle, TJ 48 Abignano, G 70, 47 Abinun, M 66 Abji, F 57, 58 Ablin, JN 955 Abouassi, H 8 Abraham, DJ 785, 854, 9, 05, 07 Abrahamowicz, M 70, 64, 688 Abram, F 4 Abramowitz, M 949 Abrams, K 749, 759, 76 Abramsky-Risman, S 4 Abramson, SB 60,, 6 Abreu, AS 064 Abreu, MM 96, 97 Abria, C 44, 85 Absher, D 79 Abu-Asab, M 0 Abu-Shakra, M 9, 08 Abud-Mendoza, C 679 Acasuso, M 567 Acharya, S 700 Achenbach, SJ 8 Achilleos, K 60 Acikel, C 477 Acosta, I 998, 999 Acosta Felquer, ML 5, 68, 58 Acu, R Adachi, JD 06, 08, 05, 959, 979, 00 Adam, PM 7, 405, 40 Adams, AB 6 Adams, BS Adams, M 45, 5 Adams, RJ 6 Adan, AM 85 Addimanda, O 5, 6 Addya, S 496 Adebajo, AO 57 Adeleke, GA 80 Adema, G 844 Ademowo, OS 58 Adizie, T 60 Adler, A 858 Adler, S 55 Adlowitz, DG 690, 667 Adorni, M 675 Adrianto, I 5, 54, 55, 67, 674 Adusumilli, S 400 Af Klint, E 79 Affandi, AJ 56 Aga, AB 76, 95 Agarwal, M 680 Agarwal, SK 90 Agarwal, S 77 Agarwal, V 07, 054 Agerberth, B 79 Aggarwal, A 09, 66, 60 Aggarwal, R 07, 7, 0, 756, 598, 945, 949, 950, 049 Agha, Z 97 Aghdassi, E 688 Agodoa, I 9, 976 Agoston, G 5 Agrawal, N 446, 8 Agrawal, S 8 Agrawal, S 068 Agrawal, V 07, 054 Aguado, P 75 Agudo, M 4 Aguilar-Lozano, L 446 Aguirre, MA 980,, 7 Aguirre de Cárcer, D 494 Agung, E 78 Agýldere, M 958 Ahadieh, S 697 Ahearn, JM 699 Ahedi, H 7 Ahlehoff, O 684 Ahluwalia, V 96, 87, 5 Ahmad, R 57 Ahmad, S 4 Ahmadi, N Ahn, G 99 Ahn, GE 4 Ahn, JK 0, 45, 45, 8, 6 Aiello, P 68 Aigner, S 4 Aihara, M 50 Aikawa, NE 5, 999 Aikawa, Y 074 Air, GM 645 Ajeganova, S 45 Ajimi, C 55 Akaike, H 6 Akamata, K 708, 504, 5 Akan, H 499 Akar, S 565, 8 Akashi, K 86, 76 Akhavan, P 40, 09 Akhlaghi, M 76 Akhmetshina, A 47, 54 Akhras, KS 84, 045 Akhtar, N 9 Akhter, E 69, 66, 69, 90, 45, 648, 70, 7, 55 Akikusa, J 8 Akinlade, B Akkineni, R 98 Akkoc, N 565, 8 Akman, C 66 Akpinar, M 97 Akram, A 64 Aksentijevich, I 0 Aksu, K 8, 5, 858, 64 Aktay Ayaz, N 66, 477 Akter, T 5 AL Achkar, W 40 Al Haj, R 59 Al Snih, S 57, 589 Al-Ashkar, FT 557 Al-Mayouf, S 0, 477 Al-Mudhaffer, S 48, 8 Al-Sarraj, S 955 Alam, MM 406 Alarakhia, A 95, 066 Alarcon, GS 87, 604, 67, 9, 4, 4, 665 Alarcon-Riquelme, ME 84 Alarcon-Riquelme on behalf of BIOLUPUS, ME 8 Alarcon-Riquelme on behalf of BIOLUPUS and GENLES, ME 970 Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network, ME 846 Alarcün-Riquelme on behalf of BIOLUPUS and GENLES networks, ME 6 Alasti, F 4, 608 Alaupovic, P 55 Alba, MA 859, 479, 5, 57, 59 Albani, S 47, 59, 594, 595 Albath-Sadiki, A 656 Albert, CJ 8 Albert, D 57, 05, 64 Albert, DA 97, 98 Albrecht, A 09 Albrecht, E 60 Alcaraz, MJ Aldag, JC 65, 66 Aldaghlawi, F 58 ALE0 Study Team, 687 Alegre, JJ 9 Alekseeva, E 4, 48, 597 Alekseyev, Y 59 Alessandri, C 9 Alessio, M 66, 676, 0 Aletaha, D 77 Aletaha, D 09,, 405, 4, 908,, 6, 608 Alevizos, I 506, 57, 50 Alexander, K 09, 54 Alexander, MY 6, 667 Alexander, S 80 Alexander, T 686, 979 Alexandersen, P 984 Alexanderson, H 08, 754 Alexiades, M 09, 44 Alexopoulos, N 6 Alexsson, A 7 Alfaro-Lozano, JL 99 Alfie, J 68 Alfredsson, L 6, 64, 75, 978, 604, 0 AlHomood, I 6, 50 Ali, A 60 Ali, J 8 Alibaz-Oner, F 64, 67, 70, 7, 77 Alibaz-Öner, F 94 Aliprantis, AO 0, 75 Alivernini, S 97 AlJohani, G 54 Allaart, CF 94, 97, 469, 0, 594, 98, 606 Allaart, CF 00 Allaire, N 68, 886 Allanore, Y 696, 000, 46, 487, 50, 5, 98 Allen, KD 795, Allen, P 66 Allen, R 8 Allenbach, Y 0, 5, 757 Allison, J 90, 085 Ally, MM 794 Alm, GV 845, 7 Almagor, O 4, 467 Almeida, I 48 Almeida de Jesus, A 0, 65 Alnaqbi, KA 64, 59, 4 Alon, L 88 Alonso, A 998, 999, 00 Alonzo, C 56 Aloush, V 6 Alpay-Kanitez, N 707, 5 Alperin, R 6 Alpérovitch, A 68 Alpsoy, E Program Book 55 abstract author Index

358 abstract author Index 56 Alsaleh, G 5, 785 Alstergren, P 00 Alten, R 460, 46, 695, 9, 59, 547 Alten, R 44, 74 Alten, R 67, 77, 6, 640 Althoff, C 57, 9 Alunno, A 8, 84, 85 Alvarez, AC 60, 4 Alvarez, D 54 Alvarez de la Rosa, D 505 Alvarez-Rodriguez, L 49 Alves, C 768 Alves, C 85 Alves, G 874 Aly, IM 490 Alzua, BR 74 Amani, Z 9 Amano, K 444, 445, 4, 56 Amano, K 98, 47, 89 Amano, K 444, 445, 4, 56 Amara, K 578 Amaricai, E 876 Amarilyo, G 70, 899 Amaryan, G 0 Amato, AA 75, 755 Ambarus, C 585 Ambarus, CA 59, 60 Ambler, N 579 Ambrožič, A 05 Ambrus, J Jr. 55 Ambudkar, I 506, 57 Amdur, RL 49 Amengual, O 79, 460 Amezcua-Guerra, LM 7, 644 Amft, EN 55 Amin, MA, 0, 4, 77, 879, 60 Amin, S 44, 80, 8 Amital, H 550 Amity, CL 7 Amiya, E 700 Ammann, CG 8 Ammitzbøll, CG 5 Amorosa, V 74 Amoura, Z 5, 64, 75, 649, 459, 5, 5 Ampel, NM 7 Amudala, N 868, 58, 48 An, J 8 An, L 067 Anan, R 86 Anandarajah, AP, 07, 99, Anaya, JM 5, 54, 55, 84, 0, 67, 674 Ancuta, I 448, 449, 8 Andersen, AR 6, 6 0 Program Book Andersen, J 984 Andersen, MD 558 Anderson, DW 60, 70 Anderson, JK 6 Anderson, JR 645, 740, 44 Anderson, M 7 Anderson, R 794 Anderson, RJ 9 Andersson, C 080, 08 Andersson, H Andersson, ML 90, 45 Andhivarothai, N 486 Andou, A 78 Andrade, F 69, 689 Andrade, L Andrade, LEC 657, 07, 8, 69 Andreef, M 447 Andreoli, L 5, 76, 458 Andres, M 908, 9 Andres Cerezo, L 47 Andreu, JL 980 Andrews, C 749 Andrieu, M 600 Andrigueti, FV 704 Andringa, KK 79 Ang, DC 95, 965 Angeles-Han, S 57 Angeles-Han, ST 44, 55, 005 Angerer, P 944 Angioloni, S 47 Ångström, L 44 Anink, J 4 Anis, AH 87, 46 Anisfeld, AM Anolik, JH 5, 07, 99, 666, 667, 678 Anouk, M 6 Anslik, T 5 Antal-Szalmas, P 54 Anthony, KK 40 Antoch, G 040 Antolić, A 87 Anton, A 4 Anton, J 76, 66, 7, 477 Antypa, E 99, 8 Aoi, J 86 Aoki, A 046 Aoki, J 48 Aoyagi, K 046, 05,, 4 Aozasa, N 708, 504, 5 Aparicio, M 7 Apatira, A 9 Apaz, M 66 Apaz, MT 47 Apkarian, AV 08 Appel, H 496 Appenzeller, S 99, 00, 46 Appleberry, HC 765 Appleton, SL 6 APS Action, OBO 76, 458 Arai, S 98 Aral, O 5 Aramburu, F 47 Arami, S 454 Arana Fraustro, A 04 Arana Guajardo, A 096 Aranow, C 649, 656, 570, 57, 69, 687 Araujo, D 7 Araujo, E 00, 58 Arayssi, T 40 Arbab, A 60 Arbogast, P 960 Arce-Franco, MT 505 Ardelean, DS 07 Arden, NK 78, 95, 98 Ardoin, SP 840, 09, 60 Ardouin, E 0 Arend, WP 059 Arendt, C 50 Arendt-Nielsen, L 5 Arentz, G 676 Arguis, P 59 Arima, K 046, 05,, 4 Ariño i Torregrosa, M 7 Arinobu, Y 86 Arinuma, Y 684 Arismendi, MI 704 Arito, M 8, 5 Ariza, R 58 Ariza, Y 660, 799 Arkachaisri, T 74 Arkema, EV 605 Arkfeld, D 94 Arledge, T 777, 6 Arlestig, L 4 Arlet, P 9 Armas-Gonzalez, E 505 Arnaud, L 75, 459, 5, 5 Arndt, F 79 Arnett, DK 996, 997 Arnett, FC 04 Arnett, H 659 Arnold, K 97 Arnold, LM 64 Arnold, MH 40 Arnold, S 408 Arntz, OJ 896, 089 Arola, J 90 Arold, G 07 Arora, J 89 Arora, S 08 Arora, V 995, 678, 00 Aróstegui, JI 9 Arquizan, C 55 Arribas, F 546 Arroyo-Villa, I 75 Arsenyeva, S 676 Artim-Esen, B 707, 75, 5 Arts, EEA 68 Arturi, P 56 Arufe, MC 7 Arundine, M 84 Arvidsson, B 559 Arvikar, SL 04 Asahara, H 8, 645 Asako, K 84, 7 Asami, Y 809, 4 Asano, Y 700, 708, 504, 5 Asashima, H 58, 59 Aschauer, C 4 Asche, CV 84 Ascherman, DP 07, 756, 598 Ash, E 6 Asher, I 456 Ashihara, E 070 Ashizawa, T 046 Ashlock, M 67 Ashofteh, F 76 Ashrani, A 77 Ashruf, U 68 Ashworth, WD 509 Askanase, A 47, 9 Askanase, AD 48 Askling, J 86, 9, 65, 0 Aslam, A 650 Aslam, T 46 Aslanov, R 46, 95 Aslanyan, E 4 Aslibekyan, S 996, 997 Asmawidjaja, PS 79, 8 Asmussen, K 580 Assaf, NY 490 Assaraf, YG 54 Assassi, S 9, 545, 85, 464, 474, 475, 509, 704, 90, 0, 04 Assis, MR 880 Astudillo, L 9 Atanelishvili, I 5 Atay, K 707 Ateka-Barrutia, O 900 Ather, S 99 Atkinson, EJ 8 Atroshi, I 9, 648 Atsumi, T 79, 460 Atta, A 77 Attur, M, 6 Attwell, S 4 Atzeni, F 80

359 Atzeni, F 6 Au, K 900 Aubert, R 978 Aubrun, E 68, 80 Aubry, B Sr. 5 Audo, R 78 Auffret, M 85 Auger, I 755 Auger, JL 056, 45 Augustin, T 9 Augusto, KL 6 Aulie, H 68 Aumaitre, O 64, 65 Aurrecoechea, E 49 Austad, C 90 Austin, CR 90 Austin, HA 50 Australian-Anglo-American Spondylitis Consortium (TASC), 6 Australo-Anglo-American Spondyloarthritis Consortium, 595 Autran, B 0 Avaux, M 5 Avcin, T 66, 040, 47, 598 Avendano, C 8 Ávila, G 980 Avila Campos, MJ 5 Ávila-Casado, C 44 Avina-Zubieta, JA 568, 685 Avins, AL 87 Avouac, J 47, 46, 50, 5 Awada, A 0 Awasthi, R 07, 054 Axelsen, MB 045, 67 Axmann, R 6 Ayabe, F 8, 645 Ayadi, H 577 Ayanian, JZ 84 Ayano, M 86 Aydin, SZ 70, 98, 6 Ayearst, R 75, 8 Ayers, D 085, 086, 087, 585, 65 Aynsley, S 800, 80 Aytekin, S 77 Ayyagari, R 75 Azar, L 544 Aziz Khan, K 87 Azuma, K Azuma, N 8 Baas, F 754 Baba, S 94, 94 B Bach, D 94 Bach, M 46 Bach, MH 49 Bachelot, A 64 Backhaus, M 9, 8 Backlin, C 9 Backman, CL 870, 7, 405, 40 Baddley, J 76, 70, 09, 54 Badley, EM 95, 47, 64 Badley, EM 44, 60 Badurski, J 596 Bae, J 6 Bae, KT 5 Bae, SC 78, 84, 846, 970, 0, 0, 47, 686 Bae, S 408 Baechler Gillespie, E 44, 658, 576 Baecklund, E 9 Baek, IW 6, 68 Baer, AN 0, 74, 74, 9, 9, 67 Baerlecken, NT 586, 80 Baerwald, CG 8, 408 Baeten, D 574, 888 Baeten, DL 59, 585, 77, 60, 5, 45 Baeuerle, M 747 Bagavant, H 675 Bagchi, S 95 Bagdonas, E 48 Bagga, A 477 Baggott, J 996 Baglaenko, Y 744, 40 Bagnari, V 00 Bagnasco, M 6 Bagnato, G 507, 508 Bagnato, G 507, 508 Bahner, M 9 Bahrt, KM 69, 70 Baildam, E 45, 59, 6, 009 Baillet, N 740 Bain, LJ 40 Bair, M 965 Baird, E 6 Bajocchi, G 5, 6 BAK, WS 889 Baker, D 56, 8, 9, 0, 4, 5, 60, 86 Baker, GR 044 Baker, J, 60, 9 Baker, MF 08 Baker, NA 45, 48 Bakir-Gungor, B 005 Bakken, J 784, 498 Bakker, MF 5 Bakker, MF 996 Bala, SV 90 Balanescu, A 90 Balasingh, V 578 Balbir-Gurman, A 450 Balci, N 06 Baldassari, AA 69 Baldi, C 9 Baldini, C 6, 59, 546, 8, 84, 85 Baldissera, E 68 Baldo, G 04 Baldovino, S 547 Balfour, HH Jr. 45 Baliki, M 08 Balint, P 80, 8 Balint, PV Balogh, B 50, 506 Balogh, E 9, 806 Balow, JE 50 Balsa, A 46 Balsa, A 546, 000, 75, 05 Balser, S 0, 047, 78 Bananis, E 0, 85, 54,, 66 Bancroft, T 94, 9 Banda, NK 059 Bandeira, M 96 Bandinelli, F 79 Bandos, A 756 Banerjee, P 5, Bang, SY 48, 0, 47, 686 Bankhurst, A 08 Bannock, J Sr. 77 Bannuru, RR 964 Bansal, R 46 Bansback, N 46 Bantia, S 6 Banzato, A 76, 458 Bao, C 66, 457 Bao, G 95, 945, 695 Bao, M 545 Bao, Y 4 Baptista, AS 867 Baraf, HSB 59, 60, 85,, 9, 96 Baraliakos, X 56, 574, 586, 780, 69, 5 Baram, N 08 Baratz, M 45 Barbaglia, AL 60, 4 Barbarroja, N, 7 Barber, CE 7 Barber, G 57 Barbosa, JW 08 Barbosa, L 77 Barbour, KE 89, 46 Barcellos, LF 5 Bardelli, M 9 Bardin, N 70 Bardin, T 9 Bardin, T 44, 5, 08, 09,, 68 Barendregt, PJ 768, 095 Barham, T 407 Barile-Fabris, L 467 Barinas-Mitchell, E 7 Barinstein, LV 6 Barker, A 509 Barker, M 07 Barleben, M 440 Barnabe, C 007, 009, 06, Barnes, DE 89 Barnes, I 065, 60 Barnetche, T 5, 566, 0 Barohn, RJ 75, 598 Baron, G 08, 09,, 68, 89, 47 Baron, M 7, 78, 85, 467, 480, 4, 44, 66 Baronaite Hansen, R 49 Barone, P 66 Barr, SG 009, 570 Barra, LJ 4, 6 Barreira, JC 00 Barrera, P 80 Barrera-Cruz, A 76 Barrett, R 66 Barriere, F 649 Barron, KS 79 Barros, R 988 Barros, TBM 6, 0 Barsalou, J 79 Barsness, LO 576 Bartels, CM 86, 667 Bartels, EM 69 Bartlett, SJ 476, 6, 099 Bartley, Y 644 Bartok, B 659, 775 Bartoloni Bocci, E 8, 84, 85 Barton, A 6, 974 Barton, B 085 Barton, DL 869 Barton, J 47, 9, 440 Bartos, A 498 Bas, S 48 Baser, O 46, Bashmakov, A 07 Basiaga, M 64 Basic, J 54 Basra, G 456, 457 Bastian, I 504, 676 Basu, N 55 Bateman, L 8 0 Program Book 57 abstract author Index

360 abstract author Index 58 Bathon, JM 8, 467, 484, 59, 659 Batruch, I 560 Batsis, JA 974 Batt, CM 68 Battafarano, DF 87,, 69, 84, 4 Battagliese, A 0 Batten, RL 466 Batteux, F 565 Batthish, M 7, 044 Battisti, R 96, 97 Battistone, MJ 509 Baud, L 87 Baudouin, C 780 Bauer, G 4 Bauer, TK 57 Baum, W 47 Baumeister, J 6, Baumgratz, TD 96, 97 Bautista, E 94 Bautista-Caro, MB 75 Bay-Jensen, AC 5, 575, 59, 59, 9, 66, 67, 65 Baynes, KE 06 Bayoumi, A 68 Bazeli, R 007 Bazin, D 657 Bazzichi, L 09 Beaart-van de Voorde, LJJ 6 Bearne, LM 050, 49 Beaton, D 47 Beattie, KA 06, 08, 05, 00 Beattie, SD 487, 488 Beatty, M 89 Beaulieu, A 4 Beaulieu, AD 47, 47 Beauvais, C 895 Beavers, D 54 Beavers, D 56 Becerra, E 50, 757, 758 Becker, ML 5, 008, 09, 597 Becker, MA 50, 59, 60, 84, 9, 96 Becker, MO 49 Becvar, R 47 Bedran, Z 60, 68, 58 Beekman, M 00 Beham, AW 09 Behera, A Behin, A 5 Behrbalk, E 955 Behrens, EM 4, 058 Behrens, F 7 Behrens, TW 60 Beier, F 4 0 Program Book Beilke, JN 796 Beitinger, N 8 Bejarano, V 78 Bek, S 76, 5 Belasco, J 49 Belenotti, P 6 Belilos, E 57 Belke-Voss, E 59 Bell, DA 4 Bell, E 48 Bell, L 9 Bell, MJ 48 Bell, SW 904 Bell-Peter, A 84, 85 Bellamy, N 54, 55, 7, 596 Bellando Randone, S 5, 09 Bellando-Randone, S 485 Bello, AE 59 Bello, KJ 70 Bello, N 47 Bellomio, V 4 Belmar, N Belmont, HM 47 Belmonte, M 9 Belmonte-Serrano, M 46 Belomestnov, P 7 Belostocki, KB 57 Belot, A 477 Belsom, R 40, 06 Beltramo, A 476 Bemrich-Stolz, CJ 655 Ben Sedrine, W 966 Benavidez, J 00 Bencivelli, W 48 Benda, B 77, 77, 485 Benda, B 8, 97 Bendix, K 877 Béné, J 85 Benech, P Sr. 77 Benegas, M 60, 4 Benessiano, J 80 Bengtsson, A 654, 88, 44 Bengtsson, AA 66, 66, 680, 90, 76 Bengtsson, C 6, 64, 604, 607 Bengtsson, K 46 Benham, H 49, 494 Benhamou, CL 959, 97, 5 Benhamou, M 556 Benichou, J 80, 87 Benitez, A 759 Benítez-del-Castillo, JM 40 Benito, P 0 Benjamin, M 874 Benjamin, WH Jr. 94 Benn, B 95 Bennett, B 9 Bennett, K 540 Bennett, L 69 Bennett, M 05, 474 Bennett, M 56, Bennett, RM 80, 804, 857, 868, 880 Bennett, TD 8 Bennin, D 60 Bennink, MB 896, 089 Benos, A 058 Benseler, SM 84, 85, 95, 04, 05, 478 Bensen, R 979 Bensen, W 460, 47, 49, 596 Bensen, W 494, 08 Bensen, WG 84, 456, 06, 08, 979, 055, 00 Benveniste, O 0, 5, 757 Bérard, A 69 Berardi, G 486 Berclaz, PY 447, 76, 5,, 487, 488 Berenbaum, F 09 Berenbaum, F, 8, 9, 80, 0, 67 Beresford, M 45 Beresford, MW 040 Beretta, L 0 Berg, KL 96 Bergegård, J 08 Berger, A 507 Berger, J 8, 9 Bergerhausen, HJ 65 Berggren, O 7 Bergin, D 85, 55, 686 Bergknut, C 7, 96 Berglin, EH 45 Berglind Schepp, J 9 Bergman, MJ 75, 84, 04, 048, 04, 05 Bergman, S 95, 559, 88, 87, 409 Bergmann, JF 5 Bergström, U 4, 84 Berinstein, J 590 Berkun, Y 759 Berlucchi, M 05 Berman, A 60, 479, 56, 4 Berman, B 58 Berman, H 60 Berman, M 955 Bermas, BL 608, 97 Bernal, WE 4, 987 Bernardi, L 75 Bernasconi, C 454, 550 Bernatowicz, P 98 Bernatsky, S 55, 457, 649, 96, 69,, 87, 4, 48, 887, 6, 475, 5, 570 Bernelot Moens, HJ 607, 67 Berner Hammer, H 80, 8 Bernhardt, G 50 Bernini, F 675 Bernstein, CN 99, 54 Bernstein, EJ 7 Bernton, E 8 Berrocal, V 9, 58, 464 Bertamino, M 58 Bertani, L 46 Berthelot, JM 04, 55, 554 Berthier, CC 445, 499 Bertin, P 9 Bertini, F 0, 04, 07 Bertleff, M 048 Bertolaccini, ML 74, 75, 900 Bertoli, AM 4 Bertolini, E 87, 756 Bertolino, A 5 Bertrand, J 40 Bertsias, G 989, 46 Bessette, L 457, 4 Bessis, N 505 Bethunaickan, R 445, 454 Bettencourt, B 7 Bettenworth, D 779 Betteridge, Z 9, 854, 67 Beukelman, T 76, 94, 46, 68, 60, 655 Beutler, A 8 Beyer, C 47, 499, 500, 50, 505, 57 Beysen, C 90 Bezanahary, H 649 Bhadra, P 0 Bhangle, S 74 Bhansing, KJ 8 Bharadwaj, A 85 Bharat, A 94 Bharucha, KN 760 Bhattacharyya, S 58, 89 Bhatti, P 904 Bhattoa, HP 54 Bian, A 8, 6 Bianchi, G 998 Bibalo, C 0 Bica, BE 96, 66 Bicov, P 876 Bidonde, J 586 Biear, J 07, 667 Bielecki, M 9, 98 Bienkowska, J 68, 886 Bienvenu, B 545, 55, 656 Bienvenu, T 7 Bierma-Zeinstra, S 47 Bierma-Zeinstra, SMA 5, 6 Biermasz, NR 00

361 Bierut, L 67 Biesen, R 686, 979 Bijanki, V 66 Bijkerk, C 94 Bijl, M 9 Bijlsma, JWJ 50,, 788, 8, 5, 5 Bijlsma, JWJ 996 Bijlsma, JW 6 Bijsterbosch, J 00 Bijzet, J 9 Bikker, A 509, 50, 96 Bilgic, H 44, 658 Bili, A, 4, 604 Billard, MJ 66 Binder, NB 58 Bingham, CO III 84 Bingham, CA 60 Bingham, CO III 459, 476, 8, 6, 9, 0, 694, 86, 480 Bingham, C III 49, 099, 8 Biniecka, M 9, 6, 806 Binkley, N 995, 997 Binstadt, BA 056, 45 BIOBADASER Study Group, 64 Biolo, G 60, 97 Biondi, K 07 Biotherapy, C 87 Bird, H 78 Bird, P 87, 40 Birkett, R 074, 076, 06, 69, 54 Birmingham, D 79, 840, 5 Birmingham, JD 8 Birnbaum, J 609 Birolo, C 676 Birru Talabi, M 6 Birt, J 488 Bischoff, S 77 Bisconte, A 6 Bishop, GA 44 Bissonauth, A 70 Biswas, S 080 Bitman, B 644 Biton, J 505 Bitto, A 507, 508 Björk, J 9, 94 Björnådal, L 70 Blaauw, M 6 Black, J 6 Black, MA 68 Blackburn, MR 90 Blackburn, T 970 Blagojevic, J 485 Blalock, SJ 906 Blanc, F 657 Blancette, N 04 Blanch, J 78 Blanchard-Delaunay, C 65 Blanco, F 679 Blanco, FJ 6, 7,, 48, 54, 988, 99, 994, 59, 60, 7 Blanco, I 6, 88, 89, 949, 570 Blanco, R 980, 40, 548, 88, 89 Blanco Alonso, R 05 Blanco Garcia, FJ 4 Blaney Davidson, EN 7, Blankenstein, K 4 Blanshard, A 994 Blaschke, S 09 Blasius, AL 796 Blattes, R 7 Blauvelt, A 55 Blazevic, I 4 Bleakley, C 986 Bleck, E 46 Bleijenberg, G Bliddal, H 04, 045, 69 Blier, PR 76 Blits, M 54 Blitz, JR 86, 58 Blizzard, L 7, 55 Bloch, DB 57 Bloch, M 9 Bloch, M 44 Block, AJ 679 Block, JA 4, 6, 6, 64, 65, 05, 4, 56, 58, 56, 6 Bloem, JL 05 Blom, AB 7, 7, 895, 089 Blueml, S 086 Blum, A 68 Blum, M 85 Blumberg, H 796 Blüml, S 5, 070 Boackle, SA 8 Bobba, RS 06, 08, 00 Boccassini, L 80 Bochkov, V 07 Bochud, M 60 Bode, C 87 Bodi, I 955 Boehm, C 47 Boers, M 58, 5, 74, 8, 69 Boesen, M 04, 045 Boettner, F 479 Bogatkevich, GS 5 Bogdanova, AA 06 Boger, HA 45 Bogot, N 54 Bohgaki, T 79, 460 Böhler, C 6 Bøhme, W 6, 6 Bohm, M 7, 654 Bohndorf, K 07 Bohnsack, JF 76, 8, 974, 64, 657 Boiardi, L 47, 5, 6 Boin, F 697, 99 Boire, G 40, 465, 769, 6, 5, 8, 099, 09,, 60 Boismenu, R 6 Boissier, MC 479, 844, 505 Bojalil, R 644 Bojinca, M 448, 449, 8 Bolat, A 984 Bolce, R, 86,, 6, 664 Bolge, S 84, 95 Bolis, M 05 Bolognese, MA 997, 998 Bolster, MB 46 Bolt, I 66 Bolten, WW 57 Bombardier, C 55, 40, 96, 908, 5 Bombardieri, S 4, 6, 88, 59, 09, 48, 546, 057, 8, 84, 85, 6, 55 Bompane, D 46 Bonafede, M 89 Bonaffini, P Bonciani, D 79 Bond, D 78 Bond, H 564, 565, 698 Bond, J 80 Bonderman, D 85 Bondt, A 76 Bone, HG 959, 96, 997 Boneparth, M 798 Bonetti, LA 57 Bonfa, E 7, 77, 5, 6, 9, 74, 999, 95, 497, 500, 50, 68 Bonfiglioli, KR 7, 74, 064 Bongardt, S 69 Bonilla, G 546, 75, 9 Bonjoch, A 967 Bonner, A 8, 40, 7, 467 Bonner, M 476, 5 Bonnet, F 6 Bonnick, S 77, 976, 997 Bonnotte, B 65 Bontadelli, K 080 Bonvin, A 09 Bookbinder, LH 70 Boonen, A 6, 76, 77, 54, 844, 845 Boonen, S 959, 977 Booth, A 58 Bootsma, H 54, 56, 55 Boracchi, P 47 Borah, B 574 Borba, EF 77, 6, 497, 500, 68 Borba Neto, EF 50 Borg, R 54 Borghi, M 47, 455 Borghi, O 675 Borgia, E 0 Borlawsky, T 60 Boros, CA 7 Bos, MI 0 Bos, WH 765 Bosco, M 07 Bosello, SL 486, 764 Bossini-Castillo, L 0 Bostan, C 76 Boström, C 554 Bosworth, HB 795 Botsios, C 75 Bottai, M 75 Bottini, N 659, 45 Botusan, IR 789 Bouaziz, W 5, 44 Boudaoud, S Boudreau, RM 49, 50, 5, 908, 909, 0, 8, 469, 470 Bougault, C, 8, 9 Boumans, MJ 754 Boumpas, D 460, 46 Bourgeois, C Bourgeois, P 5 Bourré-Tessier, J 7, 4, 6 Bourrel, R 84 Bousser, MG 55 Bouta, EM Boutin, D 64 Boutsen, Y 479 Bouttier, R 5 Bowcock, A 808 Bowes, J 974, 64 Bowes, MA 7, 04 Bowman, EP 75 Bowman, SJ 55 Box, J 46 Boy, MG 485 Boy, MG 697 Boyd, SK 009 Boyer, O 0, 485, 78 Boyesen, P Bøyesen, P 6, 6, 04 Boyle, DL 46, 878, 60, 659, 076, 70 Boyle, JF 08 Boyle, J 48 abstract author Index 0 Program Book 59

362 abstract author Index 60 Braakman-Jansen, A 67 Brabosa, R 00 Bracciolini, G 65, 7 Brach, C 57 Brachat, A 76, 5 Bradbury, LA 595 Bradley, J 77, 84 Bradley, JD 77, 485 Bradley, J 04, 90, 97, 486 Bradley, JD 8, 8 Bradshaw, JM 6 Brady, S Brady, TJ 40, 46, 695 Brahn, E 9 Brakenhoff, LKPM 05 Brameld, K 6 Branch, M 979 Branch, W 650 Branco, JC 7 Brand, C 64 Brandao, L 79 Brandi, ML 96, 969, 0, 04 Brandt, H 84 Brasil, F 66 Bratton, SL 8 Brault, Y 64 Braun, A 55 Braun, J 55, 780 Braun, J 574, 777, 7, 69, 705, 5 Braun, J 586, 76 Braun, J 56, 70, 5 Braun, T Sr. 95 Brauner, S 77 Bray, MS 997 Breban, MA 594, 597, 598, 600 Breda, L 66 Breedveld, E Breedveld, FC 05, 0, 04 Breland, HL 6 Bremander, ABI 7, 95, 88, 409 Brembilla, NC 9 Brennan, M 690 Brennan, MT 67 Brennan-Speranza, TC 4 Breton, G 5 Breuer, GS 54, 450 Brewer, J 88 Brewer, M 06 Brey, RL 67 Breysach, C 09 Briasouli, P 776 Bricel, S 94 Brickmann, K 7 Bridges, SL Jr. 975, 996, 997, 0, 6, 5 Briggs, L 80 0 Program Book Briggs, T 80 Briggs, TA 8 Brik, R 759, 76, 00 Brink, M 4, 49 Brink, P 4 Brinkman, DMC 00 Brinkman, WB 04 Brinks, R 944 Brinson, D 8 Briot, K 8, 0 Brites, F 56 Britsemmer, K 4 Britten, N 48 Brixen, K 99 Brizendine, K 09 Brizzolara, R 49, 64 Brkic, Z 58, 0 Brock, M 89 Broderick, S 847 Brodmerkel, C 65 Broekstra, P 090 Broen, J 80, 98 Brogan, P 674, 477 Brohawn, P 755, 784, 675, 760, 68 Bromberg, MH 40 Brookhart, MA 84 Brooks, S 7, 48, 405 Brophy, M 87 Broucksou, KA 57 Broussard, C 774 Brouwer, E 894, 0 Brouwer, J 40 Brown, D 78, 65 Brown, E 996, 997 Brown, EE 79, 4 Brown, J 55 Brown, JP 84 Brown, K 055 Brown, KK 7, 7 Brown, KM 06 Brown, MT 59 Brown, MA 595, 05, 6, 495 Brown, M 04 Brown, PM 774 Brown, RD Jr. 566 Brown MPH, EE 970 Brown on behalf of PROFILE, EE 67, 84, 846, 6, 8 Browning, J 886 Bru Morón, C 00 Brucato, A 5 Bruce, IN 6, 667, 406, 65 Bruges Armas, J 7 Bruk, S 07 Brulhart, L 07 Brun, JG 86, 55 Brundidge, AD 000 Brune, T 440 Bruner, BF 670 Bruni, C 5, 09, 485 Brunner, H 80, 8, 764, 597, 890, 0 Brunner, HI 88, 94, 05,, 759, 76, 4, 040, 474, 475, 60 Bruyere, O 55 Bruyere, O 56 Bryceson, Y 845 Brynes, RK 99 Brähler, E 859 BSRBR, OBOT 88, 59 BSRBR Control Centre Consortium, 59 BSRBR Control Centre Consortium, BSFRBR 88 BT506, C 755, 756 Buatois, V 75 Bubb, MR 470 Bucala, RJ 875 Buch, MH 66, 47 Buchbender, C 040 Buchbinder, R 908 Buchdaul, AL 95 Buckholz, JM 606 Buckley, B 66 Buckley, CD 75, 89 Buckley, F 7 Buckner, JH 7, 44, 44 Buckner, T 455 Budoff, M 5, 685 Buechler, MB 446 Buechler, Y 67 Bueno, C 74, 95 Bufton, KK 405 Bugatti, S 888 Bugni, VM 60 Bui, J 080, 796 Buie, HR 007, 009 Buie, J 68 Bujak, DI 5 Bujan, J 48 Bujor, A 56 Buk, S 955 Bukhari, M 994 Bukowski, J 549 Bulatovic, M 58, 6, 654 Bulbin, D 46 Bull, H 689 Bullard, DC 99 Bultink, I 8 Bunin, VM 497 Bunn, C 854 Bunn, J 78 Bunni, M 9 Buoncompagni, A 476 Burbage, G 78 Burbine, SA 9 Burden, AD 46 Burden-Teh, E 46 Burghardt, AJ 58, 584 Burgos-Vargas, R 679 Burgos-Vargas, R 56, 90 Burguera, EF 6 Burkhardt, H 7 Burkly, LC 88 Burlingame, RW 0 Burmester, G 749 Burmester, GR 460, 59, 545 Burmester, GR 47, 8, 50, 777 Burnett, H 68 Burns, CM 96 Burns, K, 99 Burri, A 4 Burton, MJ 09 Burudpakdee, C 86 Burwell, T 784, 498 Busch, AJ 586 Buschiazzo, E 60 Bushnell, D 656 Bushnell, MC 96, 64 Buskila, D 955 Bussone, G 774 Bustabad-Reyes, S butbul Aviel, Y 00 Butjosa, M 5, 57 Butt, D 96, 5 Butters, T 848 Buttgereit, F 4, 47, 67, 74, 777, 085 Butz, S 68 Buyon, JP 90,, 60, 64, 65, 666, 87, 889, 47, 647, 650, 776, 6 Buyske, S 866 Bykerk, VP 8, 40, 465, 50, 977, 6, 5, 8, 099, 09, 8,, 579, 60 Byrjalsen, I 59, 9, 66, 67 Byrne, JC 56 Bzarova, T 4, 48 Cabal, A 99 Cabas-Vargas, J 88 Cabrera, S 88 Cabrera-Perez, J 57 Cacoub, P Sr. 6, 6, 67, 657, 77, 787, 65 Cacoub, PP Sr. 08,, 699, 68 C

363 Cadet, C 09 Cadet, C 0 Cadzow, M 68 Caeiro, F 60, 4 Caetano-Lopes, J 988 Cai, T 68 Cai, W 66 Cailotto, F 98 Cairns, E 4 Cakar, A 989, 6 Calabrese, LH 550 Calamia, V 988 Calandra, S 58 Caldana, WI 04 Calderillo, ML 44 Caldwell, KL 099 Caldwell, T 8 Calich, AL 6, 68 Calich, ALG 7, 74 Calich, AL 50 Callahan, K 07, 99 Callahan, LF 0, 57, 4, 69 Callahan, M 7 Callahan, S 69 Callegari, A 66 Callhoff, J 780 Callon, KE 7 Calmon-Hamaty, F 78 Calvo, E 9 Calvo, I, 759 Calvo Penades, I 597 Calvo-Alen, J 4, 44, 9, 49 Calvo-Río, V 40, 548, 88, 89 Cambridge, G 50, 65, 757, 758 Camellino, D 50 Camont, L 56 Campana, C 596 Campanilho-Marques, R 988 Campbell, A 45 Campbell, P 77 Campbell, PL 0, 4, 879 Campos, LM 999 Campos, LMA 77, 96 Can, M 67, 7, 94 Canadian ArThritis CoHort, Canadian Early Arthritis Cohort (CATCH) Investigators, 5 Canadian Scleroderma Research Group, 7, 467, 480 Canalis, E 790 canas Silva, J 7 Cançado, EL 50 Cancro, MP 48 Canestri, S 679, 97, 764 Cañete, JD 998, 8 Cañete, JD 85, 999, 9, 88, 64, 45 Canhao, H 7 Canizares, M 95, 44, 60 Canna, SW 4, 058 Cannella, AC 676, 87, 589, 59 Cannon, GW 89, 05, 87, 70, 09, 48, 48, 509, 54, 640 Cano, L 7 Canova, M 75 Cantaert, T 45 Cantagrel, AG 5, 80, 049, 08, 09,, 699, 68, 545 Cantarini, L 0 Canter, D 80 Cantero Hinojosa, J 64, 5, 6 Cantini, F 88 Cantor, RM 6 Cantor, RS 4 Cao, X 49 Cao, Y Cao, Y 57 Caorsi, R 0 Capannini, S 08 Caparbo, V 9, 9, 4 Capela, S 988 Caperon, AR 46 Caplan, L 9, 0, 48, 48, 640 Caporali, R 9, 5, 907,, 55 Cappelleri, JC 855 Cappelli, LC Cappelli, S 06 Caputi, A 907 Caramella, D 6 Carbone, G 78 Carbonella, A 764 Carcelain, G 0 Cárdenas-Velázquez, F 44 Cardiel, M 78 Cardiel, MH 77 Cardiel, MH 94 Cardoso, FP 867 Cardozo, T 788 Carette, S 9, 97 Carey, JJ 85, 55, 686, 70 Carey, TS 094, Caricchio, R 89 Caritey, BD 895 Carle, A 0 Carlens, C 65 Carli, L 4, 057 Carli, P 699 Carlsen, AL 76 Carlson, CS 7 Carlson, JJ 46 Carlton, V 588 Carmona, FD 04 Carmona, L 696, 70, 908 Carmona-Fernandes, D 7 Carmona-Rivera, C 50 Carneiro-Sampaio, M 657, 8 Carnesecchi, G 485, 0, 04, 06, 07 Carns, MA 76 Carpenter, L 5, Carpintero-Fernandez, P 4 Carr, AJ 89 Carr, JJ 54 Carr, J 49, 40, 8 CARRA Registry Investigators, 0 CARRAnet Investigators, 76 Carrara, G 67 Carrasco, S 497 Carreira, P 9, 0, 04 Carreira, PE 696, 980 Carreño, L 980, 47 Carrera, GF 06 Carrera Marin, AL 77, 7, 456, 457 Carretero-Prieto, RM, 7 Carrideo, M 80 Carron, PL 65 Carruthers, E 447 Carruthers, M, 54, 75, 9, 57, 58 Carruthers, R 58 Carsons, SE 57 Carta, S 658 Carter, L 450 Carthen, FC 48 Cartin-Ceba, R 77 Carty, A 57, 64, 75, 4 Carubbi, F 8 Carvalho, JF 74 Casagrande, F 60, 97 Casali, B 858 Casano, AV 65 Casciola Rosen, L Casciola-Rosen, L 56, 758, 95, 954 Casey, VA 790, 79, 79, 79 Caspard, H 64, 940 Casper, C 8 Caspi, D 9, 6 Castañeda-Sanz, S 05 Casteilla, L 7 Castejón, MA Castelino, FV 468 Castillo, R 89, 006 Castillo-Gallego, C Jr. 546, 70 Castillo-Ortiz, JD 446, 77 Castrejón, I 45, 04, 048, 04, 05, 605, 69 Catalan Pellet, A 60, 4 Catan, L 876 Catanoso, MG 5, 6 Catanoso, M 47 Catay, E 9, 40, 68, 58 CATCH, 6, 8, 09, 60 CATCH Investigators, 8, 40, 465 Catoggio, LJ 56, 68, 58 Catrina, AI, 08, 65, 69, 769, 789, 79, 0 Catrina, AI 578 Catrina, AI 59 Catrina, SB 789 Cats, H 895 Cattalini, M 05 Cattani, P 97 Cauley, JA 89 Caulfield, M 60 Cauli, A 498, 599 Cavagna, L 907 Cavalcanti, A 96 Cavalcanti, FS 455 Cavalli, L 0, 04 Cavazza, A 5 Caversaccio, MD 55 Cavet, G 5, 59 Cavet, G, 0, 6, 664 Caviggioli, F 77 Cavill, C 57 Cawthon, P 8 Cazenave, T 06 Cazzato, M 48 Cebi Olgun, D 66 Ceccato, F 60, 4 Cedeno, C 604 Cederlund, I 47 Cefle, A 858 Ceko, M 96, 64 Celik, AF 74 Celis, R 9 Cellucci, T 04, 886, 478 Cena, S 468 Cendes, F 99, 00 Cénit, MC 04 Cerami, A 770 Cerbu, S 876 Ceri, L 08 Ceribelli, A 64, 684, 7, 7, 470, 747, 956 Cerio, R 46 Cerniglia, RM 06 Cerqueira, C, 769 abstract author Index 0 Program Book 6

364 abstract author Index 6 Cerrahoglu, L 06 Cervera, R 85, 64, 65, 459 Cespedes-Cruz, A 47 Cetinkaya, F 7 Cha, CC 4 Cha, HS 78, 0, 45, 45, 8, 6, 47 Chaara, W 6 Chabra, SS Chadha-Boreham, H 85 Chaer, FGG 66 Chagadama, D 78 Chahal, A 8 Chai, JY 0, 6 Chaisson, CE 4, 5, 74, 650 Chakhtoura, Z 64 Chakravarty, EF 605, 67, 6 Chakravarty, K 57 Chakravarty, SD 900 Challacombe, S 74, 67 Chalom, E 764 Chalom, EC 4 Cham, WT 7 Chamberlain, ND 8, 454, 669 Chambers, CD 466 Champion, HC 699, 5 Chan, AC 45 Chan, CH 60 Chan, EKL, 64, 684, 7, 7, 470, 747, 956 Chan, ES 805 Chan, G 69 Chan, H 88 Chan, JYF, Chan, JY 7, 747, 956 Chan, KL 488 Chan, K 65 Chan, K 87 Chan, MO 9 Chan, PT 67, 44, 488 Chan, S 548, 778, 04 Chan, TM 69 Chan, W 56 Chandran, V 57, 540, 560, 57, 58, 590, 47, 48, 50, 5, 68, 69, 70, 7, 75,, 6 Chang, AY 40 Chang, BY 9 Chang, DM 846 Chang, E 0 Chang, HC 8, 549, 77, 67 Chang, HJ 796 Chang, JT 475, 509 Chang, J 47 Chang, KM 74 Chang, L 69 Chang, NH 674, 744,, 40 0 Program Book Chang, RW 4, 4, 99, 588, 664 Chang, SH 99, 5, 88, 95, 8 Chantepie, S 56 Chao, CC 75 Chao, D Chaparro del Moral, R 60, 4 Chapelle, DC 0, 65 Chapelle, JP 4 Chaperot, L 8 Chapman, J 56 Chapman, PT 9 Chapurlat, R 596 Chapurlat, R 54, 77, 96, 99, 998, 5 Charles, JF 0 Charles, PJ, 00 Charles, P 8 Charles-Schoeman, C 69, 5, 90, 709 Charlier, E 4, 50 Chartier, M 460 Chartier-Logan, CJ 4 Chartrand, S 70, 7 Chartrand-Lefebvre, C 7 Chary-Valckenaere, I 68 Chasnyk, V 66, 597 Chataway, TK 676 Chatel, L 75 Chatelus, E 87 Chatham, WW 60, 94, 5, 69, 6 Chatterton, RT 65, 66 Chattopadhyay, C 46 Chaturvedi, S 58, 59 Chatzidionysiou, K 776 Chaudhari, AJ 7 Chaudhary, D 06 Chaudhary, SH 05 Chauffe, AD 470 Chauhan, AK 0, 4, 5, 6 Chauveheid, MP 5 Chavez, H 0 Chavez, J 679 Chavez, J 597 Chavez, R 8 Chavez-Corrales, J 56 Checchio, T 697 CHECK steering group, 6 Chefo, S 5 Chen, C 66 Chen, CY 44, 976, 608 Chen, C 784 Chen, C 4, 5, 74 Chen, F 940, 94 Chen, H 76 Chen, J 4 Chen, J 874 Chen, JH 477 Chen, J 57 Chen, L 54, 74, 40, 489, 76, 94, 70, 960, 09, 06, 54, 54 Chen, N 5 Chen, PH 95 Chen, SY 6 Chen, W 69, 846, 984, 6 Chen, WH 45 Chen, X 699 Chen, YW 68 Chen, YW 946 Chen, Y 045 Chen, Y 808, 65 Chen, Z 545, 704 Cheng, CH 49 Cheng, G 45 Cheng, L 784, 68 Cheng, W 69 Cheng, Y 699 Cheon, EJ, 0, 7 Cheon, YH 40 Cherkas, Y 65 Chernitskiy, V 4 Chernoff, D 5 Chernoff, D, 6, 664 Cheryk, LA 57 Cheung, AM 99 Cheung, VG 987 Cheuret, E 47 Chevalier, X 55, 596 Chevalier, X 47 Chevreul, K 80 Chew, CS 68 Chew, R 78, 490 Chhana, A 7 Chia, JJ 08 Chiang, KP 67 Chiba, A 0 Chiche, L Sr. 6, 554 Chida, AS 690 Chida, K 98 Chieng, A 59, 6, 009 Chiewchengchol, D 069 Chighizola, CB 76, 458 Childhood Myositis Heterogeneity Study Group, 9 Chin, AS 7 Chindalore, V Chino, Y 88 Chinoy, H 9, 46, 67 Chiocchia, G 597, 598, 600, 000, 50, 5 Chiorini, JA 57 Chipping, J 767 Chiriac, R 479 Chironi, G 56 Chistyakova, E 4, 48 Chiswell, K 847 Chitkara, D 549, 779, 65 Chiu, YH 66 Chiu, YG 99 Chizzolini, C 9 Chmiel, JS 4, 467 Chng, HH 78 Cho, CS 6 Cho, CS 68 Cho, HJ 797 Cho, ML 9 Cho, ML, 4, 664, 745 Cho, NS 889 Cho, SK 78, 0, 0, 47 Cho, YN 06 Chodosh, J 5, 55, 0, 674 Choe, JY 78, 967, 6, 47 Choi, BY 797, 8 Choi, CB 78, 47, 686 Choi, D 680 Choi, H 5, 60, 854, 980, 64 Choi, HK 4, 74, 74, 849, 559, 568 Choi, IA 9 Choi, JY 686 Choi, JY, 497 Choi, JJ 96, 968 Choi, J 95 Choi, K 4 Choi, ST 6, 95, Choi, SW 54 Choi, SW 968 Choi, SJ 409, 67 Choi, TY 5, 685 Choi, YK 89 Choi, YY 0, 0 Choi, YJ 6 Choinière, M 86 Chomakhidze, A 4, 48 Chon, Y 8 Chong, C 754 Choo, C 658 Choong, LM 9 Choong, PF 69 Chopra, A 58, 59 Chopra, P 84 Chopra, R 65 Choquette, D 7, 458, 467, 494, 4, 84, 08 Choromanski, TL 76, 94 Chou, IJ 58, 8, 549, 77, 67 Chou, YK 8, 0 Choudhury, A 975 Chow, A 496

365 Chow, SL 888, 047 Chowdhary, VR 444 Chowdhury, M 00 Choy, E 9, 6, 6, 8, 804, 099, 49, 609 Christensen, G 87, 94 Christensen, R 959, 69, 609 Christensen, TG 6, 6, 580 Christianakis, S 94 Christiansen, C 575, 9, 596, 984, 66, 67, 65 Christianson, TJH 566 Christmann, R 56, 7 Christopher-Stine, L,, 468, 95 Chu, BC 89 Chu, CQ 8, 90, 0 Chu, H 00 Chu, LH 54 Chu, SY 76 Chuang, CS 97 Chuang, E 9 Chubinskaya, S Chun, L 60 Chung, C 456, 467, 80 Chung, CP 86, 66 Chung, L 706, 74, 758, 46, 465, 47, 95, 954 Chung, WT 78, 47 Churchill, MA 94 Churchill, S 68 Churchman, S 766 Chwiesko-Minarowska, S 98 Chyczewski, L 9, 98 Ciancio, G 00 Ciani, B 80 Ciani, L 56 Cibere, J 0, 0, Cibo, H Sr. 60 Cicero-Casarrubias, A 650 Cicutinni, F 0 Cicuttini, F 7, 8, 55 Cid, MC 855, 859, 5, 57, 59 Ciesielski, R 64 Cieza, A 76 Cifaldi, M 54 Cifaldi, M 75, 79, 468, 484, 45 Cifaldi, MA 84, 69, 7, 746, 5 Cimaz, R 6, 66, 676, 47, 598 Cimmino, MA 67, 50 Cinquegrani, M 507, 508 Ciocca, G 0 Cioffi, E 4 Cirelli, JA 5 Cisternas, M 898 Cistrone, CA 07, 666, 667 Citera, G 60, 06, 579, 56, 4, 449 Ciullo, M 60 Cividino, AA 06, 08, 00 Cizgici, AY 707 Claessen, KMJA 00 Clair, A 64 Clancy, MM 4 Clancy, RM, 666, 87, 889, 776 Clare, J 059 Clark, B 05 Clark, J 49 Clark, LF 006 Clark, P 875 Clark, TM 544 Clarke, AE 649, 9, 69, 87, 4, 48, 887, 6, 4, 475, 570 Claudepierre, P 555 Claushuis, D 595 Clauw, DJ 58, 80, 80, 80, 805, 806, 866, 96, 96, 0, 869, 450, 644 Clegg, DO 05, 545, 0 Cleland, LG 45 Clement, C Clemente, G 96 Clements, PJ 9, 464, 004 Cleveland, RJ 4, 69 Clewell, J 79, 468 Cloonan, Y 74, 908, 909, 7 Clowse, M 64, 6 Clowse, MEB 69 Coates, LC 55, 46 Cobb, J 974, 6, 64, 654 Coblyn, JS 8, 06, 06 Cobraiville, G 4 Coca, A 5, 69 Cockell, SJ 774 Codreanu, C 448, 449, 8 Codullo, V 078 Coelho, ERW 867 Coenen, MJH 4, 80 Coenen, M 869, 67 Coffey, BM 56 Coffman, C 795 Cofield, S 54 Coggon, D 800 Coghlan, JG 4, 7, 85 Cogman, A 67 Cohen, C 78 Cohen, L 649 Cohen, P 545, 65, 656 Cohen, PL 660, 688, 065, 067 Cohen, RB 695 Cohen, S 485 Cohen, SB 77 Cohen, SB 80 Cohen-Aubart, F 75 Cohen-Solal, M 5, 44 Coit, PS 858, 70 Colafrancesco, S 9, 84, 85 Colbert, CJ 4 Colbert, C 85 Colbert, RA 0, 545, 000 Colburn, KK 69, 759 Cole, B 650 Coleman, B 7 Coleman, C 46 Coley, K 86 Colin, E 8 Colin, MJ 50 Colina, M 00 Collado, P, Collaku, L 79 Collantes-Estevez, E, 56, 70, 7 Collee, G 594 Collette, J 56, 969 Collier, DH 8, 8, 495, 865, 698, 84 Collier, DS 04 Collins, CE 67 Collins, ES 58 Collins, FL 804 Collins, JE 8, 75, 090 Colombato, LA 00 Colonna, M 50 Comarmond, C 65 Combe, B 5, 5, 96, 47, 47, 480, 566, 08, 09,, 44, 78, 89, 849, 8, 68, 47, 549, 605, 69 Combe, BG 80, 699 Comeau, ME 79, 970 Comet, D 555 Compagno, M 88 Company, C 0 Conaghan, PG 57, 7, 04, 60, 550 Condino-Neto, A 69 Conn, DL 0, 6 Connell, CA 77 Connell, C 04 Connell, CA 8 Connelly, M 40 Connolly, M 5, 9 Connolly, S 59 Connor, J 784, 498, 68 Connors, G 659 Conrad, K 496 Conroy, MB 4 Cons, L 75 Consolaro, A 58, 65, 7, 7, 476 Constantin, AL 000, 049 Constantin, T 759, 004 Constantinescu, FM 56 Conway, R 75, 85, 054, 056, 70 Cook, CE 094 Cooney, M 55 Cooper, C 54, 55, 78, 95, 596, Cooper, DML 9 Cooper, MA 6 Cooper, RG 9, 67 Cooper, S 78, Cooper, S 4 Cooray, D 4, 645 Cootes, TF 7 Corbera, M 57 Corbera Bellalta, M 5 Corbera-Bellalta, M 855, 859, 59 Cordero Coma, M 700 Cordero-Coma, M 40 Coresh, J 0, 74 Corkill, D 784, 68 Cornec, D 97 Cornejo, J 56 Cornélis, F 577 Cornish, J 7 Corona, F 66, 06, 47 Corr, M 46 Corradin, S 04 Corrales, A 05 Cortes, A 595, 6, 495 Cortes, C 059 Cortes Pereira, E 994 Cortes-Hernandez, J 4 Cortese, A Corti, D 578 Cosman, F 984 Cossette, P 769 Cosson, C 44 Costa, JA 7 Costa, PR 497 Costa Reis, AP 4 Costa Reis, P 5 Costallat, L 46 Costantino, F 598 Coste, J 98, 5 Costedoat-Chalumeau, N 0, 9, 64, 647, 649, 65, 5 Costenbader, KH 87, 07, 44, 608, 79, 9, 97, 976, 605, 608, 609, 665, 570, 600 Cöster, L 776 Coteur, G 557, 558, 777 Coughlan, RJ 85, 55, 686, 70 Couillault, G 47 abstract author Index 0 Program Book 6

366 abstract author Index 64 Couraud, PO 55 Cournia, Z 875 Coussieu, C 64 Coustet, B 000 Cova, MA 60, 97 Covarrubias, A 46 Covert, K 60 Coviello, AD 45 Cowen, E 0 Cox, JH 796 Cox, T 58 Cox, T 796 Cox-Dublanski, M 48 Coy, VA 90 Coyle, A 784, 68 Cozic, C 55 Crabol, Y 78 Craft, JE, 497 Cragin, L 856 Craig, C 59 Craig, TJ 99 Cramb, C 87, 47, 605, 688, 659 Crassard, I 55 Crema, M 5, 0, 9, 467 Crespo, M 4 Crespo-Pagnussat, S 4, 5 Cretu, D 560 Creveaux, I 577 Criado, G 8, 5, 4 Cricelli, C 907 Criscione-Schreiber, LG 69 Crisostomo, M 455 Crispín, JC 68 Cristol, JP 480 Criswell, LA 5, 79, 970, 997, 74, 9, 9, 8, 67 Crittenden, DB 65, 66 Croca, S 607, 65, 40, 40 Crockett, S 9 Cron, RQ 67, 66, 677, 475, 655 Cronin, ME 65 Cronstein, BN 4, 5, 6, 65, 788, 55, 778, 805, 964, 965, 56 Crooks, MG 00 Crotti, TN, 58 Crow, MK, 65, 694, 75, 809 Crow, YJ 8 Crowson, CS 4, 07, 658, 709, 754, 80, 950, 0,, 5, 48, 49, 49, 9, 55, 95, 75, 98, 55, 56, 58, 48 Cruz, JD 4, 45 Cruz, VG 65 Cruz-Dominguez, MP 70 0 Program Book Cruz-Reyes, C, 956 Cryer, B 6 Csuka, ME 46 Cua, D 75, 677 Cuadrado, MJ, 7 Cucho-Venegas, JM 99 Cuda, CM 077, 679 Cuellar, C 898 Cui, J 7, 44, 976, 98, 98, 605, 609, 68, 40 Cui, X 0 Cule, E 654 Cummings, SR 89, 98, 995 Cunha, FQ 5 Cunha, GFD 064 Cunnane, G 75, 60, 68, 58, 59, 85, 575, 054, 056 Cunningham, A 8 Cunningham, C 907 Cunningham, M 66 Cunningham, MA 45, 45, 89 Cuoco, F 06 Cuomo, G 47 Cupples, LA 45 Curhan, G 60 Curin Serbec, V 598 Curran, M 65 Curran, ML 0, Curteis, B 585 Curtis, J 54, 74, 40, 489, 70, 8, 840, 995, 0, 06, 54 Curtis, JR 76, 90, 94, 996, 997, 960, 978, 09, 4, 54, 68 Cush, JJ 80, 49, 50, 69, 94 Custodio, M 576, 694 Cuthbertson, D 655, 9, 97 Cutillas, P 750 Cutinha, A 88, 676 Cutolo, M 49, 5, 64 Cuttica, R 66 Cuttica, RJ 597, 47, 477 Cuziol, M 96, 97 Cymet, A 688 Czapiga, M 675 Czeloth, N 4 Czerwinski, E 54 Czerwinski, E 997 Cziumplik, M 9 D D Agostino, M 80, 8 D Almeida, V 96 D Angelo, G 66 D Artois, J 07 d Ascanio, A 88, 48, 057, 6 D Cruz, DP 9 D Onghia, S 97 D souza, A 670 da Silva, A 5 Da Silva, JAP 7 Dabelea, DM 097 DaCosta, D 688 Daele, PLV 58 Daelken, B 4 Dagna, L 75 Dagnæs-Hansen, F 07 Dahlberg, LE 5, 9, 94 Dai, C 444 Dai, D 597 Dai, L 09, 5 Daien, CI 480 Daigle, ME 90, 9 Daizadeh, N 959, 998 Dal Bello Haas, V 586 Dalbeth, N 6, 7, 48, 85, 05, 80, 68, 90, 585, 586 Dale, J 66 Dall Era, M 67, 69 Dalm, VA 58, 0 Dalprà, S 65 Daluiski, A 08 Dalvi, S Damian, LO 9 Damjanov, N 54 Dancey, P 0 Danchin, N 68 Dang, N 405, 456 Danielides, S 00 Daniels, T 74, 67 Danila, MI 997, 0 Dankbar, B 46, 779 Dankers, W 8 Danko, K 9, 67 Danneskiold-Samsoe, B 69 Danoff, S 468, 659 Danoff, SK, Danyliw, A 586 Dao, KH 69 Darbie, LM 60 Dardzinski, B 99 Daridon, C 749 Darrah, E 94, 689 Das, L 74, 65 Das, R 74 Das, S 474 Dasgupta, B 47, 47, 60 DaSilva, C 77 Dastmalchi, M 08 Datta, K 58, 59 Datta Mitra, A 44, 589, 85 Daugherty, B 960 Daurès, JP 80 Davatchi, F 05, 76 Dave, AJ 706 Davelaar, N 79, 8 Davì, S 66, 7 David, CS 444 Davids, ML 694, 75 Davidson, A 445, 454 Davidson, J 59, 6, 009 Davies, O 6, 9 Davies, R 88, 45 Davignon, I 59 Davignon, J 90 Davine, A 590 Davis, AM 95 Davis, EC 786 Davis, HM 9 Davis, JC Jr. 60, 57, 6 Davis, JM III 48, 48 Davis, K 587 Davis, LA 0, 48, 48, 640 Davis, MM 4 Davis, M 6 Davis, MM 890 Davis, MW 9 Davis, N 748, 749, 750 Davis, S Jr. 985 Davis, T 85 Davis, WE 95 Dawidowicz, K 478 Dawood, MM 498 Dawson-Hughes, B 969 De, G 75 De Benedetti, F 760, 597, 47 de Bock, L 670 de Boysson, H 55 de Broucker, T 5 De Bruyn, S 07, de Buck, M 94 de Buosi, ALP 0, 807, 864 De Cock, D 56 De Domenico, I 855 De Gennaro Colonna, V 80 de Hair, MJH 4 de Hooge, M 564, 80, 06, 07, 09,,, 6 de Iorio, M 654 de Jager, JP 87, 40 de Jager, W 509 de Jong, TD 8 De Jonge, R 58, 6, 654 De Keyser, F 05 de Kroon, L De La Fuente, A 7 de la Torre, I 47, 757, 758 De La Torre Ortega, I 65

367 de Leeuw, K 9 de Longueville, M 50, 6 De Luca, G 486 De Lucia, O 67 de Man, YA 609 De Marchi, D 09 de Mendez, I 784 De Miguel, E 78, 70, de Min, C 75 de Munter, W 55 de Pablo, P 4 de Papp, A 99 De Ranieri, DI 897 de Ridder, MAJ 4 de Rooij, M 66 de Rooy, DPC 894 de Rooy, DPC 97, 670 De Rotte, MCFJ 58, 6 De Rycke, L 59 De Sanctis, J 57 de Seny, D 4, 50 de Smit, MJ 0 de Sonnaville, PB 94 de Souza, AWS 69, 9 de Steenwinkel, FDO 4 De Swert, K 07 De Toro, FJ, 48 de Toro-Santos, FJ 54, 60 De Villiers, T 77, 97 de Visser, M 75 De Vita, S 8, 84, 85, 89, 555 de Vlam, KL 597 de Vries, MC 00 de Vries, N 56, 754 de Vries, TJ 0 de Wazières, B 656 de Wazieres, B 95 de-mendez, I 68 Deal, CL 909 Deamude, M 84, 055 Deane, KD 7, 7, 44, 4, 44, 69, 097, 6 DeBerardine, M 65, 66 Debost-Legrand, A 577 Debré, P 0 Decaux, O 95, 65, 8 Dechant, C 407 Decker, P 844, 505 Decktor, D 86 Dedeoglu, F 008, 09 Deehan, M 75 Deelder, AM 76, 0 Dees, C 47, 78, 499, 500, 50, 505, 57 Defranoux, N, 6, 664 DeHoratius, RJ 86 Dejaco, C 08, 7, 044,, 8 Dejaco, C 67 Dejonckheere, F 7, 46 Dekis, A 87 Dekker, J 66, 5 Del Galdo, F 70, 47, 496, 50, 0 Del Papa, N 77 Del Rey, MJ 8, 9, 5 del Rincon, I 87,, 69, 4 Delaet, I 46, 695, 547 Delaney, T 784, 68 DeLaurier, A 7 Delcour, JP 780 Delgado, E 69 Deligny, C 649, 8 Dell, S 85 Dell Accio, F 40, 57 Della Rossa, A 48, 057 Dellaripa, PF 7 Delle Sedie, A 4 Deloch, L 505 DelVecchio, B 604 Delzell, ES 54, 74, 489, 76, 94, 70, 960, 09, 54, 54 Dema, B 00 DeMartino, J 075, 74, 55 Demary, W 65 Demattei, C 544 Demirkaya, E 66, 0, 477 Demoruelle, MK 4, 44, 69 Dempsey-Robertson, M 4 Demuth, HU 08 den Boer, E 6 den Broeder, AA 7, 68, 609, 67 den Heijer, M 097, 58 den Uyl, D 5, 58 Denaro, V 79, 06 Dencker, D 6, 6 Deng, X 950 Deng, Y 846, 984, 6, 78 Denio, AE 46, 604 Denis, G 95 Denisova, E 676 Denisova, R 4, 48 Deniz, G 707 Denker, A 97 Dennis, G 945, 856, 67 Denny, MF 660 Denton, C 04 Denton, CD 85, 854 Denton, CP 4, 69, 696, 698, 7, 785, 478, 7, 76, 9, 0, 05, 07, 65 Deodhar, AA 545, 55, 558, 777, 6 Depresseux, G 5 Derambure, C 78 Derber, LA 44, 4, 44, 765, 097 Derer, A 888 Dernis, E 67 Derrett-Smith, E 785 Dervieux, T 60 Desai, M 006 Desai, S 06, 06 Desai, S 854 Descalzo, MA 78, 64, 70, Descarreaux, M 647 Deschamps, M 755 Deshmukh, U 675 Deshpande, GA 99 Deshpande, V, 54, 58 Desjarlais, JR 76 Deslandre, C 676, 87 Desmoulins, F 89, 555 Desmurs-Clavel, H 65 Dessault, O 65 Dessole, G 498, 599 Detante, O 55 Deurloo, EE 09 Devarajan, P 05, 474 Devauchelle-Pensec, V 04, 88, 97, 554 Devaux, JY 65 DeVeauuse Brown, N 407 Devenport, J 454, 49, 00, Devich, J Jr. 8 Devilliers, H 545, 5 DeVita, P 54 Devogelaer, J 54 Dewalt, D 57 Dewar, L DH Kim, 7 Dhaun, N 55 Dhellin, O 479 Dhir, V 499 Dhote, R 78 Di Luca, G 77 Diab, IA 9 Diamandis, E 560 Diamantopoulos, AP, 975, 54, 90 Diamond, B 656, 57, 69, 687 Dias, VC 644 Díaz, P 898 Diaz-Deza, KE 99 Díaz-Gallo, LM 04 Diaz-Gonzalez, F 505 Díaz-Llopis, M 40 Diaz-Prado, S, 48 Dib, H 774 DiCarlo, JC 488 DiCioccio, AT 7 Dickson, MC 07 Dieffenbach, B 46 Diehl, S 78 Dieppe, PA 69 Dietrich, T 4 Dietz, HC 786 Dieude, P 478, 000, 487, 88 Díez-Álvarez, E 44 Díez-Pérez, A 78, 95, Dijkmans, BAC 58 Dikranian, AH 77, Dillon, AM 59, 60 Dillon, SP 670, 677 Dima, C 455 Dimopoulou, D 058 Dinant, HJ 59 Ding, C 8, 0, 55, 57 Ding, L 567 Ding, Y 76 DiNitto, JP 8 Dinsdale, G 695 Diogo, D 595, 68 Diot, E 649, 656 DiPaolo, R 6 DiPonio, L 59 Direskeneli, H 858, 6, 64, 67, 70, 7, 77, 94 Dirven, L 469, 98 Distler, A 78, 499, 500, 50, 505, 57 Distler, JHW 54 Distler, JH 47, 78, 499, 500, 50, 505, 50, 57 Distler, JH 04 Distler, O 47, 77, 78, 85, 90, 46, 499, 500, 50, 505, 54, 7, 9, 57 Divers, J 74 Dixon, WG 88, 59 Do, H 57 Do, MHT 67 do Prado, LL 6 Dobarro, D 4, 7 Doelberg, M 85 Doering Maurer, K 56 Doheny, K 67 Doherty, M 58, 84, 8, 77, 67 Dohi, M 98 Dokoupilova, E 86 Dolezalova, P 654 Dolhain, RJEM 76, 76, 4, 40 Dolman, KM 09 Domiciano, D 064 abstract author Index 0 Program Book 65

368 abstract author Index 66 Domiciano, DS 9, 9 Dominguez, N 795 Dominguez-Gutierrez, PR 64, 684 Dominguez-Luis, MJ 505 Domino, SE 0, 879 Domsic, RT 698, 699, 74, 46, 465 Domyslawska, I 9 Donati, V 59 Donatti, C 406 Dong, Y 74, 67 Donnell-Fink, L 650 Donnelly, S 48, 8 Donovan, J 05 Doobay, K 694, 75 Dooley, MA 570 Doorenspleet, ME 56, 754 Doornbos-van der Meer, B 0 Dorais, M 4 Doran, M 75, 60, 68, 054, 056 Dore, D 7, 8, 0 Dorfleutner, A 54 Dorgham, K 75, 5 Doria, AS 4 Dorman, CW 09 Dorman, J 6 Dorner, T 749, 55 Dörner, T 76 Doschak, MR 8 Doshi, D 95 Dotta, L 05 Dougados, M 5, 544, 555, 556, 59, 777, 80, 08, 09, 0,, 6, 699, 68, 550, 605, 69 Dougados, MR 80 Doveri, M 09 Dow, ER 5, Dower, K 08 Dowsey, M 69 Doyle, A 85, 05, 585, 586 Doyle, K 46 Doyle, MK 80, 569, 557, 56 Doyle, TM 90 Dozmorov, MG 795 Draeger, HT 85, 474 Drago, L 80 Dragone, LL 507, 596 Drake, J 9 Dranitzki, Z 9 Draper, T 576, 694 Dreffs, A 58 Drenkard, C 95, 945, 407, 695 Drescher, E 487 Dressler, F 47 Drews-Botsch, C 55, 005 Drexhage, HA 58 0 Program Book Dreyer, L 79, 7, 684 Driban, J 745 Driban, JB 9, 798,, 5 Drijfhout, J 770 Driscoll, PC 77 Drosos, AA 55 Droz, N 67 Druce, K 6 Druey, KM 575 Drynda, S 440, 004 Du, F 457 Du, J 46 Du, X 875 du Bois, R 854 Dua, AB 4, 6 Duarte, C 7 Duarte, CW 970 Dubko, M 676 DuBois, MS 06 Dubost, J 577, 88, 554 Dubourg, O 5 Dubrau, C 79 Dubreuil, M 849, 64 Duby, C Ducret, M 65 Ducreux, J 548 Duculan, R 847, 809 Duda, G 47 Dudler, J 8 Dudler, J 68 Duer, A 67 Duff, GW 985 Duffy, CM 69, 475 Duffy, S 8 Dufour, AB 789, 790, 79, 79, 79 Duftner, C 8 Duggan, D 986 Duggan, J 446 Duhaut, P 64 Duke, A 748 Dunbar, J 8 Duncan, G 846 Duncan, M Dunlop, DD 9, 4, 4, 4, 99, 588, 467 Dunlop-Thomas, CM 407, 695 Dunne, A 6 Dunne, E 9 Dunne, R 58, 59 Dunstan, CR 4 Dupin, N 0 Dupuy Gorce, AM 480 Dür, M 869, 67 Duran, S 67 Durán-Barragan, S 4 Durand, G 0 Durand-Zaleski, I 80 Durcan, LJ 85, 575 Durden, E 9, 94 Dures, E 579 Durez, P 46, 59, 547 Durez, P 47, 47, 479, 05, 5, 694, 548 Duruoz, MT 574 Durusoy, R 8 Duruöz, MT 690 Duryea, JW 470, 5 Duryee, MJ 6, 7, 4 Dusad, A 6, 7, 4 Dussault, P 985 Dusser, DJ 7 Dustin, M 90 Dutmer, E 7 Duval, X 565 DuVall, S 09, 54 DuVall, SL 49, 70 Duyckaerts, C 5 Duzanski, MO 5, Duzgun, N 858 Dvergsten, JA 6 Dvorchik, I 06 Dwivedi, A 404 Dwyer, N 460 Dwyer, T 55 Dyer, A 49, 40 Dyer, S 476 E E Smedby, K 9 EASIC, 780 Easley, K 695 Eathakkattu Antony, BS 55, 57 Eaton, C 9, 4, 4, 745, 467, 5 Ebbing, PCC 704 Ebbo, M 67 Eberhard, BA 94, 890 Eberhardt, K 7 Eberl, G 75 Ebina, K 500 Echtermeyer, F 40, 779 Eckstein, F 49, 50, 5, 469, 470, 54 Eda, H 78 Edberg, JC 79, 84, 970, 99, 6, 8 Eder, L 57, 547, 5, 75 Eder, V 78 Edgerton, S 4 Edison, J 44 Edmundowicz, D 49, 40, 8 Edwan, JH 0 Edwards, CJ 908 Edwards, JA 57 Edwards, K 47 Edwards, RR 0 Edwards, S 069 Edworthy, SM 570 Egberts, F 50 Egelston, C 06 Eggebeen, AT 8 Egholm, CL 79 Egri, N 4 Eguchi, K 70,,, 4 Egurbide, MV 479 Ehrenfeld, MZ 450 Ehrenstein, BP 8, 0, 8, 047, 78 Ehrlich-Jones, LS 4, 99, 588 Ehst, B 55 Eilertsen, G 88 Einarsson, JT 48 Eisuke, O 669 Ekholm, L Eklund, A 69 Ekman, EF 59 El Torgomen, N 90 El-Gabalawy, HS 79, 94, 688, 06 El-Sherbiny, Y 766 Elashoff, D 9, 5 Elboudwarej, E 5 Eldridge, H 95 Elewaut, D 597, 6, 08 Elford, K 88 Elgeioushi, N 69 Elhai, M 50, 007 Elkayam, J 44 Elkayam, O 9 Elkon, KB 446, 79, 8 Ellert, GA 7, 405 Ellingsen, T 79, 46, 959, 54, 877, 5 Elliott-Penry, L 8 Ellis, J 8 Ellis, L 84, 95 Elmesmari, A 88 Elmore, KB 65, 66 Eloranta, ML 5, 845, 8, 7 ElSallabi, O 56 Elvin, K 574 Emans, PJ Embi, PJ 60 Embuldeniya, G 48 Emery, P 80, 66, 68, 69, 7, 456, 459, 467, 474, 487, 574, 70, 77, 775, 0, 80, 47, 60, 78, 766, 5, 0, 488, 549 Emilie, S 89 Emir, B 64

369 Emmungil, H 8, 5 Emond, P 08 Emrence, Z 989, 6 Endo, H 50 Eng, H 7 Engel-Nitz, NM 78 Engelke, K 008, 58 Englbrecht, M 594, 09, 58, 58 Engler, A 47 Engling, A 4 English, C 55 Englund, M 7, 5, 86, 9, 94, 96, 0, 9 Engström, M 79, 578 Ennis, H 695 Enocsson, H 67 Enomoto, N 98 Ensrud, KE 89 Epis, O 56 Eprac, 577 Epstein, R 978 Equity In Access To Treatment of RA Across Europe, 844 Equity in Clinical Eligibility Criteria for RA treatment, 845 Erausquin, C 44 Erba, G 56 Erdogan, M 5 Erer, B 750 Erer, B 989, 6, 5, 64 Ergen, A 858 Ergun, T 7, 94 Erguven, M 759 Erickson, AR 676, 87 Erika, M 984 Eriksson, C 665 Eriksson, J 86 Eriksson, K 554 Eriksson, P 5 Eriksson, S 66 Erkan, D 7, 76, 46, 404, 456, 457, 458, 696, 697 Erken, E 64 Ernste, F 709 Ernste, FC 754, 95, 588 Erondu, N 8 Erra, A 998, 999 Ertan-Demir, S 707, 5 Erten, G 707 Ervin, D 60 Erwig, L 55 Erwin, J 47 Erzin, Y 74 Esaki, K 899 Esbensen, BA 689 Escalante, A 87, 67,, 69, 4 Escorpizo, R 77 Escudero, P 0 Esdaile, J 7, 64 Eshed, I 06, 66, 67 Eskehave, TN 5 Eskelinen, A 095 Eskiyurt, N 97 Eskra, D 60 Esmaeilzadeh, S 97 Espada, G 760, 040, 477 Esperanza Group, 78, 70, Espesen, J 6, 6 Espígol, G 57 Espígol Frigolé, G 5 Espígol-Frigolé, G 859, 59 Espiño- Lorenzo, P 7 Espinosa, G 85, 479 Espinosa, M 656 Espinoza, LR 0 Esquivel Valerio, J 096 Essers, I 6 Estensen, ME 68 Estrada, P 7 Estrela, GBQ 6 Esveldt, RE 56, 754 Etau, P 47 Etchepare, F 470, 8 Eudaly, JG 45 EUMUSC.net working group WP 5, 7 EuMyoNet, 9, 67 Eun, JS 0 Eustar, 696 Evangelisto, AM 59 Evans, DS 98 Evans, D 595, 6 Evans, RR 5, 8 Evans-Young, G 440 Everett, S 404, 406, 697 Everts, V 0 Ewing, E 0 Eyal, R 899 Eymard, B 5 Ezealah, E 07 Ezeamuzie, O 55 Ezzat, AM 0, 44 F F, NS 7 Fabi, M 00 Fabio, G 0 Fabreguet, I 5 Fabris, M 89, 555 Faccin, F 487, 0 Faezi, T 76 Fagerland, M 84 Fagerli, KM 95, 50, 85, 560, 56 Faham, M 588 Fahmi, H 70 Faia, K 8 Fain, O 95, 5, 649, 699, 78 Faivre, A 55 Faivre, B 75, 5 Falaus, S 9 Falcini, F 676, 0, 04, 06, 07, 08 Falgarone, G 95 Falzer, P 578, 66 Fan, H 798 Fang, F 787, 57, 58, 89 Fang, H 609, 68, 69, 66, 6, 640, 69, 886, 98, 89, 90, 9, 96, 400, 4, 648, 70, 70, 7, 45, 55, 569, 57 Fanouriakis, A 46 Faraawi, RY 54 Fardellone, P 80, 969 Faré, R 8, 9 Faregh, N 865 Farewell, D 9 Farge, D 0, 64 Fargetti, S 6 Faria, AGA 8 Farina, I 00 Färkkilä, M 90 Farkouh, M 50, 6 Farmani, NL 69 Farouk, HM 490 Farrell, J 0, 60 Farrerons, J 959 Farris, AD 0 Farrokhi, S 7 Fauchais, AL 88 Faucherre, M 5 Faust, E 69 Fautrel, B 8, 8, 64, 96, 479, 80, 98, 0, 67, 80, 89, 849, 895, 605, 69 Fava, A 99 Favari, E 675 Favors, K 5 Fayad, Z 50, 6 Fearon, U 9, 6, 658, 800, 806, 5, 9 Fedele, AL 764 Federici, C 774 Feehan, LM 007, 447 Feely, J 58, 59 Feghali-Bostwick, CA 9, 74 Fei, K 66 Feig, JL 788, 805 Feinstein, JA 9 Feitosa de Oliveira, SK 96, 76 Feld, J 547 Feldman, BM 95, 68, 7, 54, 598, 044 Feldman, CH 87, 9, 570, 600 Feldman, D 545 Feldman, DE 69 Felea, I 9 Felli, L 64 Felson, DT 7, 796, 799, 098, 04, 4, 9, 55, 666, 8, 6 Fenaux, P 95 Feng, M 76 Fengxiao, Z 60 Ferbert, SM 867, 566, 858 Ferguson, C 7 Ferguson, JE 695 Ferguson, LJ 0, 948 Ferguson, PJ 0 Ferguson, S 468 Ferlin, W 75 Fermont, L 649 Fernánde-Berrizbeitia, O 44 Fernandes, AW 94, 9, 94, 68 Fernandes, AJ 769 Fernandes, ARC Fernandes, G 864 Fernandes, P 4, 45 Fernandez, D 45 Fernández, JA 5 Fernandez, NC 00 Fernández de Castro, M 44 Fernandez Garcia, JL 99 Fernandez Moreno, M 994 Fernandez-Cid, JC 40 Fernández-Espartero, C 78 Fernández-Gutierrez, B 006, 05 Fernandez-Llaca, H 548, 88, 89 Fernandez-Lopez, C 54, 55, 99, 994 Fernandez-Moreno, M 99 Fernández-Nebro, A 980, 998, 999, 7, 44 Fernandez-Perez, ER 7 Fernandez-Puente, P 4, 988 Fernandez-Rodriguez, B 578 Fernandez-Sueiro, JL 54, 550, 55, 567, 998, 999, 59, 60 Fernandez-Tajes, J 99, 994 Ferraccioli, G 679, 97, 486, 764, 8 Ferracin, M 00 Ferrajolo, C 907 Ferrand, C 755 Ferrari, C 88, 6 Ferrari, C 7 0 Program Book 67 abstract author Index

370 abstract author Index Ferreira, GA 6 Ferreira, I 976, 997 Ferreira, VP 059 Ferreira, WG 99 Ferrell, EG 44, 57 Ferreyra Garrott, L 5, 68, 58 Ferri, C 456 Ferriani, VP 96 Ferro, F 6, 59, 546 Ferrucci, L 95 Fert, I 600 Fertala, J 09 Fertig, N 0, 945, 949, 950 Ferucci, ED 76, 94, 688 Fervenza, F 54, 567 Feslon, DT 0 Fesmire, J 677 Fessier, C 85 Fessler, J, 8 Fetrow, JS 7 Feudtner, C 00 Feydy, A 556, 007 Fichtner, A 777, 705 Fidder, HH 05 Fidelus-Gort, RK 487 Fiehn, C 59 Fielding, R 794 Figgie, MP 09, 44, 479, 57, 649 Figueira, R 988 Figueiredo, CP 9, 9, 4 Figus, M 88 Filer, A 89 Filgueira-Fernandez, P 4 Filho, MAGP 6 Filipescu, I 46, 9 Filippucci, E 80, 8 Filkova, M Fill Malfertheiner, S 440 Finckh, A 48, 456, 467, 48, 766, 770, 0, 577, 44, 7 Fine, JS 55 Fine, MJ 698 Finès, P 46 Finetti, M 0, 0 Finkenstaedt, M 466 Finlay, K 06, 00 Finnegan, S Finnerty, D 059 Finzel, S 594, 008, 00, 09, 58, 58 Fiocco, GP 59, 85 Fiorentino, D 706, 755, 758, 95, 954 Firestein, GS 46, 878, 56, 60, 659, 775, 076, 70 Fischbach, M 47 Fischer, A Fischer, A 7, 46, 468 Fischer, L 48 Fischer, MA 87, 9, 600 Fischer, S 4 Fisheleva, E 694 Fisher, BA 00 Fisher, MC 66, 04 Fitz-Patrick, D 50 Fitzcharles, MA 96, 86, 865, 879, 64 Fitzgerald, GK 7 FitzGerald, JD 69, 5, 709 FitzGerald, OM 55, 54, 58, 00, 55, 059, 8,, 540, 549 Fitzpatrick, JD 06 Fitzpatrick, LA 984 Flaherty, K 7 Flannery, MP 88 Flato, B 760 Flatø, B 87, 68, 94 Flavin, NE 964 Fleck, M 8, 0, 8, 047, 78 Fleckner, J 65 Fleischer, SJ 749 Fleischmann, R 547 Fleischmann, RM 77 Fleischmann, R 80, 487, 775, 85, 8, 9, 40, 4, 449 Fleischmann, RM 459, 557, 86, 90,, 6, 0, 486, 6, 66 Fleisher, TA 06 Fleming, M 08 Fletcher, D 579 Fletcher, J 7 Fleury, T 668 Fligelstone, K 77 Flipo, RM 8, 8, 5, 80, 08, 09,, 68 Flipon, E 895 Flondell, M 648 Florentinus, S 7, 487, 775, 0, 04 Flores, C 04 Flores, D 56 Flores Alvarado, D 096 Flores Nunez, A 679 Flores-Suarez, LF 94 Flossmann, O 55 Flurey, CA 864, 558 Flynn, E 974, 654 Foeldvari, I 679 Foeldvari, I 56, 004 Foelkel, ALDA 064 Foerger, F 55 Foering, K 40 Fogg, LF 6, 64 Foltz, V 049, 47 Fong, HHS 58 Fonollosa, V 479 Fonollosa Calduch, A 40 Fonseca, C 0, 04 Fonseca, C 6 Fonseca, JE 7 Font, P Fontaine, KR 95 Fontes, JDT 45 for the CARRA Registry Investigators, 79 for the Vasculitis Clinical Research Consortium, 655 Forastiero, R 459 Forbess, LJ 540 Ford, DA 8 Ford, J 9 Forejtova, S 96 Förger, F 766 Formisano, D 6 Førre, T 84 Forsblad-d Elia, H 46, 5 Forslind, K 90 Forsthoefel, A 88 Fortin, I 494 Fortin, PR 40, 674, 47, 570, 688 Fortina, P 496 Fossati, G Fossel, AH 8 Foster, HE 9, 59, 6 Foster, HE 45, 009 Foucher, KC 6, 797, Fowler, R 89 Fox, B 080 Fox, C 60 Fox, DA, 88, 74 Fox, E 690 Fraenkel, L 868, 907, 08, 58, 578, 48, 444, 66 Fragoulis, G 99 Fraley, A 80 Frallonardo, P 596 Frampton, C 9 Francès, C 64 Franchimont, N 959, 998 Franchini, S 68 Franciosi, A Francis, L 498 Francois, A 785 Frane, J 760 Franek, BS 7 Frank, MB 5, 55, 674 Frank, MM 5 Frank Bertoncelj, M 90 Franke, B 4, 80 Frankel, S 468 Franklin, KE 765 Franklin, PD 085, 086, 087, 585, 65 Franks, AG 47, 805 Fransen, J Fransen, J 6, 85, 68, 65, 67 Fransen, R 7 Fransoo, R 99, 54 Fraser, AR 88 Fraser, A 95 Freburger, JK 094 Frech, TM 69, 46, 489 Fredberg, U 959, 877 Frederiksen, KS 65 Fredi, M 5 Freedman, BI 79, 970, 6 Freedman, JE 567 Freeman, T 96 Freeston, JE 66 Frei, CR 84 Freimuth, WW 64, 65, 66, 4, 6 Freire, M 44, 9 Freire, V 556, 007 Freire González, M 980 French, J 697 French Vasculitis Study Group (FVSG), 65, 656, 56 French Vasculitis Study Group and NeuroVascular Society, 55 Frenkel, J 0, 0 Freuh, F 978 Freundlich, B 57, 9 Frey, S 888 Frey-Law, L 55 Friday, RP 66 Friday, SC 88 Fridlund, B 559 Frie, BL 48 Friedman, A 678, 840, 67 Friedman, D 400, 406 Friedman, D 90, 647 Friend, SF 507 Friese, M 50 Frits, MA 798, 954, 584, 8, 06, 660 Fritschel, EK Fritschy, D 48 Fritz, C 5 Fritzler, MJ 94, 9, 688, 06 Frizelle, S 09 Frobell, R 96 Frommer, K 890 Frommer, KW Program Book

371 Frost, J 975 Frostegård, J 45 Frydrych, LM 7 Frye, LL 06 Fröhling, M 779 Fu, SM 444 Fu, SM 675 Fudge, K 95 Fuentes, IM 48 Fuentes, M 968 Fuentes-Boquete, IM Fuentes-Silva, Y 57 Fuhlbrigge, RC 008, 09 Fuhr, U 9 Fuhrman, C 7 Fuiman, J 54 Fujieda, Y 79, 460 Fujii, H 8, 665 Fujii, T 6, 96, 96 Fujii, W 070 Fujii, Y 084 Fujimoto, M 6 Fujimoto, M 59 Fujio, K 98 Fujio, N Fujioka, K 070 Fujishiro, M Fujita, K 8 Fujita, M 48 Fukuda, T 70 Fukuda, T 98 Fukushima, S 86 Fukuyo, S, 77, 64, Fuller, R 6, 68 Funahashi, K 4, 7 Funauchi, M 96 Funck-Brentano, T 5, 44 Fung, L 4 Funk, RS 5, 597 Funke, R 78 Furer, V 50, 6 Furie, R 60, 47, 4 Furie, RA 6 Furst, D 9 Furst, DE 050 Furst, D 9, 4, 475 Furst, DE 9, 94, 459, 468, 9, 4, 46, 509, 69 Furst, D 486, 78, 70, 464, 899 Furtado, RNV 0, 04, 6, 45, 807, 808 Furtado, RN 60 Furu, M 40 Furukawa, H 000, 55 Furukawa, KI 60 Furusawa-Carballeda, J 5 Furuya, T 97, 957, 96 Fusama, M 569 Futai, K 084 FVSG, FVSG 545 G Gabay, C 48, 77 Gaber, T 47, 777, 085 Gabriel, B 57 Gabriel, SE 80, 8, 0,, 48, 49, 48 Gabriel, S 40 Gachályi, B 07 Gaedigk, R 597 Gaffen, SL 76 Gaffney, PM 54, 84, 846, 970, 6, 67 Gaffney on behalf of LLAS, PM 8 Gaffo, AL 40, 06 Gage, JR 644 Gago-Fuentes, R 4 Gaich, CL 488, 490 Gaillard, N 55 Gaillez, C 80, 8, 59 Gainer, V 68 Gait, AD 7 Gajalakshmi, V 59 Gajria, K 9, 94 Galarza Delgado, D 096 Galateanu, C 59 Galbiati, V 47 Galeazzi, M 460, 80, 8 Galeazzi, M 9 Galgiani, J 7 Galicier, L 64 Galien, R Galindo, M 44, 4 Gallagher, J 959 Gallagher, P 55 Gallagher, S 450 Gallegos-Nava, S 644 Gallizzi, R 0 Gallo, A 506, 59 Gallo, G 64 Gallo, MC 58, 7 Galloway, JB 88, 59 Gambert Abdel Rahman, C 0 Gamble, G 7, 585 Gamboa-Cardenas, RV 99 Gamez-Nava, J Gamir, M, Gamonet, C 755 Gan, JB 64 Gan, RW 7, 7 Gandavadi, S 875 Gande, A 07 Gandjbakhch, F 049 Gangji, V 0 Ganguli, A 79, 484 Gannon, W Jr. 8 Ganser, G 49, 0 Ganser, M 47, 067 Gantes, M 44 Ganz, R 6 Gao, A 585 Gao, F 69 Gao, H 76 Gao, N 9 Gao, W 9, 658 Garau, P 498, 599 Garay, SM 00 Garay, SM 477 Garces, A 75 García, AC 4 García, ML Garcia, MV 68, 58 García, N 0 Garcia, R 498 Garcia, S 90, 60 Garcia de Aquino, S 5 García Meijide, J 7 Garcia Salinas, R 4 García-Aparicio, M 40 García-Bermúdez, M 05 Garcia-Carazo, S 546 Garcia-Carrasco, M 606, 958 García-Martínez, A 5, 57, 59 Garcia-Melchor, E 9 Garcia-Mendez, S 90 Garcia-Monaco, R 5, 9, 40 Garcia-Valladares, I 468 Garcia-Verdugo, J 505 García-Vicuña, C 40 García-Vicuña, R 46 Gardette, A 478 Gardner, GC 46, 97 Gardner-Medwin, J 59, 6, 009 Garen, T, 98 Garg, A 76 Garg, N 55 Garg, V 9 Gargani, L 5, 09 Garland, A 99, 54 Garnero, P 580 Garrido, M 787 Garris, C 94, 946 Gärtner, M 09 Garvey, WT 74 Garyfallos, A 058 Garyfallos, G 058 Garza Elizondo, M 096 Garza-Garcia, A 77 Gascon, C 7 Gasparello de Almeida, R 96 Gathany, T 9, 86 Gattamelata, A 84, 85 Gattinara, M 67, 08 Gattorno, M 749, 0, 0, 657, 658 Gauba, V 67 Gaudin, P 470, 8, 09 Gaugler, B 755, 756 Gaujoux-Viala, C 8, 8, 98, 89 Gaur, P 09 Gauri, L 58, 59 Gauthier, G 840 Gautier, S 85 Gay, R 78 Gay, RE 49, 47, 48, 89, 90, 54, Gay, S 49, 47, 48, 89, 90, 54, 78,, 9, 670 Gaydukova, I 56 Gaylord, S 68, 549 Gašperšič, N 87 Geborek, P 48, 86, 7 Gebretsadik, T 6 Gedmintas, L 98 Gee, A 84 Geetha, D 54, 98 Geetha, N 08 Geier, JL 697 Geisser, ME 58 Geitz, K 56 Gelber, AC 697, 95, 98 Gelderman, K 8 Gelfand, J 559, 64 Genant, H 596 Genin, E 000, 7 Genovese, MC 46, 695, 547 Genovese, MC 80, 490, 5, 0, 640, 487, 488 Gensler, LS 78 Gent, YYJ Geoffroy, V 5 Georgantas, R III 675 George, M 8 Georgel, P 785 Georgiopoulos, G 66 Geppert, TD 69 Geraldino-Pardilla, L 59 Gerards, AH 768, 095 Gerber, EE 786 Gerdes, VEA 5 Gerhold, K 65, 0 Geri, G 6 Gerlag, D 8 abstract author Index 0 Program Book 69

372 abstract author Index 70 Gerlag, DM 58, 77, 89, 4, 754 Gerlag, DM 078, 4 Gerli, R 8, 84, 85, 55 Gerloni, V 679 Gerloni, V 760, 76, 76, 67, 08, 47 Germanò, G 5 Gerona, D 65 Gerosa, M 675, 5 Gerritsen, M 66 Gershell, L 960 Gershoni, R 00 Gertner, E 97, 65 Gesner, EM 4 Gestermann, N Getsios, S 58 Geusens, PP 0 Gewanter, HL 75 Ghazarian, SR 95 Ghelani, P 976, 997 Gheyle, L Ghib, L 9 Ghomrawi, H 404 Ghoreishi-Haack, N 74 Ghorpade, R 58, 59 Ghosh, A 58, 59 Ghosh, A 94 Ghosh, P 46 Giacchi, J 984 Giacobbe, L 576 Giacomelli, C 59 Giacomelli, R 8 Giacuzzo, S 56 Giampoli, E Giani, I 485 Giannelou, M 99 Giannini, C 566 Giannini, E 764 Giannini, EH 4 Giansante, C 60, 97 Gianturco, L 80 Gibbs, YC 4 Gibofsky, A 79 Gibson, DS Gibson, K 7 Gibson, R 45 Giclas, PC 475 Gieger, C 60 Gierut, AK 077 Gigante, MR 679 Gignac, MA 47 Gignac, MA 49, 64 Giguére, PM 66 Gil, D 90 Gil, KM 40 Gilardin, L 67 0 Program Book Gilbane, A 05 Gilboe, IM 98 Gilchrist, DS 88 Giles, BM 8 Giles, C 795 Giles, I 40, 40, 75, 77, 78 Giles, JT 00, 689, 484, 59, 659 Gilkeson, GS 86, 668, 67, 846, 970, 44, 45, 45, 6, 65, 74, 8 Gill, G 478 Gill, TM 444 Gill, TK 6 Gillespie, J 0 Gilliam, B 0, 4, 5 Gilliland, WR 44 Ginsburg, L 40 Ginzler, EM 570 Ginzler, EM 87, 6 Giovannoni, L 9 Giraldez, T 505 Girdish, C 00 Giugliani, R 04 Giwercman, A 84 Gkrouzman, E 65, 809 Glace, B Sr. 0 Gladman, DD 57, 6, 65, 646, 647, 648, 84, 84, 95, 50, 7, 4, 4, 45, 706, 54, 66 Gladman, D 560, 57, 590, 75, 8, 8,, 56, 6, 66 Gladman, DD 540, 557, 58, 674, 47, 48, 5, 54, 8, 40, 4, 570, 68 Gladman, DDG 55, 68, 69, 70, 65, 047 Gladue, H 464 Glaesmer, H 859 Glant, TT 06 Glaser, N 048 Glass, DN 64 Glass, JM 644 Glenn, SB 5, 54, 55, 674 Glintborg, B 79, 6, 6, 7, 558 Gloetzner, M 004 Gnanasakthy, A 4 Gnann, H 55 Gobbo, M 78, 70, Gobert, P 65 Godeau, B 08,, 67, 80, 68 Godfrin-Valnet, M 6 Godmann, L 9, 40 Godmer, P 65, 656 Godo, JR 75 Goeb, V 554 Goekoop, R 606 Goff, I 885 Goffin, L 759 Gofita, I 45 Goilav, B 48 Goker, B 05, 4 Gold, JI 47 Goldbach-Mansky, RT 0, 808, 0, 65, 656 Goldberg, AZ 69, 46 Goldberg, G 4 Goldblum, R 7 Goldenberg, DM 69, 5 Goldenberg, DL 86 Goldenstein-Schainberg, C 6 Goldfarb, DS 5 Goldfien, RD 87 Goldhaber-Fiebert, J 46 Golding, A 506 Goldman, JA 86 Goldmuntz, EA 69, 687 Goldring, SR, 58 Goldsmith, DP 4 Goldsmith, S 400, 406 Goldstein, BL 605 Goldstein, DM 6 Golightly, YM 789 Gomar, F Gomberg-Maitland, M 46 Gombert, B 95 gomez Rosso, L 56 Gomez-Caballero, ME 88 Gomez-Gerique, J 4 Gomez-Gracia, I Gomez-Puerta, JA 608, 88, 665 Gomez-Reino, J 78 Gomez-Reino, JJ 454 Gomez-Seco, J 75 Gómez-Vaquero, C 05 Goncalves, CR 064, 497 Goncalves Marangoni, R 787 Gong, K 7 Gong, W 7 Gong, Y 5 Gono, T 74, 94, 94, 49, 97, 4 Gonter, NJ 9 Gonzalez, C 998 Gonzalez, CM 999 Gonzalez, E 54, 550, 59, 60 Gonzalez, EB 69, 85, 405, 474, 456, 457 Gonzalez, J 759 Gonzalez, MI 7 Gonzalez, S 89 Gonzalez, T 00 Gonzalez Della Valle, A 09 Gonzalez Fernandez, C 47 Gonzalez Molina, MDR 9 González-Álvaro, I 05 Gonzalez-Gay, MA 548, 88, 89 González-Gay, MA 000, 40, 05 Gonzalez-Hernandez, MJ González-Juanatey, C 05 Gonzalez-Lopez, L Gonzalez-Lopez, MA 548, 88, 89 Gonzalez-Pulido, C 607 Gonzalez-Roca, E 9 González-Rodríguez, C 58 Gonzalez-Vela, C 548, 49, 88, 89 Gonzalo, E 4 Goode, AP 7, 094, Goodfellow, R 804 Goodfield, MJD 46 Goodman, SM 09, 44, 479 Goodwin, KA 90 Gopalakrishnan, R 5, 54, 55, 674 Gordon, C 406, 570 Gordon, CP 48 Gordon, C 08 Gordon, JK 694, 74, 465, 7, 75 Gordon, P 955 Gordon, TP 504 Gordon, T 676 Gorelik, A 64 Gorelik, G 7 Gorelik, M 656 Gorlova, OY 0 Gorman, D 75 Gorn, AH 69, 709 Gorochov, G 75, 5 Goronzy, JJ 857, 665 Gosciniak, P 5 Gossec, L 556, 895 Gosset, M, 8, 9 Gota, CE 884 Göthberg, M 86 Goto, D 88 Gottenberg, JE 5, 456, 467, 5, 08, 09,, 699, 785, 68, 88, 87, 55, 554 Gottlieb, AB 569, 557, 56 Gottlieb, BS 4, 60 Gou, P 7 Goudeau, D 756, 945, 949, 950, 7 Goudie, CT 06 Goulabchand, R 566 Goules, AV 90, 55

373 Goules, JD 90 Goulet, JR 70, 7 Goulvestre, C 565 Goupille, PM 59 Goupille, PM 80 Gourzi, VC 507, 508 Govind, N 975 Govoni, M 67, 56, 00 Gow, PJ 68 Gowdie, PJ 04 Goyal, JR 59 Goyal, P 499 Grabner, M 045 Gracely, R 7, 95 Gracey, E 65 Grader, A 798 Grados, D 9, 967 Graffin, B Sr. 6 Graham, GJ 88 Graham, JE 589 Graham, RR 79 Graham, T 545 Grahn, A 67, 74 Grainge, MJ 58, 84, 8, 77, 67 Grainger, AJ 00 Gram, H 76 Gramling, A 89 Grammatikos, AP 79 Gran, JT Graña, J Sr., Granados, CE 90 Granger, B 89, 849 Granholm-Bentley, ACE 45 Graninger, WB 08, 044,, 8 Grant, S 77, 79, 8, 468, 00, 480 GRAPPA Composite Exercise (GRACE) collaboration, 55 Gratacós, J 998, 999 Grateau, G 04 Graudal, N 6, 6 Gravani, F 8 Gray, F 55 Graybill, JL 6 Grayson, PC 868, 58, 59, 9, 48, 59 Grazio, S 45, 479 Greaves, J 64 Greco, CM 699 Green, AB 07, 658, 754, 49, 9, 95, 58 Green, D 96 Green, J 77 Green, S 78 Green, SM 09, 00, 0 Greenberg, JD 65, 79, 80, 464, 49, 89, 50, 6, 00, 05, 0, 8,, 50, 577 Greenberg, JO 06 Greenberg, SA 755, 675 Greene, M 9 Greenhill, Y 69 Greenlees, L V 675 Greenler, AJ 88, 040 Greenspan, JS 74, 67 Greenwald, MW 447, 76, 9 Greenwood, J 590 Greenwood, J 06 Greger, G 7 Gregersen, PK 7, 894, 0 Gregersen, PK 7, 44, 44, 97, 975, 57, 670, 687 Gregson, CK 48 Greidinger, EL 57 Grein, J 75 Gremese, E 679, 97, 764 Greth, W 94, 755, 9, 94 Gretler, J 08, 7, 044 Greve, JM 67 Grevers, LC 0 Grewal, HK 468 Griffin, KW 540 Griffin, M 960 Griffin, N 60 Griffin, R 498 Griffiths, B 466 Griffiths, CEM 695, 477 Griffiths, G 89 Griffiths, H 87, 40 Grifka, J 8, 55 Grigorian, M 47 Grigoriev, G 874 Grijalva, C 76, 960 Grillet, BA 94, 594, 606 Grimaldi, L 64 Grimaldi-Bensouda, L 68, 80 Grodzicky, T 70, 7 Grogan, S 8 Grom, AA 0, 657 Gronwall, C 577 Gross, AJ 440 Gross, KD 794, 799, 04 Gross, RL 60 Gross, T 670 Gross, TF 44 Gross, WL 54, 79, 80 Grossbard, EB 9 Grossi, C 675, 47, 455 Grossman, JM 69, 846, 984, 709 Grotzke, M 509 Grouard-Vogel, G 479 Groves, C 760, 68 Große, K 80 Gruben, D 77, 77, 485 Gruben, D 04, 8, 8, 97, 486, 546 Gruenke, M 554, 747 Grundahl, K 0 Grunewald, J 69 Grunke, M 0, 7, 407, 07 Gruntmanis, U 977 Grün, JR 686, 979 Grünig, E 85 Grützkau, A 686, 979 Grönwall, C 6, 45 Gu, R 798 Gu, Y 075 Gualtierotti, R 47 Guan, W 44 Gudbjornsson, B 7 Guedes, LKN 7, 064 Guennoc, X 04 Guenther, J 49 Guerin, A 84 Guermazi, A 49, 50, 5, 7, 07, 09, 00, 0, 0, 04, 4, 9,, 467, 469, 470, 54 Guerne, PA 48 Guerra, MM 650 Guettrot-Imbert, G 9, 64, 649 Guiducci, S 5, 09, 485 Guiguet, M 0 Guild, C 8 Guillemin, F 8, 8, 80, 98, 740, 80, 87, 849, 69 Guillemot, D 80 Guillén, MI Guillevin, L 0, 08,, 54, 545, 55, 67, 65, 656, 774, 87, 68, 8, 56 Guillou, C 485, 78 Gul, A 750, 78 Gul, A 005, 5, 64 Gül, A 989, 6 Gulati, N 49 Gulgielmi, B 68 Gullstrand, B 66 Gulseth, HC 84 Guma, M 878 Gumus, S 5 Gunawardena, H 9, 67 Gunawardhana, L 5 Gunay, N 565 Gunn, G 86 Gunnarsson, I 554, 574 Gunnarsson, R 98 Gunraj, N 5 Guo, S 48 Guo, X 8 Guochun, W 60 Gupta, N 40 Gupta, RK 07, 054 Gupta, S 847, 880 Gupta, V 666 Guralnik, JM 800 Gurner, D 77 Gustafson, N 45 Gustafsson, J 574 Guthery, S 974, 64 Guthridge, JM 67, 645, 67, 795 Gutierrez, MJ 99 Gutiérrez, M 898 Gutierrez, MA 56 Gutierrez-Achury, J 858 Gutierrez-Alamillo, L 56 Gutierrez-Cruz, G 6 Guymer, EK 88 Guzman P., RN 68 Guzmán Úbeda, MA 46 Gvozdenovic, E 97, 469 H Ha, A 6 Ha, CM 4, 60 Ha, YJ 95, Haas, JP 974, 49, 5, 64 Haas, M 45 Haas, R Haas, RW 87, 69, 4 Haavardsholm, EA 76, 95, 660 Hachulla, E 0, 748, 08,, 487, 04, 68, 88, 55, 554 Hack, CE 064, 786, 96, 5 Hackney, B 57, 4 Hackshaw, KV 969 Hacquard-Bouder, C 555, 5 Haddad, A 57, 47, 48, 5, 69, 70, 4, 40 Hadziyannis, E 66 Haecke, E 56 Haffizulla, K 57 Hafström, I 90, 45 Haga, S 659, 68 Hagberg, N 845 Hagedorn, TJ 790, 79, 79, 79 Hagel, S 7 Hagelberg, S 47 Hagerty, D 40, 4 Hagihara, K 500 Hagiwara, S 88 Hagiwara, Y 98 Hagiyama, H 98, Haglund, E 95, 88, 409 abstract author Index 0 Program Book 7

374 abstract author Index 7 Hahn, BH 69, 846, 984, 6, 709, 5, 45 Hahne, M 47, 777 Hahne, M 78 Hai, O 57 Haibel, H 56, 57, 70, 9, 9, 5, 496 Haiduc, V 404, 697 Haines, GK III 44, 879, 60, 69, 679 Haines, KA 94, 475 Haiying, C 60 Haj Hensvold, A 65, 69, 0 Hajdu, Z 5 Haji, Y 99, 948, 47 Hajj-Ali, R 57, 550 Hakimiyan, A Hakulinen, P 48 Halbwachs, M 0 Hale, C 78 Hale, E 45 Hale, S 80 Hales, P 750 Hall, C 45 Hall, C 848 Hall, JP 08 Hall, JW 977, 997 Hall, JC Hall, M 58, 59 Hall, PC 88 Hall, S 486, 545 Halse, J 959 Halushka, M 776 Halvorsen, A 588 Hama, M 809,, 4 Hamaguchi, Y 6 Hämäläinen, M 88 Hamann, J 89 Hamburger, MI 904 Hamer, C 4 Hamerman, JA 446 Hamidou, M 649, 65, 04 Hamilton, BC III 7 Hamilton, J 0, 7 Hamilton, P 986 Hamm-Alvarez, SF 94 Hammaker, D 878, 775 Hammam, N 705 Hammenfors, D 86 Hammer, HB 8 Hammer, M 49 Hammond, A 446, 69 Hamoudeh, M 549 Hampson, JP 80, 80, 805, 806, 644 Han, C 80, 569, 9, 86 Han, J 49 0 Program Book Han, KH 0 Han, K 469 Han, L 444 Han, MK 0, 0 Han, S 4 Hanami, K Hanaoka, K 084 Hanaoka, M 74, 94, 94, 49, 97, 4 Hanci, I 87 Hanczko, R 498 Handa, R 58, 59 Handa, T 98 Handler, C 4, 7 Haney, DJ 5 Haney, D 59 Haney, DJ, 664 Hanidu, A 96 Hanly, JG 5, 6, 9 Hanna, H 84 Hanna, MG Hannan, MT 789, 790, 79, 79, 79, 45, 49 Hannon, MJ 49, 50, 5, 5, 908, 909, 09, 00, 0, 8, 469, 470 Hans, D 96 Hansell, D 7 Hansen, A 6, 6, 7 Hansen, HC 4 Hansen, MS 7 Hansen, PR 684 Hansson, M 4, 4, 49, 65 Haour, G 80 Haq, S 69 Haqqi, TM 9, 59 Haque, UJ 476 Hara, T 748 Harada, Y 94 Haraoui, B 8, 84, 40, 458, 465, 4, 6, 5, 8, 7, 099, 09,, 60 Harari, O 597 Harbers, JB 94 Hare, AA 875 Hareendran, A 94 Harel, L 76 Hargrove, JB 80 Harigae, H 8 Harigai, M 98, 7, 4, 5, 55 Harju, A 69 Harlé, JR 64 Harley, ITW 670 Harley, JB 5, 54, 55, 67, 79, 740, 846, 970, 606, 6, 0, 74, 8, 67, 674 Harman, L 6 Haro Martínez, ADC 9 Haroche, J 75, 5 Haroldson, KL 76 Haroon, M 00, 55, 9 Haroon, N 54, 78, 59, 4 Harper, BE 69, 85, 405, 474 Harper, L 55 Harre, U, 00 Harrer, T 6 Harriman, G 06 Harrington, JT 05 Harrington, TM 604 Harris, CC 76 Harris, EL 67 Harris, JK 69 Harris, J 40 Harris, L 65 Harris, N 484 Harris, RE 80, 80, 805, 806, 866, 450, 644 Harris, TB 800, 5 Harris, ZL 86 Harris-Love, M 598 Harrison, A 80, 68 Harrison, DJ 86, 495, 698, 89 Harrison, H 46 Harrold, LR 464, 085, 087, 8, 50 Harsanyi, AM 0 Hart, DM 688 Hart, LE 06, 08, 05, 00 Hart, SP 00 Harte, S 80 Harte, SE 805, 806, 866 Hartkamp, A 7 Hartkamp, LM 90, 55 Hartlage, GR 6 Hartman, T Hartmann, B 857 Hartung, W 8, 0, 8, 047, 78 Harty, LC 6, 059,, 540 Harvard, S 80 Harvey, BP 5 Harvey, E 84 Harvey, P 688 Harvey, WF 964 Hase, K 8 Haseeb, A 59 Hasegawa, A 645 Hasegawa, H 060 Hasegawa, M 6 Hashimoto, A 6 Hashimoto, H 96 Hashimoto, H 55, 56 Hashimoto, J 94 Hashimoto, M 6, 96 Hashimoto, N 8 Hashimoto, Y 60 Hashiramoto, A 48, 97 Hashizume, M 899, 077, 079 Hasni, SA 50, 506 Hassanali, A 49 Hassett, AL 866, 45 Hasunuma, T 50 Hatakeyama, S 79 Hatano, M 700 Hatemi, G 74 Hatemi, I 74 Hatron, PY 65, 88 Hatta, K 444, 445, 56 Hatta, K 96 Hatzara, C 66 Hauenstein, S 9 Hauge, EM 07 Haugeberg, G, 975, 54, 90 Haugen, IK Häupl, T 686, 979 Häuser, W 95, 859, 860, 64 Haupt, S 44, 508 Hawk, V 57 Hawker, GA 9, 44, 799, 907 Hawkins, C 95 Hawkins, FG 998 Hawkins, P 80 Hawtree, S 80 Hay, E 5, 44 Hayashi, D 07, 09, 00, 0 Hayashi, H 48 Hayashi, M 4, 465 Hayashi, T 88 Hayat, S 57 Haye Salinas, M 60, 4 Hayem, G 554 Hayer, S 5, 4, 947, 08 Hayes, KW 4 Haynes, K 74, 559 Hays, T 58 Hazel, E 69 Hazelhurst, S 975 Hazen, MM 76 Hazes, J 048 Hazes, JMW 76, 768, 76, 4, 40, 560, 570, 79, 095, 58, 6, 6, 8 Hazlewood, GS 40, 465, 54 Haznedaroglu, S 4 He, J 76 He, P 84 He, T 75 He, W 964, 965 Head, AJ 8 Healy, L Healy, M 58, 59

375 Heap, D 055 Hearth-Holmes, M 676, 89 Hebert, D 84 Hebert, L 840 Hebsgaard, J 080, 08 Hecht, C 58 Hecht, I 7 Hedemann-Andersen, A 54 Heegaard, C 0 Heegaard, NHH 680, 88, 76 Heelas, EO 757 Heeringa, P 860, 5 Heezen, K 58 Heffernan, EJ 55, 6 Hefner, K 54 Hefner, KS 5, 55, 0, 674 Heiberg, MS 560, 56 Heijda, TF 59 Heike, T 748 Heimans, L 94, 0, 594, 606 Heimbürger, M 776 Hein, M 07, 658, 95 Heintzman, N 97 Heinze, E 69 Heinzl, H 85 Heiser, U 08 Heitzmann, M 68 Heldmann, F 586, 780, 69 Helfenstein, M Jr. 880 Hellbacher, E 574 Hellgren, K 9 Helling, B 4 Helliwell, PS 474, 55, 00, 46 Hellmark, T 76 Hellvard, A 08 Helmer, Q 670 Helmick, CG 099, 46 Helsen, MM 55 Hemke, R 0, 09 Hemmati, I Henchoz, Y 4, 647 Hendler, T 6 Hendrickson, AF 50 Hendrikx, J 65 Hendrikz, J 7 Henrickson, M 94, 896, 0, 0, 040 Henriksen, K 984 Henrotin, Y 780 Henson, J 97 Hentgen, V 04 Heo, YJ 745 Her, YM Herbein, G 87 Herborn, G 57 Herbst, R 784, 450, 498, 760, 68 Herenius, MM 8 Herlin, T 00 Herman, S 6 Herman-Kideckel, S 888 Hermann, J 08, 7, 044 Hermann, KGA 56, 9 Hermine, O Sr. 6 Hernandez, C 446 Hernández, MV 85 Hernández, MV 88, 64 Hernández, VC 90 Hernández-Cruz, B 58 Hernández-Díaz, C 7 Hernández-Hernández, C 44 Hernandez-Molina, G 5, 44 Hernandez-Molinero, M 006 Hernández-Rodríguez, J 855, 859, 5, 57, 59 Herrera-Garcia, A 505 Herrero de Padura, I 567 Herrero-Beaumont, G 75 Herrero-Beites, AM 45, 905, 906 Herrick, A 695, 477, 48, 0, 04 Herrinton, L 960 Herrmann, K 08 Herrmann, M 07 Herrmann, S 44 Hersh, AO 76, 8, 98 Herson, S 0, 5 Hervier, B 75 Herz, B 09 Herzog, R 0 Heslop, PS 79 Hesselstrand, R 77, 98, 0 Hester, CG 5 Hetland, ML 79,, 6, 6, 46, 4, 045, 7, 5, 558 Heur, M 94 Hewitt, S 688 Hewlett, S 864, 558, 579, 7 Heymann, RE 880 Heymans, MW 5 Heynen, G 0 Hidaka, D 8 Hidaka, T 70 Hides, JA 68 Hiepe, F 686, 979, 449, 50 Higa, J 8 Higa, S 569 Higami, K 96 Higashi, K 569 Higashi, Y 084 Higgins, G 09 Higgins, GC 008 Higgs, BW 8, 755, 675 Higgs, JB 589, 59 Highton, J 80, 68 Hilário, M 76 Hilario, MO 96, 04 Hilderson, D 86 Hiligsmann, M 966 Hill, CL 6 Hill, J 78 Hill, J, 96, 58 Hill, J 87 Hill, PL 9 Hill, RJ 6 Hill, SC 000, 0 Hillegass, WB 54 Hillen, J 68 Hillen, MR 786, 96 Hilliard, BA 688 Hilligoss, J 95 Hillstrom, HJ 789, 790, 79 Hilton-Jones, D Hinchcliff, ME 76, 787, 46, 58 Hinks, A 974, 64, 654 Hinojosa, M 47 Hinojosa-Azaola, A 650 Hinsch-Gylvin, L 456, 467 Hinson, G Hirai, H 070 Hirakata, M 98 Hiraki, LT 87, 44, 9, 976, 608, 609, 79 Hirano, F 7 Hirano, T 500 Hirata, S 77,, 6, 664 Hirata, Y 700 Hirohata, S 6,, 458, 7, 684 Hiron, M 485, 78 Hirono, S 074 Hirsch, JD 4 Hirsch, R 656 Hirsh, JM 9, 655, 7 Hisamoto, S 86 Hiscock, A Hiscock, R 8, 840 Hishitani, Y 500 Hissink Muller, PCE 00 Hitchon, CA 8, 40, 465, 99, 79, 6, 5, 8, 099, 09,, 54, 60 Hix, S 96 Hjalte, F 90 Hmamouchi, I 96 Ho, A 5, Ho, HE 497 Ho, LY 407, 40, 4, 44, 488, 5 Hočevar, A 87 Hobbs, K 69, 5 Hobday, PM 056 Hochberg, MC 695 Hochberg, MC 9, 58, 60, 744, 9, 99, 986, 975, 995, 467, 5 Hodgson, RJ 00 Hodkinson, B 975, 794 Hoeck, HC 5 Hoeger, P 004 Hoehle, M 466 Hoekstra, M 607 Hoeltzel, MF 597 Hoepken, B 777, 705, 6 Hoese, G 77 Hoetjes, N Hofbauer, A 668 Hofer, M 648 Hofer, M 759, 679, 0 Hoff, M 975 Hoff, P 47, 777 Hoffart, CM 00 Hoffman, GS 855, 57, 57, 544, 65, 655, 9, 97, 567 Hoffman, H 80 Hoffman, HM 656 Hoffman, I 05 Hoffman, J 804 Hoffman, J 09 Hoffman, M Hoffman, RW 5, Hoffman, S 476, 5 Hoffmann, N 944 Hoffmann, PM 79 Hoffmann-Vold, AM 0 Hoffmeyer, P 48, 09 Hoffstetter, P 8, 047 Hoftman, AD 0 Hoganson, DD 709 Hoh, SF 74 Hoi, AY 57 Hokken-Koelega, ACS 4 Holers, VM 7, 7, 44, 4, 44, 059, 69, 765, 097, 6 Holgado, S 967 Holla, JFM 5 Hollan, I 84 Holland-Fischer, M 558 Hollander, MC 040 Hollister, AS 50, 6 Hollister, JR 596 Holmdahl, R 4, 4, 49, 769 Holmes, AM 05 Holmqvist, M 0 Holz, JB 6, 07, Hommes, DW 05 abstract author Index Hömmö, T 88Honda, F Program Book 7

376 abstract author Index 74 Honda, S 70 Hong, MJ 884, 96, 968 Hong, SD 896, 008, 09 Hong, SJ 78, 967, 47, 6, 88 Hong, SY 680 Hong, YS 4 Hong, YK 884 Hooper, M 644 Hooten, WM 866 Hoover, P 58 Hoover, SE 7 Hopkinson, D 7, 04 Horai, Y 70, 05,, 4 Horcada, L 44 Horikoshi, M 88 Horita, T 79, 460 Horiuchi, T 86 Horkayne-Szakaly, I 06 Horn, EM 465, 7 Hörnberg, K 44 Horne, A 66 Horne, A 90 Horneff, G 759, 760, 47, 49, 5, 5, 597 Hornum, L 08 Horslev-Petersen, K 46 Hørslev-Petersen, K 045, 5 Hortobagyi, T 955 Horton, R 406 Horton, SC 66 Horwitz, DA 4, 50 Hoshi, D 9, 400, 8 Hosoi, T 957 Hosono, O 600 Hosono, Y 6, 96, 98 Hosoya, T 7 Hosseini, K 8, 8, 98 Hossler, J 07, 99, 667, 678 Hostnik, B 87 Hot, A Sr. 6, 8 Hotchkiss, RN 08 Hotta, S 660, 799 Hou, Y 9 Houard, X, 8, 9 Houghton, K 76 Houk, C 604 House, M 90 Houssiau, FA 5, 548 Houston, GD 5, 54, 55, 0, 674 Houvenagel, E 09 Houwing-Duistermaat, J 97 Houwing-Duistermaat, JJ 670 Houx, L 04 Howard, D 970, 987 Howard, DG 60, 68 0 Program Book Howard, TD, 84 Howe, HS 78 Howsmon, R Howson, TL 69, 70 Hoyer, BF 50 Hoyles, R 785 Hoyt, J 8 Hsia, EC 80, 66, 60 Hsia, SH 549 Hsieh, C 60 Hsu, B 56 Hsu, HC 5, 575, 677 Hsu, S 759 Hsu, VM 69, 46, 46 Hsu, YH 49 Hu, C 9 Hu, F 065 Hu, X 900 Hua, C 5 Huang, A Huang, B 0 Huang, B 8 Huang, CC 0, 948 Huang, CH 97 Huang, F 66 Huang, J 0, 48 Huang, JL 549 Huang, J 505, 57 Huang, QQ 074, 076, 06, 69 Huang, Q 54 Huang, WT 465 Huang, Y 808, 65 Huang, Y 74 Hubbard, Y 08 Huber, AM 9 Huber, KA 55 Huber, LC 89 Hubert, P 0 Hudson, M 7, 78, 467, 4, 44, 66 Hueber, AJ 888, 00, 58 Huemer, C 679 Huffman, KM 68, 8 Huggins, JL 8,, 0, 040, 60 Hughes, LB 997 Hughes, P 5, 55, 0, 674 Hughes, RA 488, 864, 558, 89, 94 Hughes, T 858 Hughes-Austin, JM 7, 44, 097 Huhtala, TA 509 Huie, TJ 7 Huitema, MG 54, 5 Huizinga, TWJ 97, 894, 6, 0, 77, 98, 550 Huizinga, T 94, 564, 80, 594, 770, 06, 07, 09,,, 606, 6 Huizinga, TWJ 97, 768, 7, 670 Huizinga, TWJ 0, 0, 767 Hulscher, M 56 Hulsey, TC 60 Hummel, J 80, 8, 05,, 474 Hummers, LK 697, 79, 7, 46, 468 Humphreys, J 767, 544 Hunder, GG 566 Hung, K 8 Hung, MY 5 Hungerford, DS 60 Hunter, CD 7, 4 Hunter, D 49 Hunter, DJ 4, 5, 50, 5, 74, 07, 469, 470, 54 Hunzelmann, N 04 Huppertz, H 679 Hurford, M 460 Hurley, MV 590, 050, 49 Hurley, M 58, 46, 448, 6 Hurley, PM 99 Huscher, D 77, 46, 7, 085 Husic, R 08, 7, 044,, 8 Huso, DL 786 Hutcheson, J 679 Hutchinson, CE 7 Huttenlocher, A 60 Huvard, M Hviscova, K 96 Hwang, J 0, 45, 45, 8, 6 Hwe, A 87 Hübbe-Tena, C 644 Hyrich, K 767 Hyrich, KL 6, 88, 45, 59, 6, 59, 009 Hyun, DS 6 Hyzy, M 47, 067 Iagnocco, A 80, 8 Iaiani, G 9 Iannaccone, CK 954, 40, 660 Iannicelli, P 546 Ibanez, D 6, 65, 646, 647, 648, 84, 84, 4, 4, 45, 706, 4, 54, 66, 68 Ibanez Estrella, A 477 Ibarra, MF 008, 09, 597 Ibba, V 498, 599 Ibrahim, S 908, 909 I Ice, JA 5, 54, 55, 0, 67, 674 Ichesco, E 80, 805, 806, 644 Ichida, H 74, 94, 94, 49, 97, 4 Ichihara, H 600 Ichimura, Y 700, 708, 504, 5 Ichinose, K 046, 05, 448,, 4, 68 Ichinose, S Ichise, Y 98 Ickinger, C 975 Idbrik, L 87 Idrees, IM Iga, S 7 Igarashi, K 48 Igarashi, T 569 IGAS, IGOASC 6 Iglesias-Gamarra, AA 90 Ignatenko, S 79 Igney, A 844 Ihata, A 809,, 4 Ihn, H 86 Iizuka, M 58, 075, 59 Iizuka, N 8, 5 Ikari, K 089, 96, 4 Ikawa, T 96 Ikeda, K Ikeda, K Ikezawa, Z 50 Ilhan, B 67 Ilhan, B 94 Illei, GG 506, 00, 50, 506, 67 Ilowite, N 764 Ilowite, NT, 657 Im, CH 406, 67, 0 Imai, K 97 Imamura, PM 68 Imanaka, H 6 Imboden, JB 9, 440, 58, 584 Imundo, LF 406 Imura, Y 6, 96, 98 Inal, V 5 Inami, M 084 Inanc, M 707, 5, 64 Inase, N 98 Ince, A 0 Inciarte-Mundo, J 88 Ing, S 95 Ingegnoli, F 675, 47 Ingrand, P 0 Ingvarsson, R 654, 90, 44 Inman, CJ 890, 068 Inman, RD 7, 587, 588, 64, 65

377 Inman, RD 54, 78, 8, 59, 64, 4 Innala, L 45 Inoue, A 65 Inoue, E 9, 400, 8, 96 Inoue, N 55 Inoue, T 084 Inoue, Y 86, 9, 400, 8 Inoue, Y 86 Insalaco, A 0, 0 International RA Consortium on Therapy (InteRACT), 98 International Scleroderma Renal Crisis Study Investigaots, 78 International Spondyloarthritis Genetics Consortium, 495 Inverardi, F 5 Ioakeimidis, D 99, 8 Ioan-Fascinay, A 097 Ioannidis, G 08 Ioannou, Y 40, 40, 75, 77, 78 Iolascon, G 976 Ionescu, R 448, 449, 8 Iorga, SR 94, 9 Ipseiz, N 90 Irazoque, F 456 Irigoyen, MV 7 Irino, Y 80 Irrera, N 507, 508 Irrgang, JJ 07 Irshad, V 58 Irvine, J 94 Irwin, MR 576, 694 Isaacs, J 6 Isaacs, JD 0, 774 Isayeva, K 4, 48 Isenberg, DA 607, 40, 570 Isenberg, DA 65, 848, 40, 40, 406, 75 Isgro, J 847 Ishida, MA 68 Ishigatsubo, Y 809, 989,, 4, 6, 046 Ishiguro, N, 4, 5, 4, 465 Ishii, M 76 Ishii, T 70, 8 Ishii, Y 5 Ishikawa, M 40 Ishimori, ML 67 Ishino, H 070 Ishizaka, Y 659, 68 Ishizaki, J 060 Ishizaki, T 7 Ishorari, J 40 Isnard, R 65 Isobe, M 856 Isobe, T 4 Isola, M 8, 89 Isozaki, T 0, 4, 77, 879, 60 Israelsson, L 08, 65, 769, 578 Ito, H 40 Ito, H 45 Ito, I 55 Ito, M 084 Ito, S 094 Ito-Ihara, T 56 Itoh, K 504 Iung, B 565 Ivan Polk, B 48, 640 Ivanco, D 699 Ivanov, JP 408 Ivashkiv, LB 874, 900, 88, 96 Ivers, N 96, 5 Iversen, C 608, 97 Iversen, LV 680 Iversen, MD 798, 584 Iversen, P 86 Iverson, E 006 Iwabuchi, K Iwahashi, M 4 Iwamoto, K 084 Iwamoto, N 046, 05,, 4 Iwamoto, T 089 Iwamoto, T Iwata, S 600 Iwata, S 76, 50 Iyer, R 54 Izac, B 597, 598 Izmirly, PM 90, 50, 647 Izquierdo, E 8, 9, 5 Izuhara, K 50 Izumi, K 455 Izumihara, T 4, 7 J.M Kerkhof, H 98 Jaakkimainen, RL 96, 5 Jabbar-Lopez, Z 660 Jacek, EE 809 Jackson, J 006 Jackson, M 676 Jackson, MW 504 Jackson, R 4 Jackson, RD 9, 986, 467 Jackson, SW 580 Jacob, CO 84, 846, 970, 48, 6, 8 Jacob, N 48 Jacobs, JWG 5 Jacobs, JWG 048, 996 Jacobs, S 6 J Jacobsen, E 87 Jacobsen, S 680, 88, 49, 76, 570 Jacobsson, LTH 4, 86, 905, 84 Jacobsson, LT 95, 46, 88, 409 Jacques, C, 8, 9 Jacquot, S 0 Jadon, D 57 Jahagirdar, R 4 Jain, A 40, 06 Jain, M 50, 6 Jain, MS 06 Jain, S 60 Jain, V 85 Jajoria, P 69 Jakicic, JM 09, 00, 0 Jakobsen, MS 7 Jakobsson, K 905 Jakobsson, PJ, 4, 4, 49, 769 Jakstadt, M 777 Jallal, B 755, 675 Jallouli, M 649 James, D 74, 5, James, JA 54, 67, 645, 670, 67, 79, 740, 846, 970, 44, 606, 6, 748, 795, 8, 67 James, MT 7 James, M 45 Jan, R 404 Jandali, R 77 Jang, SI 506, 50 Janga, S 94 Jani, J 96 Janini, ACR 96, 97 Janow, GL Jansen, AV 06, 07 Jansen, G 54 Jansen, JP 7 Jansen, TL 6, 7 Janssen, G 770 Janssen, KMJ 0 Jara, LJ 956 Jara-Quezada, LJ, 70, 76 Jaramillo, D 90 Jaremko, J 8, 0 Jariwala, M 680 Jarjour, WN 678, 840, 67 Jarosova, K 764, 96 Jarraya, M 09, 00, 0 Jarrin, J 4 Jaskal, K 455 Jasson, M 0, 7 Jatwani, S 456 Javaid, MK 78, 95 Jayakar, J 5 Jayne, D 55, 564 Jebakumar, A 4, 0, 75, 98 Jefferies, C 60, 68, 56 Jeffries, MA 70 Jenkins, K 55, 005 Jenks, S 690 Jennings, F 09,, 864, 65 Jennum, P 689 Jensen, DV 6, 6, 558 Jensen, MA 7 Jensen, MP 95 Jensen, P 840 Jensen, P 959 Jensen, TD 6 Jensen-Urstad, K 70 Jensenius, JC 5 Jeon, CH 45, 8 Jeon, JY 75 Jeong, H 0 Jessep, S 46 Jessup, HJ 796 Jesus, AA 8 Jetanalin, P 97 Jetha, A 47, 49 Jeudy, A 87 Jhangri, GS 088 Jhingran, PM 945 Ji, JD 409, 67 Jia, Y 088 Jian, J 90 Jiang, H 5 Jiang, W 068 Jiang, X 978 Jiang, X 96 Jibatake, A Jimenez, JL 466 Jimenez, SA 496, 95, 06, 09 Jimenez- Núñez, FG 7 Jiménez-Hernández, M 958 Jin, HM 06 Jin, JP 06 Jin, Y 45 Jinnin, M 86 Jinying, L 60 Jiries, N 9 JM, G 7 Job Deslandre, C 679 Job-Deslandre, C 007 Jog, N 89 Johansen, J 5 Johansen, JS 4, 580 Johansson, I 69 Johansson, UB 57 John, A 464, 49, 00 John, MR 9 abstract author Index 0 Program Book 75

378 abstract author Index 76 John, MR 44, 49, 50, 5, 470 John, S 550 Johns, C 97 Johnson, BH 855 Johnson, BK 479 Johnson, DL 466 Johnson, H 667 Johnson, L 490 Johnson, MR 0 Johnson, SR 85, 64 Johnson, VM 07 Johnston, S 89, 855 Johnston Jr., CC 97 Jolly, M 4, 56, 6 Joly, F Sr. 77 Joly, J 56 Joly, M 0 Jonas, BL 0, 57 Jonas-Dwyer, D 590 Jones, AV 98 Jones, A 7, 405 Jones, A 09,, 867 Jones, A 79 Jones, CA 088 Jones, DM 7 Jones, GT 60, 966, 6, 55 Jones, G 454, 7, 8, 0, 55, 57 Jones, H 98 Jones, JD 75 Jones, KB 09 Jones, KL 466 Jones, KD 804 Jones, M 650 Jones, OY 8 Jones, PBB 68 Jones, RV 8 Jones, TV 87 Jones-Taha, R 447, 76 Jönsen, A 654, 66, 90, 88, 44 Jonsson, MV 50, 86 Jonsson, R 50, 5, 86, 67 Joos, R 76, 86 Jordan, JM 7, 789, 986, 094, 099,, 49, 468 Jorgensen, C 7, 505 Jorgensen, WL 875 Jorns, JM Joseph, G 86, 495, 698, 89 Joseph, R 4 Joshi, V 58, 59 Joshua, V 08, 69 Jouen, F 0, 485 Joung, CI 967, 88 Jousse-Joulin, S 97, 554 Joven, BE 696, 0 Program Book Joyce-Shaikh, B 75 JP Lin, Ju, JH 46, 664, 745, 58, 8 Ju, Y 4 Juan, M 9 Juanola, X 7, 700 Judge, A 78, 95 Juengel, A 90 Juhl Pedersen, S 67 Julià, A 980, 998, 999, 00 Julian, BA 79 Julian, LJ 580 Jun, JB 78, 47 Junca, A 90 Juneau, P 9, 94 Junfang, L 60 Jung, HA 7 Jung, J 45, 577 Jung, KJ 6 Jung, LK 4 Jung, M 7 Jung, SM 664, 58 Jung, YO 745 Jung, Y 4 Jungel, A 48 Junker, P 46, 045, 5 Junker, S 890 Jurgens, MS 996 Jurriaans, E 06, 00 Jury, EC 848 Juvenile Dermatomyositis Research Group, 97 Jüngel, A Jüni, P 6 K Kabasakal, Y 5 Kabraki, M 50 Kaburaki, J 850 Kachalia, A 06 Kachaochana, A 670 Kadi, A 597, 598 Kadono, T 504 Kaegi, T 770, 44 Kaeley, GS 589, 59 Kaffenberger, B 67 Kageyama, G 80 Kahaleh, B 494, 506, 96, 97 Kahan, A 50, 007 Kahlenberg, JM 44, 50 Kahn, JE 64, 6, 8 Kaieda, S 897 Kaine, J 695, 547 Kaine, J 94 Kairys, AE 80, 805, 806, 866, 644 Kaiser, MJ 05 Kaji, K 6 Kajihara, I 86 Kalabic, J 486 Kalampokis, I 6 Kaldas, M 69 Kale, M 475 Kalfa, M 8, 5, 64 Kalishman, S 08 Kallas, EG 497 Källberg, H 978, 607, 574 Kalled, S 68, 886 Kallenberg, CGM 860, 5, 9, 567 Kallinich, T 759 Kalliolias, GD 874, 96 Kalluru, R 586 Kalstad, S 404, 560, 56 Kalunian, K 69, 5, 6 Kalunian, KC 60 Kamali, S 5, 64 Kamath, T 89 Kamauu, A 09, 54 Kamble, S 984 Kamdar, AA 475 Kameda, H 455, 47, 877, 9, 60 Kamen, DL 67, 79, 84, 846, 970, 47, 6, 89, 65, 74, 4, 69, 687 Kamen, LA 057 Kamensek, O 7, 405 Kaminski, N 7 Kaminsky, P 740 Kamiyama, A, 0, 989, 990 Kamogawa, Y 8 Kamp, S 48, 795 Kampolis, C 78 Kan, H 945 Kan, M 009 Kanamono, T 4, 465 Kanariou, M 99 Kanazawa, M 4 Kandiah, DA 590 Kandili, A 66 Kandimalla, ER 068 Kaneko, A 4 Kaneko, H 64 Kaneko, H 4 Kaneko, K 50 Kaneko, T Kaneko, Y 98, 455, 86, 9, 60 Kanellos, M 055 Kanetsuka, Y 79, 460 Kang, EH 797, 85 Kang, EJ 95, Kang, JS 408 Kang, JH 406 Kang, JW 67, 0 Kang, J 664 Kang, MI 7 Kang, Y 7 Kang, YM 78, 406, 67, 0 Kanno, Y Kantarci, A 04 Kao, AH 690, 7, 699 Kao, W 088 Kaouache, M 649, 69, 48 Kapeller, R 06 Kapetanovic, MC 48, 7 Kaplan, I 90 Kaplan, J 855 Kaplan, MJ, 660, 440, 44, 499, 50 Kapoor, M 70 Kapsogeorgou, EK 507, 508, 56 Karabulut, G 5 Karadag, O 64 Karberg, K 77 Kargard, M 06 Karimi, R 69 Karin, M 46 Karlson, EW 7, 44, 97, 976, 98, 0, 605, 608, 609, 664, 68, 8, 79 Karmarkar, A 589 Karouzakis, E 49, 48 Karp, DR 67, 685, 060 Karp, G 08 Karpouzas, GA 69, 5, 645, 685 Karpus, KON 090 Karpus, ON 89 Karras, A 65, 657, 8 Karsdal, MA 5, 575, 59, 59, 9, 984, 66, 67, 65 Kasapcopur, O 750 Käsermann, F 79 Kaskari, D 958 Kåss, A 84 Kassoumeri, L 654 Kast, M 455 Kastelein, R 75 Kastner, DL 79, 989, 005, 6, 657 Katada, Y 94 Kataoka, S 74, 97, 4 Katashima, Y 8 Katayama, K 4 Katayama, M 94 Katayose, T 600 Kates, S Kato, T 8, 5 Katsaros, EP 4

379 Katsicas, MM 0, 74 Katsumata, Y 74, 94, 94, 49, 97, 4 Katz, BJ 855 Katz, C 956 Katz, JD 8 Katz, JN 8, 90, 9, 090, 08, 84, 98, 650 Katz, PP 47, 79, 87, 580, 9, 4 Katz, RS 605, 867, 95, 956, 564, 565, 566, 567, 858, 86, 878, 64, 698 Kauffman, M 678 Kaufman, JM 96, 969 Kaufman, KM 84, 846, 970, 6, 74, 8 Kaufmann, C 404 Kaul, I 47 Kaul, P 70 Kauppi, MJ 67, 68 Kaushik, P 89, 0 Kautiainen, H 67, 68, 75 Kavanaugh, A 7, 80, 487, 569, 77, 775, 995, 0, 7, 8, 557, 56 Kawabata, K 660, 799 Kawabata, T 78, 84, 490 Kawachi, H 95 Kawaguchi, Y 98, 74, 94, 94, 49, 97, 4 Kawahito, Y 96, 070 Kawai, S 50 Kawai, T 04 Kawai, VK 960 Kawakami, A 70, 046, 05, 448,, 4 Kawamoto, K 569 Kawamoto, T 09, 94 Kawano, S 40, 80 Kawarasaki, S 700 Kawasaki, A 55 Kawasaki, H 600 Kawasaki, M Kawasaki, Y 97 Kawashima, H Kawashiri, SY 046, 05,, 4 Kawata, AK 94 Kawatkar, AA 54 Kay, L 46, 78 Kaya, A 4 Kaya, D 5 Kaymakcalan, Z 5 Kayser, C 704 Kazi, S 065 Kazkaz, L 40 Keane, C 597 Kearns, GM 60, 68, 56 Kearsley-Fleet, L 45 Keating, RM 7, 44, 44 Kedar, E 97 Keddache, M 64 Kee, SJ 06 Keeling, SO 70 Keen, KJ 77 Keenan, G 67 Keenan, RT 66, 94 Kehler, T 479 Keir, G 7 Keirstead, N 74 Keiserman, M 46 Keith, MP 740 Kekow, J 440, 004 Kekow, M 440 Kelleher, K 09 Keller, KK 07 Kelley, GA 408 Kelley, KS 408 Kellner, H 7, 574, 5 Kelly, JA 5, 54, 55, 846, 970, 6, 0, 8, 84, 674 Kelly, S 547 Kelly, VM Kelsey, C 9, 008, 09, 06 Kelsey, S 46 Keltsev, V 597 Kendler, DL 998 Kendzerska, T 44 Kendzicky, A 506 Keniston, A 655, 7 Kennedy, A 6 Kennedy, AC 447 Kennedy, CW 44, 55, 57, 005 Kennedy, F 059 Kennedy, M 540 Kennedy, WP 60, 6 Kenny, D 9, 48, 8 Kent, M 55, 005 Kenwright, A 760, 9, 597, 66 Keogh, JC 88 Keogh, K 77 Keren, R 99 Kerkman, P 767 Kermani, TA 754, 55, 56, 58 Kerola, AM 67, 68 Kerola, T 67, 68 Kerr, GS 89, 49, 56, 87, 0, 0, 48, 48, 640 Kerschen, P 55 Kerstens, PJSM 58, 0, 98 Keränen, T 88 Keser, G 8, 5, 858 Kessel, A 746 Kessler, E 76 Kettle, A 90 Ketzer, JB 7 Key, JD 60 Keyes-Elstein, L 69 Keysor, JJ 796, 55 Keystone, E 80, 6, 77, 695, 09 Keystone, E 8, 40, 459, 465, 490, 5, 8, 80, 87, 99, 7, 099,, 487, 488, 60 Keystone, EC 05, 0, 04 Keyßer, G 696 Khakban, A 9 Khalidi, NA 9, 97 Khalil, H 49, 494, 496, 497, 08 Khalilova, I 90 Khamashta, MA 406, 647, 74, 75, 900, 7 Khan, A 58 Khan, FM 850 Khan, HI 8 Khan, K 785 Khan, MA 559, 66, 76 Khan, M 88 Khan, NA 850, 870, 87, 098 Khandpur, R 440 Khanna, D 9, 9, 40, 47, 59, 60, 78, 78, 85, 4, 464, 475, 50, 506, 509, 7, 6 Khanna, P 40, 47, 58 Khanna on behalf of ACR/EULAR Classification Criteria SSc, D 85 Kharlamova, N 769 Khellaf, M 8 Khetan, S 80 Khim, S 580 Khosroshahi, A, 54, 75, 9, 57, 58 Khoutra, C 65 Khraishi, MM 496, 46, 95 Khubchandani, R 477 Khun, H 950 Kiani, A 66, 90, 4, 45, 55 Kichikawa, Y 600 Kick-off of the Italina Network for Gout (KING) Study Group, 67 Kickler, T 96 Kieffer, NA 48 Kiel, DP 45 Kielar, D 777, 705, 6 Kiely, PD 74, 5, Kievit, W 4, 7, 65, 67 Kikly, K 49 Kikuchi, H 84, 7 Kikuta, J 76 Kilgallen, B 69, 5 Kilgore, KM 904 Kilgore, M 90 Kill, A 49 Kilpatrick, D 460 Kiltz, U 55, 76 Kim, AH 74 Kim, BM 9 Kim, CH 866 Kim, DJ 58, 8 Kim, D 664 Kim, D 686 Kim, EO 6 Kim, G 65 Kim, G 4 Kim, HR 9 Kim, HJ 88 Kim, HY 745 Kim, HY, 664, 58, 8 Kim, H 5 Kim, HW 5, 88, 9, 95, 85 Kim, HE 97 Kim, HA 88 Kim, HA 75 Kim, HA, 0, 7, 7, 967 Kim, HS 967, 88 Kim, IJ 7 Kim, IS 406 Kim, JH 6 Kim, JS 88 Kim, JY 0, 0 Kim, JH 680 Kim, JM 96, 968 Kim, JY 6 Kim, J 80 Kim, JS 95 Kim, JH 9 Kim, J 95 Kim, J 78, 46, 45, 47 Kim, J 7 Kim, KJ 6, 68 Kim, KW, 9 Kim, KC 4 Kim, KH 9 Kim, KH 67 Kim, L 8, 9, 0, 86 Kim, NR 67, 0 Kim, NH 876 Kim, ST Kim, SH 88 Kim, SJ 709 Kim, SH 88 KIM, SHK 967 Kim, SK 967, 6, 47, 88 Kim, SC 687, 84, 87 Kim, SJ 8, 669 abstract author Index 0 Program Book 77

380 abstract author Index 78 Kim, S 64, 6 Kim, SS 46 Kim, TY 48 Kim, TH 78, 47 Kim, TJ 78, 06, 4, 49 Kim, TY 44 Kim, WU 6, 68 Kim, Y 74 Kim, YG 50 Kim, YG 54 Kim, YH 889 Kim, Y 989, 6 Kim, YJ 784, 50 Kim, YJ 54 Kim, YG 784 Kim, YJ 67 Kim, Y 46 Kim, YA 8 Kimberly, RP 79, 84, 846, 970, 997, 4, 6, 5, 74, 8 Kimberly on behalf of PROFILE investigators, RP 67 Kimmel, JC 65 Kimura, E 48 Kimura, F 504 Kimura, M 6 Kimura, Y 84, 7 Kimura, Y 76, 46 Kimyon, G 64 Kindred, C 56 Kinds, MB King, A 955 Kingsbury, D 76 Kingsbury, DJ 678 Kinjo, M 99 Kiraz, S 64 Kirchner, HL Kiridly, J 670 Kirino, Y 989, 6 Kirkham, BW 46, 74 Kirou, KA 60, 65, 847, 809, 46, 696 Kirwan, JR 74, 7, 94, 69 Kishimoto, D 809,, 4 Kishimoto, M 8, 99, 948, 47 Kislinsky, D 055 Kislinsky, K 055 Kissel, K 550 Kissin, EY 59 Kita, J, 4 Kitahara, K 50 Kitani, A 49 Kitano, M 8, 96 Kitano, S 8 Kitchin, E 90 Kivity, S 9 Kivitz, A Program Book Kivitz, AJ 49, 558, 9 Kiyokawa, T Kjær, SG 877 Klammer, A 7 Klarenbeek, PL 56, 754 Klareskog, L, 6, 64, 4, 4, 49, 978, 08, 604, 65, 69, 769, 0, 0, 578 Klassen, LW 6, 7, 676, 4 Klatt, S 49 Klatzman, D 757 Klatzmann, D Sr. 6, 77 Klearman, M 49, 77 Kleimann, JF 87 Klein, I 565 Klein, K 78, 670 Klein, M Klein-Gitelman, MS 80, 8, 94,, 890, 040 Kleinert, S 76 Kleyer, A 00 Klinger, M 77 Klinker, MW 74 Klinkhoff, AV 494 Kloppenburg, M 6 Kloppenburg, M 097, 00, 6, 58 Klotsche, J 49, 5, 5 Kluger, E 580 Knaapen, H 0 Knappertz, V 760 Kneissel, M 46 Knevel, R 894 Knevel, R 670 Knickle, K 48 Knight, A 99 Knight, A 776 Knight, JS 440 Knoop, H Knoop, J 66 Knowles, S 7 Knudsen, S 76 Ko, G 86 Ko, K 689 Kobayakawa, T 4, 465 Kobayashi, A 9, 400, 8 Kobayashi, D 094 Kobayashi, H 4 Kobayashi, N 9 Kobayashi, S 55, 56 Kobayashi, T 8 Kobayashi, T Kobayashi, Y 4 Kocanaogullari, H 5 Koch, AE, 0, 4, 77, 879, 50, 506, 60 Koch, T 944 Kodera, T 70 Koehm, M 7 Koehn, C 7, 405 Koehoorn, M 0 Koeleman, BPC 894 Koeleman, BPC 0 Koelling, S 09 Koenders, MI 089, 5 Koenig, AS 8, 68, 8, 98, 865, 0, 85, 54, 87, 84, 848,, 549, 66 Koenig, M 70, 7 Koenig, M 4 Koening, CL 855, 9, 97 Koerner, A 44 Koerner, M 55 Koes, B 47 Koessler, RE 074, 69, 54 Koetse, W 9 Koetter, I 858 Koevoets, R 97 Koga, T 70, 68 Kogata, Y 80 Koh, EM 78, 0, 45, 45 Koh, E 8, 6, 47 Koh, MX 08 Kohane, I 68 Köhlin, L 56 Kohno, M 070 Kohrt, WM 408 Kohsaka, H 98, 95 Koido, N Koike, R 98 Koike, T, 4, 5 Koike, T, 0, 989, 990 Kojima, M 877 Kojima, T 4, 465 Kokkonen, H 49 Koldobskaya, Y 689 Kolfenbach, JR 46 Kolhatkar, N 580 Kollerup, G 6, 6 Kolta, S 0 Komocsar, W 76 Komocsar, WJ 5, Komuro, Y 8 Koncz, T 486 Kondo, M 64 Kondo, Y 58, 075, 88, 5, 59 Kondos, G 49, 40, 8 Kone-Paut, I 05, 04, 0 Kong, HH 06 Kong, KO 78 Kong, PL 796 Kono, H 84, 7 Kono, M 460 Konstantellis, L 404 Kontush, A 56 Koo, BS 784, 50 Koo, BS 54 Koolwijk, P 599 Koontz, D 7, 0, 756, 945, 949, 950 Koopman, FA 45 Koos, B 64, 06 Kopec, JA 46, 568 Korb-Pap, A 68, 779 Korchynskyi, O 77 Korean Observational Study Network for Arthritis (KORONA), 47 Korendowych, E 57 Koretzky, GA 59 Korevaar, JC 5 Korhonen, R 88, 095, 50 Korkosz, M 07 Korn, LL 46 Kornyat, T 4 Korotkova, M 946 Kosco-Vilbois, M 75 Kosinski, M 4, 6 Koskas, F 65 Koskinen, A 50 Kosmac, M 598 Kostik, M 7 Kostine, M 0 Kostman, J 74 Kosutic, G 64 Kotak, S 8, 68, 865, 87, 84, 848 Kotha, R 76 Kothari, KK Kotisalmi, E 90 Kotkin, S 57 Kötter, I 844 Kottgen, A 0 Köttgen, A 60 Kottyan, LC 84, 606 Koumpouras, F 69 Koutsilieris, M 99, 8 Kowal, K 9, 98 Kowal-Bielecka, OM 7, 9, 98 Kowalczuk, O 98 Kowalski, M 79 Koyama, Y 8 Koyano, S 4, 7 Kozaci, DL 565 Kozu, KT 77 Krabben, A 894 Kracht, K 764 Kraft, P 79 Kragsnæs, MS 877 Kral, MC 86 Kramer, I 46

381 Kramers-de Quervain, IA 669 Krammer, G 9 Krammer, G 44 Krantz, E 8 Krasnokutsky Samuels, S 50 Krasowska, D 98 Krastins, B 75 Kratz, A 58 Kraus, S 58 Kraus, VB 68 Kraus, WE 68, 8 Krause, D 59 Krause, DM 57 Krause, K 07 Krause, L 600 Krause, ML 9 Krausz, S 60 Kreiger, PA 59, 058 Kremer, JM 77 Kremer, JM 8, 80, 8, 464, 468, 49, 89, 865, 80, 00, 640, 84, 05, 8 Kretsos, K 9 Kretzler, M 445, 499 Kreuter, A 04 Kreutz, DE 85 Kreuzer, JT 44, 508 Krieckaert, CLM 8 Krieg, MA 96 Krintel, SB 4 Krischer, J 655 Krishnamurthy, A, 789 Krishnan, E 56, 57, 706, 86,, 690, 4, 46 Krishnaswami, S 77, 77, 485, 490 Krishnaswami, S 97, 697, 486 Kristensen, KD 00 Kristensen, LE 69 Kristensen, LE 46 Kristensen, L 54 Kristensen, SL 684 Krivitzky, A 0 Kroenke, G 47 Kroese, F 54, 56 Krogh, NS 7, 7, 558 Krogh, T 959 Krol, P 674 Kronke, G 90, 07 Kronthaler, U 5 Kroon, HM 00 Krueger, GG 8 Krueger, JG 49 Krug, HE 09 Kruize, AA 509, 50, 96, 55 Krumbholz, G 890 Krummel-Lorenz, B 7 Krumsiek, J 60 Kruse, K 080 Ku, BS 9, 8 Ku, BS 5, 95 Ku, J 55 Kubassova, O 04, 045 Kubilay, Z 7 Kubo, S 77, 50, 6 Kubota, T 6 Kudo, T 04 Kudo-Tanaka, E 94 Kuemmerle-Deschner, JB 05 Kuemmerle-Deschner, JB 80 Kuemmerle-Deschner, JB 748 Kuh, D 800 Kuhn, K 66 Kuijpers, TW 0, 09 Kulakodlu, M 78 Kuller, L 6 Kumabe, M 7 Kumagai, S 40, 48, 707, 98, 80 Kumanogoh, A 500 Kumar, AA 7 Kumar, A 589 Kumar, T 58, 59 Kumar, V 55 Kume, K 444, 445, 4, 56 Kunjeer, V 58, 59 Kunkel, GA 05, 87 Kuno, M 0 Kuntz, K 854 Kunugiza, Y 500, 084 Kuo, CF 58, 84, 8, 549, 77, 67 Kuper, IH 607, 67 Kupper, H 487, 764, 775, 995, 0, 04, 678 Kurasawa, K 98 Kurasawa, T 47 Kurien, BT 670, 677 Kurita, M 084 Kurita, T 98, 460 Kuritani, T 569 Kuriya, B 60 Kurko, J 06 Kuroda, T 5 Kuroiwa, T 96 Kuroiwa, T 67 Kurokawa, M 8, 5 Kuroki, K 79 Kurosaka, M 97 Kurowska-Stolarska, M 88, 90 Kurreeman, F 97 Kurzinski, K 9, 06 Kusaba, A 45 Küseler, A 00 Kusunoki, N 50 Kusunoki, Y 50 Kutty, S 9 Kuwaba, N 444, 445, 4, 56 Kuwana, M 455, 850, 86, 459, 97, 9 Kuwano, Y 708, 5 Kvarnstrom, M 77 Kvien, TK 69, 90, 76, 95, 404, 50,, 80, 85, 844, 845, 560, 56, 660 Kvist, P 080 Kwan, C 88 Kwan, L 564, 565, 698 Kwoh, CK 9, 4, 49, 50, 5, 5, 698, 908, 909, 09, 00, 0, 8, 4, 467, 469, 470 Kwok, R 45 Kwok, SK 745 Kwok, SK 664, 58, 8 Kwon, H Kwon, YJ 44 Kyburz, D 669 Kydd, A 908 Kyndt, X 656 Kyogoku, C 686, 979 Kyriakidis, NC 507, 508 La Cava, A 5 La Monica, N 068 La Torre, F 676, 06, 08 Laavola, M 88 Labitigan, M 949 Labrecque, J 475 Labroquère, K 600 Lacaille, D 64, 7, 405, 568 Lacerda, AP 486 Lachaine, J 457 Lachenbruch, PA 8, 9 Lachmann, HJ 748, 749 Lacomis, D 0 Lacraz, A 6 LaCroix, A 995 Lada, F 058 LaFace, D 75 Lafaille, J 90 Lafeber, FPJG 509, 50, 064,, 786, 788, 5, 96, 5 Lafeber, FPJG 8 Lafleur, J 9 Laforgue, P 47 Lafyatis, R 56 Laheurte, C 756 Lahey, LJ 690 L Lai, Z 57 Lai, ZW 498 Laiguillon, MC Lainez, B Lajeunesse, D 70 Lakhanpal, A 685 Lakos, G 455 Lale, R 4 Lam, C 069 Lam, KH 048 Lam, MY 74, 9, 9, 67 Lamas, JR 990, 006 Lambert, M 459 Lambert, PH 80 Lambert, RG 8, 54, 548, 577, 578, 59, 59, 778, 04, 08, 0, 0, 65 Lambert, S 55, 005 Lamberth, S 65 Lambotte, O 64 Lan, Q 079 Lanata, L 6 Lanciano, E 56 Lancioni, E 68 Land, J 860 Landewe, R 469, 574, 977, 4, 908, 8, 5, 579 Landewé, R 495, 56, 57, 576, 05, 0, 698, Landewé, RBM 97, 558, 777, 04, 078, 6, 705, 4, 546 Landi, M 56 Landolt-Marticorena, C 674, 56,, 68 Landon, JE 87 Landsittel, DP 5 Landsman, T 80 Lane, NE 8, 98, 468 Lanfranchi, H 74, 67 Lang, V 00 Langdahl, B 97 Lange, E 9 Langefeld, CD, 84, 846, 970, 974, 6, 64, 74, 79, 8, 84, 657 Langenberg, P 58 Langer, HE 9 Langfeld, CD 79 Langford, CA 57, 544, 65, 655, 9, 97, 567 Lanni, S 58, 7 Lannon, CM 04 Lao, L 58 Lao, WS 887 Laor, A 547 Lapa, AT 99, 00, 46 Lapeyre-Mestre, M 84 Lapinska, A 9 abstract author Index 0 Program Book 79

382 abstract author Index 80 Larche, M 06, 08, 05, 00 Larcombe, L 79 Laria, A 486 Larida, B 8 Larroca, V 6 Larroche, C 88 Larson, RJ 974 Larsson, I 559 Larsson, P 776 Laskin, CA 650 Laskosz, 896 Laskosz, L 0 Lasky, A 597 Lassen, E 49 LaStant, J 74 Latorre, M 546 Lau, AN 08, 979 Lau, CS 9 Laufer, TM 46 Laughlin, S 95, 478 Launay, D 95 Laura, D 658 Laurent, DD 574 Laurent, V 68 Laurie, C 67 Laurindo, I 7, 064 Lauterio, T 9 Lauwerys, B 5, 548 LaValley, MP 794 Lavan, BE 6 Laven, JSE 40 Law, A 0 Law, G 569 Law, WG 78 Lawrence, N 985 Lawrence Ford, T 0 Lawson, EF 76, 98 Lawson, V 969 Laxer, RM 84, 7, 886, 008, 07, 09, 044, 60 Lazarevic, D 54 Lazaro, DM 88 Lazarou, I 48 Lazzari, AA 985 Lazzaroni, MG 5 Le, C 755 Le Bailly De Tilleghem, C 77 Le Bars, M 460, 80, 8, 59 Le Bars, M 6 Le Bidois, J 649 le Cessie, S 0 Le Guern, V 64, 88, 554 Le Loët, X 96, 09,, 78, 849 Le Loet, XX 80, 08, 68 Le Marshall, KF 69 Le Riche, NGH 85 0 Program Book Leandro, M 65 Leandro, MJ 50, 757, 758 Learch, TJ 54, 78 Leary, B 8 Leavitt, F 86, 878 Leberruyer, PY 656 Leboime, A 597, 598 LeBras, E 0, 047, 78 Lebray, P Sr. 657 Lebre, MC 066 Lebre, MC 8, 090, 6 Leclerc-Jacob, S 68 Leclercq, S 06 Lecluze, Y Lecompte, T 740 Ledbetter, JA 446 Lederman, H 04 Lederman, S 960 Leduc, R 868, 58, 48 Lee, A 874 Lee, A 45 Lee, AT 975 Lee, CH 884, 96, 968 Lee, CK 784, 50 Lee, CK 54 Lee, C 69 Lee, CH 447, 490, 76, 487, 488 Lee, CK 47 Lee, CK 78 Lee, D 67 Lee, DYW 58 Lee, EB 84 Lee, EB 99, 88, 9, 8, 95, 8, 85, 486 Lee, EY 5, 88, 9, 95, 8, 85 Lee, EG 884 Lee, E 4 Lee, H 967, 6 Lee, HS 7 Lee, HS 78, 48, 967, 0, 47, 88 Lee, HW 6 Lee, I 89 Lee, JH 664, 58 Lee, JH 8 Lee, JS Lee, J 78, 45, 45, 8, 6 Lee, J 664, 58 Lee, JL 475 Lee, JH 967, 88 Lee, J 589 Lee, J 78, 47 Lee, JY 9 Lee, JH 0 Lee, JA 9 Lee, J 4, 4, 99, 588 Lee, KL 88 Lee, K 08 Lee, K 666 Lee, KH 95, Lee, KH 406 Lee, KW 0 Lee, KE 4, 49 Lee, L Lee, M 94, 946 Lee, MS 884 Lee, P Lee, R 5 Lee, R 60, 68 Lee, SH 889 Lee, SH 9, 47 Lee, SH 64, 6 Lee, SI 40 Lee, SW 44, 7, 680 Lee, SJ 95, 95, 79 Lee, SY Lee, S 0 Lee, SS 78, 967, 47, 4, 88, 49 Lee, SK 6, 44, 680 Lee, SK 7 Lee, SW 78 Lee, SH 76 Lee, SJ 06 Lee, SJ 97 Lee, TL 040 Lee, TC 76 Lee, YA 78, 64, 6, 88 Lee, YM 9 Lee, YH 409, 67 Lee, YY 5 Lee, YJ 797, 85 Lee, YC 954, 0, 46 Leeder, JS 597 Leeder, JS 5 Leesch, D 004 Leese, J 7, 40, 44, 447 Lefevre, G 85 Leffers, H 7 Legare, J 84 Legault, C 54 Legendre, M Léger, JM 6 Legerton, C III 46 Lehane, PB 459, 80, 694 Lehman, AJ 49 Lehman, TJA 6 Lehmann, K 760 Lehr, A 4, 890, 89 Leib, ES 970, 987 Leighton, P 80 Leipe, J 407, 500 Leirisalo-Repo, M 86 Leiss, H 070 Lemaire, R 784, 498 Lemeiter, D 505 Lemelle, I 04 Lemire, L 05 Lemonnier, I 4 Lems, WF 98 Lems, WF 58, 469, 0 Lems, WF 66, 5, 5, 8 Len, C 657 Len, CA 60 Lenaerts, J 549, 779, 65 Leng, L 875 Leo, P 595, 6 Leo-Summers, L 444 Leon, EP 95, 500, 50 Leon, G 46 Leonard, MB Leonard, WJ 5 Lepley, D 454 Lepore, L 0 Leport, C 5 Lepri, G 485 Lepse, N 860 Lequerré, T 485, 78, 04 Lerchbaum, E Lerman, MA 79 Lerner, V 090 Lertratanakul, A 49, 40 LeSage, D 468 Lesende-Rodriguez, IA 7 Lessa, M 96 Lessard, CJ 5, 54, 55, 0, 67, 674 Lessard, JA 5, 54, 55, 67, 674 Leszczynski, P 545 Letho-Gyselinck, H 6 Letschert, K 55 Leu, JH 9 Leung, A 69, 77 Leung, AM 9 Leung, AYF 447 Leung, B 70 Leung, BPL 78 Leung, I 76 Leung, YT 68 Leunig, M 6 Levarht, N 77 Levesque, K 9, 649 Levesque, MC 56, 07, 756, 5, 598, 85, 945, 949, 950, 7, 69 Levin, SD 796 Levine, A 969 Levine, AB 7, 89

383 Levine, J 55 Levine, SM 95, 98 Levine, T 969 Levine, Y 45 Levis, B 4 Levy, AR 746 Levy, A 54 Levy, B 650 Levy, DM 80, 94, 79 Levy, O 9 Levy, RA 96 Levy, RA Sr. 64, 65, 97 Levy Neto, M 95 Lew, R 87 Lewallen, D 096, 445 Lewandowski, L 0 Lewiecki, EM 995 Lewis, CE 794, 799, 0 Lewis, CE 796, 098, 04, 9 Lewis, C 086, 087 Lewis, DM 5, 54, 55, 0, 674 Lewis, EE 404 Lewis, H 07 Lewis, J 74 Lewis, M 78 Lewis, P 460, 68 Lewis, W 66 Lexberg, S 85, 560, 56 Leyva, AL 060 Lheritier, K 759 Lhomme, M 56 Li, A 085 Li, C 86, 66 Li, C 6 Li, D 855 Li, E 69 Li, G 595 Li, H 677 Li, H 5, 54, 55, 0, 67, 674 Li, J 6 Li, J Li, J 64, 940 Li, J 409 Li, J, 5, 575, 677 Li, LC 007, 0, 7, 405, 40, 44, 447 Li, L 07 Li, L Li, M 9 Li, N 49, 69 Li, N Li, R 984 Li, S 569, 557, 56 Li, S 4 Li, SC 4, 008, 09 Li, T 674 Li, W 664 Li, W 085, 086, 087, 585, 65 Li, W 87 Li, X 66, 687, 9, 409, 646 Li, X 66 Li, X 58, 584 Li, X 66 Li, X 6 Li, YH 09 Li, Y 684, 7, 470, 747, 956 Li, YT 6 Li, ZG 088, 76 Li, Z 065 Li, Z 95 Li*, W 0 Liang, J 5 Liang, KP 905, 5 Liang, MH 75 Liang, M 497 Liang, P 769 Liang, WM 477 Lianza, AC 5 Liao, J 857 Liao, KP 98, 68, 8 Libanati, C 84, 96 Liburd, NL 4 Lichuaco, JJ 57 Lidar, M 9 Lidar, Z 955 Liddle, J 07 Lidove, O 656 Lidtke, RH 6, 64, 65, 05 Lie, BA 80 Lie, E 76, 95, 404, 50, 85, 560, 56, 609 Lieberman, SM 59 Lieberthal, JG 97 Liebhaber, A 65 Liebling, MS 4 Liedmann, I 5 Lienesch, DW 049 Liew, D 86 Liggitt, D 446 Lilleby, V 68 Lillegraven, S 50, 06, 660 Lim, AR 8 Lim, E 6 Lim, JE 70 Lim, JH 44 Lim, KK 69 Lim, LSH 95 Lim, MK 47, 584, 97 Lim, SS 95, 945, 695 Lim, SY 44 Lima, CS 96 Lima, G 5 Lima, I 77 Limacher, A 6 Limal, N 65 Limaye, VS 05 Limburg, PC 5, 9 Lin, G 599 Lin, H 90 Lin, H 5, 44 Lin, J 90 Lin, K Lin, LL 08 Lin, NY 505 Lin, NY 57 Lin, SL 8 Lin, T 854 Linan, MK 688 Lindau, D 844 Lindblad, S 57 Linde, L 684 Lindegaard, HM 6, 6, 558 Lindell, K 7 Lindhardsen, J 684 Lindop, R 676 Lindquist, JH 795 Lindqvist, E 894 Lindqvist, E 7, 776, 7 Lindsley, HB Lindwall, E 95 Lingala, B 706,, 95, 954 Link, TM 58, 584 Linsenmeyer, KD 4 Lintner, KE 948 Liphaus, B 8 Lipman, TH 760 Lippuner, K 959, 96 Lipson, A 6 Lipstein, EA 04 Lira, FS 65 Lisanti, MP 95 Lisse, JR 7 Listing, J 65, 57, 780, 70, 9, 9, 5 Litinsky, I 6 Little, M 55 Littlefield, MJ 57 Littlejohn, GO 87, 957, 88, 40 Liu, CC 699 Liu, CC 06 Liu, C 90, 49 Liu, F 468 Liu, H 80 Liu, J 87, 9, 665, 687, 600 Liu, K 664 Liu, L 57, 89 Liu, L 960 Liu, MF 6 Liu, P 66 Liu, Q 00 Liu, Q 497 Liu, R 6 Liu, R 9 Liu, S 0 Liu, S 05, 0, 04 Liu, S 69 Liu, X 87 Liu, X 85, 474, 475, 90 Liu, X 57 Liu, X 9 Liu, Y 99, 50 Liu, Y 808, 65 Liu, Y 986, 49 Liu, ZA 44 Liubchenko, G 765 Liufu, C 60 Livingston, D 80 Livingston, SE 76 Ljung, L 45 Llorca, J 05 Llorens, V 85 Llorente, L 5 Lloyd, A 488 Lloyd, DC 57 Lloyd, TE Lo, GH 9,, 5 Lo, MS 07 Lo Gullo, A 5, 6 Lo Nigro, A 596 Lo Re, V 74 Lo-Ciganic, WH 4 Lobosco, S 59 Locher, JL 90 Lockshin, MD 650, 7, 76, 89, 458 Lockton, S 9 Lodi Rizzini, S 47 Loef, M 097, 58 Loeffelholz, MJ 405 Loell, IM 946 Loeppenthin, K 689 Loeser, RF 9, 7, 54, 56 Loeuille, D 544, 0, 09, 68, 0, 5, 47 Loft, AG 580, 558 Logeart, I 80 Løgstrup, B 54 Lögters, T 46 Loh, C 40 Lohan, D 85, 55, 686 Lois-Iglesias, A 40 Lojacono, A 5 Lojo, L 546 Lombardi, M 09 abstract author Index 0 Program Book 8

384 abstract author Index 8 Lombeida, JI 850 Lonati, P 9 Long, L 90 Longson, A 870 Loo, C 56 Lood, C 66, 680, 76 Lööf, H 57 Looney, RJ 07 Lopes, JB 9, 9, 4 Lopez, JA 657 Lopez, LR 455 Lopez, M 75 Lopez de Padilla, C 07, 658, 95 Lopez-Colombo, A 606, 958 Lopez-Hoyos, M 49 López-Lasanta, MA 980, 998, 999, 7 López-Longo, FJ 44 López-Longo, FJ 9 Lopez-Longo, J 47 López-Mejías, R 05 Lopez-Pedrera, C, 7 Lopez-Reyes, A 7 Lopez-Robledillo, JC López-Vives, L 7 Lorant, A 748 Lorcerie, B 740 Lorenz, HM 460 Lorenzen, T 79, 7 Lorenzi, AR 0 Lorenzin, M 596 Loricera, J 40, 548, 88, 89 Lories, R 65 Lories, RJ 98 Lortholary, O 0 Losina, E 8, 75, 90, 9, 090, 98, 650 Lotz, MK 8, 988, 645 Louder, AM 6 Lough, KM 8 Louie, GH Louie, JS 49 Louis-Plence, P 505 Lourenco, E 69, 709, 45 Lourido, L 988 Louw, I 47, 47 Love, T 559, 64 Loveless, JE 80 Lovell, CR 46 Lovell, DJ 759, 760, 76, 764, 4, 597, 679, 0, 59, 594, 60 LoVerde, ZJ 479 Lovy, MR 99 Low, AS 88, 59 Low, C 056, 70 Low, YC 55 0 Program Book Low Horn, C 06 Lowes, M 808 Loza, E Sr., 78 Loza Cortina, E 46 Lozada, CJ 54 Lozano, E 859, 5 Lu, B 745, 97, 976, 0, 608, 8, 84, 06 Lu, C 986 Lu, G 075 Lu, H 98 Lu, JD 60, 8 Lu, J 8, 9, 0, 86 Lu, L 646 Lu, PY 606 Lu, Q 69 Lu, TT 08 Lu, TT 404 Lu, X 940, 94, 944, 95 Lu, Z 687 Lubatti, C 47 Lubbers, J 668 Lubberts, E 79, 8 Lubrano, E 88 Luca, N 68 Lucas, J 798 Lucas, M 74, 945 Lucena, J 66 Lucero, E 479 Luchi, ME 487, 488 Luciano, N 6, 59, 546, 8 Lucier, S 80 Luckey, D 66 Lucman, A 6 Lucron, H 649 Ludivico, CL 545 Luedtke, CA 96, 866 Lugli, EB 00 Lui, LY 89 Luijtens, K 50 Luime, JJ 768, 048, 560, 570, 095, 6 Lukas, C 96, 566 Lukkahatai, N 874 Lumb, S 750 Lunardi, C 0 Lund, OI 899 Lundberg, IE 08, 9,, 75, 555, 587, 67, 946 Lundberg, K, 769 Lundsgaard, D 65 Lundy, SK 74 Luneburg, P 744 Lunt, M 767, 88, 59, 65, 544 Luo, B 575 Luo, J 087 Luo, S 69 Luo, SF 58, 84, 8, 77, 67 Luo, Y 46 Luo, Y 466 Luo, Z 90 Luong, M 08 Luong, ML 4 Lupash, D 049 Lupus Nephritis-ESRD Consortium, 79 Luqmani, R 55 Lurati, A 46 Luster, AD 66 Lutalo, PMK 9 Luthra, HS 66 Lutt, JR 87 Lutteri, L 4 Lux, G 68 Luz, KR 04, 808 Lübbeke, A 48, 09 Lügering, A 779 Lüring, C 8 Lyles, M 54, 56 Lyman, SL 694, 08, 465, 75, 7, 649 Lynch, JA 0, 04, 468, 5 Lyon, K 4 Lyons, K 986 Lyubchenko, T 765 M Ma, JD 09 Ma, T 49 Ma, Y 00 Ma, Y 96 Maas, M 0, 09, 4 MacBride, A 808 Macchioni, P 47, 5, 6 MacDermott, EJ 6 Macdonald, C 447 MacDonald, D 57 MacDonald, PA 5 Macfarlane, GJ 60, 966, 6, 55 Machado, FS 0, 807 Machado, LG 9, 9 Machado, LSG 96 Machado, NP 45 Machado, P, 56 Macharoni, LM 08 Machida, T 44 Machold, KP 09 Macias, W 487, 488, 65 Maciuca, R 60, 6 MacIver, H 474 Mack, M 9, 0, 86 Mack, WJ 94 Mackay, M 656, 57 Mackay, MC 649, 69, 687 Mackey, R 6 Mackie, I 75 Mackie, S 94 MacMullan, PA 9, 48, 8 MacPherson, KE 44 Madaio, MP 45 Madary, J 498 Madaule, S 95 Madeo, A 476 Madger, L 604 Madigan, AM 9, 48, 8 Madsen, OR 06, 66 Maeda, A Maeda, K 96, 569 Maekawa, T 070 Maenaka, K 79 Maestre, M 659 Maetzel, A 50, 6 Maeyama, K 0 Maezawa, R 98 Magder, LS 640, 89, 90, 96, 648, 708, 70, 569, 57 Magee, AI 848 Magee, K 9 Magnani, L 6 Magner, RP 464 Magnusson, PK 65 Magnusson, S 45 Magrey, MN 559 Magro, C 694, 75 Magro Checa, C 64, 5, 6 Maguire, C 5 Magy-Bertrand, N 740 Mahadevan, U 64 Mahajan, A 58, 59 Mahajan, V 75 Mahendira, D 888, 4 Mahendranath, K 58, 59 Maheswaranathan, M 89 Maheu, E 09 Maheu, E 0, 47 Mahieu, MA 8 Mahler, M 7, 9 Mahmood, Z 76 Mahowald, ML 09 Mahr, A 80, 564, 565 Mai, B 09 Maier-Moore, JS 670, 0 Maisonobe, T 5 Majgaard, O 6, 6 Majithia, V 98, 0 Majka, DS 664 Major, GA 70 Majumdar, S 99

385 Makino, H 55 Makino, K 86 Makino, T 86 Makol, A 5, 55, 48 Makris, UE 444 Maksimowicz-McKinnon, K 9, 97 Maksymowych, WP 8, 54, 54, 548, 556, 568, 575, 577, 578, 59, 59, 746, 777, 778, 977, 04, 05, 08, 0, 76, 8, 705, 8, 0, 579, 65 Malah, V 56 Malaise, D 4 Malaise, MG 4, 50 Malaise, O 4, 50 Malamet, RL 70, 9 Malattia, C 476 Malaviya, AP 06 Malchus, AM 554 Malcus-Johnsson, P 56 Maldini, C 564 Maldonado, M 547 Maldonado, MA 40, 4, 449 Maldonado Ficco, H 60 Maldonado-Cocco, JA 579, 56 Maldonado-Ficco, H 579, 56 Maleki-Fischbach, M 7, 79 Malfait, AM 74 Malheiro, OB 6 Malheiros, DM 500 Malik, A 0, 049 Malik, F 55 Malin, K 957 Malmström, V, 08, 65, 769, 0, 578 Malone, DG 59 Malone, M 4 Maloney, A 750 Maloney, C 7, 405 Malpeso, J 5, 685 Malspeis, S 44, 976, 605, 609 Maltret, A 9, 649 Malul, G 595 Malvar Fernandez, B 60 Malvin, NP 66 Malysheva, O 8, 408 Mamchaoui, K 674 Mammen, AL, 95 Mamoto, K, 0, 989, 990 Mamyrova, G 8, 9 Man, A 74, 849, 64 Manara, M 67 Mandell, BF 909 Mandhadi, R 58 Mandl, LA 09, 08, 7, 44, 479, 57, 649, 650 Mandl, P 09,, 5, 08 Mandl, T 77, 0 Mangalam, A 66 Manger, B 00 Manheim, L 4 Mani, V 50, 6 Maniaci, B 8 Manieri, NA 66 Maniu, A 9 Mankee, A 648 Mann, AD 48, 640 Mann, HF Manning, G Manning, J 477 Manning, VL 050, 49 Mannion, AA 669 Mannion, ML 76 Manno, RL 697, 95, 98, 480 Manoharan, AP 79 Manoussakis, MN 507 Manrique-Arija, S 7 Mansi, I 84 Mansour, A 08 Manu, A 46 Manz, RA 449 Manzi, S 47, 7, 4, 570, 699 Maoulida, H 80 Marak, R 054 Marangoni, RG 94 Maranian, P 050 Maranian, P 9, 9, 464 Maratha, A 5 Marcelli, C 09 March, L 54, 55 Marchesoni, A 88 Marchetti, S 97 Marchi, S 77 Marcos, J 60, 4 Marcos, JC 60, 4 Marcuz, J 7 Mardekian, J 848 Marder, W 47, 067 Marenco, JL 980, 44 Margaretten, M 47, 8, 4 Margolis, P 60 Marguerie, L 895 Margulis, A Marhadour, T 97 Maria, NI 58 Mariampillai, K 0 Marie, I 0, 6, 05, 8 Marie, SKN 99 Marietta, E 66 Mariette, X 5, 479, 50, 59, 80, 08, 09, 0,, 6, 699, 80, 9, 68, 88, 89,, 55, 554, 555, 67 Marijnissen, ACA Marin, C 47 Marin, J 58 Marinho, A 48 Marini, R 99, 00 Marino, L 60 Mariñoso, L 967 Marion, MC, 84, 64, 84 Marjanovic, EJ 7 Märker-Hermann, E 70 Markovitz, D Markt, J 89 Markward, N 978 Maron, DD 49 Marotta, A 568, 977, 8, 579 Marra, CA 9 Marras, C 46 Marras, C 44, 9 Marrazza, M 46 Marri, R 0 Marrie, RA 99, 54 Marroquín, M 44 Marsal, S 980, 998, 999, 00 Marshall, L 85, 66 Marshall, T 767, 544 Marsolo, K 60 Martel-Pelletier, J 70, 8, 0, 4 Martin, C 8 Martin, DA 94 Martin, J 000, 05, 0, 04 Martin, JE 0 Martin, KR 800, 5 Martin, L 009 Martin, RW 8, 94 Martin, S 650 Martin, TM 90, 595 Martin Marquez, T Martín-Esteve, I 7 Martin-Mola, E 546 Martín-Mola, E 75, 550 Martinelli, B 04 Martinelli, R 80 Martínez, C 78, 70 Martinez, F Martinez, JE 880 Martinez, LA 968, 04 Martínez Taboada, V 456, 467 Martínez-Barrio, J 47 Martinez-Estupiñan, L 47 Martinez-Godinez, MA 70 Martinez-Jimeno, C 505 Martinez-Lavin, M 968 Martinez-Lopez, J Sr. Martínez-Morillo, M 967 Martinez-Sanchez, AH, 48 Martínez-Taboada, VM 980, 4, 9, 49 Martini, A 679, 476 Martini, A 759, 760, 76, 764, 58, 65, 66, 7, 7, 597, 0, 47, 477, 657, 658 Martini, D 59, 546 Martini, G 06, 0, 04 Martins Ramos, MI 090 Marx, R 650 Marzan, KA 78, 89, 86, 006 Marzo-Ortega, H 46, 76 Masatlioglu-Pehlivan, S 87 Masdar, H 585 Maselou, K 8 Maset, M 8, 84, 85 Masetto, A 769 Mashmoushi, A 668 Mashour, G 80 Masi, AT 65, 66 Masi, L 0, 04 Maskeri, B 6 Mason, TG II 008, 09 Masri, R 0 Massad, C Sr. 77 Massarotti, EM 60, 608, 40, 69 Masse, CE 06 Massollo, M 50 Mastaglio, C 47 Masteller, EL 90 Masters, S 90 Mastrovic, K 479 Masui, Y 504 Masuoka, M 50 Mata-Arnaiz, C 548, 88 Mateo Bernardo, I 46 Mateo-Soria, L 967 Mateos, J 7, 988 Mathai, SC 7, 46 Mather, A 9 Mathes, A 56 Mathews, A 58, 59 Mathian, A 459, 5 Mathieu, A 56, 498, 599, 88 Mathsson, L 4, 4, 49 Matsubara, T 89, 4, 7 Matsuda, S 40 Matsudaira, R 0 Matsui, K 8, 47 Matsui, K 8, 96 Matsui, Y 99, 948, 47 Matsukawa, T 645 Matsumoto, I 58, 65, 075, 079, 88, 5, 59 Matsumoto, M 79 Matsumoto, T 060 abstract author Index 0 Program Book 8

386 abstract author Index Matsumoto, Y 899, 077, 079 Matsuno, H 4, 7 Matsuo, K 59 Matsushima, K 856 Matsushita, M 09, 94 Matsushita, M 94 Matsushita, R 6 Matsushita, T 6 Matsutani, T 96 Matte, U 04 Mattes-György, K 040 Matteson, E 709, 75 Matteson, EL 4, 905, 0,, 5, 48, 49, 49, 55, 7, 98, 55, 56, 58, 6, 48 Matthias, T 8 Mattoo, H 75 Matucci Cerinic, M 5, 09, 485 Matucci-Cerinic, M 67, 696, 85, 79, 0, 04, 06, 07, 98 Maugars, Y 47 Maurer, B 54 Maurer, K 68 Maurier, F 65 Maurouard, T 69 Mautz, AP 06 Mavragani, CP, 99, 8, 99 Maxwell, JR 6, 985 Maxwell, JL 55 Mayan, MD 4 Mayer, F 04 Mayer, L 90 Mayes, MD 9, 85, 464, 474, 475, 509, 90, 0, 04 Maynard, JW 0, 74 Mayor Gonzalez, M 9 Mazet, AA 0 Mazieres, B 5 Mazumder, A 965 Mazur, M 489 Mazurov, V 549, 779, 65 Mazzaglia, G 907 Mazzoni, M 476 Mc Bride, P 667 McAdams DeMarco, M 0, 74, 9, 9 McAlear, C 868, 58, 655, 48 McAlindon, T 745 McAlindon, TE 9, 964,, 5 McBride, D 85 McBride, E 0 McBride, JM 60, 6 McBurney, C 7, 049 McCann, A 986 McCann, L 759, 76 McCarthy, CJ 48, 8 McCarthy, EM 8 McCarthy, E 60 McCarthy, E 48 McCarthy, EM 60, 68, 56 McCarthy, GM 48, 8 McCarthy, GM 9, 6 McCarty, GA 8 McCaskill, R 79 McCaughtry, T 450 McCauley, D 678 McClanahan, T 75 McClean, A 55 McCleary, S 07 McClenaghan, V 986 McCloud, P 87 McClung, MR 84, 959, 96 McConnachie, A 66 McCormick, J 5, 9 McCowen, K 9 McCracken, C 55, 005 McCune, WJ 404, 57 McCurdy, DK 0, 96, 70, 899 McDaniel, GE 8 McDermott, G 89 McDonald, FS 588 McDonald, G 848 McDonald-Blumer, H 888, 047 McDonough, E 75 McDougall, JJ 069 McEachern, J 978 McGinnis, JP 97 McGinnis, MW 66, 80 McGonagle, D 70 McGowan, D 89 McGuckin, M 49, 494 McGuire, MB 67 McGwin, G Jr. 604, 67, 4, 6 McHugh, C 67 McHugh, G 04 McHugh, KP, 58 McHugh, N 9, 854, 46, 57, 484, 495, 67 McHugh, NJ 55 McInnes, IB 569, 574, 88, 90, 90, 8, 5, 557, 56, 66 McIntosh, D 69 McIvor, E 78 McKay, HA 007 McKay, JD 6 McKee, C 8 McKee, E 748 McKeever, K 760 McKenna, M 059 Mckernan, P 748 McLaren, J 55 McLaughlin, V 85 McLean, L 5 McLean, RR 79, 45 McLure, KG 4 McMahan, ZH 79 McMahon, BJ 76 McMahon, MA 69, 5, 709 McNamee, K 7 McNulty, MA 7 McQueen, FM 7, 85, 05, 69, 90, 585, 586 McQueenie, R 88 McSherry, T 986 McVeigh, G 986 McWherter, CA 6 McWilliams, L 45 Meade, T 0 Means, TK 66 Mease, P 55, 557, 570, 96, 45, 5, 857, 868, 8, 4, 8, 6 Mease, PJ 54 Mebus, C 77 Mebus, CA 485 Mebus, CA 8, 97 Mecchella, JN 57, 974 Mech, C 055 Medea, G 907 Medeiros, DM 74 Mediero, A 4, 5, 6, 56 Medina, G 76 Medina-Chinchon, M 99 Medsger, TA Jr. 698, 699, 74 Meednu, N 07, 666 Meek, IL 6 Meekings, A 70 Meffre, E Sr. 77, 578 Meguro, A 005, 6 Mehbob, A 459 Mehta, A 8 Mehta, G 059 Mehta, NM 984 Mei, HE 749 Meijers, JCM 5 Meijide Failde, R 6 Meikinian, A 67 Meiners, PM 54 Meini, A 749, 05 Mejia, C 54 Mejia, JC 479 Mekinian, A 95, 78 Melander, O 905 Melchiorre, D 07 Melguizo-Madrid, E 58 Meliconi, R 6 Melikoglu, M 75 Melikoglu, M 7 Melikoglu, MA 75 Melissourgaki, M 46 Mellins, ED 657 Mello, FM 6, 064 Melo, M 66 Melo-Gomes, JA 679 Melton, LJ III 80, 8 Mendelsohn, A 569, 8, 9, 9, 0, 86, 557, 56 Mendelson, CF 6, 64 Méndez-Martínez, S 958 Mendlein, J 67 Mendoza, J 90 Mendoza Pinto, C 606 Mendoza-Pinto, C 958 Menon, S 697 Mercer, LK 88, 59 Meric de Bellefon, L 5 Merino, R, Merkel, PA 9, 79, 868, 464, 54, 57, 58, 59, 655, 6, 9, 97, 48, 44, 567 Merola, JF 608, 97 Meroni, PL 675, 67, 47, 5, 08, 9, 455 Meroño, T 56 Merrihew, K 05 Merrill, JT 48 Merrill, JT 67, 645, 79, 84, 650, 795, 8, 6, 6 Merriman, ME 80, 68 Merriman, TR 80, 68 Mersten, JN 75 Mertelsmann-Voss, C 57, 649 Mertens, MT 65 Merwe, JPVD 58 Mesdaghinia, S 07 Mesquida, M 85 Messbacher, ME 888 Messier, SP 54, 56 Messineo, S 7 Messing, SP 89 Messuti, L 679 Metes, ID 56, 85 Metter, J 95 Metzler, C 54 Meulenbelt, I 00 Meurer, L 04 Meyer, A 87 Meyer, I 5 Meyer, O 478, 80, 649, 699 Meyer, PWA 794 Meyfroidt, S 56 Meyhoas, MC 5 Meysami, A Program Book

387 Mia, B 4 Miao, Y 8 Miceli-Richard, C 59, 9,, 67 Michael, D 57 Michaelson, JS 88 Michaud, K 88, 495, 605, 698, 89, 068, 6, 48 Michel, BA 49, 47, 48, 89, 90, 54, 78, Michels, H 764 Michet, CJ 49 Middleton, JE 4, 7 Midtgaard, J 689 Miescher, S 79 Miese, F 040 Miettinen, A 90 Miggin, SM 5 Migliorini, P 577 Migone, TS 48 Miguel, L 848 Mihalko, S 54 Mihu, R 9 Mikage, H Mikdashi, J 68, 86 Mikecz, K 06 Miki, K 96 Mikkelsen, K 404, 85, 560, 56 Mikolaitis, RA 4, 6, 6, 64, 4, 56, 6 Mikuls, TR 6, 7, 7, 89, 40, 44, 44, 676, 87, 70, 87, 09, 06, 6, 4, 48, 54, 640 Milad, M 90 Milette, K 44 Milewski, R 98 Miliar-Garcia, A 70 Miljko, S 45 Millar, AM 986 Miller, A Miller, DR 666, 8 Miller, E 5 Miller, FW 06, 8, 9, 75, 07, 598 Miller, GD 54 Miller, L 70, 7 Miller, ML 60 Miller, PD 977, 998 Miller, PSJ 48 Miller, RE 74 Miller, RJ 74 Miller, SD 7 Milligan, A 05 Millner, J 68 Mills, E 6 Mills, K 6 Mills, S 40 Milman, N 54 Milner, A 080 Miloslavsky, E 654 Mimori, A 659, 68 Mimori, T 6, 96, 96, 98 Min, C 99, 948, 47 Min, JK 4, 745 Min, S 74 Min, S 07 Mina, R 94, 05, 474, 60 Mina-Osorio, P 74 Minardo, G 04 Minden, K 679 Minden, K 49, 5, 5, 0 Miniaci, A 650 Minisola, G 67 Minisola, S 959 Minniti, A 9 Minoda, M 8 Minoia, F 66 Minopetrou, M 66 Minor, L 44, 57 Mintsioulis, S 06 Miosge, N 09 Mirabet, V Miraglia, J 999, 68 Miranda, P 505 Miranda, P 479 Miranda, V 8, 5 Miranda, Y 76 Miranda-Carús, ME 75 Miranda-Filloy, JA 05 Mirel, D 40 Mirrasoul, N 466 Mischler, R 40, 4 Miserocchi, E 676 Misharin, AV 44, 077, 679 Mishima, M 98 Mismetti, P 740 Misra, D 098, 980 Misra, R 60 Mistretta, F 5 Mitchell, BD 744, 9, 986 Mitchell, EF Jr. 960 Mitenko, E 4, 48 Mitomi, H, 45 Mitra, A 7, 44, 85 Mitraud, SDAV 60 Mitsui, H 49 Mitta, SJ 984 Mittoo, S 468 Miura, H 0 Miura, N 856 Miura, T 4, 7 Miura, Y 569, 59 Mix, KS 898 Miyabe, C 856 Miyabe, Y 856 Miyachi, K Miyagi, K Miyake, S 0 Miyaki, S 8 Miyasaka, N 98, 7, 856, 89,, 4, 5, 55 Miyashita, T 6 Miyata, S 084 Miyazaki, M 708 Miyazaki, Y 98 Miyazaki, Y 885, Miyoshi, H 66 Mizuguchi, K 4 Mizui, M 68 Mizuki, N 005, 6 Mizushima, M, 7 Mladenovic, Z Mo, YQ 09, 5 Moazedi-Fürst, F 7 Mociran, E 479 Moder, KG 950, 9 Modesti, M 84, 85 Modesti, V 596 Modesto, C, 0 Modi, S 049, 7 Modica, RF 75 Moehling, K 45, 48 Moeller, B 07 Moffett, A Jr. 997 Moggi Pignone, A 5 Mohammad, A 85, 55, 686 Mohammadi, S 700 Mohan, C 67, 4, 447, 07, 679 Mohan, S 857, 665 Mohanta, A 4 Moharir, M 79 Moi, J 908 Moi, JH 64 Moilanen, E 88, 095, 50 Moilanen, T 095, 50 Mojazi Amiri, H 44 Mok, CC 4, 88, 67, 65, 407, 40, 4, 44, 45, 488, 5 Molad, Y 74 Molberg, O, 68 Molberg, 98 Moldovan, I 4, 759 Molenaar, THE 94, 469, 606 Moll, M 004 Moller, B 766, 8 Möller, B 45 Moller, I 80, 8 Møller, JM 06, 66 Møller, JM 04, 045, 67 Möller, S 574 Molloy, D 5, 9 Molloy, ES 48, 5, 8, 9, 56 Molta, CT 945, 67 Moltó, A 555, 556 Momohara, S 9, 400, 089, 8, 957, 96, 4 Monach, PA 59, 655, 9, 97, 567 Moncrieffe, H 654 Mondéjar-García, R 58 Mondot, S 494 Monette, R 08 Monfort, J 0 Monrad, SU 59 Montagna, P 49, 64 Montanari, E 9 Montañés, F 0 Montastruc, JL 84 Monteagudo, I, 47 Montealegre, GA 0, 65 Montealegre Sanchez, GA 000 Montecucco, C 67, 888, 5, 907, Monteiro de Castro, T 04 Montes García, S 64 Montes-Cortes, DH 70 Montgomery, CG 5, 54, 55, 0, 67, 674 Monti, S 59 Montilla, C 998, 999, 44, 9 Montoro Álvarez, M 47 Mookherjee, N 79 Moon, SJ 4, 46 Moon, YM Mooney, S 85, 55, 686 Moons, P 86 Moore, B Moore, CE 09, 00, 0 Moore, GF 676 Moore, KF 596 Moore, T 477 Moore, TL 0,, 4, 5, 6 Moore, T 695, 48 Moorehead, S 66 Moorthy, A 57 Moorthy, LN 6, 890 Moosig, F 79, 80 Moots, R 069 Mor-Vaknin, N Mora, T 968 Morabito, P 907 Moraes, JCB 7, 5, 999 Moraes, MT 0 Moraitis, E 97 Morales, K 99 abstract author Index 0 Program Book 85

388 abstract author Index 86 Morales, M 68 Morales-Torres, J 446 Moran, RC 645 Morand, E 798 Morand, EF 088, 57 Morassi, P 60, 97 Morasso, E 47 Morbach, H 578 Morbelli, S 50 Morehouse, C 755, 675, 760, 68 Moreira, E 09, Moreira-Navarrete, V 58 Morel, J 5, 5, 480, 566, 78, 88, 554 Morel, N 64, 649 Moreland, LW 56, 996, 997, 0, 5, 85, 6, 7, 6 Moreno, M 5 Moret, FM 064, 786, 788, 5 Moretti, R 60, 97 Morgacheva, O 050 Morgan, AW 6 Morgan, GA 0, 670, 948 Morgan, SL 996, 997 Morgan DeWitt, EM 88, 46, 0, 04, 60, 60 Mörgelin, M 66 Moriguchi, M 67 Moriguichi, Y 67 Morimoto, A 60, 6 Morimoto, C 600 Morimoto, S Morin, F 4 Morinobu, A 40, 48, 707, 80 Morio, T 856 Morioka, M Morita, S 96 Morita, Y 084 Moriyama, M 59 Morlandt, AB 677 Morley, MP 987 Morlock, R 40, 4 MORMED consortium, 900 Morris, M 864, 558, 7, 94 Morris, PW 4 Morris, S 74 Morrison, M 494 Morrison, S 56, 688 Morros, R 70 Morrow, F 80 Morrow, J Morrow, O 47 Mortensen, E 78, 490 Mortensen, EM 84 Morton, AH 904 Morton, LE 60 0 Program Book Morton, R 59 Morvan, J 5 Mosca, M 48, 5, 057, 84 Moser, KL 8, 84 Moser, K 449 Moser Sivils, K 5, 54, 55, 67, 79, 84, 846, 970, 6, 0, 55, 67, 674 Mosher, DP 06, 47 Moshref, M 59, 594 Mosley-Williams, AD 0 Mosquera Rey, A 99 Motojima, S Motta, F 68 Motta, M 5 Mouassess, F 40 Moulin, D 86 Moulis, G 85, 9 Moulton, VR 79 Mountz, JD 5, 575, 677 Mouritzen, U 79 Moussallieh, FM 87 Mouterde, G 566 Mouthon, L Sr. 0, 545, 67, 65, 656, 774, 56 Moutsopoulos, HM 507, 508, 99, 78, 8, 99, 55 Mouy, R 679 Mowbray, K 45 Moyssakis, I 78 Mozaffarian, N 79, 468, 486, 764, 05, 678, 00 Mozes, E 456 Mpofu, C 454, 456 MrOS Investigators Group, 8 Msika, P 780 Mu, R 065 Muangchan, C 480 Muckelbauer, R 0 Mudano, A 90 Muehlbauer, M 8 Mueller, BA 904 Mueller, DL 44, 576 Mueller, F 0, 07 Mueller, GA 09 Mueller, R 770, 0, 44 Mueller-Schmucker, S 6 Muhammad, K 76 Muiños, E 48 Muiños-Lopez, E Mukai, M 89 Mukhopadhyay, P 595 Mulani, PM 4 Mulder, M 768 Mulero, J 70 Mulleman, D 47 Muller, S 60 Mullikin, J 6 Mulukutla, SR 5 Mumcu, G 7, 94 Munoz, LE 500, 50 Munoz, S 5, 685 Muñoz-Fernandez, S, 998, 999 Muñoz-Ortego, J 78, Munro, J 8 Munroe, ME 645, 67, 740, 44 Muntner, PM 54 Mura, T 480 Murad, S 6 Murakami, A 98 Murakami, K 070 Murakami, K 96 Murakami, S 5 Murakami, Y 4 Muraoka, S 50 Murasawa, A 094 Murata, K 40 Muratore, F 5, 58 Muratore, V 7 Murfitt, L 77 Murgo, A 47 Murphy, C Murphy, C 5, 9 Murphy, EA 08 Murphy, L 46 Murphy, R 46 Murphy, SN 68 Murphy, SL 58 Murray, A 695, 477, 48 Murray, F 578 Murray, JA 66 Murray, L 498 Murru, V 74 Murtaugh, M 489 Murthy, VL 456, 457 Mus, AM 8 Muscal, E 80, 890 Musenge, E 794 Museyko, O 008 Mussard, J 844 Musselman, D 77 Musselman, M 85 Musset, L 0 Mustelin, T 659 Muth, T 944 Muthana, M 800, 80 Muther, J 748 Mwaniki, L 47 Myasoedova, E 49 Myasoutova, L 549, 779, 65 Mydel, P 08 Myklebust, G, 90 Myles, A 09 Müller, M 8, 0, 8, 047, 78 Müller, T 0 Müller-Ladner, U 4, 7, 696, 85, 890, 89 Müller-Nordhorn, J 0 Myones, BL 475, 760 Mysiw, A 4 Mysiw, WJ 986, 467 Mysler, E 46 Myslinski, R 065, 60 N Nab, H 64, 85 Nabozny, GH,, 96, 58 Naden, RP 85 Nadji, A 76 Nafees, B 488 Naga, OS 45, 45 Nagafuchi, H Nagahara, H 070 Nagai, K 8, 5 Nagai, R 700 Nagai, T 6, 458 Nagai, Y 47 Nagakura, T 6 Nagano, S 8 Nagaoka, S, 046 Nagaraju, K 946 Nagasaka, K 98 Nagasawa, H 47 Nagasawa, J 98 Naggara, O 55 Nagore, D 546 Nagpal, K Nah, SS 967, 88 Nahm, M 94 Naiman, B 68 Nair, A Nair, P 4, 45 Nair, RG 0 Nair, SC 8 Naishiro, Y 97 Naka, T 59 Nakagawa, N 59 Nakagomi, D Nakahara, H 96, 569 Nakahara, H 8, 645 Nakajima, A 9, 400, 8, 957 Nakajima, H Nakamura, H 046, 05,, 4 Nakamura, H, 0, 989, 990 Nakamura, H 8 Nakamura, K 070 Nakamura, K 48 Nakamura, K 8

389 Nakamura, MC 0 Nakamura, S 59 Nakamura, T 4, 7 Nakamura, Y 60 Nakano, H 8, Nakano, H 8, 47 Nakano, K, 64, 76 Nakano, M 5 Nakao, T 700 Nakashima, M 70 Nakashima, R 6, 96, 98 Nakashima, Y 046, 05,, 4 Nakashita, T Nakatani, T 96 Nakatsue, T 5 Nakayamada, S 64, Nalesso, G 40 Nam, EJ 406, 67, 0 Nam, S 40 Namer, IJ 87 Namiki, M 96 Namiuchi, S 96 Namjou, B 84 Namour, F Nangle, L 67 Nanki, T 98, 856 Nannini, C 75, 98 Nantz, EP 5, Naot, D 7 Napadow, V 80 Napalkov, P 09, 54 Narang, N 758, 4 Narayanan, S 9, 94, 94, 946, 856, 67 Narazaki, M 500 Nardi, G 00 Naredo, E 80, 8 Narimatsu, S 6 Narita, H 074 Narita, I 5, 094 Narita, M 660, 799 Narula, S 74, 55 Narváez, J 9, 44, 9 Nash, A 7 Nash, P 46, 695, 547 Nash, PT 77 Nash, P 568 Nashi, EP 649, 87 Nasonov, E 46, 596 Nasr, R 97 Nasrallah, M 857 Nassikas, N 0 Nastacio, M 96 Nataf, H 895 Naterop, J 76 Natour, J 0, 04, 6, 45, 807, 808, 09, 60,, 864, 867, 65 Natter, MD 890 Navarra, SV 64, 65, 4 Navarro, F 596 Navarro, IE 09, 54 Navarro-Compán, V 58, 44, 80, 07, 09,,, 6 Navarro-Millan, I 70 Navarro-Sarabia, F 58 Navarta, DA 9, 40, 68 Nawata, M 77 Nazeri, SK 759 Ndosi, M 78 Nduaka, CI 8 Neau, JP 55 Nebesky, JM 80, 9 Nebesky, JM 44 Nedergaard, B 984 Neel, A 55, 8 Negrete López, R 096 Negrini, M 00 Negro, G 65, 7 Neidhart, M 49, 48 Nelson, AE 099,, 468 Nelson, JL 904 Nelson, RE 509 Nelson, S 88, 94, 05,, 474 Nemcova, D 764, 004 Nemes, D 876 Nemeth, L 4 Neogi, T 6, 4, 5, 4, 6, 74, 74, 794, 799, 098, 55, 980, 6 Neovius, M 86 Neregård, P 79 Neri, D 9 Neri, R 057 Neria, E 7 Nerome, Y 6 Nery, MV 864 Nesbitt, A Nesher, G 54 Neumann, E 4, 890, 89 Neuville, S 4, 50 Neven, B 04 Neville, C 688 Nevitt, MC 9, 794, 796, 799, 99, 98, 0, 098, 04, 9, 55, 467, 470 New, JS 575 Newell, J 85, 55, 686 Newkirk, MM 79, 94, 688, 75 Newman, AB 89, 4 Newman, ED 604 Newman, S 654 Newmark, R 8 Newsom-Davis, T 6 Nezos, A 8 Ng, B 88 Ng, CT 806 Ng, CT 9, 6 Ng, MS 87 Ng, R 55 Ng, WF 55, 67 Ngcozana, T 65 Ngian, GS 70 Ngo, D 798 Nguyen, D 44 Nguyen, D 08 Nguyen, H 049 Nguyen, V 49 Ni Gabhann, J 60, 68, 56 Ni Mhuircheartaigh, O 754, 80 Nicassio, PM 576, 694 Nicholls, D 87, 568 Nicholls, D 40 Nicklas, BJ 54, 56 Nicolaou, S Nicolini, A 5 Niddrie, F 70 Niederreiter, B 4, 947, 086 Niehaus, S 0 Nielen, MMJ 5 Nielsen, CT 680, 76 Nielsen, S 0 Niemi, E 0 Nieminen, T 67, 68 Nienhuis, HLA 9 Niestroj, A 08 Nieto, JC 7, 47 Nieves, L 7 Niewerth, M 49, 5, 0 Niewold, TB 67, 689, 79, 740, 846, 970, 6, 7, 8 Nigg, A 07 Nigg, AP 407, 554 Nigon, D 0 Nigrovic, PA 897, 890 Nihtyanova, S 698, 7 Nihtyanova, SI 478, 76 Niiro, H 86, 76 Nikaï, E 5 Nikiphorou, E 74, 5, Nikishina, I 597, 676 Nikitorowicz Buniak, J 9, 07 Niklinski, J 98 Nilsson, AM 77 Nilsson, J 84, 7 Ninet, J 656, 740 Ning, B 7 Ning, T 68 Nino, AJ 984 Nirmala, NR 76 Nishi, K 04 Nishida, J 77 Nishikawa-Matsumura, T 4 Nishimoto, N 96 Nishimoto, T 86 Nishimura, R 69 Nishina, N 9 Nishio, MJ 59 Nishioka, K 569 Nishioka, K 86 Nishioka, Y 98 Nistala, K 674 Nititham, J 67 Niu, J 4, 799, 0, 9, 55, 6 Nived, O 654, 66, 90, 44, 56, 570 Noaiseh, G 9 Noamani, B 56, Noble, P 086, 087 Nocturne, G 59, Noda, S 708, 504, 5 Noddings, R 7 Nolla, JM, 980, 7 Nomoto, S 45 Nonaka, A 67 Nonaka, Y 6 Noonan, L 8, 8 Noort, AR 066, 599 Nordin, A 70 Nordin, A 0 Nordin, H 79, 558 Nordmark, G 50, 5, 77, 67 Norek, K 4 Noronha, IL 500 Nørregaard, J 580 Norris, JM 7, 7, 44, 4, 44, 67, 69, 097 Northington, R 54 Norton, S 5, Norton, T 608, 97, 06 Nossent, JC 88 Nourissat, G Novack, DV 599 Novack, V 08 Noveck, RJ 88 Nowak, E 554 Nowik, M 679 Nowling, TK 86, 9 Noworolski, SM 58 Noyes Essex, M 6, 0 Nozaki Shibata, T 45 Nozato, S 569 Nozawa, K Nugent, K 44 Nukiwa, T 98 abstract author Index 0 Program Book 87

390 abstract author Index 88 Nuñez-Alvarez, CA 44 Nunna, R 05 Nuño, L 546, 75 Nunziato, CA 49, 0 Nurmohamed, MT 5, 460, 5, 8 Nurmohamed, M 4 Nurmohamed, MT 50, 58, 87, 668, 70 Nusman, CM 09 Nutter, B 65, 884 Nyengaard, JR 07 Nyhof-Young, J 48 Nyman, E 48 Nyren, S 69 Nüßlein, H 460 Nzeusseu Toukap, A 5, 548 O O Connell, PG 60, 68 O Connor, M 58, 59 O Dell, AA 440 O Dell, JR 6, 7, 7, 44, 44, 676, 996, 997, 87, 4 O Donnell, JL 9 O Donnell, M 85, 55, 686, 70 O Hearn, P 8 O Leary, DH 69 O Malley, C 976 O Neil, KM 94, 475 O Neill, T 667 O Reilly, A 85 O Riordan, M 595 O Seaghdha, C 60 O Shea, FD 75, 85, 575, 054, 056 O Shea, JJ O Toole, G 540 Oaks, ZA 455, 45 Oates, J 668, 68 Oatis, CA 585, 65 Oba-Shinjo, SM 99 Obata, J Obermayer-Pietsch, B Obermeyer, K 570, 4 Obici, L 749 Ocal, L 5, 64 Ocampo-Torres, MC 650 Ochi, K 089, 67, 96, 4 Ochi, S 98 Ochs, W 77, 7 Oda, K Odani, T 79, 460 Oddis, CV 06, 07, 7, 0, 756, 598, 7, 945, 949, 950 Oddone, EZ Program Book Odegard, VH 796 Odhav, A 9 Odio, A 77 Oei, E 47 Oen, K 475 Oeser, A 86, 66 Oeser, AM 8, 6 Ofer-Shiber, S 74 Oflaz, H 707 Ogale, S 78, 46 Ogata, A 500, 95 Ogata, H 877 Ogawa, E 458, 684 Ogawa, H Ogdie, A 74, 559, 64 Ogedebe, G 8 Ogishima, H 88 Oglesby, A 9, 94, 94, 946, 856, 67 Oh, BM 5 Oh, C 50, 6 Oh, HJ 5, 95, 8 Oh, HJ Oh, H 9 Oh, JS 54 Oh, TH 96, 866, 869 Ohara, Y 8, 99, 948, 47 Ohbu, S 046 Ohde, S 99, 046 Ohkawa, R 48 Ohkura, M 86 Ohmura, K 6, 96, 96 Ohno, N 856 Ohno, S Ohno-Macado, L 97 Ohrmund, L 9 Ohshige, T 60 Ohshima, S 94 Ohta, H 86 Ohta, H 444, 445, 4, 56 Ohta, S 50 Ohta, S 89 Ohta, SI 86 Oier, AB 406 Oka, H 86 Okada, A 70, 046,, 4 Okada, J 458 Okada, M 99, 948, 47 Okada, N 98 Okada, Y, 64 Okada, Y 40 Okamoto, K 8, 5 Okamoto, Y 74, 94, 94, 49, 97, 4 Okamura, K Okamura, R 44 Okano, T, 0, 989, 990 Okano, T 48, 97 Okano, Y 04 Okawa, J 947, 40 Okazaki, T Oksel, F 5 Oksenhendler, E 0 Oku, K 79 Okubo, A Okuda, K 4, 7 Okuma, K 084 Okuno, H 70 Olea, JL 40 Olenginski, TP 604 Olex, AL 7 Olferiev, M 65, 809 Olin, AI 66 Olivas, C 08 Olivé, A 9, 980, 44, 967 Oliveira, ASF 8 Oliveira, A 995 Oliveira, ACD 96 Oliveira, HA 09,, 65 Oliveira, P 04 Oliveira, R 77 Oliveira, S 47, 477 Oliveira, SK 657 Oliver, R 9 Oliveri, B 998 Olofsson, T 86 Olschowka, N 455 Olsen, H 69 Olsen, IC 69 Olsen, NJ 685 Olson, AL 7 Olsson, P 0 Ombrello, AK 79 Ombrello, MJ 989, 6, 657 Omdal, R 5, 67 Omenetti, A 658 OMERACT Flare Working Group, 6 OMERACT Ultrasound Task Force, 8 OMERACT-US Task Force, 80 Ometto, F 75 Omma, A 5, 64 On behalf of RESPONDIA Group, 56 Onat, AM 64 Onel, K 94, 760, 76, 4, 897, 60 Ong, HL 506 Ong, V 65 Ong, VH 478, 76 Onishi, A 707 Onishi, S 060 Ono, J 50 Ono, Y 7 Onofrei, AU Ooka, S 8, Oomatia, A 609 OPAL Consortium, 87, 40 Opitz, S 4 Opoka-Winiarska, V 597 Oppenheim, C 55 Orabi, H 705 ORAL Scan Investigators, 77 Ørnbjerg, LM 6, 6 Ordi-Ros, J 4 Ordoñez-Cañizares, MC 7 Oreiro, N 99, 994 Orellana, C 604 Orellana, C 0 Oren, A 7 Orenti, A 47 Oribe, M 4 Origasa, H Origuchi, T 046, 05,, 4 Orlandi, A 867 Ormseth, MJ 8, 6 Ormseth, SR 576, 694 Orquevaux, P 649 Ortego, N 40 Ortiz Sanjuan, F 548, 88 Ortiz-Sanjuan, F 89 Ortolan, A 596 Orwoll, E 8, 977 Orzechowski, NM 04 Osborn, T 709 Oshikawa, H 8 Oshima, H 67 Oshita, K Oskolkova, O 07 Ospelt, C 47, 48, 78,, 670 Ossipova, E, 769 Ostendorf, B 040 Ostendorf, B 46 Osteoarthritis Initiative Investigators, 470 Ostergaard, M 46, 548, 578, 778, 80, 8, 04, 8 Østergaard, M 6, 6, 577, 580, 06, 04, 045, 7, 66, 67, 60, 0, 5, 558, 689 Østergaard, O 680 Osterroth, F 4 Ostor, AJ 06 Ostrowski, RA 0 Oswald, M 57, 687 Ota, T 8 Ota, Y 74, 94, 94, 49, 97, 4 Otabe, K 8, 645

391 Otawa, SM 49, 494, 496, 08 OTIS Research Group, 466 Otomo, K 79, 460 Oton, T 9 Ottaviani, S 478, 487 Otten, MH 4 Ottenbacher, KJ 589 Ottery, FD 47, 59, 60, 69, 96 Ottosson, C 08 Ou, P 9 Ouary, S 479 Oukka, M 677 Outcalt, S 965 Outman, RC 90, 978 Ouyang, W 6 Ouyang, X 09, 5 Ovalles-Bonilla, JG 47 Overman, RA 909 Owada, T 98 Owen, T 07, 666, 667, 678 Owens, T 6 Oyoo, OG 47 Ozaki, S 8,, 7, 45, 5, 55 Ozarka, N 455 Ozata, B 8 Ozdogan, H 750 Ozdogan, H 87, 759, 76, 0 Ozeki, A 700 Ozen, G 7 Ozen, S 0, 477, 657 Ozguler, Y 7 Ozyazgan, Y 989, 6 P Pablos, JL 8, 9, 5, 4 Pace, AV 78 Pachecho, RA 985 Pacheco-Tena, C 46 Pachman, LM 0, 670, 948 Pack, JW Padilla, C 56 Padilla-Ibarra, J 446 Padova, H 9 Padovan, M 56 Padovano, I 5, 6 Padyukov, L, 978, 607 Paessler, ME 4, 058 Page, C 69 Page, M 750 Pagès-Castellà, A 95 Pagnier, A 04 Pagnini, I 598 Pagnoux, C 84, 54, 545, 55, 65, 656, 56 Pahau, H 98 Pain, C 004 Paira, S 60, 4 Paira, SO 56 Paiva, ES 880 Pal, S 58, 59 Pal, S 47, 47 Palacios, S 77, 976 Palanichamy, A 07, 667 Palazzo, E 478 Palleiro, D 56 Pallot Prades, B 699, 895 Palma Sanchez, D 9 Palmer, E 690 Palmer, L 9 Palmer, RH 96, 857, 868 Palmisani, E 65 Palmisano, J 650 Palombella, VJ 8 Palumbo-Zerr, K 47, 78, 50 Pamfil, C 46 Pan, N 809 Pan, S 4 Pan, TJ 57, 649 Panahifar, A 8 Panchal, S 57 Pande, I 57 Pandey, A 057 Pandey, C 07, 054 Pane, I 08, 09,, 699, 68 Pang, J 5 Pang, WG 74 Pang, W 87 Pang, WK 850, 870, 99 Pangan, AL 570, 05, 5, 6, 08, 4 Pangburn, MK 059 Panicker, S 075 Panopalis, P 86 Pantell, M 5 Paoli, CJ 9 Paolicchi, A 6 Pap, T 9, 40, 46, 68, 779 Papac, D 6 Papadaki, I 99 Papadopoulou, C 7 Papadopoulou-Alataki, E 0 Papaioannou, A 979 Papalardo, E 7 Papandrikopoulou, A 5 Papanikolaou, K 058 Papapoulos, S 959, 998 Paparo, F 50 Papneja, A 540, 4 Papo, T 565 Papon, M 577 Pappas, DA 49, 00, 480, 659 Pappu, R 67 Paramarta, JE 59, 5 Paramore, C 856 Paran, D 450, 6 Parasu, N 06, 05, 00 Parekh, TM 405 Parikh, K 484 Parimi, N 8, 98 Parish, M 4, 44 Park, C 85 Park, DJ 06, 4, 88, 49 Park, E 6 Park, EJ 0, 8 Park, HJ 7 Park, H 4 Park, H 47, 584, 97 Park, J 46, 97 Park, JA 408 Park, JK 99, 99 Park, JW 8, 85 Park, K 64 Park, KH 680 PARK, KS 745 Park, KS, 664, 58 Park, MK 745 Park, MC 44 Park, SH 78 Park, SY 686 Park, SJ, 0, 7 Park, SJ 6 Park, SH 6 PARK, SH 745 Park, SH 78 Park, SH, 4, 549, 664, 779, 65, 58, 8 Park, SH 95 Park, S 680 Park, YB 6, 44, 7, 680 Park, YW 06, 4, 49 Park-Min, KH 88 Parker, B 6, 65 Parker, C 6 Parker, L 65 Parkes, MJ 7 Parperis, KM 06 Parra, AD 759 Parton, M Parton, S 5 Paruzel, P 779 Parvu, M 448, 449, 8 Pascale, R 6 Pascual, MV 69 Pascual Ramos, V 90 Pascual-Salcedo, D 546 Pasma, A 560, 570 Pasoto, SG 6, 95, 497, 68 Pasquali, JL 740 Pasqualin, VD 880 Pasqualoni, E 65 Pass, J 080 Passalent, LA 64, 59, 4 Passo, MH 86, 60, 76, 60 Pastor-Asurza, CA 99 Patel, A 049 Patel, AM 56 Patel, A 74 Patel, DR 7 Patel, G 678 Patel, G 95 Patel, J 656 Patel, J Patel, K 5 Patel, N 79 Patel, PJ 0 Patel, RD 65 Patel, R 66 Patel, S 547 Patel, S 7 Patel, T 666, 87 Pater, K 86 Paternotte, S 555, 556, 0 Paterson, JM 55, 96, 5 Patil, P 60 Patkar, NM 76, 70, 09, 54 Patki, A 970 Patrick, F 654 Patten, D 885 Patterson, KC 7 Patterson, OV 49 Patwardhan, A 75, 06, 896, 09 Pau, E 744,, 40 Paudyal, P 966 Pauer, L 64 Paukkeri, EL 095 Paul, B 58, 59 Paul, S 98 Paul, S 455 Pauling, JD 484, 495 Paulissen, SMJ 79 Paulus, HE 9 Pauly, T 46 Pavelka, K 54 Pavelka, K 460, 8, 96, Pavenstädt, H 68 Pavlova, M 844 Pavri, T 46 Pavri, TM 847 Pavy, S 59, 9 Payet, S 68 Payne, J 89 Payne, KJ 759 Payne, PRO 60 abstract author Index 0 Program Book 89

392 abstract author Index Paz, E 679 Pazzola, G 47, 5, 6 Pearce, W 49, 40 Pease, CT 94 Peat, G 96 Pecchioli, S 907 Pedersen, R 68, 0,, 549, 66 Pedersen, SJ 548, 577, 578, 580, 778, 04, 06, 04, 66, 0 Pedersen, TK 00 Pederzoli, S 7, 476 Pedraza, I 4 Peeters, AJ 594, 98 Pego-Reigosa, JM, 980, 44 Pehlivan, 707, 5 Peikert, T 77 Peiteado, D 546 Peixoto, M 487 Pelck, R 6, 6 Pelegrin, L 85 Peliçari, K 46 Pelletier, JP 8, 4 Pelletier, JP 70, 0 Pellett, F 57, 560, 57, 58, 590, Peloquin, C 849, 980 Pelzek, AJ 577 Pelzer, H 080 Peña-Sagredo, JL 4, 88 Pendl, JD 040 Peng, Q 944, 95 Peng, SL 69, 5 Pengo, V 459 Pennaforte, JL 649 Pennington, SR, 58 Penny, MA 5, Penny Prizer, L 57 Penrod, J 489 Peoples, C 74, 049 Pepe, P 85 Pepmueller, PH 77 Peralta-Sastre, A 006 Perazzio, SF 657, 07, 69 Perdriger, A 470, 8, 88, 554 Pereira, AM 00 Pereira, D 540, 5 Pereira, DF 45 Pereira, JX 86 Pereira, KMC 8 Pereira, PVS 69 Pereira, RMR 77, 9, 9, 999, 4 Pereira da Silva, JA 988 Pereira Silva, JA 7 Pérez, R 967 Perez Alamino, R 4 Perez Aso, M 55, 778 Pérez Barbosa, L 096 Pérez Pampin, E 46 Perez Venegas, J 998, 999 Pérez Venegas, JJ 980 Perez-Aso, M 788 Perez-Ferro, M 75 Pérez-Lorenzo, MJ 4 Perez-Ruiz, F 45, 905, 906 Perez-Sanchez, C, 7 Perich-Campos, RA 99 Pericleous, C 75, 77, 78 Perka, C 47 Perl, A 455, 45, 498 Perl, Y 08 Perlman, HR 44, 0, 074, 076, 077, 69, 078, 679 Pernis, AB 847, 880 Peron, CR 5 Perricone, C 9 Perrodeau, E 09, 656, 68 Perrot, S 487 Perry, B 476 Pers, JO 97, 554 Pers, YM 505 Persson, U 90 Pertega-Diaz, S 54, 550, 55, 567, 59, 60 Pertuiset, E 699 Peschken, C 99, 54, 570 Peschken, CA 79 Pesesse, L 780 Pesu, M 095 Petaccia, A 06 Peter, HH 460 Peter, R 09 Peter, WF 66 Peterfy, CG 488 Peters, MJL 87, 668, 70 Petersen, N 88 Peterson, EJ 44, 45, 576 Peterson, LK 507 Petersson, IF 7, 95, 5, 86, 9, 94, 90, 88, 409 Petinoit, L 4 Petit-Teixeira, E 577 Petri, M, 956 Petri, M 604, 609, 68, 69, 66, 6, 640, 658, 67, 69, 886, 98, 89, 90, 9, 94, 96, 400, 4, 47, 4, 45, 648, 650, 708, 70, 70, 7, 45, 55, 68, 85, 569, 570, 57 Petri, MA 64, 65, 79, 84, 4, 6 Petricca, L 679, 97 Petrie, KJ 90 Petterle, GS 04, 808 Pettersson, S 554, 555, 574 Pettersson, T 90 Pettysan, N Peyrin-Biroulet, L 68 Pezic, A 8 Pfirrmann, CW 6 PGRx MI Group, 68 Pham, T 5 Phan, A 645 PHAROS Investigators, 78, 74, 465 Phibbs, C 87 Philippe, L 785 Philippski, P 46 Phillips, K 9, 94, 464, 7 Phillips, PE 498 Phippard, DJ 567 Phipps-Green, A 80, 68 Pialoux, G 657 Pianta, M 08 Piao, C 899 Picano, E 5, 09 Picarelli, G 8 Pichardo, DM 406 Pichavant, M 44, 57 Piché, M 647 Pickford, H 009 Pickles, D 66 Pieper, C 68 Piera-Velazquez, S 09 Pierangeli, SS 69, 405, 77, 7, 455, 456, 457 Pierce, R 75 Piette, AM 67 Piette, EW 40 Piette, JC 64, 647, 649, 5 Piga, M 498, 599 Pikwer, M 4, 84 Pilataxi, F 760 Pilkington, C 97 Pilkington, CA 75 Pillai, S 75 Pillen, S 8 Pillet, P 04 Pillinger, MH 65, 66 Pimentel-Santos, F 7, 56 Pimienta, O 050 Pincus, T 79, 45, 04, 048, 04, 05, 605, 69 Pine, P 9 Pineau, CA 649, 69,, 87, 48, 887, 688 Pineda, C 7 Ping, Z 60 Pingitore, A 09 Pinheiro, FAG 96 Pinheiro, MM 04, 808 Pink, M 8 Pinney, AJ 50 Pinney, SM 606 Pinot, E 480 Pinto, J 54, 550, 55, 567, 59, 60 Pipitone, N 5, 6 Piqueras, L 0 Pisetsky, DS 90 Pisoni, C 647 Pistorio, A 47 Pittrow, D 7 Pitts, L 640 Pitzalis, C 46 Pizzino, G 507, 508 Pizzorni, C 5 Plaisier, E 6, 657 Planas, E 57 Planas Rigol, E 5 Planas-Rigol, E 859, 59 Plant, D 6 Plasencia, C 546 Plass, N 0, 65 Platas, J Platt, A 66 Platt, PN 0 Platt, RW 649, 48 Plenge, RM 7, 40, 976, 98, 997, 595, 60, 68, 754, 8 Plestilova, L 9,, 67 Pletcher, S 05 Plešivčnik Novljan, M 05 Pluijm, SMF 58, 6 Plumas, J 8 PLUS, 64 Poddubnyy, D 56, 84, 70, 9, 496 Podenphant, J 46 Pødenphant, J 045, 5 Podlusky, S 76 Podojil, JR 7 Poelmans, S 6 Poggenborg, RP 06, 04, 66 Poilvert, RM 895 Pointon, J 595 Pokora, T 856 Pol, S 67, 657 Polak, JF 69 Polasek, E 447 Polat, A 0 Polat, O 67 Polido Pereira, J 7 Polido-Pereira, J 988 Pollock, J 864, 558, 7 Pollock, R 57, 58, 590, Polyak, JL 564, 565, 567, 698 Ponce de Leon, D Program Book

393 Poncet, C 460 Ponchel, F 766 Ponder, L 44, 57 Pong, A 97 Pong, E 76 Pons-Estel, GJ 76, 458 Ponsonby, AL 8 Ponte, C 988 Ponticos, M 05 Pontikaki, I 67, 08 Pool, B 7 Pool, C 86 Poole, JL 6, 64 Poole, K 84 Popa, C 68 Popa, D 876 Pope, D 579 Pope, E 008, 09 Pope, J 465, 8, 6, 09 Pope, JE 55, 8, 40, 7, 85, 85, 6, 5, 7, 467, 480, 85, 9, 099,, 60, 688 Pope, RM 074, 076, 06, 69, 664, 54 Popovich, J 9 Porcelli, SA Porrini, AA 579 Porru, G 498, 599 Portales, P 505 Porter, D 66 Porter, JR 8 Porter, V 48 Portugal, C 54 Possemato, N 5, 6 Postal, M 99, 00, 46 Postelnek, J 74 Posthumus, MD 607 Potapov, A 660 Potempa, J 08 Potier, ML 485, 78 Pottel, T 696 Pouchot, J 98, 5 Poulin-Costello, M 7 Poulsen, UE 6, 6 Poulton, K 78 Pourrat, J 64 Poveda, J 7 Powe, T 67 Powell, TC 67 Prager, G 08 Prahalad, S 974, 44, 55, 57, 64, 890, 005, 657 Pratali, L 5 Pratap, A 60 Prati, C 544, 6 Pratt, AG 0, 774 Pratt, IV 9 Precioso, AR 95 Preissner, KT 4 Presa, T 75 Pressman, A 87 Prestigiacomo, T 455 Prevel, N 757 Priam, S, 8 Price, LL 9, 5 Prieto-Alhambra, D 70, 78, 95, Prieto-González, S 859, 5, 57, 59 Prieto-Parra, RE Prignano, F 79 Primiano, MJ 08 Prince, JM 84 Prince-Fiocco, M 59 Princic, N 89 Prinz, JC 554 Priori, R 9, 8, 84, 85, 55 Prisco, E 9 Proctor, J 8 Prodinger, B 4 Proft, F 747 Proglhof, JEP 6 Propert, K 947 Prots, I 407 Proudman, S 05, 45 Proulx, J 86 Provenza, JR 5, 880 Providenti, A 476 Provost, Y 7 Prowse, R 6 Pruijn, GJ 5 Puato, M 596 Pucciani, F 485 Puchner, A 070, 086 Puechal, X 7, 545, 65, 656, 88, 554 Pugnet, G 9, 8, 84 Puig, J 455 Puig, L 569, 557, 56 Puig-Kröger, A 75 Puliaiev, M 45, 7 Pullenayegum, E 95 Pullman-Mooar, SW 8 Pulsatelli, L 6 Punaro, MG 94, 76, 008, 09, 040 Pundole, X 98 Punzi, L 55 Punzi, L 596, 75 Puolakka, K 67, 68, 75 Purcaru, O 8, 7 Purdue, PE, 58 Purves, D 66 Pushparajah, DS 59 Puskas, GJ 48 Putrik, P 844, 845 Putterman, C 60, 6, 88, 89, 48 Puyraveau, M 6 Pyne, L 8 Q Qaiyumi, S 56 Qi, J 7 Qi, L 474 Qi, Z 0, 74, 949 Qidwai, K 99 Qiu, J 497 Qiu, X 065 Quach, D 5 Quach, HL 5 Quadrini, NA 00 Quan, J 685 Quartier, P 759, 76, 597, 678, 04, 0, 47, 477 Quartuccio, L 8, 84, 85, 89, 555 Quasthoff, S 7 Queiro, R 998, 999 Quemeneur, T 6, 65, 656 Querci, F 057 Quesada Calvo, F 4, 50 QUEST-RA, 098 Quillinan, NP 69 Quimbo, R 045 Quinet, R 95, 066 Quinn, H 78 Quinn, T 584 Quinn, WJ III 48 Quinteros, A 60 Quintin, E 478 Quinzanos, I 9, 655, 7 Quiroga, C 55 Quiroz, C 5, 68, 4 Quismorio, FP Jr. 99 Qvist, P 59 R Rabinovich, EC 76, 008, 09, 0 Rabois, E 0 Rabquer, BJ, 506 Rabsteyn, A 844 Racewicz, A 84 Raches, CM 08 Rachlis, AC 7 Radbruch, A 686, 979 Radbruch, AH 50 Rader, T 586 Radfar, L 5, 54, 55, 0, 674 Radford, K 574 Radhakrishna, SM 89, 47 Radhakrishnan, S 4, 45 Radicati, A 485 Radics, N 9 Radin, AR 0, 7 Radin, D 59 Radner, H 09,,, 6, 608 Radstake, TRDJ 064, 786, 788, 0, 04, 5 Radstake, T 80, 0 Radstake, TR 98 Radusky, RC 805 Radvanski, DC 45 Raffeiner, B 75 Raffray, L 95 Ragavendra, N 709 Raggi, P 6, 86, 66 Rahbar, M 545, 704 Rahim, A 58, 59 Rahman, A 40, 40, 75, 77, 78, 570 Rahman, M 46 Rahman, P 569, 570, 8, 557, 56 Rahme, E 457 Raicht, A 8 Rainer, F 460 Rainey, AA 90 Rainis, CA 7 Rajan, B 760 Rajendran, C 59 Ram, S 44 Ramanathan, A 6, 47 Ramessar, N 88 Ramires de Jesus, G 76, 458 Ramirez, F 545 Ramirez, G 644 Ramirez, J 88 Ramirez, M 8 Ramirez-Molina, C 07 Ramiro, S 495, 57, 576, 0, 6, 698, 844, 845, Ramji, F 4 Rammensee, HG 844 Ramon, G 7 Ramonda, R 596 Ramoni, V 5 Ramos, F 988 Ramos, PS, 889, 74, 84 Ramos-Casals, M 55 Ramos-Remus, C 446 Ramsay, M 975 Ramsey-Goldman, R 570 abstract author Index 0 Program Book 9

394 abstract author Index 9 Ramsey-Goldman, R 60, 67, 79, 84, 47, 4, 49, 40, 8, 475 Ramwadhdoebe, TH 4 Rana, N 57 Ranade, K 675, 760 Rand, J 7 Rand, JH 7 Ranganath, VK 050 Ranganath, VK 9, 5 Ranganathan, P 55 Rangaraj, MJ 545 Rangel-Moreno, J 678 Ranieri, E 7 Rannou, F 556 Rantapaa-Dahlqvist, SM 4, 49 Rantapää Dahlqvist, S 665, 69 Rantapää-Dahlqvist, SM 45 Rantz, T 6 Ranzolin, A 880 Rao, S 54, 746, 45, 5 Rao, VR 08 Rappaport, L Rask, K 95 Rasker, J 859 Rasmussen, A 54, 0 Rasmussen, C 79 Rasmussen, M 69 Rat, AC 8, 8, 98, 5, 4, 68, 740, 89, 895 Raterman, HG 58 Rathmann, SS 487, 775, 05 Rathore, RKS 07, 054 Rau, R 57, 59 Rauch, C 460 Rauch, TA 06 Rauer, B 80 Ravaud, P 80, 08, 09,, 65, 656, 699, 68, 89, 47, 555 RAVE/ITN Research Group, 654 Ravelli, A 58, 65, 66, 7, 7, 47 Ravetch, JV 056 Ravindra, L 80 Rawlings, DJ 580 Ray, DW 667 Raya, E 9 Raya Álvarez, E 64, 5, 6 Raychaudhuri, SP 7, 44, 589, 85 Raychaudhuri, SK 7, 44, 589, 85 Raynauld, JP 458, 4 Razykov, I 66 Re, KA 46 Reardon, G 8 Reaume, M 7 0 Program Book Rech, J 7, 00, 09, 58, 58 Rech, J 594, 9 Recillas-Gispert, C 44 Reckley, KA 85, 7 Recknor, C 997 Recuero, S 75 Redden, D 0 Redden, DT 996, 997, 978 Reddy, R 9 Reddy, SP 85 Reddy, SM 50 Reddy, ST 5 Reddy, V 65 Redegeld, F 509 Redlich, K 5, 4, 070, 947, 08, 086 Redman, R 89 Redmond, AC 00 Rednic, S 46, 9 Reed, AM 07, 44, 658, 754, 756, 598, 95, 0 Reed, E 769 Reed, G 80, 89, 05, 480 Reed, GW 8, 79, 464, 49, 865, 00, 84, 0,, 50 Reed, JH 666, 889 Reed, MD 86 Reed, TJ 74 Reedquist, KA 90, 60, 55 Reese, C 476, 5 Reeves, Q 585 Reeves, WH 64, 684, 7, 470, 747, 956 Refino, C 4, 45 Regardt, M 587 Régent, A 0, 774 Regev, G 955 Reginster, JY 966 Reginster, JY 55, 56, 596, 969, 998 Reginster, J 54 Regnault, V 740 Rego-Perez, I 99, 994, 60 Rehart, S 4, 890, 89 Rehaume, L 49, 494 Rehman, AA 65, 66 Reichenbach, S 6 Reichert, H 499, 500 Reichlin, M 677 Reichlin, M 677 Reichmann, WM 8, 75 Reid, DM 55 Reiff, A 78 Reiff, AO 89 Reijman, M 47 Reijnierse, M 05 Reijnierse, M 564, 80, 06, 07, 09,,, 58, 6 Reilly, C 44 Reily, M 489 Reimert, M 9 Reimold, AM 89, 87, 0, 48, 640 Reindl, C 07 Reindl, CS 407 Reinhardt, AL 65 Reinke, E 650 Reis, E 77 Reis, FM 6 Reis, MG 77 Reis, RC 66 Reis, SE 5 Reiss, AB 57 Reiss, W 89, 464 Reistetter, TA 589 Reiter, K 749 Reiter, K 46 Reksten, TR 50 Rekvig, OP 88 Relaño-Fernandez, S 994 Relic, B 4, 50 Remmers, E 005, 657 Remmers, EF 989, 6 Ren, K 4 Renaudineau, Y 97 Renduchintala, K 94 Rennebohm, RM 76 Renner, J 7, 094, Renner, JB 986, 099, 468 Reny, JL 656 Repa, A 46 Repping-Wuts, H Resche Rigon, M 65 Resche-Rigon, M 564 RESCLE investigators, A 479 Resnick, EM 64 Restrepo, JF, 4, 90 Restuccia, G 5 Reuter, S 8 Reuwer, AQ 078 Reveille, JD 545, 595, 67, 78, 84, 85, 76, 4, 474, 704, 90 Revicki, D 45 Revu, S 789 Reyes-Leyva, J 606 Reyes-Salazar, A 70 Reyes-Thomas, J 60 Reynisdottir, G 69 Reynolds, JA 667 Reynolds, N 46 Reynolds, RJ 975, 996, 997, 0 Rezende, CP 6 Rezende, GM 500 Rezende, MC 880 Rhee, C 85 Rhee, RL 44 Rheumatoid Arthritis Consortium International (RACI), 595 Rho, YH 849, 854, 64 Rhodus, NL 5, 54, 55, 0, 67, 674 Rialland, A 47 Ribeiro, AC 95 Ribeiro, ACM 7, 5 Ribeiro, AC 999 Ribeiro, ACM 74 Ribeiro, ACM 064 Ribi, C 48, 545 Ribon, M 844 Ricci, F 05 Rice, P 67, 74, 84 Rich, E 70, 7 Richards, A 86, 58 Richards, D 48 Richards, JS 49, 0, 48 Richards, JS 56 Richards, P 864, 558 Richards, R 586 Richardson, BC 60, 7 Richardson, C 690 Richesson, R 868, 58, 48 Richette, P 55, 544 Richette, P 68, 47 Richey, MC 404, 696, 697 Richez, C 0, 04 Richman, J 07 Richman, L 755, 675 Richter, A 65 Richter, JG 944 Rickert, M 4, 890 Rider, LG 06, 8, 9, 75, 07, 598 Riebschleger, MP 76, 890 Riega Torres, J 096 Riemekasten, G 49, 98, 04 Riente, L 4 Riera, E 9 Riese, R 78, 84, 485, 490 Riese, R 8, 90, 697 Rigante, D 06 Rigby, WFC 75 Rigolet, A 0, 67 Riis, BJ 984 Rillo, OL 60, 00, 479, 4 Rincheval, N 80 Rincon, M 78 Ringold, S, 50, 00, 595 Ringsdal, VS 6, 6 Rinsche, A 900

395 Rintek Madsen, O 79, 6, 6, 04, 0 Rinzis, M 46 Rioja, J 7 Ripoll, V 78 Rischmueller, M 45, 67 Riskowski, JL 790, 79, 79, 79 Rist, S 09, 88 Ritchlin, CT, 4, 569, 8,, 557, 56, 66 Ritter, SY 75 Rivas-Chacon, RF 0 Rivera, J 00 Rivera, Y 5 Riveros, A 9 Rivière, S 67 Rivoire, J 58 Riyazi, N 98 Rizo Rodriguez, JC 490 Rizvi, TJ 894, 587 Rizzo, WC 49 Rizzoli, R 969 Roane, G 545 Robazzi, T 96 Robbins, L 400 Roberts, C 64 Roberts, K 069 Roberts, L 400 Roberts, L 87, 86, 40 Roberts, MS 85 Roberts, MEP 5 Roberts, N 507, 508 Roberts, VC 67, 645 Robertson, JM 740 Robertson, S 99 Robillard, P 56 Robin, C 0 Robinson, DB 94, 688 Robinson, F 579 Robinson, G 7 Robinson, P 6, 495 Robinson, SM 79 Robinson, S 06 Robinson, WH 87, 47, 605, 688, 690, 097, 6, 59, 659 Roccatello, D 547, 74, 75 Rocha, F 7 Rocha, FA 5 Rødevand, E 404, 85, 560, 56 Rodrigues, AM 7, 988 Rodrigues, JF 496 Rodriguez, GR 00 Rodriguez, J 998 Rodriguez, MA 57 Rodriguez, VA 08 Rodríguez Amado, J 096 Rodriguez Moreno, J 999 Rodriguez-Ariza, A, 7 Rodriguez-Bellido, Z 99 Rodríguez-Gallegos, A 958 Rodríguez-García, V 7 Rodríguez-Gómez, M 46 Rodríguez-Moreno, J 7 Rodriguez-Nieto, MJ 75 Rodriguez-Pla, A 69 Rodriguez-Rodriguez, L 670 Rodriguez-Ulloa, S 99 Roebuck-Spencer, T 80, 8 Roemer, F 49, 50, 5, 07, 09, 00, 0, 0, 0, 04, 9, 467, 469, 470 Roger, VL 80, 48 Rohekar, G 85 Rohekar, S 8, 85 Rohrer, M 5, 54, 55, 0, 674 Roig, D 998, 999 Rojkovich, B 07 Rojo, JM 4 Rokutanda, R 99, 948, 47 Roland, B 95 Roll, P 76 Rollefstad, S 69 Rollins, M Romas, E 5 Romay-Penabad, Z 77, 7 Rombouts, Y 0 Rome, BN 090 Rømer, J 796, 080 Romera-Baures, M Sr. Romero, D 06 Romero, FI 75 Romero Silva, AB 46 Romero-Barco, CM 7 Romero-Diaz, J 650, 44 Romeu, J 988 Romijn, HA 00 Romviel, S 66 Ronda, N 675 Ronday, HK 0 Ronday, HK 594 Rondon-Herrera, F 90 Rong, M 60 Ronis, T 60 Rönnblom, L 5, 845, 8, 7 Ronnelid, J 4 Rönnelid, J 4, 49 Rontogianni, D 99 Rooke, R 579 Rooney, C 58 Rooney, M Rooney, P 5 Roorda, LD 66, 5 Rosa, J 5, 9, 40, 68, 58 Rosal, M 085, 585, 65 Rosales-Alexander, J 64, 5, 6 Rosario, V 88 Rosas, J 44, 9 Rose, JA 406 Rose, S 078 Rose, SM 0 Rosemffet, MG 06 Rosen, A 56, 758, 94, 689, 95, 954, 99 Rosen, C 57, 5, 75 Rosen, P 08 Rosenbaum, JT 595, 49 Rosenberg, AM 9, 47, 475 Rosenberg, A 5 Rosenberg, DM 85 Rosenberg, E 97, 99 Rosenberg, WM 47, 47 Rosenblum, GC 57 Rosendaal, FR 097, 58 Rosenfeld, A 6 Rosenthal, AK 55, 65 Rosenthal, PB 50 Rosenzwajg, M Sr. 6, 77 Rosenzweig, E 689 Rosina, S 65 Roskell, S 846 Rosner, I 9, 450 Ross, H 055 Ross, S 48 Rossen, RD 9 Rossenu, S 6 Rossetti, M 47, 59, 594 Rossi, C 59 Rossi, D 547 Rossignol, M 68, 80 Rotar, 87, 05 Roth, J 7, 674 Rothe, T 07 Rother, I Rother, M, 57 Rothkegel, M 50 Rotman, G 7 Rottinghaus, S 84 Rouanet, S 470, 8 Rouru, J 48 Roussos, C 09 Roussy, JP 457 Rouster-Stevens, K 75, 57, 005 Rouster-Stevens, KA 44, 55 Roux, C 470, 59, 8, 0, 5, 47 Rovin, BH 840, 5 Rowe, MW 6 Royant, V 895 Royston, P 576 Rozadilla, A Sr. Rozman, B 90 Rua-Figueroa, I Rúa-Figueroa, 44, 9 Rubartelli, A 658 Rubbert-Roth, A 456, 467, 640, 545 Rubell, A 69 Rubinstein, E 45 Rubio Velazquez, E 9 Rubio-Perez, N 679 Rubio-Perez, N 597 Ruck, A 48 Rudd, RE 6, 57 Rudwaleit, M 555, 57, 777, 7, 84, 70, 4, 9, 496 Rueda-Gotor, J 548, 88, 89 Ruffatti, A 459 Rufibach, K 548, 04 Ruiz, B 5 Ruiz, XD 049 Ruiz Jimeno, T 49 Ruiz Limon, P 7, 456, 457 Ruiz-Arruza, I 4 Ruiz-Esquide, V 88 Ruiz-Irastorza, G 570 Ruiz-Limon, P, 77, 7 Ruiz-Lucea, E 9 Ruiz-Martin, J 5 Ruiz-Romero, C 988 Rull-Gabayet, M 90 Rullo, OJ 0, 70 Rundell, SD 094 Runhaar, J 47 Ruperto, N 679 Ruperto, N 66 Ruperto, N 759, 760, 76, 764, 58, 597, 0, 47, 477 Rus, H 49 Rus, V 49 Rushe, P Russell, CB 94 Russell, GM 7, 79 Russell, M 846 Russo, P 5 Russo, R 0, 47 Russo, RAG 74, 657 Ruta, S 5, 9, 40, 58 Rutgers, A 860, 5 Ruth, JH 0, 4, 77, 879, 60 Ruth, NM 80, 86, 60, 65 Rutkowska-Sak, L 759, 76 Ruutu, M 49, 494 Ruyssen-Witrand, A 049 Ryan, HS 76 abstract author Index 0 Program Book 9

396 abstract author Index Ryan, J 6 Ryan, LM 55, 06 Ryan, S 78 Rydberg, B 776 Ryu, JH 75, 98 Ryu, JA 0 S Sa, KH 406 Saad, CGS 7, 5 Saad-Magalhaes, C 679 Saad-Magalhães, C 477 Saadoun, D 6, 657, 77, 65 Saag, KG 54, 48, 74, 489, 76, 90, 94, 74, 97, 978, 995, 09, 54 Saas, P 755, 756 Saavedra, MA 956 Saavedra Salinas, MA 76 Saavedra-Salinas, MA Sabbadini, MG 68 Sabelli, M 68, 58 Saber, R 077, 679 Saboonchi, F 57 Saccenti, E 00 Sacchetti, S 96 Sachdeva, S 759 Sack, KE 74 Sacksen, I 97 Sacli, FS 989, 6 Sacre, K 64 Sada, KE 55 Sadatsafavi, M 9 Sadeghi Abdollahi, B 05, 76 Sadik, CD 66 Sadji, F 895 Saegusa, J 40, 48, 98, 80 Saeki, Y 94 Saevarsdottir, S 607, 0 Saevarsdottir*, S 0 Saferding, V 5, 070, 086 Safford, MM 70, 978, 09, 54, 54 Safran-Norton, C 650 Sagar, V 499 Sagawa, A 4, 7 Sage, JM 040, 04, 60 Saha, AK Saha, C 95 Sahakian, L 69, 709 Sahani, D Sahhar, J 70 Sahin, E 086 Sahinkaya, Y 707, 5 Sahl, S 647 Sahoo, P 054 Sahu, R 454 Said-Nahal, R 594, 597, 598 Sailler, L 9, 84 Saito, K 77,, 6, 664 Saito, S 8 Saitou, A 089 Saitta, A 507, 508 Sajuthi, S, 74, 84 Sakai, K 86 Sakai, R 98 Sakai, Y 97, 7 Sakamoto, N 44 Sakellariou, G Saketkoo, LA 77, 468, 7 Sakuma, Y 089 Sakurai, D 846, 984, 6 Sakurai, T 67 Sakurai, T 4, 7 Salaffi, F 67 Salas, A 4 Salas, E 466 Salazar Cintora, GA 509 Salazar-Paramo, M Salbato, J 9 Saldanha, P 055 Sale, J 48 Sale, MM 74 Saligan, L 874 Salinger, DH 94 Sallum, AM 77, 96 Salmaso, A 67, 08 Salmon, J 46 Salmon, JE 44, 79, 847, 880, 8, 650 Salmon, JH 699 Salom, D 40 Salomao, R 657, 07 Salomon, B 757 Salonen, D 54, 5 Saluja, M 58, 59 Salvarani, C 858, 88, 47, 5, 6, 566 Salvat, C 8, 9 Salvatierra, G 60, 4 Salvatierra, J 64, 5, 6 Salvin, S 8, 89, 555 Samanta, A 57 Samba, SD 05 Sambataro, D 77 Sambrook, P 596 Sambuceti, G 50 Samedy, LA Sammaritano, LR 650 Sampaio-Barros, P 56 Samson, M 545 Samuels, J 50 Samuelson, T 69 San Marco, M 70 Sanayama, Y Sanchez, C 780 Sánchez-Atrio, A 44 Sanchez-Guerrero, J 650, 674, 44, 56, 57 Sanchez-Pernaute, O 75 Sanchez-Torres, AA 99 Sanderson, T 7 Sandhu, S 48 Sandner, P 499 Sandorfi, N 7 Sandoval-Castro, C 446 Sands, GH 0 Sangari, D 507, 508 Sangle, S 9 Sanjurjo-Rodriguez, C, 48 Sanmarti, R 85, 998, 999, 88, 64 Sanna, G 74 Sanner, H 87, 94 Sano, H 8, 96 Santambrogio, L Santiago, M 77 Santiago-Casas, YC 67, 4 Santini, E 59 Santora, A 97 Santos, H 7, 56 Santos, MC 96 Santos, MJ 7 Santos-Rey, J 5 Sanz, I 690, 07, 667 Sanz, I 5 Sanz, MJ 0 Saperstein, D 969 Saracbasi, E 55 Saraon, P 560 Saraux, A 5, 80, 5, 80, 87, 849, 9, 88, 97, 55, 554 Sardano, E 4 Sargeant, J 48 Sargentini-Maier, L 07, Sargious, P 40 Sari, I 565, 8 Sari Surmeli, Z 574 Sarkin, A 4 Sarmukkadam, S 58, 59 Sarracino, D 75 Saruhan-Direskeneli, G 858, 70 Sarvagil-Maman, H 9 Sarzi-Puttini, P 80 Sarzi-Puttini, PC 6 Sarzi-Puttini, P 467 Sassolas, F 649 Satake, M 64 Sathe, M 75 Sato, C 8 Sato, E 8 Sato, H 5 Sato, H 4 Sato, M 6, 4 Sato, S 700, 708, 504, 5 Sato, S 9 Sato, T 8, 5 Satoh, M,, 7, 64, 684, 7, 7, 470, 747, 956 Satoh, T 459 Satorius, C 989, 6, 657 Saucedo, C 56, 68 Saul, M 56, 86 Saunders, KC 8, 77, 79, 80, 464, 49, 89, 865, 00, 84, 05, 8,, 480, 50 Sauvageau, D 458 Savage, LM 545, 4 Savoldi, G 05 Sawada, T 48 Sawalha, AH 858, 70 Sawant, A 586 Sawhney, S 680 Sawitzke, AD 650 Saxena, A 90, 647 Saxne, T 894 Saxne, T 48, 7 Sayers, J 59 Sayles, H 89, 89, 6, 48 Sayre, EC 0, 0,, 64, 46, 568 Scali, JJ 640 Scalzi, L 64 Scanzello, CR Scarpa, R 88 Scarpellini, M 46 Schabbauer, G 086 Schabert, VF 86 Schachter, C 586 Schaeverbeke, T 5, 470, 8, 80, 000, 0, 08, 09,, 9, 5, 68 Schafer, L 586 Schafer, P 45, 5 Schaffir, BC 867 Schanberg, LE 88, 46, 40, 475 Schantz, A 86 Schaub, SC 987 Scheffer, H 4 Schelbergen, R 7 Schellevis, FG 5 Scher*, JU Scherer, A 07, 8 Scherer, A 040 Scherer, HU 0, Program Book

397 Scherrer, CB 669 Schett, G, 7, 00, 09, 07, 4, 499, 500, 50, 58, 58 Schett, GA 47, 594, 78, 888, 890, 90, 008, 505, 6, 57, 550 Schetter, AJ 76 Schiappapietra, B 65 Schiff, M 7, 547 Schiff, MH 9, 40, 4, 449 Schillinger, D 440 Schindler, SC 499 Schiodt, M 67 Schioppo, T 47 Schiopu, E 69, 78, 50, 506 Schipper, I 40 Schirmer, M 8 Schirner, M 9 Schiødt, M 74 Schlager, J 474 Schlemmer, A 6, 6 Schlenk, EA 4 Schlesinger, N 9 Schlesinger, N 44 Schlichting, DE 490, 487, 488 Schlottmann, I 78 Schmajuk, G 47, 8, 464, 599 Schmidmaier, G 47 Schmidt, I 594 Schmidt, KM 75 Schmidt, RE 80 Schmidt, S 594, 58, 58 Schmidt, TW 84 Schmidt-Bleek, K 47 Schmidt-Wilcke, T 80, 805, 806, 644 Schneider, F 7 Schneider, M 46, 7, 65, 944, 040 Schneider, R 85, 759, 76, 46, 890 Schnittker, J 55 Schnitzer, TJ 08 Schoen, P 07 Schoenhoff, F 79 Schoettler, N 9 Scholtysek, C 47 Schonenberg, D 09 Schonkeren, J 670 Schouffoer, AA 94 Schousboe, JT 995 Schramm, MA 407 Schreiber, BE 4, 7 Schreiner, B 8 Schroeder, LL 4 Schue, JR Schuerwegh, A 0, 04 Schult, ML 587 Schulze-Koops, H 0, 407, 47, 47, 554, 747, 995, 500, 07, 44, 508 Schumacher, HR 6, 48 Schumacher, HR 8, 44, 74, 8, 44 Schumacher, M 76 Schur, PH 608, 97 Schwartz, G 68 Schwartz, H 90 Schwartz, MA 580 Schwartz, N 87 Schwartz, T 87, 94 Schwartz, TA 099, 468 Schwartzman, S 49 Schwarz, EM, 4, 66 Schweinhardt, P 96, 64 Schweizer, HP 855 Schwetz, V Schwinger, W 8 Schädel-Höpfner, M 46 Schäfer, C 696 Schäfer, VS 8, 047 Schäffler, A 89 Sciascia, S 547, 74, 75 Scinocca, M 4 Scirè, CA 67, Scofield, RH 5, 54, 55, 0, 8, 67, 674 Scofield, RH 670, 677, 970, 6 Scolnik, M 5, 68, 58 Scotland and Ireland Registry for Ankylosing Spondylitis, 60 Scott, B 77 Scott, DL 050, 49 Scott, JC 87 Scott, K 58, 59 Screaton, GR 6 Scully, MA 757 Searle, N 894, 587 Sebba, A 454, 640 Seccia, V 546 Secco, A 60 Sedlis, SP 65 Sedova, L 96 See, LC 58, 84, 8, 77, 67 Seebach, J 48 Seel, W 7 Segal, BM 5, 54, 55, 0, 67, 674 Segal, M 79 Segal, N 04 Segawa, S 88 Segelmark, M 76 Segers, P 68 Seibel, MJ 4, 085 Seibold, JR 9, 85, 464, 7 Seidel, EJ Seki, Y 78 Sekigawa, I Sekiguchi, H 98 Sekiguchi, M 8, 96 Sekine, H 44 Sellam, J, 0 Sellari Franceschini, S 546 Selles, RW 048 Selman, MHJ 76, 0 Selvaag, AM 68 Selvi, E 9 Semanik, PA 4, 4, 99, 588 Semb, AG 69 Semerano, L 505 Sen, E 97 Sendo, S 98 Sene, D Sr. 64, 6, 77, 88 Senécal, JL 70, 7, 9 Senet, P 6 Seno, T 070 Senolt, L 47 ŠEnolt, L 86, Seo, P 655, 9, 95, 97, 98, 567 Seo, WJ 784, 50 Sepkowitz, M 47 SER group for the study of systemic autoimmune diseases, Serada, S 59 Serafin, DS 80 Seri, M 00 Serikawa, K 080 Seriolo, B 64 Serne, EH 70 Sernissi, F 59 Seror, R 0, 9, 88, 89, 55, 555 Serra-Bonett, N 57 Serrano, B 90 Serrano, C 75 Serre, GB 4 Sesseng, S Sessoms, SL 9 Seta, N 455, 86 Seth, R 908 Seto, M 98 Seto, Y 9, 400, 8 Seve, P 649 Sevgi, S 750 Sewerin, P 46, 040 Seyahi, E 87, 989, 6, 66, 7 Sezerman, OU 005 Sfriso, P 75 Sha, J 996, 997 Shacham, S 678 Shackleton, DP 768 Shadakshari, A 498 Shademan, A 07 Shadick, NA 954, 98, 8, 06, 40, 660 Shafaie, N 05 Shah, AA 697, 468 Shah, A 847 Shah, B 65 Shah, M 94 Shah, M 8 Shah, SJ 76 Shah, S 9 Shah, U 44 Shah, V 674 Shaham, B 78 Shahram, F 76 Shahrara, S 8, 454, 669 Shahzad, F 798 Shaikh, SA 49, 9 Shakoor, N 4, 6, 6, 64, Shamliyan, T 854 Shams, H 76 Shan, Y 0, 8, 50 Shane, PY 56 Shangguan, J 57 Shankar, G 86 Shanmugarajah, S 57, 5, 75 Shao, WH 067 Shao, W 065 Shaoxian, H 60 Shapira-Lichter, I 6 Sharabi, A 456 Share, O 690 Sharif, B 46 Sharif, MI 474 Sharim, R 85 Sharma, A 499 Sharma, A 77 Sharma, K 07, 054 Sharma, L 4, 4, 4, 467, 470 Sharma, R 67 Sharma, SK 499 Sharma, TS 700 Shaul, A 856 Shaw, AS 74 Shaw, J 79, 468 Shaw, JW 75, 84, 69, 7 Shaw, Y 85 Sheane, BJ 58, 59 Sheen, D 47, 584, 97 Sheikh, S 84, 95, 04, 478 Shelef, I 08 Shelef, MA 60 Shelley, M 06 abstract author Index 0 Program Book 95

398 abstract author Index Shen, L 55 Shen, Z 58 Sheng, S 8 Shenoi, S 904 Shenoy, N 4 Shereff, D 868, 58, 48 Sheridan, WP 50 Sheriff, MK 49 Sherlock, J 75 Sherrer, YRS 0 Sherry, DD 00 Sherwood, J 40 Sheth, H 049 Shevach, EM 506 Shewade, A 464, 49 Shewede, A 00 Shi, B 54 Shi, J 768, 770, 77 Shi, K 500, 084 Shi, L 065 Shi, L 68, 85 Shi, N 89 Shi, XA 7, 099 Shiau, AL 6 Shibanuma, N 48, 97 Shibata, S 504, 5 Shibata, T Shiboski, C 74, 9, 9, 67 Shiboski, S 9, 9, 67 Shibuya, H 40 Shidara, K 9, 400, 8 Shields, KJ 7 Shiels, P 0, 04 Shiff, NJ 47 Shiina, M 077, 079 Shikano, K 50 Shim, J 47, 686 Shim, SC 47, 584, 97 Shim, SC 47 Shima, Y 78 Shima, Y 500 Shimada, K 47 Shimizu, H 99, 948, 47 Shimizu, K 6, 4 Shimizu, N 084 Shin, J 08 Shin, KC 95 Shin, K 408 Shin, SY 580 Shinagare, S 54, 58 Shingler, W 474 Shinjo, SK 0, 6, 5, 99 Shinohe, R 6, 4 Shinomura, Y 97 Shinozaki, N 77 Shintani, A 8, 6 Shiozawa, S 48, 885, 055, 074, Shipley, JA 484 Shir, Y 86, 879 Shirai, T 8 Shirai, Y 459 Shirakami, S 084 Shiwen, X 07 Shiyanov, P 474 Shock, A 749, 750 Shoemaker, R 60, 70 Shojania, K 007 Shoji, A 48 Shoji, T Shono, E 4, 7 Shortsleeves, K 80 Shott, S 867, 956, 564, 565, 566, 858, 698 Shourt, C 588 Shoushtari, A 699 Shoyama, FM 45 Shrader, JA 06, 07 Shrady, G 855 Shringarpure, R 9 Shu, X 940, 94, 944, 87 Shuling, H 60 Shum, KM 47, 48 Shuman, SA 60 Shunsei, H 669 Shyu, I 75 Sibilia, J 5, 5, 80, 08, 09,, 699, 785, 87, 5, 68, 87, 554 Sicari, R 5 SICCA, 67 Siddhanti, S 997 Siddle, HJ 00 Siderovski, DP 66 Sidhu, J 9 Sidiropoulos, P 46 Siebuhr, AS 575 Siegelman, SS 659 Sieger, N 749 Siegerink, B 0 Siegrist, J 944 Siegwald, E 404 Siemerink, MJ 599 Sieper, J 574 Sieper, J 549, 558, 56, 570, 57, 777, 779, 05, 6, 65, 84, 70, 08, 9, 5, 9, 5, 496 Sierakowski, S 9 Sigmon, K 88 Signorello, MC 80 Signorovitch, J 75, 84, 69, 4 Silka, K 94 Silva, CA 679 Silva, C 7 Silva, C 500 Silva, C 96, 8 Silva, CA 597 Silva, CA 77, 5, 74, 999, 477, 50 Silva, I 48 Silva, JM 5 Silva, L 44, 9 Silva, NA 500 Silva, NP 657, 07 Silveira, LH 04 Silver, L 690 Silver, RM 476, 5 Silver, TI 9 Silverberg, M 59 Silverfield, JC 8 Silverman, ED 95, 597, 79, 475 Silverman, G 6 Silverman, GJ 45, 694, 577 Silverman, SL 855 Silverstein, RL 57 Simard, JF 574 Simeón, CP 04 Simeon, CP 479, 0 Simkin, PA 46 Simmet, NE 7 Simmons, F 65 Simms, RW 9, 69, 849, 46, 464 Simon, A 56 Simon, LS 6 Simon, SP 9 Simon-Campos, JA 46 Simonelli, PF 604 Simoneta, F Simonetti, M 907 Simonini, G 6, 598 Simonsen, O 5 Simpson, N 55 Sims, NA 5 Singer, J Singer, NG 94, 59, 595 Singh, AG 56 Singh, A 60 Singh, G 6, 4, 45 Singh, JA 4, 48, 75, 096, 70, 55, 8, 07, 09, 445, 54 Singh, N 660 Singh, R 58, 59 Singh, S 9 Singla, M 499 Sinha, U 057 Sinha, V 700 Sinicato, NA 99, 00, 46 Sinico, R 5 Sinissen, P 670 Siskind, L 9 Sivera, F 908 Six, A 6 Sjaastad, I 87, 94 Sjögren s International Collaborative Clinical Alliance, 74 Sjöwall, C 67, 66 Skaggs, B 69, 709, 45 Skapenko, A 407, 995, 500, 44, 508 Skedgel, C 5 Skinner Taylor, C 096 Skipper, B 6 Skoedt, J 580 Skogh, T 67, 66 Skold, M 69 Skoniecki, DJ 650 Skopouli, FN 55 Skosey, JL 904 Skrumsager, BK 79 Slagboom, PE 00 Slan, S 86 Slatkowsky-Christensen, B Sleimann Jacobsen, R 88 Sleptsova, T 4, 48 SLICC, 647, 648, 706 Sloëtjes, AW 55 Slot, O 04 Small, A 867, 956, 566, 567 Small, BJ 567, 858 Smart, D 454 Smedby, T 45 Smets, B Smit, AJ 9 Smith, CK 50 Smith, CH 46 Smith, D 06 Smith, DM 9 Smith, DD Smith, JR 86, 66 Smith, K 748 Smith, MD 80 Smith, M 667 Smith, M 55 Smith, MD 59, 60 Smith, M 66 Smith, P 080 Smith, S 60, 68 Smith, V 50 Smith, V 5 Smithers, N 07 Smolen, JS 77 Smolen, J 96 0 Program Book

399 Smolen, JS 80, 09,, 5, 4, 7, 405, 4, 487, 490, 775, 869, 995, 7, 947, 08, 086, 6,, 4, 608, 67 Smolik, I 94, 688 Smulders, YM 87, 668, 70 Snapir, A 48 Snir, O 578 Snyder, B 085, 086, 087 Snyder, MR 950, 9 So, A 9 So, A 44, 4 So, AK Sr. 5 So, MW 784, 50 So, MW 54 Soares, MB 670 Sobel, ES 64, 684, 7, 470, 747, 956 Sobel, RE 4, 50 Soep, JB 596 Sofat, N 99 Soglia, J 8 Sohn, JH 48 Sohn, MW 99, 588 Sokka, T 75, 844, 845, 098 Sokoll, K 474 Sokolove, J 87, 605, 688, 690, 097, 6, 59, 659 Sokolovic, S 45 Solakov, P 479 Solans-Laqué, R 55 Solari, N 65, 7 Solau-Gervais, E 0 Soldano, S 49, 64 Solini, A 59 Solmaz, D 565, 8 Solomon, DH 7, 0, 665, 687, 84, 87, 960, 98, 99, 995, 06, 06, 660 Solomon, DH 650 Solomon, JJ 7 Solomons, N 87 Soloviova, K 45, 7 Solow, EB 060 Solus, JF 86, 66 Som, D 08 Soma, K 84 Soma, K 8 Somers, EC 60, 47, 067 Somers, K 670 Somers, V 670 Sommarin, Y 769 Son, KM 7, 7 Son, MBF 07 Song, GG 409, 67 Song, H 49 Song, IH 56, 57, 84, 9, 9 Song, JS 88 Song, J 9, 4, 4, 4, 99, 588 Song, J 85 Song, JS 6, 46, 95, Song, L 68 Song, R 64, 6 Song, SNJ 4 Song, W 088 Song, Y 77 Song, YW 549, 779, 65, 78 Song, YW 7, 408, 846, 88, 797, 95, 8, 85 Song, YW 9 Sonigra, A 460 Sonnaville, PBJ 594 Sonomoto, K, 64, 6 Soo, Y 5 Sordet, C 895, 87 Soriano, E 60, 56, 68, 4 Soriano, ER 5, 9, 40, 58 Sorkin, JD 5 Sornasse, T 9, 66 Soro Marin, S 9 Sorroche, P 56, 68 Soto, R 075 Soto Saez, L 479 Soto-Hermida, A 994 Soubrier, M 5, 577, 68 Soudan, M 87 Sousa, MC 65 Soussan, M 78 Southwood, TR 45 Souza, AWS 96 Souza, B 66 Souza, D Souza, FHC 7, 0 Souza, T 08 Soyfoo, MS 50, 0 Spadaro, A 88 Spalding, DM 5 Spandley, A 846 Spargo, L 45 Sparsa, L 0 Specker, C 040 Specks, U 57, 654, 655, 77, 9, 97, 567 Spector, T 596 Spector, TD 98 Spencer, CH 75, 06, 896, 09 Spencer, H 850, 098 Spencer, J 9 Sperber, D 400 Sperber, NR 795 Speyer, I 94 Spieler, W 7, 68 Spiera, RF 694, 57, 540, 7, 75, 567 Spies, CM 085 Spijkervet, F 56 Spiller, I 84 Spindler, A 597 Spindler, KP 650 Spira, A 59 Spits, H 45 Spoonamore, J 595 Spratt, KF 96 Spreafico, R 47, 59, 594 Spriewald, BM 50 Springer, J 544, 65 Spronk, S 4 Spruill, T 8, 50 Squadrito, F 507, 508 Sramek, P 07 Sreih, A 56, 58 Sridharan, ST 795 Srikhum, W 58, 584 Srinivasalu, H 000 Srinivasan, D 075 Srinivasan, M 67 Sriranganathan, MK 908 Srivastava, R 8 Srivastava, S 60 St. Clair, EW 8, 57, 567 Stabile, A 0 Stacey, D 7, 405 Stacey, K 56 Stach, C 777, 6, 64, 705, 6 Staelens, F 9 Stagi, S 0, 04 Stagnaro, C 88, 6 Stahl, E 595 Stahl de Castrillon, F 64 Stamm, TA 869, 7, 4, 67 Stamp, LK 9, 80, 68, 90 Stancati, A 759 Stanek, E 978 Stanford, S 659, 45 Stange, R 40 Stangler, T 5 Stannus, O 57 Stansfield, RB 59 Stappenbeck, TS 66 Starling, GC Statache, G 90 Ste-Marie, PA 86, 865, 879 Steel, KJA 974 Steel, KJA 64 Steen, J 578 Steen, VD 78, 7, 74, 46, 46, 465, 47 Steensberg, A 79 Steer, S 80 Steere, AC 04 Stefanik, JJ 04 Stefanov, D 88 Stefanova, S 74 Steffey, A 64, 940 Steg, AD 0 Stegeman, CA 860, 5, 9 Stehlik, C 54 Steiling, K 59 Steiman, AJ 4, 68 Stein, CM 8, 6, 86, 960, 66 Stein, N 747 Steinberg, G 470, 8 Steiner, JL 95 Steinhart, AH 59 Steinkasserer, A 07 Steinkellner, A 978 Steinman, M 8 Steinmeyer, J 890 Stemmer-Rachamimov, A 58 Stengaard-Pedersen, K 46, 959, 045, 07, 5 Stepaniants, S 5, Stephans, C 945, 949, 950 Stephens, G 057 Sterba, G 47 Sterling, KL 490 Stern, SM 78, 86, 006 Stern, W 984 Steultjens, MPM 66, 5 Steup-Beekman, G 594 Stevens, AM, 84, 040 Stevens, E 94 Stevens, W 60 Stewart, E 46 Stewart, KG 008, 09 Stewart, KJ 95 Sthoeger, ZM 456 Stichman, J 655, 7 Stiegler, C Stifano, G 56 Stillman, M 550 Stineman, M 00 Stock, JA 60 Stoeken-Rijsbergen, G 894 Stoeken-Rijsbergen, G 768, 670 Stoenoiu, MS 5 Stoffer, M 7, 4 Stohl, W 48, 76, 94, 6 Stojan, G 640, 89 Stolfa, J 96 Stoll, ML 677 Stolwijk, C 57, 576, 0, 6, 77, Stomp, W 05 abstract author Index 0 Program Book 97

400 abstract author Index Stone, D 65 Stone, DU 5, 54, 55, 0, 674 Stone, J 75 Stone, JH, 57, 54, 654, 9, 57, 58, 567 Stone, MD 804 Storgard, C 40, 4 Stoustrup, P 00 Straaten van der, T 00 Stradner, M 7 Strand, V 69, 5, 59 Strand, V 55, 0, 8, 8, 7, 87 Strangfeld, A 65 Stratis, A 46, 779 Stratton, RJ 9, 07 Straub, RH 49 Strehl, C 47, 777 Streicher, K 675, 760 Stribolt, K 877 Striebich, CC 765 Strigini, F 84 Strle, K 04 Strojny, L 678 Strunin, L 54 Strutton, G 49 Strömbeck, B 409 Stucki, G 76 Stucky, JA 796 Studenic, P 405 Stuijver, DJF 5 Stults, BM 489 Stunz, LL 44 Sturfelt, G 654, 66, 66, 44 Sturfelt, GK 88, 56 Sturmer, AM 984 Su, K 676 Su, L 4 Suarez-Almazor, ME 088, 88 Suarez-de-Figueroa, M 40 Suarez-Farinas, M 49 Subich, D 66 Suda, A 046 Sudano, D 7 Sudman, M 64 Suematsu, N 8, 5 Suemori, K 060 Suffia, C 66 Sugai, S 74, 67 Sugamoto, K 084 Sugihara, M 88 Sugihara, T 98, 7 Sugii, S 47 Sugimoto, N 9, 400, 8 Sugioka, Y, 0, 989, 990 Sugita, M 708 Sugiura, T 97 Sugiyama, D 707 Sugiyama, H 98 Suh, CH 75 Sulcs, E 94, 946 Sulli, A 49, 5, 64 Sullivan, K 85 Sullivan, KE 4, 5, 68 Sullivan, S 00, 46 Sumida, H 708, 504, 5 Sumida, T 58, 55, 65, 075, 079, 88, 5, 59, 55 Summer, R 89 Sun, HW 6 Sun, K 4, 99 Sun, L 66, 687, 9, 409, 646, 556 Sun, L 6 Sun, Q 9 Sun, W 08 Sun, X 446 Sun, Y 99 Sundaram, S 48 Sundstrom, C 9 Sundström, B 69 Sundy, JS 59, 60, 85, 88, 847, 96 Sung, MS 884 Sung, YK 78, 0, 0, 47 Sunkari, V 789 Suntharaligam, J 7 Supp, G 09, Suppiah, R 69 Suresh, G 974 Suresh, L 55 Susic, G 54 Suter, LG 907, 08 Sutton-Tyrrell, K 7 Suttorp-Schulten, MSA 5 Suva, D 48 Suyama, Y 99, 948, 47 Suzuki, C 97 Suzuki, E 44 Suzuki, JI 856 Suzuki, K 877 Suzuki, K 56 Suzuki, M 86 Suzuki, M 077, 079 Suzuki, N 8 Suzuki, T 046, 05,, 4 Suzuki, Y 9 Svensson, B 90 Svenungsson, E 70, 554, 574 Sverzelatti, N 7 Swaim, B 57 Swantek, J, 96 Swantek, JL 58 Swart, A 9 Swearingen, CJ 0 Swedler, W 669 Sweiss, NJ 8 Swigris, JJ 468 Swigris, JJ 7 Syed, A 700 Syed, RH 5 Sykoutri, D 5, 08 Sylvester, K 798 Symmons, D 767 Symmons, DP 88, 59 Symmons, DPM 544 Syrbe, U 496 Systemic Lupus International Collaborating Clincs, 6 Systemic Lupus International Collaborating Clinic (SLICC), 65 Systemic Lupus International Collaborating Clinics (SLICC), 647 Syverson, GD 75 Syvänen, AC 7 Szabo, S 54, 746 Szalai, A 99 Szczepanski, L 447 Szczerba, B 675 Szekanecz, Z 54 Szent-gyorgyi, L 06 Szentpetery, A 54, 55 Szmyrka-Kaczmarek, M 9 Sztajnbok, F 96 Szumski, A 98, 85,, 66 Szymanski, KA 6 Szymkowski, DE 76 Szymula, A 675 Södergren, A 45 Sørensen, IJ 580, 06, 04, 66 T t Hart, B 6 t Hart, BA Tabechian, D 07, 59 Tabera-Bahillo, I 859 Tabeya, T 97 Taboada-Cole, A 606 Tacey, M 64 Tachmazidou, I 657 Tada, M, 0, 989, 990 Taddeo, A 50 Taghavi-Zadeh, S 646 Taguchi, H 04 Taguchi, M 569 Tahami, A 497 Tahara, K 48 Tahara, M 075, 5 Tai, M 66 Tajima, Y 8 Tak, PP 066, 599, 59 Tak, PP 59, 58, 585, 77, 90, 4, 8, 60, 090, 6, 4, 45, 55 Tak, PP 568, 078, 89, 8 Tak, PP 45, 56, 754 Takada, S 8 Takada, Y 40 Takagi, K 74, 94, 94, 49, 97, 4 Takagi, K 50 Takagishi, K Takahashi, H 97 Takahashi, K 50 Takahashi, K 856 Takahashi, K Takahashi, O 046 Takahashi, R 504 Takahashi, RD 0, 807 Takahashi, S 58, 65, 075, 5 Takahashi, T 700, 708, 504, 5 Takahashi, Y 70 Takahashi, Y 659, 68 Takakuwa, Y 8 Takao, M 77 Takasaki, Y 98, 09,, 98, 94, 0 Takase, K Takayama, L 9, 9, 4 Takayama, M 7 Takeda, A 99, 948, 47 Takehara, K 6 Takei, S 6 Takemura, M 6, 4 Takeno, M 809, 989,, 4, 6, 046 Takeshita, S 78 Takeuchi, A 84 Takeuchi, E 569 Takeuchi, K Takeuchi, T 455, 47, 850, 877, 86, 89,, 4, 5, 459, 98, 9, 60 Takezaki, T 6 Talaber, G 45 Talaei, N Talarico, R 88, 6 Tam, LS 88 Tam, M 60 Tamai, M 046, 05,, 4 Tamaki, Z 700, 708, 58 Tamariz, L 6 Tamas, N 774 Tamayo Novas, M 99 Tamborrini, G 07 Tamby, MC 774 Tamura, N 09, 94, 0 Tamura, Y 459 Tan, FK 474, 509, 90, Program Book

401 Tan, SL 075 Tan, W 80 Tanaka, A 59 Tanaka, A 86 Tanaka, A 98 Tanaka, D 006 Tanaka, E 9, 400, 8, 957 Tanaka, H 600 Tanaka, K 077, 079 Tanaka, M 877 Tanaka, M 98 Tanaka, N 50 Tanaka, S 40, 48, 80 Tanaka, S 458 Tanaka, T 500 Tanaka, Y 77 Tanaka, Y, 98, 77, 89,, 4, 5, 64, 76,, 50, 6,, 664 Tanaka, Y 65 Tandon, M 506, 50 Taneja, V 66 Tang, I Tang, MW 078 Tang, M 69 Tang, X 4 Tani, C 5, 057, 84 Taniguchi, A 9, 400, 8, 957, 96, 4 Taniguchi, T 700, 708, 504, 5 Tanner, SB 8 Tanriverdi, K 567 Tansley, S 9, 67 Tao, A 9 Tao, A 44 Tao, J 66 Taoufik, Y 0 Tardif, JC 688 Targoff, IN 9, 670 Taroumian, S 7 Tarp, S 69 Tarp, U 6, 6, 7, 558 Tarrant, TK 66, 80 Tarride, JE 06, 00 Tarter, LL 060 Tarvin, SE 08 Tas, SW 066, 599 Tasaka, H Tascilar, K 00, 7 Tashjian, RZ 509 Tashman, S 7 Tasneem, A 847 Tateishi, K 59 Tatewaki, M 98 Tatibouet, S 78 Tatouli, IP 55 Tatour, S 00 Tatsuo, N 669 Taubenheim, B 6 Taurog, JD 0, 49 Taurok, D 4 Tavakkol, R 984 Tavares, R 06, 08, 05, 00 Tavera-Bahillo, I 5, 57, 59 Taverna, DM 986 Tavoni, A 546, 057, 85 Tawfik, O Tawk, RH 84, 045 Taylor, J 60 Taylor, J 78 Taylor, KE 67 Taylor, LH 985 Taylor, MB 9, 5 Taylor, NM 08 Taylor, P 490, 487, 488 Taylor, T 87 Taylor, W 6, 48, 76, 90 Tayyareci, Y 77 Tazzyman, S 80 Tchao, N 567 Tchérakian, C 8 Tchetverikov, I 6 Teal, TH 446 Teare, MD 985 Tecktonidou, M 459 Tedder, T 6 Teerawattanapong, S 677 Teglbjaerg, C 984 Tegzova, D 77 Tegzova, D 96 Tehrani, R 0 Tejera, B 967 Tektonidou, M 78 Telarico, T 455, 45, 498 Teleman, A 776, 559 Ten Cate, DF 048 Ten Cate, R 00 ten Dijke, P Tenner, CT 65 Tensfeldt, T 697 Teodorescu, MC 664, 455 Tepper, S 550 ter Huurne, MC 7 ter Wee, MM 5, 58 Terai, C 67 Terao, C 96 Terashima, Y 856 Terkeltaub, R 50, 8 Terpstra, I 64 Terrabuio, DR 50 Terreri, MT 96, 04, 60 Terrett, N 80 Terricabras, M Sr. Terrier, B Sr. 0, 6, 6, 67, 77, 787, 56 Teruel, M 000, 05 Teruel Antolin, JR 58 Tesher, MS 897 Teshigawara, S 94 Tesser, JR 7, 904 Tétreau, C 647 Teumer, A 60 Tezcan, ME 4 Thaci, D 7 Thakkar, A 0 Thakuria, B 58, 59 Thamsborg, G 580 Thanarajasingam, U 588 Thavaneswaran, A 540, 57, 590, 47, 48, 50, 5, 68, 69, 70, 7, 75, 4, 6 the Arthritis Research UK Working Group on Complementary and, 966 the Childhood Myositis Heterogeneity Group, 8 the CSP55 RACAT Research Group, 87 The Global Urate Genetics Consortium (GUGC), 60 the International Myositis Classification Criteria Project, 75 the MUSASHI study group, 95 the ORAL Start Investigators, 486 the RIM Study Group, 598 the RPDAI study group, 5 the Spanish Scleroderma Group, 0, 04 The Swedish-Norwegian Sjögren s syndrome Network, 50 Theander, E 5, 77, 0, 55 Theis, KA 46 Theodoridou, A 058 Theorell, J 845 Therkleson, T 556 Therneau, TM 48, 48 Theulin, A 649, 87 Thevenot, C 895 Thiel, S 5 Thiele, GM 6, 7, 87, 4 Thiele, K 77 Thiele, RG 07 Thiolat, A 505 Thirstrup, S 69 Thomas, EC 80, 8, Thomas, EP 796 Thomas, H 069 Thomas, J 9 Thomas, O 84 Thomas, R 98, 49, 494 Thomas, T 74 Thomas, W 56 Thombs, BD 4, 44, 66 Thome, D Thompson, AE 85 Thompson, J 866 Thompson, JM 96 Thompson, K 5 Thompson, LF 645 Thompson, SD 974, 64, 595, 657 Thomsen, JS 07 Thomsen, T 689 Thomson, W 974, 45, 59, 6, 64, 009, 654, 657 Thon, A 0 Thonhofer, R 7 Thormann, A 6, 6 Thorne, A Thorne, JC 55, 8, 84, 40, 465, 49, 96, 6, 8, 7, 099, 09,, 40, 5, 60 Thornton-Johnson, D 64 Thorp, LE 6, 64, 05 Thorstensson, CA 66 Thrower, R 40 Thurgood, L 676 Thurlings, RM 754 Thygesen, P 080 Tian, A 80 Tian, Q 49 Tian, S 08 Tian, X 944 Tian, X 60 Tieulié, N 8 Tikly, M 975, 794 Tillett, W 57 Tillotson, B 8 Tilson, H 80 Tily, HI 498 Timenetsky, MDCS 999, 95 Timlin, H 640 Timoshanko, J 846 Timoshchenko, R 66, 80 Tin, D 465, 6, 8, 09,, 40, 60 Tinazzi, I 50 Tincani, A 5 Ting, TV 0, 60 Tio, L 0 Tipton, C 690 Tissot, M 87 Titcombe, P 576 Tive, L 60 Tivon, D 788 Tiwari, H 970 Tiwari, P 4 Tjarnlund, A Tjärnlund, A 75 0 Program Book 99 abstract author Index

402 abstract author Index 400 To, CH 4, 67, 407, 488 Toda, E 856 Todd, J 6 Todesco, S 75 Todiere, G 09 Toepfer, D 008 Toes, REM 894, 77 Toes, REM 768 Toes, REM 97, 0, 767, 770, 670 Tohma, S 98, 99, 000, 89, 55 Tokuda, Y 948 Tolliday, N 595 Tolosa, C 479 Toloza, SMA 67, 48, 4 Tolusso, B 679, 97, 764 Tomasson, G 57, 567 Tombetti, E 68 Tomcik, M 47, 50, 50 Tomero, E 44, 70, 9 Tomic, K 9 Tomietto, P 60, 97 Tomita, M 55 Tomita, RB 6 Tomita, T 500, 084, 67 Tomlinson, GA 40, 96, 64, 54 Tomomi Date, 074 Tomsic, M 55 Tomšič, M 87, 05 Toncheva, A 479 Tong, G 8 Tonkin, BA 5 Tonner, C 87, 84, 05, 464, 599 Tonon, R 48 Tony, HP 76 Too, CL 6 Topcu, E 574 Toplak, N 598 Topless, R 80, 68 Topoleweski, K 076 Topolewski, K 878 Torbett, N 750 Torbey, S 08 Torjesen, P 84 Tormey, V 749 Torner, J 794, 796, 799, 0, 098, 9 Tornero-Esteban, P 006 Toro, JB 88 Torok, KS 9, 004, 008, 09, 06 Torp-Pedersen, C 684 Torralba, KD 850, 870, 87, 589 Torralba, KMD 4 0 Program Book Torre-Alonso, JC 5, 998, 999 Torrelo, A 65 Torrente, V 7 Törring, O 959 Tortosa, R 980, 998, 999, 00 Totaro, MC 97 Toubi, E 746 Touma, Z 646, 84, 84, 64, 7, 40, 66 Tourkina, E 476, 5 Tourtellotte, W 787 Toussaint, LL 96, 869 Toussirot, E 95, 87, 6, 755, 756 Touze, E 55 Tovar Beltrán, JV 46 Townsend, AF 7, 405, 40 Townsend, MJ 60, 6 Townsend, R 59 Townshend-Bulson, LJ 76 Toyama, T 700, 708, 504, 5 Toyama, Y 4 Toyos, F 9 Tracey, K 45 Trad, S 64 Tran, M 468 Tran, P 74 Tran, TM 0 Tran, TN 64, 940 Trang, JM 984 Trapiella, L 479 Trautmann, S 09 Treadwell, EL 0 Tree, T 9 Treece, G 84 Trenkmann, M 49, 89 Trespidi, L 5 Treudler, R 90 Trifirò, G 907 Trijau, S 5 Trinder, SL 05 Triolo, P 64 Tripathi, D 07, 054 Tripathi, LP 4 Trivedi, AN 599 Trotta, F 00 Troum, O 050, 550 Trouw, LA 767, 768, 770, 77 Troxel, A 559 Truchetet, ME 9 Trudes, G 999 Truedsson, L 66, 88 Trugman, JM 96 Truong, B 55 Trupin, L 47, 98, 87, 05, 9, 440 Tryniszewska, B 06 Tsai, A 585 Tsao, BP 79, 84, 846, 970, 984, 6, 78, 8 Tsao, H 608, 40 Tsao, PH 97 Tse, S 044 Tse, SM 7 Tseng, CE 47 Tsikrika, S 66 Tsitsi, P 058 Tsokos, GC 79, 740, 448,, 68 Tsonaka, R 97 Tsou, PS 50, 506 Tsuboi, H 58, 075, 88, 5, 59 Tsuboi, R 856 Tsuchida, K Tsuchida, T 4 Tsuchiya, N 000, 55 Tsuji, G 98, 80 Tsuji, S 94 Tsukamoto, H 86 Tsukamoto, M 60 Tsumiyama, K 885, 055, Tsunoda, S 8 Tsuru, T 4 Tsutsumi, T 67 Tsuzaka, K 77 Tsuzuki, S 59 Tu, JW 085 Tu, K 55, 96, 5 Tu, W 00 Tubiana, S 565 Tucker, LB 94, 47 Tudor-Locke, C 794 Tufan, A 05 Tugal-Tutkun, I 989, 6 Tugwell, P 54, 48 Tunceli, O 68 Turchin, A 06 Ture-Ozdemir, F 70 Turesson, C 4, 776, 905, 84 Turiel, M 80 Turker, T 0, 477 Turkiewicz, A 5, 9, 94, 9 Turnbull, EM 475 Turner, H 750 Turner, ML 06 Turner, R 90 Turner, S 75, 90 Tustumi, F 50 Tuylu, T 565 Twickler, MT 078 Twilt, M 84, 85, 04 Tyler, JR 9 Tymms, K 87, 40 Tyndall, AG 85 Tyrrell, H 80 Tyrrell, PN 04, 05, 478 Tyson, N 459, 694 Tyson, S 446, 69 Tytus, S 08 Tytus, SR 05 Tzaribachev, C 06 Tzaribachev, N 64, 06 Tzelepis, G 78 Tzioufas, AG 507, 508, 56, 90, 55, 55 U Ucar, U 690 Ucgul, A 66 Uchida, T 5 Uchino, A 8 Uchino, K 550 Udall, M 855 Udayakumar, PD 4, 55 Udayakumar, PD 0 Uderhardt, S 90, 07 Ueda, A 809,, 4, 6 Ueda, N 86 Ueda, S 86 Ueda, Y 660, 799 Uehara, T 809,, 4 Ueki, N 86 Ueki, Y 70 Ueng, J 65 Uetani, M 046,, 4 Ugarte-Gil, MF 99 Ugurlu, S 750 Ugurlu, S 87, 66, 7 Uherek, C 4 Uhlig, T 90, 76, 95, 404, 50, 85, 844, 845 UK JDRG, 9, 67 Ukmar, M 60, 97 Uleryk, E 40 Ulgiati, D 8 Ulici, V 4 Ulrichts, H 6 Umeda, N 65, 88 Umehara, H 74, 67 Umicevic-Mirkov, M 4 Ungar, W 68 Unger, E 947 Unni, S 84 Unno, M 094 Uno, M 99 Unson, V 700 Upmanyu, R 49 Urata, Y 60 Urbina, EM 7

403 Ureña, I 7 Uriarte, E 44 Uriarte-Isacelaya, E 9 Urowitz, MB 6, 65, 646, 647, 648, 674, 84, 84, 4, 4, 45, 65, 706, 40, 4, 54, 56, 66, 570, 68 Ursu, S 654 Ursum, J 5 Usategui, A 8, 9, 5 Usher, P 08 Usmani, SE 4 Ustek, D 989, 6 Usui, C 86 Uyar, B 8 Uziel, Y 0 Uzunhan, Y 78 V Vacca, A 498, 599 Vadasz, Z 746 Vaglio, A 75, 857 Vagnani, S 057 Vahedi, G Vahldiek, J 84 Vaishnani, M 557 Vaknin, I 7 Valdazo-De Diego, P 5 Valdes, AM 58, 84, 98, 8, 77, 67 Valdez, H 78, 490 Valdivielso, P 7 Valencia, X 86 Valente, R 46 Valente, R 449 Valentin, MA 5 Valentin, MA 76 Valentini, G 47 Valesini, G 9, 8, 84, 85 Valeyre, D 78 Vali, S 4, 45 Valieva, S 4, 48 Valim, V 55 Valiunas, V 4 Vallejo-Ruiz, V 606 Valls-Garcia, R Sr. Vallucci, M 5 Valluri, U Valter, I 984 van t Klooster, G, 489 van t Spijker, A 560, 570 van Baarsen, LGM 4 van Beuningen, HM 7 van Bon, L 0 van Busschbach, J 560 van Caam, AP Van Daele, PL 0 van Dartel, S van de Laar, MAFJ 6, 4, 607, 67 van de Loo, FA 7, 5 van de Loo, FAJ 896, 089 van de Sande, MGH 4 van de Stadt, LA 0 van de Stadt, L 765, 0, 77 van de Stadt, LA 668 van den Bemt, BJF 7 Van den Berg, JM 00, 09 van den Berg, R 564, 80, 06, 07, 09,,, 6 van den Berg, W 0 van den Berg, WB 7, 0,, 7, 895, 896, 089, 55, 5 Van den Bosch, F 570, 6, 4 van den Bosch, MH 7, 895 van Den Brand, BT 896 van den Broek, M 469, 98 van den Broek, M 0 van den Hoogen, FHJ 85 van den Oever, IAM 50, 5, 87, 668 van Denderen, JC 5 Van der Aa, A, 489 Van Der Broek, T 47 Van der Elst, K 56 van der Esch, M 66 van der Goes, MC 996 van der Graaf, AM 9 van der Heijde, D 574, 05, 0, 77 van der Heijde, D 69, 97, 495, 555, 56, 564, 57, 576, 59, 777, 977, 04, 05, 0, 05,, 8, 0, 44, 5, 6, 6, 7, 76, 80, 698, 705, 908, 8, 06, 07, 08, 09,,, 4, 8,, 5, 449, 546, 560, 56, 579, 6, 6, 66 van der Helm - van Mil, AHM 670 van der Helm-van Mil, AHM 894 van der Helm-van Mil, AHM 97 van der Horst-Bruinsma, IE 5 Van der Kaap, J 6 Van Der Kamp, S 059 van der Kraan, PM 7,, 895 van der Laken, CJ van der Leeden, M 66, 5 van der Leij, C 4 van der Maas, A 7, 609 van der Poll, T 80 van der Veen, MJ 996 van der Veer, M 095 van der Voort, EIH 767 van der Werf, JH 996 van Dillen, N 58 Van Domelen, D 5 van Dongen, CJJ 8 Van Doornum, S 64, 70, 86 van Duivenvoorde, LM 585 van Durme, C 908 van Echteld, IA 908 van Eijk, IC 70 van Engelen, BGM 8 van Es, IE 90, 55 van Eyk, J 79 van Gaalen, FA 05 van Gaalen, F 564, 44, 80, 06, 07, 09,,, 6 van Geffen, EW Van Gelder, RN 49 Van Groenendael, JHLM 594 van Haandel, L 5, 597 van Halm, VP 87, 668 van Hamburg, JP 79, 8 van Helden-Meeuwsen, CG 58, 0 van Herwaarden, N 7 Van Holder, K 80, 8 van Hoogmoed, D van Hulst, L 56 van Kampen, AH 754 van Kuijk, AW 568, 58 van Laar, J 574 Van Laar, J 0 van Laar, JM 5, 04 van Leeuwen, J 8 van Lent, PL 7 van Lent, PLEM 0, 7, 895, 089, 55 Van Lunen, B 6 Van Mater, H 0 van Meurs, JB 98 van Middelkoop, M 47 van Nies, JAB 894 van Nies, J 670 van Oosterhout, M 594 van Osch, G 47 Van Riel, P 80 van Riel, PLC van Riel, PLCM 4, 7, 68, 607, 609, 65, 67 Van Riel, PL 8 van Roon, JAG 509, 50, 064, 786, 788, 96, 5 Van Rossum, MAJ 0, 00 Van Rossum, MAJ 09 Van Roy, M 6 van Royen-Kerkhoff, A 0 van Schaardenburg, D 5, 58, 0, 0, 4, 4 van Schaardenburg, D 765, 77, 8, 668 van Schaik, BD 754 van Sijl, AM 87, 668, 70 Van Suijlekom-Smit, LWA 4, 00 van Tok, MN 585, 45 Van Tubergen, AM 558, 57, 576, 0, 6, 77, van Veelen, P 770 van Veenendaal, M 0 van Vollenhoven, RF 59 van Vollenhoven, R 50 van Vollenhoven, RF 69, 7, 459, 487, 64, 65, 77, 775, 776, 97, 0, 6, 8, 47, 640, 694,, 4, 486 van Winkelhoff, AJ 0 van Zaane, B 5 van Zeben, D 095 van Zelst, BD 654 van Zoest, KPM 066, 599 Vanarsa, K 07 Vandam, W 455 Vandenhende, F 574 Vandepapeliere, P 479 Vander Bilt, J 4 Vandrell, I 750 Vanhaesebroeck, B 750 Vanhille, P 656 Vanhoutte, F, 489 Vanin, EF 670 Vanstone, L 055 Varela Guidetti, F 68 Varga, A 5 Varga, J 76, 787, 57, 58, 89, 94 Vargas, A 7, 968 Vargas-Serafin, C 446 Vargo, J 0 Vargova, V 764 Varisco, PA 5 Varnier, GC 58 Varsani, H 674 Vas, J 577 Vasama, K 095 Vasconcelos, C 48 Vassiliadis, E 575, 65 Vassilopoulos, D 66 Vastesaeger, N 47, 47, 549, 779, 65 Vaughan, D 88 Vaughn, S 84 Vayssière, B Vazquez, DL 4 Vazquez, T Sr. 77 Vazquez Mosquera, ME 994 abstract author Index Vazquez-Del Mercado, M, Program Book 40

404 abstract author Index Vazquez-Mellado, J 59, 60, 56, 90 Veale, DJ 9, 6, 658, 806, 5, 9 Vedanarayanan, VJ 98 Veenhuizen, M 447, 76 Vega, J 7, 456, 457 Vega Morales, D 096 Vega-Fernandez, P 80, 8 Veinot, P 48 Veizaga-Udaeta, D 49 Vela, P 980, 44 Vela Anero, A 6 Velasco, F 7 Velasco, J 49, 494 Vellas, B 969 Velozo, EJ 60, 4 Venables, PJ 00 Vencovsky, J 9,, 6, 67, 96, Vende, F 65 Vendramini, M 68 Venn, A 55 Venugopalan, A 58, 59 Vera-Lastra, O 70 Vera-Lastra, OL Verazza, S 58 Verbeek, JS 0, 056 Verbruggen, N 99 Verburg, KM 59, 60 Verdet, M 485 Verdoni, L 05 Vergnaud, P 47 Verheyden, G 6 Verhoef-Jurgens, M 5 Verma, SM 947 Vermeer, M 607, 67 Vermeij, EA 896, 089 Vermeulen, SH 4 Verner, E 6 Vernon, E 640 Verrouil, E 5 Versari, A 6 Verschueren, K 07, Verschueren, P 56 Versnel, MA 58, 0 Verstappen, G 54 Verstappen, S 767, 59, 6, 544 Ververken, C Verweij, CL, 8, 54, 668 Vester, JC 57 Vestergaard, P 78, Vestweber, D 68 Vettori, S Vezzari, C 75 Via, CS 45, 7 Viana, VS 77, 74 Viana, VST 500, 50 Viana, VST 95, 68 Vicena, V 6 Vidal, E 64 Videm, V 98 Vidmar, G 05 Vidva, R 4, 45 Vieira, A 7 Vieira, PL 6 Vieira-Sousa, E 078, 56, 988 Vierboom, M 6 Vierboom, MPM Viergever, MA Vignon, EP 60 Vikerfors, A 574 Vila, LM 67, 84, 4, 4 Vila, OM 454 Vila Fayos, V 46 Vila-Inda, C 6 Vilardell-Tarres, M 4 Villa, I 4, 49 Villa-Forte, A 65 Villafuertes, E 006 Villaggio, B 49, 64 Villagra, N 955 Villain, E 9, 649 Villalba, A 546 Villanueva, FS 5 Villarreal, A 455 Villarreal Alarcon, M 096 Villarroel, I 0 Villeneuve, S 555 Villiger, PM 766, 8, 55 Vina, ER 908, 909 Vincent, A 80 Vincent, A 96, 866, 869 Vincent, GR 7, 04 Vinci, V 77 Vincze, M 9, 67 Vinet, E 649, 69,, 87, 48, 887 Vinik, O 908 Viola, S 476 Virayavanich, W 584 Virta, LJ 67, 68 Vis, M 6 Visconti, R 5 Visconti, RP 476 Visman, IM 5 Visser, AW 097, 58 Visser, A 56 Visser, JM 5 Visser, K 94, 594, 606 Vissink, A 0 Vissink, A 54 Vista, EG 5, 55, 674 Vistnes, M 87, 94 Viswanathan, H 976 Vital, EM 474, 766 Vitali, C 55 Vitart, V 60 Vittadello, F 04 Vittecoq, D 5 Vittecoq, O 80, 8, 000 Vittecoq, O 5, 485, 78, 5, 88 Vitters, EL Vivar Pomiano, N Vivino, FB 74, 9, 67 Vizioli, CR 064 Vlachoyiannopoulos, P 78 Vlad, SC 4, 666, 8 Vlahos, B 68, 549 Vlak, T 479 Voelker, K 86, 667 Vogetseder, A 78 Vogl, T 7, 674 Vogler, LB 44, 55, 57, 005 Vogt, M 669 Vojinovic, J 54 Volin, M 8, 454, 669 Volkov, S 454, 669 Vollath, S 50 Vollenweider, CF 74, 55 Volochayev, R 06 Voloshyna, I 57 von Blomberg, M 8 Von Feldt, JM, 44 von Hinüber, U 77 von Kempis, J 770, 0, 44 von Muehlenen, I 577 von Scheven, E 76, 98, 0, 475 Vonk, MC 8, 85, 98, 0, 0, 04 Vonkeman, HE 6 Voorneman, RE 66 Vora, S 60 Vordenbäumen, S 46 Vos, K 59, 4 Voskuyl, AE Voskuyl, A 58, 8, 0, 04 Voskuyl, AE 87, 668 Voss, A 680, 76 Vosslamber, S, 8, 54, 668 Vostretsova, K 685 Vray, M 470, 8 Vroegindeweij, D 47 Vrtovsnik, F 565 Vu, K 98 Vu, THT 664 Vuillemin, A 4 Vuolteenaho, K 50 Vyse, TJ 84, 846, 970, 6, 8 W Wachsmann, D 785 Wada, T 458 Wada, Y 5 Wade, JP 84 Wagman, R 997 Wagman, RB 959, 976, 977, 998 Wagner, F 9 Wagner, GS 4 Wagner-Weiner, L 897 Wahl, D 740, 459 Wahle, J 080 Wahle, JA 796 Wahren-Herlenius, M 5, 77, 67 Waikar, S 665 Waimann, CA 60, 06, 4 Waisberg, MG 7 Waisman, G 68 Wait, R 99 Waite, PD 677 Wakefield, R 80, 8 Wakefield, RJ 00 Wald, JA 984 Waldman, G 797 Waldron, N 57 Walgreen, B 55 Walitt, BT 860, 874, 64 Walker, D 79 Walker, R 455 Walker, UA 80, 696 Wallace, C 594, 595 Wallace, CA 76, 50, 00, 59 Wallace, DJ 69, 5 Wallace, D 47, 570 Wallace, DJ 69, 67, 94, 4, 60, 6 Wallace, RB 995 Wallace, ZS 58 Wållberg Jonsson, S 44 Wållberg-Jonsson, S 45 Wallenstein, G 77, 485 Wallenstein, G 8, 486 Wallis, D 57 Wallitt, B 95, 6 Wallmeier, H 4 Walsh, D 74, 5, Walsh, DNE 58, 590, 99, 46, 448, 6 Walsh, JB 58, Program Book

405 Walsh, J 0 Walsh, M 94 Walsh, N 80 Walsh, NC 5 Walter, MJM 570 Walton, NR 56 Wan Tain, WR 80 Wang, A 84, 959, 96, 998 Wang, B 69 Wang, C 798, 646 Wang, CR 6 Wang, D 66, 409, 646, 556 Wang, D 6, 7, 4 Wang, EC 804 Wang, F 80 Wang, F 67 Wang, G 940, 94, 944, 95, 87 Wang, H 46 Wang, H 670, 450 Wang, J 86 Wang, JC 00 Wang, JH 575 Wang, J 644, 99, 4 Wang, JX 897 Wang, K 04 Wang, L 46,, 69 Wang, L 8 Wang, M 66 Wang, M 96 Wang, Q 9 Wang, SP 76 Wang, SL 9 Wang, S 556 Wang, W 60 Wang, W 667, 678 Wang, W 58 Wang, Y 45 Wang, Y 857, 868 Wang, Y 494, 96, 97 Wang, Y 450 Wang, Y 569, 557, 56 Wang, Z 49, 50, 5, 8, 469, 470 Wang, Z 88 Wangjam, K 58, 59 Waraich, SA 645 Ward, M 6 Ward, MM 54, 78, 000, 600 Ward, RJ Wardemann, H 578 Waris, M 58 Warner, AJ 544 Warren, RB 46 Warren, S 87 Warriner, AH 978, 995 Warrington, KJ 857, 905, 55, 55, 56, 58 Wasan, A 0 Wasko, MCM 4, 690 Wason, S 9 Wassenberg, S 59 Watanabe, A 94 Watanabe, A Watanabe, A 700 Watanabe, K 98 Watanabe, KS Watanabe, K 98 Watanabe, M 700 Watanabe, R 809,, 4 Watanabe, R 70, 8 Watanabe, S 0 Watanabe, T 460 Watanabe, T 6, 4 Watcher, SJ 47 Waters, EA 0 Watkins, M 455 Watson, C 86, 89 Watson, JM 07 Watson, K 59 Watson, KD 88 Watts, A 7 Watts, S 06 Webb-Detiege, TA 95 Webber, CE 06, 05, 00 Webber, M 4 Webber, S 586 Weber, D 99 Weber, U 548, 778, 04, 08, 0, 0 Webster, F 48 Wechalekar, MD 908 Wedderburn, LR 9, 59, 6, 64, 67, 674, 009, 654, 657 Weel, AEAM 095 Wegener, WA 69, 5 Wehmeyer, C 46, 779 Wei, F 90, 49 Wei, JC 97 Wei, J 7 Wei, J 5 Wei, J 787, 89, 94 Wei, N 49 Wei, X 6 Wei, XN 5 Weibel, L 004 Weichselbaum, L 50 Weinberger, M 795 Weinblatt, M 954, 547 Weinblatt, ME, 695 Weinblatt, M 8, 98, 9, 0, 86, 06, 06, 40, 660 Weinblatt, ME 40, 4, 449 Weinstein, A 60 Weinstein, AM 90 Weinstein, A 856, 4, 6 Weinstein, SP 5, 8 Weis, L 08 Weis, L 60, 97 Weisbart, RH 69 Weisman, MH 576, 694 Weisman, MH 7, 7, 44, 4, 44, 54, 545, 69, 67, 78, 4, 704 Weiss, A 9 Weiss, B 8 Weiss, JE 76, 4, 46, 60 Weiss, P 99, 00 Weiß, A 57, 9 Weldon, AJ 759 Welin Henriksson, E 57 Welin Henriksson, EM 554, 555, 587 Weller, M 57 Wells, AU 7, 854, 7 Wells, GA 8 Welsch, G 09 Welsing, PMJ, 5 Welsing, PMJ 8, 996 Wen, H 8 Wenander, C 08 Wendling, D 544, 87, 6, 67, 756, 87, 47 Wener, MH 76 Weng, H 47, 47 Weng, S 88 Wenkert, D 8, 644 Wenting-van Wijk, M 96 Werlen, S 6 Wermuth, PJ 496, 95, 06 Werner, SG 9 Wershba, E 0 Werth, VP 75, 947, 40 Wessel, MD 06 Wesseling, J 6 Wesseling, JG 668 West, CR 59, 60 Wester, RT 06 Westhoff, G 4 Westhovens, R 8, 86, 9, 0, 05, 56, 86 Westmacott, R 04 Westman, K 564 Westra, J 0 Westra, J 9 Westwood, B 7 Westwood, JP 757 Wetterö, J 67, 66 Wevers-de Boer, KVC 94, 594, 606 Weyand, CM 857, 56, 665 Whelton, SA 56 Whipple, MO 96, 869 Whitbred, JM 595 White, C 84 White, CJ 65 White, DK 794, 799 White, ES 58 White, J 78 White, K 8 White, T 06 White, W 8, 755 Whiteside, J 48 Whitmore, M 798 Whitney-Mahoney, KJ 7 Whitt, IZ 709 Whitt, SE 94 Whittard, T 74 Whitworth, A 05 Whyte, A 676 Wichuk, S 575, 578, 59, 59, 65 Wick, JA Wicks, I 70 Widdifield, J 55, 96, 5 Widmer, A 748 Wiebe, E 085 Wiedeman, A 446, 79, 8 Wiell, C 04 Wiesel, R 406 Wigerinck, P 489 Wigley, FM 697, 79, 786, 48 Wijbrandts, CA 8 Wijmenga, C 858 Wiland, P 68 Wilder, T 56 Wildi, LM 4 Wildman, HF 694, 75 Wiley, GB 54 Wilke, LD 59 Wilke, W 884 Wilkinson, B 84 Wilkinson, B 97 Wilkinson, BE 486 Willburger, M 947 Willemze, A 768 Williams, AH 79 Williams, AS 804 Williams, DA 58, 866, 96, 58, 869 Williams, M 60 Williams, M 585 Williams, R 5, Williams, RO 7 abstract author Index 0 Program Book 40

406 abstract author Index Williams, SA 48 Williams, S 64 Williams, T 68, 549 Williamson, JD 54 Willim, M 90 Willis, CR 50 Willis, R 69, 455, 456, 457 Willis, VC 4 Wills, AK 800 Wilson, AG 894 Wilson, AG 6, 985, 800, 80 Wilson, A 78 Wilson, F 85, 575 Wilson, G 0, 774 Wilson, HE 46 Wilson, KL 9, 94 Wilson, PC 748 Wilson-Gerwing, TD 9 Wimmer, MA 6 Winchester, R 00, 659 Winkelmayer, WC 87, 9, 665 Winkler, A 08 Winkler, DG 8 Winkler, S 594 Winter, O 449 Winterstein, A 07 Winther, SA 684 Winthrop, KL 84, 490 Winthrop, KL 54, 76, 78, 87, 09 Wipff, J 007 Wirth, W 470 Wise, B 8 Wisniewski, SR 56, 698, 85, 7 Wither, JE 674, 744, 56,, 40, 68 Witt, M 0, 407, 747, 07 Witte, BI 765 Witte, D 05 Witte, T 586, 04, 80, 67 Witteman, H 067 Witter, JP 545 Wittig, B 7 Wittkowski, H 674 Wittkowski, KM 4 Wittsack, HJ 040 Woelfel, J 95 Wolak, A 08 Wolak, T 08 Wolbink, G 4, 8 Wolf, DC 64, 9 Wolf, G 09 Wolf, JM 9 Wolf, S 89 Wolfe, F 88, 495, 605, 95, 698, 89, 859, 860, 068, 64 Wolfe, S 08 Wolff, M 565 Wolff, RK 48 Wolff, V 47 Wolfgang, H 574, 5 Wolfson, M 70 Wollenhaupt, J 574, 8, 5 Wollenhaupt, J 47, 47, 549, 779, 65, 6 Wollmer, P 77 Wolman, S 59 Wolstenholme, CB 7, 04 Wolterbeek, R 97 Woltering, F 557, 558, 6 Wong, B 7 Wong, BR 90 Wong, EE Wong, H 46 Wong, JB 646 Wong, M 5, 45 Wong, P 80 Wong, RH 97 Wong-Pack, W 979 Woo, J Woo, JMP 0, 70, 899 Woo, P 76, 0, 657 Woo, YJ Wood, J 78 Wood, R, 4 Wood, S 84 Wood, SP 8 Woodhead, F 854 Woods, A 697 Woods, D 70 Woods, J 74, 55 Woodward, AL 86 Woodward, TC 68 Woodworth, T 050 Woodworth, T 69 Woodworth, TG 609 Woody, SE 4 Wooley, PH 7 Woolf, AD 7, 4, 47 Wootton, J 88 Wordsworth, P 574, 595, 78, 5 Worthington, J 0 Wouters, C 764 Wouters, CH 86 Wozniak, M 86 Wren, JD 795 Wright, A 574, 5 Wright, D 885 Wright, E 98 Wright, H 069 Wright, J 650 Wright, K, 49 Wright, NC 54, 995 Wright, R 650 Wrobel, J 058 WTCCC 6 Wu, CT 549 Wu, CL 6 Wu, D 595 Wu, EQ 69, 484 Wu, EY 5 Wu, H 06, 00 Wu, H 69 Wu, J 4 Wu, J 9 Wu, J 99 Wu, J 965 Wu, LC 678 Wu, L 5 Wu, M 474, 509, 90 Wu, PW 49, 40 Wu, P 88 Wu, Q 587 Wu, Q 5, 575, 677 Wu, R 8 Wu, S 8 Wu, T 67, 4, 447 Wu, W 00 Wu, XX 7, 7 Wu, YL 948 Wu, Z 66 Wuhrer, M 76, 0 Wulffraat, N 759, 76, 47 Wulffraat, NM 76, 654 Wunrau, C 46 Wyllie, R 9 Wyman, B 77 Wynant, W 688 X Xavier, R 597 Xavier, RM 04, 550 Xia, Y 69 Xiangyuan, L 60 Xiao, J 59 Xiaofeng, L 60 Xiaomin, L 60 Xie, C 606 Xie, F 54, 74, 489, 76, 94 Xie, J 484 Xie, L 46, Xing, L, 4, 074, 666 Xingfu, L 60 Xiong, J 6, 8, 99, 099, 09,, 60 Xiuyan, Y 60 Xu, AP 50 Xu, D 74 Xu, D 670, 9 Xu, J 66, 6, 98 Xu, J 556 Xu, L 07, 09 Xu, L 80 Xu, M 544 Xu, M 894, 587 Xu, Z 9 Xu, Z 8 Xu, Z 67 Y Yılmaz-Öner, S 94 Yabe, H 67 Yacyshyn, E 7, 405 Yaffe, K 89 Yagüe, J 9 Yahya, A 6 Yalavarthi, S 440, 44 Yamada, H, 7, 45,, 55 Yamada, S 444, 445, 56 Yamagami, K 084 Yamagata, M Yamaguchi, A Yamaguchi, KI 99, 948, 47 Yamaguchi, Y 50 Yamaji, K 09, 94 Yamamoto, A 070 Yamamoto, K, 4, 5, 98 Yamamoto, M 97 Yamamoto, T 78 Yamamoto, T 50 Yamamoto, T 86 Yamamoto, T 074 Yamamura, T 0 Yamanaka, H 9, 400, 74, 94, 94, 89,, 4, 5, 49, 8, 97, 957, 96, 4, 4 Yamanishi, Y 56 Yamaoka, K, 77, 64, 76,, 50, 6, 664 Yamasaki, M 7, Yamasaki, Y, 7, 45 Yamasaki, Y 6 Yamashita, H 45 Yamashita, S 8 Yamatou, T 6 Yamazaki, H 98 Yamazaki, K Program Book

407 Yamazaki, S 084 Yamazaki, T 084 Yan, M 447, 07 Yan, Q 457 Yan, Z 67 Yanaba, K 708, 504, 5 Yanagida, M Yancopoulos, GD 5 Yang, H 484 Yang, HI 6 Yang, P 5, 575, 677 Yang, SY 7 Yang, S 40, 489, 70, 09, 06, 54 Yang, T 796, 55 Yang, Y 57, 89 Yang, YC 977 Yang, YH 088 Yang, Z 665 Yao, L 07 Yao, Q 89 Yao, R 47, 47, 549, 779, 65 Yao, Y 8, 69, 755, 675, 760 Yap, KS 57 Yargucu Zihni, F 8 Yarlina, A 96 Yasuda, S 98, 79, 460 Yasuda, T 89 Yasukawa, M 060 Yasuoka, H 455, 459 Yatomi, Y 48 Yau, MS 9, 986 Yavuz, S 98 Yawalkar, N 8 Yazdany, J 47, 98, 655, 9, 8, 05, 06, 065, 7, 464, 599, 600 Yazici, A 858, 98 Yazici, H 00, 87, 66, 7, 74 Yazici, Y 45, 40, 0, 8 Ye, B 57, 89 Ye, S Ye, X 84 Ye, Y 67, 447 Yearley, J 75 Yee, B 69 Yee, C 808 Yeh, S 55, 005 Yelin, E 47, 76, 84, 05, 9, 570 Yelin, EH 98, 440 Yen, EY 96 Yeo, AE 69, 70 Yeo, KJ 97 Yeon, JT 96 Yeremenko, N 585, 45 Yerges-Armstrong, L 744, 9, 986 Yeter, K 76, 870, 87 Yeung, RS 657 Yi, ES 98 Yi, H 46 Yi, N 69 Yi, W 60 Yildiz, B 00 Yildiz, F 64 Yilmaz, N 98, 64 Yilmaz, V 858 Yin, H 58 Yin, H 57 Yin, S 60 Ying, J 8, 94, Ying, KY 4 Yip, AL 06, 07 Yip, GM 87 Yip, M 4, 56 Yip, P 65, 45 Yokoe, I 4 Yokogawa, N 47 Yokota, S 748 Yokoyama, W 7 Yomogida, K 8, 0 Yonemoto, Y Yonezawa, T 645 Yongfu, W 60 Yoo, B 54, 784, 50 Yoo, DH 78, 47 Yoo, KY 889 Yoo, MC 889 Yoo, S 69 Yoo, WH 78, 884, 47, 96, 968 Yood, RA 59, 60, 96 Yoon, BY, 78, 47 Yoon, CH 6, 68 Yoon, MJ 5, 9, 95 Yoshida, H 077, 079 Yoshida, K 8 Yoshida, K 77 Yoshida, K 48 Yoshida, M 80 Yoshida, S 089, 4 Yoshifuji, H 6, 96 Yoshii, I 96 Yoshikawa, H 084 Yoshikawa, T 8 Yoshimi, R 809,, 4 Yoshimoto, K 877, 60 Yoshimura, A 504 Yoshimura, M 94 Yoshinari, T 4 Yoshioka, T 8 Yoshitomi, H 40 Yoshiyuki, A 669 Yoshizaki, K 4 Yoshizawa, T 660, 799 Young, A 74, 5, Young, D 677 Young, J 96 Young, JP 4 Young, J 84 Young, KA 44 Young, N 678, 840, 67 Young, PR 4 Yousefi, C 7, 405 Ytterberg, J 69 Ytterberg, SR 655, 77, 9, 97 Yu, A 584 Yu, CY 948 Yu, CY 78 Yu, D 068 Yu, HJ 88 Yu, HG 85 Yu, J 498 Yu, KL 407, 40, 4, 44 Yu, KH 58, 84, 8, 77, 67 Yu, N 66, 48 Yu, X 69 Yu, Y 676 Yu, Z 965 Yuan, K 87 Yuan, W 880 Yucel, AE 958 Yukawa, N 6, 96 Yukioka, M 569 Yun, H 489 Yun, J 96 Yura, A 94 Yurdakul, S 66 Yurdakul, S 77 Yurgin, N 9 Yurkovich, M 685 Yusuf, I 450 Yýlmaz Oner, S 7 Z Zaba, L 954 Zaccara, E 77 Zagatti, B 00 Zaheer, I 509 Zaiss, M 6 Zakem, JM 95 Zaki, A 6 Zaman, S 685 Zamanian, RT 47 Zamanpoor, M 80 Zambrana, L 89 Zamir, B 547 Zamora-Legoff, T 44 Zanchetta, JR 96, 998 Zannin, ME 676 Zanon, G 04 Zanoteli, E 04 Zanotti, S 790 Zapalowski, C 96 Zarco, P 998, 999, 70 Zarnitsky, C 554 Zarotsky, V 48 Zauner, D 7 Zavada, J 96 Zavadil, J 889 Zazzetti, F 00 Zbehlik, AJ 04 Zea, A 980, 44, 9 Zeddou, M 50 Zeft, A 657 Zeggini, E 657 Zeidler, H 70 Zeitlmann, L 08 Zelko, F 80, 8 Zell, J 655, 7 Zeller, J 59 Zeng, X 9 Zengbiao, Q 756, 945, 950 Zeni, S 47 Zerbe, GO 7, 097 Zerbini, C 77 Zerbini, C 47, 47 Zerbini, CAF 8 Zerr, P 47, 78, 50 Zgibor, JC 4 Zhai, G 8 Zhan, JY 97 Zhang, BY 5 Zhang, F 8, 840, 4 Zhang, G 9 Zhang, H 9 Zhang, H 666 Zhang, H 59, 594 Zhang, H 66 Zhang, J 54, 74, 70, 0, 54 Zhang, J 476, 5 Zhang, L 95 Zhang, M 90 Zhang, M 409 Zhang, M 80 Zhang, M 655 Zhang, Q 69 Zhang, S 4 Zhang, T 87 Zhang, W 58, 84, 8, 77, 67 Zhang, W 74 Zhang, X 44 Zhang, X, 64 Zhang, X 45 abstract author Index 0 Program Book 405

408 abstract author Index Zhang, X 59 Zhang, X 840 Zhang, X 95 Zhang, X 76 Zhang, XJ 467 Zhang, Y 409 Zhang, Y 4, 5, 74, 849, 0, 9, 666, 8, 980, 64, 6 Zhang, Y 90 Zhang, Z 68, 85 Zhanguo, L 60 Zhao, C 449 Zhao, J 846, 984, 6, 8 Zhao, M 69 Zhao, W 76 Zhao, W 440, 44, 499 Zhao, Y 74 Zhao, Y 9 Zhao, Y 49 Zhao, Z 578, 59, 59, 778, 0, 65 Zhenbin, L 60 Zheng, DH 09, 5 Zheng, J Zheng, SG 079, 4, 50 Zheng, SG 99 Zheng, S 49 Zheng, TS 88 Zheng, X 789 Zhernakova, A 894 Zhernakova, S 97 Zhong, ZJ 64, 65, 66, 4, 6 Zhou, H 9 Zhou, H 4, 085 Zhou, H 50 Zhou, J 7 Zhou, JJ 67 Zhou, J 49 Zhou, Q 44, 508 Zhou, Q 6 Zhou, S 68 Zhou, W 45 Zhou, X 00 Zhou, XJ 447 Zhou, Y 99 Zhou, Y 8 Zhu, F 068 Zhu, J 94 Zhu, J 065 Zhu, LJ 09, 5 Zhu, T Zhu, W 8, 755, 675 Zhu, X 497 Zhu, Y 74, 849, 64 Zhu, Y 8 Zhuang, X 87 Zhuoli, Z 60 Ziabakhsh, S 40 Zickert, A 574 Zickmund, SL 85 Zijlstra, TR 67 Zimetti, F 675 Zimmer, R 60 Zimmermann, B 4 Zimmermann, D 09 Zinger, H 456 Zink, A 77, 65, 4 Zinser, E 07 Zisman, D 450, 547 Ziswiler, HR 07 Zitnik, R 45 Ziza, JM 95, 8 Zizzo, G 688 Zlotnick, S 464 Zochling, J 87, 460, 40, 68 Zollars, E 68 Zoller, E 84 Zou, CJ 09, 5 Zou, H 497, 00 Zu, N 95 Zubarev, R 69 Zuber, C 4 Zuber, M 55 Zuber, Z 597 Zubieta, JK 450 Zubler, V 548, 778, 04, 0 Zucchetta, P 04 Zuckerman, A 90 Zuckerman, SH 65 Zufferey, P 07, 5, 4 Zuily, S 740, 459 Zulian, F 676, 0, 04, 47, 477 Zwillich, SH 77, 77, 84, 485 Zwillich, SH 8, 8, 97, Program Book

409 A Alarcon, Graciela S., MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy Aletaha, Daniel, MD, MSc Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase (JAK) Inhibitors Disclosure: Pfizer Inc., 5 Aliprantis, Antonios O., MD Biology and Pathology of Bone and Joint: Regulation of Bone Cells Aringer, Martin, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety & Efficacy of Janus Activated-Kinase (JAK) Inhibitors Disclosure: Abbott Immunology Pharmaceuticals, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; UCB, 8 Asahara, Hiroshi, MD Biology and Pathology of Bone and Joint: Osteoarthritis Askanase, Anca, MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Renal Assassi, Shervin, MD, MS Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, Etiology B Barnabe, Cheryl, MD, MSc Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease Disclosure: Amgen, Pfizer, Bristol-Myers Squibb, Roche, UCB, 5 Baron, Murray, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics I Battistone, Michael J., MD Medical Education Beam, Thuy T., BSN, RN Pediatrics: Disease Flares Becker, Michael A., MD Metabolic and Crystal Arthropathies: Clinical Disclosure: Ardea Biociences Inc, 5; BioCryst Pharmaceuticals Inc, 5; Metabolex Pharmaceuticals Inc, 5; Regeneron Pharmaceuticals Inc, 5; Savient Pharmaceuticals Inc, 5; Takeda Pharmaceuticals Inc, 5; UpToDate Inc, 7; URL Pharmaceuticals Inc, 5 Belza, Basia, PhD Education/Community Programs Birnbaum, Neal S., MD Rheumatoid Arthritis - Clinical Aspects IV: Nonbiologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events Disclosure: Amgen, Pfizer, Janssen, Abbott, 8 Blalock, Susan J., PhD Programs and Literacy in Patients with Rheumatologic Diseases Blitz, Jill R., PT, DPT Doing Is Believing: Health Beliefs Before and After an Exercised-Based Rehabilitation Programme for Chronic Knee Pain Physical/Occupational Therapy and Exercise in Patients with Rhematologic Disease Brady, Teresa J., PhD Education/Community Programs Bykerk, Vivian P., MD Rheumatoid Arthritis - Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis C Calabrese, Leonard H., DO Infection-related Rheumatic Disease Disclosure: Amgen, 8; Bristol-Myers Squibb, 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 5; Sanofi-Aventis Pharmaceutical, 5; ucb, 5 Callahan, Leigh F., PhD Clinical and Rehabilitative Aspects of Osteoarthritis Caplan, Liron, MD, PhD Epidemiology and Health Services Research I: Epidemiology and Outcomes in Rheumatic Disease Carrino, John, MD, MPH Imaging of Rheumatic Diseases II: Magnetic Resonance Imaging Disclosure: Carestream, Siemens, General Electric, 6; Medtronic, General Electric, Quality Medical Metrics, Vital Images, 5; Merge Healthcare, ; Siemens, Toshiba, Carestream, Chatham, W. Winn, MD Miscellaneous Rheumatic and Inflammatory I Disclosure: Centocor, Inc., ; GlaxoSmithKline, 9; Human Genome Sciences, Inc.,, 5; UCB Pharma, Chow, Shingpui Betty, PT, MA, OCS Associations of Foot Forces and Pressures to Regional Foot Pain: The Framingham Foot Study Foot and Gait Disorders Choy, Ernest, MD Rheumatoid Arthritis - Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis Disclosure: Chugai, 5, 8; Daiichi Pharmaceutical Corporation, 5; Eli Lilly and Company, 5; Ferring Pharmaceuticals, 5; GSK, 5; Jazz Pharmaceuticals, 5; MedImmune, 5; Merck Pharmaceuticals, 5, 8; NovImmune, 5; Pfizer Inc, 5, 8; Roche Pharmaceuticals,, 5, 8; UCB,, 5, 8 Cid, Maria C., MD Vasculitis: Pathogenesis Clauw, Daniel J., MD Fibromyalgia and Soft Tissue Disorders I Disclosure: Pfizer Inc, Forest Laboratories, Merck, Nuvo, ; Pfizer, Forest, Lilly, Merck, Nuvo, J and J, 5 Cohen, Philip L., MD B-cell Biology and Targets in Autoimmune Disease Colbert, Robert A., MD, PhD Spondyloarthritis and Psoriatic Arthritis - Pathogenesis, Etiology Cook, Dane B., PhD Fibromyalgia and Soft Tissue Disorders I Costenbader, Karen H., MD, MPH ACR/ARHP Combined Epidemiology Abstract Session Coty, Mary-Beth, PhD, RN Beliefs, Perceptions and Coping Criswell, Lindsey A., MD, MPH Sjögren s Syndrome I - Pathogenesis Crow, Mary K., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II Disclosure: Baxter, 5; Celgene, 5; EMD Merck Serono, 5; Genentech and Biogen IDEC Inc., 5; Idera, 5; Johnson & Johnson, ; Johnson and Johnson, 5; MedImmune, 5; Novo Nordisk, ; Pfizer Inc, ; Takeda, 5 Curtis, Jeffrey, MD, MPH, MS Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treatto-Target Era Deal, Chad L., MD Osteoporosis and Metabolic Bone Disease Disclosure: Amgen, Lilly, 5, 8 Dellaripa, Paul F., MD Rheumatoid Arthritis - Clinical Aspects V: Comorbidities in Rheumatoid Arthritis Disclosure: Genentech and Biogen IDEC Inc., ; Intermune, Inc., ; Novartis Pharmaceutical Corporation, ; Stomedix, Inc., D Abstract Moderator disclosure 0 Program Book 407

410 Deodhar, Atul A., MD Systemic Lupus Erythematosus Dewing, Kori A., DNP, ARNP Research Domsic, Robyn T., MD, MPH Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics II Dunlop, DOrothy D., PhD ARHP Epidemiology & Public Health Oral Session -Lifestyle Factors in Relation to Arthritis Clinical and Rehabilitative Aspects of Osteoarthritis E Eggebeen, Aaron T., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics Eisenberg, Robert A., MD B-cell Biology and Targets in Autoimmune Disease Disclosure: Genentech and Biogen IDEC Inc., 5 Elewaut, Dirk, MD, PhD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis and Spondyloarthritis Elkon, Keith B., MBBCh Systemic Lupus Erythematosus - Animal Models Englund, Martin, MD, PhD Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments Escalante, Agustin, MD Orthopedics, Low Back Pain, and Rehabilitation French, Anthony R., MD, PhD Pediatric Rheumatology - Pathogenesis and Genetics Furie, Richard A., MD Plenary Session III: Discovery 0 G Gall, Victoria, PT, MEd Programs and Literacy in Patients with Rheumatologic Diseases Genovese, Mark C., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis Disclosure: Eli Lilly and Company,, 5 Gensler, Lianne S., MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I Disclosure: Abbott Immunology Pharmaceuticals, 5 Giles, Jon T., MD Rheumatoid Arthritis - Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease Disclosure: Roche/Genentech, 5 Gilkeson, Gary S., MD Genetics and Genomics of Rheumatic Diseases Goldenberg, DOn L., MD Fibromyalgia and Soft Tissue Disorders II Disclosure: Forest, Lilly, Pfizer Inc, 5; Pfizer Inc, Goldring, Mary B., PhD Biology and Pathology of Bone and Joint: Osteoarthritis Disclosure: Abbott Laboratories, ; Biogen Idec, ; Fidia Farmaceutici S.p.A., 5; Merck-Serono, Gomez-Puerta, Jose A., MD, PhD Systemic Lupus Erythematosus - Clinical Aspects and Treatment IV: Therapeutics Greco, Carol M., PhD Psychological Aspects of Rheumatologic Disease Disclosure: NIAMS-NIH, ; Pfizer Inc, Systemic Lupus Erythematosus Disclosure: NIAMS-NIH, ; Pfizer Inc, Grisanti, Joseph M., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety II Grom, Alexei A., MD Pediatric Rheumatology - Pathogenesis and Genetics Disclosure: Novartis Pharmaceutical Corporation, 5; NovImmune, 9; Roche Pharmaceuticals, 5 Gross, K. Douglas, DPT, MSc ARHP Epidemiology & Public Health Oral Session -Biomechanics & Foot Disorders Grossman, Jennifer M., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment I: Renal Disclosure: medimmune, UCB, Pfizer, TEVA, Cephalon, American College of Rheumatology, Eli Lilly, Guccione, Andrew A., DPT, PhD ARHP Epidemiology & Public Health Oral Session - Predictors & Consequences of Arthritis Guermazi, Ali, MD, PhD Imaging of Rheumatic Diseases II: Magnetic Resonance Imaging Disclosure: AstraZeneca, 5; Boston Imaging Core Lab, ; Genzyme Corporation, 5; Merck Serono, 5; Novartis Pharmaceutical Corporation, 5; Stryker, 5 Guillevin, Loic P., MD Vasculitis: Clinical Aspects Disclosure: Roche Pharmaceuticals,, 5 H Hajj- Ali, Rula, MD Vasculitis: Clinical Trials Hanaoka, Beatriz Y., MD Factors Associated with Rheumatoid Arthritis Hannan, Marian T., DSc, MPH ARHP Epidemiology & Public Health Oral Session -Biomechanics & Foot Disorders Haqqi, Tariq M., PhD Biology and Pathology of Bone and Joint: Regulation of Bone Cells Hassett, Afton L., PsyD Factors Associated with Rheumatoid Arthritis Head, Andrew J., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities Helfgott, Simon M., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I Disclosure: Abbott Immunology Pharmaceuticals, 5; Roche Pharmaceuticals, 5 Helmick, Charles G., MD Osteoarthritis Abstract Moderator disclosure F Fitzcharles, Mary-Ann, MBChB, MD Fibromyalgia and Soft Tissue Disorders II Disclosure: Pfizer Inc, Lilly, Purdue, Valeant, 5 FitzGerald, John D., MD, PhD ACR/ARHP Combined Rehabilitation Abstract Session Forbess, Lindsy J., MD ACR/REF Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients Hetland, Merete L., MD, PhD, DMSc Rheumatoid Arthritis - Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis Disclosure: Abbott Laboratories, 5; Bristol-Myers Squibb, 5; MSD, 5; Pfizer Inc, 5; Roche, 5; UCB Nordic, Program Book

411 Hobbs, Kathryn, MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy and Safety of Novel Entities Disclosure: HGS, UCB, 6 Hootman, Jennifer M., ATC, PhD ARHP Epidemiology & Public Health Oral Session -Lifestyle Factors in Relation to Arthritis Care of Patients with Rheumatoid Arthritis Education/Research/Health Services Research Hyrich, Kimme, MD, PhD Rheumatoid Arthritis - Clinical Aspects III: Rheumatoid Arthritis and Cardiovascular Disease Rheumatoid Arthritis - Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies I Ishimori, Mariko L., MD Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment Iversen, Maura D., BSc, DPT, SD, MPH Doing Is Believing: Health Beliefs Before and After an Exercised-Based Rehabilitation Programme for Chronic Knee Pain Physical/Occupational Therapy and Exercise in Patients with Rhematologic Disease J Jamal, Shahin, MD, MSc Rheumatoid Arthritis - Clinical Aspects VI: Remission and Flare in Rheumatoid Arthritis Disclosure: Abbott, Amgen, Pfizer, Janssen, Roche, BMS, UCB, 5 Jolly, Meenakshi, MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy Disclosure: GlaxoSmithKline, 5; Lupus Foundation of America, ; MedImmune, 7; The Binding Site, Jordan, Joanne M., MD, MPH Osteoarthritis - Clinical Aspects I: Weight, Activity, and Metabolic Effects on Osteoarthritis Disclosure: Algynomics, Inc., ; Eli Lilly and Company, 5; Interleukin Genetics, Inc., 5; Johnson & Johnson, ; Johnson and Johnson, 5; Mutual Pharmaceutical Company, 5 K Kalunian, Kenneth C., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Clinical Aspects Kaplan, Mariana J., MD Innate Immunity and Rheumatic Disease Disclosure: Boehringer Ingelheim, 5 Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II Disclosure: Takeda, Boehringer-Ingelheim, 9 Karlson, Elizabeth, MD Rheumatoid Arthritis - Clinical Aspects I: Risk Factors and Prediction of Rheumatoid Arthritis Katz, Patricia P., PhD Consequences of Stress and Depression Kay, Jonathan, MD Rheumatoid Arthritis - Clinical Aspects IV: Nonbiologic Drugs for Rheumatoid Arthritis: New Insights on Comorbidities and Adverse Events Disclosure: Abbott Immunology Pharmaceuticals, ; Amgen, 5; Ardea Biosciences, ; Bristol-Myers Squibb, 5; Celgene, 5; Crescendo BioScience, 5; Eli Lilly and Company, ; Fidia Farmaceutici SpA, ; fourteen, 5; Genentech and Biogen IDEC Inc., 5; Horizon Pharma, 5; Janssen Biotech, 5; Molecular Partners AG, 5; Pfizer Inc, 5; Roche Pharmaceuticals, ; Sanofi-Aventis Pharmaceutical, ; Savient, 5; UCB, 5 Keating, Richard M., MD Miscellaneous Rheumatic and Inflammatory I Keysor, Julie J., PhD, PT ACR/ARHP Combined Rehabilitation Abstract Session Khan, Nasim A., MD Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease Kivitz, Alan J., MD, CPI Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety II Koch, Alisa E., MD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis Krishnan, Eswar, MD, MPhil ACR/ARHP Epidemiology Abstract Session Kyburz, Diego, MD Innate Immunity and Rheumatic Disease Kyttaris, Vasileios C., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I L Langford, Carol A., MD, MHS Plenary Session II: Discovery 0 Disclosure: Bristol-Myers Squibb, 9; Genentech and Biogen IDEC Inc., 9 Lee, Yvonne C., MD, MMedSc Rheumatoid Arthritis - Clinical Aspects VII: Prediction of Outcome in Rheumatoid Arthritis Disclosure: China Med Tech, ; Cubist Pharmaceuticals, ; Elan Corporation, ; Forest Laboratories, ; Given Imaging, ; Medco Health Solutions, ; Merck Pharmaceuticals, ; Novartis Pharmaceutical Corporation, Lems, Willem F., MD Osteoporosis and Metabolic Bone Disease Levy, Roger, MD Antiphospholipid Syndrome Li, Suzanne C., MD, PhD Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response Lisse, Jeffrey R., MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis Disclosure: UCB Pharmaceuticals, 5 Lohr, Kristine M., MD, MS Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes Losina, Elena, PhD Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease Louie, James S., MD Infection-related Rheumatic Disease Lovell, Daniel J., MD, MPH Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II Lubberts, Erik, PhD Cytokines, Mediators, and Gene Regulation I Cytokines, Mediators, and Gene Regulation II Lundberg, Ingrid E., MD, PhD Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies Disclosure: Bristol-Myers Squibb, ; MedImmune, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, Abstract Moderator disclosure 0 Program Book 409

412 Abstract Moderator disclosure M Manzi, Susan, MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Cardiovascular Disclosure: SEE ATTACHED,, 5, 7 Mariette, Xavier, MD, PhD Sjögren s Syndrome I - Pathogenesis Markenson, Joseph A., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Comparative Efficacy and Novel Treatment Strategies in Rheumatoid Arthritis Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; Bristol-Myers Squibb, 8; Genentech and Biogen IDEC Inc., 8; Janssen Pharmaceutica Product, L.P., 8; Novartis Pharmaceutical Corporation, 8; Pfizer Inc, 8; Roche Pharmaceuticals, 8; UCB, 8 Martin, Richard W., MD, MA Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Efficacy of Approved Biologics Matteson, Eric L., MD Rheumatoid Arthritis - Clinical Aspects V: Comorbidities in Rheumatoid Arthritis McMahon, Maureen A., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment III: Cardiovascular Disclosure: Glaxo Smith Klein, 8; Human Genome Sciences, Inc., 8 Systemic Lupus Erythematosus - Clinical Aspects and Treatment V: Clinical Aspects Disclosure: Glaxo Smith Klein, 8; Human Genome Sciences, Inc., 8 McQueen, Fiona M., MBChB, MD Imaging of Rheumatic Diseases III: Computed Tomography McTigue, Joan C., PA-C, MS Care of Patients with Rheumatoid Arthritis Merkel, Peter A., MD, MPH Vasculitis: Clinical Aspects Disclosure: Actelion Pharmaceuticals US, 5; Bristol-Myers Squibb, ; Celgene, ; Genentech and Biogen IDEC Inc., ; Genzyme Corporation, 5; Human Genome Sciences, Inc., ; Proteon Therapeutics, Meroni, Pier Luigi, MD Antiphospholipid Syndrome Michaud, Kaleb, PhD Epidemiology and Health Services Research IV: Outcomes and Costs in Rheumatic Disease Miossec, Pierre, MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies Monach, Paul A., MD, PhD Vasculitis: Pathogenesis Morgan DeWitt, Esi M., MD, MSCE Quality Measures and Innovations in Practice Management and Care Delivery Mouthon Sr., Luc, MD Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics II N Neogi, Tuhina, MD, PhD Osteoarthritis - Clinical Aspects II: Structural Risks for Osteoarthritis End-points and Potential Treatments Nguyen, Uyen Sa D.T., DSc, MPH Osteoarthritis Nicassio, Perry M., PhD Beliefs, Perceptions and Coping O Dell, James R., MD Plenary Session I: Discovery 0 Oddis, Chester V., MD Plenary Session III: Discovery 0 Onel, Karen, MD Pediatric Rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus Erythematosus and Other Vasculidities Pachman, Lauren M., MD Muscle Biology, Myositis and Myopathies: Pathogenesis in Idiopathic Inflammatory Myopathies Disclosure: NIH- R0- ; Education grant from Behring for $5,000, Perez-Ruiz, Fernando, MD, PhD Metabolic and Crystal Arthropathies: Clinical Disclosure: Ardea Biosciences, 5, 8; Menarini, 5, 8; Metabolex, 5; Novartis Pharmaceutical Corporation, 5, 8; Savient, 5, 8 Perlman, Harris R., PhD Rheumatoid Arthritis - Animal Models O P Pernis, Alessandra, MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I Pillinger, Michael H., MD Medical Education Metabolic and Crystal Arthropathies: Basic Science Disclosure:. Takeda Inc;. Savient Inc, 5 Pisetsky, David S., MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Cellular Effectors of Rheumatoid Arthritis and Novel Rheumatoid Arthritis Genome-Wide Association Studies Disclosure: Bio-Rad, 5; Pfizer Inc, 5 Poole, Janet L., OTR, PhD Independence At Home: Real or Perceived Pope, Richard M., MD Plenary Session II: Discovery 0 Q Quismorio Jr., Francisco P., MD ACR/REF Edmond L. Dubois, MD Memorial Lectureship: Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients R Ranganath, Veena K., MD, MS ACR/ARHP Epidemiology Abstract Session Disclosure: BMS, ; Cellgene, ; UCB,, 9 Rao, Smita, PT, PhD Associations of Foot Forces and Pressures to Regional Foot Pain: The Framingham Foot Study Foot and Gait Disorders Ravelli, Angelo, MD Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I Reimold, Andreas M., MD Quality Measures and Innovations in Practice Management and Care Delivery Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis Rider, Lisa G., MD Muscle Biology, Myositis and Myopathies: Classification, Treatment and Outcome in Idiopathic Inflammatory Myopathies 40 0 Program Book

413 Robinson, William H., MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Early Pathogenesis of Rheumatoid Arthritis Rose, Jillian A., LMSW Independence At Home: Real or Perceived Ruderman, Eric M., MD Rheumatoid Arthritis - Clinical Aspects II: Long-term Outcome of Rheumatoid Arthritis, Observational Studies Disclosure: Abbott Immunology Pharmaceuticals,, 5; Amgen, 5; Bristol-Myers Squibb, 5; Celgene, ; CVS/Caremark, 5; Pfizer Inc,, 5; The Rheumatology Education Group, 4 S Salt, Elizabeth G., PhD Systemic Sclerosis, Vasculitis, Crohn s and Spondylarthropathies Schett, Georg A., MD, PhD Imaging of Rheumatic Diseases III: Computed Tomography Schmidt, Wolfgang A., MD Imaging of Rheumatic Diseases I: Ultrasound and X-ray Disclosure: Abbott Immunology Pharmaceuticals,, 5, 8; Actelion Pharmaceuticals US, ; Berlin-Chemie / Menarini, 5, 8; Esaote, ; General Electric, ; Medac, 8; Merck Sharp Dohme,, 8; Novartis Pharmaceutical Corporation, ; Pfizer Inc, 8; Roche Pharmaceuticals,, 5, 8; UCB, 8 Schneider, Rayfel, MBBCh Pediatric Rheumatology: Clinical and Therapeutic Disease I: Juvenile Idiopathic Arthritis I Disclosure: Hoffmann-La Roche, Inc.,, 5, 8; Innomar Strategies, 5; Novartis Pharmaceutical Corporation, Schulze-Koops, Hendrik, MD, PhD Cytokines, Mediators, and Gene Regulation I Disclosure: Abbott, AB Science, Astra-Zeneca, BMS, Biotest, Celgene, Cephalon, Chugai, Essex, Haspira, Janssen biologics, MSD, Merck, Novartis, Pfizer, Roche, UCB, ; Abbott, Actelion, Biotest, BMS, Chugai, Essex, GSK, MSD, Medac, Merck, Mundai Pharma, Novartis, Nycomed, Pfizer, Roche, UCB, 5 Shah, Ami A., MD, MHS Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics I Shahrara, Shiva, PhD Cell-cell Adhesion, Cell Trafficking and Angiogenesis Sharma, Leena, MD Orthopedics, Low Back Pain, and Rehabilitation Osteoarthritis - Clinical Aspects I: Weight, Activity, and Metabolic Effects on Osteoarthritis Shen, Nan, MD Genetics and Genomics of Rheumatic Diseases Simon, Lee S., MD Epidemiology and Health Services Research V: Rheumatoid Arthritis Management in the Treatto-Target Era Disclosure: Affinergy, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Nitec, Bayer, Rigel, Chelsea, 5; Alder, Cephalon, Purdue, EMDSerono, Altea, Talagen, Tigenix, Antigenics, Forest, Genzyme, CaloSyn, King, Horizon, Pozen, ILPharma, Analgesic Solutions, Creabilis, Kowa, Array, Astra Zeneca, 5; Regeneron, Cypress, Savient, Nicox, Fidelity, Extera, Wyeth, Asahi, Winterex, Metabolix, Solace, Puretechventures, White Mountain Pharma, Abbott, Omeros, Jazz, Takeda, Teva, Zydus, Proprius, Savient, 5 Singh, Jasvinder A., MBBS ACR/ARHP Combined Epidemiology Abstract Session Disclosure: OMERACT, 9; Savient, Takeda, Ardea, Regeneron, Allergan, URL pharmaceuticals and Novartis, 5; Takeda and Savient, Systemic Lupus Erythematosus - Animal Models Smarr, Karen L., PhD Consequences of Stress and Depression Psychological Aspects of Rheumatologic Disease Smith, Benjamin J., PA-C Plenary Session I: Discovery 0 Smolen, Josef S., MD Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy: Safety I Disclosure: Abbott, Astra-Zeneca, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, MedImmune, MSD, Novo-Nordisk, Pfizer, Inc., Roche, Sandoz, Sanofi, UCB, 5; Abbott, Bristol-Myers Squibb, MSD, Pfizer, Inc., Roche, UCB, ; Rheumatology Textbook, Mosby-Elsevier, 7 Somers, Emily C., PhD, ScM ARHP Epidemiology & Public Health Oral Session - Predictors & Consequences of Arthritis Systemic Sclerosis, Vasculitis, Crohn s and Spondylarthropathies Soriano, Enrique R., MD, MSc Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis II Disclosure: Abbott Immunology Pharmaceuticals, ; Bristol-Myers Squibb, ; Genzyme Corporation, ; Janssen Pharmaceutica Product, L.P., 8; Pfizer Inc, 8 Southwood, Taunton R., BM, BS Pediatric Rheumatology: Clinical and Therapeutic Disease IV: Childhood Therapeutics and Response St.Clair, E. William, MD Sjögren s Syndrome II - Clinical Disclosure: Biogen Idec, 9; Bristol-Myers Squibb, ; Merck Pharmaceuticals, Stone, John, MD, MPH Vasculitis: Clinical Trials Disclosure: Genentech and Biogen IDEC Inc.,, 5; Roche Pharmaceuticals,, 5 Sundy, John S., MD, PhD Metabolic and Crystal Arthropathies: Basic Science T Tarter, Laura L., MD Epidemiology and Health Services Research III: Rheumatic Diseases and Cardiovascular Disease and Risk Assessment Taylor, Janalee, CNS, CPNP, MSN Pediatrics: Disease Flares Temprano, Katherine K., MD Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes Thiele, Ralf G., MD Imaging of Rheumatic Diseases I: Ultrasound and X-ray Disclosure: Abbott Laboratories, 8; American College of Rheumatology, 6; Amgen, 8; Equipment support, 9 Trojanowska, Maria, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Tsokos, George C., MD T-cell Biology and Targets in Autoimmune Disease Tzioufas, Athanasios G., MD Sjögren s Syndrome II - Clinical Abstract Moderator disclosure 0 Program Book 4

414 V W Abstract Moderator disclosure Valle-Oñate, Rafael, MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Psoriatic Arthritis and Spondyloarthritis Van den Bosch, Filip, MD, PhD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis II Varga, John, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Disclosure: JBT, Veale, DOuglas J., MD Cell-cell Adhesion, Cell Trafficking and Angiogenesis Vehe, Richard K., MD Pediatric Rheumatology: Clinical and Therapeutic Disease II: Juvenile Idiopathic Arthritis II Vencovsky, Jiri, MD, DSc Muscle Biology, Myositis and Myopathies: Pathogenesis in Idiopathic Inflammatory Myopathies Via, Charles S., MD Rheumatoid Arthritis - Animal Models Vinet, Evelyne, MD Epidemiology and Health Services Research II: Epidemiologic Risk Factors in the Development of Rheumatic Disease Volin, Michael, PhD Cytokines, Mediators, and Gene Regulation II von Scheven, Emily, MD Pediatric Rheumatology: Clinical and Therapeutic Disease III: Childhood Systemic Lupus Erythematosus and Other Vasculidities Wallace, Daniel J., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment IV: Therapeutics Ward, Michael M., MD Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I Weyand, Cornelia M., MD, PhD T-cell Biology and Targets in Autoimmune Disease 4 0 Program Book

415 Notes

416 Notes

417

418